PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Rose, SC; Fischer, AN; Heyer, GL				Rose, Sean C.; Fischer, Anastasia N.; Heyer, Geoffrey L.			How long is too long? The lack of consensus regarding the post-concussion syndrome diagnosis	BRAIN INJURY			English	Article						Concussion; head injury; mild brain injury; post-concussion syndrome; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; DSM-IV CRITERIA; HIGH-SCHOOL; POSTCONCUSSIONAL DISORDER; PROLONGED RECOVERY; FOOTBALL; STATEMENT; SEVERITY; AGE	Background/aim: A standard definition of Post-concussion Syndrome (PCS) does not exist. The objective was to determine consensus regarding the definition of PCS among physician members of the American College of Sports Medicine (ACSM). Methods: Physician members of the ACSM were sent an electronic survey to determine opinions regarding the PCS diagnosis. Results: Five hundred and ninety-seven physicians completed the survey. When asked the minimum duration of symptoms required to diagnose PCS, respondents answered: <2 weeks (26.6%), 2 weeks to 1 month (20.4%), 1-3 months (33%) and >3 months (11.1%). Physicians who see >= 10% concussion patients in their practise, as well as physicians whose concussion population consists of >50% paediatric patients, were more likely to require >1 month of symptoms (p<0.001). When asked the minimum number of symptoms required to diagnose PCS, responses varied: one symptom (55.9%), two symptoms (17.6%), three symptoms (14.6%) and four or more symptoms (3.2%). Respondents from the US were more likely than non-US respondents to require only one symptom for the PCS diagnosis (p = 0.01). Conclusions: There is a lack of consensus regarding the definition of PCS among physician members of the ACSM. A standard definition would improve consistency in concussion research and in clinical practise.	[Rose, Sean C.; Fischer, Anastasia N.; Heyer, Geoffrey L.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; [Rose, Sean C.; Heyer, Geoffrey L.] Nationwide Childrens Hosp, Dept Neurol, Columbus, OH 43205 USA; [Fischer, Anastasia N.] Nationwide Childrens Hosp, Dept Sports Med, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA		Heyer, GL (corresponding author), Nationwide Childrens Hosp, Dept Neurol, 700 Childrens Dr, Columbus, OH 43205 USA.	geoffrey.heyer@nationwidechildrens.org		Rose, Sean/0000-0001-5177-7715; Heyer, Geoffrey/0000-0001-9334-3739			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kaye AJ, 2010, J TRAUMA, V68, P1396, DOI 10.1097/TA.0b013e3181cf7d1b; Kraus JF, 2014, BRAIN INJURY, V28, P1248, DOI 10.3109/02699052.2014.916420; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; World Health Organization, 1993, ICD 10 CLASS MENT BE; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220	30	47	47	0	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2015	29	7-8					798	803		10.3109/02699052.2015.1004756			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CO0BJ	WOS:000358814800002	25870975				2022-02-06	
J	Baldwin, SA; Larson, MJ; Clayson, PE				Baldwin, Scott A.; Larson, Michael J.; Clayson, Peter E.			The dependability of electrophysiological measurements of performance monitoring in a clinical sample: A generalizability and decision analysis of the ERN and Pe	PSYCHOPHYSIOLOGY			English	Article						Reliability; Error-related negativity; ERN; Error positivity; Pe; Generalizability	MAJOR DEPRESSIVE DISORDER; OBSESSIVE-COMPULSIVE DISORDER; ERROR-RELATED-NEGATIVITY; EVENT-RELATED POTENTIALS; TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; CONFLICT ADAPTATION; FUNCTIONAL-SIGNIFICANCE; COGNITIVE CONTROL; ANXIETY DISORDER	Psychometric studies of the ERN, CRN, Pe, and Pc ERPs are increasing. Coherent integration of these results is difficult with classical test theory because the definition of error depends on the measure of reliability. This study used generalizability theory, which extends the ideas of classical test theory, as a framework for evaluating the influence of psychopathology and number of trials on dependability of measurement. Participants included 34 people meeting criteria for major depression, 29 meeting criteria for an anxiety disorder, and 319 controls. For all ERPs, within-person variance was larger than between-person variance across groups, indicating many trials are needed for adequate dependability (at least 13). Slightly fewer trials were needed to achieve adequate dependability in the control group than the pathology groups. Regions of interest had higher dependability than single sensors.	[Baldwin, Scott A.; Larson, Michael J.] Brigham Young Univ, Dept Psychol, Provo, UT 84660 USA; [Clayson, Peter E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA		Baldwin, SA (corresponding author), Brigham Young Univ, Dept Psychol, 268 TLRB, Provo, UT 84660 USA.	scott_baldwin@byu.edu	Clayson, Peter/AAC-9207-2019; Larson, Michael J/C-8543-2012; Clayson, Peter E/F-5438-2011; Clayson, Peter/AAC-4028-2022; Baldwin, Scott/G-4021-2017	Clayson, Peter/0000-0003-4437-6598; Larson, Michael J/0000-0002-8199-8065; Clayson, Peter E/0000-0003-4437-6598; Baldwin, Scott/0000-0003-3428-0437	Brigham Young University College of Family, Home, and Social Sciences	This research was supported by the Brigham Young University College of Family, Home, and Social Sciences.	Aarts K, 2013, J ABNORM PSYCHOL, V122, P939, DOI 10.1037/a0034616; Bartholow BD, 2005, PSYCHOPHYSIOLOGY, V42, P33, DOI 10.1111/j.1469-8986.2005.00258.x; Bates AT, 2004, J PSYCHIATR RES, V38, P347, DOI 10.1016/j.jpsychires.2003.11.002; Brazdil M, 2005, J PSYCHOPHYSIOL, V19, P244, DOI 10.1027/0269-8803.19.4.244; Brennan R.L., 2001, GEN THEORY; Cassidy SM, 2012, PSYCHOPHYSIOLOGY, V49, P659, DOI 10.1111/j.1469-8986.2011.01349.x; Chen SF, 2009, BRAIN RES, V1297, P89, DOI 10.1016/j.brainres.2009.08.003; Chiu PH, 2007, AM J PSYCHIAT, V164, P608, DOI 10.1176/appi.ajp.164.4.608; Clawson A, 2013, PSYCHOPHYSIOLOGY, V50, P711, DOI 10.1111/psyp.12066; Clayson PE, 2013, PSYCHOPHYSIOLOGY, V50, P174, DOI 10.1111/psyp.12001; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Clayson PE, 2011, BIOL PSYCHOL, V87, P282, DOI 10.1016/j.biopsycho.2011.03.011; Di Nocera F, 2001, PSYCHOPHYSIOLOGY, V38, P796, DOI 10.1017/S004857720101040X; Dien J, 2010, BRAIN RES, V1355, P126, DOI 10.1016/j.brainres.2010.07.099; Dien J, 2010, J NEUROSCI METH, V187, P138, DOI 10.1016/j.jneumeth.2009.12.009; Endrass T, 2007, EUR J NEUROSCI, V26, P1714, DOI 10.1111/j.1460-9568.2007.05785.x; Endrass T, 2012, PSYCHOPHYSIOLOGY, V49, P733, DOI 10.1111/j.1469-8986.2012.01365.x; Endrass T, 2010, BIOL PSYCHOL, V84, P257, DOI 10.1016/j.biopsycho.2010.02.002; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Fallgatter AJ, 2001, CLIN NEUROPHYSIOL, V112, P198, DOI 10.1016/S1388-2457(00)00505-8; Ford JM, 1999, PSYCHOPHYSIOLOGY, V36, P667, DOI 10.1111/1469-8986.3660667; Foti D, 2013, J ABNORM PSYCHOL, V122, P520, DOI 10.1037/a0032618; Gehring WJ, 2000, PSYCHOL SCI, V11, P1, DOI 10.1111/1467-9280.00206; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gelman A., 1992, STAT SCI, V7, P457, DOI DOI 10.1214/SS/1177011136; Gelman A, 2006, BAYESIAN ANAL, V1, P515, DOI 10.1214/06-BA117A; Georgiadi E, 2011, PSYCHOPHYSIOLOGY, V48, P1192, DOI 10.1111/j.1469-8986.2011.01198.x; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Hajcak G, 2008, AM J PSYCHIAT, V165, P116, DOI 10.1176/appi.ajp.2007.07010143; Hammer A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006553; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hoffmann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017482; Holmes AJ, 2008, ARCH GEN PSYCHIAT, V65, P179, DOI 10.1001/archgenpsychiatry.2007.19; Holmes AJ, 2010, COGN AFFECT BEHAV NE, V10, P119, DOI 10.3758/CABN.10.1.119; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Huffmeijer R, 2014, PHYSIOL BEHAV, V130, P13, DOI 10.1016/j.physbeh.2014.03.008; Hughes G, 2011, NEUROPSYCHOLOGIA, V49, P405, DOI 10.1016/j.neuropsychologia.2010.11.036; Johannes S, 2001, PSYCHIAT RES-NEUROIM, V108, P101, DOI 10.1016/S0925-4927(01)00117-2; Junghofer M, 1999, CLIN NEUROPHYSIOL, V110, P1149, DOI 10.1016/S1388-2457(99)00044-9; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2014, INT J PSYCHOPHYSIOL, V93, P283, DOI 10.1016/j.ijpsycho.2014.06.007; Larson MJ, 2013, BIOL PSYCHOL, V94, P408, DOI 10.1016/j.biopsycho.2013.08.006; Larson MJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00308; Larson MJ, 2012, J INT NEUROPSYCH SOC, V18, P323, DOI 10.1017/S1355617711001779; Larson MJ, 2011, PSYCHIAT RES, V187, P198, DOI 10.1016/j.psychres.2010.11.006; Larson MJ, 2010, PSYCHOPHYSIOLOGY, V47, P1167, DOI 10.1111/j.1469-8986.2010.01022.x; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Masaki H., 2004, JPN J PHYSL PSYCHOL, V22, P3; Meyer A, 2013, PSYCHOPHYSIOLOGY, V50, P1220, DOI 10.1111/psyp.12132; Munte TF, 2008, FRONT HUM NEUROSCI, V1, DOI 10.3389/neuro.09.011.2007; Nieuwenhuis S, 2005, PSYCHIAT RES, V134, P111, DOI 10.1016/j.psychres.2005.02.005; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; Olvet DM, 2010, PSYCHIAT RES, V179, P30, DOI 10.1016/j.psychres.2010.06.008; Olvet DM, 2009, PSYCHOPHYSIOLOGY, V46, P957, DOI 10.1111/j.1469-8986.2009.00848.x; Olvet DM, 2009, BRAIN RES, V1284, P89, DOI 10.1016/j.brainres.2009.05.079; Olvet DM, 2008, CLIN PSYCHOL REV, V28, P1343, DOI 10.1016/j.cpr.2008.07.003; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Pailing PE, 2004, BRAIN COGNITION, V56, P215, DOI 10.1016/j.bandc.2004.06.005; Pontifex MB, 2010, PSYCHOPHYSIOLOGY, V47, P767, DOI 10.1111/j.1469-8986.2010.00974.x; R Development Core Team,, 2012, R LANG ENV STAT COMP; Ruchsow M, 2006, J PSYCHIATR RES, V40, P37, DOI 10.1016/j.jpsychires.2005.02.002; Ruchsow M, 2004, PSYCHOPHYSIOLOGY, V41, P833, DOI 10.1111/j.1469-8986.2004.00237.x; Scheffers MK, 2000, J EXP PSYCHOL HUMAN, V26, P141, DOI 10.1037/0096-1523.26.1.141; Schrijvers D, 2008, CORTEX, V44, P569, DOI 10.1016/j.cortex.2007.08.014; Schrijvers D, 2009, INT J PSYCHOPHYSIOL, V71, P218, DOI 10.1016/j.ijpsycho.2008.09.005; Segalowitz SJ, 2010, PSYCHOPHYSIOLOGY, V47, P260, DOI 10.1111/j.1469-8986.2009.00942.x; Shalgi S, 2009, EUR J NEUROSCI, V29, P1522, DOI 10.1111/j.1460-9568.2009.06690.x; Shavelson R., 1991, GENERALIZABILITY THE; Stan Development Team, 2014, STAN C LIB PROB SAMP; Stemmer B, 2004, NEUROPSYCHOLOGIA, V42, P118, DOI 10.1016/S0028-3932(03)00121-0; Stern ER, 2010, PSYCHOPHYSIOLOGY, V47, P913, DOI 10.1111/j.1469-8986.2010.00988.x; Tang YY, 2013, INT J PSYCHOPHYSIOL, V90, P282, DOI 10.1016/j.ijpsycho.2013.09.001; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vidal F, 2003, BIOL PSYCHOL, V64, P265, DOI 10.1016/S0301-0511(03)00097-8; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; Weinberg A, 2011, PSYCHOPHYSIOLOGY, V48, P1420, DOI 10.1111/j.1469-8986.2011.01206.x; Weinberg A, 2010, BIOL PSYCHOL, V85, P472, DOI 10.1016/j.biopsycho.2010.09.011; Wiersema JR, 2007, NEUROPSYCHOLOGIA, V45, P1649, DOI 10.1016/j.neuropsychologia.2007.01.004; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	82	47	47	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	JUN	2015	52	6					790	800		10.1111/psyp.12401			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	CI2HL	WOS:000354566600007	25581577				2022-02-06	
J	Jalloh, I; Carpenter, KLH; Helmy, A; Carpenter, TA; Menon, DK; Hutchinson, PJ				Jalloh, Ibrahim; Carpenter, Keri L. H.; Helmy, Adel; Carpenter, T. Adrian; Menon, David K.; Hutchinson, Peter J.			Glucose metabolism following human traumatic brain injury: methods of assessment and pathophysiological findings	METABOLIC BRAIN DISEASE			English	Article						C-13 labelling; Glucose; Magnetic resonance spectroscopy; Microdialysis; Positron emission tomography; Traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; TRICARBOXYLIC-ACID CYCLE; PENTOSE-PHOSPHATE PATHWAY; FLUID PERCUSSION INJURY; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; COMBINED MICRODIALYSIS; C-13-LABELED MICRODIALYSIS; SUBSTRATE DELIVERY; LACTATE UPTAKE	The pathophysiology of traumatic brain (TBI) injury involves changes to glucose uptake into the brain and its subsequent metabolism. We review the methods used to study cerebral glucose metabolism with a focus on those used in clinical TBI studies. Arterio-venous measurements provide a global measure of glucose uptake into the brain. Microdialysis allows the in vivo sampling of brain extracellular fluid and is well suited to the longitudinal assessment of metabolism after TBI in the clinical setting. A recent novel development is the use of microdialysis to deliver glucose and other energy substrates labelled with carbon-13, which allows the metabolism of glucose and other substrates to be tracked. Positron emission tomography and magnetic resonance spectroscopy allow regional differences in metabolism to be assessed. We summarise the data published from these techniques and review their potential uses in the clinical setting.	[Jalloh, Ibrahim; Carpenter, Keri L. H.; Helmy, Adel; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Carpenter, T. Adrian; Menon, David K.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge CB2 0QQ, England		Jalloh, I (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167 Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	ij232@cam.ac.uk	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727; Hutchinson, Peter/0000-0002-2796-1835	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277 ID 98489]; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond and Beverly Sackler Fellowship; National Institute for Health Research Senior Investigator Awards; National Institute for Health Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1002277, G0802251] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B, G0802251, G0001354, G1002277, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	We gratefully acknowledge financial support as follows. Authors' support: I.J. - Medical Research Council (Grant no. G1002277 ID 98489) and National Institute for Health Research Biomedical Research Centre, Cambridge; K.L.H.C. - National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); A.H. - Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (Grant no. G0802251) and Raymond and Beverly Sackler Fellowship; D.K.M. - National Institute for Health Research Senior Investigator Awards; P.J.H. - National Institute for Health Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship.	Aaen GS, 2010, PEDIATRICS, V125, P295, DOI 10.1542/peds.2008-3312; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen T, 2000, ACT NEUR S, V76, P359; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529; FERRIS EB, 1946, AM J PHYSIOL, V147, P517, DOI 10.1152/ajplegacy.1946.147.3.517; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRUETTER R, 1994, J NEUROCHEM, V63, P1377; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hamilton G, 2006, J MAGN RESON IMAGING, V23, P459, DOI 10.1002/jmri.20524; Hattori N, 2003, J NUCL MED, V44, P1709; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Hetherington HP, 2001, MAGNET RESON MED, V45, P46, DOI 10.1002/1522-2594(200101)45:1<46::AID-MRM1008>3.0.CO;2-N; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P161, DOI 10.1038/jcbfm.1987.39; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Leegsma-Vogt G, 2001, J NEUROSCI RES, V66, P795, DOI 10.1002/jnr.10046; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2009, J NEUROTRAUM, V26, P1281, DOI [10.1089/neu.2008.0827, 10.1089/neu.2008-0827]; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Moreno A, 2001, MAGNET RESON MED, V46, P39, DOI 10.1002/mrm.1158; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Osteen CL, 2004, AGE DEPENDENCY 45CAL; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Paraforou Theoniki, 2011, BMC Res Notes, V4, P540, DOI 10.1186/1756-0500-4-540; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; Pattinson K, 2005, BJA EDUC, V5, P130, DOI 10.1093/bjaceaccp/mki035; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PHELPS ME, 1991, NEUROCHEM RES, V16, P929, DOI 10.1007/BF00965836; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rostami Elham, 2011, J Diabetes Sci Technol, V5, P596; Rothman DL, 2011, NMR BIOMED, V24, P943, DOI 10.1002/nbm.1772; Sampol Denys, 2013, Front Neuroenergetics, V5, P5, DOI 10.3389/fnene.2013.00005; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schonfeld P, 2013, J CEREBR BLOOD F MET, V33, P1493, DOI 10.1038/jcbfm.2013.128; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	96	47	47	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	JUN	2015	30	3					615	632		10.1007/s11011-014-9628-y			18	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	CH1YZ	WOS:000353821000002	25413449	Green Submitted, Green Published, hybrid			2022-02-06	
J	King, D; Gissane, C; Hume, PA; Flaws, M				King, D.; Gissane, C.; Hume, P. A.; Flaws, M.			The King-Devick test was useful in management of concussion in amateur rugby union and rugby league in New Zealand	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Brain injury; Sport-related concussion; King-Devick; SCAT3; Vision; Saccadic	SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; STATEMENT; SACCADES	Aim: To use the King-Devick (K-D) test in senior amateur rugby union and rugby league players over a domestic competition season to see if it could identify witnessed and unwitnessed episodes of concussion that occurred from participation in competition matches over three years. Methods: A prospective observational cohort study was conducted on a club level senior amateur rugby union team (n = 36 players in 2012 and 35 players in 2013) and a rugby league team (n = 33 players in 2014) during competition seasons in New Zealand. All 104 players completed two trials 10 min apart of the K-D at the beginning of their competition season. Concussions (witnessed or unwitnessed) were only recorded if they were formally diagnosed by a health practitioner. Results: A total of 52 (8 witnessed; 44 unwitnessed) concussive events were identified over the duration of the study resulting in a concussion injury incidence of 44 (95% CI: 32 to 56) per 1000 match participation hours. There was a six-fold difference between witnessed and unwitnessed concussions recorded. There were observable learning effects observed between the first and the second K-D test baseline testing (50 vs. 45 s; z = -8.81; p < 0.001). For every 1 point reduction in each of the post-injury SAC components there was a corresponding increase (worsening) of K-D test times post-match for changes in orientation (2.9 s), immediate memory (1.8 s) concentration (2.8 s), delayed recall (2.0 s) and SAC total score (1.7 s). Discussion: The rate of undetected concussion was higher than detected concussions by using the K-D test routinely following matches. Worsening of the K-D test post-match was associated with reduction in components of the SAC. The appeal of the K-D test is in the rapid, easy manner of its administration and the reliable, objective results it provides to the administrator. The K-D test helped identify cognitive impairment in players without clinically observable symptoms. (C) 2015 Elsevier B.V. All rights reserved.	[King, D.; Hume, P. A.] Auckland Univ Technol, Fac Hlth & Environm Sci, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Gissane, C.] St Marys Univ, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England; [Flaws, M.] Hutt Valley Dist Hlth Board, Emergency Dept, Lower Hutt, New Zealand		King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Hume, Patria/AAN-5514-2021; Hume, Patria Anne/P-1084-2017; Gissane, Conor/I-3661-2019	Hume, Patria/0000-0003-1847-8128; Hume, Patria Anne/0000-0003-1847-8128; Gissane, Conor/0000-0003-4677-3853			ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; Austin D, 2011, J SCI MED SPORT, V14, P259, DOI 10.1016/j.jsams.2011.01.003; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; DeSouza JFX, 2003, J NEUROPHYSIOL, V89, P1016, DOI 10.1152/jn.00562.2002; Dhawan PSA, 2014, NEUROL CLIN PRACT, V82, pS11; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Krumholtz I, 2000, Optometry, V71, P426; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lin TP, 2014, PARKINSONISM RELAT D, V20, P226, DOI 10.1016/j.parkreldis.2013.10.009; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Marinides Z, 2014, NEUROL CLIN PRACT; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Spradley B, 2014, SPORT J         0314; Stepanek J, 2014, AVIAT SPACE ENVIR MD, V85, P700, DOI 10.3357/ASEM.3645.2014; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Vartiainen MV, 2014, SCAND J MED SCI SPOR	39	47	47	0	31	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	APR 15	2015	351	1-2					58	64		10.1016/j.jns.2015.02.035			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CH0UP	WOS:000353738200012	25748294				2022-02-06	
J	Sun, D; Daniels, TE; Rolfe, A; Waters, M; Hamm, R				Sun, Dong; Daniels, Teresa E.; Rolfe, Andrew; Waters, Michael; Hamm, Robert			Inhibition of Injury-Induced Cell Proliferation in the Dentate Gyrus of the Hippocampus Impairs Spontaneous Cognitive Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						neurogenesis; hippocampus; traumatic brain injury; cognition; Morris water maze; Ara-C	ENDOTHELIAL GROWTH-FACTOR; ADULT NEUROGENESIS; CYTOSINE-ARABINOSIDE; GRANULE CELLS; FOREBRAIN NEUROGENESIS; ENHANCED NEUROGENESIS; CONDITIONAL ABLATION; NEURONS; RATS; MEMORY	Neurogenesis persists throughout life in the neurogenic regions of the mature mammalian brain, and this response is enhanced after traumatic brain injury (TBI). In the hippocampus, adult neurogenesis plays an important role in hippocampal-dependent learning and memory functions and is thought to contribute to the spontaneous cognitive recovery observed after TBI. Utilizing an antimitotic agent, arabinofuranosyl cytidine (Ara-C), the current study investigated the direct association of injury-induced hippocampal neurogenesis with cognitive recovery. In this study, adult rats received a moderate lateral fluid percussion injury followed by a 7-day intraventricular infusion of 2% Ara-C or vehicle. To examine the effect of Ara-C on cell proliferation, animals received intraperitoneal injections of 5-bromo-2-deoxyuridine (BrdU), to label dividing cells, and were sacrificed at 7 days after injury. Brain sections were immunostained for BrdU or doublecortin (DCX), and the total number of BrdU(+) or DCX+ cells in the hippocampus was quantified. To examine the outcome of inhibiting the injury-induced cell proliferative response on cognitive recovery, animals were assessed on Morris water maze (MWM) tasks at 21-25 or 56-60 days postinjury. We found that a 7-day infusion of Ara-C significantly reduced the total number of BrdU(+) and DCX+ cells in the dentate gyrus (DG) in both hemispheres. Moreover, inhibition of the injury-induced cell proliferative response in the DG completely abolished the innate cognitive recovery on MWM performance at 56-60 days postinjury. These results support the causal relationship of injury-induced hippocampal neurogenesis on cognitive functional recovery and suggest the importance of this endogenous repair mechanism on restoration of hippocampal function.	[Sun, Dong; Rolfe, Andrew; Hamm, Robert] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Sun, Dong; Daniels, Teresa E.; Waters, Michael] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia Campus,POB 980631, Richmond, VA 23298 USA.	dsun@vcu.edu		Daniels, Teresa/0000-0002-7826-1556	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086, NS078710]; NIH-NINDS (National Institute of Neurological Disorders and Stroke) center core grant [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078710, P30NS047463, R01NS055086] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health (NIH; grant nos.: NS055086 and NS078710; to D.S.). Microscopy work was performed at the Virginia Commonwealth University Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS (National Institute of Neurological Disorders and Stroke) center core grant 5P30NS047463.	Arruda-Carvalho M, 2011, J NEUROSCI, V31, P15113, DOI 10.1523/JNEUROSCI.3432-11.2011; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013; Calderon-Martinez D, 2002, J NEUROSCI METH, V114, P1, DOI 10.1016/S0165-0270(01)00493-9; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Hamada A, 2002, CLIN PHARMACOKINET, V41, P705, DOI 10.2165/00003088-200241100-00002; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hernandez-Rabaza V, 2009, NEUROSCIENCE, V159, P59, DOI 10.1016/j.neuroscience.2008.11.054; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Lau BWM, 2009, NEUROREPORT, V20, P371, DOI 10.1097/WNR.0b013e328324edcd; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; Mizumatsu S, 2003, CANCER RES, V63, P4021; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OORSCHOT DE, 1989, NEUROSCI LETT, V102, P332, DOI 10.1016/0304-3940(89)90101-8; Parent JM, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01631.x; Rhodes KE, 2003, NEUROSCIENCE, V120, P41, DOI 10.1016/S0306-4522(03)00285-9; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Singer BH, 2009, J COMP NEUROL, V514, P567, DOI 10.1002/cne.22052; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Suarez-Pereira I, 2015, HIPPOCAMPUS, V25, P51, DOI 10.1002/hipo.22349; Sun CR, 2013, J NEUROSCI, V33, P17314, DOI 10.1523/JNEUROSCI.2129-13.2013; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00095; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wei YJ, 2009, CELL TISSUE RES, V337, P361, DOI 10.1007/s00441-009-0836-4; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015	55	47	47	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					495	505		10.1089/neu.2014.3545			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400009	25242459	Green Published			2022-02-06	
J	Hahn, YK; Podhaizer, EM; Farris, SP; Miles, MF; Hauser, KF; Knapp, PE				Hahn, Yun Kyung; Podhaizer, Elizabeth M.; Farris, Sean P.; Miles, Michael F.; Hauser, Kurt F.; Knapp, Pamela E.			Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior	BRAIN STRUCTURE & FUNCTION			English	Article						Striatum; NeuroAIDS; Tat; HIV-1; Sex; Behavior	HUMAN-IMMUNODEFICIENCY-VIRUS; FIBRILLARY ACIDIC PROTEIN; MULTICENTER AIDS COHORT; TRAUMATIC BRAIN-INJURY; LIGHT/DARK BOX TEST; NEUROCOGNITIVE DISORDERS; ANTIRETROVIRAL THERAPY; OXIDATIVE STRESS; PARKINSONS-DISEASE; GENDER-DIFFERENCES	HIV-associated damage to the central nervous system results in cognitive and motor deficits. Anti-retroviral therapies reduce the severity of symptoms, yet the proportion of patients affected has remained the same or increased. Although approximately half of HIV-infected patients worldwide are women, the question of whether biological sex influences outcomes of HIV infection has received little attention. We explored this question for both behavioral and cellular/morphologic endpoints, using a transgenic mouse that inducibly expresses HIV-1 Tat in the brain. After 3 months of HIV-1 Tat exposure, both sexes showed similar reduced open field ambulation. Male Tat(+) mice also showed reduced forelimb grip strength and enhanced anxiety in a light-dark box assay. Tat(+) males did not improve over 12 weeks of repeated rotarod testing, indicating a motor memory deficit. Male mice also had more cellular deficits in the striatum. Neither sex showed a change in volume or total neuron numbers. Both had equally reduced oligodendroglial populations and equivalent microglial increases. However, astrogliosis and microglial nitrosative stress were higher in males. Dendrites on medium spiny neurons in male Tat(+) mice had fewer spines, and levels of excitatory and inhibitory pre- and post-synaptic proteins were disrupted. Our results predict sex as a determinant of HIV effects in brain. Increased behavioral deficits in males correlated with glial activation and synaptic damage, both of which are implicated in cognitive/motor impairments in patients. Tat produced by residually infected cells despite antiretroviral therapy may be an important determinant of the synaptodendritic instability and behavioral deficits accompanying chronic infection.	[Hahn, Yun Kyung; Knapp, Pamela E.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Podhaizer, Elizabeth M.; Farris, Sean P.; Miles, Michael F.; Hauser, Kurt F.; Knapp, Pamela E.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Miles, Michael F.; Hauser, Kurt F.; Knapp, Pamela E.] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA 23298 USA		Knapp, PE (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia MCV Campus,POB 980709, Richmond, VA 23298 USA.	peknapp@vcu.edu	Hauser, Kurt/AAX-8361-2020	Hauser, Kurt/0000-0001-7886-0332; Farris, Sean/0000-0002-9158-1984	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA024461, NS069216, DA018633, DA027374, U01AA016667]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS069216, P30NS047463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01AA016667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA024461, K02DA027374, R01DA018633] Funding Source: NIH RePORTER	We gratefully acknowledge NIH support: DA024461 and NS069216 (PEK); DA018633 and DA027374 (KFH); U01AA016667 (MFM). Electron microscopy was performed at the VCU-Dept. Anatomy and Neurobiology Microscopy Facility, supported in part with funding from NIH-NINDS Center Core Grant 5P30NS047463.	Adams SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037540; Adams SM, 2010, SYNAPSE, V64, P829, DOI 10.1002/syn.20793; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Asin SN, 2008, AIDS RES HUM RETROV, V24, P701, DOI 10.1089/aid.2007.0108; Balleine BW, 2007, J NEUROSCI, V27, P8161, DOI 10.1523/JNEUROSCI.1554-07.2007; Basso MR, 2000, J CLIN EXP NEUROPSYC, V22, P208, DOI 10.1076/1380-3395(200004)22:2;1-1;FT208; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Bouwman FH, 1998, NEUROLOGY, V50, P1814, DOI 10.1212/WNL.50.6.1814; Brooke S, 1997, P NATL ACAD SCI USA, V94, P9457, DOI 10.1073/pnas.94.17.9457; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Bruce-Keller AJ, 2008, GLIA, V56, P1414, DOI 10.1002/glia.20708; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Burger ME, 2005, PHARMACOL BIOCHEM BE, V81, P608, DOI 10.1016/j.pbb.2005.05.002; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Carey AN, 2013, PROG NEURO-PSYCHOPH, V43, P49, DOI 10.1016/j.pnpbp.2012.12.018; Carey AN, 2012, BEHAV BRAIN RES, V229, P48, DOI 10.1016/j.bbr.2011.12.019; Centers for Disease Control and Prevention, 2009, HIV SURV REP DIAGN H, V21; Cheng HW, 1997, EXP NEUROL, V147, P287, DOI 10.1006/exnr.1997.6618; Cheng JA, 2010, STEROIDS, V75, P754, DOI 10.1016/j.steroids.2009.10.014; Chiesi A, 1996, J ACQ IMMUN DEF SYND, V11, P39, DOI 10.1097/00042560-199601010-00005; Cho W, 2009, J NEUROCHEM, V110, P343, DOI 10.1111/j.1471-4159.2009.06146.x; Cohen RA, 2010, J NEUROVIROL, V16, P435, DOI 10.3109/13550284.2010.520817; Corasaniti MT, 2005, NEUROTOXICOLOGY, V26, P893, DOI 10.1016/j.neuro.2005.01.019; Cordeau P, 2008, STROKE, V39, P935, DOI 10.1161/STROKEAHA.107.501460; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crabbe JC, 2003, GENES BRAIN BEHAV, V2, P201, DOI 10.1034/j.1601-183X.2003.00023.x; CRAWLEY J, 1980, PHARMACOL BIOCHEM BE, V13, P167, DOI 10.1016/0091-3057(80)90067-2; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; D'Astous M, 2004, NEUROPHARMACOLOGY, V47, P1180, DOI 10.1016/j.neuropharm.2004.08.020; Das Gupta J, 2007, J NEUROVIROL, V13, P195, DOI 10.1080/13550280701258407; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Disshon KA, 1999, BRAIN RES, V842, P399, DOI 10.1016/S0006-8993(99)01863-6; Dore GJ, 2003, AIDS, V17, P1539, DOI 10.1097/00002030-200307040-00015; Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040; European Centre for Disease Prevention and Control, 2011, HIV AIDS SURV EUR 20; Everall IP, 1999, BRAIN PATHOL, V9, P209; Failde-Garrido JM, 2008, PSYCHIAT CLIN NEUROS, V62, P494, DOI 10.1111/j.1440-1819.2008.01841.x; Farinpour R, 2003, J CLIN EXP NEUROPSYC, V25, P654, DOI 10.1076/jcen.25.5.654.14577; FERRANTE RJ, 1991, J NEUROSCI, V11, P3877; Fitting S, 2013, BIOL PSYCHIAT, V73, P443, DOI 10.1016/j.biopsych.2012.09.026; Fitting S, 2010, AM J PATHOL, V177, P1397, DOI 10.2353/ajpath.2010.090945; Fitting S, 2010, HIPPOCAMPUS, V20, P469, DOI 10.1002/hipo.20648; Fitting S, 2010, J PROTEOME RES, V9, P1795, DOI 10.1021/pr900926n; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Gillies GE, 2010, HORM BEHAV, V57, P23, DOI 10.1016/j.yhbeh.2009.06.002; Giordano G, 2013, FREE RADICAL BIO MED, V58, P98, DOI 10.1016/j.freeradbiomed.2013.01.019; Gongvatana A, 2013, J NEUROVIROL, V19, P209, DOI 10.1007/s13365-013-0162-1; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Goodkin K, 1997, NEUROIMAG CLIN N AM, V7, P561; Grant I, 1995, CURR TOP MICROBIOL, V202, P11; Gupta S, 2010, NEUROSCI LETT, V485, P233, DOI 10.1016/j.neulet.2010.09.019; Hahn YK, 2012, GLIA, V60, P1871, DOI 10.1002/glia.22403; Hahn YK, 2010, J NEUROCHEM, V114, P97, DOI 10.1111/j.1471-4159.2010.06744.x; HAUSER KF, 1989, J COMP NEUROL, V281, P13, DOI 10.1002/cne.902810103; Hauser KF, 2009, GLIA, V57, P194, DOI 10.1002/glia.20746; Heaton R K, 1995, J Int Neuropsychol Soc, V1, P231; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1; Hel Z, 2010, ENDOCR REV, V31, P79, DOI 10.1210/er.2009-0018; Helfinstein SM, 2012, DEV PSYCHOL, V48, P815, DOI 10.1037/a0026402; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Hestad KA, 2012, J NERV MENT DIS, V200, P336, DOI 10.1097/NMD.0b013e31824cc225; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Johnson TP, 2013, P NATL ACAD SCI USA, V110, P13588, DOI 10.1073/pnas.1308673110; Joint United Nations Programme on HIV/AIDS, 2010, GLOB REP UNAIDS REP; Joint United Nations Programme on HIV/AIDS, 2010, OUTL UNAIDS OUTL REP; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Joska JA, 2011, AIDS BEHAV, V15, P1197, DOI 10.1007/s10461-010-9744-6; Kim BO, 2003, AM J PATHOL, V162, P1693, DOI 10.1016/S0002-9440(10)64304-0; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Kumar P, 2011, NEUROSCI LETT, V502, P56, DOI 10.1016/j.neulet.2011.07.024; Lawrence DM, 2002, MICROBES INFECT, V4, P301, DOI 10.1016/S1286-4579(02)01542-3; Lee AW, 1997, AIDS RES HUM RETROV, V13, P1235, DOI 10.1089/aid.1997.13.1235; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Liu M, 2010, J NEUROCHEM, V112, P773, DOI 10.1111/j.1471-4159.2009.06497.x; Liu X, 1996, J NeuroAIDS, V1, P17, DOI 10.1300/J128v01n04_03; Lopes M, 2012, J CLIN PSYCHIAT, V73, P384, DOI 10.4088/JCP.10m06304; Lundkvist J, 1999, AM J PHYSIOL-REG I, V276, pR644, DOI 10.1152/ajpregu.1999.276.3.R644; Maki PM, 2009, NEUROPSYCHOL REV, V19, P204, DOI 10.1007/s11065-009-9093-2; Malmberg-Aiello P, 2002, PHARMACOL BIOCHEM BE, V71, P313, DOI 10.1016/S0091-3057(01)00691-8; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; McArthur JC, 2010, ANN NEUROL, V67, P699, DOI 10.1002/ana.22053; MCNEILL TH, 1988, BRAIN RES, V455, P148, DOI 10.1016/0006-8993(88)90124-2; Mehal JM, 2013, AMYOTROPH LAT SCL FR, V14, P346, DOI 10.3109/21678421.2013.787629; Mouton P. R., 2002, PRINCIPLES PRACTICES; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Nakasujja N, 2005, J NEUROVIROL, V11, P26, DOI 10.1080/13550280500511782; Ramezani A, 2011, PHARMACOL BIOCHEM BE, V100, P144, DOI 10.1016/j.pbb.2011.07.010; Rao AK, 2011, J STEROID BIOCHEM, V127, P382, DOI 10.1016/j.jsbmb.2011.06.008; Rau SW, 2003, J NEUROSCI, V23, P11420; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Robertson KR, 2007, AIDS, V21, P1915, DOI 10.1097/QAD.0b013e32828e4e27; Robertson KR, 2004, JAIDS-J ACQ IMM DEF, V36, P817, DOI 10.1097/00126334-200407010-00008; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Russo R, 2005, NEUROTOXICOLOGY, V26, P905, DOI 10.1016/j.neuro.2005.01.009; Ryu JK, 2006, EXP NEUROL, V198, P552, DOI 10.1016/j.expneurol.2005.12.016; Sa MJ, 2004, ACTA NEUROPATHOL, V107, P97, DOI 10.1007/s00401-003-0781-3; Sacktor N, 2001, NEUROLOGY, V56, P257, DOI 10.1212/WNL.56.2.257; Shavali S, 2006, NEUROCHEM RES, V31, P85, DOI 10.1007/s11064-005-9233-x; Shin AH, 2012, BRIT J PHARMACOL, V166, P1002, DOI 10.1111/j.1476-5381.2011.01805.x; Shin AH, 2013, MOL CELL NEUROSCI, V54, P22, DOI 10.1016/j.mcn.2012.12.005; Shiotsuki H, 2010, J NEUROSCI METH, V189, P180, DOI 10.1016/j.jneumeth.2010.03.026; Shishehbor Mehdi H, 2004, Curr Atheroscler Rep, V6, P243, DOI 10.1007/s11883-004-0038-1; Simioni S, 2010, AIDS, V24, P1243, DOI 10.1097/QAD.0b013e3283354a7b; Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013; Suzuki M, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-78; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Tozzi V, 2005, AIDS RES HUM RETROV, V21, P706, DOI 10.1089/aid.2005.21.706; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Viviani B, 2006, J BIOL CHEM, V281, P30212, DOI 10.1074/jbc.M602156200; Voytek B, 2010, P NATL ACAD SCI USA, V107, P18167, DOI 10.1073/pnas.1007277107; Vu QB, 2009, AM J TROP MED HYG, V81, P747, DOI 10.4269/ajtmh.2009.09-0214; Wallace DR, 2006, SYNAPSE, V59, P51, DOI 10.1002/syn.20214; Wallace VCJ, 2008, NEUROSCI LETT, V448, P153, DOI 10.1016/j.neulet.2008.10.005; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wojna V, 2006, J NEUROVIROL, V12, P356, DOI 10.1080/13550280600964576; Wong MH, 2007, NEUROLOGY, V68, P350, DOI 10.1212/01.wnl.0000252811.48891.6d; Woodruff RH, 2001, INT J DEV NEUROSCI, V19, P379, DOI 10.1016/S0736-5748(00)00083-6; Woods SP, 2009, NEUROPSYCHOL REV, V19, P152, DOI 10.1007/s11065-009-9102-5; Yang YJ, 2011, GLIA, V59, P200, DOI 10.1002/glia.21089; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zhang MJ, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-82; Zou W, 2007, AM J PATHOL, V171, P1923, DOI 10.2353/ajpath.2007.070333	124	47	48	0	8	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAR	2015	220	2					605	623		10.1007/s00429-013-0676-6			19	Anatomy & Morphology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anatomy & Morphology; Neurosciences & Neurology	CC4UU	WOS:000350350300002	24352707	Green Published, hybrid			2022-02-06	
J	Blaya, MO; Tsoulfas, P; Bramlett, HM; Dietrich, WD				Blaya, Meghan O.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton			Neural progenitor cell transplantation promotes neuroprotection, enhances hippocampal neurogenesis, and improves cognitive outcomes after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neural progenitor cell transplantation; Multineurotrophin; Hippocampal neurogenesis; Neuroprotection; Spatial memory	ADULT NEUROGENESIS; DENTATE GYRUS; NEURONS; DIFFERENTIATION; NEUROTROPHINS; ACTIVATION; RECEPTORS; SURVIVAL; POINT	Transplantation of neural progenitor cells (NPCs) may be a potential treatment strategy for traumatic brain injury (TBI) due to their intrinsic advantages, including the secretion of neurotrophins. Neurotrophins are critical for neuronal survival and repair, but their clinical use is limited. In this study, we hypothesized that pericontusional transplantation of NPCs genetically modified to secrete a synthetic, human multineurotrophin (MNTS1) would overcome some of the limitations of traditional neurotrophin therapy. MNTS1 is a multifunctional neurotrophin that binds all three tropomyosin-related kinase (Trk) receptors, recapitulating the prosurvival activity of 3 endogenous mature neurotrophins. NPCs obtained from rat fetuses at E15 were transduced with lentiviral vectors containing MNTS1 and GFP constructs (MNTS1-NPCs) or fluorescent constructs alone (control GFP-NPCs). Adult rats received fluid percussion-induced TBI or sham surgery. Animals were transplanted 1 week later with control GFP-NPCs, MNTS1-NPCs, or injected with saline (vehicle). At five weeks, animals were evaluated for hippocampal-dependent spatial memory. Six weeks post-surgery, we observed significant survival and neuronal differentiation of MNTS1-NPCs and injury-activated tropism toward contused regions. NPCs displayed processes that extended into several remote structures, including the hippocampus and contralateral cortex. Both GFP- and MNTS1-NPCs conferred significant preservation of pericontusional host tissues and enhanced hippocampal neurogenesis. NPC transplantation improved spatial memory capacity on the Morris water maze (MWM) task. Transplant recipients exhibited escape latencies approximately half that of injured vehicle controls. While we observed greater transplant survival and neuronal differentiation of MNTS1-NPCs, our collective findings suggest that MNTS1 may be superfluous in terms of preserving the cytoarchitecture and rescuing behavioral deficits given the lack of significant difference between MNTS1- and GFP-control transplanted groups. Nevertheless, our overall findings support the potential of syngeneic NPC transplantation to enhance endogenous neuroreparative responses and may therefore be an effective treatment for TBI. (C) 2014 Elsevier Inc. All rights reserved.	[Blaya, Meghan O.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL 33125 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	Moconnell2@med.miami.edu; Ptsoulfa@med.miami.edu; Hbramlett@med.miami.edu; Ddietrich@miami.edu		Tsoulfas, Pantelis/0000-0003-1974-6366	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, W81XWH-06-1-0187]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER	The studies were supported by NIH NS030291 to WDD and W81XWH-06-1-0187 awarded to WDD. The authors wish to thank Mrs. Ofelia Furones-Alonso, Mr. Pingping Jia and Mrs. Yunfang Wang for their technical contributions to this study, and to Dr. Coleen Atkins for proofreading the manuscript.	Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Cossetti C, 2012, CELL TISSUE RES, V349, P321, DOI 10.1007/s00441-012-1341-8; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Follenzi A, 2002, METHOD ENZYMOL, V346, P454; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Kumagai G, 2013, EXP NEUROL, V248, P369, DOI 10.1016/j.expneurol.2013.06.028; Lessmann V, 2003, PROG NEUROBIOL, V69, P341, DOI 10.1016/S0301-0082(03)00019-4; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Walker PA, 2012, J NEUROINFLAMM, V9, P1742; Wu Y., 2012, TRANSL NEURODEGENER, V1, P2047; Xu Q, 2007, CLIN EXP PHARMACOL P, V34, P624, DOI 10.1111/j.1440-1681.2007.04619.x; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011	37	47	47	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2015	264						67	81		10.1016/j.expneurol.2014.11.014			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4IC	WOS:000349590400008	25483396	Green Accepted			2022-02-06	
J	Bledsoe, BE; Casey, MJ; Feldman, J; Johnson, L; Diel, S; Forred, W; Gorman, C				Bledsoe, Bryan E.; Casey, Michael J.; Feldman, Jay; Johnson, Larry; Diel, Scott; Forred, Wes; Gorman, Codee			Glasgow Coma Scale Scoring is Often Inaccurate	PREHOSPITAL AND DISASTER MEDICINE			English	Article						emergency care; Emergency Medical Services; Glasgow Coma Score; trauma care	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; EMERGENCY-DEPARTMENT; INTERRATER RELIABILITY; SCORES; CONSCIOUSNESS	Introduction: The Glasgow Coma Scale (GCS) is widely applied in the emergency setting; it is used to guide trauma triage and for the application of essential interventions such as endotracheal intubation. However, inter-rater reliability of GCS scoring has been shown to be low for inexperienced users, especially for the motor component. Concerns regarding the accuracy and validity of GCS scoring between various types of emergency care providers have been expressed. Hypothesis/Problem: The objective of this study was to determine the degree of accuracy of GCS scoring between various emergency care providers within a modern Emergency Medical Services (EMS) system. Methods: This was a prospective observational study of the accuracy of GCS scoring using a convenience sample of various types of emergency medical providers using standardized video vignettes. Ten video vignettes using adults were prepared and scored by two board-certified neurologists. Inter-rater reliability was excellent (Cohen's kappa = 1). Subjects viewed the video and then scored each scenario. The scoring of subjects was compared to expert scoring of the two board-certified neurologists. Results: A total of 217 emergency providers watched 10 video vignettes and provided 2,084 observations of GCS scoring. Overall total GCS scoring accuracy was 33.1% (95% CI, 30.2-36.0). The highest accuracy was observed on the verbal component of the GCS (69.2%; 95% CI, 67.8-70.4). The eye-opening component was the second most accurate (61.2%; 95% CI, 59.5-62.9). The least accurate component was the motor component (59.8%; 95% CI, 58.1-61.5). A small number of subjects (9.2%) assigned GCS scores that do not exist in the GCS scoring system. Conclusions: Glasgow Coma Scale scoring should not be considered accurate. A more simplified scoring system should be developed and validated.	[Bledsoe, Bryan E.; Casey, Michael J.; Feldman, Jay; Johnson, Larry; Forred, Wes; Gorman, Codee] Univ Nevada, Sch Med, Dept Emergency Med, Las Vegas, NV 89106 USA; [Bledsoe, Bryan E.; Casey, Michael J.; Feldman, Jay; Johnson, Larry; Forred, Wes; Gorman, Codee] Univ Nevada, Sch Med, Dept Trauma Surg, Las Vegas, NV 89106 USA; [Bledsoe, Bryan E.; Johnson, Larry; Diel, Scott] MedicWest Ambulance Amer Med Response, Las Vegas, NV USA		Bledsoe, BE (corresponding author), Univ Nevada, Sch Med, Dept Emergency Med, 901 Ranch Lane,Suite 135, Las Vegas, NV 89106 USA.	bbledsoe@medicine.nevada.edu					Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; BRAAKMAN R, 1977, CLIN NEUROL NEUROSUR, V80, P104; Brain Trauma Foundation, 2007, PREHOSP EMERG CAR S1, V12, pS14; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Heron R, 2001, Aust Crit Care, V14, P100, DOI 10.1016/S1036-7314(01)80026-6; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; JENNETT B, 1977, LANCET, V1, P878; JENNETT B, 1976, LANCET, V1, P1031; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; Lane Peter L, 2002, Prehosp Disaster Med, V17, P142; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; SEGATORE M, 1992, HEART LUNG, V21, P548; Stevens RD, 2013, CRIT CARE MED, V41, P1104, DOI 10.1097/CCM.0b013e318287ee79; TEASDALE G, 1974, LANCET, V2, P81; Tuijn S, 2012, J EVAL CLIN PRACT, V18, P887, DOI 10.1111/j.1365-2753.2011.01705.x	21	47	53	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1049-023X	1945-1938		PREHOSP DISASTER MED	Prehospital Disaster Med.	FEB	2015	30	1					46	53		10.1017/S1049023X14001289			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CN4NP	WOS:000358407200008	25489727				2022-02-06	
J	Finley, EP; Bollinger, M; Noel, PH; Amuan, ME; Copeland, LA; Pugh, JA; Dassori, A; Palmer, R; Bryan, C; Pugh, MJV				Finley, Erin P.; Bollinger, Mary; Noel, Polly H.; Amuan, Megan E.; Copeland, Laurel A.; Pugh, Jacqueline A.; Dassori, Albana; Palmer, Raymond; Bryan, Craig; Pugh, Mary Jo V.			A National Cohort Study of the Association Between the Polytrauma Clinical Triad and Suicide-Related Behavior Among US Veterans Who Served in Iraq and Afghanistan	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DIAGNOSES; SUBSTANCE USE DISORDERS; DEPLOYED MILITARY PERSONNEL; PSYCHIATRIC DIAGNOSES; COMMUNITY SAMPLE; WAR VETERANS; RISK; IDEATION	Objectives. We examined the association of posttraumatic stress disorder (PTSD), traumatic brain injury, and chronic pain-the polytrauma clinical triad (PCT)-independently and with other conditions, with suicide-related behavior (SRB) risk among Operation Enduring Freedom (OEF; Afghanistan) and Operation Iraqi Freedom (OIF) veterans. Methods. We used Department of Veterans Affairs (VA) administrative data to identify OEF and OIF veterans receiving VA care in fiscal years 2009-2011; we used International Classification of Diseases, Ninth Revision, Clinical Modification codes to characterize 211 652 cohort members. Descriptive statistics were followed by multinomial logistic regression analyses predicting SRB. Results. Co-occurrence of PCT conditions was associated with significant increase in suicide ideation risk (odds ratio [OR] = 1.9; 95% confidence interval [CI] = 1.5, 2.4) or attempt and ideation (OR = 2.6; 95% CI = 1.5, 4.6), but did not exceed increased risk with PTSD alone (ideation: OR = 2.3; 95% CI = 2.0, 2.6; attempt: OR = 2.0; 95% CI = 1.4, 2.9; ideation and attempt: OR = 1.8; 95% CI = 1.2, 2.8). Ideation risk was significantly elevated when PTSD was comorbid with depression (OR = 4.2; 95% CI = 3.6, 4.8) or substance abuse (OR = 4.7; 95% CI = 3.9, 5.6). Conclusions. Although PCT was a moderate SRB predictor, interactions among PCT conditions, particularly PTSD, and depression or substance abuse had larger risk increases.	[Finley, Erin P.; Bollinger, Mary; Noel, Polly H.; Pugh, Jacqueline A.; Dassori, Albana; Pugh, Mary Jo V.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; [Palmer, Raymond] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Amuan, Megan E.] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA; [Copeland, Laurel A.] Hlth Care Syst, Cent Texas Vet, Ctr Appl Hlth Res, Temple, TX USA; [Copeland, Laurel A.] Scott & White Healthcare Syst, Temple, TX USA; [Bryan, Craig] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT USA; [Bryan, Craig] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA		Finley, EP (corresponding author), South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	finleye@uthscsa.edu	Copeland, Laurel A/C-3763-2017; Pugh, Mary Jo/K-5336-2019; Pugh, Jacqueline/I-6199-2013	Copeland, Laurel A/0000-0002-9478-0209; Pugh, Mary Jo/0000-0003-4196-7763; palmer, ray/0000-0001-6621-9038; Finley, Erin/0000-0003-4497-7721; Pugh, Jacqueline/0000-0003-4933-141X; Bryan, Craig/0000-0002-9714-0733; Noel, Polly/0000-0002-1519-7489	Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; South Texas Veterans Health Care System; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25MH080916] Funding Source: NIH RePORTER	This study was funded by Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). J. A. Pugh's and A. Dassori's salaries were funded by the South Texas Veterans Health Care System. E. P. Finley is an investigator with the Implementation Research Institute, at the George Warren Brown School of Social Work, Washington University in St Louis, through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative.	Allison PD, 2001, LOGISTIC REGRESSION; [Anonymous], 2013, VA DOD CLIN PRACT GU; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bell NS, 2010, SUICIDE LIFE-THREAT, V40, P407, DOI 10.1521/suli.2010.40.4.407; Bonn-Miller MO, 2012, MIL MED, V177, P786, DOI 10.7205/MILMED-D-12-00052; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Britton PC, 2012, AM J PUBLIC HEALTH, V102, pS125, DOI 10.2105/AJPH.2011.300415; Brotman DJ, 2007, LANCET, V370, P1089, DOI 10.1016/S0140-6736(07)61305-1; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Bryan CJ, 2011, PSYCHOL SERV, V8, P94, DOI 10.1037/a0023451; Buck CJ, 2012, 2012 ICD 9 CM PHYS 2, V1; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Defense Casualty Analysis System, 2012, ACT DUT MIL DEATHS Y; Department of Defense, DEP DEF ICD 9 COD GU; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FONTANA A, 1995, AM J PSYCHIAT, V152, P102; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Grossman LS, 1997, PSYCHIAT SERV, V48, P393; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holtzheimer PE, 2005, AM J PSYCHIAT, V162, P970, DOI 10.1176/appi.ajp.162.5.970; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Ilgen MA, 2012, J CONSULT CLIN PSYCH, V80, P323, DOI 10.1037/a0028266; Ilgen MA, 2012, AM J PUBLIC HEALTH, V102, pS88, DOI 10.2105/AJPH.2011.300392; Ilgen MA, 2010, SUICIDE LIFE-THREAT, V40, P597, DOI 10.1521/suli.2010.40.6.597; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Jakupcak M, 2011, J NERV MENT DIS, V199, P272, DOI 10.1097/NMD.0b013e3182124604; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kaplan MS, 2012, AM J PUBLIC HEALTH, V102, pS131, DOI 10.2105/AJPH.2011.300445; Katz IR, 2012, AM J PUBLIC HEALTH, V102, pS105, DOI 10.2105/AJPH.2011.300503; Kemp J, 2012, SUICIDE DATA REPORT; Kim HM, 2012, J CLIN PSYCHIAT, V73, pE1269, DOI 10.4088/JCP.12m07658; Kim HM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-18; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; MacLean A, 2010, ARMED FORCES SOC, V36, P765, DOI 10.1177/0095327X09356166; Magruder KM, 2012, AM J PUBLIC HEALTH, V102, pS118, DOI 10.2105/AJPH.2011.300451; Mattocks KM, 2012, SOC SCI MED, V74, P537, DOI 10.1016/j.socscimed.2011.10.039; Olson-Madden JH, 2012, J HEAD TRAUMA REHAB, V27, P370, DOI 10.1097/HTR.0b013e318268d496; Owens D, 2002, BRIT J PSYCHIAT, V181, P193, DOI 10.1192/bjp.181.3.193; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; Skopp Nancy A, 2012, MSMR, V19, P7; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Weiner J, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-374; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432; WICKENS T. D., 1989, MULTIWAY CONTINGENCY; Wilcox HC, 2009, ARCH GEN PSYCHIAT, V66, P305, DOI 10.1001/archgenpsychiatry.2008.557; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	59	47	47	0	21	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	FEB	2015	105	2					380	387		10.2105/AJPH.2014.301957			8	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	CE6CD	WOS:000351922500046	25033126	Green Published			2022-02-06	
J	Dennis, EL; Jin, Y; Villalon-Reina, JE; Zhan, L; Kernan, CL; Babikian, T; Mink, RB; Babbitt, CJ; Johnson, JL; Giza, CC; Thompson, PM; Asarnow, RF				Dennis, Emily L.; Jin, Yan; Villalon-Reina, Julio E.; Zhan, Liang; Kernan, Claudia L.; Babikian, Talin; Mink, Richard B.; Babbitt, Christopher J.; Johnson, Jeffrey L.; Giza, Christopher C.; Thompson, Paul M.; Asarnow, Robert F.			White matter disruption in moderate/severe pediatric traumatic brain injury: Advanced tract-based analyses	NEUROIMAGE-CLINICAL			English	Article						Diffusion tensor imaging; Traumatic brain injury; Longitudinal; Pediatric; Tractography	DIFFUSION-TENSOR; AXONAL INJURY; CORPUS-CALLOSUM; CELLULAR EDEMA; MRI; MICROSTRUCTURE; ANISOTROPY; CHILDREN	Traumatic brain injury (TBI) is the leading cause of death and disability in children and can lead to a wide range of impairments. Brain imaging methods such as DTI (diffusion tensor imaging) are uniquely sensitive to the white matter(WM) damage that is common in TBI. However, higher-level analyses using tractography are complicated by the damage and decreased FA (fractional anisotropy) characteristic of TBI, which can result in premature tract endings. We used the newly developed autoMATE (automated multi-atlas tract extraction) method to identify differences in WM integrity. 63 pediatric patients aged 8-19 years with moderate/severe TBI were examined with cross sectional scanning at one or two time points after injury: a post-acute assessment 1-5 months post-injury and a chronic assessment 13-19 months post-injury. A battery of cognitive function tests was performed in the same time periods. 56 children were examined in the first phase, 28 TBI patients and 28 healthy controls. In the second phase 34 children were studied, 17 TBI patients and 17 controls (27 participants completed both post-acute and chronic phases). We did not find any significant group differences in the post-acute phase. Chronically, we found extensive group differences, mainly for mean and radial diffusivity (MD and RD). In the chronic phase, we found higher MD and RD across a wide range of WM. Additionally, we found correlations between these WM integrity measures and cognitive deficits. This suggests a distributed pattern of WM disruption that continues over the first year following a TBI in children. (C) 2015 The Authors. Published by Elsevier Inc.	[Dennis, Emily L.; Jin, Yan; Villalon-Reina, Julio E.; Zhan, Liang; Thompson, Paul M.] Univ So Calif, Keck Sch Med, Inst Neuroimaging & Informat, Imaging Genet Ctr, Los Angeles, CA 90033 USA; [Kernan, Claudia L.; Babikian, Talin; Asarnow, Robert F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Mink, Richard B.] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA; [Mink, Richard B.] Los Angeles BioMed Res Inst, Torrance, CA USA; [Babbitt, Christopher J.] Miller Childrens Hosp, Dept Pediat, Long Beach, CA USA; [Johnson, Jeffrey L.] LAC USC Med Ctr, Dept Pediat, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, Div Pediat Neurol, UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Thompson, Paul M.] Univ So Calif, Dept Neurol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Pediat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Psychiat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Radiol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Engn, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90033 USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA		Thompson, PM (corresponding author), Univ So Calif, Keck Sch Med, 2001 N Soto St, Los Angeles, CA 90033 USA.	pthomp@usc.edu	Jin, Yan/N-5037-2016; Thompson, Paul M/C-4194-2018; Dennis, Emily/AAD-5223-2021	Jin, Yan/0000-0001-9392-5552; Thompson, Paul M/0000-0002-4720-8867; Dennis, Emily/0000-0001-7112-4009	NICHDS [R01 HD061504]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EB008432, R01 AG040060, U54 EB020403, R01 NS080655]; UCLA BIRC [NS027544, NS05489]; Child Neurology Foundation; Jonathan Drown Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB008432, P41EB015922, U54EB020403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99NS096116, R01NS080655, R01NS027544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040060] Funding Source: NIH RePORTER	This study was supported by the NICHDS (R01 HD061504). ELD, YJ, JV, LZ, and PT are also supported by NIH grants to PT: R01 EB008432, R01 AG040060, U54 EB020403, and R01 NS080655. CCG is supported by the UCLA BIRC, NS027544, NS05489, Child Neurology Foundation, and the Jonathan Drown Foundation. Scanning was supported by the Staglin IMHRO Center for Cognitive Neuroscience. We gratefully acknowledge the contributions of Alma Martinez and Alma Ramirez in assisting with participant recruitment and study coordination. Finally, the authors thank the participants and their families for contributing their time to this study.	Aganj I, 2011, MED IMAGE ANAL, V15, P414, DOI 10.1016/j.media.2011.01.003; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Catani M., 2012, ATLAS HUMAN BRAIN CO; Catani M, 2007, P NATL ACAD SCI USA, V104, P17163, DOI 10.1073/pnas.0702116104; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Delis DC., 2001, DELIS KAPLAN EXECUTI; Delis DC., 1994, CALIFORNIA VERBAL LE; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Hoogman M., 2014, BRAIN STRUCTURE ADHD; Hua X, 2008, NEUROIMAGE, V43, P458, DOI 10.1016/j.neuroimage.2008.07.013; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jin Y, 2014, NEUROIMAGE, V100, P75, DOI 10.1016/j.neuroimage.2014.04.048; Jin Y, 2013, I S BIOMED IMAGING, P512, DOI 10.1109/isbi.2013.6556524; Jin Yan, 2012, Multimodal Brain Image Anal (2012), V7509, P147, DOI 10.1007/978-3-642-33530-3_12; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinnunen K. M., 2010, BRAIN; Kochunov P, 2012, NEUROBIOL AGING, V33, P9, DOI 10.1016/j.neurobiolaging.2010.01.014; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Prasad G., 2011, ATLAS BASED FIBER CL, P1; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Thomason ME, 2011, ANNU REV CLIN PSYCHO, V7, P63, DOI 10.1146/annurev-clinpsy-032210-104507; Wechsler D, 2003, WECHSLER INTELLIGENC; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	50	47	48	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	7						493	505		10.1016/j.nicl.2015.02.002			13	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI0GE	WOS:000373172600054	25737958	gold, Green Submitted, Green Published			2022-02-06	
J	Koski, L; Kolivakis, T; Yu, C; Chen, JK; Delaney, S; Ptito, A				Koski, Lisa; Kolivakis, Theodore; Yu, Camilla; Chen, Jen-Kai; Delaney, Scott; Ptito, Alain			Noninvasive Brain Stimulation for Persistent Postconcussion Symptoms in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						rTMS; brain trauma; head injury; concussion; fMRI	TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT-RESISTANT DEPRESSION; CONCUSSION; FMRI; MIGRAINE; CORTEX; RTMS	Mild traumatic brain injury (mTBI) is typically followed by various postconcussive symptoms (PCS), including headache, depression, and cognitive deficits. In 15-25% of cases, PCS persists beyond the usual 3-month recovery period, interfering with activities of daily living and responding poorly to pharmacotherapy. We tested the safety, tolerability, and efficacy of repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) for alleviating PCS. Fifteen eligible patients with mTBI and PCS>3 months postinjury consented to 20 sessions of rTMS (20x5-sec trains; 10 Hz at 110% threshold), with clinical and functional magnetic resonance imaging (fMRI) assessments before and after intervention and clinical assessment at 3-month follow-up. Primary outcomes were tolerability, safety, and efficacy, as measured with the PCS Scale. Secondary outcomes included the Cognitive Symptoms Questionnaire, neuropsychological test performance, and working memory task-associated activity as assessed with fMRI. Twelve patients completed all sessions. Three withdrew because of worsening symptoms or for an unrelated event. Stimulation intensity was increased gradually across sessions, and all subjects tolerated the protocol by the sixth session. Commonly reported side effects among completers were increased headache (n=3) and greater sleep disturbance (n=3). Participants also reported positive outcomes such as less sleep disturbance (n=3), and better mental focus (n=3). On average, PCS scores declined by 14.6 points (p=0.009) and fMRI task-related activation peaks in the DLPFC increased after rTMS. rTMS is safe, tolerated by most patients with mTBI, and associated with both a reduction in severity of PCS and an increase in task-related activations in DLPFC. Assessment of this intervention in a randomized, control trial is warranted.	[Koski, Lisa] McGill Univ, Dept Psychol, MUHC, Dept Neurol Neurosurg, Montreal, PQ, Canada; [Koski, Lisa] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Koski, Lisa] McGill Univ, MUHC, Res Inst, Montreal, PQ, Canada; [Kolivakis, Theodore; Ptito, Alain] McGill Univ, Dept Neurol Neurosurg, Montreal, PQ, Canada; [Kolivakis, Theodore] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Yu, Camilla] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [Chen, Jen-Kai] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Delaney, Scott] McGill Univ, McGill Univ Hlth Ctr, Dept Emergency Med, Montreal, PQ, Canada; [Delaney, Scott] McGill Univ, McGill Sport Med Clin, Montreal, PQ, Canada; [Ptito, Alain] McGill Univ, McGill Univ Hlth Ctr, Dept Psychol, Montreal, PQ, Canada		Koski, L (corresponding author), Allan Mem Inst Psychiat, P2-142,1025 Pine Ave West, Montreal, PQ H3A 1A1, Canada.	lisa.koski@mcgill.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); AstraZenecaAstraZeneca; LundbeckLundbeck Corporation; Sunovion; Eli LillyEli Lilly; Janssen-Ortho; GlaxoSmithKlineGlaxoSmithKline; Bristol-Myers SquibbBristol-Myers Squibb; CIHRCanadian Institutes of Health Research (CIHR)	Dr. Koski reports grants from the Canadian Institutes of Health Research (CIHR) and nonfinancial support from the MS Society of Canada during the conduct of the study. Dr. Kolivakis reports personal fees and sat on the advisory board of AstraZeneca, personal fees and sat on the advisory board of Lundbeck, personal fees and sat on the advisory board of Sunovion, personal fees and sat on the advisory board of Eli Lilly, personal fees and sat on the advisory board of Janssen-Ortho, personal fees and sat on the advisory board of GlaxoSmithKline, and personal fees and sat on the advisory board of Bristol-Myers Squibb, outside the submitted work. Dr. Ptito reports grants from the CIHR.	Angelakis E, 2014, ARCH PHYS MED REHAB, V95, P283, DOI 10.1016/j.apmr.2013.09.002; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borckardt JJ, 2009, PAIN MED, V10, P840, DOI 10.1111/j.1526-4637.2009.00657.x; Bottari C., 2008, BRAIN INJ S1, V22, P1; Bottari C, 2009, NEUROPSYCHOL REHABIL, V19, P177, DOI 10.1080/09602010802188435; Bottari C, 2009, BRAIN INJURY, V23, P322, DOI 10.1080/02699050902788436; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Cosentino G, 2010, NEUROCASE, V16, P267, DOI 10.1080/13554790903456191; Daskalakis ZJ, 2008, CAN J PSYCHIAT, V53, P555, DOI 10.1177/070674370805300902; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Epstein CM, 2007, CLIN NEUROPHYSIOL, V118, P2189, DOI 10.1016/j.clinph.2007.07.010; Fitzgerald PB, 2011, J ECT, V27, P38, DOI 10.1097/YCT.0b013e3181eb30c6; Friston KJ, 1998, NEUROIMAGE, V7, P30, DOI 10.1006/nimg.1997.0306; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Jorge RE, 2004, BIOL PSYCHIAT, V55, P398, DOI 10.1016/j.biopsych.2003.08.017; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreuzer PM, 2013, J HEAD TRAUMA REHAB, V28, P386, DOI 10.1097/HTR.0b013e318254736e; Lam RW, 2008, CAN J PSYCHIAT, V53, P621, DOI 10.1177/070674370805300909; Leung A, 2009, J PAIN, V10, P1205, DOI 10.1016/j.jpain.2009.03.010; Loo CK, 2008, INT J NEUROPSYCHOPH, V11, P131, DOI 10.1017/S1461145707007717; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Misra UK, 2013, J NEUROL, V260, P2793, DOI 10.1007/s00415-013-7072-2; Nahmias F, 2009, PAIN, V147, P224, DOI 10.1016/j.pain.2009.09.016; O'Reardon JP, 2007, CNS SPECTRUMS, V12, P921, DOI 10.1017/S1092852900015716; Passard A, 2007, BRAIN, V130, P2661, DOI 10.1093/brain/awm189; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rose EJ, 2006, NEUROIMAGE, V29, P203, DOI 10.1016/j.neuroimage.2005.07.002; Schutter DJLG, 2009, PSYCHOL MED, V39, P65, DOI 10.1017/S0033291708003462; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Worsley KJ, 2005, NEUROIMAGE, V26, P635, DOI 10.1016/j.neuroimage.2005.02.007; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933	39	47	48	0	35	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2015	32	1					38	44		10.1089/neu.2014.3449			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AX4JX	WOS:000346900100006	24955920				2022-02-06	
J	Saunders, GH; Frederick, MT; Arnold, M; Silverman, S; Chisolm, TH; Myers, P				Saunders, Gabrielle H.; Frederick, Melissa T.; Arnold, Michelle; Silverman, ShienPei; Chisolm, Theresa H.; Myers, Paula			Auditory difficulties in blast-exposed Veterans with clinically normal hearing	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory processing disorder; blast injuries; central auditory dysfunction; combat disorders; hearing; hearing loss; mild traumatic brain injury; rehabilitation; traumatic brain injury; Veterans; Veterans health	TRAUMATIC BRAIN-INJURY; IN-NOISE TEST; TEST-PERFORMANCE; GAP DETECTION; MEMORY SPAN; SPEECH; DYSFUNCTION; AGE; FREQUENCY; CHANNEL	Vast numbers of blast-injured Operation Iraqi Freedom/Operation Enduring Freedom/Operation New Dawn personnel report postconcussive symptoms that include headache, dizziness, poor memory, and difficulty concentrating. In addition, many report hearing problems, such as difficulty understanding speech in noise, yet have no measureable peripheral auditory deficits. In this article, self-report and performance-based measures were used to assess 99 blast-exposed Veterans. All participants reported auditory problems in difficult listening situations but had clinically normal hearing. Participants' scores on self-report questionnaires of auditory difficulties were more similar to scores of older individuals with hearing impairment than to those of younger individuals with normal hearing. Participants showed deficits relative to published normative data on a number of performance-based tests that have demonstrated sensitivity to auditory processing deficits. There were several measures on which more than the expected number of participants (15.9%) performed one or more standard deviations below the mean. These were assessments of speech understanding in noise, binaural processing, temporal resolution, and speech segregation. Performance was not universally poor, with approximately 53% of participants performing abnormally on between 3 and 6 of the 10 measures. We concluded that participants exhibited task-specific deficits that add to the evidence suggesting that blast injury results in damage to the central auditory system.	[Saunders, Gabrielle H.; Frederick, Melissa T.; Silverman, ShienPei] Dept Vet Affairs Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA; [Saunders, Gabrielle H.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA; [Arnold, Michelle; Chisolm, Theresa H.] Univ S Florida, Dept Commun Sci & Disorders, Tampa, FL 33620 USA; [Arnold, Michelle; Myers, Paula] James A Haley Vet Hosp, Tampa, FL USA		Saunders, GH (corresponding author), VA Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	gabrielle.saunders@va.gov	Saunders, Gabrielle/V-2288-2019	Saunders, Gabrielle/0000-0002-9997-0845	Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development [C7054R]; Veterans AffairsUS Department of Veterans Affairs [I01RX000209] Funding Source: NIH RePORTER	This material was based on work supported by the Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development (grant C7054R).	American Speech-Language-Hearing Association, 2005, GUID MAN PUR TON THR; [Anonymous], 1969, IEEE T ACOUST SPEECH, VAU17, P225; [Anonymous], 2014, POSTD HEALTHC CHALL; Banh J, 2012, J AM ACAD AUDIOL, V23, P81, DOI 10.3766/jaaa.23.2.2; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Brown DK, 2010, J AM ACAD AUDIOL, V21, P629, DOI 10.3766/jaaa.21.10.3; Cameron S, 2006, J AM ACAD AUDIOL, V17, P306, DOI 10.3766/jaaa.17.5.2; Cameron S, 2009, J AM ACAD AUDIOL, V20, P128, DOI 10.3766/jaaa.20.2.6; Chan RK, 2012, J TRAUMA ACUTE CARE, V73, pS453, DOI 10.1097/TA.0b013e3182754868; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fischer H., 2014, GUIDE US MILITARY CA; Formby C, 1998, J ACOUST SOC AM, V103, P3554, DOI 10.1121/1.423084; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Gatehouse S, 2004, INT J AUDIOL, V43, P85, DOI 10.1080/14992020400050014; Golden CJ., 2002, STROOP COLOR WORD TE; Grose JH, 2001, J ACOUST SOC AM, V109, P1587, DOI 10.1121/1.1354983; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; House Ear Institute, 2001, HINT WIND 6 1 US GUI; JERGER J, 1984, ARCH OTOLARYNGOL, V110, P290; Katz J., 1998, SSW TEST MANUAL, Vfifth; Killion MC, 2004, J ACOUST SOC AM, V116, P2395, DOI 10.1121/1.1784440; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lister JJ, 2011, INT J AUDIOL, V50, P211, DOI 10.3109/14992027.2010.526967; Lister Jennifer J, 2006, Am J Audiol, V15, P133, DOI 10.1044/1059-0889(2006/017); Lister JJ, 2005, J SPEECH LANG HEAR R, V48, P482, DOI 10.1044/1092-4388(2005/033); Lister JJ, 2000, EAR HEARING, V21, P141, DOI 10.1097/00003446-200004000-00008; Macera CA, 2012, J REHABIL RES DEV, V49, P1197, DOI 10.1682/JRRD.2011.07.0131; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; MATHER M, 2001, EXAMINERS MANUAL WOO; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Musiek FE, 2005, EAR HEARING, V26, P608, DOI 10.1097/01.aud.0000188069.80699.41; MUSIEK FE, 1983, EAR HEARING, V4, P79, DOI 10.1097/00003446-198303000-00002; MUSIEK FE, 1987, AUDIOLOGY, V26, P79; NILSSON M, 1994, J ACOUST SOC AM, V95, P1085, DOI 10.1121/1.408469; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Psychological Corporation, 1997, WAIS 3 WESCHL AD INT; Reynolds CR, 1997, ARCH CLIN NEUROPSYCH, V12, P29, DOI 10.1016/S0887-6177(96)00015-7; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Saunders GH, 2012, J REHABIL RES DEV, V49, P1043, DOI 10.1682/JRRD.2010.08.0157; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; U.S. Institute of Medicine, 2014, GULF WAR HLTH LONG T; Vander Werff KR, 2012, PERSPECTIVES HEARING, V16, P3, DOI DOI 10.1044/HHD16.13; Vaughan N, 2006, J AM ACAD AUDIOL, V17, P506, DOI 10.3766/jaaa.17.7.6; Wilde NJ, 2004, J CLIN EXP NEUROPSYC, V26, P539, DOI 10.1080/13803390490496605; Wilson Richard H, 2003, J Am Acad Audiol, V14, P1, DOI 10.3766/jaaa.14.1.2; Zendel BR, 2012, PSYCHOL AGING, V27, P410, DOI 10.1037/a0024816	56	47	48	0	9	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2015	52	3					343	359		10.1682/JRRD.2014.11.0275			17	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	CN0NR	WOS:000358111100009	26237266	Bronze			2022-02-06	
J	Baugh, CM; Kroshus, E; Bourlas, AP; Perry, KI				Baugh, Christine M.; Kroshus, Emily; Bourlas, Alexandra P.; Perry, Kaitlyn I.			Requiring Athletes to Acknowledge Receipt of Concussion-Related Information and Responsibility to Report Symptoms: A Study of the Prevalence, Variation, and Possible Improvements	JOURNAL OF LAW MEDICINE & ETHICS			English	Article							TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; HIGH-SCHOOL FOOTBALL; RECURRENT CONCUSSION; ASSOCIATION; EPIDEMIOLOGY; IMPAIRMENT; EDUCATION; COLLEGE; DISEASE	State concussion laws and sport-league policies are important tools for protecting public health, but also present implementation challenges. Both state laws and league policies often require athletes provide written acknowledgement of having received concussion-related information and/or of their responsibility to report concussion-related symptoms. This paper examines these requirements in two ways: an analysis of the variation in state laws and sport-league policies and a study of their effects in a cohort of collegiate football players.	[Baugh, Christine M.; Bourlas, Alexandra P.] Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA; [Baugh, Christine M.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA; [Bourlas, Alexandra P.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA; [Perry, Kaitlyn I.] Univ Kansas, Lawrence, KS 66045 USA		Baugh, CM (corresponding author), Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA.		Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338			Allen E, 2013, BOSTON GLOBE; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Bazarian J. J., 2013, MAGNETIC RESONANCE I, V30, P171; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Horton D, 2003, UCLA LAW REV, V51, P339; Kettle KL, 2011, J CONSUM RES, V38, P474, DOI 10.1086/659753; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Krauss SE, 2005, QUAL REP, V10, P758; Kroshus E., 2014, CONCUSSION IN PRESS; Kroshus E., 2014, NORMS ATHLE IN PRESS; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCabe DL, 2002, RES HIGH EDUC, V43, P357, DOI 10.1023/A:1014893102151; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; NCAA, 2013, 2013 2014 NCAA SPORT, P56; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; ROGERS RW, 1988, J APPL BEHAV ANAL, V21, P263, DOI 10.1901/jaba.1988.21-263; Saldana J, 2012, CODING MANUAL QUALIT; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stevens MM, 2002, PEDIATRICS, V109, P490, DOI 10.1542/peds.109.3.490; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; White JS, 2013, AM J PREV MED, V45, P533, DOI 10.1016/j.amepre.2013.06.020; Williams BR, 2005, TOP GERIATR REHABIL, V21, P332	51	47	47	1	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1105	1748-720X		J LAW MED ETHICS	J. Law Med. Ethics	FAL	2014	42	3			SI		297	313		10.1111/jlme.12147			17	Ethics; Law; Medical Ethics; Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	AQ4ED	WOS:000342745000005	25264088				2022-02-06	
J	Jacobsen, A; Nielsen, TH; Nilsson, O; Schalen, W; Nordstrom, CH				Jacobsen, A.; Nielsen, T. H.; Nilsson, O.; Schalen, W.; Nordstrom, C. H.			Bedside diagnosis of mitochondrial dysfunction in aneurysmal subarachnoid hemorrhage	ACTA NEUROLOGICA SCANDINAVICA			English	Article						cerebral energy metabolism; microdialysis; mitochondrial dysfunction; ischemia; lactate; pyruvate; subarachnoid hemorrhage	CEREBRAL ENERGY-METABOLISM; TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; INTRACEREBRAL MICRODIALYSIS; GLYCOLYTIC METABOLITES; PERFUSION-PRESSURE; AMINO-ACIDS; ISCHEMIA; VASOSPASM; RATS	Objectives - Aneurysmal subarachnoid hemorrhage (SAH) is frequently associated with delayed neurological deterioration (DND). Several studies have shown that DND is not always related to vasospasm and ischemia. Experimental and clinical studies have recently documented that it is possible to diagnose and separate cerebral ischemia and mitochondrial dysfunction bedside. The study explores whether cerebral biochemical variables in SAH patients most frequently exhibit a pattern indicating ischemia or mitochondrial dysfunction. Methods - In 55 patients with severe SAH, intracerebral microdialysis was performed during neurocritical care with bedside analysis and display of glucose, pyruvate, lactate, glutamate, and glycerol. The biochemical patterns observed were compared to those previously described in animal studies of induced mitochondrial dysfunction as well as the pattern obtained in patients with recirculated cerebral infarcts. Results - In 29 patients, the biochemical pattern indicated mitochondrial dysfunction while 10 patients showed a pattern of cerebral ischemia, six of which also exhibited periods of mitochondrial dysfunction. Mitochondrial dysfunction was observed during 5162 h. An ischemic pattern was obtained during 688 h. Four of the patients (40%) with biochemical signs of ischemia died at the neurosurgical department as compared with three patients (10%) in the group of mitochondrial dysfunction. Conclusions - The study documents that mitochondrial dysfunction is a common cause of disturbed cerebral energy metabolism in patients with SAH. Mitochondrial dysfunction may increase tissue sensitivity to secondary adverse events such as vasospasm and decreased cerebral blood flow. The separation of ischemia and mitochondrial dysfunction bedside by utilizing microdialysis offers a possibility to evaluate new therapies.	[Jacobsen, A.; Nielsen, T. H.; Nordstrom, C. H.] Odense Univ Hosp, Dept Neurosurg, DK-5000 Odense, Denmark; [Nilsson, O.; Schalen, W.] Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden		Nordstrom, CH (corresponding author), Persikevagen 77, SE-22355 Lund, Sweden.	carl-henrik.nordstrom@med.lu.se	Nielsen, Troels Halfeld/G-3456-2015	Nielsen, Troels Halfeld/0000-0002-3943-8128	Lund University Hospital; Odense University Hospital; University of Southern Denmark	We thank Katarina Nielsen, Department of Neurosurgery, Lund University Hospital, for help with the microdialysis equipment and biochemical analyses. The study was supported by grants from Lund University Hospital, Odense University Hospital, and University of Southern Denmark.	Akdemir G, 2005, NEUROL RES, V27, P827, DOI 10.1179/016164105X63610; Amer-Wahlin I, 2010, J MATERN-FETAL NEO M, V23, P158, DOI 10.3109/14767050903067360; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Etminan N, 2011, J CEREBR BLOOD F MET, V31, P1443, DOI 10.1038/jcbfm.2011.7; Gardenfors A, 2002, ACTA NEUROCHIR, V144, P601, DOI 10.1007/s00701-002-0954-1; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hillman J, 2002, J NEUROSURG, V97, P771, DOI 10.3171/jns.2002.97.4.0771; Hwang JH, 2010, BRAIN RES, V1359, P208, DOI 10.1016/j.brainres.2010.08.047; JENNETT B, 1977, LANCET, V1, P878; Kronvall E, 2009, J NEUROSURG, V110, P58, DOI 10.3171/2008.7.JNS08178; MACMILLAN VH, 1989, J CEREBR BLOOD F MET, V9, P156, DOI 10.1038/jcbfm.1989.23; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; NIELSEN TH, 2013, NEUROCRIT CARE, DOI [10.1007/6s12028-013-9875-5, DOI 10.1007/6S12028-013-9875-5]; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schmidt JM, 2011, STROKE, V42, P1351, DOI 10.1161/STROKEAHA.110.596874; Siesj? BK., 1978, BRAIN ENERGY METABOL; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Washington CW, 2011, NEUROCRIT CARE, V15, P312, DOI 10.1007/s12028-011-9594-8	31	47	47	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	SEP	2014	130	3					156	163		10.1111/ane.12258			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN4OX	WOS:000340568500003	24796605				2022-02-06	
J	Kurowski, B; Pomerantz, WJ; Schaiper, C; Gittelman, MA				Kurowski, Brad; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.			Factors that influence concussion knowledge and self-reported attitudes in high school athletes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Concussion; sports; adolescents; knowledge	EPIDEMIOLOGY STROBE STATEMENT; SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; IMPACT; INJURY; BRAIN; YOUNG; INTERVENTION; GUIDELINES	BACKGROUND: Many organizations and health care providers support educating high school (HS) athletes about concussions to improve their attitudes and behaviors about reporting. The objectives of this study were to determine if previous education, sport played, and individual factors were associated with better knowledge about concussion and to determine if more knowledge was associated with improved self-reported attitudes toward reporting concussions among HS athletes. METHODS: We conducted a survey of HS athletes aged 13 years to 18 years from two large, urban HSs. Players were recruited from selected seasonal (fall and winter) as well as men and women's sports. During preseason, each participant was given a survey asking about his or her previous education, current knowledge, and self-reported attitudes and behaviors about reporting concussions. Bivariate and multivariate linear regression was used to evaluate the association of age, sex, sport, and previous concussion education with knowledge and self-reported attitudes and behaviors about reporting concussions. RESULTS: Surveys were completed by 496 athletes. The median age was 15 years, and 384 (77.4%) were male. A total of 212 (42.7%) participated in football, 123 (24.8%) in soccer, 89 (17.9%) in basketball, and 72 (14.5%) in wrestling. One hundred sixteen (23.4%) reported a history of concussion. Improved knowledge regarding concussions was not associated with improved self-reported behaviors (p = 0.63) in bivariate regression models. The multivariate model demonstrated that older age (p = 0.01) and female sex (p = 0.03) were associated with better knowledge. Younger age (p = 0.01), female sex (p = 0.0002), and soccer participation (p = 0.02) were associated with better self-reported behaviors around reporting concussions. CONCLUSION: Previous education on concussions was less predictive of knowledge about concussions when controlling for other factors such as sport and sex. Younger age, female sex, and soccer participation were more likely to be associated with better self-reported behaviors. Future studies need to focus on the development of interventions to improve concussion-specific knowledge and behaviors. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Kurowski, Brad] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp,Div Phys Med & Rehabil, Cincinnati, OH USA; [Kurowski, Brad; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.] Cincinnati Childrens Hosp, Comprehens Childrens Injury Ctr, Cincinnati, OH USA; [Pomerantz, Wendy J.; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Dept Pediat, Div Emergency Med,Cincinnati Childrens Hosp, Cincinnati, OH USA		Kurowski, B (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org			NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001425] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [L40 HD066480, K23 HD074683, K12 HD001097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683, K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER		[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Bramley HP, 2011, CLIN PEDIAT PHILA, V51, P332; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; CHAFFEE SH, 1986, COMMUN RES, V13, P373, DOI 10.1177/009365086013003006; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Fisher JD, 1996, HEALTH PSYCHOL, V15, P114, DOI 10.1037/0278-6133.15.2.114; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MERMELSTEIN RJ, 1992, HEALTH PSYCHOL, V11, P371, DOI 10.1037/0278-6133.11.6.371; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Moreno MA, 2012, ARCH PEDIAT ADOL MED, V166, P296, DOI [10.1001/archpediatrics.2012.8, 10.1001/archpediatrics.2012.79]; Moreno MA, 2011, ARCH PEDIAT ADOL MED, V165, P376, DOI 10.1001/archpediatrics.2011.31; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1371/journal.pmed.0040297, 10.1371/journal.pmed.0040296, 10.1157/13119325, 10.1016/S0140-6736(07)61602-X]; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986	34	47	47	1	48	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2014	77			1			S12	S17		10.1097/TA.0000000000000316			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	AO2BK	WOS:000341120300004	25153048	Green Accepted			2022-02-06	
J	Huang, YY; Nagata, K; Tedford, CE; Hamblin, MR				Huang, Ying-Ying; Nagata, Kazuya; Tedford, Clark E.; Hamblin, Michael R.			Low-level laser therapy (810 nm) protects primary cortical neurons against excitotoxicity in vitro	JOURNAL OF BIOPHOTONICS			English	Article						low-level laser therapy; cultured cortical neurons; excitotoxicity; reactive oxygen species; mitochondrial membrane potential glutamate. NMDA; kainic acid	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; TERM NEUROLOGICAL DEFICITS; NITRIC-OXIDE; CELL-DEATH; CYTOCHROME-C; HIPPOCAMPAL-NEURONS; ISCHEMIC-STROKE; INFRARED LIGHT; SPINAL-CORD	Excitotoxicity describes a pathogenic process whereby death of neurons releases large amounts of the excitatory neurotransmitter glutamate, which then proceeds to activate a set of glutamatergic receptors on neighboring neurons (glutamate, N-methyl-D-aspartate (NMDA), and kainate), opening ion channels leading to an influx of calcium ions producing mitochondrial dysfunction and cell death. Excitotoxicity contributes to brain damage after stroke, traumatic brain injury, and neurodegenerative diseases, and is also involved in spinal cord injury. We tested whether low level laser (light) therapy (LLLT) at 810 nm could protect primary murine cultured cortical neurons against excitotoxicity in vitro produced by addition of glutamate, NMDA or kainate. Although the prevention of cell death was modest but significant, LLLT (3 J/cm(2) delivered at 25 mW/cm(2) over 2 min) gave highly significant benefits in increasing ATP, raising mitochondrial membrane potential, reducing intracellular calcium concentrations, reducing oxidative stress and reducing nitric oxide. The action of LLLT in abrogating excitotoxicity may play a role in explaining its beneficial effects in diverse central nervous system pathologies.	[Huang, Ying-Ying; Nagata, Kazuya; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Dept Pathol, Nanning, Guangxi, Peoples R China; [Nagata, Kazuya] Univ Tokyo, Grad Sch Med, Tokyo 1138654, Japan; [Tedford, Clark E.] Photothera Inc, Carlsbad, CA USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, yingying/J-7329-2012; Hamblin, Michael R/H-2758-2019; Huang, Yingying/G-3153-2011	Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Huang, Yingying/0000-0003-3066-6981	Photothera Inc; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by sponsored research funding from Photothera Inc and by NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research (FA9950-04-1-0079).	Albertini R, 2007, J PHOTOCH PHOTOBIO B, V89, P50, DOI 10.1016/j.jphotobiol.2007.08.005; Almeida A, 1999, BRAIN RES, V816, P580, DOI 10.1016/S0006-8993(98)01240-2; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Antunes F, 2004, P NATL ACAD SCI USA, V101, P16774, DOI 10.1073/pnas.0405368101; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Calabrese V, 2009, ANTIOXID REDOX SIGN, V11, P2717, DOI [10.1089/ars.2009.2721, 10.1089/ARS.2009.2721]; COOK TM, 1986, NEUROSCIENCE, V18, P79, DOI 10.1016/0306-4522(86)90180-6; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; DUNN KW, 1994, FASEB J, V8, P573, DOI 10.1096/fasebj.8.9.8005385; Dutta R, 2011, PROG NEUROBIOL, V93, P1, DOI 10.1016/j.pneurobio.2010.09.005; Codocedo JF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057626; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y, 2010, KOREAN J PHYSIOL PHA, V14, P21, DOI 10.4196/kjpp.2010.14.1.21; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Huang Y Y, 2012, J BIOPHOTONICS; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011-1344(89)80088-0; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim HJ, 2005, NEUROPHARMACOLOGY, V49, P265, DOI 10.1016/j.neuropharm.2005.03.007; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3; Marks JD, 2005, J NEUROSCI, V25, P6561, DOI 10.1523/JNEUROSCI.1450-05.2005; McGeer E G, 1981, Int Rev Neurobiol, V22, P173, DOI 10.1016/S0074-7742(08)60293-7; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Nakamura T, 2010, MITOCHONDRION, V10, P573, DOI 10.1016/j.mito.2010.04.007; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Palmada Monica, 1998, Frontiers in Bioscience, V3, pD701; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Rochkind S, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E8; Schinder AF, 1996, J NEUROSCI, V16, P6125; Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Stavrovskaya IG, 2005, FREE RADICAL BIO MED, V38, P687, DOI 10.1016/j.freeradbiomed.2004.11.032; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; White RJ, 1996, J NEUROSCI, V16, P5688; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729	52	47	48	0	20	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	AUG	2014	7	8					656	664		10.1002/jbio.201300125			9	Biochemical Research Methods; Biophysics; Optics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Optics	AO9VY	WOS:000341708600011	24127337	Green Accepted			2022-02-06	
J	Jadhav, SP; Kamath, SP; Choolani, M; Lu, J; Dheen, ST				Jadhav, Shweta P.; Kamath, Sandhya P.; Choolani, Mahesh; Lu, Jia; Dheen, S. Thameem			microRNA-200b modulates microglia-mediated neuroinflammation via the cJun/MAPK pathway	JOURNAL OF NEUROCHEMISTRY			English	Article						c-Jun; cJun-N terminal kinase; microglia; miRNA-200b; neuroinflammation	KINASE SIGNALING CASCADES; NEURONAL CELL-DEATH; NITRIC-OXIDE; MAP KINASE; PROINFLAMMATORY CYTOKINES; MESENCHYMAL TRANSITION; ACTIVATED MICROGLIA; PARKINSONS-DISEASE; PROTEIN-KINASE; MIR-200 FAMILY	Chronic activation of microglia, the macrophages of the CNS, has been shown to enhance neuronal damage because of excessive release of proinflammatory cytokines and neurotoxic molecules in a number of neurodegenerative diseases. Recent reports showed altered microRNA (miRNA) expression in immune-mediated pathologies, thus suggesting that miRNAs modulate expression of genes involving immune responses. This study demonstrates that miRNA-200b is expressed in microglia and modulates inflammatory response of microglia by regulating mitogen-activated protein kinase pathway. miRNA-200b expression was found to be down-regulated in activated microglia in vivo (traumatic brain injury rat model) and in vitro. A luciferase assay and loss- and gain-of-function studies revealed c-Jun, the transcription factor of cJun-N terminal kinase (JNK) mitogen-activated protein kinase pathway to be the target of miR-200b. Knockdown of miR-200b in microglia increased JNK activity along with an increase in pro-inflammatory cytokines, inducible nitric oxide synthase expression and nitric oxide (NO) production. Conversely, over-expression of miRNA-200b in microglia resulted in a decrease in JNK activity, inducible nitric oxide synthase expression, NO production and migratory potential of activated microglia. Furthermore, miR-200b inhibition resulted in increased neuronal apoptosis after treatment of neuronal cells with conditioned medium obtained from microglial culture. Taken together, these results indicate that miRNA-200b modulates microglial inflammatory process including cytokine secretion, NO production, migration and neuronal survival.	[Jadhav, Shweta P.; Kamath, Sandhya P.; Dheen, S. Thameem] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Choolani, Mahesh] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynecol, Singapore 117597, Singapore; [Lu, Jia] DSO Natl Labs, Def Med & Environm Res Inst, Singapore, Singapore		Dheen, ST (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Blk MD10,4 Med Dr, Singapore 117597, Singapore.	antstd@nus.edu.sg	Dheen, S. Thameem/AAU-8627-2020	Dheen, S. Thameem/0000-0001-9600-6789	ASTAR-MINDEF-NUS [09/1/50/19/621, R-181-000-141-305]; NMRC, SingaporeNational Medical Research Council, Singapore [NMRC/EDG/1039/2011, R-181-000-139-275]	This research was supported by the joint ASTAR-MINDEF-NUS grant (09/1/50/19/621 and R-181-000-141-305) and NMRC Exploratory/Developmental Grant (NMRC/EDG/1039/2011; R-181-000-139-275), Singapore. The authors declare no conflict of interest.	Babcock AA, 2003, J NEUROSCI, V23, P7922; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Brecht S, 2005, EUR J NEUROSCI, V21, P363, DOI 10.1111/j.1460-9568.2005.03857.x; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHAO CC, 1992, J IMMUNOL, V149, P2736; Ciesielski-Treska J, 2004, GLIA, V46, P101, DOI 10.1002/glia.10363; Colombo A, 2007, CELL DEATH DIFFER, V14, P1845, DOI 10.1038/sj.cdd.4402202; Deng ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036739; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Fiore R, 2008, BBA-GENE REGUL MECH, V1779, P471, DOI 10.1016/j.bbagrm.2007.12.006; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hashimoto Y, 2003, J NEUROCHEM, V84, P864, DOI 10.1046/j.1471-4159.2003.01585.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Juhila J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021495; Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mehan S, 2011, J MOL NEUROSCI, V43, P376, DOI 10.1007/s12031-010-9454-6; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mizuno T., 2012, INT J ALZHEIMERS DIS, V2012, P1; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Nayak D, 2010, NEUROSCIENCE, V166, P132, DOI 10.1016/j.neuroscience.2009.12.020; Ouyang YB, 2012, NEUROBIOL DIS, V45, P555, DOI 10.1016/j.nbd.2011.09.012; Park JY, 2008, GLIA, V56, P1215, DOI 10.1002/glia.20691; Phani Sudarshan, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS207, DOI 10.1016/S1353-8020(11)70064-5; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Qi JN, 2012, FEBS LETT, V586, P1201, DOI 10.1016/j.febslet.2012.03.011; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Tuppo EE, 2005, INT J BIOCHEM CELL B, V37, P289, DOI 10.1016/j.biocel.2004.07.009; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wendlandt EB, 2012, INNATE IMMUN-LONDON, V18, P846, DOI 10.1177/1753425912443903; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404	47	47	50	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2014	130	3					388	401		10.1111/jnc.12731			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AL9RU	WOS:000339479200006	24749688	Bronze			2022-02-06	
J	Pietrzak, E; Pullman, S; McGuire, A				Pietrzak, Eva; Pullman, Stephen; McGuire, Annabel			Using Virtual Reality and Videogames for Traumatic Brain Injury Rehabilitation: A Structured Literature Review	GAMES FOR HEALTH JOURNAL			English	Article							GAME-BASED EXERCISES; BALANCE REHABILITATION; STROKE REHABILITATION; PEOPLE; PROGRAMS	Objective: This article reviews the available literature about the use of novel methods of rehabilitation using virtual reality interventions for people living with posttraumatic brain injuries. Materials and Methods: The MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases were searched using the terms "virtual reality'' OR "video games'' AND "traumatic brain injury.'' Included studies investigated therapeutic use of virtual reality in adults with a brain trauma resulting from acquired closed head injury, reported outcomes that included measures of motor or cognitive functionality, and were published in a peer-reviewed journal written in English. Results: Eighteen articles fulfilled inclusion criteria. Eight were case studies, five studies had a quasi-experimental design with a pre-post comparison, and five were pilot randomized control trials or comparative studies. The virtual reality systems used were commercial or custom designed for the study and ranged from expensive, fully immersive systems to cheap online games or videogames. In before-after comparisons, improvements in balance were seen in four case studies and two small randomized control trials. Between-group comparisons in these randomized control trials showed no difference between virtual reality and traditional therapy. Post-training improvements were also seen for upper extremity functions (five small studies) and for various cognitive function measures (four case studies and one pilot randomized control trial). Attitudes of participants toward virtual reality interventions was more positive than for traditional therapy (three studies). Conclusions: The evidence that the use of virtual reality in rehabilitation of traumatic brain injury improves motor and cognitive functionality is currently very limited. However, this approach has the potential to provide alternative, possibly more affordable and available rehabilitation therapy for traumatic brain injury in settings where access to therapy is limited by geographical or financial constraints.	[Pietrzak, Eva; Pullman, Stephen; McGuire, Annabel] Univ Queensland, Ctr Australian Mil & Vet Hlth, Sch Populat Hlth, Herston, Qld 4006, Australia		McGuire, A (corresponding author), Univ Queensland, Ctr Australian Mil & Vet Hlth, Sch Populat Hlth, Ground Floor,Publ Hlth Bldg,Herston Rd, Herston, Qld 4006, Australia.	a.mcguire@uq.edu.au			E-Health Research Unit, UQ Node, Centre for Australian Military and Veterans' Health	This review was undertaken on behalf of and funded by the E-Health Research Unit, UQ Node, Centre for Australian Military and Veterans' Health.	Almeida TLT, 2012, ACTA FISIATR, V19, P130; Baptista A, 2011, INT J DISABIL HUM DE, V10, P309, DOI [10.1515/ijdhd.2011.049], DOI 10.1515/IJDHD.2011.049]; Betker AL, 2007, PHYS THER, V87, P1389, DOI 10.2522/ptj.20060229; Betker AL, 2006, ARCH PHYS MED REHAB, V87, P1141, DOI 10.1016/j.apmr.2006.04.010; Caglio M, 2012, NEUROCASE, V18, P123, DOI 10.1080/13554794.2011.568499; Caglio M, 2009, COGN PROCESS, V10, pS195, DOI 10.1007/s10339-009-0295-6; Centers for Disease Control and Prevention, INF PREV CONTR TRAUM; Cox DJ, 2010, MIL MED, V175, P411, DOI 10.7205/MILMED-D-09-00081; Eisenzopf L, 2010, BRAIN INJURY, V24, P167; Entertainment Software Association, ESS FACTS COMP VID G; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Flaghouse, GESTURETEK IREX SYST; Flynn S., 2010, P 8 INT C DIS VIRT R, P185; Fondren M, 2011, VIRTUAL REHABILITATI; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Holden MK, 2001, ST HEAL T, V81, P192; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Lange BS, 2010, PHYS MED REH CLIN N, V21, P339, DOI 10.1016/j.pmr.2009.12.007; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4, 10.1002/14651858.CD008349.pub2]; Mumford N, 2012, BRAIN INJURY, V26, P166, DOI 10.3109/02699052.2011.648706; Mumford N, 2010, BRAIN INJURY, V24, P780, DOI 10.3109/02699051003652807; National Stroke Foundation, 2010, NAT STROK AUD REH SE; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shopboat, NINT WII FIT; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; The Stroke Center University Hospital Newark New Jersey, 2013, STROK STAT 2013; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Ustinova KI, 2011, 2011 INT C VIRT REH, P1, DOI [10.1109/ICVR.2011.5971864, DOI 10.1109/ICVR.2011.5971864]; Ustinova KI, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-61; Yip BCB, 2013, NEUROREHABILITATION, V32, P103, DOI [10.3233/NRE-130827, 10.3233/NRE-30827]; Yip BCB, 2009, BRAIN INJURY, V23, P1017, DOI 10.3109/02699050903379412	39	47	48	3	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2161-783X	2161-7856		GAMES HEALTH J	Games Health J.	AUG	2014	3	4					202	214		10.1089/g4h.2014.0013			13	Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation	Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation	CU2WC	WOS:000363383300003	26192369				2022-02-06	
J	Lange, RT; Brickell, TA; Kennedy, JE; Bailie, JM; Sills, C; Asmussen, S; Amador, R; Dilay, A; Ivins, B; French, LM				Lange, Rael T.; Brickell, Tracey A.; Kennedy, Jan E.; Bailie, Jason M.; Sills, Cheryl; Asmussen, Sarah; Amador, Ricardo; Dilay, Angelica; Ivins, Brian; French, Louis M.			Factors Influencing Postconcussion and Posttraumatic Stress Symptom Reporting Following Military-Related Concurrent Polytrauma and Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Postconcussion; Posttraumatic stress; Depression; Traumatic brain injury; Military	MILD HEAD-INJURY; MENTAL-HEALTH PROBLEMS; POST-CONCUSSION SYNDROME; GOOD OLD DAYS; SERVICE MEMBERS; COMPENSATION-SEEKING; RISK-FACTORS; BASE RATES; EARLY INTERVENTION; TEST-PERFORMANCE	The purpose of this study was to identify factors that are predictive of, or associated with, high endorsement of postconcussion and posttraumatic stress symptoms following military-related traumatic brain injury (TBI). Participantswere 1,600 U. S. service members (age: M = 27.1, SD = 7.1; 95.4% male) who had sustained a mild-to-moderateTBI and who had been evaluated by the Defense and Veterans Brain Injury Center at one of six military medical centers. Twenty-two factors were examined that included demographic, injury circumstances/severity, treatment/evaluation, and psychological/physical variables. Four factors were statistically and meaningfully associated with clinically elevated postconcussion symptoms: (i) low bodily injury severity, (ii) posttraumatic stress, (iii) depression, and (iv) military operation where wounded (p<.001, 43.2% variance). The combination of depression and posttraumatic stress symptoms accounted for the vast majority of unique variance (41.5%) and were strongly associated with, and predictive of, clinically elevated postconcussion symptoms [range: odds ratios (OR) 4.24-7.75; relative risk (RR) 2.28-2.51]. Five factors were statistically and meaningfully associated with clinically elevated posttraumatic stress symptoms: (i) low bodily injury severity, (ii) depression, (iii) a longer time from injury to evaluation, (iv) military operation where wounded, and (v) current auditory deficits (p<.001; 65.6% variance accounted for). Depression alone accounted for the vast majority of unique variance (60.0%) and was strongly associated with, and predictive of, clinically elevated posttraumatic stress symptoms (OR=38.78; RR=4.63). There was a very clear, strong, and clinically meaningful association between depression, posttraumatic stress, and postconcussion symptoms in this sample. Brain injury severity, however, was not associated with symptom reporting following TBI.	[Lange, Rael T.; Brickell, Tracey A.; Kennedy, Jan E.; Bailie, Jason M.; Sills, Cheryl; Asmussen, Sarah; Amador, Ricardo; Dilay, Angelica; Ivins, Brian; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Kennedy, Jan E.; Sills, Cheryl; Amador, Ricardo] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA; [Bailie, Jason M.; Dilay, Angelica] Naval Med Ctr San Diego, San Diego, CA USA; [Asmussen, Sarah] 33 Area Branch Clin Camp Pendleton, Camp Pendleton, CA USA		Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.t.lange@us.army.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brickell T. A., J NEUROTRAU IN PRESS; Bryant RA, 2003, BEHAV RES THER, V41, P489, DOI 10.1016/S0005-7967(02)00179-1; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Ciorba A, 2012, CLIN INTERV AGING, V7, P159, DOI 10.2147/CIA.S26059; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Defense and Veterans Brain Injury Center D, 2012, DOD NUMB TRAUM BRAIN; Department of Defense, 2013, OP IR FREED OP END F; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Goodwin L, 2012, J NERV MENT DIS, V200, P429, DOI 10.1097/NMD.0b013e31825322fe; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Horesh D, 2013, PSYCHIAT RES, V208, P265, DOI 10.1016/j.psychres.2012.12.004; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kreutzer R.D, 2012, BRAIN INJURY MED PRI; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J., 2007, INT NEUR SOC 35 ANN; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Veterans for Common Sense, 2012, IR AFGH IMP REP; Weathers F. W., 1994, PTSD CHECKLIST CIVIL; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2004, ICD 10 INT STAT CLAS; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	100	47	47	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2014	29	4					329	347		10.1093/arclin/acu013			19	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	AM6BY	WOS:000339947100003	24723461	Bronze			2022-02-06	
J	Liu, X; Zhang, X; Zhang, J; Kang, N; Zhang, N; Wang, H; Xue, J; Yu, J; Yang, Y; Cui, H; Cui, L; Wang, L; Wang, X				Liu, X.; Zhang, X.; Zhang, J.; Kang, N.; Zhang, N.; Wang, H.; Xue, J.; Yu, J.; Yang, Y.; Cui, H.; Cui, L.; Wang, L.; Wang, X.			DIOSMIN PROTECTS AGAINST CEREBRAL ISCHEMIA/REPERFUSION INJURY THROUGH ACTIVATING JAK2/STAT3 SIGNAL PATHWAY IN MICE	NEUROSCIENCE			English	Article						cerebral ischemia/reperfusion; diosmin; apoptosis; JAK2/STAT3	CHRONIC VENOUS INSUFFICIENCY; TRAUMATIC BRAIN-INJURY; DAFLON 500 MG; ISCHEMIA-REPERFUSION; NEURONAL APOPTOSIS; STAT3 ACTIVATION; OXIDATIVE STRESS; ARTERY OCCLUSION; ALPHA EXPRESSION; GENE-EXPRESSION	Background and object: Apoptosis is a major form of cell death in cerebral ischemia/reperfusion (I/R) pathogenesis and may represent a target for treatment. Diosmin (DM), a micronized purified flavonoid drug, possesses an anti-apoptotic effect in the treatment of varicose veins and renal injury. However, the effect of DM in the acute phase of cerebral I/R is not clear. This study investigated DM's role in cerebral I/R and its potential mechanism. Methods: Male CD-1 mice were subjected to transient middle cerebral artery occlusion (tMCAO). Experiment 1 was used to evaluate the time course expression of Janus tyrosine kinase-2 (JAK2), signal transducer and activator of transcription-3 (STAT3), phosphorylated JAK2 (pJAK2) and phosphorylated STAT3 (pSTAT3) after cerebral I/R, and six time points were included. In experiment 2, DM was given orally at doses of 50 mg/kg or 100 mg/kg for 6 consecutive days before receiving tMCAO. At 24 h after reperfusion, neurological deficit, Nissl staining, brain water content and infarct volume were examined. Bcl-2, Bax, pJAK2, and pSTAT3 were detected by immunohistochemistry, qRT-PCR and Western blot. Confocal microscope was used to observe the location of pSTAT3 in the cerebral cortex. Results: Compared with Vehicle group, the high dose of DM significantly alleviated neurological deficit, brain water content, infarct volume, increased the Nissl-positive cells, upregulated the expression of pJAK2, pSTAT3 and Bcl-2 and downregulated Bax (P < 0.05). Conclusion: These results showed that DM protected against cerebral I/R injury through activating JAK2/STAT3 signal pathway. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Liu, X.; Zhang, X.; Zhang, J.; Kang, N.; Zhang, N.; Wang, H.; Xue, J.; Yu, J.; Yang, Y.; Cui, H.; Cui, L.; Wang, L.] Hebei Med Univ, Hosp 2, Dept Neurol, Shijiazhuang 050000, Hebei, Peoples R China; [Zhang, X.; Cui, L.; Wang, L.; Wang, X.] Hebei Collaborat Innovat Ctr Cardiocerebrovasc Di, Shijiazhuang 050000, Hebei, Peoples R China; [Zhang, X.; Cui, L.; Wang, L.] Hebei Key Lab Neurol, Shijiazhuang 050000, Hebei, Peoples R China		Zhang, X (corresponding author), Hebei Med Univ, Hosp 2, Dept Neurol, 215 Hepingxi Rd, Shijiazhuang 050000, Hebei, Peoples R China.	zhang6xj@aliyun.com; wangxl2014@yahoo.com		Zhang, Nan/0000-0002-6814-214X; Zhang, Xiangjian/0000-0003-0114-1668	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371287]; Natrural Science Foundation of Hebei Province [10276104D]	This work was funded by the National Natural Science Foundation of China (Grant No. 81371287) and Natrural Science Foundation of Hebei Province (Grant No. 10276104D). We thank technicians Ruichun Liu, Zhongyao Li and Hongran Wu for their technical assistance and Prof. Yansu Guo M.D. PhD. and Weisong Duan M.D. PhD. for providing valuable suggestions.	Amantea D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.125; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Benavente-Garcia O, 2008, J AGR FOOD CHEM, V56, P6185, DOI 10.1021/jf8006568; Bergan JJ, 2001, ANGIOLOGY, V52, pS43, DOI 10.1177/0003319701052001S06; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Buckshee K, 1997, INT J GYNECOL OBSTET, V57, P145, DOI 10.1016/S0020-7292(97)02889-0; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen LY, 2012, BRAIN RES, V1475, P80, DOI 10.1016/j.brainres.2012.07.052; Chiba T, 2009, EXPERT OPIN THER TAR, V13, P1155, DOI 10.1517/14728220903213426; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark WM, 1997, NEUROL RES, V19, P641; COVA D, 1992, INT J CLIN PHARM TH, V30, P29; Cui LL, 2010, PHARMACOL BIOCHEM BE, V96, P469, DOI 10.1016/j.pbb.2010.07.007; Dholakiya SL, 2011, TOXICOL IN VITRO, V25, P1039, DOI 10.1016/j.tiv.2011.04.003; Di Domenico F, 2012, J NEUROCHEM, V121, P680, DOI 10.1111/j.1471-4159.2012.07721.x; Dirnagl U, 2004, E SCHERING RES FDN W, V47, P87; Dong LP, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370804; Du YY, 2012, NEUROSCI LETT, V509, P110, DOI 10.1016/j.neulet.2011.12.054; Dziennis S, 2007, J NEUROSCI, V27, P7268, DOI 10.1523/JNEUROSCI.1558-07.2007; Forte R, 2013, J OCUL PHARMACOL TH, V29, P733, DOI 10.1089/jop.2013.0010; Friesenecker B, 1995, INT J MICROCIRC, V15, P17, DOI 10.1159/000179090; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Iriz E, 2008, VASA-J VASCULAR DIS, V37, P233, DOI 10.1024/0301-1526.37.3.233; Ji H, 2012, BRAIN RES BULL, V87, P50, DOI 10.1016/j.brainresbull.2011.09.021; Jiang CJ, 2013, INT J NEUROSCI, V123, P684, DOI 10.3109/00207454.2013.817409; Korthuis RJ, 1997, INT J MICROCIRC, V17, P11, DOI 10.1159/000179261; Le Devehat C, 1997, INT J MICROCIRC, V17, P27, DOI 10.1159/000179264; Lin SB, 2006, MOL ENDOCRINOL, V20, P3376, DOI 10.1210/me.2006-0177; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu GY, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-36; Liu HC, 2012, BRAIN RES, V1474, P73, DOI 10.1016/j.brainres.2012.07.028; Liu J, 2005, STROKE, V36, P1264, DOI 10.1161/01.STR.0000166180.91042.02; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Lyseng-Williamson KA, 2003, DRUGS, V63, P71, DOI 10.2165/00003495-200363010-00005; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Ramelet AA, 2001, ANGIOLOGY, V52, pS49, DOI 10.1177/0003319701052001S07; Rehman MU, 2013, BRIT J NUTR, V110, P699, DOI 10.1017/S0007114512005752; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Sehara Y, 2013, J NEUROSCI, V33, P12364, DOI 10.1523/JNEUROSCI.1852-13.2013; Sepulveda P, 2007, CELL DEATH DIFFER, V14, P378, DOI 10.1038/sj.cdd.4402007; Shyu WC, 2004, NEUROBIOL AGING, V25, P935, DOI 10.1016/j.neurobiolaging.2003.10.012; Smith C, 1999, J VASC RES, V36, P24, DOI 10.1159/000054071; Solaroglu I, 2006, NEUROSCIENCE, V143, P965, DOI 10.1016/j.neuroscience.2006.09.014; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Tanrikulu Y, 2013, BOSNIAN J BASIC MED, V13, P218, DOI 10.17305/bjbms.2013.2305; Dung TD, 2012, FOOD CHEM TOXICOL, V50, P1802, DOI 10.1016/j.fct.2012.01.021; Wang G, 2008, INT J BIOCHEM CELL B, V40, P461, DOI 10.1016/j.biocel.2007.08.008; Wen TC, 2001, NEUROSCI LETT, V303, P153, DOI 10.1016/S0304-3940(01)01711-6; Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631; Xia DY, 2013, BRAZ J MED BIOL RES, V46, P580, DOI 10.1590/1414-431X20133161; Xu XS, 2006, STROKE, V37, P2613, DOI 10.1161/01.STR.0000242772.94277.1f; Yamashita T, 2005, J NEUROCHEM, V94, P459, DOI 10.1111/j.1471-4159.2005.03227.x; Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zhang L, 2013, BRAIN RES BULL, V96, P45, DOI 10.1016/j.brainresbull.2013.04.009; Zhu HB, 2013, EUR J PHARMACOL, V714, P23, DOI 10.1016/j.ejphar.2013.05.043; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	63	47	57	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 30	2014	268						318	327		10.1016/j.neuroscience.2014.03.032			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AG6AX	WOS:000335501900029	24680937				2022-02-06	
J	Green, REA; Colella, B; Maller, JJ; Bayley, M; Glazer, J; Mikulis, DJ				Green, Robin E. A.; Colella, Brenda; Maller, Jerome J.; Bayley, Mark; Glazer, Joanna; Mikulis, David J.			Scale and pattern of atrophy in the chronic stages of moderate-severe TBI	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						atrophy; chronic; degeneration; traumatic brain injury; progression; MRI	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; DIFFUSION-TENSOR; CORTICAL IMPACT; STRUCTURAL MRI; HEAD-INJURY; RECOVERY; PROGRESSION; PERFORMANCE; NEURONS	Background: Moderate-severe traumatic brain injury (TBI) is increasingly being understood as a progressive disorder, with growing evidence of reduced brain volume and white matter (WM) integrity as well as lesion expansion in the chronic phases of injury. The scale of these losses has yet to be investigated, and pattern of change across structures has received limited attention. Objectives: (1) To measure the percentage of patients in our TBI sample showing atrophy from 5 to 20 months post-injury in the whole brain and in structures with known vulnerability to acute TBI, and (2) To examine relative vulnerability and patterns of volume loss across structures. Methods: Fifty-six TBI patients [complicated mild to severe, with mean Glasgow Coma Scale (GCS) in severe range] underwent MRI at, on average, 5 and 20 months post-injury; 12 healthy controls underwent MRI twice, with a mean gap between scans of 25.4 months. Mean monthly percent volume change was computed for whole brain (ventricle-to-brain ratio; VBR), corpus callosum (CC), and right and left hippocampi (HPC). Results: (1) Using a threshold of 2 z-scores below controls, 96% of patients showed atrophy across time points in at least one region; 75% showed atrophy in at least 3 of the 4 regions measured. (2) There were no significant differences in the proportion of patients who showed atrophy across structures. For those showing decline in VBR, there was a significant association with both the CC and the right HPC (P < 0.05 for both comparisons). There were also significant associations between those showing decline in (i) right and left HPC (P < 0.05); (ii) all combinations of genu, body and splenium of the CC (P < 0.05), and (iii) head and tail of the right HPC (P < 0.05 all sub-structure comparisons). Conclusions: Atrophy in chronic TBI is robust, and the CC, right HPC and left HPC appear equally vulnerable. Significant associations between the right and left HPC, and within substructures of the CC and right HPC, raise the possibility of common mechanisms for these regions, including transneuronal degeneration. Given the 96% incidence rate of atrophy, a genetic explanation is unlikely to explain all findings. Multiple and possibly synergistic mechanisms may explain findings. Atrophy has been associated with poorer functional outcomes, but recent findings suggest there is potential to offset this. A better, understanding of the underlying mechanisms could permit targeted therapy enabling better long-term outcomes.	[Green, Robin E. A.; Colella, Brenda; Bayley, Mark; Glazer, Joanna] Toronto Rehabil Inst, Res Dept, Cognit Neurorehabil Sci Lab, Toronto, ON M5G 2A2, Canada; [Green, Robin E. A.] Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON M5S 1A1, Canada; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Brain Stimulat & Neuroimaging Lab, Melbourne, Vic, Australia; [Mikulis, David J.] Toronto Western Res Inst, Div Appl & Intervent Res, MRI Lab, Toronto, ON, Canada; [Mikulis, David J.] Univ Toronto, Fac Med, Dept Med Imaging, Toronto, ON, Canada		Green, REA (corresponding author), Toronto Rehabil Inst, 550 Univ Ave,Rm 11-207, Toronto, ON M5G 2A2, Canada.	robin.green@uhn.ca	Mikulis, David J/H-5167-2019; Maller, Jerome J/H-4963-2014	Maller, Jerome J/0000-0003-4685-1508; Green, Robin/0000-0001-9451-3963; Mikulis, David/0000-0003-3956-0892; Bayley, Mark/0000-0001-7860-9463	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians Services Incorporated Foundation; Ontario Neurotrauma Foundation; Canada Research Chairs ProgramCanada Research Chairs	The authors acknowledge the support of the Canadian Institute of Health Research, Physicians Services Incorporated Foundation, Ontario Neurotrauma Foundation and the Canada Research Chairs Program.	Adnan A, 2013, BRAIN INJURY, V27, P1415, DOI 10.3109/02699052.2013.823659; Amaral OB, 2008, PHYSIOL BEHAV, V93, P388, DOI 10.1016/j.physbeh.2007.09.009; Analysisgroup, 2012, FMRIB SOFTW LIB V4 0; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brayne C, 2010, BRAIN, V133, P2210, DOI 10.1093/brain/awq185; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Coulson EJ, 2008, J NEUROSCI, V28, P315, DOI 10.1523/JNEUROSCI.2699-07.2008; Curlik DM, 2013, NEUROPHARMACOLOGY, V64, P506, DOI 10.1016/j.neuropharm.2012.07.027; Curlik DM, 2011, J COGNITIVE NEUROSCI, V23, P2159, DOI 10.1162/jocn.2010.21597; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Draganski B, 2006, J NEUROSCI, V26, P6314, DOI 10.1523/JNEUROSCI.4628-05.2006; Duering M, 2012, NEUROLOGY, V79, P2025, DOI 10.1212/WNL.0b013e3182749f39; Evans J. J., 2008, NEUROPSYCHOL REHABIL, V18, P372, DOI [10.1080/09602010801909153, DOI 10.1080/09602010801909153]; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Frisoni GB, 2010, NAT REV NEUROL, V6, P67, DOI 10.1038/nrneurol.2009.215; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Hollingshead ADB., 1958, SOCIAL CLASS MENTAL, DOI [10.1037/10645-000, DOI 10.1037/10645-000]; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Maguire EA, 2006, HIPPOCAMPUS, V16, P1091, DOI 10.1002/hipo.20233; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Miller LS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00506; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Talairach J., 1988, COPLANAR STEREOTAXIC; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Watson C, 1997, ARCH NEUROL-CHICAGO, V54, P67, DOI 10.1001/archneur.1997.00550130049015; Weschler D., 2001, WECHSLER TEST ADULT; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Zijdenbos A, 1998, LECT NOTES COMPUT SC, V1496, P439	63	47	47	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 31	2014	8								67	10.3389/fnhum.2014.00067			9	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	AD9NH	WOS:000333591300001	24744712	gold, Green Published			2022-02-06	
J	Hartings, JA; Vidgeon, S; Strong, AJ; Zacko, C; Vagal, A; Andaluz, N; Ridder, T; Stanger, R; Fabricius, M; Mathern, B; Pahl, C; Tolias, CM; Bullock, MR				Hartings, Jed A.; Vidgeon, Steven; Strong, Anthony J.; Zacko, Chris; Vagal, Achala; Andaluz, Norberto; Ridder, Thomas; Stanger, Richard; Fabricius, Martin; Mathern, Bruce; Pahl, Clemens; Tolias, Christos M.; Bullock, M. Ross		Co-Operative Studies Brain Injury	Surgical management of traumatic brain injury: a comparative-effectiveness study of 2 centers Clinical article	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; intracranial hypertension; cortical spreading depression; traumatic brain injury; acute subdural hematoma; brain contusion	CORTICAL SPREADING DEPRESSION; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; DENDRITIC INJURY; DEPOLARIZATIONS; CRANIOTOMY; MULTICENTER; STROKE; HEMICRANIECTOMY; INTERVENTION	Object. Mass lesions from traumatic brain injury (TBI) often require surgical evacuation as a life-saving measure and to improve outcomes, but optimal timing and surgical technique, including decompressive craniectomy, have not been fully defined. The authors compared neurosurgical approaches in the treatment of TBI at 2 academic medical centers to document variations in real-world practice and evaluate the efficacies of different approaches on postsurgical course and long-term outcome. Methods. Patients 18 years of age or older who required neurosurgical lesion evacuation or decompression for TBI were enrolled in the Co-Operative Studies on Brain Injury Depolarizations (COSBID) at King's College Hospital (KCH, n = 27) and Virginia Commonwealth University (VCU, n = 24) from July 2004 to March 2010. Subdural electrode strips were placed at the time of surgery for subsequent electrocorticographic monitoring of spreading depolarizations; injury characteristics, physiological monitoring data, and 6-month outcomes were collected prospectively. CT scans and medical records were reviewed retrospectively to determine lesion characteristics, surgical indications, and procedures performed. Results. Patients enrolled at KCH were significantly older than those enrolled at VCU (48 vs 34 years, p < 0.01) and falls were more commonly the cause of TBI in the KCH group than in the VCU group. Otherwise, KCH and VCU patients had similar prognoses, lesion types (subdural hematomas: 30%-35%; parenchymal contusions: 48%-52%), signs of mass effect (midline shift >= 5 mm: 43%-52%), and preoperative intracranial pressure (ICP). At VCU, however, surgeries were performed earlier (median 0.51 vs 0.83 days posttrauma, p < 0.05), bone flaps were larger (mean 82 vs 53 cm(2), p < 0.001), and craniectomies were more common (performed in 75% vs 44% of cases, p < 0.05). Postoperatively, maximum ICP values were lower at VCU (mean 22.5 vs 31.4 mm Hg, p < 0.01). Differences in incidence of spreading depolarizations (KCH: 63%, VCU: 42%, p = 0.13) and poor outcomes (KCH: 54%, VCU: 33%, p = 0.14) were not significant. In a subgroup analysis of only those patients who underwent early (< 24 hours) lesion evacuation (KCH: n = 14; VCU: n = 16), however, VCU patients fared significantly better. In the VCU patients, bone flaps were larger (mean 85 vs 48 cm(2) at KCH, p < 0.001), spreading depolarizations were less common (31% vs 86% at KCH, p < 0.01), postoperative ICP values were lower (mean: 20.8 vs 30.2 mm Hg at KCH, p < 0.05), and good outcomes were more common (69% vs 29% at KCH, p < 0.05). Spreading depolarizations were the only significant predictor of outcome in multivariate analysis. Conclusions. This comparative-effectiveness study provides evidence for major practice variation in surgical management of severe TBI. Although ages differed between the 2 cohorts, the results suggest that a more aggressive approach, including earlier surgery, larger craniotomy, and removal of bone flap, may reduce ICP, prevent cortical spreading depolarizations, and improve outcomes. In particular, patients requiring evacuation of subdural hematomas and contusions may benefit from decompressive craniectomy in conjunction with lesion evacuation, even when elevated ICP is not a factor in the decision to perform surgery.	[Hartings, Jed A.; Andaluz, Norberto] Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Coll Med, Cincinnati, OH 45267 USA; [Vagal, Achala] Univ Cincinnati, Dept Radiol, Inst Neurosci, Coll Med, Cincinnati, OH 45267 USA; [Vidgeon, Steven; Strong, Anthony J.; Tolias, Christos M.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England; [Pahl, Clemens] Kings Coll London, Dept Crit Care Med, London WC2R 2LS, England; [Zacko, Chris; Bullock, M. Ross] Univ Miami, Dept Neurol Surg, Coral Gables, FL 33124 USA; [Ridder, Thomas; Stanger, Richard; Mathern, Bruce] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Fabricius, Martin] Glostrup Cty Hosp, Dept Clin Neurophysiol, Copenhagen, Denmark		Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jed.hartings@uc.edu		Hartings, Jed/0000-0001-8583-3471	US Army CDMRP PH/TBI Research Program [W81XWH-08-2-0016]; HeadFirst; King's College Hospital Foundation Trust's Research and Development Fund; Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited	This work was funded in part by the US Army CDMRP PH/TBI Research Program, Contract No. W81XWH-08-2-0016. Dr. Strong acknowledges support from HeadFirst; Dr. Pahl from King's College Hospital Foundation Trust's Research and Development Fund; and Dr. Fabricius from the Novo Nordisk Foundation. Funding sources had no role in study design or in the collection, analysis, interpretation, or reporting of data.	Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons AANS/CNS Joint Section on Neurotrauma and Critical Care, 2008, J NEUROTRAUM, V25, P276; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2013, NEUROSCIENTIST, V19, P25, DOI 10.1177/1073858412453340; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Ghajar J, 2009, MT SINAI J MED, V76, P190, DOI 10.1002/msj.20095; Guedes RCA, 1996, BRAZ J MED BIOL RES, V29, P1407; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Marion DW, 2006, NEUROSURGERY, V58, P655; Maslarova A, 2011, STROKE, V42, P2917, DOI 10.1161/STROKEAHA.111.621581; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	56	47	48	0	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2014	120	2					434	446		10.3171/2013.9.JNS13581			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	301UA	WOS:000330556400027	24180566				2022-02-06	
J	Abner, EL; Nelson, PT; Schmitt, FA; Browning, SR; Fardo, DW; Wan, LJ; Jicha, GA; Cooper, GE; Smith, CD; Caban-Holt, AM; Van Eldik, LJ; Kryscio, RJ				Abner, Erin L.; Nelson, Peter T.; Schmitt, Frederick A.; Browning, Steven R.; Fardo, David W.; Wan, Lijie; Jicha, Gregory A.; Cooper, Gregory E.; Smith, Charles D.; Caban-Holt, Allison M.; Van Eldik, Linda J.; Kryscio, Richard J.			Self-Reported Head Injury and Risk of Late-Life Impairment and AD Pathology in an AD Center Cohort	DEMENTIA AND GERIATRIC COGNITIVE DISORDERS			English	Article						Head injury; Alzheimer's disease; Neuropathology; Dementia; Cognition	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; AMYLOID-BETA; DEMENTIA; DEATH; TRANSITIONS; CONCUSSION; SEQUELAE; PLAQUES	Aims: To evaluate the relationship between self-reported head injury and cognitive impairment, dementia, mortality, and Alzheimer's disease (AD)-type pathological changes. Methods: Clinical and neuropathological data from participants enrolled in a longitudinal study of aging and cognition (n = 649) were analyzed to assess the chronic effects of self-reported head injury. Results: The effect of self-reported head injury on the clinical state depended on the age at assessment: for a 1-year increase in age, the OR for the transition to clinical mild cognitive impairment (MCI) at the next visit for participants with a history of head injury was 1.21 and 1.34 for the transition from MCI to dementia. Without respect to age, head injury increased the odds of mortality (OR = 1.54). Moreover, it increased the odds of a pathological diagnosis of AD for men (OR = 1.47) but not women (OR = 1.18). Men with a head injury had higher mean amyloid plaque counts in the neocortex and entorhinal cortex than men without. Conclusions: Self-reported head injury is associated with earlier onset, increased risk of cognitive impairment and dementia, increased risk of mortality, and AD-type pathological changes. (C) 2013 S. Karger AG,	[Abner, Erin L.; Nelson, Peter T.; Schmitt, Frederick A.; Fardo, David W.; Jicha, Gregory A.; Smith, Charles D.; Caban-Holt, Allison M.; Van Eldik, Linda J.; Kryscio, Richard J.] Univ Kentucky, Alzheimers Dis Ctr, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; [Schmitt, Frederick A.; Jicha, Gregory A.; Smith, Charles D.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; [Abner, Erin L.; Browning, Steven R.] Univ Kentucky, Dept Epidemiol, Lexington, KY 40536 USA; [Fardo, David W.; Kryscio, Richard J.] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Wan, Lijie; Kryscio, Richard J.] Univ Kentucky, Dept Stat, Lexington, KY 40536 USA; [Caban-Holt, Allison M.] Univ Kentucky, Dept Behav Sci, Lexington, KY 40536 USA; [Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Cooper, Gregory E.] Baptist Neurol Ctr, Lexington, KY USA		Abner, EL (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 800 S Limestone St, Lexington, KY 40536 USA.	erin.abner@uky.edu	Wan, Lijie/AAS-8090-2020	Abner, Erin/0000-0002-9566-4111; Fardo, David/0000-0002-7207-4696	University of Kentucky's Sanders-Brown Center on Aging from the National Institute on Aging [R01 AG038651, R01 AG019241, P30 AG028383]; National Center for Advancing Translational Sciences to the University of Kentucky's Center for Clinical and Translational Science [UL1TR000117]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG038651, P30AG028383, K25AG043546, R01AG019241] Funding Source: NIH RePORTER	We thank the participants and their families, as well as the University of Kentucky Alzheimer's Disease Center staff members. This work was supported by grants to the University of Kentucky's Sanders-Brown Center on Aging from the National Institute on Aging (grant No. R01 AG038651, R01 AG019241, and P30 AG028383), as well as a grant from the National Center for Advancing Translational Sciences to the University of Kentucky's Center for Clinical and Translational Science (grant No. UL1TR000117). The NIA did not play any role in the study design, in the collection, analysis, and interpretation of data, in the writing of the paper, or in the decision to submit the article for publication. The authors submitted the manuscript independent of funding sources.	Abner Erin L, 2012, Int J Alzheimers Dis, V2012, P291920, DOI 10.1155/2012/291920; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Brayne C, 1998, DEMENT GERIATR COGN, V9, P175, DOI 10.1159/000017043; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Iverson G, 2006, INT BRAIN INJURY ASS, V4; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; KONDO K, 1994, DEMENTIA, V5, P314, DOI 10.1159/000106741; Kryscio RJ, 2006, NEUROLOGY, V66, P828, DOI 10.1212/01.wnl.0000203264.71880.45; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Murphy TE, 2011, J GERONTOL A-BIOL, V66, P109, DOI 10.1093/gerona/glq188; Nelson PT, 2007, J NEUROPATH EXP NEUR, V66, P1136, DOI 10.1097/nen.0b013e31815c5efb; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Salazar JC, 2007, STAT MED, V26, P568, DOI 10.1002/sim.2437; SAS Institute Inc, 2011, SAS STAT 9 3 PROC GU; Schmitt FA, 2012, CURR ALZHEIMER RES, V9, P724; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; U.S. Census Bureau, 2011, 2011 AM COMM SURV; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Yu L, 2010, STAT MED, V29, P639, DOI 10.1002/sim.3828	43	47	47	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-8008	1421-9824		DEMENT GERIATR COGN	Dement. Geriatr. Cogn. Disord.		2014	37	5-6					294	306		10.1159/000355478			13	Geriatrics & Gerontology; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry	AJ6IL	WOS:000337795500005	24401791	Green Accepted, Bronze, Green Published			2022-02-06	
J	Klose, M; Stochholm, K; Janukonyte, J; Christensen, LL; Frystyk, J; Andersen, M; Laurberg, P; Christiansen, JS; Feldt-Rasmussen, U				Klose, Marianne; Stochholm, Kirstine; Janukonyte, Jourgita; Christensen, Louise Lehman; Frystyk, Jan; Andersen, Marianne; Laurberg, Peter; Christiansen, Jens Sandahl; Feldt-Rasmussen, Ulla			Prevalence of Posttraumatic Growth Hormone Deficiency Is Highly Dependent on the Diagnostic Set-up: Results From The Danish National Study on Posttraumatic Hypopituitarism	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							TRAUMATIC BRAIN-INJURY; GH-RELEASING HORMONE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY INSUFFICIENCY; ENDOCRINE-SOCIETY; ARGININE; TESTS; PYRIDOSTIGMINE; DYSFUNCTION; SECRETION	Context: Recent international guidelines suggest pituitary screening in patients with moderate and severe traumatic brain injury (TBI). Predominantly isolated GH deficiency (GHD) was reported in the literature, raising the question of potential methodological bias. Objective: Our objective was to assess the prevalence of GHD in patients admitted in 2008 with TBI, with concurrent assessment of methodological bias. Design and Setting: We conducted a nationwide population-based cohort study at tertiary referral university hospitals. Participants: Participants were Danish patients with a head trauma diagnosis from the Danish Board of Health diagnostic code registry; 439 patients and 124 healthy controls underwent dynamic assessment of GH secretion 2.5 years (median) after TBI. Main Outcome: We evaluated the prevalence of GHD given use of 1) local versus guideline cutoffs, 2) insulin tolerance test (ITT), pyridostigmine (PD)-GHRH or GHRH-arginine (arg) test, 3) single versus repeated testing, and 4) GH assessment by assays with different isoform specificities. Results: The prevalence of GHD was lower by local than by guideline cutoffs (12% vs 19% [PD-GHRH/GHRH-arg, P < .001]; 4.5% vs 5% [ITT, P = .9]), and by ITT than by PD-GHRH/GHRH-arg (P = .006 [local cutoffs]; P < .001 [guideline cutoffs]). Only 1% of patients had GHD according to 2 tests. GH assessment by the Immulite or iSYS assay caused no significant diagnostic differences. Conclusions: The study confirmed a high risk of bias in the management of pituitary testing of patients with TBI and stresses the importance of a proper control group and stringent GH testing including confirmatory testing in cohorts with low a priori likelihood of GHD such as in TBI. Our results question the evidence for newly introduced recommendations for routine pituitary assessment in TBI.	[Klose, Marianne; Feldt-Rasmussen, Ulla] Rigshosp, Copenhagen Univ Hosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; [Stochholm, Kirstine; Janukonyte, Jourgita; Frystyk, Jan; Christiansen, Jens Sandahl] Aarhus Univ Hosp, Dept Internal Med & Endocrinol, DK-8000 Aarhus, Denmark; [Christensen, Louise Lehman; Andersen, Marianne] Odense Univ Hosp, Dept Med Endocrinol, DK-5000 Odense, Denmark; [Laurberg, Peter] Aalborg Univ Hosp, Dept Med Endocrinol, DK-9100 Aalborg, Denmark		Klose, M (corresponding author), Rigshosp, Copenhagen Univ Hosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	klose@rh.dk	Feldt-Rasmussen, Ulla/AAB-9218-2021; Andersen, Marianne Skovsager/AAE-1751-2019	Feldt-Rasmussen, Ulla/0000-0002-5903-3355; Andersen, Marianne Skovsager/0000-0002-4603-9504; Frystyk, Jan/0000-0002-5379-0961; Stochholm, Kirstine/0000-0002-4408-3413	Danish Agency for Science, Technology, and Innovation; Reseach Council of the Capital Region of Denmark; Lundbeck FoundationLundbeckfonden; Novo NordiskNovo Nordisk; A.P. Moller Foundation for the Advancement of Medical Science; Arvid Nilsson's Foundation; Christenson-Ceson's Foundation; Axel-Muusfeldt's Foundation; Else and Mogens Wedell-Wedellsborg's Foundation	The study was funded by unrestricted grants from The Danish Agency for Science, Technology, and Innovation; The Reseach Council of the Capital Region of Denmark; The Lundbeck Foundation; Novo Nordisk; The A.P. Moller Foundation for the Advancement of Medical Science; Arvid Nilsson's Foundation; Christenson-Ceson's Foundation; Axel-Muusfeldt's Foundation; and Else and Mogens Wedell-Wedellsborg's Foundation. Immunodiagnostic Systems provided iSYS GH kits free of charge but had no influence on results or their interpretation.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Clemmons DR, 2011, CLIN CHEM, V57, P555, DOI 10.1373/clinchem.2010.150631; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; CORDIDO F, 1990, J CLIN ENDOCR METAB, V70, P1361, DOI 10.1210/jcem-70-5-1361; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Fisker S, 1998, CLIN ENDOCRINOL, V48, P109; Gardner CJ, 2013, EUR J ENDOCRINOL, V168, P473, DOI 10.1530/EJE-12-0849; GHIGO E, 1989, METABOLISM, V38, P631, DOI 10.1016/0026-0495(89)90099-1; GHIGO E, 1990, J CLIN ENDOCR METAB, V71, P1481, DOI 10.1210/jcem-71-6-1481; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hoeck HC, 1999, GROWTH HORM IGF RES, V9, P18, DOI 10.1054/ghir.1998.0085; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Lissett CA, 1999, CLIN ENDOCRINOL, V51, P551, DOI 10.1046/j.1365-2265.1999.00836.x; Makimura H, 2008, J CLIN ENDOCR METAB, V93, P4254, DOI 10.1210/jc.2008-1333; Manolopoulou J, 2012, CLIN CHEM, V58, P1446, DOI 10.1373/clinchem.2012.188128; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Procopio M, 1998, PANMINERVA MED, V40, P13; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; Wilkinson C. W., 2012, FRONT NEUROL, V3, P11, DOI DOI 10.3389/FNEUR.2012.00011; [No title captured]	36	47	48	0	4	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	JAN	2014	99	1					101	110		10.1210/jc.2013-2397			10	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	AD6WP	WOS:000333402200044	24243629	Bronze			2022-02-06	
J	Sillesen, M; Rasmussen, LS; Jin, G; Jepsen, CH; Imam, A; Hwabejire, JO; Halaweish, I; DeMoya, M; Velmahos, G; Johansson, PI; Alam, HB				Sillesen, Martin; Rasmussen, Lars S.; Jin, Guang; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; Halaweish, Ihab; DeMoya, Marc; Velmahos, George; Johansson, Par I.; Alam, Hasan B.			Assessment of coagulopathy, endothelial injury, and inflammation after traumatic brain injury and hemorrhage in a porcine model	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Coagulopathy; brain; injury; shock; inflammation; porcine	LARGE-ANIMAL-MODEL; UNCONTROLLED HEMORRHAGE; GLYCOCALYX DEGRADATION; COMPLEMENT ACTIVATION; COAGULATION TESTS; NERVOUS-SYSTEM; PROTEIN-C; DYSFUNCTION; RESUSCITATION; TISSUE	BACKGROUND: Traumatic brain injury (TBI) and hemorrhagic shock (HS) can be associated with coagulopathy and inflammation, but the mechanisms are poorly understood. We hypothesized that a combination of TBI and HS would disturb coagulation, damage the endothelium, and activate inflammatory and complement systems. METHODS: A total of 33 swine were allocated to either TBI + HS (n = 27, TBI and volume-controlled 40% blood loss) or controls (n = 6, anesthesia and instrumentation). TBI + HS animals were left hypotensive (mean arterial pressure, 30-35 mm Hg) for 2 hours. Blood samples were drawn at baseline, 3 minutes and 15 minutes after injury, as well as following 2 hours of hypotension. Markers of coagulation, anticoagulation, endothelial activation/glycocalyx shedding, inflammation, complement, and sympathoadrenal function were measured. RESULTS: The TBI + HS group demonstrated an immediate (3 minutes after injury) activation of coagulation (prothrombin fragment 1 + 2, 289 ng/mL vs. 232 ng/mL, p = 0.03) and complement (C5a, 2.83 ng/mL vs. 2.05 ng/mL, p = 0.05). Shedding of the endothelial glycocalyx (syndecan 1) was evident 15 minutes after injury (851.0 ng/ml vs. 715.5 ng/ml, p = 0.03) while inflammation (tumor necrosis factor alpha [ TNF-alpha], 81.1 pg/mL vs. 50.8 pg/mL, p = 0.03) and activation of the protein C system (activated protein C, 56.7 ng/mL vs. 26.1 ng/mL, p = 0.01) were evident following the 2-hour hypotension phase. CONCLUSION: The combination of TBI and shock results in an immediate activation of coagulation and complement systems with subsequent endothelial shedding, protein C activation, and inflammation. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Sillesen, Martin; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; DeMoya, Marc; Velmahos, George] Harvard Univ, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg,Massachusetts Gen Hos, Boston, MA 02115 USA; [Jin, Guang; Halaweish, Ihab; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Johansson, Par I.] Univ Texas Med Sch, Dept Surg, Houston, TX USA; [Sillesen, Martin; Rasmussen, Lars S.] Rigshosp, Copenhagen Univ Hosp, Dept Anesthesia, Copenhagen, Denmark; [Jepsen, Cecilie H.; Johansson, Par I.] Rigshosp, Copenhagen Univ Hosp, Ctr Head & Orthoped, Copenhagen, Denmark; [Jepsen, Cecilie H.; Johansson, Par I.] Rigshosp, Copenhagen Univ Hosp, Capital Reg Blood Bank, Copenhagen, Denmark		Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu	Johansson, Par I/P-9283-2015	Johansson, Par I/0000-0001-9778-5964; Sillesen, Martin/0000-0001-9494-5475; Rasmussen, Lars/0000-0002-7480-3004	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; Copenhagen University Hospital, Rigshospitalet (Denmark); Laerdal Foundation (Norway); Aase and Ejnar Danielsen Foundation (Denmark); Olof Norlander Foundation (Sweden); Maersk Foundation (Denmark); Tryg Foundation (Denmark); Lundbeck Foundation (Denmark)Lundbeckfonden	The study was funded by a grant from the US Army Medical Research and Materiel Command (GRANTT00521959) to H. B. A. and grants from Copenhagen University Hospital, Rigshospitalet (Denmark), The Laerdal Foundation (Norway), The Aase and Ejnar Danielsen Foundation (Denmark), The Olof Norlander Foundation (Sweden), and The Maersk Foundation (Denmark) to M. S.; L. S. R. has received funding from the Tryg Foundation (Denmark).; P.I.J. received funding from the Lundbeck Foundation (Denmark).	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Barklin A, 2009, ANESTHESIOLOGY, V110, P1287, DOI 10.1097/ALN.0b013e3181a10352; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; Esmon CT, 2004, TRENDS IMMUNOL, V25, P536, DOI 10.1016/j.it.2004.08.003; Faul M, 2010, TRAUMATIC BRAIN INJU; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943, DOI 10.1055/s-0037-1613338; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; Giesen PLA, 2000, SEMIN THROMB HEMOST, V26, P379, DOI 10.1055/s-2000-8456; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Grenegard M, 2008, J BIOL CHEM, V283, P18493, DOI 10.1074/jbc.M800358200; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2012, J TRAUMA ACUTE CARE, V72, P428, DOI 10.1097/TA.0b013e31821e0f93; Kanse SM, 2012, J IMMUNOL, V188, P2858, DOI 10.4049/jimmunol.1103029; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; MAKHMUDOV RM, 1985, COR VASA, V27, P456; Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Neate SL, 2013, BLOOD COAGUL FIBRIN, V24, P581, DOI 10.1097/MBC.0b013e32835fad68; Nieuwdorp M, 2006, DIABETES, V55, P480, DOI 10.2337/diabetes.55.02.06.db05-1103; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Ostrowski SR, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-64; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schrieber M, 2007, J TRAUMA, V63, P1261; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Teranishi K, 2012, INJURY, V43, P585, DOI 10.1016/j.injury.2010.09.042; van der Poll T, 2012, CURR VASC PHARMACOL, V10, P632, DOI 10.2174/157016112801784549; White NJ, 2013, SHOCK, V39, P210, DOI 10.1097/SHK.0b013e31827fd62b; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	44	47	48	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					12	19		10.1097/TA.0b013e3182aaa675			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200004	24368352				2022-02-06	
J	Patton, DA; McIntosh, AS; Kleiven, S				Patton, Declan A.; McIntosh, Andrew S.; Kleiven, Svein			The Biomechanical Determinants of Concussion: Finite Element Simulations to Investigate Brain Tissue Deformations During Sporting Impacts to the Unprotected Head	JOURNAL OF APPLIED BIOMECHANICS			English	Article						biomechanics; head injury; modeling; sport	DIFFUSE AXONAL INJURY; BRIDGING VEINS; STRAIN-RATE; FOOTBALL; DAMAGE; RUGBY; ACCELERATION; EPIDEMIOLOGY; PREDICTORS; COLLEGIATE	Concussion is an injury of specific interest in collision and contact sports, resulting in a need to develop effective preventive strategies. A detailed finite element model of the human head was used to approximate the regional distribution of tissue deformations in the brain by simulating reconstructions of unhelmeted concussion and no-injury head impacts. The results were evaluated using logistic regression analysis and it was found that angular kinematics, in the coronal plane, and maximum principal strains, in all regions of the brain, were significantly associated with concussion. The results suggested that impacts to the temporal region of the head cause coronal rotations, which render injurious strain levels in the brain. Tentative strain tolerance levels of 0.13, 0.15, and 0.26 in the thalamus, corpus callosum, and white matter, respectively, for a 50% likelihood of concussion were determined by logistic regression. The tentative strain tolerance levels compared well with previously reported results from reconstruction studies of American football and single axon, optic nerve, and brain slice culture model studies. The methods used in the current study provide an opportunity to collect unique kinematic data of sporting impacts to the unprotected head, which can be employed in various ways to broaden the understanding of concussion.	[Patton, Declan A.; McIntosh, Andrew S.] Univ New S Wales, Fac Sci, Kensington, NSW 2033, Australia; [McIntosh, Andrew S.] Monash Univ, Australian Ctr Res Sports Injury & Its Prevent, Caulfield, Vic, Australia; [Kleiven, Svein] Royal Inst Technol, Sch Technol & Hlth, Stockholm, Sweden		Patton, DA (corresponding author), Univ New S Wales, Fac Sci, POB 1, Kensington, NSW 2033, Australia.						Ackerman MJ, 1998, P IEEE, V86, P504, DOI 10.1109/5.662875; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Allsop D. L., 1988, P 32 STAPP CAR CRASH, P139; [Anonymous], 2009, PASW STAT; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baumgartner D, 2002, INT CRASHW C 2002 ME; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beusenberg MC., 2000, P INT RES C BIOM IMP; Bewick V, 2005, CRIT CARE, V9, P112, DOI 10.1186/cc3045; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chinn B., 2001, COST 327 MOTORCYCLE; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, STAPP CAR CRASH J, V16, P296; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Holbourn AHS, 1943, LANCET, V2, P438; JENNETT B, 1975, LANCET, V1, P480; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S., 2006, SCAND J FORENS SCI, V2, P73; Kleiven S, 2002, THESIS SCH TECHNOLOG; Kleiven S, 2002, TRAFFIC INJ PREV, V3, P303, DOI DOI 10.1080/15389580214633; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2001, BRIT J SPORT MED, V35, P146, DOI 10.1136/bjsm.35.3.146; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mellor A, 2000, MOT ENG C EXP; Menard S, 1995, QUNAT APP SOC SCI; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Newman J., 1999, INT RES COUNC BIOM I, P17; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Poirier MP, 2000, PEDIATR EMERG CARE, V16, P278, DOI 10.1097/00006565-200008000-00018; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schreiber DI, 1997, 41 STAPP CAR CRASH C, P277; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thibault L., 1971, P 15 STAPP CAR CRASH; Thibault L.E., 1990, P INT C BIOM IMP LYO, P191; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	63	47	48	2	22	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483	1543-2688		J APPL BIOMECH	J. Appl. Biomech.	DEC	2013	29	6					721	730		10.1123/jab.29.6.721			10	Engineering, Biomedical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	AB7QX	WOS:000331986900010	23434739				2022-02-06	
J	Caeyenberghs, K; Leemans, A; Leunissen, I; Michiels, K; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Leunissen, Inge; Michiels, Karla; Swinnen, Stephan P.			Topological correlations of structural and functional networks in patients with traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						functional connectivity; structural connectivity; brain networks; graph theoretical analysis; brain injury	WHITE-MATTER INTEGRITY; BEHAVIOR RELATIONSHIPS; GRAPH ANALYSIS; CONNECTIVITY; MRI; TRACTOGRAPHY; SCHIZOPHRENIA; ORGANIZATION; TRACKING; TISSUE	Despite an increasing amount of specific correlation studies between structural and functional connectivity, there is still a need for combined studies, especially in pathological conditions. Impairments of brain white matter (WM) and diffuse axonal injuries are commonly suspected to be responsible for the disconnection hypothesis in traumatic brain injury (TBI) patients. Moreover, our previous research on TBI patients shows a strong relationship between abnormalities in topological organization of brain networks and behavioral deficits. In this study, we combined task-related functional connectivity (using event-related fMRI) with structural connectivity (derived from fiber tractography using diffusion MRI data) estimates in the same participants (17 adults with TBI and 16 controls), allowing for direct comparison between graph metrics of the different imaging modalities. Connectivity matrices were computed covering the switching motor network, which includes the basal ganglia, anterior cingulate cortex/supplementary motor area, and anterior insula/inferior frontal gyrus. The edges constituting this network consisted of the partial correlations between the fMRI time series from each node of the switching motor network. The interregional anatomical connections between the switching-related areas were determined using the fiber tractography results. We found that graph metrics and hubs obtained showed no agreement in both groups. The topological properties of brain functional networks could not be solely accounted for by the properties of the underlying structural networks. However, combining complementary information from both imaging modalities could improve accuracy in prediction of switching performance. Direct comparison between functional task-related and anatomical structural connectivity, presented here for the first time in TBI patients, links two powerful approaches to map the patterns of brain connectivity that may underlie behavioral deficits in brain-injured patient	[Caeyenberghs, Karen] Univ Ghent, Fac Med & Hlth Sci, Dept Phys Therapy & Motor Rehabil, B-9000 Ghent, Belgium; [Caeyenberghs, Karen] Univ Ghent, Fac Med & Hlth Sci, Dept Movement & Sport Sci, B-9000 Ghent, Belgium; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, PROVIDI Lab, Utrecht, Netherlands; [Leunissen, Inge; Swinnen, Stephan P.] Katholieke Univ Leuven, Grp Biomed Sci, Movement Control & Neuroplast Res Grp, Louvain, Belgium; [Michiels, Karla] Katholieke Univ Leuven Hosp, Dept Phys Med & Rehabil, Louvain, Belgium		Caeyenberghs, K (corresponding author), Univ Ghent, Campus Heymans 1B3,De Pintelaan 185, B-9000 Ghent, Belgium.	karen.caeyenberghs@ugent.be	Leemans, Alexander/A-1784-2011	Leemans, Alexander/0000-0002-9306-6126; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843	Interuniversity Attraction Poles Programme initiated by the Belgian Science Policy Office [P7/11]; Research Fund KU LeuvenKU Leuven [OT/11/071]; FWO VlaanderenFWO [G.0482.10, G.A114.11, G.0483.10, G.0721.12]	This research was supported by the Interuniversity Attraction Poles Programme initiated by the Belgian Science Policy Office (P7/11). Additional funding was obtained by the Research Fund KU Leuven (OT/11/071) and FWO Vlaanderen (G.0482.10, G.A114.11, G.0483.10; G.0721.12).	Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; Beaulieu C, 2005, NEUROIMAGE, V25, P1266, DOI 10.1016/j.neuroimage.2004.12.053; Bosma I, 2008, J NEURO-ONCOL, V88, P77, DOI 10.1007/s11060-008-9535-3; Bullmore ET, 2012, NAT REV NEUROSCI, V13, P336, DOI 10.1038/nrn3214; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Cheng H, 2012, NEUROIMAGE, V61, P1153, DOI 10.1016/j.neuroimage.2012.03.036; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; Damoiseaux JS, 2009, BRAIN STRUCT FUNCT, V213, P525, DOI 10.1007/s00429-009-0208-6; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Griffa A, 2013, NEUROIMAGE, V80, P515, DOI 10.1016/j.neuroimage.2013.04.056; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Heitger MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062133; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Leemans A., 2009, 17 ANN M INT SOC MAG, DOI DOI 10.1093/OCCMED/KQR069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Leunissen I, 2014, HUM BRAIN MAPP, V35, P2459, DOI 10.1002/hbm.22341; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Li YH, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000395; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Lowe MJ, 2008, HUM BRAIN MAPP, V29, P818, DOI 10.1002/hbm.20576; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori T, 2007, PSYCHIAT RES-NEUROIM, V154, P133, DOI 10.1016/j.pscychresns.2006.09.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Rocca MA, 2007, NEUROLOGY, V69, P2136, DOI 10.1212/01.wnl.0000295504.92020.ca; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Skudlarski P, 2010, BIOL PSYCHIAT, V68, P61, DOI 10.1016/j.biopsych.2010.03.035; Skudlarski P, 2008, NEUROIMAGE, V43, P554, DOI 10.1016/j.neuroimage.2008.07.063; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; TEASDALE G, 1974, LANCET, V2, P81; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vaessen MJ, 2012, CEREB CORTEX, V22, P2139, DOI 10.1093/cercor/bhr298; van den Heuvel M, 2008, J NEUROSCI, V28, P10844, DOI 10.1523/JNEUROSCI.2964-08.2008; van den Heuvel MP, 2010, J NEUROSCI, V30, P15915, DOI 10.1523/JNEUROSCI.2874-10.2010; Veraart J., 2012, MAGN RESON MED, DOI [10.1002/mrm.24529, DOI 10.1002/MRM.24529.[]; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642	66	47	48	0	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	NOV 5	2013	7								726	10.3389/fnhum.2013.00726			11	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	245WK	WOS:000326494400001	24204337	Green Published, gold			2022-02-06	
J	Reinke, SN; Walsh, BH; Boylan, GB; Sykes, BD; Kenny, LC; Murray, DM; Broadhurst, DI				Reinke, Stacey N.; Walsh, Brian H.; Boylan, Geraldine B.; Sykes, Brian D.; Kenny, Louise C.; Murray, Deirdre M.; Broadhurst, David I.			H-1 NMR Derived Metabolomic Profile of Neonatal Asphyxia in Umbilical Cord Serum: Implications for Hypoxic Ischemic Encephalopathy	JOURNAL OF PROTEOME RESEARCH			English	Article						asphyxia; hypoxic ischemic encephalopathy; nuclear magnetic resonance; cord serum; metabolomics; succinate; ketone; 3-hydroxybutryate	TRAUMATIC BRAIN-INJURY; ADAPTATION; EEG; HYPOTHERMIA; DISCOVERY; INFANTS; MODEL; NMR; HIF	Neonatal hypoxic ischemic encephalopathy (HIE) is a severe consequence of perinatal asphyxia (PA) that can result in life-long neurological disability. Disease mechanisms, including the role and interaction of individual metabolic pathways, remain unclear. As hypoxia is an acute condition, aerobic energy metabolism is central to global metabolic pathways, and these metabolites are detectable using H-1 NMR spectroscopy, we hypothesized that characterizing the NMR-derived umbilical cord serum metabolome would offer insight into the consequences of PA that lead to HIE. Fifty-nine at-risk infants were enrolled, together with 1:1 matched healthy controls, and stratified by disease severity (n = 25, HIE; n = 34, non HIE PA). Eighteen of 37 reproducibly detectable metabolites were significantly altered between study groups. Acetone, 3-hydroxybutyrate, succinate, and glycerol were significantly differentially altered in severe HIE. Multivariate data analysis revealed a metabolite profile associated with both asphyxia and HIE. Multiple-linear regression modeling using 4 metabolites (3-hydroxybutyrate, glycerol, O-phosphocholine, and succinate) predicted HIE severity with an adjusted R-2 of 0.4. Altered ketones. suggest that systemic metabolism may play a critical role in preventing neurological injury, while altered succinate provides a possible explanation for hypoxia-inducible factor 1-alpha (HIF-1 alpha) stabilization in HI injury.	[Reinke, Stacey N.; Broadhurst, David I.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Reinke, Stacey N.; Sykes, Brian D.] Univ Alberta, Dept Biochem, Edmonton, AB, Canada; [Walsh, Brian H.; Boylan, Geraldine B.; Murray, Deirdre M.] Natl Univ Ireland Univ Coll Cork, Neonatal Brain Res Grp, Dept Paediat & Child Hlth, Cork, Ireland; [Walsh, Brian H.; Boylan, Geraldine B.; Murray, Deirdre M.] Natl Univ Ireland Univ Coll Cork, Irish Ctr Fetal & Neonatal Translat Res INFANT, Cork, Ireland; Cork Univ Matern Hosp, Cork, Ireland; [Kenny, Louise C.] Natl Univ Ireland Univ Coll Cork, Dept Obstet & Gynaecol, Cork, Ireland		Broadhurst, DI (corresponding author), Univ Alberta, Dept Med, Edmonton, AB, Canada.	dbroadhu@ualberta.ca	Walsh, Brian/AAA-6421-2020; Kenny, Louise/X-6329-2019; Kenny, Louise C/G-1112-2011	Kenny, Louise/0000-0002-9011-759X; Kenny, Louise C/0000-0002-9011-759X; Broadhurst, David/0000-0003-0775-9581; Murray, Deirdre/0000-0002-2201-9912; Reinke, Stacey/0000-0002-0758-0330; Boylan, Geraldine/0000-0003-0920-5291; Walsh, Brian/0000-0003-4665-6884	Alberta Innovates-Health Solutions (AIHS) studentship program; Molecular Medicines Ireland; Health Research Board Clinical Scientist Award [CSA/201240]; (Ireland) National Children's Research Centre (BASELINE); Canadian Institutes of Health Research (CIHR) (BDS)Canadian Institutes of Health Research (CIHR) [37769]; Pfizer CanadaPfizer	The authors wish to thank the nurses and clinical staff of the labour ward and neonatal intensive care unit for their help in identifying potential candidates for this study. S.N.R. was funded through the Alberta Innovates-Health Solutions (AIHS) studentship program. B.H.W. was funded through Molecular Medicines Ireland. This study was supported by grants from the Health Research Board Clinical Scientist Award (DMM and BiHiVE study, CSA/201240), the (Ireland) National Children's Research Centre (BASELINE), and Canadian Institutes of Health Research (CIHR) (BDS no. 37769). D.I.B. holds salary support from Pfizer Canada.	Amiel-Tison C, 2002, PEDIATR NEUROL, V27, P196, DOI 10.1016/S0887-8994(02)00436-8; Atzori L, 2010, J MATERN-FETAL NEO M, V23, P134, DOI 10.3109/14767058.2010.517033; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Beckstrom AC, 2011, J CHROMATOGR A, V1218, P1899, DOI 10.1016/j.chroma.2011.01.086; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Chen WQ, 2008, ACTA NEUROCHIR SUPPL, V102, P395, DOI 10.1007/978-3-211-85578-2_77; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dunn WB, 2012, BIOANALYSIS, V4, P2249, DOI [10.4155/bio.12.204, 10.4155/BIO.12.204]; Dunn WB, 2011, CHEM SOC REV, V40, P387, DOI 10.1039/b906712b; Fan X, 2009, BRAIN RES REV, V62, P99, DOI 10.1016/j.brainresrev.2009.09.006; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Hastie T., 2009, ELEMENTS STAT LEARNI, V2nd ed., P745, DOI DOI 10.1007/978-0-387-84858-7; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Huang CC, 1999, NEW ENGL J MED, V341, P328, DOI 10.1056/NEJM199907293410504; Kanelakis KC, 2009, J BIOMOL SCREEN, V14, P627, DOI 10.1177/1087057109333976; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kirwan JA, 2013, ANAL BIOANAL CHEM, V405, P5147, DOI 10.1007/s00216-013-6856-7; Krzanowski W.J., 1988, PRINCIPLES MULTIVARI, P563; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; LEVENE MI, 1986, LANCET, V1, P67, DOI 10.1016/S0140-6736(86)90718-X; Liu J, 2011, J CEREBR BLOOD F MET, V31, P547, DOI 10.1038/jcbfm.2010.125; Locatelli A, 2008, EUR J OBSTET GYN R B, V139, P146, DOI 10.1016/j.ejogrb.2008.01.003; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; Murray DM, 2008, ARCH DIS CHILD-FETAL, V93, pF183, DOI 10.1136/adc.2006.100800; Murray DM, 2006, PEDIATRICS, V118, P41, DOI 10.1542/peds.2005-1524; Murray DM, 2009, PEDIATRICS, V124, pE459, DOI 10.1542/peds.2008-2190; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Peres-Neto PR, 2003, ECOLOGY, V84, P2347, DOI 10.1890/00-0634; Platt MW, 2005, SEMIN FETAL NEONAT M, V10, P341, DOI 10.1016/j.siny.2005.04.001; Pressler RM, 2001, CLIN NEUROPHYSIOL, V112, P31, DOI 10.1016/S1388-2457(00)00517-4; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Reinke SN, 2010, MOL GENET METAB, V100, P274, DOI 10.1016/j.ymgme.2010.03.013; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Solberg R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009606; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Suzuki Y, 2009, BRAIN RES, V1268, P17, DOI 10.1016/j.brainres.2009.02.074; Szeto SSW, 2010, J PROTEOME RES, V9, P6729, DOI 10.1021/pr100880y; US FDA, 2001, US FDA BIOAN METH VA; Veech RL, 2001, IUBMB LIFE, V51, P241; VOLPE JJ, 2001, NEUROLOGY NEWBORN, P912; Wallace DC, 2007, EMERY RIMOINS PRINCI, P194; Walsh BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050520; Xia JG, 2013, METABOLOMICS, V9, P280, DOI 10.1007/s11306-012-0482-9	54	47	49	1	21	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	SEP	2013	12	9					4230	4239		10.1021/pr400617m			10	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295WT	WOS:000330147800036	23931672				2022-02-06	
J	Zickefoose, S; Hux, K; Brown, J; Wulf, K				Zickefoose, Samantha; Hux, Karen; Brown, Jessica; Wulf, Katrina			Let the games begin: A preliminary study using Attention Process Training-3 and Lumosity (TM) brain games to remediate attention deficits following traumatic brain injury	BRAIN INJURY			English	Article						Acquired brain injury remediation; APT; APT-3; attention deficits; attention deficits following traumatic brain injury; Attention Process Training; attention treatment; brain games; computer-based brain injury treatment; Lumosity	MEMORY	Primary objective: Computer-based treatments for attention problems have become increasingly popular and available. The researchers sought to determine whether improved performance by survivors of severe traumatic brain injury (TBI) on two computer-based treatments generalized to improvements on comparable, untrained tasks and ecologically-plausible attention tasks comprising a standardized assessment. Research design: The researchers used an -A-B-A-C-A treatment design repeated across four adult survivors of severe TBI. Methods and procedures: Participants engaged in 8 weeks of intervention using both Attention Process Training-3 (APT-3) and Lumosity (TM) (2010) Brain Games. Two participants received APT-3 treatment first, while the other two received Lumosity (TM) treatment first. All participants received both treatments throughout the course of two, 1-month intervention phases. Main outcomes and results: Individual growth curve analyses showed participants made significant improvements in progressing through both interventions. However, limited generalization occurred: one participant demonstrated significantly improved performance on one of five probe measures and one other participant showed improved performance on some sub-tests of the Test of Everyday Attention; no other significant generalization results emerged. These findings call into question the assumption that intervention using either APT-3 or Lumosity (TM) will prompt generalization beyond the actual tasks performed during treatment.	[Zickefoose, Samantha; Hux, Karen; Brown, Jessica] Univ Nebraska, Barkley Mem Ctr, Lincoln, NE 68583 USA; [Wulf, Katrina] Qual Living, Omaha, NE USA		Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr 351, Lincoln, NE 68583 USA.	khux1@unl.edu	Hux, Karen/AAQ-2078-2020				ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Dakim Inc., 2010, DAK BRAIN FITN CLIN; Fuyuno I, 2007, NATURE, V447, P18, DOI 10.1038/447018a; George DR, 2011, GERONTOLOGIST, V51, P590, DOI 10.1093/geront/gnr042; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Hardy Joseph., 2009, SCI LUMOSITY; Kawashima R, 2005, J GERONTOL A-BIOL, V60, P380, DOI 10.1093/gerona/60.3.380; Kertesz A., 2006, W APHASIA BATTERY RE; Kesler SR, 2011, BRAIN INJURY, V25, P101, DOI 10.3109/02699052.2010.536194; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Labs Lumos, 2010, LUM RECL YOUR BRAIN; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Palmese CA, 2000, BRAIN INJURY, V14, P535; Papp KV, 2009, ALZHEIMERS DEMENT, V5, P50, DOI 10.1016/j.jalz.2008.10.008; Park N, 1999, NEUROPSYCHOL REHABIL, V9, P117; Pierce SM, 2001, J HEAD TRAUMA REHAB, V16, P406, DOI 10.1097/00001199-200108000-00009; Robertson I., 1994, TEST EVERYDAY ATTENT; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Smith GE, 2009, J AM GERIATR SOC, V57, P594, DOI 10.1111/j.1532-5415.2008.02167.x; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 2011, ATTENTION PROCESS TR; Sohlberg M.M., 1986, ATTENTION PROCESS TR; Sohlberg M. M., 1994, ATTENTION PROCESS TR; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Sullivan K, 2011, ANN CONV AM SPEECH L; World Health Organization, 2007, INT CLASS FUNCT DIS	29	47	49	1	93	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2013	27	6					707	716		10.3109/02699052.2013.775484			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	143QO	WOS:000318882500010	23672446				2022-02-06	
J	Mac Donald, C; Johnson, A; Cooper, D; Malone, T; Sorrell, J; Shimony, J; Parsons, M; Snyder, A; Raichle, M; Fang, R; Flaherty, S; Russell, M; Brody, DL				Mac Donald, Christine; Johnson, Ann; Cooper, Dana; Malone, Thomas; Sorrell, James; Shimony, Joshua; Parsons, Matthew; Snyder, Abraham; Raichle, Marcus; Fang, Raymond; Flaherty, Stephen; Russell, Michael; Brody, David L.			Cerebellar White Matter Abnormalities following Primary Blast Injury in US Military Personnel	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; EXPOSURE; COMBAT; SCALE; IRAQI; DEPRESSION; VETERANS; SEQUELAE	Little is known about the effects of blast exposure on the human brain in the absence of head impact. Clinical reports, experimental animal studies, and computational modeling of blast exposure have suggested effects on the cerebellum and brainstem. In US military personnel with isolated, primary blast-related 'mild' traumatic brain injury and no other known insult, we found diffusion tensor MRI abnormalities consistent with cerebellar white matter injury in 3 of 4 subjects. No abnormalities in other brain regions were detected. These findings add to the evidence supporting the hypothesis that primary blast exposure contributes to brain injury in the absence of head impact and that the cerebellum may be particularly vulnerable. However, the clinical effects of these abnormalities cannot be determined with certainty; none of the subjects had ataxia or other detected evidence of cerebellar dysfunction. The details of the blast events themselves cannot be disclosed at this time, thus additional animal and computational modeling will be required to dissect the mechanisms underlying primary blast-related traumatic brain injury. Furthermore, the effects of possible subconcussive impacts and other military-related exposures cannot be determined from the data presented. Thus many aspects of topic will require further investigation.	[Mac Donald, Christine; Johnson, Ann; Cooper, Dana; Malone, Thomas; Sorrell, James; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Shimony, Joshua; Parsons, Matthew; Snyder, Abraham; Raichle, Marcus] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Fang, Raymond; Flaherty, Stephen] Landstuhl Reg Med Ctr, Dept Trauma Surg, Landstuhl, Germany; [Russell, Michael] USA, Rehabil & Reintegrat Div, San Antonio, TX USA		Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0061]; United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32NS062529, 5K23HD053212, P30NS048056, P50NS06833, 5K08NS49237]; U.S. Army Medical Research Acquisition Activity [W81XWH-09-2-0057]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD053212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS048056, F32NS062529, P50NS006833, K08NS049237] Funding Source: NIH RePORTER	The study was supported by grants from the Congressionally Directed Medical Research Program (W81XWH-08-2-0061, to Dr. Brody), the United States National Institutes of Health (F32NS062529, to Dr. Mac Donald; 5K23HD053212, to Dr. Shimony; P30NS048056, to Dr. Snyder; P50NS06833, to Drs. Raichle and Snyder; and 5K08NS49237, to Dr. Brody) and U.S. Army Medical Research Acquisition Activity (W81XWH-09-2-0057) to Dr. Russell, under a protocol approved by Brooke Army Medical Center, San Antonio, TX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Conners C. K., 2000, CONNERS CONTINUOUS P; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delis D.C., 2000, CALIFORNIA VERBAL LE; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hamster K., 1983, MULTILINGUAL APHASIA; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Matthews CG., 1964, INSTRUCTION MANUAL A; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1917, J ROY ARMY MED CORPS, V29, P662; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Peskind ER, 2010, NEUROIMAGE; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Reitan RM, 1992, TRAIL MAKING TEST MA; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Smith A., 1991, SYMBOL DIGIT MODALIT; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stoodley CJ, 2009, BRAIN LANG, V110, P149, DOI 10.1016/j.bandl.2009.07.006; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Talavage TM, 2010, J NEUROTRAUMA; Taylor L, 1991, COMPENDIUM NEUROPSYC; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WechslerD, 2001, WECHSLER TEST ADULT; Wilkinson C. W., 2012, FRONT NEUROL, V3, P11, DOI DOI 10.3389/FNEUR.2012.00011; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	53	47	47	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e55823	10.1371/journal.pone.0055823			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092XV	WOS:000315157200070	23409052	Green Published, gold, Green Submitted			2022-02-06	
J	Dreier, JP; Isele, T; Reiffurth, C; Offenhauser, N; Kirov, SA; Dahlem, MA; Herreras, O				Dreier, Jens P.; Isele, Thomas; Reiffurth, Clemens; Offenhauser, Nikolas; Kirov, Sergei A.; Dahlem, Markus A.; Herreras, Oscar			Is Spreading Depolarization Characterized by an Abrupt, Massive Release of Gibbs Free Energy from the Human Brain Cortex?	NEUROSCIENTIST			English	Article						spreading depression; stroke; subarachnoid hemorrhage; intracerebral hemorrhage; traumatic brain injury; epilepsy; migraine	LOW EXTRACELLULAR MAGNESIUM; FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; EPILEPTIFORM ACTIVITY; MIGRAINE AURA; IN-VIVO; CORTICAL ACTIVITY; ION HOMEOSTASIS; BLOOD-FLOW; DC SHIFTS	In the evolution of the cerebral cortex, the sophisticated organization in a steady state far away from thermodynamic equilibrium has produced the side effect of two fundamental pathological network events: ictal epileptic activity and spreading depolarization. Ictal epileptic activity describes the partial disruption, and spreading depolarization describes the near-complete disruption of the physiological double Gibbs-Donnan steady state. The occurrence of ictal epileptic activity in patients has been known for decades. Recently, unequivocal electrophysiological evidence has been found in patients that spreading depolarizations occur abundantly in stroke and brain trauma. The authors propose that the ion changes can be taken to estimate relative changes in Gibbs free energy from state to state. The calculations suggest that in transitions from the physiological state to ictal epileptic activity to spreading depolarization to death, the cortex releases Gibbs free energy in a stepwise fashion. Spreading depolarization thus appears as a twilight state close to death. Consistently, electrocorticographic recordings in the core of focal ischemia or after cardiac arrest display a smooth transition from the initial spreading depolarization component to the later ultraslow negative potential, which is assumed to reflect processes in cellular death.	[Dreier, Jens P.; Reiffurth, Clemens; Offenhauser, Nikolas] Charite, Ctr Stroke Res Berlin, D-10117 Berlin, Germany; [Dreier, Jens P.] Charite, Dept Neurol, D-10117 Berlin, Germany; [Dreier, Jens P.; Reiffurth, Clemens; Offenhauser, Nikolas] Charite, Dept Expt Neurol, D-10117 Berlin, Germany; [Isele, Thomas; Dahlem, Markus A.] Tech Univ Berlin, Inst Theoret Phys, Berlin, Germany; [Kirov, Sergei A.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA USA; [Herreras, Oscar] CSIC, Inst Cajal, Dept Syst Neurosci, E-28002 Madrid, Spain		Dreier, JP (corresponding author), Charite, Ctr Stroke Res, Campus Charite Mitte,Charitepl 1, D-10117 Berlin, Germany.	jens.dreier@charite.de	herreras, oscar/D-5256-2016; Herreras, Oscar/O-1711-2019; Dahlem, Markus/A-8805-2008	herreras, oscar/0000-0002-8210-3710; Herreras, Oscar/0000-0002-8210-3710; Dahlem, Markus/0000-0002-7532-0127; Reiffurth, Clemens/0000-0002-1372-1240; Dreier, Jens/0000-0001-7459-2828	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG DR 323/3-1, 323/5-1, 323/6-1]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, )Federal Ministry of Education & Research (BMBF) [01 EO 0801, 01GQ1001C B2]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057113]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057113] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported by grants of the Deutsche Forschungsgemeinschaft (DFG DR 323/3-1, 323/5-1, 323/6-1), the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801, Bernstein Center for Computational Neuroscience Berlin 01GQ1001C B2 and Era-Net Neuron SDSVD) to Dr. Dreier and the National Institutes of Health, NS057113 to Dr. Kirov.	Alle H, 2009, SCIENCE, V325, P1405, DOI 10.1126/science.1174331; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; AVOLI M, 1991, ANN NEUROL, V30, P589, DOI 10.1002/ana.410300412; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Berger M, 2008, CEPHALALGIA, V28, P558, DOI 10.1111/j.1468-2982.2008.01556.x; BRANSTON NM, 1977, J NEUROL SCI, V32, P305, DOI 10.1016/0022-510X(77)90014-4; BURES J, 1957, PFLUG ARCH GES PHYS, V264, P325, DOI 10.1007/BF00364173; Canals S, 2005, J NEUROPHYSIOL, V94, P943, DOI 10.1152/jn.01145.2004; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Dalkara T, 2010, LANCET NEUROL, V9, P309, DOI 10.1016/S1474-4422(09)70358-8; DIETZEL I, 1989, GLIA, V2, P25, DOI 10.1002/glia.440020104; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978, DOI 10.1097/00004647-199809000-00007; Dreier JP, 2002, BRAIN, V125, P102, DOI 10.1093/brain/awf007; DREIER JP, 1991, EXP BRAIN RES, V87, P581; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Eikermann-Haerter K, 2012, CIRCULATION, V125, P335, DOI 10.1161/CIRCULATIONAHA.111.045096; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; Gerich FJ, 2006, J NEUROPHYSIOL, V96, P492, DOI 10.1152/jn.01015.2005; Gorji A, 2001, BRAIN RES, V906, P74, DOI 10.1016/S0006-8993(01)02557-4; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154, DOI 10.1152/jn.1956.19.2.154; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; HERRERA FC, 1992, COMP BIOCHEM PHYS A, V103, P29, DOI 10.1016/0300-9629(92)90238-L; HERRERAS O, 1993, BRAIN RES, V610, P283, DOI 10.1016/0006-8993(93)91412-L; HERRERAS O, 1994, J NEUROSCI, V14, P7087; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Kager H, 2002, J NEUROPHYSIOL, V88, P2700, DOI 10.1152/jn.00237.2002; Kleeberg J, 2004, AM J PHYSIOL-HEART C, V286, pH1339, DOI 10.1152/ajpheart.00227.2003; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Kurth T, 2012, LANCET NEUROL, V11, P92, DOI 10.1016/S1474-4422(11)70266-6; LAMANNA JC, 1975, BRAIN RES, V88, P145, DOI 10.1016/0006-8993(75)90963-4; Largo C, 1996, J NEUROSCI, V16, P1219; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LEAF A, 1956, BIOCHEM J, V62, P241, DOI 10.1042/bj0620241; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; LEAO AAP, 1945, J NEUROPHYSIOL, V8, P33; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Makarova J, 2010, J NEUROPHYSIOL, V103, P2446, DOI 10.1152/jn.01045.2009; MARTINSFERREIRA H, 1974, J NEUROPHYSIOL, V37, P773, DOI 10.1152/jn.1974.37.4.773; Maslarova A, 2011, STROKE, V42, P2917, DOI 10.1161/STROKEAHA.111.621581; Matsushima K, 1996, J CEREBR BLOOD F MET, V16, P221, DOI 10.1097/00004647-199603000-00006; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MODY I, 1987, J NEUROPHYSIOL, V57, P869, DOI 10.1152/jn.1987.57.3.869; Muller M, 2000, J NEUROPHYSIOL, V83, P735, DOI 10.1152/jn.2000.83.2.735; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Ohta K, 2001, STROKE, V32, P535, DOI 10.1161/01.STR.32.2.535; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; Oliveira-Ferreira AI, 2012, FUTUR NEUROL, V7, P45, DOI 10.2217/FNL.11.69; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Risher WC, 2009, GLIA, V57, P207, DOI 10.1002/glia.20747; Selman WR, 2004, BRAIN RES, V999, P167, DOI 10.1016/j.brainres.2003.11.016; Shapiro BE, 2001, J COMPUT NEUROSCI, V10, P99, DOI 10.1023/A:1008924227961; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; SOMJEN GG, 2004, IONS BRAIN; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891, DOI 10.1152/jn.1997.78.2.891; TASAKI I, 1991, BIOCHEM BIOPH RES CO, V174, P293, DOI 10.1016/0006-291X(91)90519-D; Tidow H, 2010, TRENDS BIOCHEM SCI, V35, P653, DOI 10.1016/j.tibs.2010.05.004; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; VANHARREVELD A, 1965, J CELL BIOL, V25, P117, DOI 10.1083/jcb.25.1.117; VANHARREVELD A, 1959, J NEUROCHEM, V3, P300; Vorisek I, 1997, J CEREBR BLOOD F MET, V17, P191; Windmuller O, 2005, BRAIN, V128, P2042, DOI 10.1093/brain/awh545; Yanamoto H, 2005, STROKE, V36, P1544, DOI 10.1161/01.STR.0000169903.09253.c7	82	47	47	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	FEB	2013	19	1					25	42		10.1177/1073858412453340			18	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	057FZ	WOS:000312549600008	22829393	Green Accepted, Green Published			2022-02-06	
J	Maggio, N; Cavaliere, C; Papa, M; Blatt, I; Chapman, J; Segal, M				Maggio, Nicola; Cavaliere, Carlo; Papa, Michele; Blatt, Ilan; Chapman, Joab; Segal, Menahem			Thrombin regulation of synaptic transmission: Implications for seizure onset	NEUROBIOLOGY OF DISEASE			English	Article						Thrombin; Seizures; Epilepsy; Inhibition; Hemorrhage; Hippocampus	PROTEASE-ACTIVATED RECEPTOR-1; CORTICOSTEROID MODULATION; STATUS EPILEPTICUS; MESSENGER-RNA; CELL-DEATH; EXPRESSION; BRAIN; PROTHROMBIN; EPILEPSY; NEURODEGENERATION	Seizures are a common outcome of cerebrovascular events as well as of traumatic brain injuries. Thrombin, a protease-activated receptor (PAR) agonist, has been implicated in the onset of seizures in these settings, yet its mode of action is not entirely clear. In this study, the effect of thrombin and a PAR-1 agonist on neuronal excitability and synaptic currents was assessed by whole cell-patch recordings of pyramidal neurons in rat hippocampal slices. In addition, PAR-1 distribution in different hippocampal regions was assessed using immunohistochemistry. We found that thrombin caused an increase in spontaneous action potential discharges of CA3 but not of CA1 pyramidal neurons. When excitatory synaptic activity was blocked, thrombin caused a marked reduction in spontaneous IPSCs in CA3 neurons and a marked increase in the frequency of IPSCs in CA1 neurons. These effects are likely to be local, as they were reproduced in TTX-treated slices. In parallel, thrombin increased both the frequency and the amplitude of mEPSCs only in CA3 neurons. These effects were blocked by a selective PAR-1 antagonist. The higher expression of PAR-1 in stratum lucidum of CA3 is correlated with the effects of thrombin in this region. These results suggest that thrombin triggers the generation of epileptic seizures by reducing the inhibitory and increasing the excitatory tone in CA3 neurons, providing a novel insight to the pathophysiology of seizures following cerebrovascular events and present new avenues for therapeutic intervention. (C) 2012 Elsevier Inc. All rights reserved.	[Maggio, Nicola] Chaim Sheba Med Ctr, Talpiot Med Leadership Program, IL-52621 Tel Hashomer, Israel; [Maggio, Nicola; Blatt, Ilan; Chapman, Joab] Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel; [Maggio, Nicola; Blatt, Ilan; Chapman, Joab] Chaim Sheba Med Ctr, Joseph Sagol Neurosci Ctr, IL-52621 Tel Hashomer, Israel; [Maggio, Nicola; Segal, Menahem] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Cavaliere, Carlo; Papa, Michele] Univ Naples 2, Dipartimento Med Pubbl Clin & Preventiva, Lab Morphol Neuronal Networks, I-80138 Naples, Italy; [Chapman, Joab] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; [Blatt, Ilan; Chapman, Joab] Tel Aviv Univ, Sackler Fac Med, Dept Neurol, IL-69978 Tel Aviv, Israel		Maggio, N (corresponding author), Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel.	nicola.maggio@sheba.health.gov.il	Papa, Michele/AAB-1759-2021; Chapman, Joab/E-4598-2010; Papa, Michele/A-7228-2017; Cavaliere, Carlo/K-6544-2016; SEGAL, MENAHEM/K-1577-2012	Papa, Michele/0000-0002-6609-7453; Papa, Michele/0000-0003-4834-7970; Cavaliere, Carlo/0000-0002-3297-2213; Maggio, Nicola/0000-0001-5041-2108	Sheba Medical Center	NM is the recipient of a Talpiot Fellowship at the Sheba Medical Center. The funding agency did not have a role in study design: collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Arai T, 2006, J NEUROPATH EXP NEUR, V65, P19, DOI 10.1097/01.jnen.0000196133.74087.cb; Atkinson L, 2004, NEUROSCIENCE, V123, P761, DOI 10.1016/j.neuroscience.2003.08.065; Camilo O, 2004, STROKE, V35, P1769, DOI 10.1161/01.STR.0000130989.17100.96; Cavaliere C, 2007, NEURON GLIA BIOL, V3, P141, DOI 10.1017/S1740925X07000695; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2007, NEUROSURGERY, V61, P60, DOI 10.1227/01.neu.0000279724.05898.e7; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; FRENCH CR, 1990, J GEN PHYSIOL, V95, P1139, DOI 10.1085/jgp.95.6.1139; Gilmore E, 2010, NEUROLOGIST, V16, P165, DOI 10.1097/NRL.0b013e3181c7cd0b; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Hashimotodani Y, 2011, J NEUROSCI, V31, P3104, DOI 10.1523/JNEUROSCI.6000-10.2011; Heinemann U, 2004, CURR OPIN NEUROL, V17, P155, DOI 10.1097/00019052-200404000-00012; Heinemann U, 2002, PROG BRAIN RES, V135, P197; Isaeva E, 2012, ANN NEUROL; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Lee CJ, 2007, J PHYSIOL-LONDON, V581, P1057, DOI 10.1113/jphysiol.2007.130377; Lee DY, 2006, BIOCHEM BIOPH RES CO, V346, P727, DOI 10.1016/j.bbrc.2006.05.174; Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073; Lossius MI, 2005, EPILEPSIA, V46, P1246, DOI 10.1111/j.1528-1167.2005.57904.x; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Luo W, 2007, BRAIN RES REV, V56, P331, DOI 10.1016/j.brainresrev.2007.08.002; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; Maggio N, 2012, EXP NEUROL, V234, P200, DOI 10.1016/j.expneurol.2011.12.035; Maggio N, 2009, J NEUROSCI, V29, P2857, DOI 10.1523/JNEUROSCI.4399-08.2009; Olsen T S, 2001, Curr Atheroscler Rep, V3, P340, DOI 10.1007/s11883-001-0029-4; Papa M, 2003, J COMP NEUROL, V466, P119, DOI 10.1002/cne.10886; Shavit E, 2011, J NEUROCHEM, V119, P460, DOI 10.1111/j.1471-4159.2011.07436.x; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Wang YF, 2006, J NEUROCHEM, V98, P1046, DOI 10.1111/j.1471-4159.2006.03950.x; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257	32	47	47	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2013	50						171	178		10.1016/j.nbd.2012.10.017			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	073QR	WOS:000313758100019	23103417				2022-02-06	
J	Honeybul, S; Ho, KM; Lind, CRP				Honeybul, Stephen; Ho, Kwok M.; Lind, Christopher R. P.			What Can Be Learned from the DECRA Study	WORLD NEUROSURGERY			English	Article						Decompressive craniectomy; DECRA; Neurotrauma	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; IMPACT; DEATH	BACKGROUND There has been a resurgence of interest in the use of decompressive craniectomy for severe traumatic brain injury (TBI). Numerous studies have shown that the procedure can consistently reduce intracranial pressure (ICP), and a significant number of patients achieve a good long-term functional recovery. However, there has been debate regarding clinical indications and patient selection. METHODS The DECRA (Decompressive Craniectomy in Patients with Severe Traumatic Brain Injury) study compared patients who underwent early decompressive craniectomy for diffuse TBI with patients who received standard medical therapy. Of patients, 70% in the craniectomy group had an unfavourable outcome versus 51% in the standard care group (odds ratio 2.21 [ 95% confidence interval 1.14-4.26]; P = 0.02). Based on these results, the authors concluded that decompressive craniectomy was associated with more unfavorable outcomes and that by adopting standard medical therapy rather than surgical decompression the health care system would save millions of dollars. These conclusions are not really supported by closer examination of the basic data. There were problems with randomization such that the patients in the surgical arm appeared to have sustained a more severe primary TBI, the ICP threshold of >20 mm Hg for >15 minutes did not reflect clinical practice, and there was a high crossover rate from the standard care arm to the surgical arm. Because of these problems, the DECRA trial has received a great deal of criticism, and some authorities have claimed that the results should have no influence on clinical practice. This claim is perhaps unfair, and an alternative interpretation is offered. RESULTS Overall, the results of the DECRA study showed that a relatively transient and mild increase in ICP (>20 mm Hg for 15 minutes as recruitment criterion) does not imply that there is significant ongoing secondary brain injury, and any potential improvement obtained by surgical decompression may well be offset by surgical morbidity. CONCLUSIONS The role of decompressive craniectomy when ICP continues to increase >= 20 mm Hg remains to be established. The ongoing RESCUEicp (Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intra-Cranial Pressure) study hopes to address this issue.	[Honeybul, Stephen; Lind, Christopher R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Honeybul, Stephen; Lind, Christopher R. P.] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Lind, Christopher R. P.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Lind, Christopher/K-3629-2012	Ho, Kwok M./0000-0002-6705-6004; Lind, Christopher/0000-0001-9991-1725			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Cooper DJ, 2011, MED J AUSTRALIA, V194, P437, DOI 10.5694/j.1326-5377.2011.tb03053.x; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Hossain-Ibrahim MK, 2011, BRIT J NEUROSURG, V25, P538, DOI 10.3109/02688697.2011.584641; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; Komotar RJ, 2011, NEUROSURGERY, V69, pN22, DOI 10.1227/01.neu.0000400020.24025.21; Marion DW, 2011, LANCET NEUROL, V10, P497, DOI 10.1016/S1474-4422(11)70098-9; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Timmons SD, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Vashu R, 2011, ACTA NEUROCHIR, V153, P2065, DOI 10.1007/s00701-011-1101-7; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616	25	47	48	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2013	79	1					159	161		10.1016/j.wneu.2012.08.012			3	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	100RB	WOS:000315717800039	23022646				2022-02-06	
J	MacGregor, AJ; Dougherty, AL; Tang, JJ; Galarneau, MR				MacGregor, Andrew J.; Dougherty, Amber L.; Tang, Janet J.; Galarneau, Michael R.			Postconcussive Symptom Reporting Among US Combat Veterans With Mild Traumatic Brain Injury From Operation Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						combat; concussion; depression; mild traumatic brain injury; military; posttraumatic stress disorder; PTSD	MENTAL-HEALTH PROBLEMS; AFGHANISTAN; DISORDER; DEPLOYMENT; OUTCOMES; RATES	Objective: To examine the association between postconcussive symptoms and mild traumatic brain injury (MTBI) among combat veterans while adjusting for posttraumatic stress disorder (PTSD) and depression. Patients: Military personnel with provider-diagnosed MTBI (n = 334) or nonhead injury (n = 658) were identified from the Expeditionary Medical Encounter Database. Main Outcome Measures: Post-Deployment Health Assessments and Re-Assessments were used to examine postconcussive symptoms and self-rated health. Results: Personnel with MTBI were more likely to report headache (odds ratio [OR] = 3.37; 95% confidence interval [CI] = 2.19-5.17), back pain (OR = 1.79; 95% CI = 1.23-2.60), memory problems (OR = 1.86; 95% CI = 1.20-2.88), tinnitus (OR = 1.63; 95% CI = 1.10-2.41), and dizziness (OR = 2.13; 95% CI = 1.06-4.29) compared with those with non-head injuries. Among those with MTBI, self-reported decline in health was associated with memory problems (OR = 5.07; 95% CI = 2.56-10.02) and dizziness (OR = 10.60; 95% CI = 3.48-32.27). Conclusions: Mild traumatic brain injury is associated with reports of negative health consequences among combat veterans even when accounting for co-occurring psychological morbidity. The identification of postconcussive symptoms related to declines in a service member's self-rated health may be important in targeting and prioritizing clinical interventions.	[MacGregor, Andrew J.; Dougherty, Amber L.; Tang, Janet J.; Galarneau, Michael R.] USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA		Dougherty, AL (corresponding author), USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Navy Bureau of Medicine under the Wounded, Ill and Injured/Psychological Health/Traumatic Brain Injury Program [60819]	This work was supported by the US Navy Bureau of Medicine under the Wounded, Ill and Injured/Psychological Health/Traumatic Brain Injury Program, Work Unit No. 60819.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; [Anonymous], 2005, POSTD HLTH REASS FOR; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Commission on Professional Hospital Activities, 1977, INT CLASS DIS; Deployment Health Clinical Center, 2003, POSTD HLTH ASS DD FO; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Institute of Medicine, 2009, GULF WAR HLTH LONG T, V7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; MacGregor AJ, 2009, MIL MED, V174, P224, DOI 10.7205/MILMED-D-03-9107; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; McCrea M., 2008, OXFORD WORKSHOP SERI; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	42	47	47	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					59	67		10.1097/HTR.0b013e3182596382			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400007	22688214				2022-02-06	
J	Kamnaksh, A; Kwon, SK; Kovesdi, E; Ahmed, F; Barry, ES; Grunberg, NE; Long, J; Agoston, D				Kamnaksh, Alaa; Kwon, Sook-Kyung; Kovesdi, Erzsebet; Ahmed, Farid; Barry, Erin S.; Grunberg, Neil E.; Long, Joseph; Agoston, Denes			Neurobehavioral, cellular, and molecular consequences of single and multiple mild blast exposure	ELECTROPHORESIS			English	Article						Blast; Cumulative effect; Neurobehavior; Protein biomarkers; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ENDOTHELIAL GROWTH-FACTOR; COMBAT VETERANS; NEUROGENESIS; HIPPOCAMPUS; EXPRESSION; CELLS; MODEL; RAT	Mild traumatic brain injury, caused by the exposure to single or repeated blast overpressure, is a principal concern due to its pathological complexity and neurobehavioral similarities with posttraumatic stress disorder. In this study, we exposed rats to a single or multiple (five total; administered on consecutive days) mild blasts, assessed their behavior at 1 and 16 days postinjury) and performed histological and protein analyses of brains and plasma at an early (2 h) and a late (22 days) termination time point. One day postinjury, multiple-injured (MI) rats showed the least general locomotion and the most depression- and anxiety-related behaviors among the experimental groups; there were no such differences at 16 days. However, at the later time point, both injured groups displayed elevated levels of select protein biomarkers. Histology showed significantly increased numbers of TUNEL+ (terminal-deoxy-transferase-mediated dUTP nick-end labeling)-positive cells in the dorsal and ventral hippocampus (DHC and VHC) of both injured groups as early as 2 h after injury. At 22 days, the increase was limited to the VHC of MI animals. Our findings suggest that the exposure to mild blast overpressure triggers early hippocampal cell death as well as neuronal, glial, and vascular damage that likely contribute to significant, albeit transient increases in depression- and anxiety-related behaviors. However, the severity of the observed pathological changes in MI rats failed to support the hypothesized cumulative effect of repeated injury. We infer that at this blast frequency, a potential conditioning phenomenon counteracts with and reduces the extent of subsequent damage in MI rats.	[Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Sch Med, Bethesda, MD 20814 USA; [Kamnaksh, Alaa; Kwon, Sook-Kyung; Ahmed, Farid; Barry, Erin S.; Grunberg, Neil E.; Agoston, Denes] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Barry, Erin S.; Grunberg, Neil E.] Walter Reed Army Inst Res, Dept Med & Clin Psychol, Silver Spring, MD USA; [Long, Joseph] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA		Agoston, D (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu		Barry, Erin/0000-0003-0788-7153	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1703F]	We thank the Neurotrauma Team at the Walter Reed Army Institute of Research for their technical help during the exposures. This work was supported by the Center for Neuroscience and Regenerative Medicine grant number G1703F. The views, opinions, and/or findings contained herein are those of the authors and should not be construed as an official position, policy, or decision of the Department of the Army or the Department of Defense. Animal handling and treatments were conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations related to animals and experiments involving animals, and adhered to principles stated in the Guide to the Care and Use of Laboratory Animals, National Research Council. The facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Andrew Richard J., 2002, P157, DOI 10.1017/CBO9780511546372.007; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; Barr TL, 2011, BIOL RES NURS, V13, P140, DOI 10.1177/1099800410385671; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Engin E, 2007, BEHAV PHARMACOL, V18, P365, DOI 10.1097/FBP.0b013e3282de7929; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Gu XL, 2003, INVEST OPHTH VIS SCI, V44, P3219, DOI 10.1167/ivos.02-0852; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kempermann G, 2002, E SCHERING RES FDN W, V35, P17; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G., 2000, NOVART FDN SYMP, V231, P302; Kempermann G, 2000, NOVART FDN SYMP, V231, P235; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Pun P, 2011, FRONT NEUROL, V2, P1; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Ren CH, 2011, NEUROL RES, V33, P514, DOI 10.1179/016164111X13007856084241; Robinson RG, 1985, CEREBRAL LATERALIZAT, P135; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sook-Kyung CK, 2011, FRONT NEUROL, V2, P1; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Tan G, 2009, PAIN MED, V10, P1237, DOI 10.1111/j.1526-4637.2009.00712.x; Thompson JM, 2008, CAN FAM PHYSICIAN, V54, P1549; Tischler L, 2006, ANN NY ACAD SCI, V1071, P405, DOI 10.1196/annals.1364.031; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Zhao H, 2009, J CEREBR BLOOD F MET, V29, P873, DOI 10.1038/jcbfm.2009.13	68	47	48	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	DEC	2012	33	24			SI		3680	3692		10.1002/elps.201200319			13	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	057FT	WOS:000312548900011	23161523				2022-02-06	
J	Sajja, VSSS; Galloway, MP; Ghoddoussi, F; Thiruthalinathan, D; Kepsel, A; Hay, K; Bir, CA; VandeVord, PJ				Sajja, Venkata Siva Sai Sujith; Galloway, Matthew P.; Ghoddoussi, Farhad; Thiruthalinathan, Dhananjeyan; Kepsel, Andrea; Hay, Kathryn; Bir, Cynthia A.; VandeVord, Pamela J.			Blast-induced neurotrauma leads to neurochemical changes and neuronal degeneration in the rat hippocampus	NMR IN BIOMEDICINE			English	Article						neurotrauma; apoptosis; 1H MRS; blast; hippocampus	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; N-ACETYL ASPARTATE; MOUSE MODEL; INTRACRANIAL-PRESSURE; MAJOR DEPRESSION; TIME-COURSE; DYSFUNCTION; MECHANISMS; VETERANS	Blast-induced neurotrauma is a major concern because of the complex expression of neuropsychiatric disorders after exposure. Disruptions in neuronal function, proximal in time to blast exposure, may eventually contribute to the late emergence of clinical deficits. Using magic angle spinning 1H MRS and a rodent model of blast-induced neurotrauma, we found acute (2448 h) decreases in succinate, glutathione, glutamate, phosphorylethanolamine and ?-aminobutyric acid, no change in N-acetylaspartate and increased glycerophosphorylcholine, alterations consistent with mitochondrial distress, altered neurochemical transmission and increased membrane turnover. Increased levels of the apoptotic markers Bax and caspase-3 suggested active cell death, consistent with increased FluoroJade B staining in the hippocampus. Elevated levels of glial fibrillary acidic protein suggested ongoing inflammation without diffuse axonal injury measured by no change in beta-amyloid precursor protein. In conclusion, blast-induced neurotrauma induces a metabolic cascade associated with neuronal loss in the hippocampus in the acute period following exposure. Copyright (c) 2012 John Wiley & Sons, Ltd.	[Sajja, Venkata Siva Sai Sujith; Thiruthalinathan, Dhananjeyan; Kepsel, Andrea; Bir, Cynthia A.; VandeVord, Pamela J.] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA; [Galloway, Matthew P.; Ghoddoussi, Farhad] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Hay, Kathryn; VandeVord, Pamela J.] John D Dingell Vet Adm Med Ctr, Detroit, MI USA		VandeVord, PJ (corresponding author), Virginia Polytech & State Univ, Sch Biomed Engn & Sci, 447 ICTAS Bldg,Stanger St, Blacksburg, VA 24060 USA.	pvord@vt.edu	Sajja, Sujith/I-5289-2019; Kepsel, Andrea/U-1596-2019	Sajja, Sujith/0000-0002-1992-9501; Kepsel, Andrea/0000-0002-9651-6700; Galloway, Matthew/0000-0002-7856-9606; Bir, Cynthia/0000-0002-0777-0951	United States Office of Naval ResearchOffice of Naval Research [N000140810585]; Joe Young Fund for Research in Psychiatry; Anesthesiology Fund for Medical Research; Wayne State University Rumble Graduate Fellowship	This research was supported in part by the United States Office of Naval Research Grant Award Number N000140810585 (CAB, PJV), The Joe Young Fund for Research in Psychiatry (MPG), The Anesthesiology Fund for Medical Research (MPG, FG) and a Wayne State University Rumble Graduate Fellowship (VSSSS).	Barker PB, 2001, ANN NEUROL, V49, P423, DOI 10.1002/ana.90; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Bremner JD, 2006, ANN NY ACAD SCI, V1071, P80, DOI 10.1196/annals.1364.008; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Cavassila S, 2001, NMR BIOMED, V14, P278, DOI 10.1002/nbm.701; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cheng LL, 1997, P NATL ACAD SCI USA, V94, P6408, DOI 10.1073/pnas.94.12.6408; Cirstea CM, 2011, STROKE, V42, P1004, DOI 10.1161/STROKEAHA.110.601047; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Ghoddoussi F, 2010, J NEUROL SCI, V290, P41, DOI 10.1016/j.jns.2009.11.013; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Greco T, 2010, J ALZHEIMERS DIS, V20, pS427, DOI 10.3233/JAD-2010-100519; Haan C, 2007, J IMMUNOL METHODS, V318, P11, DOI 10.1016/j.jim.2006.07.027; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Keller JN, 1998, J NEUROSCI, V18, P4439; Kochanek PM, 2009, J NEUROTRAUM, V26, P813, DOI 10.1089/neu.2008.0893; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; MacQueen G, 2011, MOL PSYCHIATR, V16, P252, DOI 10.1038/mp.2010.80; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McNally RJ, 2006, TRENDS COGN SCI, V10, P271, DOI 10.1016/j.tics.2006.04.007; MOFFET JR, 2006, N ACETYLASPARTATE UN; Moore GJ, 2000, PSYCHOPHARMACOL BULL, V36, P5; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Paxinos G., 2008, MOUSE BRAIN STEREOTA; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rooney WD, 1998, NEUROLOGY, V50, P1800, DOI 10.1212/WNL.50.6.1800; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Salek RM, 2010, NEUROCHEM INT, V56, P937, DOI 10.1016/j.neuint.2010.04.001; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stanley JA, 2000, BIOL PSYCHIAT, V48, P357, DOI 10.1016/S0006-3223(00)00949-5; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90	54	47	49	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	DEC	2012	25	12					1331	1339		10.1002/nbm.2805			9	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	025ZR	WOS:000310237600004	22549883				2022-02-06	
J	Thompson, JW; Narayanan, SV; Perez-Pinzon, MA				Thompson, John W.; Narayanan, Srinivasan V.; Perez-Pinzon, Miguel A.			Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning	CURRENT NEUROPHARMACOLOGY			English	Article						Epsilon PKC; HIF; Ischemic preconditioning; Nrf2; Reactive oxygen species; Sirtuin; SIRT1; Reperfusion	PROTEIN-KINASE-C; HYPOXIA-INDUCIBLE FACTOR; FOCAL CEREBRAL-ISCHEMIA; CYSTATHIONINE BETA-SYNTHASE; NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL ELECTRON-TRANSPORT; ORGANOTYPIC HIPPOCAMPAL SLICE; HEME OXYGENASE-1 INDUCTION; ALCOHOL SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY	There is extensive evidence that the restoration of blood flow following cerebral ischemia contributes greatly to the pathophysiology of ischemia mediated brain injury. The initiating stimulus of reperfusion injury is believed to be the excessive production of reactive oxygen (ROS) and nitrogen (RNS) species by the mitochondria. ROS and RNS generation leads to mitochondrial protein, lipid and DNA oxidation which impedes normal mitochondrial physiology and initiates cellular death pathways. However not all ROS and RNS production is detrimental. It has been demonstrated that low levels of ROS production are protective and may serve as a trigger for activation of ischemic preconditioning. Ischemic preconditioning is a neuroprotective mechanism which is activated upon a brief sublethal ischemic exposure and is sufficient to provide protection against a subsequent lethal ischemic insult. Numerous proteins and signaling pathways have been implicated in the ischemic preconditioning neuroprotective response. In this review we examine the origin and mechanisms of ROS and RNS production following ischemic/reperfusion and the role of free radicals in modulating proteins associated with ischemic preconditioning neuroprotection.	[Thompson, John W.; Narayanan, Srinivasan V.; Perez-Pinzon, Miguel A.] Univ Miami, Miller Sch Med, Dept Neurol, Cerebral Vasc Dis Res Ctr, Miami, FL 33136 USA		Perez-Pinzon, MA (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, D4-5,POB 016960, Miami, FL 33101 USA.	perezpinzon@miami.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS45676-01, NS054147-01, NS34773]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034773, F31NS080344, R29NS034773, R01NS054147, R01NS045676] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants NS45676-01, NS054147-01 and NS34773.	Abe K, 1996, J NEUROSCI, V16, P1066; Abraham NG, 2005, FREE RADICAL BIO MED, V39, P1, DOI 10.1016/j.freeradbiomed.2005.03.010; Abraham P, 2009, CANCER CHEMOTH PHARM, V64, P279, DOI 10.1007/s00280-008-0868-6; Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a; Allen B.S., 2012, EUR J CARDIOTHORAC S; Altup S, 2001, EUR J PHARMACOL, V415, P239, DOI 10.1016/S0014-2999(01)00843-3; AMBROSIO G, 1995, J MOL CELL CARDIOL, V27, P1035, DOI 10.1016/0022-2828(95)90072-1; Ara J, 2011, NEUROBIOL DIS, V43, P473, DOI 10.1016/j.nbd.2011.04.021; AUCHAMPACH JA, 1991, J PHARMACOL EXP THER, V259, P961; AUCHAMPACH JA, 1993, AM J PHYSIOL, V264, pH1327, DOI 10.1152/ajpheart.1993.264.5.H1327; Bachschmid M, 2003, FASEB J, V17, P914, DOI 10.1096/fj.02-0530fje; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Ball KA, 2012, BIOCHEM BIOPH RES CO, V420, P727, DOI 10.1016/j.bbrc.2012.03.050; Beal MF, 1998, BRAIN RES, V783, P109, DOI 10.1016/S0006-8993(97)01192-X; Becatti M, 2012, CELL MOL LIFE SCI, V69, P2245, DOI 10.1007/s00018-012-0925-5; Bell KF, 2011, P NATL ACAD SCI USA, V108, pE1, DOI 10.1073/pnas.1015229108; Bell KFS, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/689524; Bergeron M, 2000, ANN NEUROL, V48, P285, DOI 10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.3.CO;2-#; Bertrand X, 2005, MED MALADIES INFECT, V35, P329, DOI 10.1016/j.medmal.2005.05.002; Blondeau N, 2000, NEUROSCIENCE, V100, P465, DOI 10.1016/S0306-4522(00)00304-3; Boyle EM, 1996, ANN THORAC SURG, V62, P1868, DOI 10.1016/S0003-4975(96)00950-2; Bright R, 2008, NEUROSCI LETT, V441, P120, DOI 10.1016/j.neulet.2008.05.080; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burwell LS, 2006, BIOCHEM J, V394, P627, DOI 10.1042/BJ20051435; Caito S, 2010, FASEB J, V24, P3145, DOI 10.1096/fj.09-151308; Calvert JW, 2010, CIRCULATION, V122, P11, DOI 10.1161/CIRCULATIONAHA.109.920991; Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919; Carroll R, 2001, CARDIOVASC RES, V51, P691, DOI 10.1016/S0008-6363(01)00330-3; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen R, 2011, J BIOL CHEM, V286, P13869, DOI 10.1074/jbc.M110.175414; CHEN W, 1995, CIRC RES, V77, P424, DOI 10.1161/01.RES.77.2.424; Chen W, 2011, FOOD CHEM TOXICOL, V49, P2439, DOI 10.1016/j.fct.2011.06.066; Cho DH, 2009, SCIENCE, V324, P102, DOI 10.1126/science.1171091; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Csonka C, 2001, BIOCHEM BIOPH RES CO, V285, P1217, DOI 10.1006/bbrc.2001.5308; Das DK, 2003, ARCH BIOCHEM BIOPHYS, V420, P305, DOI 10.1016/j.abb.2003.09.023; De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226; Della-Morte D, 2011, NEUROSCI LETT, V487, P158, DOI 10.1016/j.neulet.2010.10.013; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Dong J, 2008, ANTIOXID REDOX SIGN, V10, P2023, DOI 10.1089/ars.2007.2019; Dreger H, 2009, CARDIOVASC RES, V83, P354, DOI 10.1093/cvr/cvp107; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Enokido Y, 2005, FASEB J, V19, P1854, DOI 10.1096/fj.05-3724fje; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fridovich I, 1979, Adv Neurol, V26, P255; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Girbovan C, 2012, BEHAV PHARMACOL, V23, P1, DOI 10.1097/FBP.0b013e32834eafa3; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; GROSS GJ, 1992, CIRC RES, V70, P223, DOI 10.1161/01.RES.70.2.223; Habeos IG, 2008, J MOL MED, V86, P1279, DOI 10.1007/s00109-008-0393-4; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hasegawa K, 2008, BIOCHEM BIOPH RES CO, V372, P51, DOI 10.1016/j.bbrc.2008.04.176; Hausenloy DJ, 2007, BASIC RES CARDIOL, V102, P445, DOI 10.1007/s00395-007-0656-1; Hausenloy DJ, 2011, NAT REV CARDIOL, V8, P619, DOI 10.1038/nrcardio.2011.85; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Hsu CP, 2010, CIRCULATION, V122, P2170, DOI 10.1161/CIRCULATIONAHA.110.958033; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Hwang I, 2012, DIABETES, V61, P728, DOI 10.2337/db11-0584; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jennings R B, 1995, Monogr Pathol, V37, P47; JENNINGS RB, 1985, CIRC RES, V56, P262, DOI 10.1161/01.RES.56.2.262; Jones NM, 2001, J CEREBR BLOOD F MET, V21, P1105, DOI 10.1097/00004647-200109000-00008; Jones SP, 2004, AM J PHYSIOL-HEART C, V286, pH276, DOI 10.1152/ajpheart.00129.2003; Kaspar J.W., 2012, J CELL SCI 4, V125, P1027; Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173; Kikuchi N, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-31; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661; KINUTA Y, 1989, J NEUROSURG, V71, P417, DOI 10.3171/jns.1989.71.3.0417; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kudin A.P., 2012, BIOCH BIOPHYS ACTA; Kumar A, 2011, MOL PHARMACOL, V80, P446, DOI 10.1124/mol.111.071126; Lange-Asschenfeldt C, 2004, J CEREBR BLOOD F MET, V24, P636, DOI 10.1097/01.WCB.0000121235.42748.BF; Lee BS, 2006, BIOCHEM BIOPH RES CO, V343, P965, DOI 10.1016/j.bbrc.2006.03.058; Li QF, 2012, BRAIN RES, V1451, P1, DOI 10.1016/j.brainres.2012.02.055; Liang HW, 2005, BRAIN RES, V1042, P169, DOI 10.1016/j.brainres.2005.02.031; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu J, 2005, STROKE, V36, P1264, DOI 10.1161/01.STR.0000166180.91042.02; Liu XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200; Liu Y, 2008, BASIC RES CARDIOL, V103, P54, DOI 10.1007/s00395-007-0683-y; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Liverman CS, 2004, MOL BRAIN RES, V126, P57, DOI 10.1016/j.molbrainres.2004.02.028; Luciano JA, 2008, CELL PHYSIOL BIOCHEM, V21, P421, DOI 10.1159/000129634; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; Maines MD, 2005, ANTIOXID REDOX SIGN, V7, P1761, DOI 10.1089/ars.2005.7.1761; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; McPherson BC, 2001, CIRCULATION, V103, P290; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Moreno DM, 2011, ARCH BIOCHEM BIOPHYS, V507, P304, DOI 10.1016/j.abb.2010.12.011; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nadtochiy SM, 2011, AM J PHYSIOL-HEART C, V301, pH1506, DOI 10.1152/ajpheart.00587.2011; Nadtochiy SM, 2011, CARDIOVASC RES, V89, P643, DOI 10.1093/cvr/cvq287; Nadtochiy SM, 2007, J MOL CELL CARDIOL, V42, P812, DOI 10.1016/j.yjmcc.2007.01.010; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Obata T, 2000, ARCH BIOCHEM BIOPHYS, V378, P195, DOI 10.1006/abbi.2000.1830; OHTSUKI T, 1992, BRAIN RES, V599, P246, DOI 10.1016/0006-8993(92)90398-S; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Oladipupo S, 2011, P NATL ACAD SCI USA, V108, P13264, DOI 10.1073/pnas.1101321108; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Palacios-Callender M, 2004, P NATL ACAD SCI USA, V101, P7630, DOI 10.1073/pnas.0401723101; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43; Perez-Pinzon MA, 1999, J CEREBR BLOOD F MET, V19, P39, DOI 10.1097/00004647-199901000-00004; Perez-Pinzon MA, 1999, NEUROSCIENCE, V89, P453, DOI 10.1016/S0306-4522(98)00560-0; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; PHILIPSON KA, 1985, J STEROID BIOCHEM, V23, P1059, DOI 10.1016/0022-4731(85)90067-6; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; PIANTADOSI CA, 1987, J APPL PHYSIOL, V62, P1277, DOI 10.1152/jappl.1987.62.3.1277; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Pugliese AM, 2003, BRIT J PHARMACOL, V140, P305, DOI 10.1038/sj.bjp.0705442; Puisieux F, 2004, BRAIN RES, V1027, P30, DOI 10.1016/j.brainres.2004.08.067; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Rao SM, 2011, DEV NEUROSCI-BASEL, V33, P288, DOI 10.1159/000327241; Raval AP, 2007, BRAIN RES, V1184, P345, DOI 10.1016/j.brainres.2007.09.073; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Raval AP, 2005, J CEREBR BLOOD F MET, V25, P730, DOI 10.1038/sj.jcbfm.9600071; Raval AP, 2003, J NEUROSCI, V23, P384, DOI 10.1523/JNEUROSCI.23-02-00384.2003; Reichard JF, 2007, NUCLEIC ACIDS RES, V35, P7074, DOI 10.1093/nar/gkm638; Ren JW, 2011, NEUROCHEM RES, V36, P2352, DOI 10.1007/s11064-011-0561-8; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; Rosenthal M, 1997, ADV EXP MED BIOL, V428, P189; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; SALDIVA PHN, 1985, ACTA PHYSIOL PHARM L, V35, P109; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schildknecht S, 2011, J BIOL CHEM, V286, P4991, DOI 10.1074/jbc.M110.169565; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Schulke S, 2012, GENE, V500, P199, DOI 10.1016/j.gene.2012.03.019; Schultz JE, 1997, J MOL CELL CARDIOL, V29, P1055, DOI 10.1006/jmcc.1996.0358; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; Simao F, 2012, NEUROCHEM INT; Simao F., 2012, EUR J NEUROSCI; Singh S, 2009, J BIOL CHEM, V284, P22457, DOI 10.1074/jbc.M109.010868; Sivaraman V, 2009, J MOL CELL CARDIOL, V46, P758, DOI 10.1016/j.yjmcc.2009.02.013; Stevens JF, 2003, CHEM RES TOXICOL, V16, P1277, DOI 10.1021/tx020100d; Sugimoto K, 2003, CIRC J, V67, P295; Suliman HB, 2007, J CELL SCI, V120, P299, DOI 10.1242/jcs.03318; Sumbayev VV, 2003, FEBS LETT, V535, P106, DOI 10.1016/S0014-5793(02)03887-5; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Tritto I, 1997, CIRC RES, V80, P743, DOI 10.1161/01.RES.80.5.743; Um HC, 2011, NITRIC OXIDE-BIOL CH, V25, P161, DOI 10.1016/j.niox.2011.06.001; Usta E, 2011, J CARDIOVASC SURG, V52, P399; van der Kooij MA, 2009, NEUROSCI LETT, V451, P109, DOI 10.1016/j.neulet.2008.12.013; van der Veen RC, 1999, J NEUROIMMUNOL, V95, P1, DOI 10.1016/S0165-5728(98)00239-2; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Vlahakos D, 2012, ARTIF ORGANS, V36, P400, DOI 10.1111/j.1525-1594.2011.01385.x; VLESSIS AA, 1990, J NEUROCHEM, V54, P1412, DOI 10.1111/j.1471-4159.1990.tb01977.x; Walsh SR, 2008, EUR J CARDIO-THORAC, V34, P985, DOI 10.1016/j.ejcts.2008.07.062; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang B, 2011, STROKE, V42, P2605, DOI 10.1161/STROKEAHA.110.607101; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22; Xing YQ, 2009, BRAIN RES, V1291, P113, DOI 10.1016/j.brainres.2009.07.032; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027798; Yasinska IM, 2003, FEBS LETT, V549, P105, DOI 10.1016/S0014-5793(03)00807-X; YELLON DM, 1993, LANCET, V342, P276, DOI 10.1016/0140-6736(93)91819-8; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang Jian, 2007, Zhonghua Wai Ke Za Zhi, V45, P1253; Zhang JL, 2005, AM J PHYSIOL-CELL PH, V288, pC840, DOI 10.1152/ajpcell.00325.2004; Zhang Y, 2010, J MOL CELL CARDIOL, V49, P576, DOI 10.1016/j.yjmcc.2010.05.011; Zhao Y, 2010, CURR PHARM BIOTECHNO, V11, P868, DOI 10.2174/138920110793262105; Zhu H, 2007, CARDIOVASC TOXICOL, V7, P202, DOI 10.1007/s12012-007-9001-z; Zuckerbraun BS, 2007, FASEB J, V21, P1099, DOI 10.1096/fj.06-6644com	188	47	50	0	6	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X			CURR NEUROPHARMACOL	Curr. Neuropharmacol.	DEC	2012	10	4					354	369					16	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	048KH	WOS:000311909700008	23730259	Green Submitted, Green Published			2022-02-06	
J	Slobounov, S; Sebastianelli, W; Hallett, M				Slobounov, Semyon; Sebastianelli, Wayne; Hallett, Mark			Residual brain dysfunction observed one year post-mild traumatic brain injury: Combined EEG and balance study	CLINICAL NEUROPHYSIOLOGY			English	Article						EEG; Mild traumatic brain injury; Balance; Center of pressure (COP) area	SPORTS-RELATED CONCUSSION; CEREBRAL CONCUSSION; HEAD-INJURIES; HIGH-SCHOOL; RECOVERY; STABILITY; TASK; OSCILLATIONS; RELIABILITY; PERFORMANCE	Objectives: There is still considerable debate and controversy about whether EEG can be used as a robust clinical tool for assessment of mild traumatic brain injury (MTBI). Nonhomogeneous subject populations, inaccurate assessment of severity of brain injury, time since injury when EEG testing was performed, the lack of EEG research conducted serially and in conjunction with other behavioral measures as injury evolves over time may contribute to the existing controversies. In this study, we implemented a concussion assessment protocol combining a series of EEG and balance measures throughout one year post-injury to document the efficacy of EEG and balance measures as relate to differential recovery of patients suffering from MTBI. Methods: Three hundred and eighty subjects at risk for MTBI were initially recruited for baseline testing. Forty nine from this initial subjects pool subsequently suffered a single episode of concussive blow and were tested on day 7, 15, 30 days, 6 months and 12 months post-injury. EEGs were recorded while sitting, standing on the force plate and then on a foam base of support with eyes open/closed conditions. EEG alpha power (8-12 Hz) and its percent suppression from sitting to standing postures were computed. The center of pressure (COP) measures were obtained from the force platform and analyzed for eyes open and eyes closed conditions. Results: Percent alpha power suppression from sitting to standing postural conditions significantly increased in MTBI subjects shortly after the injury (p < 0.01). Percent alpha power suppression significantly correlated with increased area of COP during standing posture with eye closed (r(2) = 0.53, p < 0.01). The magnitude of alpha power suppression predicted the rate of recovery of this measure in sub-acute and chronic phases of injury (r(2) = 0.609, p < 0.01). Finally, 85% of MTBI subjects who showed more than 20% of alpha power suppression in the acute phase of injury did not return to pre-injury status up to 12 months post-injury. Conclusions: The efficacy of serially implemented EEG measures in conjunction with balance assessment over the course of MTBI evolution to document residual cerebral dysfunction was demonstrated. Specifically, alteration of EEG alpha power dynamics in conjunction with balance data in the acute phase of injury with respect to baseline measures may predict the rate of recovery from a single concussive blow. Significance: Neurophysiological measures are excellent tools to assess the status and prognosis of patients with MTBI. (C) 2012 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Slobounov, Semyon; Sebastianelli, Wayne] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Slobounov, Semyon; Sebastianelli, Wayne] Penn State Univ, HMC, Dept Orthoped & Med Rehabil, University Pk, PA 16802 USA; [Slobounov, Semyon; Hallett, Mark] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227, ZIANS002667] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury".	Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; BARIN K, 1992, IEEE ENG MED BIOL, V11, P52, DOI 10.1109/51.256960; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Buzsaki G., 2006, RHYTHMS BRAIN CYCLE, P341; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Gevins A, 1997, CEREB CORTEX, V7, P374, DOI 10.1093/cercor/7.4.374; Glaser MA, 1940, W SURG, V48, P6989; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hessen E., 2010, PEDIAT TRAUMATIC BRA, P118; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jasper HH, 1940, ARCH NEURO PSYCHIATR, V44, P328, DOI 10.1001/archneurpsyc.1940.02280080088005; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Newell K, 1994, GAIT POSTURE, V2, P85, DOI [10.1016/0966-6362(94)90097-3, DOI 10.1016/0966-6362(94)90097-3]; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OKEN BS, 1986, ANN NEUROL, V19, P493, DOI 10.1002/ana.410190511; Palva S, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00204; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pfurtscheller G, 2000, CLIN NEUROPHYSIOL, V111, P1873, DOI 10.1016/S1388-2457(00)00428-4; Pfurtscheller G, 2003, EPILEPSIA, V44, P2, DOI 10.1111/j.0013-9580.2003.12001.x; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rau C, 2003, CLIN NEUROPHYSIOL, V114, P1819, DOI 10.1016/S1388-2457(03)00174-3; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	57	47	47	0	31	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	SEP	2012	123	9					1755	1761		10.1016/j.clinph.2011.12.022			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	984IR	WOS:000307183800016	22361265	Green Accepted			2022-02-06	
J	Walker, KR; Kang, EL; Whalen, MJ; Shen, Y; Tesco, G				Walker, Kendall R.; Kang, Eugene L.; Whalen, Michael J.; Shen, Yong; Tesco, Giuseppina			Depletion of GGA1 and GGA3 Mediates Postinjury Elevation of BACE1	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE PATHOGENESIS; APP TRANSGENIC MICE; TRANSLATIONAL REGULATION; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; CLEAVING ENZYME-1	Traumatic brain injury (TBI) is one of the most robust environmental risk factors for Alzheimer's disease (AD). Compelling evidence is accumulating that a single event of TBI is associated with increased levels of A beta. However, the underlying molecular mechanisms remain unknown. We report here that the BACE1 interacting protein, GGA3, is depleted while BACE1 levels increase in the acute phase after injury (48 h) in a mouse model of TBI. We further demonstrated the role of GGA3 in the regulation of BACE1 in vivo by showing that BACE1 levels are increased in the brain of GGA3-null mice. We next found that head trauma potentiates BACE1 elevation in GGA3-null mice in the acute phase after TBI, and discovered that GGA1, a GGA3 homolog, is a novel caspase-3 substrate depleted at 48 h after TBI. Moreover, GGA1 silencing potentiates BACE1 elevation induced by GGA3 deletion in neurons in vitro, indicating that GGA1 and GGA3 synergistically regulate BACE1. Accordingly, we found that levels of both GGA1 and GGA3 are depleted while BACE1 levels are increased in a series of postmortem AD brains. Finally, we show that GGA3 haploinsufficiency results in sustained elevation of BACE1 and A beta levels while GGA1 levels are restored in the subacute phase (7 d) after injury. In conclusion, our data indicate that depletion of GGA1 and GGA3 engender a rapid and robust elevation of BACE1 in the acute phase after injury. However, the efficient disposal of the acutely accumulated BACE1 solely depends on GGA3 levels in the subacute phase of injury.	[Walker, Kendall R.; Kang, Eugene L.; Tesco, Giuseppina] Tufts Univ, Sch Med, Dept Neurosci, Alzheimers Dis Res Lab, Boston, MA 02111 USA; [Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Boston, MA 02129 USA; [Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02129 USA; [Shen, Yong] Roskamp Inst, CATSBD, Sarasota, FL 34243 USA		Tesco, G (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, Alzheimers Dis Res Lab, 136 Harrison Ave,St 328A, Boston, MA 02111 USA.	Giuseppina.Tesco@Tufts.edu			National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033016, 1R01AG025952]; Cure Alzheimer's Fund; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034155, R01AG033016, R01AG025952, R01AG025888] Funding Source: NIH RePORTER	This work was supported by Award Number R01AG033016 (to G.T.) and 1R01AG025952 (to G.T.) from the National Institute on Aging, and a grant from Cure Alzheimer's Fund (to G.T.). We thank Dr. Rudy Tanzi for his useful comments in the preparation and editing of this manuscript.	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI 10.1089/neu.2008-0765; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Boissonneault V, 2009, J BIOL CHEM, V284, P1971, DOI 10.1074/jbc.M807530200; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cho HJ, 2009, BIOCHEM BIOPH RES CO, V386, P175, DOI 10.1016/j.bbrc.2009.06.006; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Cole SL, 2008, J BIOL CHEM, V283, P29621, DOI 10.1074/jbc.R800015200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Frohlich S, 2011, IRISH J MED SCI, V180, P423, DOI 10.1007/s11845-011-0674-8; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; He XY, 2005, J BIOL CHEM, V280, P11696, DOI 10.1074/jbc.M411296200; Hebert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105; Hirata-Fukae C, 2008, NEUROSCI LETT, V435, P186, DOI 10.1016/j.neulet.2008.02.032; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kang EL, 2010, J BIOL CHEM, V285, P24108, DOI 10.1074/jbc.M109.092742; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; Lammich S, 2004, EMBO REP, V5, P620, DOI 10.1038/sj.embor.7400166; LeBlanc Andrea C., 2005, Current Alzheimer Research, V2, P389, DOI 10.2174/156720505774330573; Lee EB, 2005, J CELL BIOL, V168, P291, DOI 10.1083/jcb.200407070; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Mihailovich M, 2007, NUCLEIC ACIDS RES, V35, P2975, DOI 10.1093/nar/gkm191; Ninan I, 2004, NEURON, V42, P129, DOI 10.1016/S0896-6273(04)00143-6; Nowak K, 2006, J NEUROCHEM, V96, P1696, DOI 10.1111/j.1471-4159.2006.03692.x; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI [10.1038/nrneurol.2011.2, 10.1101/cshperspect.a006239]; Rockenstein E, 2005, J BIOL CHEM, V280, P32957, DOI 10.1074/jbc.M507016200; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Rogers GW, 2004, P NATL ACAD SCI USA, V101, P2794, DOI 10.1073/pnas.0308576101; Rossner S, 2006, PROG NEUROBIOL, V79, P95, DOI 10.1016/j.pneurobio.2006.06.001; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Sena-Esteves M, 2004, J VIROL METHODS, V122, P131, DOI 10.1016/j.jviromet.2004.08.017; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; Tamagno E, 2003, NEUROBIOL DIS, V14, P291, DOI 10.1016/S0969-9961(03)00131-1; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Tesco G, 2003, J BIOL CHEM, V278, P46074, DOI 10.1074/jbc.M307809200; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Tonelli DD, 2004, NUCLEIC ACIDS RES, V32, P1808, DOI 10.1093/nar/gkh348; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2009, J NEUROSCI, V29, P12787, DOI 10.1523/JNEUROSCI.3657-09.2009; Velliquette RA, 2005, J NEUROSCI, V25, P10874, DOI 10.1523/JNEUROSCI.2350-05.2005; von Arnim CAF, 2006, J NEUROSCI, V26, P9913, DOI 10.1523/JNEUROSCI.2290-06.2006; Wahle T, 2005, MOL CELL NEUROSCI, V29, P453, DOI 10.1016/j.mcn.2005.03.014; Wahle T, 2006, J NEUROSCI, V26, P12838, DOI 10.1523/JNEUROSCI.1982-06.2006; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Wen Y, 2008, NEURON, V57, P680, DOI 10.1016/j.neuron.2008.02.024; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhou WH, 2006, MOL CELL BIOL, V26, P3353, DOI 10.1128/MCB.26.9.3353-3364.2006	77	47	49	1	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 25	2012	32	30					10423	10437		10.1523/JNEUROSCI.5491-11.2012			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983NF	WOS:000307125300030	22836275	Green Published, Green Accepted, Bronze			2022-02-06	
J	Chabok, SY; Moghadam, AD; Saneei, Z; Amlashi, FG; Leili, EK; Amiri, ZM				Chabok, Shahrokh Yousefzadeh; Moghadam, Anoush Dehnadi; Saneei, Zahra; Amlashi, Fatemeh Ghazanfari; Leili, Ehsan Kazemnezhad; Amiri, Zahra Mohtasham			Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Diffuse axonal injury; neuron-specific enolase; S100BB; severe traumatic brain injury; outcome	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SERUM S-100B; PROTEIN; MARKERS; DAMAGE	BACKGROUND: Diffuse axonal injury (DAI) is a common type of traumatic brain injury, mostly associated with mild changes on computed tomography (CT) scan. Serum biomarkers might be used in the diagnosis and prognosis of this injury type. Our purpose was to determine temporal profile and predictive values of serum concentrations of protein S100BB and neuron-specific enolase (NSE) after DAI. METHODS: Twenty-eight isolated severe DAI patients (Glasgow Coma Scale score <= 8) with normal CT were enrolled in the study. Serum levels of S100BB and NSE were determined at 6 hours, 24 hours, 48 hours, and 72 hours after injury, using enzyme-linked immunosorbent assay. Clinical outcome variables of DAI comprised survival at discharge and Glasgow Outcome scale (GOS) after 3 months and also 2 years. RESULTS: S100BB concentration was maximum in 6 hours after injury (median = 280.75 ng/L) followed by a quick drop. Its value was significantly higher on third day in patients with unfavorable outcome (GOS score = 1-3) versus favorable outcome (GOS score = 4, 5) (p < 0.0001). The values of NSE had mild changes during 3 days; however, these measured values at 72 hours after trauma manifested higher in unfavorable outcome (p < 0.05). CONCLUSIONS: Increased serum concentrations of NSE and S100BB within first 3 days after DAI are associated with poor outcome despite mild CT findings. S100BB level at 72 hours after injury can predict late outcome in DAI patients. (J Trauma Acute Care Surg. 2012;72: 1654-1657. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Chabok, Shahrokh Yousefzadeh; Moghadam, Anoush Dehnadi; Saneei, Zahra; Amlashi, Fatemeh Ghazanfari; Leili, Ehsan Kazemnezhad; Amiri, Zahra Mohtasham] Poursina Hosp, Guilan Rd Trauma Res Ctr, Rasht, Guilan Province, Iran; [Chabok, Shahrokh Yousefzadeh] Guilan Univ Med Sci, Dept Neurosurg, Rasht, Guilan, Iran; [Moghadam, Anoush Dehnadi] Guilan Univ Med Sci, Dept Anesthesiol, Rasht, Guilan, Iran; [Leili, Ehsan Kazemnezhad] Guilan Univ Med Sci, Dept Biostat, Rasht, Guilan, Iran; [Amiri, Zahra Mohtasham] Guilan Univ Med Sci, Dept Social Med, Rasht, Guilan, Iran		Moghadam, AD (corresponding author), Poursina Hosp, Guilan Rd Trauma Res Ctr, Namjoo St, Rasht, Guilan Province, Iran.	dehnadi@gtrc.ir	Mogha, Anoush Dehnadi/E-4722-2019; Mohtasham-Amiri, Zahra/C-4469-2012; amlashi, fatemeh ghazanfari/H-9981-2019	Mohtasham-Amiri, Zahra/0000-0002-4896-6248; amlashi, fatemeh ghazanfari/0000-0002-1306-2150; Ghazanfari Amlashi, Fatemeh/0000-0001-5702-1169; Yousefzadeh-Chabok, Shahrokh/0000-0002-8825-3015; Dehnadi Moghadam, Anoush/0000-0002-8408-2909	Guilan Trauma and Road Traffic Accidents Research Center	Supported by Guilan Trauma and Road Traffic Accidents Research Center (www.gtrc.ir).	Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Ogata Mamoru, 2007, Legal Medicine, V9, P105, DOI 10.1016/j.legalmed.2006.11.013; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Vajtr D, 2007, Soud Lek, V52, P43; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	25	47	55	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2012	72	6					1654	1657		10.1097/TA.0b013e318246887e			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	960WH	WOS:000305422900038	22695436				2022-02-06	
J	Freund, P; Wheeler-Kingshott, CA; Nagy, Z; Gorgoraptis, N; Weiskopf, N; Friston, KJ; Thompson, AJ; Hutton, C				Freund, Patrick; Wheeler-Kingshott, Claudia A.; Nagy, Zoltan; Gorgoraptis, Nikos; Weiskopf, Nikolaus; Friston, Karl J.; Thompson, Alan J.; Hutton, Chloe			Axonal integrity predicts cortical reorganisation following cervical injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SPINAL-CORD-INJURY; VOXEL-BASED MORPHOMETRY; WHITE-MATTER; MULTIPLE-SCLEROSIS; WALLERIAN DEGENERATION; RADIAL DIFFUSIVITY; QUANTITATIVE MRI; 1.5 T; BRAIN; MOTOR	Background Traumatic spinal cord injury (SCI) leads to disruption of axonal architecture and macroscopic tissue loss with impaired information flow between the brain and spinal cord-the presumed basis of ensuing clinical impairment. Objective The authors used a clinically viable, multimodal MRI protocol to quantify the axonal integrity of the cranial corticospinal tract (CST) and to establish how microstructural white matter changes in the CST are related to cross-sectional spinal cord area and cortical reorganisation of the sensorimotor system in subjects with traumatic SCI. Methods Nine volunteers with cervical injuries resulting in bilateral motor impairment and 14 control subjects were studied. The authors used diffusion tensor imaging to assess white matter integrity in the CST, T1-weighted imaging to measure cross-sectional spinal cord area and functional MRI to compare motor task-related brain activations. The relationships among microstructural, macrostructural and functional measures were assessed using regression analyses. Results Diffusion tensor imaging revealed significant differences in the CST of SCI subjects-compared with controls-in the pyramids, the internal capsule, the cerebral peduncle and the hand area. The microstructural white matter changes observed in the left pyramid predicted increased task-related responses in the left M1 leg area, while changes in the cerebral peduncle were predicted by reduced cord area. Conclusion The observed microstructural changes suggest trauma-related axonal degeneration and demyelination, which are related to cortical motor reorganisation and macrostructure. The extent of these changes may reflect the plasticity of motor pathways associated with cortical reorganisation. This clinically viable multimodal imaging approach is therefore appropriate for monitoring degeneration of central pathways and the evaluation of treatments targeting axonal repair in SCI.	[Freund, Patrick; Gorgoraptis, Nikos; Thompson, Alan J.] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London WC1N 3BG, England; [Freund, Patrick; Nagy, Zoltan; Weiskopf, Nikolaus; Friston, Karl J.; Hutton, Chloe] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England; [Freund, Patrick] UCL, Spinal Cord Injury Ctr, Royal Natl Orthopaed Hosp, London WC1N 3BG, England; [Freund, Patrick] Swiss Parapleg Res, Nottwil, Switzerland; [Wheeler-Kingshott, Claudia A.] UCL, UCL Inst Neurol, Dept Neuroinflammat, London WC1N 3BG, England		Freund, P (corresponding author), UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, Queen Sq, London WC1N 3BG, England.	p.freund@ucl.ac.uk	Wheeler-Kingshott, Claudia A M Gandini/AAH-7480-2019; Thompson, Alan J/C-2654-2008; Nagy, Zoltan/AAI-2485-2019; Freund, Patrick/D-4193-2013; Weiskopf, Nikolaus/B-9357-2008; Friston, Karl/D-9230-2011	Wheeler-Kingshott, Claudia A M Gandini/0000-0002-4832-1300; Thompson, Alan J/0000-0002-4333-8496; Nagy, Zoltan/0000-0001-6611-6362; Freund, Patrick/0000-0002-4851-2246; Weiskopf, Nikolaus/0000-0001-5239-1881; Friston, Karl/0000-0001-7984-8909; Gorgoraptis, Nikos/0000-0002-2588-9235	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBFR33-120920]; Schweizerische Stiftung fur medizinische und biologische Stipendien [PASMP3-124194]; Swiss Paraplegic Research (Nottwil); Wellcome TrustWellcome TrustEuropean Commission; Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR)	This work was supported by the Swiss National Science Foundation (Grant No: PBFR33-120920), Schweizerische Stiftung fur medizinische und biologische Stipendien (Grant No: PASMP3-124194), Swiss Paraplegic Research (Nottwil) and the Wellcome Trust. This work was undertaken at UCLH/UCL which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme.	Andersson JLR, 2001, NEUROIMAGE, V13, P903, DOI 10.1006/nimg.2001.0746; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Calancie B, 1996, ELECTROMYOGR MOTOR C, V101, P304, DOI 10.1016/0924-980X(96)95194-2; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; COOK PA, 2006, P INT SOC MAGN RESON, V14, P2759; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Deichmann R, 2004, NEUROIMAGE, V21, P757, DOI 10.1016/j.neuroimage.2003.09.062; Dietz V, 2010, NAT REV NEUROL, V6, P167, DOI 10.1038/nrneurol.2009.227; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Freund P, 2011, EUR J NEUROSCI, V34, P1839, DOI 10.1111/j.1460-9568.2011.07895.x; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund P, 2010, MULT SCLER J, V16, P1193, DOI 10.1177/1352458510376180; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Gonzenbach RR, 2008, CELL MOL LIFE SCI, V65, P161, DOI 10.1007/s00018-007-7170-3; Gouw AA, 2008, BRAIN, V131, P3286, DOI 10.1093/brain/awn265; Henderson LA, 2011, J NEUROSCI, V31, P2630, DOI 10.1523/JNEUROSCI.2717-10.2011; Jansons KM, 2003, LECT NOTES COMPUT SC, V2732, P672; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kapreli E, 2006, NEUROIMAGE, V32, P1709, DOI 10.1016/j.neuroimage.2006.05.043; Kim JH, 2010, J NEUROTRAUM, V27, P587, DOI 10.1089/neu.2009.1063; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Kozlowski P, 2008, J NEUROTRAUM, V25, P653, DOI 10.1089/neu.2007.0462; Lee JE, 2009, NEUROIMAGE, V44, P870, DOI 10.1016/j.neuroimage.2008.09.041; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Ward NS, 2003, BRAIN, V126, P873, DOI 10.1093/brain/awg071; Weiskopf N, 2006, NEUROIMAGE, V33, P493, DOI 10.1016/j.neuroimage.2006.07.029; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	51	47	51	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2012	83	6					629	637		10.1136/jnnp-2011-301875			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	939NA	WOS:000303816800012	22492214	hybrid, Green Submitted, Green Published			2022-02-06	
J	Zhang, K; Johnson, B; Gay, M; Horovitz, SG; Hallett, M; Sebastianelli, W; Slobounov, S				Zhang, Kai; Johnson, Brian; Gay, Michael; Horovitz, Silvina G.; Hallett, Mark; Sebastianelli, Wayne; Slobounov, Semyon			Default Mode Network in Concussed Individuals in Response to the YMCA Physical Stress Test	JOURNAL OF NEUROTRAUMA			English	Article						default mode network; resting state functional magnetic resonance imaging; subacute phase of mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; FUNCTIONAL CONNECTIVITY; STRUCTURAL CONNECTIVITY; CORTICAL NETWORKS; SHORT-TERM; DYSFUNCTION; CORTEX; ABNORMALITIES; OSCILLATIONS; DISORDERS	We hypothesize that the evolution of mild traumatic brain injury (mTBI) may be related to differential effects of a concussive blow on the functional integrity of the brain default mode network (DMN) at rest and/or in response to physical stress. Accordingly, in this resting-state functional magnetic resonance imaging (fMRI) study, we examined 14 subjects 10 +/- 2 days post-sports-related mTBI and 15 age-matched normal volunteers (NVs) to investigate the possibility that the integrity of the DMN is disrupted at the resting state and/or following the physical stress test. First, all mTBI subjects were asymptomatic based upon clinical evaluation and neuropsychological (NP) assessments prior to the MRI session. Second, the functional integrity within the DMN, a main resting-state network, remained resilient to a single concussive blow. Specifically, the major regions of interest (ROIs) constituting the DMN (e. g., the posterior cingulate cortex [PCC]/precuneus area, the medial prefrontal cortex [MPFC], and left and right lateral parietal cortices [LLP and RLP]) and the connectivity within these four ROIs was similar between NVs and mTBI subjects prior to the YMCA physical stress test. However, the YMCA physical stress test disrupted the DMN, significantly reducing the magnitude of the connection between the PCC and left lateral parietal ROI, and PCC and right lateral parietal ROI, as well as between the PCC and MPFC in mTBI subjects. Thus while the DMN remained resilient to a single mTBI without exertion at 10 days post-injury, it was altered in response to limited physical stress. This may explain some clinical features of mTBI and provide some insight into its mechanism. This important finding should be considered by clinical practitioners when making decisions regarding return-to-play and clearing mTBI athletes for sports participation.	[Zhang, Kai; Johnson, Brian; Gay, Michael; Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Horovitz, Silvina G.; Hallett, Mark; Slobounov, Semyon] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA; [Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, Dept Orthopaed & Med Rehabil, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	; Zhang, Kai/F-3261-2015	Horovitz, Silvina G./0000-0002-5501-5918; Zhang, Kai/0000-0002-5460-6150	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227, ZIANS002667] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury'' awarded to Dr. Slobounov, Principal Investigator.	Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Broyd SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017325; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Cherkassky VL, 2006, NEUROREPORT, V17, P1687, DOI 10.1097/01.wnr.0000239956.45448.4c; Ciftci K, 2011, ANN BIOMED ENG, V39, P1493, DOI 10.1007/s10439-011-0258-9; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fransson P, 2006, NEUROPSYCHOLOGIA, V44, P2836, DOI 10.1016/j.neuropsychologia.2006.06.017; Grabner RH, 2007, NEUROIMAGE, V38, P346, DOI 10.1016/j.neuroimage.2007.07.041; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Jang JH, 2011, SCHIZOPHR RES, V127, P58, DOI 10.1016/j.schres.2010.12.022; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; JOHNSON PB, 1993, EXP BRAIN RES, V97, P361; Kennedy DP, 2008, SOC COGN AFFECT NEUR, V3, P177, DOI 10.1093/scan/nsn011; Kennedy DP, 2006, P NATL ACAD SCI USA, V103, P8275, DOI 10.1073/pnas.0600674103; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Laird AR, 2009, J NEUROSCI, V29, P14496, DOI 10.1523/JNEUROSCI.4004-09.2009; Liddle EB, 2011, J CHILD PSYCHOL PSYC, V52, P761, DOI 10.1111/j.1469-7610.2010.02333.x; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nelson SM, 2010, NEURON, V67, P156, DOI 10.1016/j.neuron.2010.05.025; Noirhomme Q, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00160; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Sharp D, 2010, J NEUROL NEUROSUR PS, V81, pE23, DOI 10.1136/jnnp.2010.226340.25; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Supekar K, 2010, NEUROIMAGE, V52, P290, DOI 10.1016/j.neuroimage.2010.04.009; Swanson N, 2011, HUM BRAIN MAPP, V32, P654, DOI 10.1002/hbm.21055; Tian LX, 2006, NEUROSCI LETT, V400, P39, DOI 10.1016/j.neulet.2006.02.022; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Uddin LQ, 2008, J NEUROSCI METH, V169, P249, DOI 10.1016/j.jneumeth.2007.11.031; Uddin LQ, 2009, HUM BRAIN MAPP, V30, P625, DOI 10.1002/hbm.20531; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Wu X, 2011, HUM BRAIN MAPP, V32, P1868, DOI 10.1002/hbm.21153; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	71	47	47	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					756	765		10.1089/neu.2011.2125			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900006	22040294	Green Published			2022-02-06	
J	Siegel, JA; Haley, GE; Raber, J				Siegel, Jessica A.; Haley, Gwendolen E.; Raber, Jacob			Apolipoprotein E isoform-dependent effects on anxiety and cognition in female TR mice	NEUROBIOLOGY OF AGING			English	Article						Aging; Anxiety; Apolipoprotein E; Cognition	TRAUMATIC BRAIN-INJURY; TARGETED-REPLACEMENT MICE; KNOCKOUT HDC(-/-) MICE; E GENE POLYMORPHISMS; RAT ADRENAL-GLAND; EPSILON 4 ALLELE; E MESSENGER-RNA; ALZHEIMERS-DISEASE; E GENOTYPE; APOE GENOTYPE	Compared with apoE3, apoE4 is associated with increased risk to develop age-related cognitive decline, particularly in women. In this study, young, middle-aged, and old female mice expressing human apoE under control of the mouse apoE promoter were behaviorally analyzed. Cognitive performance in the water maze decreased with age in all mice. Compared with apoE2 and apoE3 mice, apoE4 mice showed better cognitive performance and higher measures of anxiety than apoE2 and apoE3 mice. Measures of anxiety correlated with cognitive performance in the water maze and passive avoidance tests and might have contributed to the enhanced cognitive performance of the apoE4 mice. ApoE4 mice showed better water maze learning and higher cortical apoE levels than mice expressing apoE4 in astrocytes under control of the GFAP promoter. This was not seen in apoE3 mice. There were no line differences in either genotype in spatial memory retention in the probe trial following the last day of hidden platform training. Thus, the promoter used to express apoE4 critically modulates its effects on brain function. (C) 2012 Elsevier Inc. All rights reserved.	[Siegel, Jessica A.; Haley, Gwendolen E.; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci ONPRC, Portland, OR 97239 USA		Raber, J (corresponding author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 8131 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	raberj@ohsu.edu			Alzheimer's AssociationAlzheimer's Association [IIRG-05-14021]; NASANational Aeronautics & Space Administration (NASA) [NNJ05HE63G]; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32DA07262]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007262] Funding Source: NIH RePORTER	The authors thank Summer Acevedo, Wendy McGinnis, and Anthony Bader for their help with the data analysis. This work was supported by IIRG-05-14021 (Alzheimer's Association), NNJ05HE63G (NASA) grants, and T32DA07262 (NIDA).	Abrari K, 2009, NEUROBIOL LEARN MEM, V91, P260, DOI 10.1016/j.nlm.2008.10.008; Acevedo SF, 2006, BRAIN RES, V1071, P113, DOI 10.1016/j.brainres.2005.11.067; Acevedo SF, 2008, RADIAT RES, V170, P422, DOI 10.1667/RR1494.1; Acevedo SF, 2010, PEDIATR RES, V67, P293, DOI 10.1203/PDR.0b013e3181cb8e68; Acevedoa SF, 2006, BEHAV BRAIN RES, V168, P92, DOI 10.1016/j.bbr.2005.10.016; Alexander DM, 2007, BIOL PSYCHOL, V75, P229, DOI 10.1016/j.biopsycho.2007.03.001; Amaral DG, 2002, BIOL PSYCHIAT, V51, P11, DOI 10.1016/S0006-3223(01)01307-5; Andreano JM, 2006, PSYCHOL SCI, V17, P466, DOI 10.1111/j.1467-9280.2006.01729.x; Arendt T, 1997, J NEUROSCI, V17, P516; BARCLAY LL, 1985, BIOL PSYCHIAT, V20, P86, DOI 10.1016/0006-3223(85)90139-8; Benice TS, 2006, NEUROSCIENCE, V137, P413, DOI 10.1016/j.neuroscience.2005.08.029; Berteau-Pavy F, 2007, NEUROSCIENCE, V147, P6, DOI 10.1016/j.neuroscience.2007.03.005; Bongers G, 2004, NEUROPSYCHOPHARMACOL, V29, P441, DOI 10.1038/sj.npp.1300352; Bour A, 2008, BEHAV BRAIN RES, V193, P174, DOI 10.1016/j.bbr.2008.05.008; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; BURVILL PW, 1991, BRIT J PSYCHIAT, V158, P64, DOI 10.1192/bjp.158.1.64; Cahill L, 2003, NEUROBIOL LEARN MEM, V79, P194, DOI 10.1016/S1074-7427(02)00036-9; Caselli RJ, 2004, J NEUROPSYCH CLIN N, V16, P320, DOI 10.1176/appi.neuropsych.16.3.320; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.ne.15.030192.002033; de Toledo M, 2004, REV NEUROLOGIA, V38, P901, DOI 10.33588/rn.3810.2003520; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; den Heijer T, 2002, NEUROLOGY, V59, P746, DOI 10.1212/WNL.59.5.746; Domes G, 2005, BEHAV NEUROSCI, V119, P512, DOI 10.1037/0735-7044.119.2.512; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GILLEY DW, 1991, J GERONTOL, V46, pP362, DOI 10.1093/geronj/46.6.P362; Gochee PA, 2004, PSYCHOSOMATICS, V45, P49, DOI 10.1176/appi.psy.45.1.49; Greenwood PM, 2005, NEUROPSYCHOLOGY, V19, P830, DOI 10.1037/0894-4105.19.6.830; Greenwood PM, 2005, NEUROPSYCHOLOGY, V19, P199, DOI 10.1037/0894-4105.19.2.199; Grootendorst J, 2005, BEHAV BRAIN RES, V159, P1, DOI 10.1016/j.bbr.2004.09.019; Guangda Xiang, 1999, Atherosclerosis, V147, P293, DOI 10.1016/S0021-9150(99)00198-7; Gustavson A., 2004, CURRENT CLIN NEUROLO; Jorm AF, 2000, PSYCHOL MED, V30, P11, DOI 10.1017/S0033291799001452; Kang JE, 2005, NEUROBIOL AGING, V26, P475, DOI 10.1016/j.neurobiolaging.2004.05.003; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Lehtovirta M, 1996, J NEUROL NEUROSUR PS, V60, P644, DOI 10.1136/jnnp.60.6.644; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARTIN RJ, 1994, ALZ DIS ASSOC DIS, V8, pS360; Morris CM, 1996, J NEURAL TRANSM-SUPP, P205; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOSIA M, 1992, MOL ENDOCRINOL, V6, P288, DOI 10.1210/me.6.2.288; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PLOMIN R, 1995, INTELLIGENCE, V21, P31, DOI 10.1016/0160-2896(95)90037-3; Porter VR, 2003, J NEUROPSYCH CLIN N, V15, P180, DOI 10.1176/appi.neuropsych.15.2.180; PRACK MM, 1991, J LIPID RES, V32, P1611; Pritchard AL, 2007, J NEUROL NEUROSUR PS, V78, P123, DOI 10.1136/jnnp.2006.092122; Putman P, 2004, PSYCHONEUROENDOCRINO, V29, P953, DOI 10.1016/j.psyneuen.2003.09.001; Raber J, 2000, J NEUROSCI, V20, P2064; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raber J, 1997, J BIOL CHEM, V272, P15057, DOI 10.1074/jbc.272.24.15057; Raber J, 2002, J NEUROSCI, V22, P5204, DOI 10.1523/JNEUROSCI.22-12-05204.2002; Raber Jacob, 2004, Sci Aging Knowledge Environ, V2004, pre2, DOI 10.1126/sageke.2004.11.re2; Raber Jacob, 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/91236; RABINS PV, 1982, JAMA-J AM MED ASSOC, V248, P333, DOI 10.1001/jama.248.3.333; Ramaswamy G, 2005, J NEUROSCI, V25, P10658, DOI 10.1523/JNEUROSCI.1922-05.2005; Rizk A, 2004, EUR J NEUROSCI, V19, P1992, DOI 10.1111/j.1460-9568.2004.03251.x; Robertson J, 2005, NEUROBIOL AGING, V26, P637, DOI 10.1016/j.neurobiolaging.2004.06.003; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shaw P, 2007, LANCET NEUROL, V6, P494, DOI 10.1016/S1474-4422(07)70106-0; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Sullivan PM, 2004, NEUROSCIENCE, V124, P725, DOI 10.1016/j.neuroscience.2003.10.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; van Meer P, 2007, BEHAV BRAIN RES, V176, P372, DOI 10.1016/j.bbr.2006.10.024; Villasana L., 2008, RAD BIOL RADIOECOL, V48, P191; Villasana L, 2006, RADIAT RES, V166, P883, DOI 10.1667/RR0642.1; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Yu VWY, 2000, NEUROSCI LETT, V294, P179, DOI 10.1016/S0304-3940(00)01569-X	73	47	47	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	FEB	2012	33	2					345	358		10.1016/j.neurobiolaging.2010.03.002			14	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	863NR	WOS:000298171800013	20400205	Green Accepted			2022-02-06	
J	Kigerl, KA; Ankeny, DP; Garg, SK; Wei, P; Guan, Z; Lai, WM; McTigue, DM; Banerjee, R; Popovich, PG				Kigerl, Kristina A.; Ankeny, Daniel P.; Garg, Sanjay K.; Wei, Ping; Guan, Zhen; Lai, Wenmin; McTigue, Dana M.; Banerjee, Ruma; Popovich, Phillip G.			System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo	EXPERIMENTAL NEUROLOGY			English	Article						System x(c)(-); Redox; Neuroinflammation; Spinal cord injury; Glutamate	SPINAL-CORD-INJURY; CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; CYSTINE TRANSPORT; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; PROTEIN-KINASE; BLOOD-BRAIN; CELL-DEATH; IFN-GAMMA; NEUROTOXICITY	It is widely believed that microglia and monocyte-derived macrophages (collectively referred to as central nervous system (CNS) macrophages) cause excitotoxicity in the diseased or injured CNS. This view has evolved mostly from in vitro studies showing that neurotoxic concentrations of glutamate are released from CNS macrophages stimulated with lipopolysaccharide ([PS), a potent inflammogen. We hypothesized that excitotoxic killing by CNS macrophages is more rigorously controlled in vivo, requiring both the activation of the glutamate/cystine antiporter (system x(c)(-)) and an increase in extracellular cystine, the substrate that drives glutamate release. Here, we show that non-traumatic microinjection of low-dose LPS into spinal cord gray matter activates CNS macrophages but without causing overt neuropathology. In contrast, neurotoxic inflammation occurs when LPS and cystine are co-injected. Simultaneous injection of NBQX, an antagonist of AMPA glutamate receptors, reduces the neurotoxic effects of LPS + cystine, implicating glutamate as a mediator of neuronal cell death in this model. Surprisingly, neither LPS nor LPS + cystine adversely affects survival of oligodendrocytes or oligodendrocyte progenitor cells. Ex vivo analyses show that redox balance in microglia and macrophages is controlled by induction of system x(c)(-) and that high GSH:GSSG ratios predict the neurotoxic potential of these cells. Together, these data indicate that modulation of redox balance in CNS macrophages, perhaps through regulating system x(c)(-), could be a novel approach for attenuating injurious neuroinflammatory cascades. (C) 2011 Elsevier Inc. All rights reserved.	[Kigerl, Kristina A.; Ankeny, Daniel P.; Wei, Ping; Guan, Zhen; Lai, Wenmin; McTigue, Dana M.; Popovich, Phillip G.] Ohio State Univ, Coll Med, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Kigerl, Kristina A.; Wei, Ping; Guan, Zhen; Lai, Wenmin; McTigue, Dana M.; Popovich, Phillip G.] Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA; [Garg, Sanjay K.; Banerjee, Ruma] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA		Popovich, PG (corresponding author), Ohio State Univ, Coll Med, Ctr Brain & Spinal Cord Repair, 786 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	phillip.popovich@osumc.edu		Kigerl, Kristina/0000-0002-1652-0882	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS37846, NS059776, DK64959, P30-NS045758]; Craig H. Neilsen Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK064959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047175, R01NS037846, P30NS045758, R01NS059776] Funding Source: NIH RePORTER	This work was supported in part by grants NIH-NS37846 (PGP), NS059776 (DMM) and DK64959 (RB), P30-NS045758, and Craig H. Neilsen Foundation (PGP).	ANDERSON ME, 1989, FASEB J, V3, P2527, DOI 10.1096/fasebj.3.13.2572501; Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Burdo J, 2006, J HISTOCHEM CYTOCHEM, V54, P549, DOI 10.1369/jhc.5A6840.2006; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P197, DOI 10.2174/1567202054368317; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Dobashi K, 2001, CLIN EXP IMMUNOL, V124, P290, DOI 10.1046/j.1365-2249.2001.01535.x; Domercq M, 2007, J IMMUNOL, V178, P6549, DOI 10.4049/jimmunol.178.10.6549; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; DROGE W, 1991, AM J MED, V91, pS140, DOI 10.1016/0002-9343(91)90297-B; Farso MC, 2009, NEUROCHEM RES, V34, P1721, DOI 10.1007/s11064-009-9999-3; Fogal B, 2007, J NEUROSCI, V27, P10094, DOI 10.1523/JNEUROSCI.2459-07.2007; Gan HT, 2005, J GASTROEN HEPATOL, V20, P1016, DOI 10.1111/j.1440-1746.2005.03862.x; Garg S, 2006, J BIOL CHEM, V281, P38712, DOI 10.1074/jbc.M606235200; Garg SK, 2008, J IMMUNOL, V180, P3866, DOI 10.4049/jimmunol.180.6.3866; Gensel JC, 2009, J NEUROSCI, V29, P3956, DOI 10.1523/JNEUROSCI.3992-08.2009; Glezer I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000310; Hauss-Wegrzyniak B, 1998, BRAIN RES, V780, P294, DOI 10.1016/S0006-8993(97)01215-8; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Hosoya K, 2001, MICROVASC RES, V62, P136, DOI 10.1006/mvre.2001.2328; Johnson JM, 2008, CLIN CHIM ACTA, V396, P43, DOI 10.1016/j.cca.2008.06.020; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; McMillian MK, 1997, J NEUROPATH EXP NEUR, V56, P301, DOI 10.1097/00005072-199703000-00009; Miller BA, 2005, NEUROCHEM RES, V30, P867, DOI 10.1007/s11064-005-6880-x; Murata Y, 2002, EUR J IMMUNOL, V32, P2866, DOI 10.1002/1521-4141(2002010)32:10<2866::AID-IMMU2866>3.0.CO;2-V; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Noh JH, 2006, NEUROPHARMACOLOGY, V50, P1, DOI 10.1016/j.neuropharm.2005.07.020; OKA A, 1993, J NEUROSCI, V13, P1441; OLNEY JW, 1994, J NEURAL TRANSM-SUPP, P47; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; PIANI D, 1994, J IMMUNOL, V152, P3578; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Qin S, 2006, J NEUROSCI, V26, P3345, DOI 10.1523/JNEUROSCI.5186-05.2006; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Schonberg D.L, 2007, J NEUROPATHOL EXP NE, V66; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; WADE LA, 1981, J NEUROCHEM, V37, P730; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999	59	47	49	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2012	233	1					333	341		10.1016/j.expneurol.2011.10.025			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	890CY	WOS:000300123900037	22079587	Green Accepted			2022-02-06	
J	Ono, H; Nishijima, Y; Adachi, N; Sakamoto, M; Kudo, Y; Kaneko, K; Nakao, A; Imaoka, T				Ono, Hirohisa; Nishijima, Yoji; Adachi, Naoto; Sakamoto, Masaki; Kudo, Yohei; Kaneko, Kumi; Nakao, Atsunori; Imaoka, Takashi			A basic study on molecular hydrogen (H-2) inhalation in acute cerebral ischemia patients for safety check with physiological parameters and measurement of blood H-2 level	MEDICAL GAS RESEARCH			English	Article								Background: In animal experiments, use of molecular hydrogen (H-2) has been regarded as quite safe and effective, showing benefits in multiple pathological conditions such as ischemia-reperfusion injury of the brain, heart, kidney and transplanted tissues, traumatic and surgical injury of the brain and spinal cord, inflammation of intestine and lung, degenerative striatonigral tissue and also in many other situations. However, since cerebral ischemia patients are in old age group, the safety information needs to be confirmed. For the feasibility of H-2 treatment in these patients, delivery of H-2 by inhalation method needs to be checked for consistency. Methods: Hydrogen concentration (HC) in the arterial and venous blood was measured by gas chromatography on 3 patients, before, during and after 4% (case 1) and 3% (case2,3) H-2 gas inhalation with simultaneous monitoring of physiological parameters. For a consistency study, HC in the venous blood of 10 patients were obtained on multiple occasions at the end of 30-min H-2 inhalation treatment. Results: The HC gradually reached a plateau level in 20 min after H-2 inhalation in the blood, which was equivalent to the level reported by animal experiments. The HC rapidly decreased to 10% of the plateau level in about 6 min and 18 min in arterial and venous blood, respectively after H-2 inhalation was discontinued. Physiological parameters on these 3 patients were essentially unchanged by use of hydrogen. The consistency study of 10 patients showed the HC at the end of 30-min inhalation treatment was quite variable but the inconsistency improved with more attention and encouragement. Conclusion: H-2 inhalation of at least 3% concentration for 30 min delivered enough HC, equivalent to the animal experiment levels, in the blood without compromising the safety. However, the consistency of H-2 delivery by inhalation needs to be improved.	[Ono, Hirohisa; Nishijima, Yoji; Adachi, Naoto; Sakamoto, Masaki; Kudo, Yohei; Kaneko, Kumi; Imaoka, Takashi] Nishijima Hosp, Dept Neurosurg, Numazu, Sizuoka, Japan; [Nakao, Atsunori] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA		Ono, H (corresponding author), Nishijima Hosp, Dept Neurosurg, Numazu, Sizuoka, Japan.	hirohisa.ono@live.jp					Cardinal JS, 2010, KIDNEY INT, V77, P101, DOI 10.1038/ki.2009.421; CHRISTL SU, 1992, GASTROENTEROLOGY, V102, P1269; Cornet AD, 2012, ARCH INTERN MED, V172, P289, DOI 10.1001/archinternmed.2011.624; Eckermann S, 2012, MRDICAL GAS RES, V2, P12; Eisenmann A, 2008, J BREATH RES, V2, DOI 10.1088/1752-7155/2/4/046002; GLUECKAUF E, 1957, Q J ROY METEOR SOC, V83, P522, DOI 10.1002/qj.49708335808; Henninger N, 2007, J CEREBR BLOOD F MET, V27, P1632, DOI 10.1038/sj.jcbfm.9600463; Hertzler SR, 1997, DIGEST DIS SCI, V42, P348, DOI 10.1023/A:1018822103911; Kagaya M, 1998, J GASTROENTEROL, V33, P472, DOI 10.1007/s005350050117; LEVITT MD, 1969, NEW ENGL J MED, V281, P122, DOI 10.1056/NEJM196907172810303; Nagata K, 2009, NEUROPSYCHOPHARMACOL, V34, P501, DOI 10.1038/npp.2008.95; Nakashima-Kamimura N, 2009, CANCER CHEMOTH PHARM, V64, P753, DOI 10.1007/s00280-008-0924-2; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ono H, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-14; Ono H, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-12; PERMAN JA, 1981, J CLIN INVEST, V67, P643, DOI 10.1172/JCI110079; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Wenlan L, 2011, MED GAS RES, V1, P22	18	47	52	1	8	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	2045-9912			MED GAS RES	Med. Gas Res.		2012	2								21	10.1186/2045-9912-2-21			7	Medicine, Research & Experimental	Emerging Sources Citation Index (ESCI)	Research & Experimental Medicine	V32YZ	WOS:000215734400021	22916706	Green Accepted, hybrid, Green Published			2022-02-06	
J	Soares, FMS; de Souza, NM; Schwarzbold, ML; Diaz, AP; Nunes, JC; Hohl, A; da Silva, PNA; Vieira, J; de Souza, RL; Bertotti, MM; Prediger, RDS; Linhares, MN; Bafica, A; Walz, R				Schneider Soares, Flavia Mahatma; de Souza, Nicole Menezes; Schwarzbold, Marcelo Liborio; Diaz, Alexandre Palm; Nunes, Jean Costa; Hohl, Alexandre; Abreu da Silva, Priscilla Nunes; Vieira, Juliana; de Souza, Rafael Lisboa; Bertotti, Melina More; Schoder Prediger, Rui Daniel; Linhares, Marcelo Neves; Bafica, Andre; Walz, Roger			Interleukin-10 Is an Independent Biomarker of Severe Traumatic Brain Injury Prognosis	NEUROIMMUNOMODULATION			English	Article						Cytokines; IL-10; TNF-alpha; Traumatic brain injury; Prognosis	CEREBROSPINAL-FLUID; PLASMA-LEVELS; IMPACT; IL-10; SERUM; INFLAMMATION; PARAMETERS; MORTALITY; ALPHA; PTX3	Background: Cytokines have been shown to be involved in traumatic brain injury (TBI). We investigated the independent association between serum levels of IL-10 and TNF-alpha and hospital mortality of patients with severe TBI. Methods: Serum IL-10 and TNF-alpha levels were determined after a median period (interquartile range (IQ) 25-75) of 10 h (IQ 5-18) after severe TBI in 93 consecutive patients and in randomly selected patients with mild (n = 18) and moderate (n = 16) TBI. In patients with severe TBI, additional blood samples were analyzed 30 h (IQ 22-37) and 68 h (IQ 55-78) after TBI. Age, gender, computed tomography findings, Glasgow Coma Scale score (GCS) and pupil reactions at admission, associated trauma and hospital mortality were collected. Results: Elevated serum levels of IL-10, but not TNF-alpha, correlated significantly with GCS severity (R-2 coefficient, p < 0.0001) and were found to be associated with hospital mortality in patients with severe TBI. Elevated IL-10 remained associated with mortality (p = 0.01) in a subset of patients with isolated severe TBI (n = 74). Multiple logistic regression analysis showed that higher IL-10 levels (>90 pg/ml) at 10 or 30 h after TBI were 6 times (odds ratio (OR) 6.2, 95% confidence interval (CI) 1.2-25.1, p = 0.03) and 5 times (OR 5.4, 95% CI 1.2-25.1, p = 0.03), respectively, more frequently associated with hospital mortality than lower levels (<50 pg/ml), independently of age, GCS as well as pupil reactions at admission and associated trauma. Conclusions: Serum IL-10 levels may be a useful marker for severe TBI prognosis. Copyright (C) 2012 S. Karger AG, Basel	[Walz, Roger] Univ Fed Santa Catarina, Univ Hosp, Dept Clin Med, BR-88040900 Florianopolis, SC, Brazil; [Schneider Soares, Flavia Mahatma; Schwarzbold, Marcelo Liborio; Diaz, Alexandre Palm; Nunes, Jean Costa; Hohl, Alexandre; Abreu da Silva, Priscilla Nunes; Vieira, Juliana; Linhares, Marcelo Neves; Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas, BR-88040900 Florianopolis, SC, Brazil; [Linhares, Marcelo Neves] Univ Fed Santa Catarina, Dept Cirurgia, BR-88040900 Florianopolis, SC, Brazil; [de Souza, Nicole Menezes; Bafica, Andre] Univ Fed Santa Catarina, Lab Imunofarmacol & Doencas Infecciosas, BR-88040900 Florianopolis, SC, Brazil; [Schoder Prediger, Rui Daniel] Univ Fed Santa Catarina, Dept Farmacol, Lab Expt Doencas Neurodegenerat, BR-88040900 Florianopolis, SC, Brazil; [Linhares, Marcelo Neves] Hosp Governador Celso Ramos, Serv Neurocirurgia, Florianopolis, SC, Brazil; [de Souza, Rafael Lisboa] Hosp Governador Celso Ramos, Serv Terapia Intens, Florianopolis, SC, Brazil		Walz, R (corresponding author), Univ Fed Santa Catarina, Univ Hosp, Dept Clin Med, 3 Andar,Campus Univ 88-040-970, BR-88040900 Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Hohl, Alexandre/R-9269-2019; Schwarzbold, Marcelo Liborio/J-8960-2014; Diaz, Alexandre Paim/J-9042-2014; Diaz, Alexandre Paim/AAD-8323-2019; Bafica, Andre/ABF-5986-2020; Prediger, Rui D/C-4036-2013; Neurociencia, Inct/I-1011-2013; Prediger, Rui Daniel/AAV-3419-2020; Walz, Roger/K-9096-2013	Hohl, Alexandre/0000-0002-8073-5837; Diaz, Alexandre Paim/0000-0002-6591-6648; Bafica, Andre/0000-0002-5148-600X; Prediger, Rui D/0000-0002-7547-6463; Prediger, Rui Daniel/0000-0002-7547-6463; Walz, Roger/0000-0002-9875-6687; Mahatma Schneider Soares, Flavia/0000-0001-5968-1312	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Programa de Apoio aos Nucleos de Excelencia; Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (Brazil); CNPq - BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This work was supported by grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, the Programa de Apoio aos Nucleos de Excelencia and the Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (all from Brazil). R.D.S.P., A.B. and R.W. are supported by research fellowships from CNPq - Brazil. The authors received technical support for the biological sample collection from the Laboratorio Biomedico (Florianopolis) under the supervision of Pharm. Saulo Correia de Mello. The authors thank all medical and nursing staff of the Servico de Terapia Intensiva (Hospital Governador Celso Ramos) for their kind cooperation during the study.	Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Thais MERD, 2012, CNS NEUROSCI THER, V18, P606, DOI 10.1111/j.1755-5949.2012.00346.x; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Doni A, 2006, J LEUKOCYTE BIOL, V79, P797, DOI 10.1189/jlb.0905493; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Gullo JD, 2011, NEUROCRIT CARE, V14, P194, DOI 10.1007/s12028-010-9462-y; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Soriano SG, 2008, EUR J ANAESTH, V25, P154, DOI 10.1017/S0265021507003390; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808	28	47	47	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation		2012	19	6					377	385		10.1159/000342141			9	Endocrinology & Metabolism; Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	033AK	WOS:000310764400007	23075771	Bronze			2022-02-06	
J	Rafaels, K; Bass, CR; Salzar, RS; Panzer, MB; Woods, W; Feldman, S; Cummings, T; Capehart, B				Rafaels, Karin; Bass, Cameron R. 'Dale'; Salzar, Robert S.; Panzer, Matthew B.; Woods, William; Feldman, Sanford; Cummings, Thomas; Capehart, Bruce			Survival Risk Assessment for Primary Blast Exposures to the Head	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; injury risk; primary blast; rabbit	BRAIN-INJURY; NEUROTRAUMA	Many soldiers returning from the current conflicts in Iraq and Afghanistan have had at least one exposure to an explosive event and a significant number have symptoms consistent with traumatic brain injury. Although blast injury risk functions have been determined and validated for pulmonary injury, there is little information on the blast levels necessary to cause blast brain injury. Anesthetized male New Zealand White rabbits were exposed to varying levels of shock tube blast exposure focused on the head, while their thoraces were protected. The specimens were euthanized and evaluated when the blast resulted in respiratory arrest that was non-responsive to resuscitation or at 4 h post-exposure. Injury was evaluated by gross examination and histological evaluation. The fatality data from brain injury were then analyzed using Fisher's exact test to determine a brain fatality risk function. Greater blast intensity was associated with post-blast apnea and the need for mechanical ventilation. Gross examination revealed multifocal subdural hemorrhages, most often near the brainstem, at more intense levels of exposure. Histological evaluation revealed subdural and subarachnoid hemorrhages in the non-responsive respiratory-arrested specimens. A fatality risk function from blast exposure to the head was determined for the rabbit specimens with an LD(50) at a peak overpressure of 750 kPa. Scaling techniques were used to predict injury risk at other blast overpressure/duration combinations. The fatality risk function showed that the blast level needed to cause fatality from an overpressure wave exposure to the head was greater than the peak overpressure needed to cause fatality from pulmonary injury. This risk function can be used to guide future research for blast brain injury by providing a realistic fatality risk to guide the design of protection or to evaluate injury.	[Rafaels, Karin; Salzar, Robert S.] Univ Virginia, Ctr Appl Biomech, Charlottesville, VA 22911 USA; [Woods, William] Univ Virginia, Dept Emergency Med, Charlottesville, VA 22911 USA; [Feldman, Sanford] Univ Virginia, Ctr Comparat Med, Charlottesville, VA 22911 USA; [Bass, Cameron R. 'Dale'; Panzer, Matthew B.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Cummings, Thomas] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Capehart, Bruce] Durham VA Med Ctr, Dept Psychiat, Durham, NC USA		Rafaels, K (corresponding author), Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	kar3k@virginia.edu	Feldman, Sanford/AAH-7070-2021				ZUCKERMAN S., 1941, Proceedings of the Royal Society of Medicine, V31, P171; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bogo V., 1971, 2659 DASA LOV FDN ME; Bowen I., 1968, 2113 DASA LOV FDN ME; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; CLEMEDSON CJ, 1953, AM J PHYSIOL, V174, P316, DOI 10.1152/ajplegacy.1953.174.2.316; Clemedson CJ, 1949, ACTA PHYSL SCAND, V18, P1; Cox D.R., 1989, ANAL BINARY DATA, V2nd ed.; EPPINGER RH, 1984, SAE GOVT IND M EXP S; Hooker DR, 1924, AM J PHYSIOL, V67, P219; Hosmer D. W., 2004, APPL LOGISTIC REGRES; Hyde DW, 2004, CONWEP 2 1 0 8 CONVE; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; KROHN PL, 1941, 19511249 UK MIN HOM; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Richmond DR, 1962, DASA1335 LOV FDN MED; Rusca F, 1915, Z CHIR, V132, P315; TENNEY SM, 1963, NATURE, V197, P54, DOI 10.1038/197054a0; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Warden DL, 2005, J NEUROTRAUM, V22, P1178; WHITE CS, 1968, ANN NY ACAD SCI, V152, P89, DOI 10.1111/j.1749-6632.1968.tb11969.x; Zhu F, 2010, P STAPP CAR CRASH C	24	47	48	0	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2319	2328		10.1089/neu.2009.1207			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600010	21463161				2022-02-06	
J	Diedler, J; Zweifel, C; Budohoski, KP; Kasprowicz, M; Sorrentino, E; Haubrich, C; Brady, KM; Czosnyka, M; Pickard, JD; Smielewski, P				Diedler, Jennifer; Zweifel, Christian; Budohoski, Karol P.; Kasprowicz, Magdalena; Sorrentino, Enrico; Haubrich, Christina; Brady, Kenneth M.; Czosnyka, Marek; Pickard, John D.; Smielewski, Peter			The Limitations of Near-Infrared Spectroscopy to Assess Cerebrovascular Reactivity: The Role of Slow Frequency Oscillations	ANESTHESIA AND ANALGESIA			English	Article							CEREBRAL-BLOOD-FLOW; PRESSURE REACTIVITY; INTRACRANIAL-PRESSURE; AUTOREGULATION; OXYGENATION; TIME; HEMODYNAMICS; METABOLISM	BACKGROUND: A total hemoglobin reactivity index (THx) derived from near-infrared spectroscopy (NIRS) has recently been introduced to assess cerebrovascular reactivity noninvasively. Analogously to the pressure reactivity index (PRx), THx is calculated as correlation coefficient with arterial blood pressure (ABP). However, the reliability of THx in the injured brain is uncertain. Although slow oscillations have been described in NIRS signals, their significance for assessment of autoregulation remains unclear. In the current study, we investigated the role of slow oscillations of total hemoglobin for NIRS-based cerebrovascular reactivity monitoring. METHODS: This study was based on a retrospective analysis of data that were consecutively recorded for a different project published previously. Thirty-seven patients with traumatic brain injury and admitted to Addenbrooke's Neurosciences Critical Care Unit between June 2008 and June 2009 were included. After artifact removal, we performed spectral analysis of the tissue hemoglobin index (THI, a measure of oxy- and deoxygenated hemoglobin) and intracranial pressure (ICP) signal. PRx and THx were calculated as moving correlations between ICP and ABP, and THI and ABP, respectively. The agreement between PRx and THx as a function of normalized power of slow oscillations (0.015-0.055 Hz) contained in the input signals was assessed performing between-subject and within-subject correlation analyses. Furthermore, the correlation between the THx values derived from the right and left sides was analyzed. RESULTS: The agreement between PRx and THx depended on the power of slow oscillations in the input signals. Between-subject comparisons revealed a significant correlation between THx and PRx (r = 0.80, 95% confidence interval 0.53-0.92, P < 0.01) for patients with normalized slow wave activity > 0.4 in the THI signal, compared with r = 0.07 (95% confidence interval = 0.40 to 0.51, P = 0.79) in the remaining files. Furthermore, within-subject comparisons suggested that THx may be used as a substitute for PRx only when there is an at least moderate agreement (r = 0.36) between the THx values derived from the right and left sides. CONCLUSIONS: Our results suggest that the NIRS-based cerebrovascular reactivity index THx can be used as a noninvasive substitute for PRx, but only during phases with sufficient slow wave power in the input signal. Furthermore, a good agreement between the THx measures on both sides seems to be a prerequisite for comparison of a global (PRx) versus the more local (THx) index. Nevertheless, noninvasive assessment of cerebrovascular reactivity may be desirable in patients without ICP monitoring and help to guide ABP management in these patients. (Anesth Analg 2011;113:849-57)	[Diedler, Jennifer] Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany; [Diedler, Jennifer; Zweifel, Christian; Budohoski, Karol P.; Kasprowicz, Magdalena; Sorrentino, Enrico; Haubrich, Christina; Brady, Kenneth M.; Czosnyka, Marek; Pickard, John D.; Smielewski, Peter] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Brady, Kenneth M.] Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol & Pediat, Houston, TX 77030 USA; [Zweifel, Christian] Univ Basel, CH-4003 Basel, Switzerland; [Kasprowicz, Magdalena] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, Wroclaw, Poland; [Sorrentino, Enrico] Univ Wroclaw, PL-50138 Wroclaw, Poland; [Haubrich, Christina] Univ Aachen, Aachen, Germany		Diedler, J (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	jennifer.diedler@med.uni-heidelberg.de		Kasprowicz, Magdalena/0000-0002-2271-7737; Smielewski, Peter/0000-0001-5096-3938	Medical Faculty, University of Heidelberg; National Institute of Health Research, Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; NIHRNational Institute for Health Research (NIHR); Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBBSP3-125550]; Hamamatsu Photonics, Welwyn Garden City, Hertfordshire, UK; Foundation for Polish ScienceFoundation for Polish ScienceEuropean Commission; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	JD was supported by a scholarship from the Medical Faculty, University of Heidelberg. This work was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (grants G0600986 and G9439390), NIHR Senior Investigator Awards (JDP), the Swiss National Science Foundation (PBBSP3-125550 to CZ, Bern, Switzerland, and the Foundation for Polish Science (MK). CZ received a travel grant from Hamamatsu Photonics, Welwyn Garden City, Hertfordshire, UK.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Calderon-Arnulphi M, 2009, NEUROL RES, V31, P605, DOI 10.1179/174313209X383286; Cheng OSK, 2002, ACTA NEUROCHIR SUPPL, V81, P135; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Einhaupl K, 1986, OSCILLATIONS ICP REL; Elwell CE, 1999, ADV EXP MED BIOL, V471, P57; FERRARI M, 1992, AM J PHYSIOL, V262, pH1908, DOI 10.1152/ajpheart.1992.262.6.H1908; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Li ZY, 2010, MICROVASC RES, V80, P142, DOI 10.1016/j.mvr.2010.02.004; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; Nissen P, 2009, NEUROCRIT CARE, V11, P235, DOI 10.1007/s12028-009-9226-8; Obrig H, 2000, NEUROIMAGE, V12, P623, DOI 10.1006/nimg.2000.0657; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P591, DOI 10.1089/neu.1995.12.591; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; VENES JL, 1979, CHILD BRAIN, V5, P352; Wagner BP, 2002, CRIT CARE MED, V30, P2014, DOI 10.1097/00003246-200209000-00010; Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	32	47	47	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2011	113	4					849	857		10.1213/ANE.0b013e3182285dc0			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	824PT	WOS:000295215100028	21821514				2022-02-06	
J	Eckner, JT; Kutcher, JS; Richardson, JK				Eckner, James T.; Kutcher, Jeffrey S.; Richardson, James K.			Between-Seasons Test-Retest Reliability of Clinically Measured Reaction Time in National Collegiate Athletic Association Division I Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						intraclass correlation coefficient; concussions; traumatic brain injuries; assessment	SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; REPRODUCIBILITY; MANAGEMENT; STATEMENT; IMPACT; LONG	Context: Reaction time is typically impaired after concussion. A clinical test of reaction time (RT(clin)) that does not require a computer to administer may be a valuable tool to assist in concussion diagnosis and management. Objective: To determine the test-retest reliability of RT(clin) measured over successive seasons in competitive collegiate athletes and to compare these results with a computerized measure of reaction time (RT(comp)). Design: Case series with repeated measures. Setting: Preparticipation physical examinations for the football, women's soccer, and wrestling teams at a single university. Patients or Other Participants: 102 National Collegiate Athletic Association Division I athletes. Intervention(s): The RT(clin) was measured using a measuring stick embedded in a weighted rubber disk that was released and caught as quickly as possible. The RT(comp) was measured using the simple reaction time component of CogState Sport. Main Outcome Measure(s): Data were collected at 2 time points, 1 season apart, during preparticipation physical examinations. Outcomes were mean simple RT(clin) and RT(comp). Results: The intraclass correlation coefficient estimates from season 1 to season 2 were 0.645 for RT(clin), (n=102, entire sample) and 0.512 for RT(comp) (n=62 athletes who had 2 consecutive valid baseline CogState Sport test sessions). Conclusions: The test-retest reliability of RT(clin) over consecutive seasons compared favorably with that of a concurrently tested computerized measure of reaction time and with literature-based estimates of computerized reaction time measures. This finding supports the potential use of RT(clin) as part of a multifaceted concussion assessment battery. Further prospective study is warranted.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48108 USA		Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 100A, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			University of MichiganUniversity of Michigan System [UL1RR024986]; Foundation for Physical Medicine and Rehabilitation (Chicago, IL); University of Michigan Bone & Joint Injury Prevention & Rehabilitation Center (Ann Arbor, MI); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024986] Funding Source: NIH RePORTER	We thank Dr. David Darby, chief medical officer for CogState Ltd, for his advice and assistance relating to the CogState Sport program and Mr. Steve Nordwall and his athletic training staff for their support in organizing and conducting this project. We also thank Katherine Bohard, James Burke, Sri Krishna Chandran, Heather Eckner, Burton Engel, Shawn Heiler, Jennifer Kendall, Michael Louwers, Raman Malhotra, Stephen Oh, and Devon Shuchman for their assistance with data collection and management. We thank the University of Michigan Biostatistics Core (UL1RR024986 Clinical & Translational Science Award funded) for its statistical advice. We acknowledge the support of our sponsors, the Foundation for Physical Medicine and Rehabilitation (Chicago, IL; awarded to J.T.E.) and the University of Michigan Bone & Joint Injury Prevention & Rehabilitation Center (Ann Arbor, MI; awarded to J.T.E. and J.K.R.).	ANASTASI A, 1998, PSYCHOL TESTING; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Eckner JT, 2011, PM&R, V3, P212, DOI 10.1016/j.pmrj.2010.12.003; Eckner JT, 2011, MED SCI SPORT EXER, V43, P382, DOI 10.1249/MSS.0b013e3181f1cc51; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; TAMMEMAGI MC, 1995, J CLIN EPIDEMIOL, V48, P1123, DOI 10.1016/0895-4356(94)00243-J; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	27	47	48	0	21	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2011	46	4					409	414					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	808NA	WOS:000293983200011	21944073				2022-02-06	
J	Tiesman, HM; Konda, S; Bell, JL				Tiesman, Hope M.; Konda, Srinivas; Bell, Jennifer L.			The Epidemiology of Fatal Occupational Traumatic Brain Injury in the US	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							UNITED-STATES; SAFETY; FALLS; HEALTH; SLIPS; TRIPS	Background: Although traumatic brain injury (TBI) is one of the leading causes of death and disability in the U. S., work-related TBI has not been well documented. Purpose: The aim of this study was to describe the epidemiologic characteristics and temporal trends of fatal occupational TBI in the U. S between 2003 and 2008. Methods: A cross-sectional analysis of the Census of Fatal Occupational Injury database was performed. Both the Occupational Injury and Illness Classification System nature of injury codes and body part codes were used to define TBIs. Fatality rates were calculated using denominators derived from the Current Population Survey. Fatality rates were compared among industries, cause of death, and demographics with rate ratios (RRs) and 95% CIs. Poisson regression was used to assess trends in fatality rates. Data were analyzed in 2009-2010. Results: Nearly 7300 occupational TBI deaths occurred between 2003 and 2008, for an average fatality rate of 0.8 per 100,000 workers per year. The leading causes of occupational TBI death were as follows: motor vehicle (31%); falls (29%); assaults and violent acts (20%); and contact with objects/equipment (18%). Fatality rates were 15 times higher in men compared with women (RR = 15, 95% CI = 13.7, 16.3). Workers aged >= 65 years experienced the highest TBI fatality rate of all age groups (2.5 per 100,000 per year). Construction, transportation, and agriculture/forestry/fishing industries recorded nearly half of all TBI fatalities (n = 1828, n = 825, n = 761, respectively). Occupational TBI death rates declined 23% over the 6-year period (p < 0.0001). Conclusions: This study provides the first national profile of fatal TBIs occurring in the U. S. workplace. Prevention efforts should be directed at those industries with the highest frequency and/or highest risk. The construction industry had the highest number of TBIs, and the agriculture, forestry, and fishing industry had the highest rates. Additionally, workers aged >65 years in all industries would be a good target for future prevention efforts. (Am J Prev Med 2011; 41(1): 61-67) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine	[Tiesman, Hope M.; Konda, Srinivas; Bell, Jennifer L.] NIOSH, Div Safety Res, Anal & Field Evaluat Branch, Morgantown, WV 26506 USA		Tiesman, HM (corresponding author), NIOSH, Div Safety Res, Anal & Field Evaluat Branch, 1095 Willowdale Rd,M-S 1811, Morgantown, WV 26506 USA.	htiesman@cdc.gov	Konda, Srinivas/G-2747-2015	Konda, Srinivas/0000-0002-8934-4111			AGNEW J, 1993, HUM FACTORS, V35, P731, DOI 10.1177/001872089303500411; Alexander BH, 1999, AM J IND MED, V36, P317, DOI 10.1002/(SICI)1097-0274(199908)36:2<317::AID-AJIM11>3.3.CO;2-I; Aschkenasy MT, 2006, EMERG MED CLIN N AM, V24, P413, DOI 10.1016/j.emc.2006.01.005; BELL CA, 1990, JAMA-J AM MED ASSOC, V263, P3047, DOI 10.1001/jama.263.22.3047; Bell JL, 2006, J SAFETY RES, V37, P53, DOI 10.1016/j.jsr.2005.10.019; Bell JL, 2002, J SAFETY RES, V33, P463, DOI 10.1016/S0022-4375(02)00048-8; Bentley TA, 2005, APPL ERGON, V36, P165, DOI 10.1016/j.apergo.2004.10.009; Bobick TG, 2010, J SAFETY RES, V41, P203, DOI 10.1016/j.jsr.2010.02.008; Bohle P, 2010, INT J HEALTH SERV, V40, P23, DOI 10.2190/HS.40.1.b; *BUR LAB STAT, 1992, OCC INJ ILLN CLASS M; *BUR LAB STAT, 1998, COMP WORK COND LOGG; *BUR LAB STAT, 2009, 1015 US DEP LAB BUR; *BUR LAB STAT, 2009, 1014 US DEP LAB BUR; *BUR LAB STAT, BLS SPOTL STAT OLD W; Bureau of Labor Statistics, BLS HDB METH; Choi SD, 2009, WORK, V33, P307, DOI 10.3233/WOR-2009-0878; Colantonio A, 2010, CAN J PUBLIC HEALTH, V101, pS58, DOI 10.1007/BF03403848; Colantonio A, 2009, BRAIN INJURY, V23, P873, DOI 10.1080/02699050903036033; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Finkelstein E., 2006, INCIDENCE EC BURDEN; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Ho SC, 2010, OCCUP ENVIRON MED, V67, P251, DOI 10.1136/oem.2009.047407; Kemmlert K, 1998, SAFETY SCI, V28, P59, DOI 10.1016/S0925-7535(97)00071-4; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kisner SM, 1999, AM J IND MED, P24; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; Layne LA, 2004, AM J IND MED, V46, P32, DOI 10.1002/ajim.20038; MESSING K, 1994, J OCCUP ENVIRON MED, V36, P913; MYERS JR, 1994, J SAFETY RES, V25, P97, DOI 10.1016/0022-4375(94)90021-3; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; National Center for Injury Prevention and Control, TRAUM BRAIN INJ US E; Office of Management and Budget, 2002, N AM IND CLASS SYST; Rodriguez-Acosta, 1997, Int J Occup Environ Health, V3, P259; Scott DF, 2004, INJURY PREV, V10, P239, DOI 10.1136/ip.2003.004663; Silverstein M, 2008, AM J IND MED, V51, P269, DOI 10.1002/ajim.20569; Smith GS, 2005, J OCCUP ENVIRON MED, V47, P640, DOI 10.1097/01.jom.0000165746.26873.d1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiesman HM, 2007, AM J PREV MED, V33, P464, DOI 10.1016/j.amepre.2007.07.034; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; Tricco AC, 2006, BRAIN INJURY, V20, P719, DOI 10.1080/02699050600664640; West R, 1996, AM J FOREN MED PATH, V17, P299, DOI 10.1097/00000433-199612000-00004; Wrona RM, 2006, J SAFETY RES, V37, P75, DOI 10.1016/j.jsr.2005.08.008	42	47	47	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	JUL	2011	41	1					61	67		10.1016/j.amepre.2011.03.007			7	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine	775OC	WOS:000291468700010	21665064				2022-02-06	
J	Chi, Y; Fan, Y; He, L; Liu, W; Wen, XY; Zhou, S; Wang, XF; Zhang, C; Kong, H; Sonoda, L; Tripathi, P; Li, CJ; Yu, MS; Su, CA; Hu, G				Chi, Ying; Fan, Yi; He, Lei; Liu, Wei; Wen, Xiaoyun; Zhou, Sha; Wang, Xuefeng; Zhang, Cui; Kong, Hui; Sonoda, Laura; Tripathi, Prem; Li, Carrie J.; Yu, Michelle S.; Su, Chuan; Hu, Gang			Novel role of aquaporin-4 in CD4+CD25+T regulatory cell development and severity of Parkinson's disease	AGING CELL			English	Article						aquaporin-4; CD4+CD25+Treg cells; microglia; neuroinflammation; neuroprotection; Parkinson's disease	NIGROSTRIATAL DOPAMINERGIC NEURODEGENERATION; INSENSITIVE WATER CHANNEL; NITRIC-OXIDE SYNTHASE; T-CELLS; MOUSE MODEL; MULTIPLE-SCLEROSIS; MPTP MODEL; MICROGLIAL ACTIVATION; SUBSTANTIA-NIGRA; MICE	P>Aquaporin-4 (AQP4) is highly expressed in mammalian brains and is involved in the pathophysiology of cerebral disorders, including stroke, tumors, infections, hydrocephalus, epilepsy, and traumatic brain injury. We found that AQP4-deficient mice were hypersensitive to stimulations such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or lipopolysaccharide compared to wild-type (WT) littermates. In a mouse model of MPTP-induced Parkinson's disease (PD), AQP4-deficient animals show more robust microglial inflammatory responses and more severe loss of dopaminergic neurons (DNs) compared with WT mice. However, a few studies have investigated the association of abnormal AQP4 levels with immune dysfunction. Here, for the first time, we report AQP4 expression in mouse thymus, spleen, and lymph nodes. Furthermore, the significantly lower numbers of CD4+ CD25+ regulatory T cells in AQP4-deficient mice compared to WT mice, perhaps resulting from impaired thymic generation, may be responsible for the uncontrolled microglial inflammatory responses and subsequent severe loss of DNs in the substantia nigra pars compacta in the MPTP-induced PD model. These novel findings suggest that AQP4 deficiency may disrupt immunosuppressive regulators, resulting in hyperactive immune responses and potentially contributing to the increased severity of PD or other immune-associated diseases.	[Chi, Ying; He, Lei; Liu, Wei; Wen, Xiaoyun; Zhou, Sha; Wang, Xuefeng; Zhang, Cui; Su, Chuan] Nanjing Med Univ, Jiangsu Key Lab Pathogen Biol, Dept Pathogen Biol & Immunol, Nanjing 210029, Jiangsu, Peoples R China; [Chi, Ying] Minist Hlth, Jiangsu Prov Ctr Dis Prevent & Control, Key Lab Enter Pathogen Microbiol, Nanjing 210009, Jiangsu, Peoples R China; [Fan, Yi; Kong, Hui; Hu, Gang] Nanjing Med Univ, Dept Pharmacol, Jiangsu Key Lab Neurodegenerat, Nanjing 210029, Jiangsu, Peoples R China; [Sonoda, Laura; Tripathi, Prem; Li, Carrie J.; Yu, Michelle S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA		Su, CA (corresponding author), Nanjing Med Univ, Jiangsu Key Lab Pathogen Biol, Dept Pathogen Biol & Immunol, Nanjing 210029, Jiangsu, Peoples R China.	chuansu@njmu.edu.cn	Fan, Yi/Q-9252-2018; He, Lei/L-4726-2019; Fan, Yi/AAQ-1874-2021	Fan, Yi/0000-0003-1783-3220; Fan, Yi/0000-0003-1783-3220; He, Lei/0000-0002-3821-2047	National Basic Research Program of China (973 Program)National Basic Research Program of China [2006CB5007006, 2007CB513106]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30701017, 30872206]; Jiangsu Province [07KJA31023]	This work was supported by grants from the National Basic Research Program of China (973 Program) (No. 2006CB5007006 to Gang Hu and No. 2007CB513106 to Chuan Su), the National Natural Science Foundation of China (No. 30701017 to Yi Fan and No. 30872206 to Chuan Su) and a grant (No. 07KJA31023) from Jiangsu Province to Chuan Su.	Agre P, 2004, BIOSCIENCE REP, V24, P127, DOI 10.1007/s10540-005-2577-2; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Benner EJ, 2004, P NATL ACAD SCI USA, V101, P9435, DOI 10.1073/pnas.0400569101; Benner EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001376; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; Chade AR, 2006, J NEURAL TRANSM-SUPP, P147; Chen HL, 2005, ANN NEUROL, V58, P963, DOI 10.1002/ana.20682; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; CHI DS, 1992, INT J IMMUNOPHARMACO, V14, P739, DOI 10.1016/0192-0561(92)90070-2; Choi DK, 2005, J NEUROSCI, V25, P6594, DOI 10.1523/JNEUROSCI.0970-05.2005; Czlonkowska A, 1996, NEURODEGENERATION, V5, P137, DOI 10.1006/neur.1996.0020; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dhib-Jalbut S, 2006, J NEUROIMMUNOL, V176, P198, DOI 10.1016/j.jneuroim.2006.03.027; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fan Y, 2005, J NEUROSCI RES, V82, P458, DOI 10.1002/jnr.20664; Fan Y, 2008, NEUROBIOL AGING, V29, P1226, DOI 10.1016/j.neurobiolaging.2007.02.015; Fontenot JD, 2005, J EXP MED, V202, P901, DOI 10.1084/jem.20050784; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GIOVANNI A, 1994, J PHARMACOL EXP THER, V270, P1008; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim WK, 2004, J IMMUNOL, V172, P7015, DOI 10.4049/jimmunol.172.11.7015; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kurkowska-Jastrzebska I, 2004, INT IMMUNOPHARMACOL, V4, P1307, DOI 10.1016/j.intimp.2004.05.006; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Liberatore GT, 1999, NAT MED, V5, P1403; Liu B, 2006, AAPS J, V8, pE606, DOI 10.1208/aapsj080369; Lorincz MT, 2006, SEMIN NEUROL, V26, P492, DOI 10.1055/s-2006-951621; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; Matyszak MK, 1998, PROG NEUROBIOL, V56, P19, DOI 10.1016/S0301-0082(98)00014-8; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Ng SW, 2008, J LEUKOCYTE BIOL, V83, P288, DOI 10.1189/jlb.0807575; Nielsen S, 1997, J NEUROSCI, V17, P171; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Ortiz GG, 2003, ENVIRON MOL MUTAGEN, V41, P64, DOI 10.1002/em.10133; Powrie F, 2003, SCIENCE, V299, P1030, DOI 10.1126/science.1082031; Przedborski S, 2000, RESTOR NEUROL NEUROS, V16, P135; Przedborski S, 2004, J BIOENERG BIOMEMBR, V36, P375, DOI 10.1023/B:JOBB.0000041771.66775.d5; Przedborski S, 2001, J NEUROCHEM, V76, P1265, DOI 10.1046/j.1471-4159.2001.00183.x; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; Reynolds AD, 2007, J LEUKOCYTE BIOL, V82, P1083, DOI 10.1189/jlb.0507296; Reynolds AD, 2010, J IMMUNOL, V184, P2261, DOI 10.4049/jimmunol.0901852; Reynolds AD, 2009, J IMMUNOL, V182, P4137, DOI 10.4049/jimmunol.0803982; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Smeyne RJ, 2005, MOL BRAIN RES, V134, P57, DOI 10.1016/j.molbrainres.2004.09.017; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; Thomas MP, 2007, J NEUROCHEM, V100, P503, DOI 10.1111/j.1471-4159.2006.04315.x; UHL GR, 1985, LANCET, V1, P956; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; YAMADA T, 1992, ACTA NEUROPATHOL, V84, P100, DOI 10.1007/BF00427222; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	72	47	52	2	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1474-9726			AGING CELL	Aging Cell	JUN	2011	10	3					368	382		10.1111/j.1474-9726.2011.00677.x			15	Cell Biology; Geriatrics & Gerontology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Geriatrics & Gerontology	763CR	WOS:000290531900002	21255222	Bronze			2022-02-06	
J	Gomez-Pinilla, F				Gomez-Pinilla, Fernando			The combined effects of exercise and foods in preventing neurological and cognitive disorders	PREVENTIVE MEDICINE			English	Article						Neurotrophin; Synaptic plasticity; Brain trauma; Diet; Omega-3-fatty acids	TRAUMATIC BRAIN-INJURY; CAMP-RESPONSIVE ELEMENT; SATURATED-FAT DIET; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; DOCOSAHEXAENOIC ACID; METABOLIC DEPRESSION; ENERGY-METABOLISM; OXIDATIVE STRESS; HUMAN-MEMORY	Objective. Exercise and select diets have important influences on health and plasticity of the nervous system, and the molecular mechanisms involved with these actions are starting to be elucidated. New evidence indicates that exercise, in combination with dietary factors, exerts its effects by affecting molecular events related to the management of energy metabolism and synaptic plasticity. Methods. Published studies in animals and humans describing the effects of exercise and diets in brain plasticity and cognitive abilities are discussed. Results. New evidence indicates that exercise and select diets exert their effects by affecting molecular events related to the management of energy metabolism and synaptic plasticity. An important instigator in the molecular machinery stimulated by exercise is brain-derived neurotrophic factor (BDNF), which acts at the interface of metabolism and plasticity. Conclusions. Recent studies show that selected dietary factors share similar mechanisms with exercise, and in some cases they can complement the action of exercise. Therefore, exercise and dietary management appear as a non-invasive and effective strategy to counteract neurological and cognitive disorders. (C) 2011 Elsevier Inc. All rights reserved.	[Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	Fgomezpi@ucla.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465-06, NS068473, NS56413]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC1NS068473, R01NS056413, R01NS050465] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Awards NS50465-06, NS068473, and NS56413.	AGRAWAL R, 2010, 2010 NEUR M PLANN SO; Andres-Lacueva C, 2005, NUTR NEUROSCI, V8, P111, DOI 10.1080/10284150500078117; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Cammarota M, 2000, NEUROCHEM RES, V25, P567, DOI 10.1023/A:1007590415556; Chao HT, 2009, P NATL ACAD SCI USA, V106, P4577, DOI 10.1073/pnas.0901518106; Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x; Chytrova G, 2010, BRAIN RES, V1341, P32, DOI 10.1016/j.brainres.2009.05.018; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460-9568.2006.05026.x; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Feng JA, 2007, PEDIATR RES, V61, p58R, DOI 10.1203/pdr.0b013e3180457635; Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x; Gomez-Pinilla F, 2010, NEUROSCIENCE, V168, P130, DOI 10.1016/j.neuroscience.2010.02.070; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021, DOI 10.1523/JNEUROSCI.15-03-02021.1995; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1987, EXP NEUROL, V97, P391, DOI 10.1016/0014-4886(87)90099-9; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Jacka FN, 2010, AM J PSYCHIAT, V167, P305, DOI 10.1176/appi.ajp.2009.09060881; Joseph JA, 2003, NUTR NEUROSCI, V6, P153, DOI 10.1080/1028415031000111282; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Lyons WE, 1999, P NATL ACAD SCI USA, V96, P15239, DOI 10.1073/pnas.96.26.15239; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nestler EJ, 2009, BIOL PSYCHIAT, V65, P189, DOI 10.1016/j.biopsych.2008.10.030; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Song DK, 1998, BRAIN RES, V799, P176, DOI 10.1016/S0006-8993(98)00474-0; Suzuki H, 1998, MECH AGEING DEV, V101, P119, DOI 10.1016/S0047-6374(97)00169-3; Sweatt JD, 2009, BIOL PSYCHIAT, V65, P191, DOI 10.1016/j.biopsych.2008.09.002; Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659; Tsuchida A, 2002, DIABETES OBES METAB, V4, P262, DOI 10.1046/j.1463-1326.2002.00206.x; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van Praag H, 2009, TRENDS NEUROSCI, V32, P283, DOI 10.1016/j.tins.2008.12.007; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184; Wei QY, 2006, BBA-GEN SUBJECTS, V1760, P70, DOI 10.1016/j.bbagen.2005.09.008; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313	66	47	49	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0091-7435	1096-0260		PREV MED	Prev. Med.	JUN 1	2011	52			1			S75	S80		10.1016/j.ypmed.2011.01.023			6	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; General & Internal Medicine	779DS	WOS:000291758900013	21281667	Green Accepted			2022-02-06	
J	Dai, SS; Zhou, YG				Dai, Shuang-Shuang; Zhou, Yuan-Guo			Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury	REVIEWS IN THE NEUROSCIENCES			English	Article						acute neurological injury; adenosine 2A receptor; bidirectional effect; neuroprotection	SPINAL-CORD-INJURY; TUMOR-NECROSIS-FACTOR; CEREBRAL ISCHEMIC-INJURY; EXCITATORY AMINO-ACIDS; BONE-MARROW-CELLS; A(2A) RECEPTOR; INDUCED EXCITOTOXICITY; FACTOR-ALPHA; NEUROLOGICAL DEFICIT; GLUTAMATE RELEASE	This review summarizes recent developments that have contributed to our understanding of how adenosine 2A receptors (A2ARs) modulate brain damage in various animal models of acute neurological injuries, including brain ischemia, traumatic brain injury, spinal cord injury and hemorrhage stroke. The main conclusions are: (1) pharmacological, neurochemical and molecular/genetic approaches to the complex actions of A2AR in different cellular elements suggest that A2AR activation exerts bidirectional effect (detrimental or protective) after brain insults; (2) modulation of glutamate excitotoxicity and neuroinflammation are involved in the protection of A2AR agonists or antagonists, but the bidirectional effect of A2AR is largely due to the bidirectional regulation of neuroinflammation (anti-inflammation or proinflammation) by A2AR on immune cells such as microglia cells and peripheral bone marrow cells; and (3) the bidirectional effect of A2AR on neuroinflammation and brain injury depends on the distinct and sometimes opposite actions of A2AR in various cellular elements and on different injury models and associated pathological conditions. The local glutamate level in the brain injury is one of the crucial factors that contribute to the direction of A2AR effect on neuroinflammation and brain injury outcome. These developments presented here clearly highlight the complexity of using A2AR agents therapeutically in acute neuronal injuries and confirm that A2AR ligands have many promising characteristics that encourage the pursuit of their full therapeutic potential.	[Zhou, Yuan-Guo] Third Mil Med Univ, Inst Surg Res, State Key Lab Trauma Burn & Combined Injury, Ctr Mol Biol, Chongqing 400042, Peoples R China; [Zhou, Yuan-Guo] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Dai, Shuang-Shuang] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China		Zhou, YG (corresponding author), Third Mil Med Univ, Inst Surg Res, State Key Lab Trauma Burn & Combined Injury, Ctr Mol Biol, Chongqing 400042, Peoples R China.	ygzhou@cta.cq.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30900587]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]; Science Foundation of Third Military Medical University	We gratefully thank Dr. Jiang-Fan Chen for critical reading and editing the review. The work in the authors' laboratories is supported by grants from the National Natural Science Foundation of China (No. 30900587), Natural Science Foundation of Chongqing, China (No. CSTC2009BB5317) and the Science Foundation of Third Military Medical University (to S.-S.D.).	Aden U, 2003, STROKE, V34, P739, DOI 10.1161/01.STR.0000060204.67672.8B; Bates B, 2002, MOL BRAIN RES, V109, P18, DOI 10.1016/S0169-328X(02)00458-8; Blum D, 2003, J NEUROSCI, V23, P5361; Boison D, 2010, CELL DEATH DIFFER, V17, P1071, DOI 10.1038/cdd.2009.131; Bona E, 1997, NEUROPHARMACOLOGY, V36, P1327, DOI 10.1016/S0028-3908(97)00139-1; Bouma MG, 1997, J IMMUNOL, V158, P5400; Brown J., 1996, THESIS NATL LIB CANA; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Cassada DC, 2002, J VASC SURG, V35, P994, DOI 10.1067/mva.2002.123091; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Chaparro-Huerta V, 2005, J NEUROIMMUNOL, V165, P53, DOI 10.1016/j.jneuroim.2005.04.025; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Chen JF, 2008, CURR PHARM DESIGN, V14, P1490, DOI 10.2174/138161208784480126; Chen JF, 2007, PROG NEUROBIOL, V83, P310, DOI 10.1016/j.pneurobio.2007.09.002; Chen Jiang-Fan, 2011, Handb Exp Pharmacol, P267, DOI 10.1007/978-3-642-13443-2_10; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Cunha GMA, 2006, NEUROSCIENCE, V141, P1775, DOI 10.1016/j.neuroscience.2006.05.024; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dias R. A., 2009, PUR 80 YEARS VER MUC; Dionisotti S, 1997, BRIT J PHARMACOL, V121, P353, DOI 10.1038/sj.bjp.0701119; Duarte JMN, 2006, NEUROCHEM INT, V48, P144, DOI 10.1016/j.neuint.2005.08.008; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2; Fink JS, 2004, J NEUROCHEM, V88, P538, DOI 10.1046/j.1471-4159.2003.02145.x; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731; Frenguelli BG, 2007, J NEUROCHEM, V101, P1400, DOI 10.1111/j.1471-4159.2006.04425.x; GAO Y, 1994, LIFE SCI, V55, pPL61, DOI 10.1016/0024-3205(94)00889-2; Gott VL, 2002, ANN THORAC SURG, V74, P849; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gubitz AK, 1996, J NEUROCHEM, V67, P374; HAGBERG H, 1987, NEUROSCI LETT, V78, P311, DOI 10.1016/0304-3940(87)90379-X; Heese K, 1997, NEUROSCI LETT, V231, P83, DOI 10.1016/S0304-3940(97)00545-4; Hettinger BD, 2001, J COMP NEUROL, V431, P331, DOI 10.1002/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W; Higashi H, 2002, J NEUROSURG, V96, P117, DOI 10.3171/jns.2002.96.1.0117; Jenner P, 2009, PARKINSONISM RELAT D, V15, P406, DOI 10.1016/S1353-8020(09)70829-6; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Latini S, 1998, BRAIN RES, V794, P325, DOI 10.1016/S0006-8993(98)00304-7; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Lee YC, 2003, EUR J NEUROSCI, V18, P1786, DOI 10.1046/j.1460-9568.2003.02907.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Li Y, 2006, NEUROSCIENCE, V141, P2029, DOI 10.1016/j.neuroscience.2006.05.014; LIBERT F, 1991, GENOMICS, V11, P225, DOI 10.1016/0888-7543(91)90125-X; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Lin CL, 2007, J NEUROSURG, V106, P436, DOI 10.3171/jns.2007.106.3.436; Manjunath S, 2009, INDIAN J PHARMACOL, V41, P97, DOI 10.4103/0253-7613.55202; Marcoli M, 2004, NEUROPHARMACOLOGY, V47, P884, DOI 10.1016/j.neuropharm.2004.06.022; Marcoli M, 2003, NEUROPHARMACOLOGY, V45, P201, DOI 10.1016/S0028-3908(03)00156-4; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; MATSUMOTO K, 1992, BRAIN RES, V579, P309, DOI 10.1016/0006-8993(92)90066-I; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Meistrell ME, 1997, SHOCK, V8, P341; Melani A, 2006, BRAIN RES, V1073, P470, DOI 10.1016/j.brainres.2005.12.010; Melani A, 2003, BRAIN RES, V959, P243, DOI 10.1016/S0006-8993(02)03753-8; Melani A, 1999, STROKE, V30, P2448, DOI 10.1161/01.STR.30.11.2448; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; Monopoli A, 1998, J PHARMACOL EXP THER, V285, P9; Murphree LJ, 2005, BIOCHEM J, V391, P575, DOI 10.1042/BJ20050888; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishizaki T, 2002, GLIA, V39, P133, DOI 10.1002/glia.10100; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Okonkwo DO, 2006, J NEUROSURG-SPINE, V4, P64, DOI 10.3171/spi.2006.4.1.64; Ongini E, 1997, ANN NY ACAD SCI, V825, P30, DOI 10.1111/j.1749-6632.1997.tb48412.x; Pedata F, 2005, NEUROL RES, V27, P169, DOI 10.1179/016164105X21913; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; PHILLIS JW, 1994, NEUROCHEM RES, V19, P1387, DOI 10.1007/BF00972467; Pintor A, 2004, J NEUROCHEM, V89, P152, DOI 10.1111/j.1471-4159.2003.02306.x; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; Rebola N, 2005, EPILEPSIA, V46, P159, DOI 10.1111/j.1528-1167.2005.01026.x; Reece TB, 2008, J CARDIOVASC MED, V9, P363, DOI 10.2459/JCM.0b013e3282eee836; Reece TB, 2006, J VASC SURG, V44, P392, DOI 10.1016/j.jvs.2006.04.032; Reece TB, 2006, ANN THORAC SURG, V81, P902, DOI 10.1016/j.athoracsur.2005.09.023; Reece TB, 2004, J THORAC CARDIOV SUR, V128, P925, DOI 10.1016/j.jtcvs.2004.08.019; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; Ribeiro JA, 2010, ACTA PHYSIOL, V199, P161, DOI 10.1111/j.1748-1716.2010.02115.x; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Rosin Diane L., 2003, Neurology, V61, pS12; Saura J, 2005, J NEUROCHEM, V95, P919, DOI 10.1111/j.1471-4159.2005.03395.x; SCHIFFMANN SN, 1991, J NEUROCHEM, V57, P1062, DOI 10.1111/j.1471-4159.1991.tb08257.x; Skeberdis VA, 2001, NEUROPHARMACOLOGY, V40, P856, DOI 10.1016/S0028-3908(01)00005-3; Svenningsson P, 1999, PROG NEUROBIOL, V59, P355, DOI 10.1016/S0301-0082(99)00011-8; Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200; Tomimoto H, 1996, ACTA NEUROPATHOL, V92, P281, DOI 10.1007/s004010050519; VonLubitz DKJE, 1995, EUR J PHARMACOL, V287, P295, DOI 10.1016/0014-2999(95)00498-X; Xu K, 2010, NEUROSCIENCE, V167, P475, DOI 10.1016/j.neuroscience.2010.02.020; Yu LQ, 2008, ANN NEUROL, V63, P338, DOI 10.1002/ana.21313; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	102	47	49	1	5	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	APR	2011	22	2					231	239		10.1515/RNS.2011.020			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	889QR	WOS:000300088800007	21476942				2022-02-06	
J	Kelleher, MA; Palliser, HK; Walker, DW; Hirst, JJ				Kelleher, Meredith A.; Palliser, Hannah K.; Walker, David W.; Hirst, Jonathan J.			Sex-dependent effect of a low neurosteroid environment and intrauterine growth restriction on foetal guinea pig brain development	JOURNAL OF ENDOCRINOLOGY			English	Article							NEUROACTIVE STEROIDS; SLICE CULTURES; NERVOUS-SYSTEM; LATE-GESTATION; CELL-DEATH; PROGESTERONE; ALLOPREGNANOLONE; PREGNANCY; INJURY; SHEEP	Progesterone and its neuroactive metabolite, allopregnanolone, are present in high concentrations during pregnancy, but drop significantly following birth. Allopregnanolone influences foetal arousal and enhances cognitive and behavioural recovery following traumatic brain injury. Inhibition of allopregnanolone synthesis increases cell death in foetal animal brains with experimental hypoxia. We hypothesised that complications during pregnancy, such as early or preterm loss of placental steroids and intrauterine growth restriction (IUGR), would disrupt the foetal neurosteroid system, contributing to poor neurodevelopmental outcomes. This study aimed to investigate the effects of chronic inhibition of allopregnanolone synthesis before term and IUGR on developmental processes in the foetal brain. Guinea pig foetuses were experimentally growth restricted at mid-gestation and treated with finasteride, an inhibitor of allopregnanolone synthesis. Finasteride treatment reduced foetal brain allopregnanolone concentrations by up to 75% and was associated with a reduction in myelin basic protein (MBP) (P=0.001) and an increase in glial fibrillary acidic protein expression in the subcortical white matter brain region (P < 0.001). IUGR resulted in decreased MBP expression (P < 0.01) and was associated with a reduction in the expression of steroidogenic enzyme 5 alpha-reductase (5 alpha R) type 2 in the foetal brain (P=0.061). Brain levels of 5 alpha R1 were higher in male foetuses (P=0.008). Both IUGR and reduced foetal brain concentrations of allopregnanolone were associated with altered expression of myelination and glial cell markers within the developing foetal brain. The potential role of neurosteroids in protecting and regulating neurodevelopmental processes in the foetal brain may provide new directions for treatment of neurodevelopmental disorders in infants who are exposed to perinatal insults and pathologies. Journal of Endocrinology (2011) 208, 301-309	[Kelleher, Meredith A.; Palliser, Hannah K.; Hirst, Jonathan J.] Univ Newcastle, Mothers & Babies Res Ctr, John Hunter Hosp, Newcastle, NSW 2310, Australia; [Kelleher, Meredith A.; Palliser, Hannah K.; Hirst, Jonathan J.] Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2310, Australia; [Walker, David W.] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia		Kelleher, MA (corresponding author), Univ Newcastle, Mothers & Babies Res Ctr, John Hunter Hosp, Newcastle, NSW 2310, Australia.	meredith.kelleher@uon.edu.au	HIRST, JONATHAN JAMES/G-7822-2013; Kelleher, Meredith Anne/L-2317-2019; Hirst, Jonathan/ABC-3250-2021	HIRST, JONATHAN JAMES/0000-0002-9362-5303; Kelleher, Meredith Anne/0000-0002-5313-004X; Hirst, Jonathan/0000-0002-9362-5303; Palliser, Hannah/0000-0001-5783-9737	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [455527]	This work was supported by the National Health and Medical Research Council of Australia (project grant ID#455527).	Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Di Renzo GC, 2007, GENDER MED, V4, P19, DOI 10.1016/S1550-8579(07)80004-0; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Evans SEG, 2005, GYNECOL ENDOCRINOL, V21, P268, DOI 10.1080/09513590500361747; Faturi CD, 2006, PHARMACOL BIOCHEM BE, V85, P569, DOI 10.1016/j.pbb.2006.10.011; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hirst JJ, 2006, NEUROENDOCRINOLOGY, V84, P264, DOI 10.1159/000097990; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Lackman F, 2001, AM J OBSTET GYNECOL, V184, P946, DOI 10.1067/mob.2001.111719; Larroque B, 2001, PEDIATRICS, V108, P111, DOI 10.1542/peds.108.1.111; Mallard C, 2000, NEUROSCIENCE, V100, P327, DOI 10.1016/S0306-4522(00)00271-2; McKendry AA, 2010, J NEUROENDOCRINOL, V22, P166, DOI 10.1111/j.1365-2826.2009.01949.x; Mitchell BF, 2009, AM J PHYSIOL-REG I, V297, pR525, DOI 10.1152/ajpregu.00153.2009; Nguyen PN, 2004, J PHYSIOL-LONDON, V560, P593, DOI 10.1113/jphysiol.2004.069336; Nguyen PN, 2003, PEDIATR RES, V54, P840, DOI 10.1203/01.PDR.0000088066.47755.36; Nicol MB, 1997, J ENDOCRINOL, V152, P379, DOI 10.1677/joe.0.1520379; NITSOS I, 1990, INT J DEV NEUROSCI, V8, P233, DOI 10.1016/0736-5748(90)90029-2; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Poletti A, 1998, STEROIDS, V63, P246, DOI 10.1016/S0039-128X(98)00018-X; Rees S, 1998, COMP BIOCHEM PHYS A, V119, P653, DOI 10.1016/S1095-6433(98)01001-0; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Kruse MS, 2009, BRAIN RES, V1303, P1, DOI 10.1016/j.brainres.2009.09.078; Turner AJ, 2009, PLACENTA, V30, P236, DOI 10.1016/j.placenta.2008.11.023; Yawno T, 2007, NEUROSCIENCE, V146, P1726, DOI 10.1016/j.neuroscience.2007.03.023; Yawno T, 2009, NEUROSCIENCE, V163, P838, DOI 10.1016/j.neuroscience.2009.07.009	31	47	49	0	6	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795			J ENDOCRINOL	J. Endocrinol.	MAR	2011	208	3					301	309		10.1677/JOE-10-0248			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	720TF	WOS:000287304000012	21149437	Bronze			2022-02-06	
J	Sastre, M; Richardson, JC; Gentleman, SM; Brooks, DJ				Sastre, M.; Richardson, J. C.; Gentleman, S. M.; Brooks, D. J.			Inflammatory Risk Factors and Pathologies Associated with Alzheimer's Disease	CURRENT ALZHEIMER RESEARCH			English	Article						Alzheimer's disease; diabetes; imaging; infection; inflammation; microglia; stroke; trauma	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MILD COGNITIVE IMPAIRMENT; MICROGLIAL ACTIVATION; PLAQUE DEPOSITION; HEAD-INJURY; INDUCED-NEUROINFLAMMATION; INSULIN-RESISTANCE; GENE POLYMORPHISM	The importance of inflammatory processes in Alzheimer's disease ( AD) progression has been confirmed during the past decade by the intensive investigation of inflammatory mediators in the brain of AD patients as well as by the genetic and drug manipulation of animal models of AD. Imaging studies have revealed that the activation of microglia occurs in early stages of the disease, even before plaque and tangle formation, and is correlated with early cognitive deficits. In this review, we analyze how different risk factors, such as trauma, stroke, infection, and metabolic diseases can lead to an acceleration of the inflammatory response in the AD brain and to an increased risk of developing this disorder. The use of imaging techniques for early detection of glial activation which offer the advantage of investigating how potential anti-inflammatory therapies may influence disease progression and levels of cognition is also discussed.	[Richardson, J. C.] GlaxoSmithKline, Neurosci CEDD, Harlow, Essex, England; [Sastre, M.; Gentleman, S. M.; Brooks, D. J.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Ctr Neurosci, London W12 0NN, England		Sastre, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Neurosci, Div Expt Med, Du Cane Rd, London W12 0NN, England.	m.sastre@imperial.ac.uk		Brooks, David/0000-0003-2602-2518	Alzheimer's Research Trust [ART/PG2009/5, ART/PPG2009B/10]	We would like to thank the Alzheimer's Research Trust for their support ( grants ART/PG2009/5 and ART/PPG2009B/10).	Allen B, 2002, J NEUROSCI, V22, P9340; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Anderson AN, 2007, NEUROIMAGE, V36, P28, DOI 10.1016/j.neuroimage.2007.02.017; Anthony IC, 2006, ACTA NEUROPATHOL, V111, P529, DOI 10.1007/s00401-006-0037-0; Archer HA, 2006, ANN NEUROL, V60, P145, DOI 10.1002/ana.20889; Arnaud L, 2006, NEURODEGENER DIS, V3, P313, DOI 10.1159/000095638; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; BALES KR, 2010, NEUROPHARMACOLOGY; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; BANATI RB, 1997, J CEREB BLOOD FLOW M, V17, pS435; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013; Bellelli G, 2009, J AM GERIATR SOC, V57, P178, DOI 10.1111/j.1532-5415.2009.02067.x; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Boche D, 2010, ACTA NEUROPATHOL, V120, P13, DOI 10.1007/s00401-010-0705-y; Breitner JCS, 2009, NEUROLOGY, V72, P1899, DOI 10.1212/WNL.0b013e3181a18691; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Britschgi M, 2009, ARCH NEUROL-CHICAGO, V66, P161, DOI 10.1001/archneurol.2008.530; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brown AK, 2007, J NUCL MED, V48, P2072, DOI 10.2967/jnumed.107.044842; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Capurso C, 2004, EXP GERONTOL, V39, P1567, DOI 10.1016/j.exger.2004.07.006; Chakrabarty P, 2010, J IMMUNOL, V184, P5333, DOI 10.4049/jimmunol.0903382; Chakrabarty P, 2010, FASEB J, V24, P548, DOI 10.1096/fj.09-141754; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2008, J ALZHEIMERS DIS, V15, P571; Craft S, 1999, ARCH GEN PSYCHIAT, V56, P1135, DOI 10.1001/archpsyc.56.12.1135; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Edison P, 2007, NEUROLOGY, V68, P501, DOI 10.1212/01.wnl.0000244749.20056.d4; Edison P, 2008, NEUROBIOL DIS, V32, P412, DOI 10.1016/j.nbd.2008.08.001; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Engler H, 2006, BRAIN, V129, P2856, DOI 10.1093/brain/awl178; Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerard HC, 2006, FEMS IMMUNOL MED MIC, V48, P355, DOI 10.1111/j.1574-695X.2006.00154.x; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; Gold M, 2010, DEMENT GERIATR COGN, V30, P131, DOI 10.1159/000318845; Gouin JP, 2008, NEUROIMMUNOMODULAT, V15, P251, DOI 10.1159/000156468; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Heneka MT, 2001, J NEUROPATH EXP NEUR, V60, P906, DOI 10.1093/jnen/60.9.906; HENEKA MT, 2006, GLIA INIFLAMMATION N, P117; Herber DL, 2004, EXP NEUROL, V190, P245, DOI 10.1016/j.expneurol.2004.07.007; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Honjo K, 2009, ALZHEIMERS DEMENT, V5, P348, DOI 10.1016/j.jalz.2008.12.001; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Jaeger LB, 2009, BRAIN BEHAV IMMUN, V23, P507, DOI 10.1016/j.bbi.2009.01.017; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Jolivalt CG, 2008, J NEUROSCI RES, V86, P3265, DOI 10.1002/jnr.21787; JOLIVALT CG, 2009, EXP NEUROL; Kaddai V, 2009, DIABETOLOGIA, V52, P932, DOI 10.1007/s00125-009-1273-3; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Klunk WE, 2003, J NEUROSCI, V23, P2086; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Koistinaho M, 2005, BRAIN RES REV, V48, P240, DOI 10.1016/j.brainresrev.2004.12.014; Koivisto AM, 2006, DEMENT GERIATR COGN, V22, P449, DOI 10.1159/000095857; Kriz J, 2009, ACTA NEUROPATHOL, V117, P497, DOI 10.1007/s00401-009-0496-1; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Lee JW, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-37; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; McCusker SM, 2001, LANCET, V357, P436, DOI 10.1016/S0140-6736(00)04008-3; Miklossy J, 2008, J ALZHEIMERS DIS, V13, P381; Mintun MA, 2005, CNS SPECTRUMS, V10, P13, DOI 10.1017/S1092852900014188; Nicoll JAR, 2003, TRENDS MOL MED, V9, P281, DOI 10.1016/S1471-4914(03)00109-6; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; Okello A, 2009, NEUROLOGY, V72, P56, DOI 10.1212/01.wnl.0000338622.27876.0d; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Petersen R C, 2000, Neurologia, V15, P93; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rasgon N, 2004, J GERONTOL A-BIOL, V59, P178; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Roberts JC, 2009, EXP NEUROL, V216, P459, DOI 10.1016/j.expneurol.2009.01.002; ROGERS JT, 1999, J BIOL CHEM, V274, P6231; Rossner S, 2005, J NEUROCHEM, V92, P226, DOI 10.1111/j.1471-4159.2004.02857.x; Sastre M, 2003, J NEUROSCI, V23, P9796; Sastre M, 2006, INT J DEV NEUROSCI, V24, P167, DOI 10.1016/j.ijdevneu.2005.11.014; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; SASTRE M, 2010, NEUROSCIENCE, V2, P20; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Sauder S, 2005, J NEURAL TRANSM, V112, P1381, DOI 10.1007/s00702-004-0267-z; Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450; Sheng JG, 2003, NEUROBIOL DIS, V14, P133, DOI 10.1016/S0969-9961(03)00069-X; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Szekely CA, 2008, NEUROLOGY, V70, P2291, DOI 10.1212/01.wnl.0000313933.17796.f6; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Takeda S, 2010, P NATL ACAD SCI USA, V107, P7036, DOI 10.1073/pnas.1000645107; Thirumangalakudi L, 2008, J NEUROCHEM, V106, P475, DOI 10.1111/j.1471-4159.2008.05415.x; Tobinick Edward, 2006, MedGenMed, V8, P25; Turner MR, 2004, NEUROBIOL DIS, V15, P601, DOI 10.1016/j.nbd.2003.12.012; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Verhoeff NPLG, 2004, AM J GERIAT PSYCHIAT, V12, P584, DOI 10.1176/appi.ajgp.12.6.584; Verma NK, 2004, BRIT J PHARMACOL, V143, P1006, DOI 10.1038/sj.bjp.0706002; Verreault R, 2001, CAN MED ASSOC J, V165, P1495; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Whitehead SN, 2007, STROKE, V38, P3245, DOI 10.1161/STROKEAHA.107.492660; Wozniak MA, 2009, J PATHOL, V217, P131, DOI 10.1002/path.2449; WOZNIAK MA, 2010, THERAPEUTIC ADV NEUR; Wozniak MA, 2007, NEUROSCI LETT, V429, P95, DOI 10.1016/j.neulet.2007.09.077; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xu F, 2007, STROKE, V38, P2598, DOI 10.1161/STROKEAHA.106.480103; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	132	47	49	0	15	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	MAR	2011	8	2					132	141		10.2174/156720511795256062			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	744TV	WOS:000289118300003	21345169				2022-02-06	
J	Itoh, T; Imano, M; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, A; Satou, T				Itoh, Tatsuki; Imano, Motohiro; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Akihiko; Satou, Takao			Exercise increases neural stem cell proliferation surrounding the area of damage following rat traumatic brain injury	JOURNAL OF NEURAL TRANSMISSION			English	Article						Exercise; Neural stem cell; Traumatic brain injury; Nestin; Neurosphere	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; DENTATE GYRUS; CEREBRAL-CORTEX; NEUROGENESIS; EXPRESSION; HIPPOCAMPUS; ASTROCYTES; NEURONS; NESTIN	Exercise enhances neuronal stem cell (NSC) proliferation and neurogenesis. However, the effect of exercise on NSC proliferation surrounding the area of damage after traumatic brain injury (TBI) is unknown. Here, we investigate the effect of running on NSC proliferation following TBI in the rat. Wistar rats received TBI and were randomly divided into two groups: (1) non-exercise group and (2) exercise group. The exercise group ran on a treadmill for 30 min/day at 22 m/min for 7 consecutive days. Immunohistochemistry was used to monitor NSC proliferation around the damaged area, and ex vivo techniques were used to isolate NSCs from the damaged region in both groups. The number of nestin- and Ki67-positive cells observed at 3 and 7 days after TBI was significantly greater in the exercise group than in the non-exercise group (P < 0.01). Furthermore, most nestin-positive cells in the exercise group co-localized with Ki67-positive cells. In ex vivo studies, spheres could be isolated from injured brain tissue from the exercise group at 3 and 7 days following TBI, but at only 3 days in the non-exercise group. The number of spheres isolated from injured brain tissue was greater in the exercise group than in the non-exercise group. Spheres were immunopositive for nestin and comprised NSCs that could differentiate into neurons and glia. Exercise increases the proliferation of NSCs around the damaged area following TBI. Therefore, exercise therapy (rehabilitation) in the early phase following TBI is important for recuperation from cerebral dysfunction induced by TBI.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Sch Med, Dept Pathol, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Sch Med, Dept Surg, Osaka 5898511, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Div Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Div Hosp Pathol, Sch Med, Osaka, Japan; [Satou, Takao] Kinki Univ, Div Sports Med, Inst Life Sci, Osaka 5898511, Japan		Itoh, T (corresponding author), Kinki Univ, Sch Med, Dept Pathol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			ZENRYOKEN;  [20500472];  [21500803]	This work was supported by a Grant-in-Aid for Scientific Research (20500472 and 21500803) and ZENRYOKEN. The authors thank Mari Yachi for technical assistance.	AZBILL R, 1997, STEM CELLS, V765, P2044; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Itoh T, 2010, J MOL NEUROSCI, V41, P55, DOI 10.1007/s12031-009-9279-3; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Komitova M, 2005, EUR J NEUROSCI, V21, P2397, DOI 10.1111/j.1460-9568.2005.04072.x; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leasure JL, 2010, EXP NEUROL, V226, P58, DOI 10.1016/j.expneurol.2010.08.003; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Luo CX, 2007, J NEUROSCI RES, V85, P1637, DOI 10.1002/jnr.21317; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Parent JM, 1997, J NEUROSCI, V17, P3727; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Radak Z, 2001, NEUROCHEM INT, V38, P17, DOI 10.1016/S0197-0186(00)00063-2; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Tani M, 2010, J NEUROCHEM, V115, P854, DOI 10.1111/j.1471-4159.2010.06727.x; Uda M, 2006, BRAIN RES, V1104, P64, DOI 10.1016/j.brainres.2006.05.066; Wu CW, 2008, J APPL PHYSIOL, V105, P1585, DOI 10.1152/japplphysiol.90775.2008; Wu CW, 2007, J NEUROCHEM, V103, P2471, DOI 10.1111/j.1471-4159.2007.04987.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yagita Y, 2006, NEUROSCI LETT, V409, P24, DOI 10.1016/j.neulet.2006.09.040; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Yi SS, 2009, NEUROCHEM RES, V34, P1039, DOI 10.1007/s11064-008-9870-y	34	47	51	0	11	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564			J NEURAL TRANSM	J. Neural Transm.	FEB	2011	118	2					193	202		10.1007/s00702-010-0495-3			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	732JE	WOS:000288180000006	20924619				2022-02-06	
J	Kulkarni, J; de Castella, A; Headey, B; Marston, N; Sinclair, K; Lee, S; Gurvich, C; Fitzgerald, PB; Burger, H				Kulkarni, Jayashri; de Castella, Anthony; Headey, Barbara; Marston, Natasha; Sinclair, Kelly; Lee, Stuart; Gurvich, Caroline; Fitzgerald, Paul B.; Burger, Henry			Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?	SCHIZOPHRENIA RESEARCH			English	Article						Oestrogen/estrogen; Schizophrenia; Men; Sex hormones	QUALITY-OF-LIFE; AGGRESSIVE-BEHAVIOR; NEGATIVE SYMPTOMS; ELDERLY-PATIENTS; CONTROLLED-TRIAL; DOUBLE-BLIND; SHORT-TERM; BRAIN; WOMEN; ESTRADIOL	Adjunctive use of estrogen therapy has been shown to be effective in enhancing the treatment of schizophrenia in women. In men, consideration of estrogen therapy has been impacted by concerns of feminising side effects, however, clinical trials of the use of estrogen in treating prostate cancer, bone density loss and even aggression and psychosis in dementia or traumatic brain injury, show this to be a safe and effective therapy. The current 14-day randomised placebo-controlled trial in 53 men with schizophrenia was conducted to evaluate the efficacy of 2 mg oral estradiol valerate as an adjunct to atypical antipsychotic treatment. Results demonstrated for estradiol participants a more rapid reduction in general psychopathology that occurred in the context of greater increases in serum estrogen levels and reductions in FSH and testosterone levels. Approximately 28% of estradiol participants did not achieve an increase (at least a 50% from baseline) in serum estrogen suggesting that further research is needed to refine the type, dose and administration route for estrogen therapy in men. Findings do, however, suggest further exploration of a therapeutic role for adjunctive estradiol treatment in men with schizophrenia is warranted. (C) 2010 Elsevier B.V. All rights reserved.	[Kulkarni, Jayashri; de Castella, Anthony; Headey, Barbara; Marston, Natasha; Sinclair, Kelly; Lee, Stuart; Gurvich, Caroline; Fitzgerald, Paul B.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia; [Kulkarni, Jayashri; de Castella, Anthony; Headey, Barbara; Marston, Natasha; Sinclair, Kelly; Lee, Stuart; Gurvich, Caroline; Fitzgerald, Paul B.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Burger, Henry] Monash Med Ctr, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia		Kulkarni, J (corresponding author), Alfred Hosp, Monash Alfred Psychiat Res Ctr, Level 1,Old Baker Bldg,Commercial Rd, Melbourne, Vic 3004, Australia.	jayashri.Kulkarni@med.monash.edu.au	Kulkarni, Jayashri/B-8917-2012; Fitzgerald, Paul B/A-1225-2008; Gurvich, Caroline/AAB-9115-2019	Kulkarni, Jayashri/0000-0002-3875-5623; Fitzgerald, Paul B/0000-0003-4217-8096; Gurvich, Caroline/0000-0002-5663-3419; Burger, Henry/0000-0002-5333-6144; Lee, Stuart James/0000-0002-5071-7443	National Health and Medical Research Council (NHMRC), Canberra, AustraliaNational Health and Medical Research Council of Australia [1997/8]	Funding for the study was provided by the National Health and Medical Research Council (NHMRC), Canberra, Australia (Grant ID: 1997/8), The NHMRC had no further role in study design; collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.	Akhondzadeh S, 2003, PROG NEURO-PSYCHOPH, V27, P1007, DOI 10.1016/S0278-5846(03)00161-1; Akhondzadeh S, 2006, SCHIZOPHR RES, V84, P405, DOI 10.1016/j.schres.2006.02.008; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ARNOLD SE, 1993, AM J PSYCHIAT, V150, P1564; Bergemann N, 2007, PSYCHOL MED, V37, P1427, DOI 10.1017/S0033291707000578; Cornil CA, 2006, BRAIN RES, V1126, P2, DOI 10.1016/j.brainres.2006.07.098; Cyr M, 2002, J PSYCHIATR NEUROSCI, V27, P12; DELIGNIERES B, 1986, J CLIN ENDOCR METAB, V62, P536, DOI 10.1210/jcem-62-3-536; DELRIO G, 1994, J CLIN ENDOCR METAB, V79, P836, DOI 10.1210/jc.79.3.836; Drake RJ, 2007, J CLIN PSYCHIAT, V68, P81, DOI 10.4088/JCP.v68n0111; *EXP CONS PAN, 2003, J CLIN PSYCHIAT S12, V64, P26; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gillies GE, 2010, PHARMACOL REV, V62, P155, DOI 10.1124/pr.109.002071; Hafner H, 2003, PSYCHONEUROENDOCRINO, V28, P17, DOI 10.1016/S0306-4530(02)00125-7; HAFNER H, 1991, PSYCHIAT RES, V38, P125, DOI 10.1016/0165-1781(91)90038-Q; Hall KA, 2005, INT PSYCHOGERIATR, V17, P165, DOI 10.1017/S1041610205001535; Hedlund PO, 2000, UROLOGY, V55, P328, DOI 10.1016/S0090-4295(99)00580-4; Hofer A, 2004, J CLIN PSYCHIAT, V65, P932; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kirschbaum C, 1996, J CLIN ENDOCR METAB, V81, P3639, DOI 10.1210/jc.81.10.3639; Ko YH, 2007, PSYCHONEUROENDOCRINO, V32, P385, DOI 10.1016/j.psyneuen.2007.02.002; Kulkarni J, 1996, SCHIZOPHR RES, V20, P247, DOI 10.1016/0920-9964(96)82949-5; Kulkarni J, 1999, SCHIZOPHR RES, V36, P286; Kulkarni J, 2001, SCHIZOPHR RES, V48, P137, DOI 10.1016/S0920-9964(00)00088-8; Kulkarni J, 2008, ARCH GEN PSYCHIAT, V65, P955, DOI 10.1001/archpsyc.65.8.955; Kyomen HH, 2002, AM J PSYCHIAT, V159, P1225, DOI 10.1176/appi.ajp.159.7.1225; Kyomen HH, 1999, AM J GERIAT PSYCHIAT, V7, P339; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P981, DOI 10.1016/0002-9378(95)90246-5; MAURER K, 1995, SCHIZOPHR RES, V15, P265, DOI 10.1016/0920-9964(94)00051-9; Pallanti S, 1997, AM J PSYCHIAT, V154, P792; Perez-Neri I, 2006, NEUROCHEM RES, V31, P1279, DOI 10.1007/s11064-006-9162-3; Rossler W, 2005, EUR NEUROPSYCHOPHARM, V15, P399, DOI 10.1016/j.euroneuro.2005.04.009; Sayed Y, 2003, CURR OPIN PHARMACOL, V3, P650, DOI 10.1016/j.coph.2003.07.004; Seeman MV, 1996, J PSYCHIATR NEUROSCI, V21, P123; Sumner BEH, 1998, MOL BRAIN RES, V59, P205, DOI 10.1016/S0169-328X(98)00148-X; Taherianfard M, 2004, Indian J Med Sci, V58, P3; Tollefson GD, 1999, J CLIN PSYCHIAT, V60, P23	37	47	48	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	FEB	2011	125	2-3					278	283		10.1016/j.schres.2010.10.009			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	733ZW	WOS:000288304000021	21062669				2022-02-06	
J	Turner, GR; McIntosh, AR; Levine, B				Turner, Gary R.; McIntosh, Anthony R.; Levine, Brian			Prefrontal compensatory engagement in TBI is due to altered functional engagement of existing networks and not functional reorganization	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						traumatic brain injury; fMRI; working memory; functional connectivity; partial least squares; diffuse axonal injury		Functional neuroimaging studies of traumatic brain injury (TBI) have demonstrated altered neural recruitment, specifically within prefrontal cortex (PFC). This is manifest typically as increased recruitment of homologous regions of PFC (e.g., right ventrolateral PFC during performance of a verbal working memory task, possibly in response to damage involving the left PFC). The behavioral correlates of these functional changes are poorly understood. We used fMRI and multivariate analytic methods to investigate changes in spatially distributed activity patterns and their behavioral correlates in a sample of TBI patients with diffuse axonal injury (DAI, but without focal injury) and matched healthy controls. Participants performed working memory tasks with varying memory load and executive demand. We identified networks within left and right PFC that uniquely and positively correlated with performance in our control and TBI samples respectively, providing evidence of compensatory functional recruitment. Next we combined brain-behavior and functional connectivity analyses to investigate whether compensatory brain changes were facilitated by functional reorganization (i.e., recruitment of brain regions not engaged by our control sample) or altered functional engagement (i.e., differential recruitment of similar brain regions between the two groups based on task demands). In other words, does altered recruitment represent the instantiation of novel neural networks to support working memory performance after injury or the unmasking of extant, but behaviorally latent, functional connectivity? Our results support an altered functional engagement hypothesis. Areas within PFC that are normally coactivated during working memory are behaviorally relevant at an earlier stage of difficulty for TBI patients as compared to controls. This altered functional engagement, also evident in the aging literature, is attributable to distributed changes owing to significant DAI.	[Turner, Gary R.] Heart & Stroke Fdn, Sunnybrook Hlth Sci Ctr, Ctr Stroke Recovery, 2075 Bayview Ave,Room A447, Toronto, ON M4N 3M5, Canada; [Turner, Gary R.] Univ Toronto, Fac Med, Dept Occupat & Rehabil Sci, Toronto, ON, Canada; [Turner, Gary R.; McIntosh, Anthony R.; Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON, Canada; [Levine, Brian] Univ Toronto, Fac Med, Dept Neurol, Toronto, ON, Canada; [Levine, Brian] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada		Turner, GR (corresponding author), Heart & Stroke Fdn, Sunnybrook Hlth Sci Ctr, Ctr Stroke Recovery, 2075 Bayview Ave,Room A447, Toronto, ON M4N 3M5, Canada.	gary.turner@sunnybrook.ca	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; McIntosh, Anthony/0000-0002-1784-5662			Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; D'Esposito M, 2006, J INT NEUROPSYCH SOC, V12, P248, DOI 10.1017/S1355617706060322; D'Esposito M, 2003, NAT REV NEUROSCI, V4, P863, DOI 10.1038/nrn1246; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Erickson KI, 2007, NEUROBIOL AGING, V28, P272, DOI 10.1016/j.neurobiolaging.2005.12.012; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Grady CL, 2003, J NEUROSCI, V23, P986, DOI 10.1523/jneurosci.23-03-00986.2003; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lustig C, 2009, NEUROPSYCHOL REV, V19, P504, DOI 10.1007/s11065-009-9119-9; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McIntosh AR, 1999, MEMORY, V7, P523, DOI 10.1080/096582199387733; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; McIntosh AR, 2004, NEUROIMAGE, V23, P764, DOI 10.1016/j.neuroimage.2004.05.018; Molteni E, 2009, PROC SPIE, V7161, DOI 10.1117/12.808972; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Newsome MR, 2009, BRAIN IMAGING BEHAV, V3, P298, DOI 10.1007/s11682-009-9072-5; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Paxton JL, 2008, CEREB CORTEX, V18, P1010, DOI 10.1093/cercor/bhm135; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Postle BR, 1999, P NATL ACAD SCI USA, V96, P12959, DOI 10.1073/pnas.96.22.12959; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Rypma B, 2000, NAT NEUROSCI, V3, P509, DOI 10.1038/74889; Rypma B, 1999, NEUROIMAGE, V9, P216, DOI 10.1006/nimg.1998.0404; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; TEASDALE G, 1974, LANCET, V2, P81; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255	38	47	47	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5137			FRONT SYST NEUROSCI	Front. Syst. Neurosci.		2011	5								9	10.3389/fnsys.2011.00009			12	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V19VH	WOS:000214846000009	21412403	gold, Green Published			2022-02-06	
J	Melo, JRT; Di Rocco, F; Blanot, S; Oliveira, J; Roujeau, T; Sainte-Rose, C; Duracher, C; Vecchione, A; Meyer, P; Zerah, M				Tude Melo, Jose Roberto; Di Rocco, Federico; Blanot, Stephane; Oliveira-Filho, Jamary; Roujeau, Thomas; Sainte-Rose, Christian; Duracher, Caroline; Vecchione, Antonio; Meyer, Philippe; Zerah, Michel			Mortality in Children With Severe Head Trauma: Predictive Factors and Proposal for a New Predictive Scale	NEUROSURGERY			English	Article						Craniocerebral trauma; Mortality; Pediatric; Prognosis	SEVERE BRAIN-INJURY; PREHOSPITAL EMERGENCY CARE; PROGNOSTIC FACTORS; HYPERGLYCEMIA; EPIDEMIOLOGY; EXPERIENCE; MANAGEMENT; IMPACT; HYPOTHERMIA; OUTCOMES	BACKGROUND: Traumatic brain injury is a public health problem around the world, and recognition of systemic sources of secondary brain lesions is crucial to improve outcome. OBJECTIVE: To identify the main predictors of mortality and to propose a grading scale to measure the risk of death. METHODS: This retrospective study was based on medical records of children with severe traumatic brain injury who were hospitalized at a level I pediatric trauma center between January 2000 and December 2005. Multiple logistic regression analysis was done to identify independent factors related to mortality. A receiver-operating characteristics curve was performed to verify the accuracy of the multiple logistic regression, and associations that increased mortality were verified. RESULTS: We identified 315 children with severe head injury. Median Glasgow Coma Scale score was 6, and median Pediatric Trauma Score was 4. Global mortality rate was 30%, and deaths occurred despite adequate medical management within the first 48 hours in 79% of the patients. Age < 2 years (P = .02), Glasgow Coma Scale <= 5 (P < 10(-5)), accidental hypothermia (P = .0002), hyperglycemia (P = .0003), and coagulation disorders (P = .02) were all independent factors predicting mortality. A prognostic scale ranging from 0 to 6 that included these independent factors was then calculated for each patient and resulted in mortality rates ranging from 1% with a score of 6 to 100% with a score of 0. CONCLUSION: Independent and modifiable mortality predictors could be identified and used for a new grading scale correlated with the risk of mortality in pediatric traumatic brain injury.	[Tude Melo, Jose Roberto; Di Rocco, Federico; Roujeau, Thomas; Sainte-Rose, Christian; Zerah, Michel] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Dept Pediat Neurosurg, Paris, France; [Tude Melo, Jose Roberto; Oliveira-Filho, Jamary] Univ Fed Bahia, Sch Med, Postgrad Program Med & Hlth, BR-41170290 Salvador, BA, Brazil; [Blanot, Stephane; Duracher, Caroline; Vecchione, Antonio; Meyer, Philippe] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Pediat Surg Crit Care Unit & Anesthesiol, Paris, France		Melo, JRT (corresponding author), Alameda Jasmins 200,702 B Cidade Jardim, BR-40296200 Salvador, BA, Brazil.	robertotude@gmail.com	Oliveira-Filho, Jamary/B-6441-2016; ZERAH, Michel/E-6473-2012; DI ROCCO, Federico/C-6343-2015; Meyer, Philippe/ABE-4242-2020	Oliveira-Filho, Jamary/0000-0003-1915-0423; Meyer, Philippe/0000-0002-3829-6631; Di Rocco, Federico/0000-0003-2145-5533	Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	This work was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Exchange Program for PhD studies. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Balzan S, 2005, ANN SURG, V242, P824, DOI 10.1097/01.sla.0000189131.90876.9e; Bardella IJ, 1999, AM FAM PHYSICIAN, V60, P1743; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; Bochicchio GV, 2007, J TRAUMA, V63, P1353, DOI 10.1097/TA.0b013e31815b83c4; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Danzl D, 2002, SEMIN RESP CRIT CARE, V23, P57, DOI 10.1055/s-2002-20589; Davis P R, 2005, J R Army Med Corps, V151, P223; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; GAILLARD M, 1989, ANN PEDIATR-PARIS, V36, P194; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; Grinkeviciute DE, 2007, MEDICINA-LITHUANIA, V43, P861, DOI 10.3390/medicina43110111; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Jagannathan J, 2007, J NEUROSURG, V106, pA761; Javouhey E, 2006, EUR J PEDIATR, V165, P519, DOI 10.1007/s00431-006-0118-z; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; Meyer P, 2006, ARCH PEDIATRIE, V13, P737, DOI 10.1016/j.arcped.2006.03.023; Meyer P G, 2001, Curr Opin Crit Care, V7, P81, DOI 10.1097/00075198-200104000-00005; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Orliaguet C, 2000, ANN FR ANESTH, V19, P164; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Melo JRT, 2006, ARQ NEURO-PSIQUIAT, V64, P994, DOI 10.1590/S0004-282X2006000600020; Tentillier E, 2000, ANN FR ANESTH, V19, P275; Tentillier E, 2004, ANN FR ANESTH, V23, P109, DOI 10.1016/j.annfar.2003.11.019; Thelot B, 2006, Sante Publique, V18, P523; Trabold F, 2002, ANN FR ANESTH, V21, P141, DOI 10.1016/S0750-7658(01)00513-5; Tursz A, 1990, Paediatr Perinat Epidemiol, V4, P408, DOI 10.1111/j.1365-3016.1990.tb00668.x; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Weigand K, 2009, MED KLIN, V104, P331, DOI 10.1007/s00063-009-1070-2	38	47	49	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2010	67	6					1542	1547		10.1227/NEU.0b013e3181fa7049			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	685DF	WOS:000284606500026	21107185				2022-02-06	
J	Schroeppel, TJ; Fischer, PE; Zarzaur, B; Magnotti, LJ; Clement, LP; Fabian, TC; Croce, MA				Schroeppel, Thomas J.; Fischer, Peter E.; Zarzaur, Ben L.; Magnotti, Louis J.; Clement, L. Paige; Fabian, Timothy C.; Croce, Martin A.			Beta-Adrenergic Blockade and Traumatic Brain Injury: Protective?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma		Traumatic brain injury; Beta-blocker	WALL-MOTION ABNORMALITIES; FACTOR-ALPHA PRODUCTION; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; MYOCARDIAL DAMAGE; IMPROVED OUTCOMES; NERVOUS-SYSTEM; CATECHOLAMINES; MODULATION; NECROSIS	Background: Catecholamine surge after traumatic brain injury (TBI) is associated with infectious morbidity and potentially preventable mortality. Previous studies have supported the protective effect of beta-adrenergic blockade in patients with TBI. We hypothesize that suppression of the catecholamine surge in multiple-injured TBI patients with beta-adrenergic blockade decreases mortality. Methods: The trauma registry at an urban Level I trauma center was queried for blunt TBI from June 1, 2003, to December 31, 2007. Patients who received more than one dose of beta-blockers (BB) were identified by a review of the hospital pharmacy order database. chi(2) and Student's t tests were used where appropriate. After adjusting for age, injury severity score, admission Glasgow Coma Score, and transfusions multivariable logistic regression was performed to analyze whether receiving BB was protective in patients sustaining TBI. Results: A total of 2,601 patients were admitted with blunt TBI during the study period. Of these, 506 patients (20%) received BB. Despite higher age (51 years vs. 38 years, p < 0.0001) and more severe head injury (head Abbreviated Injury Scale score 4.14 vs. 3.81, p < 0.0001), there was no difference in mortality (15% vs. 16%). Multivariable logistic regression identified BB as protective in patients sustaining head injury (odds ratio, 0.347; confidence interval, 0.246-0.490), when compared with those who did not receive BB, reducing mortality by 65%. Conclusions: BB are associated with significantly reduced mortality in patients with TBI. This simple, inexpensive intervention may have a profound effect on mortality in this population of injured patients and requires further prospective study.	[Schroeppel, Thomas J.; Fischer, Peter E.; Zarzaur, Ben L.; Magnotti, Louis J.; Clement, L. Paige; Fabian, Timothy C.; Croce, Martin A.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Memphis, TN 38163 USA		Schroeppel, TJ (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Surg, 910 Madison Bldg,2nd Floor,220, Memphis, TN 38163 USA.	tschroep@utmem.edu	Zarzaur, Ben/S-6572-2019	Schroeppel, Thomas/0000-0001-9164-5004; Zarzaur, Ben/0000-0001-9988-9572			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Amory DW, 2002, J CARDIOTHOR VASC AN, V16, P270, DOI 10.1053/jcan.2002.124132; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Deng JP, 2004, AM J PHYSIOL-CELL PH, V287, pC730, DOI 10.1152/ajpcell.00562.2003; ELENKOV IJ, 1995, J NEUROIMMUNOL, V61, P123, DOI 10.1016/0165-5728(95)00080-L; Freibel JH, 1981, ANN NEUROL, V9, P340; Fukuzawa M, 2000, IMMUNOPHARMACOLOGY, V48, P65, DOI 10.1016/S0162-3109(00)00179-X; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAWKINS WE, 1971, CARDIOVASC RES, V5, P524, DOI 10.1093/cvr/5.4.524; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; JAATTELA A, 1975, BRIT J SURG, V62, P177, DOI 10.1002/bjs.1800620303; Kalinichenko VV, 1999, J IMMUNOL, V163, P2492; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Randell T, 1999, J NEUROSURG ANESTH, V11, P163, DOI 10.1097/00008506-199907000-00001; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	41	47	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2010	69	4					776	780		10.1097/TA.0b013e3181e981b8			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	664KP	WOS:000282959100021	20938265				2022-02-06	
J	Yu, I; Inaji, M; Maeda, J; Okauchi, T; Nariai, T; Ohno, K; Higuchi, M; Suhara, T				Yu, Iwae; Inaji, Motoki; Maeda, Jun; Okauchi, Takashi; Nariai, Tadashi; Ohno, Kikuo; Higuchi, Makoto; Suhara, Tetsuya			Glial Cell-Mediated Deterioration and Repair of the Nervous System after Traumatic Brain Injury in a Rat Model as Assessed by Positron Emission Tomography	JOURNAL OF NEUROTRAUMA			English	Article						glial cell response to injury; head trauma; inflammation; models of injury; positron emission tomography scanning	PERIPHERAL BENZODIAZEPINE-RECEPTOR; FLUID-PERCUSSION MODEL; MOUSE MODEL; IN-VIVO; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; QUANTITATIVE ASSESSMENT; METABOLIC DEPRESSION; GLUCOSE-UTILIZATION; AXONAL INJURY	Traumatic brain injury (TBI) is one of the most acute degenerative pathologies in the central nervous system, and in vivo indices enabling an assessment of TBI on a mechanistic basis have yet to be established. The aim of this work was to pursue neuroinflammatory changes and their link to functional disruptions of traumatically-damaged neurons in a rat model of TBI by longitudinal positron emission tomographic (PET) assays. TBI was induced in the unilateral frontal cortex of craniotomied rats according to a lateral fluid percussion brain injury protocol. The use of [F-18] fluoroethyl-DAA1106 as a PET tracer for translocator protein (TSPO) permitted demonstration of the inflammatory response to the injury, peaking at 1 week after impact. This alteration was parallel to metabolic deficits assessed by PET with [F-18] fluorodeoxyglucose, but the difference in TSPO levels between impacted and non-impacted frontal cortices was more than threefold of the interlateral metabolic difference, indicating superiority of TSPO imaging for sensitive detection of post-traumatic pathologies. Comparative PET, autoradiographic. and immunohistochemical investigations illustrated the primary contribution of hypertrophic microglia and macrophages to acute TSPO signals in the vicinity of the impact. Astrocytes also formed a TSPO-positive glial scar encompassing necrotic inflammation, and were clustered with PET-detectable TSPO signals in the bilateral external and internal capsules at late stages, putatively reacting with diffuse axonal injury. These observations support the applicability of TSPO-PET as an imaging-based preclinical and clinical biomarker assay in TBI, and indicate its potential capability to clarify aggressive and protective roles of glial responses to injury when combined with emerging anti-inflammatory and immunomodulatory treatments.	[Higuchi, Makoto] Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, Chiba 2638555, Japan; [Yu, Iwae; Inaji, Motoki; Nariai, Tadashi; Ohno, Kikuo] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan		Higuchi, M (corresponding author), Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	mhiguchi@nirs.go.jp			Molecular Imaging Program and Scientific Research on Priority Areas, Research on Pathomechanisms of Brain DisordersMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20023036]; Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	The authors thank Mr. Takeharu Minamihisamatsu for technical assistance, and the staffs at the Cyclotron Unit and the Molecular Probe Group for the cyclotron operation and production of radiochemicals. This work was supported in part by Grants-in-Aid for the Molecular Imaging Program and Scientific Research on Priority Areas, Research on Pathomechanisms of Brain Disorders 20023036 (to M.H.), and from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We also thank Taisho Pharmaceutical (Tokyo, Japan) for providing DAA1123.	Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Cavus I, 2005, ANN NEUROL, V57, P226, DOI 10.1002/ana.20380; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen MK, 2004, BRAIN, V127, P1379, DOI 10.1093/brain/awh161; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; IP EY, 2003, J CEREB BLOOD FLOW M, V23, P300; Ji B, 2008, J NEUROSCI, V28, P12255, DOI 10.1523/JNEUROSCI.2312-08.2008; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maeda J, 2004, SYNAPSE, V52, P283, DOI 10.1002/syn.20027; Maeda J, 2007, J NEUROSCI, V27, P10957, DOI 10.1523/JNEUROSCI.0673-07.2007; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rojas S, 2007, J CEREBR BLOOD F MET, V27, P1975, DOI 10.1038/sj.jcbfm.9600500; Shen J, 1999, P NATL ACAD SCI USA, V96, P8235, DOI 10.1073/pnas.96.14.8235; Shimoji K, 2004, J NUCL MED, V45, P665; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Tai YC, 2005, J NUCL MED, V46, P455; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toyama H, 2004, J NUCL MED, V45, P1398; Venneti S, 2007, J NEUROCHEM, V102, P2118, DOI 10.1111/j.1471-4159.2007.04690.x; Venneti S, 2009, NEUROBIOL AGING, V30, P1217, DOI 10.1016/j.neurobiolaging.2007.11.005; Wegman TD, 2002, APPL RADIAT ISOTOPES, V57, P505, DOI 10.1016/S0969-8043(02)00143-4; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; Yasuno F, 2008, BIOL PSYCHIAT, V64, P835, DOI 10.1016/j.biopsych.2008.04.021; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhang MR, 2004, J MED CHEM, V47, P2228, DOI 10.1021/jm0304919	47	47	50	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1463	1475		10.1089/neu.2009.1196			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900010	20504160				2022-02-06	
J	Atlasz, T; Szabadfi, K; Kiss, P; Tamas, A; Toth, G; Reglodi, D; Gabriel, R				Atlasz, Tamas; Szabadfi, Krisztina; Kiss, Peter; Tamas, Andrea; Toth, Gabor; Reglodi, Dora; Gabriel, Robert			Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration	BRAIN RESEARCH BULLETIN			English	Article						Chronic hypoperfusion; Immunohistochemistry; VGLUT 1; VGAT; Calbindin; Calretinin; Parvalbumin; PKC alpha; GFAP	CYCLASE-ACTIVATING POLYPEPTIDE; CAROTID-ARTERY OCCLUSION; PROTEIN-KINASE-C; VESICULAR GLUTAMATE TRANSPORTERS; AII-AMACRINE CELLS; ADULT-RAT RETINA; MONOSODIUM-GLUTAMATE; INDUCED NEUROTOXICITY; HORIZONTAL CELLS; KAINIC ACID	Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophic and neuroprotective peptide that has been shown to exert protective effects in different neuronal injuries, such as traumatic brain injury, models of neurodegenerative diseases and cerebral ischemia. We have provided evidence that PACAP is neuroprotective in several models of retinal degeneration in vivo. In our previous studies we showed that PACAP treatment significantly ameliorated the damaging effects of permanent bilateral common carotid artery occlusion (BCCAO). In the present study cell-type-specific markers were used in the same models in order to further specify the protective effects of PACAP. In rats BCCAO led to severe degeneration of all retinal layers that was attenuated by PACAP (100 pmol) administered unilaterally immediately following BCCAO into the vitreous body of one eye. Retinas were processed for immunohistochemistry after 3 weeks. Immunolabeling was executed for vesicular glutamate transporter 1 (VGLUT 1), vesicular gamma-aminobutyric acid transporter (VGAT), protein kinase C alpha (PKC alpha), glial fibrillary acidic protein (GFAP) and calcium-binding proteins, such as calbindin, calretinin, parvalbumin. In BCCAO retinas, intensity of immunopositivity for all antisera was dramatically decreased, except in the case of GFAP. In PACAP-treated retinas, immunostaining was similar to that of the control animals. In summary, our study presented immunohistochemical identification of cell types sensitive to chronic retinal hypoperfusion and the protective effects of PACAP. This analysis revealed that the retinoprotective effects of PACAP are not phenotype-specific, but it rather influences general cytoprotective pathways irrespective of the neuronal subtypes in the retina subjected to chronic hypoperfusion. (C) 2009 Elsevier Inc. All rights reserved.	[Atlasz, Tamas] Univ Pecs, Dept Sportbiol, H-7624 Pecs, Hungary; [Atlasz, Tamas; Szabadfi, Krisztina; Gabriel, Robert] Univ Pecs, Dept Expt Zool & Neurobiol, H-7624 Pecs, Hungary; [Kiss, Peter; Tamas, Andrea; Reglodi, Dora] Univ Pecs, Dept Anat, H-7624 Pecs, Hungary; [Toth, Gabor] Univ Szeged, Dept Med Chem, H-6720 Szeged, Hungary		Atlasz, T (corresponding author), Univ Pecs, Dept Sportbiol, Ifjusag Str 6, H-7624 Pecs, Hungary.	attam@gamma.ttk.pte.hu; kriszta.szabadfi@gmail.com; peter.kiss@aok.pte.hu; andrea.tamas@aok.pte.hu; toth@ovrisc.mdche.u-szeged.hu; dora.reglodi@aok.pte.hu; gabriel@ttk.pte.hu	Szabadfi, Krisztina/K-5955-2012	Szabadfi, Krisztina/0000-0002-8390-5408; Atlasz, Tamas/0000-0002-8112-8633	OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [T061766, K72592, CNK78480]; ETT, Bolyai Scholarship and Gedeon Richter Centenary Foundation [F67830];  [GVOP-3.2.1-2004-04-017213.0]	This work was supported by OTKA T061766, K72592, CNK78480; F67830, ETT, Bolyai Scholarship and Gedeon Richter Centenary Foundation. The purchase of Olympus Fluoview FV-1000 laser scanning confocal microscope system was supported by grant GVOP-3.2.1-2004-04-017213.0 to University of Pecs.	Abreu BJ, 2008, NEUROCHEM INT, V53, P155, DOI 10.1016/j.neuint.2008.07.004; Atlasz T, 2007, NEUROTOX RES, V12, P105, DOI 10.1007/BF03033919; Atlasz T, 2007, GEN COMP ENDOCR, V153, P108, DOI 10.1016/j.ygcen.2006.12.022; Atlasz T, 2008, J MOL NEUROSCI, V36, P97, DOI 10.1007/s12031-008-9059-5; Atlasz T, 2009, ANN NY ACAD SCI, V1163, P348, DOI 10.1111/j.1749-6632.2008.03650.x; Babai N, 2005, NEUROTOX RES, V8, P227, DOI 10.1007/BF03033976; Babai N, 2006, ANN NY ACAD SCI, V1070, P149, DOI 10.1196/annals.1317.003; Bagnoli P, 2003, HISTOL HISTOPATHOL, V18, P1219, DOI 10.14670/HH-18.1219; BARNETT NL, 1995, EXP EYE RES, V61, P83, DOI 10.1016/S0014-4835(95)80061-1; Barnett NL, 2001, NEUROCHEM INT, V39, P291, DOI 10.1016/S0197-0186(01)00033-X; BIGNAMI A, 1979, EXP EYE RES, V28, P63; BJORKLUND H, 1985, J NEUROIMMUNOL, V8, P331, DOI 10.1016/S0165-5728(85)80071-0; Borba JC, 2005, DEV BRAIN RES, V156, P193, DOI 10.1016/j.devbrainres.2005.02.016; Bourgault S, 2008, PEPTIDES, V29, P919, DOI 10.1016/j.peptides.2008.01.022; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen Y, 2006, REGUL PEPTIDES, V137, P4, DOI 10.1016/j.regpep.2006.06.016; Cheon EW, 2002, EXP EYE RES, V75, P591, DOI 10.1006/exer.2002.2051; Chun MH, 1999, NEUROSCI LETT, V260, P125, DOI 10.1016/S0304-3940(98)00973-2; COHEN E, 1986, J COMP NEUROL, V250, P1, DOI 10.1002/cne.902500102; Contini M, 2003, P NATL ACAD SCI USA, V100, P1358, DOI 10.1073/pnas.0337681100; Cueva JG, 2002, J COMP NEUROL, V445, P227, DOI 10.1002/cne.10166; Duarte CB, 1998, GEN PHARMACOL-VASC S, V30, P289, DOI 10.1016/S0306-3623(97)00360-1; Dumoulin A, 1999, J CELL SCI, V112, P811; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Fernandez DC, 2009, INVEST OPHTH VIS SCI, V50, P3922, DOI 10.1167/iovs.08-3344; Fyk-Kolodziej B, 2004, J COMP NEUROL, V475, P518, DOI 10.1002/cne.20199; Gabriel R, 1998, NEUROSCI LETT, V247, P179, DOI 10.1016/S0304-3940(98)00323-1; Gasz B, 2006, PEPTIDES, V27, P87, DOI 10.1016/j.peptides.2005.06.022; Gesslein B, 2009, MOL VIS, V15, P737; Gong J, 2006, BRAIN RES, V1082, P73, DOI 10.1016/j.brainres.2006.01.111; Hannibal J, 2004, NEUROREPORT, V15, P2317, DOI 10.1097/00001756-200410250-00003; HENDRICKSON AE, 1988, J COMP NEUROL, V273, P473, DOI 10.1002/cne.902730404; Kiagiadaki F, 2008, INVEST OPHTH VIS SCI, V49, P3080, DOI 10.1167/iovs.07-1644; Kong L, 2009, NEUROCHEM INT, V54, P172, DOI 10.1016/j.neuint.2008.08.013; Kwon OJ, 2005, MOL CELLS, V19, P382; Langoth N, 2005, INT J PHARMACEUT, V296, P103, DOI 10.1016/j.ijpharm.2005.03.007; Lavinsky D, 2006, GRAEF ARCH CLIN EXP, V244, P199, DOI 10.1007/s00417-005-0006-7; Lenti L, 2009, BRAIN RES, V1283, P50, DOI 10.1016/j.brainres.2009.06.021; Mali RS, 2005, INVEST OPHTH VIS SCI, V46, P2125, DOI 10.1167/iovs.04-1376; MANDELL JW, 1992, J NEUROSCI, V12, P1736; MARC RE, 1985, J COMP NEUROL, V232, P241, DOI 10.1002/cne.902320209; Markhotina N, 2007, IET NANOBIOTECHNOL, V1, P44, DOI 10.1049/iet-nbt:20060019; Mester L, 2009, NEUROTOX RES, V16, P68, DOI 10.1007/s12640-009-9049-6; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; OSBORNE NN, 1995, NEUROPHARMACOLOGY, V34, P1279, DOI 10.1016/0028-3908(95)00097-P; OSBORNE NN, 1991, VISUAL NEUROSCI, V7, P637, DOI 10.1017/S0952523800010427; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Racz B, 2007, NEUROTOX RES, V12, P95, DOI 10.1007/BF03033918; Racz B, 2006, ANN NY ACAD SCI, V1070, P507, DOI 10.1196/annals.1317.070; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Rodrigues LG, 2004, NEUROCHEM INT, V45, P1133, DOI 10.1016/j.neuint.2004.06.011; ROHRENBECK J, 1987, NEUROSCI LETT, V77, P255, DOI 10.1016/0304-3940(87)90508-8; SAHEL JA, 1991, EXP EYE RES, V53, P657, DOI 10.1016/0014-4835(91)90226-5; SCHWARCZ R, 1977, BRAIN RES, V127, P235, DOI 10.1016/0006-8993(77)90538-8; Seki T, 2006, ANN NY ACAD SCI, V1070, P535, DOI 10.1196/annals.1317.043; Seki T, 2000, ANN NY ACAD SCI, V921, P366; Seki T, 1998, ANN NY ACAD SCI, V865, P408, DOI 10.1111/j.1749-6632.1998.tb11205.x; Seki T, 1997, NEUROSCI LETT, V238, P127, DOI 10.1016/S0304-3940(97)00869-0; Seki T, 2006, ANN NY ACAD SCI, V1070, P531, DOI 10.1196/annals.1317.074; Seki T, 2008, J MOL NEUROSCI, V36, P57, DOI 10.1007/s12031-008-9091-5; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Staines DR, 2007, MED HYPOTHESES, V69, P1208, DOI 10.1016/j.mehy.2007.04.004; Stella SL, 2008, BRAIN RES, V1215, P20, DOI 10.1016/j.brainres.2008.03.038; Szabadfi K, 2009, NEUROSCI LETT, V455, P42, DOI 10.1016/j.neulet.2009.03.013; Tamas A, 2004, NEUROSCI LETT, V372, P110, DOI 10.1016/j.neulet.2004.09.021; VANEY DI, 1991, J COMP NEUROL, V310, P154, DOI 10.1002/cne.903100203; Vaudry D, 2000, PHARMACOL REV, V52, P269; VAUGHN JE, 1981, J COMP NEUROL, V197, P113, DOI 10.1002/cne.901970109; Vereczki V, 2006, NEUROSCIENCE, V140, P1089, DOI 10.1016/j.neuroscience.2006.02.081; Vidal-Sanz M, 2000, NEUROTOX RES, V2, P215, DOI 10.1007/BF03033795; Wassle H, 2006, J COMP NEUROL, V496, P544, DOI 10.1002/cne.20942; WASSLE H, 1993, J COMP NEUROL, V332, P407; Wood JPM, 1997, NEUROCHEM INT, V30, P119, DOI 10.1016/S0197-0186(96)00049-6; Yamamoto H, 2006, EXP EYE RES, V82, P767, DOI 10.1016/j.exer.2005.09.019; Yang ZK, 2008, NEUROCHEM INT, V52, P1176, DOI 10.1016/j.neuint.2007.12.008	81	47	49	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	MAR 16	2010	81	4-5					497	504		10.1016/j.brainresbull.2009.09.004			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	561JP	WOS:000274972800022	19751807				2022-02-06	
J	Arango-Lasprilla, JC; Kreutzer, JS				Arango-Lasprilla, Juan Carlos; Kreutzer, Jeffrey S.			Racial and Ethnic Disparities in Functional, Psychosocial, and Neurobehavioral Outcomes After Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; health status disparities; minority health; outcomes assessment	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; QUALITY-OF-LIFE; COMMUNITY INTEGRATION; AFRICAN-AMERICANS; MINORITY STATUS; RISK-FACTORS; REHABILITATION; DEPRESSION; HISPANICS; MODERATE	Because of the growing minority population in the past 3 decades in the United States and the increasing numbers of individuals who sustain a traumatic brain injury (TBI), researchers and clinicians have started to pay more attention to the role of race and ethnicity in outcomes after TBI, with the goal of better serving this population. The aim of this article is to review the literature on the influence of race/ethnicity on functional, psychosocial, and neurobehavioral outcomes after TBI. Specifically, the following 8 areas of outcomes will be examined: (1) treatment outcomes, (2) neuropsychological outcomes, (3) employment/productivity, (4) functional outcomes, (5) community integration, (6) marital status, (7) quality of life/life satisfaction, and (8) emotional/neurobehavioral outcomes. To conclude this review, suggestions for improvements in professional competency, research, systems of care, and training are proposed.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA 23219 USA		Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Theater Row Bldg,4th Floor,Room 4230A,730 E Broad, Richmond, VA 23219 USA.	jcarangolasp@vcu.edu			National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of EducationUS Department of Education [H133A070036]	This study was supported in part by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant H133A070036).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Arango-Lasprilla JC, 2009, NEUROREHABILITATION, V24, P5, DOI 10.3233/NRE-2009-0449; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Bethel JW, 2005, AM J PREV MED, V29, P143, DOI 10.1016/j.amepre.2005.04.014; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2000, BRAIN INJURY, V14, P713; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; *CDCP, TRAUM BRAIN INJ US; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; Clark R, 1999, AM PSYCHOL, V54, P805, DOI 10.1037/0003-066X.54.10.805; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85, DOI 10.1097/01.HTR.0000265096.44683.6b; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; Howard I, 2005, ETHNIC DIS, V15, pS51; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kennepohl S, 2004, J INT NEUROPSYCH SOC, V10, P566, DOI 10.1017/S1355617704104128; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615; Marin Gerardo, 1991, RES HISPANIC POPULAT, V23; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Mascialino G, 2009, NEUROREHABILITATION, V24, P29, DOI 10.3233/NRE-2009-0451; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Prieto LR, 2001, COUNS PSYCHOL, V29, P18, DOI 10.1177/0011000001291002; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rutland-Brown W, 2005, J HEAD TRAUMA REHAB, V20, P205, DOI 10.1097/00001199-200505000-00004; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Shafi S, 2008, ARCH SURG-CHICAGO, V143, P1057, DOI 10.1001/archsurg.143.11.1057; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Simoni Jane M, 2003, Cultur Divers Ethnic Minor Psychol, V9, P3, DOI 10.1037/1099-9809.9.1.3; SMART JF, 1992, J REHABIL, V58, P29; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whaley AL, 2002, J CLIN PSYCHOL, V58, P383, DOI 10.1002/jclp.1150; WHITFIELD KE, 2003, HDB PSYCHOL, P545; WILLIAMS K, 2009, BRAIN INJURY, V23, P775; [No title captured]	55	47	47	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					128	136		10.1097/HTR.0b013e3181d36ca3			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000008	20234227				2022-02-06	
J	Schneiders, AG; Sullivan, SJ; Gray, AR; Hammond-Tooke, GD; McCrory, PR				Schneiders, Anthony G.; Sullivan, S. John; Gray, Andrew R.; Hammond-Tooke, Graeme D.; McCrory, Paul R.			Normative values for three clinical measures of motor performance used in the neurological assessment of sports concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Normal values; Postural balance; Coordination impairment; Reliability; Time	TO-NOSE TEST; POSTURAL STABILITY; STANDING BALANCE; TESTS; RELIABILITY; ADULTS; SCORES; AGE	Postural control and motor coordination are essential components of normal athletic activity. Tasks involving balance and coordination are used to determine neurological function in sports-related concussion. Determining normative values for these tasks is therefore essential to provide sports medicine professionals with a frame of reference with which to interpret clinical measures obtained from players suspected of sustaining a concussion. One hundred and seventytwo healthy subjects (16-37 yrs) performed three timed tests: Tandem Gait (TG); Finger-to-Nose (FTN); Single-Lee-Stance (SLS) on firm and foam surfaces. Unadjusted geometric means (+/- SD) for each measure were averaged across three trials. Time to complete TG was 11.2 +/- 1.2 s. FTN for the dominant and non-dominant arm were 2.9 +/- 1.1 s and 3.0 +/- 1.2 s, respectively. SLS values for dominant and non-dominant leg were 20.4 +/- 3.0 s (firm), 3.4 +/- 1.6 s (foam), and 21.0 +/- 2.9 s (firm), 3.3 +/- 1.6s (foam), respectively. For TG, there was an order effect (P<.001) but no age, sex or BMI effects. FTN demonstrated a dominant arm preference (P<.001), sex (P=.006), BM I (P=.043) and order effects (P<.001). SLS demonstrated an order effect on the firm surface (P=.009) and an order (P<.001) and BMI (P=.001) effect on foam. Intra-rater reliability, as measured by ICC (3,3), demonstrated that TG and FTN had excellent reliability compared to SLS. FIN and TG should continue to be used in test batteries to determine neurological function in sports-related concussion. (C) 2009 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Schneiders, Anthony G.; Sullivan, S. John] Univ Otago, Ctr Physiotherapy Res, Christchurch, New Zealand; [Gray, Andrew R.] Univ Otago, Dept Prevent & Social Med, Christchurch, New Zealand; [Hammond-Tooke, Graeme D.] Univ Otago, Dept Med & Surg Sci, Christchurch, New Zealand; [McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia		Schneiders, AG (corresponding author), Univ Otago, Ctr Physiotherapy Res, Christchurch, New Zealand.	tony.schneiders@otago.ac.nz	McCrory, Paul/Q-8688-2019; Gray, Andrew Robert/L-9161-2015; Schneiders, Anthony/F-4212-2015	Gray, Andrew Robert/0000-0003-4299-2194; McCrory, Paul/0000-0003-4850-0568; Schneiders, Anthony/0000-0002-1583-3879	New Zealand Society of Physiotherapists Scholarship Trust Fund; University of Otago Research Grant	Supported by the New Zealand Society of Physiotherapists Scholarship Trust Fund and a University of Otago Research Grant.	BOHANNON RW, 1995, ARCH PHYS MED REHAB, V76, P994, DOI 10.1016/S0003-9993(95)81035-8; BORNSTEIN RA, 1986, J CLIN EXP NEUROPSYC, V8, P12, DOI 10.1080/01688638608401293; Bressel E, 2007, J ATHL TRAINING, V42, P42; Brouwer B, 1998, SCAND J REHABIL MED, V30, P131; Cohen H, 1996, AGE AGEING, V25, P39, DOI 10.1093/ageing/25.1.39; Deliagina TG, 2006, PHYSIOLOGY, V21, P216, DOI 10.1152/physiol.00001.2006; DESROSIERS J, 1995, AGE AGEING, V24, P108, DOI 10.1093/ageing/24.2.108; Feys PG, 2003, ARCH PHYS MED REHAB, V84, P79, DOI 10.1053/apmr.2003.50068; Frzovic D, 2000, ARCH PHYS MED REHAB, V81, P215, DOI 10.1053/apmr.2000.0810215; Giorgetti M M, 1998, Physiother Res Int, V3, P274, DOI 10.1002/pri.150; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; HAGEMAN PA, 1995, ARCH PHYS MED REHAB, V76, P961, DOI 10.1016/S0003-9993(95)80075-1; Haupstein T, 2000, Physiother Res Int, V5, P141, DOI 10.1002/pri.195; Isles RC, 2004, J AM GERIATR SOC, V52, P1367, DOI 10.1111/j.1532-5415.2004.52370.x; JOHNSTON K, 1998, CAN J NEUROL SCI, V25, pS98; Jonsson E, 2004, CLIN BIOMECH, V19, P688, DOI 10.1016/j.clinbiomech.2004.04.002; Kammerlind AS, 2005, EUR J PHYSIOTHER, V7, P96, DOI 10.1080/14038190510010403; Largo RH, 2001, DEV MED CHILD NEUROL, V43, P444, DOI 10.1017/S0012162201000822; Linnet K, 2000, CLIN CHEM, V46, P867; Madhavan S, 2005, EXP BRAIN RES, V164, P18, DOI 10.1007/s00221-004-2208-3; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Newton RA, 1997, ARCH PHYS MED REHAB, V78, P587, DOI 10.1016/S0003-9993(97)90423-8; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pendergrass TL, 2003, MIL MED, V168, P896, DOI 10.1093/milmed/168.11.896; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneiders AG, 2008, BRIT J SPORT MED, V42, P1011, DOI 10.1136/bjsm.2007.041665; Shumway-cook A., 2006, MOTOR CONTROL TRANSL; Swaine BR, 2005, ARCH PHYS MED REHAB, V86, P1665, DOI 10.1016/j.apmr.2004.11.021; SWAINE BR, 1993, PHYS THER, V73, P71, DOI 10.1093/ptj/73.2.71; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Warren J, 2006, PHYS THER SPORT, V7, P185, DOI 10.1016/j.ptsp.2006.06.002	32	47	47	0	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAR	2010	13	2					196	201		10.1016/j.jsams.2009.05.004			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	577MR	WOS:000276228100002	19560971				2022-02-06	
J	Lepelletier, D; Roquilly, A; Latte, DDD; Mahe, PJ; Loutrel, O; Champin, P; Corvec, S; Naux, E; Pinaud, M; Lejus, C; Asehnoune, K				Lepelletier, Didier; Roquilly, Antoine; Latte, Dominique Demeure Dit; Mahe, Pierre Joachim; Loutrel, Olivier; Champin, Philippe; Corvec, Stephane; Naux, Edouard; Pinaud, Michel; Lejus, Corinne; Asehnoune, Karim			Retrospective Analysis of the Risk Factors and Pathogens Associated With Early-onset Ventilator-associated Pneumonia in Surgical-ICU Head-trauma Patients	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						pneumonia; head-trauma; risk factors	EARLY ENTERAL NUTRITION; INTENSIVE-CARE-UNIT; NOSOCOMIAL PNEUMONIA; RESPIRATORY-TRACT; COLONIZATION; INFECTIONS; MANAGEMENT	Background: Early-onset ventilator associated pneumonia (EOVAP) are frequent in head-trauma patients, but specific risk factors are poorly studied in this Population. Methods: We conducted a retrospective cohort study in a Surgical intensive care unit. Consecutive severe head-trauma patients admitted from January 2000 to December 2002 were studied. Microorganisms, and risks factors for EOVAP were analyzed. Results: During the 3-year period, 161 patients were studied;, 21.1% of them developed all EOVAP. Oil univariate analysis 6 variables were associated with EOVAP: early enteral feeding, barbiturate use, immunosuppression, mean Simplified Acute Physiology Score 2, acute respiratory distress syndrome, an initial neurosurgery procedures. Oil multivariate analysis, enteral feeding > 2000 Kcal before day 5 [odds ratio (OR): 0.33, 95% confidence interval (Q: 0.21-0.85] and initial neurosurgical procedure (OR: 0.36, 95% Cl: 0.15-0.89) remained protective factors for EOVAP, whereas irnmunosuppression (OR: 7.15, 95% Cl: 1.66-30.73) and barbiturate use (OR: 2.68, 95% C. 1.06-6.80) remained risk factors for EOVAP. EOVAP was also significantly associated with a longer duration of mechanical ventilation (14.0 vs. 11.0d, P=0.024), and a longer sedation duration (8.3 vs. 5.8 d P = 0.005). Methicillin-susceptible Staphylococcus aureus was the most common pathogen involved in EOVAP (46%). Conclusions: We demonstrate for the first time that early enteral feeding is a protective factor for EOVAP, and this result could have clinical implications for the prevention of EOVAP after traumatic brain Injury. This Study also confirms that barbiturate use is an important risk factor of EOVAP whereas Methicillin-susceptible S. aureus was found to be the main pathogen involved in EOVAP.	[Roquilly, Antoine; Latte, Dominique Demeure Dit; Mahe, Pierre Joachim; Loutrel, Olivier; Champin, Philippe; Naux, Edouard; Pinaud, Michel; Lejus, Corinne; Asehnoune, Karim] CHU Nantes, Serv Anesthesie Reanim, F-44093 Nantes 1, France; [Lepelletier, Didier; Corvec, Stephane; Asehnoune, Karim] Univ Nantes, Fac Med, Lab UPRES EA 3826, Nantes, France; [Lepelletier, Didier; Corvec, Stephane] CHU Nantes, Serv Bacteriol Hyg, F-44093 Nantes 1, France		Asehnoune, K (corresponding author), CHU Nantes, Serv Anesthesie Reanim, 1 Pl Alexis Ricordeau, F-44093 Nantes 1, France.	karim.asehnoune@chu-nantes.fr	Roquilly, Antoine/P-9826-2017				Agbaht K, 2007, INTENS CARE MED, V33, P1387, DOI 10.1007/s00134-007-0729-5; Akca O, 2000, ANESTHESIOLOGY, V93, P638, DOI 10.1097/00000542-200009000-00011; Allouch H, 1999, PRESSE MED, V28, P799; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; Bonten MJM, 1996, AM J RESP CRIT CARE, V154, P1339, DOI 10.1164/ajrccm.154.5.8912745; Boulard G, 1999, PRESSE MED, V28, P793; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; *FRENCH SOC AN RES, 1999, CHIRURGIE, V124, P441; *FRENCH SOC AN RES, 1999, ANN FR ANESTH, V18, P123; Ibrahim EH, 2002, JPEN-PARENTER ENTER, V26, P174, DOI 10.1177/0148607102026003174; Kallel H, 2005, J TRAUMA, V59, P705, DOI 10.1097/01.ta.0000177749.09844.c6; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Nadal P, 1995, Eur J Emerg Med, V2, P14, DOI 10.1097/00063110-199503000-00004; Reignier J, 2004, CRIT CARE MED, V32, P94, DOI 10.1097/01.CCM.0000104208.23542.A8; Rello J, 1999, AM J RESP CRIT CARE, V160, P608, DOI 10.1164/ajrccm.160.2.9812034; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Wallace WC, 1999, AM SURGEON, V65, P987	32	47	50	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2010	22	1					32	37		10.1097/ANA.0b013e3181bdf52f			6	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	540FH	WOS:000273316200006	20027012				2022-02-06	
J	Naphade, SB; Kigerl, KA; Jakeman, LB; Kostyk, SK; Popovich, PG; Kuret, J				Naphade, Swati B.; Kigerl, Kristina A.; Jakeman, Lyn B.; Kostyk, Sandra K.; Popovich, Phillip G.; Kuret, Jeff			Progranulin expression is upregulated after spinal contusion in mice	ACTA NEUROPATHOLOGICA			English	Article						Progranulin; Spinal cord injury; Neurodegeneration; Neuroinflammation; Trauma	FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; CORD-INJURY; EPITHELIN PRECURSOR; INFLAMMATORY RESPONSE; GENETIC-VARIABILITY; MICROARRAY ANALYSIS; ALZHEIMER-DISEASE; GROWTH-FACTOR; BETA-TUBULIN	Progranulin (proepithelin) is a pleiotropic growth-factor associated with inflammation and wound repair in peripheral tissues. It also has been implicated in the response to acute traumatic brain injury as well as to chronic neurodegenerative diseases. To determine whether changes in progranulin expression also accompany acute spinal cord injury, C57BL/6 mice were subjected to mid-thoracic (T9 level) contusion spinal cord injury and analyzed by immunohistochemical and biochemical methods. Whereas spinal cord sections prepared from non-injured laminectomy control animals contained low basal levels of progranulin immunoreactivity in gray matter, sections from injured animals contained intense immunoreactivity throughout the injury epicenter that peaked 7-14 days post injury. Progranulin immunoreactivity colocalized with myeloid cell markers CD11b and CD68, indicating that expression increased primarily in activated microglia and macrophages. Immunoblot analysis confirmed that progranulin protein levels rose after injury. On the basis of quantitative polymerase chain reaction analysis, increased protein levels resulted from a tenfold rise in progranulin transcripts. These data demonstrate that progranulin is dramatically induced in myeloid cells after experimental spinal cord injury and is positioned appropriately both spatially and temporally to influence recovery after injury.	[Naphade, Swati B.; Kuret, Jeff] Ohio State Univ, Coll Med, Ctr Mol Neurobiol, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Kigerl, Kristina A.; Popovich, Phillip G.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Ctr Brain & Spinal Cord Repair, Coll Med, Columbus, OH 43210 USA; [Jakeman, Lyn B.] Ohio State Univ, Dept Cell Biol & Physiol, Ctr Brain & Spinal Cord Repair, Coll Med, Columbus, OH 43210 USA; [Kostyk, Sandra K.] Ohio State Univ, Dept Neurol, Ctr Brain & Spinal Cord Repair, Coll Med, Columbus, OH 43210 USA		Kuret, J (corresponding author), Ohio State Univ, Coll Med, Ctr Mol Neurobiol, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	kuret.3@osu.edu	Jakeman, Lyn/A-5094-2009	Kostyk, Sandra/0000-0002-3371-753X; Jakeman, Lyn/0000-0002-1760-8819; Kigerl, Kristina/0000-0002-1652-0882	Ohio State University Neuroscience Signature ProgramOhio State University; National Institute for Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Neuroscience Core Center [NS045758]; Ohio State Center for Brain and Spinal Cord Repair; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758, R01NS043246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG014452] Funding Source: NIH RePORTER	We thank Dr. Mariano Viapiano (Department of Neurosurgery) for guidance with imaging methods. This work was supported by The Ohio State University Neuroscience Signature Program (S.K.K., L.B.J., J.K.), National Institute for Neurological Disorders and Stroke (P.G.P.), Neuroscience Core Center (NS045758), and The Ohio State Center for Brain and Spinal Cord Repair.	Ahmed Z, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-7; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bhandari V, 1996, BIOCHEM J, V319, P441, DOI 10.1042/bj3190441; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Carmel JB, 2004, EXP NEUROL, V185, P81, DOI 10.1016/j.expneurol.2003.09.007; Chen-Plotkin AS, 2010, ACTA NEUROPATHOL, V119, P111, DOI 10.1007/s00401-009-0576-2; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Hanington PC, 2006, J BIOL CHEM, V281, P9963, DOI 10.1074/jbc.M600631200; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HOLNESS CL, 1993, BLOOD, V81, P1607; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kojima Y, 2009, ATHEROSCLEROSIS, V206, P102, DOI 10.1016/j.atherosclerosis.2009.02.017; KRAMPS JA, 1983, SCAND J CLIN LAB INV, V43, P427; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104, DOI 10.1002/jlb.67.1.104; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Liu NK, 2006, J NEUROTRAUM, V23, P1794, DOI 10.1089/neu.2006.23.1794; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Mackenzie IRA, 2006, BRAIN, V129, P3081, DOI 10.1093/brain/awl271; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Mukherjee O, 2006, ANN NEUROL, V60, P314, DOI 10.1002/ana.20963; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Pereson S, 2009, J PATHOL, V219, P173, DOI 10.1002/path.2580; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Qin JW, 2005, BIOL REPROD, V73, P434, DOI 10.1095/biolreprod.105.040030; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Shankaran SS, 2008, J BIOL CHEM, V283, P1744, DOI 10.1074/jbc.M705115200; Sleegers K, 2008, NEUROLOGY, V71, P253, DOI 10.1212/01.wnl.0000289191.54852.75; Solovjov DA, 2005, J BIOL CHEM, V280, P1336, DOI 10.1074/jbc.M406968200; Sparro G, 1997, PROTEIN EXPRES PURIF, V10, P169, DOI 10.1006/prep.1997.0726; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; van der Zee J, 2007, HUM MUTAT, V28, P416, DOI 10.1002/humu.9484; Youn BS, 2009, DIABETES, V58, P627, DOI 10.2337/db08-1147; Young W, 2002, PROG BRAIN RES, V137, P231; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	62	47	49	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JAN	2010	119	1					123	133		10.1007/s00401-009-0616-y			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	538HE	WOS:000273174400010	19946692	Green Accepted			2022-02-06	
J	Petraglia, AL; Marky, AH; Walker, C; Thiyagarajan, M; Zlokovic, BV				Petraglia, Anthony L.; Marky, Andrew H.; Walker, Corey; Thiyagarajan, Meenakshisundaram; Zlokovic, Berislav V.			Activated Protein C Is Neuroprotective and Mediates New Blood Vessel Formation and Neurogenesis After Controlled Cortical Impact	NEUROSURGERY			English	Article						Activated protein C; Angiogenesis; Controlled cortical impact; Neurogenesis; Neuroprotection; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; TISSUE-PLASMINOGEN ACTIVATOR; ERYTHROPOIETIN ENHANCES NEUROGENESIS; SUBVENTRICULAR ZONE; FUNCTIONAL RECOVERY; ISCHEMIC BRAIN; STROKE; RATS; ANGIOGENESIS; SYNAPTOGENESIS	OBJECTIVE: Activated protein C (APC) is neuroprotective in stroke models and promotes postischemic neovascularization and neurogenesis. We used a controlled cortical impact (CCI) in mice to determine the effects of APC on neuroprotection and angiogenesis and neurogenesis after traumatic brain injury (TBI). METHODS: Mice were given (1) single-dose APC (0.8 mg/kg intraperitoneally) 15 minutes after injury, (2) multidose APC (0.8 mg/kg intraperitoneally) 15 minutes and 6 to 48 hours after injury, or (3) vehicle. We then assessed the effects of APC on posttraumatic motor function with the rotarod and wire grip and beam balance tasks, and we determined the lesion volumes and studied the formation of new blood vessels and markers of neurogenesis. RESULTS: Mice treated with single-dose or multiclose APC, compared with vehicle, showed significantly improved motor function on all tests. In the single-dose and multiclose APC treatment groups, at 7 days after treatment, lesion volume was significantly decreased by 30% and 50%, respectively. Multidose APC, but not single-dose APC, increased new blood vessel formation as shown by CD105(+)/Ki-67(+) double immunostaining by nearly 2-fold at 7 days. Multidose APC also promoted posttraumatic proliferation of neuroblasts in the subventricular zone (SVZ) and their migration from the SVZ to the perilesional area. CONCLUSION: Activated protein C improves functional outcome and is neuroprotective after TBI. It also promotes angiogenesis and survival and migration of neuroblasts from the SVZ to the perilesional area, but the exact role of these brain repair mechanisms remains to be determined. The present findings suggest that APC therapy may hold a significant therapeutic potential for TBI.	[Petraglia, Anthony L.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Marky, Andrew H.; Walker, Corey; Thiyagarajan, Meenakshisundaram; Zlokovic, Berislav V.] Univ Rochester, Med Ctr, Ctr Neurodegenerat & Vasc Brain Disorders, Rochester, NY 14642 USA		Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Ctr Neurodegenerat & Vasc Brain Disorders, Arthur Kornberg Med Res Bldg,Room G-9613,601 Elmw, Rochester, NY 14642 USA.	berislav_zlokovic@urmc.rochester.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL63290, HL081528, TLI RR024135]; Socratech LLC; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR024135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL063290, R01HL081528] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grants HL63290, HL081528 (to B.V.Z), and TLI RR024135 (to A.H.M.). B.V.Z. is a scientific founder of Socratech LLC. a startup biotech company with a mission to develop new treatments for the aging brain, stroke, and Alzheimers disease. B.V.Z is an inventor on pending parents related to APC.	Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hirose K, 2000, ANN SURG, V232, P272, DOI 10.1097/00000658-200008000-00018; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; Thiyagarajan M, 2008, J NEUROSCI, V28, P12788, DOI 10.1523/JNEUROSCI.3485-08.2008; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 1997, J CEREBR BLOOD F MET, V17, P136, DOI 10.1097/00004647-199702000-00002; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zlokovic BV, 2005, ANN NEUROL, V58, P474, DOI 10.1002/ana.20602	31	47	52	1	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2010	66	1					165	171		10.1227/01.NEU.0000363148.49779.68			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	535KP	WOS:000272967400031	20023547	Green Accepted			2022-02-06	
J	Pistoia, F; Mura, E; Govoni, S; Fini, M; Sara, M				Pistoia, Francesca; Mura, Elisa; Govoni, Stefano; Fini, Massimo; Sara, Marco			Awakenings and Awareness Recovery in Disorders of Consciousness	CNS DRUGS			English	Article							TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; TRANSIENT IMPROVEMENT; CONTROLLED-TRIAL; CLINICAL-USE; ZOLPIDEM; AMANTADINE; AROUSAL; SLEEP; METHYLPHENIDATE	Disorders of consciousness (DOC) include coma, vegetative state (VS) and minimally conscious state (MCS). Coma is a condition of unarousability with a complete absence of wakefulness and awareness, whereas VS is characterized by a lack of awareness despite a preserved wakefulness. Patients in coma are unconscious because they lack both wakefulness and awareness. Patients in a VS are unconscious because, although they are wakeful, they lack awareness. Patients in a MCS show minimal but definite behavioural evidence of self and environmental awareness. Coma results from diffuse bilateral hemispheric lesions or selective damage to the ascending reticular system (which is functionally connected to the cerebral cortex by intralaminar thalamic nuclei). VS is a syndrome that is considered to be the result of a disconnection of different cortical networks rather than a dysfunction of a single area or a global reduction in cortical metabolism. As revealed by functional imaging studies, clinical recovery is often associated with a functional restoration of cortico-thalamo-cortical connections. Depending on the amount of network restored, patients may regain full consciousness or remain in a MCS. Molecular and neural mediators may indirectly contribute to the above restoration processes owing to their role in the phenomenon of neural synaptic plasticity. Therefore, there is growing interest in the possible effects of drugs that act at the level of the CNS in promoting emergence from DOC. Sporadic cases of dramatic recovery from DOC after the administration of various pharmacological agents, such as baclofen, zolpidem and amantadine, have been recently supported by intriguing scientific observations. Analysis of the reported cases of recovery, with particular attention paid to the condition of the patients and to the association of their improvement with the start of drug administration, suggests that these treatments might have promoted the clinical improvement of some patients. These drugs are from various and diverging classes, but can be grouped into two main categories, CNS stimulants and CNS depressants. Some of these treatments seem to directly encourage a consciousness restoration, while others play a more determinant role in improving cognitive domains, especially in patients with residual cognitive impairment, than in the field of consciousness. Given the great interest recently generated in the scientific community by the increasing number of papers addressing this issue, further investigation of the above treatments, with particular attention paid to their mechanisms of action, the neurotransmitters involved and their effects on cortico-thalamo-cortical circuitry, is needed.	[Pistoia, Francesca; Sara, Marco] Hosp San Raffaele, Postcoma Intens & Rehabil Care Unit, I-03043 Cassino, Italy; [Pistoia, Francesca] Univ Laquila, Dept Internal Med & Publ Hlth, Laquila, Italy; [Mura, Elisa; Govoni, Stefano] Univ Pavia, Dept Expt & Appl Pharmacol, Ctr Excellence Appl Biol, I-27100 Pavia, Italy; [Fini, Massimo] IRCCS San Raffaele Pisana, Rome, Italy		Pistoia, F (corresponding author), Hosp San Raffaele, Postcoma Intens & Rehabil Care Unit, Via Gaetano Di Biasio, I-03043 Cassino, Italy.	pistoiafrancesca@hotmail.com	Fini, Massimo/AAA-9948-2021; mura, elisa/ABD-9249-2020; Govoni, Stefano/K-2965-2015; Sara, Marco/AAB-3651-2019; Pistoia, Francesca/AAC-1027-2019	Govoni, Stefano/0000-0002-7243-6837; PISTOIA, Francesca/0000-0003-0790-4240			ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bates D, 2003, CLIN MED, V3, P249; Calabresi P, 2003, NEUROBIOL DIS, V12, P82, DOI 10.1016/S0969-9961(02)00016-5; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss R, 2004, NEW ENGL J MED, V351, P511, DOI 10.1056/NEJM200407293510522; Clauss RP, 2000, S AFR MED J, V90, P68; CLAUSS RP, MED HYPOTHESES; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Coulter DA, 1997, J CHILD NEUROL, V12, pS2, DOI 10.1177/0883073897012001031; Crosby NJ, 2003, COCHRANE DB SYST REV, pCD003467, DOI DOI 10.1002/14651858; D'Aleo G, 1994, Funct Neurol, V9, P189; DeMarchi R, 2005, CAN J NEUROL SCI, V32, P4, DOI 10.1017/S0317167100016826; Fridman EA, 2010, BRAIN INJURY, V24, P636, DOI 10.3109/02699051003610433; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; Ketter TA, 2003, J CLIN PSYCHOPHARM, V23, P484, DOI 10.1097/01.jcp.0000088915.02635.e8; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Lanni C, 2009, CELL MOL LIFE SCI, V66, P2985, DOI 10.1007/s00018-009-0055-x; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lee L, 2003, NEUROIMAGE, V19, P457, DOI 10.1016/S1053-8119(03)00062-4; Liepert J, 2008, CURR OPIN NEUROL, V21, P639, DOI 10.1097/WCO.0b013e32831897a3; Lo YL, 2008, ANN NEUROL, V64, P477, DOI 10.1002/ana.21183; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Moein H, 2006, CLIN NEUROL NEUROSUR, V108, P539, DOI 10.1016/j.clineuro.2005.09.003; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Plum F, 1972, Contemp Neurol Ser, V10, P1; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; Rogoz Z, 2008, PHARMACOL REP, V60, P817; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Sanger DJ, 2004, CNS DRUGS, V18, P9, DOI 10.2165/00023210-200418001-00004; Sanna E, 2002, EUR J PHARMACOL, V451, P103, DOI 10.1016/S0014-2999(02)02191-X; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; Sara M, 2010, J NEUROTRAUM, V27, P771, DOI [10.1089/neu.2008.0804, 10.1089/neu.2008-0804]; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Showalter PEC, 2000, BRAIN INJURY, V14, P997; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; Taira T, 2009, PROG BRAIN RES, V177, P317, DOI 10.1016/S0079-6123(09)17721-X; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Whyte J, 2007, AM J PHYS MED REHAB, V86, P86, DOI 10.1097/PHM.0b013e31802f0434; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Worzniak M, 1997, J FAM PRACTICE, V44, P495; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962; Zafonte RD, 1998, BRAIN INJURY, V12, P617	65	47	49	1	17	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1172-7047			CNS DRUGS	CNS Drugs		2010	24	8					625	638		10.2165/11535940-000000000-00000			14	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	640JN	WOS:000281047600001	20658796				2022-02-06	
J	Bay, E; Sikorskii, A; Saint-Arnault, D				Bay, Esther; Sikorskii, Alla; Saint-Arnault, Denise			Sex Differences in Depressive Symptoms and Their Correlates After Mild-to-Moderate Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE NURSING			English	Article							HIPPOCAMPAL VOLUME; MAJOR DEPRESSION; GENDER DIFFERENCES; RISK-FACTORS; STRESS; WOMEN; MOOD; RESPONSES; NEUROBIOLOGY; PREVALENCE	The purpose of this secondary data analysis, guided by allostatic load theory, was to compare depressive symptoms and their correlates in men and women following mild or moderate traumatic brain injury (n = 159). Using general linear modeling procedures in the Statistical Analysis Software, women reported significantly higher Center for Epidemiological Studies-Depression scores compared with men. According to the Neurobehavioral Functioning Inventory subscales, women also reported higher somatic and motor symptoms and difficulties with memory and cognition. Further, women within the first 6 months of their injury reported higher levels of depressive and depressive-somatic symptoms, perceived chronic stress, pain, memory difficulties, and somatic symptoms. These findings were no longer present at the 6- to 12-month or >12-month cutoffs. Women's depressive symptoms during the early recovery period are explained by higher symptom loads and perceived stress, yet mechanisms responsible for these differences remain to be elucidated. Future research is needed to describe hormonal, perceptual, or brain structure differences that may account for these findings. Findings from such research will most likely to contribute to our understanding of postconcussion syndrome.	[Bay, Esther; Sikorskii, Alla; Saint-Arnault, Denise] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA		Bay, E (corresponding author), Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA.	baye@msu.edu		Saint Arnault, Denise/0000-0002-4436-8347			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay E, 2007, ARCH PSYCHIAT NURS, V21, P2, DOI 10.1016/j.apnu.2006.07.005; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/rtnp.18.2.213.61278; Bay E, 2009, BIOL RES NURS, V10, P213, DOI 10.1177/1099800408326453; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bierut LJ, 1999, ARCH GEN PSYCHIAT, V56, P557, DOI 10.1001/archpsyc.56.6.557; Blehar MC, 2006, ANNU REV CLIN PSYCHO, V2, P135, DOI 10.1146/annurev.clinpsy.2.022305.095344; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cohen J., 2013, STAT POWER ANAL BEHA; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1995, HEALTH PSYCHOL, V14, P374, DOI 10.1037/0278-6133.14.5.374; Cohen S. C. R., 1995, MEASURING STRESS GUI, P1; Darnall BD, 2009, BRAIN BEHAV IMMUN, V23, P595, DOI 10.1016/j.bbi.2009.02.019; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; Fillingim R B, 2000, Curr Rev Pain, V4, P24; Gerhart KA, 1999, SPINAL CORD, V37, P183, DOI 10.1038/sj.sc.3100804; Gordon EJ, 2008, ACS CHEM BIOL, V3, P6; Hammen C, 2003, J AFFECT DISORDERS, V74, P49, DOI 10.1016/S0165-0327(02)00430-5; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Heim Christine, 2002, Semin Clin Neuropsychiatry, V7, P147, DOI 10.1053/scnp.2002.33127; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hughes RB, 2005, WOMEN HEALTH ISS, V15, P14, DOI 10.1016/j.whi.2004.09.001; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kajantie E, 2006, PSYCHONEUROENDOCRINO, V31, P151, DOI 10.1016/j.psyneuen.2005.07.002; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; KELLY M, J BEHAV THE IN PRESS; Kendler KS, 2000, AM J PSYCHIAT, V157, P1243, DOI 10.1176/appi.ajp.157.8.1243; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Lasiuk GC, 2007, BIOL RES NURS, V9, P147, DOI 10.1177/1099800407305600; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McEwen B., 2002, END STRESS WE KNOW I; MEARES S, 2007, J NEUROL NEUROSUR PS, V8, P1; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Nemeroff CB, 2005, J CLIN PSYCHIAT, V66, P5; Nolen-Hoeksema S, 2001, CURR DIR PSYCHOL SCI, V10, P173, DOI 10.1111/1467-8721.00142; NOLENHOEKSEMA S, 1987, PSYCHOL BULL, V101, P259, DOI 10.1037/0033-2909.101.2.259; PICCINELLI M, 1997, EPIDEMIOLOGY AFFECTI; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; *SAS I, 2002, SAS SYST WIND VERS; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shors TJ, 2003, J AFFECT DISORDERS, V74, P85, DOI 10.1016/S0165-0327(02)00428-7; Silverstein B, 1999, AM J PSYCHIAT, V156, P480; Silverstein B, 2002, AM J PSYCHIAT, V159, P1051, DOI 10.1176/appi.ajp.159.6.1051; SMITH B, 2001, EUROPEAN J PAIN, P257; Taylor SE, 2000, PSYCHOL REV, V107, P411, DOI 10.1037/0033-295X.107.3.411; TEASDALE G, 1974, LANCET, V2, P81; *US DEP HHS, 2007, TRAUM BRAIN INJ FACT; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WALKER EA, 1992, PSYCHOSOM MED, V54, P658, DOI 10.1097/00006842-199211000-00005; Weekes NY, 2005, STRESS HEALTH, V21, P147, DOI 10.1002/smi.1046; Weiss EL, 1999, AM J PSYCHIAT, V156, P816, DOI 10.1176/ajp.156.6.816; WHO, 2004, WORLD REP ROAD TRAFF; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	75	47	47	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	DEC	2009	41	6					298	309		10.1097/JNN.0b013e3181b6be81			12	Clinical Neurology; Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Nursing	526CL	WOS:000272265200003	19998681				2022-02-06	
J	Belmont, A; Agar, N; Azouvi, P				Belmont, Angelique; Agar, Nathalie; Azouvi, Philippe			Subjective Fatigue, Mental Effort, and Attention Deficits After Severe Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						Traumatic brain injury; Mental fatigue; Attention deficits	CLOSED-HEAD INJURY; 1ST 2 YEARS; PRACTICAL SCALE; DEPRESSION; PERFORMANCE; RECOVERY; DAMAGE	Objective. Although fatigue is one of the most frequent complaints of individuals with traumatic brain injury (TBI), its mechanisms remain poorly understood. The objective of this study was to assess the relationships between subjective mental fatigue, mental effort, attention deficits, and mood after severe TBI. Methods and participants. A total of 27 patients with subacute/chronic severe TBI were compared with matched controls. Patients first rated their baseline subjective fatigue on the Fatigue Severity Scale (FSS) and on the Visual Analog Scale for Fatigue (VAS-F). Mood was assessed with the Montgomery and Asberg Depression Rating Scale (MADRS). Then, they performed a long-duration selective attention task, separated in 2 parts. Fatigue on the VAS-F was assessed again between the 2 parts and at the end of the attention task. Patients were also asked to rate on the VAS the level of subjective mental effort devoted to the task. Results. Patients reported a higher baseline fatigue than controls. They performed significantly poorer on the selective attention task. Significant correlations were found in the group with TBI between attention performance, mental effort, and subjective fatigue. Depression did not significantly correlate with fatigue. Discussion and conclusions. These findings suggest that patients with more severe attention deficits have to produce higher levels of mental effort to manage a complex task, which may increase subjective fatigue, in line with the coping hypothesis.	[Belmont, Angelique; Agar, Nathalie; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, F-92380 Garches, France; [Belmont, Angelique; Azouvi, Philippe] INSERM, U731, Paris, France; [Belmont, Angelique; Azouvi, Philippe] Fac Med, Lab Physiol & Physiopathol Motricite, Paris, France; [Azouvi, Philippe] Univ Versailles St Quentin, Versailles, France		Azouvi, P (corresponding author), Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr		BELMONT, Angelique/0000-0002-4700-8582			Arciniegas DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; De Vries J, 2003, OCCUP ENVIRON MED, V60, P10; Dijkers MPJM, 2008, J HEAD TRAUMA REHAB, V23, P3, DOI 10.1097/01.HTR.0000308716.80590.6b; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; JENNETT B, 1975, LANCET, V1, P480; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	36	47	47	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV-DEC	2009	23	9					939	944		10.1177/1545968309340327			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	508NQ	WOS:000270939300007	19574545	Green Published			2022-02-06	
J	Garcia-Capdevila, S; Portell-Cortes, I; Torras-Garcia, M; Coll-Andreu, M; Costa-Miserachs, D				Garcia-Capdevila, Silvia; Portell-Cortes, Isabel; Torras-Garcia, Meritxell; Coll-Andreu, Margalida; Costa-Miserachs, David			Effects of long-term voluntary exercise on learning and memory processes: dependency of the task and level of exercise	BEHAVIOURAL BRAIN RESEARCH			English	Article						Running wheel exercise; Learning and memory; Object recognition; Two-way active avoidance; Anxiety-like behaviour	OXIDATIVE STRESS MARKERS; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-I; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; OBJECT RECOGNITION; PHYSICAL-EXERCISE; COGNITIVE FUNCTION; FORCED EXERCISE; GENE-EXPRESSION	The effect of long-term voluntary exercise (running wheel) on anxiety-like behaviour (plus maze and open field) and learning and memory processes (object recognition and two-way active avoidance) was examined on Wistarrats. Because major individual differences in running wheel behaviour were observed, the data were analysed considering the exercising animals both as a whole and grouped according to the time spent in the running wheel (low, high, and very-high running). Although some variables related to anxiety-like behaviour seem to reflect an anxiogenic compatible effect, the view of the complete set of variables could be interpreted as an enhancement of defensive and risk assessment behaviours in exercised animals, without major differences depending on the exercise level. Effects on learning and memory processes were dependent on task and level of exercise. Two-way avoidance was not affected either in the acquisition or in the retention session, while the retention of object recognition task was affected. In this latter task, an enhancement in low running subjects and impairment in high and very-high running animals were observed. (C) 2009 Elsevier B.V. All rights reserved.	[Garcia-Capdevila, Silvia; Portell-Cortes, Isabel; Torras-Garcia, Meritxell; Coll-Andreu, Margalida; Costa-Miserachs, David] Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, Bellaterra 08193, Spain		Costa-Miserachs, D (corresponding author), Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, Bellaterra 08193, Spain.	David.Costa@uab.cat	Costa-Miserachs, David/E-1318-2011; Coll-Andreu, Margalida/C-9119-2011; Portell-Cortes, Isabel/C-5991-2011; Torras-Garcia, Meritxell/K-9068-2014; Costa-Miserachs, David/N-2794-2019	Costa-Miserachs, David/0000-0001-5781-0774; Coll-Andreu, Margalida/0000-0003-4106-2606; Portell-Cortes, Isabel/0000-0002-7710-0101; Torras-Garcia, Meritxell/0000-0003-2511-8788; Costa-Miserachs, David/0000-0001-5781-0774	Generalitat de CatalunyaGeneralitat de CatalunyaGeneral Electric [2006FIC 00231]; Ministerio de Educacion y CienciaSpanish GovernmentEuropean Commission [SEJ2006-14226/PSIC]	S.G.-C. was supported by predoctoral fellowship from the Generalitat de Catalunya (2006FIC 00231). The research was funded by the Ministerio de Educacion y Ciencia (SEJ2006-14226/PSIC).	Afonso VM, 2003, PHYSIOL BEHAV, V80, P19, DOI 10.1016/S0031-9384(03)00216-6; Aggleton JP, 2005, Q J EXP PSYCHOL-B, V58, P218, DOI 10.1080/02724990444000131; Alaei H, 2006, EUR J PHARMACOL, V536, P138, DOI 10.1016/j.ejphar.2006.02.025; Ang ET, 2006, BRAIN RES, V1113, P186, DOI 10.1016/j.brainres.2006.07.023; Arida RM, 2004, NEUROSCI LETT, V364, P135, DOI 10.1016/j.neulet.2004.03.086; Barker GRI, 2007, J NEUROSCI, V27, P2948, DOI 10.1523/JNEUROSCI.5289-06.2007; BARNES CA, 1991, NEUROBIOL AGING, V12, P47, DOI 10.1016/0197-4580(91)90038-L; Baruch DE, 2004, BEHAV NEUROSCI, V118, P1123, DOI 10.1037/0735-7044.118.5.1123; Binder E, 2004, BEHAV BRAIN RES, V155, P197, DOI 10.1016/j.bbr.2004.04.017; Blustein JE, 2006, PHYSIOL BEHAV, V89, P582, DOI 10.1016/j.physbeh.2006.07.017; Boguszewski P, 2002, BEHAV BRAIN RES, V133, P323, DOI 10.1016/S0166-4328(02)00018-9; Braszko JJ, 2001, NEUROSCI RES, V39, P79, DOI 10.1016/S0168-0102(00)00207-8; Burghardt PR, 2006, PHARMACOL BIOCHEM BE, V84, P306, DOI 10.1016/j.pbb.2006.05.015; Burghardt PR, 2004, BRAIN RES, V1019, P84, DOI 10.1016/j.brainres.2004.05.086; Callaghan P, 2004, J Psychiatr Ment Health Nurs, V11, P476, DOI 10.1111/j.1365-2850.2004.00751.x; Carter PA, 2000, BEHAV GENET, V30, P85, DOI 10.1023/A:1001967019229; CHAOULOFF F, 1994, NEUROSCI LETT, V176, P226, DOI 10.1016/0304-3940(94)90088-4; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Da Cunha C, 2002, CELL MOL NEUROBIOL, V22, P227, DOI 10.1023/A:1020736131907; de Lima MN, 2006, NEUROSCI LETT, V405, P142, DOI 10.1016/j.neulet.2006.06.044; Dere E, 2007, NEUROSCI BIOBEHAV R, V31, P673, DOI 10.1016/j.neubiorev.2007.01.005; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Dishman RK, 1997, BRAIN RES BULL, V42, P399, DOI 10.1016/S0361-9230(96)00329-2; Dishman RK, 1996, PHYSIOL BEHAV, V60, P699; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; Dunn AL, 2001, MED SCI SPORT EXER, V33, pS587, DOI 10.1097/00005768-200106001-00027; ElMassioui N, 1997, NEUROSCI RES COMMUN, V21, P103; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; Etnier JL, 2007, MED SCI SPORT EXER, V39, P199, DOI 10.1249/01.mss.0000239399.85955.5e; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Fulk LJ, 2004, INT J SPORTS MED, V25, P78; Gobbo OL, 2005, BRAIN RES, V1046, P224, DOI 10.1016/j.brainres.2005.03.046; Greenwood BN, 2003, J NEUROSCI, V23, P2889; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gwag BJ, 1995, NEUROREPORT, V7, P93, DOI 10.1097/00001756-199512000-00022; Hansalik M, 2006, EXP GERONTOL, V41, P169, DOI 10.1016/j.exger.2005.11.002; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; HINELINE PN, 1978, J EXP ANAL BEHAV, V29, P87, DOI 10.1901/jeab.1978.29-87; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Koteja P, 1999, PHYSIOL BIOCHEM ZOOL, V72, P238, DOI 10.1086/316653; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; LARUN L, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004691.PUB2; Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041; Llorens-Martin M, 2006, HIPPOCAMPUS, V16, P480, DOI 10.1002/hipo.20175; MARTINICOLOVIUS M, 1988, PHYSIOL BEHAV, V43, P93, DOI 10.1016/0031-9384(88)90103-5; McCloskey DP, 2001, BRAIN RES, V891, P168, DOI 10.1016/S0006-8993(00)03200-5; Morishima M, 2006, NEUROPSYCHOPHARMACOL, V31, P2627, DOI 10.1038/sj.npp.1301028; Mostafa RM, 2002, PHYSIOL BEHAV, V76, P589, DOI 10.1016/S0031-9384(02)00730-8; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; O'Callaghan RM, 2007, BEHAV BRAIN RES, V176, P362, DOI 10.1016/j.bbr.2006.10.018; Ogonovszky H, 2005, NEUROCHEM INT, V46, P635, DOI 10.1016/j.neuint.2005.02.009; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; Peluso Marco Aurélio Monteiro, 2005, Clinics, V60, P61, DOI 10.1590/S1807-59322005000100012; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Petzinger GM, 2007, J NEUROSCI, V27, P5291, DOI 10.1523/JNEUROSCI.1069-07.2007; Ploughman M, 2005, NEUROSCIENCE, V136, P991, DOI 10.1016/j.neuroscience.2005.08.037; Ploughman M, 2007, BRAIN RES, V1150, P207, DOI 10.1016/j.brainres.2007.02.065; Radak Z, 2001, NEUROCHEM INT, V38, P17, DOI 10.1016/S0197-0186(00)00063-2; Radak Z, 2006, NEUROCHEM INT, V49, P387, DOI 10.1016/j.neuint.2006.02.004; Ramsden M, 2003, BRAIN RES, V971, P239, DOI 10.1016/S0006-8993(03)02365-5; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Salam JN, 2009, BEHAV BRAIN RES, V197, P31, DOI 10.1016/j.bbr.2008.07.036; Samdani AF, 1997, J NEUROSCI, V17, P4633; SAMORAJSKI T, 1985, NEUROBIOL AGING, V6, P17, DOI 10.1016/0197-4580(85)90066-1; Schweitzer NB, 2006, NEUROCHEM INT, V48, P9, DOI 10.1016/j.neuint.2005.08.006; Sherwin CM, 1998, ANIM BEHAV, V56, P11, DOI 10.1006/anbe.1998.0836; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Stranahan AM, 2006, NAT NEUROSCI, V9, P526, DOI 10.1038/nn1668; THARP GD, 1975, MED SCI SPORT EXER, V7, P123; Torras-Garcia M, 2005, EXP BRAIN RES, V164, P177, DOI 10.1007/s00221-005-2240-y; Torres JB, 2006, EXP BRAIN RES, V175, P292, DOI 10.1007/s00221-006-0549-9; Tou JCL, 2002, EXP BIOL MED, V227, P587, DOI 10.1177/153537020222700806; Uysal N, 2005, NEUROSCI LETT, V383, P241, DOI 10.1016/j.neulet.2005.04.054; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Wall PM, 2001, NEUROSCI BIOBEHAV R, V25, P275, DOI 10.1016/S0149-7634(01)00013-6; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008	86	47	47	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	SEP 14	2009	202	2					162	170		10.1016/j.bbr.2009.03.020			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	458HK	WOS:000267006300003	19463697				2022-02-06	
J	Shoakazemi, A; Flannery, T; McConnell, RS				Shoakazemi, Alireza; Flannery, Thomas; McConnell, Robert Scoff			LONG-TERM OUTCOME OF SUBCUTANEOUSLY PRESERVED AUTOLOGOUS CRANIOPLASTY	NEUROSURGERY			English	Article						Abdominal wall; Autologous bone flap; Cranial defect; Cranioplasty; Decompressive craniectomy	TRAUMATIC BRAIN-INJURY; CRANIOTOMY BONE FLAPS; DECOMPRESSIVE CRANIECTOMY; POSTTRAUMATIC HYDROCEPHALUS; DEFECTS; FROZEN; FRESH; FATE; HEAD	OBJECTIVE: Decompressive craniectomy for intracranial hypertension mandates later cranioplasty. Autologous cranioplasties can be preserved either by freezing or placement in a subcutaneous pocket. There are few data on the long-term follow-up of patients treated in such a fashion. METHODS: A retrospective study was conducted on 100 consecutive patients who underwent decompressive craniectomy and placement of the bone flap in a subcutaneous pocket in the abdominal wall between 2000 and 2005. Initial diagnosis, Glasgow Coma Scale score on admission, complications, and Glasgow Outcome Score were recorded. RESULTS: Of the 100 patients who underwent autocranioplasty, the primary diagnosis was traumatic brain injury (76%), subarachnoid hemorrhage (17%), primary intracerebral hemorrhage (3%), and tumor (4%). The mean age of the sample was 39 years (age range, 10-72 years). The mean follow-up duration was 25 months. The average Glasgow Coma Scale score on admission was 7. Eight patients died before replacement of the bone flap. The average time between craniectomy and replacement of bone flap was 42 days. The mean Glasgow Outcome Score was 4 at the time of the 1-year follow-up evaluation. Seven of the 79 patients (9%) for whom 1-year review data were available had a cosmetic result that was unacceptable and required removal of the flap (bone flap infections in 5 patients, unacceptable bone flap resorption in 2 patients) CONCLUSION: Our study indicates that storage of a cranioplasty flap in a subcutaneous pouch in the abdominal wall has a favorable long-term outcome.	[Shoakazemi, Alireza; Flannery, Thomas; McConnell, Robert Scoff] Royal Victoria Hosp, Dept Neurosurg, Reg Neurosci Unit, Belfast BT12 6BA, Antrim, North Ireland		McConnell, RS (corresponding author), Royal Victoria Hosp, Dept Neurosurg, Reg Neurosci Unit, Level 6A OPC, Belfast BT12 6BA, Antrim, North Ireland.	roy.mcconnell@belfasttrust.hscni.net					ABBOTT KH, 1953, J NEUROSURG, V10, P380, DOI 10.3171/jns.1953.10.4.0380; ACIKGOZ B, 1986, SURG NEUROL, V26, P557, DOI 10.1016/0090-3019(86)90339-3; CABANELA ME, 1972, J BONE JOINT SURG AM, VA 54, P278, DOI 10.2106/00004623-197254020-00005; CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; COULDWELL WT, 1994, J NEUROSURG, V81, P483, DOI 10.3171/jns.1994.81.3.0483; Curry WT, 2005, NEUROSURGERY, V56, P681, DOI 10.1227/01.NEU.0000156604.41886.62; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; ELLIOTT H, 1951, BRIT J SURG, V39, P31, DOI 10.1002/bjs.18003915305; Flannery T, 2001, BRIT J NEUROSURG, V15, P518, DOI 10.1080/02688690120097732; Goel A, 1995, SURG NEUROL, V44, P181, DOI 10.1016/0090-3019(95)00161-1; GORDON DS, 1974, BRIT MED J, V2, P478, DOI 10.1136/bmj.2.5917.478; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; HANCOCK DO, 1963, J NEUROSURG, V20, P983, DOI 10.3171/jns.1963.20.11.0983; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; KAWAKAMI K, 1989, Neurological Surgery, V17, P1023; KORFALI E, 1988, SURG NEUROL, V30, P269, DOI 10.1016/0090-3019(88)90297-2; KORLOF B, 1973, PLAST RECONSTR SURG, V52, P378, DOI 10.1097/00006534-197352040-00009; KREIDER GN, 1920, JAMA-J AM MED ASSOC, V64, P1024; KREUZ FP, 1951, J BONE JOINT SURG AM, V33-A, P863, DOI 10.2106/00004623-195133040-00005; Krishnan P, 2006, NEUROL INDIA, V54, P291; KRISS F C, 1969, Journal of Neurosurgery, V30, P698, DOI 10.3171/jns.1969.30.6.0698; LEIVY DM, 1970, NEUROCHIRURGIA, V13, P82; LONGACRE J J, 1957, Plast Reconstr Surg (1946), V20, P281, DOI 10.1097/00006534-195710000-00003; LONGACRE J J, 1958, Plast Reconstr Surg Transplant Bull, V21, P372, DOI 10.1097/00006534-195805000-00005; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; MCCLINTOCK HG, 1951, SURGERY, V30, P955; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Nakajima T, 1975, No Shinkei Geka, V3, P925; Nakajima T, 1977, No Shinkei Geka, V5, P1329; ODOM GL, 1952, J NEUROSURG, V9, P606, DOI 10.3171/jns.1952.9.6.0606; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; PRABHU SS, 2004, YOUMANS NEUROLOGICAL, V6, P5174; PROLO DJ, 1984, NEUROSURGERY, V15, P846, DOI 10.1227/00006123-198412000-00013; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Tsukagoshi T, 1998, PLAST RECONSTR SURG, V102, P2114, DOI 10.1097/00006534-199811000-00047; Tybor Krzysztof, 2005, Neurol Neurochir Pol, V39, P220; Valentini LG, 2008, NEUROSURGERY, V62, P88, DOI 10.1227/01.NEU.0000311065.95496.C5; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Wegeforth P, 1919, ANN SURG, V69, P384, DOI 10.1097/00000658-191904000-00005; Yano H, 2006, J CRANIOFAC SURG, V17, P1076, DOI 10.1097/01.scs.0000244916.84511.b6	47	47	47	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2009	65	3					505	510		10.1227/01.NEU.0000350870.69891.86			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	488CB	WOS:000269325600011	19687696				2022-02-06	
J	Gibson, CL; Coomber, B; Rathbone, J				Gibson, Claire L.; Coomber, Ben; Rathbone, James			Is Progesterone a Candidate Neuroprotective Factor for Treatment following Ischemic Stroke?	NEUROSCIENTIST			English	Article						progesterone; focal ischemia; neuroprotection; steroids; stroke	CEREBRAL-ARTERY OCCLUSION; ESTROGEN PLUS PROGESTIN; TRAUMATIC BRAIN-INJURY; BINDING PROTEIN 25-DX; INFARCT VOLUME; UP-REGULATION; COGNITIVE DEFICITS; HORMONE-THERAPY; CLINICAL-TRIAL; CELL-DEATH	Gender differences in stroke outcome have implicated steroid hormones as potential neuroprotective candidates. However, no clinical trials examining hormone replacement therapy on outcome following ischemic stroke have investigated the effect of progesterone-only treatment. In this review the authors examine the experimental evidence for the neuroprotective potential of progesterone and give an insight into potential mechanisms of action following ischemic stroke. To date, 17 experimental studies have investigated the neuroprotective potential of progesterone for ischemic stroke in terms of ability to both reduce cell loss and increase functional Outcome. Of these 17 published studies the majority reported a beneficial effect with three studies reporting a nil effect and only one study reporting a negative effect. However, there are important issues that the authors address in this review in terms of the methodological quality of studies in relation to the STAIR recommendations. In terms of the proposed mechanisms of progesterone neuroprotection we show that progesterone is versatile and acts at Multiple targets to facilitate neuronal survival and minimize cell damage and loss. A large amount of experimental evidence indicates that progesterone is a neuroprotective candidate for ischemic stroke: however, to progress to clinical trial a number of key experimental studies remain outstanding.	[Gibson, Claire L.; Coomber, Ben; Rathbone, James] Univ Leicester, Sch Psychol, Leicester LE1 9HN, Leics, England		Gibson, CL (corresponding author), Univ Leicester, Sch Psychol, Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	cg95@le.ac.uk		Gibson, Claire/0000-0002-3358-7341			Aggarwal R, 2008, J PHARM PHARMACOL, V60, P731, DOI 10.1211/jpp.60.6.0008; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Bingham D, 2005, J CEREBR BLOOD F MET, V25, P414, DOI 10.1038/sj.jcbfm.9600031; Brann DW, 2005, NEUROENDOCRINOLOGY, V81, P120, DOI 10.1159/000086405; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Coughlan T, 2005, J NEUROCHEM, V93, P932, DOI 10.1111/j.1471-4159.2005.03068.x; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2006, J CEREBR BLOOD F MET, V26, P1103, DOI 10.1038/sj.jcbfm.9600270; Ginsberg MD, 2009, STROKE, V40, pS111, DOI 10.1161/STROKEAHA.108.528877; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Green AR, 2003, TRENDS PHARMACOL SCI, V24, P402, DOI 10.1016/S0165-6147(03)00192-5; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; HURN PD, 2002, PHARM CEREBRAL ISCHE, P17; Irwin RW, 2008, ENDOCRINOLOGY, V149, P3167, DOI 10.1210/en.2007-1227; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LENA C, 1993, TRENDS NEUROSCI, V16, P181, DOI 10.1016/0166-2236(93)90150-K; Liu XQ, 2008, J CEREBR BLOOD F MET, V28, P1898, DOI 10.1038/jcbfm.2008.83; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Macleod MR, 2005, J CEREBR BLOOD F MET, V25, P713, DOI 10.1038/sj.jcbfm.9600064; Macrae IM, 2006, BIOCHEM SOC T, V34, P1362, DOI 10.1042/BST0341362; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Maurice T, 2006, PHARMACOL BIOCHEM BE, V84, P581, DOI 10.1016/j.pbb.2006.07.009; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2004, ILAR J, V45, P147, DOI 10.1093/ilar.45.2.147; MURPHY SJ, 2002, J CEREB BLOOD FLOW M, V22, P367; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Prencipe M, 1997, STROKE, V28, P531, DOI 10.1161/01.STR.28.3.531; Quick AM, 2005, FASEB J, V19, P170, DOI 10.1096/fj.04-1901hyp; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Reglodi D, 2003, BRAIN RES BULL, V59, P459, DOI 10.1016/S0361-9230(02)00962-0; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Sacco RL, 1997, STROKE, V28, P1507, DOI 10.1161/01.STR.28.7.1507; Savitz SI, 2008, STROKE, V39, P1389, DOI 10.1161/STROKEAHA.107.504415; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Singh M, 2006, ENDOCRINE, V29, P271, DOI 10.1385/ENDO:29:2:271; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Toung TJ, 2004, J CEREBR BLOOD F MET, V24, P1160, DOI 10.1097/01.WCB.0000135594.13576.D2; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; Turtzo LC, 2008, CEREBROVASC DIS, V26, P462, DOI 10.1159/000155983; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	86	47	49	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	AUG	2009	15	4					324	332		10.1177/1073858409333069			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	479KP	WOS:000268658500008	19359672				2022-02-06	
J	Orsucci, D; Calsolaro, V; Mancuso, M; Siciliano, G				Orsucci, D.; Calsolaro, V.; Mancuso, M.; Siciliano, G.			Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Mitochondria; Neurodegeneration; PARP-1; ROS; Tetracyclines	FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; RAT TEMPORAL CORTEX; MICROGLIAL ACTIVATION; MULTIPLE-SCLEROSIS; HUNTINGTONS-DISEASE; MOUSE MODEL	Tetracyclines are a class of antibiotics which could play a therapeutic role in several neurological disorders. Minocycline, extensively studied in animal models, decreased the size of ischaemic and haemorrhagic infarct. In Parkinson's disease models minocycline protected the nigrostriatal pathway, and in Huntington's disease and motoneuron disease models delayed the progression of disease extending the lifespan. Finally, in human diseases such as stroke and multiple sclerosis tetracyclines seem to play some neuroprotective role. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis, and the suppression of reactive oxygen species production. These mechanisms are involved in the pathogenesis of several neurodegenerative disorders. Several reports showed that minocycline reduced mitochondrial Ca2+ uptake, stabilized mitochondrial membranes, and reduced the release into the cytoplasm of apoptotic factors. Other effects include upregulation of mitochondrial bcl-2 (an antiapoptotic protein), direct scavenging of reactive oxygen species, and inhibition of mitogen activated protein kinases. It is still unclear which of these mechanisms plays the pivotal role in neuroprotective properties of tetracyclines. The anti-apoptotic effect of tetracyclines probably involves the mitochondrion. The major target for tetracyclines in neurodegeneration could lie within the complex network that links mitochondria, oxidative stress, poly (ADP-ribose) polymerase-1 and apoptosis. Here, we review the neuroprotective effects of tetracyclines in animal models and in human disease, and we focus on their possible mechanism(s) of action, with special regard to mitochondrial dysfunction in neurodegeneration.	[Orsucci, D.; Calsolaro, V.; Mancuso, M.; Siciliano, G.] Univ Pisa, Neurol Clin, Dept Neurosci, I-56126 Pisa, Italy		Orsucci, D (corresponding author), Univ Pisa, Neurol Clin, Dept Neurosci, Via Roma 67, I-56126 Pisa, Italy.	d.orsucci@sssup.it	Siciliano, Gabriele/K-7259-2016; Mancuso, Michelangelo/K-4170-2016; Orsucci, Daniele/AAA-7576-2019	Siciliano, Gabriele/0000-0002-6142-2384; Mancuso, Michelangelo/0000-0003-2738-8562; Orsucci, Daniele/0000-0003-4847-7812			Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Bilousova TV, 2009, J MED GENET, V46, P94, DOI 10.1136/jmg.2008.061796; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bonelli RM, 2004, INT CLIN PSYCHOPHARM, V19, P337, DOI 10.1097/00004850-200411000-00004; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Burggraf D, 2007, NEUROBIOL DIS, V25, P506, DOI 10.1016/j.nbd.2006.10.013; Burgos-Ramos E, 2008, NEUROSCIENCE, V154, P1458, DOI 10.1016/j.neuroscience.2008.04.036; Burgos-Ramos E, 2009, LIFE SCI, V84, P205, DOI 10.1016/j.lfs.2008.11.019; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Zhi-You, 2008, Neurosci Bull, V24, P305, DOI 10.1007/s12264-008-0324-y; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Choi Y, 2007, NEUROPSYCHOPHARMACOL, V32, P2393, DOI 10.1038/sj.npp.1301377; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Davies JE, 2005, NAT MED, V11, P672, DOI 10.1038/nm1242; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Duan YT, 2007, J PHYSIOL-LONDON, V585, P741, DOI 10.1113/jphysiol.2007.145409; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; Gieseler A, 2009, BIOCHEM PHARMACOL, V77, P888, DOI 10.1016/j.bcp.2008.11.003; Girgenrath M, 2009, ANN NEUROL, V65, P47, DOI 10.1002/ana.21523; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Haroon MF, 2007, NEUROBIOL DIS, V28, P237, DOI 10.1016/j.nbd.2007.07.021; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; Hu W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004151; Jantzie LL, 2005, J CEREBR BLOOD F MET, V25, P314, DOI 10.1038/sj.jcbfm.9600025; Jiang SX, 2005, J BIOL CHEM, V280, P33811, DOI 10.1074/jbc.M503113200; Jordan J., 2007, Current Drug Delivery, V4, P225; Keilhoff G, 2008, EXP NEUROL, V212, P189, DOI 10.1016/j.expneurol.2008.03.028; Krantic S, 2005, TRENDS NEUROSCI, V28, P670, DOI 10.1016/j.tins.2005.09.011; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; LACKNER LL, 2009, BIOCH BIOPH IN PRESS; Lai Y, 2008, J NEUROCHEM, V104, P1700, DOI 10.1111/j.1471-4159.2007.05114.x; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009; LEE H, NEUROBIOL D IN PRESS; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Luccanini I, 2008, EXP NEUROL, V211, P214, DOI 10.1016/j.expneurol.2008.01.022; Ludolph Albert C, 2007, Amyotroph Lateral Scler, V8, P217, DOI 10.1080/17482960701292837; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Maier K, 2007, NEUROBIOL DIS, V25, P514, DOI 10.1016/j.nbd.2006.10.022; Malm TM, 2008, GLIA, V56, P1767, DOI 10.1002/glia.20726; Mancuso M, 2008, CURR ALZHEIMER RES, V5, P457, DOI 10.2174/156720508785908946; Mancuso M, 2006, J ALZHEIMERS DIS, V10, P59; Mancuso Michelangelo, 2008, Human Genomics, V3, P71; Metz LM, 2004, ANN NEUROL, V55, P756, DOI 10.1002/ana.20111; Minagar A, 2008, ARCH NEUROL-CHICAGO, V65, P199, DOI 10.1001/archneurol.2007.41; Mishra MK, 2008, J NEUROCHEM, V105, P1582, DOI 10.1111/j.1471-4159.2008.05238.x; Miyaoka T, 2008, CNS NEUROL DISORD-DR, V7, P376, DOI 10.2174/187152708786441858; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Murata Y, 2008, STROKE, V39, P3372, DOI 10.1161/STROKEAHA.108.514026; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Nessler S, 2002, ANN NEUROL, V52, P689, DOI 10.1002/ana.10353; *NITS NET PD INV, 2006, NEUROLOGY, V66, P664; Noble W, 2009, FASEB J, V23, P739, DOI 10.1096/fj.08-113795; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Omar A, 2007, NEUROLOGY, V68, P1159, DOI 10.1212/01.wnl.0000258659.21421.b0; Pontieri FE, 2005, NEUROL SCI, V26, P285, DOI 10.1007/s10072-005-0474-x; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rosa A, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-57; Ruggieri M, 2008, J NEUROIMMUNOL, V197, P140, DOI 10.1016/j.jneuroim.2008.04.032; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Seabrook TJ, 2006, GLIA, V53, P776, DOI 10.1002/glia.20338; Shefer G, 2008, J CELL PHYSIOL, V215, P265, DOI 10.1002/jcp.21306; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Viscomi MT, 2008, CEREBELLUM, V7, P401, DOI 10.1007/s12311-008-0042-z; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wu JM, 2009, NEUROL RES, V31, P183, DOI 10.1179/174313209X385680; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zabad RK, 2007, MULT SCLER, V13, P517, DOI 10.1177/1352458506070319; Zhang ZY, 2009, J CELL MOL MED, V13, P341, DOI 10.1111/j.1582-4934.2008.00333.x; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	90	47	50	0	15	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	JUL	2009	8	3					222	231					10	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	474BE	WOS:000268256400006	19601819				2022-02-06	
J	Eckner, JT; Whitacre, RD; Kirsch, NL; Richardson, JK				Eckner, James T.; Whitacre, Ross D.; Kirsch, Ned L.; Richardson, James K.			EVALUATING A CLINICAL MEASURE OF REACTION TIME: AN OBSERVATIONAL STUDY	PERCEPTUAL AND MOTOR SKILLS			English	Article							TRAUMATIC BRAIN-INJURY; TASK; CONVERSATIONS	The present study was an initial evaluation into the reliability and validity of a novel clinical measure of reaction time that consists of a vertical cylinder that is released and caught as quickly as possible. 65 healthy adults performed clinical and Computerized reaction time tasks (RT(clin) and RT(comp)) under simple and dual-task conditions. RT(clin) demonstrated excellent test-retest and interrater reliabilities and was significantly correlated with the criterion standard RT(comp). RT(clin) increased with increasing age and when tested under dual-task conditions. These preliminary results suggest that RT(clin) is a reliable and valid measure of reaction time.	[Eckner, James T.; Whitacre, Ross D.; Kirsch, Ned L.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA		Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 100, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu					ALM H, 1995, ACCIDENT ANAL PREV, V27, P707, DOI 10.1016/0001-4575(95)00026-V; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Der G, 2006, PSYCHOL AGING, V21, P62, DOI 10.1037/0882-7974.21.1.62; Irwin M, 2000, PERCEPT MOTOR SKILL, V90, P1130, DOI 10.2466/PMS.90.3.1130-1134; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Strayer DL, 2004, HUM FACTORS, V46, P640, DOI 10.1518/hfes.46.4.640.56806	7	47	47	1	5	AMMONS SCIENTIFIC, LTD	MISSOULA	PO BOX 9229, MISSOULA, MT 59807-9229 USA	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	JUN	2009	108	3					717	720		10.2466/PMS.108.3.717-720			4	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	479XO	WOS:000268695700007	19725308				2022-02-06	
J	Shandro, JR; Rivara, FP; Wang, J; Jurkovich, GJ; Nathens, AB; MacKenzie, EJ				Shandro, Jamie R.; Rivara, Frederick P.; Wang, Jin; Jurkovich, Gregory J.; Nathens, Avery B.; MacKenzie, Ellen J.			Alcohol and Risk of Mortality in Patients With Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Alcohol; Traumatic brain injury; Intoxication	GLASGOW COMA SCALE; ETHANOL INTOXICATION; MULTIPLE IMPUTATION; MISSING DATA; SEVERITY; ABUSE; SCORE; ASSOCIATION; OUTCOMES; LEVEL	Background: Laboratory and clinical studies demonstrate inconsistent findings on the effect of alcohol on traumatic brain injury (TBI) outcome. The purpose of this study is to use a comprehensive trauma database to determine whether blood alcohol concentration (BAC) is associated with mortality in patients with TBI. Methods. Design: Cohort study. Setting: Eighteen trauma centers and 51 non-trauma centers in the United States. Patients: A total of 1,529 patients aged 18 years to 84 years of age admitted to hospital with TBI between July 2001 and November 2002. Exposure: BAC assessed in the index hospital emergency department. Outcome: Mortality in-hospital, 90 and 365 days after injury. Results. After adjusting for confounding variables, there was no significant difference for in-hospital, 90-day, and 365-day mortality by BAC. Conclusions: When fully adjusted for injury severity, alcohol intoxication is not associated with significantly lower mortality after TBI. The trend toward lower mortality at higher BACs prompts questions about the complex interaction of alcohol and TBI, and warrants further investigation of the possible protective effect of alcohol.	[Shandro, Jamie R.; Rivara, Frederick P.; Wang, Jin; Jurkovich, Gregory J.] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Nathens, Avery B.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Nathens, Avery B.] Univ Toronto, Toronto, ON, Canada; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Dept Hlth Policy & Management, Baltimore, MD USA		Shandro, JR (corresponding author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359702, Seattle, WA 98104 USA.	jshandro@u.washington.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01/AG20361] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR316840] Funding Source: Medline		Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; *ASS ADV AUT MED C, 1989, ABBR INJ SCAL 1998 R; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dischinger PC, 2001, J TRAUMA, V51, P877, DOI 10.1097/00005373-200111000-00009; Gentilello LM, 1999, J TRAUMA, V47, P1131, DOI 10.1097/00005373-199912000-00027; Golan JD, 2007, J TRAUMA, V63, P365, DOI 10.1097/TA.0b013e31811ec178; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KLEIN T, 1998, MULTIPLE IMPUTATION; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Raghunathan T.E., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186; Raghunathan TE, 2004, ANNU REV PUBL HEALTH, V25, P99, DOI 10.1146/annurev.publhealth.25.102802.124410; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; Rootman DB, 2007, J TRAUMA, V63, P1370, DOI 10.1097/TA.0b013e31815b837a; Rootman DB, 2007, J TRAUMA, V62, P755, DOI 10.1097/TA.0b013e318031aa7f; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Rubin D.B., 1987, MULTIPLE IMPUTATION; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Soderstrom CA, 2001, J TRAUMA, V51, P557, DOI 10.1097/00005373-200109000-00024; Sperry JL, 2006, J TRAUMA, V61, P1305, DOI 10.1097/01.ta.0000240113.13552.96; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Subramanian R., 2002, TRANSITIONING MULTIP; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Wacholder S, 1996, EPIDEMIOLOGY, V7, P144, DOI 10.1097/00001648-199603000-00007; Waller PF, 2003, ALCOHOL CLIN EXP RES, V27, P695, DOI 10.1097/01.ALC.0000062758.18918.7C; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461	43	47	49	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1584	1590		10.1097/TA.0b013e318182af96			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	457PN	WOS:000266944500011	19509618				2022-02-06	
J	Makdissi, M; Ugoni, A; Darby, D; Brukner, P				Makdissi, Michael; Ugoni, Antony; Darby, David; Brukner, Peter			A Prospective Study of Postconcussive Outcomes After Return to Play in Australian Football	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain trauma; concussion; Australian football	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; AGREEMENT STATEMENT; 2ND-IMPACT SYNDROME; HEAD-INJURY; CONCUSSION; SPORT; SEQUELAE; RISK	Background: Decisions regarding safe return to play after concussion in sport remain difficult. Objective: To determine whether a concussed player returned to play using an individual clinical management strategy is at risk of impaired performance or increased risk of injury or concussion. Study Design: Cohort study; Level of evidence, 3. Methods: All elite Australian football players were followed for 4 seasons. Players were recruited into the study after sustaining a concussive injury. Outcome measures included performance statistics (disposals per hour match-time), injury rates, and recurrence of concussion on return to play. A subset of players had brief screening cognitive tests performed at baseline and after their concussion. Noninjured players matched for team, position, age, and size were chosen as controls. Results: A total of 199 concussive injuries were observed in 158 players. Sixty-one concussive injuries were excluded from analysis because of incomplete data (45 players) or presence of concurrent injury (16 players). Of the 138 concussive injuries assessed, 127 players returned to play without missing a game (92%). The remainder of concussed players returned to play after missing a single game (8%). Overall, there was no significant decline in disposal rates in concussed players on return to competition. Furthermore, there were no significant differences in injury rates between concussed and team, position, and game-matched controls. In the subset of players who had completed screening cognitive tests, all had returned to their individual baseline performance before being returned to play. Conclusion: Return to play decisions based on individual clinical assessment of recovery allows safe and appropriate return to sport following a concussive injury.	[Makdissi, Michael; Ugoni, Antony; Brukner, Peter] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Darby, David] CogState Ltd, Melbourne, Vic, Australia		Makdissi, M (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	makdissi@unimelb.edu.au		makdissi, michael/0000-0003-0334-7133; McCrory, Paul/0000-0003-4850-0568			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, VIn: Vol 12, P386; EFRON B, 1993, INTRO BOOTSTRAP MONO; Fleiss J.L., 1981, STAT METHODS RATES P; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Norton K I, 1999, J Sci Med Sport, V2, P389, DOI 10.1016/S1440-2440(99)80011-5; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; RUTHERFORD WH, 1977, LANCET, V1, P1; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; WESCHLER D, 1981, WESCHLER ADULT INTEL	27	47	47	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2009	37	5					877	883		10.1177/0363546508328118			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	440GU	WOS:000265689600002	19204366				2022-02-06	
J	Paintlia, AS; Paintlia, MK; Singh, I; Skoff, RB; Singh, AK				Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Skoff, Robert B.; Singh, Avtar K.			Combination Therapy of Lovastatin and Rolipram Provides Neuroprotection and Promotes Neurorepair in Inflammatory Demyelination Model of Multiple Sclerosis	GLIA			English	Article						combination therapy; EAE/MS; demyelination; inflammation	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; COA REDUCTASE INHIBITOR; TRAUMATIC BRAIN-INJURY; GLATIRAMER ACETATE; SPINAL-CORD; PHOSPHODIESTERASE INHIBITOR; AXONAL REGENERATION; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH	Drug combination therapies for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS) are gaining momentum over monotherapy. Over the past decade, both in vitro and in vivo studies established that statins (HMG-CoA reductase inhibitors) and rolipram (phosphodiesterase-4 inhibitor; blocks the degradation of intracellular cyclic AMP) can prevent the progression of MS in affected individuals via different mechanisms of action. In this study, we evaluated the effectiveness of lovastatin (LOV) and rolipram (RLP) in combination therapy to promote neurorepair in an inflammatory CNS demyelination model of MS, experimental autoimmune encephalomyelitis (EAE). Combination treatment with suboptimal doses of these drugs in an established case of EAE (clinical disease score >= 2.0) significantly attenuated the infiltration of inflammatory cells and protected myelin sheath and axonal integrity in the CNS. It was accompanied with elevated level of cyclic AMP and activation of its associated protein kinase A. Interestingly, combination treatment with these drugs impeded neurodegeneration and promoted neurorepair in established EAE animals (clinical disease score >= 3.5) as verified by quantitative real-time polymerase chain reaction, immunohistochemistry and electron microscopic analyses. These effects of combination therapy were minimal and/or absent with either drug alone in these settings. Together, these data suggest that combination therapy with LOV and RLP has the potential to provide neuroprotection and promote neurorepair in MS, and may have uses in other related CNS demyelinating diseases. (C) 2008 Wiley-Liss, Inc.	[Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Singh, Avtar K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Skoff, Robert B.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA		Singh, AK (corresponding author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA.	paintlia@musc.edu; singhi@musc.edu		Skoff, Robert/0000-0001-5049-9020; Paintlia, Ajaib/0000-0003-4525-5333	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, C06-RR018823]; Merck CompanyMerck & Company; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018823, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034741, R01NS038236, R37NS022576, R01NS037766, R01NS040144, R01NS022576] Funding Source: NIH RePORTER	NIH; Grant number: NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, C06-RR018823; Grant sponsor; Merck & Company.	Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Arbizu T, 2000, ACTA NEUROL SCAND, V102, P209, DOI 10.1034/j.1600-0404.2000.102004209.x; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Barnett FH, 2004, NEUROSURGERY, V55, P468, DOI 10.1227/00006123-200408000-00083; Besser M, 1999, J IMMUNOL, V162, P6303; Bielekova B, 2000, J IMMUNOL, V164, P1117, DOI 10.4049/jimmunol.164.2.1117; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Bolton S, 2006, EXP NEUROL, V202, P36, DOI 10.1016/j.expneurol.2006.05.009; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Cui Qi, 2004, Anatomical Science International, V79, P209, DOI 10.1111/j.1447-073x.2004.00089.x; Dhib-Jalbut S, 2003, PHARMACOL THERAPEUT, V98, P245, DOI 10.1016/S0163-7258(03)00036-6; Dhib-Jalbut S, 2002, MULT SCLER, V8, P485, DOI 10.1191/1352458502ms862oa; Domeniconi M, 2005, J NEUROL SCI, V233, P43, DOI 10.1016/j.jns.2005.03.023; Echeverria V, 2005, EUR J NEUROSCI, V22, P2199, DOI 10.1111/j.1460-9568.2005.04427.x; ENG LF, 1989, GLIA, V2, P308, DOI 10.1002/glia.440020504; Eralinna JP, 1996, J NEUROIMMUNOL, V66, P103, DOI 10.1016/0165-5728(96)00031-8; GENAIN CP, 1995, P NATL ACAD SCI USA, V92, P3601, DOI 10.1073/pnas.92.8.3601; Giuliani F, 2005, J NEUROIMMUNOL, V165, P83, DOI 10.1016/j.jneuroim.2005.04.020; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Hanson MG, 1998, J NEUROSCI, V18, P7361; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Jeffery DR, 2005, MULT SCLER, V11, P296, DOI 10.1191/1352458505ms1154oa; Johnson-Anuna LN, 2007, J NEUROCHEM, V101, P77, DOI 10.1111/j.1471-4159.2006.04375.x; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Kirstein M, 2002, CELL MOL LIFE SCI, V59, P1787, DOI 10.1007/PL00012506; KRAUSE W, 1988, XENOBIOTICA, V18, P561, DOI 10.3109/00498258809041693; Kwak B, 2001, SWISS MED WKLY, V131, P41; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; LUBLIN FD, 1985, SPRINGER SEMIN IMMUN, V8, P197; Luccanini I, 2008, EXP NEUROL, V211, P214, DOI 10.1016/j.expneurol.2008.01.022; Markovic-Plese S, 2001, Curr Neurol Neurosci Rep, V1, P257, DOI 10.1007/s11910-001-0028-4; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; Miron VE, 2007, GLIA, V55, P130, DOI 10.1002/glia.20441; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; O'Garra A, 1997, CURR OPIN IMMUNOL, V9, P872, DOI 10.1016/S0952-7915(97)80192-6; Paintlia AS, 2006, AM J PATHOL, V169, P1012, DOI 10.2353/ajpath.2006.051309; Paintlia AS, 2008, MOL PHARMACOL, V73, P1381, DOI 10.1124/mol.107.044230; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Paintlia AS, 2004, J NEUROSCI RES, V77, P63, DOI 10.1002/jnr.20130; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Paul F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001928; PENDER MP, 1989, J NEUROIMMUNOL, V25, P125, DOI 10.1016/0165-5728(89)90130-6; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Pooler AM, 2006, J NEUROCHEM, V97, P716, DOI 10.1111/j.1471-4159.2006.03763.x; Ransohoff RM, 2002, TRENDS IMMUNOL, V23, P512, DOI 10.1016/S1471-4906(02)02321-9; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Sanchez AJ, 2005, J NEUROIMMUNOL, V168, P13, DOI 10.1016/j.jneuroim.2005.03.024; Schulz JG, 2004, J NEUROCHEM, V89, P24, DOI 10.1046/j.1471-4159.2003.02305.x; SOMMER N, 1995, NAT MED, V1, P244, DOI 10.1038/nm0395-244; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Sorensen PS, 2003, J NEUROL SCI, V206, P123, DOI 10.1016/S0022-510X(02)00343-X; Stankoff B, 2002, J NEUROSCI, V22, P9221; Stuve O, 2006, J CLIN INVEST, V116, P1037, DOI 10.1172/JCI25805; TORPHY TJ, 1991, THORAX, V46, P512, DOI 10.1136/thx.46.7.512; Tullman Mark J, 2005, Curr Neurol Neurosci Rep, V5, P245, DOI 10.1007/s11910-005-0053-9; Vanderlocht J, 2006, J NEUROIMMUNOL, V177, P189, DOI 10.1016/j.jneuroim.2006.04.012; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Ytterberg C, 2007, ACTA NEUROL SCAND, V116, P96, DOI 10.1111/j.1600-0404.2007.00801.x; Zhang B, 2002, NEUROPHARMACOLOGY, V42, P262, DOI 10.1016/S0028-3908(01)00174-5	65	47	48	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN 15	2009	57	2					182	193		10.1002/glia.20745			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	383OA	WOS:000261681700005	18720408	Bronze, Green Accepted			2022-02-06	
J	Attix, DK; Story, TJ; Chelune, GJ; Ball, JD; Stutts, ML; Hart, RP; Barth, JT				Attix, Deborah K.; Story, Tyler J.; Chelune, Gordon J.; Ball, J. D.; Stutts, Michael L.; Hart, Robert P.; Barth, Jeffrey T.			THE PREDICTION OF CHANGE: NORMATIVE NEUROPSYCHOLOGICAL TRAJECTORIES	CLINICAL NEUROPSYCHOLOGIST			English	Article						Change; Trajectory; Normal change	POSTOPERATIVE COGNITIVE DYSFUNCTION; ANTERIOR TEMPORAL LOBECTOMY; RELIABLE CHANGE INDEXES; TRAUMATIC BRAIN-INJURY; WAIS-III/WMS-III; ALTERNATE FORMS; AGES 56; MEASURING RECOVERY; NORMAL INDIVIDUALS; TEST-PERFORMANCE	While the application of normative standards is vital to the practice of clinical neuropsychology, data regarding normative change remains scarce despite the frequency of serial assessments. Based on 285 normal individuals, we provide co-normed baseline data with demographic adjustments and test-retest standardized regression based (SRB) models for three time points for several measures. These models delineate normal, expected change across time, and yield standardized z-scores that are comparable across tests. Using a new approach, performance on any previous trial was accounted for in the subsequent models of change, yielding serial normative formulas that model change trajectories rather than simple change from point to point. These equations provide indices of deviation from expected baseline and change for use in clinical or research settings.	[Attix, Deborah K.; Story, Tyler J.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; [Attix, Deborah K.; Story, Tyler J.] Duke Univ, Med Ctr, Div Med Psychol, Durham, NC 27710 USA; [Chelune, Gordon J.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Ball, J. D.; Stutts, Michael L.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA; [Hart, Robert P.] Virginia Commonwealth Univ, Richmond, VA USA; [Barth, Jeffrey T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA		Attix, DK (corresponding author), Duke Univ, Med Ctr, Div Neurol, Box 3333, Durham, NC 27710 USA.	koltai@duke.edu	Ball, J.D./T-9440-2019	Koltai, Deborah/0000-0002-4254-9902			Andrew MJ, 2001, J CARDIOTHOR VASC AN, V15, P9, DOI 10.1053/jcan.2001.20210; Apa Pesidential Task Force, 2006, AM PSYCHOL, V61, P271, DOI 10.1037/0003-066X.61.4.271; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Benton A., 1978, MULTILINGUAL APHASIA; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Bruggemans EF, 1999, ANN THORAC SURG, V67, P297; Busch R.M., 2006, GERIATRIC NEUROPSYCH, P133; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Chelune GJ, 2003, PREDICTION IN FORENSIC AND NEUROPSYCHOLOGY, P123; Chelune GJ, 2002, NEUROPSYCHOLOGY, V16, P422, DOI 10.1037//0894-4105.16.3.422; CHELUNE GJ, 2007, J INT NEUROPSYCH SOC, V13, P107; CHELUNE GJ, 2006, ALZHEIMERS DEMENT, V2, P374; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2002, ANN THORAC SURG, V73, P2005, DOI 10.1016/S0003-4975(01)03375-6; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Duff K, 2005, ARCH CLIN NEUROPSYCH, V20, P281, DOI 10.1016/j.acn.2004.07.007; Farag E, 2006, ANESTH ANALG, V103, P633, DOI 10.1213/01.ane.0000228870.48028.b5; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Golden CJ, 1978, STROOP COLOR WORD TE; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R.K., 2003, CLIN INTERPRETATION; Heaton R. K., 2004, REVISED COMPREHENSIV; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; Hermann BP, 1999, NEUROPSYCHOLOGY, V13, P3, DOI 10.1037/0894-4105.13.1.3; Hinton-Bayre A, 2005, PSYCHOL ASSESSMENT, V17, P237, DOI 10.1037/1040-3590.17.2.237; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Ivnik R.J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; Ivnik RJ, 1997, J CLIN EXP NEUROPSYC, V19, P676, DOI 10.1080/01688639708403753; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Ivnik RJ, 1999, NEUROPSYCHOLOGY, V13, P121, DOI 10.1037/0894-4105.13.1.121; Ivnik RJ, 2001, CLIN NEUROPSYCHOL, V15, P114, DOI 10.1076/clin.15.1.114.1904; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KlOve H, 1963, MED CLIN N AM; Kneebone AC, 1998, ANN THORAC SURG, V65, P1320, DOI 10.1016/S0003-4975(98)00158-1; Knight RG, 2007, ARCH CLIN NEUROPSYCH, V22, P513, DOI 10.1016/j.acn.2007.03.005; Kurl, 1992, CLIN NEUROPSYCHOL, V6, P49, DOI [10.1080/13854049208401879, DOI 10.1080/13854049208401879]; Kurland, 1992, CLIN NEUROPSYCHOL, V6, P31, DOI [10.1080/13854049208401878, DOI 10.1080/13854049208401878]; Ledbetter M., 2003, CLIN INTERPRETATION, P211, DOI 10.1016/B978-012703570-3/50011-0; Lehrner J, 2005, J CLIN EXP NEUROPSYC, V27, P859, DOI 10.1080/13803390490919083; Lewis M, 2004, NEUROSCI BIOBEHAV R, V28, P433, DOI 10.1016/j.neubiorev.2004.05.002; Lewis MS, 2006, ACTA ANAESTH SCAND, V50, P50, DOI 10.1111/j.1399-6576.2006.00893.x; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LINEWEAVER TT, 2003, CLIN INTERPRETATION, P303; Lucas JA, 1998, J CLIN EXP NEUROPSYC, V20, P536, DOI 10.1076/jcen.20.4.536.1469; Martin R, 2002, EPILEPSIA, V43, P1551, DOI 10.1046/j.1528-1157.2002.23602.x; Maze M, 2007, ANESTHESIOLOGY, V106, P418, DOI 10.1097/00000542-200703000-00003; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; MCSWEENY AJ, 1993, CLIN NEUROPSYCHOL, V7, P460; Meyers JE., 1995, REY COMPLEX FIGURE T; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; MOE C, 2004, FINAL REPORT N UNPUB; Murkin JM, 2001, J CARDIOTHOR VASC AN, V15, P1, DOI 10.1053/jcan.2001.2028; Powell D. H., 1993, MICROCOG ASSESSMENT; Randolph C., 1998, REPEATABLE BATTERY A; Raymond PD, 2006, CLIN NEUROPSYCHOL, V20, P261, DOI 10.1080/13854040590947416; Ruff R. M, 1996, RUFF FIGURAL FLUENCY; Salthouse TA, 2007, NEUROPSYCHOLOGY, V21, P401, DOI 10.1037/0894-4105.21.4.401; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Sawrie SM, 1999, J GERONTOL B-PSYCHOL, V54, pP116, DOI 10.1093/geronb/54B.2.P116; Schmidt M., 1996, REY AUDITORY VERBAL; SCHMIDT R, 1994, NEUROLOGY, V44, P964, DOI 10.1212/WNL.44.5.964; Seidenberg M, 1998, NEUROPSYCHOLOGY, V12, P303, DOI 10.1037/0894-4105.12.2.303; Smith A., 1982, SYMBOL DIGIT MODALIT; Stern R.A., 2001, NEUROPSYCHOLOGICAL A; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tangalos, 1992, CLIN NEUROPSYCHOL, V6, P83, DOI [10.1080/13854049208401880, DOI 10.1080/13854049208401880]; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Tombaugh TN, 2005, ARCH CLIN NEUROPSYCH, V20, P485, DOI 10.1016/j.acn.2004.11.004; Turf Elizabeth, 1999, Virginia Journal of Science, V50, P299; *US ARM, 1944, ARM IND TEST BATT; Vanderploeg RD, 2000, CLIN NEUROPSYCHOL, V14, P318, DOI 10.1076/1385-4046(200008)14:3;1-P;FT318; WAIS-III-WMS-III-WIAT-II Writer (Version 1.0), 2002, WAIS 3 WMS 3 WIAT 2; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME	81	47	47	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	1					21	38		10.1080/13854040801945078			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	399LR	WOS:000262801900003	18720272	Green Submitted			2022-02-06	
J	Lane-Brown, AT; Tate, RL				Lane-Brown, A. T.; Tate, R. L.			Measuring apathy after traumatic brain injury: Psychometric properties of the Apathy Evaluation Scale and the Frontal Systems Behavior Scale	BRAIN INJURY			English	Article						Apathy; traumatic brain injury; measurement	VERBAL-LEARNING TEST; DEPRESSION; RELIABILITY; PREVALENCE; VALIDITY; STRESS; STRATEGIES; FATIGUE; DASS	Objectives: To evaluate the reliability and validity of the Apathy Evaluation Scale (AES) and Apathy sub-scale of the Frontal Systems Behavior Scale (FrSBe-A) for people with traumatic brain injury (TBI). To identify an optimal cut-off score indicating presence of apathy according to the AES. Methods and procedures: A sample of 34 participants with severe TBI currently residing in the community underwent neuropsychological and psychosocial assessment to evaluate reliability, discriminant, convergent and divergent validity. Receiver Operating Characteristic (ROC) curve analysis was undertaken to identify an optimal cut-off score on the AES. Results: AES and FrSBe-A correlated moderately with each other (r=0.71). Both AES and FrSBe-A have good internal consistency and discriminant validity with measures of depression and fatigue. Support for hypothesized correlations with similar and dissimilar constructs was not shown. ROC analysis identified a cut-off score of 37 or higher on AES indicated presence of apathy. Conclusions: AES and FrSBe-A are reliable and valid measures of apathy following TBI. It is suggested that the two scales measure slightly differing aspects of the apathy construct, with AES addressing emotional-affective aspects of apathy more than FrSBe-A, which focuses more heavily on cognitive and behavioral elements of goal-directed behavior.	[Lane-Brown, A. T.; Tate, R. L.] Univ Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia; [Lane-Brown, A. T.; Tate, R. L.] Royal Rehabil Ctr, Sydney, NSW, Australia		Lane-Brown, AT (corresponding author), Univ Sydney, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	amandal@med.usyd.edu.au			University of SydneyUniversity of Sydney; Rehabilitation Studies Unit, University of SydneyUniversity of Sydney; Northern Medical Research Foundation; Northern Clinical School, University of SydneyUniversity of Sydney; Australian GovernmentAustralian GovernmentCGIAR	This study was supported by the University of Sydney and funding has been provided by the Rehabilitation Studies Unit, University of Sydney; the Northern Medical Research Foundation and the Northern Clinical School, University of Sydney; and the Australian Government through an Australian Postgraduate Award. The authors thank Regina Schultz for assistance in data collection and for her support.	Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Betz N., 2000, PSYCHOL RES HDB GUID, P239; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Cahn-Weiner DA, 2002, NEUROPSY NEUROPSY BE, V15, P79, DOI 10.1097/01.WNN.0000012908.05122.F4; Cohen MJ, 2000, ARCH CLIN NEUROPSYCH, V15, P267, DOI 10.1016/S0887-6177(99)00017-7; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; CROSSEN JR, 1994, J CLIN EXP NEUROPSYC, V16, P190, DOI 10.1080/01688639408402630; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DELANEY RC, 1992, ARCH CLIN NEUROPSYCH, V7, P523, DOI 10.1016/0887-6177(92)90142-A; Delis DC., 2001, DELIS KAPLAN EXECUTI; Diehl M, 1996, PSYCHOL AGING, V11, P127, DOI 10.1037/0882-7974.11.1.127; Duffy J, 2006, GUIDE NEUROPSYCHIATR, P1; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Finset A, 2000, BRAIN INJURY, V14, P887; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Gray J.M, 1994, CLIN REHABIL, V8, P188, DOI [10.1177/026921559400800302, DOI 10.1177/026921559400800302, DOI 10.1080/09602010902949207]; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kuzis G, 1999, NEUROLOGY, V52, P1403, DOI 10.1212/WNL.52.7.1403; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Marin, 1996, Semin Clin Neuropsychiatry, V1, P304; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1993, J AFFECT DISORDERS, V28, P7, DOI 10.1016/0165-0327(93)90072-R; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Matud MP, 2004, PERS INDIV DIFFER, V37, P1401, DOI 10.1016/j.paid.2004.01.010; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Murphy KJ., 2000, NEUROPSYCHOLOGY EMOT, P340; Norton LE, 2001, AM J GERIAT PSYCHIAT, V9, P41; Rey A., 1964, EXAMEN CLIN PSYCHOL; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; Starkstein SE, 2006, J NEUROL NEUROSUR PS, V77, P8, DOI 10.1136/jnnp.2005.069575; Starkstein SE, 2000, INT PSYCHOGERIATR, V12, P135, DOI 10.1017/S1041610200006918; Starkstein SE, 2006, EUR J PSYCHIAT, V20, P96, DOI 10.4321/s0213-61632006000200005; Tate R.L., 2009, BRAIN IMPAIR, V10, P228; Thurstone L. L, 1962, PRIMARY MENTAL ABILI	45	47	49	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	13-14					999	1007		10.3109/02699050903379347			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	529YR	WOS:000272556000002	19891539				2022-02-06	
J	Li, W; Dai, SS; An, JH; Xiong, RP; Li, PY; Chen, X; Zhao, Y; Liu, P; Wang, H; Zhu, PF; Chen, JF; Zhou, YG				Li, Wei; Dai, Shuangshuang; An, Janhong; Xiong, Renping; Li, Ping; Chen, Xingyun; Zhao, Yan; Liu, Ping; Wang, Hua; Zhu, Peifang; Chen, Jiangfan; Zhou, Yuanguo			Genetic inactivation of adenosine A(2A) receptors attenuates acute traumatic brain injury in the mouse cortical impact model	EXPERIMENTAL NEUROLOGY			English	Article						Adenosine A(2A) receptor; Traumatic brain injury; Cortical impact injury, glutamate; Inflammatory cytokines	MARROW-DERIVED CELLS; INDUCED EXCITOTOXICITY; PARKINSONS-DISEASE; HEAD-INJURY; PROTECTION; NEUROPROTECTION; RAT; ACTIVATION; ISCHEMIA; BLOCKADE	The inactivation of the A(2A) receptor (A(2A)R) has been shown to neuroprotect against brain injury in several animal models of neurological disorders including stroke and Parkinson's disease. However, despite marked elevation of adenosine level, the role of the A(2A) in traumatic brain injury (TBI) remains unclear. In the present study, we investigated the effects of genetic inactivation of A(2A)Rs in the acute stage. The A(2A)R knock-out (KO) mice and their wild-type (WT) littermates Were subjected to cortical impact injury by a dropping weight. The control group Was only craniotomized withoyt TBI. At 24 h post-TBI, the neurological deficit scores of the KO mice were significantly lower than that of WT littermates. Consistent with the behavioral changes, the brain water contents as well as histological changes and the TUNEL-positive cells of the injured cortex of the KO mice were significantly lower than that of WT littermates. Furthermore, the glutamate level in the cerebral spinal fluid (CSF) of the KO mice was also significantly lower than that of WT littermates. In addition, we found that at 12 h post-TBI the mRNA and protein levels of TNF-alpha and IL-1 beta were higher in the KO mice than that in the WT littermates. However, at 24 h post-TBI, the level of TNF-alpha and IL-1 beta continually increased in the WT mice but largely declined in the KO mice. These results suggest that the genetic inactivation of A(2A)R protects against TBI, which is mainly associated with the Suppression of glutamate level. (C) 2008 Elsevier Inc. All rights reserved.	[Chen, Jiangfan] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Li, Wei; Dai, Shuangshuang; An, Janhong; Xiong, Renping; Li, Ping; Chen, Xingyun; Zhao, Yan; Liu, Ping; Wang, Hua; Zhu, Peifang; Zhou, Yuanguo] Third Mil Med Univ, Inst Surg Res, Ctr Mol Biol, State Key Lab Trauma Burn & Combined Injury, Chongqing, Peoples R China; [Li, Wei; Dai, Shuangshuang; An, Janhong; Xiong, Renping; Li, Ping; Chen, Xingyun; Zhao, Yan; Liu, Ping; Wang, Hua; Zhu, Peifang; Zhou, Yuanguo] Third Mil Med Univ, Daping Hosp, Chongqing, Peoples R China		Chen, JF (corresponding author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St,C329, Boston, MA 02118 USA.	chenjf@bu.edu; ygzhou@cta.cq.cn	Li, ping/J-6507-2019	Chen, Xingyun/0000-0001-7699-4425	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30328015, 30671918]	We thank Mr. Nan Yang for handling the animals. We gratefully acknowledge the proofreading and correcting suggestion for the manuscript of Ms. Eileen Crehan. This work was supported by the grants from National Natural Science Foundation of China (No. 30328015 and No. 30671918).	BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Blum D, 2003, LANCET NEUROL, V2, P366, DOI 10.1016/S1474-4422(03)00411-3; BOLY DL, 1996, ARTHRITIS RHEUM, V39, P923; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cerqueira MD, 2004, AM J CARDIOL, V94, p33D; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Chen JF, 2007, PROG NEUROBIOL, V83, P310, DOI 10.1016/j.pneurobio.2007.09.002; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; ENGLER RL, 1991, CIRCULATION, V84, P951, DOI 10.1161/01.CIR.84.2.951; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiser SM, 2002, J THORAC CARDIOV SUR, V124, P973, DOI 10.1067/mtc.2002.124886; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Fredholm BB, 2001, DRUG DEVELOP RES, V52, P274, DOI 10.1002/ddr.1124; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Fredholm Bertil B., 2003, Neurology, V61, pS5; GOLDBERG MP, 1988, NEUROSCI LETT, V89, P323, DOI 10.1016/0304-3940(88)90547-2; Huang QY, 2006, J NEUROSCI, V26, P11371, DOI 10.1523/JNEUROSCI.1907-06.2006; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Maddock HL, 2001, J AUTON PHARMACOL, V21, P263, DOI 10.1046/j.1365-2680.2001.00238.x; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Rosin DL, 1998, J COMP NEUROL, V401, P163; Schwarzschild Michael A., 2003, Neurology, V61, pS55; Silva CG, 2007, NEUROBIOL DIS, V27, P182, DOI 10.1016/j.nbd.2007.04.018; Sitkovsky MV, 2005, TRENDS IMMUNOL, V26, P299, DOI 10.1016/j.it.2005.04.004; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Yu LQ, 2004, BRAIN RES, V1000, P156, DOI 10.1016/j.brainres.2003.11.072	40	47	50	2	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2009	215	1					69	76		10.1016/j.expneurol.2008.09.012			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	394QM	WOS:000262462300009	18938161				2022-02-06	
J	Maillard-Wermelinger, A; Yeates, KO; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M				Maillard-Wermelinger, Anne; Yeates, Keith Owen; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha			Mild traumatic brain injury and executive functions in school-aged children	DEVELOPMENTAL NEUROREHABILITATION			English	Article						traumatic barin injury; executive functions; children; concussion	WORKING-MEMORY; HEAD-INJURY; YOUNG-CHILDREN; SHORT-TERM; OUTCOMES; VALIDITY; BEHAVIOR	Objective: This study sought to examine the effects of mild traumatic brain injury (TBI) on executive functions in school-aged children. Participants and method: The prospective, longitudinal study involved 8-15 year old children, 186 with mild TBI and 99 with mild orthopaedic injuries (OI). They were administered the Stockings of Cambridge and Spatial Working Memory sub-tests from the Cambridge Neuropsychological Testing Automated Battery (CANTAB) similar to 10 days, 3 months and 12 months post-injury. Parents completed the Behavior Rating Inventory of Executive Functions (BRIEF) on each occasion, with ratings at the initial assessment intended to assess pre-morbid functioning retrospectively. Results: On the CANTAB, the groups did not differ on the Stockings of Cambridge and the mild TBI group unexpectedly performed better than the OI group on Spatial Working Memory. On the BRIEF, children with mild TBI showed a marginally significant trend toward more problems than the OI group on the Metacognition Index composite. The only BRIEF sub-scale on which they demonstrated significantly more problems was Organization of Materials. The presence of intracranial abnormalities on MRI was associated with more problems on the BRIEF Organization of Materials sub-scale at 3 months, but other findings were not consistent with hypothesized effects of TBI severity. The CANTAB sub-tests were significant predictors of later ratings on the BRIEF, but accounted for modest variance. Discussion: Children with mild TBI show limited evidence of deficits in executive functions, either cognitively or behaviourally, irrespective of injury characteristics. Cognitive tests of executive functions are modest predictors of ratings of executive functions in everyday life, for children both with and without mild TBI.	[Maillard-Wermelinger, Anne] Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Univ Hosp Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Maillard, Anne/N-4779-2017; Yeates, Keith/AAJ-4223-2020	Maillard, Anne/0000-0002-4811-0693; Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	This work was supported by grants HD44099 and HD39834 from the National Institutes of Health to the second author (KOY).	*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Benson D.F., 1986, FRONTAL LOBES; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; *CAMBR COGN, 2005, CAMBR NEUR TEST AUT; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gioia G.A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Luciana M, 2000, FDN FUTURE FUNCTIONA; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Wechsler D., 1999, ABBREVIATED SCALE IN; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, pXVII; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	43	47	47	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	5					330	341		10.3109/17518420903087251			12	Clinical Neurology; Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FS	WOS:000207788500008	20477562	Green Accepted			2022-02-06	
J	Tokutomi, T; Miyagi, T; Takeuchi, Y; Karukaya, T; Katsuki, H; Shigemori, M				Tokutomi, Takashi; Miyagi, Tomoya; Takeuchi, Yasuharu; Karukaya, Takashi; Katsuki, Hiroshi; Shigemori, Minoru			Effect of 35 degrees C Hypothermia on Intracranial Pressure and Clinical Outcome in Patients With Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Hypothermia; Intracranial hypertension; Intracranial pressure; Traumatic brain injury	SEVERE HEAD-INJURY; SERUM POTASSIUM CONCENTRATION; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; PLATELET-FUNCTION; PROTEIN-LEVELS; DEEP HYPOTHERMIA; FOLLOW-UP	Background. From 1994, we have used therapeutic hypothermia in patients with severe traumatic brain injury (Glasgow Coma Scale scores of 5 or less). In 2000, we altered the target temperature to 35 degrees C from the former 33 degrees C, as our findings suggested that cooling to 35 degrees C is sufficient to control intracranial hypertension, and that hypothermia below 35 degrees C may predispose patients to persistent cumulative oxygen debt. We attempted to clarify whether 35 degrees C hypothermia has the same effect as 33 degrees C hypothermia in reducing intracranial hypertension and whether it is associated with fewer complications and improved outcomes. Methods. we compared intracranial pressure (ICP) and biochemical parameters in the 30 patients treated with 35 degrees C hypothermia (January 2000 to June 2005) with those in the 31 patients treated with 33 degrees C hypothermia (July 1994 to December 1999). Results: Patient characteristics were similar in the two groups. The mean temperature during hypothermia was 35.1 +/- 0.7 degrees C in the 35 degrees C hypothermia group and 33.4 +/- 0.8 degrees C in the 33 degrees C hypothermia group. Mean ICP was controlled tinder 20 mm Hg during hypothermia in both the 35 degrees C hypothermia and 33 degrees C hypothermia groups. The incidence of intracranial hypertension and low cerebral perfusion pressure did not differ between the two groups. The 35 degrees C hypothermic patients exhibited a significant improvement in the decline of serum potassium concentrations during hypothermia and in the increment of C-reactive protein after rewarming. The mortality rate and the incidence of systemic complications tended to be lower in the 35 degrees C group. Conclusions. Cooling patients to 35 degrees C is safe and the ICP reduction effects of 35 degrees C hypothermia are similar to those of 33 degrees C hypothermia.	[Tokutomi, Takashi; Miyagi, Tomoya; Takeuchi, Yasuharu; Karukaya, Takashi; Katsuki, Hiroshi; Shigemori, Minoru] Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan		Tokutomi, T (corresponding author), Kurume Univ, Sch Med, Dept Neurosurg, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	toku@med.kurume-u.ac.jp					Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Birdi I, 1997, J THORAC CARDIOV SUR, V114, P475, DOI 10.1016/S0022-5223(97)70196-X; BOELHOUWER RU, 1987, CRIT CARE MED, V15, P310, DOI 10.1097/00003246-198704000-00006; BOLDT J, 1993, ANN THORAC SURG, V55, P652, DOI 10.1016/0003-4975(93)90269-N; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BULLOCK R, 1995, GUIDELINE MANAGEMENT; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cortiana M, 1986, J Neurosurg Sci, V30, P133; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HESSEL EA, 1980, J SURG RES, V28, P23, DOI 10.1016/0022-4804(80)90078-5; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOHNSTON TD, 1994, J TRAUMA, V37, P413, DOI 10.1097/00005373-199409000-00014; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kettner SC, 2003, ANESTH ANALG, V96, P1772, DOI 10.1213/01.ANE.0000062520.65192.C9; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lobo SMA, 2003, CHEST, V123, P2043, DOI 10.1378/chest.123.6.2043; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Matsui T, 2006, J NEUROSURG ANESTH, V18, P189, DOI 10.1097/01.ana.0000188639.39844.f6; MAZER CD, 1995, ANN THORAC SURG, V59, P1481, DOI 10.1016/0003-4975(95)00153-C; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Miller PR, 1999, J TRAUMA, V47, P1004, DOI 10.1097/00005373-199912000-00003; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NAYLOR CD, 1994, LANCET, V343, P559; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Polderman KH, 2002, INTENS CARE MED, V28, P1, DOI 10.1007/s00134-001-1154-9; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Reny JL, 2002, CRIT CARE MED, V30, P529, DOI 10.1097/00003246-200203000-00006; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; SHEFFIELD CW, 1994, ACTA ANAESTH SCAND, V38, P201, DOI 10.1111/j.1399-6576.1994.tb03873.x; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SPRUNG J, 1992, ACTA ANAESTH SCAND, V36, P825, DOI 10.1111/j.1399-6576.1992.tb03572.x; SPRUNG J, 1991, CRIT CARE MED, V19, P1545, DOI 10.1097/00003246-199112000-00018; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tveita T, 1998, J APPL PHYSIOL, V85, P2135, DOI 10.1152/jappl.1998.85.6.2135; VALERI CR, 1992, J THORAC CARDIOV SUR, V104, P108; VECHT CHJ, 1973, J NEUROL NEUROSUR PS, V38, P567; VILLALOBOS TJ, 1958, J CLIN INVEST, V37, P1, DOI 10.1172/JCI103576; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	62	47	50	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					166	173		10.1097/TA.0b013e318157dbec			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	395SJ	WOS:000262543500022	19131820				2022-02-06	
J	Wells, R; Minnes, P; Phillips, M				Wells, Rebecca; Minnes, Patricia; Phillips, Marjory			Predicting social and functional outcomes for individuals sustaining paediatric traumatic brain injury	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Traumatic brain injury; paediatrics; clinicians; quality of life; severity; outcomes	MILD HEAD-INJURY; GLASGOW COMA SCALE; CHILDREN; ADOLESCENTS; REHABILITATION; PERFORMANCE; BEHAVIOR; FAMILY; PARTICIPATION; MEMORY	Objective: To determine the efficacy of models employing the classification of severity of injury, based on either GCS scores or clinical findings using standardized test scores for Occupational Therapy, Physiotherapy and Psychology in predicting outcomes associated with paediatric traumatic brain injury (TBI). Method: Medical records were reviewed to obtain GCS scores and standardized tests used in the clinically based classification of severity of injury for 30 individuals who sustained a paediatric TBI and were patients of a brain injury treatment programme. Interviews were conducted with parents to obtain current data on social participation, cognitive functioning and environmental factors. Results: Three variables emerged as significant predictors of outcome: age at injury, clinical ratings of injury severity and environmental factors. Conclusion: Findings offer preliminary support for the idea that a combination of factors, including age at injury, clinical expertise and the environment, provide the best estimate of long-term outcome.	[Wells, Rebecca] Univ Waterloo, Waterloo, ON N2L 3G1, Canada; [Minnes, Patricia] Queens Univ, Kingston, ON, Canada; [Phillips, Marjory] Integra Fdn, Toronto, ON, Canada		Wells, R (corresponding author), Univ Waterloo, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	remwells@uwaterloo.ca					ALVAREZ A, ONT ASS DEV DIS C 20; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Apa Pesidential Task Force, 2006, AM PSYCHOL, V61, P271, DOI 10.1037/0003-066X.61.4.271; Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; BEAULIEU CL, 2002, SURG CLIN N AM, V82, P1; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; BEERY K, 1997, BEERY DEV TEST VISUA; BIJUR PE, 1990, PEDIATRICS, V86, P337; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUININKS RH, 1978, BRUININKSOSERETKSY T; BUTTERBAUGH G, 1993, ASSESSING ADOLESCENT, P293; CASEY R, 1986, PEDIATRICS, V78, P497; Cassidy LD, 2003, J PEDIATR SURG, V38, P482, DOI 10.1053/jpsu.2003.50084; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Cohen M.J., 1997, CHILDRENS MEMORY SCA; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Gil AM, 2003, J SCHOOL PSYCHOL, V41, P337, DOI 10.1016/S0022-4405(03)00085-2; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; GUPTA A, 1996, INDIAN J CLIN PSYCHO, V23, P170; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Horowitz I, 1983, Int Rehabil Med, V5, P32; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEAHY LF, 1987, J CLIN EXP NEUROPSYC, V9, P55; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Minnes P, 2001, NEUROREHABILITATION, V16, P3; Nelson LD, 1997, PSYCHOL ASSESSMENT, V9, P368; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Solish A., 2003, J DEV DISABILITIES, V10, P115; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; VILELA T, 5 INTERURBAN BRAIN I; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	52	47	47	0	20	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	1					12	23		10.1080/17518420902773109			12	Clinical Neurology; Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FJ	WOS:000207787600003	19283530				2022-02-06	
J	Liepert, J				Liepert, Joachim			Pharmacotherapy in restorative neurology	CURRENT OPINION IN NEUROLOGY			English	Article						aphasia; drug; motor recovery; rehabilitation; stroke; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; STROKE PATIENTS; MOTOR-PERFORMANCE; COGNITIVE FUNCTION; RECOVERY; AMPHETAMINE; AMANTADINE; PHYSIOTHERAPY	Purpose of review To evaluate current evidence that recovery after stroke or traumatic brain injury (TBI) can be enhanced by drugs that modulate neurotransmission in the brain. Recent findings Small studies performed in chronic stroke patients have indicated that single doses of reboxetine or citalopram improved different aspects of motor functions and that long-lasting application of donepezil reduced aphasic symptoms. Methylphenidate shortened intensive care treatment periods in TBI patients and amantadine improved arousal and cognition. Recent studies in stroke patients did not find beneficial effects of levodopa or dextroamphetamine. Summary Evidence of drug-related improvement of functions after stroke or TBI is still limited, either because of small and highly selected patient groups or due to conflicting results. Currently, most convincing evidence exists for piracetam for improvement of poststroke aphasia and amantadine for enhancing arousal and cognition after TBI. Some evidence can be found for improvement of stroke-related motor deficits by levodopa, enhanced speed of mental processing in TBI by methylphenidate and improvement of poststroke aphasia by dextroamphetamine. Large randomized controlled trials are needed to evaluate the effectiveness of serotonin reuptake inhibitors or noradrenaline reuptake inhibitors on motor functions.	Kliniken Schmieder, Dept Neurorehabil, D-78476 Allensbach, Germany		Liepert, J (corresponding author), Kliniken Schmieder, Dept Neurorehabil, Zum Tafelholz 8, D-78476 Allensbach, Germany.	j.liepert@kliniken-schmieder.de					Berthier ML, 2006, NEUROLOGY, V67, P1687, DOI 10.1212/01.wnl.0000242626.69666.e2; Broeks JG, 1999, DISABIL REHABIL, V21, P357; Chandler M C, 1988, Brain Inj, V2, P309; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; ENDERBY P, 1994, CLIN NEUROPHARMACOL, V17, P320, DOI 10.1097/00002826-199408000-00003; Floel A, 2005, NEUROLOGY, V65, P472, DOI 10.1212/01.wnl.0000172340.56307.5e; Gladstone DJ, 2006, STROKE, V37, P179, DOI 10.1161/01.STR.0000195169.42447.78; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Greener J, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858, DOI 10.1002/14651858.CD000424]; Hankey GJ, 2007, NEUROLOGY, V68, P1583, DOI 10.1212/01.wnl.0000260967.77422.97; Huber W, 1997, ARCH PHYS MED REHAB, V78, P245, DOI 10.1016/S0003-9993(97)90028-9; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Kessler J, 2000, STROKE, V31, P2112, DOI 10.1161/01.STR.31.9.2112; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Laska AC, 2005, CEREBROVASC DIS, V19, P125, DOI 10.1159/000083256; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; Martinsson L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002090.pub2; Martinsson L, 2003, CEREBROVASC DIS, V16, P338, DOI 10.1159/000072555; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Moein H, 2006, CLIN NEUROL NEUROSUR, V108, P539, DOI 10.1016/j.clineuro.2005.09.003; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Pariente J, 2001, ANN NEUROL, V50, P718, DOI 10.1002/ana.1257; Platz T, 2005, RESTOR NEUROL NEUROS, V23, P271; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Plewnia C, 2004, NEUROLOGY, V62, P2124, DOI 10.1212/01.WNL.0000128041.92710.17; Resterneyer C, 2007, RESTOR NEUROL NEUROS, V25, P143; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Schneider WN, 1999, BRAIN INJURY, V13, P863; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Sonde L, 2007, ACTA NEUROL SCAND, V115, P55, DOI 10.1111/j.1600-0404.2006.00728.x; Sonde L, 2001, CEREBROVASC DIS, V12, P253, DOI 10.1159/000047712; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Treig T, 2003, CLIN REHABIL, V17, P590, DOI 10.1191/0269215503cr653oa; Walker-Batson D, 2001, STROKE, V32, P2093, DOI 10.1161/hs0901.095720; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whiting E, 2007, J INT NEUROPSYCH SOC, V13, P972, DOI 10.1017/S1355617707071317; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zittel S, 2008, NEUROREHAB NEURAL RE, V22, P311, DOI 10.1177/1545968307312173; Zittel S, 2007, J NEUROL, V254, P197, DOI 10.1007/s00415-006-0326-5	44	47	59	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2008	21	6					639	643		10.1097/WCO.0b013e32831897a3			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379HK	WOS:000261387100004	18989105				2022-02-06	
J	Esposito, E; Genovese, T; Caminiti, R; Bramanti, P; Meli, R; Cuzzocrea, S				Esposito, Emanuela; Genovese, Tiziana; Caminiti, Rocco; Bramanti, Placido; Meli, Rosaria; Cuzzocrea, Salvatore			Melatonin regulates matrix metalloproteinases after traumatic experimental spinal cord injury	JOURNAL OF PINEAL RESEARCH			English	Article						free radicals; inflammation; metalloproteinase; spinal cord damage; spinal cord injury	BLOOD-BRAIN-BARRIER; FOCAL CEREBRAL-ISCHEMIA; INDUCED GASTRIC-ULCER; NECROSIS-FACTOR-ALPHA; TNF-ALPHA; INFLAMMATORY RESPONSE; FUNCTIONAL RECOVERY; RADICAL SCAVENGER; BASEMENT-MEMBRANE; OXIDATIVE DAMAGE	The matrix metalloproteinases (MMPs) are important enzymes that regulate developmental processes, maintain normal physiology in adulthood and have reparative roles at specific stages after an insult to the nervous system. MMPs, particularly MMP-9/gelatinase B, promote early inflammation and barrier disruption after spinal cord injury (SCI). Recently, we have reported that the pineal secretory product melatonin exerts important anti-inflammatory effects in an experimental model of SCI induced by the application of vascular clips (force of 24 g) to the dura after a four-level T5-T8 laminectomy. However, no reports are available on the relationship between the activity of MMPs and melatonin's anti-inflammatory effects. The aim of the present study was to evaluate whether the protective effect of melatonin observed in SCI is related to the regulation of MMP-9 and MMP-2 in mice. Biochemical and zymographic methods were used to analyze MMP-9 and -2 expression and activities in spinal cord tissue from SCI-treated mice at 24 hr after the trauma. Our studies reveal that melatonin reduced SCI and lipid peroxidation in spinal cord at 24 hr after SCI. Melatonin also diminished proMMP-9 and -2 activities that were induced in the spinal cord tissues at 24 hr after SCI. The reduced activities of MMP-9 and -2 were associated with depressed expression of TNF-alpha. We propose that melatonin's ability to reduce SCI in mice is also related to a reduction in MMP-9 and MMP-2 activity and expression.	[Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; [Esposito, Emanuela; Meli, Rosaria] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; [Esposito, Emanuela; Genovese, Tiziana; Bramanti, Placido; Cuzzocrea, Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Caminiti, Rocco] Univ Messina, Sch Med, Dept Human Pathol, I-98100 Messina, Italy		Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Policlin Univ Via C, I-98100 Messina, Italy.	salvator@unime.it	Bramanti, Placido/K-5117-2016	Meli, Rosaria/0000-0002-6246-6813; GENOVESE, Tiziana/0000-0002-3335-7327			Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bilici D, 2002, DIGEST DIS SCI, V47, P856, DOI 10.1023/A:1014764705864; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Castaneda FE, 2005, GASTROENTEROLOGY, V129, P1991, DOI 10.1053/j.gastro.2005.09.017; Chen HY, 2006, J PINEAL RES, V41, P175, DOI 10.1111/j.1600-079X.2006.00351.x; Crocker SJ, 2006, AM J PATHOL, V169, P2104, DOI 10.2353/ajpath.2006.060626; Cuzzocrea S, 1999, FASEB J, V13, P1930, DOI 10.1096/fasebj.13.14.1930; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076; de Castro R, 2000, NEUROREPORT, V11, P3551, DOI 10.1097/00001756-200011090-00029; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; Duchossoy Y, 2001, CLIN CHEM LAB MED, V39, P362, DOI 10.1515/CCLM.2001.057; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; English JL, 2006, J BIOL CHEM, V281, P10337, DOI 10.1074/jbc.M512009200; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Ganguly K, 2005, J PINEAL RES, V39, P307, DOI 10.1111/j.1600-079X.2005.00250.x; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2005, J NEUROIMMUNOL, V166, P55, DOI 10.1016/j.jneuroim.2005.05.009; Genovese T, 2008, SHOCK, V29, P32, DOI 10.1097/shk.0b013e318059053a; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Hardeland R, 2007, J PINEAL RES, V43, P382, DOI 10.1111/j.1600-079X.2007.00489.x; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLTZ A, 1989, ACTA NEUROL SCAND, V79, P460, DOI 10.1111/j.1600-0404.1989.tb03815.x; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Jiang XF, 2001, NEUROSCI LETT, V305, P41, DOI 10.1016/S0304-3940(01)01800-6; Kalkan E, 2007, SPINAL CORD, V45, P722, DOI 10.1038/sj.sc.3102035; LaFleur M, 1996, J EXP MED, V184, P2311; Lempinen M, 2000, EUR SURG RES, V32, P169, DOI 10.1159/000008759; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Leon J, 2006, J NEUROCHEM, V98, P2023, DOI 10.1111/j.1471-4159.2006.04029.x; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu JB, 2004, CHINESE MED J-PEKING, V117, P571; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Manda K, 2007, J PINEAL RES, V42, P386, DOI 10.1111/j.1600-079X.2007.00432.x; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Mullane K, 1989, Prog Clin Biol Res, V301, P39; Noble LJ, 2002, J NEUROSCI, V22, P7526; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Onuki J, 2005, J PINEAL RES, V38, P107, DOI 10.1111/j.1600-079X.2004.00180.x; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; Rosen J, 2006, J PINEAL RES, V41, P374, DOI 10.1111/j.1600-079X.2006.00379.x; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; ROSENBERG GA, 1994, LAB INVEST, V71, P417; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SHAFITZAGARDO B, 1993, INT J DEV NEUROSCI, V11, P189, DOI 10.1016/0736-5748(93)90078-R; Shapiro SD, 2000, J CELL SCI 19, V113, P3355; Sharma HS, 2003, ACT NEUR S, V86, P407; Shubayev VI, 2000, BRAIN RES, V855, P83, DOI 10.1016/S0006-8993(99)02321-5; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Swarnakar S, 2007, J PINEAL RES, V43, P56, DOI 10.1111/j.1600-079X.2007.00443.x; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Vaillant C, 1999, J NEUROSCI, V19, P4994; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	77	47	49	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2008	45	2					149	156		10.1111/j.1600-079X.2008.00569.x			8	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	336QT	WOS:000258380400005	18298463				2022-02-06	
J	Solomon, GS; Haase, RF				Solomon, Gary S.; Haase, Richard F.			Biopsychosocial characteristics and neurocognitive test performance in National Football League players: An initial assessment	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						neurocognitive testing; sports concussion; mild traumatic brain injury; ImPACT; professional football athletes	SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; CONCUSSION SYMPTOMS; SPORTS; VALIDATION; HISTORY; SCORES; IMPACT	The use of neurocognitive testing in the assessment of professional athletes sustaining sports-related concussions has become widespread over the past decade. Baseline neurocognitive testing is now a requirement for athletes in the National Football League (NFL). We present preliminary normative data on a computer based neurocognitive test (Immediate Post Concussion Assessment and Cognitive Testing: ImPACT) for 159 NFL athletes. Also included are summary data on basic biopsychosocial characteristics, including medical, psychiatric, chemical dependency, concussion, learning disability/attention deficit disorder, and symptom variables, and the relevance of each to baseline neurocognitive test scores. (C) 2008 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Solomon, Gary S.] Psychiat Consultants, Nashville, TN 37203 USA; [Haase, Richard F.] SUNY Albany, Albany, NY 12222 USA		Solomon, GS (corresponding author), Psychiat Consultants, 310 25th Ave N,Suite 309, Nashville, TN 37203 USA.	Gssolomon1@yahoo.com	Solomon, Gary/K-9011-2019				American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Barth JT, 1989, MILD HEAD INJURY, P257; Belsley DA., 1980, REGRESSION DIAGNOSTI, DOI 10.1002/0471725153; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Casson IR, 2008, NEUROSURGERY, V62, P204, DOI 10.1227/01.NEU.0000311079.65895.3E; *CDCP, 2008, NUMB RAT TRAUM BRAIN; CERNICH A, 2007, ARCH CLIN NEUROPSYCH, V22, P91; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; COHEN J, 2003, MULTIPLE CORRELATION; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; DUCKRO PN, 1989, CEPHALALGIA, V9, P199, DOI 10.1046/j.1468-2982.1989.0903199.x; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; IVERSON GL, 2005, J CLIN EXP NEUROPSYC, V27, P1; Johnson RA., 1998, APPL MULTIVARIATE ST, V4; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; KRYST S, 1994, HEADACHE, V34, P344, DOI 10.1111/j.1526-4610.1994.hed3406344.x; LOVELL M, 2008, COMMUNICATION   0428; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Lovell M., 2002, IMPACT CONCUSSION MA; Lovell M. R., 2004, TRAUMATIC BRAIN INJU; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; MYERS RH, 2002, GEN LINER MODELS; National Institute of Mental Health, 2008, STAT; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen D., 2006, AM J SPORTS MED, V34, P1; Wilens E, 2004, JAMA-J AM MED ASSOC, V292, P619, DOI 10.1001/jama.292.5.619	45	47	47	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2008	23	5					563	577		10.1016/j.acn.2008.05.008			15	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	351HN	WOS:000259415400009	18614333	Bronze			2022-02-06	
J	Stein, DM; Dutton, RP; Hess, JR; Scalea, TM				Stein, Deborah M.; Dutton, Richard P.; Hess, John R.; Scalea, Thomas M.			Low-dose recombinant factor VIIa for trauma patients with coagulopathy	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article; Proceedings Paper	65th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	SEP 28, 2006	New Orleans, LA	Eastern Assoc Surg Trauma		trauma; coagulopathy; traumatic brain injury; thromboembolic complications	ACTIVATED FACTOR-VII; LIFE-THREATENING HEMORRHAGE; JEHOVAH-WITNESS PATIENTS; COAGULATION-FACTOR VIIA; CENTRAL-NERVOUS-SYSTEM; SEVERE THROMBOCYTOPENIA; PROTHROMBIN TIME; RAPID CORRECTION; WARFARIN; INJURY	Introduction: Coagulopathy in injured patients is common and is generally treated with fresh frozen plasma (FFP). Response can be variable, thus complete correction may take hours and require large volumes of fluids. High-dose recombinant factor Vila (FVIIa, Novoseven, Novo Nordisk, Bagsvaerd, Denmark) has been used off-label to treat severe coagulopathy following trauma. Expense has limited use. Recently, we began administering low dose FVIIa (1.2 mg) to patients with mild to moderate coagulopathy after trauma, hypothesising that it would be effective and safe. Patients and methods: We retrospectively reviewed consecutive patients who received a low dose of 1.2 mg of FVIIa over a 2-year period. Factor Vila is administered after approval by a gatekeeper at the discretion of the treating physician. Demographics, injury and laboratory data were abstracted as were indications for use, source of coagulopathy, effectiveness, and complications. A two-tailed paired t-test was used to determine significant changes in coagulation parameters and blood product utilisation. Results: Eighty-one patients received 84 low doses of FVIIa. The mean age of the patients was 51 (+/- 22) with a mean ISS of 29 (+/- 11). Seventy-three per cent were mate and 67% had a traumatic brain injury (TBI) as their primary injury. The aetiology of the coagulopathy in the study population included; TBI (40%), warfarin use (22%), and cirrhosis (13%). Mean prothrombin time (PT) felt from 17.0 s (+/- 3.2) to 10.6 s (+/- 1.4) (p < 0.0001). All patients had a good clinical response with no bleeding complications. Utilisation of packed red blood cells and fresh frozen plasma were significantly Less in the 24 h after FVIIa administration as compared to the 24 h prior. Subsequent thromboembolic events were observed in 12 of the 81 patients (15%) and included; cerebrovascular accident (CVA) (6), mesenteric thrombosis (2), myocardial. infarction (MI) (1), pulmonary embolism/deep venous thrombosis (PE/DVT) (2), and atrial. thrombus (1). Only four of these events were thought to be related to the FVIIa administration, with two of the four contributing to a lethal outcome. Conclusions: Low dose FVIIa rapidly and effectively treats mild to moderate coagulopathy following injury. This low dose (1.2 mg) FVIIa is the smallest available unit dose. It costs approximately the same as 8 units of plasma and may be cost-effective in patients who require high volume factor administration. Low dose FVIIa may be effective in coagulopathic trauma patients who are not in shock but require rapid normalisation of clotting function. (C) 2008 Elsevier Ltd. All rights reserved.	[Stein, Deborah M.] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Div Crit Care,Program Trauma,Sch Med, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Div Crit Care,Program Trauma,Sch Med, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu; rdutton@umaryland.edu; jhess@umm.edu; tscalea@umm.edu	Hess, John R./K-4001-2013	Hess, John R./0000-0001-8596-4420; Stein, Deborah/0000-0003-3683-3963			Barnes C, 2005, TRANSFUSION MED, V15, P145, DOI 10.1111/j.0958-7578.2005.00564.x; Bernstein DE, 1997, GASTROENTEROLOGY, V113, P1930, DOI 10.1016/S0016-5085(97)70013-1; Berntorp E, 2000, BLOOD COAGUL FIBRIN, V11, pS113, DOI 10.1097/00001721-200004001-00021; Billio A, 2002, BLOOD, V100, p83B; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Culic S, 2003, BRIT J HAEMATOL, V120, P909, DOI 10.1046/j.1365-2141.2003.04151_2.x; Viana JD, 2006, TRANSPL P, V38, P818, DOI 10.1016/j.transproceed.2006.01.045; Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Dutton RP, 2003, J CLIN ANESTH, V15, P184, DOI 10.1016/S0952-8180(03)00034-5; Eikelboom JW, 2003, BLOOD COAGUL FIBRIN, V14, P713, DOI 10.1097/00001721-200312000-00004; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Geeraedts LMG, 2005, INJURY, V36, P495, DOI 10.1016/j.injury.2004.08.001; Gerotziafas GT, 2002, AM J HEMATOL, V69, P219, DOI 10.1002/ajh.10056; Haan J, 2005, AM SURGEON, V71, P414; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hedner U, 1990, Blood Coagul Fibrinolysis, V1, P307, DOI 10.1097/00001721-199008000-00009; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jabbour N, 2005, AM SURGEON, V71, P175; Jeffers L, 2002, GASTROENTEROLOGY, V123, P118, DOI 10.1053/gast.2002.34164; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Khan AZ, 2005, AM J SURG, V189, P331, DOI 10.1016/j.amjsurg.2004.11.021; Klamroth R, 2002, BLOOD, V100, p77B; Levi M, 2005, CRIT CARE MED, V33, P883, DOI 10.1097/01.CCM.0000159087.85970.38; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Lodge JPA, 2005, ANESTHESIOLOGY, V102, P269, DOI 10.1097/00000542-200502000-00006; LODGE P, 2003, J HEPATOL, V36, P177; Martin S, 2002, PROF ENG, V15, P20; Martinowitz U, 2001, J TRAUMA, V51, P431, DOI 10.1097/00005373-200109000-00002; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mindikoglu AL, 2003, DIGEST DIS SCI, V48, P1130, DOI 10.1023/A:1023777031589; Mindikoglu AL, 2003, CHEST, V123, P956, DOI 10.1378/chest.123.3.956; Minniti C, 2001, BLOOD, V98, p62B; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; O'Connell NM, 2003, TRANSFUSION, V43, P1711, DOI 10.1046/j.0041-1132.2003.00577.x; Pardo M, 2003, WORLD J SURG, V27, P758, DOI 10.1007/s00268-003-6922-y; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Pathak A, 2005, Neurol India, V53, P178; Powner DJ, 2005, NEUROSURGERY, V57, P823, DOI 10.1227/01.NEU.0000179915.74429.b2; Romagnoli S, 2006, ANESTH ANALG, V102, P1320, DOI 10.1213/01.ane.0000209023.96418.e5; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Surudo T, 2003, TRANSPL P, V35, P2323, DOI 10.1016/S0041-1345(03)00759-0; Tanaka KA, 2003, ANESTHESIOLOGY, V98, P1513, DOI 10.1097/00000542-200306000-00034; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Waddington DP, 2002, BRIT J HAEMATOL, V119, P286, DOI 10.1046/j.1365-2141.2002.381113.x; Watson HG, 2002, BLOOD, V100, p78B	51	47	48	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2008	39	9					1054	1061		10.1016/j.injury.2008.03.032			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	352TM	WOS:000259520300013	18656871				2022-02-06	
J	Fan, Y; Kong, H; Shi, XR; Sun, XL; Ding, JH; Wu, J; Hu, G				Fan, Yi; Kong, Hui; Shi, Xueru; Sun, Xiulan; Ding, Jianhua; Wu, Jie; Hu, Gang			Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrah.ydropyrindine and astrocytic modulation	NEUROBIOLOGY OF AGING			English	Article						aquaporin 4; Parkinson's disease; astrocyte; neurodegeneration; neuroprotection	GDNF GENE-EXPRESSION; NEUROTROPHIC FACTOR; MESSENGER-RNA; PARKINSONS-DISEASE; WATER TRANSPORT; REACTIVE ASTROCYTES; SUBSTANTIA-NIGRA; DOPAMINE NEURONS; GLIAL-CELLS; BRAIN	Aquaporm 4 (AQP4) is a predominant water channel protein in mammalian brains, which is localized in the astrocyte plasma membrane. AQP4 has gained much attraction due to its involvement in the physiopathology of cerebral disorders including stroke, tumor, infection, hydrocephalus, epilepsy, and traumatic brain injury. But there is almost no evidence whether abnormal AQP4 levels are associated with degenerative diseases, such as Parkinson's disease (PD). In our studies, we established PD animal models by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to test the hypothesis that abnormal AQP4 expression is involved in the pathophysiology of this disease. We show that mutant mice lacking AQP4 were significantly more prone to MPTP-induced neurotoxicity than their wild-type littermates. Furthermore, after administration of MPTP, astroglial proliferation and GDNF protein synthesis were inhibited by AQP4 deficiency. This study demonstrates that AQP4 is important in the MPTP neurotoxic process and indicates that the therapeutic strategy targeted to astrocytic modulation with AQP4 may offer a great potential for the development of new treatment for PD. 0 2007 Elsevier Inc. All rights reserved.	[Fan, Yi; Kong, Hui; Shi, Xueru; Sun, Xiulan; Ding, Jianhua; Hu, Gang] Nanjing Med Univ, Neuropharmacol Lab, Dept Anat Histol & Pharmacol, Jiangsu 210029, Peoples R China; [Wu, Jie] St Josephs Hosp, Neurophysiol Lab, Barrow Neurol Inst, Phoenix, AZ 85013 USA		Hu, G (corresponding author), Nanjing Med Univ, Neuropharmacol Lab, Dept Anat Histol & Pharmacol, 140 Hanzhong Rd, Jiangsu 210029, Peoples R China.	ghu@njmu.edu.cn	Wu, Jie/E-8906-2010; Fan, Yi/Q-9252-2018; Sun, Xiu-Lan/AAW-5376-2021; Fan, Yi/AAQ-1874-2021	Fan, Yi/0000-0003-1783-3220; Sun, Xiu-Lan/0000-0001-8741-3833; Fan, Yi/0000-0003-1783-3220			Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Airavaara M, 2004, EUR J NEUROSCI, V20, P2336, DOI 10.1111/j.1460-9568.2004.03700.x; Asai S, 1996, NEUROREPORT, V7, P1092, DOI 10.1097/00001756-199604100-00028; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; Burke RE, 1998, J NEUROCHEM, V71, P517; Carey JR, 2002, ARCH PHYS MED REHAB, V83, P972, DOI 10.1053/apmr.2002.33026; Chen LW, 2005, CURR DRUG TARGETS, V6, P821, DOI 10.2174/138945005774574506; Dolman D, 2005, J NEUROCHEM, V93, P825, DOI 10.1111/j.1471-4159.2005.03111.x; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Drukarch B, 1998, FREE RADICAL BIO MED, V25, P217, DOI 10.1016/S0891-5849(98)00050-1; DUWU C, 2002, J NEUROVIROL, V8, P551; Eberhardt O, 2000, J NEUROSCI, V20, P9126; FAHN S, 2000, MERRITTS NEUROLOGY, P679; FAHN S, 1989, HDB EXPT PHARM, P386; Fan Y, 2005, J NEUROSCI RES, V82, P458, DOI 10.1002/jnr.20664; Fernagut PO, 2004, EXP NEUROL, V185, P47, DOI 10.1016/j.expneurol.2003.09.014; FORNO LS, 1992, PROG BRAIN RES, V94, P429; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; GRUNDL W, 1991, ACTA MED HUNG, V48, P127; Hatakeyama S, 1996, TOXICOL LETT, V89, P231, DOI 10.1016/S0378-4274(96)03825-8; HO A, 1995, NEUROREPORT, V6, P1454, DOI 10.1097/00001756-199507100-00023; HUMPEL C, 1994, NEUROSCIENCE, V59, P791, DOI 10.1016/0306-4522(94)90284-4; Hunot S, 1996, J NEURAL TRANSM, V103, P1043, DOI 10.1007/BF01291789; Inoue T, 1999, BRAIN RES, V826, P306, DOI 10.1016/S0006-8993(99)01254-8; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Liberatore GT, 1999, NAT MED, V5, P1403; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Mena MA, 2002, MOL NEUROBIOL, V25, P245, DOI 10.1385/MN:25:3:245; MUDO G, 1993, NEUROSCIENCE, V57, P901, DOI 10.1016/0306-4522(93)90036-F; MUTHANE U, 1994, EXP NEUROL, V126, P195, DOI 10.1006/exnr.1994.1058; Nakajima K, 2001, BRAIN RES, V916, P76, DOI 10.1016/S0006-8993(01)02866-9; Nielsen S, 1997, J NEUROSCI, V17, P171; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Przedborski S, 2001, J NEUROCHEM, V76, P1265, DOI 10.1046/j.1471-4159.2001.00183.x; RANSOM BR, 1987, NEUROSCI LETT, V75, P323, DOI 10.1016/0304-3940(87)90543-X; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Smeyne M, 2005, GLIA, V52, P144, DOI 10.1002/glia.20233; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; Teismann P, 2004, CELL TISSUE RES, V318, P149, DOI 10.1007/s00441-004-0944-0; Teismann P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332; Tokumine J, 2003, ACT NEUR S, V86, P231; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wang S, 2005, NEUROPHARMACOLOGY, V48, P984, DOI 10.1016/j.neuropharm.2005.01.009; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; WEST RW, 1993, CARCINOGENESIS, V14, P285, DOI 10.1093/carcin/14.2.285	55	47	50	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	AUG	2008	29	8					1226	1236		10.1016/j.neurobiolaging.2007.02.015			11	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	321KF	WOS:000257302900013	17353068				2022-02-06	
J	Bedell, G; Coster, W				Bedell, Gary; Coster, Wendy			Measuring participation of school-aged children with traumatic brain injuries: Considerations and approaches	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; International Classification of Functioning; Disability and Health; outcomes; pediatric rehabilitation; social integration	INPATIENT REHABILITATION; SOCIAL-PARTICIPATION; SHORT-TERM; DISABILITIES; ADOLESCENTS; OUTCOMES; YOUTH; LIFE	This article discusses key issues to consider and selected approaches for assessing participation of school-aged children with traumatic brain injury. Approaches discussed include measures that explicitly assess participation, subsections from other measures that implicitly assess participation, and tailored methods that assess outcomes linked to person-centered goals or programs and interventions that address participation. Key considerations discussed include what should be measured, how should it be measured, what is the level of focus (individual, program, or population), and how does or could the selected approach address stakeholders' "information goals," that is, what stakeholders want and need to know?.	[Bedell, Gary] Tufts Univ, Dept Occupat Therapy, Medford, MA 02155 USA; [Coster, Wendy] Boston Univ, Dept Occupat Therapy, Boston, MA 02215 USA; [Coster, Wendy] Boston Univ, Rehabil Counseling Sargent Coll, Boston, MA 02215 USA		Bedell, G (corresponding author), Tufts Univ, Dept Occupat Therapy, 26 Winthrop St,Room 211, Medford, MA 02155 USA.	gary.bedell@tufts.edu		Bedell, Gary/0000-0002-9555-8861			Achenbach TM, 1991, MANUAL CHILD BEHAV C; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Bedell GM, 2005, AM J OCCUP THER, V59, P273, DOI 10.5014/ajot.59.3.273; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Bedell GM, 2002, BRAIN INJURY, V16, P659, DOI 10.1080/02699050210128924; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; BROWN M, 1987, ARCH PHYS MED REHAB, V68, P828; Coster W., 1998, SCH FUNCTION ASSESSM; Coster W, 2008, DISABIL REHABIL, V30, P639, DOI 10.1080/09638280701400375; Cusick A, 2006, Pediatr Rehabil, V9, P149, DOI 10.1080/13638490500235581; Dunst CJ, 2002, PSYCHOL REP, V91, P875, DOI 10.2466/pr0.2002.91.3.875; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; Hwang JL, 2002, OTJR-OCCUP PART HEAL, V22, P48, DOI 10.1177/153944920202200202; King G, 2004, CHILDRENS ASSESSMENT; King GA, 2007, CHILD CARE HLTH DEV, V33, P28, DOI 10.1111/j.1365-2214.2006.00613.x; King Gillian, 2003, Physical & Occupational Therapy in Pediatrics, V23, P63, DOI 10.1300/J006v23n01_05; Landgraf JM, 1996, CHILD HLTH QUESTIONN; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Law M, 2002, AM J OCCUP THER, V56, P640, DOI 10.5014/ajot.56.6.640; Mahoney JL, 2003, J EDUC PSYCHOL, V95, P409, DOI 10.1037/0022-0663.95.2.409; Mancini MC, 2000, ARCH PHYS MED REHAB, V81, P339, DOI 10.1016/S0003-9993(00)90081-9; McConachie H, 2006, DISABIL REHABIL, V28, P1157, DOI 10.1080/09638280500534507; NOREAU L, 2005, MEASURE LIFIE HABITS; Noreau L, 2007, DEV MED CHILD NEUROL, V49, P666, DOI 10.1111/j.1469-8749.2007.00666.x; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Sakzewski L, 2007, DEV MED CHILD NEUROL, V49, P232, DOI 10.1111/j.1469-8749.2007.00232.x; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schmidt LJ, 2002, CHILD CARE HLTH DEV, V28, P227, DOI 10.1046/j.1365-2214.2002.00266.x; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Simeonsson RJ, 2001, DISABIL REHABIL, V23, P49; Simeonsson RJ, 2003, DISABIL REHABIL, V25, P602, DOI 10.1080/0963828031000137117; Sparrow S.S., 2005, VINELAND ADAPTIVE BE; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Thomas-Stonell N, 2006, Pediatr Rehabil, V9, P14, DOI 10.1080/13638490500050097; Ueda S, 2003, DISABIL REHABIL, V25, P596, DOI 10.1080/0963828031000137108; World Health Organization, INT CLASS FUNCT DIS; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 2007, BRAIN INJ PROF, V3, P20; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	42	47	47	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					220	229		10.1097/01.HTR.0000327254.61751.e7			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900004	18650766				2022-02-06	
J	Moussaieff, A; Shein, NA; Tsenter, J; Grigoriadis, S; Simeonidou, C; Alexandrovich, AG; Trembovler, V; Ben-Neriah, Y; Schmitz, ML; Fiebich, BL; Munoz, E; Mechoulam, R; Shohami, E				Moussaieff, Arieh; Shein, Naama A.; Tsenter, Jeanna; Grigoriadis, Savvas; Simeonidou, Constantina; Alexandrovich, Alexander G.; Trembovler, Victoria; Ben-Neriah, Yinon; Schmitz, Michael L.; Fiebich, Bernd L.; Munoz, Eduardo; Mechoulam, Raphael; Shohami, Esther			Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Boswellia; cembranoids; incensole acetate; inflammation; neuroprotection; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; NECROSIS-FACTOR-ALPHA; FLUORO-JADE-B; NF-KAPPA-B; INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; NEURONAL INJURY; MOUSE MODEL; TNF-ALPHA	Boswellia resin has been used as a major anti-inflammatory agent and for the healing of wounds for centuries. Incensole acetate (IA), isolated from this resin, was shown to inhibit the activation of nuclear factor-kappa B, a key transcription factor in the inflammatory response. We now show that IA inhibits the production of inflammatory mediators in an in vitro model system of C6 glioma and human peripheral monocytes. Given the involvement of postinjury inflammation in the pathophysiology and outcome of traumatic brain injury, we examined the effect of IA on the inflammatory process and on the recovery of neurobehavioral and cognitive functions in a mouse model of closed head injury (CHI). In the brains of post-CHI mice, IA reduced glial activation, inhibited the expression of interleukin-1 beta, and tumor necrosis factor-alpha mRNAs, and induced cell death in macrophages at the area of trauma. A mild hypothermic effect was also noted. Subsequently, IA inhibited hippocampal neurodegeneration and exerted a beneficial effect on functional outcome after CHI, indicated by reduced neurological severity scores and improved cognitive ability in an object recognition test. This study attributes the anti-inflammatory activity of Boswellia resin to IA and related cembranoid diterpenes and suggests that they may serve as novel neuroprotective agents.	[Moussaieff, Arieh; Shein, Naama A.; Tsenter, Jeanna; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Moussaieff, Arieh; Mechoulam, Raphael] Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; [Tsenter, Jeanna] Hebrew Univ Jerusalem, Hadassah Med Ctr, Rehabil Ctr, IL-91120 Jerusalem, Israel; [Grigoriadis, Savvas] AHEPA Univ Hosp, Lab Expt Neurol, Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Fac Med, Physiol Lab, GR-54006 Thessaloniki, Greece; [Ben-Neriah, Yinon] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel; [Schmitz, Michael L.] Univ Giessen, Fac Med, Inst Biochem, Giessen, Germany; [Fiebich, Bernd L.] Univ Freiburg, Sch Med, Dept Psychiat, Freiburg, Germany; [Munoz, Eduardo] Univ Cordoba, Fac Med, Dept Biol Celular Fisiol & Inmunol, Cordoba, Spain		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Munoz, Eduardo/I-5225-2012; Ben-Neriah, Yinon/L-6285-2019; Schmitz, M. Lienhard/D-9328-2017	Munoz, Eduardo/0000-0001-8478-5842; Schmitz, M. Lienhard/0000-0002-6984-7192			Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ben-Neriah Y, 2004, EMBO REP, V5, P668, DOI 10.1038/sj.embor.7400187; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Caballero FJ, 2007, BIOCHEM PHARMACOL, V73, P1013, DOI 10.1016/j.bcp.2006.12.001; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; CORSANO S, 1967, TETRAHEDRON, V23, P1977, DOI 10.1016/S0040-4020(01)82601-6; El Sayed KA, 2007, EXPERT OPIN INV DRUG, V16, P877, DOI 10.1517/13543784.16.6.877; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Hamm S, 2005, PHYTOCHEMISTRY, V66, P1499, DOI 10.1016/j.phytochem.2005.04.025; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; Marshall S., 2003, Pharmaceutical Journal, V271, P862; Moussaieff A, 2005, J ETHNOPHARMACOL, V101, P16, DOI 10.1016/j.jep.2005.03.028; Moussaieff A, 2007, MOL PHARMACOL, V72, P1657, DOI 10.1124/mol.107.038810; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Poeckel D, 2006, MOL PHARMACOL, V70, P1071, DOI 10.1124/mol.106.024836; Potts Mathew B, 2006, NeuroRx, V3, P143; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHUHMANN MU, 2005, J CEREB BLOOD FLOW M, V25, pS261; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Watt J. M., 1962, MED POISONOUS PLANTS, P151; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	39	47	47	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2008	28	7					1341	1352		10.1038/jcbfm.2008.28			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	318DZ	WOS:000257073100007	18414499	Bronze			2022-02-06	
J	George, ME; Skarda, DE; Watts, CR; Pham, HD; Beilman, GJ				George, Mark E.; Skarda, David E.; Watts, Charles R.; Pham, Hoai D.; Beilman, Greg J.			Aggressive red blood cell transfusion: No association with improved outcomes for victims of isolated traumatic brain injury	NEUROCRITICAL CARE			English	Article						anemia; resuscitation; trauma; head injury; transfusion	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; CRITICALLY-ILL PATIENTS; SUBARACHNOID HEMORRHAGE; SEVERITY SCORE; ANEMIA; CARE; OXYGENATION; MANAGEMENT; RISK	Background Clinical studies have caused blood transfusion practices in critically ill patients to become more conservative in the last decade. However, few studies have focused on trauma patients, particularly those with severe isolated traumatic brain injury. Methods We conducted a retrospective study to test the hypothesis that patients with severe brain injury would not benefit from aggressive red blood cell transfusion (RBCT). End points of the study were in-hospital mortality and morbidity (pneumonia, urinary tract infection, deep venous thrombosis, pulmonary embolus, decubitus ulcer, bacteremia, septic shock, myocardial infarction, and seizure). Included in our retrospective study were patients at two urban, level I trauma centers who were admitted with a diagnosis of isolated head injury and with a Glasgow Coma Scale (GCS) score of 8 or less. We recorded demographic, interventional, and outcome variables. Results In 289 patients, 24 of 25 (96%) were transfused if their lowest recorded intensive care unit (ICU) hemoglobin level was 8.0 g/dl or less. In contrast, only 9/182 (5%) of these 289 patients were transfused if the hemoglobin levels were 10.0 g/dl or greater. In the remaining 82 patients with lowest ICU hemoglobin levels of 8.0-10.0 g/dl, 52% were transfused. These 82 patients (43 underwent RBCT and 39 did not) were included in our analysis. Discussion The overall in-hospital mortality rate was 32%; rates were similar between the two groups (29%, non-RBCT; 35%, RBCT) (P = 0.64). Likewise, in-hospital morbidity was similar between groups. Logistic and proportional hazard regression analyses identified RBCT as one predictor of mortality. Conclusions Our results suggest that a restrictive transfusion practice is safe for severely head-injured patients.	[George, Mark E.; Skarda, David E.; Pham, Hoai D.; Beilman, Greg J.] Univ Minnesota, Dept Surg, Div Crit Care, Med Ctr, Minneapolis, MN 55455 USA; [Watts, Charles R.] Hennepin Cty Med Ctr, Dept Surg, Minneapolis, MN 55415 USA; [Beilman, Greg J.] N Mem Med Ctr, Robbinsdale, MN USA		George, ME (corresponding author), Univ Minnesota, Dept Surg, Div Crit Care, Med Ctr, Fairview,MMC 11,420 Delaware St SE, Minneapolis, MN 55455 USA.	geor0040@umn.edu	Watts, Charles R./AAK-9849-2020	Watts, Charles R./0000-0002-5011-487X; Beilman, Gregory/0000-0001-5036-3027			AUDET AM, 1992, ANN INTERN MED, V116, P403, DOI 10.7326/0003-4819-116-5-403; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BORDIN JO, 1994, BLOOD, V84, P1703; *BRAIN TRAUM FDN, GUID PREH MAN TRAUM; *BRAIN TRAUM FDN I, 2000, GUID MAN SEV TRAUM B, P165; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; DIETRICH KA, 1990, CRIT CARE MED, V18, P940, DOI 10.1097/00003246-199009000-00007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; LORENTE JA, 1993, CRIT CARE MED, V21, P1312, DOI 10.1097/00003246-199309000-00013; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Nilsson KR, 2007, ARCH SURG-CHICAGO, V142, P126, DOI 10.1001/archsurg.142.2.126; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shapiro MJ, 2003, J TRAUMA, V55, P269, DOI 10.1097/01.TA.0000080530.77566.04; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; TEASDALE G, 1974, LANCET, V2, P81; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Winn HR, 2004, YOUMANS NEUROLOGICAL, V5	33	47	49	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	JUN	2008	8	3					337	343		10.1007/s12028-008-9066-y			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	301DT	WOS:000255877300005	18273711				2022-02-06	
J	Fan, YJ; Wu, LLY; Li, HY; Wang, YJ; Zhou, XF				Fan, Yong-jun; Wu, Linda Lin-yan; Li, Hong-yun; Wang, Yan-Jiang; Zhou, Xin-Fu			Differential effects of pro-BDNF on sensory neurons after sciatic nerve transection in neonatal rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						p75NTR; proneurotrophins; sciatic nerve injury; sensory neurons; sortilin	DORSAL-ROOT GANGLIA; ACTIVITY-DEPENDENT SECRETION; P75 NEUROTROPHIN RECEPTOR; GROWTH-FACTOR; HIPPOCAMPAL-NEURONS; AXONAL-TRANSPORT; PERIPHERAL-NERVE; MESSENGER-RNA; CELL-DEATH; ADULT-RAT	Brain-derived neurotrophic factor (BDNF) plays a critical role in the development of the central and peripheral nervous systems, and also in neuronal survival after injury. The actions of BDNF are mediated by its high-affinity receptors TrkB and p75NTR. Recent studies have shown that proneurotrophins bind p75NTR and sortilin with high affinity, and trigger apoptosis of neurons in vitro. As proneurotrophins are a dominant form of gene products in developing and adult animals, it is imperative to understand their physiological functions in animals. Here, we showed differential roles of proBDNF in injured and uninjured sensory neurons. proBDNF, p75NTR and sortilin are highly expressed in dorsal root ganglia (DRG) neurons. Recombinant proBDNF induced a dose-dependent death of PC12 cells and the death activity was completely abolished in the presence of antibodies against the prodomain of BDNF. The exogenous proBDNF enhanced the death of axotomized sensory neurons and the neutralizing antibodies to the prodomain or exogenous sortilin-extracellular domain-Fc fusion molecule reduced the death of axotomized sensory neurons. Interestingly, the treatment of neutralizing antibody in vivo increased the number of sensory neurons in the contralateral DRG. We conclude that proBDNF may induce the death of axotomized sensory neurons and suppress neuronal addition in the intact DRG in neonatal rats, and the suppression of endogenous proBDNF may protect neurons after neurotrauma.	[Zhou, Xin-Fu] Flinders Univ S Australia, Dept Human Physiol, Adelaide, SA 5001, Australia; Flinders Univ S Australia, Ctr Neurosci, Adelaide, SA 5001, Australia		Zhou, XF (corresponding author), Flinders Univ S Australia, Dept Human Physiol, GPO Box 2100, Adelaide, SA 5001, Australia.	Xin-fu.zhou@flinders.edu.au	Zhou, Xiaofang/C-6169-2013; Li, Hongyun/G-2301-2011; Wang, Yanjiang/F-3703-2012; zhou, xin-fu/F-4119-2013; zhou, xin-fu/G-6643-2011	Zhou, Xiaofang/0000-0001-6343-1455; Li, Hongyun/0000-0003-3332-3132; Wang, Yanjiang/0000-0002-6227-6112; zhou, xin-fu/0000-0002-8687-0175; 			ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Agthong S, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-45; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Arnett MG, 2007, BRAIN RES, V1183, P32, DOI 10.1016/j.brainres.2007.09.051; Balkowiec A, 2002, J NEUROSCI, V22, P10399; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bruno MA, 2006, P NATL ACAD SCI USA, V103, P6735, DOI 10.1073/pnas.0510645103; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Conner JM, 1997, J NEUROSCI, V17, P2295; Deinhardt K, 2007, TRAFFIC, V8, P1736, DOI 10.1111/j.1600-0854.2007.00645.x; Domeniconi M, 2007, MOL CELL NEUROSCI, V34, P271, DOI 10.1016/j.mcn.2006.11.005; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; ElShamy WM, 1997, J NEUROSCI, V17, P8667; Erickson JT, 1996, J NEUROSCI, V16, P5361; Fahnestock M, 2004, J NEUROCHEM, V89, P581, DOI 10.1111/j.1471-4159.2004.02360.x; Fayard B, 2005, J NEUROSCI RES, V80, P18, DOI 10.1002/jnr.20432; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Gu CH, 1999, J NEUROSCI, V19, P3043; Gueorguiev VD, 1999, AM J PHYSIOL-CELL PH, V276, pC54, DOI 10.1152/ajpcell.1999.276.1.C54; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hashimoto K, 2007, BIOESSAYS, V29, P116, DOI 10.1002/bies.20534; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; Hu P, 2002, NEUROSCIENCE, V112, P23, DOI 10.1016/S0306-4522(02)00065-9; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Kenchappa RS, 2006, NEURON, V50, P219, DOI 10.1016/j.neuron.2006.03.011; KOLBECK R, 1994, EUR J BIOCHEM, V225, P995, DOI 10.1111/j.1432-1033.1994.0995b.x; Lagares A, 2007, J NEUROSCI, V27, P7939, DOI 10.1523/JNEUROSCI.1203-07.2007; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Li HY, 2007, STEM CELLS, V25, P2053, DOI 10.1634/stemcells.2007-0080; Li WP, 1999, NEUROSCI LETT, V260, P49, DOI 10.1016/S0304-3940(98)00958-6; Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717; Matsumoto T, 2008, NAT NEUROSCI, V11, P131, DOI 10.1038/nn2038; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mowla SJ, 1999, J NEUROSCI, V19, P2069; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; Numata S, 2006, NEUROSCI LETT, V401, P1, DOI 10.1016/j.neulet.2006.02.054; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tonra JR, 1998, J NEUROSCI, V18, P4374; Traficante A, 2007, NEUROREPORT, V18, P1997, DOI 10.1097/WNR.0b013e3282f262ca; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Wang H, 2006, EUR J NEUROSCI, V24, P2444, DOI 10.1111/j.1460-9568.2006.05138.x; Woo NH, 2005, NAT NEUROSCI, V8, P1069, DOI 10.1038/nn1510; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zhou XF, 2005, NEUROSCIENCE, V132, P591, DOI 10.1016/j.neuroscience.2004.12.034; Zhou XF, 1999, NEUROSCIENCE, V92, P841, DOI 10.1016/S0306-4522(99)00027-5; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0; Zhou XF, 2004, J NEUROCHEM, V91, P704, DOI 10.1111/j.1471-4159.2004.02775.x	61	47	57	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2008	27	9					2380	2390		10.1111/j.1460-9568.2008.06215.x			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	292SG	WOS:000255285800018	18430030				2022-02-06	
J	Broglio, SP; Ferrara, MS; Sopiarz, K; Kelly, MS				Broglio, Steven P.; Ferrara, Michael S.; Sopiarz, Kay; Kelly, Michael S.			Reliable change of the sensory organization test	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						postural control; concussion; reliable change index	NEUROPSYCHOLOGICAL TEST PROTOCOL; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; COGNITIVE CHANGE; STATISTICAL PROCEDURES; NCAA CONCUSSION; RECOVERY; STATEMENT; SYMPTOMS	Objective: To establish the sensitivity and specificity of the NeuroCom Sensory Organization Test (SOT) and provide practitioners with cut-scores for clinical decision making using estimates of reliable change. Design: Retrospective cohort study. Setting: Research laboratory. Patients: Healthy (n = 66) and concussed (n = 63) young adult participants. Interventions: Postural control assessments on the NeuroCom SOT were completed twice (baseline and follow-up) for both groups. Postconcussion assessments were administered within 24 hours of injury diagnosis. Main Outcome Measurements: The reliable change technique was used to calculated cut-scores for each SOT variable (composite balance; somatosensory visual, and vestibular ratios) at the 95%, 90%, 85%, 80%, 75%, and 70% confidence interval levels. Results: When cut-scores were applied to the post-concussion evaluations, sensitivity and specificity varied with SOT variable and confidence interval. An evaluation for change on one or more SOT variable resulted in the highest combined sensitivity (57%) and specificity (80%) at the 75% confidence interval. Conclusions: Use of reliable change scores to detect significant changes in performance on the SOT resulted in decreased sensitivity and improved specificity compared to a previous report. These findings indicate that some concussed athletes may not show large changes in postconcussion postural control and this postural control evaluation should not be used in exclusion of other assessment techniques. The postural control assessment should be combined with other evaluative measures to gain the highest sensitivity to concussive injuries.	[Broglio, Steven P.; Sopiarz, Kay; Kelly, Michael S.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Ferrara, Michael S.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA		Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu					Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 1989, MILD HEAD INJURY; Bland JM, 1996, BRIT MED J, V313, P744; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; CANTU R, 2000, NEUROSURG FOCUS, V21, P1; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, BRIT J SPORT MED, V37, P370, DOI 10.1136/bjsm.37.4.370-a; Collie A, 2002, ANN THORAC SURG, V73, P2005, DOI 10.1016/S0003-4975(01)03375-6; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, 2002, HEADMINDER CONCUSSIO; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maassen GH, 2005, BRIT J SPORT MED, V39, P483, DOI 10.1136/bjsm.2004.015594; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; Nashner L.M., 1997, HDB BALANCE FUNCTION, P280; *NAT COLL ATHL ASS, 2003, INJ SURV SYST FOOTB; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; VANKAMPEN DA, 2006, AM J SPORT MED, V30, P1; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003	44	47	47	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2008	18	2					148	154		10.1097/JSM.0b013e318164f42a			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	273LQ	WOS:000253932600008	18332690				2022-02-06	
J	Ottens, AK; Golden, EC; Bustamante, L; Hayes, RL; Denslow, ND; Wang, KKW				Ottens, Andrew K.; Golden, Erin C.; Bustamante, Liliana; Hayes, Ronald L.; Denslow, Nancy D.; Wang, Kevin K. W.			Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry	JOURNAL OF NEUROCHEMISTRY			English	Article						biomarkers; mass spectrometry; myelin basic protein; neurotrauma; proteolysis; quantification	TRAUMATIC BRAIN-INJURY; SCLEROSIS; CALPAIN; DEMYELINATION; DEGRADATION; MECHANISM; QUANTIFICATION; IDENTIFICATION; INHIBITION; PROTEOMICS	Neurotrauma, as in the case of traumatic brain injury, promotes protease over-activation characterized by the select fragmentation of brain proteins. The resulting polypeptides are indicators of biochemical processes, which can be used to study post-injury dynamics and may also be developed into biomarkers. To this end, we devised a novel mass spectrometry approach to characterize post-injury calpain proteolytic processing of myelin basic protein (MBP), a biomarker of brain injury that denotes white matter damage and recovery. Our approach exceeds conventional immunological assays in its deconvolution of multiple protein isoforms, its absolute quantification of proteolytic fragments and its polypeptide selectivity. We quantified and characterized post-injury proteolytic processing of all MBP isoforms identified in adult rat cortex. Further, the translation of calpain-cleaved MBP into CSF was verified following brain injury. We ascertained that the exon-6 sequence of MBP resulted in a characteristic shift in gel migration for intact and fragmented protein alike. We also found evidence for a second post-TBI cleavage event within exon-2 and for the dimerization of the post-TBI 4.3 kDa fragment. Ultimately, the novel methodology described here can be used to study MBP dynamics and other similar proteolytic events of relevance to brain injury and other CNS processes.	[Ottens, Andrew K.; Bustamante, Liliana; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarker Res, Dept Psychiat, Gainesville, FL 32611 USA; [Ottens, Andrew K.; Bustamante, Liliana; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Psychiat, Gainesville, FL 32611 USA; [Ottens, Andrew K.; Golden, Erin C.; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32611 USA; [Ottens, Andrew K.; Golden, Erin C.; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarker Res, Dept Neurosci, Gainesville, FL 32611 USA; [Denslow, Nancy D.] Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarker Res, Dept Physiol Sci, Gainesville, FL 32611 USA; [Denslow, Nancy D.] Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Physiol Sci, Gainesville, FL 32611 USA		Ottens, AK (corresponding author), POB 100256, Gainesville, FL 32610 USA.	aottens@mbi.ufl.edu	Ottens, Andrew/K-3352-2012	Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25NS055012, K25 NS055012] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25NS055012] Funding Source: NIH RePORTER		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Akiyama K, 2002, J NEUROSCI RES, V68, P19, DOI 10.1002/jnr.10188; Arroyo EJ, 2000, HISTOCHEM CELL BIOL, V113, P1, DOI 10.1007/s004180050001; Banik NL, 2000, NEUROCHEM RES, V25, P1509, DOI 10.1023/A:1007684311023; Banik NL, 1997, BRAIN RES, V748, P205, DOI 10.1016/S0006-8993(96)01302-9; Barr JR, 1996, CLIN CHEM, V42, P1676; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Blackler AR, 2006, ANAL CHEM, V78, P1337, DOI 10.1021/ac051486a; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; Boggs JM, 2000, BBA-BIOMEMBRANES, V1463, P81, DOI 10.1016/S0005-2736(99)00181-9; BOULIAS C, 1995, ARCH BIOCHEM BIOPHYS, V322, P174, DOI 10.1006/abbi.1995.1449; Capello E, 1997, ANN NEUROL, V41, P797, DOI 10.1002/ana.410410616; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Givogri MI, 2000, J NEUROSCI RES, V59, P153, DOI 10.1002/(SICI)1097-4547(20000115)59:2<153::AID-JNR1>3.0.CO;2-F; Godovac-Zimmermann J, 2005, PROTEOMICS, V5, P699, DOI 10.1002/pmic.200401051; Harauz G, 2004, MICRON, V35, P503, DOI 10.1016/j.micron.2004.04.005; Kimura M, 1998, BRAIN RES, V785, P245, DOI 10.1016/S0006-8993(97)01383-8; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOBEISSY FH, 2006, PROTOEMICS, V5, P1887; Kruger GM, 1999, J NEUROSCI RES, V56, P241; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Maatta JA, 1997, BIOCHEM BIOPH RES CO, V238, P498, DOI 10.1006/bbrc.1997.7318; Massaro AR, 1998, MULT SCLER J, V4, P1; Michalowska-Wender G, 2001, FOLIA NEUROPATHOL, V39, P1; NAKAJIMA K, 1993, J NEUROCHEM, V60, P1554, DOI 10.1111/j.1471-4159.1993.tb03321.x; Norton WT, 1984, MYELIN, V2nd, P147; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Ray SK, 2003, J CHEM NEUROANAT, V26, P119, DOI 10.1016/S0891-0618(03)00044-9; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; SATO S, 1984, ANN NEUROL, V15, P264, DOI 10.1002/ana.410150310; Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SMITH ME, 1977, NEUROCHEM RES, V2, P233, DOI 10.1007/BF00969354; THOMAS D G T, 1978, Lancet, V1, P113; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; VOSKUHL RR, 1994, J IMMUNOL, V153, P4834; WOOD DD, 1989, J BIOL CHEM, V264, P5121; Yura K, 2006, GENE, V380, P63, DOI 10.1016/j.gene.2006.05.015	41	47	49	0	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2008	104	5					1404	1414		10.1111/j.1471-4159.2007.05086.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	264AI	WOS:000253257200023	18036155	Green Accepted			2022-02-06	
J	Moro, V; Berlucchi, G; Lerch, J; Tomaiuolo, F; Aglioti, SM				Moro, Valentina; Berlucchi, Giouanni; Lerch, Jason; Tomaiuolo, Francesco; Aglioti, Salvatore M.			Selective deficit of mental visual imagery with intact primary visual cortex and visual perception	CORTEX			English	Article						visual imagery and perception; V1; higher order visual cortices; non-visual and motor imagery; brain damaged patients	CORTICAL BLINDNESS; BRAIN; DISSOCIATION; EXTINCTION; AREAS; FMRI	There is a vigorous debate as to whether visual perception and imagery share the same neuronal networks, whether the primary visual cortex is necessarily involved in visual imagery, and whether visual imagery functions are lateralized in the brain. Two patients with brain damage from closed head injury were submitted to tests of mental imagery in the visual, tactile, auditory, gustatory, olfactory and motor domains, as well as to an extensive testing of cognitive functions. A computerized mapping procedure was used to localize the site and to assess the extent of the lesions. One patient showed pure visual mental imagery deficits in the absence of imagery deficits in other sensory domains as well as in the motor domain, while the other patient showed both visual and tactile imagery deficits. Perceptual, language, and memory deficits were conspicuously absent. Computerized analysis of the lesions showed a massive involvement of the left temporal lobe in both patients and a bilateral parietal lesion in one patient. In both patients the calcarine cortex with the primary visual area was bilaterally intact. our study indicates that: (i) visual imagery deficits can occur independently from deficits of visual perception; (ii) visual imagery deficits can occur when the primary visual cortex is intact and (iii) the left temporal lobe plays an important role in visual mental imagery. (C) 2007 Elsevier Masson Srl. All rights reserved.	[Moro, Valentina] Univ Verona, Dept Psychol & Culture Anthropol, I-37122 Verona, VR, Italy; [Berlucchi, Giouanni] Univ Verona, Dept Neurol & Visual Sci, Physiol Sect, I-37122 Verona, VR, Italy; [Tomaiuolo, Francesco; Aglioti, Salvatore M.] IRCCS Fondazione S Lucia, Rome, Italy; [Lerch, Jason] McGill Univ, Brain Imaging Ctr, Montreal Neurol Inst, Montreal, PQ, Canada; [Tomaiuolo, Francesco] Auxilium Vitae Volterra SpA, Pisa, Italy; [Aglioti, Salvatore M.] Univ Roma La Sapienza, Dept Psychol, Rome, Italy		Moro, V (corresponding author), Univ Verona, Dept Psychol & Culture Anthropol, Lung Porta Vittoria 17, I-37122 Verona, VR, Italy.	valentina.moro@univr.it; salvatoremaria.aglioti@uniroma1.it	Moro, Valentina/AAM-2224-2021; Aglioti, Salvatore M/E-9829-2012; Moro, Valentina/K-6464-2016; Tomaiuolo, Francesco/AAC-1534-2019	Moro, Valentina/0000-0002-7119-7264; Moro, Valentina/0000-0002-7119-7264; Tomaiuolo, Fancesco/0000-0003-1230-2770			ARRIGONI G, 1964, CORTEX, V1, P170; Bartolomeo P, 2002, CORTEX, V38, P357, DOI 10.1016/S0010-9452(08)70665-8; BEHRMANN M, 1992, NATURE, V359, P636, DOI 10.1038/359636a0; BENTON AL, 1975, LINE ORIENTATION JUD; Bueti D, 2004, NEUROPSYCHOLOGIA, V42, P1689, DOI 10.1016/j.neuropsychologia.2004.04.005; Chatterjee A, 1995, NEUROLOGY, V45, P2189, DOI 10.1212/WNL.45.12.2189; Driver J, 2001, COGNITION, V79, P39, DOI 10.1016/S0010-0277(00)00124-4; Economo C.von, 1925, CYTOARCHITEKTONIK HI; FARAH M, 2001, NEUROPSYCHOLOGY, V4, P238; Ganis G, 2004, COGNITIVE BRAIN RES, V20, P226, DOI 10.1016/j.cogbrainres.2004.02.012; GOLDENBERG G, 1995, NEUROPSYCHOLOGIA, V33, P1373, DOI 10.1016/0028-3932(95)00070-J; HUBER W, 1938, AACHENER APHASIE TES; Johnson SH, 2002, J COGNITIVE NEUROSCI, V14, P841, DOI 10.1162/089892902760191072; Kaski D, 2002, PERCEPTION, V31, P717, DOI 10.1068/p3360; Kobayashi M, 2004, NEUROIMAGE, V23, P1271, DOI 10.1016/j.neuroimage.2004.08.002; KOSSLYN SM, 1987, PSYCHOL REV, V94, P148, DOI 10.1037/0033-295X.94.2.148; Luzzatti C, 1998, CORTEX, V34, P461, DOI 10.1016/S0010-9452(08)70768-8; Mechelli A, 2004, CEREB CORTEX, V14, P1256, DOI 10.1093/cercor/bhh087; Mellet E, 2000, J COGNITIVE NEUROSCI, V12, P98, DOI 10.1162/08989290051137620; Miceli G, 2001, NAT NEUROSCI, V4, P662, DOI 10.1038/88497; Newman SD, 2005, COGNITIVE BRAIN RES, V23, P235, DOI 10.1016/j.cogbrainres.2004.10.020; Policardi E, 1996, NEUROCASE, V2, P381, DOI 10.1093/neucas/2.5.381; PYLYSHYN ZW, 1973, PSYCHOL BULL, V80, P1, DOI 10.1037/h0034650; Raven J. C., 1954, STANDARD PROGR MATRI; Sack AT, 2005, SCIENCE, V308, P702, DOI 10.1126/science.1107784; Slotnick SD, 2005, CEREB CORTEX, V15, P1570, DOI 10.1093/cercor/bhi035; SMANIA N, 1995, EUROPA MEDICOPHISICA, V31, P169; SPINNLER H, 1987, SCIENCE S8, V6; Talairach J., 1988, COPLANAR STEREOTACTI; TROJANO L, 1994, BRAIN COGNITION, V24, P213, DOI 10.1006/brcg.1994.1012; Warrington E. K., 1991, VISUAL OBJECT SPACE; Weschler D., 1974, WESCHLER ADULT INTEL; WILSON B, 1985, RIVERMED BEHAV MEMOR; ZATORRE RJ, 1993, NEUROPSYCHOLOGIA, V31, P221, DOI 10.1016/0028-3932(93)90086-F	34	47	49	1	11	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2008	44	2					109	118		10.1016/j.cortex.2006.06.004			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	276OK	WOS:000254151700003	18387540				2022-02-06	
J	Cole, WR; Gerring, JP; Gray, RM; Vasa, RA; Salorio, CF; Grados, M; Christensen, JR; Slomine, BS				Cole, Wesley R.; Gerring, Joan P.; Gray, Robert M.; Vasa, Roma A.; Salorio, Cynthia F.; Grados, Marco; Christensen, James R.; Slomine, Beth S.			Prevalence of aggressive behaviour after severe paediatric traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; aggression; predictors of aggression; overt aggression scale	OVERT AGGRESSION; RELATIONAL AGGRESSION; PHYSICAL AGGRESSION; CHILDREN; SCALE; ADOLESCENTS; PREDICTORS; DISORDERS; ANXIETY; FAMILY	Objective: The goals of this study were to explore the prevalence of aggressive behaviours after severe paediatric traumatic brain injury (TBI) and identify predictors of aggressive behaviours 1 year post-injury. Methods: A cohort of 97 children aged 4-19 years at time of severe TBI (GCS 3-8) were prospectively followed for 1 year. Pre-injury psychiatric status was obtained retrospectively at enrolment and post-injury behavioural and functional concerns were assessed at 1 year. Aggression was measured with a modified version of the Overt Aggression Scale (OAS). Results: Results revealed aggressive behaviour increased from pre-injury to post-injury. Pre-injury factors including aggression, attention problems and anxiety were associated with increased post-injury aggressive behaviour. Children with greater disability after injury were also at increased risk for aggressive behaviours. Conclusions: Aggression is a prevalent symptom after paediatric TBI and can significantly impede rehabilitation. Awareness of these predictors can aid in early identification of children at risk in order to help appropriately design rehabilitation programmes.	[Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21202 USA; [Cole, Wesley R.; Gerring, Joan P.; Vasa, Roma A.; Salorio, Cynthia F.; Grados, Marco; Christensen, James R.; Slomine, Beth S.] Johns Hopkins Sch Med, Baltimore, MD USA; [Gray, Robert M.] Univ Calif San Diego, San Diego, CA 92103 USA		Slomine, BS (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21202 USA.	slomine@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH00997]; NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD07414]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH071567, K20MH000997] Funding Source: NIH RePORTER	This work was supported by NIMH grant K20 MH00997 and NIH-NICHD grant T32-HD07414.	Achenbach TM, 1991, MANUAL CHILD BEHAV C; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beyers JM, 2001, J ABNORM CHILD PSYCH, V29, P369, DOI 10.1023/A:1010491218273; Bittner A, 2007, J CHILD PSYCHOL PSYC, V48, P1174, DOI 10.1111/j.1469-7610.2007.01812.x; Blum RW, 2000, AM J PUBLIC HEALTH, V90, P1879, DOI 10.2105/AJPH.90.12.1879; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Capaldi D M, 1994, Prog Exp Pers Psychopathol Res, P165; Crick NR, 2006, J ABNORM CHILD PSYCH, V34, P131, DOI 10.1007/s10802-005-9009-4; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Farrington D P, 1989, Violence Vict, V4, P79; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; GRAY JA, 1990, COGNITION EMOTION, V4, P269, DOI 10.1080/02699939008410799; Guttmann-Steinmetz S, 2006, J AM ACAD CHILD PSY, V45, P440, DOI 10.1097/01.chi.0000196422.42599.63; Halperin JM, 2003, J AM ACAD CHILD PSY, V42, P965, DOI 10.1097/01.CHI.0000046899.27264.EB; Herrenkohl TI, 2007, J INTERPERS VIOLENCE, V22, P386, DOI 10.1177/0886260506296986; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kempes M, 2005, EUR CHILD ADOLES PSY, V14, P11, DOI 10.1007/s00787-005-0432-4; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Nagin DS, 2001, ARCH GEN PSYCHIAT, V58, P389, DOI 10.1001/archpsyc.58.4.389; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Recklitis CJ, 2004, CHILD PSYCHIAT HUM D, V34, P341; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rojahn J, 2001, J AUTISM DEV DISORD, V31, P577, DOI 10.1023/A:1013299028321; SCHATZ DB, 1996, J ATTEN DISORD, V10, P141; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Swaim Randall C, 2006, J Prim Prev, V27, P229, DOI 10.1007/s10935-006-0031-2; Swan L, 2004, BRAIN INJURY, V18, P143, DOI 10.1080/02699050310001596923; SZARTMARI P, 1994, INT J METH PSYCH RES, V4, P231; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tremblay RE, 2004, PEDIATRICS, V114, pE43, DOI 10.1542/peds.114.1.e43; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; WALKER JL, 1991, J AM ACAD CHILD PSY, V30, P187, DOI 10.1097/00004583-199103000-00004; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	44	47	47	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					932	939	PII 905454051	10.1080/02699050802454808			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900004	19005885	Green Accepted			2022-02-06	
J	Lachapelle, J; Bolduc-Teasdale, J; Ptito, A; Mckerral, M				Lachapelle, Julie; Bolduc-Teasdale, Julie; Ptito, Alain; Mckerral, Michelle			Deficits in complex visual information processing after mild TBI: Electrophysiological markers and vocational outcome prognosis	BRAIN INJURY			English	Article; Proceedings Paper	2nd International Conference on Vocational Outcomes in Traumatic Brain Injury	MAY 24-26, 2007	Vancouver, CANADA			mild traumatic brain injury; electrophysiology; vision; cognition intervention; return to work	TRAUMATIC BRAIN-INJURY; TEXTURE SEGREGATION; EVOKED-POTENTIALS; COGNITIVE DEFICITS; MOTION; HEAD; CONCUSSION; PERCEPTION; PATHOPHYSIOLOGY; ABNORMALITIES	Primary objective: To evaluate low-level to complex information processing using visual electrophysiology and to examine the latter's prognostic value in regards to vocational outcome in persons having sustained a mild traumatic brain injury (mTBI). Research design/methods: Event-related potentials (ERPs) were recorded to pattern-reversal, simple motion, texture segregation and cognitive oddball paradigms from 17 participants with symptomatic mTBI at onset of specialized clinical intervention and from 15 normal controls. The relationship between abnormal electrophysiology and post-intervention return to work status was also examined. Main outcomes and results: Participants with mTBI showed a statistically significant (p 0.05) amplitude reduction for cognitive ERPs and delayed latencies for texture (p 0.05) and cognitive paradigms (p 0.005) compared to controls. Furthermore, participants with mTBI presenting texture or cognitive ERP latency delays upon admission were at significantly (p 0.01) greater risk of negative vocational outcome than mTBI participants with normal electrophysiology. Conclusions: The findings suggest that individuals with symptomatic mTBI can present selective deficits in complex visual information processing that could interfere with vocational outcome. ERP paradigms such as those employed in this study thus show potential for evaluating outcome prognosis and merit further study.	[Bolduc-Teasdale, Julie; Mckerral, Michelle] Univ Montreal, Dept Psychol, Montreal, PQ H2H 2N8, Canada; [Lachapelle, Julie; Ptito, Alain] McGill Univ, Dept Neurol Neurosurg, Montreal, PQ, Canada; [Lachapelle, Julie; Bolduc-Teasdale, Julie; Ptito, Alain; Mckerral, Michelle] CRLB, CRIR, Montreal, PQ, Canada		Mckerral, M (corresponding author), Univ Montreal, Dept Psychol, 2275 Laurier Ave E, Montreal, PQ H2H 2N8, Canada.	michelle.mckerral@umontreal.ca			CIHRCanadian Institutes of Health Research (CIHR) [42843] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Armitage P, 2002, STAT METHODS MED RES, V4th; Bach M, 2000, VISION RES, V40, P3559, DOI 10.1016/S0042-6989(00)00195-4; Bach M, 1997, VISION RES, V37, P1409, DOI 10.1016/S0042-6989(96)00322-7; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bertone A, 2003, J COGNITIVE NEUROSCI, V15, P218, DOI 10.1162/089892903321208150; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Caputo G, 1999, VISION RES, V39, P1597, DOI 10.1016/S0042-6989(98)00270-3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; CHEN JK, 2007, J NEUROLOGY NEUROSUR; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Finkelstein E., 2006, INCIDENCE EC BURDEN; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; FORGET R, 2007, PHYSIOTHERAPY, V93, pS402; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gagnon I, 2004, J HEAD TRAUMA REHAB, V19, P391, DOI 10.1097/00001199-200409000-00004; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GUERIN F, 2005, CRIF PUBLICATIONS IN, P145; Guerin F, 2006, NEUROREHABILITATION, V21, P295; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holbourn AHS, 1943, LANCET, V2, P438; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; KAY T, 1993, REHABILITATION POST; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; KUBA M, 1992, DOC OPHTHALMOL, V80, P83, DOI 10.1007/BF00161234; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, 1993, VISUAL NEUROSCI, V10, P781, DOI 10.1017/S0952523800006039; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Luck S.J., 2005, INTRO EVENT RELATED, V1st ed.; MARCOTTE AC, 2005, ORIENTATIONS MINISTE; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MCCRORY P, 2005, J SPORTS MED, V39, P78; McKerral M, 2001, VISION RES, V41, P1085, DOI 10.1016/S0042-6989(01)00037-2; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; *NIH, 1998, REH PERS TRAUM BRAIN, V16, P1; Odom JV, 2004, DOC OPHTHALMOL, V108, P115, DOI 10.1023/B:DOOP.0000036790.67234.22; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Regan, 1989, HUMAN BRAIN ELECTROP; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; SELZER ME, 1995, J NEUROL REHABIL, V9, P55; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; STULEMEIJER M, 2006, J NEUROTRAUM, V23, P1450; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Vaina LM, 1996, P ROY SOC B-BIOL SCI, V263, P1225, DOI 10.1098/rspb.1996.0180; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	73	47	47	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					265	274		10.1080/02699050801938983			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500007	18297598				2022-02-06	
J	Malojcic, B; Mubrin, Z; Coric, B; Susnic, M; Spilich, GJ				Malojcic, Branko; Mubrin, Zdenko; Coric, Bojana; Susnic, Mirica; Spilich, George J.			Consequences of mild traumatic brain injury on information processing assessed with attention and short-term memory tasks	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; cognitive function; traumatic brain injury	HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE FUNCTIONS; RECOVERY; DEFICITS; EPIDEMIOLOGY; PREDICTION; MIGRAINE; HISTORY	In this investigation, we explored the impact of mild traumatic brain injury (mTBI) upon short term or working memory and attention. The performance of 37 individuals with mTBI was compared with that of 53 age, sex and education-matched controls. All participants were staff members or individuals seeking medical care at a University hospital serving a large metropolitan area. A battery of computerized tests measured sustained visual attention, short-term memory (STM), simple reaction time, and decision time. Individuals with mTBI showed a performance deficit at sustained visual attention, STM scanning and a trend towards slowing in choice decision making. These observed changes in the cognitive performance of mTBI individuals are hypothesized to be a consequence of impaired central information processing. Our results suggest that mTBI can elicit meaningful cognitive deficits for several months post-injury. Additionally, we believe that the tasks employed in the current investigation demonstrate their utility for understanding cognitive deficits in mTBI individuals.	[Malojcic, Branko; Mubrin, Zdenko; Coric, Bojana] Univ Hosp Ctr, Dept Neurol, Zagreb 10000, Croatia; [Susnic, Mirica] Trauma Clin, Dept Neurol, Zagreb, Croatia; [Spilich, George J.] Washington Coll, Dept Psychol, Chestertown, MD USA		Malojcic, B (corresponding author), Univ Hosp Ctr, Dept Neurol, Kispaticeva 12, Zagreb 10000, Croatia.	branko12@yahoo.com	Malojcic, Branko/B-7076-2018				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Atkinson L, 2001, WORLD J SURG, V25, P1224, DOI 10.1007/s00268-001-0086-4; CALLANAN MM, 1989, BRAIN, V112, P361, DOI 10.1093/brain/112.2.361; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; DeNavas-Walt C., 2006, INCOME POVERTY HLTH; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Ferraro FR, 1999, AGING NEUROPSYCHOL C, V6, P260, DOI 10.1076/1382-5585(199912)06:04;1-B;FT260; Gazzaniga M., 2002, COGNITIVE NEUROSCIEN; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Janculjak D, 2002, CLIN NEUROL NEUROSUR, V104, P221, DOI 10.1016/S0303-8467(02)00042-2; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kent D, 2007, AM SCI, V95, P60, DOI 10.1511/2007.63.1016; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Macciocchi SN, 1998, NEUROREHABILITATION, V11, P67, DOI 10.1016/S1053-8135(98)00010-9; Malojcic B, 2000, NEUROL CROATICA, V49, P159; MUBRIN Z, 1996, EUR J NEUROL, V5, pS235; Nakamura N, 2002, NEUROL RES, V24, P45, DOI 10.1179/016164102101199530; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; PEYSER JM, 1990, ARCH NEUROL-CHICAGO, V47, P94, DOI 10.1001/archneur.1990.00530010120030; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SMITH PJ, 1981, HUM FACTORS, V23, P701, DOI 10.1177/001872088102300607; SPILICH GJ, 1992, BRIT J ADDICT, V87, P1313; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Waldie KE, 2002, NEUROLOGY, V59, P904, DOI 10.1212/WNL.59.6.904; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P239, DOI 10.1016/j.acn.2005.12.004	44	47	49	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2008	25	1					30	37		10.1089/neu.2007.0384			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	258IJ	WOS:000252861300003	18355156				2022-02-06	
J	Sveen, U; Mongs, M; Roe, C; Sandvik, L; Bautz-Holter, E				Sveen, Unni; Mongs, Malin; Roe, Cecilia; Sandvik, Leiv; Bautz-Holter, Erik			Self-rated competency in activities predicts functioning and participation one year after traumatic brain injury	CLINICAL REHABILITATION			English	Article							COMMUNITY INTEGRATION QUESTIONNAIRE; RATING-SCALE; REHABILITATION; EMPLOYMENT; OUTCOMES; CONSCIOUSNESS	Objective: To investigate whether the Patient Competency Rating Scale at three months predicts global functioning and participation one year after traumatic brain injury. Design: Prospective cohort study with follow-up at 3 and 12 months post injury. The Patient Competency Rating Scale was analysed in a logistic regression model with the outcomes Community Integration Questionnaire, Glasgow Outcome Scale Extended and return to work/study. Setting: The neurosurgical department of a trauma referral centre in a metropolitan hospital. Subjects: A cohort of 70 patients with acute traumatic brain injury, ranging from mild to severe injury. Main measures: The Patient Competency Rating Scale, assessing competency in activities, was applied as a predictor. Outcomes describing community participation at 12 months were the Community Integration Questionnaire and return to work/study. Global functioning was evaluated by the Glasgow Outcome Scale Extended. Results: Factor analysis of the Patient Competency Rating Scale items yielded three domains: activities demanding cognition, interpersonal/emotional skills, and activities of daily living (ADL) competency. The first two of these domains significantly predicted return to work/study and community integration, whilst global functioning at one year was predicted by interpersonal/emotional competency. Conclusions: The Patient Competency Rating Scale at three months predicted functioning and participation one year after traumatic brain injury. This indicates that rehabilitation interventions should focus on cognitive and interpersonal competency in order to enhance participation after traumatic brain injury.	[Sveen, Unni; Mongs, Malin; Roe, Cecilia; Bautz-Holter, Erik] Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway		Sveen, U (corresponding author), Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	Unni.sveen@uus.no					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Fleming J, 1999, BRAIN INJURY, V13, P417; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Linden MA, 2005, DISABIL REHABIL, V27, P1353, DOI 10.1080/09638280500164180; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winer B. J., 1991, STAT PRINCIPLES EXPT, V3rd; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	30	47	48	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2008	22	1					45	55		10.1177/0269215507080768			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	276NT	WOS:000254149900005	18089663				2022-02-06	
J	Brommeland, T; Rosengren, L; Fridlund, S; Hennig, R; Isaksen, V				Brommeland, T.; Rosengren, L.; Fridlund, S.; Hennig, R.; Isaksen, V.			Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas	ACTA NEUROLOGICA SCANDINAVICA			English	Article						GFAP; glioma; Ki-67; S-100B; tumour marker; tumour volume	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; S-100B PROTEIN; ACUTE STROKE; MARKER; KI-67; S100-BETA; PREDICTOR	Objectives - To investigate serum levels of glial fibrillary acidic protein (GFAP) and S-100B in patients with newly diagnosed high-grade gliomas. Materials and methods - GFAP and S-100B were measured by enzyme-linked immunosorbent assay techniques in preoperative serum from 31 patients with high-grade gliomas. A database with clinical, radiological and histological variables was created for statistical analyses. Results - Mean serum levels of 239 ng/l (range 30-1210 ng/l) for GFAP and 58.3 ng/l (range 22-128 ng/l) for S-100B were found. Of the 31 patients, 16 had elevated levels of GFAP while only two showed increased S-100B concentrations. Tumour size was the only variable significantly associated with serum levels of GFAP (P < 0.0001) with a linear correlation coefficient of 0.67. Conclusions - Serum levels of GFAP demonstrated a linear correlation to tumour volume in patients with high-grade gliomas. GFAP seems to be a more reliable biomarker in patients with high-grade gliomas than the commercially available S-100B.	Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; Gothenburg Univ, Dept Neurol, Sahlgrenska Univ Hosp, Inst Clin Neurosci, Gothenburg, Sweden; Univ Hosp N Norway, Dept Pathol, Tromso, Norway		Brommeland, T (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.	tor.brommeland@unn.no	Brommeland, Tor/AAJ-8483-2020; Brommeland, Tor/AAW-4941-2021	Rosengren, Lars/0000-0003-0505-8896			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Blennow M, 2001, ACTA PAEDIATR, V90, P1171, DOI 10.1080/080352501317061594; COONS SW, 1993, J NEUROPATH EXP NEUR, V52, P609, DOI 10.1097/00005072-199311000-00008; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Fukuda ME, 2005, CANCER RES, V65, P5190, DOI 10.1158/0008-5472.CAN-04-4134; Haapasalo J, 2005, J CLIN PATHOL, V58, P263, DOI 10.1136/jcp.2004.018606; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; IWA N, 1988, DIAGN CYTOPATHOL, V4, P74, DOI 10.1002/dc.2840040118; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kayaselcuk F, 2002, J NEURO-ONCOL, V57, P115, DOI 10.1023/A:1015739130208; LAMERS KJB, 1995, ACTA NEUROL SCAND, V92, P247; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; Molina R, 2002, TUMOR BIOL, V23, P39, DOI 10.1159/000048687; Moskowitz SI, 2006, J NEURO-ONCOL, V76, P193, DOI 10.1007/s11060-005-5262-1; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Rajendra A, 2004, J NEURO-ONCOL, V67, P345, DOI 10.1023/B:NEON.0000024216.15923.77; ROSENGREN LE, 1995, J NEUROL SCI, V133, P61, DOI 10.1016/0022-510X(95)00152-R; RUUTIAINEN J, 1981, ACTA NEUROL SCAND, V63, P297; Sampath Prakash, 2004, Cancer Control, V11, P174; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Sorensen AG, 2001, J CLIN ONCOL, V19, P551, DOI 10.1200/JCO.2001.19.2.551; Tanwar MK, 2002, CANCER RES, V62, P4364; VANDEPOL M, 1994, J NEURO-ONCOL, V19, P149, DOI 10.1007/BF01306456; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; Vos MJ, 2004, ANTICANCER RES, V24, P2511; Wakimoto H, 1996, CANCER-AM CANCER SOC, V77, P373, DOI 10.1002/(SICI)1097-0142(19960115)77:2<373::AID-CNCR21>3.0.CO;2-Y; Yoshida S, 2000, J SURG ONCOL, V75, P131, DOI 10.1002/1096-9098(200010)75:2<131::AID-JSO10>3.0.CO;2-L; Zheng PP, 2005, CLIN CANCER RES, V11, P4388, DOI 10.1158/1078-0432.CCR-04-2512	34	47	53	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	DEC	2007	116	6					380	384		10.1111/j.1600-0404.2007.00889.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	226VZ	WOS:000250617900006	17986096				2022-02-06	
J	Hou, DJ; Tong, KA; Ashwal, S; Oyoyo, U; Joo, E; Shutter, L; Obenaus, A				Hou, Daniel J.; Tong, Karen A.; Ashwal, Stephan; Oyoyo, Udochukwu; Joo, Elliott; Shutter, Lori; Obenaus, Andre			Diffusion-weighted magnetic resonance Imaging improves outcome prediction in adult traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apparent diffusion coefficient; brain; diffuse axonal injury; gray matter; white matter	CLOSED-HEAD INJURY; GLASGOW COMA SCALE; AXONAL INJURY; CORPUS-CALLOSUM; ACUTE STROKE; MR; SEVERITY; EDEMA; COEFFICIENT; EXPERIENCE	In patients with traumatic brain injury TBI), diffuse axonal injury (DAI) accounts for a significant amount of parenchymal injury. Diffusion weighted magnetic resonance imaging (DWI) is known to be sensitive for detecting visible DAI lesions. We focused on detection of non-visible, quantifiable diffusion changes in specific normal-appearing brain regions, using apparent diffusion coefficient (ADC) maps. Thirty-seven adults with TBI were compared to 35 age-matched control patients. DWI was performed and ADC maps were generated. Thirty-one regions of interest (ROI) were manually drawn on ADC maps and ADC values extracted. Brain ROIs were categorized into five zones: peripheral gray matter, peripheral white matter, deep gray matter, deep white matter, and posterior fossa. ADC results were compared with the severity of injury based on the admission Glasgow Coma Scale (GCS 3-8; severe; GSC 9-15 mild/moderate) and with long-term outcome (6-12 months after injury) using the Glasgow Outcome Scale (GOS 1-3, unfavorable; GOS: 4-5, favorable) score. Mean ADC values in all five brain zones were significantly different between TBI subjects and controls (P <= 0.05). Patients with more severe injury (i.e., GCS 3-8) had significantly different mean ADC values than control patients (p :5 0.05) and patients with unfavorable outcomes had significantly higher mean deep gray and white matter ADC values compared to those with favorable outcomes and to controls (p :5 0.05). Thus, ADC maps can be used to detect non-visible DAI lesions. In addition, injuries in the deep gray and white matter may be useful to predict outcome in adult TBI patients.	Loma Linda Univ, Med Ctr, Dept Neuroradiol, Loma Linda, CA 92354 USA; Univ British Columbia, Fac Med, Vancouver, BC, Canada; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA 92354 USA; Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA		Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Neuroradiol, Schuman Pavil,Rm B623,112354 Anderson St, Loma Linda, CA 92354 USA.	ktong@llu.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bydder GM, 2001, CHILD NERV SYST, V17, P190, DOI 10.1007/s003810000280; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Galloway N, 2005, J NEUROTRAUM, V22, P1244; Gean AD, 1994, IMAGING HEAD TRAUMA; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Helenius J, 2002, AM J NEURORADIOL, V23, P194; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Karibe H, 2000, J NEUROSURG, V92, P58, DOI 10.3171/jns.2000.92.1.0058; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mateo Magdalena A, 2003, Lippincotts Case Manag, V8, P203, DOI 10.1097/00129234-200309000-00005; McGraw P, 2002, AM J ROENTGENOL, V179, P1515, DOI 10.2214/ajr.179.6.1791515; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Prayer D, 2003, EUR J RADIOL, V45, P235, DOI 10.1016/S0720-048X(02)00312-1; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SCHAEFFER P, 1998, 36 ANN M AM SOC NEUR; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	51	47	54	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2007	24	10					1558	1569		10.1089/neu.2007.0339			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	227HZ	WOS:000250649100002	17970619				2022-02-06	
J	Gorio, A; Madaschi, L; Zadra, G; Marfia, G; Cavalieri, B; Bertini, R; Di Giulio, AM				Gorio, Alfredo; Madaschi, Laura; Zadra, Giorgia; Marfia, Giovanni; Cavalieri, Barbara; Bertini, Riccardo; Di Giulio, Anna Maria			Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							TUMOR NECROSIS FACTOR; TNF-ALPHA; INJURY; METHYLPREDNISOLONE; BRAIN; ERYTHROPOIETIN; ISCHEMIA; NEUTROPHIL; REPERTAXIN; EXPRESSION	It has been shown that the blockade of CXCR1 and CXCR2 receptors prevents ischemia/reperfusion damage in several types of vascular beds. Reparixin is a recently described inhibitor of human CXCR1/R2 and rat CXCR2 receptor activation. We applied reparixin in rats following traumatic spinal cord injury and determined therapeutic temporal and dosages windows. Treatment with reparixin significantly counteracts secondary degeneration by reducing oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells. The observed preservation of the white matter might also be secondary to the enhanced proliferation of NG2-positive cells. The expression of macrophage-inflammatory protein-2, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1 beta was also counteracted, and the proliferation of glial fibrillary acidic protein-positive cells was markedly reduced. These effects resulted in a smaller post-traumatic cavity and in a significantly improved recovery of hind limb function. The best beneficial outcome of reparixin treatment required 7-day administration either by i.p. route (15 mg/kg) or subcutaneous infusion via osmotic pumps (10 mg/kg), reaching a steady blood level of 8 mu g/ml. Methylprednisolone was used as a reference drug; such treatment reduced cytokine production but failed to affect the rate of hind limb recovery.	Univ Milan, Pharmacol Labs, Fac Med, Dept Med Surg & Dent, Milan, Italy; Ist Ric & Cura & Cavattere Sci Humanitas, Milan, Italy; Dompe Pharma SPA, Laquila, Italy		Gorio, A (corresponding author), Dept Med Surg & Dent, Pharmacol Labs, Via A Rydubu 8, I-20142 Milan, Italy.	alfredo.gorio@unimi.it	Marfia, Giovanni/N-4650-2014; Marfia, Giovanni/AAB-8702-2020	Marfia, Giovanni/0000-0002-5849-7000; Marfia, Giovanni/0000-0002-5849-7000; Di Giulio, Anna Maria/0000-0002-5702-4623			BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Ballermann M, 2006, EUR J NEUROSCI, V23, P1988, DOI 10.1111/j.1460-9568.2006.04726.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Boyle EM, 1999, ANN THORAC SURG, V68, P1949, DOI 10.1016/S0003-4975(99)01033-4; Bracken MB, 2002, J NEUROSURG, V96, P140; Cavalieri B, 2005, INT J IMMUNOPATH PH, V18, P475, DOI 10.1177/039463200501800307; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; Cugini D, 2005, KIDNEY INT, V67, P1753, DOI 10.1111/j.1523-1755.2005.00272.x; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Fu ES, 2005, J NEUROSURG ANESTH, V17, P82, DOI 10.1097/01.ana.0000163199.10365.38; Garau A, 2005, CYTOKINE, V30, P125, DOI 10.1016/j.cyto.2004.12.014; Gilmont RR, 1996, J SURG RES, V61, P175, DOI 10.1006/jsre.1996.0101; GIULIAN D, 1993, J NEUROSCI, V13, P29; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lankhorst AJ, 2000, BRAIN RES, V859, P334, DOI 10.1016/S0006-8993(00)02025-4; MERCHANT SH, 2003, AM J PHYSIOL, V284, P1260; Merola A, 2002, J ORTHOP TRAUMA, V16, P155, DOI 10.1097/00005131-200203000-00003; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miura M, 2001, AM J PATHOL, V159, P2137, DOI 10.1016/S0002-9440(10)63065-9; Nakashima S, 2004, NEUROREPORT, V15, P2337, DOI 10.1097/00001756-200410250-00007; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; SCHLAYER HJ, 1988, J HEPATOL, V7, P239, DOI 10.1016/S0168-8278(88)80488-4; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; Souza DG, 2004, BRIT J PHARMACOL, V143, P132, DOI 10.1038/sj.bjp.0705862; Souza DG, 2001, BRIT J PHARMACOL, V134, P985, DOI 10.1038/sj.bjp.0704336; Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Vitellaro-Zuccarello L, 2007, NEUROSCIENCE, V144, P865, DOI 10.1016/j.neuroscience.2006.10.023; Willerson J T, 1997, Adv Pharmacol, V39, P291, DOI 10.1016/S1054-3589(08)60074-5; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	41	47	47	0	6	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	SEP	2007	322	3					973	981		10.1124/jpet.107.123679			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	202FM	WOS:000248887400009	17601981				2022-02-06	
J	Dvorak, J; McCrory, P; Kirkendall, DT				Dvorak, Jiri; McCrory, Paul; Kirkendall, Donald T.			Head injuries in the female football player: incidence, mechanisms, risk factors and management	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SOCCER INJURIES; EUROPEAN FOOTBALL; SEX-DIFFERENCES; CONCUSSION; STATEMENT; SEASON; LEAGUE	Although all injuries in sports are a concern for participants, head injuries are particularly troublesome because of the potential for long-term cognitive deficits. To prevent any specific injury, it is important to understand the basic frequency and incidence of injury and then the mechanism of injury. Once these are established, prevention programmes can be tested to see if the rate of injury changes. A primary problem with head injuries is recognising that the injury has occurred. Many athletes are not aware of the seriousness of concussive injury, thus this type of injury is probably under-reported. Once the diagnosis of a concussion is made, the next difficult decision is when to return a player to the game. These two management issues dominate the continuing development of understanding of concussive head injury. This paper explores the known gender differences between head injuries and highlights the areas that need to be considered in future research.	Schulthess Klin, Zurich, Switzerland; FIFA Med Assessment & Res Ctr, Zurich, Switzerland; Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia		Dvorak, J (corresponding author), Schulthess Klin, Zurich, Switzerland.	jiri.dvorak@kws.ch	McCrory, Paul/Q-8688-2019				Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Arnason A, 1996, SCAND J MED SCI SPOR, V6, P40, DOI 10.1111/j.1600-0838.1996.tb00069.x; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Balestreri M, 2003, J NEUROSURG, V99, P616; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; EKSTRAND J, 1983, AM J SPORT MED, V11, P63, DOI 10.1177/036354658301100203; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; Farace E, 2000, Neurosurg Focus, V8, pe6; Faude O, 2006, BRIT J SPORT MED, V40, P785, DOI 10.1136/bjsm.2006.027540; Faude O, 2005, AM J SPORT MED, V33, P1694, DOI 10.1177/0363546505275011; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Hawkins RD, 2001, BRIT J SPORT MED, V35, P43, DOI 10.1136/bjsm.35.1.43; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Junge A, 2004, AM J SPORT MED, V32, p23S, DOI 10.1177/0363546503261246; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Kraus J F, 2000, Neurosurg Focus, V8, pe5; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCCRORY P, 2003, AMJ, V327, P352; Morgan BE, 2001, AM J SPORT MED, V29, P426, DOI 10.1177/03635465010290040701; Ostenberg A, 2000, SCAND J MED SCI SPOR, V10, P279, DOI 10.1034/j.1600-0838.2000.010005279.x; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA	31	47	47	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2007	41			1			I44	I46	i44-i46	10.1136/bjsm.2007.037960			3	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	193DM	WOS:000248254400009	17496069	Green Published			2022-02-06	
J	Borekci, B; Aksoy, H; Al, RA; Demircan, B; Kadanali, S				Borekci, Bunyamin; Aksoy, Hulya; Al, Ragip Atakan; Demircan, Berna; Kadanali, Sedat			Maternal serum interleukin-10, interleukin-2 and interleukin-6 in pre-eclampsia and eclampsia	AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY			English	Article						convulsion; cytokines; eclampsia; IL-10; pre-eclampsia	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID; ANTIINFLAMMATORY CYTOKINES; RECEPTOR ANTAGONIST; PLASMA-LEVELS; WOMEN; IL-10; EPILEPSY; RELEASE	Problem The aim of the study was to investigate and compare the concentrations of interleukin (IL)-2, IL-6, and IL-10 in serum of women with mild pre-eclampsia, severe pre-eclampsia, eclampsia, and normotensive pregnancy. Method of study A total of 69 consecutive cases, 38 mild pre-eclampsia, 20 severe pre-eclampsia, 11 eclampsia, and 20 normotensive controls were included in this study. Serum IL-2, IL-6, and IL-10 levels were determined using enzyme-linked immunosorbent assay method. Results Gestational age (P = 0.210) and body mass index (P = 0.214) between the groups were similar. The mean concentration of serum IL-2 and IL-6 were not different between the groups (P = 0.261, P = 0.141 respectively). The median concentrations of serum IL-10 in patients with mild and severe pre-eclampsia were similar (P < 0.282) and was significantly lower than those of controls (P < 0.001) and patients with eclampsia (P < 0.001). In patients with eclampsia, the median concentration of IL-10 was significantly higher than that of all other groups (P < 0.001 for each comparison). Conclusion Pre-eclampsia is associated with a deficiency serum IL-10. High serum IL-10 is correlated with the presence of eclampsia.	Ataturk Univ, Sch Med, Dept Obstet & Gynecol, Erzurum, Turkey; Ataturk Univ, Sch Med, Dept Biochem, Erzurum, Turkey		Borekci, B (corresponding author), Atalar Mah Pasalar Cad,Pasalar Apt Kat 5,11, TR-25100 Erzurum, Turkey.	borekcib@gmail.com	Kadanali, Sedat/ABH-3487-2021; al, ragip a/A-1177-2012	al, ragip a/0000-0003-2921-1891			Al-Othman S, 2001, GYNECOL OBSTET INVES, V52, P60, DOI 10.1159/000052943; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Azizieh F, 2005, AM J REPROD IMMUNOL, V54, P30, DOI 10.1111/j.1600-0897.2005.00278.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Benian A, 2002, OBSTET GYNECOL, V100, P327, DOI 10.1016/S0029-7844(02)02077-X; Benyo DF, 2001, J CLIN ENDOCR METAB, V86, P2505, DOI 10.1210/jc.86.6.2505; Bowen JM, 2002, PLACENTA, V23, P239, DOI 10.1053/plac.2001.0781; Conrad KP, 1998, AM J REPROD IMMUNOL, V40, P102; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cunningham FG, 2000, AM J OBSTET GYNECOL, V182, P94, DOI 10.1016/S0002-9378(00)70496-0; Cunningham FG, 2005, HYPERTENSIVE DISORDE, V22nd, P761; Darmochwal-Kolarz D, 1999, EUR J OBSTET GYN R B, V86, P165, DOI 10.1016/S0301-2115(99)00065-2; De Sarro Giovambattista, 1994, Neuroimmunomodulation, V1, P361, DOI 10.1159/000097189; Del Gobbo V, 2000, AM J REPROD IMMUNOL, V44, P214, DOI 10.1111/j.8755-8920.2000.440405.x; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Dziedzic T, 2002, STROKE, V33, P2334, DOI 10.1161/01.STR.0000027211.73567.FA; Eneroth E, 1998, ACTA OBSTET GYN SCAN, V77, P591, DOI 10.1034/j.1600-0412.1998.770602.x; Gant NF, 1996, INT J GYNECOL OBSTET, V53, P175; Gratacos E, 1998, OBSTET GYNECOL, V92, P849, DOI 10.1016/S0029-7844(98)00300-7; GREER IA, 1994, OBSTET GYNECOL, V84, P937; Hennessy A, 1999, J IMMUNOL, V163, P3491; Hulkkonen J, 2004, EPILEPSY RES, V59, P199, DOI 10.1016/j.eplepsyres.2004.04.007; Jonsson Y, 2004, AM J REPROD IMMUNOL, V51, P302, DOI 10.1111/j.1600-0897.2004.00161.x; Jonsson Y, 2006, J REPROD IMMUNOL, V70, P83, DOI 10.1016/j.jri.2005.10.007; Katz VL, 2000, AM J OBSTET GYNECOL, V182, P1389, DOI 10.1067/mob.2000.106178; Kaufmann P, 2003, BIOL REPROD, V69, P1, DOI 10.1095/biolreprod.102.014977; KAUMA SW, 1995, J SOC GYNECOL INVEST, V2, P614, DOI 10.1016/1071-5576(95)00007-2; Loureiro R, 2003, AM J OBSTET GYNECOL, V189, P1350, DOI 10.1067/S0002-9378(03)00651-3; Madazli R, 2003, ACTA OBSTET GYN SCAN, V82, P797, DOI 10.1034/j.1600-0412.2003.00206.x; Makris A, 2006, PLACENTA, V27, P445, DOI 10.1016/j.placenta.2005.05.003; Morriss MC, 1997, OBSTET GYNECOL, V89, P561; NISTICO G, 1991, ANN NY ACAD SCI, V621, P119; Olusi SO, 2000, ANN SAUDI MED, V20, P4, DOI 10.5144/0256-4947.2000.4; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Orange S, 2005, CYTOKINE, V29, P176, DOI 10.1016/j.cyto.2004.10.011; Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200; PACIFICI R, 1995, EPILEPSIA, V36, P384, DOI 10.1111/j.1528-1157.1995.tb01013.x; Pelidou SH, 1999, EUR J NEUROL, V6, P437, DOI 10.1046/j.1468-1331.1999.640437.x; Peltola J, 1998, EPILEPSY RES, V31, P129, DOI 10.1016/S0920-1211(98)00024-2; Peltola J, 2002, SEIZURE-EUR J EPILEP, V11, P44, DOI 10.1053/seiz.2001.0575; Peltola J, 2000, EPILEPSY RES, V41, P205, DOI 10.1016/S0920-1211(00)00140-6; Perini F, 2001, NEUROL SCI, V22, P289, DOI 10.1007/s10072-001-8170-y; Redmon D, 2003, DEVIANT BEHAV, V24, P27, DOI 10.1080/10639620390117174; Rein DT, 2003, CYTOKINE, V23, P119, DOI 10.1016/S1043-4666(03)00220-5; Rinehart BK, 1999, AM J OBSTET GYNECOL, V181, P915, DOI 10.1016/S0002-9378(99)70325-X; Schwartz RB, 2000, RADIOLOGY, V217, P371, DOI 10.1148/radiology.217.2.r00nv44371; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; Sotgiu S, 2006, EUR J NEUROL, V13, P505, DOI 10.1111/j.1468-1331.2006.01280.x; Straussberg R, 2001, PEDIATR NEUROL, V24, P49, DOI 10.1016/S0887-8994(00)00234-4; Takano T, 2002, PEDIATR NEUROL, V26, P71, DOI 10.1016/S0887-8994(01)00345-9; Takano T, 2001, ANN NEUROL, V49, P685, DOI 10.1002/ana.1043.abs; Tarkowski E, 1997, CLIN EXP IMMUNOL, V110, P492, DOI 10.1046/j.1365-2249.1997.4621483.x; Vatten LJ, 2004, BJOG-INT J OBSTET GY, V111, P298, DOI 10.1111/j.1471-0528.2004.00071.x; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vila N, 2003, STROKE, V34, P671, DOI 10.1161/01.STR.0000057976.53301.69; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Virta M, 2002, EPILEPSIA, V43, P920, DOI 10.1046/j.1528-1157.2002.02002.x; Zeeman GG, 2004, AM J OBSTET GYNECOL, V191, P1425, DOI 10.1016/j.ajog.2004.05.069; Zeeman GG, 2004, AM J OBSTET GYNECOL, V190, P714, DOI 10.1016/j.ajog.2003.09.015	59	47	48	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1046-7408	1600-0897		AM J REPROD IMMUNOL	Am. J. Reprod. Immunol.	JUL	2007	58	1					56	64		10.1111/j.1600-0897.2007.00491.x			9	Immunology; Reproductive Biology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Reproductive Biology	178EX	WOS:000247205100007	17565548				2022-02-06	
J	Reeves, TM; Phillips, LL; Lee, NN; Povlishock, JT				Reeves, Thomas M.; Phillips, Linda L.; Lee, Nancy N.; Povlishock, John T.			Preferential neuroprotective effect of tacrolimus (FK506) on unmyelinated axons following traumatic brain injury	BRAIN RESEARCH			English	Article						traumatic axonal injury; traumatic brain injury; FKS06; compound action potential; corpus callosum; neuroprotection	SPINAL-CORD-INJURY; RAT CORPUS-CALLOSUM; FUNCTIONAL RECOVERY; WHITE-MATTER; DAMAGE; CALCINEURIN; EXPRESSION; PROTEIN; DEPHOSPHORYLATION; CYCLOSPORINE	Prior investigations of traumatic axonal injury (TAI), and pharmacological treatments of TAI pathology, have focused exclusively on the role of myelinated axons, with no systematic observations directed towards unmyelinated axon pathophysiology. Recent electrophysiological evidence, however, indicates that unmyelinated axons are more vulnerable than myelinated axons in a rodent model of experimental TAL Given their susceptibility to TAI, the present study examines whether unmyelinated axons also respond differentially to FK506, an immunophilin ligand with well-established neuroprotective efficacy in the myelinated fiber population. Adult rats received 3.0 mg/kg FK506 intravenously at 30 min prior to midline fluid percussion injury. in brain slice electrophysiological recordings, conducted at 24 h postinjury, compound action potentials (CAPs) were evoked in the corpus callosum, and injury effects quantified separately for CAP waveform components generated by myelinated axons (Ni wave) and unmyelinated axons (N-2 wave). The amplitudes of both CAP components were suppressed postinjury, although this deficit was 16% greater for the N2 CAP. While FK506 treatment provided significant neuroprotection for both N-1 and N-2 CAPS, the drug benefit for the N-2 CAP amplitude was 122% greater than that for the N-1 CAPs, and improved postinjury strength - duration and refractoriness properties only in N-2 CAPS. Immunocytochemical observations, of TAI reflected in intra-axonal pooling of amyloid precursor protein, indicated that FK506 reduced the extent of postinjury impairments to axonal transport and subsequent axonal damage. Collectively, these studies further substantiate a distinctive role of unmyelinated axons in TAI, and suggest a highly efficacious neuroprotective strategy to target this axonal population. (C) 2007 Elsevier B.V. All rights reserved.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Reeves, TM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, 1217 E Marshall St,Room 740,Med Campus Box 980709, Richmond, VA 23298 USA.	tmreeves@vcu.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD055813, HD055813, R01 HD055813-24] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56 NS044372, NS44372, R01 NS056247, R01 NS044372, R01 NS044372-04, P30 NS047463] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS056247, R01NS044372, R56NS044372] Funding Source: NIH RePORTER		ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; BOSTOCK H, 1983, J PHYSIOL-LONDON, V341, P41, DOI 10.1113/jphysiol.1983.sp014791; Bostock H, 1997, J PHYSIOL-LONDON, V498, P277, DOI 10.1113/jphysiol.1997.sp021857; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Burke D, 2000, BRAIN, V123, P992, DOI 10.1093/brain/123.5.992; Butcher SP, 1997, J NEUROSCI, V17, P6939; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; GRAVEL C, 1990, J COMP NEUROL, V291, P147, DOI 10.1002/cne.902910110; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; LAMANTIA AS, 1990, J COMP NEUROL, V291, P520, DOI 10.1002/cne.902910404; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mobley Lloyd W 3rd, 2003, Spine J, V3, P11, DOI 10.1016/S1529-9430(02)00442-4; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; Noto T, 2004, MOL BRAIN RES, V128, P30, DOI 10.1016/j.molbrainres.2004.06.003; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Partadiredja G, 2003, J NEUROCYTOL, V32, P1165, DOI 10.1023/B:NEUR.0000021910.65920.41; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PRESTON RJ, 1983, EXP NEUROL, V79, P808, DOI 10.1016/0014-4886(83)90044-4; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Springer JE, 2000, J NEUROSCI, V20, P7246; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; SWADLOW HA, 1980, ARCH NEUROL-CHICAGO, V37, P114, DOI 10.1001/archneur.1980.00500510072016; Swanson TH, 1998, BRAIN RES, V784, P188, DOI 10.1016/S0006-8993(97)01323-1	49	47	49	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	2007	1154						225	236		10.1016/j.brainres.2007.04.002			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	187OK	WOS:000247857400025	17481596	Green Accepted			2022-02-06	
J	Pascual, JM; Solivera, J; Prieto, R; Barrios, L; Lopez-Larrubia, P; Cerdan, S; Roda, JM				Pascual, Jose M.; Solivera, Juan; Prieto, Ruth; Barrios, Laura; Lopez-Larrubia, Pilar; Cerdan, Sebastian; Roda, Jose M.			Time course of early metabolic changes following diffuse traumatic brain injury in rats as detected by H-1 NMR spectroscopy	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; H-1-NMR spectroscopy; myo-inositol; organic osmolyte; taurine; traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; ORGANIC OSMOLYTES; CELLULAR EDEMA; TAURINE; GLUTAMATE; VOLUME; MODEL; PATHOPHYSIOLOGY	Experimental models of traumatic brain injury (TBI) provide a useful tool for understanding the cerebral metabolic changes induced by this pathological condition. Here, we report on the time course of changes in cerebral metabolites after TBI and its correlation with early brain morphological changes using a combination of high-resolution proton magnetic resonance spectroscopy (H-1 MRS) and magnetic resonance imaging (MRI). Adult male Sprague-Dawley rats were subjected to closed head impact and examined by MRI at 1, 9, 24, 48, and and 72 h after the injury. Extracts from funnel frozen rat brains were then obtained and analyzed quantitatively by high-resolution 1H MRS. Finally, statistical multivariate analysis was carried out to identify the combination of cerebral metabolites that best described the time evolution of diffuse TBI. The temporal changes observed in the concentration of cerebral metabolites followed three different patterns. The first pattern included taurine, threonine, and glycine, with concentrations peaking 24 h after the injury. The second pattern included glutamate, GABA, and alanine, with concentrations remaining elevated between 24 and 48 h post-injury. The third one involved creatine-phosphocreatine, N-acetylaspartate, and myo-inositol, with concentrations peaking 48 h after the injury. A multivariate stepwise discriminant analysis revealed that the combination of the organic osmolytes taurine and myo-inositol allowed optimal discrimination among the different time groups. Our findings suggest that the profile of some specific brain molecules that play a role as organic osmolytes can be used to follow-up the progression of the early diffuse brain edema response induced by TBI.	Hosp Univ La Princesa, Dept Neurosurg, C Diego de Leon 62, E-28006 Madrid, Spain; Sant Creu & Sant Pau Univ Hosp, Dept Neurosurg, Barcelona, Spain; La Paz Univ Hosp, Dept Neurosurg, Madrid, Spain; CSIC, Comp Tech Ctr, Dept Stat, Madrid, Spain; CSIC, Biomed Res Inst Alberto Sols, Madrid, Spain		Pascual, JM (corresponding author), Hosp Univ La Princesa, Dept Neurosurg, C Diego de Leon 62, E-28006 Madrid, Spain.	jmpascual@iib.uam.es	Solivera, Juan/AAG-8863-2019; Pascual, Jose Maria/AAA-6111-2022; Lopez-Larrubia, Pilar/B-3902-2013; Lopez-Larrubia, Pilar/AAC-7964-2020	Pascual, Jose Maria/0000-0002-3114-0474; Lopez-Larrubia, Pilar/0000-0002-5141-8736; Lopez-Larrubia, Pilar/0000-0002-5141-8736; Cerdan, Sebastian/0000-0001-9965-0270; Solivera Vela, Juan/0000-0003-2860-6656			Afifi A., 2004, COMPUTER AIDED MULTI, V4th edn). Chapman and Hall CRC.; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alexander JJ, 2005, NEUROCHEM INT, V47, P143, DOI 10.1016/j.neuint.2005.04.016; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P243; BAUMGARTEN CM, 2001, CELL PHYSL SOURCE BO, P253; BEHAR KL, 1991, MAGNET RESON MED, V17, P285, DOI 10.1002/mrm.1910170202; Bothwell JH, 2001, J NEUROCHEM, V77, P1632, DOI 10.1046/j.1471-4159.2001.00403.x; Bouma GJ, 1998, ACT NEUR S, V71, P272; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; CERDAN S, 1990, ANNU REV BIOPHYS BIO, V19, P43; CERDAN S, 1985, FEBS LETT, V187, P167, DOI 10.1016/0014-5793(85)81235-7; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gruetter R, 1998, J MAGN RESON, V135, P260, DOI 10.1006/jmre.1998.1542; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KEMPSKI OS, 1994, ACT NEUR S, V60, P7; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lobato R D, 1993, Adv Tech Stand Neurosurg, V20, P3; LUST WD, 1989, NEUROMETHODS, V11, P1; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, ACT NEUR S, V60, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MONGIN AA, 2005, NEUROGLIA, P550; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NAGELHUS EA, 1993, NEUROSCIENCE, V54, P615, DOI 10.1016/0306-4522(93)90233-6; Nonaka M, 1998, J NEUROL SCI, V157, P25, DOI 10.1016/S0022-510X(98)00062-8; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pasantes-Morales H, 2000, CELL PHYSIOL BIOCHEM, V10, P361, DOI 10.1159/000016369; PASANTESMORALES H, 1994, AM J PHYSIOL, V266, pC172, DOI 10.1152/ajpcell.1994.266.1.C172; PasantesMorales H, 1997, AMINO ACIDS, V12, P281, DOI 10.1007/BF01373008; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; PAXINOS G, 1998, PHARM RES, V48, P101; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Rumpel H, 2003, J MAGN RESON IMAGING, V17, P11, DOI 10.1002/jmri.10233; SCHNEIDER GH, 1993, J PHYSIOL PHARMACOL, V70, pS334; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Seki Y, 2005, NEUROCHEM RES, V30, P123, DOI 10.1007/s11064-004-9693-4; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; SON BC, 2000, ACTA NEUROCHIR S, V76, P6; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; STRANGE K, 1992, AM J PHYSIOL, V263, pC412, DOI 10.1152/ajpcell.1992.263.2.C412; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Tkac I, 2001, MAGNET RESON MED, V46, P451, DOI 10.1002/mrm.1213; TORP R, 1991, NEUROSCIENCE, V41, P433, DOI 10.1016/0306-4522(91)90339-P; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Weber D.C., 2000, 1 COURSE DESIGN EXPT	68	47	50	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					944	959		10.1089/neu.2006.0190			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700004	17600512	Green Submitted			2022-02-06	
J	Kline, AE; Massucci, JL; Zafonte, RD; Dixon, CE; Defeo, JR; Rogers, EH				Kline, Anthony E.; Massucci, Jaime L.; Zafonte, Ross D.; Dixon, C. Edward; DeFeo, Judith R.; Rogers, Emily H.			Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma	CRITICAL CARE MEDICINE			English	Article						beam balance; catecholamines; cognition; controlled cortical impact; functional recovery; Morris water maze; traumatic brain injury	CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; RAT FRONTAL-CORTEX; METHYLPHENIDATE TREATMENT; ATYPICAL ANTIPSYCHOTICS; COGNITIVE DEFICITS; WORKING-MEMORY; INJURY; RECOVERY; DAMAGE	Objectives: Antipsychotics are routinely administered to patients with traumatic brain injury, even though the benefits vs. risks of this approach on behavioral recovery are unclear. To clarify the issue, the present study evaluated the effect of single and multiple administrations of haloperidol and risperidone on functional outcome after traumatic brain injury. Design: Prospective and randomized study in rodents. Setting: Experimental research laboratory at the University of Pittsburgh. Subjects: A total of 60 adult male Sprague-Dawley rats weighing 300-325 g. Interventions: Anesthetized rats received either a cortical impact or sham injury and then were randomly assigned to five traumatic brain injury groups (0.045 mg/kg, 0.45 mg/kg, or 4.5 mg/kg risperidone; 0.5 mg/kg haloperidol; or 1 mL/kg vehicle) or three sham groups (4.5 mg/kg risperidone, 0.5 mg/kg haloperidol, or 1 mL/kg vehicle). The experiment consisted of three phases. In the first phase, a single treatment was provided (intraperitoneally) 24 hrs after surgery, and motor and cognitive function was assessed on postoperative days 1-5 and 14-18, respectively. During the second phase, after completion of the initial behavioral tasks, the same rats were treated once daily for 5 days and behavior was reevaluated. During the third phase, treatments were discontinued, and 3 days later, the rats were assessed one final time. Measurements and Main Results: Time (seconds) to maintain beam balance, traverse an elevated beam, and to locate a submerged platform in a Morris water maze was recorded. Neither motor nor cognitive performance was affected after a single treatment, regardless of group assignment (p > .05). In contrast, both behavioral deficits reoccurred after daily treatments of risperidone (4.5 mg/kg) and haloperidol (p < .05). The cognitive deficits persisted even after a 3-day washout period during the third phase. Conclusions: These data suggest that although single or multiple low doses of risperidone and haloperidol may be innocuous to subsequent recovery after traumatic brain injury, chronic high-dose treatments are detrimental.	Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Kline, AE (corresponding author), Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046700-03, R01 HD069620, R03 HD043851-01, HD043851, R03 HD043851, R03 HD043851-02, R01 HD046700-01A1, R01 HD046700-04, R01 HD046700, HD046770, R01 HD046700-02] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851, R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER		Alleva E, 1996, PROG NEURO-PSYCHOPH, V20, P483, DOI 10.1016/0278-5846(96)00010-3; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 2004, RESTOR NEUROL NEUROS, V22, P175; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Feeney DM, 1997, ADV NEUROL, V73, P383; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P1; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Levy M, 2005, NEUROREHABILITATION, V20, P279; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 1997, BEHAV BRAIN RES, V87, P105, DOI 10.1016/S0166-4328(96)02266-8; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; SCHOTTE A, 1993, BRAIN RES, V631, P191, DOI 10.1016/0006-8993(93)91535-Z; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	39	47	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2007	35	3					919	924		10.1097/01.CCM.0000256722.88854.C0			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139ZE	WOS:000244470800033	17255872	Green Accepted			2022-02-06	
J	Nekludov, M; Antovic, J; Bredbacka, S; Blomback, M				Nekludov, Michael; Antovic, Jovan; Bredbacka, Sixten; Blomback, Margareta			Coagulation abnormalities associated with severe isolated traumatic brain injury: Cerebral arterio-venous differences in coagulation and inflammatory markers	JOURNAL OF NEUROTRAUMA			English	Article						coagulopathy; inflammation; jugular bulb catheter; transcranial gradient; traumatic brain injury (TBI)	MEMBRANE ATTACK COMPLEX; HEAD TRAUMA; PROCOAGULANT ACTIVITY; COAGULOPATHY; DYSFUNCTION; ACTIVATION; CYTOKINES; TIME	Although coagulopathy is known to be the major contributor to a poor outcome of traumatic brain injury (TBI), the mechanisms that trigger coagulation abnormalities have not been studied in detail. We undertook a prospective observational study at a neurosurgical ICU (NICU) in a university hospital. We examined 11 patients with severe isolated TBI, at admittance to the hospital and during the next 3 days. We collected cerebrovenous blood samples from a jugular bulb catheter, arterial blood, and cerebrospinal fluid (CSF) samples. We measured concentrations of thombin-antithrombin complex (TAT), fibrin D-dimer (DD), prothrombin fragment 1+2 (F1+2), interleukin-6 (IL-6), and complement complex (C5b-9). All patients had some degree of consumption coagulopathy at the study start and a tendency to thrombocytopenia during the next few days. Levels of DD (3.6 +/- 2.7 mg/L), TAT (86 +/- 72 mu g/L) and F1+2 (5.9 +/- 6.8 nmol/L) were significantly increased shortly after the trauma compared to reference values, with considerable transcranial gradients for TAT (49 mu g/L) and F1+2 (3.2 nmol/L). Compared to controls, IL-6 levels were increased more than a hundredfold in both blood (283 +/- 192 ng/L) and CSF (424 +/- 355 ng/L) samples, with a transcranial gradient at the study start (107 ng/L). C5b-9 levels were moderately increased in blood samples, 270 114 mu g/L, versus controls, 184 39 (p < 0.05). We conclude that activation of the coagulation system takes place during the passage of blood through the damaged brain, and is already evident hours after the trauma. IL-6 and activation of the complement system (C5b-9) co-vary with hemostatic parameters in TBI patients.	Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden; Karolinska Inst, S-10401 Stockholm, Sweden; St Goran Hosp, Dept Anesthesiol, Stockholm, Sweden		Nekludov, M (corresponding author), Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden.	michael.nekludov@karolinska.se		Nekludov, Michael/0000-0001-9916-7086			BELL A, 1958, AM J MED TECHNOL, P264; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; Esmon CT, 1999, BEST PRACT RES CL HA, V12, P343, DOI 10.1053/beha.1999.0029; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943, DOI 10.1055/s-0037-1613338; Grignani G, 2000, HAEMATOLOGICA, V85, P967; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Matta B.F., 2000, TXB NEUROANAESTHESIA; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SIMS PJ, 1995, SEMIN CELL BIOL, V6, P275, DOI 10.1006/scel.1995.0037; Singer AJ, 2003, AM J EMERG MED, V21, P441, DOI 10.1016/S0735-6757(03)00100-1; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Ungerstedt JS, 2003, J NEUROSURG ANESTH, V15, P13, DOI 10.1097/00008506-200301000-00003	21	47	51	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					174	180		10.1089/neu.2006.0173			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100017	17263681				2022-02-06	
J	Sara, M; Sacco, S; Cipolla, F; Onorati, P; Scoppetta, C; Albertini, G; Carolei, A				Sara, Marco; Sacco, Simona; Cipolla, Francesco; Onorati, Paolo; Scoppetta, Ciriaco; Albertini, Giorgio; Carolei, Antonio			An unexpected recovery from permanent vegetative state	BRAIN INJURY			English	Article						vegetative state; consciousness; spasticity; baclofen	MANAGEMENT	Primary objective: To challenge the Multi-Society Task Force's ruling that a persistent vegetative state (PVS) can be judged to be permanent for non traumatic brain injury after three months. Method: We report the case of a 44-year-old man who had recovery of consciousness with persistent severe disability 19 months after a non-traumatic brain injury at least in part triggered and maintained by intrathecal baclofen administration. Result: This unexpected and late recovery of consciousness raises an interesting hypothesis of possible effects of partially regained spinal cord outputs on reactivation of cognition. Conclusion: Considering that several ethical, legal, and socio-economic issues have been raised about the opportunity of withdrawing treatment and life support in patients with PVS the report of this case might add further documentation to the ongoing debate.	Ist San Raffaele Tosinvest Sanita, Post Coma Intens & Rehabil Care Unit, Cassino, Italy; Univ Laquila, Dept Neurol, Laquila, Italy; San Raffaele Pisana Tosinvest Sanita, Pediat Adult & Dev Ctr, Rome, Italy; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, Rome, Italy; Osped San Camillo, Neurol Unit 2, Rome, Italy		Sara, M (corresponding author), Casa Cura San Raffaele Via Gaetano Di Biasio 1, I-03043 Cassino, FR, Italy.	marco.sara@sanraffaele.it	Sara, Marco/AAB-3651-2019; Sacco, Simona/I-5253-2012	Sacco, Simona/0000-0003-0651-1939			ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; McLean SAM, 1999, J CLIN PATHOL, V52, P490, DOI 10.1136/jcp.52.7.490; MOTOKIZAWA F, 1964, JPN J PHYSIOL, V14, P344; Penn RD, 1989, NEUROSURGERY, V4, P325; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Taira T, 2003, ACT NEUR S, V87, P37; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	12	47	50	2	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2007	21	1					101	103		10.1080/02699050601151761			3	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600012	17364525				2022-02-06	
J	Hoane, MR; Gilbert, DR; Holland, MA; Pierce, JL				Hoane, Michael R.; Gilbert, David R.; Holland, Michael A.; Pierce, Jeremy L.			Nicotinamide reduces acute cortical neuronal death and edema in the traumatically injured brain	NEUROSCIENCE LETTERS			English	Article						vitamin B-3; neuroprotection; nicotinamide; rat; fluoro-jade; edema; TBI	FOCAL CEREBRAL-ISCHEMIA; COGNITIVE DEFICITS; INFARCTION; INHIBITOR; APOPTOSIS; PRECURSOR; RECOVERY; MODEL; RATS	Previous studies have shown that administration of nicotinamide (Vitamin B-3) in animal models of traumatic brain injury (TBI) and ischemia significantly reduced the size of infarction or injury and improved functional recovery. The present study evaluated the ability of nicotinamide to provide acute neuroprotection and edema reduction following TBI. Groups of rats were assigned to nicotinamide (500 mg/kg) or saline (1.0 ml/kg) treatment conditions and received contusion injuries or sham surgeries. Drug treatment was administered 15 min following injury. Brains were harvested 24 h later and either processed for histology or water content. Frozen sections were stained with the degenerating neuron stain (Fluoro-Jade (R) B) (FJ) and cell counts were performed at the site of injury. Additional brains were processed for water content (a measure of injury-induced edema). Results of this study showed that administration of nicotinamide following TBI significantly reduced the number of FJ(+) neurons in the injured cortex compared to saline-treated animals. Examination of the water content of the brains also revealed that administration of nicotinamide significantly attenuated the amount of water compared to saline-treated animals in the injured cortex. These results indicate that nicotinamide administration significantly reduced neuronal death and attenuated cerebral edema following injury. The current findings suggest that nicotinamide significantly modulates acute pathophysiological processes following injury and that this may account for its beneficial effects on recovery of function following injury. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	So Illinois Univ, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Restorat Neurosci Lab,Brain & Cognit Sci Program, Carbondale, IL 62901 USA		Hoane, MR (corresponding author), So Illinois Univ, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Restorat Neurosci Lab,Brain & Cognit Sci Program, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Gupta S, 2004, NEUROL RES, V26, P103, DOI 10.1179/016164104773026624; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; MODUDAI T, 2000, STROKE, V31, P1679; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Tan A, 2006, J NEUROTRAUM, V23, P1032; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ungerstedt JS, 2003, J THROMB HAEMOST, V1, P2554, DOI 10.1046/j.1538-7836.2003.00463.x; Ungerstedt JS, 2003, CLIN EXP IMMUNOL, V131, P48, DOI 10.1046/j.1365-2249.2003.02031.x	27	47	48	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 6	2006	408	1					35	39		10.1016/j.neulet.2006.07.011			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108UR	WOS:000242265200008	16987607				2022-02-06	
J	Lu, KT; Wu, CY; Cheng, NC; Wo, YYP; Yang, JT; Yen, HH; Yang, YL				Lu, Kwok-Tung; Wu, Chang-Yen; Cheng, Nai-Chi; Wo, Yu-Yuan Peter; Yang, Jen-Tsung; Yen, Hao-Han; Yang, Yi-Ling			Inhibition of the Na+-K+-2Cl(-)-cotransporter in choroid plexus attenuates traumatic brain injury-induced brain edema and neuronal damage	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						traumatic brain injury; Na-K-2Cl cotransporter; brain edema; bumetanide	K+-CL-COTRANSPORTER; FOCAL CEREBRAL-ISCHEMIA; NA+-K+-2CL(-) COTRANSPORTER; CEREBROSPINAL-FLUID; NA-K-2CL COTRANSPORTER; POTASSIUM COTRANSPORT; GLOBAL-ISCHEMIA; EAA RELEASE; RAT-BRAIN; CHLORIDE	The present study was aimed to elucidate the possible role of Na+-K+-2Cl(-)-cotransporter (NKCC1) on traumatic brain injury-induced brain edema, cerebral contusion and neuronal death by using traumatic brain injury animal model. Contusion volume was verified by 2,3,5,triphenyltetrazolium chloride momohydrate staining. NKCC1 mRNA expression was detected by RT-PCR and the protein expression of NKCC1 was measured by Western blot. We found that the expression of NKCC1 RNA and protein were up-regulated in choroid plexus apical membrane from 2 h after traumatic brain injury, peaked at 8 h, and lasted for 24 h. Rats in the experimental group displayed severe brain edema (water content: 81.45 +/- 0.32% compared with 78.38 +/- 0.62% of sham group) and contusion volume significantly increased 8 h after traumatic brain injury (864.14 +/- 28.07 mm(3)). Administration of the NKCC1 inhibitor bumetanide (15 mg/kg, I.V.) significantly attenuated the contusion volume (464.03 +/- 23.62 mm(3)) and brain edema (water content: 79.12 +/- 0.28%) after traumatic brain injury. Our study demonstrates that NKCC1 contributes to traumatic brain injury-induced brain edema and neuronal damage. (c) 2006 Elsevier B.V. All rights reserved.	Natl Chiayi Univ, Dept Biochem & Mol Biol, Inst Biotechnol, Chiayi, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Neurosurg, Chiayi, Taiwan		Yang, YL (corresponding author), Natl Chiayi Univ, Dept Biochem & Mol Biol, Inst Biotechnol, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw	Yang, Jen-Tsung/C-3187-2011				Anderson CM, 2000, GLIA, V32, P1; BAIRAMIAN D, 1991, J NEUROCHEM, V56, P1623, DOI 10.1111/j.1471-4159.1991.tb02060.x; Betz AL, 1996, ADV NEUROL, V71, P301; Busse S, 2005, BRAIN RES, V1046, P116, DOI 10.1016/j.brainres.2005.03.055; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; Emerich DF, 2005, BIOESSAYS, V27, P262, DOI 10.1002/bies.20193; Ferrand-Drake M, 1999, NEUROSCIENCE, V93, P537, DOI 10.1016/S0306-4522(99)00181-5; Ferrand-Drake M, 2001, MICROSC RES TECHNIQ, V52, P130, DOI 10.1002/1097-0029(20010101)52:1<130::AID-JEMT14>3.0.CO;2-6; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HOLOPAINEN I, 1990, NEUROSCIENCE, V36, P115, DOI 10.1016/0306-4522(90)90355-8; HOSSMANN KA, 1989, NEUROSURG REV, V12, P263, DOI 10.1007/BF01780838; Iadecola C, 1999, CONT NEUROS, P3; Ikebe M, 2001, J AM SOC NEPHROL, V12, P423, DOI 10.1681/ASN.V123423; JAVAHERI S, 1991, J APPL PHYSIOL, V71, P795, DOI 10.1152/jappl.1991.71.3.795; JOHNSON DC, 1987, J APPL PHYSIOL, V63, P1591, DOI 10.1152/jappl.1987.63.4.1591; KEEP RF, 1994, AM J PHYSIOL-CELL PH, V267, pC1616, DOI 10.1152/ajpcell.1994.267.6.C1616; Kimelberg HK, 1999, CONT NEUROS, P45; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kraus JF, 1996, OCCUP MED, V11, P201; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; O'Donnell ME, 2005, AM J PHYSIOL-CELL PH, V289, pC283, DOI 10.1152/ajpcell.00001.2005; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; Obermuller N, 1996, J CLIN INVEST, V98, P635, DOI 10.1172/JCI118834; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Ringel F, 2000, J NEUROCHEM, V75, P125, DOI 10.1046/j.1471-4159.2000.0750125.x; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schomberg SL, 2001, J NEUROPHYSIOL, V85, P2563, DOI 10.1152/jn.2001.85.6.2563; Segal MB, 2000, CELL MOL NEUROBIOL, V20, P183, DOI 10.1023/A:1007045605751; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Speake T, 2001, MICROSC RES TECHNIQ, V52, P49, DOI 10.1002/1097-0029(20010101)52:1<49::AID-JEMT7>3.0.CO;2-C; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sun DD, 1998, AM J PHYSIOL-CELL PH, V275, pC772, DOI 10.1152/ajpcell.1998.275.3.C772; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; VOGH BP, 1981, BRAIN RES, V221, P171, DOI 10.1016/0006-8993(81)91071-4; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Wu Q, 1998, AM J PHYSIOL-CELL PH, V275, pC1565, DOI 10.1152/ajpcell.1998.275.6.C1565; Yan YP, 2003, BRAIN RES, V961, P22, DOI 10.1016/S0006-8993(02)03832-5; Yan YP, 2001, BRAIN RES, V911, P43, DOI 10.1016/S0006-8993(01)02649-X	50	47	49	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	OCT 24	2006	548	1-3					99	105		10.1016/j.ejphar.2006.07.048			7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	093MO	WOS:000241172600013	16962576				2022-02-06	
J	Hoane, MR; Tan, AA; Pierce, JL; Anderson, GD; Smith, DC				Hoane, Michael R.; Tan, Arlene A.; Pierce, Jeremy L.; Anderson, Gail D.; Smith, Douglas C.			Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						behavior; GFAP; neuroprotection; recovery of function; TBI; vitamin B-3	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CONTUSION INJURY; EDEMA FORMATION; RECOVERY; VITAMIN-B-3; APOPTOSIS; EXPRESSION; INFARCTION; INHIBITOR	This study examined the ability of nicotinamide (vitamin B-3) to improve functional outcome in a dose-dependent manner following fluid percussion injury (FPI). Injured (duration of unconsciousness mean = 85.8 sec; apnea = 9.9 sec), rats were administered nicotinamide (500 or 50 mg/kg; ip) or saline at 15 min and 24 h. Serum analysis of nicotinamide concentrations were conducted 1 h following the last injection. Sensorimotor and cognitive tests were conducted for 35 days following FPI. Both the 500 and 50 mg/kg doses of nicotinamide significantly facilitated recovery on the vibrissae-forelimb placing test compared to saline treatment, which showed chronic impairments. Both treatments also significantly improved performance on the bilateral tactile adhesive removal test. On the cognitive tests, the 500 mg/kg dose, but not the 50 mg/kg dose, improved performance on a working memory task in the Morris water maze (MWM). However, acquisition of a reference memory task in the MWM was not improved. Serum analysis showed that the 500 mg/kg dose significantly raised nicotinamide concentrations by 30-fold and the 50 mg/kg dose by 3-fold compared to the saline administration. This study demonstrated that raising nicotinamide concentrations resulted in the reduction of the behavioral impairments following FPI. In fact, the 500 mg/kg dose prevented the occurrence of the behavioral deficits on the bilateral tactile removal and working memory tests. Both doses significantly reduced tissue loss and glial fibrillary acid protein (GFAP) expression in the cortex. The 500 mg/kg dose reduced GFAP expression in the hippocampus. This data suggests that nicotinamide has substantial preclinical efficacy for TBI, and there appears to be some differences in the ability of the doses to improve performance in the MWM.	So Illinois Univ, Dept Psychol, Restorat Neurosci Labs, Carbondale, IL 62901 USA; So Illinois Univ, Dept Psychol, Brain & Congnit Sci Program, Carbondale, IL 62901 USA; So Illinois Univ, Ctr Res Cognit & Neural Sci, Carbondale, IL 62901 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA		Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Labs, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647, NS041551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551, R15NS045647] Funding Source: NIH RePORTER		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; BARTH TM, 1990, STROKE, V21, P153; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Ellis AL, 2004, J NEUROTRAUM, V21, P1334; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gilbert DR, 2004, J NEUROTRAUM, V21, P1316; Gillmor HA, 1999, BIOMED CHROMATOGR, V13, P360, DOI 10.1002/(SICI)1099-0801(199908)13:5<360::AID-BMC893>3.0.CO;2-S; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; GREEN RG, 1970, SCHIZOPHRENIA, V2, P70; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Kolb H, 1999, DIABETES CARE, V22, pB16; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MODUDAI T, 2000, STROKE, V31, P1679; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Schallert T, 2005, BEHAV LAB RAT, P129; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; STRATFORD MRL, 1992, RADIOTHER ONCOL, V25, P37, DOI 10.1016/0167-8140(92)90193-X; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ungerstedt JS, 2003, J THROMB HAEMOST, V1, P2554, DOI 10.1046/j.1538-7836.2003.00463.x; Ungerstedt JS, 2003, CLIN EXP IMMUNOL, V131, P48, DOI 10.1046/j.1365-2249.2003.02031.x	36	47	48	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1535	1548		10.1089/neu.2006.23.1535			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500013	17020488				2022-02-06	
J	Wunderlich, MT; Wallesch, CW; Goertler, M				Wunderlich, M. T.; Wallesch, C. W.; Goertler, M.			Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						glial fibrillary acidic protein; outcome; sonography; stroke	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY STROKE; CEREBROSPINAL-FLUID; S-100 PROTEIN; NEUROBIOCHEMICAL MARKERS; INFARCTION; DAMAGE; BLOOD; SERUM; CLASSIFICATION	This study aimed at an analysis of glial fibrillary acidic protein (GFAP) in acute ischemic stroke, its association with the neurovascular status and its potential value as monitoring parameter. In 53 consecutive patients, serial venous blood samples were taken on admission, 6, 12, 18, 24, 48, 72, 96, and 120 h after stroke onset. The neurovascular status was assessed by repetitive extracranial and transcranial duplex sonography. Neurologic deficits were quantified by the National Institutes of Health stroke scale, and functional outcome was assessed with the modified Rankin Scale. Mean GFAP values were elevated from admission on with highest levels 48 h after stroke onset. GFAP release was highly correlated with severity of neurologic deficits and infarct volume. In patients with persistent middle cerebral artery occlusion, GFAP increased significantly compared with patients with normal sonographic findings (P = 0.019) and recanalization after thrombolysis resulted in a significant reduced increase (P = 0.038). GFAP concentrations were associated with the functional outcome after 3 months. Release kinetics of GFAP are associated with patients clinical deficits and infarct volume, depend on the neurovascular status on admission and on early recanalization after thrombolysis, and may be used as an additional predictor of the early course and functional outcome.	Univ Magdeburg, Dept Neurol, D-39120 Magdeburg, Germany		Wunderlich, MT (corresponding author), Univ Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	michael.wuderlich@medizin.uni-magdeburg.de					Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Burgin WS, 2000, STROKE, V31, P1128, DOI 10.1161/01.STR.31.5.1128; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Foerch C, 2003, J NEUROL NEUROSUR PS, V74, P322, DOI 10.1136/jnnp.74.3.322; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Missler U, 1999, CLIN CHEM, V45, P138; Norgren N, 2004, NEUROLOGY, V63, P1586, DOI 10.1212/01.WNL.0000142988.49341.D1; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Schiemanck SK, 2005, RESTOR NEUROL NEUROS, V23, P257; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Verbeek MM, 2003, ANN CLIN BIOCHEM, V40, P25, DOI 10.1258/000456303321016141; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Yasuda Y, 2004, BRAIN RES, V1021, P20, DOI 10.1016/j.brainres.2004.06.015; ZANETTE EM, 1989, STROKE, V20, P899, DOI 10.1161/01.STR.20.7.899	28	47	56	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	OCT	2006	13	10					1118	1123		10.1111/j.1468-1331.2006.01435.x			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	085UY	WOS:000240631100016	16987165				2022-02-06	
J	Yeo, RA; Phillips, JP; Jung, RE; Brown, AJ; Campbell, RC; Brooks, WM				Yeo, Ronald A.; Phillips, John P.; Jung, Rex E.; Brown, April J.; Campbell, Richard C.; Brooks, William M.			Magnetic resonance spectroscopy detects brain injury and predicts cognitive functioning in children with brain injuries	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	14th Annual Conference on Traumatic Brain Injury - From Molecule to Family Systems	2004	Rotman Res Inst, Toronto, CANADA		Rotman Res Inst	cognitive; outcome; pediatric; spectroscopy; traumatic brain injury	PROTON MR SPECTROSCOPY; N-ACETYLASPARTATE; IN-VIVO; VERTEBRATE BRAIN; AXONAL INJURY; METABOLISM; GLUTAMATE/GLUTAMINE; REPRODUCIBILITY; ADOLESCENTS; DYSFUNCTION	Proton magnetic resonance spectroscopy (H-1-MRS) and neuropsychological assessment were utilized in a longitudinal investigation of traumatic brain injury (TBI) in children. A spectroscopic imaging protocol was implemented, and neurometabolite ratios of NAA/Cre and Cho/Cre were calculated for anterior and posterior halves of a supraventricular slab of brain tissue. NAA/Cre was reduced and Cho/Cre increased in TBI patients as compared to controls, for both brain regions. Each ratio predicted aspects of neuropsychological performance; though the specific relationships varied somewhat by region and function. Anterior NAA/Cre increased and anterior Cho/Cre decreased from 3 to 21 weeks post-injury, suggesting neurometabolic recovery.	Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; MIND Inst, Albuquerque, NM USA; Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM USA; Univ Kansas, Med Ctr, Sch Med, Hogland Brain Imaging Ctr, Kansas City, KS USA		Yeo, RA (corresponding author), Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA.	ryeo@unm.edu		Jung, Rex/0000-0003-3718-0597; brooks, william/0000-0001-6227-7636	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123, R21NS041390] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR00997] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41390, NS39123] Funding Source: Medline		Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Bergman ML, 2001, J AUTOIMMUN, V16, P105, DOI 10.1006/jaut.2000.0474; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Boulanger Y, 2000, BRAIN RES REV, V33, P380, DOI 10.1016/S0165-0173(00)00037-0; BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P69, DOI 10.1007/BF01267948; Brooks WM, 1999, MAGNET RESON MED, V41, P193, DOI 10.1002/(SICI)1522-2594(199901)41:1<193::AID-MRM27>3.3.CO;2-G; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; *CDCP, 2006, TRAUM BRIAN INJ US A; Dautry W, 2000, J CEREBR BLOOD F MET, V20, P789, DOI 10.1097/00004647-200005000-00005; DAVIE CA, 1994, BRAIN, V34, P721; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GENTLEMAN SM, 1999, J NEUROTRAUM, V16, P994; GONIDARAJU V, 1999, NMR BIOMED, V13, P129; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hugg JW, 1996, ANN NEUROL, V40, P236, DOI 10.1002/ana.410400215; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; LEZAK M, 1995, NEUROPSYCHOLOGICAL E; Mason GF, 2005, ALCOHOL CLIN EXP RES, V29, P150, DOI 10.1097/01.ALC.0000150010.72739.58; Moses P, 2002, DEV PSYCHOBIOL, V40, P266, DOI 10.1002/dev.10031; Mullins PG, 2003, MAGNET RESON MED, V50, P704, DOI 10.1002/mrm.10598; Parry L, 2004, CHILD NEUROPSYCHOL, V10, P248, DOI 10.1080/09297040490909279; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Sager TN, 2000, J CEREBR BLOOD F MET, V20, P780, DOI 10.1097/00004647-200005000-00004; Saks VA, 1996, BBA-BIOENERGETICS, V1274, P81, DOI 10.1016/0005-2728(96)00011-4; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shetty HU, 2000, CURR ORG CHEM, V4, P1, DOI 10.2174/1385272003376382; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; STEFANO GD, 2000, J NEUROL NEUROSUR PS, V69, P210; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Verger K, 2000, BRAIN INJURY, V14, P495; WEERS DC, 2004, ANN M INT NEUR SOC B; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010	51	47	49	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1427	1435		10.1089/neu.2006.23.1427			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500005	17020480				2022-02-06	
J	Wennersten, A; Holmin, S; Al Nimer, F; Meijer, X; Wahlberg, LU; Mathiesen, T				Wennersten, Andre; Holmin, Staffan; Al Nimer, Faiez; Meijer, Xia; Wahlberg, Lars U.; Mathiesen, Tiit			Sustained survival of xenografted human neural stem/progenitor cells in experimental brain trauma despite discontinuation of immunosuppression	EXPERIMENTAL NEUROLOGY			English	Article						fetal stem cell; traumatic brain injury; immunosuppressed; neural progenitor; immunesuppressed; xenotransplantation; xenogeneic; cyclosporine	CENTRAL-NERVOUS-SYSTEM; EMBRYONIC HUMAN CNS; STEM-CELLS; CYCLOSPORINE-A; PROGENITOR CELLS; FUNCTIONAL RECOVERY; DOPAMINE NEURONS; ADULT RATS; INJURY; TRANSPLANTATION	Neural stein cells have emerged as a promising therapeutic tool in CNS disease and injuries. In the clinical setting, cultured human neural stem/progenitor cells (hNSC) are an attractive possibility for transplantation to the damaged brain. However, transplantation of hNSC requires toxic immunosuppressive treatment to avoid rejection. The aim of the current study was to evaluate if shortening the duration of immuno suppression by cyclosporin A would affect hNSC survival and differentiation after transplantation to the site of a focal brain injury in the rat. hNSC were xenografted to the hippocampus and the medial limit of an experimentally induced cortical contusion. The animals received immumosuppression for either 6 or 3 weeks or no immunosuppression. The status of the grafted human cells was analysed by immunohistochemistry. No statistically significant differences were observed between the two immunosuppressed groups regarding graft survival, migration or proliferation at 6 weeks post-transplantation. In contrast, the graft survival was extremely poor in the non-immunosuppressed group. Furthermore, the expression of the differentiation markers nestin, neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) in the transplanted cells did not differ significantly between the two immunosuppressed groups. Moreover, a fourth group of eight animals that were immunosuppressed for 3 weeks were allowed to survive for 6 months. Five of these rats demonstrated robust graft survival in the hippocampus and scattered cells in the cortex. This study demonstrates the importance of immunosuppression but also the possibility of shortening immunosuppression without impacting on the phenotype of the grafted hNSC. (c) 2006 Elsevier Inc. All rights reserved.	Sect Clin CNS Res, Dept Clin Neurosci, S-17176 Stockholm, Sweden; NS Gene AS, Copenhagen, Denmark		Wennersten, A (corresponding author), Sect Clin CNS Res, Dept Clin Neurosci, S-17176 Stockholm, Sweden.	andre.wennersten@ki.se	mathiesen, tiit/ABC-3627-2021; Nimer, Faiez Al/ABB-9465-2020	Al Nimer, Faiez/0000-0003-0937-5995; Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Akhlaghi F, 2002, CLIN PHARMACOKINET, V41, P615, DOI 10.2165/00003088-200241090-00001; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Aleksandrova MA, 2002, DEV BRAIN RES, V134, P143, DOI 10.1016/S0165-3806(02)00273-0; Armstrong RJE, 2001, NEUROSCIENCE, V106, P201, DOI 10.1016/S0306-4522(01)00273-1; Brevig T, 2000, TRENDS NEUROSCI, V23, P337, DOI 10.1016/S0166-2236(00)01605-2; BRUNDIN P, 1989, EXP BRAIN RES, V75, P195; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Castilho RF, 2000, EXP NEUROL, V164, P94, DOI 10.1006/exnr.2000.7405; Chu K, 2003, STROKE, V34, P241; Cicchetti F, 2003, XENOTRANSPLANTATION, V10, P41, DOI 10.1034/j.1399-3089.2003.01130.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; Duan WM, 2002, NEUROSCIENCE, V115, P495, DOI 10.1016/S0306-4522(02)00382-2; Ehtesham M, 2002, CANCER RES, V62, P5657; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ishibashi S, 2004, J NEUROSCI RES, V78, P215, DOI 10.1002/jnr.20246; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Larsson LC, 2003, TRANSPLANTATION, V75, P1448, DOI 10.1097/01.TP.0000058807.45320.A2; Larsson LC, 2000, SCAND J IMMUNOL, V52, P249; Le Belle JE, 2004, J NEUROSCI RES, V76, P174, DOI 10.1002/jnr.20035; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; MATHIESEN T, 1989, CANCER LETT, V44, P151, DOI 10.1016/0304-3835(89)90010-4; Mirza B, 2004, BRAIN RES BULL, V63, P105, DOI 10.1016/j.brainresbull.2004.01.009; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Ortega J D, 1992, Cell Transplant, V1, P33; OUREDNIK J, 2002, NAT BIOTECHNOL, V15, P15; PAKZABAN P, 1994, NEUROSCIENCE, V62, P989, DOI 10.1016/0306-4522(94)90338-7; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Snyder EY, 2004, J NEUROSCI RES, V76, P157, DOI 10.1002/jnr.20033; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wennberg L, 2001, TRANSPLANTATION, V71, P1797, DOI 10.1097/00007890-200106270-00016; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y	49	47	50	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2006	199	2					339	347		10.1016/j.expneurol.2005.12.035			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	063DB	WOS:000238995200014	16490195				2022-02-06	
J	Heppner, P; Ellegala, DB; Durieux, M; Jane, JA; Lindner, JR				Heppner, P; Ellegala, DB; Durieux, M; Jane, JA; Lindner, JR			Contrast ultrasonographic assessment of cerebral perfusion in patients undergoing decompressive craniectomy for traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral perfusion; microvasculature; blood flow; ultrasonography	SEVERE HEAD-INJURY; BLOOD-FLOW; ENHANCED ULTRASOUND; PRESSURE; QUANTIFICATION; MICROBUBBLES; MANAGEMENT; ECHOCARDIOGRAPHY; HYPERTENSION; DESTRUCTION	Object. The aims of this study were to determine whether contrast-enhanced ultrasonography (CEU) could be used for noninvasive evaluation of cerebral perfusion in patients with traumatic brain injury (TBI) and to assess the effect of decompressive surgery on cerebral perfusion as measured by CEU. Methods. Contrast-enhanced ultrasonography with intravenous administration of a microbubble contrast agent was performed in six patients with TBI undergoing decompressive craniectomy. Contrast-enhanced ultrasonography was performed through a bur hole before craniectomy and through the calvarial defect immediately after craniectomy and on postoperative Days 1 and 2. For the latter two studies, patients were placed in the recumbent position and at a 35 degrees incline to investigate changes in perfusion produced by modulation of intracranial pressure (ICP). Cerebral microvascular blood flow increased by almost threefold immediately after craniectomy, from a mean of 7.5 +/- 6.9 (standard deviation [SD]) to 20.9 +/- 11.6 (p < 0.05), and further improved on postoperative Day 1 (mean 37.1 +/- 13.9 [SD], p < 0.05, compared with postcraniectomy microvascular blood flow) without subsequent change on Day 2. The change in microvascular perfusion correlated inversely with the initial ICP (p < 0.01), indicating less recovery of flow when preoperative ICP was markedly elevated. On postoperative Days I and 2, head-of-bed elevation produced an increase in microvascular perfusion on CEU (mean 37 11 compared with 51 20, p < 0.05) and a small decrease in ICP (mean 16 +/- 5 mm Hg compared with 12 +/- 4 mm Hg, p < 0.05). In patients with parenchymal hematoma, CEU provided spatial information on perfusion abnormalities in the hemorrhagic core and surrounding tissues. Conclusions. Contrast-enhanced ultrasonography has potential for the intraoperative and bedside assessment of cerebral perfusion in patients with TBI. The technique may be appropriate for evaluating responses to therapies aimed at preventing secondary ischemia and for assessing regional perfusion abnormalities.	Univ Virginia, Hlth Syst, Div Cardiovasc, Charlottesville, VA USA; Univ Virginia, Hlth Syst, Dept Neurol Surg, Charlottesville, VA USA; Univ Virginia, Hlth Syst, Dept Anesthesiol, Charlottesville, VA USA; Auckland City Hosp, Dept Neurosurg, Auckland, New Zealand		Lindner, JR (corresponding author), Oregon Hlth & Sci Univ, Div Cardiovasc, UHN62, Portland, OR 97239 USA.	lindnerj@ohsu.edu	Jane, John/AAY-3201-2021	Durieux, Marcel/0000-0003-1479-7666	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK063508] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01-DK-063508] Funding Source: Medline		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dawson D, 2002, AM J PHYSIOL-ENDOC M, V282, pE714, DOI 10.1152/ajpendo.00373.2001; Ellegala DB, 2003, CIRCULATION, V108, P336, DOI 10.1161/01.CIR.0000080326.15367.0C; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Eyding J, 2004, J NEUROL NEUROSUR PS, V75, P926, DOI 10.1136/jnnp.2003.026195; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Jayaweera AR, 1999, AM J PHYSIOL-HEART C, V277, pH2363, DOI 10.1152/ajpheart.1999.277.6.H2363; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KENNING JA, 1981, SURG NEUROL, V15, P148, DOI 10.1016/0090-3019(81)90037-9; Kern R, 2004, STROKE, V35, P1665, DOI 10.1161/01.STR.0000129332.10721.7e; KETY SS, 1945, AM J PHYSIOL, V143, P53, DOI 10.1152/ajplegacy.1945.143.1.53; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Lindner JR, 2002, J AM SOC ECHOCARDIOG, V15, P396, DOI 10.1067/mje.2002.117290; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin N A, 1994, Neurosurg Clin N Am, V5, P607; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; OBRIST WD, 1967, CIRC RES, V20, P124, DOI 10.1161/01.RES.20.1.124; Rim SJ, 2001, CIRCULATION, V104, P2582, DOI 10.1161/hc4601.099400; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Seidel G, 2002, ULTRASOUND MED BIOL, V28, P183, DOI 10.1016/S0301-5629(01)00501-4; Vogel R, 2005, J AM COLL CARDIOL, V45, P754, DOI 10.1016/j.jacc.2004.11.044; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wei K, 1998, CIRCULATION, V97, P473; Wei K, 2001, J AM COLL CARDIOL, V37, P1135, DOI 10.1016/S0735-1097(00)01210-9; Winkelman C, 2000, Am J Crit Care, V9, P373; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Zauner A, 1996, ACT NEUR S, V67, P40; 2000, J NEUROTRAUMA, V17	33	47	56	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2006	104	5					738	745		10.3171/jns.2006.104.5.738			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	041CD	WOS:000237429800008	16703878				2022-02-06	
J	Conti, L; Reitano, E; Cattaneo, E				Conti, Luciano; Reitano, Erika; Cattaneo, Elena			Neural stem cell systems: Diversities and properties after transplantation in animal models of diseases	BRAIN PATHOLOGY			English	Article							FIBROBLAST GROWTH FACTOR-2; MARROW STROMAL CELLS; PROGENITOR CELLS; IN-VITRO; PRECURSOR CELLS; BONE-MARROW; DOPAMINERGIC-NEURONS; SELF-RENEWAL; OLIGODENDROCYTE PROGENITORS; LINEAGE RESTRICTION	Currently available effective treatments of the diseased or damaged central nervous system (CNS) are restricted to a limited pharmacological relief of symptoms or those given to avoid further damage. Therefore the search is on for treatments that can restore function in the CNS. During recent years replacement of damaged neurons by cell transplantation is being enthusiastically explored as a potential treatment for many neurodegenerative diseases, stroke and traumatic brain injury. Several references in both scientific journals and popular newspapers concerning different types of cultured stem cells, potentially exploitable to treat pathological conditions of the brain, raise important questions pertinent to the fundamental and realistic differences between grafts of primary neural cells and the transplantation of in vitro expanded neural stem cells (NSCs). Our aim is to review the available information on the grafting of different NSC types into the adult rodent brain, focusing on critical aspects for the development of clinical therapies to replace damaged neurons.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy		Cattaneo, E (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	Elena.Cattaneo@unimi.it	Conti, Luciano/H-4184-2012	Conti, Luciano/0000-0002-2050-9846; CATTANEO, ELENA/0000-0002-0755-4917	TelethonFondazione Telethon [GGP02457] Funding Source: Medline		Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Armstrong RJE, 2002, EXP NEUROL, V175, P98, DOI 10.1006/exnr.2002.7889; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bachoud-Levi AC, 2000, EXP NEUROL, V161, P194, DOI 10.1006/exnr.1999.7239; Bain G, 1998, PERSPECT DEV NEUROBI, V5, P175; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bartlett PF, 1998, IMMUNOL CELL BIOL, V76, P414, DOI 10.1046/j.1440-1711.1998.00762.x; Benoit BO, 2001, J NEUROBIOL, V46, P265, DOI 10.1002/1097-4695(200103)46:4<265::AID-NEU1007>3.0.CO;2-B; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; BJORKLUND A, 2005, NOVART FDN SYMP, V265, P204; Bjorklund Anders, 2005, V265, P174; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Brustle O, 1999, BRAIN PATHOL, V9, P527; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Campos LS, 2004, J NEUROSCI RES, V78, P761, DOI 10.1002/jnr.20333; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; Chu K, 2004, BRAIN RES, V1016, P145, DOI 10.1016/j.brainres.2004.04.038; Chung S, 2002, EUR J NEUROSCI, V16, P1829, DOI 10.1046/j.1460-9568.2002.02255.x; Conti L, 2005, PLOS BIOL, V3, P1594, DOI 10.1371/journal.pbio.0030283; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Dunnett SB, 1997, BRAIN RES PROTOC, V1, P91, DOI 10.1016/S1385-299X(96)00015-3; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; Gomes WA, 2003, DEV BIOL, V255, P164, DOI 10.1016/S0012-1606(02)00037-4; Gorba T, 2003, PHARMACOL RES, V47, P269, DOI 10.1016/S1043-6618(03)00036-7; Gotz M, 2002, BRAIN RES BULL, V57, P777, DOI 10.1016/S0361-9230(01)00777-8; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Gritti A, 1999, J NEUROSCI, V19, P3287; Halfpenny CA, 2003, J NEUROIMMUNOL, V139, P9, DOI 10.1016/S0165-5728(03)00125-5; Harper JM, 2004, P NATL ACAD SCI USA, V101, P7123, DOI 10.1073/pnas.0401103101; Hartfuss E, 2001, DEV BIOL, V229, P15, DOI 10.1006/dbio.2000.9962; Hauser RA, 2002, NEUROLOGY, V58, P687, DOI 10.1212/WNL.58.5.687; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kelly CM, 2003, CELL TRANSPLANT, V12, P215, DOI 10.3727/000000003108746777; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x; Kitajima H, 2005, J NEUROSCI RES, V80, P467, DOI 10.1002/jnr.20469; Kriegstein AR, 2003, GLIA, V43, P37, DOI 10.1002/glia.10250; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lee ST, 2006, J NEUROSCI METH, V152, P250, DOI 10.1016/j.jneumeth.2005.09.013; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Lie DC, 2002, J NEUROSCI, V22, P6639; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lindvall Olle, 2004, NeuroRx, V1, P382; Liour SS, 2003, GLIA, V42, P109, DOI 10.1002/glia.10202; Louis Sharon A, 2005, Methods Mol Biol, V290, P265; Lowit Alison, 2005, BMC Fam Pract, V6, P38, DOI 10.1186/1471-2296-6-38; Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8; McBride JL, 2004, J COMP NEUROL, V475, P211, DOI 10.1002/cne.20176; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2000, EUR J PHARMACOL, V405, P297, DOI 10.1016/S0014-2999(00)00561-6; Mezey E, 2003, SCIENCE, V299; Morshead CM, 2004, DEV NEUROSCI-BASEL, V26, P93, DOI 10.1159/000082130; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Ostenfeld T, 2002, J NEUROSCI RES, V69, P955, DOI 10.1002/jnr.10396; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Peschanski M., 2001, Journal de la Societe de Biologie, V195, P51; Pluchino S, 2005, BRAIN RES REV, V48, P211, DOI 10.1016/j.brainresrev.2004.12.011; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Richardson RM, 2004, J NEUROSURG, V100, P659, DOI 10.3171/jns.2004.100.4.0659; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Schmandt T, 2005, STEM CELLS DEV, V14, P55, DOI 10.1089/scd.2005.14.55; Schuurmans C, 2002, CURR OPIN NEUROBIOL, V12, P26, DOI 10.1016/S0959-4388(02)00286-6; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; SCOLDING NJ, 1995, NEUROREPORT, V6, P441, DOI 10.1097/00001756-199502000-00009; Shetty AK, 1998, J NEUROBIOL, V35, P395, DOI 10.1002/(SICI)1097-4695(19980615)35:4<395::AID-NEU7>3.0.CO;2-U; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Sun PZ, 2003, J MAGN RESON, V161, P168, DOI 10.1016/S1090-7807(02)00199-4; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Wernig M, 2002, J NEUROSCI RES, V69, P918, DOI 10.1002/jnr.10395; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Xu Y, 2003, J NEUROSCI RES, V74, P533, DOI 10.1002/jnr.10769; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Ying QL, 2003, METHOD ENZYMOL, V365, P327; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zeng XM, 2004, STEM CELLS, V22, P925, DOI 10.1634/stemcells.22-6-925; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zhou FC, 2000, EXP NEUROL, V164, P200, DOI 10.1006/exnr.2000.7425	119	47	59	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	APR	2006	16	2					143	154		10.1111/j.1750-3639.2006.00009.x			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	051ET	WOS:000238144600007	16768755	Green Published			2022-02-06	
J	Williams, GP; Greenwood, KM; Robertson, VJ; Goldie, PA; Morris, ME				Williams, GP; Greenwood, KM; Robertson, VJ; Goldie, PA; Morris, ME			High-level mobility assessment tool (HiMAT): Interrater reliability, retest reliability, and internal consistency	PHYSICAL THERAPY			English	Article						brain injuries; neurologic gait disorders; outcome assessment; reliability	TRAUMATIC BRAIN-INJURY; REHABILITATION; VALIDITY	Background and Purpose. The High-Level Mobility Assessment Tool (HiMAT) assesses high-level mobility in people who have sustained a traumatic brain injury (TBI). The purpose of this study was to investigate the interrater reliability, retest reliability, and internal consistency of data obtained with the HiMAT. Subjects. Three physical therapists and 103 people with TBI were recruited from a rehabilitation hospital. Methods. Three physical therapists concurrently assessed a subset of 17 subjects with TBI to investigate interrater reliability. One physical therapist assessed a different subset of 20 subjects with TBI on 2 occasions, 2 days apart, to investigate retest reliability. Data from the entire sample of 103 subjects were used to investigate the internal consistency of this new scale. Results. Both the interrater reliability (intraclass correlation coefficient [ICC]=.99) and the retest reliability (ICC=.99) of the HiMAT data were very high. For retest reliability, a small systematic change was detected (t=3.82, df=19), indicating a marginal improvement of 1 point at retest. Internal consistency also was very high (Cronbach alpha=.97). Discussion and Conclusion. The HiMAT is a new tool specifically designed to measure high-level mobility, which currently is not a component of existing scales used in TBI. This study demonstrated that the HiMAT is a reliable tool for measuring high-level mobility.	Epworth Med Fdn, Physiotherapy Dept, Melbourne, Vic 3121, Australia; Univ Canberra, Sch Hlth Sci, Belconnen, ACT 2616, Australia; Univ Newcastle, Newcastle, NSW 2308, Australia; La Trobe Univ, Sch Physiotherapy, Bundoora, Vic, Australia; Univ Melbourne, Sch Physiotherapy, Parkville, Vic 3052, Australia		Williams, GP (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Melbourne, Vic 3121, Australia.	gavinw@epworth.org.au	Greenwood, Kenneth M/J-8993-2015	Greenwood, Kenneth M/0000-0002-8420-6588; Morris, Meg/0000-0002-0114-4175; Williams, Gavin/0000-0003-2758-7473			Baumgartner T., 1991, MEASUREMENT EVALUATI; Beaton DE, 2001, J CLIN EPIDEMIOL, V54, P1204, DOI 10.1016/S0895-4356(01)00407-3; BLOOM M, 1995, EVALUATING PRACTICE; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; MENDENHALL W, 1977, STAT PSYCHOL; Norman, 1995, HLTH MEASUREMENT SCA; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; ROTHSTEIN JM, 1985, MEASUREMENT PHYSICAL, P1; Stratford PW, 1999, PHYSIOTHER CAN, V51, P107; Williams G, 2005, BRAIN INJURY, V19, P925, DOI 10.1080/02699050500058687; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Williams G, 2001, BRAIN INJURY, V15, P831; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711	15	47	47	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	MAR	2006	86	3					395	400		10.1093/ptj/86.3.395			6	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation	022DV	WOS:000236035800008	16506875	Bronze			2022-02-06	
J	Hukkelhoven, CWPM; Rampen, AJJ; Maas, AIR; Farace, E; Habbema, JDF; Marmarou, A; Marshall, LF; Murray, GD; Steyerberg, EW				Hukkelhoven, CWPM; Rampen, AJJ; Maas, AIR; Farace, E; Habbema, JDF; Marmarou, A; Marshall, LF; Murray, GD; Steyerberg, EW			Some prognostic models for traumatic brain injury were not valid	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						traumatic brain injury; prognosis; models, statistical; validation studies; Glasgow Outcome Scale; mortality	LOGISTIC-REGRESSION ANALYSIS; SIMPLE CLINICAL-VARIABLES; HEAD-INJURIES; SURVIVAL; SELECTION; PREDICTION; COMA; OUTCOMES; TREE	Objective: Various prognostic models have been developed to predict outcome after traumatic brain injury (TBI). We aimed to determine the validity of six models that used baseline clinical and computed tomographic characteristics to predict mortality or unfavorable outcome at 6 months or later after severe or moderate TBI. Study Design and Setting: The validity was studied in two selected series of TBI patients enrolled in clinical trials (Tirilazad trials; n = 2,269; International Selfotel Trial; n = 409) and in two unselected series of patients consecutively admitted to participating centers (European Brain Injury Consortium [EBIC] survey; n = 796; Traumatic Coma Data Bank; n = 746). Validity was indicated by discriminative ability (AUC) and calibration (Hosmer-Lemeshow goodness-of-fit test). Results: The models varied in number of predictors (four to seven) and in development technique (two prediction trees and four logistic regression models). Discriminative ability varied widely (AUC:.61-.89), but calibration was poor for most models. Better discrimination was observed for logistic regression models compared with trees, and for models including more predictors. Further, discrimination was better when tested on unselected series that contained more heterogeneous populations. Conclusion: Our findings emphasize the need for external validation of prognostic models. The satisfactory discrimination indicates that logistic regression models, developed on large samples, can be used for classifying TBI patients according to prognostic risk. (c) 2006 Elsevier Inc. All rights reserved.	Erasmus Univ, Med Ctr, Dept Publ Hlth, Ctr Med Decis Making Sci, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Neurol Surg, NL-3000 DR Rotterdam, Netherlands; Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22903 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Univ Calif San Diego, Dept Community Hlth Sci, La Jolla, CA 92093 USA		Steyerberg, EW (corresponding author), Erasmus Univ, Med Ctr, Dept Publ Hlth, Ctr Med Decis Making Sci, POB 1739, NL-3000 DR Rotterdam, Netherlands.	E.Steyerberg@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Hukkelhoven, Chantal/0000-0002-0015-1883; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042691-01A1] Funding Source: Medline		Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO;2-X; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Baltas I, 1998, J Neurosurg Sci, V42, P85; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Breiman L., 1984, CLASSIFICATION REGRE; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Clark TG, 2003, J CLIN EPIDEMIOL, V56, P28, DOI 10.1016/S0895-4356(02)00539-5; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; Efron B., 1993, INTRO BOOTSTRAP; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrell FE Jr, 2017, REGRESSION MODELING; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hukkelhoven CWPM, 2000, J NEUROL NEUROSUR PS, V68, P396; JENNETT B, 1975, LANCET, V1, P480; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; Sakellaropoulos GC, 1999, METHOD INFORM MED, V38, P37; Schaan M, 2002, J TRAUMA, V52, P667, DOI 10.1097/00005373-200204000-00009; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; TEASDALE G, 1974, LANCET, V2, P81; TITTERINGTON DM, 1981, J ROY STAT SOC A STA, V144, P145, DOI 10.2307/2981918; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109	42	47	50	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	FEB	2006	59	2					132	143		10.1016/j.jclinepi.2005.06.009			12	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; Public, Environmental & Occupational Health	011FL	WOS:000235253400004	16426948				2022-02-06	
J	Teasdale, TW; Engberg, AW				Teasdale, TW; Engberg, AW			Subjective well-being and quality of life following traumatic brain injury in adults: A long-term population-based follow-up	BRAIN INJURY			English	Article						quality of life; follow-up; traumatic brain injury	CLOSE RELATIVES; INDIVIDUALS; EXPERIENCE; SCALE; REHABILITATION; QUESTIONNAIRE; DISABILITY; SYMPTOMS; SEQUELAE; DENMARK	Primary objective: To assess subjective well-being and quality-of-life in nationally representative samples of patients at long intervals following traumatic brain injuries. Methods and procedures: Patients with either cranial fractures or cerebral lesions were identified in a national computer-based register of hospital admissions and random samples were selected among those who had suffered the injury at 5, 10 or 15 years prior to the follow-up. Postal questionnaires were sent to them covering quality of life, e. g. return to employment, family relations and current subjective well-being in terms of symptomatology, e. g. somatic complaints, cognitive dysfunction. A response rate of 76% was obtained, comprising 114 patients with cranial fracture and 126 with cerebral lesions. Main outcomes and results: The group with cerebral lesions had markedly poorer quality of life and subjective well-being than the group with cranial fractures and this did not vary across time. In both groups, the most common symptoms concerned cognition. Among the cerebral lesion group, quality of life outcome was fairly well predicted by severity of injury, but subjective well-being was less well predicted. Conclusions: The negative consequences of traumatic cerebral lesions are marked and do not vary at long periods following injury.	Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen, Denmark; Copenhagen Univ Hosp, Div Neurol Rehabil, Hvidovre, Denmark		Teasdale, TW (corresponding author), Univ Copenhagen, Dept Psychol, Njalsgade 88, DK-2300 Copenhagen, Denmark.	tom.teasdale@psy.ku.dk					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersen TF, 1999, DAN MED BULL, V46, P263; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Caetano R, 2003, ADDICTION, V98, P791, DOI 10.1046/j.1360-0443.2003.00407.x; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hoofien D, 2001, BRAIN INJURY, V15, P189; Howell DC., 2002, STAT METHODS PSYCHOL, V5; JENNETT B, 1975, LANCET, V1, P480; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kotaniemi JT, 2001, EUR J EPIDEMIOL, V17, P809, DOI 10.1023/A:1015615130459; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089	33	47	48	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					1041	1048		10.1080/02699050500110397			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700011	16263647				2022-02-06	
J	Wade, SL; Wolfe, CR; Brown, TM; Pestian, JP				Wade, SL; Wolfe, CR; Brown, TM; Pestian, JP			Can a web-based family problem-solving intervention work for children with traumatic brain injury?	REHABILITATION PSYCHOLOGY			English	Article						brain injury; telehealth; adaptation; problem solving	SHORT-TERM; ADOLESCENTS; PREDICTORS; BEHAVIOR; RELIABILITY; DISORDERS; OUTCOMES; EPILEPSY; BURDEN; HOME	Objective: To examine the feasibility and efficacy of a Web-based intervention for children with traumatic brain injury (TBI). Participants: 6 families comprising 8 parents, 5 siblings, and 6 children with TBI (mean age = 10.5 years). Intervention: Families received computers, Web cameras, and Internet access. Participants completed 7-11 online sessions and accompanying weekly videoconferences with the therapist. Main Outcome Measures: Outcomes included child behavior problems, social competence, executive function skills, and parent-child conflict. Results: Children with TBI rated Web site content as very to extremely helpful and reported high overall satisfaction. There was a trend for children with TBI to rate the videoconferences as less helpful than did other family members and relative to a face-to-face visit. Parents reported improvements in antisocial behaviors, and children with TBI reported reductions in conflict with parents regarding school. Conclusions: Web-based interventions hold promise for improving child outcomes following pediatric TBI.	Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA; Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA; Med Coll Wisconsin, Dept Psychol, Milwaukee, WI 53226 USA; Childrens Hosp, Med Ctr, Dept Biomed Informat, Cincinnati, OH 45229 USA		Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, MLC 4009,3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN T, 2000, P AUSTR US INT C AUI, V1, P11; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gega L, 2004, J CLIN PSYCHOL, V60, P147, DOI 10.1002/jclp.10241; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Greist JH, 1998, PSYCHIAT SERV, V49, P887, DOI 10.1176/ps.49.7.887; Hewson CM, 1996, BEHAV RES METH INSTR, V28, P186, DOI 10.3758/BF03204763; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Joinson, 1998, PSYCHOL INTERNET INT, P43; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Marks I, 1998, CLIN PSYCHOL-SCI PR, V5, P151, DOI 10.1111/j.1468-2850.1998.tb00141.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Robin AL, 1989, NEGOTIATING PARENT A; ROBIN AL, 1990, PSYCHOL ASSESSMENT J, V2, P451, DOI DOI 10.1037/1040-3590.2.4.451; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Sitarenios G., 1999, USE PSYCHOL TESTING, P267; Sturges JW, 1998, PROF PSYCHOL-RES PR, V29, P183, DOI 10.1037/0735-7028.29.2.183; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WADE SL, IN PRESS NEURODEVELO; WADE SL, IN PRESS J HEAD TRAU; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ylvisaker M., 1998, COLLABORATIVE BRAIN; [No title captured]	42	47	47	0	10	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2005	50	4					337	345		10.1037/0090-5550.50.4.337			9	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	990KL	WOS:000233741700003					2022-02-06	
J	Aquilani, R; Iadarola, P; Contardi, A; Boselli, M; Verri, M; Pastoris, O; Boschi, F; Arcidiaco, P; Viglio, S				Aquilani, R; Iadarola, P; Contardi, A; Boselli, M; Verri, M; Pastoris, O; Boschi, F; Arcidiaco, P; Viglio, S			Branched-chain amino acids enhance the cognitive recovery of patients with severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amino acids; branched-chain; brain injuries; rehabilitation	P70 S6 KINASE; HEPATIC-ENCEPHALOPATHY; CONTROLLED TRIAL; HUNTINGTONS-DISEASE; DIABETES-MELLITUS; PROTEIN TURNOVER; INSULIN-RECEPTOR; DIETARY-PROTEIN; SKELETAL-MUSCLE; NERVOUS-SYSTEM	Objective: To investigate whether Supplementation with branched-chain amino acids (BCAAs) in patients with severe traumatic brain injury (TBI) improves recovery of cognition and influences plasma concentrations of tyrosine and tryptophan, which are precursors of, respectively, catecholamine and serotonin neurotransmitters in the brain. Design: Forty patients with TBI were randomly assigned to 15 days of intravenous BCAA supplementation (19.6g/d) (n=20) or an isonitrogenous placebo (n=20). Setting: Tertiary care rehabilitation setting in Italy. Participants: Forty men (mean age, 32 +/- 15y) with TBI and 20 healthy subjects (controls) matched for age, sex, and sedentary lifestyle. Intervention: Supplementation with BCAAs. Main Outcome Measures: Disability Rating Scale (DRS) and plasma concentrations of BCAAs, tyrosine, and tryptophan. Results: Fifteen days after admission to the rehabilitation department, the DRS score had improved significantly in both the placebo group (P <.05 vs baseline) and in the BCAA-supplemented group (P <.01 vs baseline). The difference between the 2 groups was significant (P <.004). Plasma tyrosine concentration improved in the group given BCAA supplementation, and tryptophan concentration increased in patients receiving placebo. Conclusions: Supplemental BCAAs enhance the retrieval of DRS without causing negative effects on tyrosine and tryptophan concentration. Key Words: Amino acids, branched-chain; Brain injuries; Rehabilitation.	Univ Pavia, Dipartimento Biochim A Castellani, I-27100 Pavia, Italy; IRCCS, Fdn S Maugeri, Serv Fisiopatol Metab Nutr & Nutr Clin, Pavia, Italy; IRCCS, Fdn S Maugeri, Div Neuroriabilitaz 1, Pavia, Italy; IRCCS, Fdn S Maugeri, Div Neuroriabilitaz, Pavia, Italy; IRCCS, Fdn S Maugeri, IstSci Montescano, Pavia, Italy; Univ Pavia, Dipartimento Sci Fisiol & Farmacol, Sez Farmacol, I-27100 Pavia, Italy; Univ Pavia, Ctr Grandi Strumenti, I-27100 Pavia, Italy		Viglio, S (corresponding author), Univ Pavia, Dipartimento Biochim A Castellani, Via Taramelli 3-B, I-27100 Pavia, Italy.	simona.viglio@unipv.it		Pastoris, Ornella/0000-0003-0273-1010; Boselli, Mirella/0000-0003-4545-5271; Viglio, Simona/0000-0001-5020-478X			Aquilani R, 2003, ARCH PHYS MED REHAB, V84, P1258, DOI 10.1016/S0003-9993(03)00148-5; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1053/apmr.2000.0810176; Banks WA, 1998, PEPTIDES, V19, P883, DOI 10.1016/S0196-9781(98)00018-7; BASKIN DG, 1988, TRENDS NEUROSCI, V11, P107, DOI 10.1016/0166-2236(88)90155-5; BASUN H, 1990, J NEURAL TRANSM-PARK, V2, P295, DOI 10.1007/BF02252924; BERRY HK, 1990, AM J DIS CHILD, V144, P539, DOI 10.1001/archpedi.1990.02150290033020; Bessman SP, 1997, MOL CELL BIOCHEM, V174, P91, DOI 10.1023/A:1006834408181; BISTRIAN BR, 1975, SURG GYNECOL OBSTET, V141, P512; BLACKBURN GL, 1979, SURGERY, V86, P307; Blomstrand E, 1997, ACTA PHYSIOL SCAND, V159, P41, DOI 10.1046/j.1365-201X.1997.547327000.x; BOWER RH, 1986, ANN SURG, V203, P13, DOI 10.1097/00000658-198601000-00003; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CERRA FB, 1985, JPEN-PARENTER ENTER, V9, P288, DOI 10.1177/0148607185009003288; CHAPLIN ER, 1976, J NEUROCHEM, V26, P701, DOI 10.1111/j.1471-4159.1976.tb04440.x; CHIARELLI A, 1990, AM J CLIN NUTR, V51, P1035, DOI 10.1093/ajcn/51.6.1035; Clarke D.D., 1998, BASIC NEUROCHEMISTRY, P637; COTMAN CW, 1981, PHYSIOL REV, V61, P684, DOI 10.1152/physrev.1981.61.3.684; Craft S, 1999, ARCH GEN PSYCHIAT, V56, P1135, DOI 10.1001/archpsyc.56.12.1135; CRAFT S, 1993, BEHAV NEUROSCI, V107, P926; DAVIS SN, 1995, J CLIN INVEST, V95, P593, DOI 10.1172/JCI117703; EGBERTS EH, 1985, GASTROENTEROLOGY, V88, P887, DOI 10.1016/S0016-5085(85)80004-4; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; ENZI G, 1990, CRIT CARE MED, V18, P719, DOI 10.1097/00003246-199007000-00007; FERNSTROM JD, 1978, J NEUROCHEM, V30, P1531, DOI 10.1111/j.1471-4159.1978.tb10489.x; FERNSTROM JD, 1972, SCIENCE, V178, P414, DOI 10.1126/science.178.4059.414; FERRANDO AA, 1995, JPEN-PARENTER ENTER, V19, P47, DOI 10.1177/014860719501900147; FIACCADORI F, 1985, ITAL J GASTROENTEROL, V17, P5; FISCHER JE, 1976, SURGERY, V80, P77; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Fox HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1232, DOI 10.1152/ajpcell.1998.275.5.C1232; FREUND H, 1978, SURGERY, V83, P611; FREUND HR, 1981, SURGERY, V90, P237; FULKS RM, 1975, J BIOL CHEM, V250, P290; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; GAMBERINO WC, 1994, J NEUROCHEM, V63, P1392; Gijsman HJ, 2002, PSYCHOPHARMACOLOGY, V160, P192, DOI 10.1007/s00213-001-0970-5; GOLDBERG AL, 1978, FED PROC, V37, P2301; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HASSMEN P, 1994, NUTRITION, V10, P405; HAVRANKOVA J, 1978, P NATL ACAD SCI USA, V75, P5737, DOI 10.1073/pnas.75.11.5737; HENLEY M, 1989, BURNS, V15, P351, DOI 10.1016/0305-4179(89)90098-3; HORST D, 1984, HEPATOLOGY, V4, P279, DOI 10.1002/hep.1840040218; Hoyer S, 1996, ANN NY ACAD SCI, V777, P374, DOI 10.1111/j.1749-6632.1996.tb34448.x; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; JORDAN MK, 1985, DEV MED CHILD NEUROL, V27, P33; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KUHL DE, 1984, ANN NEUROL, V15, pS119; MADSEN DC, 1983, ADV CLIN NUTRITION, P1; MALAISSE WJ, 1968, J LAB CLIN MED, V72, P438; MCGHEE A, 1983, ANN SURG, V197, P288, DOI 10.1097/00000658-198303000-00008; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MILNER RDG, 1970, J ENDOCRINOL, V47, P347, DOI 10.1677/joe.0.0470347; Mittleman KD, 1998, MED SCI SPORT EXER, V30, P83, DOI 10.1097/00005768-199801000-00012; MOJA EA, 1991, LIFE SCI, V49, P1121, DOI 10.1016/0024-3205(91)90600-G; MOROO I, 1994, ACTA NEUROPATHOL, V87, P343; Nielsen DH, 1981, CARDIAC REHABILITATI, P11; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; ODESSEY R, 1972, AM J PHYSIOL, V223, P1376, DOI 10.1152/ajplegacy.1972.223.6.1376; Oomura Y, 1976, HUNGER BASIC MECH CL, P145; PALOVCIK RA, 1984, BRAIN RES, V309, P187, DOI 10.1016/0006-8993(84)91028-X; Park CR, 2001, NEUROSCI BIOBEHAV R, V25, P311, DOI 10.1016/S0149-7634(01)00016-1; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PHILLIPS MI, 1989, METHOD ENZYMOL, V168, P129; PLASCHKE K, 1993, INT J DEV NEUROSCI, V11, P477, DOI 10.1016/0736-5748(93)90021-5; PODOLSKY S, 1977, GERONTOLOGY, V23, P55, DOI 10.1159/000212174; PRONCZUK AW, 1970, J NUTR, V100, P1249, DOI 10.1093/jn/100.11.1249; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; RICHARDSON JTE, 1990, NEUROSCI BIOBEHAV R, V14, P385, DOI 10.1016/S0149-7634(05)80060-0; RODWELL VW, 1988, HERPES BIOCH, P271; RUDERMAN NB, 1977, AM J PHYSIOL, V233, pE109, DOI 10.1152/ajpendo.1977.233.2.E109; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITOU S, 1993, NEUROSCI LETT, V149, P12, DOI 10.1016/0304-3940(93)90335-I; SCHMIDT GM, 1980, EXP HEMATOL, V8, P506; SHIBATA S, 1986, PHYSIOL BEHAV, V36, P79, DOI 10.1016/0031-9384(86)90077-6; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Stewart R, 1999, DIABETIC MED, V16, P93, DOI 10.1046/j.1464-5491.1999.00027.x; STRAUSS E, 1986, NUTR SUPP SERVICES, V6, P18; Sweeney G, 1998, MOL CELL BIOCHEM, V182, P121, DOI 10.1023/A:1006805510749; TANAKA K, 1993, J AUTONOM NERV SYST, V42, P225, DOI 10.1016/0165-1838(93)90367-4; VORHEES CV, 1989, PEDIATR RES, V25, P568, DOI 10.1203/00006450-198906000-00002; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; YOKOGOSHI H, 1992, J NUTR, V122, P2210, DOI 10.1093/jn/122.11.2210; YOUNG W, 1996, NEUROTRAUMA, P1421	86	47	49	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1729	1735		10.1016/j.apmr.2005.03.022			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	962QM	WOS:000231747300003	16181934				2022-02-06	
J	Tilford, JM; Aitken, ME; Anand, KJS; Green, JW; Goodman, AC; Parker, JG; Killingsworth, JB; Fiser, DH; Adelson, PD				Tilford, John M.; Aitken, Mary E.; Anand, K. J. S.; Green, Jerril W.; Goodman, Allen C.; Parker, James G.; Killingsworth, Jeffrey B.; Fiser, Debra H.; Adelson, P. David			Hospitalizations for critically ill children with traumatic brain injuries: A longitudinal analysis	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; children; mortality; insurance; economic evaluation	UNITED-STATES; HEAD-INJURY; INTRACRANIAL-PRESSURE; CEREBRAL PERFUSION; MANAGEMENT; CARE; HEALTH; TRENDS; MORTALITY; OUTCOMES	Objective: This study examines the incidence, utilization of procedures, and outcomes for critically ill children hospitalized with traumatic brain injury over the period 1988-1999 to describe the benefits of improved treatment. Design: Retrospective analysis of hospital discharges was conducted using data from the Health Care Cost and Utilization Project Nationwide Inpatient Sample that approximates a 20% sample of U.S. acute care hospitals. Setting., Hospital inpatient stays from all types of U.S. community hospitals. Participants., The study sample included all children aged 0-21 with a primary or secondary ICD-9-CM diagnosis code for traumatic brain injury and a procedure code for either endotracheal intubation or mechanical ventilation. Interventions., None. Measurements and Main Results. Deaths occurring during hospitalization were used to calculate mortality rates. Use of intracranial pressure monitoring and surgical openings of the skull were investigated as markers for the aggressiveness of treatment. Patients were further classified by insurance status, household income, and hospital characteristics. Over the 12-yr study period, mortality rates decreased 8 percentage points whereas utilization of intracranial pressure monitoring increased by 11 percentage points. The trend toward more aggressive management of traumatic brain injury corresponded with improved hospital outcomes over time. Lack of insurance was associated with vastly worse outcomes. An estimated 6,437 children survived their traumatic brain injury hospitalization because of improved treatment, and 1,418 children died because of increased mortality risk associated with being uninsured. Improved treatment was valued at approximately $17 billion, whereas acute care hospitalization costs increased by $1.5 billion (in constant 2000 dollars). Increased mortality in uninsured children was associated with a $3.76 billion loss in economic benefits. Conclusions. More aggressive management of pediatric traumatic brain injury appears to have contributed to reduced mortality rates over time and saved thousands of lives. Additional lives could be saved it mortality rates could be equalized between insured and uninsured children.	Univ Arkansas Med Sci Hosp, Arkansas Childrens Hosp, Ctr Appl Res & Evaluat, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA; Wayne State Univ, Dept Econ, Detroit, MI USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA		Tilford, JM (corresponding author), Univ Arkansas Med Sci Hosp, Arkansas Childrens Hosp, Ctr Appl Res & Evaluat, 800 Marshall St, Little Rock, AR 72202 USA.	tilfordmickj@uams.edu	Adelson, David/W-2083-2019; Aitken, Mary/ABG-6119-2021; Anand, Kanwaljeet/B-3287-2014	Anand, Kanwaljeet/0000-0001-6498-1483			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; *AG HEALTHC RES QU, 2003, HEALTHC COST UT PROJ; *AG HEALTHC RES QU, 2004, CALC NAT INP SAMPL V; Agency for Healthcare Research and Quality, 2002, DES HCUP NAT INP SAM; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock R, 1995, GUIDELINES MANAGEMEN; Chang RKR, 2003, PEDIATRICS, V111, P1124, DOI 10.1542/peds.111.5.1124; Chang RKR, 2002, PEDIATRICS, V110, P292, DOI 10.1542/peds.110.2.292; *CTR INJ RES POL J, 1997, ICDMAP90 J HOPK U TR; Cutler David M., 2004, YOUR MONEY YOUR LIFE; Cutler DM, 2000, NBER FR HLTH POL RES, V3, P33, DOI 10.1162/109623100300091069; CUTLER DM, 2001, HLTH AFF MILLWOOD, V20, P11; David MCutler, 1999, MEASURING PRICES MED, P34; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Diesner F, 1997, NEUROSURG REV, V20, P274, DOI 10.1007/BF01105899; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; Durbin DR, 2000, AM J PUBLIC HEALTH, V90, P1782, DOI 10.2105/AJPH.90.11.1782; FESSLER RD, 1993, ANN EMERG MED, V22, P998, DOI 10.1016/S0196-0644(05)82741-6; Frank RG, 1999, HEALTH AFFAIR, V18, P71, DOI 10.1377/hlthaff.18.5.71; Friedman Bernard, 2002, J Health Care Finance, V29, P1; GADKARY CS, 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001048; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JB, 1996, NEUROTRAUMA; Greenspan A I, 1996, Curr Probl Pediatr, V26, P170, DOI 10.1016/S0045-9380(96)80004-1; Greenwald B M, 1995, Adv Pediatr, V42, P47; Hadley J, 2003, MED CARE RES REV, V60, p3S, DOI 10.1177/1077558703254101; Harper Rita G, 2002, J Perinatol, V22, P555, DOI 10.1038/sj.jp.7210789; Heidenreich PA, 2001, AM J MED, V110, P165, DOI 10.1016/S0002-9343(00)00712-9; Holman RC, 2003, PEDIATRICS, V111, P448, DOI 10.1542/peds.111.2.448; *I MED, 2003, HIDD COSTS VAL LOST; Kaiser Jeffrey R, 2004, J Perinatol, V24, P343, DOI 10.1038/sj.jp.7211113; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Kraus J, 1996, NEUROTRAUMA, P13; LOPEZ AM, IN PRESS PEDIAT CRIT; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1990, J TRAUMA, V30, P681, DOI 10.1097/00005373-199006000-00005; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; TORNER J, 1998, TRAUMATIC BRAIN INJU, P9; Volpp KGM, 2003, HEALTH SERV RES, V38, P515, DOI 10.1111/1475-6773.00131; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006	51	47	49	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2005	33	9					2074	2081		10.1097/01.CCM.0000171839.65687.F5			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	042CG	WOS:000237504200026	16148483				2022-02-06	
J	van den Broek, MD				van den Broek, MD			Why does neurorehabilitation fail?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						goal setting; motivation; neurorehabilitation; outcome	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION	Following neurorehabilitation, many patients show limited benefit, generalization, or maintenance of gains over time. Some of the reasons that account for modest outcomes are discussed with particular reference to the differences between patients' needs and aspirations, the nature of patient-clinician interactions, and patients' rehabilitation readiness. The role of a more client-centered approach is reviewed, as well as the importance of facilitating patients' capacity to identify problems, develop goals, consider options, and make choices. It is proposed that effective outcomes depend on the clinicians' success in harnessing patients' intrinsic motivation to change.	Wolfson Neurorehabil Ctr, London SW20 0NE, England; Gen Hosp St Georg, Reg Neurosci Ctr, London SW20 0NE, England		van den Broek, MD (corresponding author), Wolfson Neurorehabil Ctr, Copse Hill, London SW20 0NE, England.	martin.vandenbroek@stgeorges.nhs.uk					Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; D'Zurilla T.J., 1999, PROBLEM SOLVING THER, V2nd edn; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Ingersoll KS, 2000, MOTIVATIONAL GROUPS; Langer KG., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [DOI 10.1080/09602019208401395, 10.1080/09602019208401395]; Miller W.R., 2002, MOTIVATIONAL INTERVI; Miller WR., 1999, MOTIVATIONAL ENHANCE; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROLLNICK S, 2000, HLTH BEHAV CHANGE GU; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; SOHLBERG MM, 1994, MANUAL TEACHING PATI; VANDENBROEK MD, 2002, HEAD INJURY ED GROUP	15	47	47	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					464	473		10.1097/00001199-200509000-00007			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600008	16170254				2022-02-06	
J	Ducreux, D; Huynh, I; Fillard, P; Renoux, J; Petit-Lacour, MC; Marsot-Dupuch, K; Lasjaunias, P				Ducreux, D; Huynh, I; Fillard, P; Renoux, J; Petit-Lacour, MC; Marsot-Dupuch, K; Lasjaunias, P			Brain MR diffusion tensor imaging and fibre tracking to differentiate between two diffuse axonal injuries	NEURORADIOLOGY			English	Article								We report here two cases of diffuse axonal injury (DAI) studied by MR diffusion tensor imaging (DTI) and fibre tracking (FT) focused on the corpus callosum. In one case, DTI and FT pattern matched the diagnosis of broken white matter tracts. In the other case there was a discrepancy between DTI and FT data that showed unaltered white matter tracts with the presence of intra-cellular oedema. These data suggested that DTI and FT are able to differentiate between traumatic cytotoxic oedema and broken fibres in the case of DAI.	Univ Paris 11, CHU Bicetre, Dept Neuroradiol, F-94270 Le Kremlin Bicetre, France; Univ N Carolina, Dept Comp Sci, Chapel Hill, NC USA		Ducreux, D (corresponding author), Univ Paris 11, CHU Bicetre, Dept Neuroradiol, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.	denis.ducreux@bct.ap-hop-paris.fr	FILLARD, PIERRE/AAS-1384-2021				Atlas S. W., 1996, MAGNETIC RESONANCE I; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1998, 6 ISMRM SYDN AU, P1226; FILLARD P, 2003, MICCAI, V2, P967; Holbourn AHS, 1943, LANCET, V2, P438; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; Le Bihan D, 1991, Magn Reson Q, V7, P1; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491; Wang HD, 1998, CHINESE MED J-PEKING, V111, P59; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1	12	47	52	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	AUG	2005	47	8					604	608		10.1007/s00234-005-1389-1			5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	958CD	WOS:000231421400007	15973535				2022-02-06	
J	Soeda, A; Nakashima, T; Okumura, A; Kuwata, K; Shinoda, J; Iwama, T				Soeda, A; Nakashima, T; Okumura, A; Kuwata, K; Shinoda, J; Iwama, T			Cognitive impairment after traumatic brain injury: a functional magnetic resonance imaging study using the Stroop task	NEURORADIOLOGY			English	Article						cognitive function; functional MRI; brain injury; Stroop task	POSITRON-EMISSION-TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; CLOSED HEAD-INJURY; WORKING-MEMORY; COUNTING STROOP; INTERFERENCE TASK; PREFRONTAL CORTEX; MRI; ATTENTION; FMRI	The anterior cingulate cortex (ACC) plays a key role in cognition, motor function, and emotion processing. However, little is known about how traumatic brain injury (TBI) affects the ACC system. Our purpose was to compare, by functional magnetic resonance imaging (fMRI) studies, the patterns of cortical activation in patients with cognitive impairment after TBI and those of normal subjects. Cortical activation maps of 11 right-handed healthy control subjects and five TBI patients with cognitive impairment were recorded in response to a Stroop task during a block-designed fMRI experiment. Statistical parametric mapping (SPM99) was used for individual subjects and group analysis. In TBI patients and controls, cortical activation, found in similar regions of the frontal, occipital, and parietal lobes, resembled patterns of activation documented in previous neuroimaging studies of the Stroop task in healthy controls. However, the TBI patients showed a relative decrease in ACC activity compared with the controls. Cognitive impairment in TBI patients seems to be associated with alterations in functional cerebral activity, especially less activation of the ACC. These changes are probably the result of destruction of neural networks after diffuse axonal injury and may reflect cortical disinhibition attributable to disconnection or compensation for an inefficient cognitive process.	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5011194, Japan; Kizawa Mem Hosp, Dept Neurosurg, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Minokamo, Japan; Gifu Univ, Sch Med, Dept Biochem & Biophys, Gifu 500, Japan		Soeda, A (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, 1-1 Yanagido, Gifu 5011194, Japan.	ccd29400@nyc.odn.ne.jp		Iwama, Toru/0000-0002-9426-284X			Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bullmore E, 1999, HUM BRAIN MAPP, V8, P86, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<86::AID-HBM3>3.0.CO;2-S; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cabeza R, 1997, NEUROREPORT, V8, P3479, DOI 10.1097/00001756-199711100-00013; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; COHEN JD, 1990, PSYCHOL REV, V97, P332, DOI 10.1037/0033-295X.97.3.332; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Gruber SA, 2002, NEUROIMAGE, V16, P349, DOI 10.1006/nimg.2002.1089; GUR RC, 1982, SCIENCE, V217, P659, DOI 10.1126/science.7089587; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Menon RS, 1999, TRENDS COGN SCI, V3, P207, DOI 10.1016/S1364-6613(99)01329-7; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Stamatakis EA, 2002, J NUCL MED, V43, P476; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Talairach J., 1988, COPLANAR STEREOTACTI; TEASDALE G, 1974, LANCET, V2, P81; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; Wechsler D, 1985, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Weiss EM, 2003, PSYCHIAT RES-NEUROIM, V123, P1, DOI 10.1016/S0925-4927(03)00019-2; Whalen PJ, 1998, BIOL PSYCHIAT, V44, P1219, DOI 10.1016/S0006-3223(98)00251-0	35	47	53	1	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	JUL	2005	47	7					501	506		10.1007/s00234-005-1372-x			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	947NR	WOS:000230653400002	15973537				2022-02-06	
J	Haskins, WE; Kobeissy, FH; Wolper, RA; Ottens, AK; Kitlen, JW; McClung, SH; O'Steen, BE; Chow, MM; Pineda, JA; Denslow, ND; Hayes, RL; Wang, KKW				Haskins, WE; Kobeissy, FH; Wolper, RA; Ottens, AK; Kitlen, JW; McClung, SH; O'Steen, BE; Chow, MM; Pineda, JA; Denslow, ND; Hayes, RL; Wang, KKW			Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact (CCI); differential in-gel electrophoresis (DIGE); sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE); tandem mass spectometry (MS2); traumatic brain injury (TBI)	CONTROLLED CORTICAL IMPACT; DIFFERENTIAL GEL-ELECTROPHORESIS; NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; BREAKDOWN PRODUCTS; PROTEOMICS TECHNOLOGY; SHOTGUN PROTEOMICS; RAT; IMMUNOREACTIVITY; ACCUMULATION	We report the rapid discovery of putative protein biomarkers of traumatic brain injury (TBI) by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry (SDS-PAGE-Capillary LC-MS2). Ipsilateral hippocampus (111) samples were collected from naive rats and rats subjected to controlled cortical impact (a rodent model of TBI). Protein database searching with 15,558 uninterpreted MS2 spectra, collected in 3 days via data-dependent capillary LC-MS2 of pooled cyanine dye-labeled samples separated by SDS-PAGE, identified more than 306 unique proteins. Differential proteomic analysis revealed differences in protein sequence coverage for 170 mammalian proteins (57 in naive only, 74 in injured only, and 39 of 64 in both), suggesting these are putative biomarkers of TBI. Confidence in our results was obtained by the presence of several known biomarkers of TBI (including all-spectrin, brain creatine kinase, and neuron-specific enolase) in our data set. These results show that SDS-PAGE prior to in vitro proteolysis and capillary LC-MS2 is a promising strategy for the rapid discovery of putative protein biomarkers associated with a specific physiological state (i.e., TBI) without a priori knowledge of the molecules involved.	Univ Florida, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Interdisciplinary Ctr Biotechnol Res, Gainesville, FL 32610 USA		Wang, KKW (corresponding author), Univ Florida, McKnight Brain Inst, L4-100F,POB 100256,100 S Newell Dr, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017; Ottens, Andrew/K-3352-2012; Pineda, Jose/W-2806-2019	Kobeissy, Firas/0000-0002-5008-6944; Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40182, R01 NS39091] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER		BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bodovitz S, 2004, TRENDS BIOTECHNOL, V22, P4, DOI 10.1016/j.tibtech.2003.10.013; Bramlett HM, 2003, EXP NEUROL, V184, P27, DOI 10.1016/S0014-4886(03)00401-1; Buki A, 2000, J NEUROSCI, V20, P2825; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOMANSKAJANIK K, 1992, MOL CHEM NEUROPATHOL, V16, P273, DOI 10.1007/BF03159974; Fountoulakis M, 1999, ELECTROPHORESIS, V20, P3572; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; GERBER SA, 2003, MS P NATL ACAD SCI U, V100, P6940; Gharbi S, 2002, MOL CELL PROTEOMICS, V1, P91, DOI 10.1074/mcp.T100007-MCP200; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Haskins WE, 2001, ANAL CHEM, V73, P5005, DOI 10.1021/ac010774d; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kernec F, 2001, PHYSIOL GENOMICS, V6, P117, DOI 10.1152/physiolgenomics.2001.6.2.117; Kornblum HI, 2001, NAT REV NEUROSCI, V2, P843, DOI 10.1038/35097597; Leimgruber RM, 2002, PROTEOMICS, V2, P135, DOI 10.1002/1615-9861(200202)2:2<135::AID-PROT135>3.0.CO;2-1; Macdonald N, 2001, ARCH TOXICOL, V75, P415, DOI 10.1007/s002040100259; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pike BR, 2002, J NEUROCHEM, V81, P73; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; PRUITT KD, 2001, NUCLEIC ACIDS RES, V29, P137; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Shaw J, 2003, PROTEOMICS, V3, P1181, DOI 10.1002/pmic.200300439; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tonge R, 2001, PROTEOMICS, V1, P377; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Yan JX, 2002, PROTEOMICS, V2, P1682, DOI 10.1002/1615-9861(200212)2:12<1682::AID-PROT1682>3.0.CO;2-Y; Yates JR, 1998, ANAL CHEM, V70, P3557, DOI 10.1021/ac980122y; ZELMAN FP, 2002, BRAIN RES, V947, P131	40	47	48	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					629	644		10.1089/neu.2005.22.629			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400003	15941373				2022-02-06	
J	Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Garbe, J; Bouillon, B; Neugebauer, E; Klug, N; Lefering, R; Neiss, WF; Angelov, DN				Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Garbe, J; Bouillon, B; Neugebauer, E; Klug, N; Lefering, R; Neiss, WF; Angelov, DN			Multimodal early onset stimulation combined with enriched environment is associated with reduced CNS lesion volume and enhanced reversal of neuromotor dysfunction after traumatic brain injury in rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						brain injury; enriched environment; lesion volume; neurological recovery; rat; stimulation	FLUID PERCUSSION INJURY; NEURON-SPECIFIC ENOLASE; SPATIAL MEMORY; VOLUNTARY EXERCISE; COGNITIVE FUNCTION; CEREBRAL EDEMA; UP-REGULATION; ADULT-RAT; IN-VITRO; RECOVERY	This study was designed to determine whether exposure to multimodal early onset stimulation (MEOS) combined with environmental enrichment (EE) after traumatic brain injury (TBI) would improve neurological recovery and to elucidate its morphological correlates. Male Sprague-Dawley rats were subjected to lateral fluid percussion (LFP) brain injury or to sham operation. After LFP, one-third of the animals (injured and sham) were placed under conditions of standard housing (SH), one-third were kept in EE only, and one-third received EE + MEOS. Assessment of neuromotor function 24 h post-injury using a standardized composite neuroscore test revealed an identical pattern of neurological impairment in all animals subjected to LFP. Neuromotor dysfunction in SH animals remained on a similar level throughout the experiment, while improvements were noted in both other groups 7 days post-injury (dpi). On 15 dpi, reversal of neuromotor dysfunction was significantly better in EE + MEOS animals vs. SH- and EE-only groups. In parallel, the comparison of lesion volume in EE + MEOS- vs. EE-only vs. SH rats revealed that animals exposed to EE + MEOS had consistently the lowest values (mm(3), mean +/- SD; n = 6 rats in each group) as measured in serial brain sections immunostained for neuron-specific enolase (5.2 +/- 3.4 <= 5.5 +/- 4.1 < 9.5 +/- 1.9), caspase 3-active/C3A (5.9 +/- 4.0 <= 6.4 +/- 3.9 < 10.3 +/- 1.8) and glial fibrillary acidic protein (6.0 +/- 3.4 <= 6.5 +/- 4.3 < 10.7 +/- 1.2). This first report on the effect of EE + MEOS treatment strongly indicates that the combined exposure reduces CNS scar formation and reverses neuromotor deficits after TBI in rats.	Univ Cologne, Inst Anat 1, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Biochem & Expt Div, D-5000 Cologne, Germany; Univ Witten Herdecke, Merheim Med Ctr, Dept Surg, Cologne, Germany; Univ Cologne, Fac Med, Dept Neurosurg, D-5000 Cologne, Germany; Merheim Med Ctr, Dept Neurol, Cologne, Germany		Angelov, DN (corresponding author), Univ Cologne, Inst Anat 1, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	angelov.anatomie@uni-koeln.de					Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANGELOV DN, 1994, J NEUROCYTOL, V23, P218, DOI 10.1007/BF01275526; ANGELOV DN, 1995, GLIA, V13, P113, DOI 10.1002/glia.440130205; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Czeh B, 1998, HIPPOCAMPUS, V8, P647, DOI 10.1002/(SICI)1098-1063(1998)8:6<647::AID-HIPO7>3.0.CO;2-L; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gruner ML, 2000, BRAIN INJURY, V14, P585; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; INGLIS FM, 1995, NEUROSCIENCE, V66, P81, DOI 10.1016/0306-4522(94)00578-S; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449	68	47	51	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2005	21	9					2406	2418		10.1111/j.1460-9568.2005.04070.x			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	928PN	WOS:000229284100010	15932599				2022-02-06	
J	Masedo, AI; Hanley, M; Jensen, MP; Ehde, D; Cardenas, DD				Masedo, AI; Hanley, M; Jensen, MP; Ehde, D; Cardenas, DD			Reliability and validity of a self-report FIMTM(FIM-SR) in persons with amputation or spinal cord injury and chronic pain	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						FIMTM (TM)instrument; reliability; validity; amputation; spinal cord injury	FUNCTIONAL INDEPENDENCE MEASURE; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; COGNITIVE DYSFUNCTION; IMPAIRMENT; DISABILITY; AMITRIPTYLINE; PERFORMANCE; HANDICAP; OUTCOMES	Objective: To evaluate the reliability and validity of a self-report FIM(TM) (FIM-SR) in two samples of adults with disabilities. Design: Participants in a clinical trial of amitriptyline for pain (n = 84 with spinal cord injury [SCI], n = 38 with amputation) provided responses to the study measures via telephone interview. Reliability was estimated using Cronbach's alpha and test-retest correlation coefficients, and validity was examined by comparing FIM-SR scores with the Craig Handicap Assessment and Reporting Technique (CHART) by comparing the CHART scores between the participants with SCI and amputation, and by comparing CHART scores between subjects with different levels of SCI. Results: In the SCI sample, the FIM-SR demonstrated adequate reliability, and correlational analyses supported the validity of the FIM-SR motor scales. In addition, the FIM-SR motor scales discriminated subjects with different diagnoses (SCI vs. amputation) and injury levels (paraplegia vs. tetraplegia). The psychometric properties of the entire FIM-SR in the amputation sample and of the FIM-SR cognitive scales in the SCI sample were difficult to determine due to a ceiling effect in which these scale scores were skewed toward the top end of the range. Conclusions: The FIM-SR motor scales and total FIM-SR score are reliable and valid measures of perceived functional independence in individuals with SCI. However, all of the FIM-SR scales in the amputation sample, and the FIM-SR cognitive scales in the SCI sample, seem to be less useful measures of functioning due to subjects reporting high levels of independence. The FIM-SR should be retested in amputation samples with more variable levels of functioning.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98105 USA; Univ Washington, Med Ctr, Ctr Multidisciplinary Pain, Seattle, WA 98105 USA		Jensen, MP (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98105 USA.		Ehde, Dawn/K-1883-2016	Masedo Gutierrez, Ana Isabel/0000-0003-3495-6265; Ehde, Dawn/0000-0002-9555-2347	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD033988] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000037] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR-0037] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1P01-HD/NS-33988] Funding Source: Medline		Alarcon GS, 2002, ARTHRIT RHEUM-ARTHR, V47, P310, DOI 10.1002/art.10457; Brewer NT, 2004, MED CARE, V42, P875, DOI 10.1097/01.mlr.0000135817.31355.6b; Cardenas DD, 2002, PAIN, V96, P365, DOI 10.1016/S0304-3959(01)00483-3; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Cotter EM, 2002, CLIN REHABIL, V16, P36, DOI 10.1191/0269215502cr465oa; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Ehde DM, 2003, CLIN J PAIN, V19, P3, DOI 10.1097/00002508-200301000-00002; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; Garber MC, 2004, MED CARE, V42, P649, DOI 10.1097/01.mlr.0000129496.05898.02; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GREY N, 1993, PARAPLEGIA, V31, P457, DOI 10.1038/sc.1993.74; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hinkin CH, 1996, J CLIN EXP NEUROPSYC, V18, P431, DOI 10.1080/01688639608408999; Hoenig H, 1999, SPINE, V24, P539, DOI 10.1097/00007632-199903150-00007; Hoenig H, 1998, ARCH PHYS MED REHAB, V79, P378, DOI 10.1016/S0003-9993(98)90137-X; Hoenig H, 2001, ARCH PHYS MED REHAB, V82, P613, DOI 10.1053/apmr.2001.20832; Iezzoni LI, 2000, MED CARE, V38, P1051, DOI 10.1097/00005650-200010000-00009; Jensen MP, 2005, ARCH PHYS MED REHAB, V86, P116, DOI 10.1016/j.apmr.2004.01.040; Liu C, 2003, J NEUROL, V250, P1214, DOI 10.1007/s00415-003-0187-0; Magaziner J, 1997, AM J EPIDEMIOL, V146, P418, DOI 10.1093/oxfordjournals.aje.a009295; Marshall HM, 2002, ARCH PHYS MED REHAB, V83, P1116, DOI 10.1053/apmr.2002.33121; Mendelsohn ME, 2003, AM J PHYS MED REHAB, V82, P766, DOI 10.1097/00002060-200310000-00005; MUECKE L, 1992, ARCH PHYS MED REHAB, V73, P851; ODELL MW, 1991, AM J PHYS MED REHAB, V70, P91, DOI 10.1097/00002060-199104000-00008; OTOOLE DM, 1991, WESTERN J MED, V155, P384; REUBEN DB, 1995, J AM GERIATR SOC, V43, P17, DOI 10.1111/j.1532-5415.1995.tb06236.x; Robinson LR, 2004, ARCH PHYS MED REHAB, V85, P1, DOI 10.1016/S0003-9993(03)00476-3; Simondson JA, 2003, CLIN REHABIL, V17, P558, DOI 10.1191/0269215503cr650oa; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILSON DB, 1991, WESTERN J MED, V154, P587	32	47	47	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR	2005	84	3					167	176		10.1097/01.PHM.0000154898.25609.4A			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	898TE	WOS:000227098300004	15725790				2022-02-06	
J	Blackman, JA; Worley, G; Strittmatter, WJ				Blackman, JA; Worley, G; Strittmatter, WJ			Apolipoprotein E and brain injury: implications for children	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							E-DEFICIENT MICE; INCREASED NEURONAL DAMAGE; GLOBAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; EPSILON 4 ALLELE; E GENOTYPE; ALZHEIMERS-DISEASE; APOE GENOTYPE; APOE-EPSILON-4 ALLELE		Univ Virginia, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, Charlottesville, VA 22903 USA; Duke Univ, Ctr Med, Dept Neurol, Durham, NC USA		Blackman, JA (corresponding author), Univ Virginia, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, 2270 Ivy Rd, Charlottesville, VA 22903 USA.	jab5u@virginia.edu					ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Bartres-Faz D, 2002, J NEUROPSYCH CLIN N, V14, P80, DOI 10.1176/appi.neuropsych.14.1.80; Bedlack RS, 2000, ARCH NEUROL-CHICAGO, V57, P1561, DOI 10.1001/archneur.57.11.1561; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Berr C, 1996, NEUROSCI LETT, V218, P9, DOI 10.1016/S0304-3940(96)13059-7; Blackman JA, 2004, DEV MED CHILD N S100, V46, P26; Bondi MW, 1995, NEUROLOGY, V45, P2203, DOI 10.1212/WNL.45.12.2203; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Buttini M, 1999, J NEUROSCI, V19, P4867; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DelBo R, 1997, J NEUROL SCI, V145, P87, DOI 10.1016/S0022-510X(96)00249-3; DeMattos RB, 2001, J LIPID RES, V42, P976; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Fernandez T, 1999, AM J MED GENET, V88, P211, DOI 10.1002/(SICI)1096-8628(19990416)88:2<211::AID-AJMG20>3.0.CO;2-M; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Gaynor JW, 2003, J THORAC CARDIOV SUR, V126, P1736, DOI 10.1016/S0022-5223(03)01188-7; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HANLON CS, 1995, ATHEROSCLEROSIS, V112, P85, DOI 10.1016/0021-9150(94)05402-5; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kerr ME, 1999, ADV EXP MED BIOL, V471, P117; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Masullo C, 2001, NEUROSCI LETT, V303, P87, DOI 10.1016/S0304-3940(01)01673-1; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Morrison KE, 1999, NEUROMUSCULAR DISORD, V9, P372, DOI 10.1016/S0960-8966(99)00036-X; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMEARA ES, 1997, AM J EPIDEMIOL, V8, P707; ORIA RB, 2004, IN PRESS PEDIAT RES; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Raiford KL, 2004, AM J MED GENET B, V125B, P57, DOI 10.1002/ajmg.b.20104; Saito Y, 2002, ANN NEUROL, V52, P351, DOI 10.1002/ana.10266; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schmidt S, 2002, AM J HUM GENET, V70, P708, DOI 10.1086/339269; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Strittmatter WJ, 2002, CURR OPIN LIPIDOL, V13, P119, DOI 10.1097/00041433-200204000-00002; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Ti LK, 2003, J THORAC CARDIOV SUR, V125, P211, DOI 10.1067/mtc.2003.123; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9	79	47	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JAN	2005	47	1					64	70		10.1017/S0012162205000113			7	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	891UA	WOS:000226605300011	15686292				2022-02-06	
J	Xiang, HY; Kelleher, K; Shields, BJ; Brown, KJ; Smith, GA				Xiang, HY; Kelleher, K; Shields, BJ; Brown, KJ; Smith, GA			Skiing- and snowboarding-related injuries treated in US emergency departments, 2002	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						skiing; snowboarding; injuries; United States	HEAD-INJURIES; CHILDREN; SKIERS; PATTERNS; SPORTS	Background: This study aims to describe the characteristics of skiing- and snowboarding-related injuries treated in U.S. emergency departments (EDs). Methods: Skiing- and snowboarding-related injuries collected by the National Electronic Injury Surveillance System in 2002 were analyzed. Data regarding skiing and snowboarding participation were used to calculate injury rates by age group and activity (skiing versus snowboarding). Results: An estimated 77,300 (95% CI = 11,600-143,000) skiing- and 62,000 (95% CI = 32,800-91,200) snowboarding-related injuries were treated in U.S. hospital EDs in 2002. Wrist injuries (17.9%) and arm injuries (16.6%) among snowboarders and knee injuries (22.7%) among skiers were the most common injuries. The age groups that have the highest skiing-related injury rates were the 55-64 years (29.0 per 1,000 participants), the 65+ years (21.7 per 1,000 participants), and the 45-54 years (15.5 per 1,000 participants). The age groups that have the highest snowboarding-related injuries were the 10-13 years (15.9 per 1,000 participants), the 14-17 years (15.0 per 1,000 participants), and the 18-24 years (13.5 per 1,000 participants). Traumatic brain injury (TBI) rates were higher among older skiers, 55-64 years (2.15 per 1,000 participants), and younger skiers, 10-13 years (1.69 per 1,000 participants). Conclusions: Our study is the first to demonstrate that older skiers are at highest risk for injury. Adolescents are at highest risk for snowboarding-related injury. Prevention of TBI should be a top injury control priority among skiers and snowboarders.	Ohio State Univ, Ctr Injury Res & Policy, Childrens Res Inst, Columbus Childrens Hosp,Coll Med & Publ Hlth, Columbus, OH 43205 USA		Xiang, HY (corresponding author), Ohio State Univ, Ctr Injury Res & Policy, Childrens Res Inst, Columbus Childrens Hosp,Coll Med & Publ Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	xiangh@pediatrics.ohio-state.edu	Kelleher, Kelly/E-3361-2011; Xiang, Huiyun/E-4335-2011				*AM MED ASS, 1997, HELM RECR SKIING OTH; BLITZER CM, 1984, AM J SPORT MED, V12, P142, DOI 10.1177/036354658401200210; BOUTER LM, 1989, PHYSICIAN SPORTSMED, V17, P81; BROWN JM, 1997, CONT PEDIAT, V14, P115; CADMAN R, 1996, ASTM STP, V1266; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; EKELAND A, 1993, SKIING TRAUM SAF 9 I; Ferrera PC, 1999, AM J EMERG MED, V17, P575, DOI 10.1016/S0735-6757(99)90199-7; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; Goulet C, 1999, AM J SPORT MED, V27, P644, DOI 10.1177/03635465990270051701; Hagel BE, 2004, EPIDEMIOLOGY, V15, P279, DOI 10.1097/01.ede.0000120044.62029.b4; Hagel BE, 2003, CAN J PUBLIC HEALTH, V94, P458, DOI 10.1007/BF03405085; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; LYNCH J, 2003, SNOW SPORTS IND INTE; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; Marshall SW, 2003, INJURY PREV, V9, P100, DOI 10.1136/ip.9.2.100; MORROW PL, 1988, J TRAUMA, V28, P95, DOI 10.1097/00005373-198801000-00014; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; SANDEGAARD J, 1991, SKIING TRAUM SAF 9 I; SAS, 1999, SAS STAT US GUID VER, V10th; SHAH BV, 1996, SUDAAN USERS MANUAL; Shephard RJ, 2003, INJURY PREV, V9, P99, DOI 10.1136/ip.9.2.99; SHERRY E, 1988, MED J AUSTRALIA, V149, P615, DOI 10.5694/j.1326-5377.1988.tb120803.x; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Smith GA, 1998, PEDIATRICS, V101, P406, DOI 10.1542/peds.101.3.406; SUGAWARA M, 1985, SKIING TRAUM SAF 6 I; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TOUGH SC, 1993, AM J FOREN MED PATH, V14, P12, DOI 10.1097/00000433-199303000-00003; *US CONS PROD SAF, 1999, EV POT RED HEAD INJ; *US CONS PROD SAF, 2001, NAT EL INJ SURV NEIS; US Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; WARME WJ, 1995, AM J SPORT MED, V23, P597, DOI 10.1177/036354659502300514; Xiang HY, 2003, INJURY, V34, P892, DOI 10.1016/S0020-1383(03)00055-X	38	47	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2005	58	1					112	118		10.1097/01.TA.0000151270.26634.DD			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	894HS	WOS:000226782300020	15674160				2022-02-06	
J	Goetz, P; Blamire, A; Rajagopalan, B; Cadoux-Hudson, T; Young, D; Styles, P				Goetz, P; Blamire, A; Rajagopalan, B; Cadoux-Hudson, T; Young, D; Styles, P			Increase in apparent diffusion coefficient in normal appearing white matter following human traumatic brain injury correlates with injury severity	JOURNAL OF NEUROTRAUMA			English	Article						ADC; diffuse axonal injury; diffusion weighted imaging; T1 relaxation; T2 relaxation; traumatic brain injury; white matter	CLOSED-HEAD-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; AMYLOID PRECURSOR PROTEIN; CEREBRAL BLOOD-VOLUME; AXONAL INJURY; WEIGHTED MR; WALLERIAN DEGENERATION; WATER-DIFFUSION; TIME-COURSE; T2-WEIGHTED MRI	Following diffuse traumatic brain injury, there may be persistent functional or psychological deficits despite the presence of normal conventional MR images. Previous experimental animal and human studies have shown diffusion abnormalities following focal brain injury. Our aim was to quantify changes in apparent diffusion coefficient (ADC) and absolute relaxation times of normal appearing white matter (NAWM) in humans following traumatic brain injury. Twenty-three patients admitted with a diagnosis of head injury (nine mild, eight moderate, and six severe) were scanned an average of 7.6 days after injury using a quantitative echo planar imaging acquisition to obtain co-registered T1, T2, and ADC parametric maps. Mean NAWM values were compared with a control group (n = 13). The patient group showed a small but significant increase in ADC in NAWM, with no significant change in T1 or T2 relaxation times. There was a correlation between injury severity and increasing ADC (p = 0.03) but no correlation with either T1 or T2, suggesting that ADC is a sensitive and independent marker of diffuse white matter tissue damage following traumatic insult. None of the patients had a reduced ADC, making ischaemia unlikely in this cohort. Pathophysiological mechanisms that may explain diffusely raised ADC include vasogenic edema, chronic ischemic phenomena, or changes in tissue cytoarchitecture or neurofilament alignment.	John Radcliffe Hosp, MRC Biochem & Clin Magnet Resonance Unit, Oxford 0X3 9DU, England; Radcliffe Infirm, Dept Neurosurg, NHS Trust, Oxford OX2 6HE, England; John Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 9DU, England		Goetz, P (corresponding author), John Radcliffe Hosp, MRC Biochem & Clin Magnet Resonance Unit, Oxford 0X3 9DU, England.	pgoetz@bioch.ox.ac.uk	Blamire, Andrew/AAU-6100-2021; Young, John D/M-9756-2016	Blamire, Andrew/0000-0002-8749-1257; Young, John Duncan/0000-0002-6838-4835			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Anderson AW, 1996, MAGN RESON MED, V35, P162, DOI 10.1002/mrm.1910350206; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Blamire AM, 2000, J NEUROSCI, V20, P8153; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Helenius J, 2002, AM J NEURORADIOL, V23, P194; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI 10.2307/1390807; Karibe H, 2000, J NEUROSURG, V92, P58, DOI 10.3171/jns.2000.92.1.0058; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; MURTAGH F, 1983, COMPUT J, V26, P354, DOI 10.1093/comjnl/26.4.354; Naganawa S, 2003, EUR RADIOL, V13, P6, DOI 10.1007/s00330-002-1549-1; NOMURA Y, 1994, AM J NEURORADIOL, V15, P231; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Ripley B.D, 2002, MODERN APPL STAT S, DOI DOI 10.1007/978-0-387-21706-2; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rousseeuw P.J., 1987, ROBUST REGRESSION OU; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Sawlani V, 1997, J NEUROL SCI, V146, P103, DOI 10.1016/S0022-510X(96)00299-7; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; Sibson NR, 2002, BRAIN, V125, P2446, DOI 10.1093/brain/awf256; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; STONE JR, 2000, RESTOR NEUROL NEUROS, V16, P304; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135; [No title captured]	53	47	50	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					645	654		10.1089/0897715041269731			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600001	15253793				2022-02-06	
J	Mathias, CW; Stanford, MS; Houston, RJ				Mathias, CW; Stanford, MS; Houston, RJ			The physiological experience of the Paced Auditory Serial Addition Task (PASAT): Does the PASAT induce autonomic arousal?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						arousal; Paced Auditory Serial Attention Task; heart rate; blood pressure	TRAUMATIC BRAIN-INJURY; BLOOD-PRESSURE; HEAD-INJURY; PERFORMANCE; ASSOCIATION; DISEASE; SCORES	Previous research suggests that the Paced Auditory Serial Attention Task (PASAT) alters mood states, which may induce performance changes and complicate interpretation test scores. In the current design, we examined arousal as one mechanism moderating PASAT performance. It was expected that arousal level would increase during the test, and performance on the test would be related to arousal level. Heart rate and blood pressure (systolic and diastolic) were recorded from 42 healthy adult men during rest and PASAT challenge. Heart rate and blood pressure were significantly higher and stable across the PASAT procedure, while performance scores showed a steady decrease in correct responses. No association of arousal level and performance was found. Although, PASAT induced arousal changes were not significantly related to performance among healthy adults, the observed arousal changes do raise concerns about interpretation of PASAT performance among more sensitive populations and indicate new areas of application of the procedure. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA; Univ Texas, Hlth Sci Ctr, Neurobehav Res Lab & Clin, Houston, TX USA; Univ Connecticut, Sch Med, Dept Psychiat, Farmington, CT USA		Stanford, MS (corresponding author), Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA.	Matthew_Stanford@baylor.edu		Mathias, Charles/0000-0003-1902-673X			AlAbsi M, 1997, PSYCHOPHYSIOLOGY, V34, P266, DOI 10.1111/j.1469-8986.1997.tb02397.x; ANDERSON CA, 1995, PERS SOC PSYCHOL B, V21, P434, DOI 10.1177/0146167295215002; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Catipovic-Veselica K, 1999, PSYCHOL REP, V84, P433, DOI 10.2466/PR0.84.2.433-442; Chen Y, 1998, INT J OBESITY, V22, P771, DOI 10.1038/sj.ijo.0800658; Chronicle EP, 1998, NEUROPSYCHOL REHABIL, V8, P273; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; DEARY IJ, 1991, PERS INDIV DIFFER, V12, P983, DOI 10.1016/0191-8869(91)90027-9; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; GEISSER S, 1958, ANN MATH STAT, V29, P885, DOI 10.1214/aoms/1177706545; Graham RE, 1996, PSYCHOPHYSIOLOGY, V33, P566, DOI 10.1111/j.1469-8986.1996.tb02433.x; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HEBB DO, 1955, PSYCHOL REV, V62, P243, DOI 10.1037/h0041823; Holdwick DJ, 1999, ARCH CLIN NEUROPSYCH, V14, P273, DOI 10.1016/S0887-6177(98)00021-3; HUMPHREYS MS, 1984, PSYCHOL REV, V91, P153, DOI 10.1037/0033-295X.91.2.153; *JOHN JOHN MED INC, 1997, DINAMAP MPS SEL PORT; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MANOLIO TA, 1988, AM J HYPERTENS, V1, pS161, DOI 10.1093/ajh/1.3.161S; Mathias CW, 2003, PERS INDIV DIFFER, V35, P355, DOI 10.1016/S0191-8869(02)00195-2; Matthews G, 1998, PERSONALITY TRAITS; PAPILLO JF, 1990, PRINCIPLES PSYCHOPHY; Patton J.H., 1991, CLIN NEUROPSYCHOL, V5, P33, DOI [10.1080/13854049108401840, DOI 10.1080/13854049108401840]; *PSYCH CORP, 1998, PASAT PAS AUD SER AT; SCHACHTER S, 1962, PSYCHOL REV, V69, P379, DOI 10.1037/h0046234; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; Sjogren P, 2000, J PAIN SYMPTOM MANAG, V19, P100, DOI 10.1016/S0885-3924(99)00143-8; Snyder PJ, 2001, NEUROPSYCHOLOGY, V15, P617, DOI 10.1037//0894-4105.15.4.617; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stevens JP., 1996, APPL MULTIVARIATE ST; Weersink EJM, 1997, AM J RESP CRIT CARE, V156, P1144, DOI 10.1164/ajrccm.156.4.9701001; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503; ZANZOMERAN AH, 1994, CLIN NEUROPSYCHOLOGY	35	47	48	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2004	19	4					543	554		10.1016/j.acn.2003.08.001			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	830DL	WOS:000222101700008	15163455				2022-02-06	
J	Cernak, I; Vink, R; Natale, J; Stoica, B; Lea, PM; Movsesyan, V; Ahmed, F; Knoblach, SM; Fricke, ST; Faden, AI				Cernak, I; Vink, R; Natale, J; Stoica, B; Lea, PM; Movsesyan, V; Ahmed, F; Knoblach, SM; Fricke, ST; Faden, AI			The "dark side" of endocannabinoids: A neurotoxic role for anandamide	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						endocannabinoids; anandamide; cell death; microarray; magnetic resonance imaging; cognitive deficit	TRAUMATIC BRAIN-INJURY; CULTURED CORTICAL-NEURONS; VANILLOID-INDUCED APOPTOSIS; CB1 CANNABINOID RECEPTOR; FOCAL CEREBRAL-ISCHEMIA; INDUCED AXONAL INJURY; CELL-DEATH; N-ACYLETHANOLAMINE; RAT-BRAIN; MATRIX METALLOPROTEINASES	Endocannabinoids, including 2-arachidonoylglycerol and anandamide (N-arachidonoylethanolamine; AEA), have neuroprotective effects in the brain through actions at CB1 receptors. However, AEA also binds to vanilloid (VR1) receptors and induces cell death in several cell lines. Here we show that anandamide causes neuronal cell death in vitro and exacerbates cell loss caused by stretch-induced axonal injury or trophic withdrawal in rat primary neuronal cultures. Administered intracerebroventricularly, AEA causes sustained cerebral edema, as reflected by diffusion-weighted magnetic resonance imaging, regional cell loss, and impairment in long-term cognitive function. These effects are mediated, in part, through VR1 as well as through calpain-dependent mechanisms, but not through CB1 receptors or caspases. Central administration of AEA also significantly upregulates genes involved in proinflammatory/microglial-related responses. Thus, anandamide produces neurotoxic effects both in vitro and in vivo through multiple mechanisms independent of the CB1 receptor.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Univ Adelaide, Dept Pathol, Adelaide, SA, Australia		Cernak, I (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd,Res Bldg,Room EP04, Washington, DC 20057 USA.	ifc@georgetown.edu	Cernak, Ibolja/A-6399-2008; STOICA, BOGDAN/H-9782-2013; Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	STOICA, BOGDAN/0000-0002-2501-6434; Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; Boisvert D P, 1990, Adv Neurol, V52, P407; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Campbell VA, 2001, NEUROPHARMACOLOGY, V40, P702, DOI 10.1016/S0028-3908(00)00210-0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chan D, 1998, NETW COMPUT, V9, P18; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Di Marzo V, 2000, J NEUROCHEM, V75, P2434, DOI 10.1046/j.1471-4159.2000.0752434.x; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Downer E, 2001, NEUROREPORT, V12, P3973, DOI 10.1097/00001756-200112210-00024; Downer EJ, 2003, BRIT J PHARMACOL, V140, P547, DOI 10.1038/sj.bjp.0705464; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; EPPS DE, 1980, BIOCHIM BIOPHYS ACTA, V618, P420, DOI 10.1016/0005-2760(80)90260-X; Faden AI, 2003, ANN NEUROL, V54, pS77; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Galve-Roperh I, 2002, MOL PHARMACOL, V62, P1385, DOI 10.1124/mol.62.6.1385; GRAY GM, 1976, BIOCHIM BIOPHYS ACTA, V431, P1, DOI 10.1016/0005-2760(76)90253-8; Guzman M, 2003, BRIT J PHARMACOL, V140, P439, DOI 10.1038/sj.bjp.0705465; Hail N, 2003, APOPTOSIS, V8, P251, DOI 10.1023/A:1023620821878; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Hansen HS, 1997, J NEUROCHEM, V69, P753; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jiang Q, 1998, J CEREBR BLOOD F MET, V18, P758, DOI 10.1097/00004647-199807000-00007; Kim SY, 2002, MOL CELLS, V13, P429; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; LaFleur M, 1996, J EXP MED, V184, P2311; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Li FH, 1996, DRUG TODAY, V32, P615; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2001, J NEUROCHEM, V76, P594, DOI 10.1046/j.1471-4159.2001.00092.x; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Mechoulam R, 2003, SCIENCE, V302, P65, DOI 10.1126/science.1091256; Mechoulam R, 2002, PROSTAG LEUKOTR ESS, V66, P93, DOI 10.1054/plef.2001.0340; MECHOULAM R, 2002, SCI STKE; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; Mombouli JV, 1999, BRIT J PHARMACOL, V126, P1593, DOI 10.1038/sj.bjp.0702483; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Nagayama T, 1999, J NEUROSCI, V19, P2987; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Povlishock JT, 1999, ACT NEUR S, V73, P15; Qiao M, 2001, STROKE, V32, P958, DOI 10.1161/01.STR.32.4.958; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Sagan S, 1999, EUR J NEUROSCI, V11, P691, DOI 10.1046/j.1460-9568.1999.00480.x; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Szallasi A, 2002, AM J CLIN PATHOL, V118, P110; SZALLASI A, 1990, LIFE SCI, V47, P1399, DOI 10.1016/0024-3205(90)90518-V; Szoke E, 2000, NEUROREPORT, V11, P1949; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Toman RE, 2002, J NEUROSCI RES, V68, P323, DOI 10.1002/jnr.10190; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; VEECH RL, 1979, J BIOL CHEM, V254, P6538; Veldhuis WB, 2003, J NEUROSCI, V23, P4127; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1990, Magnes Res, V3, P163; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	100	47	47	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2004	24	5					564	578		10.1097/00004647-200405000-00011			15	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	818SP	WOS:000221265100011	15129189	Bronze			2022-02-06	
J	Kotani, N; Kudo, R; Sakurai, Y; Sawamura, D; Sessler, DI; Okada, H; Nakayama, H; Yamagata, T; Yasujima, M; Matsuki, A				Kotani, N; Kudo, R; Sakurai, Y; Sawamura, D; Sessler, DI; Okada, H; Nakayama, H; Yamagata, T; Yasujima, M; Matsuki, A			Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia	AMERICAN JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; HERPES-ZOSTER; RISK; PAIN; METHYLPREDNISOLONE; PREVENTION; INFECTION; SEQUELAE; CHILDREN	PURPOSE: Other than age, the risk factors for postherpetic neuralgia are not well established. We studied whether the concentration of interleukin 8 in the cerebrospinal fluid is associated with the risk of postherpetic neuralgia. METHODS: We enrolled 170 patients more than 50 years old who had a typical painful and nontrigeminal herpetic rash. Patients were treated with acyclovir; no corticosteroids were given. Cerebrospinal fluid was taken for analysis of interleukin 8 during and at full crusting of the herpetic rash. Age, sex, comorbid conditions, prodromal pain, localization and severity of herpetic rash, number of skin lesions, and degree of pain were recorded. We used multivariate logistic regression modeling to identify significant predictive factors. Receiver operating characteristic (ROC) curves were evaluated to determine the contribution of each factor. RESULTS: Six months after healing, 31 patients (18%) had postherpetic neuralgia; 27 patients still had it after 1 year. Only three variables-age (odds ratio [OR] = 2.7 per 10-year increase; 95% confidence interval [Cl]: 1.2 to 6.2), acute pain (OR = 1.8 per unit increase in visual analog scale; 95% CI: 1.2 to 2.8), and interleukin 8 concentration in the cerebrospinal fluid at full crusting of the herpetic rash (OR = 1.6 per 20-mug/L increase; 95% Cl: 1.3 to 2.0)-were significant predictors of postherpetic neuralgia at I year. Interleukin 8 concentration also had the highest area under the ROC curve at these evaluation points (P <0.001). CONCLUSION: Our results suggest that interleukin 8 concentration in the cerebrospinal fluid at full crusting of herpetic rash may be useful for identifying patients who are likely to develop intractable postherpetic neuralgia. (C) 2004 by Excerpta Medica Inc.	Yamagata Univ, Sch Med, Dept Anesthesiol, Outcomes Res Grp, Yamagata 9909585, Japan; Hirosaki Univ, Dept Anesthesiol, Hirosaki, Aomori, Japan; Hirosaki Univ, Dept Lab Med, Hirosaki, Aomori, Japan; Natl Def Med Coll, Dept Hyg, Tokorozawa, Saitama 359, Japan; Hokkaido Univ, Dept Dermatol, Sapporo, Hokkaido, Japan; Univ Louisville, Dept Anesthesiol, Louisville, KY 40292 USA; Iwate Med Univ, Dept Anesthesiol, Morioka, Iwate 020, Japan; Tohoku Chem Co Ltd, Hirosaki, Aomori, Japan		Kotani, N (corresponding author), Yamagata Univ, Sch Med, Dept Anesthesiol, Outcomes Res Grp, Yamagata 9909585, Japan.	kotani@med.id.yamagata-u.ac.jp	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM061655-01A2, R01 GM058273-04, GM061655, GM58273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM058273, R01GM061655] Funding Source: NIH RePORTER		ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Choo PW, 1997, ARCH INTERN MED, V157, P1217, DOI 10.1001/archinte.157.11.1217; DWORKIN RH, 1992, J ABNORM PSYCHOL, V101, P200, DOI 10.1037/0021-843X.101.1.200; Dworkin RH, 1998, J INFECT DIS, V178, pS76, DOI 10.1086/514260; Galil K, 1997, ARCH INTERN MED, V157, P1209, DOI 10.1001/archinte.157.11.1209; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Higa K, 1997, PAIN, V69, P245, DOI 10.1016/S0304-3959(96)03229-0; Jiang N, 1998, BRAIN RES, V788, P25, DOI 10.1016/S0006-8993(97)01503-5; Kikuchi A, 1999, REGION ANESTH PAIN M, V24, P287, DOI 10.1016/S1098-7339(99)90101-3; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kost RG, 1997, ARCH INTERN MED, V157, P1166, DOI 10.1001/archinte.157.11.1166; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; Kotani N, 2000, NEW ENGL J MED, V343, P1514, DOI 10.1056/NEJM200011233432102; Lopez-Cortes LF, 2000, CRIT CARE MED, V28, P215, DOI 10.1097/00003246-200001000-00035; Matsumoto T, 1997, LAB INVEST, V77, P119; Meister W, 1998, INFECTION, V26, P359, DOI 10.1007/BF02770836; Ostergaard C, 1999, INFECT IMMUN, V67, P3430; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003; SCHMIDBAUER M, 1992, BRAIN, V115, P383, DOI 10.1093/brain/115.2.383; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; WATSON CPN, 1991, PAIN, V44, P105, DOI 10.1016/0304-3959(91)90124-G; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whitley RJ, 1999, J INFECT DIS, V179, P9, DOI 10.1086/314562; Whitley RJ, 1998, J INFECT DIS, V178, pS71, DOI 10.1086/514274; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; Xia MQ, 1997, AM J PATHOL, V150, P1267	30	47	52	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	MAR 1	2004	116	5					318	324		10.1016/j.amjmed.2003.10.027			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777RL	WOS:000189191300005	14984817				2022-02-06	
J	Fock, J; Galea, MP; Stillman, BC; Rawicki, B; Clark, M				Fock, J; Galea, MP; Stillman, BC; Rawicki, B; Clark, M			Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury	BRAIN INJURY			English	Article							CHRONIC HEMIPARETIC PATIENTS; UPPER EXTREMITY SPASTICITY; LIMB EXTENSOR SPASTICITY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; FOOT; THERAPY; STROKE; COST; GAIT	Primary objective : The aim of this study was to assess the effect of Botulinum toxin A in the management of spastic equinus resulting from traumatic brain injury. Research design : A before-after intervention design was used without controls. Methods and procedures : Subjects were seven patients suffering from traumatic brain injury of average duration 14 (4-38) months as a result of motor vehicle trauma, who had spastic equinus interfering with gait. Experimental intervention : The patients were treated with injections of Botulinum toxin A into the spastic calf muscles: gastrocnemius, soleus and tibialis posterior. Assessments were made pre-injection and at 2 weeks and 3 months post-injection. Main outcome and results : At the end of the 3-month period, all patients showed a significant improvement in gait velocity, cadence and stride length. Conclusions : The findings suggest that Botulinum toxin A may be useful in the management of spastic equinus following traumatic brain injury.	Brighton Rehabil Ctr, Brighton, Vic 3186, Australia; Univ Melbourne, Sch Physiotherapy, Parkville, Vic 3010, Australia; Monash Univ, Dept Math & Stat, Clayton, Vic 3168, Australia		Galea, MP (corresponding author), Univ Melbourne, Sch Physiotherapy, 200 Berkeley St, Parkville, Vic 3052, Australia.		Galea, Mary/F-4242-2010	Galea, Mary/0000-0003-0045-7978			*AM AC ORTH SURG, 1965, JOINT MOT METH MEAS, P68; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BRAUN RM, 1973, J BONE JOINT SURG AM, VA 55, P580, DOI 10.2106/00004623-197355030-00015; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; Hesse S, 1996, STROKE, V27, P455, DOI 10.1161/01.STR.27.3.455; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Radensky PW, 2001, NEUROREHAB NEURAL RE, V15, P57, DOI 10.1177/154596830101500108; Reiter F, 1998, ARCH PHYS MED REHAB, V79, P532, DOI 10.1016/S0003-9993(98)90068-5; Sheean GL, 1997, EUR J NEUROL, V4, pS41; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; Wallesch CW, 1997, EUR J NEUROL, V4, pS53; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610; Wilson DJ, 1997, J NEUROL REHABIL, V11, P81; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; YOSHIMURA DM, 1992, NEUROLOGY, V42, P627, DOI 10.1212/WNL.42.3.627; [No title captured]	21	47	49	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2004	18	1					57	63		10.1080/0269905031000149498			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	749PB	WOS:000186928200004	14660236				2022-02-06	
J	Miller, LJ; Donders, J				Miller, LJ; Donders, J			Prediction of educational outcome after pediatric traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; ACADEMIC PLACEMENT; WISC-III; CHILDREN; ADOLESCENTS; SEVERITY; MEMORY; SENSITIVITY; ATTENTION; RECOVERY	Objective: Evaluation of the predictive value of neuropsychological test scores with respect to special education placement following pediatric traumatic brain injury (TBI). Study Design: Longitudinal follow-up and hierarchical logistic regression analyses. Setting: Regional rehabilitation center. Participants: Consecutive series of referrals, including 58 children with TBI and no confounding premorbid histories or other complicating factors. Main Outcome Measures: Special education placement at, respectively, 12 and 24 months postinjury. Results: Children who obtained a composite T score of less than 45 on the California Verbal Learning Test-Children's Version during initial postinjury neuropsychological assessment were 8-13 times more likely to be placed in special education 12-24 months later compared with children who obtained higher scores. Conclusions: Neuropsychological test scores are not only sensitive to acute injury severity but also explain a substantial proportion of the variance in educational outcome after pediatric TBI, above and beyond that accounted for by demographic and medical variables.	Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						BOLL T, 1993, CHILDRENS CATEGORY T; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Clark E, 1999, SCHOOL PSYCHOL REV, V28, P242; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DELIS D, 1994, CALIFORNIA VERBAL LE; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Papero PH, 1997, J HEAD TRAUMA REHAB, V12, P51, DOI 10.1097/00001199-199706000-00006; Reitan R. M., 1992, NEUROPSYCHOLOGICAL E; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P185	29	47	47	0	4	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2003	48	4					237	241		10.1037/0090-5550.48.4.237			5	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	741ER	WOS:000186446200002					2022-02-06	
J	Scheibel, RS; Pearson, DA; Faria, LP; Kotrla, KJ; Aylward, E; Bachevalier, J; Levin, HS				Scheibel, RS; Pearson, DA; Faria, LP; Kotrla, KJ; Aylward, E; Bachevalier, J; Levin, HS			An fMRI study of executive functioning after severe diffuse TBI	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; WORKING-MEMORY; PREFRONTAL CORTEX; ACTIVATION; DEFICITS; INTERFERENCE; INVOLVEMENT; PERFORMANCE; ANTERIOR	Primary objective: Preliminary study of whether severe diffuse traumatic brain injury (TBI) increases extent of frontal tissue recruited by cognitive control tasks. Research design: Functional magnetic resonance imaging (fMRI) on N-back working memory (WM) and arrows inhibition tasks in a 46 year old man who had severe diffuse TBI 1 year earlier, a 44 year old man ( inhibition task) and three women ( working memory task), age 20 - 26 years. Images were acquired by 1.5 T magnet with BOLD method and PRESTO pulse sequence and analysed using SPM. Main outcomes and results: Frontal activation increased under 2-back relative to 1-back condition of working memory in all participants with more extensive activation in the TBI patient relative to controls. Frontal activation increased with inhibition on the arrows task, but was greater in the TBI patient. Conclusion: Severe diffuse TBI results in recruitment of additional neural resources for cognitive control.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Psychiat & Behav Sci, Houston, TX USA; Baylor Coll Med, Sect Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Washington, Dept Radiol, Seattle, WA 98195 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889, NS-42772] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042772, R01NS021889] Funding Source: NIH RePORTER		BADDELEY AD, 1986, COMPTES RENDUS L A 3, V321, P167; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen J, 2000, NEUROIMAGE, V11, P378, DOI 10.1006/nimg.2000.0573; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DREWE E A, 1975, Cortex, V11, P8; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Goldman-Rakic P., 1998, PREFRONTAL CORTEX EX, P87; JENNETT B, 1975, LANCET, V1, P480; Kahneman D., 1973, ATTENTION EFFORT; Kawashima R, 1996, BRAIN RES, V728, P79, DOI 10.1016/0006-8993(96)00389-7; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; PEARSON DA, 2000, SOC NEUROSCIENCE, V26, P2003; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Proctor A, 2000, BRAIN INJURY, V14, P633; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1983, NEUROPSYCHOLOGIA, V21, P235, DOI 10.1016/0028-3932(83)90040-4; TEASDALE G, 1974, LANCET, V2, P81; VANGELDEREN P, 1995, P NATL ACAD SCI USA, V92, P6906, DOI 10.1073/pnas.92.15.6906; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	48	47	48	1	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2003	17	11					919	930		10.1080/0269905031000110472			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	725GE	WOS:000185534800001	14514445				2022-02-06	
J	Mauler, F; Hinz, V; Augstein, KH; Fassbender, M; Horvath, E				Mauler, F; Hinz, V; Augstein, KH; Fassbender, M; Horvath, E			Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271	BRAIN RESEARCH			English	Article						BAY 38-7271; neuroprotection; CB1; transient middle cerebral artery occlusion; acute subdural hematoma; intracranial pressure; brain edema	ACUTE SUBDURAL-HEMATOMA; NITRIC-OXIDE SYNTHASE; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; RAT-BRAIN; NEUROTRANSMITTER RELEASE; AMEBOID MICROGLIA; CB2 RECEPTORS; INJURY; EXPRESSION	BAY 38-7271 is a new high-affinity cannabinoid receptor agonist with strong neuroprotective efficacy in a rat model of traumatic brain injury (acute subdural hematoma, SDH). In the present study we investigated CB1 receptor signal transduction by [S-35]GTPgammaS binding in situ and in vitro to assess changes in receptor functionality after SDH. Further, we continued to investigate the neuroprotective properties of BAY 38-7271 in the rat SDH and transient middle cerebral artery occlusion (tMCA-O) model as well as the efficacy with respect to SDH-induced brain edema. [S-35]GTPgammaS binding revealed minor attenuation of CB1 receptor functionality on brain membranes from injured hemispheres when compared to non-injured hemispheres or controls. In the rat SDH model, BAY 38-7271 displayed strong neuroprotective efficacy when administered immediately after SDH either as a 1 h (65% infarct volume reduction at 0.1 mug/kg) or short-duration (15 min) infusion (53% at 10 mug/kg). When administered as a 4 h infusion with a 5 It delay after injury, significant neuroprotection was observed (49% at 1.0 mua/kg/h). This was also observed when BAY 38-7271 was administered as a 5 h delayed 15 min short-duration infusion (64% at 3 mug/kg). In addition, the neuroprotective potential of BAY 38-7271 was demonstrated in the rat tMCA-O model. displaying pronounced neuroprotective efficacy in the cerebral cortex (91% at 1 ng/kg/h) and striatum (53% at 10 ng/kg/h). BAY 38-7271 also reduced intracranial pressure (28% at 250 ng/kg/h) and brain water content (20% at 250 ng/kg/h) when determined 24 h post-SDH. Based on these data it is concluded that the neuroprotective efficacy of BAY 38-7271 is mediated by multiple mechanisms triggered by cannabinoid receptors. (C) 2003 Elsevier B.V. All rights reserved.	Bayer Hlth Care, PH R EU CNS, D-42096 Wuppertal, Germany		Mauler, F (corresponding author), Bayer Hlth Care, PH R EU CNS, Aprather Weg 18a, D-42096 Wuppertal, Germany.						Barth F, 1998, EXPERT OPIN THER PAT, V8, P301, DOI 10.1517/13543776.8.3.301; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632; Cai GP, 2002, J PHARMACOL EXP THER, V302, P1105, DOI 10.1124/jpet.102.036673; Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3; CHAO CC, 1992, J IMMUNOL, V149, P2736; Coffey RG, 1996, BIOCHEM PHARMACOL, V52, P743, DOI 10.1016/0006-2952(96)00356-5; De Vry J, 2002, EUR J PHARMACOL, V457, P147, DOI 10.1016/S0014-2999(02)02697-3; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FUJISAWA H, 1994, ACT NEUR S, V60, P193; GAOINI Y, 1964, J AM CHEM SOC, V86, P1646; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468, DOI 10.1152/jn.2001.85.1.468; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; Grundy RI, 2002, EXPERT OPIN INV DRUG, V11, P1365, DOI 10.1517/13543784.11.10.1365; Grundy RI, 2001, MOL NEUROBIOL, V24, P29; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holtz ML, 2001, BRAIN RES, V898, P49, DOI 10.1016/S0006-8993(01)02140-0; HORVATH E, 1997, J NEUROTRAUMA ABSTR, V14, P170; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.3.CO;2-G; Kim DJ, 2000, BRAIN RES, V852, P398, DOI 10.1016/S0006-8993(99)02210-6; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; LEONG SK, 1992, GLIA, V6, P39, DOI 10.1002/glia.440060106; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Molina-Holgado F, 2002, J NEUROSCI RES, V67, P829, DOI 10.1002/jnr.10165; Mu J, 1999, J PHARMACOL EXP THER, V291, P893; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2001, J CEREBR BLOOD F MET, V21, P15, DOI 10.1097/00004647-200101000-00003; Paxinos G, 1996, RAT BRAIN STEREOTAXI; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Puebla L, 2003, J NEUROCHEM, V84, P145, DOI 10.1046/j.1471-4159.2003.01510.x; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shimizu-Sasamata M, 1998, J NEUROSCI, V18, P9564; Sim-Selley LJ, 2002, LIFE SCI, V71, P2217, DOI 10.1016/S0024-3205(02)02017-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TSUCHIDA E, 1995, J NEUROTRAUM, V12, P279, DOI 10.1089/neu.1995.12.279; Waksman Y, 1999, J PHARMACOL EXP THER, V288, P1357; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; ZHAO Q, 1995, THESIS LUND U LUND; Zwienenberg M, 1999, J NEUROTRAUM, V16, P1095, DOI 10.1089/neu.1999.16.1095	53	47	48	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 31	2003	989	1					99	111		10.1016/S0006-8993(03)03376-6			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	733GL	WOS:000185991500012	14519516				2022-02-06	
J	Soustiel, JF; Glenn, TC; Vespa, P; Rinsky, B; Hanuscin, C; Martin, NA				Soustiel, JF; Glenn, TC; Vespa, P; Rinsky, B; Hanuscin, C; Martin, NA			Assessment of cerebral blood flow by means of blood-flow-volume measurement in the internal carotid artery - Comparative study with a (133)xenon clearance technique	STROKE			English	Article						cerebral blood flow; hemodynamics; ultrasonography, Doppler	POSITRON-EMISSION-TOMOGRAPHY; COLOR DUPLEX MEASUREMENT; ACUTE HEAD-INJURY; VERTEBRAL ARTERIES; HEALTHY-ADULTS; STROKE; INHALATION; METABOLISM; VASOSPASM; REPRODUCIBILITY	Background and Purpose-We sought to evaluate a new, angle-independent ultrasonic device for assessment of blood flow volume (BFV) in the internal carotid artery (ICA). Methods-Nineteen patients and 4 healthy volunteers were enrolled in a comparative study conducted in the Care Unit of the Division of Neurosurgery at UCLA Medical Center. All patients had been admitted because of severe brain injury: 15 patients with severe head trauma (Glasgow Coma Scale scoreless than or equal to8) and 4 patients with subarachnoid hemorrhage due to aneurysm rupture. In all patients and subjects, cerebral blood flow (CBF) values obtained with the (133)xenon-clearance technique were compared with BFV measurements in the ipsilateral ICA. Results-Hemispheric CBF values showed a close and linear correlation with BFV measurements (r=0.76, P<0.0001). Global CBF values showed a higher correlation with the total BFV value obtained from both ICAs (r=0.84, P<0.0001). With 37 mL . min(-1) . 100 g(-1) as a cutoff value for the ischemic range, a BFV value of 220 mL/min would yield a positive predictive value of 91.7% and a negative predictive value of 82.6% ( sensitivity 73.3%, specificity 95%). Conversely, BFV sensitivity and specificity were 60% and 96%, respectively, for the hyperemic range defined by a CBF value >55 mL . min(-1) . 100 g(-1) (positive predictive value of 85.7% and negative prediction value of 85.7%). Conclusions-BFV measurements with this new technology proved to accurately correlate with CBF values evaluated by the (133)xenon-clearance technique. These results support the implementation of this technique for bedside assessment of cerebral hemodynamics in critically ill neurosurgical patients.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel		Martin, NA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA.			Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131			Ascher E, 2002, J VASC SURG, V35, P439, DOI 10.1067/mva.2002.120044; Blizhevsky A, 1997, MED ENG PHYS, V19, P352, DOI 10.1016/S1350-4533(96)00048-3; DOBERSTEIN C, 1996, NEUROLOGICAL SURG, V1; Dorfler P, 2000, J CEREBR BLOOD F MET, V20, P269; Eicke B M, 1995, J Neuroimaging, V5, P115; GILL RW, 1985, ULTRASOUND MED BIOL, V11, P625, DOI 10.1016/0301-5629(85)90035-3; Ho SSY, 2002, AM J ROENTGENOL, V178, P551, DOI 10.2214/ajr.178.3.1780551; Ho SSY, 2000, STROKE, V31, P1342, DOI 10.1161/01.STR.31.6.1342; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; KETY SS, 1945, AM J PHYSIOL, V143, P53, DOI 10.1152/ajplegacy.1945.143.1.53; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LENZI GL, 1981, EUR NEUROL, V20, P285, DOI 10.1159/000115248; Licht PB, 1999, EUR J VASC ENDOVASC, V17, P219, DOI 10.1053/ejvs.1998.0741; MADSEN PL, 1993, J CEREBR BLOOD F MET, V13, P646, DOI 10.1038/jcbfm.1993.83; Martin N A, 1994, Neurosurg Clin N Am, V5, P607; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1967, CIRC RES, V20, P124, DOI 10.1161/01.RES.20.1.124; PERLMUTTER JS, 1987, J CEREBR BLOOD F MET, V7, P64, DOI 10.1038/jcbfm.1987.9; PODREKA I, 1989, STROKE, V20, P183, DOI 10.1161/01.STR.20.2.183; Sakoh M, 2000, STROKE, V31, P1958, DOI 10.1161/01.STR.31.8.1958; Sakoh M, 2000, J NEUROSURG, V93, P647, DOI 10.3171/jns.2000.93.4.0647; Scheel P, 2000, STROKE, V31, P147, DOI 10.1161/01.STR.31.1.147; SCHONING M, 1994, STROKE, V25, P17, DOI 10.1161/01.STR.25.1.17; Schoning M, 1996, J CEREBR BLOOD F MET, V16, P523, DOI 10.1097/00004647-199605000-00020; SHIRAHATA N, 1985, J COMPUT ASSIST TOMO, V9, P861, DOI 10.1097/00004728-198509000-00004; Sorensen AG, 1999, RADIOLOGY, V210, P519, DOI 10.1148/radiology.210.2.r99fe06519; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; Soustiel JF, 2001, STROKE, V32, P629, DOI 10.1161/01.STR.32.3.629; Steinman AH, 2001, ULTRASOUND MED BIOL, V27, P655, DOI 10.1016/S0301-5629(01)00352-0; Tan TY, 2002, J NEUROIMAGING, V12, P144, DOI 10.1111/j.1552-6569.2002.tb00111.x; ZIERLER BK, 1992, J VASC SURG, V16, P520, DOI 10.1016/0741-5214(92)90159-6	32	47	50	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	AUG	2003	34	8					1876	1880		10.1161/01.STR.0000080942.32331.39			5	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	706YF	WOS:000184482100014	12843349	Bronze			2022-02-06	
J	Makaroff, KL; Putnam, FW				Makaroff, KL; Putnam, FW			Outcomes of infants and children with inflicted traumatic brain injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							YOUNG-CHILDREN; HEAD-INJURY; SHAKEN; PROGNOSIS; ABUSE		Childrens Hosp, Med Ctr, Mayerson Ctr Safe & Healthy Children, Cincinnati, OH 45229 USA		Makaroff, KL (corresponding author), Childrens Hosp, Med Ctr, Mayerson Ctr Safe & Healthy Children, SEB 5,3333 Burnet Ave, Cincinnati, OH 45229 USA.	makok0@chmcc.org					Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; Fung ELW, 2002, PEDIATR INT, V44, P37, DOI 10.1046/j.1442-200X.2002.01500.x; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Matthews GP, 1996, J PEDIATR OPHTHALMOL, V33, P260, DOI 10.3928/0191-3913-19960701-13; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; OLIVER JE, 1975, BRIT MED J, V2, P262, DOI 10.1136/bmj.2.5965.262; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; Sugar NF, 1999, ARCH PEDIAT ADOL MED, V153, P399, DOI 10.1001/archpedi.153.4.399; Swenson J, 1997, Minn Med, V80, P41; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037	26	47	47	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUL	2003	45	7					497	502		10.1017/S0012162203000926			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	698DD	WOS:000183981600012	12828406				2022-02-06	
J	Webbe, FM; Barth, JT				Webbe, FM; Barth, JT			Short-term and long-term outcome of athletic closed head injuries	CLINICS IN SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; SOCCER INJURIES; NEUROPSYCHOLOGICAL ASSESSMENT; GENDER-DIFFERENCES; NECK INJURIES; FOOTBALL; IMPACT; COLLEGIATE; PERFORMANCE	This article reviews the basic mechanisms of sport-related closed head injury, primary risk factors for differential outcome, and findings of neurocognitive deficit that characterize the immediate, short, and long-term aftermath of athletic head injury, and points toward known or theoretically sound mechanisms that might be candidates for clarifying differences.	Univ Virginia Hlth Syst, Dept Psychiat Med, Charlottesville, VA 22908 USA; Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA		Barth, JT (corresponding author), Univ Virginia Hlth Syst, Dept Psychiat Med, POB 800203, Charlottesville, VA 22908 USA.	jtb4y@virginia.edu	Webbe, Frank/A-8074-2009	Webbe, Frank/0000-0002-4370-5698			ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Baker Robert J., 2000, Indian Journal of Pediatrics, V67, P317, DOI 10.1007/BF02820676; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT, 1989, MILD HEAD INJURY, P257; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BROSHEK DK, 2002, 26 AN WILL TRAUM BRA; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Butterwick DJ, 2002, AM J SPORT MED, V30, P193, DOI 10.1177/03635465020300020801; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; ECHEMENDIA RJ, IN PRESS SPORTS NEUR; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; ERLANGER DM, 2002, CONCUSSION RESOLUTIO; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; FU K, 1992, J NEUROTRAUM, V9, P59; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GENTRY LR, 1994, RADIOLOGY, V191, P1; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P225; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Holbourn AHS, 1943, LANCET, V2, P438; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Jagoda A, 2000, EMERG MED CLIN N AM, V18, P355, DOI 10.1016/S0733-8627(05)70130-9; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kronisch RL, 2002, CLIN J SPORT MED, V12, P158, DOI 10.1097/00042752-200205000-00003; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LANDRY G, 1994, P MILD BRAIN INJURY; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; OCHS SR, IN PRESS BR J SPORTS; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; SYMONDS C, 1962, LANCET, V1, P1; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WITOL AD, IN PRESS ARCH CLIN N; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; 2002, NCCA NEWS       0401, P10	82	47	48	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2003	22	3					577	+		10.1016/S0278-5919(02)00103-5			17	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	692LT	WOS:000183663100012	12852687				2022-02-06	
J	Steiner, LA; Coles, JP; Czosnyka, M; Minhas, PS; Fryer, TD; Aigbirhio, FI; Clark, JC; Smielewski, P; Chatfield, DA; Donovan, T; Pickard, JD; Menon, DK				Steiner, LA; Coles, JP; Czosnyka, M; Minhas, PS; Fryer, TD; Aigbirhio, FI; Clark, JC; Smielewski, P; Chatfield, DA; Donovan, T; Pickard, JD; Menon, DK			Cerebrovascular pressure reactivity is related to global cerebral oxygen metabolism after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; POSITRON EMISSION TOMOGRAPHY; K+ CHANNEL FUNCTION; BLOOD-FLOW; MITOCHONDRIAL DYSFUNCTION; PERFUSION-PRESSURE; AUTOREGULATION; HEMODYNAMICS; U-101033E; ISCHEMIA	Background: After head injury, impaired cerebrovascular autoregulation has been associated with abnormally high or low cerebral blood flow. The physiological relevance of cerebral blood flow levels is difficult to assess in these patients, whose cerebral metabolic rate for oxygen (CMRO2) is known to be abnormal. Investigation of these relations requires quantitative measures of cerebral blood flow and CMRO2, to allow assessment of oxygen supply and demand relations. Objectives: To investigate the relation between dysautoregulation and global cerebral oxygen metabolism following head injury. Methods: Using positron emission tomography, global cerebral blood flow, CMRO2, and oxygen extraction fraction were determined in 22 patients who were investigated in 26 examinations on days 1 to 11 (mean (SD), 3.5 (2.3)) after head injury. Cerebrovascular pressure reactivity was assessed using a pressure reactivity index, calculated as the moving linear correlation coefficient between mean arterial blood pressure and intracranial pressure. Outcome was assessed six months after injury using the Glasgow outcome scale. Results: Low CMRO2 was associated with disturbed pressure reactivity (inverse function, R-2 = 0.21, p = 0.018) and there was a correlation between disturbed pressure reactivity and oxygen extraction fraction (quadratic function, R-2 = 0.55, p = 0.0001). There was no significant relation between pressure reactivity and cerebral blood flow. An unfavourable outcome was associated with disturbed pressure reactivity. There was no significant relation between outcome and CMRO2 or oxygen extraction fraction. Conclusions: There is a close relation between dysautoregulation and abnormal cerebral metabolism but not blood flow. Further studies are needed to determine whether metabolic dysfunction is a result of or a cause of disturbed pressure reactivity, and to establish if there is a relation between cerebral oxygen metabolism and outcome.	Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge, England		Steiner, LA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 167, Cambridge CB2 2QQ, England.		Donovan, Tim/AAF-3563-2019; Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019	Donovan, Tim/0000-0003-4112-861X; Smielewski, Peter/0000-0001-5096-3938; Coles, Jonathan/0000-0003-4013-679X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI		Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HARRIS RJ, 1984, J CEREBR BLOOD F MET, V4, P178, DOI 10.1038/jcbfm.1984.26; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; JENNETT B, 1975, LANCET, V1, P480; KANNO I, 1984, J CEREBR BLOOD F MET, V4, P224, DOI 10.1038/jcbfm.1984.31; KANNO I, 1987, J CEREBR BLOOD F MET, V7, P143, DOI 10.1038/jcbfm.1987.37; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; LAMMERTSMA AA, 1981, J COMPUT ASSIST TOMO, V5, P544, DOI 10.1097/00004728-198108000-00016; LAMMERTSMA AA, 1992, J CEREBR BLOOD F MET, V12, P291, DOI 10.1038/jcbfm.1992.39; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oshima T, 2002, ACTA ANAESTH SCAND, V46, P831, DOI 10.1034/j.1399-6576.2002.460713.x; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531	37	47	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2003	74	6					765	770		10.1136/jnnp.74.6.765			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	679QC	WOS:000182932600017	12754348	Bronze, Green Published			2022-02-06	
J	Esen, F; Erdem, T; Aktan, D; Kalayci, R; Cakar, N; Kaya, M; Telci, L				Esen, F; Erdem, T; Aktan, D; Kalayci, R; Cakar, N; Kaya, M; Telci, L			Effects of magnesium administration on brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						magnesium; trauma; diffuse brain injury; blood-brain barrier; brain edema	CLOSED-HEAD INJURY; CEREBRAL EDEMA; AXONAL INJURY; NEUROTOXICITY; RELEASE; THERAPY; BLOCKER; MODEL	In this study, we examined the effects of magnesium sulfate administration on brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats. Seventy-one adult male Sprague-Dawley rats were anesthetized, and experimental closed head trauma was induced by allowing a 450-g weight to fall from a 2-m height onto a metallic disk fixed to the intact skull. Sixty-eight surviving rats were randomly assigned to receive an intraperitoneal bolus of either 750 mumol/kg magnesium sulfate (group 4; n = 30) or I mL of saline (group 2; n = 30) 30 minutes after induction of traumatic brain injury; 39 nontraumatized animals received saline (group 1; n = 21) or magnesium sulfate (group 3; n = 18) with an identical protocol of administration. Brain water content and brain tissue specific gravity, as indicators of brain edema, were measured 24 hours after traumatic brain injury. Blood-brain barrier integrity was evaluated quantitatively 24 hours after injury by spectrophotometric assay of Evans blue dye extravasations. In the magnesium-treated injured group, brain water content was significantly reduced (left hemisphere: group 2, 83.2 +/- 0.8; group 4, 78.4 +/- 0.7 [P < .05]; right hemisphere: group 2, 83.1 +/- 0.7; group 4, 78.4 +/- 0.5. [P < .05]) and brain tissue specific gravity was significantly increased (left hemisphere: group 2, 1.0391 +/- 0.0008; group 4, 1.0437 +/- 0.001 [P < .05]; right hemisphere, group 2, 1.0384 +/- 0.001; group 4, 1.0442 +/- 0.005 [P < .05]) compared with the saline-treated injured group. Evans blue dye content in the brain tissue was significantly decreased in the magnesium-treated injured group (left hemisphere: group 2, 0.0204 +/- 0.03; group 4, 0.0013 +/- 0.0002 [P < .05]; right hemisphere: group 2, 0.0064 +/- 0.0009; group 4, 0.0013 +/- 0.0003 [P < .05]) compared with the saline-treated injured group. The findings of the present study support that beneficial effects of magnesium sulfate exist after severe traumatic brain injury in rats. These results also indicate that a blood-brain barrier permeability defect occurs after this model of diffuse traumatic brain injury, and magnesium seems to attenuate this defect.	Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, TR-34390 Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Expt Med Res Inst, TR-34390 Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Dept Physiol, TR-34390 Istanbul, Turkey		Esen, F (corresponding author), Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, Capa, TR-34390 Istanbul, Turkey.		Esen, Figen/AAS-6115-2020	Cakar, Nahit/0000-0002-1302-9596; ESEN, FIGEN/0000-0003-4419-4903			ALTURA B M, 1985, Magnesium, V4, P245; ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHOI DW, 1987, J NEUROSCI, V7, P369; CLARK AF, 1980, J BIOL CHEM, V255, P6556; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GIBSON BL, 1985, NEUROSCI LETT, V57, P13, DOI 10.1016/0304-3940(85)90033-3; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MULLINS PGM, 1995, NEUROREPORT, V6, P1633, DOI 10.1097/00001756-199508000-00011; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Polderman KH, 2000, CRIT CARE MED, V28, P2022, DOI 10.1097/00003246-200006000-00057; Regan RF, 1998, J NEUROCHEM, V70, P77; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SOARES HD, 1992, J NEUROCHEM, V58, P135; VANDENBRINK WA, 1990, ACTA NEUROCHIR SUPP, V55, P261; Vink R, 1990, Magnes Res, V3, P163; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1987, BIOCHEM BIOPH RES CO, V70, P895; VINK R, 1991, MAGNESIUM EXCITABLE, P695	38	47	57	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2003	15	2					119	125		10.1097/00008506-200304000-00009			7	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	660ZL	WOS:000181865900008	12657997				2022-02-06	
J	Englander, J; Cifu, DX; Wright, JM; Black, K				Englander, J; Cifu, DX; Wright, JM; Black, K			The association of early computed tomography scan findings and ambulation, self-care, and supervision needs at rehabilitation discharge and at 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	American Congress of Rehabilitation Medicine Annual Meeting	OCT, 2001	TUCSON, ARIZONA			activities of daily living; brain injuries; locomotion; rehabilitation; tomography; x-ray computed	SEVERE HEAD-INJURY; RATING-SCALE; COMA	Objective: To ascertain the association between early computed tomography (CT) scan findings and the need for assistance with ambulation, activities of daily living (ADLs), and supervision at rehabilitation discharge and at 1 year after traumatic brain injury (TBI). Design: Prospective longitudinal design. Setting: Seventeen Traumatic Brain Injury Model Systems (TBIMS) centers. Participants: A total of 1839 adults with TBI admitted to TBIMS trauma centers with subsequent acute rehabilitation; 849 were followed to 1 year after injury. Interventions: Not applicable. Main Outcome Measures: Accumulated CT scan pathology from the first week after injury; FIM(TM) instrument and Disability Rating Scale at rehabilitation discharge and 1 year after injury; and Supervision Rating Scale at 1 year. Results: Chi-square analyses showed that individuals with a midline shift greater than 5mm (lateral compression) were more likely to require the assistance of another person at discharge from acute rehabilitation with ambulation (29% vs 17%-19%, P=.02), toileting (47% vs 33%-38%, P=.05), lower-body dressing (57% vs 39%-46%, P=.015), bladder continence (32% vs 19%-23%, P=.03;), and overall supervision (53% vs 44%, P=.0006) than patients with a midline shift of lesser degree. At 1 year, 57% of patients with a midline shift greater than 5mm on acute CT scans were being supervised in the home versus 30% to 39% of those with a shift of lesser degree (P=.003); there were no significant differences in the percentages of those needing assistance for ambulation or ADLs. The association of subdural hematoma with ambulation, self-care, and supervision needs was related to the degree of midline shift but not to the presence of subdural hematoma. Individuals with subcortical contusions were more likely to require assistance at rehabilitation discharge for ambulation (32% vs 18%, P<.0001), lower-body dressing (61% vs 44%), toileting (52% vs 35%), bladder continence (34% vs 22%), and overall supervision (61% vs 44%) than those without subcortical contusions (P<.0001). At 1 year, individuals with acute subcortical contusions were more likely to need assistance with ambulation (15% vs 8%, P=.004) and stair climbing (15% vs 9%, P=.03). Those with bilateral frontal (54% vs 46%, P=.009) or bilateral temporal (58% vs 46%, P=.03) contusions were more likely to need assistance with overall supervision at rehabilitation discharge, compared with those with unilateral or no cortical contusions. Conclusions: The presence of either a midline shift greater than 5mm or a subcortical contusion on acute CT scans is associated with a greater need of assistance with ambulation, ADLs, and global supervision at rehabilitation discharge. Patients with bilateral cortical contusions require more global supervision at rehabilitation discharge but no more supervision for ambulation and ADLs. These findings may aid health care professionals and potential caregivers in planning for rehabilitation and supervision needs after rehabilitation discharge and, to a lesser extent, at 1 year after TBI.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; Rehabil Inst Michigan, Detroit, MI USA		Englander, J (corresponding author), Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, 751 S Bascom Ave, San Jose, CA 95128 USA.			Cifu, David/0000-0003-1600-9387			[Anonymous], 1997, GUIDE UNIFORM DATA S; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAUM; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; QUATTROCCHI KB, 1991, SURG NEUROL, V35, P183, DOI 10.1016/0090-3019(91)90069-L; RAO N, 1984, ARCH PHYS MED REHAB, V65, P18; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118	11	47	49	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					214	220		10.1053/apmr.2003.50094			7	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700010	12601652				2022-02-06	
J	Lu, J; Moochhala, S; Shirhan, M; Ng, KC; Teo, AL; Tan, MH; Moore, XL; Wong, MC; Ling, EA				Lu, J; Moochhala, S; Shirhan, M; Ng, KC; Teo, AL; Tan, MH; Moore, XL; Wong, MC; Ling, EA			Neuroprotection by aminoguanidine after lateral fluid-percussive brain injury in rats: a combined magnetic resonance imaging, histopathologic and functional study	NEUROPHARMACOLOGY			English	Article						aminoguanidine; lateral fluid-percussive brain injury; neuronal apoptosis; magnetic resonance imaging; behaviour; neuroprotection	NITRIC-OXIDE SYNTHASE; CORTICAL IMPACT INJURY; CENTRAL-NERVOUS-SYSTEM; SELECTIVE-INHIBITION; DNA FRAGMENTATION; FREE-RADICALS; HEAD-INJURY; PEROXYNITRITE; APOPTOSIS; DAMAGE	The present study examined the effects of a selective inducible nitric oxide synthase (iNOS) inhibitor, aminoguanidine (AG), on neuronal cell survival and post-traumatic recovery in rats following a lateral fluid percussive brain injury. Daily treatment of AG at the dosage of 100 mg/kg or normal saline was given intraperitoneally into rats starting 2 h before or 30 min after brain injury. Treatment with AG significantly reduced lesion volumes in the brains of rats after injury, as evaluated by high-resolution magnetic resonance imaging (MRI). Immunohistochemical analysis showed a marked induction of iNOS expression in brain macrophages ipsilateral to the injury. Apoptotic neurons were observed in the ipsilateral cerebral cortex by in situ terminal transferase d-UTP nick-end labelling (TUNEL) and caspase-3 immunohistochemistry, In rats receiving prophylactic or post-injury treatment of AG. the number of degenerating neurons was markedly reduced in the cerebrum compared to those receiving saline injection. The location and extent of these pathologic changes correlated with MRI findings. Neurobehavioral studies showed that rotametric performance, grip-strength score, total and ambulatory locomotor responses and acoustic startle response were reduced in rats subjected to the injury but were significantly improved in AG-treated rats. It is suggested that inhibition of iNOS by AG may represent a potential therapeutic strategy for the treatment of traumatic brain injury. (C) 2003 Elsevier Science Ltd. All rights reserved.	NUS, Def Sci & Technol Agcy, Med Res Inst Chem Def, Singapore 117597, Singapore; Natl Canc Ctr, Brain Tumor Res Lab, Singapore, Singapore; Natl Univ Singapore, Dept Anat, Singapore 117597, Singapore		Moochhala, S (corresponding author), NUS, Def Sci & Technol Agcy, Med Res Inst Chem Def, 18 Med Dr,01-06,MD2, Singapore 117597, Singapore.	nmiv6@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192			Akaike T, 1998, P SOC EXP BIOL MED, V217, P64; BUSTER BL, 1995, INFECT IMMUN, V63, P3835, DOI 10.1128/IAI.63.10.3835-3839.1995; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; Castillo J, 2000, STROKE, V31, P852, DOI 10.1161/01.STR.31.4.852; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; Deckel AW, 2001, J NEUROSCI RES, V64, P99, DOI 10.1002/jnr.1057; DICKSON DW, 1994, NEUROPATH APPL NEURO, V20, P211; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; HOWARDJONES N, 1985, WHO CHRON, V39, P51; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; Iadecola C, 1997, J NEUROSCI, V17, P9157; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Matsui T, 1999, CELL MOL NEUROBIOL, V19, P177, DOI 10.1023/A:1006966012266; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Roufail E, 1998, DIABETOLOGIA, V41, P1419, DOI 10.1007/s001250051087; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; SESSA A, 1994, AGENTS ACTIONS, V43, P69, DOI 10.1007/BF02005768; SHERMAN MP, 1992, MED HYPOTHESES, V39, P143, DOI 10.1016/0306-9877(92)90175-C; Shinoda J, 2001, BRIT J NEUROSURG, V15, P213, DOI 10.1080/02688690120057628; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith MA, 1997, J NEUROSCI, V17, P2653; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; SULLIVAN SJ, 1994, BRAIN INJURY, V8, P613, DOI 10.3109/02699059409151014; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki Y, 1999, J CEREBR BLOOD F MET, V19, P1175, DOI 10.1097/00004647-199911000-00001; Tatsumi T, 2000, J AM COLL CARDIOL, V35, P1338, DOI 10.1016/S0735-1097(00)00526-X; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yildiz G, 1998, BRIT J PHARMACOL, V124, P905, DOI 10.1038/sj.bjp.0701924; YOUDIM MBH, 1994, ANN NY ACAD SCI, V738, P64; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	59	47	50	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2003	44	2					253	263		10.1016/S0028-3908(02)00380-5			11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	647DL	WOS:000181077100012	12623224				2022-02-06	
J	O'Neal, PD; Cote, GL; Motamedi, M; Chen, J; Lin, WC				O'Neal, PD; Cote, GL; Motamedi, M; Chen, J; Lin, WC			Feasibility study using surface-enhanced Raman spectroscopy for the quantitative detection of excitatory amino acids	JOURNAL OF BIOMEDICAL OPTICS			English	Article						surface-enhanced Raman scattering; excitatory amino acids; glutamate; aspartate; silver colloid	TRAUMATIC BRAIN INJURY; SCATTERING NIR-SERS; COLLOIDAL SILVER; CEREBROSPINAL-FLUID; HEAD-INJURY; MICRODIALYSIS; GLUTAMATE; NEUROTRANSMITTERS; SPECTROMETRY; HIPPOCAMPUS	The release of excitatory amino acids (EAAs) from injured neurons has been associated with secondary injury following head trauma.-The development of a rapid and sensitive method for the quantification of EAAs may provide a means for clinical management of patients affected by head trauma. We explore the potential application of surface-enhanced Raman spectroscopy (SERS) for rapid quantification of the concentration of EAAs in aqueous silver colloids. The EAAs glutamate (Glu) and aspartate (Asp) are released following head injury and have been observed to exhibit SERS spectra that should enable them to be distinguished in a complex aqueous media. Of the two EAAs, the concentration of Glu has been shown to be more indicative of injury to the central nervous system. Using 30-s scans and a 50-mW argon laser, aqueous Glu is quantifiable from 0.4 to 5 mumol/L and is spectrally distinguishable from Asp. In addition, initial in vivo microdialysis experiments suggest that this SERS system is capable of measuring chemical changes following head trauma in the rat brain. Compared with current high-performance liquid chromatography (HPLC) techniques for amino acid detection, the short scanning and processing time associated with the SERS approach enables measurement on a near-real-time basis, providing clinical information in anticipation of pharmaceutical intervention. (C) 2003 Society of Photo-Optical Instrumentation Engineers.	Texas A&M Univ, Biomed Engn Program, College Stn, TX 77843 USA; Univ Texas, Med Branch, Ctr Biomed Engn, Galveston, TX 77551 USA; Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA		O'Neal, PD (corresponding author), Texas A&M Univ, Biomed Engn Program, College Stn, TX 77843 USA.						BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BOATELL ML, 1995, J NEUROCHEM, V64, P285; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CHOI DW, 1987, J NEUROSCI, V7, P357; CHUMANOV GD, 1990, J RAMAN SPECTROSC, V21, P43, DOI 10.1002/jrs.1250210109; CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790; HENGLEIN A, 1979, J PHYS CHEM-US, V83, P2209, DOI 10.1021/j100480a006; Hillered L, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p695A; Jongsma FHM, 1997, OPT ENG, V36, P3193, DOI 10.1117/1.601529; Joseph B., 1986, PSYCHOANAL PSYCHOTHE, V2, P13; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KNEIPP K, 1994, APPL SPECTROSC, V48, P951, DOI 10.1366/0003702944029776; KNEIPP K, 1995, APPL SPECTROSC, V49, P780, DOI 10.1366/0003702953964480; KNEIPP K, 1995, SPECTROCHIM ACTA A, V51, P481, DOI 10.1016/0584-8539(94)00235-4; Kraus J, 1996, NEUROTRAUMA, P13; Lakke JPWF, 1986, ADV NEUROL, V45, P243; LEE NS, 1988, ANAL CHEM, V60, P442, DOI 10.1021/ac00156a014; MONTES R, 1992, ANAL CHEM, V64, P2715, DOI 10.1021/ac00046a012; NAVARRETE JTL, 1994, BIOPOLYMERS, V34, P1065, DOI 10.1002/bip.360340810; ONEAL DP, 1999, THESIS TEXAS A M U; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; SHURVELL HF, 1989, J RAMAN SPECTROSC, V20, P163, DOI 10.1002/jrs.1250200307; THOMAS RJ, 1995, J AM GERIATR SOC, V43, P1279, DOI 10.1111/j.1532-5415.1995.tb07407.x; TORRES EL, 1987, ANAL CHEM, V59, P1626, DOI 10.1021/ac00140a010; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zauner A, 1996, ACT NEUR S, V67, P40	32	47	47	1	27	SPIE-INT SOCIETY OPTICAL ENGINEERING	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668			J BIOMED OPT	J. Biomed. Opt.	JAN	2003	8	1					33	39		10.1117/1.1528208			7	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	641QA	WOS:000180755400004	12542377				2022-02-06	
J	Lu, DY; Li, Y; Mahmood, A; Wang, L; Rafiq, T; Chopp, M				Lu, DY; Li, Y; Mahmood, A; Wang, L; Rafiq, T; Chopp, M			Neural and marrow-derived stromal cell sphere transplantation in a rat model of traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; transplantation; rat	BONE-MARROW; SPINAL-CORD; ADULT-RATS; EXPRESSION; RECOVERY; NEURONS; TISSUE; NEUROTROPHIN; ASTROCYTES; DEFICITS	Object. This study was designed to investigate the effect of treatment with a novel composite material consisting of C.. F embryonic neurospheres and bone marrow-derived stromal cell spheres (NMSCSs) in a rat model of traumatic brain injury (TBI). Methods. The NMSCS composite was injected into the TBI contusion site 24 hours after injury, and all rats were killed on Day 14 after the transplantation. The Rotarod test and the neurological severity score were used to evaluate neurological function. The transplanted NMSCS was analyzed in recipient rat brains by using histological staining and laser scanning confocal microscopy. The lesion Volumes in the brains were also calculated using computer image analysis. Conclusions. Rats that received NMSCS transplants had reduced lesion volume and showed improved motor and neurological function when compared with control groups 14 days after the treatment. These results suggest that transplantation of this novel biological material (NMSCS) may be useful in the treatment of TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 42259] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER		Bi LX, 1999, CALCIFIED TISSUE INT, V64, P63, DOI 10.1007/s002239900580; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; CANEVA L, 1995, BLOOD CELL MOL DIS, V21, P73, DOI 10.1006/bcmd.1995.0011; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gressens P, 2000, PEDIATR RES, V48, P725, DOI 10.1203/00006450-200012000-00004; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; Kaddis FG, 2000, BRAIN RES BULL, V51, P203, DOI 10.1016/S0361-9230(99)00216-6; KESSLAK JP, 1986, EXP NEUROL, V94, P615, DOI 10.1016/0014-4886(86)90241-4; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Laurenzi MA, 1998, J LEUKOCYTE BIOL, V64, P228, DOI 10.1002/jlb.64.2.228; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; NETTO CA, 1993, BEHAV BRAIN RES, V58, P107, DOI 10.1016/0166-4328(93)90095-8; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Park KW, 2001, NEUROSCI RES, V40, P315, DOI 10.1016/S0168-0102(01)00242-5; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; Subramanian T, 2001, SEMIN NEUROL, V21, P103, DOI 10.1055/s-2001-13125; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403; Yurek DM, 2000, J COMP NEUROL, V423, P462, DOI 10.1002/1096-9861(20000731)423:3<462::AID-CNE9>3.0.CO;2-U; Zhang ZG, 1999, J NEUROSCI, V19, P10898, DOI 10.1523/JNEUROSCI.19-24-10898.1999; Zurita M, 2001, SURG NEUROL, V55, P249, DOI 10.1016/S0090-3019(01)00442-6	29	47	50	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2002	97	4					935	940		10.3171/jns.2002.97.4.0935			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	604MY	WOS:000178626400033	12405384				2022-02-06	
J	Sanz, O; Acarin, L; Gonzalez, B; Castellano, B				Sanz, O; Acarin, L; Gonzalez, B; Castellano, B			NF-kappa B and I kappa B alpha expression following traumatic brain injury to the immature rat brain	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						astrocyte; microglia; glial response; developing brain; transcription factor; inflammation	THALAMIC GLIAL RESPONSE; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; HIPPOCAMPAL-NEURONS; CYTOKINE EXPRESSION; EXCITOTOXIC LESION; YOUNG BRAIN; ACTIVATION; PROTEINS; SUPPRESSION	NF-kappaB is one of the most important modulators of stress and inflammatory gene expression in the nervous system. In the adult brain, NF-kappaB upregulation has been demonstrated in neurons and glial cells in response to experimental injury and neuropathological disorders, where it has been related to both neurodegenerative and neuroprotective activities. Accordingly, the aim of this study was to evaluate the cellular and temporal patterns of NF-kappaB activation and the expression of its endogenous inhibitor IkappaBalpha following traumatic brain injury (TBI) during the early postnatal weeks, when the brain presents elevated levels of plasticity and neuroprotection. Our results showed that cortical trauma to the 9-day-old rat brain induced a very fast upregulation of NF-kappaB, which was maximal within the first 24 hours after injury. NF-kappaB was mainly observed in neuronal cells of the degenerating cortex as well as in astrocytes located in the corpus callosum adjacent to the injury, where a pulse-like pattern of microglial NF-kappaB activation was also found. In addition, astrocytes of the corpus callosum, and microglial cells to a lower extent, also showed de novo expression Of IkappaBalpha within the time of NF-kappaB activation. This study suggests an important role of NF-kappaB activation in the early mechanisms of neuronal death or survival, as well as in the development of the glial and inflammatory responses following traumatic injury to the immature rat brain. (C) 2002 Wiley-Liss, Inc.	Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Fac Med, Unit Histol, Bellaterra 08193, Spain		Acarin, L (corresponding author), Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Fac Med, Unit Histol, Bellaterra 08193, Spain.	laia.acarin@uab.es	Acarin, Laia/G-2620-2010; Gonzalez, Berta/G-6250-2010; Castellano, Bernardo/G-1428-2010; Gonzalez, Berta/G-1428-2010	Castellano, Bernardo/0000-0003-1976-971X; Gonzalez, Berta/0000-0002-1860-3980			Acarin L, 1999, NEUROSCIENCE, V89, P549, DOI 10.1016/S0306-4522(98)00331-5; Acarin L, 1999, NEUROSCIENCE, V92, P827, DOI 10.1016/S0306-4522(99)00022-6; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Acarin L, 1998, NEUROREPORT, V9, P2869, DOI 10.1097/00001756-199808240-00035; Acarin L, 1997, EXP NEUROL, V147, P410, DOI 10.1006/exnr.1997.6593; Acarin L, 2001, STROKE, V32, P2394, DOI 10.1161/hs1001.097243; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Bancroft J., 1996, THEORY PRACTICE HIST, P735; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dalmau I, 1997, J COMP NEUROL, V377, P70; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; Kolb B, 1996, BEHAV BRAIN RES, V79, P1, DOI 10.1016/0166-4328(95)00254-5; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 1998, INT REV NEUROBIOL, V42, P103, DOI 10.1016/S0074-7742(08)60609-1; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sanz O, 2001, GLIA, V36, P259, DOI 10.1002/glia.1114; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Warr W.B., 1981, NEUROANATOMICAL TRAC, P207; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	38	47	51	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAR 15	2002	67	6					772	780		10.1002/jnr.10140			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	526ZC	WOS:000174158700009	11891791				2022-02-06	
J	Greve, KW; Love, JM; Sherwin, E; Mathias, CW; Ramzinski, P; Levy, J				Greve, KW; Love, JM; Sherwin, E; Mathias, CW; Ramzinski, P; Levy, J			Wisconsin Card Sorting Test in chronic severe traumatic brain injury: factor structure and performance subgroups	BRAIN INJURY			English	Article; Proceedings Paper	19th Annual Meeting of the National-Academy-of-Neuropsychology	NOV, 1999	SAN ANTONIO, TEXAS	Natl Acad Neuropsychol			DAMAGE	Objective: The present study further investigated the factor structure of the WCST in traumatic brain injury and investigated the construct validity and relationships among scores through the use of cluster analysis. Design: Participants were 68 survivors of chronic severe TBI, living at a residential brain injury rehabilitation facility. Methods and procedures: Three sets of WCST scores were submitted to factor analysis; the regression factor scores based on the standard WCST were examined using cluster analysis. Results Factor analysis of the WCST raw scores replicated the three-factor solution which has been previously reported. When t-scores were analysed, two-to-four-factor solutions could be justified. The cluster analysis identified four groups representing; (1) impaired response maintenance, (2) problem-solving deficits; (3) intact WCST performance; and (4) deficits in set shifting. Conclusions: The results support previous research indicating that the WCST is sensitive to three distinct cognitive processes: cognitive flexibility, problem-solving, and response maintenance. However, unlike the cognitive processes underlying WCST performance, the WCST scores representing these processes are not independent. The potential clinical relevance of these results is discussed.	Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA; Georgia So Univ, Statesboro, GA 30460 USA; Tangram Premier, San Marcos, TX USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA.			Mathias, Charles/0000-0003-1902-673X			*AM PSYCH ASS, 1992, AM PSYCH, V0047, P01597, DOI DOI 10.1037/0003-066X.47.12.1597; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Cattell R. B., 1966, HDB MULTIVARIATE EXP, P174, DOI 10.1007/978-1-4613- 0893-5_4; Greve KW, 1997, BRIT J CLIN PSYCHOL, V36, P283, DOI 10.1111/j.2044-8260.1997.tb01414.x; Greve KW, 1999, ARCH CLIN NEUROPSYCH, V14, P497; Greve KW, 1998, ARCH CLIN NEUROPSYCH, V13, P597; GREVE KW, IN PRESS HDB REYOSTE; Heaton PDRK., 1993, WISCONSIN CARD SORTI; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; *PSYCH ASS RES, 1993, WISC CARD SORT TEST; SCHNEIDER SG, 1987, J ABNORM CHILD PSYCH, V15, P29, DOI 10.1007/BF00916464; Stevens JP., 1996, APPL MULTIVARIATE ST; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; STUSS DT, 1983, NEUROPSYCHOLOGIA, V21, P235, DOI 10.1016/0028-3932(83)90040-4; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Varney NR, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P115; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	19	47	48	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2002	16	1					29	40		10.1080/0269905011008803			12	Neurosciences; Rehabilitation	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600003	11796097				2022-02-06	
J	Schoppen, T; Boonstra, A; Groothoff, JW; van Sonderen, E; Goeken, LN; Eisma, WH				Schoppen, T; Boonstra, A; Groothoff, JW; van Sonderen, E; Goeken, LN; Eisma, WH			Factors related to successful job reintegration of people with a lower limb amputation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amputees; employment; Netherlands; prosthesis; rehabilitation; reintegration	TRAUMATIC BRAIN INJURY; VOCATIONAL-REHABILITATION; NORTHERN SWEDEN; EMPLOYMENT; WORK; AMPUTEES; RETURN; DISABILITY; ARTHRITIS; IMPACT	Objective: To study demographically, amputation-, and employment-related factors that show a relationship to successful job reintegration of patients after lower limb amputation. Design: Cross-sectional study. Setting: University hospital. Patients: Subjects had an acquired unilateral major amputation of the lower limb at least 2 years before, were aged 18 to 60 years (mean, 46yr), and were living in the Netherlands. All 322 patients were working at the time of amputation and were recruited from orthopedic workshops. Intervention: Questionnaires sent to subjects to self-report (1) demographic and amputation information and (2) job characteristics and readjustment postamputation. Questionnaire sent to rehabilitation specialists to assess physical work load. Main Outcome Measures: Demographically related (age, gender); amputation-related (comorbidity; reason and level; problems with stump, pain, prosthesis use and problems, mobility, rehabilitation); and employment-related (education, physical workload) information about the success of job reintegration. Results: Job reintegration was successful in 79% and unsuccessful in 21% of the amputees. Age at the time of amputation, wearing comfort of the prosthesis, and education level were significant indicators of successful job reintegration. Subjects with physically demanding jobs who changed type of job before and after the amputation more often successfully returned to work than subjects who tried to stay at the same type of job. Conclusions: Older patients with a low education level and problems with the wearing comfort of the prosthesis are a population at risk who require special attention during the rehabilitation process in order to return to work. Lowering the physical workload by changing to another type of work enhances the chance of successful reintegration.	Univ Groningen Hosp, Dept Rehabil Med, NL-9700 RB Groningen, Netherlands; Rehabil Ctr Revalidatie Friesland, Groningen, Netherlands; Univ Groningen, No Ctr Hlth Care Res, Groningen, Netherlands; Univ Groningen, Inst Movement Sci, Groningen, Netherlands		Schoppen, T (corresponding author), Univ Groningen Hosp, Dept Rehabil Med, POB 30-001, NL-9700 RB Groningen, Netherlands.						ANDRIES F, 1998, WERKEN MET VOORZIENI; ANDRIES F, 1996, WERKEN MET NEUROMUSC; ANDRIES F, 1993, SOCICAL MAANDBLAD AR, V48, P350; EKLUND M, 1991, SCAND J REHABIL MED, V23, P73; Fugl-Meyer, 1991, J REHABIL SCI, V4, P29; FUGLMEYER AR, 1991, SCAND J REHABIL MED, V23, P83; GERHARDS F, 1984, INT J REHABIL RES, V7, P379, DOI 10.1097/00004356-198412000-00001; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; HOWARD G, 1985, JAMA-J AM MED ASSOC, V253, P226, DOI 10.1001/jama.253.2.226; Krause JS, 1998, ARCH PHYS MED REHAB, V79, P615, DOI 10.1016/S0003-9993(98)90033-8; LIVINGSTON DH, 1994, J TRAUMA, V37, P495, DOI 10.1097/00005373-199409000-00027; MILLSTEIN S, 1985, PROSTHET ORTHOT INT, V9, P69; MITCHELL JM, 1991, MED CARE, V29, P362, DOI 10.1097/00005650-199104000-00005; NARANG IC, 1984, PROSTHET ORTHOT INT, V8, P43; NIJBOER ID, 1990, JOB QUALITY HANDICAP; NIJBOER ID, 1989, JOB PERSPECTIVES YOU; PURRY NA, 1989, INJURY, V20, P32, DOI 10.1016/0020-1383(89)90041-7; Rozin R, 1982, Int Rehabil Med, V4, P75; SCHMIDT SH, 1995, ARCH PHYS MED REHAB, V76, P950, DOI 10.1016/S0003-9993(95)80073-5; Schoppen T, 2001, ARCH PHYS MED REHAB, V82, P239, DOI 10.1053/apmr.2001.18231; SHEIKH K, 1985, J SOC OCCUP MED, V35, P114; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wevers C W, 1993, Disabil Rehabil, V15, P24; YELIN E, 1980, ANN INTERN MED, V93, P551, DOI 10.7326/0003-4819-93-4-551	25	47	49	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2001	82	10					1425	1431		10.1053/apmr.2001.26074			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	479NQ	WOS:000171410800014	11588749				2022-02-06	
J	Beer, R; Franz, G; Krajewski, S; Pike, BR; Hayes, RL; Reed, JC; Wang, KK; Klimmer, C; Schmutzhard, E; Poewe, W; Kampfl, A				Beer, R; Franz, G; Krajewski, S; Pike, BR; Hayes, RL; Reed, JC; Wang, KK; Klimmer, C; Schmutzhard, E; Poewe, W; Kampfl, A			Temporal and spatial profile of caspase 8 expression and proteolysis after experimental traumatic bra in injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; astrocyte; caspase 8; neuron; oligodendrocyte; traumatic brain injury	APOPTOTIC CELL-DEATH; CORTICAL IMPACT INJURY; SPINAL-CORD INJURY; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; IN-VIVO; ACTIVATED CASPASE-3; ALZHEIMERS-DISEASE; SIGNALING COMPLEX; NERVOUS-SYSTEM	Recent studies have demonstrated that the downstream caspases, such as caspase 3, act as executors of the apoptotic cascade after traumatic brain Injury (TBI) in vivo. However, little is known about the involvement of caspases in the initiation phase of apoptosis, and the interaction between these initiator caspases (e.g. caspase 8) and executor caspases after experimental brain injuries in vitro and In vivo. This study investigated the temporal expression and cell subtype distribution of procaspase 8 and-cleaved caspase 8 p20 from 1 h to 14 days after cortical impact-induced TBI in rats. Caspase 8 messenger RNA levels, estimated by semi-quantitaive RT-PCR, were elevated from 1 h to 72 h in the traumatized cortex. Western blotting revealed increased immunoreactivity for procaspase 8 and the proteolytically active subunit of caspase 8, p20, in the ipsilateral cortex from 6 to 72 h after injury, with a peak at 24 h after TBI. Similar to our previous studies, immunoreactivity for the p18 fragment of activated caspase 3 also increased in the current study from 6 to 72 h after TBI, but peaked at a later timepoint (48 h) as compared with proteolyzed caspase 8 p20. Immunohistologic examinations revealed increased expression of caspase 8 In neurons, astrocytes and oligodendrocytes. Assessment of DNA damage using TUNEL identified caspase 8- and caspase 3-immunopositive cells with apoptotic-like morphology in the cortex ipsilateral to the injury site, and immunohistochemical investigations of caspase 8 and activated caspase 3 revealed expression of both proteases in cortical layers 2-5 after TBI. Quantitative analysis revealed that the number of caspase 8 positive cells exceeds the number of caspase 3 expressing cells up to 24 h after impact injury. In contrast, no evidence of caspase 8 and caspase 3 activation was seen in the ipsilateral hippocampus, contralateral cortex and hippocampus up to 14 days after the impact. Our results provide the first evidence of caspase 8 activation after experimental TBI and suggest that this may occur in neurons, astrocytes and oligodendrocytes. Our findings also suggest a contributory role of caspase 8 activation to caspase 3 mediated apoptotic cell death after experimental TBI In vivo.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Burnham Inst, La Jolla, CA 92037 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Gainesville, FL USA		Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	andreas.kampfl@uibk.ac.at	Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473; Schmutzhard, Erich/0000-0003-3295-7491	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01 NS40182, NS36921] Funding Source: Medline		Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Charriaut-Marlangue C, 1998, BIOMED PHARMACOTHER, V52, P264, DOI 10.1016/S0753-3322(98)80012-7; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gu CH, 1999, J NEUROSCI, V19, P3043; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Hayashi T, 1998, STROKE, V29, P1007, DOI 10.1161/01.STR.29.5.1007; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Khan SM, 2000, ANN NEUROL, V48, P148, DOI 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7; Kokaia Z, 1998, NEUROSCIENCE, V84, P1113, DOI 10.1016/S0306-4522(97)00579-4; Krajewska M, 1997, CANCER RES, V57, P1605; Krinke GJ, 2000, LAB RAT; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Liu XZ, 1997, J NEUROSCI, V17, P5395; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mogi M, 2000, J NEURAL TRANSM, V107, P335, DOI 10.1007/s007020050028; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NITATORI T, 1995, J NEUROSCI, V15, P1001; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Xerri L, 2000, J PATHOL, V192, P194, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH685>3.0.CO;2-M; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	69	47	51	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2001	78	4					862	873		10.1046/j.1471-4159.2001.00460.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	463TV	WOS:000170494100021	11520907				2022-02-06	
J	Hartlage, LC; Durant-Wilson, D; Patch, PC				Hartlage, LC; Durant-Wilson, D; Patch, PC			Persistent neurobehavioral problems following mild traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						persistent neurobehavioral problems; brain; MTBI	CLOSED-HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL ASSESSMENT; BASE RATES; SYMPTOMS; SEQUELAE; CHILDREN; RECOVERY	Accumulating research documents typical rates in the range of 85% of mild traumatic brain injury (MTBI) showing prompt, complete resolution with 15% suffering from persistent neurobehavioral impairments. Studies of neurobehavioral symptoms of MTBI have not separated these two populations, resulting in either inconclusive or contradictory conclusions concerning the relationship of MTBI with residual behavioral problems. This project studied 70 MTBI patients with persistent neurobehavioral problems at two time intervals post-injury to determine whether there are consistent neurobehavioral patterns considered to be sequelae of MTBI A matched group of 40 normal subjects provided control data. While most behavioral problems showed improvement, 21% tended to show significant behavioral impairment compared to controls at 12 or more months post-injury. Neurochemical bases of neuronal degeneration may account for some of the behavioral deterioration following MTBI. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Augusta Neuropsychol Ctr, Evans, GA 30809 USA; US Penitentiary, Atlanta, GA USA		Hartlage, LC (corresponding author), Augusta Neuropsychol Ctr, 4227 Evans Locks Rd, Evans, GA 30809 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROWN GW, 1978, LANCET, V1, P378; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; CAVENESS WF, 1977, ANN NEUROL, V1, P507; CAVENESS WF, 1979, ADV NEUROL, P1; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; Cullum C M, 1997, Appl Neuropsychol, V4, P6, DOI 10.1207/s15324826an0401_2; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gouvier WD, 1998, CRIT ISS NE, P55; GOUVIER WD, 1988, ARCH CLIN NEUROPSYCH, V3, P279; GRONWALL D, 1975, LANCET, V2, P995; Hart WE, 1997, J COMPUT BIOL, V4, P1, DOI 10.1089/cmb.1997.4.1; HARTLAGE LB, 1988, ANN M NAT ACAD NEUR; HARTLAGE LC, 1990, NEUROPSYCHOLOGICAL A; HARTLAGE LC, 1988, ANN M NAT AC NEUR OR; HARTLAGE LC, 1989, BEHAV CHANGE INVENTO; HARTLAGE LC, 1984, AUTO TORTS, V7, P187; HATCHER I, 1996, MORE JUST BUMP HEAD; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1989, MILD HEAD INJURY, P54; Hovda D. A., 1998, BRAIN INJURY SOURCE, V2, P22; HOVDA DA, 1998, BRAIN INJURY SOURCE, V2, P42; JOHNSON DJ, 1989, ANN M AM PSYCH SOC A; KIXMILLER JS, 1993, J CLIN PSYCHOL, V49, P233, DOI 10.1002/1097-4679(199303)49:2<233::AID-JCLP2270490217>3.0.CO;2-E; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kontos H.A., 1980, CLIN ASS T, V92, P111; KRAUS JF, 1989, MILD HEAD INJURY, P8; KURTZKE JF, 1993, CLIN NEUROLOGY, P66; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1989, MILD HEAD INJURY, P223; LEWIS P, 1986, ANN M AM PSYCH ASS W; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OMMAYA AK, 1982, NEUROLOGICAL INJURY; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER RS, 1994, ANAL UNDERSTANDING P; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Reitan R. M., 1986, TRAUMATIC BRAIN INJU, VI; Reynolds CR, 1998, CRIT ISS NE, P261; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROTH JS, 1998, ANN M NAT AC NEUR WA; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SIEJO BK, 1985, CENTRAL NERVOUS SYST; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; SPENCER J, 1992, ARCH CLIN NEUROPSYCH, V7, P457, DOI 10.1016/0887-6177(92)90159-K; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Varney N R, 1995, Appl Neuropsychol, V2, P47, DOI 10.1207/s15324826an0202_1; VARNEY NR, 1990, COGNITIVE REHABILITA, V8, P30; WHITLOCK FA, 1977, AUST NZ J PSYCHIAT, V11, P127, DOI 10.3109/00048677709159549; WILSON D, 1999, ANN M SE PSYCH ASS S; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; WOOD RLL, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P3; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	85	47	47	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2001	16	6					561	570		10.1016/S0887-6177(00)00067-6			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	457GN	WOS:000170128900004	14590154	Bronze			2022-02-06	
J	Marwitz, JH; Cifu, DX; Englander, J; High, WM				Marwitz, JH; Cifu, DX; Englander, J; High, WM			A multi-center analysis of rehospitalizations five years after brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehospitalization; TBI Model Systems; traumatic brain injury	MULTICENTER ANALYSIS; COMMUNITY; IMPACT; REHABILITATION; LENGTH; STAY	Objective: To investigate the incidence and cause of rehospitalizations I and 5 years after traumatic brain injury. Design: Descriptive statistics were computed in a prospective study of the cause and incidence of rehospitalizations at years I and 5 after injury. Analysis of variance and chi-square tests were used to identify factors relating to rehospitalization factors included length of stay, admission and discharge functional status, payer source, medical complications, injury severity, and demographics. Setting: Seventeen medical centers in the federally sponsored Traumatic Brain Injury Model Systems. In each setting, the continuum of care includes emergency medical services, intensive and acute medical care. inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Eight hundred ninety five rehabilitation patients admitted to acute care within 24 hours of traumatic brain injury between 1989 and 1999 were examined at I-year follow-up. Main Outcome Measures: Incidence and cause of rehospitalization at I and 5 years after injury. Results: The incidence of rehospitalization ranged from 22.9% 1 year after injury to 17.0% at 5 years after injury. At 1 year after injury a third of the rehospitalizations were for elective reasons. At 5 years after injury the incidence of readmissions for seizures and psychiatric difficulties and general health maintenance increased substantially, T-tests and chi-square analyses were performed on the 5-year follow-up data to compare those rehospitalized for unplanned reasons with those not rehospitalized, Conclusions: There remains a relatively high rate of rehospitalization in the long term after traumatic brain injury, The costs of rehospitalization should be considered when evaluating the longterm consequences of injury.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Dept Rehabil, San Jose, CA 95128 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA		Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.			Cifu, David/0000-0003-1600-9387			BURNS TJ, 1990, ARCH PHYS MED REHAB, V71, P138; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DAVIDOFF G, 1990, ARCH PHYS MED REHAB, V71, P121; DINCIN J, 1993, HOSP COMMUNITY PSYCH, V44, P833; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; GRANT JP, 1986, NUTR CLIN PRACT, V1, P3; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MCKINLAY W, 1999, REHABILITATION ADULT, P74; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	20	47	47	0	3	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2001	16	4					307	317		10.1097/00001199-200108000-00002			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	459YA	WOS:000170278000002	11461654				2022-02-06	
J	Matsushita, Y; Bramlett, HM; Kuluz, JW; Alonso, O; Dietrich, WD				Matsushita, Y; Bramlett, HM; Kuluz, JW; Alonso, O; Dietrich, WD			Delayed hemorrhagic hypotension exacerbates the hemodynamic and histopathologic consequences of traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						autoregulation; fluid-percussion injury; hypoxia; pathology; rat; regional cerebral blood flow	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; OXYGEN DELIVERY; METABOLISM; ISCHEMIA; MILD; CONTUSION; RESPONSES; CATS	Alterations in cerebral autoregulation and cerebrovascular reactivity after traumatic brain injury (TBI) may increase the susceptibility of the brain to secondary insults, including arterial hypotension. The purpose of this study was to evaluate the consequences of mild hemorrhagic hypotension on hemodynamic and histopathologic outcome after TBI. Intubated, anesthetized male rats were subjected to moderate (1.94 to 2.18 atm) parasagittal fluid-percussion (FP) brain injury. After TBI, animals were exposed to either normotension (group 1: TBI alone, n = 6) or hypotension (group 2: TBI + hypotension, n = 6). Moderate hypotension (60 mm Hg/30 min) was induced 5 minutes after TBI or sham procedures by hemorrhage. Sham-operated controls (group 3, n = 7) underwent an induced hypotensive period, whereas normotensive controls (group 4, n = 4) did not. For measuring regional cerebral blood flow (rCBF), radiolabeled microspheres were injected before, 20 minutes after, and 60 minutes after TBI (n = 23). For quantitative histopathologic evaluation, separate groups of animals were perfusion-fixed 3 days after TBI (n = 22). At 20 minutes after TBI, rCBF was bilaterally reduced by 57% + 6% and 48% +/- 11%; in cortical and subcortical brain regions, re spectively, under normotensive conditions. Compared with normotensive TBI rats, hemodynamic depression was significantly greater with induced hypotension in the histopathologically vulnerable (P1) posterior parietal cortex (P < 0.01). Secondary hypotension also increased contusion area at specific bregma levels compared with normotensive TBI rats (P < 0.05), as well as overall contusion volume (0.96 +/- 0.46 mm(3) vs. 2.02 +/- 0.51 mm(3), mean +/- SD, P < 0.05). These findings demonstrate that mild hemorrhagic hypotension after FP injury worsens local histopathologic outcome, possibly through vascular mechanisms.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, 1095 NW 14 Ter,R48, Miami, FL 33136 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		Adams JH, 1982, RECENT ADV NEUROPATH, P165; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; ARMSTEAD WM, 1999, AM J PHYSIOL, pH1884; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Davis KL, 1998, J NEUROTRAUM, V15, P615, DOI 10.1089/neu.1998.15.615; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DEWITT DS, 1995, NEW HORIZONS, P3376; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, P11289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609000-00010; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MALIK AB, 1976, J APPL PHYSIOL, V40, P472, DOI 10.1152/jappl.1976.40.3.472; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; TYSON GW, 1984, ANN NEUROL, V15, P559, DOI 10.1002/ana.410150608; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	58	47	49	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2001	21	7					847	856		10.1097/00004647-200107000-00010			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	448WV	WOS:000169653700010	11435797	Bronze			2022-02-06	
J	Varney, NR; Pinkston, JB; Wu, JC				Varney, NR; Pinkston, JB; Wu, JC			Quantitative PET findings in patients with posttraumatic anosmia	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						positron emission tomography; posttraumatic anosmia; single photon emission computed tomography	CLOSED HEAD-INJURY; TRAUMATIC BRAIN INJURY; SPECT	Objective: To investigate quantitative positron emission tomography (PET) findings, particularly from orbitofrontal cortex. in patients with posttraumatic anosmia. Setting: Neuropsychology outpatient clinic and university brain imaging center. Subjects: Eleven patients with head injury resulting in severe anosmia and 11 controls matched for age. All 11 head-injured patients had their head injuries at least 2 years before involvement in the study Measures: Regional cerebral glucose metabolism was measured with PET. Results: Quantitative evaluation of PET findings fur anosmic patients as a group showed orbitofrontal hypometabolism compared with controls. Decreased activity was also noted in mesial temporal lobe. Activity in subcortical white matter was essentially identical between groups. Conclusions: Findings strongly suggest that posttraumatic anosmia is closely associated with hypometabolism in the orbitofrontal cortex and the medial prefrontal cortex. The results also underscore the importance of posttraumatic anosmia as a clinical sign of orbitofrontal damage, as has been shown previously with neuroSPECT (single photon emission computed tomography).	VA Med Ctr, Psychiat Serv 116B, Iowa City, IA 52246 USA; Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73190 USA; Univ Calif Irvine, Brain Imaging Ctr, Irvine, CA USA		Varney, NR (corresponding author), VA Med Ctr, Psychiat Serv 116B, Iowa City, IA 52246 USA.						American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Medical Association, 1993, GUID EV PERM IMP; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V0005, P00213, DOI DOI 10.1037/0894-4105.5.3.213; Newberg AB, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199612000-00009; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Ogawa T, 1999, ACTA OTO-LARYNGOL, P50; Pinkston JB, 2000, ARCH CLIN NEUROPSYCH, V15, P545, DOI 10.1016/S0887-6177(99)00051-7; SUMNER D, 1976, HDN CLIN NEUROLOGY, V2; Varney N R, 1998, Appl Neuropsychol, V5, P100, DOI 10.1207/s15324826an0502_6; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wu J, 1999, AM J PSYCHIAT, V156, P1149; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	22	47	47	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2001	16	3					253	259		10.1097/00001199-200106000-00004			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	442YY	WOS:000169313600004	11346447				2022-02-06	
J	Munch, EC; Bauhuf, C; Horn, P; Roth, HR; Schmiedek, P; Vajkoczy, P				Munch, EC; Bauhuf, C; Horn, P; Roth, HR; Schmiedek, P; Vajkoczy, P			Therapy of malignant intracranial hypertension by controlled lumbar cerebrospinal fluid drainage	CRITICAL CARE MEDICINE			English	Article						adults; brain injury; cerebral edema; herniation; intracranial hypertension; lumbar drainage; outcome; subarachnoid hemorrhage	SEVERE HEAD-INJURY; PRESSURE; MANAGEMENT	Objectives: To evaluate the effect of controlled lumbar cerebrospinal fluid drainage in adult patients with refractory intracranial hypertension. Design: Prospective, pre- vs, postintervention study. Setting: Surgical intensive care unit of a university hospital. Patients: Twenty-three patients with severe traumatic brain injury or delayed ischemia after subarachnoid hemorrhage with intracranial hypertension refractory to aggressive treatment, including repeated applications of tromethamine, hypertonic saline solution, barbiturate coma, and decompressive craniectomy, Patients were considered for controlled lumbar cerebrospinal fluid drainage if basal cisterns on computerized tomography scan were discernible. Interventions: After institution of a lumbar drain, cerebrospinal fluid was gradually aspirated, and then, continuous cerebrospinal fluid drainage was maintained under control of intracranial pressure (ICP) and pupillary status. Measurements and Main Results: ICP and cerebral perfusion pressure before and after initiation of lumbar cerebrospinal fluid drainage and related complications were documented. The neurologic outcome of the patients was assessed according to the Glasgow Outcome Scale 6 months after injury. As a result of lumbar cerebrospinal fluid drainage, all patients demonstrated an immediate and lasting decrease of ICP and a concomitant increase of cerebral perfusion pressure. Two patients temporarily showed a unilateral fixed and dilated pupil 6 and 8 hrs after onset of lumbar cerebrospinal fluid drainage, respectively. Ten patients showed a favorable outcome, four patients survived with a severe permanent neurologic deficit, one patient remained in a persistent vegetative state, and eight patients died. Conclusions: Controlled lumbar cerebrospinal fluid drainage significantly reduces refractory intracranial hypertension. The danger of transtentorial or tonsillar herniation is minimized by considering lumbar drainage in the presence of discernible basilar cisterns only.	Heidelberg Univ, Fac Clin Med Mannheim, Dept Anesthesiol & Crit Care Med, D-68167 Mannheim, Germany; Heidelberg Univ, Fac Clin Med Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany		Munch, EC (corresponding author), Heidelberg Univ, Fac Clin Med Mannheim, Dept Anesthesiol & Crit Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.						BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; Cushing H, 1909, BOSTON MED SURG J, V161, P71, DOI 10.1056/NEJM190907151610301; Fremont-Smith F, 1932, J NERV MENT DIS, V76, P261; Fritsch MJ, 1997, ZBL NEUROCHIR, V58, P192; Hepburn HH, 1938, CAN MED ASSOC J, V39, P449; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JENNETT B, 1975, LANCET, V1, P480; KOREIN J, 1959, NEUROLOGY, V9, P290, DOI 10.1212/WNL.9.4.290; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NASH CS, 1937, ANN OTO RHINOL LARYN, V46, P673; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SENCER W, 1956, J Mt Sinai Hosp N Y, V23, P808; VERBRUGGHEN A, 1946, SURG CLIN N AM, V26, P78; Willemse RB, 1998, ACT NEUR S, V71, P37	19	47	58	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2001	29	5					976	981					6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	431DB	WOS:000168615700011	11378607				2022-02-06	
J	Bryant, RA; Guthrie, RM; Moulds, ML				Bryant, RA; Guthrie, RM; Moulds, ML			Hypnotizability in acute stress disorder	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN INJURY; MULTIPLE PERSONALITY; DISSOCIATION; HYPNOSIS; SCALE; EXPECTANCY; ABSORPTION	Objective: This study investigated the relationship between acute dissociative reactions to trauma and hypnotizability. Method: Acutely traumatized patients (N=61) with acute stress disorder, subclinical acute stress disorder (no dissociative symptoms), and no acute stress disorder were administered the Stanford Hypnotic Clinical Scale within 4 weeks of their trauma. Results: Although patients with acute stress disorder and patients with subclinical acute stress disorder displayed comparable levels of nondissociative psychopathology, acute stress disorder patients had higher levels of hypnotizability and were more likely to display reversible posthypnotic amnesia than both patients with subclinical acute stress disorder and patients with no acute stress disorder. Conclusions: The findings may be interpreted in light of a diathesis-stress process mediating trauma-related dissociation. People who develop acute stress disorder in response to traumatic experience may have a stronger ability to experience dissociative phenomena than people who develop subclinical acute stress disorder or no acute stress disorder.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Moulds, Michelle/B-2928-2010; Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; Moulds, Michelle/0000-0001-7064-4248			Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck AT, 1990, BECK ANXIETY INVENTO; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; BLISS EL, 1984, J NERV MENT DIS, V172, P203, DOI 10.1097/00005053-198404000-00003; BOWERS KS, 1991, INT J CLIN EXP HYP, V39, P155, DOI 10.1080/00207149108409632; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 2000, HDB THEORY ASSESSMEN; Butler LD, 1996, AM J PSYCHIAT, V153, P42; Carlson E.B., 1989, DISSOCIATION, V2, P32; COUNCIL JR, 1986, J PERS SOC PSYCHOL, V50, P182, DOI 10.1037/0022-3514.50.1.182; COVINO NA, 1994, J ABNORM PSYCHOL, V103, P455, DOI 10.1037/0021-843X.103.3.455; Fleiss J.L., 1981, STAT METHODS RATES P; FRANKEL FH, 1990, AM J PSYCHIAT, V147, P823; FRANKEL FH, 1976, ARCH GEN PSYCHIAT, V33, P1259; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Janet P., 1907, MAJOR SYMPTOMS HYSTE; KIHLSTROM JF, 1985, ANNU REV PSYCHOL, V36, P385, DOI 10.1146/annurev.ps.36.020185.002125; KIHLSTROM JF, 1994, J ABNORM PSYCHOL, V103, P117, DOI 10.1037/0021-843X.103.1.117; KIHLSTROM JF, 1984, INT J CLIN EXP HYP, V32, P51, DOI 10.1080/00207148408416000; LAVOIE G, 1973, INT J CLIN EXP HYP, V21, P157, DOI 10.1080/00207147308409120; LIEBERMAN J, 1978, INT J CLIN EXP HYP, V26, P268, DOI 10.1080/00207147808411252; MORGAN AH, 1979, AM J CLIN HYPN, V21, P134; NASH MR, 1993, J CONSULT CLIN PSYCH, V61, P276, DOI 10.1037/0022-006X.61.2.276; PICCIONE C, 1989, J PERS SOC PSYCHOL, V56, P289, DOI 10.1037/0022-3514.56.2.289; ROCHE SM, 1990, J PERS SOC PSYCHOL, V59, P91, DOI 10.1037/0022-3514.59.1.91; SILVA CE, 1992, J PERS SOC PSYCHOL, V63, P847, DOI 10.1037/0022-3514.63.5.847; SPIEGEL D, 1988, AM J PSYCHIAT, V145, P301; SPIEGEL D, 1984, PSYCHIAT CLIN N AM, V7, P101; Spiegel David, 1996, P367; STUTMAN RK, 1985, AM J PSYCHIAT, V142, P741; Waller NG, 1996, PSYCHOL METHODS, V1, P300, DOI 10.1037/1082-989X.1.3.300; Weitzenhoffer A., 1963, STANFORD HYPNOTIC SU; WOODY EZ, 1992, CONT HYPNOSIS RES, P3	39	47	48	0	2	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	APR	2001	158	4					600	604		10.1176/appi.ajp.158.4.600			5	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	419CN	WOS:000167931900013	11282695				2022-02-06	
J	Coward, K; Aitken, A; Powell, A; Plumpton, C; Birch, R; Tate, S; Bountra, C; Anand, P				Coward, K; Aitken, A; Powell, A; Plumpton, C; Birch, R; Tate, S; Bountra, C; Anand, P			Plasticity of TTX-sensitive sodium channels PNI and brain III in injured human nerves	NEUROREPORT			English	Article						brain III; human; nerve injury; pain; PNI	SPINAL SENSORY NEURONS; SUBUNIT MESSENGER-RNAS; ALPHA-SUBUNIT; EXPRESSION; PAIN; RAT; EXCITABILITY; CNS	Sensory neurones co-express voltage-gated sodium channels that mediate TTX-sensitive (TTX-S) and TTX-resistant (TTX-R) currents, which may contribute to chronic pain after nerve injury. We previously demonstrated that TTX-R channels were decreased acutely in human sensory cell bodies after central axotomy, but accumulated in nerve terminals after peripheral axotomy. We have now studied the TTX-S channels PNI and Brain III, using specific antibodies for immunohistochemistry, in dorsal root ganglia (DRG) from 10 patients with traumatic central axotomy, nerves from 16 patients with peripheral axotomy, and controls. PNI showed temporal changes similar to the TTX-R channels in sensory cell bodies of injured DRG. In contrast, Brain III was found only in injured nerves (not control nerves, or control/central axotomy DRG). PNI and Brain III are distinct targets for novel analgesics. NeuroReport 12:495-500 (C) 2001 Lippincott Williams & Wilkins.	Hammersmith Hosp, Univ London Imperial Coll Sci Technol & Med, Dept Neurol, Peripheral Neuropathy Unit, London W12 0NN, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Dept Mol Pharmacol, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Recognit Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Neurosci & Rheumatol Syst Dept, Stevenage SG1 2NY, Herts, England; Royal Natl Orthopaed Hosp, Peripheral Nerve Injury Unit, Stanmore HA7 4LP, Middx, England		Anand, P (corresponding author), Hammersmith Hosp, Univ London Imperial Coll Sci Technol & Med, Dept Neurol, Peripheral Neuropathy Unit, Area A,Ground Floor,Du Cane Rd, London W12 0NN, England.			Powell, Andrew/0000-0003-1540-537X			AHMED CMI, 1992, P NATL ACAD SCI USA, V89, P8220, DOI 10.1073/pnas.89.17.8220; Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BAINES D, 1992, MOL BRAIN RES, V16, P330, DOI 10.1016/0169-328X(92)90243-5; Black JA, 1999, J NEUROPHYSIOL, V82, P2776, DOI 10.1152/jn.1999.82.5.2776; Black JA, 1996, MOL BRAIN RES, V43, P117, DOI 10.1016/S0169-328X(96)00163-5; BLACK JA, 1994, MOL BRAIN RES, V22, P275, DOI 10.1016/0169-328X(94)90056-6; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; ENGLAND JD, 1998, NEUROLOGY, V50; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; LU CM, 1992, FEBS LETT, V303, P53, DOI 10.1016/0014-5793(92)80476-W; Lu CM, 1998, J MOL NEUROSCI, V10, P67, DOI 10.1007/BF02737087; Powell AJ, 1998, EUR J NEUROSCI, V10, P68; ROY ML, 1992, J NEUROSCI, V12, P2104; Sangameswaran L, 1997, J BIOL CHEM, V272, P14805, DOI 10.1074/jbc.272.23.14805; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; ToledoAral JJ, 1997, P NATL ACAD SCI USA, V94, P1527, DOI 10.1073/pnas.94.4.1527; Waxman SG, 1999, PAIN, pS133, DOI 10.1016/S0304-3959(99)00147-5; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; Waxman SG, 1999, MUSCLE NERVE, V22, P1177, DOI 10.1002/(SICI)1097-4598(199909)22:9<1177::AID-MUS3>3.3.CO;2-G; Whitaker WRJ, 1999, ANN NY ACAD SCI, V868, P88, DOI 10.1111/j.1749-6632.1999.tb11278.x	24	47	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	MAR 5	2001	12	3					495	500		10.1097/00001756-200103050-00014			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	403XT	WOS:000167069000014	11234752				2022-02-06	
J	Bell, MJ; Robertson, CS; Kochanek, PM; Goodman, JC; Gopinath, SP; Carcillo, JA; Clark, RSB; Marion, DW; Mi, ZC; Jackson, EK				Bell, MJ; Robertson, CS; Kochanek, PM; Goodman, JC; Gopinath, SP; Carcillo, JA; Clark, RSB; Marion, DW; Mi, ZC; Jackson, EK			Interstitial brain adenosine and xanthine increase during jugular venous oxygen desaturations in humans after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	27th Annual Meeting of the Society-of-Neuroscience	OCT 25-30, 1997	NEW ORLEANS, LA	Soc Neurosci		adenosine; humans; jugular venous oxygen desaturation; microdialysis; xanthine; head injury	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; CORTICAL-NEURONS; RAT; MICRODIALYSIS; ISCHEMIA; METABOLISM; RELEASE; THEOPHYLLINE; RECEPTOR	Objective: Adenosine decreases the cerebral metabolic rate for oxygen and increases cerebral blood flow, and it may play an important role in cerebrometabolic and cerebrovascular responses to hypoperfusion after traumatic brain injury. Jugular venous oxygen saturation is monitored after traumatic brain injury to assess brain oxygen extraction, and desaturations may reflect secondary brain insults. We hypothesized that brain interstitial adenosine and related purine metabolites would be increased during jugular venous oxygen saturation desaturations (<50%) and determined associations between the purines, lactate, and glucose to assess the role of adenosine during secondary insults in humans. Design: Study of critically ill adults with severe traumatic brain injury, Setting: Adult neurointensive care unit. Patients: We prospectively defined periods of normal saturation and desaturation in six patients after severe traumatic brain injury. Interventions: During these periods, cerebral microdialysis samples of brain interstitial fluid were collected, and adenosine and purine metabolites were measured by high-pressure liquid chromatography, Measurements and Main Results: Adenosine increased 3.1-fold and xanthine increased 2.5-fold during desaturation periods (both p <.05 vs. normal saturation period, signed rank). Adenosine, xanthine, hypoxanthine, and cyclic-adenosine monophosphate correlated with lactate over both study periods (r(2) =.32, .14, .31, .07, and .26, respectively, all p < .05, Pearson product moment correlation). Conclusion: The marked increases in interstitial brain adenosine that occur during jugular venous oxygen desaturations suggest that adenosine may play an important role during periods of secondary insults after traumatic brain injury. The correlation of these metabolites with lactate further suggests that adenosine is increased during periods of enhanced glycolytic metabolism.	Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Bell, MJ (corresponding author), Safar Ctr Resuscitat Res, Pittsburgh, PA USA.		Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087, NS27616, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, R01NS038087, P01NS027616, P50NS027616, P50NS030318] Funding Source: NIH RePORTER		ANGELLO DA, 1991, AM J PHYSIOL, V260, pH193, DOI 10.1152/ajpheart.1991.260.1.H193; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; DONAGHY KM, 1994, BRAIN RES, V656, P174, DOI 10.1016/0006-8993(94)91380-3; FLEISCHER AS, 1977, J NEUROSURG, V47, P517, DOI 10.3171/jns.1977.47.4.0517; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; Geiger Jonathan D., 1997, P55; GIDDAY JM, 1995, PEDIATR RES, V38, P306, DOI 10.1203/00006450-199509000-00006; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; Goodman JC, 1996, ACT NEUR S, V67, P37; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HYLLAND P, 1994, J CEREBR BLOOD F MET, V14, P877, DOI 10.1038/jcbfm.1994.110; KIM YB, 1994, J NEUROSURG, V81, P877, DOI 10.3171/jns.1994.81.6.0877; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; LAUDIGNON N, 1990, J APPL PHYSIOL, V68, P1534, DOI 10.1152/jappl.1990.68.4.1534; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; MI ZC, 1995, J PHARMACOL EXP THER, V273, P728; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; MORI M, 1992, NEUROSCIENCE, V46, P301, DOI 10.1016/0306-4522(92)90052-4; MORII S, 1987, AM J PHYSIOL, V253, pH165, DOI 10.1152/ajpheart.1987.253.1.H165; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PHILLIS JW, 1975, EUR J PHARMACOL, V30, P125, DOI 10.1016/0014-2999(75)90214-9; PINARD E, 1990, BRAIN RES, V511, P303, DOI 10.1016/0006-8993(90)90175-B; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; vonLubitz DKJE, 1997, ANN NY ACAD SCI, V825, P49; WINN HR, 1981, AM J PHYSIOL, V241, pH235, DOI 10.1152/ajpheart.1981.241.2.H235; WINN HR, 1979, CIRC RES, V45, P486, DOI 10.1161/01.RES.45.4.486; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU L, 1991, BRAIN RES, V540, P307, DOI 10.1016/0006-8993(91)90525-Z; Zauner A, 1996, ACT NEUR S, V67, P40	43	47	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2001	29	2					399	404		10.1097/00003246-200102000-00033			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	405UR	WOS:000167179400027	11246323				2022-02-06	
J	Langburt, W; Cohen, B; Akhthar, N; O'Neill, K; Lee, JC				Langburt, W; Cohen, B; Akhthar, N; O'Neill, K; Lee, JC			Incidence of concussion in high school football players of Ohio and Pennsylvania	JOURNAL OF CHILD NEUROLOGY			English	Article							MINOR HEAD-INJURY; COLLEGE FOOTBALL; SPORTS	Football injuries account for more concussions than any other sport in North America. A 1977 survey of high school football players in Minnesota found that 19% of players reported at least one concussion (characterized by loss of awareness) during a season. These results have not been confirmed in subsequent studies. This study sought to estimate the incidence of concussion among high school football players in our region, establish the frequency of the most common symptoms, and determine the duration of subsequent restriction from participation in the sport. The athletic boards of area high schools distributed a three-page survey to 450 high school football players. Of the 450 surveys distributed, 234 (52%) were returned, only I of which was excluded because of contradictory information. The incidence of concussion in football players was 47.2% (110/233, P < .001 versus a previously determined rate of 19%). Eighty-one of 233 players (34.9%) had multiple concussions. A total of 376 concussions were reported. The distribution of severity of the 376 reported concussive events was grade I, 87.8%; grade II, 9.9%; and grade III, 2.4%. Only 12 athletes were required to stop play for one or more games. The incidence of high school football players sustaining a concussion is much higher than previously established. The majority of these are mild (grade I) concussions. Further research is needed since multiple low-grade concussions may incur cumulative neuropsychologic impairments.	Cleveland Clin Fdn, Dept Pediat Neurol, Cleveland, OH 44195 USA		Langburt, W (corresponding author), 3540 S Poplar,Suite 200, Denver, CO 80237 USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; BIJUR PE, 1990, PEDIATRICS, V86, P337; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CLARK KS, 1982, ATHLETIC INJURY HEAD; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Greenspan A I, 1996, Curr Probl Pediatr, V26, P170, DOI 10.1016/S0045-9380(96)80004-1; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; *NAT ATHL INJ ILLN, 1976, NAIRS SPORT REL INC; 1966, CLIN NEUROSURG, V12, P386	16	47	48	0	9	B C DECKER INC	HAMILTON	20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	FEB	2001	16	2					83	85		10.1177/088307380101600203			3	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	473DT	WOS:000171025300003	11292230				2022-02-06	
J	Mirski, MA; Denchev, DI; Schnitzer, MS; Hanley, DF				Mirski, MA; Denchev, DI; Schnitzer, MS; Hanley, DF			Comparison between hypertonic saline and mannitol in the reduction of elevated intracranial pressure in a rodent model of acute cerebral injury	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						hypertonic saline; mannitol; intracranial pressure; brain injury	7.5-PERCENT SODIUM-CHLORIDE; CRYOGENIC BRAIN INJURY; HEMORRHAGIC-SHOCK; CEREBROSPINAL-FLUID; CELL-VOLUME; HEAD TRAUMA; PLASMA OSMOLALITY; MULTICENTER TRIAL; NEUROLOGIC STATUS; COLLOID SOLUTIONS	Clinically both mannitol and hypertonic saline (HTS) have been used successfully to treat elevated intracranial pressure (ICP), although which therapy is superior is yet unclear. Most experimental data have been derived from animal models of brain injury using general anesthesia, which may not be applicable under other conditions. Our laboratory compared the efficacy of single, equi-osmolar bolus doses of HTS and mannitol in reducing elevated ICP in a lightly sedated, unrestrained rodent model of acute brain injury. Sprague-Dawley rats were mask anesthetized for craniectomy and placement of invasive monitors. Following emergence from anesthesia, continuous sedation was provided (0.25% halothane in oxygen). A focal, liquid nitrogen cold lesion was introduced to the right parietal cortex. Animals were continuously monitored and then treated with a single bolus of 0.9% saline (control group) or 11.0 mOsm/kg equivalents of either mannitol or HTS (experimental groups) at time of maximal ICP increase (60 minutes). Both mannitol and HTS reduced LCP, but HTS was more effective-53.9% reduction versus 35.0% (P < .01). The therapeutic action of HTS was also more durable, lasting up to 500 minutes whereas the mannitol treated animals were observed to return to, and overshoot the baseline elevated ICP by 10% to 25% by 120 minutes following dosing (P < .01). Despite these differences, brain water content was similar between groups. We conclude that HTS was more effective in reducing elevated ICP in this awake model of traumatic brain injury.	Johns Hopkins Med Inst, Baltimore, MD 21287 USA		Mirski, MA (corresponding author), Johns Hopkins Med Inst, 600 N Wolfe St,Meyer 8-134, Baltimore, MD 21287 USA.			Hanley, Daniel/0000-0002-9536-4258			BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BRUSSEL T, 1991, ANESTH ANALG, V73, P758; Bullock R, 1995, New Horiz, V3, P448; CANTORE C, 1964, J NEUROSURG, V21, P278; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; DIMATTIO J, 1975, PFLUG ARCH EUR J PHY, V359, P253, DOI 10.1007/BF00587383; DONATO T, 1994, ANESTH ANALG, V78, P58; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; FOXWORTHY JC, 1990, J NEUROSURG ANESTH, V2, P266; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KOFKE WA, 1993, J NEUROSURG ANESTH, V5, P1; MANINGAS PA, 1989, AM J SURG, V157, P528, DOI 10.1016/0002-9610(89)90654-5; MANNINEN PH, 1987, CAN J ANAESTH, V34, P442, DOI 10.1007/BF03014345; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MCGILLICUDDY JE, 1985, CHEST, V87, P85, DOI 10.1378/chest.87.1.85; MCMANUS ML, 1993, ANESTHESIOLOGY, V78, P1132, DOI 10.1097/00000542-199306000-00017; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MORENO M, 1969, J LAB CLIN MED, V73, P291; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; PROUGH D S, 1991, Anesthesia and Analgesia, V73, P738; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; Prough DS, 1999, J NEUROSURG ANESTH, V11, P102, DOI 10.1097/00008506-199904000-00006; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; RUDEHILL A, 1993, J NEUROSURG ANESTH, V5, P4; SAHAR A, 1978, EXP NEUROL, V60, P584, DOI 10.1016/0014-4886(78)90012-2; SCHELLER MS, 1991, J NEUROSURG ANESTH, V3, P291, DOI 10.1097/00008506-199112000-00009; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; TODD MM, 1987, ANESTHESIOLOGY, V60, P1090; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Weed LH, 1919, AM J PHYSIOL, V48, P512, DOI 10.1152/ajplegacy.1919.48.4.512; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YOUNES RN, 1994, SHOCK S, V1, P2; YOUNES RN, 1992, SURGERY, V111, P70; ZORNOW MH, 1990, ACT NEUR S, V51, P324; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	59	47	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2000	12	4					334	344		10.1097/00008506-200010000-00006			11	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	360PL	WOS:000089676400006	11147382				2022-02-06	
J	Cornwall, R; Radomisli, TE				Cornwall, R; Radomisli, TE			Nerve injury in traumatic dislocation of the hip	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							MAGNETIC-RESONANCE NEUROGRAPHY; BRACHIAL-PLEXUS; DIAGNOSIS	Neurologic injury often accompanies traumatic dislocation and fracture-dislocation of the hip. A review of the literature reveals an incidence of approximately 10% in adults and 5% in children. The sciatic nerve, usually the peroneal branch, is most often injured, and this complication can be seen after all types of posterior fracture-dislocations and simple posterior dislocations. The sciatic nerve can be acutely lacerated, stretched, or compressed, or later encased in heterotopic ossification. Neurologic examination at the time of injury often is difficult but is extremely important. Once a nerve injury is discovered, prompt closed reduction must be attempted to relieve distortion of the nerve from a dislocated femoral head or displaced acetabular fracture. Considerable controversy surrounds the recommendations for additional treatment of nerve injury once the hip has been reduced. At least partial recovery of nerve function occurs in 60% to 70% of patients, with no clear correlation with injury or treatment type. Rehabilitation of patients with sciatic nerve injury must begin as early as possible and should focus on the prevention of an equinus foot deformity. Magnetic resonance neurography may become useful in the future for initial evaluation of patients with this injury.	Mt Sinai Hosp, Mt Sinai Sch Med, Dept Orthopaed Surg, New York, NY 10029 USA		Radomisli, TE (corresponding author), Mt Sinai Hosp, Mt Sinai Sch Med, Dept Orthopaed Surg, 5 E 98th St,Box 1188, New York, NY 10029 USA.						Aagaard B D, 1998, Magn Reson Imaging Clin N Am, V6, P179; ARMSTRONG JR, 1948, J BONE JOINT SURG BR, V30, P430, DOI 10.1302/0301-620X.30B3.430; BARQUET A, 1979, ACTA ORTHOP SCAND, V50, P549, DOI 10.3109/17453677908989803; Beaton LE, 1937, ANAT REC, V70, P1, DOI 10.1002/ar.1090700102; BROMBERG E, 1977, SOUTHERN MED J, V70, P8, DOI 10.1097/00007611-197701000-00005; Carvalho GA, 1997, ORTHOPADE, V26, P599, DOI 10.1007/PL00003417; COLLINS JD, 1988, J NATL MED ASSOC, V81, P129; DELEE JC, 1996, ROCKWOOD GREENS FRAC, V2, P1659; DERIAN PS, 1974, SOUTH MED J, V67, P209, DOI 10.1097/00007611-197402000-00020; DREINHOFER KE, 1994, J BONE JOINT SURG BR, V76B, P6, DOI 10.1302/0301-620X.76B1.8300683; EISENBERG KS, 1972, J BONE JOINT SURG AM, VA 54, P1083, DOI 10.2106/00004623-197254050-00016; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; FASSLER R, 1993, J BONE JOINT SURG AM, V75, P1157; Filler AG, 1996, J NEUROSURG, V85, P299, DOI 10.3171/jns.1996.85.2.0299; FILLER AG, 1993, LANCET, V341, P659, DOI 10.1016/0140-6736(93)90422-D; GLASS A, 1961, J BONE JOINT SURG BR, V43, P29; GREGORY CF, 1973, INSTR COURSE LECT, V22, P105; Hart VL, 1942, J BONE JOINT SURG, V24, P458; HAW DWM, 1965, BRIT MED J, V1, P1111, DOI 10.1136/bmj.1.5442.1111; HIRASAWA Y, 1977, CLIN ORTHOP RELAT R, P172; Hoenig LJ, 1997, SEMIN ARTHRITIS RHEU, V26, P684, DOI 10.1016/S0049-0172(97)80004-2; HOWE FA, 1992, MAGNET RESON MED, V28, P328, DOI 10.1002/mrm.1910280215; HUNTER G A, 1969, Journal of Bone and Joint Surgery British Volume, V51, P38; JACOB JR, 1987, CLIN ORTHOP RELAT R, P249; KLEIMAN SG, 1971, J BONE JOINT SURG AM, VA 53, P781, DOI 10.2106/00004623-197153040-00019; LAORR A, 1995, SKELETAL RADIOL, V24, P239; Larson C, 1973, CLIN ORTHOP RELAT R, V92, P147; LEVIN P, 1998, SKELETAL TRAUMA, V2, P1713; McCarthy M, 1996, LANCET, V348, P674, DOI 10.1016/S0140-6736(05)65085-4; NERUBAY J, 1973, J TRAUMA, V13, P1050, DOI 10.1097/00005373-197312000-00003; OCHI M, 1994, J HAND SURG-BRIT EUR, V19B, P55, DOI 10.1016/0266-7681(94)90050-7; OFFIERSKI CM, 1981, J BONE JOINT SURG BR, V63, P194, DOI 10.1302/0301-620X.63B2.7217141; PATTERSON FP, 1973, J TRAUMA, V12, P1013; PEARSON DE, 1973, CLIN ORTHOP RELAT R, P189; PIGGOT J, 1961, J BONE JOINT SURG BR, V43, P38; PLATTNER P, 1993, SURG FOOT ANKLE, V2, P805; POGGI JJ, 1995, CLIN ORTHOP RELAT R, P249; PROCTOR H, 1973, INJURY, V5, P1, DOI 10.1016/S0020-1383(73)80002-6; RAPOPORT S, 1988, RADIOLOGY, V167, P161, DOI 10.1148/radiology.167.1.3347719; ROGER B, 1988, CLIN ORTHOP RELAT R, P57; SCHLONSKY J, 1973, J BONE JOINT SURG AM, VA 55, P1057, DOI 10.2106/00004623-197355050-00015; Seddon H.J., 1972, SURG DISORDERS PERIP; Steinke CR, 1914, ANN SURG, V60, P617, DOI 10.1097/00000658-191411000-00008; STEWART MJ, 1954, J BONE JOINT SURG AM, V36-A, P315, DOI 10.2106/00004623-195436020-00010; STEWART MJ, 1975, ACTA ORTHOP SCAND, V46, P507; Sunderland S., 1978, NERVE NERVE INJURIES, V2nd; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548, DOI 10.1302/0301-620X.63B4.7298682; WILCHINSKY ME, 1985, J PEDIATR ORTHOPED, V5, P534, DOI 10.1097/01241398-198509000-00005; WILSON JN, 1960, P ROY SOC MED, V53, P941, DOI 10.1177/003591576005301111; YANG RS, 1991, CLIN ORTHOP RELAT R, P218	53	47	50	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	2000		377					84	91					8	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	340WM	WOS:000088559100013	10943188				2022-02-06	
J	Di Stefano, G; Bachevalier, J; Levin, HS; Song, JX; Scheibel, RS; Fletcher, JM				Di Stefano, G; Bachevalier, J; Levin, HS; Song, JX; Scheibel, RS; Fletcher, JM			Volume of focal brain lesions and hippocampal formation in relation to memory function after closed head injury in children	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; magnetic resonance imaging; verbal learning and memory; frontal lobe; hippocampus	DIFFUSE AXONAL INJURY; POSTNATAL-DEVELOPMENT; FRONTAL-CORTEX; DENTATE GYRUS; MOSSY CELLS; LOBE; ADOLESCENTS; DEFICIT; MONKEYS; HUMANS	Objectives-(1) A study of verbal learning and memory in children who had sustained a closed head injury (CHI) at least 3 months earlier. (2) To relate memory function to focal brain lesion and hippocampal formation volumes using morphometric analysis of MRI. Methods-A group of 245 children who had been admitted to hospital for CHI graded by the Glasgow coma scale (GCS), including 161 patients with severe and 84 with mild CHI completed the California verbal learning test (CVLT) and underwent MRI which was analysed for focal brain lesion volume independently of memory test data. Brain MRI with 1.5 mm coronal slices obtained in subsets of 25 patients with severe and 25 patients with mild CHI were analysed for hippocampal formation volume. Interoperator reliability in morphometry was satisfactory. Results-Severity of CHI and age at study significantly affected memory performance. Regression analysis showed that bifrontal, left frontal, and right frontal lesion volumes incremented prediction of various learning and memory indices after entering the GCS score and age into the model. Extrafrontal lesion volume did not contribute to predicting memory performance. Conclusions-Prefrontal lesions contribute to residual impairment of learning and memory after severe CHI in children. Although effects of CHI on hippocampal formation volume might be difficult to demonstrate in non-fatal paediatric CHI, further investigation using functional brain imaging could potentially demonstrate hippocampal dysfunction.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Neurobiol & Anat, Houston, TX USA; Univ Houston, Hlth Sci Ctr, Dept Pediat, Houston, TX USA		Di Stefano, G (corresponding author), Univ Bern, Inselspital, Dept Psychiat, Murtenstr 21, CH-3010 Bern, Switzerland.	giuseppe.distefano@papk.unibe.ch	fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Chugani H T, 1999, Adv Neurol, V79, P883; Cohen NJ., 1993, MEMORY AMNESIA HIPPO; DIAMOND A, 1990, P394; FREE SL, 1995, AM J NEURORADIOL, V16, P637; Fuster J., 1989, PREFRONTAL CORTEX AN; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giedd JN, 1996, J COMP NEUROL, V366, P223, DOI 10.1002/(SICI)1096-9861(19960304)366:2<223::AID-CNE3>3.0.CO;2-7; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; PETRIDES M, 1995, P NATL ACAD SCI USA, V92, P5803, DOI 10.1073/pnas.92.13.5803; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Schacter DL, 1996, NEUROREPORT, V7, P1165, DOI 10.1097/00001756-199604260-00014; SERESS L, 1995, J COMP NEUROL, V355, P93, DOI 10.1002/cne.903550111; SERESS L, 1992, HIPPOCAMPUS, V2, P127, DOI 10.1002/hipo.450020205; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; STRICH SJ, 1961, LANCET, V2, P443; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555; [No title captured]	41	47	47	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2000	69	2					210	216		10.1136/jnnp.69.2.210			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	338XM	WOS:000088448600014	10896695	Green Published, Bronze			2022-02-06	
J	Jones, DK; Dardis, R; Ervine, M; Horsfield, MA; Jeffree, M; Simmons, A; Jarosz, J; Strong, AJ				Jones, DK; Dardis, R; Ervine, M; Horsfield, MA; Jeffree, M; Simmons, A; Jarosz, J; Strong, AJ			Cluster analysis of diffusion tensor magnetic resonance images in human head injury	NEUROSURGERY			English	Article						cluster analysis; diffusion tensor; edema; magnetic resonance imaging; MRI; traumatic brain injury	TRAUMATIC BRAIN INJURY; ISCHEMIC RAT-BRAIN; ECHO-PLANAR IMAGES; APPARENT DIFFUSION; CEREBRAL-ISCHEMIA; WATER DIFFUSION; HUMAN STROKE; MRI; NMR; MODEL	OBJECTIVE: issues surrounding the nature of the edema associated with traumatic brain injury in humans, and its evolution in the acute phase, remain unresolved. This study aimed to characterize the topographical nature of the pathophysiological changes in human traumatic brain injury with diffusion tensor magnetic resonance imaging. METHODS: Multislice diffusion-weighted magnetic resonance imaging data were acquired from five patients undergoing elective ventilation for management of traumatic focal contusion or hematomas. The diffusion tensor and the Ta-weighted intensity were then computed for every voxel in the image data set for each patient The topographical distribution of abnormalities in the trace of the diffusion tensor and T2-weighted images were characterized by cluster analysis. RESULTS: In four patients with technically satisfactory data, a narrow band of tissue was observed in the periphery of focal lesions, which was characterized by selective reduction in the trace of the diffusion tensor, without any associated increase in the T2-weighted signal intensity. CONCLUSION: This change is interpreted as indicating either a partial redistribution of water from the extra- to intracellular compartment, or a reduction in the diffusivity of water in the intracellular or cytosolic environment. These diffusion and T2-weighted characteristics are also found in early ischemic change, hence, such regions may represent potentially salvageable tissue at risk of permanent damage. The study illustrates the advantage of using information contained within the diffusion tensor in addition to more conventional imaging sequences.	Kings Coll Hosp London, Sch Med, London SE5 9RS, England; St Thomas Hosp, Sch Med, Kings Coll, London SE5 9RS, England; Guys Hosp, Sch Med, Kings Coll, London SE5 9RS, England; Kings Coll London, Inst Psychiat, Old Age Psychiat Sect, London WC2R 2LS, England; Inst Psychiat, Dept Clin Neurosci, London, England; Kings Coll Hosp London, Dept Anaesthesia, London, England; Univ Leicester, Leicester Royal Infirm, Div Med Phys, Leicester LE1 7RH, Leics, England		Strong, AJ (corresponding author), Kings Coll Hosp London, Sch Med, London SE5 9RS, England.	dkj2@le.ac.uk	Jones, Derek K/D-1460-2009; Simmons, Andrew/B-8848-2008; Horsfield, Mark A/C-6569-2013	Simmons, Andrew/0000-0003-2306-5811; Horsfield, Mark A/0000-0002-0815-6697; Strong, Anthony/0000-0003-2432-5945; Jones, Derek K/0000-0003-4409-8049			Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CADOUXHUDSON TAD, 1998, 6 ANN SCI M INT SOC; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; DORAN M, 1990, J COMPUT ASSIST TOMO, V14, P856; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HASEGAWA Y, 1995, J CEREB BLOOD FLOW M, V15, P176; Haselgrove JC, 1996, MAGNET RESON MED, V36, P960, DOI 10.1002/mrm.1910360620; HELPERN JA, 1992, 11 ANN M SOC MAGN RE; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; KATAYAMA Y, IN PRESS ACTA NEUR S; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1985, CR ACAD SCI II, V301, P1109; LIU AY, 1998, 6 ANN SCI M INT SOC; MARMAROU A, IN PRESS ACTA NEUR S; MERBOLDT KD, 1985, J MAGN RESON, V64, P479, DOI 10.1016/0022-2364(85)90111-8; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Neil JJ, 1996, MAGNET RESON MED, V35, P329, DOI 10.1002/mrm.1910350310; NORRIS DG, 1994, NMR BIOMED, V7, P304, DOI 10.1002/nbm.1940070703; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Rordorf G, 1998, STROKE, V29, P939, DOI 10.1161/01.STR.29.5.939; Simmons A, 1999, INT J IMAG SYST TECH, V10, P273, DOI 10.1002/(SICI)1098-1098(1999)10:3<273::AID-IMA8>3.0.CO;2-E; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TAYLOR DG, 1985, PHYS MED BIOL, V30, P345, DOI 10.1088/0031-9155/30/4/009; TURNER R, 1990, RADIOLOGY, V177, P407, DOI 10.1148/radiology.177.2.2217777; Ulug AM, 1997, STROKE, V28, P483, DOI 10.1161/01.STR.28.3.483; WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983; WICK M, 1995, STROKE, V26, P1930, DOI 10.1161/01.STR.26.10.1930; ZACHAROPOULOS N, 1998, 6 ANN SCI M INT SOC; ZHONG J, 1993, MAGN RESON MED, V30, P241, DOI 10.1002/mrm.1910300214	42	47	49	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2000	47	2					306	313		10.1097/00006123-200008000-00008			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	339WZ	WOS:000088502000017	10942003				2022-02-06	
J	Kane, NM; Butler, SR; Simpson, T				Kane, NM; Butler, SR; Simpson, T			Coma outcome prediction using event-related potentials: P-3 and mismatch negativity	AUDIOLOGY AND NEURO-OTOLOGY			English	Article						coma; outcome prediction; evoked and event-related potentials; mismatch negativity (MMN)	SOMATOSENSORY-EVOKED POTENTIALS; TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; NONTRAUMATIC COMA; P300; RECOVERY; EMERGENCE; STATES; NAME	The prediction of the outcome from coma is of considerable importance to the patients, their relatives and attendant medical staff, and yet current clinical methods lack sensitivity and specificity. Objective investigations can enhance the accuracy of such predictions and are an important adjuvant when reaching decisions to continue or terminate life support. Of the neurophysiological methods available, electroencephalography and short-latency somatosensory evoked potentials have proved the most useful in the clinical setting. These tests are good predictors of an adverse outcome; however, they tell us only about the ongoing cerebral activity and integrity of the primary somatosensory pathways, respectively. The presence of long-latency event-related potentials has been shown to be a useful predictor of a favourable neurological outcome, and thus their use complements other neurophysiological techniques. Their potential application in clinical practice is reviewed. Copyright (C) 2000 S. Karger AG, Basel.	Frenchay Hosp, Grey Walter Dept Cin Neurophysiol, Bristol BS16 1LE, Avon, England; Burden Neurol Inst, Bristol BS16 1QT, Avon, England		Kane, NM (corresponding author), Frenchay Hosp, Grey Walter Dept Cin Neurophysiol, Bristol BS16 1LE, Avon, England.						BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Bolton C. F., 1998, COMA IMPAIRED CONSCI; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DEGIORGIO CM, 1993, ACTA NEUROL SCAND, V87, P423; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Folmer RL, 1997, BRAIN LANG, V56, P306, DOI 10.1006/brln.1997.1828; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; JONES SJ, IN PRESS ELECTROENCE; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; KANE NM, 1995, J PSYCHOPHYSIOL, V9, P183; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KANE NM, IN PRESS ELECTROENCE; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KEREN O, 1994, BRAIN INJURY, V8, P239, DOI 10.3109/02699059409150976; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; OMAHONY D, 1990, LANCET, V336, P1265, DOI 10.1016/0140-6736(90)92887-N; Ozbudak-Demir S, 1999, ARCH PHYS MED REHAB, V80, P252, DOI 10.1016/S0003-9993(99)90134-X; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P138, DOI 10.1016/0013-4694(86)90007-6; Prevec T., 1993, ELECTROENCEPHALOGR C, V87, pS130; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RAPPAPORT M, 1986, J HEAD TRAUMA REHABI, P00015, DOI DOI 10.1097/00001199-198603000-00005; Reuter B., 1989, TOPOGRAPHIC BRAIN MA, P192; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; SIGNORINO M, 1995, LANCET, V345, P255, DOI 10.1016/S0140-6736(95)90252-X; *SOC CRIT CAR MED, 1988, CRIT CARE MED, V16, P807; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O	37	47	47	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-3030			AUDIOL NEURO-OTOL	Audiol. Neuro-Otol.	MAY-AUG	2000	5	3-4					186	191		10.1159/000013879			6	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	326MR	WOS:000087739800006	10859412				2022-02-06	
J	Chan, RCK				Chan, RCK			Attentional deficits in patients with closed head injury: a further study to the discriminative validity of the test of everyday attention	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DEFICITS; SUBJECTIVE COMPLAINTS; RECOVERY; QUESTIONNAIRE; SYMPTOMS; AROUSAL	This study aimed to explore the attentional performance of patients with dosed head injury (CHI) and to examine the discriminative validity of the Test of Everyday Attention (TEA) in this clinical population. A sample of 21 patients with CHI was recruited for this study. Another sample of matched controls was also recruited for comparison. In addition, other clinical tests of attention and questionnaires on everyday life cognitive failures were also given to the participants during the assessment session. The results showed that patients with CHI exhibited significant differences in most of the TEA subtests, as well as clinical tests of attention, as compared with the matched controls. These findings suggest that the majority of the TEA subtests are able to discriminate out those patients with attentional deficits from the normal population in terms of sustained attention, selective attention, divided attention, and attentional switching.	Univ Hong Kong, Dept Psychol, Hong Kong, Hong Kong, Peoples R China		Chan, RCK (corresponding author), Univ Hong Kong, Dept Psychol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	ckrchan@hkusua.hku.hk	Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1997, J CLIN EXPT NEUROPSY, V19, P529; BLANCGARIN J, 1994, NEUROPSYCHOL REHABIL, V4, P359, DOI 10.1080/09602019408401606; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess PW., 1996, BEHAV ASSESSMENT DYS; CHAN RC, UNPUB VALIDATION CAN; CHAN RCK, 1999, 19 ANN C NAT AC NEUR; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Crawford JR, 1997, BRIT J CLIN PSYCHOL, V36, P609, DOI 10.1111/j.2044-8260.1997.tb01265.x; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldstein, 1996, ECOLOGICAL VALIDITY, P75; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; KERNS KA, 1996, ECOLOGICAL VALIDITY, P147; Levin H.S., 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Long, 1996, ECOLOGICAL VALIDITY, P15; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; PARASURAMAN R, 1984, VARIEITES ATTENTION; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBERTS A, 1990, EUR J NEUROSCI, V2, P11, DOI 10.1111/j.1460-9568.1990.tb00377.x; Robertson I., 1994, TEST EVERYDAY ATTENT; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; *U VICT NEUR LAB, STROOP TEST VICT VER; van Zomeren AH, 1994, CLIN NEUROPSYCHOL AT, P250; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	39	47	51	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2000	14	3					227	236		10.1080/026990500120709			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	294EE	WOS:000085897700003	10759040				2022-02-06	
J	Hanten, G; Bartha, M; Levin, HS				Hanten, G; Bartha, M; Levin, HS			Metacognition following pediatric traumatic brain injury: A preliminary study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; DEVELOPMENTAL-CHANGES; MEMORY VARIABLES; KNOWLEDGE; ORGANIZATION; METAMEMORY; ATTENTION	Metacognition is one of the cognitive processes included under the general term executive functions. The executive functions are widely held to be under the control of the prefrontal cortex, an area often damaged after severe traumatic brain injury (TBI). We examined the metacognitive processing of a group of 9 children with TBI, and a group of 9 healthy, age-matched control children. Children with TBI showed significant impairments in their accuracy of prediction of the ease with which an item would be learned and their ability to predict recall of an item after a 2-hr delay. No significant differences in recall performance between the TBI and control groups were exhibited. The results are interpreted as suggesting an impairment in metacognitive processing resulting from frontal lobe damage after TBI in children. Additional research is necessary to confirm the relation of frontal lobe pathology and severity of injury to metacognitive impairments.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Hanten, G (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin,Suite 1144, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Brown AL, 1978, ADV INSTRUCTIONAL PS, P367; BROWN AL, 1978, CHILDRENS THINKING D; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FLAVELL JH, 1970, COGNITIVE PSYCHOL, V1, P324, DOI 10.1016/0010-0285(70)90019-8; Flavell John H., 1981, CHILDRENS ORAL COMMU, P35; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; JANOWSKY JS, 1989, PSYCHOBIOLOGY, V17, P3; KEENEY TJ, 1967, CHILD DEV, V38, P953, DOI 10.1111/j.1467-8624.1967.tb04373.x; KENNEDY BA, 1976, CHILD DEV, V47, P566, DOI 10.2307/1128824; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; LEONESIO RJ, 1990, J EXP PSYCHOL LEARN, V16, P464, DOI 10.1037/0278-7393.16.3.464; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LYON TD, 1993, CHILD DEV, V64, P789, DOI 10.2307/1131218; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; METCALFE J, 1996, METACOGNITION KNOWIN; MOYNAHAN ED, 1973, CHILD DEV, V44, P238; ROGOFF B, 1974, CHILD DEV, V45, P972, DOI 10.2307/1128084; SHIMAMURA AP, 1986, J EXP PSYCHOL LEARN, V12, P452, DOI 10.1037/0278-7393.12.3.452; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; TEASDALE G, 1974, LANCET, V2, P81; WELLMAN HM, 1981, CHILD DEV, V52, P1313, DOI 10.2307/1129522; WELLMAN HM, 1978, DEV PSYCHOL, V14, P24, DOI 10.1037/0012-1649.14.1.24; YUSSEN SR, 1979, DEV PSYCHOL, V15, P447; [No title captured]	29	47	47	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2000	18	3					383	398		10.1207/S1532694206Hanten			16	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	432UW	WOS:000168714900006	11385831				2022-02-06	
J	Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Marion, DW; Ho, C				Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Marion, DW; Ho, C			Early perfusion after controlled cortical impact in rats: Quantification by arterial spin-labeled MRI and the influence of spin-lattice relaxation time heterogeneity	MAGNETIC RESONANCE IN MEDICINE			English	Article; Proceedings Paper	5th Scientific Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine	APR 12-18, 1997	VANCOUVER, CANADA	Int Soc Magnet Resonance Med		cerebral blood flow; spin-lattice relaxation time; magnetic resonance imaging (MRI); traumatic brain injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; PARTITION-COEFFICIENT; WATER-CONTENT; TRANSIT-TIME; INVERSION; IODOANTIPYRINE; HYPOTHERMIA; ISOFLURANE; ISCHEMIA	Early posttraumatic cerebral hypoperfusion is implicated in the evolution of secondary damage after experimental and clinical traumatic brain injury (TBI). This is the first report of cerebral blood flow (CBF) measurement by continuous arterial spin-labeled magnetic resonance imaging (MRI) early after TBI in rats using the controlled cortical impact (CCI) model. CGI reduced CBF globally at similar to 3 hr (versus normal), with 85% and 49% reductions in a contused cortical region and contralateral cortex, respectively. In contrast, a prior MRI study from this laboratory showed at 24 hr post trauma a focal CBF reduction restricted to the injury site. In vivo spin-lattice relaxation time (T-1obs), which is used in CBF quantification, was spatially heterogeneous early after CCI, a time when edema is developing in injured brain tissue. At 4.7 T, T-1obs values are increased 29% in the contusion (versus normal), consequently reducing CBF quantification to a similar degree. MRI should facilitate coupling posttraumatic CBF with long-term functional outcome. Magn Reson Med 42:673-681, 1999. (C) 1999 Wiley-Liss, Inc.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA		Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021; Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR003631, R01RR010962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR10962, RR03631] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS30318] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alsop DC, 1996, J CEREBR BLOOD F MET, V16, P1236, DOI 10.1097/00004647-199611000-00019; BESSON JAO, 1989, MAGN RESON IMAGING, V7, P141, DOI 10.1016/0730-725X(89)90696-6; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHI OZ, 1993, ANESTHESIOLOGY, V79, P299, DOI 10.1097/00000542-199308000-00015; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; DETRE JA, 1994, NMR BIOMED, V7, P75, DOI 10.1002/nbm.1940070112; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; HANSEN TD, 1988, ANESTHESIOLOGY, V69, P332, DOI 10.1097/00000542-198809000-00008; HENDRICH K, 1997, P ISMRM 5 ANN M VANC, P260; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JIANG Q, 1994, J CEREBR BLOOD F MET, V14, P732, DOI 10.1038/jcbfm.1994.94; KATAYAMA Y, 1997, P INTR PRESS NEUR BR, P6; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Pekar J, 1996, MAGNET RESON MED, V35, P70, DOI 10.1002/mrm.1910350110; Roberts DA, 1996, JMRI-J MAGN RESON IM, V6, P363, DOI 10.1002/jmri.1880060217; ROBERTS DA, 1994, P NATL ACAD SCI USA, V91, P33, DOI 10.1073/pnas.91.1.33; Schwab M, 1997, BRAIN RES, V749, P82, DOI 10.1016/S0006-8993(96)01165-1; Silva AC, 1997, MAGNET RESON MED, V38, P232, DOI 10.1002/mrm.1910380211; Strupp JP, 1996, NEUROIMAGE, V3, pS607, DOI DOI 10.1016/S1053-8119(96)80609-4; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Unterberg AW, 1997, ACT NEUR S, V70, P106; VANUITERT RL, 1981, BRAIN RES, V222, P365, DOI 10.1016/0006-8993(81)91039-8; WARNER DS, 1991, J CEREBR BLOOD F MET, V11, P794, DOI 10.1038/jcbfm.1991.137; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; WILLIAMS JL, 1991, AM J PHYSIOL, V261, pH252, DOI 10.1152/ajpheart.1991.261.1.H252; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Ye FQ, 1996, MAGNET RESON MED, V36, P219, DOI 10.1002/mrm.1910360208; Ye FQ, 1997, MAGN RESON MED, V37, P226, DOI 10.1002/mrm.1910370215; ZHANG WG, 1992, MAGNET RESON MED, V25, P362, DOI 10.1002/mrm.1910250216; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	40	47	48	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	OCT	1999	42	4					673	681		10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Radiology, Nuclear Medicine & Medical Imaging	242MG	WOS:000082944400008	10502755	Bronze			2022-02-06	
J	Mattsson, P; Meijer, B; Svensson, M				Mattsson, P; Meijer, B; Svensson, M			Extensive neuronal cell death following intracranial transection of the facial nerve in the adult rat	BRAIN RESEARCH BULLETIN			English	Article						proximal nerve transection; microglia; astroglia; oligodendroglia; nerve cell death	HYPOGLOSSAL NUCLEUS; NEUROTROPHIC FACTOR; MOTOR-NEURONS; NITRIC-OXIDE; MOTONEURON DEATH; GLIAL REACTION; TOXIC RICIN; AXOTOMY; INJURY; SURVIVAL	The aim of the present study is to examine the neuronal degeneration and the glial response following intracranial transection of the facial nerve close to the brainstem and furthermore to compare the results with a distal nerve injury, The facial nerve was cut either intracranially in the posterior cranial fossa or further distally, where it passes the parotid gland, in adult rats. Intracranial axotomy caused a massive loss of neuronal profiles, Only 26.8 +/- 11.3% of facial motor neuronal profiles were found ipsilateral to the nerve injury when compared to the contralateral side, following intracranial axotomy, This was statistically significant in comparison to the distal injury (72.4 +/- 9.5%), 4 weeks post-lesion, Reactive microglial cells expressed ED1 immunoreactivity following the intracranial axotomy but not following the distal nerve injury. In conclusion, there was a large discrepancy in neuronal degeneration as well as presence of phagocytic (ED1 positive) microglia between the two lesions. The intracranial lesion model used in the present study generates a massive neuronal cell death and should therefore be a useful tool for studies on proximal cranial nerve injuries and in particular mechanisms causing cell death, which may occur following, for example, head trauma. (C) 1999 Elsevier Science Inc.	Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden		Mattsson, P (corresponding author), Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden.		Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003			ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALDSKOGIUS H, 1980, J COMP NEUROL, V193, P165, DOI 10.1002/cne.901930111; ALDSKOGIUS H, 1993, ADV STRUCTURAL BIOL, V2, P191; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Cajal Y, 1928, DEGENERATION REGENER; COLTON CA, 1993, ADV NEUROL, V59, P321; CRAGG BG, 1970, BRAIN RES, V23, P1, DOI 10.1016/0006-8993(70)90345-8; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVIES DC, 1977, J ANAT, V127, P43; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FERNANDEZ HL, 1981, NEUROSCI LETT, V25, P7, DOI 10.1016/0304-3940(81)90092-6; FUNKOSHI H, 1993, J CELL BIOL, V123; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; HARDY DG, 1997, BRIT J NEUROSURG, V11, P455; Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367; KOLIATSOS VE, 1994, J COMP NEUROL, V342, P35, DOI 10.1002/cne.903420105; Kreutzberg GW, 1997, BRAIN PATHOL, V7, P1231; KREUTZBERG GW, 1989, METAB BRAIN DIS, V4, P81, DOI 10.1007/BF00999498; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; Lieberman AR., 1974, ESSAYS NERVOUS SYSTE, P71; LINDA H, 1993, STUDIES SPINAL MOTON; LUNN ER, 1990, NEUROSCIENCE, V35, P157, DOI 10.1016/0306-4522(90)90130-V; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; POLLIN MM, 1991, DEVELOPMENT, V112, P83; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; RUAN RS, 1995, BRAIN RES, V698, P163, DOI 10.1016/0006-8993(95)00887-V; RUAN RS, 1994, ACTA OTO-LARYNGOL, V114, P271, DOI 10.3109/00016489409126055; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SINGER PA, 1982, J NEUROSCI, V2, P1299; SJOSTRAND J, 1971, EXP NEUROL, V30, P178, DOI 10.1016/0014-4886(71)90232-9; SNIDER WD, 1992, J NEUROBIOL, V23, P1231, DOI 10.1002/neu.480230913; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; SVENSSON M, 1993, BRAIN RES BULL, V30, P499, DOI 10.1016/0361-9230(93)90284-I; SVENSSON M, 1993, EUR J NEUROSCI, V5, P85, DOI 10.1111/j.1460-9568.1993.tb00208.x; SVENSSON M, 1993, GLIA, V7, P286, DOI 10.1002/glia.440070404; SVENSSON M, 1992, J NEUROIMMUNOL, V40, P99, DOI 10.1016/0165-5728(92)90217-9; SVENSSON M, 1994, J ANAT, V185, P537; SWETT JE, 1991, J COMP NEUROL, V304, P234, DOI 10.1002/cne.903040207; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; THOENEN H, 1980, PHYSL REV, V60; Tornquist E, 1997, NEUROSCI RES, V28, P167, DOI 10.1016/S0168-0102(97)00040-0; TORNQVIST E, 1994, J NEUROSCI RES, V39, P159, DOI 10.1002/jnr.490390206; TORVIK A, 1975, BRAIN RES, V95, P519, DOI 10.1016/0006-8993(75)90125-0; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; Wu W., 1995, Society for Neuroscience Abstracts, V21, P279; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YU WHA, 1988, EXP NEUROL, V102, P230, DOI 10.1016/0014-4886(88)90098-2	54	47	51	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	JUL 15	1999	49	5					333	341		10.1016/S0361-9230(98)00178-6			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	222DU	WOS:000081768800004	10452353				2022-02-06	
J	Daniel, JC; Olesniewicz, MH; Reeves, DL; Tam, D; Bleiberg, J; Thatcher, R; Salazar, A				Daniel, JC; Olesniewicz, MH; Reeves, DL; Tam, D; Bleiberg, J; Thatcher, R; Salazar, A			Repeated measures of cognitive processing efficiency in adolescent athletes: Implications for monitoring recovery from concussion	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article							MILD HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT	Objective: The objective of this study was to determine whether an adolescent athlete, in the absence of concussion, would be expected to show an improvement in cognitive function during the course of a high school football season. Background: At least 60,000 American high school football players suffer cerebral concussion every year, and symptoms may persist for 4 or more years in as many as 24%. Method: 34 members of a cohort of healthy athletes, aged 13-18, were administered a computerized neuropsychologic test battery from the Automated Neuropsychological Assessment Metrics (ANAM) before and after the 1997 high school football season, with a mean interval of 16.1 (range 12.3-20.4) weeks between tests. Preseason and postseason scores on eight tests were compared, with significance determined by paired t-test. For those tests in which an improvement was noted, one-way analysis of variance and Wilcoxon tests were used with both preseason and postseason data to determine if there was a measurable difference in cognitive processing efficiency between older and younger subjects. Results: Improvements in processing efficiency (p < 0.001) were noted on tests designed to measure visual scanning and sustained attention (CDS), immediate recall (CDI), and short-term memory (CDD). Older subjects generally performed better on each of these tests, though the difference was significant in only one case (postseason CDI, 17-18 year olds vs. 13-14 year olds, Wilcoxon, p = 0.043). Conclusions: Our findings suggest that ANAM is sensitive to differences and improvements in cognitive function during a 4 month interval in adolescence. They also suggest that using "return to baseline" cognitive function as the criterion for evidence of recovery from concussion may be insufficient, especially when the baseline measurement was obtained 4 or more months prior to the date of "full recovery."	USN, Med Ctr, Med Editing Div, Dept Clin Res, San Diego, CA 92134 USA; USN, Med Ctr, Dept Pediat, Adolescent Med Div, San Diego, CA 92134 USA; Uniformed Serv Univ Hlth Sci, Dept Family Med, Bethesda, MD 20814 USA; Univ Calif San Diego, Dept Family & Prevent Med, Sch Med, San Diego, CA 92103 USA; Henry M Jackson Fdn, Rockville, MD USA; USN, Med Ctr, Dept Pediat, Child Neurol Div, San Diego, CA 92152 USA; Natl Rehabil Hosp, Psychol Serv, Washington, DC USA; Vet Affairs Med Ctr, Med Res & Dev Serv, Bay Pines, FL USA; Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA		Daniel, JC (corresponding author), USN, Med Ctr, Med Editing Div, Dept Clin Res, Code AVA,34800 Bob Wilson Dr, San Diego, CA 92134 USA.						Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Fischer K. W., 1996, DEV NEUROIMAGING MAP, P263; GASTALDO E, 1997, ANAM NORMATIVE DATA; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; POWELL JW, 1997, SPORTS REL CONC NERV; Reeves DL., 1997, NEUROPSYCHOLOGY HDB, V1, P423; THATCHER RW, 1998, CORRELATIONS EEG MRI; YACOVLEV PI, 1967, REGIONAL DEV BRAIN E, P3	16	47	49	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	JUL	1999	12	3					167	169					3	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	224LF	WOS:000081900000005	10456800				2022-02-06	
J	Royo, NC; Wahl, F; Stutzmann, JM				Royo, NC; Wahl, F; Stutzmann, JM			Kinetics of polymorphonuclear neutrophil infiltration after a traumatic brain injury in rat	NEUROREPORT			English	Article						inflammation; leukocytes; myeloperoxydase; polymorphonuclear; traumatic brain injury	ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; CEREBRAL-ISCHEMIA; INFLAMMATION; ACCUMULATION; RECRUITMENT; LEUKOCYTES; RILUZOLE; TISSUE; EDEMA	THE aim of our study was to assess polymorphonuclear neutrophil infiltration into the injured parenchyma after a traumatic brain injury (TBI). Myeloperoxidase (MPO) activity was assayed on the hippocampus, temporal and parietal cortex 6, 24, 48, 72, and 120 h post-trauma. MPO activity occurred in these structures from 6 h post-trauma and was maximum at 24-48 h. It was resolved by 72 h in the hippocampus and the parietal cortex, but persisted in the temporal cortex until 120 h after trauma. This suggests that neutrophil infiltration is a delayed phenomenon in the physiopathology of TBI. Considering that a large therapeutic window may be crucial in the management of TBI, inhibition of neutrophil infiltration needs to be further investigated following cerebral trauma. (C) 1999 Lippincott Williams & Wilkins.	Rhone Poulenc Rorer SA, Pharmaceut Discovery, Ischemia Trauma Dept, Vitry Sur Seine, France		Wahl, F (corresponding author), Rhone Poulenc Rorer SA, Pharmaceut Discovery, Ischemia Trauma Dept, 13 Quai Jules Guesde, Vitry Sur Seine, France.						Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YUI Y, 1991, J BIOL CHEM, V266, P3369	24	47	49	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	APR 26	1999	10	6					1363	1367		10.1097/00001756-199904260-00038			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	199NH	WOS:000080488200039	10363954				2022-02-06	
J	Geurts, ACH; Knoop, JA; van Limbeek, J				Geurts, ACH; Knoop, JA; van Limbeek, J			Is postural control associated with mental functioning in the persistent postconcussion syndrome?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; MILD HEAD; SWAY; BALANCE; STABILITY; RECOVERY	Objective: To investigate whether balance is associated with mental functioning after mild traumatic brain injury (MTBI). Design: Experimental two-group design. Setting: Outpatient rehabilitation department. Patients and Other Participants: From a consecutive sample of referred MTBI patients, 15 subjects who complained of imbalance were included (8 men and 7 women, age 35.9 +/- 8.6yrs), Subjects with detectable neurologic impairments were excluded. Twenty healthy control subjects of the same age group also were tested. Main Outcome Measures: In both groups, a force platform recorded center-of-pressure (CP) fluctuations during standing and weight shifting in different conditions. For the patients, attention and mental speed were assessed with the Symbol-Digit Substitution Test of the Wechsler Adult Intelligence Scale (Dutch version), verbal learning and memory were assessed with the 15-Words Test, and emotional distress was assessed with the Symptom Checklist-90. Results: Compared with controls, patients showed an overall increase of 60% in CP velocity and an overall weight-shifting speed 25% slower (p <.005), indicating static and dynamic postural instability. Only performance on the Symbol-Digit Substitution Test was associated with both static and dynamic balance (p <.02), giving an explained variance of over 40%. Conclusion: The results indicate a possible association of balance with cognitive performance but not with emotional well-being after MTBI, suggesting an organic rather than a functional cause of postural instability. Further research is needed to assess the possible clinical implications. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Sint Maartensklin, Dept Rehabil Med, NL-6500 GM Nijmegen, Netherlands; Sint Maartensklin, Dept Res & Dev, NL-6500 GM Nijmegen, Netherlands; Sint Maartensklin, Dept Clin Neuropsychol, NL-6500 GM Nijmegen, Netherlands		Geurts, ACH (corresponding author), Sint Maartensklin, Dept Rehabil Med, POB 9011, NL-6500 GM Nijmegen, Netherlands.		Knoop, Hans/D-3264-2009; Geurts, Alexander/H-8032-2014	Knoop, Hans/0000-0001-7763-3517; Geurts, Alexander/0000-0001-7478-1119			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; BERG IJ, 1993, THESIS U GRONINGEN N; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bickerstaff ER, 1989, NEUROLOGICAL EXAMINA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; *DEP NEUR U HOSP G, 1986, 15 WORDS TESTS A B D; Ettema J.H.M., 1986, SCL 90 MANUAL MULTID; GEURTS ACH, 1993, ARCH PHYS MED REHAB, V74, P1144; GEURTS ACH, 1994, J MOTOR BEHAV, V26, P162, DOI 10.1080/00222895.1994.9941670; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; INGERSOLL CD, 1993, SPORTS MED, V16, P342, DOI 10.2165/00007256-199316050-00005; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kleinbaum DG., 1988, APPL REGRESSION ANAL; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M.D., 1987, NEUROPSYCHOL REHABIL, P41; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MAYO NE, 1991, AM J PHYS MED REHAB, V70, P118, DOI 10.1097/00002060-199106000-00002; Newton R, 1989, Brain Inj, V3, P335, DOI 10.3109/02699058909004558; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUBIN AM, 1995, AM J OTOL, V16, P216; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; STINISSEN W, 1970, MANUAL DUTCH VERSION; Swaine BR, 1996, BRAIN INJURY, V10, P263, DOI 10.1080/026990596124449; TEASDALE G, 1974, LANCET, V2, P81; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	38	47	47	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1999	80	2					144	149		10.1016/S0003-9993(99)90111-9			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	165YG	WOS:000078549000004	10025487				2022-02-06	
J	Shreiber, DI; Bain, AC; Ross, DT; Smith, DH; Gennarelli, TA; McIntosh, TK; Meaney, DF				Shreiber, DI; Bain, AC; Ross, DT; Smith, DH; Gennarelli, TA; McIntosh, TK; Meaney, DF			Experimental investigation of cerebral contusion: Histopathological and immunohistochemical evaluation of dynamic cortical deformation	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						biomechanics; brain injury; cerebral contusion	TRAUMATIC BRAIN INJURY; ACUTE SUBDURAL-HEMATOMA; EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; MISSILE HEAD-INJURY; RAT; MECHANISMS; INDEX	We used a new approach, termed dynamic cortical deformation (DCD), to study the neuronal, vascular, and glial responses that occur in focal cerebral contusions. DCD produces experimental contusion by rapidly deforming the cerebral cortex with a transient, nonablative vacuum pulse of short duration (25 milliseconds) to mimic the circumstances of traumatic injury. A neuropathological evaluation was performed on brain tissue from adult rats sacrificed 3 days following induction of either moderate (4 psi, n = 6) or high (8 psi, n = 6) severity DCD. In all animals, DCD produced focal hemorrhagic lesions at the vacuum site without overt damage to other regions. Examination of histological sections showed localized gross tissue and neuronal loss in the cortex at the injury site, with the volume of cell loss dependent upon the mechanical loading (p < 0.001). Axonal pathology shown with neurofilament immunostaining (SMI-31 and SMI-32) was observed in the subcortical white matter inferior to the injury site and in the ipsilateral internal capsule. No axonal injury was observed in the contralateral hemisphere or in any remote regions. Glial fibrillary acidic protein (GFAP) immunostaining revealed widespread reactive astrocytosis surrounding the necrotic region in the ipsilateral cortex. This analysis confirms that rapid mechanical deformation of the cortex induces focal contusions in the absence of primary damage to remote areas 3 days following injury. Although it is suggested that massive release of neurotoxic substances from a contusion may cause damage throughout the brain, these data emphasize the importance of combined injury mechanisms, e.g. mechanical distortion and excitatory amino acid mediated damage, that underlie the complex pathology patterns observed in traumatic brain injury.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.		Shreiber, David/ABE-8254-2021; smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122; Shreiber, David/0000-0001-8248-419X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS035712] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG122527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS35712, P01 NS-08803] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ADAMS JH, 1985, SCI FDN NEUROLOGY; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CERVOSNAVARRO J, 1991, J NEUROL SCI, V102, pS3; CHOI DW, 1987, J NEUROSCI, V7, P357; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; Eacott MJ, 1995, CRIT REV NEUROBIOL, V9, P311; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1985, NEUROSURGERY, P1531; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; MATHEW P, 1994, ACTA NEUROCHIR, P428; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; ROSS DT, 1992, SOC NEUR ABSTR, P1088; SHREIBER DI, 1996, J NEUROTRAUM, V13, P595; Smith D H, 1995, New Horiz, V3, P562; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	33	47	47	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	1999	58	2					153	164		10.1097/00005072-199902000-00005			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	172BW	WOS:000078903300005	10029098	Bronze			2022-02-06	
J	Barnes, MP				Barnes, MP			Rehabilitation after traumatic brain injury	BRITISH MEDICAL BULLETIN			English	Article							UPPER EXTREMITY SPASTICITY; SEVERE HEAD-INJURY; EARLY INTERVENTION; CONTROLLED TRIAL; BOTULINUM TOXIN; FOLLOW-UP; RELATIVES; EFFICACY	Head injury is a common disabling condition but regrettably facilities for rehabilitation are sparse. There is now increasing evidence of the efficacy of a comprehensive multidisciplinary rehabilitation team compared to natural recovery following brain injury. This chapter outlines some basic concepts of rehabilitation and emphasises the importance of valid and reliable outcome measures. The evidence of the efficacy of a rehabilitation programme is discussed in some detail. A number of specific rehabilitation problems are outlined including the management of spasticity, nutrition, pressure sores and urinary continence. The increasingly important role of assistive technology is illustrated, particularly in terms of communication aids and environmental control equipment. However, the major long-term difficulties after head injury focus around the cognitive, intellectual, behavioural and emotional problems. The complex management of these disorders is briefly addressed and the evidence of the efficacy of some techniques discussed. The importance of recognition of the vegetative state and avoidance of misdiagnosis is emphasised. Finally, the important, but often neglected, area of employment rehabilitation is covered.	Univ Newcastle Upon Tyne, Hunters Moor Reg Neurorehabil Ctr, Acad Unit Neurol Rehabil, Newcastle Upon Tyne NE2 4NR, Tyne & Wear, England		Barnes, MP (corresponding author), Univ Newcastle Upon Tyne, Hunters Moor Reg Neurorehabil Ctr, Acad Unit Neurol Rehabil, Hunters Rd, Newcastle Upon Tyne NE2 4NR, Tyne & Wear, England.						Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Bader DL, 1990, PRESSURE SORES CLIN; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; BROOKS DN, 1984, CLOSED HEAD INJURY P; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FOSTER HG, 1989, PROG NEURO-PSYCHOPH, V13, P865, DOI 10.1016/0278-5846(89)90038-9; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850; GRANGER CV, 1986, GUIDE USE UNIFORM DA; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; LIPIDES J, 1974, J UROLOGY, V111, P184; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MATTES JA, 1985, AM J PSYCHIAT, V142, P1108; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; Semlyen JK, 1997, J NEUROL REHABIL, V11, P213; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SIMPSON DM, 1986, J CLIN PSYCHIAT, V47, P191; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; TENNANT A, 1995, TRAUMATIC BRAIN INJU; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Turner-Stokes L, 1998, CLIN REHABIL, V12, P304, DOI 10.1191/026921598669173600; Wade D, 1992, MEASUREMENT NEUROLOG; Wade D T, 1988, Int Disabil Stud, V10, P64; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1984, CLIN MANAGEMENT MEMO; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	38	47	49	0	6	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND	0007-1420			BRIT MED BULL	Br. Med. Bull.		1999	55	4					927	943		10.1258/0007142991902727			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	272YD	WOS:000084678300016	10746340	Bronze			2022-02-06	
J	Vukic, M; Negovetic, L; Kovac, D; Ghajar, J; Glavic, Z; Gopcevic, A				Vukic, M; Negovetic, L; Kovac, D; Ghajar, J; Glavic, Z; Gopcevic, A			The effect of implementation of guidelines for the management of severe head injury on patient treatment and outcome	ACTA NEUROCHIRURGICA			English	Article						severe head injury; intracranial pressure monitoring; the implementation of Guidelines	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CEREBRAL PERFUSION-PRESSURE; POST-TRAUMATIC SEIZURES; INTRACRANIAL-PRESSURE; CLINICAL-TRIAL; BRAIN INJURY; FAILURE; COMA; MANNITOL; SCALE	The authors retrospectively analysed two groups of consecutive patients who were similarly matched for brain injury severity. From a total of 39 severe head injury patients, 23 were treated according to the Guidelines for the Management of Severe Severe Head Injury with intracranial pressure (ICP) monitoring ("Guidelines group"). Such an approach allowed the maintenance of ICP within normal values, especially in patients with intraventricular ICP monitoring allowing the release of cerebrospinal fluid (CSF) From the ventricular system. In the Guidelines group only two patients were administered barbiturates, after all other means of ICP lowering had been exhausted. The second group consisted of 16 patients who were not monitored for ICP ("non-Guidelines group"). In this group, management consisted of the prophylactic administration of barbiturates, high dose osmotic diuretics and hyperventilation usually at levels below 25 mm Hg. In the Guidelines group the mortality rate was 30% compared to 44% in the non-Guidelines group. Almost twice as many patients achieved a "favourable" (good recovery and moderate disability) outcome (49%) compared to the non-Guidelines treated patients (25%). Furthermore, there was a 32% decrease in severe neurological disabilities in those patients in the Guidelines group. It seems that the implementation of "Guidelines" in the treatment of severe head injury, based on the result of our clinical study, reduces death and disability rates in patients with severe head injury. The administration of therapy based on the "Guidelines principles" and monitoring of ICP, can minimise the application of those therapeutic modalities (barbiturate coma and prolonged hyperventilation) which, in addition to favourable effects, may also have harmful effects on patients with severe head injury.	Sisters Mercy Univ Hosp, Dept Neurosurg, Zagreb 10000, Croatia; Cornell Univ, Weill Med Coll, Div Neurosurg, New York, NY USA; Aitken Neurosci Ctr, New York, NY USA; Pozega Gen Hosp, Dept Surg, Pozega, Croatia; Sisters Mercy Univ Hosp, Dept Anesthesiol, Zagreb 10000, Croatia		Vukic, M (corresponding author), Sisters Mercy Univ Hosp, Dept Neurosurg, Vinogradska 29, Zagreb 10000, Croatia.		Pozega, County Hospital/X-7568-2019				BECKER DP, 1987, TXB HEAD INJURY, P192; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; Bullock R, 1995, GUIDELINES MANAGEMEN; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1992, P AM ASS NEUR SURG S; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; GULLIAUME J, 1951, REV NEUROL, V84, P131; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENETT B, 1975, LANCET, V1, P480; KOVAC D, 1987, ACTA CHIR JUGOSLAV S, V34, P73; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MURRAY LS, 1993, LANCET, V341, P1478; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; WARD JD, 1985, J NEUROSURG, V69, P15; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	33	47	49	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1999	141	11					1203	1208		10.1007/s007010050419			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	258BH	WOS:000083817800020	10592121				2022-02-06	
J	Levin, HS				Levin, HS			Cognitive function outcomes after traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article							CLOSED-HEAD-INJURY	Investigations of cognitive recovery from traumatic brain injury have utilized experimental cognitive tasks, including measures of executive function and discourse processing, to elucidate specific sequelae, The scope of research, which includes brain imaging and pharmacologic intervention, could potentially enhance rehabilitation of patients with brain injury. Curr Opin Neurol 11:643-646. (C) 1998 Lippincott Williams & Wilkins.	Baylor Coll Med, Phys Med & Rehab Res Off, Houston, TX 77030 USA		Levin, HS (corresponding author), Baylor Coll Med, Phys Med & Rehab Res Off, 1333 Moursund Ave,Room A205, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu					Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Eslinger P. J, 1996, ATTENTION MEMORY EXE, P367; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; GRONWALL D, 1974, LANCET, V2, P605; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9	15	47	47	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	1998	11	6					643	646		10.1097/00019052-199812000-00006			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	148EC	WOS:000077490900006	9870131				2022-02-06	
J	Smith, SL; Andrus, PK; Gleason, DD; Hall, ED				Smith, SL; Andrus, PK; Gleason, DD; Hall, ED			Infant rat model of the shaken baby syndrome: Preliminary characterization and evidence for the role of free radicals in cortical hemorrhaging and progressive neuronal degeneration	JOURNAL OF NEUROTRAUMA			English	Article						cortical hemorrhaging; free radicals; shaken baby syndrome; tirilazad mesylate	TRAUMATIC BRAIN INJURY; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; TIRILAZAD MESYLATE U-74006F; ENERGY PHOSPHATE-METABOLISM; EXPERIMENTAL HEAD-INJURY; MAJOR CEREBRAL-ARTERIES; EXCITATORY AMINO-ACIDS; BARRIER DISRUPTION; HYPOXIA-ISCHEMIA; LIPID-PEROXIDATION	Infants subjected to repeated episodes of violent shaking develop brain damage characterized by intracranial hemorrhage and progressive cortical atrophy. We have developed an animal model that mimics this pathological state and investigated its etiology and treatment. Anesthetized male rats, 6 days of age, were subjected to one episode of shaking per day for 3 consecutive days. Separate groups of rats were sacrificed 1 h postinjury on the third day of shaking for HPLC quantification of cortical . OH and vitamin E levels, and histological assessment of cortical hemorrhaging. Additional groups were sacrificed 7 or 14 days postinjury to demonstrate progressive neuronal degeneration via cortical wet weight comparisons. In comparison to noninjured shams, the results indicated that cortical vitamin E and . OH levels rose 53.7% (p < 0.005) and 457.1% (p < 0.001), respectively, in shaken infant rats. Brain histologies revealed a moderate-to-severe degree of cortical hemorrhaging in these animals 1 h postinjury. By 7 and 14 days postinjury, there was a 13.3% and 28.7% (p < 0.0001 vs. sham) loss of cortical tissue in shaken infants, respectively, indicating progressive neuronal degeneration. Treatment with 10 mg/kg (ip) of the 21-aminosteroid antioxidant, tirilazad mesylate, 10 min before and 2 h after each episode of shaking, resulted in a 53.1% attenuation of cortical . OH levels and a 34.9% decrease in brain hemorrhaging (p < 0.05 vs, vehicle). Tirilazad treatment did not, however, significantly effect cortical vitamin E concentrations at 1 h postinjury or the extent of progressive neuronal degeneration at either 7 or 14 days postinjury. The present animal model mimics the brain pathology seen in abused children. Our observation that tirilazad mesylate, an antioxidant-lipid peroxidation inhibitor, significantly reduces cortical . OH levels and brain hemorrhaging in shaken infant rats supports a role for oxygen radicals in the pathophysiology of this type of CNS injury. The failure of tirilazad to block progressive cortical degeneration suggests that mechanisms other than free radicals may be of prime importance in the mediation of this aspect of the pathology.	Pharmacia & Upjohn Inc, CNS Dis Res, Kalamazoo, MI 49001 USA		Smith, SL (corresponding author), Pharmacia & Upjohn Inc, CNS Dis Res, 7251-209-4,301 Henrietta St, Kalamazoo, MI 49001 USA.		Hall, Edward D/F-8930-2013				ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER RC, 1989, RADIOLOGY, V173, P653; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANDINE P, 1990, J NEUROSCI METH, V35, P253, DOI 10.1016/0165-0270(90)90131-X; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; Bagenholm R, 1996, PEDIATR RES, V40, P399, DOI 10.1203/00006450-199609000-00006; Bostrom K, 1992, Acta Neurochir Suppl (Wien), V55, P25; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; DEHAIME AC, 1996, NEUROLOGICAL SURG, V3, P1777; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Duhaime AC, 1988, J PEDIAT NEUROSCI, V4, P77; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRANCEL PC, 1996, NEUROLOGICAL SURG, V3, P1730; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENTLEMAN D, 1992, INT SURG, V77, P297; GILLAND E, 1994, DEV BRAIN RES, V83, P79, DOI 10.1016/0165-3806(94)90181-3; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; GRAFE MR, 1994, BRAIN RES, V653, P161, DOI 10.1016/0006-8993(94)90385-9; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAGBERG H, 1994, BIOL NEONATE, V66, P205; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1996, EUR J ANAESTH, V13, P279, DOI 10.1046/j.1365-2346.1996.00980.x; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1997, HDB SYNTHETIC ANTIOX, P261; Hall ED, 1993, IRON CENTRAL NERVOUS, P173; HINZMANN JS, 1992, CHEM PHYS LIPIDS, V62, P123, DOI 10.1016/0009-3084(92)90090-C; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KANAMARU K, 1991, J NEUROSURG, V74, P454, DOI 10.3171/jns.1991.74.3.0454; LIAU LM, 1996, NEUROLOGICAL SURG, V3, P1549; MACHLIN LJ, 1982, ANN NY ACAD SCI, V393, P48, DOI 10.1111/j.1749-6632.1982.tb31231.x; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1989, EXP NEUROL, V106, P289, DOI 10.1016/0014-4886(89)90162-3; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Povlishock John T., 1993, P185; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; SASAKI T, 1986, NEUROSURGERY, V19, P177, DOI 10.1227/00006123-198608000-00002; SASAKI T, 1985, J NEUROSURG, V63, P433, DOI 10.3171/jns.1985.63.3.0433; SCHMIDT I, 1987, CAN J PHYSIOL PHARM, V65, P1355, DOI 10.1139/y87-214; SILVERSTEIN FS, 1986, STROKE, V17, P477, DOI 10.1161/01.STR.17.3.477; Smith SL, 1996, J NEUROSURG, V84, P229, DOI 10.3171/jns.1996.84.2.0229; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SPAIDE RF, 1990, AM FAM PHYSICIAN, V41, P1145; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; WHYTE K M, 1989, Australasian Radiology, V33, P344, DOI 10.1111/j.1440-1673.1989.tb03308.x; ZHANG JR, 1993, J NEUROCHEM, V61, P1640, DOI 10.1111/j.1471-4159.1993.tb09798.x; ZUCCARELLO M, 1989, STROKE, V20, P367, DOI 10.1161/01.STR.20.3.367	57	47	49	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1998	15	9					693	705		10.1089/neu.1998.15.693			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	118ZT	WOS:000075871400005	9753217				2022-02-06	
J	Umile, EM; Plotkin, RC; Sandel, ME				Umile, EM; Plotkin, RC; Sandel, ME			Functional assessment of mild traumatic brain injury using SPECT and neuropsychological testing	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; CEREBRAL BLOOD-FLOW; HM-PAO-SPECT; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; MOOD DISORDERS; EMISSION TOMOGRAPHY; CT; CONCUSSION; PERFORMANCE	The aim of this study was to ascertain whether SPECT and neuropsychological testing provide converging evidence of normal and abnormal regional cerebral function in patients with mild traumatic brain injury (mTBI). Four patients with mTBI were evaluated with SPECT and selected neuropsychological tests with putative localizing capabilities to specific cortical regions. The performance of each patient on each test was graded as either normal or abnormal. Additionally, SPECT images were graded for normal and/or abnormal patterns of regional cerebral blood now (rCBF) in eight regions of the cortex. These data were then used to predict outcomes from one modality to the other, i.e. rCBF patterns on SPECT were used to predict either normal or abnormal performance on specific tests and performance on specific tests was used to predict the presence or absence of rCBF abnormalities on SPECT. Statistical analysis of composite data from all four patients showed that test performance predicted SPECT findings, but SPECT findings did not predict test performance.	Univ Penn, Med Ctr, Dept Rehabil Med, Philadelphia, PA 19104 USA; Kaiser Permanente Med Ctr, Kaiser Fdn Rehabil Ctr, Vallejo, CA 94589 USA		Umile, EM (corresponding author), Univ Penn, Med Ctr, Dept Rehabil Med, 6 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ABDELDAYEM HM, 1994, EUROPEAN J NUCL MED, V21, P750; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; AUSTIN MP, 1992, J AFFECT DISORDERS, V26, P31, DOI 10.1016/0165-0327(92)90032-2; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENTON AL, 1989, MULTILINGUAL ALPHASI, P14; BENTON AL, 1994, CONTIRUBIONS NEUROPS; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FUMEYA H, 1990, ACT NEUR S, V51, P283; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GEORGE MS, 1993, J CLIN PSYCHIAT, V54, P6; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GONCALVES JM, 1992, ACTA NEUROCHIRURGI S, V51, P11; GRAY BG, 1992, J NUCL MED, V33, P52; GRAY KF, 1994, LOCALIZATION NEUROIM, P621; GRONWALL D, 1974, LANCET, V2, P605; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1981, MANUAL WISCONSIN CAR; Holbourn AHS, 1943, LANCET, V2, P438; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KAY T, 1992, Neurology, V42, P411; KELLNER CH, 1991, BIOL PSYCHIAT, V29, pS564; KIERNAN RJ, 1976, J CONSULT CLIN PSYCH, V44, P951, DOI 10.1037/0022-006X.44.6.951; LEHMAN RS, 1991, STAT RES DESIGN BEHA, P476; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Masdeu J C, 1994, J Neuroimaging, V4, P177; MAYBERG H S, 1991, Journal of Nuclear Medicine, V32, P951; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRAYER L, 1993, ACTA RADIOL, V34, P593; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROPER SN, 1991, J NUCL MED, V32, P1684; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SACKEIM HA, 1990, ARCH GEN PSYCHIAT, V47, P60; TRAHAN DE, 1987, J CLIN EXP NEUROPSYC, V9, P52; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Trites R. L., 1977, NEUROPSYCHOLOGICAL T; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler D, 1987, MEMORY SCALE REVISED; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	62	47	47	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1998	12	7					577	594					18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200004	9653521				2022-02-06	
J	Okiyama, K; Smith, DH; White, WF; McIntosh, TK				Okiyama, K; Smith, DH; White, WF; McIntosh, TK			Effects of the NMDA antagonist CP-98,113 on regional cerebral edema and cardiovascular, cognitive, and neurobehavioral function following experimental brain injury in the rat	BRAIN RESEARCH			English	Article						cerebral edema; fluid-percussion brain injury; ifenprodil; memory; neurologic motor function; NMDA receptor blocker	METHYL-D-ASPARTATE; RECEPTOR ANTAGONISTS; GLUTAMATE RELEASE; H-3 IFENPRODIL; BINDING; SL-82.0715; POLYAMINES; AGENTS; DAMAGE; ACID	The present study examined the effects of CP-98,113, an N-methyl-D-aspartate (NMDA) receptor blocker, on cardiovascular variables, neurobehavioral motor function, spatial memory deficits, and cerebral edema formation following lateral (parasagittal) fluid-percussion (EP) brain injury in the rat. In Study 1, we compared the cardiovascular effects of i.p. administration of CP-98,113 at 15 min postinjury at doses of 1 mg/kg, 2 mg/kg, 5 mg/kg, or 20 mg/kg (n = 8/dose). Animals receiving 1 mg/kg to 5 mg/kg CP-98,113 showed slight but nonsignificant decreases in blood pressure, while those receiving the highest dose (20 mg/kg) showed significant hypotension. Based upon those observations, the 5 mg/kg dose was chosen as the optimal dose for subsequent behavioral studies. In Study 2, 15 min following lateral FP brain injury of moderate severity (2.5 atm), animals randomly received either CP-98,113 (5 mg/kg, i.p., n = 23) followed by a 24-h subcutaneous infusion (1.5 mg kg(-1) h(-1)) by means of a miniature osmotic pump, or identical volume of vehicle (n = 24), and were evaluated for neurologic motor function (n = 11/drug vs. 11/vehicle), memory function, and cerebral edema (n = 12/drug vs. 13/vehicle). CP-98,113 (5 mg/kg) significantly attenuated neurologic motor dysfunction at 24 h (p < 0.01) and 2 weeks (p < 0.05) postinjury, reduced posttraumatic impairment in spatial memory observed at 48 h postinjury (p < 0.001), and significantly reduced focal brain edema in the cortex adjacent to the site of maximal injury at 48 h postinjury (injury penumbra) (p < 0.001). These results suggest that blockade of the NMDA receptor may attenuate the deleterious sequelae of traumatic brain injury. (C) 1998 Elsevier Science B.V.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	mcintosh@eniac.seas.upenn.edu	smith, douglas/A-1321-2007		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R0I-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0I-NS26818, P0I-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CARRON C, 1971, ARZNEI-FORSCHUNG, V21, P1992; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CARTER CJ, 1992, MOL NEUROPHARMACOL, V2, P107; CHAN PH, 1990, ACT NEUR S, V51, P7; CHENARD BL, 1991, J MED CHEM, V34, P3085, DOI 10.1021/jm00114a018; CHOI DW, 1988, J NEUROSCI, V8, P185; COOK P, 1981, NEW ENGL J MED, V305, P1508; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DANA C, 1991, NEUROSCI LETT, V125, P45, DOI 10.1016/0304-3940(91)90127-F; DELAGE I, 1981, EUR NEUROL, V20, P258, DOI 10.1159/000115244; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P789; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; HARGREAVES RJ, 1991, J CEREB BLOOD FLO S2, V11, pS301; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HONDA H, 1987, ARCH INT PHARMACOD T, V285, P211; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCGURK JF, 1990, P NATL ACAD SCI USA, V87, P9971, DOI 10.1073/pnas.87.24.9971; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P316; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANGER DJ, 1991, PSYCHOPHARMACOLOGY, V104, P27, DOI 10.1007/BF02244550; SCHOEMAKER H, 1990, EUR J PHARMACOL, V183, P1670, DOI 10.1016/0014-2999(90)91963-C; SHALABY I A, 1990, Society for Neuroscience Abstracts, V16, P193; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SQUIRE LR, 1996, MEMORY BRAIN; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; YOUNG AR, 1981, J CEREBR BLOOD F MET, V1, P117, DOI 10.1038/jcbfm.1981.12; ZEEVALK GD, 1990, BRAIN RES, V522, P135, DOI 10.1016/0006-8993(90)91588-8	54	47	47	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 11	1998	792	2					291	298		10.1016/S0006-8993(98)00158-9			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZU326	WOS:000074185500013	9593949				2022-02-06	
J	Emanuelson, I; vonWendt, L				Emanuelson, I; vonWendt, L			Epidemiology of traumatic brain injury in children and adolescents in south-western Sweden	ACTA PAEDIATRICA			English	Article						brain injury; children; epidemiology	UNITED-STATES; HEAD-INJURY; DEATHS; AGE	The objectives of this study were to outline the incidence, gender distribution, external causes, severity and early outcome of traumatic brain injury (TBI). The subjects were children and adolescents in the southwestern Swedish health care region, aged 0-17 y in 1987-1991 and fulfilling the criteria for TBI. Identification was made from the discharge registers of the hospitals in the region admitting patients with TBI, and outcome data were obtained from medical records. The mean incidence rate was 12/100 000 for TBI. The dominant external cause was traffic (60%), followed by falls (22%). At discharge, 49% of these surviving were healthy, 48% suffered from one functional impairment and 52% suffered from two or more impairments. In conclusion, although the incidence rate of TBI is low in Sweden, the condition causes permanent functional impairment in 6/100 000 cases every year.	UNIV HELSINKI,DEPT PEDIAT NEUROL,HELSINKI,FINLAND		Emanuelson, I (corresponding author), BRACKE OSTERGARD REG PEDIAT REHABIL CTR,PL-21062,S-41804 GOTHENBURG,SWEDEN.						ARNARSON EO, 1995, ACTA PAEDIATR, V84, P96, DOI 10.1111/j.1651-2227.1995.tb13496.x; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR; BERNEY J, 1994, CHILD NERV SYST, V10, P509, DOI 10.1007/BF00335073; BERNEY J, 1995, CHILD NERV SYST, V11, P256, DOI 10.1007/BF00301755; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; ENGBERG A, 1995, ACTA NEUR SCAND S164, V92, P48; GELLES RJ, 1986, CHILD ABUSE NEGLECT, V10, P501, DOI 10.1016/0145-2134(86)90055-4; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; Hansen T B, 1991, Ugeskr Laeger, V153, P2944; HENRY CP, 1992, J NEUROSCI NURS, V24, P311; JENNETT B, 1975, LANCET, V1, P480; KLEINMAN JC, 1990, PEDIATRICS, V86, P1091; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kramhoft M, 1986, Ugeskr Laeger, V148, P738; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1995, TRAUMATIC HEAD INJUR; LOHMANN M, 1990, UGESKRIFT LAEGER, V150, P1591; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; RANTAKALLIO P, 1985, J EPIDEMIOL COMMUN H, V39, P353, DOI 10.1136/jech.39.4.353; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; *SWED EQ FED, 1995, RIDSP VERK; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; *WHO, 1995, WORLD HLTH STAT ANN; World Health Organization, 1977, INT CLASS DIS	27	47	49	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0803-5253			ACTA PAEDIATR	Acta Paediatr.	JUL	1997	86	7					730	735		10.1111/j.1651-2227.1997.tb08576.x			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	XM187	WOS:A1997XM18700011	9240881				2022-02-06	
J	Otte, A; Weiner, SM; Peter, HH; MuellerBrand, J; Goetze, M; Moser, E; Gutfleisch, J; Hoegerle, S; Juengling, FD; Nitzsche, EU				Otte, A; Weiner, SM; Peter, HH; MuellerBrand, J; Goetze, M; Moser, E; Gutfleisch, J; Hoegerle, S; Juengling, FD; Nitzsche, EU			Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study	EUROPEAN JOURNAL OF NUCLEAR MEDICINE			English	Article						neuropsychiatric systemic lupus erythematosus; positron emission tomography; fluorine-18 fluorodeoxyglucose; parieto-occipital brain hypometabolism	CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; TECHNETIUM-99M-HMPAO SPECT; CT; MRI; PATHOGENESIS; DIAGNOSIS; PET	In contrast to morphological imaging [such as magnetic resonance imaging (MRI) or computed tomography], functional imaging may be of advantage in the detection of brain abnormalities in cases of neuropsychiatric systemic lupus erythematosus (SLE). Therefore, we studied 13 patients (aged 40+/-14 years, 11 female, 2 male) with neuropsychiatric SLE who met four of the American Rheumatism Association criteria for the classification of SLE. Ten clinically and neurologically healthy volunteers served as controls (aged 40+/-12 years, 5 female, 5 male). Both groups were investigated using fluorine-18-labelled fluorodeoxyglucose brain positron emission tomography (PET) and cranial MRI. The normal controls and 11 of the 13 patients showed normal MRI scans. However, PET scan was abnormal in all 13 SLE patients. Significant group-to-group differences in the glucose metabolic index (GMI=region of interest uptake/global uptake at the level of the basal ganglia and thalamus) were found in the parieto-occipital region on both sides: the GMI of the parieto-occipital region on the right side was 0.922+/-0.045 in patients and 1.066+/-0.081 in controls (P<0.0001, Mann Whitney U test), while on the left side it was 0.892+/-0.060 in patients and 1.034+/-0.051 in controls (P=0.0002). Parietooccipital hypometabolism is a conspicuous finding in mainly MRI-negative neuropsychiatric SLE. As the parieto-occipital region is located at the boundary of blood supply of all three major arteries, it could be the most vulnerable zone of the cerebrum and may be affected at an early stage of the cerebrovascular disease.	UNIV FREIBURG KLINIKUM,DEPT RHEUMATOL & IMMUNOL,FREIBURG,GERMANY; UNIV FREIBURG KLINIKUM,DEPT NUCL MED,FREIBURG,GERMANY		Otte, A (corresponding author), UNIV BASEL HOSP,SCH MED,INST NUCL MED,DEPT RADIOL SCI,PETERSGRABEN 4,CH-4031 BASEL,SWITZERLAND.		Juengling, Freimut/L-8071-2016; Nitzsche, Egbert U./A-1243-2011	Juengling, Freimut/0000-0002-2538-3074; Otte, Andreas/0000-0002-6290-6786			BAUM KA, 1993, CLIN NEUROL NEUROSUR, V95, P29, DOI 10.1016/0303-8467(93)90088-X; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; BRUYN GAW, 1995, ANN RHEUM DIS, V54, P159, DOI 10.1136/ard.54.3.159; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; FRIBERG L, 1991, J NEUROL, V238, pS12, DOI 10.1007/BF01642900; GonzalezCrespo MR, 1995, BRIT J RHEUMATOL, V34, P1055; GRAHAM DG, 1984, NEUROPATHOLOGY, P125; GRAY BG, 1992, J NUCL MED, V33, P52; GRUNWALD F, 1995, EUR J NUCL MED, V22, P1073, DOI 10.1007/BF00808421; HAMACHER K, 1986, J NUCL MED, V27, P235; HOW A, 1985, ARTHRITIS RHEUM, V28, P789, DOI 10.1002/art.1780280710; HUANG SC, 1981, J NUCL MED, V22, P627; ISSHI K, 1994, J RHEUMATOL, V21, P1758; KOVACS JAJ, 1995, J RHEUMATOL, V22, P1247; Masdeu J C, 1994, J Neuroimaging, V4, P177; MCINNES PM, 1994, ARTHRITIS RHEUM, V37, P1000, DOI 10.1002/art.1780370704; MILLER BL, 1990, DEMENTIA, V0001, P00041; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; OTTE A, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91075-1; Otte A, 1997, J VASC INVEST, V3, P1; PRAYER L, 1993, ACTA RADIOL, V34, P593; ROPER SN, 1991, J NUCL MED, V32, P1684; SIBBITT WL, 1993, RHEUM DIS CLIN N AM, V19, P851; STOPPE G, 1989, NUKLEARMED-NUCL MED, V28, P187; SZER IS, 1993, J RHEUMATOL, V20, P2143; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VANDAM AP, 1991, RHEUMATOL INT, V11, P1; WALDEMAR G, 1994, J NEUROL NEUROSUR PS, V57, P285, DOI 10.1136/jnnp.57.3.285; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7	31	47	48	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0340-6997			EUR J NUCL MED	Eur. J. Nucl. Med.	JUL	1997	24	7					787	791					5	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	XP344	WOS:A1997XP34400013	9211766				2022-02-06	
J	Emshoff, R; Schoning, H; Rothler, G; Waldhart, E				Emshoff, R; Schoning, H; Rothler, G; Waldhart, E			Trends in the incidence and cause of sport-related mandibular fractures: A retrospective analysis	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							FACIAL FRACTURES; ETIOLOGY	Purpose: This study assessed changes in the incidence and causes of mandibular fractures occurring in Innsbruck, Austria between 1984 and 1993. Patients and Methods: Records from 712 patients sustaining 982 mandibular fractures were reviewed and analyzed according to age, sex, date of fracture, place of trauma, cause, anatomic site of fracture, and associated orofacial and craniocerebral injuries. Results: Sports were the most common cause of mandibular fractures, accounting for 31.5% of the entire sample, followed by road traffic accidents (27.2%) and falls (20.8%). The yearly distribution of sport-related mandibular fractures showed an increase from 28.6% in 1984 to 1988 to 34.5% in 1989 to 1993. The major causative factor in sports-related mandibular fractures was skiing (55.3%), whereas cycling and soccer accounted for 25.4% and 8.9%, respectively. Significant changes in the occurrence of cycling-related mandibular fractures were observed, with an increase of 19.3% from 1984 to 1988 to 1989 to 1993, whereas skiing-related mandibular fractures showed a decrease of similar magnitude (19.5%). Sex distribution showed a male-to-female ratio of 2.5:1, with the percentage of females involved increasing, In cases of cycling-related accidents, there was a considerable prevalence of associated injuries (133.3 injuries per 100 mandibular fractures), with significantly higher rates of facial lacerations (73.2), tooth fractures (39), tooth luxations (24.4), and orbital fractures (3.7) than in the case of skiing-related injuries, whereas in patients sustaining mandibular fractures caused by soccer, mucosal lacerations, tooth luxations, and cerebral concussions were the only associated injuries found. Conclusions: The results of this study indicate a considerable change in the cause of mandibular fractures, showing that sporting injuries are becoming increasingly common. The high incidence of associated maxillofacial injuries in patients involved in skiing and cycling accidents may suggest an increasing need for preventive and protective measures.	UNIV INNSBRUCK, DEPT ORAL & MAXILLOFACIAL SURG, A-6020 INNSBRUCK, AUSTRIA				Emshoff, Rudiger/AAW-4773-2020	Emshoff, Rudiger/0000-0002-1527-1458			AFZELIUS LE, 1982, INT J ORAL SURG, V9, P252; BROOK IM, 1983, INT J ORAL MAXILLOF, V12, P293, DOI 10.1016/S0300-9785(83)80016-7; ELLIS E, 1985, ORAL SURG ORAL MED O, V59, P120, DOI 10.1016/0030-4220(85)90002-7; HILL CM, 1984, J MAXILLOFAC SURG, V12, P267, DOI 10.1016/S0301-0503(84)80257-X; LINDQVIST C, 1986, INT J ORAL MAX SURG, V15, P12, DOI 10.1016/S0300-9785(86)80005-9; LINN EW, 1986, J MAXILLOFAC SURG, V14, P83, DOI 10.1016/S0301-0503(86)80266-1; MELMED EP, 1975, PLAST RECONSTR SURG, V56, P323, DOI 10.1097/00006534-197509000-00011; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; VOSS R, 1982, J MAXILLOFAC SURG, V10, P146, DOI 10.1016/S0301-0503(82)80031-3	9	47	51	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUN	1997	55	6					585	592		10.1016/S0278-2391(97)90490-0			8	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	XD372	WOS:A1997XD37200014	9191640				2022-02-06	
J	Sakamoto, KI; Fujisawa, H; Koizumi, H; Tsuchida, E; Ito, H; Sadamitsu, D; Maekawa, T				Sakamoto, KI; Fujisawa, H; Koizumi, H; Tsuchida, E; Ito, H; Sadamitsu, D; Maekawa, T			Effects of mild hypothermia on nitric oxide synthesis following contusion trauma in the rat	JOURNAL OF NEUROTRAUMA			English	Article						nitric oxide; cerebral contusion; microdialysis; capillary electrophoresis; rodent	FOCAL CEREBRAL-ISCHEMIA; CONCUSSIVE BRAIN INJURY; INFARCT VOLUME; GLUTAMATE; RELEASE; ELEVATION; INHIBITOR; SYNTHASE; PLASMA; MODEL	The exact mechanism of hypothermic cerebroprotection after traumatic brain injury (TBI) is not fully understood. The present study was conducted to investigate the effects of mild hypothermia on trauma-induced synthesis of nitric oxide (NO), which has been implicated in the pathogenesis of ischemic brain damage associated with glutamate neurotoxicity. Cerebral contusion was created in the rat parietal cortex by a weight-drop method, and extracellular concentrations of the NO end products nitrite and nitrate were measured using in vivo brain microdialysis and capillary electrophoresis under normothermic (37 degrees C) and mild hypothermic (32 degrees C) conditions. In normothermic animals, the level of NO end products increased markedly 10 min after contusion, reaching a maximum level at 20 min. In the hypothermic rats, such increases were absent. Although it is unknown whether endothelial NO synthase, neuronal NO synthase, or both caused the elevation of the NO end products seen in the normothermic animals, the present results indicate that inhibition of NO synthesis may play a part in hypothermic cerebroprotection following TBI.	YAMAGUCHI UNIV,SCH MED,DEPT NEUROSURG,UBE,YAMAGUCHI 755,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT CRIT CARE MED,UBE,YAMAGUCHI 755,JAPAN								ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHOI DW, 1987, J NEUROSCI, V7, P369; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; DAWSON DA, 1992, NEUROSCI LETT, V142, P151, DOI 10.1016/0304-3940(92)90361-A; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KOZNIEWSKA E, 1992, J CEREBR BLOOD F MET, V12, P311; KUMURA E, 1994, J CEREBR BLOOD F MET, V14, P487, DOI 10.1038/jcbfm.1994.60; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; NAGAFUJI T, 1992, NEUROSCI LETT, V147, P159, DOI 10.1016/0304-3940(92)90584-T; PALMER RM, 1994, J NEUROTRUAMA, V10, P363; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; UEDA T, 1995, ELECTROPHORESIS, V16, P1002, DOI 10.1002/elps.11501601167; WANG Q, 1995, J CEREBR BLOOD F MET, V15, P774, DOI 10.1038/jcbfm.1995.97; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x; ZHANG ZG, 1995, J CEREB BLOOD FLOW S, V15, pS90	33	47	50	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1997	14	5					349	353		10.1089/neu.1997.14.349			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	XE298	WOS:A1997XE29800006	9199400				2022-02-06	
J	Ommaya, AK; Salazar, AM; Dannenberg, AL; Ommaya, AK; Chervinsky, AB; Schwab, K				Ommaya, AK; Salazar, AM; Dannenberg, AL; Ommaya, AK; Chervinsky, AB; Schwab, K			Outcome after traumatic brain injury in the US military medical system	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; outcome; behavior	HEAD-INJURY; FOLLOW-UP; SEVERITY	Personality and behavioral change after traumatic brain injury (TBI) are often the most significant concerns for the families of TBI patients, This report examines discharge from military service after TBI for medical and behavioral criteria, When compared with the total discharge population (n = 1,879,724), the relative risk for behavioral discharge was 1.8 times greater for those with mild TBI (n = 1,778), and no difference for those with moderate (n = 174) or severe TBI (n = 274). Discharge for alcoholism or drug use was 2.6 times for mild TBI, 5.4 times for moderate TBI, and no difference for severe TBI compared with the total discharge population, Discharge for criminal conviction was 2.7 times for those with mild head injury, and no difference for those with moderate or severe TBI when compared with the total discharge population. Discharge for medical disability ranged from 7.5 times to 40.4 times, and mortality ranged from 11.6 to 142.4 times the total discharge population. Total sick days defined as the time from admission to return to duty or separation from service increased with head injury severity. Mean Injury Severity Score for mild TBI was 5.5, and 20.9 for severe TBI. Patients who sustain TBI should be monitored after injury for development of behavioral problems, The most effective way to reduce the cost of TBI is primary prevention of these injuries and examining military practices to reduce exposure to risk of TBI. Secondary and tertiary prevention measures such as evaluation and rehabilitation, where indicated, should be undertaken on a routine basis after TBI.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; JOHNS HOPKINS UNIV,SCH PUBL HLTH,CTR INJURY RES & POLICY,BALTIMORE,MD; GEORGE WASHINGTON UNIV,DEPT NEUROSURG,WASHINGTON,DC		Ommaya, AK (corresponding author), WALTER REED ARMY MED CTR,DEF & VET HEAD INJURY PROGRAM,BLDG 1,RM B219A,WASHINGTON,DC 20307, USA.				AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R03 HS08414-01] Funding Source: Medline		BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; *DEF MANP DAT CTR, ACT DUT MIL MAST LOS; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HARMAN DE, 1995, NEUROPSYCHOLOGICAL T, P225; HONKANEN R, 1990, INJURY, V21, P353, DOI 10.1016/0020-1383(90)90117-D; KHAN HA, 1989, STAT METHODS EPIDEMI, P56; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LI GH, 1995, J TRAUMA, V38, P871, DOI 10.1097/00005373-199506000-00007; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	17	47	47	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1996	41	6					972	975		10.1097/00005373-199612000-00005			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	VY407	WOS:A1996VY40700005	8970548				2022-02-06	
J	Oulis, CJ; Berdouses, ED				Oulis, CJ; Berdouses, ED			Dental injuries of permanent teeth treated in private practice in Athens	ENDODONTICS & DENTAL TRAUMATOLOGY			English	Article						dental trauma; permanent teeth; private practice	TRAUMATIC INJURIES; CHILDREN	Although there are several epidemiological studies on dental trauma internationally, there are not many studies that record, analyse and follow different kinds of dental trauma treated in a private office, and that evaluate how parameters such as type of dental trauma, as well as time lapse until treatment might influence the final outcome and the prognosis of the teeth. The sample consisted of 242 patients, 6-17 years of age, with 369 injured teeth treated within a period of 5 years. All the cases were treated by the first author and were followed for at least 3 years. The treatment modalities used were based upon the clinical examination and the history of the case and included direct and indirect pulp capping, partial pulpotomy, pulpotomy, pulpectomy and splinting. The type of trauma was classified based on WHO classification partially modified. Seventy six percent of the teeth suffered only hard tissue injuries and 22% had only periodontal ligament (PDL) trauma. Of the total number of teeth class I represented 3%, class II 59%, class III 20% and class IV 2%. Of the PDL injuries 14% of the teeth suffered concussion, 69% luxation and 17% exarticulation. The highest incidence of dental trauma was observed at the age of 10. Sixty eight percent of the patients sought treatment 3 days or more after the trauma had occurred (delayed treatment), while only 32% within the first 3 days (immediate treatment). The main reasons for delayed treatment were neglect (50%) and unawareness (37%). Of the teeth with delayed treatment 43% became necrotic, while only 28% of the teeth that were treated on time needed pulpectomy. Luxations caused more pulp necrosis (46%) than class I (0%) Class II (7%) or Class III (34%) type of trauma. The data from this study suggested that a) most of the dental injuries on permanent teeth were class II or III type, b) a high percentage (68%) of the patients sought treatment more than 3 days after the injury (delayed treatment), c) delayed treatment caused more necrotic teeth, d) the public should be informed of the importance of immediate treatment in an effort to improve the prognosis of the pulp, e) dentists should be informed of the appropriate treatment of dental injuries since 10.3% of the cases were mistreated.	UNIV ATHENS, DEPT PAEDIAT DENT, SCH DENT, ATHENS, GREECE				Berdouses, Elias/AAG-4349-2020; OULIS, CONSTANTINE/AAG-5931-2021	Berdouses, Elias Demetrios/0000-0002-6718-2967			Andreasen J O, 1970, Scand J Dent Res, V78, P273; Andreasen J O, 1970, Scand J Dent Res, V78, P329; Andreasen J O, 1972, Int J Oral Surg, V1, P235, DOI 10.1016/S0300-9785(72)80042-5; ANDREASEN JO, 1990, ENDOD DENT TRAUMATOL, V6, P78; Andreasen JO, 1981, TRAUMATIC INJURIES T, P19; BECK JJ, 1968, DEP HLTH SPECIAL REP, V29, P65; Clarkson B H, 1973, J Int Assoc Dent Child, V4, P21; CRONALARSSON G, 1989, ENDOD DENT TRAUMATOL, V5, P176; DELROSARIO MEL, 1992, ENDOD DENT TRAUMATOL, V8, P213; EICHENBAUM IW, 1963, J DENT CHILD, V30, P229; Ellis RG, 1970, CLASSIFICATION TREAT, V5th; Ferguson F S, 1979, J Pedod, V4, P3; FORSBERG CM, 1993, SWED DENT J, V17, P183; GALEA H, 1984, J AM DENT ASSOC, V109, P434, DOI 10.14219/jada.archive.1984.0419; GARCIA-GODOY F, 1987, Endodontics and Dental Traumatology, V3, P126; GARCIAGODOY F, 1989, ENDOD DENT TRAUMATOL, V5, P180; GARCIAGODOY F, 1986, COMMUNITY DENT ORAL, V14, P287, DOI 10.1111/j.1600-0528.1986.tb01074.x; GARCIAGODOY F, 1979, J CAN DENT ASSOC, V45, P181; Gelbier S, 1967, Br Dent J, V123, P331; GUTZ DP, 1971, J DENT CHILD, V38, P94; Haavikko K, 1976, Proc Finn Dent Soc, V72, P152; HARGRAVES JA, 1970, MANAGEMENT TRAUMATIS; HAYRINENIMMONEN R, 1990, ENDOD DENT TRAUMATOL, V6, P208; Hedegard B, 1973, Sven Tandlak Tidskr, V66, P431; HUNTER ML, 1990, ENDOD DENT TRAUMATOL, V6, P260; JARVINEN S, 1979, ACTA ODONTOL SCAND, V37, P47, DOI 10.3109/00016357909004684; JARVINEN S, 1980, ACTA ODONTOL SCAND, V38, P151, DOI 10.3109/00016358009004714; KABA AD, 1989, J DENT CHILD, V56, P417; KORNS RD, 1960, J DENT CHILD, V27, P244; KRAMER LR, 1973, J AM DENT, V28, P1351; Lewis TE, 1959, ANGLE ORTHOD, V29, P128; MACKO DJ, 1979, J DENT CHILD, V46, P130; MAGNUSON B, 1969, SWED DENT J, V62, P72; MCEWEN JD, 1967, J DENT RES, V46, P1290; MEADOW D, 1984, Pediatric Dentistry, V6, P248; NEEDLEMAN H L, 1986, Pediatric Dentistry, V8, P71; Nicholas N K, 1980, N Z Dent J, V76, P8; Oluwole T O, 1986, Pediatr Dent, V8, P221; OMULLANE DM, 1973, BRIT DENT J, V134, P328, DOI 10.1038/sj.bdj.4803000; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; ROCK WP, 1974, BRIT DENT J, V136, P236, DOI 10.1038/sj.bdj.4803162; Skieller V., 1960, ACTA ODONTOL SCAND, V18, P171; Stalhane I, 1975, Sven Tandlak Tidskr, V68, P157; STOCKWELL AJ, 1988, COMMUNITY DENT ORAL, V16, P294, DOI 10.1111/j.1600-0528.1988.tb01779.x; SUGANIDIS D, 1984, ODONT PROG, V38, P311; *WHO, 1978, APPL INT CLASS DIS S; ZADIK D, 1976, COMMUNITY DENT ORAL, V4, P149, DOI 10.1111/j.1600-0528.1976.tb00973.x; ZADIK D, 1972, J DENT CHILD, V39, P185; ZADIK D, 1979, ORAL SURG, P173	49	47	51	0	4	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0109-2502			ENDOD DENT TRAUMATOL	Endod. Dent. Traumatol.	APR	1996	12	2					60	65					6	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	UR760	WOS:A1996UR76000004	9028198				2022-02-06	
J	Levin, HS; Scheller, J; Richard, T; Grafman, J; Martinkowski, K; Winslow, M; Mirvis, S				Levin, HS; Scheller, J; Richard, T; Grafman, J; Martinkowski, K; Winslow, M; Mirvis, S			Dyscalculia and dyslexia after right hemisphere injury in infancy	ARCHIVES OF NEUROLOGY			English	Article							UNILATERAL BRAIN-LESIONS; AGE ONE	Objective: To use the findings from neuropsychological evaluation and functional magnetic resonance imaging (fMRI) to assess interhemispheric reorganization of function after early unilateral brain injury. Design and Methods: The study focused on one case of early brain injury that resulted in both dyscalculia and dyslexia. Brain injury was studied using both structural and fMRI. Intellectual function was evaluated using the Wechsler Intelligence Scale for Children, Third Edition, awhile visuospatial skins were assessed using the Block Design subtest of the Wechsler Intelligence Scale for Children, Third Edition, and Judgment of line Orientation subtest. The Selective Reminding Test and the Recurring Figures Test were used to evaluate memory and orientation; language and speech skills were evaluated using the Boston Naming Test, Controlled Oral Word Association, Gates-MacGinitie Reading Test, and color naming. Various methods were used to study arithmetic skills, including the Wide Range Achievement Test-Revised and the Peabody Individual Achievement Test. The control group for fMRI consisted of nine normal subjects. Setting: Neuropsychological laboratory in primary care hospital. Patient: A 17-year-old boy who had sustained a closed head injury associated with a partially depressed, right parietal skull fracture, and right temporal hemorrhage in a motor vehicle crash at age 7 months (November 9, 1977). Subsequent social behavior was normal, but the patient had difficulty throughout school in mathematics and spelling and was characterized as having a ''short attention span.'' Intervention: None. Main Outcome Measures: Standardized tests of arithmetic and reading supplemented by an assessment of calculation and quantitative skills. While performing calculations, fh?RI disclosed predominantly left hemisphere activation involving the frontal and posterior parietal regions, whereas this task produced bilateral activation of the supramarginal gyrus in seven of nine normal subjects. Results: Neuropsychological findings confirmed the presence of dyscalculia and dyslexia despite normal intellectual functioning. Visuospatial skills ranged from the low normal to average level. The fMRI findings were consistent with early interhemispheric transfer of visuospatial skills normally committed to the right parietal area to the left parietal region. The patient's dyscalculia and reading ability raise a question of acquired left parietal dysfunction as a consequence of the competition between verbal and visuospatial functions for left hemisphere representation. Conclusion: Interhemispheric reorganization of function may be bidirectional rather than a feature unique to the left hemisphere substrate for language.	NINCDS,MNB,COGNIT NEUROSCI SECT,BETHESDA,MD 20892; UNIV MARYLAND,MED SYST,DIV NEUROSURG,BALTIMORE,MD 21201; UNIV MARYLAND,MED SYST,DEPT PEDIAT,BALTIMORE,MD 21201					Grafman, Jordan H./0000-0001-8645-4457	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; Benton A., 1994, CONTRIBUTIONS NEUROP; BENTON AL, 1993, MANUAL MULTILINGUAL; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Damasio H., 1989, LESION ANAL NEUROPSY; DUNN LM, 1970, PEABODY INDIVIDUAL A; GATES AI, 1969, GATES MACGINITIE REA; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; JASTAK S, 1984, WIDE RANGE ACHLEVEME; Kaplan E, 1983, BOSTON NAMING TEST; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; MCCLOSKEY M, 1985, BRAIN COGNITION, V4, P171, DOI 10.1016/0278-2626(85)90069-7; Mesulam M. M., 1985, PRINCIPLES BEHAV NEU, P71; RIVA D, 1986, NEUROPSYCHOLOGIA, V24, P423, DOI 10.1016/0028-3932(86)90029-1; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHAYWITZ BA, 1995, HUMAN BRAIN MAP, V2, P197; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; STILESDAVIS J, 1988, NEUROPSYCHOLOGIA, V26, P359, DOI 10.1016/0028-3932(88)90091-7; STRAUSS E, 1990, NEUROPSYCHOLOGIA, V28, P1221, DOI 10.1016/0028-3932(90)90057-U; Talairach J., 1988, COPLANAR STEREOTAXIC; Teuber H. L., 1974, NEUROSCIENCES 3 STUD, P71; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WEINSTEIN S, 1957, SCIENCE, V125, P1036, DOI 10.1126/science.125.3256.1036; WOODS BT, 1980, NEUROPSYCHOLOGIA, V18, P65, DOI 10.1016/0028-3932(80)90084-6	24	47	49	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JAN	1996	53	1					88	96		10.1001/archneur.1996.00550010108024			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP709	WOS:A1996TP70900015	8599565				2022-02-06	
J	PACE, GM; IVANCIC, MT; JEFFERSON, G				PACE, GM; IVANCIC, MT; JEFFERSON, G			STIMULUS FADING AS TREATMENT FOR OBSCENITY IN A BRAIN-INJURED ADULT	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article						ANTECEDENT TREATMENT PROCEDURES; STIMULUS FADING; NEGATIVE REINFORCEMENT; OBSCENITY; BRAIN INJURY	INJURIOUS ESCAPE BEHAVIOR; EXTINCTION	Obscene verbalizations of a person with traumatic brain injury were treated using stimulus fading as the singular form of intervention. Results of a functional assessment revealed that obscenity was maintained by negative reinforcement. Stimulus fading (initial elimination of instructional demands followed by their gradual reintroduction) produced immediate and substantial reductions in obscenity that were maintained as the frequency of demands increased to baseline levels. Potential applications of the use of antecedent treatment strategies are discussed.	KENNEDY KRIEGER INST,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; WESTERN CAROLINA CTR,MORGANTON,NC; UNIV OREGON,EUGENE,OR 97403								CARR EG, 1976, J ABNORM CHILD PSYCH, V4, P139, DOI 10.1007/BF00916518; IWATA BA, 1987, J APPL BEHAV ANAL, V20, P361, DOI 10.1901/jaba.1987.20-361; IWATA BA, 1982, ANAL INTERVEN DEVEL, V2, P3, DOI 10.1016/0270-4684(82)90003-9; IWATA BA, 1990, J APPL BEHAV ANAL, V23, P11, DOI 10.1901/jaba.1990.23-11; MASON SA, 1990, J APPL BEHAV ANAL, V23, P361, DOI 10.1901/jaba.1990.23-361; MICHAEL J, 1993, BEHAV ANALYST, V16, P191, DOI 10.1007/BF03392623; PACE GM, 1993, J APPL BEHAV ANAL, V26, P205, DOI 10.1901/jaba.1993.26-205; Sidman M., 1960, TACTICS SCI RES; STEEGE MW, 1989, J APPL BEHAV ANAL, V22, P23, DOI 10.1901/jaba.1989.22-23; ULMAN JD, 1975, BEHAVIOR ANAL AREAS, P359; ZARCONE JR, 1993, J APPL BEHAV ANAL, V26, P353, DOI 10.1901/jaba.1993.26-353; ZARCONE JR, 1994, J APPL BEHAV ANAL, V27, P307, DOI 10.1901/jaba.1994.27-307	12	47	47	1	3	JOURNAL APPL BEHAV ANAL	LAWRENCE	DEPT HUMAN DEVELOPMENT, UNIV KANSAS, LAWRENCE, KS 66045	0021-8855			J APPL BEHAV ANAL	J. Appl. Behav. Anal.	SUM	1994	27	2					301	305		10.1901/jaba.1994.27-301			5	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	NV446	WOS:A1994NV44600010	8063628	Green Published			2022-02-06	
J	WOBER, C; ODER, W; KOLLEGGER, H; PRAYER, L; BAUMGARTNER, C; WOBERBINGOL, C; WIMBERGER, D; BINDER, H; DEECKE, L				WOBER, C; ODER, W; KOLLEGGER, H; PRAYER, L; BAUMGARTNER, C; WOBERBINGOL, C; WIMBERGER, D; BINDER, H; DEECKE, L			POSTUROGRAPHIC MEASUREMENT OF BODY SWAY IN SURVIVORS OF SEVERE CLOSED-HEAD INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							DIFFUSE AXONAL INJURY; COMA DATA-BANK; TRAUMA; MR; SEQUELAE; FEATURES; LESIONS; CT		UNIV VIENNA,DEPT MAGNET RESONANCE IMAGING,VIENNA,AUSTRIA; UNIV VIENNA,DEPT NEUROPSYCHIAT CHILDHOOD & ADOLESCENCE,VIENNA,AUSTRIA		WOBER, C (corresponding author), UNIV VIENNA,NEUROL KLIN,DEPT NEUROL,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.		Wober, Christian/I-3574-2019	Wober, Christian/0000-0003-1382-1978			ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BORNSTEIN RA, 1988, NEUROSURGERY, V23, P622, DOI 10.1227/00006123-198811000-00013; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; DIENER HC, 1984, ELECTROEN CLIN NEURO, V57, P134, DOI 10.1016/0013-4694(84)90172-X; DUNCAN PW, 1990, REHABILITATION ADULT, P264; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; JENNETT B, 1990, REHABILITATION ADULT, P3; KOLLEGGER H, 1992, EUR NEUROL, V32, P253, DOI 10.1159/000116836; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; NADJMI M, 1981, KRANIELLE COMPUTERTO; Newton R, 1989, Brain Inj, V3, P335, DOI 10.3109/02699058909004558; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SINCLAIR A J, 1990, Comprehensive Therapy, V16, P44; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; 1985, SAS USERS GUIDE STAT; [No title captured]	32	47	49	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1993	74	11					1151	1156					6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	MD088	WOS:A1993MD08800005	8239952				2022-02-06	
J	KIHTIR, T; IVATURY, RR; SIMON, RJ; NASSOURA, Z; LEBAN, S				KIHTIR, T; IVATURY, RR; SIMON, RJ; NASSOURA, Z; LEBAN, S			EARLY MANAGEMENT OF CIVILIAN GUNSHOT WOUNDS TO THE FACE	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	6TH SCIENTIFIC ASSEMBLY OF THE EASTERN-ASSOC-FOR-THE-SURGERY-OF-TRAUMA	JAN 13-16, 1993	LONGBOAT KEY, FL	E ASSOC SURG TRAUMA				We analyzed 54 civilian patients (1988-1992) with gunshot wounds (GSWs) of the face to review the management principles and results. Urgent airway control was needed in 18 cases (33%): by orotracheal intubation in 13, cricothyroidotomy in two, tracheostomy in two, and nasotracheal intubation in one. Central nervous system injury was seen in 12 (22%): 40% with orbital, 38% with mid-face, and 0% with lower face injuries. Two patients died of intracranial injuries (mortality, 4%). Vascular injury was present in five patients (9%), all detected by angiography. The local complication rate was 39% in the presence of intra-oral injury and 0% without intra-oral injury (p < 0.001). The maxilla was the most commonly fractured facial bone (41%) followed by the mandible in 28%. All maxillary, orbital, and zygomatic fractures were treated without reduction. One of the seven nasal fractures required open reduction for deformity. Six of the 15 mandible fractures were treated without reduction. Of eight patients treated with closed reduction, one developed nonunion. One patient treated with immediate open reduction developed osteomyelitis of the mandible and nonunion. Five patients (9%) had palate injuries. Two of them later developed intraoral fistulas following conservative treatment. The airway needs immediate attention in GSWs of the face. Computed tomographic scanning of the head or spine should be done when the bullet trajectory is above the lower face (the level of the mandible). Angiography is indicated when the trajectory of the bullet is suggestive. A conservative approach that effectively reduces the fractures is the procedure of choice. Open reductions should not be performed in the initial treatment. Palate injuries should be repaired early in an attempt to prevent intra-oral fistula formation.	NEW YORK MED COLL,DEPT SURG,BRONX,NY; NEW YORK MED COLL,DEPT ORAL & MAXILLOFACIAL SURG,BRONX,NY				Ivatury, Rao R./H-2922-2019				BROADBENT TR, 1972, J TRAUM, V12, P229, DOI 10.1097/00005373-197203000-00006; DOLIN J, 1992, J TRAUMA, V33, P508, DOI 10.1097/00005373-199210000-00004; IRBY WB, 1979, FACIAL TAUMA CONCOMI, P1; JOY ED, 1973, J ORAL SURG, V31, P425; KELLY JF, 1973, J ORAL SURG, V31, P438; KHALIL AF, 1980, BRIT J ORAL SURG, V18, P205, DOI 10.1016/0007-117X(80)90064-5; KIHTIR T, 1991, J TRAUMA, V31, P6; MANSON PN, 1990, PLASTIC SURG, V2, P1124; MAY M, 1973, LARYNGOSCOPE, V83, P969, DOI 10.1288/00005537-197306000-00016; Nahum A M, 1975, Clin Plast Surg, V2, P59; NEUPERT EA, 1991, ORAL SURG ORAL MED O, V72, P383, DOI 10.1016/0030-4220(91)90544-M; OSBORNE TE, 1991, ORAL MAXILLOFACIAL T, V2, P672; SHUCK LW, 1980, J TRAUMA, V20, P370, DOI 10.1097/00005373-198020050-00002; WHITLOCK RIH, 1978, INT J ORAL MAXILLOF, V7, P240, DOI 10.1016/S0300-9785(78)80087-8; YAO ST, 1972, J TRAUM, V12, P523, DOI 10.1097/00005373-197206000-00011	15	47	50	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1993	35	4					569	577		10.1097/00005373-199310000-00012			9	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	MD998	WOS:A1993MD99800012	8411281				2022-02-06	
J	FADEN, AI				FADEN, AI			COMPARISON OF SINGLE AND COMBINATION-DRUG TREATMENT STRATEGIES IN EXPERIMENTAL BRAIN TRAUMA	JOURNAL OF NEUROTRAUMA			English	Article							THYROTROPIN-RELEASING-HORMONE; SPINAL-CORD INJURY; INTRACELLULAR FREE MG-2+; RATS; ANTAGONIST; RECEPTORS; HYPOTENSION; NALOXONE; RECOVERY; ISCHEMIA	Effects of single-drug and combination drug treatments were examined in a model of lateral fluid percussion-induced traumatic brain injury (TBI) in rats. Treatments included the opioid receptor antagonist nalmefene, the thyrotropin releasing hormone (TRH) analog YM14673, the noncompetitive N-methyl-D-aspartate (NMDA) antagonist dextrorphan, nalmefene + dextrorphan, YM14673 + nalmefene, YM14673 + dextrorphan, and equal volume saline. Single-dose treatment with nalmefene, YM14673, or dextrorphan at 30 min after trauma each significantly improved behavioral recovery at two weeks as compared with vehicle-treated controls, confirming earlier studies with these agents. No combination treatment was superior to treatment with the most effective individual drug alone. Combination treatment with the TRH analog and the NMDA antagonist resulted in significantly less effectiveness than treatment with either drug alone. These findings indicate the need for preclinical studies to examine potential drug-drug interactions in the treatment of central nervous system (CNS) trauma.			FADEN, AI (corresponding author), GEORGETOWN UNIV, MED CTR, MED DENT BLDG, NW 101, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 306634-02] Funding Source: Medline		ALZHEIMER C, 1990, J PHARMACOL EXP THER, V255, P900; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHOI DW, 1987, J NEUROSCI, V7, P369; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; GEORGE CP, 1988, BRAIN RES, V440, P375, DOI 10.1016/0006-8993(88)91011-6; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; KOSKINEN LOD, 1989, ANN NY ACAD SCI, V553, P353; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MICHEL ME, 1984, PHARMACOLOGIST, V26, P201; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; VINK R, 1991, AM J PHYSIOL, V261, pR1527, DOI 10.1152/ajpregu.1991.261.6.R1527; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; YAMAMOTO M, 1989, STROKE, V20, P1089, DOI 10.1161/01.STR.20.8.1089; YAMAMOTO M, 1989, STROKE, V20, P362, DOI 10.1161/01.STR.20.3.362; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061; 1984, KEY PHARM	36	47	47	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					91	100		10.1089/neu.1993.10.91			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600001	8411221				2022-02-06	
J	MIYAZAWA, T; BONNEKOH, P; HOSSMANN, KA				MIYAZAWA, T; BONNEKOH, P; HOSSMANN, KA			TEMPERATURE EFFECT ON IMMUNOSTAINING OF MICROTUBULE-ASSOCIATED PROTEIN-2 AND SYNAPTOPHYSIN AFTER 30 MINUTES OF FOREBRAIN ISCHEMIA IN RAT	ACTA NEUROPATHOLOGICA			English	Article						CEREBRAL ISCHEMIA; HYPOTHERMIA; SELECTIVE VULNERABILITY; MICROTUBULE-ASSOCIATED PROTEIN-2; SYNAPTOPHYSIN	TRANSIENT CEREBRAL-ISCHEMIA; SYNAPTIC VESICLE MEMBRANE; GERBIL HIPPOCAMPUS; BRAIN TEMPERATURE; PRESYNAPTIC TERMINALS; MILD HYPOTHERMIA; CA1 REGION; OCCLUSION; DAMAGE; ULTRASTRUCTURE	The regional distribution of the postsynaptic microtubule-associated protein 2 (MAP2) and the presynaptic marker protein synaptophysin was investigated by immunohistochemistry in brains of rats submitted to 30-min forebrain ischemia by four-vessel occlusion. The following brain temperature profiles during ischemia were compared: (1) constant brain temperature of 36-degrees-C (normothermia; n = 5); (2) spontaneous temperature decline from 36-degrees to 31-degrees-C (spontaneous hypothermia; n = 5) and (3) constant temperature of 30-degrees-C (induced hypothermia; n = 5). Normothermia was produced by exposing the ischemic head to an external heat source, and induced hypothermia by cooling the head with liquid nitrogen vapours. Sham-operated animals were either kept at ambient temperature or exposed to the same heat source, as required for maintaining normothermia during ischemia. Seven days after sham operation or ischemia, brains were fixed by perfusion and processed for immunohistochemistry using monoclonal antibodies against MAP2 and synaptic vesicle-specific protein (synaptophysin). Normothermic ischemia resulted in complete loss of MAP2 immunostaining in the whole hippocampus, spontaneous hypothermic ischemia in complete loss of MAP2 in CA1 sector, and induced hypothermic ischemia only in variable loss of MAP2 in Ca sector. Post-ischemic immunostaining of synaptophysin revealed a temperature-dependent increase in stratum lacunosum-moleculare of CA1 sector, the density of which correlated inversely with MAP2 staining. Comparison with morphological alterations showed a close relationship between loss of MAP2 staining and histological injury. The post-ischemic activation of synaptophysin may reflect regenerative processes associated with synaptic remodelling and, therefore, is an indirect marker of the severity of ischemic injury.	MAX PLANCK INST NEUROL RES,DEPT EXPTL NEUROL,GLEUELER STR 50,D-50866 COLOGNE 41,GERMANY								ARAI H, 1991, NEUROSCI RES COMMUN, V9, P143; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BONNEKOH P, 1990, ACTA NEUROPATHOL, V80, P18, DOI 10.1007/BF00294217; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, STROKE, V20, P113; CACERES A, 1984, J NEUROSCI, V4, P394; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GEISERT EE, 1990, P NATL ACAD SCI USA, V87, P3967, DOI 10.1073/pnas.87.10.3967; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; JOHANSEN FF, 1984, BRAIN RES, V291, P373, DOI 10.1016/0006-8993(84)91272-1; JORGENSEN MB, 1987, ACTA NEUROPATHOL, V73, P189, DOI 10.1007/BF00693788; KIRINO T, 1990, BRAIN RES, V510, P17, DOI 10.1016/0006-8993(90)90722-N; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KITAGAWA K, 1990, NEUROSCIENCE, V35, P551, DOI 10.1016/0306-4522(90)90328-2; KITAGAWA K, 1992, NEUROSCIENCE, V46, P287, DOI 10.1016/0306-4522(92)90051-3; KNAUS P, 1986, J NEUROCHEM, V47, P1302; KUDO T, 1990, STROKE, V21, P1205, DOI 10.1161/01.STR.21.8.1205; KUNKEL DD, 1988, SYNAPSE, V2, P382, DOI 10.1002/syn.890020405; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; KUWAKI T, 1989, STROKE, V20, P78, DOI 10.1161/01.STR.20.1.78; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; MILESON BE, 1992, J NEUROCHEM, V58, P600, DOI 10.1111/j.1471-4159.1992.tb09761.x; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P488; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PETRUSZ P, 1980, HISTOCHEM J, V12, P333, DOI 10.1007/BF01006954; Pickel V.M., 1981, NEUROANATOMICAL TRAC, P483; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; RISCHKE R, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P129; SCHMIDTKASTNER R, 1989, STROKE, V20, P938, DOI 10.1161/01.STR.20.7.938; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOMIOKA C, 1992, BRAIN RES, V586, P352, DOI 10.1016/0006-8993(92)91648-X; WALAAS SI, 1988, SYNAPSE, V2, P516, DOI 10.1002/syn.890020507; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; WESTERBERG E, 1989, J NEUROSCI, V9, P798; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YAMAMOTO K, 1990, ACTA NEUROPATHOL, V80, P487, DOI 10.1007/BF00294608; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610; YOSHIMI K, 1991, BRAIN RES, V560, P149, DOI 10.1016/0006-8993(91)91225-P	49	47	50	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	APR	1993	85	5					526	532					7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	KX439	WOS:A1993KX43900013	8493860				2022-02-06	
J	ABRUNZO, TJ				ABRUNZO, TJ			COMMOTIO CORDIS - THE SINGLE, MOST COMMON CAUSE OF TRAUMATIC DEATH IN YOUTH BASEBALL	AMERICAN JOURNAL OF DISEASES OF CHILDREN			English	Article							SUDDEN-DEATH; YOUNG-ADULTS; CHILDREN; INJURY	Two cases of blunt chest trauma caused by a baseball are reported, including one death. At least one of these was in consequence of cardiac concussion or commotio cordis, an entity not described in the pediatric literature. Concussion of the heart is a functional injury, in contrast to cardiac contusion or cardiac rupture, which pertains to structural injury. However, a cardiac concussion appears more likely to have immediate, dire consequences than the structural injury of cardiac contusion. Both of the cases presented occurred in the Little League baseball setting. Blunt chest trauma is reported to cause two to three deaths in youth baseball each year. There appears to be an increased pediatric susceptibility to this type of injury. Unfortunately, these cases are quite resistant to resuscitative therapy. Devices and techniques for primary and secondary prevention exist, but have yet to be systematically verified and implemented.	ST JOSEPHS HOSP,PEDIAT EMERGENCY SERV,TAMPA,FL								ALBARRANSOTELO R, 1987, TXB ADV CARDIAC LIFE; ANDERSON DM, 1985, DORLANDS ILLUSTRATED, P370; ANDERSON RH, 1987, PEDIATRIC CARDIOLOGY; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC; CHAMEIDES L, 1988, TXB PEDIATRIC ADV LI; COHN PF, 1988, HEART DISEASE TXB CA, P1535; DENFIELD SW, 1990, PEDIATR CLIN N AM, V37, P215; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; EICHELBERGER MR, 1988, PEDIATRIC TRAUMA CAR; FERSTLE J, 1978, PHYSICIAN SPORTSMED, V6, P21; FLEISHER GR, 1988, TXB PEDIATRIC EMERGE; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FROEDE RC, 1979, J FORENSIC SCI, V24, P752; GOLDBERG B, 1989, Physician and Sportsmedicine, V17, P175; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; Hale Creighton J, 1979, Phys Sportsmed, V7, P59, DOI 10.1080/00913847.1979.11948455; HALLER JA, 1983, JAMA-J AM MED ASSOC, V245, P47; KAROFSKY PS, 1990, PHYSICIAN SPORTSMED, V18, P99, DOI 10.1080/00913847.1990.11709976; KING AI, 1986, BASEBALL RELATED CHE; LANGER JC, 1989, J PEDIATR SURG, V24, P1091, DOI 10.1016/S0022-3468(89)80225-8; LAU VK, 1982, J TRAUMA, V21, P39; LIEDTKE AJ, 1980, J TRAUMA, V20, P777, DOI 10.1097/00005373-198009000-00012; LINDSEY D, 1978, CHEST, V74, P15, DOI 10.1378/chest.74.1.15; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MAYER TA, 1985, EMERGENCY MANAGEMENT; MCINTYRE KM, 1981, TXB ADV CARDIAC LIFE; MOSS AJ, 1989, HEART DISEASE INFANT; Mueller F, 1982, Clin Sports Med, V1, P343; NEUSPIEL DR, 1985, JAMA-J AM MED ASSOC, V254, P1321, DOI 10.1001/jama.254.10.1321; ROGERS MC, 1987, TXB PEDIATRIC INTENS; RUDOLPH AM, 1987, PEDIATRICS; RUTHERFORD GW, 1984, HAZARD ANAL BASEBALL; Shoemaker WC., 1984, TXB CRITICAL CARE; TELLEZ DW, 1987, J PEDIATR SURG, V12, P1223; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; WELCH KJ, 1986, PEDIATRIC SURGERY; ZUCKERMAN BS, 1985, PEDIATR CLIN N AM, V32, P17	40	47	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0002-922X			AM J DIS CHILD	Am. J. Dis. Child.	NOV	1991	145	11					1279	1282		10.1001/archpedi.1991.02160110071023			4	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	GN260	WOS:A1991GN26000021	1951221				2022-02-06	
J	BOYER, MG; EDWARDS, P				BOYER, MG; EDWARDS, P			OUTCOME 1 TO 3 YEARS AFTER SEVERE TRAUMATIC BRAIN INJURY IN CHILDREN AND ADOLESCENTS	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article								This study reports a consecutive series of 220 children and adolescents who sustained traumatic brain injury (BI) and were admitted to a comprehensive paediatric rehabilitation programme. Progress in areas of mobility, activities of daily living, education and cognitive function were documented for up to 3 years after the injury. Physical recovery was most rapid in the first years and cognitive and language gains generally occurred later, even up to 3 years after the injury. Cognitive assessment at the time of admission proved helpful in predicting outcome; of those patients admitted in a conscious state only one remained dependent for any aspect of self care. Even for those admitted unconscious at a median of 62 days after injury there was good potential for recovery with 27-43 per cent achieving independence in the activities of daily living. For those still unconscious at 6 months, 72 per cent remained vegetative and none achieved the highest cognitive level. Overall, 14 per cent returned to regular education while 25 per cent remained incapable of any educational programme. In a well planned and multidisciplinary rehabilitation programme, patients with severe BI have potential for continued recovery and measurable improvement for at least 3 years. The emphasis should be targeted on differing areas of the therapy programme at different phases of recovery. A realistic appraisal of the ultimate potential for recovery can usually be made by 6 months.			BOYER, MG (corresponding author), ACCID HOSP BIRMINGHAM,BATH ROW,BIRMINGHAM B15 1NA,ENGLAND.							0	47	47	0	2	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0020-1383			INJURY	Injury-Int. J. Care Inj.	JUL	1991	22	4					315	320		10.1016/0020-1383(91)90014-6			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	FX584	WOS:A1991FX58400014	1937730				2022-02-06	
J	KINAL, ME				KINAL, ME			TRAUMATIC THROMBOSIS OF DURAL VENOUS SINUSES IN CLOSED HEAD INJURIES	JOURNAL OF NEUROSURGERY			English	Article																	Batson OV, 1944, FED PROC, V3, P139; BELLER AJ, 1964, J NEUROL NEUROSUR PS, V27, P149, DOI 10.1136/jnnp.27.2.149; CARRIE AW, 1954, J NEUROSURG, V11, P173, DOI 10.3171/jns.1954.11.2.0173; ECKER AD, 1946, NEW YORK STATE J MED, V46, P1120; FOLEY J, 1955, BRAIN, V78, P1, DOI 10.1093/brain/78.1.1; KINAL ME, 1959, 1 INT C NEUR SCIENC, P178; MARTIN JP, 1955, BRIT MED J, V2, P467, DOI 10.1136/bmj.2.4937.467	7	47	47	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1967	27	2					142	&		10.3171/jns.1967.27.2.0142			0	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	97846	WOS:A19679784600009					2022-02-06	
J	MEYER, JS; DENNYBROWN, D				MEYER, JS; DENNYBROWN, D			STUDIES OF CEREBRAL CIRCULATION IN BRAIN INJURY .2. CEREBRAL CONCUSSION	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article																	BROWN GW, 1954, AMA ARCH NEUROL PSY, V71, P707, DOI 10.1001/archneurpsyc.1954.02320420035004; BROWN GW, 1951, 6737 AIR FORC TECH R; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Denny-Brown D., 1942, NEW ENGL J MED, V227, P771; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; DENNYBROWN D, 1950, YB PUBLICATIONS, V2, P127; DODGE PR, 1952, J NEUROSURG, V9, P472, DOI 10.3171/jns.1952.9.5.0472; GOLDRING S, 1951, J NEUROPHYSIOL, V14, P275, DOI 10.1152/jn.1951.14.4.275; Groat RA, 1944, AM J PHYSIOL, V141, P0117, DOI 10.1152/ajplegacy.1944.141.1.117; Jasper H, 1941, J NEUROPHYSIOL, V4, P333, DOI 10.1152/jn.1941.4.5.333; KEMPINSKY WH, 1954, ELECTROENCEPHALOG CL, V6, P315; KNAUER A, 1922, J PSYCHOL NEUROL, V29, P1; KREMS A. D., 1942, PROC SOC EXP BIOL AND MED, V49, P73; MERRITT HH, 1943, WAR MED, V4, P61; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; MEYER JS, 1954, AMA ARCH NEUROL PSY, V72, P296, DOI 10.1001/archneurpsyc.1954.02330030030003; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P511, DOI 10.1016/0013-4694(55)90077-8; MEYER JS, 1955, ARCH NEUROL PSYCHIAT; MEYER JS, 1955, UNPUB STUDIES CEREBR; POLIS A, 1894, REV CHIR, V14, P645; Polis A, 1894, REV CHIR, V14, P273; RUSSELL WR, 1945, BRAIN, V68, P79, DOI 10.1093/brain/68.2.79; SPIEGEL EA, 1946, AM J PHYSIOL, V146, P12, DOI 10.1152/ajplegacy.1946.146.1.12; SPIEGEL EA, 1947, RES PUBL ASS RES NER, V26, P84; STONE WE, 1945, RES PUBL ASS NERV ME, V24, P226; Trotter W, 1924, LANCET, V1, P935; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEIL A, 1945, RES PUBL ASS NERV ME, V24, P250; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; [No title captured]; [No title captured]	31	47	48	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.		1955	7	4					529	544		10.1016/0013-4694(55)90078-X			16	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	WR944	WOS:A1955WR94400002	13270685				2022-02-06	
J	White, JC; Brooks, JR; Goldthwait, JC; Adams, RD				White, JC; Brooks, JR; Goldthwait, JC; Adams, RD			Changes in brain volume and blood content after experimental concussion	ANNALS OF SURGERY			English	Article									Harvard Univ, Med Sch, Massachusetts Gen Hosp, Surg Res Labs, Boston, MA USA; Harvard Univ, Med Sch, Boston City Hosp, Dept Neurol,Neuropathol Lab, Boston, MA USA								Alexander L, 1938, ARCH NEURO PSYCHIATR, V40, P877, DOI 10.1001/archneurpsyc.1938.02270110031002; Apfelbach CW, 1922, ARCH SURG-CHICAGO, V4, P434, DOI 10.1001/archsurg.1922.01110110180007; ARNAUD M, 1933, B MEM SOC NAT CHIR, V59, P843; Bing FC, 1931, J BIOL CHEM, V92, P589; COURVILLE CB, 1942, B LOS ANGELES NEUROL, V7, P55; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gurdjian ES, 1943, SURGERY, V13, P333; MAHONEY W, 1941, WAR MED, V1, P816; McConnell AA, 1942, BRAIN, V65, P266, DOI 10.1093/brain/65.3.266; Pilcher C, 1937, ARCH SURG-CHICAGO, V35, P512, DOI 10.1001/archsurg.1937.01190150095009; PILCHER C, 1941, SURG GYNECOL OBSTET, V72, P755; REICHARDT M, 1927, HDB NORMALEN PATHOLO, V10, P103; Shapiro P, 1939, ARCH SURG-CHICAGO, V38, P443, DOI 10.1001/archsurg.1939.01200090048005; White JC, 1942, ARCH SURG-CHICAGO, V44, P1; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	15	47	47	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	JUL-DEC	1943	119						619	634		10.1097/00000658-194310000-00010			16	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	V21QX	WOS:000201463500056	17858295	Green Published			2022-02-06	
J	Chesnut, R; Aguilera, S; Buki, A; Bulger, E; Citerio, G; Cooper, DJ; Arrastia, RD; Diringer, M; Figaji, A; Gao, GY; Geocadin, R; Ghajar, J; Harris, O; Hoffer, A; Hutchinson, P; Joseph, M; Kitagawa, R; Manley, G; Mayer, S; Menon, DK; Meyfroidt, G; Michael, DB; Oddo, M; Okonkwo, D; Patel, M; Robertson, C; Rosenfeld, JV; Rubiano, AM; Sahuquillo, J; Servadei, F; Shutter, L; Stein, D; Stocchetti, N; Taccone, FS; Timmons, S; Tsai, E; Ullman, JS; Vespa, P; Videtta, W; Wright, DW; Zammit, C; Hawryluk, GWJ				Chesnut, Randall; Aguilera, Sergio; Buki, Andras; Bulger, Eileen; Citerio, Giuseppe; Cooper, D. Jamie; Arrastia, Ramon Diaz; Diringer, Michael; Figaji, Anthony; Gao, Guoyi; Geocadin, Romer; Ghajar, Jamshid; Harris, Odette; Hoffer, Alan; Hutchinson, Peter; Joseph, Mathew; Kitagawa, Ryan; Manley, Geoffrey; Mayer, Stephan; Menon, David K.; Meyfroidt, Geert; Michael, Daniel B.; Oddo, Mauro; Okonkwo, David; Patel, Mayur; Robertson, Claudia; Rosenfeld, Jeffrey V.; Rubiano, Andres M.; Sahuquillo, Juan; Servadei, Franco; Shutter, Lori; Stein, Deborah; Stocchetti, Nino; Taccone, Fabio Silvio; Timmons, Shelly; Tsai, Eve; Ullman, Jamie S.; Vespa, Paul; Videtta, Walter; Wright, David W.; Zammit, Christopher; Hawryluk, Gregory W. J.			A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC)	INTENSIVE CARE MEDICINE			English	Article						Brain injury; Head trauma; Algorithm; Protocol; Consensus; Intracranial pressure; Brain oxygen; Tiers; Seattle; SIBICC; PbtO2	GUIDELINES; TRIAL	Background Current guidelines for the treatment of adult severe traumatic brain injury (sTBI) consist of high-quality evidence reports, but they are no longer accompanied by management protocols, as these require expert opinion to bridge the gap between published evidence and patient care. We aimed to establish a modern sTBI protocol for adult patients with both intracranial pressure (ICP) and brain oxygen monitors in place. Methods Our consensus working group consisted of 42 experienced and actively practicing sTBI opinion leaders from six continents. Having previously established a protocol for the treatment of patients with ICP monitoring alone, we addressed patients who have a brain oxygen monitor in addition to an ICP monitor. The management protocols were developed through a Delphi-method-based consensus approach and were finalized at an in-person meeting. Results We established three distinct treatment protocols, each with three tiers whereby higher tiers involve therapies with higher risk. One protocol addresses the management of ICP elevation when brain oxygenation is normal. A second addresses management of brain hypoxia with normal ICP. The third protocol addresses the situation when both intracranial hypertension and brain hypoxia are present. The panel considered issues pertaining to blood transfusion and ventilator management when designing the different algorithms. Conclusions These protocols are intended to assist clinicians in the management of patients with both ICP and brain oxygen monitors but they do not reflect either a standard-of-care or a substitute for thoughtful individualized management. These protocols should be used in conjunction with recommendations for basic care, management of critical neuroworsening and weaning treatment recently published in conjunction with the Seattle International Brain Injury Consensus Conference.	[Chesnut, Randall] Univ Washington, Harborview Med Ctr, Dept Neurol Surg, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98109 USA; [Chesnut, Randall] Univ Washington, Harborview Med Ctr, Dept Orthopaed Surg, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98109 USA; [Aguilera, Sergio] Almirante Nef Naval Hosp, Vina Del Mar, Chile; [Aguilera, Sergio] Univ Valparaiso, Valparaiso, Chile; [Buki, Andras] Sch Med, Dept Neurosurg, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Szentagothai Res Ctr, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Univ Pecs, Pecs, Hungary; [Bulger, Eileen] Univ Washington, Harborview Med Ctr, Dept Surg, 325 Ninth Ave, Seattle, WA 98104 USA; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] San Gerardo Hosp, ASST, Dept Emergency & Intens Care, Neurointens Care, Monza, Italy; [Cooper, D. Jamie] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Intens Care Med, Monash, Australia; [Cooper, D. Jamie] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Arrastia, Ramon Diaz] Univ Penn, Perelman Sch Med, Penn Presbyterian Med Ctr, 51 North 39th St, Philadelphia, PA 19104 USA; [Diringer, Michael] Washington Univ, Sch Med, Dept Neurol, Barnes Jewish Hosp, 1 Barnes Jewish Hosp Plaza, St Louis, MO 63110 USA; [Figaji, Anthony] Univ Cape Town, Div Neurosurg, Groote Schuur Hosp, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Figaji, Anthony] Univ Cape Town, Inst Neurosci, Groote Schuur Hosp, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Gao, Guoyi] Shandong Jiaotong Univ, Renji Hosp, Shanghai Inst Head Trauma, Sch Med,Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China; [Geocadin, Romer] Johns Hopkins Univ, Sch Med, 1800 Orleans St Sheikh Zayed Tower, Baltimore, MD 21287 USA; [Ghajar, Jamshid] Stanford Neurosci Hlth Ctr, 213 Quarry Rd 4th Fl MC 5958, Palo Alto, CA 94304 USA; [Harris, Odette] Dept Neurosurg, Pasteur Dr,Room R205,Edwards Bldg,MC 5327, Stanford, CA 94305 USA; [Hoffer, Alan] Case Western Reserve Univ, Sch Med, Dept Neurol Surg, 11100 Euclid Ave,HAN 5042, Cleveland, OH 44106 USA; [Hutchinson, Peter] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Hutchinson, Peter] Univ Cambridge, Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Joseph, Mathew] Christian Med Coll & Hosp, Dept Neurol Sci, Ida Scudder Rd, Vellore, Tamil Nadu, India; [Kitagawa, Ryan] McGovern Med Sch UTHlth, Vivian L Smith Dept Neurosurg, 6400 Fannin St,Suite 2800, Houston, TX 77030 USA; [Manley, Geoffrey] Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Manley, Geoffrey] Trauma Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Mayer, Stephan] Henry Ford Hosp, Neurol, K-11,2799 W Grand Blvd, Detroit, MI 48202 USA; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Menon, David K.] Addenbrookes Hosp, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Meyfroidt, Geert] Univ Hosp Leuven, Dept & Lab Intens Care Med, Herestr 49,Box 7003 63, B-3000 Louvain, Belgium; [Meyfroidt, Geert] Katholieke Univ Leuven, Herestr 49,Box 7003 63, B-3000 Louvain, Belgium; [Michael, Daniel B.] Oakland Univ, William Beaumont Sch Med, Beaumont Hlth, Michigan Head & Spine Inst, Southfield, MI USA; [Oddo, Mauro] Univ Lausanne, CHUV Lausanne Univ Hosp, Dept Intens Care Med, Fac Biol & Med, Lausanne, Switzerland; [Okonkwo, David] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Robertson, Claudia] Baylor Coll Med, One Baylor Plaza, Houston, TX 77030 USA; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Rubiano, Andres M.] El Bosque Univ, INUB MEDITECH Res Grp, Neurosci Inst, Bogota, Colombia; [Rubiano, Andres M.] MEDITECH Fdn, Clin Res, Calle 7-A 44-95, Cali 760036, Colombia; [Sahuquillo, Juan] Univ Hosp Vall Hebron, Barcelona, Spain; [Servadei, Franco] Humanitas Univ, Dept Neurosurg, Milan, Italy; [Servadei, Franco] Res Hosp, Milan, Italy; [Servadei, Franco] World Federat Neurosurg Soc, Nyon, Switzerland; [Shutter, Lori] Univ Pittsburgh, Med Ctr, 3550 Terrace St,Room 646, Pittsburgh, PA 15261 USA; [Stein, Deborah] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stein, Deborah] Univ Calif San Francisco, Ctr Trauma, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Neurosci Intens Care Unit, Milan, Italy; [Taccone, Fabio Silvio] Univ Libre Bruxelles ULB, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Timmons, Shelly] Penn State Univ, Milton S Hershey Med Ctr, Dept Neurol Surg, 30 Hope Dr,Suite 1200,Bldg B, Hershey, PA 17033 USA; [Tsai, Eve] Univ Ottawa, Suruchi Bhargava Chair Spinal Cord & Brain Regene, Ottawa Hosp, Neurosci Unit C2, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada; [Ullman, Jamie S.] Shore Univ Hosp, Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Neurosurg, 300 Community Dr,9 Tower, Manhasset, NY USA; [Vespa, Paul] UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Santa Monica, CA USA; [Videtta, Walter] Posadas Hosp, Buenos Aires, DF, Argentina; [Wright, David W.] Emory Univ, Sch Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA; [Zammit, Christopher] Univ Rochester, Med Ctr, Sch Med & Dent, 601 Elmwood Ave,Box 655C, Rochester, NY 14642 USA; [Hawryluk, Gregory W. J.] Univ Manitoba, Neurosurg Sect, GB1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada		Hawryluk, GWJ (corresponding author), Univ Manitoba, Neurosurg Sect, GB1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	ghawryluk@hsc.mb.ca	Tsai, Eve/ABE-6056-2021; Cooper, D. James/G-7961-2013; Sahuquillo, Juan/B-3577-2008; Shutter, Lori A/G-2957-2013; Tsai, Eve/D-7007-2014	Cooper, D. James/0000-0002-5872-9051; Sahuquillo, Juan/0000-0003-0713-5875; Figaji, Anthony/0000-0002-3357-6490; Shutter, Lori/0000-0002-1390-0628; Tsai, Eve/0000-0002-8152-349X			Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Hawryluk GWJ, 2019, INTENS CARE MED, V45, DOI 10.1007/s00134-019-05805-9; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hendrickson P, 2018, WORLD NEUROSURG, V110, pE952, DOI 10.1016/j.wneu.2017.11.142; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, pS1, DOI 10.1097/PCC.0000000000001735; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360	11	46	46	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2020	46	5					919	929		10.1007/s00134-019-05900-x			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK9CU	WOS:000531156300006	31965267	Green Accepted, Green Published, hybrid			2022-02-06	
J	Burek, M; Konig, A; Lang, M; Fiedler, J; Oerter, S; Roewer, N; Bohnert, M; Thal, SC; Blecharz-Lang, KG; Woitzik, J; Thum, T; Forster, CY				Burek, Malgorzata; Koenig, Anna; Lang, Mareike; Fiedler, Jan; Oerter, Sabrina; Roewer, Norbert; Bohnert, Michael; Thal, Serge C.; Blecharz-Lang, Kinga G.; Woitzik, Johannes; Thum, Thomas; Foerster, Carola Y.			Hypoxia-Induced MicroRNA-212/132 Alter Blood-Brain Barrier Integrity Through Inhibition of Tight Junction-Associated Proteins in Human and Mouse Brain Microvascular Endothelial Cells	TRANSLATIONAL STROKE RESEARCH			English	Article						MicroRNA-212; 132; Blood-brain barrier; Tight junctions; Oxygen-glucose deprivation; Traumatic brain injury; Stroke	HIPPOCAMPAL-NEURONS; INJURY; EXPRESSION; MIGRATION; MIR-132; CLAUDIN-1; PROTECTS; MIR-212; TARGETS; MODEL	Blood-brain barrier (BBB) integrity is one of the important elements of central nervous system (CNS) homeostasis. MicroRNAs (miRs) have been demonstrated to play a role in many CNS disorders such as stroke and traumatic brain injury. MiR-212/132 are highly expressed in the CNS but their role at the BBB has not been characterized yet. Thus, we analyzed the expression of miR-212/132 in hypoxic mouse and human brain microvascular endothelial cells (BMEC) as well as in posttraumatic mouse and human brain tissue and serum exosomes. MiR-212/132 expression was detected in brain capillaries by in situ hybridization and was increased up to ten times in hypoxic BMEC. Over-expression of pre-miR-212/132 in BMEC decreased barrier properties and reduced migration of BMEC in the wound healing assay. We identified and validated tight junction proteins claudin-1 (Cldn1), junctional adhesion molecule 3 (Jam3), and tight junction-associated protein 1 (Tjap1) as potential miR-212/132 targets. Over-expression of miRs led to a decrease in mRNA and protein expression of Cldn1, Jam3, and Tjap1, which could be rescued by a respective anti-miR. In conclusion, our study identifies miR-212/132 as critical players at the hypoxic BBB. In addition, we propose three new direct miR-212/132 targets to be involved in miR-212/132-mediated effects on BBB properties.	[Burek, Malgorzata; Koenig, Anna; Lang, Mareike; Roewer, Norbert; Foerster, Carola Y.] Univ Wurzburg, Dept Anesthesia & Crit Care, Wurzburg, Germany; [Fiedler, Jan; Thum, Thomas] Hannover Med Sch, IMTTS, Hannover, Germany; [Oerter, Sabrina; Bohnert, Michael] Univ Wurzburg, Inst Forens Med, Wurzburg, Germany; [Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, Mainz, Germany; [Blecharz-Lang, Kinga G.] Charite Univ Med Berlin, Dept Expt Neurosurg, Berlin, Germany; [Blecharz-Lang, Kinga G.] Free Univ Berlin, Berlin, Germany; [Blecharz-Lang, Kinga G.] Humboldt Univ, Berlin, Germany; [Blecharz-Lang, Kinga G.] Berlin Inst Hlth, Berlin, Germany; [Woitzik, Johannes] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany; [Woitzik, Johannes] Charite Univ Med Berlin, Ctr Stroke Res Berlin CSB, Berlin, Germany		Burek, M (corresponding author), Univ Wurzburg, Dept Anesthesia & Crit Care, Wurzburg, Germany.	Burek_M@ukw.de	Burek, Malgorzata/AAF-3283-2021; Thal, Serge/D-6593-2011	Burek, Malgorzata/0000-0001-6148-2195; Thal, Serge/0000-0002-1222-8729; Woitzik, Johannes/0000-0002-1865-4606; Oerter, Sabrina/0000-0002-2493-4866	European UnionEuropean Commission [HEALTH-F2-2009-241778]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG-WO 1704/1-1]	This work was supported in part by the grant from the European Union (HEALTH-F2-2009-241778) to CF and MB and Deutsche Forschungsgemeinschaft (DFG-WO 1704/1-1) to JW.	Alvarez-Saavedra M, 2011, HUM MOL GENET, V20, P731, DOI 10.1093/hmg/ddq519; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Blecharz KG, 2015, BIOL CELL, V107, P342, DOI 10.1111/boc.201500011; Blecharz-Lang KG, 2018, J CEREBR BLOOD F MET, V38, P1940, DOI 10.1177/0271678X18768443; Burek M., 2013, J STEROIDS HORMONAL, V5, P1, DOI [10.4172/2157-7536.1000128, DOI 10.4172/2157-7536.1000128]; Burek M, 2012, JOVE-J VIS EXP, DOI 10.3791/4022; Burek M, 2010, ARTERIOSCL THROM VAS, V30, P298, DOI 10.1161/ATVBAHA.109.197582; Burek M, 2009, MOL CELL ENDOCRINOL, V298, P19, DOI 10.1016/j.mce.2008.09.041; Cambronne XA, 2012, P NATL ACAD SCI USA, V109, P20473, DOI 10.1073/pnas.1218887109; Charania MA, 2012, GASTROENTEROLOGY, V142, pS725; Cichon C, 2014, TISSUE BARRIERS, V2, DOI 10.4161/21688362.2014.944446; Coisne C, 2011, ANTIOXID REDOX SIGN, V15, P1285, DOI 10.1089/ars.2011.3929; Dilling C, 2017, J CEREBR BLOOD F MET, V37, P3391, DOI 10.1177/0271678X16688706; Fiedler J, 2011, CIRCULATION, V124, P720, DOI 10.1161/CIRCULATIONAHA.111.039008; Fletcher NF, 2012, GASTROENTEROLOGY, V142, P634, DOI 10.1053/j.gastro.2011.11.028; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; Fujibe M, 2004, EXP CELL RES, V295, P36, DOI 10.1016/j.yexcr.2003.12.014; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Helms HC, 2016, J CEREBR BLOOD F MET, V36, P862, DOI 10.1177/0271678X16630991; Hernandez-Rapp J, 2016, SCI REP-UK, V6, DOI 10.1038/srep30953; Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; Keaney J, 2015, FEBS J, V282, P4067, DOI 10.1111/febs.13412; Keasey MP, 2016, J MOL NEUROSCI, V59, P404, DOI 10.1007/s12031-016-0740-9; Kim HR, 2017, EXP CELL RES, V358, P161, DOI 10.1016/j.yexcr.2017.06.009; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Kumarswamy R, 2014, EUR HEART J, V35, P3224, DOI 10.1093/eurheartj/ehu344; Lei ZY, 2015, J CELL MOL MED, V19, P1994, DOI 10.1111/jcmm.12586; Li X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07513-0; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mochida GH, 2010, AM J HUM GENET, V87, P882, DOI 10.1016/j.ajhg.2010.10.026; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Pfeiffer F, 2011, ACTA NEUROPATHOL, V122, P601, DOI 10.1007/s00401-011-0883-2; Pichler S, 2017, NEUROBIOL AGING, V50, DOI 10.1016/j.neurobiolaging.2016.09.019; Pinczolits A, 2017, J CEREBR BLOOD F MET, V37, P1896, DOI 10.1177/0271678X17699629; Redis RS, 2012, J CELL BIOCHEM, V113, P1451, DOI 10.1002/jcb.24038; Salvador Ellaine, 2016, Curr Pathobiol Rep, V4, P135; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Smith PY, 2015, HUM MOL GENET, V24, P6721, DOI 10.1093/hmg/ddv377; Stankowski JN, 2011, ANTIOXID REDOX SIGN, V14, P1841, DOI 10.1089/ars.2010.3292; Sun ZZ, 2017, INT J IMMUNOPATH PH, V30, P253, DOI 10.1177/0394632017715837; Tang YM, 2008, ALCOHOL CLIN EXP RES, V32, P355, DOI 10.1111/j.1530-0277.2007.00584.x; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Timaru-Kast R, 2015, J NEUROTRAUM, V32, P1777, DOI 10.1089/neu.2014.3784; Tognini P, 2012, INT J BIOCHEM CELL B, V44, P6, DOI 10.1016/j.biocel.2011.10.015; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Ucar A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2090; Ucar A, 2010, NAT GENET, V42, P1101, DOI 10.1038/ng.709; Wanet A, 2012, NUCLEIC ACIDS RES, V40, P4742, DOI 10.1093/nar/gks151; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Wilhelm I, 2018, J CEREBR BLOOD F MET, V38, P563, DOI 10.1177/0271678X17732025; Wolburg H, 2001, NEUROSCI LETT, V307, P77, DOI 10.1016/S0304-3940(01)01927-9; Wyss L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045619; Yanev P, 2017, J CEREBR BLOOD F MET, V37, P2768, DOI 10.1177/0271678X16674737; Yao C, 2016, MOL NEUROBIOL, V53, P5129, DOI 10.1007/s12035-015-9449-y	58	46	47	2	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2019	10	6					672	683		10.1007/s12975-018-0683-2			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JL1KU	WOS:000495293000009	30617994	hybrid, Green Published			2022-02-06	
J	Niu, XL; Zheng, SM; Liu, HT; Li, SY				Niu, Xiaoli; Zheng, Simin; Liu, Hongtao; Li, Siyuan			Protective effects of taurine against inflammation, apoptosis, and oxidative stress in brain injury	MOLECULAR MEDICINE REPORTS			English	Article						apoptosis; brain injury; inflammation; neurons; taurine	CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL DYSFUNCTION; IN-VITRO; NEURONS; BLOOD; ACCUMULATION; EXPRESSION; CELLS; TUMOR; ACID	The protective effect of taurine against inflammation, apoptosis and oxidative stress in traumatic brain injury was investigated in the present study. Taurine is a non-proteogenic and essential amino acid in animals. It plays a critical nutritional role in brain cell growth, differentiation, and development. Taurine is involved in regeneration and neuroprotection in the injured nervous system, and is an effective antioxidant against lead-, cadmium-, and exercise-induced oxidative stress. Astrocytes and neuron cells were co-cultured and cells were treated with different concentrations of taurine (100, 200 and 300 mg/l) for 72 h, and the levels of reactive oxygen species, malondialdehyde, reduced glutathione, glutathione peroxidase, superoxide dismutase, catalase, acetylcholinesterase, tumor necrosis factor-alpha, interleukin-6, caspase-3, p53, B-cell lymphoma 2 and Bcl-2-associated X protein were determined. These inflammatory, apoptotic, and oxidative stress markers were substantially increased in injured cells, and returned to normal levels following taurine supplementation. Thus, taurine supplementation may be effective against oxidative stress, apoptosis, and inflammation in injured brain cells.	[Niu, Xiaoli; Zheng, Simin; Liu, Hongtao; Li, Siyuan] Xi An Jiao Tong Univ, Dept Anesthesiol, Affiliated Hosp 2, 157 West 5th Rd, Xian 710004, Shaanxi, Peoples R China		Li, SY (corresponding author), Xi An Jiao Tong Univ, Dept Anesthesiol, Affiliated Hosp 2, 157 West 5th Rd, Xian 710004, Shaanxi, Peoples R China.	lowesiomew@yahoo.com			Key Research and Development Project of Shaanxi Province [2017SF-180]	The present study was supported by the Key Research and Development Project of Shaanxi Province (grant no. 2017SF-180).	Afshari J Tavakkol, 2005, BMC Pregnancy Childbirth, V5, P14, DOI 10.1186/1471-2393-5-14; Birdsall T C, 1998, Altern Med Rev, V3, P128; Boda D, 2014, FARMACIA, V62, P704; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; Collins  C., 1996, OCCUPATIONAL THERAPY, P395; Dominy J, 2004, J NEUROCHEM, V89, P1195, DOI 10.1111/j.1471-4159.2004.02410.x; El Idrissi A, 2003, ADV EXP MED BIOL, V526, P515; Erden Inal M, 2003, J AM AGING ASSOC, V26, P55, DOI DOI 10.1007/S11357-003-0005-8; Foos TM, 2002, NEUROCHEM RES, V27, P21, DOI 10.1023/A:1014890219513; Gong H, 2017, FARMACIA, V65, P1; Heidari R, 2016, TOXICOL REP, V3, P870, DOI 10.1016/j.toxrep.2016.04.002; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Kaddour T., 2016, J ACUTE DIS, V5, P470, DOI DOI 10.1016/j.joad.2016.08.028; Katano H, 1999, NEUROREPORT, V10, P2439, DOI 10.1097/00001756-199908200-00002; Keelan J, 1999, BRAIN RES, V821, P124, DOI 10.1016/S0006-8993(99)01084-7; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Leon R, 2009, J NEUROSCI RES, V87, P1185, DOI 10.1002/jnr.21926; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lobos E, 2005, ENDOCRINOLOGY, V146, P1922, DOI 10.1210/en.2004-0925; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Madakkannu B, 2017, TOXICOL REP, V4, P484, DOI 10.1016/j.toxrep.2017.09.001; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Medhat D, 2017, BIOMED PHARMACOTHER, V91, P1006, DOI 10.1016/j.biopha.2017.05.043; Nakajima Y, 2010, J NEUROTRAUM, V27, P403, DOI 10.1089/neu.2009.1044; Negrei C, 2012, FARMACIA, V60, P767; Olive MF, 2002, AMINO ACIDS, V23, P345, DOI 10.1007/s00726-002-0203-1; Prentice H, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964518; Rak K, 2014, NEUROREPORT, V25, P1250, DOI 10.1097/WNR.0000000000000254; Schaffer SW, 2014, AMINO ACIDS, V46, P21, DOI 10.1007/s00726-012-1378-8; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Shaheen TI, 2016, BIOMED PHARMACOTHER, V83, P865, DOI 10.1016/j.biopha.2016.07.052; Shimada K, 2015, ADV EXP MED BIOL, V803, P581, DOI 10.1007/978-3-319-15126-7_47; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Sun M, 2012, AMINO ACIDS, V42, P1735, DOI 10.1007/s00726-011-0885-3; Sun M, 2011, AMINO ACIDS, V40, P1419, DOI 10.1007/s00726-010-0751-8; Sun QR, 2014, BIOCHEM BIOPH RES CO, V447, P485, DOI 10.1016/j.bbrc.2014.04.019; Tataranu LG, 2017, FARMACIA, V65, P766; Tsuboyama-Kasaoka N, 2006, ENDOCRINOLOGY, V147, P3276, DOI 10.1210/en.2005-1007; Vlodavsky E, 2017, J CEREBR BLOOD F MET, V37, P166, DOI 10.1177/0271678X15621068; Wang Q, 2016, AMINO ACIDS, V48, P2169, DOI 10.1007/s00726-016-2244-x; Wang X, 2001, J CEREB BLOOD FLOW M, V21, pS264; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yanagita T, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-38; Yang YJ, 2013, ACTA BIOCH BIOPH SIN, V45, P359, DOI 10.1093/abbs/gmt034; Zhang M, 2004, AMINO ACIDS, V26, P203, DOI 10.1007/s00726-003-0002-3; Zhu KJ, 2014, WORLD J GASTROENTERO, V20, P9585, DOI 10.3748/wjg.v20.i28.9585	48	46	49	3	19	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	NOV	2018	18	5					4516	4522		10.3892/mmr.2018.9465			7	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	GV9PW	WOS:000446493000038	30221665	hybrid, Green Published, Green Submitted			2022-02-06	
J	Morton, RP; Abecassis, IJ; Hanson, JF; Barber, JK; Chen, MM; Kelly, CM; Nerva, JD; Emerson, SN; Ene, CI; Levitt, MR; Chowdhary, MM; Ko, AL; Chesnut, RM				Morton, Ryan P.; Abecassis, Isaac Josh; Hanson, Josiah F.; Barber, Jason K.; Chen, Mimi; Kelly, Cory M.; Nerva, John D.; Emerson, Samuel N.; Ene, Chibawanye I.; Levitt, Michael R.; Chowdhary, Michelle M.; Ko, Andrew L.; Chesnut, Randall M.			Timing of cranioplasty: a 10.75-year single-center analysis of 754 patients	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; timing; infection; resorption; complication; traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; CLINICAL ARTICLE; CRANIAL BONES; SKULL BONE; COMPLICATIONS; PREDICTORS; EXPERIENCE; PRESERVATION; GRAFTS	OBJECTIVE Despite their technical simplicity, cranioplasty procedures carry high reported morbidity rates. The authors here present the largest study to date on complications after cranioplasty, focusing specifically on the relationship between complications and timing of the operation. METHODS The authors retrospectively reviewed all cranioplasty cases performed at Harborview Medical Center over the past 10.75 years. In addition to relevant clinical and demographic characteristics, patient morbidity and mortality data were abstracted from the electronic medical record. Cox proportional-hazards models were used to analyze variables potentially associated with the risk of infection, hydrocephalus, seizure, hematoma, and bone flap resorption. RESULTS Over the course of 10.75 years, 754 cranioplasties were performed at a single institution. Sixty percent of the patients who underwent these cranioplasties were male, and the median follow-up overall was 233 days. The 30-day mortality rate was 0.26% (2 cases, both due to postoperative epidural hematoma). Overall, 24.6% percent of the patients experienced at least 1 complication including infection necessitating explantation of the flap (6.6%), postoperative hydrocephalus requiring a shunt (9.0%), resorption of the flap requiring synthetic cranioplasty (6.3%), seizure (4.1%), postoperative hematoma requiring evacuation (2.3%), and other (1.6%). The rate of infection was significantly higher if the cranioplasty had been performed < 14 days after the initial craniectomy (p = 0.007, Holm-Bonferroni-adjusted p = 0.028). Hydrocephalus was significantly correlated with time to cranioplasty (OR 0.92 per 10-day increase, p < 0.001) and was most common in patients whose cranioplasty had been performed < 90 days after initial craniectomy. New-onset seizure, however, only occurred in patients who had undergone their cranioplasty > 90 days after initial craniectomy. Bone flap resorption was the least likely complication for patients whose cranioplasty had been performed between 15 and 30 days after initial craniectomy. Resorption was also correlated with patient age, with a hazard ratio of 0.67 per increase of 10 years of age (p = 0.001). CONCLUSIONS Cranioplasty performed between 15 and 30 days after initial craniectomy may minimize infection, seizure, and bone flap resorption, whereas waiting > 90 days may minimize hydrocephalus but may increase the risk of seizure.	[Morton, Ryan P.; Abecassis, Isaac Josh; Hanson, Josiah F.; Barber, Jason K.; Chen, Mimi; Kelly, Cory M.; Nerva, John D.; Emerson, Samuel N.; Ene, Chibawanye I.; Levitt, Michael R.; Chowdhary, Michelle M.; Ko, Andrew L.; Chesnut, Randall M.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Levitt, Michael R.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA; [Levitt, Michael R.] Univ Washington, Dept Mech Engn, Sch Med, Seattle, WA 98195 USA		Morton, RP (corresponding author), Univ Washington, Neurosci Publicat, Box 359924,325 9th Ave, Seattle, WA 98104 USA.	publications@neurosurgery.washington.edu		Chesnut, Randall/0000-0001-6377-3666; Ko, Andrew/0000-0002-6253-9891			Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jho DH, 2007, J NEUROSURG, V107, P440, DOI 10.3171/JNS-07/08/0440; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Lu Y, 2012, BRIT J NEUROSURG, V26, P216, DOI 10.3109/02688697.2011.629699; Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735; Morton RP, 2016, J NEUROSURG, V125, P766, DOI 10.3171/2015.8.JNS151390; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405	23	46	50	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2018	128	6					1648	1652		10.3171/2016.11.JNS161917			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GP2IM	WOS:000440653000006	28799868	Bronze			2022-02-06	
J	Kim, D; Doyle, EK; Wisnowski, JL; Kim, JH; Haldar, JP				Kim, Daeun; Doyle, Eamon K.; Wisnowski, Jessica L.; Kim, Joong Hee; Haldar, Justin P.			Diffusion-relaxation correlation spectroscopic imaging: A multidimensional approach for probing microstructure	MAGNETIC RESONANCE IN MEDICINE			English	Article						diffusion; relaxation; compartment modeling; correlation spectroscopy; constrained reconstruction	INVERSE LAPLACE TRANSFORM; 2D MRI RELAXOMETRY; MULTICOMPONENT T-1; MYELIN WATER; BRAIN; NMR; DISTRIBUTIONS; TIME; QUANTIFICATION; FRAMEWORK	PurposeTo propose and evaluate a novel multidimensional approach for imaging subvoxel tissue compartments called Diffusion-Relaxation Correlation Spectroscopic Imaging. Theory and MethodsMultiexponential modeling of MR diffusion or relaxation data is commonly used to infer the many different microscopic tissue compartments that contribute signal to macroscopic MR imaging voxels. However, multiexponential estimation is known to be difficult and ill-posed. Observing that this ill-posedness is theoretically reduced in higher dimensions, diffusion-relaxation correlation spectroscopic imaging uses a novel multidimensional imaging experiment that jointly encodes diffusion and relaxation information, and then uses a novel constrained reconstruction technique to generate a multidimensional diffusion-relaxation correlation spectrum for every voxel. The peaks of the multidimensional spectrum are expected to correspond to the distinct tissue microenvironments that are present within each macroscopic imaging voxel. ResultsUsing numerical simulations, experiment data from a custom-built phantom, and experiment data from a mouse model of traumatic spinal cord injury, diffusion-relaxation correlation spectroscopic imaging is demonstrated to provide substantially better multicompartment resolving power compared to conventional diffusion- and relaxation-based methods. ConclusionThe diffusion-relaxation correlation spectroscopic imaging approach provides powerful new capabilities for resolving the different components of multicompartment tissue models, and can be leveraged to significantly expand the insights provided by MRI in studies of tissue microstructure. Magn Reson Med 78:2236-2249, 2017. (c) 2017 International Society for Magnetic Resonance in Medicine.	[Kim, Daeun; Haldar, Justin P.] Univ Southern Calif, Dept Elect Engn, Los Angeles, CA USA; [Doyle, Eamon K.; Haldar, Justin P.] Univ Southern Calif, Dept Biomed Engn, Los Angeles, CA USA; [Doyle, Eamon K.] Childrens Hosp Angeles, Dept Cardiol, Los Angeles, CA USA; [Wisnowski, Jessica L.] Childrens Hosp Angeles, Dept Radiol, Los Angeles, CA USA; [Kim, Joong Hee] Washington Univ, Dept Neurol & Radiol, St Louis, MO USA		Kim, D (corresponding author), Univ Southern Calif, Univ Pk Campus,3710 McClintock Ave,RTH 317, Los Angeles, CA 90036 USA.	daeunk@usc.edu	Haldar, Justin P/B-4983-2008; Doyle, Eamon Keenan/G-4954-2011	Haldar, Justin P/0000-0002-1838-0211; Doyle, Eamon Keenan/0000-0002-8652-6518; Kim, Daeun/0000-0002-9887-5598	NSFNational Science Foundation (NSF) [CCF-1350563]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21-EB022951, R01-NS089212, R01-DK097115]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB022951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK097115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089212] Funding Source: NIH RePORTER; Direct For Computer & Info Scie & EnginrNational Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE) [1350563] Funding Source: National Science Foundation	Grant sponsor: NSF award; Grant number: CCF-1350563; Grant sponsor: NIH; Grant numbers: R21-EB022951, R01-NS089212 and R01-DK097115.	Acton F., 1990, NUMERICAL METHODS WO; Afonso MV, 2011, IEEE T IMAGE PROCESS, V20, P681, DOI 10.1109/TIP.2010.2076294; Ahola S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9363; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Assaf Y, 2008, MAGN RESON MED, V59, P1347, DOI 10.1002/mrm.21577; Bai RL, 2015, J MAGN RESON, V255, P88, DOI 10.1016/j.jmr.2015.04.002; Benjamini D, 2016, J MAGN RESON, V271, P40, DOI 10.1016/j.jmr.2016.08.004; Brunsing RL, 2017, J MAGN RESON IMAGING, V45, P323, DOI 10.1002/jmri.25419; Callaghan PT, 2003, MAGN RESON IMAGING, V21, P243, DOI 10.1016/S0730-725X(03)00131-0; Celik H, 2013, J MAGN RESON, V236, P134, DOI 10.1016/j.jmr.2013.07.008; Cloninger A, 2014, SIAM J IMAGING SCI, V7, P1775, DOI 10.1137/130932168; De Santis S, 2016, NEUROIMAGE, V141, P133, DOI 10.1016/j.neuroimage.2016.07.037; De Santis S, 2016, MAGN RESON MED, V75, P372, DOI 10.1002/mrm.25644; Deoni Sean C L, 2010, Top Magn Reson Imaging, V21, P101, DOI 10.1097/RMR.0b013e31821e56d8; Deoni SCL, 2008, MAGN RESON MED, V60, P1372, DOI 10.1002/mrm.21704; Does MD, 1998, MAGN RESON IMAGING, V16, P1033, DOI 10.1016/S0730-725X(98)00139-8; Does MD, 2002, MAGNET RESON MED, V47, P274, DOI 10.1002/mrm.10060; Edelstein WA, 2010, J AM COLL RADIOL, V7, P650, DOI 10.1016/j.jacr.2010.05.002; ENGLISH AE, 1991, MAGNET RESON MED, V22, P425, DOI 10.1002/mrm.1910220250; Epstein CL, 2008, SIAM REV, V50, P504, DOI 10.1137/060657273; Fenrich FRE, 2001, NMR BIOMED, V14, P133, DOI 10.1002/nbm.685; Freed DE, 2010, CR PHYS, V11, P181, DOI 10.1016/j.crhy.2010.06.016; Galvosas P, 2010, CR PHYS, V11, P172, DOI 10.1016/j.crhy.2010.06.014; Gatidis S, 2014, MAGN RESON MED, V72, P459, DOI 10.1002/mrm.24944; Hafftka A, 2015, 2015 INT C SAMPL THE; Hamilton J, 2016, P 24 ANN M ISMRM SIN; Hurlimann MD, 2002, J MAGN RESON, V157, P31, DOI 10.1006/jmre.2002.2567; Hwang D, 2009, J MAGN RESON IMAGING, V30, P203, DOI 10.1002/jmri.21783; Istratov AA, 1999, REV SCI INSTRUM, V70, P1233, DOI 10.1063/1.1149581; Jelescu IO, 2016, NMR BIOMED, V29, P33, DOI 10.1002/nbm.3450; Jones D., 2011, DIFFUSION MRI THEORY; Kaden E, 2016, NEUROIMAGE, V139, P346, DOI 10.1016/j.neuroimage.2016.06.002; Kim D, 2016, P 24 ANN M ISMRM SIN; Kim JH, 2009, J NEUROTRAUM, V26, P1395, DOI [10.1089/neu.2008.0728, 10.1089/neu.2008-0728]; Kumar D, 2012, MAGN RESON MED, V68, P1536, DOI 10.1002/mrm.24170; Lamanna R, 2005, CONCEPT MAGN RESON A, V26A, P78, DOI 10.1002/cmr.a.20036; LANCZOS C, 1956, APPL ANAL; Le Bihan D, 2012, NEUROIMAGE, V61, P324, DOI 10.1016/j.neuroimage.2011.11.006; LEE JH, 1993, J AM CHEM SOC, V115, P7761, DOI 10.1021/ja00070a022; Lin YG, 2014, IEEE T MED IMAGING, V33, P173, DOI 10.1109/TMI.2013.2283229; MacKay A, 2006, MAGN RESON IMAGING, V24, P515, DOI 10.1016/j.mri.2005.12.037; MACKAY A, 1994, MAGNET RESON MED, V31, P673, DOI 10.1002/mrm.1910310614; McGivney DF, 2016, P 24 ANN M ISMRM SIN; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Mitchell J, 2012, PROG NUCL MAG RES SP, V62, P34, DOI 10.1016/j.pnmrs.2011.07.002; Mulkern RV, 2009, MAGN RESON IMAGING, V27, P1151, DOI 10.1016/j.mri.2009.05.003; Mulkern RV, 1999, NMR BIOMED, V12, P51, DOI 10.1002/(SICI)1099-1492(199902)12:1<51::AID-NBM546>3.0.CO;2-E; Mulkern RV, 2016, J MAGN RESON IMAG; Niendorf T, 1996, MAGN RESON MED, V36, P847, DOI 10.1002/mrm.1910360607; PEEMOELLER H, 1981, J MAGN RESON, V45, P193, DOI 10.1016/0022-2364(81)90116-5; Prony R., 1795, J ECOLE POLYTECH, V1, P24; PROVENCHER SW, 1979, J BIOCHEM BIOPH METH, V1, P313, DOI 10.1016/0165-022X(79)90021-6; Scherrer B., 2015, MAGNETIC RESONANCE M, V76, P963; Sodickson DK, 2015, MED IMAGING 2015 BIO; Song YQ, 2002, J MAGN RESON, V154, P261, DOI 10.1006/jmre.2001.2474; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tu TW, 2010, J NEUROTRAUM, V27, P253, DOI 10.1089/neu.2009.1026; Varadarajan D, 2015, IEEE T MED IMAGING, V34, P2191, DOI 10.1109/TMI.2015.2427157; Venkataramanan L, 2002, IEEE T SIGNAL PROCES, V50, P1017, DOI 10.1109/78.995059; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Whittall KP, 1997, MAGNET RESON MED, V37, P34, DOI 10.1002/mrm.1910370107; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072	62	46	46	2	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	DEC	2017	78	6					2236	2249		10.1002/mrm.26629			14	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	FM4FE	WOS:000414967400017	28317261	Green Accepted, Bronze			2022-02-06	
J	Valera, E; Kucyi, A				Valera, Eve; Kucyi, Aaron			Brain injury in women experiencing intimate partner-violence: neural mechanistic evidence of an "invisible" trauma	BRAIN IMAGING AND BEHAVIOR			English	Article						Intimate-partner violence; Traumatic brain injury; Functional connectivity; Default mode network; Salience network; Domestic violence	DEFAULT MODE NETWORK; INTRINSIC FUNCTIONAL CONNECTIVITY; CONCUSSION SYMPTOMS QUESTIONNAIRE; RANDOMIZED CLINICAL-TRIAL; SALIENCE NETWORK; EXECUTIVE CONTROL; FMRI; DISEASE; CORTEX; COGNITION	Traumatic brain injury (TBI) in women experiencing intimate-partner violence (IPV) is common, and IPV afflicts 30 % of women worldwide. However, the neurobiology and related sequelae of these TBIs have never been systematically examined. Consequently, TBI treatments are typically absent and IPV interventions are inadequate. There has been a call for a comprehensive assessment of IPV-related TBIs and their relationship to aspects of women's cognitive and neural functioning. In response, we examined brain-network organization associated with TBI and its cognitive effects using clinical interviews and neuropsychological measures as well as structural and functional Magnetic Resonance Imaging (fMRI) in women experiencing IPV-related TBI. We hypothesized that TBI severity would be related to poorer cognitive performance and be associated with structural and functional connectivity between cognitive networks previously implicated in other TBI populations. As predicted, severity of TBI was negatively associated with inter-network intrinsic functional connectivity indicative of TBI, between the right anterior insula and posterior cingulate cortex/precuneus (FLAME1 + 2; family-wise error-corrected Z > 2.3, cluster- based p < 0.05). This association remained significant when controlling for partner-abuse severity, age, head motion, childhood trauma and psychopathology. Additionally, intrinsic functional connectivity between the same regions correlated positively with cognitive performance on indices of memory and learning. These data provide the first mechanistic evidence of TBI and its association with cognitive functioning in women sustaining IPV-related TBI. These data underscore the need to address and consider the role TBI may be playing in the efficacy of IPV interventions ranging from emergency first responder interactions to specific treatment plans.	[Valera, Eve; Kucyi, Aaron] Massachusetts Gen Hosp, Dept Psychiat, 149 Thirteenth St,Room 2660, Charlestown, MA 02129 USA; [Valera, Eve; Kucyi, Aaron] Harvard Med Sch, Dept Psychiat, Boston, MA USA		Valera, E (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, 149 Thirteenth St,Room 2660, Charlestown, MA 02129 USA.; Valera, E (corresponding author), Harvard Med Sch, Dept Psychiat, Boston, MA USA.	eve_valera@hms.harvard.edu; akucyi@mgh.harvard.edu			Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR14075, P41 EB015896]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR023043, 1S10RR023401]	EMV and AK had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. We thank all of the women who participated in this study. We thank Brittany LeBlanc for data management assistance, Drs. Michael Alexander, Margaret O'Connor and Gregory Sorensen for helpful advice in developing this project, Dr. Steven Stufflebeam for performing the clinical reads of the imaging scans, Drs. Randy Buckner, Kevin Spencer, Martha Shenton and Michael Hove for helpful feedback in preparing the manuscript. This work was supported by a Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health (EMV), the Canadian Institutes of Health Research (AK), and grants provided to the Athinoula A. Martinos Center for Biomedical Imaging, NCRR P41RR14075 and P41 EB015896. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers 1S10RR023043 and 1S10RR023401.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anticevic A, 2012, TRENDS COGN SCI, V16, P584, DOI 10.1016/j.tics.2012.10.008; Banks M. E., 2013, HLTH HEALING TRAUMAT, P153; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cai W, 2015, CAUSAL INTERACTIONS; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Committee on Mild Traumatic Brain Injury and American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P48; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Devries KM, 2013, SCIENCE, V340, P1527, DOI 10.1126/science.1240937; Eisenstat SA, 1999, NEW ENGL J MED, V341, P886, DOI 10.1056/NEJM199909163411206; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Goulden N, 2014, NEUROIMAGE, V99, P180, DOI 10.1016/j.neuroimage.2014.05.052; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klevens J, 2015, JAMA-J AM MED ASSOC, V314, P515, DOI 10.1001/jama.2015.6755; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kucyi A, 2015, HUM BRAIN MAPP, V36, P3373, DOI 10.1002/hbm.22850; Kucyi A, 2013, P NATL ACAD SCI USA, V110, P18692, DOI 10.1073/pnas.1312902110; Kucyi A, 2012, J NEUROPHYSIOL, V108, P3382, DOI 10.1152/jn.00674.2012; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Liebschutz JM, 2012, NEW ENGL J MED, V367, P2071, DOI 10.1056/NEJMp1204278; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Murray CE, 2016, TRAUMA VIOLENCE ABUS, V17, P298, DOI 10.1177/1524838015584364; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Power JD, 2015, NEUROIMAGE, V105, P536, DOI 10.1016/j.neuroimage.2014.10.044; Power JD, 2013, NEURON, V79, P798, DOI 10.1016/j.neuron.2013.07.035; Rhodes KV, 2015, JAMA-J AM MED ASSOC, V314, P466, DOI 10.1001/jama.2015.8369; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Uddin LQ, 2015, NAT REV NEUROSCI, V16, P55, DOI 10.1038/nrn3857; Uddin LQ, 2011, J NEUROSCI, V31, P18578, DOI 10.1523/JNEUROSCI.4465-11.2011; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Venkatesan UM, 2015, J NEUROTRAUM, V32, P252, DOI 10.1089/neu.2013.3318; Whitfield-Gabrieli S, 2012, ANNU REV CLIN PSYCHO, V8, P49, DOI 10.1146/annurev-clinpsy-032511-143049; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Yarkoni T, 2009, PERSPECT PSYCHOL SCI, V4, P294, DOI 10.1111/j.1745-6924.2009.01127.x; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011	64	46	46	0	25	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	DEC	2017	11	6					1664	1677		10.1007/s11682-016-9643-1			14	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FO1VO	WOS:000416555800010	27766587				2022-02-06	
J	Jin, N; Zhu, HZ; Liang, X; Huang, W; Xie, QG; Xiao, P; Ni, JZ; Liu, Q				Jin, Na; Zhu, Huazhang; Liang, Xiao; Huang, Wei; Xie, Qingguo; Xiao, Peng; Ni, Jiazuan; Liu, Qiong			Sodium selenate activated Wnt/beta-catenin signaling and repressed amyloid-beta formation in a triple transgenic mouse model of Alzheimer's disease	EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer's disease (AD); Sodium selenate; Wnt/beta-catenin signaling; Protein phosphatases of type 2A (PP2A); beta-Amyloid (A beta); Neuronal apoptosis	PROTEIN PHOSPHATASE 2A; TRAUMATIC BRAIN-INJURY; PRECURSOR PROTEIN; HYPERPHOSPHORYLATED TAU; COGNITIVE DECLINE; A-BETA; THIOREDOXIN REDUCTASE; SURVIVIN EXPRESSION; CYTOPLASMIC DOMAIN; ACQUIRED EPILEPSY	Accumulating evidences show that selenium dietary intake is inversely associated with the mortality of Alzheimer's disease (AD). Sodium selenate has been reported to reduce neurofibrillary tangles (NFT) in the tauopathic mouse models, but its effects on the Wnt/beta-catenin signaling pathway and APP processing remain unknown during AD formation. In this paper, triple transgenic AD mice (3 x Tg-AD) had been treated with sodium selenate in drinking water for 10 month before the detection of hippocampal pathology. Increased A beta generation, tau hyperphosphorylation and neuronal apoptosis were found in the hippocampus of AD model mouse. Down-regulation of Wnt/beta-catenin signaling is closely associated with the alteration of AD pathology. Treatment with sodium selenate significantly promoted the activity of protein phosphatases of type 2A (PP2A) and repressed the hallmarks of AD. Activation of PP2A by sodium selenate could increase active beta-catenin level and inhibit GSK3 beta activity in the hippocampal tissue and primarily cultured neurons of AD model mouse, leading to activation of Wnt/beta-catenin signaling and transactivation of target genes, including positively-regulated genes c-myc, survivin, TXNRD2 and negatively-regulated gene BACE1. Meanwhile, APP phosphorylation was also reduced on the Thr668 residue after selenate treatment, causing the decreases of APP cleavage and A beta generation. These findings reveal that the Wnt/beta-catenin signaling is a potential target for prevention of AD and sodium selenate may be developed as a new drug for AD treatment. (C) 2017 Published by Elsevier Inc.	[Jin, Na; Zhu, Huazhang; Ni, Jiazuan; Liu, Qiong] Shenzhen Univ, Coll Life Sci & Oceanog, Shenzhen Key Lab Marine Biotechnol & Ecol, Shenzhen 518060, Peoples R China; [Liang, Xiao; Xie, Qingguo; Xiao, Peng] Huazhong Univ Sci & Technol, Coll Life Sci, Wuhan 430073, Hubei, Peoples R China; [Huang, Wei] Natl Qual Supervis & Inspect Ctr Selenium Enriche, Enshi 445000, Peoples R China		Liu, Q (corresponding author), Shenzhen Univ, Coll Life Sci & Oceanog, Shenzhen 518060, Guangdong, Peoples R China.	liuqiong@szu.edu.cn	Liu, Qiong/AAK-1556-2021		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31470804]; Shenzhen Bureau of Science, Technology and Information [JCYJ20150529164656093, JSGG20140703163838793]	This work was supported by the National Natural Science Foundation of China (No. 31470804), the Shenzhen Bureau of Science, Technology and Information (Nos. JCYJ20150529164656093, JSGG20140703163838793).	Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Alzheimers Assoc, 2011, ALZHEIMERS DEMENT, V7, P208, DOI 10.1016/j.jalz.2011.02.004; Beaudoin GMJ, 2012, NAT PROTOC, V7, P1741, DOI 10.1038/nprot.2012.099; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brady RD, 2016, J MUSCULOSKEL NEURON, V16, P369; Buee L, 2010, BIOCHEM SOC T, V38, P967, DOI 10.1042/BST0380967; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Caraci F, 2008, NEUROCHEM RES, V33, P2401, DOI 10.1007/s11064-008-9710-0; Cardoso BR, 2014, J TRACE ELEM MED BIO, V28, P422, DOI 10.1016/j.jtemb.2014.08.009; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Chang KA, 2006, MOL CELL BIOL, V26, P4327, DOI 10.1128/MCB.02393-05; Chu XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep32935; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Feng HY, 2016, EUR J NUCL MED MOL I, V43, P113, DOI 10.1007/s00259-015-3134-2; Fortress AM, 2016, NEUROSCIENTIST, V22, P278, DOI 10.1177/1073858415574728; Grimm MOW, 2014, CELL PHYSIOL BIOCHEM, V34, P92, DOI 10.1159/000362987; Gwon AR, 2010, NEUROSCI LETT, V469, P391, DOI 10.1016/j.neulet.2009.12.035; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoffmann PR, 2007, NUCLEIC ACIDS RES, V35, P3963, DOI 10.1093/nar/gkm355; Inestrosa NC, 2014, J MOL CELL BIOL, V6, P64, DOI 10.1093/jmcb/mjt051; Inestrosa NC, 2012, J NEUROIMMUNE PHARM, V7, P788, DOI 10.1007/s11481-012-9417-5; Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755; Ishrat T, 2009, BRAIN RES, V1281, P117, DOI 10.1016/j.brainres.2009.04.010; Jones NC, 2012, NEUROBIOL DIS, V45, P897, DOI 10.1016/j.nbd.2011.12.005; Kania KD, 2011, BRAIN RES, V1418, P1, DOI 10.1016/j.brainres.2011.08.044; Kipp AP, 2012, BBA-GEN SUBJECTS, V1820, P1588, DOI 10.1016/j.bbagen.2012.05.016; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; Lin H, 2014, AM J RESP CRIT CARE, V189, P697, DOI 10.1164/rccm.201310-1776OC; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu Rong, 2009, Pathophysiology, V16, P273, DOI 10.1016/j.pathophys.2009.02.008; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Lovell MA, 2000, FREE RADICAL BIO MED, V28, P418, DOI 10.1016/S0891-5849(99)00258-0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Oliveira JM, 2015, J ALZHEIMERS DIS, V45, P495, DOI 10.3233/JAD-142664; Parr C, 2015, FASEB J, V29, P623, DOI 10.1096/fj.14-253211; Pillai R, 2014, IUBMB LIFE, V66, P229, DOI 10.1002/iub.1262; Purro SA, 2014, J MOL CELL BIOL, V6, P75, DOI 10.1093/jmcb/mjt049; Rosi MC, 2010, J NEUROCHEM, V112, P1539, DOI 10.1111/j.1471-4159.2009.06566.x; Sanchez-Elexpuru G, 2017, EPILEPSIA, V58, P467, DOI 10.1111/epi.13656; Schmitt U, 2009, NEUROSCIENCE, V162, P234, DOI 10.1016/j.neuroscience.2009.04.046; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Selenius M, 2010, ANTIOXID REDOX SIGN, V12, P867, DOI 10.1089/ars.2009.2884; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Shin RW, 2007, ACTA NEUROPATHOL, V113, P627, DOI 10.1007/s00401-007-0211-z; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Silva-Alvarez C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00097; Solovyev ND, 2015, J INORG BIOCHEM, V153, P1, DOI 10.1016/j.jinorgbio.2015.09.003; Song GL, 2014, J ALZHEIMERS DIS, V41, P85, DOI 10.3233/JAD-131805; Sontag E, 2007, J NEUROSCI, V27, P2751, DOI 10.1523/JNEUROSCI.3316-06.2007; Triaca V, 2016, AGING CELL, V15, P661, DOI 10.1111/acel.12473; Tung YT, 2008, NEUROSCI LETT, V440, P38, DOI 10.1016/j.neulet.2008.05.048; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vargas JY, 2014, J NEUROSCI, V34, P2191, DOI 10.1523/JNEUROSCI.0862-13.2014; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Voronkov M, 2011, FUTURE MED CHEM, V3, P821, DOI [10.4155/fmc.11.47, 10.4155/FMC.11.47]; Wan WB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/301575; Wang LY, 2015, PHYS MED BIOL, V60, P137, DOI 10.1088/0031-9155/60/1/137; Weekley CM, 2013, CHEM SOC REV, V42, P8870, DOI 10.1039/c3cs60272a; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Xiong SL, 2007, ANTIOXID REDOX SIGN, V9, P457, DOI 10.1089/ars.2006.1363; Yin HW, 2011, DIFFERENTIATION, V81, P49, DOI 10.1016/j.diff.2010.09.180; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540; Zenzmaier C, 2009, J NEUROCHEM, V110, P653, DOI 10.1111/j.1471-4159.2009.06158.x; Zhang JW, 2015, BRATISL MED J, V116, P184, DOI 10.4149/BLL_2015_037; Zhang S, 2010, MECH AGEING DEV, V131, P253, DOI 10.1016/j.mad.2010.02.006; Zhang T, 2001, CANCER RES, V61, P8664; Zhang Y, 2008, J BIOL CHEM, V283, P2427, DOI 10.1074/jbc.M707951200; Zhang ZH, 2017, J NEUROSCI, V37, P2449, DOI 10.1523/JNEUROSCI.3229-16.2017; Zhang ZH, 2016, METALLOMICS, V8, P782, DOI [10.1039/c6mt00117c, 10.1039/C6MT00117C]; Zheng L, 2016, SCI REP-UK, V6, DOI 10.1038/srep39290; Zheng P, 2014, MOL NEUROBIOL, V49, P1532, DOI 10.1007/s12035-013-8601-9; Zhu HX, 2010, CANCER SCI, V101, P1156, DOI 10.1111/j.1349-7006.2010.01528.x	79	46	52	2	49	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2017	297						36	49		10.1016/j.expneurol.2017.07.006			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ3GA	WOS:000412617300004	28711506				2022-02-06	
J	Sun, MJ; Brady, RD; Wright, DK; Kim, HA; Zhang, SR; Sobey, CG; Johnstone, MR; O'Brien, TJ; Semple, BD; McDonald, SJ; Shultz, SR				Sun, Mujun; Brady, Rhys D.; Wright, David K.; Kim, Hyun Ah; Zhang, Shenpeng R.; Sobey, Christopher G.; Johnstone, Maddison R.; O'Brien, Terence J.; Semple, Bridgette D.; McDonald, Stuart J.; Shultz, Sandy R.			Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Fracture; Multitrauma; IL-beta; Neuroinflammation; MRI	CLOSED-HEAD INJURY; ANIMAL-MODEL; OVEREXPRESSION; OUTCOMES; IMPACT; MILD; INFLAMMATION; POLARIZATION; LIPOCALIN-2; ACTIVATION	Traumatic brain injury (TBI) and long bone fracture are common in polytrauma. This injury combination in mice results in elevated levels of the pro-inflammatory cytokine interleukin-1p (IL-18) and exacerbated neuropathology when compared to isolated-TBI. Here we examined the effect of treatment with an IL-1 receptor antagonist (IL-1ra) in mice given a TBI and a concomitant tibial fracture (i.e., poly trauma). Adult male C57BL/6 mice were given sham-injuries or polytrauma and treated with saline vehicle or IL-lra (100 mg/1<g). Treatments were subcutaneously injected at 1,6, and 24 h, and then once daily for one week post-injury. 7-8 mice/group were euthanized at 48 h post-injury. 12-16 mice/group underwent behavioral testing at 12 weeks post-injury and MRI at 14 weeks post-injury before being euthanized at 16 weeks post-injury. At 48 h post-injury, markers for activated microglia and astrocytes, as well as neutrophils and edema, were decreased in polytrauma mice treated with IL-lra compared to polytrauma mice treated with vehicle. At 14 weeks post-injury, MRI analysis demonstrated that IL-1 ra treatment after polytrauma reduced volumetric loss in the injured cortex and mitigated track weighted MRI markers for axonal injury. As IL-1 ra (Anakinra) is approved for human use, it may represent a promising therapy in polytrauma cases involving TBI and fracture. Crown Copyright (C) 2017 Published by Elsevier Inc. All rights reserved.	[Sun, Mujun; Brady, Rhys D.; O'Brien, Terence J.; Semple, Bridgette D.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia; [Brady, Rhys D.; Kim, Hyun Ah; Zhang, Shenpeng R.; Sobey, Christopher G.; Johnstone, Maddison R.; McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3083, Australia; [Wright, David K.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Zhang, Shenpeng R.] Monash Univ, Dept Pharmacol, Melbourne, Vic 3800, Australia; [Wright, David K.; O'Brien, Terence J.; Semple, Bridgette D.; Shultz, Sandy R.] Monash Univ, Dept Neurosci, Melbourne, Vic 3004, Australia; [Wright, David K.; O'Brien, Terence J.; Semple, Bridgette D.; Shultz, Sandy R.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia		Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Melbourne Brain Ctr, Off 1-02, Parkville, Vic 3052, Australia.	sshultz@unimelb.edu.au	Sobey, Christopher G/A-2786-2008; O'Brien, Terence/L-8102-2013; O'Brien, Terence/AAU-5525-2021	Sobey, Christopher G/0000-0001-6525-9097; McDonald, Stuart/0000-0001-5190-3179; O'Brien, Terence/0000-0002-7198-8621; Sun, Mujun/0000-0002-9923-9913; Wright, David/0000-0002-7535-8651	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1062653]; La Trobe University; NHMRCNational Health and Medical Research Council of Australia	This work was supported by grants to SRS from the National Health and Medical Research Council (grant number 1062653) and to SJM from La Trobe University (RFA Understanding Disease), as well as fellowships to SRS and BDS from NHMRC. We acknowledge the scientific and technical assistance of the animal MRI facility at the Florey Institute of Neuroscience and Mental Health, a node of the National Imaging Facility.	Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Brady RD, 2016, SCI REP-UK, V6, DOI 10.1038/srep34491; Brady RD, 2014, J ORTHOP RES, V32, P1277, DOI 10.1002/jor.22686; Brait VH, 2011, BRAIN RES, V1372, P169, DOI 10.1016/j.brainres.2010.11.087; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Diamond ML, 2015, EPILEPSIA, V56, P991, DOI 10.1111/epi.13100; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Franklin K., 2007, MOUSE BRAIN STEREOTA, VThird; Greenhalgh AD, 2010, BRIT J PHARMACOL, V160, P153, DOI 10.1111/j.1476-5381.2010.00684.x; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Jin M, 2014, J CEREBR BLOOD F MET, V34, P1306, DOI 10.1038/jcbfm.2014.83; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Leitgeb J, 2013, ARCH ORTHOP TRAUM SU, V133, P659, DOI 10.1007/s00402-013-1710-0; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Masada T, 2001, J NEUROSURG, V95, P680, DOI 10.3171/jns.2001.95.4.0680; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; McDonald SJ, 2011, J ORTHOP RES, V29, P740, DOI 10.1002/jor.21302; Minter MR, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0341-4; Morganti J.M., 2016, PLOS ONE; Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x; Pape H.-C., 2010, DAMAGR CONTROL MANAG; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tournier J.D., 2010, P INT SOC MAGNETIC R, P1670; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wright D, 2017, J NEUROTRAUM, DOI DOI 10.1089/neu.2017.5204; Wright D.K., 2016, CEREB CORTEX; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2	56	46	46	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2017	66						359	371		10.1016/j.bbi.2017.08.005			13	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	FL4YE	WOS:000414236600034	28782716				2022-02-06	
J	Tavakoli, S; Peitz, G; Ares, W; Hafeez, S; Grandhi, R				Tavakoli, Samon; Peitz, Geoffrey; Ares, William; Hafeez, Shaheryar; Grandhi, Ramesh			Complications of invasive intracranial pressure monitoring devices in neurocritical care	NEUROSURGICAL FOCUS			English	Article						intracranial monitoring; infection; hemorrhage; complications; considerations; neurocritical care	EXTERNAL VENTRICULAR DRAIN; TRAUMATIC BRAIN-INJURY; HEMORRHAGIC COMPLICATIONS; INTRACEREBRAL HEMORRHAGE; ANTIBIOTIC-PROPHYLAXIS; CATHETER PLACEMENT; CLINICAL-PRACTICE; INFECTION-RATES; RISK-FACTORS; ACCURACY	Intracranial pressure monitoring devices have become the standard of care for the management of patients with pathologies associated with intracranial hypertension. Given the importance of invasive intracranial monitoring devices in the modern neurointensive care setting, gaining a thorough understanding of the potential complications related to device placement- and misplacement-is crucial. The increased prevalence of intracranial pressure monitoring as a management tool for neurosurgical patients has led to the publication of a plethora of papers regarding their indications and complications. The authors aim to provide a concise review of key contemporary articles in the literature concerning important complications with the hope of elucidating practices that improve outcomes for neurocritically ill patients.	[Tavakoli, Samon; Peitz, Geoffrey; Hafeez, Shaheryar; Grandhi, Ramesh] Univ Texas Hlth San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Ares, William] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA		Grandhi, R (corresponding author), Univ Texas Hlth San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	grandhi@uthscsa.edu					Abdoh MG, 2012, ACTA NEUROCHIR, V154, P153, DOI 10.1007/s00701-011-1136-9; AlAzri A, 2017, ACTA NEUROCHIR, V159, P1399, DOI 10.1007/s00701-017-3201-5; Bauer DF, 2011, NEUROSURGERY, V69, P255, DOI 10.1227/NEU.0b013e31821a45ba; Baum GR, 2017, J NEUROSURG, V127, P1190, DOI 10.3171/2016.9.JNS16367; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Bergdal O, 2013, CLIN NEUROL NEUROSUR, V115, P1972, DOI 10.1016/j.clineuro.2013.05.026; Binz DD, 2009, NEUROCRIT CARE, V10, P253, DOI 10.1007/s12028-009-9193-0; BLOMSTEDT GC, 1985, J NEUROSURG, V62, P694, DOI 10.3171/jns.1985.62.5.0694; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chatzi M, 2014, CRIT CARE MED, V42, P66, DOI 10.1097/CCM.0b013e31829a70a5; Citerio G, 2015, CRIT CARE MED, V43, P1630, DOI 10.1097/CCM.0000000000001019; Dandy WE, 1918, ANN SURG, V68, P5, DOI 10.1097/00000658-191807000-00002; Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901; Dengler BA, 2016, NEUROCRIT CARE, V25, P215, DOI 10.1007/s12028-016-0280-8; Dey M, 2015, NEUROSURGERY, V76, P291, DOI 10.1227/NEU.0000000000000624; Dimitriou J, 2016, WORLD NEUROSURG, V89, P641, DOI 10.1016/j.wneu.2015.11.037; Ehtisham A, 2009, NEUROCRIT CARE, V10, P241, DOI 10.1007/s12028-008-9097-4; Foreman PM, 2015, CLIN NEUROL NEUROSUR, V128, P94, DOI 10.1016/j.clineuro.2014.09.026; Fried HI, 2016, NEUROCRIT CARE, V24, P61, DOI 10.1007/s12028-015-0224-8; Gard AP, 2017, NEUROCRIT CARE; Gardner PA, 2009, J NEUROSURG, V110, P1021, DOI 10.3171/2008.9.JNS17661; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; GOPINATH SP, 1993, J NEUROSCI METH, V49, P11, DOI 10.1016/0165-0270(93)90104-Y; Gozal YM, 2014, NEUROCRIT CARE, V21, P147, DOI 10.1007/s12028-013-9936-9; Gray WP, 1996, NEUROSURGERY, V39, P927, DOI 10.1097/00006123-199611000-00008; Guyot LL, 1998, ACT NEUR S, V71, P47; Harrop JS, 2010, NEUROSURGERY, V67, P187, DOI 10.1227/01.NEU.0000370247.11479.B6; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Honda H, 2010, INFECT CONT HOSP EP, V31, P1078, DOI 10.1086/656377; Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088; Jacobs DG, 1998, J NATL MED ASSOC, V90, P417; Jensen TS, 2016, ACTA NEUROCHIR, V158, P1491, DOI 10.1007/s00701-016-2863-8; Kakarla UK, 2008, NEUROSURGERY, V63, P162, DOI 10.1227/01.NEU.0000312390.83127.7F; Koskinen LOD, 2013, ACTA NEUROCHIR, V155, P2141, DOI 10.1007/s00701-013-1856-0; Krotz M, 2004, EUR RADIOL, V14, P227, DOI 10.1007/s00330-003-2134-y; Leschke JM, 2017, NEUROCRIT CARE, V27, P11, DOI 10.1007/s12028-016-0350-y; Lewis A, 2016, BRIT J NEUROSURG, V30, P49, DOI 10.3109/02688697.2015.1080222; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Mahan M, 2013, J CLIN NEUROSCI, V20, P1718, DOI 10.1016/j.jocn.2013.03.005; Maniker AH, 2006, NEUROSURGERY, V59, P419, DOI 10.1227/01.NEU.0000222817.99752.E6; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Miller C, 2017, J NEUROSURG, V126, P289, DOI 10.3171/2015.12.JNS152341; Murthy SB, 2016, NEUROCRIT CARE, V24, P389, DOI 10.1007/s12028-015-0199-5; Naff N, 2011, STROKE, V42, P3009, DOI 10.1161/STROKEAHA.110.610949; O'Leary ST, 2000, J NEUROSURG, V92, P801, DOI 10.3171/jns.2000.92.5.0801; Park P, 2004, NEUROSURGERY, V55, P594, DOI 10.1227/01.NEU.0000134289.04500.EE; Poblete R, 2017, WORLD NEUROSURG, V99, P599, DOI 10.1016/j.wneu.2016.12.073; Pople I, 2012, NEUROSURGERY, V71, P6, DOI 10.1227/NEU.0b013e3182544e31; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Reyes MM, 2017, INFECT CONT HOSP EP, V38, P574, DOI 10.1017/ice.2017.21; ROSEGAY H, 1992, J NEUROSURG, V76, P1032, DOI 10.3171/jns.1992.76.6.1032; Saladino A, 2009, NEUROCRIT CARE, V10, P248, DOI 10.1007/s12028-008-9154-z; Srinivasan VM, 2014, J NEUROSURG, V120, P228, DOI 10.3171/2013.6.JNS121577; Stoikes NF, 2008, SURG INFECT, V9, P503, DOI 10.1089/sur.2007.032; Sussman ES, 2014, J NEUROSURG, V120, P931, DOI 10.3171/2013.12.JNS131685; Tanweer O, 2013, J NEUROSURG, V119, P1309, DOI 10.3171/2013.7.JNS13313; Tunkel AR, 2017, CLIN INFECT DIS, V64, P701, DOI 10.1093/cid/cix152; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	59	46	47	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2017	43	5							E6	10.3171/2017.8.FOCUS17450			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FL5JE	WOS:000414270800017	29088962	gold			2022-02-06	
J	Brunden, KR; Lee, VMY; Smith, AB; Trojanowski, BQ; Ballatore, C				Brunden, Kurt R.; Lee, Virginia M-Y.; Smith, Amos B., III; Trojanowski, Bjohn Q.; Ballatore, Carlo			Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs	NEUROBIOLOGY OF DISEASE			English	Article						Alzheimer; Amyotrophic lateral sclerosis; Axons; Frontotemporal lobar degeneration; Microtubules; Neurodegeneration; Parkinson; Transport; Traumatic brain injury	TRANSGENIC MOUSE MODEL; PAIRED HELICAL FILAMENTS; AXONAL-TRANSPORT DEFECTS; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; EPOTHILONE D; BRAIN-PENETRANT; TAU-HYPERPHOSPHORYLATION; NEUROFIBRILLARY TANGLES; DOPAMINERGIC-NEURONS	Many neurodegenerative diseases are characterized by deficiencies in neuronal axonal transport, a process in which cellular cargo is shuttled with the aid of molecular motors from the cell body to axonal termini and back along microtubules (MTs). Proper axonal transport is critical to the normal functioning of neurons, and impairments in this process could contribute to the neuronal damage and death that is characteristic of neurodegenerative disease. Although the causes of axonal transport abnormalities may vary among the various neurodegenerative conditions, in many cases it appears that the transport deficiencies result from a diminution of axonal MT stability. Here we review the evidence of MT abnormalities in a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and traumatic brain injury, and highlight the potential benefit of MT-stabilizing agents in improving axonal transport and nerve function in these diseases. Moreover, we discuss the challenges associated with the utilization of MT-stabilizing drugs as therapeutic candidates for neurodegenerative conditions. (C) 2016 Elsevier Inc. All rights reserved.	[Brunden, Kurt R.; Lee, Virginia M-Y.; Trojanowski, Bjohn Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Smith, Amos B., III] Univ Penn, Dept Chem, Sch Arts & Sci, Philadelphia, PA 19104 USA; [Ballatore, Carlo] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA		Brunden, KR (corresponding author), Ctr Neurodegenerat Dis Res, 3600 Spruce St,Maloney 3, Philadelphia, PA 19104 USA.	kbrunden@upenn.edu	Ballatore, Carlo/L-1034-2017	Ballatore, Carlo/0000-0002-2718-3850	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG044332, NS087059]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, P01AG017586, R01AG044332] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grants AG044332 and NS087059. The authors also gratefully acknowledge the charitable contributions to the Center for Neurodegenerative Disease Research from the "The Woods" Charitable Foundation, the Karen Cohen Segal and Christopher S. Segal Alzheimer Drug Discovery Initiative Fund, the Paula C. Schmerler Fund for Alzheimer's Research, the Barrist Neurodegenerative Disease Research Fund, the Eleanor Margaret Kurtz Endowed Fund, the Mary Rasmus Endowed Fund for Alzheimer's Research, Mrs. Gloria J. Miller and Arthur Peck, M.D.	Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; ALONSO AD, 1994, NEUROBIOL AGING, V15, pS37; Amos LA, 2004, ORG BIOMOL CHEM, V2, P2153, DOI 10.1039/b403634d; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Baldwin KR, 2016, HUM MOL GENET, V25, P2378, DOI 10.1093/hmg/ddw105; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Ballatore C, 2012, J MED CHEM, V55, P8979, DOI 10.1021/jm301079z; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Barten DM, 2012, J NEUROSCI, V32, P7137, DOI 10.1523/JNEUROSCI.0188-12.2012; Bedard PL, 2010, NAT REV CLIN ONCOL, V7, P22, DOI 10.1038/nrclinonc.2009.186; Bellouze S, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0111-6; Black MM, 1996, J NEUROSCI, V16, P3601; Boxer AL, 2014, LANCET NEUROL, V13, P676, DOI 10.1016/S1474-4422(14)70088-2; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Brizuela M, 2015, MOL CELL NEUROSCI, V66, P129, DOI 10.1016/j.mcn.2015.02.006; Brunden KR, 2014, BIOORGAN MED CHEM, V22, P5040, DOI 10.1016/j.bmc.2013.12.046; Brunden KR, 2013, ACS MED CHEM LETT, V4, P886, DOI 10.1021/ml400233e; Brunden KR, 2011, PHARMACOL RES, V63, P341, DOI 10.1016/j.phrs.2010.12.002; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Burre J, 2015, J PARKINSON DIS, V5, P699, DOI 10.3233/JPD-150642; Cappelletti G, 2005, FEBS LETT, V579, P4781, DOI 10.1016/j.febslet.2005.07.058; Cappelletti G, 1999, J NEUROSCI RES, V56, P28, DOI 10.1002/(SICI)1097-4547(19990401)56:1<28::AID-JNR4>3.0.CO;2-2; Cartelli D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01837; Cartelli D, 2010, J NEUROCHEM, V115, P247, DOI 10.1111/j.1471-4159.2010.06924.x; Cohen TJ, 2011, TRENDS MOL MED, V17, P659, DOI 10.1016/j.molmed.2011.06.004; Cortes J, 2007, ONCOLOGIST, V12, P271, DOI 10.1634/theoncologist.12-3-271; Cross DJ, 2015, BRAIN RES, V1618, P299, DOI 10.1016/j.brainres.2015.06.006; Daniels JA, 2008, AM J SURG PATHOL, V32, P473, DOI 10.1097/PAS.0b013e3181582331; Dawson HN, 2001, J CELL SCI, V114, P1179; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Falzone TL, 2010, HUM MOL GENET, V19, P4399, DOI 10.1093/hmg/ddq363; Falzone TL, 2009, J NEUROSCI, V29, P5758, DOI 10.1523/JNEUROSCI.0780-09.2009; Fanara P, 2007, J BIOL CHEM, V282, P23465, DOI 10.1074/jbc.M703434200; Fanara P, 2012, J CLIN INVEST, V122, P3159, DOI 10.1172/JCI64575; Fitzgerald DP, 2012, MOL CANCER THER, V11, P1959, DOI 10.1158/1535-7163.MCT-12-0061; Fukushima N, 2009, J NEUROCHEM, V109, P683, DOI 10.1111/j.1471-4159.2009.06013.x; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gozes I, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00205; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Haggerty T, 2011, EUR J NEUROSCI, V33, P1598, DOI 10.1111/j.1460-9568.2011.07660.x; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hempen B, 1996, J NEUROPATH EXP NEUR, V55, P964, DOI 10.1097/00005072-199609000-00003; Hirokawa N, 2008, PHYSIOL REV, V88, P1089, DOI 10.1152/physrev.00023.2007; Holy J, 1998, J TOXICOL ENV HEAL A, V54, P319, DOI 10.1080/009841098158872; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Irwin DJ, 2013, NAT REV NEUROSCI, V14, P626, DOI 10.1038/nrn3549; Ishikawa T, 2012, J STRUCT BIOL, V179, P229, DOI 10.1016/j.jsb.2012.05.016; Janning D, 2014, MOL BIOL CELL, V25, P3541, DOI 10.1091/mbc.E14-06-1099; Jiang Q, 2008, J NEUROSCI, V28, P12993, DOI 10.1523/JNEUROSCI.2860-08.2008; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kaul T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-79; Kawakami F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030834; Ke Yazi D, 2012, Int J Alzheimers Dis, V2012, P873270, DOI 10.1155/2012/873270; Kempf M, 1996, J NEUROSCI, V16, P5583; Kett LR, 2012, HUM MOL GENET, V21, P890, DOI 10.1093/hmg/ddr526; Khanna MR, 2016, ALZHEIMERS DEMENT, V12, P1051, DOI 10.1016/j.jalz.2016.06.006; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; Killinger BA, 2016, J NEUROCHEM, V136, P510, DOI 10.1111/jnc.13391; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kleele T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5827; Konzack S, 2007, J NEUROSCI, V27, P9916, DOI 10.1523/JNEUROSCI.0927-07.2007; Kovalevich J, 2016, J PHARMACOL EXP THER, V357, P432, DOI 10.1124/jpet.115.231175; Lee HJ, 2006, EUR J NEUROSCI, V24, P3153, DOI 10.1111/j.1460-9568.2006.05210.x; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leo L, 2015, CELL REP, V12, P1723, DOI 10.1016/j.celrep.2015.08.017; Lin X, 2009, NEURON, V64, P807, DOI 10.1016/j.neuron.2009.11.006; Lou K, 2014, J MED CHEM, V57, P6116, DOI 10.1021/jm5005623; Magrane J, 2014, HUM MOL GENET, V23, P1413, DOI 10.1093/hmg/ddt528; Makani V, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0378-4; Malamut R, 2013, ALZHEIMERS DEMENT, V9, DOI [10.1016/j.jalz.2013.05.1378, DOI 10.1016/j.jalz.2013.05.1378]; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; Matsuda W, 2009, J NEUROSCI, V29, P444, DOI 10.1523/JNEUROSCI.4029-08.2009; Matsuoka Y, 2008, J PHARMACOL EXP THER, V325, P146, DOI 10.1124/jpet.107.130526; Matsuoka Y, 2007, J MOL NEUROSCI, V31, P165, DOI 10.1385/JMN/31:02:165; McKee AC, 2016, NEUROSURG CLIN N AM, V27, P529, DOI 10.1016/j.nec.2016.05.009; Munch C, 2005, ANN NEUROL, V58, P777, DOI 10.1002/ana.20631; Nacharaju P, 1999, J NEUROPATH EXP NEUR, V58, P545, DOI 10.1097/00005072-199905000-00157; Nelson PT, 2016, J NEUROPATH EXP NEUR, V75, P482, DOI 10.1093/jnen/nlw033; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524; Ori-McKenney KM, 2012, NEURON, V76, P921, DOI 10.1016/j.neuron.2012.10.008; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Penazzi L, 2016, INT REV CEL MOL BIO, V321, P89, DOI 10.1016/bs.ircmb.2015.09.004; Peters OM, 2015, J CLIN INVEST, V125, P2548, DOI 10.1172/JCI82693; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Qiang L, 2006, J NEUROSCI, V26, P3120, DOI 10.1523/JNEUROSCI.5392-05.2006; Ren Y, 2005, J BIOL CHEM, V280, P34105, DOI 10.1074/jbc.M503483200; Ren Y, 2015, STEM CELLS, V33, P68, DOI 10.1002/stem.1854; Robberecht W, 2013, NAT REV NEUROSCI, V14, P248, DOI 10.1038/nrn3430; Rosso SB, 2000, TOXICOL SCI, V56, P133, DOI 10.1093/toxsci/56.1.133; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Shaw CA, 2008, NEUROMOL MED, V10, P1, DOI 10.1007/s12017-007-8016-8; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; St George-Hyslop PH, 2005, CR BIOL, V328, P119, DOI 10.1016/j.crvi.2004.10.013; Stiess M, 2010, SCIENCE, V327, P704, DOI 10.1126/science.1182179; Sudo H, 2011, HUM MOL GENET, V20, P763, DOI 10.1093/hmg/ddq521; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Toledo JB, 2013, BRAIN, V136, P2697, DOI 10.1093/brain/awt188; Vershinin M, 2007, P NATL ACAD SCI USA, V104, P87, DOI 10.1073/pnas.0607919104; Wade Richard H, 2007, Methods Mol Med, V137, P1, DOI 10.1007/978-1-59745-442-1_1; WILCOCK GK, 1982, J NEUROL SCI, V56, P343, DOI 10.1016/0022-510X(82)90155-1; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Wills J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017953; Young JS, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0719-9; Yu WQ, 2008, MOL BIOL CELL, V19, P1485, DOI 10.1091/mbc.E07-09-0878; Yuan A, 2008, J NEUROSCI, V28, P1682, DOI 10.1523/JNEUROSCI.5242-07.2008; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307; Zhang B, 2005, P NATL ACAD SCI USA, V102, P227, DOI 10.1073/pnas.0406361102; Zhang B, 2012, J NEUROSCI, V32, P3601, DOI 10.1523/JNEUROSCI.4922-11.2012; Zhao Y, 2016, PHARMACOL THERAPEUT, V162, P134, DOI 10.1016/j.pharmthera.2015.12.006; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	123	46	46	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2017	105						328	335		10.1016/j.nbd.2016.12.021			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FC3JG	WOS:000406734300027	28012891	Green Accepted			2022-02-06	
J	Schwedt, TJ; Chong, CD; Peplinski, J; Ross, K; Berisha, V				Schwedt, Todd J.; Chong, Catherine D.; Peplinski, Jacob; Ross, Katherine; Berisha, Visar			Persistent post-traumatic headache vs. migraine: an MRI study demonstrating differences in brain structure	JOURNAL OF HEADACHE AND PAIN			English	Article						Post-traumatic headache; Migraine; Traumatic brain injury; Magnetic resonance imaging; Brain structure; Brain volume; Brain curvature; Brain surface area; Cortical thickness	MEDICATION-OVERUSE HEADACHE; FUNCTIONAL CONNECTIVITY; PAIN SENSITIVITY; RESTING-STATE; SEGMENTATION; ACCURATE; TRAUMA	Background: The majority of individuals with post-traumatic headache have symptoms that are indistinguishable from migraine. The overlap in symptoms amongst these individuals raises the question as to whether post-traumatic headache has a unique pathophysiology or if head trauma triggers migraine. The objective of this study was to compare brain structure in individuals with persistent post-traumatic headache (i.e. headache lasting at least 3 months following a traumatic brain injury) attributed to mild traumatic brain injury to that of individuals with migraine. Methods: Twenty-eight individuals with persistent post-traumatic headache attributed to mild traumatic brain injury and 28 individuals with migraine underwent brain magnetic resonance imaging on a 3 T scanner. Regional volumes, cortical thickness, surface area and curvature measurements were calculated from T1-weighted sequences and compared between subject groups using ANCOVA. MRI data from 28 healthy control subjects were used to interpret the differences in brain structure between migraine and persistent post-traumatic headache. Results: Differences in regional volumes, cortical thickness, surface area and brain curvature were identified when comparing the group of individuals with persistent post-traumatic headache to the group with migraine. Structure was different between groups for regions within the right lateral orbitofrontal lobe, left caudal middle frontal lobe, left superior frontal lobe, left precuneus and right supramarginal gyrus (p < .05). Considering these regions only, there were differences between individuals with persistent post-traumatic headache and healthy controls within the right lateral orbitofrontal lobe, right supramarginal gyrus, and left superior frontal lobe and no differences when comparing the migraine cohort to healthy controls. Conclusions: In conclusion, persistent post-traumatic headache and migraine are associated with differences in brain structure, perhaps suggesting differences in their underlying pathophysiology. Additional studies are needed to further delineate similarities and differences in brain structure and function that are associated with post-traumatic headache and migraine and to determine their specificity for each of the headache types.	[Schwedt, Todd J.; Chong, Catherine D.] Mayo Clin Arizona, 5777 East Mayo Blvd, Phoenix, AZ 85255 USA; [Ross, Katherine] Phoenix VA Hlth Care Syst, Phoenix, AZ USA; [Chong, Catherine D.; Peplinski, Jacob; Berisha, Visar] Arizona State Univ, Phoenix, AZ USA		Schwedt, TJ (corresponding author), Mayo Clin Arizona, 5777 East Mayo Blvd, Phoenix, AZ 85255 USA.	Schwedt.todd@mayo.edu		Berisha, Visar/0000-0001-8804-8874	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH K23NS070891]; Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program [W81XWH-15-1-0286]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS070891] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (NIH) grant NIH K23NS070891 and by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-15-1-0286. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.	Becker S, 2012, NEUROSCI LETT, V520, P182, DOI 10.1016/j.neulet.2012.03.013; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Chanraud S, 2014, CEPHALALGIA, V34, P605, DOI 10.1177/0333102413519514; Chiapparini L, 2009, NEUROL SCI, V30, pS71, DOI 10.1007/s10072-009-0077-z; Chou KH, 2016, CEPHALALGIA; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Emerson NM, 2014, PAIN, V155, P566, DOI 10.1016/j.pain.2013.12.004; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Ferraro S, 2012, PAIN MED, V13, P255, DOI 10.1111/j.1526-4637.2011.01183.x; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Goffaux P, 2014, BRAIN TOPOGR, V27, P366, DOI 10.1007/s10548-013-0291-0; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Jia ZH, 2017, NEUROIMAGE-CLIN, V14, P130, DOI 10.1016/j.nicl.2017.01.019; Jin CW, 2013, NMR BIOMED, V26, P58, DOI 10.1002/nbm.2819; King JB, 2016, NEUROIMAGE-CLIN, V11, P81, DOI 10.1016/j.nicl.2016.01.003; Kong J, 2006, HUM BRAIN MAPP, V27, P715, DOI 10.1002/hbm.20213; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Michels L, 2017, CEPHALALGIA, V37, P764, DOI 10.1177/0333102416652625; Moulton EA, 2012, J NEUROSCI, V32, P6024, DOI 10.1523/JNEUROSCI.0006-12.2012; Obermann M, 2009, NEUROLOGY, V73, P978, DOI 10.1212/WNL.0b013e3181b8791a; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Schwedt TJ, 2017, HEADACHE, V57, P1051, DOI 10.1111/head.13121; Schwedt TJ, 2017, HEADACHE, V57, P1173, DOI 10.1111/head.13037; Schwedt TJ, 2015, HEADACHE, V55, P762, DOI 10.1111/head.12584; Schwedt TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099791; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Spielberger CD., 1983, STATE TRAIT ANXIETY; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Sussman D, 2017, NEUROSCI LETT, V650, P52, DOI 10.1016/j.neulet.2017.04.026; Tessitore A, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-89; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Xue T, 2013, NMR BIOMED, V26, P1051, DOI 10.1002/nbm.2917; Yang FC, 2015, J NEUROL NEUROSUR PS, V86, P437, DOI 10.1136/jnnp-2014-308122; Zhang JL, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0692-z	41	46	48	1	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1129-2369	1129-2377		J HEADACHE PAIN	J. Headache Pain	AUG 22	2017	18								87	10.1186/s10194-017-0796-0			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FE3UZ	WOS:000408142500002	28831776	gold, Green Published, Green Accepted			2022-02-06	
J	Esterov, D; Greenwald, BD				Esterov, Dmitry; Greenwald, Brian D.			Autonomic Dysfunction after Mild Traumatic Brain Injury	BRAIN SCIENCES			English	Article						mild traumatic brain injury; mild TBI; concussion; autonomic dysfunction; dysautonomia; heart rate variability; graded exercise testing; post concussive syndrome	HEART-RATE-VARIABILITY; NERVOUS-SYSTEM; CONCUSSION RECOVERY; MANAGEMENT; DISORDERS; HISTORY; IMPACT	A mild traumatic brain injury (mTBI) is a complex pathophysiologic process that has a systemic effect on the body aside from solely an impairment in cognitive function. Dysfunction of the autonomic nervous system (ANS) has been found to induce abnormalities in organ systems throughout the body, and may contribute to cardiovascular dysregulation and increased mortality. Autonomic dysfunction, also known as dysautonomia, has been studied in moderate and severe TBI, and has emerged as a major contributing factor in the symptomatology in mTBI as well. Analysis of the ANS has been studied through changes in heart rate variability (HRV), pupillary dynamics, eye pressure, and arterial pulse wave in those with mild TBI. Graded exercise testing has been studied as both a method of diagnosis and as a means of recovery in those with mild TBI, especially in those with persistent symptoms. Given the studies showing persistence of autonomic dysfunction after symptomatic resolution of concussions, further research is needed to establish return to play protocols	[Esterov, Dmitry] JFK Johnson Rehabil Inst, Edison, NJ 08820 USA; [Greenwald, Brian D.] JFK Johnson Rehabil Inst, JFK Ctr Head Injuries, Edison, NJ 08820 USA		Esterov, D (corresponding author), JFK Johnson Rehabil Inst, Edison, NJ 08820 USA.; Greenwald, BD (corresponding author), JFK Johnson Rehabil Inst, JFK Ctr Head Injuries, Edison, NJ 08820 USA.	desterov@jfkhealth.org; BGreenwald@jfkhealth.org					Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; AGGARWAL A, 1994, GASTROENTEROLOGY, V106, P945, DOI 10.1016/0016-5085(94)90753-6; Albalawi T., 2017, J NEUROTRAUM, DOI [10.1089/neu.2017.506028537493, DOI 10.1089/NEU.2017.506028537493]; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alvares GA, 2016, J PSYCHIATR NEUROSCI, V41, P89, DOI 10.1503/jpn.140217; Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Bishop S, 2017, BRAIN INJURY, V31, P247, DOI 10.1080/02699052.2016.1226385; Blake TA, 2016, BRAIN INJURY, V30, P132, DOI 10.3109/02699052.2015.1093659; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; Dobson JL, 2017, AM J PHYSIOL-REG I, V312, pR575, DOI 10.1152/ajpregu.00499.2016; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Fountaine M. F. L., 2016, FRONT NEUROL, V7, P13, DOI [10.3389/fneur.2016.0001326925028, DOI 10.3389/FNEUR.2016.0001326925028]; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Henden PL, 2014, J NEUROSURG ANESTH, V26, P50, DOI 10.1097/ANA.0b013e3182a47b62; Hilz MJ, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0584-5; Hilz MJ, 2015, J NEUROTRAUM, V32, P1796, DOI 10.1089/neu.2014.3842; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Kenney MJ, 2014, COMPR PHYSIOL, V4, P1177, DOI 10.1002/cphy.c130051; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lal A., 2017, AM J SPORTS MED, DOI [10.1177/036354651770613728570092, DOI 10.1177/036354651770613728570092]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy J, 2010, CLIN J SPORT MED, V20, P166, DOI 10.1097/01.jsm.0000369407.44192.40; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Lim HB, 2007, ANAESTHESIA, V62, P474, DOI 10.1111/j.1365-2044.2007.04998.x; McCorry LK, 2007, AM J PHARM EDUC, V71, DOI 10.5688/aj710478; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2010, CLIN J SPORT MED, V20, P332, DOI 10.1097/JSM.0b013e3181e92350; Senthinathan A, 2017, CLIN J SPORT MED, V27, P288, DOI 10.1097/JSM.0000000000000337; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; Truong JQ, 2016, BRAIN INJURY, V30, P1378, DOI 10.1080/02699052.2016.1195922; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9	34	46	50	2	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-3425			BRAIN SCI	Brain Sci.	AUG	2017	7	8							100	10.3390/brainsci7080100			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FF4DL	WOS:000408881300008	28800081	Green Submitted, gold, Green Published			2022-02-06	
J	Dayan, PS; Ballard, DW; Tham, E; Hoffman, JM; Swietlik, M; Deakyne, SJ; Alessandrini, EA; Tzimenatos, L; Bajaj, L; Vinson, DR; Mark, DG; Offerman, SR; Chettipally, UK; Paterno, MD; Schaeffer, MH; Wang, J; Casper, TC; Goldberg, HS; Grundmeier, RW; Kuppermann, N				Dayan, Peter S.; Ballard, Dustin W.; Tham, Eric; Hoffman, Jeff M.; Swietlik, Marguerite; Deakyne, Sara J.; Alessandrini, Evaline A.; Tzimenatos, Leah; Bajaj, Lalit; Vinson, David R.; Mark, Dustin G.; Offerman, Steve R.; Chettipally, Uli K.; Paterno, Marilyn D.; Schaeffer, Molly H.; Wang, Jun; Casper, T. Charles; Goldberg, Howard S.; Grundmeier, Robert W.; Kuppermann, Nathan		PECARN; Clinical Res Emergency; Trumatic Brain Injury-Knowledge	Use of Traumatic Brain Injury Prediction Rules With Clinical Decision Support\	PEDIATRICS			English	Article							BLUNT HEAD TRAUMA; COMPUTED-TOMOGRAPHY USE; EMERGENCY-DEPARTMENT; RADIATION-EXPOSURE; MULTICENTER TRIAL; CHILDREN; IMPLEMENTATION; RISK; ASSOCIATION; MANAGEMENT	OBJECTIVES: We determined whether implementing the Pediatric Emergency Care Applied abstract Research Network (PECARN) traumatic brain injury (TBI) prediction rules and providing risks of clinically important TBIs (ciTBIs) with computerized clinical decision support (CDS) reduces computed tomography (CT) use for children with minor head trauma. METHODS: Nonrandomized trial with concurrent controls at 5 pediatric emergency departments (PEDs) and 8 general EDs (GEDs) between November 2011 and June 2014. Patients were <18 years old with minor blunt head trauma. Intervention sites received CDS with CT recommendations and risks of ciTBI, both for patients at very low risk of ciTBI (no Pediatric Emergency Care Applied Research Network rule factors) and those not at very low risk. The primary outcome was the rate of CT, analyzed by site, controlling for time trend. RESULTS: We analyzed 16 635 intervention and 2394 control patients. Adjusted for time trends, CT rates decreased significantly (P <.05) but modestly (2.3%-3.7%) at 2 of 4 intervention PEDs for children at very low risk. The other 2 PEDs had small (0.8%-1.5%) nonsignificant decreases. CT rates did not decrease consistently at the intervention GEDs, with low baseline CT rates (2.1%-4.0%) in those at very low risk. The control PED had little change in CT use in similar children (from 1.6% to 2.9%); the control GED showed a decrease in the CT rate (from 7.1% to 2.6%). For all children with minor head trauma, intervention sites had small decreases in CT rates (1.7%-6.2%). CONCLUSIONS: The implementation of TBI prediction rules and provision of risks of ciTBIs by using CDS was associated with modest, safe, but variable decreases in CT use. However, some secular trends were also noted.	[Dayan, Peter S.] Columbia Univ, Dept Pediat, Coll Phys & Surg, Div Emergency Med, 3959 Broadway,CHN 1-116, New York, NY 10032 USA; [Ballard, Dustin W.] Kaiser Permanente, San Rafael Med Ctr, San Rafael, CA USA; [Ballard, Dustin W.; Vinson, David R.] Kaiser Permanente, Div Res, Oakland, CA USA; [Tham, Eric; Bajaj, Lalit] Univ Colorado, Dept Pediat, Sect Emergency Med, Aurora, CO USA; [Hoffman, Jeff M.] Nationwide Childrens Hosp, Columbus, OH USA; [Swietlik, Marguerite; Deakyne, Sara J.] Childrens Hosp Colorado, Dept Res Informat, Aurora, CO USA; [Alessandrini, Evaline A.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; [Vinson, David R.] Kaiser Permanente, Roseville Med Ctr, Roseville, CA USA; [Mark, Dustin G.] Kaiser Permanente, Oakland Med Ctr, Oakland, CA USA; [Offerman, Steve R.] Kaiser Permanente, South Sacramento Med Ctr, Sacramento, CA USA; [Chettipally, Uli K.] Kaiser Permanente, South San Francisco Med Ctr, San Francisco, CA USA; [Paterno, Marilyn D.; Goldberg, Howard S.] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA USA; [Schaeffer, Molly H.; Goldberg, Howard S.] Partners HealthCare Syst, Informat Syst, Boston, MA USA; [Wang, Jun; Casper, T. Charles] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Grundmeier, Robert W.] Childrens Hosp Philadelphia, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA; [Grundmeier, Robert W.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA		Dayan, PS (corresponding author), Columbia Univ, Dept Pediat, Coll Phys & Surg, Div Emergency Med, 3959 Broadway,CHN 1-116, New York, NY 10032 USA.	psd6@columbia.edu	Vinson, David R/AAK-3227-2020	Vinson, David R/0000-0001-6559-1858	American Recovery and Reinvestment Act, Office of the Secretary [S02MC19289-01-00]; Health Resources and Services Administration, Maternal and Child Health Bureau, Emergency Medical Services for Children Program [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	This work was supported by American Recovery and Reinvestment Act, Office of the Secretary grant S02MC19289-01-00. The Pediatric Emergency Care Applied Research Network is supported by the Health Resources and Services Administration, Maternal and Child Health Bureau, Emergency Medical Services for Children Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685.	Atabaki SM, 2016, ACAD EMERG MED, V23, P566, DOI 10.1111/acem.12923; Bates DW, 2003, J AM MED INFORM ASSN, V10, P523, DOI 10.1197/jamia.M1370; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Curran JA, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-25; Dayan PS, 2015, PEDIATRICS, V135, P504, DOI 10.1542/peds.2014-2695; Dayan PS, 2014, ANN EMERG MED, V64, P153, DOI 10.1016/j.annemergmed.2014.02.003; Dayan PS, 2014, ANN EMERG MED, V63, P657, DOI 10.1016/j.annemergmed.2014.01.009; Deakyne SJ, 2015, APPL CLIN INFORM, V6, P521, DOI 10.4338/ACI-2015-02-RA-0019; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Faul M, 2010, TRAUMATIC BRAIN INJU; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Goldberg HS, 2016, INT J MED INFORM, V87, P101, DOI 10.1016/j.ijmedinf.2015.12.002; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee LK, 2014, JAMA PEDIATR, V168, P837, DOI 10.1001/jamapediatrics.2014.361; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Marin JR, 2014, ACAD EMERG MED, V21, P987, DOI 10.1111/acem.12458; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Mooney JS, 2011, EMERG MED J, V28, P778, DOI 10.1136/emj.2009.083360; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Nigrovic LE, 2013, PEDIATRICS, V132, pE689, DOI 10.1542/peds.2013-0909; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Nishijima DK, 2015, JAMA PEDIATR, V169, P1141, DOI 10.1001/jamapediatrics.2015.2743; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Roshanov PS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f657; Sheehan B, 2013, J BIOMED INFORM, V46, P905, DOI 10.1016/j.jbi.2013.07.005; Sittig DF, 2010, QUAL SAF HEALTH CARE, V19, pI68, DOI 10.1136/qshc.2010.042085; Stanley RM, 2014, J PEDIATR-US, V165, P1201, DOI 10.1016/j.jpeds.2014.08.008; Stanley RM, 2014, J PEDIAT, V165, pe2; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Tavender EJ, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0264-7; Tham E, 2016, APPL CLIN INFORM, V7, P534, DOI 10.4338/ACI-2015-10-CR-0144	36	46	46	1	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2017	139	4							e2 0162709	10.1542/peds.2016-2709			10	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	ER2CU	WOS:000398602400021	28341799	Bronze			2022-02-06	
J	Skrifvars, MB; Bailey, M; Presneill, J; French, C; Nichol, A; Little, L; Duranteau, J; Huet, O; Haddad, S; Arabi, Y; McArthur, C; Cooper, DJ; Bellomo, R				Skrifvars, Markus B.; Bailey, Michael; Presneill, Jeffrey; French, Craig; Nichol, Alistair; Little, Lorraine; Duranteau, Jacques; Huet, Olivier; Haddad, Samir; Arabi, Yaseen; McArthur, Colin; Cooper, D. James; Bellomo, Rinaldo		EPO-TBI Investigators; ANZICS Clinical Trials Grp	Venous thromboembolic events in critically ill traumatic brain injury patients	INTENSIVE CARE MEDICINE			English	Article						Erythropoietin; Deep venous thrombosis; Pulmonary embolism; Traumatic brain injury; Venous thromboembolism	THROMBOTIC RISK-FACTORS; UNFRACTIONATED HEPARIN; PLATELET-FUNCTION; EPOETIN-ALPHA; ERYTHROPOIETIN	To estimate the prevalence, risk factors, prophylactic treatment and impact on mortality for venous thromboembolism (VTE) in patients with moderate to severe traumatic brain injury (TBI) treated in the intensive care unit. A post hoc analysis of the erythropoietin in traumatic brain injury (EPO-TBI) trial that included twice-weekly lower limb ultrasound screening. Venous thrombotic events were defined as ultrasound-proven proximal deep venous thrombosis (DVT) or clinically detected pulmonary embolism (PE). Results are reported as events, percentages or medians and interquartile range (IQR). Cox regression analysis was used to calculate adjusted hazard ratios (HR) with 95% confidence intervals (CI) for time to VTE and death. Of 603 patients, 119 (19.7%) developed VTE, mostly comprising DVT (102 patients, 16.9%) with a smaller number of PE events (24 patients, 4.0%). Median time to DVT diagnosis was 6 days (IQR 2-11) and to PE diagnosis 6.5 days (IQR 2-16.5). Mechanical prophylaxis (MP) was used in 91% of patients on day 1, 97% of patients on day 3 and 98% of patients on day 7. Pharmacological prophylaxis was given in 5% of patients on day 1, 30% of patients on day 3 and 57% of patients on day 7. Factors associated with time to VTE were age (HR per year 1.02, 95% CI 1.01-1.03), patient weight (HR per kg 1.01, 95% CI 1-1.02) and TBI severity according to the International Mission for Prognosis and Analysis of Clinical Trials risk of poor outcome (HR per 10% increase 1.12, 95% CI 1.01-1.25). The development of VTE was not associated with mortality (HR 0.92, 95% CI 0.51-1.65). Despite mechanical and pharmacological prophylaxis, VTE occurs in one out of every five patients with TBI treated in the ICU. Higher age, greater weight and greater severity of TBI increase the risk. The development of VTE was not associated with excess mortality.	[Skrifvars, Markus B.; Bailey, Michael; Presneill, Jeffrey; Nichol, Alistair; Little, Lorraine; Cooper, D. James; Bellomo, Rinaldo] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, 55 Commercial Rd, Melbourne, Vic 3004, Australia; [Skrifvars, Markus B.] Univ Helsinki, Dept Anaesthesiol Intens Care & Pain Med, Div Intens Care, Helsinki, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Helsinki, Finland; [Presneill, Jeffrey] Royal Melbourne Hosp, Dept Intens Care, Melbourne, Vic, Australia; [French, Craig] Western Hlth, Dept Intens Care, Melbourne, Vic, Australia; [French, Craig] Univ Melbourne, Melbourne, Vic, Australia; [Nichol, Alistair] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Nichol, Alistair; Cooper, D. James] Alfred, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia; [Duranteau, Jacques] Univ Paris Sud, Hop Univ Paris Sud, Hop Bicetre, Assistance Publ Hopitaux Paris,Dept Anesthesie Re, Paris, France; [Huet, Olivier] Univ Bretagne Occidentale, CHRU Cavale Blanche, Dept Anaesthesiol & Intens Care Med, Brest, France; [Haddad, Samir; Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Haddad, Samir; Arabi, Yaseen] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Bellomo, Rinaldo] Austin Hlth, Dept Intens Care, Melbourne, Vic, Australia		Skrifvars, MB (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, 55 Commercial Rd, Melbourne, Vic 3004, Australia.; Skrifvars, MB (corresponding author), Univ Helsinki, Dept Anaesthesiol Intens Care & Pain Med, Div Intens Care, Helsinki, Finland.; Skrifvars, MB (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.	markus.skrifvars@monash.edu	Arabi, Yaseen/ABF-3316-2020; Bailey, Michael J/A-4499-2012; French, Craig/ABF-5087-2020; Cooper, D. James/G-7961-2013	Arabi, Yaseen/0000-0001-5735-6241; Bailey, Michael J/0000-0002-5551-1401; French, Craig/0000-0003-1363-9711; Cooper, D. James/0000-0002-5872-9051; Nichol, Alistair/0000-0002-4689-1238; Bellomo, Rinaldo/0000-0002-1650-8939; Nichol, Alistair Dualta/0000-0002-4771-5615	Finska Lakaresallskapet; Medicinska Understodsforeningen Liv och Halsa; Svenska Kulturfonden	Markus Skrifvars has received unrestricted grant support from Finska Lakaresallskapet, Medicinska Understodsforeningen Liv och Halsa and Svenska Kulturfonden.	Abdel-Aziz H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0814-z; Ageno W, 2008, CIRCULATION, V117, P93, DOI 10.1161/CIRCULATIONAHA.107.709204; Allen CJ, 2016, J AM COLL SURGEONS, V222, P65, DOI 10.1016/j.jamcollsurg.2015.10.014; Aryafar Hamed, 2010, Semin Intervent Radiol, V27, P68, DOI 10.1055/s-0030-1247890; Beitland S, 2015, INTENS CARE MED, V41, P1209, DOI 10.1007/s00134-015-3840-z; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Cook D, 2011, NEW ENGL J MED, V364, P1305, DOI 10.1056/NEJMoa1014475; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; Franchini M, 2008, THROMB RES, V122, P727, DOI 10.1016/j.thromres.2007.09.010; Garcia-Olivares P, 2014, INTENS CARE MED, V40, P1698, DOI 10.1007/s00134-014-3442-1; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GLEERUP G, 1995, ANGIOLOGY, V46, P715, DOI 10.1177/000331979504600810; Ho KM, 2010, BRIT J ANAESTH, V105, P596, DOI 10.1093/bja/aeq254; KASJANOVOVA D, 1993, MECH AGEING DEV, V71, P103, DOI 10.1016/0047-6374(93)90039-T; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Ko A, 2016, JAMA SURG, V151, P1006, DOI 10.1001/jamasurg.2016.1662; Lier H, 2011, INTENS CARE MED, V37, P572, DOI 10.1007/s00134-011-2139-y; Martinelli I, 2010, CRIT CARE MED, V38, pS3, DOI 10.1097/CCM.0b013e3181c9cbd9; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nichol A, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0528-6; Nunez JM, 2015, AM SURGEON, V81, P605; Ortel TL, 2010, CRIT CARE MED, V38, pS43, DOI 10.1097/CCM.0b013e3181c9ccc8; Phelan HA, 2013, SEMIN THROMB HEMOST, V39, P541, DOI 10.1055/s-0033-1343356; Presneill Jeffrey, 2014, Trials, V15, P501, DOI 10.1186/1745-6215-15-501; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Taddei S, 2001, HYPERTENSION, V38, P274, DOI 10.1161/01.HYP.38.2.274; Tracy RP, 2002, AM J GERIATR CARDIOL, V11, P107	30	46	47	5	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2017	43	3					419	428		10.1007/s00134-016-4655-2			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM0CU	WOS:000394987200007	28028552	Green Published			2022-02-06	
J	Schurman, LD; Lichtman, AH				Schurman, Lesley D.; Lichtman, Aron H.			Endocannabinoids: A Promising Impact for Traumatic Brain Injury	FRONTIERS IN PHARMACOLOGY			English	Article						traumatic brain injury; cannabinoid; endocannabinoid; neuroprotection; phytocannabinoid	FATTY-ACID AMIDE; CLOSED-HEAD INJURY; CB1 CANNABINOID RECEPTORS; IMPROVES FUNCTIONAL RECOVERY; ACUTE LUNG INJURY; MOUSE MODEL; CELL-DEATH; MOLECULAR CHARACTERIZATION; DECOMPRESSIVE CRANIECTOMY; ISCHEMIC TOLERANCE	The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). Increases in brain levels of endocannabinoids to pathogenic events suggest this system plays a role in compensatory repair mechanisms. Traumatic brain injury (TBI) pathology remains mostly refractory to currently available drugs, perhaps due to its heterogeneous nature in etiology, clinical presentation, and severity. Here, we review pre-clinical studies assessing the therapeutic potential of cannabinoids and manipulations of the endocannabinoid system to ameliorate TBI pathology. Specifically, manipulations of endocannabinoid degradative enzymes (e.g., fatty acid amide hydrolase, monoacylglycerol lipase, and a/b-hydrolase domain-6), CB1 and CB2 receptors, and their endogenous ligands have shown promise in modulating cellular and molecular hallmarks of TBI pathology such as; cell death, excitotoxicity, neuroinflammation, cerebrovascular breakdown, and cell structure and remodeling. TBI-induced behavioral deficits, such as learning and memory, neurological motor impairments, post-traumatic convulsions or seizures, and anxiety also respond to manipulations of the endocannabinoid system. As such, the endocannabinoid system possesses potential drugable receptor and enzyme targets for the treatment of diverse TBI pathology. Yet, full characterization of TBI-induced changes in endocannabinoid ligands, enzymes, and receptor populations will be important to understand that role this system plays in TBI pathology. Promising classes of compounds, such as the plant-derived phytocannabinoids, synthetic cannabinoids, and endocannabinoids, as well as their non-cannabinoid receptor targets, such as TRPV1 receptors, represent important areas of basic research and potential therapeutic interest to treat TBI.	[Schurman, Lesley D.; Lichtman, Aron H.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23284 USA		Lichtman, AH (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23284 USA.	aron.lichtman@vcuhealth.org		O'Brien (nee Schurman), Lesley/0000-0002-5877-3976	Ruth L. Kirshchstein Institutional National Research [1F31NS095628]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DA032933, R01DA039942, P30DA033934]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS095628] Funding Source: NIH RePORTER	This research was funded by a Ruth L. Kirshchstein Institutional National Research Service Award 1F31NS095628 (LS), and NIH award R01 DA032933 (AL), R01DA039942 (AL), P30DA033934 (AL).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ahn K, 2009, CHEM BIOL, V16, P411, DOI 10.1016/j.chembiol.2009.02.013; Alger BE, 2011, TRENDS NEUROSCI, V34, P304, DOI 10.1016/j.tins.2011.03.003; ALVAREZ JM, 2015, PULM RES RESP MED OP, V2, P69; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Antoniou T, 2014, CAN MED ASSOC J, V186, P210, DOI [10.1097/MAJ.0000000000000466, 10.1503/cmaj.130510]; Arai Ken, 2009, Exp Transl Stroke Med, V1, P6, DOI 10.1186/2040-7378-1-6; Assaf F, 2011, BEHAV BRAIN RES, V220, P194, DOI 10.1016/j.bbr.2011.02.005; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Avraham Y, 2008, PROSTAG LEUKOTR ESS, V79, P35, DOI 10.1016/j.plefa.2008.07.003; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Bequet F, 2007, EUR J NEUROSCI, V26, P3458, DOI 10.1111/j.1460-9568.2007.05900.x; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Blankman JL, 2013, PHARMACOL REV, V65, P849, DOI 10.1124/pr.112.006387; Boger DL, 2000, BIOORG MED CHEM LETT, V10, P2613, DOI 10.1016/S0960-894X(00)00528-X; Brambrink AM, 1997, ANAESTHESIST, V46, P953, DOI 10.1007/s001010050492; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Buczynski MW, 2009, J LIPID RES, V50, P1015, DOI 10.1194/jlr.R900004-JLR200; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103; Casarejos MJ, 2013, J ALZHEIMERS DIS, V35, P525, DOI 10.3233/JAD-130050; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Chu CJ, 2003, J BIOL CHEM, V278, P13633, DOI 10.1074/jbc.M211231200; Corcoran L, 2015, INT REV NEUROBIOL, V125, P203, DOI 10.1016/bs.irn.2015.10.003; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Costa B, 2008, PAIN, V139, P541, DOI 10.1016/j.pain.2008.06.003; Costola-De-Souza C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077706; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2008, NAT REV DRUG DISCOV, V7, P438, DOI 10.1038/nrd2553; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Egertova M, 1998, P ROY SOC B-BIOL SCI, V265, P2081, DOI 10.1098/rspb.1998.0543; Elsohly M. A., 2017, PHYTOCANNABINOIDS, DOI [10.1007/978-3-319-45541-9, DOI 10.1007/978-3-319-45541-9]; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gertsch J, 2010, BRIT J PHARMACOL, V160, P523, DOI 10.1111/j.1476-5381.2010.00745.x; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gulyas AI, 2004, EUR J NEUROSCI, V20, P441, DOI 10.1111/j.1460-9568.2004.03428.x; Gw Research Ltd, 2016, GWP42003P CBD; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hasko G, 2008, J LEUKOCYTE BIOL, V83, P447, DOI 10.1189/jlb.0607359; Heimann AS, 2007, P NATL ACAD SCI USA, V104, P20588, DOI 10.1073/pnas.0706980105; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Hill AJ, 2014, NEUROSCI LETT, V566, P269, DOI 10.1016/j.neulet.2014.03.013; Hillard CJ, 2000, J PHARMACOL EXP THER, V294, P27; Hillard CJ, 2000, PROSTAG OTH LIPID M, V61, P3, DOI 10.1016/S0090-6980(00)00051-4; Hind WH, 2015, BRIT J PHARMACOL, V172, P3015, DOI 10.1111/bph.13106; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hu DE, 2005, BRIT J PHARMACOL, V146, P576, DOI 10.1038/sj.bjp.0706350; Huestis MA, 2007, CHEM BIODIVERS, V4, P1770, DOI 10.1002/cbdv.200790152; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Katz PS, 2015, J NEUROTRAUM, V32, P297, DOI 10.1089/neu.2014.3508; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Kwiatkoski M, 2012, NEUROTOX RES, V21, P271, DOI 10.1007/s12640-011-9273-8; Lambert DM, 1999, CURR MED CHEM, V6, P757; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73; Long JZ, 2009, P NATL ACAD SCI USA, V106, P20270, DOI 10.1073/pnas.0909411106; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Mackie K, 2006, INT J OBESITY, V30, pS19, DOI 10.1038/sj.ijo.0803273; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Martinez-Vargas M, 2013, INT J MOL SCI, V14, P23341, DOI 10.3390/ijms141223341; Mayer S. A., 2010, MERRITTS NEUROLOGY; Mayeux J, 2017, J NEUROTRAUM, V34, P436, DOI 10.1089/neu.2016.4452; Mazarati Andrey, 2006, Epilepsy Curr, V6, P213, DOI 10.1111/j.1535-7511.2006.00149.x; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2003, SCIENCE, V302, P65, DOI 10.1126/science.1091256; MECHOULAM R, 1967, FORT CHEM ORG NAT, V25, P175; Mechoulam R, 2013, ANNU REV PSYCHOL, V64, P21, DOI 10.1146/annurev-psych-113011-143739; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; Mestre L, 2005, J NEUROCHEM, V92, P1327, DOI 10.1111/j.1471-4159.2004.02979.x; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Mukhopadhyay P, 2010, BRIT J PHARMACOL, V160, P657, DOI 10.1111/j.1476-5381.2010.00769.x; Mukhopadhyay P, 2010, CARDIOVASC RES, V85, P773, DOI 10.1093/cvr/cvp369; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nguyen BM, 2014, AM SURGEON, V80, P979; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niphakis MJ, 2012, ACS CHEM NEUROSCI, V3, P418, DOI 10.1021/cn200089j; Nomura DK, 2008, BIOORG MED CHEM LETT, V18, P5875, DOI 10.1016/j.bmcl.2008.08.007; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Oka S, 2006, J IMMUNOL, V177, P8796, DOI 10.4049/jimmunol.177.12.8796; OKADA M, 1992, NEUROSCI LETT, V140, P55, DOI 10.1016/0304-3940(92)90680-6; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pelosi P, 2005, CURR OPIN CRIT CARE, V11, P37, DOI 10.1097/00075198-200502000-00006; Perez M, 2013, EUR J NEUROSCI, V38, P3424, DOI 10.1111/ejn.12341; Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341; Ping XJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158231; Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reggio PH, 2002, PROSTAG LEUKOTR ESS, V66, P143, DOI 10.1054/plef.2001.0343; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sarne Y, 2011, BRIT J PHARMACOL, V163, P1391, DOI 10.1111/j.1476-5381.2011.01280.x; Schmitt U, 2009, NEUROSCIENCE, V162, P234, DOI 10.1016/j.neuroscience.2009.04.046; Sen AP, 2010, NEUROTHERAPEUTICS, V7, P91, DOI 10.1016/j.nurt.2009.10.014; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Shiina G, 1998, AM J NEURORADIOL, V19, P297; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Siegel GJ, 1999, BASIC NEUROCHEMISTRY; Sigel E, 2011, P NATL ACAD SCI USA, V108, P18150, DOI 10.1073/pnas.1113444108; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Staiano RI, 2016, J LEUKOCYTE BIOL, V99, P531, DOI 10.1189/jlb.3HI1214-584R; Stefan A, 2016, ANN PHYS REHABIL MED, V59, P5, DOI 10.1016/j.rehab.2015.11.002; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Sticht MA, 2016, NEUROPHARMACOLOGY, V102, P92, DOI 10.1016/j.neuropharm.2015.10.039; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Stranahan AM, 2011, BEHAV NEUROSCI, V125, P791, DOI 10.1037/a0025133; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Titomanlio L, 2015, PEDIATR NEUROL, V52, P566, DOI 10.1016/j.pediatrneurol.2015.01.016; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wallace MJ, 2001, EUR J PHARMACOL, V428, P51, DOI 10.1016/S0014-2999(01)01243-2; Wang K, 2014, CHINESE MED J-PEKING, V127, P1964, DOI 10.3760/cma.j.issn.0366-6999.20120638; Wang Q, 2009, STROKE, V40, P2157, DOI 10.1161/STROKEAHA.108.541490; Wang X, 2016, BRAIN RES, V1646, P174, DOI 10.1016/j.brainres.2016.05.055; Wiley JL, 2014, LIFE SCI, V97, P55, DOI 10.1016/j.lfs.2013.09.011; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247; Zhang JC, 2005, BRAIN RES, V1050, P110, DOI 10.1016/j.brainres.2005.05.032; Zhang J, 2015, J CEREBR BLOOD F MET, V35, P443, DOI 10.1038/jcbfm.2014.216; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	158	46	47	1	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	FEB 17	2017	8								69	10.3389/fphar.2017.00069			17	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	EK9VI	WOS:000394271600001	28261100	Green Published, gold			2022-02-06	
J	Tucker, LB; Burke, JF; Fu, AH; McCabe, JT				Tucker, Laura B.; Burke, John F.; Fu, Amanda H.; McCabe, Joseph T.			Neuropsychiatric Symptom Modeling in Male and Female C57BL/6J Mice after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; depression; mouse; sex differences; TBI	CONTROLLED CORTICAL IMPACT; STRESS-INDUCED HYPERTHERMIA; ANXIETY-LIKE BEHAVIOR; ELEVATED PLUS-MAZE; SEX-DIFFERENCES; OPEN-FIELD; PSYCHIATRIC-DISORDERS; ANIMAL-MODELS; ESTROUS-CYCLE; MOUSE MODEL	Psychiatric symptoms such as anxiety and depression are frequent and persistent complaints following traumatic brain injury (TBI). Modeling these symptoms in animal models of TBI affords the opportunity to determine mechanisms underlying behavioral pathologies and to test potential therapeutic agents. However, testing these symptoms in animal models of TBI has yielded inconsistent results. The goal of the current study was to employ a battery of tests to measure multiple anxiety-and depressive-like symptoms following TBI in C57BL/6J mice, and to determine if male and female mice are differentially affected by the injury. Following controlled cortical impact (CCI) at a parietal location, neither male nor female mice showed depressive-like symptoms as measured by the Porsolt forced-swim test and sucrose preference test. Conclusions regarding anxiety-like behaviors were dependent upon the assay employed; CCI-induced thigmotaxis in the open field suggested an anxiogenic effect of the injury; however, results from the elevated zero maze, light-dark box, and marble-burying tests indicated that CCI reduced anxiety-like behaviors. Fewer anxiety-like behaviors were also associated with the female sex. Increased levels of activity were also measured in female mice and injured mice in these tests, and conclusions regarding anxiety should be taken with caution when experimental manipulations induce changes in baseline activity. These results underscore the irreconcilability of results from studies attempting to model TBI-induced neuropsychiatric symptoms. Changes in injury models or better attempts to replicate the clinical syndrome may improve the translational applicability of rodent models of TBI-induced anxiety and depression.	[Tucker, Laura B.; Burke, John F.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Preclin Studies Core, Bethesda, MD 20814 USA; [Tucker, Laura B.; Burke, John F.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, FE Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA		McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Preclin Studies Core, Bethesda, MD 20814 USA.; McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, FE Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Joseph.McCabe@usuhs.edu	McCabe, Joseph T/J-6293-2014	McCabe, Joseph T/0000-0002-1159-7442; Tucker, Laura/0000-0002-5984-6399; Burke, John/0000-0003-1519-9078	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855-300600-7.01]	This work was supported by The Center for Neuroscience and Regenerative Medicine, 60855-300600-7.01. The opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the United States Army, Department of Defense, the United States government, or the Uniformed Services University of the Health Sciences. The use of trade names does not constitute an official endorsement or approval of the use of such reagents or commercial hardware or software. This document may not be cited for purposes of advertisement. The authors express appreciation for being able to use the laboratory of Dr. Yumin Zhang for tissue sectioning.	ACKERLY DD, 1990, OECOLOGIA, V82, P474, DOI 10.1007/BF00319788; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; Angoa-Perez M, 2013, JOVE-J VIS EXP, DOI 10.3791/50978; ARCHER J, 1975, BEHAV BIOL, V14, P451, DOI 10.1016/S0091-6773(75)90636-7; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Bouwknecht JA, 2007, NEUROSCI BIOBEHAV R, V31, P41, DOI 10.1016/j.neubiorev.2006.02.002; Bouwknecht JA, 2008, BEHAV PHARMACOL, V19, P385, DOI 10.1097/FBP.0b013e32830c3658; Braun AA, 2011, PHARMACOL BIOCHEM BE, V97, P406, DOI 10.1016/j.pbb.2010.09.013; BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Cook MN, 2002, BEHAV GENET, V32, P113, DOI 10.1023/A:1015249706579; Cope EC, 2012, NEUROREHAB NEURAL RE, V26, P907, DOI 10.1177/1545968311435337; Crawley JN, 2007, WHATS WRONG MY MOUSE, V2nd; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Cryan JF, 2004, MOL PSYCHIATR, V9, P326, DOI 10.1038/sj.mp.4001457; CUNHA JM, 1978, PHARMACOLOGY, V16, P259, DOI 10.1159/000136777; DAWSON GR, 1995, PSYCHOPHARMACOLOGY, V118, P316, DOI 10.1007/BF02245961; Deacon RMJ, 2005, BEHAV BRAIN RES, V156, P241, DOI 10.1016/j.bbr.2004.05.027; Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20; Donner NC, 2013, PFLUG ARCH EUR J PHY, V465, P601, DOI 10.1007/s00424-013-1271-7; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fernandes C, 1999, PHARMACOL BIOCHEM BE, V64, P731, DOI 10.1016/S0091-3057(99)00139-2; File SE, 2001, BEHAV BRAIN RES, V125, P151, DOI 10.1016/S0166-4328(01)00292-3; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GYERTYAN I, 1995, BEHAV PHARMACOL, V6, P24; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Heredia L, 2014, J PHARMACOL TOX MET, V69, P108, DOI 10.1016/j.vascn.2013.12.005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hubscher CH, 2006, BRAIN RES, V1100, P118, DOI 10.1016/j.brainres.2006.05.003; Jirkof P, 2014, J NEUROSCI METH, V234, P139, DOI 10.1016/j.jneumeth.2014.02.001; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P273, DOI 10.1016/0149-7634(81)90009-9; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kokras N, 2014, BRIT J PHARMACOL, V171, P4595, DOI 10.1111/bph.12710; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; McAllister BB, 2015, BEHAV BRAIN RES, V290, P102, DOI 10.1016/j.bbr.2015.04.049; Millan MJ, 2003, EUR J PHARMACOL, V463, P67, DOI 10.1016/S0014-2999(03)01275-5; Milner LC, 2008, GENES BRAIN BEHAV, V7, P496, DOI 10.1111/j.1601-183X.2007.00385.x; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Morgan MA, 2002, BEHAV BRAIN RES, V132, P85, DOI 10.1016/S0166-4328(01)00398-9; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nichols JN, 2016, BEHAV BRAIN RES, V298, P111, DOI 10.1016/j.bbr.2015.10.052; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; O'Leary OF, 2013, CELL TISSUE RES, V354, P141, DOI 10.1007/s00441-013-1587-9; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Ferreira APO, 2014, PSYCHOPHARMACOLOGY, V231, P1935, DOI 10.1007/s00213-013-3336-x; Olivier B, 2003, EUR J PHARMACOL, V463, P117, DOI 10.1016/S0014-2999(03)01326-8; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Palanza P, 2001, NEUROSCI BIOBEHAV R, V25, P219, DOI 10.1016/S0149-7634(01)00010-0; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Pires GN, 2015, BEHAV NEUROSCI, V129, P621, DOI 10.1037/bne0000076; POLING A, 1981, J EXP ANAL BEHAV, V35, P31, DOI 10.1901/jeab.1981.35-31; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; RODGERS RJ, 1993, PSYCHOPHARMACOLOGY, V113, P237, DOI 10.1007/BF02245704; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sajja VSSS, 2015, SHOCK, V44, P71, DOI 10.1097/SHK.0000000000000311; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Scholten AC, 2016, J NEUROTRAUM; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Sierra-Mercado D, 2015, BRAIN RES, V1606, P133, DOI 10.1016/j.brainres.2015.02.031; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Slattery DA, 2014, ILAR J, V55, P297, DOI 10.1093/ilar/ilu026; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]; Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006; Thomas A, 2009, PSYCHOPHARMACOLOGY, V204, P361, DOI 10.1007/s00213-009-1466-y; Thompson T, 2015, PHARMACOL BIOCHEM BE, V133, P7, DOI 10.1016/j.pbb.2015.03.011; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; Voikar V, 2005, GENES BRAIN BEHAV, V4, P240, DOI 10.1111/j.1601-183X.2004.00103.x; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Weiss SM, 1998, NEUROSCI BIOBEHAV R, V23, P265, DOI 10.1016/S0149-7634(98)00027-X; Wheaton P, 2011, J PSYCHOPHARMACOL, V25, P1581, DOI 10.1177/0269881110388331; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	109	46	46	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					890	905		10.1089/neu.2016.4508			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200017	27149139	hybrid, Green Published, Green Submitted			2022-02-06	
J	Svaldi, DO; McCuen, EC; Joshi, C; Robinson, ME; Nho, Y; Hannemann, R; Nauman, EA; Leverenz, LJ; Talavage, TM				Svaldi, Diana O.; McCuen, Emily C.; Joshi, Chetas; Robinson, Meghan E.; Nho, Yeseul; Hannemann, Robert; Nauman, Eric A.; Leverenz, Larry J.; Talavage, Thomas M.			Cerebrovascular reactivity changes in asymptomatic female athletes attributable to high school soccer participation	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury; Collision sports; Head impacts; Cerebrovascular reactivity; Soccer	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; HEAD IMPACTS; BOLD FMRI; FRONTOTEMPORAL DEMENTIA; RECURRENT CONCUSSION; CORTICAL IMPACT	As participation in women's soccer continues to grow and the longevity of female athletes' careers continues to increase, prevention and care for mTBI in women's soccer has become a major concern for female athletes since the long-term risks associated with a history of mTBI are well documented. Among women's sports, soccer exhibits among the highest concussion rates, on par with those of men's football at the collegiate level. Head impact monitoring technology has revealed that "concussive hits" occurring directly before symptomatic injury are not predictive of mTBI, suggesting that the cumulative effect of repetitive head impacts experienced by collision sport athletes should be assessed. Neuroimaging biomarkers have proven to be valuable in detecting brain changes that occur before neurocognitive symptoms in collision sport athletes. Quantifying the relationship between changes in these biomarkers and head impacts experienced by female soccer athletes may prove valuable to developing preventative measures for mTBI. This study paired functional magnetic resonance imaging with head impact monitoring to track cerebrovascular reactivity changes throughout a season and to test whether the observed changes could be attributed to mechanical loading experienced by female athletes participating in high school soccer. Marked cerebrovascular reactivity changes were observed in female soccer athletes, relative both to non-collision sport control measures and pre-season measures and were localized to fronto-temporal aspects of the brain. These changes persisted 4-5 months after the season ended and recovered by 8 months after the season. Segregation of the total soccer cohort into cumulative loading groups revealed that population-level changes were driven by athletes experiencing high cumulative loads, although athletes experiencing lower cumulative loads still contributed to group changes. The results of this study imply a non-linear relationship between cumulative loading and cerebrovascular changes with a threshold, above which the risk, of injury likely increases significantly.	[Svaldi, Diana O.; McCuen, Emily C.; Hannemann, Robert; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Joshi, Chetas; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA; [Nho, Yeseul] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94729 USA; [Hannemann, Robert] VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, Boston, MA 02130 USA; [Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Nauman, Eric A.; Leverenz, Larry J.; Talavage, Thomas M.] Purdue Univ, Concuss Neuroimaging Consortium, W Lafayette, IN 47907 USA		Svaldi, DO (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.	dianaotero7@gmail.com		Talavage, Thomas/0000-0003-4977-6398; Svaldi, Diana/0000-0001-6265-1931	BrainScope Company, Inc.; General Electric HealthcareGeneral ElectricGE Healthcare	This study was funded by BrainScope Company, Inc., and General Electric Healthcare.	Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Ainslie PN, 2008, J PHYSIOL-LONDON, V586, P4005, DOI 10.1113/jphysiol.2008.158279; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Birn RM, 2008, NEUROIMAGE, V40, P644, DOI 10.1016/j.neuroimage.2007.11.059; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Bright MG, 2013, NEUROIMAGE, V83, P559, DOI 10.1016/j.neuroimage.2013.07.007; Bright MG, 2009, NEUROIMAGE, V48, P166, DOI 10.1016/j.neuroimage.2009.05.026; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chan ST, 2015, BRAIN INJURY, V29, P403, DOI 10.3109/02699052.2014.974209; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gao YZ, 2013, CURR NEUROVASC RES, V10, P49, DOI 10.2174/156720213804806016; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Jordan BD, 2000, NEUROLOGY, V54, pA410; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Lewis PM, 2014, VASCULAR MECH CNS TR; Lipp I, 2015, NEUROIMAGE, V113, P387, DOI 10.1016/j.neuroimage.2015.03.004; Lovell M., 2003, NEUROSURGERY, V98; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCuen E. C., 2015, J BIOMECHANICS; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Militana AR, 2016, BRAIN IMAGING BEHAV, V10, P559, DOI 10.1007/s11682-015-9407-3; Morris B, 2015, WHY IS US SO GOOD WO; Murphy K, 2011, NEUROIMAGE, V54, P369, DOI 10.1016/j.neuroimage.2010.07.059; Murrell CJ, 2013, AGE, V35, P905, DOI 10.1007/s11357-012-9414-x; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Snowden JS, 2002, BRIT J PSYCHIAT, V180, P140, DOI 10.1192/bjp.180.2.140; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927; Yezhuvath US, 2012, NEUROBIOL AGING, V33, P75, DOI 10.1016/j.neurobiolaging.2010.02.005; Zhang FY, 2002, J NEUROSURG, V97, P963, DOI 10.3171/jns.2002.97.4.0963; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	64	46	46	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	FEB	2017	11	1					98	112		10.1007/s11682-016-9509-6			15	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ET8TT	WOS:000400575300009	26809358				2022-02-06	
J	Fang, Q; Guo, SX; Zhou, HL; Han, R; Wu, P; Han, CM				Fang, Quan; Guo, Songxue; Zhou, Hanlei; Han, Rui; Wu, Pan; Han, Chunmao			Astaxanthin protects against early burn-wound progression in rats by attenuating oxidative stress-induced inflammation and mitochondria-related apoptosis	SCIENTIFIC REPORTS			English	Article							SUBARACHNOID HEMORRHAGE; BRAIN-INJURY; NECROSIS; INVOLVEMENT; AUTOPHAGY; CYTOKINES; TISSUE; CELLS; ZONE; MICE	Burn-wound progression can occur in the initial or peri-burn area after a deep burn injury. The stasis zone has a higher risk of deterioration mediated by multiple factors but is also considered salvageable. Astaxanthin (ATX), which is extracted from some marine organisms, is a natural compound with a strong antioxidant effect that has been reported to attenuate organ injuries caused by traumatic injuries. Hence, we investigated the potential effects of ATX on preventing early burn-wound progression. A classic "comb" burn rat model was established in this study for histological and biological assessments, which revealed that ATX, particularly higher doses, alleviated histological deterioration in the stasis zone. Additionally, we observed dose-dependent improvements in oxidative stress and the release of inflammatory mediators after ATX treatment. Furthermore, ATX dose-dependently attenuated burn-induced apoptosis in the wound areas, and this effect was accompanied by increases in Akt and Bad phosphorylation and a downregulation of cytochrome C and caspase expression. In addition, the administration of Ly 294002 further verified the effect of ATX. In summary, we demonstrated that ATX protected against early burn-wound progression in a rat deep-burn model. This protection might be mediated by the attenuation of oxidative stress-induced inflammation and mitochondria-related apoptosis.	[Fang, Quan; Guo, Songxue; Zhou, Hanlei; Wu, Pan; Han, Chunmao] Zhejiang Univ, Affiliated Hosp 2, Dept Burns, Coll Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China; [Fang, Quan] Zhejiang Univ, Affiliated Hosp 2, Binjiang Branch, Dept Plast Surg,Coll Med, 1511 Jianghong Rd, Hangzhou 310000, Zhejiang, Peoples R China; [Han, Rui] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Dermatol, 3 East Qingchun Rd, Hangzhou 310020, Zhejiang, Peoples R China		Han, CM (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Burns, Coll Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	Hanchunmao1@163.com			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81301375, 81401591, 81671909]; Zhejiang Provincial National Natural Science Foundation of China [LQ13H150001]	This work was supported by the following grants: National Natural Science Foundation of China (NSFC) Grants 81301375, 81401591 and 81671909 and Zhejiang Provincial National Natural Science Foundation of China Grant LQ13H150001. We especially appreciate the support from Miss Andrea Moscoso in improving our language presentation.	Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Arturson G, 1996, BURNS, V22, P255, DOI 10.1016/0305-4179(95)00153-0; Cao JG, 2014, ANIM SCI J, V85, P150, DOI 10.1111/asj.12103; Cao W, 2011, BASIC RES CARDIOL, V106, P1207, DOI 10.1007/s00395-011-0199-3; Chalah A, 2008, ADV EXP MED BIOL, V615, P25, DOI 10.1007/978-1-4020-6554-5_3; Chen Jui-Tung, 2016, J Clin Med Res, V8, P701, DOI 10.14740/jocmr2672w; Choi HD, 2011, BRIT J NUTR, V105, P220, DOI 10.1017/S0007114510003454; Curek GD, 2010, TOXICOLOGY, V267, P147, DOI 10.1016/j.tox.2009.11.003; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960; Eski M, 2012, BURNS, V38, P283, DOI 10.1016/j.burns.2011.08.008; Fassett RG, 2012, MOLECULES, V17, P2030, DOI 10.3390/molecules17022030; Gross A, 2016, BBA-BIOENERGETICS, V1857, P1243, DOI 10.1016/j.bbabio.2016.01.017; Guo SX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124897; Guo SX, 2015, MAR DRUGS, V13, P2105, DOI 10.3390/md13042105; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; JACKSON DM, 1953, BRIT J SURG, V40, P588, DOI 10.1002/bjs.18004016413; Johnson R. M., 2003, ADV SKIN WOUND CARE, V16, P178; JOHNSON RM, 2003, ADV SKIN WOUND CARE, V16, P188; Kidd P, 2011, ALTERN MED REV, V16, P355; Kishimoto Y, 2016, MAR DRUGS, V14, DOI 10.3390/md14020035; Knabl JS, 1999, BURNS, V25, P715, DOI 10.1016/S0305-4179(99)00086-8; Kopani M, 2006, CLIN CHIM ACTA, V364, P61, DOI 10.1016/j.cca.2005.05.016; Latha B, 2001, BURNS, V27, P309, DOI 10.1016/S0305-4179(00)00127-3; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Liu XB, 2009, BRAIN RES, V1254, P18, DOI 10.1016/j.brainres.2008.11.076; Ndiaye MA, 2014, ANTIOXID REDOX SIGN, V20, P2982, DOI 10.1089/ars.2013.5645; Park JS, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-18; Salibian AA, 2016, BURNS, V42, P1025, DOI 10.1016/j.burns.2015.11.007; Schmauss D, 2015, J BURN CARE RES, V36, pE176, DOI 10.1097/BCR.0000000000000131; Schwacha MG, 2010, J SURG RES, V158, P112, DOI 10.1016/j.jss.2008.07.034; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Shupp JW, 2010, J BURN CARE RES, V31, P849, DOI 10.1097/BCR.0b013e3181f93571; Singer AJ, 2008, ACAD EMERG MED, V15, P549, DOI 10.1111/j.1553-2712.2008.00115.x; Singer AJ, 2007, ACAD EMERG MED, V14, P1125, DOI [10.1197/j.aem.2007.07.012, 10.1111/j.1553-2712.2007.tb02330.x]; Singh V, 2007, ANN PLAS SURG, V59, P109, DOI 10.1097/01.sap.0000252065.90759.e6; SLATER TF, 1984, BIOCHEM J, V222, P1; Speranza L, 2012, MAR DRUGS, V10, P890, DOI 10.3390/md10040890; Sun LT, 2012, WOUND REPAIR REGEN, V20, P563, DOI 10.1111/j.1524-475X.2012.00813.x; Tan JQ, 2013, BURNS, V39, P1551, DOI 10.1016/j.burns.2013.04.018; Wu HJ, 2015, MAR DRUGS, V13, P5750, DOI 10.3390/md13095750; Xiao MJ, 2014, ACAD EMERG MED, V21, P383, DOI 10.1111/acem.12352; Yasui Y, 2011, CHEM-BIOL INTERACT, V193, P79, DOI 10.1016/j.cbi.2011.05.006; Ye QY, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-156; Yeh PT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146438; Yuan X, 2014, EXP THER MED, V8, P973, DOI 10.3892/etm.2014.1820; Zhang XS, 2015, BRAIN RES, V1624, P113, DOI 10.1016/j.brainres.2015.07.020; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291	48	46	52	3	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 27	2017	7								41440	10.1038/srep41440			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ4BZ	WOS:000393162200001	28128352	gold, Green Published			2022-02-06	
J	Feng, Y; Lee, CH; Sun, LN; Ji, SH; Zhao, XF				Feng, Yuan; Lee, Chung-Hao; Sun, Lining; Ji, Songhai; Zhao, Xuefeng			Characterizing white matter tissue in large strain via asymmetric indentation and inverse finite element modeling	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Soft tissue; Mechanical properties; Transversely isotropic material; Indentation; Genetic algorithm	ISOTROPIC MATERIAL MODELS; BIOLOGICAL SOFT-TISSUES; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; MECHANICAL-PROPERTIES; MITRAL-VALVE; PARAMETER-IDENTIFICATION; UNCONFINED COMPRESSION; SIMPLE SHEAR	Characterizing the mechanical properties of white matter is important to understand and model brain development and injury. With embedded aligned axonal fibers, white matter is typically modeled as a transversely isotropic material. However, most studies characterize the white matter tissue using models with a single anisotropic invariant or in a small-strain regime. In this study, we combined a single experimental procedure asymmetric indentation with inverse finite element (FE) modeling to estimate the nearly incompressible transversely isotropic material parameters of white matter. A minimal form comprising three parameters was employed to simulate indentation responses in the large-strain regime. The parameters were estimated using a global optimization procedure based on a genetic algorithm (GA). Experimental data from two indentation configurations of porcine white matter, parallel and perpendicular to the axonal fiber direction, were utilized to estimate model parameters. Results in this study confirmed a strong mechanical anisotropy of white matter in large strain. Further, our results suggested that both indentation configurations are needed to estimate the parameters with sufficient accuracy, and that the indenter-sample friction is important. Finally, we also showed that the estimated parameters were consistent with those previously obtained via a trial-and-error forward FE method in the small-strain regime. These findings are useful in modeling and parameterization of white matter, especially under large deformation, and demonstrate the potential of the proposed asymmetric indentation technique to characterize other soft biological tissues with transversely isotropic properties. (C) 2016 Elsevier Ltd. All rights reserved.	[Feng, Yuan; Sun, Lining; Zhao, Xuefeng] Soochow Univ, Sch Mech & Elect Engn, Room 1107 Engn Bldg,178 Gan Jiang Dong Lu, Suzhou 215021, Jiangsu, Peoples R China; [Feng, Yuan; Sun, Lining] Soochow Univ, Robot & Microsyst Ctr, Suzhou 215021, Jiangsu, Peoples R China; [Lee, Chung-Hao] Univ Oklahoma, Sch Aerosp & Mech Engn, Norman, OK 73019 USA; [Lee, Chung-Hao] Univ Texas Austin, Inst Computat Engn & Sci, Austin, TX 78705 USA; [Ji, Songhai] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA		Feng, Y (corresponding author), Soochow Univ, Sch Mech & Elect Engn, Room 1107 Engn Bldg,178 Gan Jiang Dong Lu, Suzhou 215021, Jiangsu, Peoples R China.	fengyuan@suda.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61503267]; Jiangsu Province [BK20140356, 16KJB460018]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education MinistryScientific Research Foundation for the Returned Overseas Chinese Scholars [K511701515]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS092853]; School of Aerospace and Mechanical Engineering (AME) at the University of Oklahoma (CHL); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092853, R21NS088781] Funding Source: NIH RePORTER	Funding is provided by Grant 61503267 (YF) from National Natural Science Foundation of China, Grant BK20140356 (YF), 16KJB460018 (YF) from Jiangsu Province, and by Grant K511701515 (YF) from Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry. In addition, supports from the NIH R01 NS092853 (SJ) and the start-up funds from the School of Aerospace and Mechanical Engineering (AME) at the University of Oklahoma (CHL) are also acknowledged.	Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bischoff JE, 2004, J BIOMECH ENG-T ASME, V126, P498, DOI 10.1115/1.1785808; Bol M, 2013, J MECH BEHAV BIOMED, V27, P204, DOI 10.1016/j.jmbbm.2013.04.009; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Chai CK, 2014, J BIOMECH, V47, P784, DOI 10.1016/j.jbiomech.2014.01.018; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Coudrillier B, 2013, BIOMECH MODEL MECHAN, V12, P941, DOI 10.1007/s10237-012-0455-y; Cox MAJ, 2008, J BIOMECH, V41, P422, DOI 10.1016/j.jbiomech.2007.08.006; Destrade M, 2015, INT J NONLIN MECH, V75, P54, DOI 10.1016/j.ijnonlinmec.2015.02.014; Destrade M, 2013, COMPUT MECH, V52, P959, DOI 10.1007/s00466-013-0857-4; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; Fahlstedt M, 2015, J BIOMECH, V48, P1331, DOI 10.1016/j.jbiomech.2015.02.057; Feng Y, 2016, J MECH BEHAV BIOMED, V61, P554, DOI 10.1016/j.jmbbm.2016.04.024; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Harb N, 2014, STRUCT MULTIDISCIP O, V49, P337, DOI 10.1007/s00158-013-0973-y; Harb N, 2011, COMPUT METHOD APPL M, V200, P208, DOI 10.1016/j.cma.2010.08.005; Hatami-Marbini H, 2013, J BIOMECH, V46, P1752, DOI 10.1016/j.jbiomech.2013.03.013; Holmes JH, 2014, J BIOMED INFORM, V49, P11, DOI 10.1016/j.jbi.2014.05.008; Horgan CO, 2012, J ELASTICITY, V108, P179, DOI 10.1007/s10659-011-9363-0; Hortin M, 2015, J MECH BEHAV BIOMED, V45, P75, DOI 10.1016/j.jmbbm.2015.01.020; Hrapko M, 2008, BIORHEOLOGY, V45, P663, DOI 10.3233/BIR-2008-0512; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Jiang Y, 2015, BIOMECH MODEL MECHAN, V14, P1119, DOI 10.1007/s10237-015-0658-0; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Khalil Ahmad S, 2006, Cardiovasc Eng, V6, P93, DOI 10.1007/s10558-006-9013-5; Kulkarni S., 2014, MATH MECH SOLIDS; LAURER HL, 2002, ENCY HUMAN BRAIN, P93; Lee C.-H., 2013, P 7 INT C FUNCT IM M, P416; Lee CH, 2015, BIOMECH MODEL MECHAN, V14, P1281, DOI 10.1007/s10237-015-0674-0; Lee CH, 2015, J THEOR BIOL, V373, P26, DOI 10.1016/j.jtbi.2015.03.004; Lee CH, 2014, J BIOMECH, V47, P2055, DOI 10.1016/j.jbiomech.2013.10.058; Liu YX, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0835; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Namani R, 2012, J BIOMECH ENG-T ASME, V134, DOI 10.1115/1.4006848; Nguyen TD, 2011, BIOMECH MODEL MECHAN, V10, P323, DOI 10.1007/s10237-010-0237-3; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Prange M T, 2000, Stapp Car Crash J, V44, P205; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Reiter R, 2014, J BIOMECH, V47, P1665, DOI 10.1016/j.jbiomech.2014.02.034; Robertson D, 2013, J MECH BEHAV BIOMED, V17, P34, DOI 10.1016/j.jmbbm.2012.07.009; Slomka N, 2011, J MECH BEHAV BIOMED, V4, P1559, DOI 10.1016/j.jmbbm.2011.04.006; Smith S., 2011, GENETIC EVOLUTIONARY; Svensson RB, 2010, J MECH BEHAV BIOMED, V3, P112, DOI 10.1016/j.jmbbm.2009.01.005; Thomopoulos S., 2012, ORTHOP BIOMECH, V49; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Witzenburg C, 2012, J BIOMECH, V45, P842, DOI 10.1016/j.jbiomech.2011.11.025; Wright AH., 1991, FDN GENETIC ALGORITH, V1, P205, DOI DOI 10.1016/B978-0-08-050684-5.50016-1; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang L, 2012, J MECH BEHAV BIOMED, V6, P148, DOI 10.1016/j.jmbbm.2011.11.008; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang MG, 2014, BIOMECH MODEL MECHAN, V13, P1, DOI 10.1007/s10237-013-0481-4; Zhang W, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4029266	62	46	48	1	26	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	JAN	2017	65						490	501		10.1016/j.jmbbm.2016.09.020			12	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	EF9BG	WOS:000390625100043	27665084	Green Accepted			2022-02-06	
S	Johnson, VE; Stewart, W; Arena, JD; Smith, DH		Beart, P; Robinson, M; Rattray, M; Maragakis, NJ		Johnson, Victoria E.; Stewart, William; Arena, John D.; Smith, Douglas H.			Traumatic Brain Injury as a Trigger of Neurodegeneration	NEURODEGENERATIVE DISEASES: PATHOLOGY, MECHANISMS, AND POTENTIAL THERAPEUTIC TARGETS	Advances in Neurobiology		English	Article; Book Chapter						Traumatic brain injury (TBI); Chronic traumatic encephalopathy (CTE); Tau; Amyloid beta; Diffuse axonal injury (DAI)	AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; CAVUM SEPTI PELLUCIDI; FRONTOTEMPORAL LOBAR DEGENERATION; PROFESSIONAL FOOTBALL PLAYERS; LONG-TERM ACCUMULATION; NONMISSILE HEAD-INJURY; ALZHEIMERS-DISEASE; DEMENTIA-PUGILISTICA	Although millions of individuals suffer a traumatic brain injury (TBI) worldwide each year, it is only recently that TBI has been recognized as a major public health problem. Beyond the acute clinical manifestations, there is growing recognition that a single severe TBI (sTBI) or repeated mild TBIs (rTBI) can also induce insidious neurodegenerative processes, which may be associated with early dementia, in particular chronic traumatic encephalopathy (CTE). Identified at autopsy examination in individuals with histories of exposure to sTBI or rTBI, CTE is recognized as a complex pathology featuring both macroscopic and microscopic abnormalities. These include cavum septum pellucidum, brain atrophy and ventricular dilation, together with pathologies in tau, TDP-43, and amyloid-beta. However, the establishment and characterization of CTE as a distinct disease entity is in its infancy. Moreover, the relative "dose" of TBI, such as the frequency and severity of injury, associated with risk of CTE remains unknown. As such, there is a clear and pressing need to improve the recognition and diagnosis of CTE and to identify mechanistic links between TBI and chronic neurodegeneration.	[Johnson, Victoria E.; Arena, John D.; Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stewart, William] Univ Penn, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland		Smith, DH (corresponding author), Univ Penn, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Arena, John/0000-0002-4322-4472; Stewart, William/0000-0003-2199-2582	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS094003, R01 NS092398] Funding Source: Medline		ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALLSOP D, 1990, AM J PATHOL, V136, P255; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; Areza-Fegyveres R, 2007, ARQ NEURO-PSIQUIAT, V65, P830, DOI 10.1590/S0004-282X2007000500019; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Brettschneider J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039216; Brettschneider J, 2012, ACTA NEUROPATHOL, V123, P395, DOI 10.1007/s00401-011-0932-x; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CDC, 1999, TRAUM BRAIN INJ US R; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; Constantinidis J, 1967, Schweiz Arch Neurol Neurochir Psychiatr, V100, P117; Control CfD, 2016, PERC DISTR TBI REL E; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Farbota KD, 2012, J INT NEUROPSYCH SOC, V18, P1; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M, 2010, TRAUMATIC BRAIN INJU; Ferguson FR, 1965, 8 INT C NEUR VIENN, V1; FERINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39, DOI 10.1159/000110750; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Geser F, 2009, J NEUROL, V256, P1205, DOI 10.1007/s00415-009-5069-7; Geser F, 2009, ARCH NEUROL-CHICAGO, V66, P180, DOI 10.1001/archneurol.2008.558; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Huber A., 1993, J NEUROTRAUMA S1, V10, pS180; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; MACPHERSON P, 1988, NEURORADIOLOGY, V30, P506, DOI 10.1007/BF00339691; MANN DMA, 1983, CLIN NEUROPATHOL, V2, P1; Marshall L F, 2000, Clin Neurosurg, V46, P105; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET, V2, P795; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NEUBUERGER KT, 1959, ARCH NEURO PSYCHIATR, V81, P403, DOI 10.1001/archneurpsyc.1959.02340160001001; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sato T, 2009, NEUROSCIENCE, V164, P1565, DOI 10.1016/j.neuroscience.2009.09.050; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SCHWIDDE JT, 1952, AMA ARCH NEUROL PSY, V67, P625, DOI 10.1001/archneurpsyc.1952.02320170043006; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Siman R, 2015, J NEUROTRAUMA; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SPILLANE J D, 1962, Br Med J, V2, P1205; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	154	46	46	0	7	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	2190-5215		978-3-319-57193-5; 978-3-319-57191-1	ADV NEUROBIOL	Adv. Neurobiol.		2017	15						383	400		10.1007/978-3-319-57193-5_15	10.1007/978-3-319-57193-5		18	Biology; Neurosciences	Book Citation Index – Science (BKCI-S)	Life Sciences & Biomedicine - Other Topics; Neurosciences & Neurology	BL2HH	WOS:000448960500016	28674990				2022-02-06	
J	Kim, HC; Kim, E; Bae, JI; Lee, KH; Jeon, YT; Hwang, JW; Lim, YJ; Min, SW; Park, HP				Kim, Hyun-Chang; Kim, Eugene; Bae, Jung Il; Lee, Kook Hyun; Jeon, Young-Tae; Hwang, Jung-Won; Lim, Young-Jin; Min, Seong-Won; Park, Hee-Pyoung			Sevoflurane Postconditioning Reduces Apoptosis by Activating the JAK-STAT Pathway After Transient Global Cerebral Ischemia in Rats	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						apoptosis; brain; ischemia; JAK/STAT signaling pathway; sevoflurane	COLONY-STIMULATING FACTOR; TRAUMATIC BRAIN-INJURY; REPERFUSION INJURY; JAK2/STAT3 PATHWAY; SIGNAL TRANSDUCER; NEURONAL APOPTOSIS; JAK/STAT PATHWAY; EXPRESSION; BCL-2; NEUROPROTECTION	Background: The antiapoptotic effects of sevoflurane post-conditioning are responsible for neuroprotection against cerebral ischemia-reperfusion injury. Phosphorylation of the Janus family tyrosine kinases (JAK) 2-signal transducers and activators of transcription (STAT) 3 pathway is linked to antiapoptosis. Here, we determined whether the antiapoptotic effects of sevoflurane postconditioning are associated with activation of the JAK2-STAT3 pathway after global transient cerebral ischemia in rats. Materials and Methods: Forty-five rats were randomly assigned to 5 groups: sham (n=5), control (10 min of ischemia, n=10), sevoflurane postconditioning (2 periods of sevoflurane inhalation after ischemia for 10 min, n=10), AG490 (a JAK2 selective inhibitor, intraperitoneal administration of 40 mg/kg before ischemia, n=10), and sevoflurane postconditioning plus AG490 group (n=10). The number of apoptotic cells as well as the expression of JAK2, phosphorylated JAK2 (P-JAK2), STAT3, phosphorylated STAT3 (P-STAT3), Bcl-2 (antiapoptotic protein), and Bax (proapoptotic protein) were evaluated 3 days after ischemia. Results: The apoptotic cell count was significantly lower in the sevoflurane postconditioning group than in the control, AG490, and sevoflurane postconditioning plus AG490 groups. JAK2 and STAT3 levels were comparable among all 5 groups. P-JAK2, P-STAT3, and Bcl-2 levels were higher and Bax levels were lower in the sevoflurane postconditioning group relative to the control, AG490, and sevoflurane postconditioning plus AG490 groups. Conclusions: Sevoflurane postconditioning reduced apoptosis by increasing P-JAK and P-STAT expression after transient global ischemia in rats, and AG490 reversed the beneficial antiapoptotic effects of sevoflurane postconditioning, suggesting that the JAK-STAT pathway may be involved in the antiapoptotic mechanism of sevoflurane postconditioning.	[Kim, Hyun-Chang] Keimyung Univ, Dongsan Hosp, Coll Med, Dept Anesthesiol & Pain Med, Daegu, South Korea; [Kim, Eugene] Hosp Catholic Univ Daegu, Dept Anesthesiol & Pain Med, Daegu, South Korea; [Bae, Jung Il; Lee, Kook Hyun; Lim, Young-Jin; Park, Hee-Pyoung] Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Min, Seong-Won] Seoul Natl Univ, Coll Med, SMG SNU Boramae Med Ctr, Dept Anesthesiol & Pain Med, 5-20 Boramae Ro, Seoul 07061, South Korea; [Jeon, Young-Tae; Hwang, Jung-Won] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam, South Korea		Min, SW (corresponding author), Seoul Natl Univ, Coll Med, SMG SNU Boramae Med Ctr, Dept Anesthesiol & Pain Med, 5-20 Boramae Ro, Seoul 07061, South Korea.; Park, HP (corresponding author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, 101 Daehakro, Seoul 03080, South Korea.	swmin@snu.ac.kr; hppark@snu.ac.kr	Kim, Eugene/E-2446-2019	Kim, Eugene/0000-0002-1926-4191; Park, Hee-Pyoung/0000-0002-4772-0780	Seoul National University Hospital [0420130360]; Keimyung University [2015-0170]	Supported by research grants funded by Seoul National University Hospital (number: 0420130360) and Keimyung University (number: 2015-0170).	Adamczyk S, 2010, BRIT J ANAESTH, V104, P191, DOI 10.1093/bja/aep365; Barry SP, 2007, TRENDS MOL MED, V13, P82, DOI 10.1016/j.molmed.2006.12.002; Boengler K, 2010, BASIC RES CARDIOL, V105, P771, DOI 10.1007/s00395-010-0124-1; Booz GW, 2002, J MOL CELL CARDIOL, V34, P1443, DOI 10.1006/jmcc.2002.2076; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Cheppudira BP, 2015, BIOMED REP, V3, P703, DOI 10.3892/br.2015.497; Constantin G, 1998, EUR J IMMUNOL, V28, P3523, DOI 10.1002/(SICI)1521-4141(199811)28:11<3523::AID-IMMU3523>3.0.CO;2-X; Damm J, 2013, NEUROPHARMACOLOGY, V71, P98, DOI 10.1016/j.neuropharm.2013.03.014; Drenger B, 2011, ANESTHESIOLOGY, V114, P1364, DOI 10.1097/ALN.0b013e31820efafd; Feng DY, 2015, EUR NEUROPSYCHOPHARM, V25, P1287, DOI 10.1016/j.euroneuro.2015.04.020; Freitas MCS, 2010, LIVER TRANSPLANT, V16, P600, DOI 10.1002/lt.22036; Gillies LA, 2014, J CELL BIOCHEM, V115, P632, DOI 10.1002/jcb.24709; Gross ER, 2006, AM J PHYSIOL-HEART C, V291, pH827, DOI 10.1152/ajpheart.00003.2006; Gustafsson LL, 1996, ANESTHESIOLOGY, V84, P415, DOI 10.1097/00000542-199602000-00021; Hausenloy DJ, 2007, HEART FAIL REV, V12, P217, DOI 10.1007/s10741-007-9026-1; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jeon YT, 2013, J NEUROSURG ANESTH, V25, P43, DOI 10.1097/ANA.0b013e31826ca3bc; Jung JE, 2011, STROKE, V42, P3574, DOI 10.1161/STROKEAHA.111.626648; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Komine-Kobayashi M, 2006, J CEREBR BLOOD F MET, V26, P402, DOI 10.1038/sj.jcbfm.9600195; Lecour S, 2009, J MOL CELL CARDIOL, V46, P607, DOI 10.1016/j.yjmcc.2009.01.003; Lee H, 2015, BRIT J ANAESTH, V114, P307, DOI 10.1093/bja/aeu268; Lei C, 2011, ANESTH ANALG, V113, P153, DOI 10.1213/ANE.0b013e31821a9fbe; Li LX, 2011, BRAIN RES BULL, V86, P390, DOI 10.1016/j.brainresbull.2011.09.005; Liu L, 2015, CELL PHYSIOL BIOCHEM, V35, P126, DOI 10.1159/000369681; Luo Y, 2008, ANESTHESIOLOGY, V109, P782, DOI 10.1097/ALN.0b013e3181895f88; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niture SK, 2013, FREE RADICAL BIO MED, V57, P119, DOI 10.1016/j.freeradbiomed.2012.12.014; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Sehara Y, 2013, J NEUROSCI, V33, P12364, DOI 10.1523/JNEUROSCI.1852-13.2013; Seo JH, 2013, BRIT J ANAESTH, V110, P988, DOI 10.1093/bja/aet009; Shyu WC, 2008, J CLIN INVEST, V118, P133, DOI 10.1172/JCI32723; Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204-014-1448-7; Song YX, 2013, NEUROCHEM RES, V38, P610, DOI 10.1007/s11064-012-0959-y; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Tian YK, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-53; Wang JK, 2010, BRAIN RES, V1357, P142, DOI 10.1016/j.brainres.2010.08.009; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yan LH, 2012, J SURG RES, V178, P578, DOI 10.1016/j.jss.2012.06.007; Yang NS, 2008, NEPHROL DIAL TRANSPL, V23, P91, DOI 10.1093/ndt/gfm509; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018; Zhou TF, 2013, J SURG RES, V183, P304, DOI 10.1016/j.jss.2012.11.035; Zhu HB, 2013, EUR J PHARMACOL, V714, P23, DOI 10.1016/j.ejphar.2013.05.043	50	46	54	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2017	29	1					37	45		10.1097/ANA.0000000000000331			9	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	EG6AY	WOS:000391127400006	27337676				2022-02-06	
J	Myer, GD; Yuan, WH; Foss, KDB; Thomas, S; Smith, D; Leach, J; Kiefer, AW; Dicesare, C; Adams, J; Gubanich, PJ; Kitchen, K; Schneider, DK; Braswell, D; Krueger, D; Altaye, M				Myer, Gregory D.; Yuan, Weihong; Foss, Kim D. Barber; Thomas, Staci; Smith, David; Leach, James; Kiefer, Adam W.; Dicesare, Chris; Adams, Janet; Gubanich, Paul J.; Kitchen, Katie; Schneider, Daniel K.; Braswell, Daniel; Krueger, Darcy; Altaye, Mekibib			Analysis of head impact exposure and brain microstructure response in a season-long application of a jugular vein compression collar: a prospective, neuroimaging investigation in American football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; DIFFUSION TENSOR; WHITE-MATTER; PROTECTIVE EQUIPMENT; RUGBY UNION; INJURY; EPIDEMIOLOGY; LOCALIZATION; ADOLESCENTS	Background Historical approaches to protect the brain from outside the skull (eg, helmets and mouthpieces) have been ineffective in reducing internal injury to the brain that arises from energy absorption during sports-related collisions. We aimed to evaluate the effects of a neck collar, which applies gentle bilateral jugular vein compression, resulting in cerebral venous engorgement to reduce head impact energy absorption during collision. Specifically, we investigated the effect of collar wearing during head impact exposure on brain microstructure integrity following a competitive high school American football season. Methods A prospective longitudinal controlled trial was employed to evaluate the effects of collar wearing (n=32) relative to controls (CTRL; n=30) during one competitive football season (age: 17.04 +/- 0.67 years). Impact exposure was collected using helmet sensors and white matter (WM) integrity was quantified based on diffusion tensor imaging (DTI) serving as the primary outcome. Results With similar overall g-forces and total head impact exposure experienced in the two study groups during the season (p>0.05), significant preseason to postseason changes in mean diffusivity, axial diffusivity and radial diffusivity in the WM integrity were noted in the CTRL group (corrected p<0.05) but not in the collar group (p>0.05). The CTRL group demonstrated significantly larger preseason to postseason DTI change in multiple WM regions compared with the collar group (corrected p<0.05). Discussion Reduced WM diffusivity alteration was noted in participants wearing a neck collar after a season of competitive football. Collar wearing may have provided a protective effect against brain microstructural changes after repetitive head impacts.	[Myer, Gregory D.; Foss, Kim D. Barber; Thomas, Staci; Smith, David; Kiefer, Adam W.; Dicesare, Chris; Gubanich, Paul J.; Kitchen, Katie; Schneider, Daniel K.; Braswell, Daniel] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.; Foss, Kim D. Barber; Thomas, Staci; Kiefer, Adam W.; Dicesare, Chris; Kitchen, Katie; Schneider, Daniel K.; Braswell, Daniel] Cincinnati Childrens Hosp Med Ctr, SPORT Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.; Kiefer, Adam W.; Gubanich, Paul J.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Penn, Dept Orthopaed, Philadelphia, PA 19104 USA; [Myer, Gregory D.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Myer, Gregory D.] Univ Cincinnati, Dept Orthopaed Surg, Cincinnati, OH USA; [Yuan, Weihong] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Cincinnati, OH 45229 USA; [Yuan, Weihong] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Foss, Kim D. Barber] Mt St Joseph Univ, Dept Athlet Training, Div Hlth Sci, Cincinnati, OH USA; [Foss, Kim D. Barber] Rocky Mt Univ Hlth Profess, Provo, UT USA; [Leach, James; Adams, Janet] Cincinnati Childrens Hosp Med Ctr, Div Radiol, Cincinnati, OH 45229 USA; [Kiefer, Adam W.] Univ Cincinnati, Dept Psychol, Ctr Cognit Act & Percept, Cincinnati, OH 45221 USA; [Schneider, Daniel K.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Krueger, Darcy] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA; [Altaye, Mekibib] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA		Myer, GD (corresponding author), Cincinnati Childrens Hosp, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	Greg.Myer@cchmc.org	Kiefer, Adam/F-1756-2018; DiCesare, Christopher/ABH-9573-2020; DiCesare, Christopher/AAA-3327-2021; Myer, Gregory/H-6572-2016	DiCesare, Christopher/0000-0002-6576-4904; Krueger, Darcy/0000-0002-7250-7391; Myer, Gregory/0000-0002-9983-8422	Q30 Innovations [FP00009108]	Q30 Innovations (Funding Proposal: FP00009108).	Babcock L, 2015, J PEDIATR REHAB MED, V8, P285, DOI 10.3233/PRM-150347; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Fridman L, 2013, BMC SPORTS SCI MED R, V5, DOI 10.1186/2052-1847-5-30; GILLAND O, 1969, AMER J ROENTGENOL RA, V106, P369, DOI 10.2214/ajr.106.2.369; Hatt A, 2015, AM J NEURORADIOL, V36, P1971, DOI 10.3174/ajnr.A4361; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Leach JL, 2013, AM SOC NEUR ANN M; Lloyd J, 2016, J NEUROSURG, V124, P667, DOI 10.3171/2014.11.JNS141742; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P575; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McGuine T, 2013, ORTHOP J SPORTS MED, P1; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mongan P, 2013, PRACTICAL APPROACH N; Mori S., 2005, AM SOC NEURORADIOLOG; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Myer GD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00074; Myer GD, 2014, J ORTHOP SPORT PHYS, V44, P164, DOI 10.2519/jospt.2014.5298; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schneider DK, 2017, BRIT J SPORT MED, V51, P1473, DOI 10.1136/bjsports-2015-095645; Smith DW, 2013, ORTHOP J SPORTS MED, V1, DOI 10.1177/2325967113511588; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Winters Jackson, 2014, General Dentistry, V62, P34; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	57	46	47	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT	2016	50	20					1276	+		10.1136/bjsports-2016-096134			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DY7AZ	WOS:000385282900015	27307271	Green Published, hybrid			2022-02-06	
J	Oresic, M; Posti, JP; Kamstrup-Nielsen, MH; Takala, RSK; Lingsma, HF; Mattila, I; Jantti, S; Katila, AJ; Carpenter, KLH; Ala-Seppala, H; Kyllonen, A; Maanpaa, HR; Tallus, J; Coles, JP; Heino, I; Frantzen, J; Hutchinson, PJ; Menon, DK; Tenovuo, O; Hyotylainen, T				Oresic, Matej; Posti, Jussi P.; Kamstrup-Nielsen, Maja H.; Takala, Riikka S. K.; Lingsma, Hester F.; Mattila, Ismo; Jantti, Sirkku; Katila, Ari J.; Carpenter, Keri L. H.; Ala-Seppala, Henna; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Coles, Jonathan P.; Heino, Iiro; Frantzen, Janek; Hutchinson, Peter J.; Menon, David K.; Tenovuo, Olli; Hyotylainen, Tuulia			Human Serum Metabolites Associate With Severity and Patient Outcomes in Traumatic Brain Injury	EBIOMEDICINE			English	Article						Biomarkers; Mass spectrometry; Metabolomics; Traumatic brain injury	CEREBRAL-ISCHEMIA; DAMAGE; HEAD; BARRIER; MARKERS; PROTEIN; S100B; ACIDS; PREDICTORS; DISRUPTION	Traumatic brain injury (TBI) is a major cause of death and disability worldwide, especially in children and young adults. TBI is an example of a medical condition where there are still major lacks in diagnostics and outcome prediction. Here we apply comprehensive metabolic profiling of serum samples from TBI patients and controls in two independent cohorts. The discovery study included 144 TBI patients, with the samples taken at the time of hospitalization. The patients were diagnosed as severe (sTBI; n=22), moderate (moTBI; n=14) or mild TBI (mTBI; n=108) according to Glasgow Coma Scale. The control group (n=28) comprised of acute orthopedic non-brain injuries. The validation study included sTBI (n=23), moTBI (n=7), mTBI (n=37) patients and controls (n=27). We show that two medium-chain fatty acids (decanoic and octanoic acids) and sugar derivatives including 2,3-bisphosphoglyceric acid are strongly associated with severity of TBI, and most of them are also detected at high concentrations in brain microdialysates of TBI patients. Based on metabolite concentrations from TBI patients at the time of hospitalization, an algorithm was developed that accurately predicted the patient outcomes (AUC=0.84 in validation cohort). Addition of the metabolites to the established clinical model (CRASH), comprising clinical and computed tomography data, significantly improved prediction of patient outcomes. The identified 'TBI metabotype' in serum, that may be indicative of disrupted blood-brain barrier, of protective physiological response and altered metabolism due to head trauma, offers a new venue for the development of diagnostic and prognostic markers of broad spectrum of TBIs. (C) 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Oresic, Matej; Hyotylainen, Tuulia] Univ Turku, Turku Ctr Biotechnol, FI-20520 Turku, Finland; [Oresic, Matej; Hyotylainen, Tuulia] Abo Akad Univ, FI-20520 Turku, Finland; [Oresic, Matej; Kamstrup-Nielsen, Maja H.; Mattila, Ismo; Hyotylainen, Tuulia] Steno Diabet Ctr A S, DK-2820 Gentofte, Denmark; [Posti, Jussi P.; Hyotylainen, Tuulia] VTT, VTT Tech Res Ctr Finland, FI-02044 Espoo, Finland; [Posti, Jussi P.; Frantzen, Janek] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, FI-20521 Turku, Finland; [Posti, Jussi P.; Ala-Seppala, Henna; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Heino, Iiro; Frantzen, Janek; Tenovuo, Olli] Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, FI-20521 Turku, Finland; [Posti, Jussi P.; Maanpaa, Henna-Riikka; Tallus, Jussi; Coles, Jonathan P.; Heino, Iiro; Frantzen, Janek; Tenovuo, Olli] Univ Turku, Dept Neurol, FI-20014 Turku, Finland; [Katila, Ari J.] Turku Univ Hosp, Perioperat Serv Intens Care Med & Pain Management, FI-20521 Turku, Finland; [Lingsma, Hester F.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Box 93,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Hyotylainen, Tuulia] Univ Helsinki, Cent Hosp, Clin Res Inst, FI-00290 Helsinki, Finland; [Hyotylainen, Tuulia] Univ Orebro, Dept Chem, S-70281 Orebro, Sweden		Oresic, M; Hyotylainen, T (corresponding author), Univ Turku, Turku Ctr Biotechnol, FI-20520 Turku, Finland.; Oresic, M; Hyotylainen, T (corresponding author), Abo Akad Univ, FI-20520 Turku, Finland.; Oresic, M; Hyotylainen, T (corresponding author), Steno Diabet Ctr A S, DK-2820 Gentofte, Denmark.; Hyotylainen, T (corresponding author), VTT, VTT Tech Res Ctr Finland, FI-02044 Espoo, Finland.; Tenovuo, O (corresponding author), Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, FI-20521 Turku, Finland.; Tenovuo, O (corresponding author), Univ Turku, Dept Neurol, FI-20014 Turku, Finland.; Menon, DK; Hyotylainen, T (corresponding author), Univ Cambridge, Dept Med, Div Anaesthesia, Box 93,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.; Hyotylainen, T (corresponding author), Univ Helsinki, Cent Hosp, Clin Res Inst, FI-00290 Helsinki, Finland.; Hyotylainen, T (corresponding author), Univ Orebro, Dept Chem, S-70281 Orebro, Sweden.; Oresic, M (corresponding author), Turku Ctr Biotechnol, Tykistokatu 6, FI-20520 Turku, Finland.	matej.oresic@utu.fi; dkm13@wbic.cam.ac.uk; olli.tenovuo@tyks.fi; tuulia.hyotylainen@oru.se	Oresic, Matej/AAV-3978-2020; Posti, Jussi P./Y-2908-2019; Hyotylainen, Tuulia/AAP-6266-2020; Oresic, Matej/K-7673-2016	Posti, Jussi P./0000-0002-5925-5193; Oresic, Matej/0000-0002-2856-9165; Coles, Jonathan/0000-0003-4013-679X; Hyotylainen, Tuulia/0000-0002-1389-8302; Heino, Iiro/0000-0002-5293-9859; Mattila, Ismo/0000-0001-9597-7831; Carpenter, Keri/0000-0001-8236-7727; Ala-Seppala, Henna/0000-0002-1577-3028	EU FP7 project TBIcare [270259]; GE-NFL Head Health Challenge I Award [7620]; EVO (Finland); Maire Taponen Foundation; National Institute for Health Research (NIHR) Research Professorship; NIHR Biomedical Research Centre (NIHR BRC) Cambridge; NIHR BRC Cambridge; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	This work was supported by the EU FP7 project TBIcare (Project ref. 270259; to M.O., D.M., and O.T.), by the GE-NFL Head Health Challenge I Award (grant no. 7620 to M.O. and T.H.), by personal EVO funding (Finland) (to J.P.P and R.S.K.T.), and by personal grant from Maire Taponen Foundation (to J.P.P.). Support for P.J.H. - National Institute for Health Research (NIHR) Research Professorship; NIHR Biomedical Research Centre (NIHR BRC) Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). Support for K.L.H.C. - NIHR BRC Cambridge (Neuroscience Theme; Brain Injury and Repair Theme).	Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Castillo S, 2011, ANAL CHEM, V83, P3058, DOI 10.1021/ac103308x; Chyan YJ, 1999, J BIOL CHEM, V274, P21937, DOI 10.1074/jbc.274.31.21937; Clausen F, 2011, ACTA NEUROCHIR, V153, P653, DOI 10.1007/s00701-010-0871-7; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; de Assis DR, 2004, BRAIN RES, V1030, P141, DOI 10.1016/j.brainres.2004.10.010; Ebert D, 2003, J NEUROSCI, V23, P5928; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harrell FE Jr, 2017, REGRESSION MODELING; Hartonen M., 2013, J CHROMATOGR A; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Hsia CCW, 1998, NEW ENGL J MED, V338, P239, DOI 10.1056/NEJM199801223380407; Hwang IK, 2009, J NEUROSCI RES, V87, P2126, DOI 10.1002/jnr.22030; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Karbownik M, 2001, J CELL BIOCHEM, V81, P507, DOI 10.1002/1097-4644(20010601)81:3<507::AID-JCB1064>3.0.CO;2-M; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Kopka J, 2005, BIOINFORMATICS, V21, P1635, DOI 10.1093/bioinformatics/bti236; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; OLDENDORF WH, 1973, AM J PHYSIOL, V224, P1450, DOI 10.1152/ajplegacy.1973.224.6.1450; Paik MJ, 2009, CLIN CHIM ACTA, V402, P25, DOI 10.1016/j.cca.2008.12.022; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Saw MM, 2014, NEUROCRIT CARE, V20, P209, DOI 10.1007/s12028-013-9933-z; Schuck PF, 2009, NEUROCHEM INT, V54, P519, DOI 10.1016/j.neuint.2009.02.009; Schuck PF, 2009, BRAIN RES, V1296, P117, DOI 10.1016/j.brainres.2009.08.053; SPECTOR R, 1988, J NEUROCHEM, V50, P639, DOI 10.1111/j.1471-4159.1988.tb02958.x; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Torabian S, 2005, CURR OPIN ONCOL, V17, P167, DOI 10.1097/01.cco.0000154039.07466.5d; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2	45	46	50	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	2352-3964			EBIOMEDICINE	EBioMedicine	OCT	2016	12						118	126		10.1016/j.ebiom.2016.07.015			9	Medicine, General & Internal; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Research & Experimental Medicine	EA8IM	WOS:000386878500026	27665050	Green Published, gold			2022-02-06	
J	Haus, DL; Lopez-Velazquez, L; Gold, EM; Cunningham, KM; Perez, H; Anderson, AJ; Cummings, BJ				Haus, Daniel L.; Lopez-Velazquez, Luci; Gold, Eric M.; Cunningham, Kelly M.; Perez, Harvey; Anderson, Aileen J.; Cummings, Brian J.			Transplantation of human neural stem cells restores cognition in an immunodeficient rodent model of traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Human neural stem cell; Cell transplantation; Spatial memory; Emotional memory; Hippocampal neuron survival; Stereology; Cell therapy; Neurotrauma	SPINAL-CORD-INJURY; CONTROLLED CORTICAL IMPACT; DELAYED NEURONAL DEATH; MORRIS WATER MAZE; LONG-TERM; PROGENITOR CELLS; RAT MODEL; STEM/PROGENITOR CELLS; THERAPEUTIC STRATEGY; REPEATED CONCUSSION	Traumatic brain injury (TBI) in humans can result in permanent tissue damage and has been linked to cognitive impairment that lasts years beyond the initial insult. Clinically effective treatment strategies have yet to be developed. Transplantation of human neural stem cells (hNSCs) has the potential to restore cognition lost due to injury, however, the vast majority of rodent TBI/hNSC studies to date have evaluated cognition only at early time points, typically <1 month post-injury and cell transplantation. Additionally, human cell engraftment and long-term survival in rodent models of TBI has been difficult to achieve due to host immunorejection of the transplanted human cells, which confounds conclusions pertaining to transplant-mediated behavioral improvement. To overcome these shortfalls, we have developed a novel TBI xenotransplantation model that utilizes immunodeficient athymic nude (ATN) rats as the host recipient for the post-TBI transplantation of human embryonic stem cell (hESC) derived NSCs and have evaluated cognition in these animals at long-term (>= 2 months) time points post-injury. We report that immunodeficient ATN rats demonstrate hippocampal-dependent spatial memory deficits (Novel Place, Morris Water Maze), but not non-spatial (Novel Object) or emotional/anxiety-related (Elevated Plus Maze, Conditioned Taste Aversion) deficits, at 2-3 months post-TBI, confirming that ATN rats recapitulate some of the cognitive deficits found in immunosufficient animal strains. Approximately 9-25% of transplanted hNSCs survived for at least 5 months post-transplantation and differentiated into mature neurons (NeuN, 18-38%), astrocytes (GFAP, 13-16%), and oligodendrocytes (Olig2, 11-13%). Furthermore, while this model of TBI (cortical impact) targets primarily cortex and the underlying hippocampus and generates a large lesion cavity, hNSC transplantation facilitated cognitive recovery without affecting either lesion volume or total spared cortical or hippocampal tissue volume. Instead, we have found an overall increase in host hippocampal neuron survival in hNSC transplanted animals and demonstrate that a correlation exists between hippocampal neuron survival and cognitive performance. Together, these findings support the use of immunodeficient rodents in models of TBI that involve the transplantation of human cells, and suggest that hNSC transplantation may be a viable, long-term therapy to restore cognition after brain injury. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Haus, Daniel L.; Gold, Eric M.; Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, Sue & Bill Gross Stem Cell Ctr, Irvine, CA 92697 USA; [Haus, Daniel L.; Gold, Eric M.; Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, Anat & Neurobiol, Irvine, CA 92697 USA; [Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, Phys & Med Rehabil, Irvine, CA 92697 USA; [Lopez-Velazquez, Luci; Cunningham, Kelly M.; Perez, Harvey; Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, UCI Inst Memory Impairments & Neurol Disorders MI, Irvine, CA 92697 USA		Cummings, BJ (corresponding author), Univ Calif Irvine, Room 2026 Gross Hall,845 Hlth Sci Rd, Irvine, CA 92697 USA.	cummings@uci.edu	Cummings, Brian J/C-9180-2012	Cummings, Brian J/0000-0003-3628-5290	California Institute for Regenerative Medicine (CIRM)California Institute for Regenerative Medicine [TR2-01767, TG2-01152, TB1-01182]	The preceding studies were supported by grants from the California Institute for Regenerative Medicine (CIRM): Early Translational Award TR2-01767 awarded to BJC, Predoctoral Fellowship in Stem Cell Biology TG2-01152 awarded to DLH, and a Bridges Training Program Award TB1-01182 awarded to KMC and HP. The authors wish to thank the following individuals for their technical contributions to the manuscript: Diane Su and Rebecca Nishi for assistance with TBI and cell transplantation surgical procedures, and Janae Bustos, George Lacuesta (TB1-01182), and Daniel Ho for assistance with animal behavioral testing and analysis. The authors would also like to thank Dr. Stephen Scheff (University of Kentucky) for training on CCI TBI models and surgical procedures.	Acharya MM, 2009, P NATL ACAD SCI USA, V106, P19150, DOI 10.1073/pnas.0909293106; Aertker B.M., 2015, EXP NEUROL; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Anderson AJ, 2011, REGEN MED, V6, P367, DOI [10.2217/RME.11.22, 10.2217/rme.11.22]; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; BRUTKOWSKI S, 1965, PHYSIOL REV, V45, P721, DOI 10.1152/physrev.1965.45.4.721; Chen JL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00382; Chen TX, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00275; CONRAD CD, 1993, J NEUROSCI, V13, P2582, DOI 10.1523/JNEUROSCI.13-06-02582.1993; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Gowing G, 2014, NEUROREPORT, V25, P367, DOI 10.1097/WNR.0000000000000092; Griesbach GS, 2015, J NEUROTRAUM, V32, P704, DOI 10.1089/neu.2014.3754; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; Haus DL, 2014, STEM CELL RES, V13, P214, DOI 10.1016/j.scr.2014.06.008; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hooshmand MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005871; Huang L, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt519; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Levy M., 2015, BRAIN RES; Li GM, 2013, NEUROL SCI, V34, P963, DOI 10.1007/s10072-012-1173-z; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lindvall O, 2012, CELL STEM CELL, V10, P660, DOI [10.1016/j.stem.2012.04.004, 10.1016/j.stem.2012.01.009]; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Lopez-Velazquez L, 2007, NEUROSCIENCE, V144, P808, DOI 10.1016/j.neuroscience.2006.09.063; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mattis VB, 2014, EXP NEUROL, V254, P90, DOI 10.1016/j.expneurol.2014.01.007; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Myczek K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106009; Nakamura M, 2013, CELL RES, V23, P70, DOI 10.1038/cr.2012.171; Nasonkin I, 2009, STEM CELLS, V27, P2414, DOI 10.1002/stem.177; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Okano H, 2003, SEMIN CELL DEV BIOL, V14, P191, DOI 10.1016/S1084-9521(03)00011-9; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Piltti KM, 2013, STEM CELL TRANSL MED, V2, P961, DOI 10.5966/sctm.2013-0064; Piltti KM, 2013, STEM CELL TRANSL MED, V2, P204, DOI 10.5966/sctm.2012-0110; Poltavtseva RA, 2012, B EXP BIOL MED+, V153, P586, DOI 10.1007/s10517-012-1772-y; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Rekha J, 2009, BEHAV NEUROSCI, V123, P1197, DOI 10.1037/a0017655; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosser A, 2014, MOVEMENT DISORD, V29, P1446, DOI 10.1002/mds.26026; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Seminatore C, 2010, STROKE, V41, P153, DOI 10.1161/STROKEAHA.109.563015; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Silva AF, 2013, BRAIN RES, V1491, P23, DOI 10.1016/j.brainres.2012.10.063; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Snyder EY, 2004, J NEUROSCI RES, V76, P157, DOI 10.1002/jnr.20033; Sontag CJ, 2014, STEM CELL REP, V2, P620, DOI 10.1016/j.stemcr.2014.03.005; Tang HL, 2013, CELL REPROGRAM, V15, P435, DOI 10.1089/cell.2012.0081; Teng YD, 2011, CURR NEUROPHARMACOL, V9, P574, DOI 10.2174/157015911798376299; Tetzlaff W, 2011, J NEUROTRAUM, V28, P1611, DOI 10.1089/neu.2009.1177; Thomsen GM, 2014, EXP NEUROL, V262, P127, DOI 10.1016/j.expneurol.2014.02.021; Tsai YC, 2015, STEM CELLS, V33, P2537, DOI 10.1002/stem.2032; Vaysse L, 2015, BIOMATERIALS, V58, P46, DOI 10.1016/j.biomaterials.2015.04.019; VOLPE BT, 1992, BEHAV NEUROSCI, V106, P457, DOI 10.1037/0735-7044.106.3.457; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Vorhees CV, 2014, ILAR J, V55, P310, DOI 10.1093/ilar/ilu013; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Wang QJ, 2016, ADV EXP MED BIOL, V854, P543, DOI 10.1007/978-3-319-17121-0_72; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xu LY, 2006, TRANSPLANTATION, V82, P865, DOI 10.1097/01.tp.0000235532.00920.7a; Xu LY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0087-0; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	92	46	49	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2016	281						1	16		10.1016/j.expneurol.2016.04.008			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DN4RO	WOS:000377055100001	27079998	hybrid			2022-02-06	
J	Bonsack, F; Alleyne, CH; Sukumari-Ramesh, S				Bonsack, Frederick; Alleyne, Cargill H., Jr.; Sukumari-Ramesh, Sangeetha			Augmented expression of TSPO after intracerebral hemorrhage: a role in inflammation?	JOURNAL OF NEUROINFLAMMATION			English	Article						Microglial activation; ICH; TSPO	PROTEIN 18 KDA; PERIPHERAL BENZODIAZEPINE-RECEPTOR; DIAZEPAM-BINDING INHIBITOR; INTERDISCIPLINARY-WORKING-GROUP; ASSOCIATION-STROKE-COUNCIL; AMERICAN-HEART-ASSOCIATION; PRESSURE-RESEARCH-COUNCIL; TRAUMATIC BRAIN-INJURY; QUALITY-OF-CARE; TRANSLOCATOR PROTEIN	Background: Intracerebral hemorrhage (ICH) is a potentially fatal stroke subtype accounting for 10-15 % of all strokes. Despite neurosurgical intervention and supportive care, the 30-day mortality rate remains 30-50 % with ICH survivors frequently displaying neurological impairment and requiring long-term assisted care. Although accumulating evidence demonstrates the role of neuroinflammation in secondary brain injury and delayed fatality after ICH, the molecular regulators of neuroinflammation remain poorly defined after ICH. Methods: In the present study, ICH was induced in CD1 male mice by collagenase injection method and given the emerging role of TSPO (18-kDa translocator protein) in neuroinflammation, immunofluorescence staining of brain sections was performed to characterize the temporal expression pattern and cellular and subcellular localization of TSPO after ICH. Further, both genetic and pharmacological studies were employed to assess the functional role of TSPO in neuroinflammation. Results: The expression of TSPO was found to be increased in the peri-hematomal brain region 1 to 7 days post-injury, peaking on day 3 to day 5 in comparison to sham. Further, the TSPO expression was mostly observed in microglia/macrophages, the inflammatory cells of the central nervous system, suggesting an unexplored role of TSPO in neuroinflammatory responses after ICH. Further, the subcellular localization studies revealed prominent perinuclear expression of TSPO after ICH. Moreover, both genetic and pharmacological studies revealed a regulatory role of TSPO in the release of pro-inflammatory cytokines in a macrophage cell line, RAW 264.7. Conclusions: Altogether, the data suggest that TSPO induction after ICH could be an intrinsic mechanism to prevent an exacerbated inflammatory response and raise the possibility of targeting TSPO for the attenuation of secondary brain injury after ICH.	[Bonsack, Frederick; Alleyne, Cargill H., Jr.; Sukumari-Ramesh, Sangeetha] Augusta Univ, Med Coll Georgia, Dept Neurosurg, 1120 15th St,CA1010, Augusta, GA 30912 USA		Sukumari-Ramesh, S (corresponding author), Augusta Univ, Med Coll Georgia, Dept Neurosurg, 1120 15th St,CA1010, Augusta, GA 30912 USA.	sramesh@gru.edu			American Heart AssociationAmerican Heart Association [14SDG18730034]	This work was supported by a grant from the American Heart Association (14SDG18730034) to SSR. None of the funding bodies had a role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.	Aguilar MI, 2010, SEMIN NEUROL, V30, P555, DOI 10.1055/s-0030-1268865; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Babu R, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11366; Banati RB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6452; BRAESTRUP C, 1977, NATURE, V269, P702, DOI 10.1038/269702a0; Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Carmichael ST, 2008, J CEREBR BLOOD F MET, V28, P1860, DOI 10.1038/jcbfm.2008.77; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; CHANG YJ, 1992, DNA CELL BIOL, V11, P471, DOI 10.1089/dna.1992.11.471; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Cosenza-Nashat M, 2009, NEUROPATH APPL NEURO, V35, P306, DOI 10.1111/j.1365-2990.2008.01006.x; COSTA E, 1994, J STEROID BIOCHEM, V49, P385, DOI 10.1016/0960-0760(94)90284-4; DIRINGER MN, 1993, CRIT CARE MED, V21, P1591, DOI 10.1097/00003246-199310000-00032; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Emsley HCA, 2002, J CEREBR BLOOD F MET, V22, P1399, DOI 10.1097/01.WCB.0000037880.62590.28; FERRERO P, 1986, P NATL ACAD SCI USA, V83, P827, DOI 10.1073/pnas.83.3.827; Ferzaz B, 2002, J PHARMACOL EXP THER, V301, P1067, DOI 10.1124/jpet.301.3.1067; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Gomez-Nicola D, 2013, J NEUROSCI, V33, P2481, DOI 10.1523/JNEUROSCI.4440-12.2013; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hong SH, 2006, J NEUROSCI RES, V83, P1293, DOI 10.1002/jnr.20829; Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Liu GJ, 2014, BRAIN PATHOL, V24, P631, DOI 10.1111/bpa.12196; Liu J, 2006, J BIOL CHEM, V281, P38879, DOI 10.1074/jbc.M608820200; Ma L, 2016, BRAIN RES BULL, V121, P192, DOI 10.1016/j.brainresbull.2016.02.001; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Morohaku K, 2014, ENDOCRINOLOGY, V155, P89, DOI 10.1210/en.2013-1556; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; Nilsson OG, 2002, J NEUROSURG, V97, P531, DOI 10.3171/jns.2002.97.3.0531; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nothdurfter C, 2012, EUR ARCH PSY CLIN N, V262, pS107, DOI 10.1007/s00406-012-0352-5; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; Politis M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00096; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Qureshi AI, 2001, CRIT CARE MED, V29, P152, DOI 10.1097/00003246-200101000-00030; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; ROMEO E, 1993, J PHARMACOL EXP THER, V267, P462; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; Sukumari-Ramesh S, 2016, J MOL NEUROSCI, V58, P525, DOI 10.1007/s12031-016-0722-y; Sukumari-Ramesh S, 2016, TRANSL STROKE RES, V7, P141, DOI 10.1007/s12975-015-0421-y; Sukumari-Ramesh S, 2012, J NEUROTRAUM, V29, P2798, DOI 10.1089/neu.2011.2243; Sukumari-Ramesh S, 2012, TRANSL STROKE RES, V3, pS80, DOI 10.1007/s12975-012-0165-x; Tu LN, 2014, J BIOL CHEM, V289, P27444, DOI 10.1074/jbc.M114.578286; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Veenman L, 2002, J NEUROCHEM, V80, P917, DOI 10.1046/j.0022-3042.2002.00769.x; Veenman L, 2007, CURR PHARM DESIGN, V13, P2385; Veiga S, 2005, J NEUROSCI RES, V80, P129, DOI 10.1002/jnr.20430; Veiga S, 2007, GLIA, V55, P1426, DOI 10.1002/glia.20558; Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357; Wang J, 2003, ANN NEUROL, V54, P655, DOI 10.1002/ana.10750; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yanase H, 2002, ARCH HISTOL CYTOL, V65, P27, DOI 10.1679/aohc.65.27; Zhang D, 2009, TOXICOL APPL PHARM, V238, P64, DOI 10.1016/j.taap.2009.04.015; Zhao Yan-Yin, 2011, Neuron Glia Biol, V7, P187, DOI 10.1017/S1740925X12000129; Zurcher NR, 2015, NEUROIMAGE-CLIN, V7, P409, DOI 10.1016/j.nicl.2015.01.009	83	46	47	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 17	2016	13								151	10.1186/s12974-016-0619-2			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DQ0BF	WOS:000378861600001	27315802	gold, Green Published			2022-02-06	
J	Zhao, ZL; Wang, M; Tian, Y; Hilton, T; Salsbery, B; Zhou, EZ; Wu, XP; Thiagarajan, P; Boilard, E; Li, M; Zhang, JN; Dong, JF				Zhao, Zilong; Wang, Min; Tian, Ye; Hilton, Tristan; Salsbery, Breia; Zhou, Eric Z.; Wu, Xiaoping; Thiagarajan, Perumal; Boilard, Eric; Li, Min; Zhang, Jianning; Dong, Jing-fei			Cardiolipin-mediated procoagulant activity of mitochondria contributes to traumatic brain injury-associated coagulopathy in mice	BLOOD			English	Article							ANNEXIN-V; HEAD-INJURY; LIPID-COMPOSITION; OUTER-MEMBRANE; RAT-LIVER; PHOSPHATIDYLSERINE; COAGULATION; BINDING; CELLS; PHOSPHATIDYLETHANOLAMINE	Cardiolipin (CL) is an anionic phospholipid located exclusively in the mitochondrial inner membrane. Its presence in blood indicates mitochondrial damage and release from injured cells. Here, we report the detection of CL-exposed brain-derived mitochondrial microparticles (mtMPs) at 17 547 +/- 2677/mu L in the peripheral blood of mice subjected to fluid percussion injury to the brain. These mtMPs accounted for 55.2% +/- 12.6% of all plasma annexin V-binding microparticles found in the acute phase of injury. They were also released from cultured neuronal and glial cells undergoing apoptosis. The mtMPs synergized with platelets to facilitate vascular leakage by disrupting the endothelial barrier. The disrupted endothelial barrier allowed the release of mtMPs into the systemic circulation to promote coagulation in both traumatically injured and mtMP-or CL-injected mice, leading to enhanced fibrinolysis, vascular fibrin deposition, and thrombosis. This mtMP-induced coagulation was mediated by CL transported from the inner to the outer mitochondrial membrane and was blocked by the scavenging molecule lactadherin. The mtMP-bound CL was similar to 1600 times as active as purified CL in promoting coagulation. This study uncovered a novel procoagulant activity of CL and CL-exposed mitochondria that may contribute to traumatic brain injury-associated coagulopathy and identified potential pathways to block this activity.	[Zhao, Zilong; Tian, Ye; Zhang, Jianning] Tianjin Med Univ, Tianjin Inst Neurol, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Zhao, Zilong; Hilton, Tristan; Salsbery, Breia; Zhou, Eric Z.; Wu, Xiaoping; Dong, Jing-fei] BloodWorks Northwest Res Inst, Seattle, WA USA; [Wang, Min; Li, Min] Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou 730000, Peoples R China; [Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Boilard, Eric] Univ Laval, Dept Infect Dis & Immun, Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ, Canada; [Boilard, Eric] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada; [Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Tianjin Inst Neurol, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China.; Li, M (corresponding author), Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou 730000, Peoples R China.; Dong, JF (corresponding author), BloodWorks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.	limin@lzu.edu.cn; jianningzhang@hotmail.com; jfdong@bloodworksnw.org	Zhao, Zilong/AAZ-2196-2020		National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS087296]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL71895]; American Society of Hematology; National Natural Science Foundation of China State Key Program [81330029]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81271359, 81372575]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant NS087296, National Heart, Lung, and Blood Institute grant HL71895, and a bridge fund from American Society of Hematology (J.-f.D.); National Natural Science Foundation of China State Key Program grant 81330029, and National Natural Science Foundation of China research grants 81271361, 81271359 (J.Z.), and 81372575 (M.L.).	Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ALBERTS B., 1994, MOL BIOL CELL, P551; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Boilard E, 2015, CURR OPIN HEMATOL, V22, P437, DOI 10.1097/MOH.0000000000000166; Bornstein NM, 2001, NEUROLOGY, V56, P529, DOI 10.1212/WNL.56.4.529; Boudreau LH, 2014, BLOOD, V124, P2173, DOI 10.1182/blood-2014-05-573543; Cairns CB, 1997, J TRAUMA, V42, P532, DOI 10.1097/00005373-199703000-00023; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Dasgupta SK, 2009, BLOOD, V113, P1332, DOI 10.1182/blood-2008-07-167148; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Exner T, 2003, BLOOD COAGUL FIBRIN, V14, P773, DOI 10.1097/00001721-200312000-00015; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; HOSTETLER KY, 1979, J LIPID RES, V20, P607; HOSTETLER KY, 1979, CANCER RES, V39, P2978; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Itagaki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120549; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; JUNKER M, 1994, BIOCHEMISTRY-US, V33, P8930, DOI 10.1021/bi00196a010; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; LECOCQ J, 1964, BIOCHEMISTRY-US, V3, P976, DOI 10.1021/bi00895a023; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; London F, 1996, BIOCHEMISTRY-US, V35, P16886, DOI 10.1021/bi960712v; Lopez-Escribano H, 2002, ARTHRITIS RHEUM, V46, P3290, DOI 10.1002/art.10684; MEERS P, 1993, BIOCHEMISTRY-US, V32, P11711, DOI 10.1021/bi00094a030; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; ROSSEN RD, 1994, CIRC RES, V75, P546, DOI 10.1161/01.RES.75.3.546; Salehpour F, 2011, J CRIT CARE, V26, P352, DOI 10.1016/j.jcrc.2010.12.005; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Simmons JD, 2013, ANN SURG, V258, P591, DOI 10.1097/SLA.0b013e3182a4ea46; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Sun YR, 2011, BRIT J NEUROSURG, V25, P363, DOI 10.3109/02688697.2011.552650; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tchaikovski SN, 2007, J THROMB HAEMOST, V5, P2079, DOI 10.1111/j.1538-7836.2007.02719.x; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Vance JE, 2013, BBA-MOL CELL BIOL L, V1831, P543, DOI 10.1016/j.bbalip.2012.08.016; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	47	46	49	4	15	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	JUN 2	2016	127	22					2763	2772		10.1182/blood-2015-12688838			10	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	DP2QS	WOS:000378335400018	27002118				2022-02-06	
J	Xu, K; Di Luca, DG; Orru, M; Xu, Y; Chen, JF; Schwarzschild, MA				Xu, K.; Di Luca, D. G.; Orru, M.; Xu, Y.; Chen, J. -F.; Schwarzschild, M. A.			NEUROPROTECTION BY CAFFEINE IN THE MPTP MODEL OF PARKINSON'S DISEASE AND ITS DEPENDENCE ON ADENOSINE A(2A) RECEPTORS	NEUROSCIENCE			English	Article						adenosine A(2A) receptors; MPTP; caffeine; neuroprotection; parkinson's disease	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ANIMAL-MODELS; RISK; RAT; INACTIVATION; TOXICITY; A(1); ANTAGONISTS; DOPAMINE	Considerable epidemiological and laboratory data have suggested that caffeine, a nonselective adenosine receptor antagonist, may protect against the underlying neurodegeneration of parkinson's disease (PD). Although both caffeine and more specific antagonists of the A(2A) subtype of adenosine receptor (A(2A)R) have been found to confer protection in animal models of PD, the dependence of caffeine's neuroprotective effects on the A(2A)R is not known. To definitively determine its A(2A)R dependence, the effect of caffeine on 1-methyl-4-phenyl-1,2,3,6 tetra-hydropyridine (MPTP) neurotoxicity was compared in wild-type (WT) and A(2A)R gene global knockout (A(2A) KO) mice, as well as in central nervous system (CNS) cell type-specific (conditional) A(2A)R knockout (cKO) mice that lack the receptor either in postnatal forebrain neurons or in astrocytes. In WT and in heterozygous A(2A)R KO mice caffeine pretreatment (25 mg/kg ip) significantly attenuated MPTP-induced depletion of striatal dopamine. By contrast in homozygous A(2A)R global KO mice caffeine had no effect on MPTP toxicity. In forebrain neuron A(2A)R cKO mice, caffeine lost its locomotor stimulant effect, whereas its neuroprotective effect was mostly preserved. In astrocytic A(2A)R cKO mice, both caffeine's locomotor stimulant and protective properties were undiminished. Taken together, these results indicate that neuroprotection by caffeine in the MPTP model of PD relies on the A(2A)R, although the specific cellular localization of these receptors remains to be determined. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Xu, K.; Di Luca, D. G.; Orru, M.; Xu, Y.; Schwarzschild, M. A.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Mol Neurobiol Lab, Charlestown, MA 02129 USA; [Xu, K.; Di Luca, D. G.; Orru, M.; Xu, Y.; Schwarzschild, M. A.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Chen, J. -F.] Boston Univ, Sch Med, Dept Neurol, 715 Albany St,C314, Boston, MA 02118 USA		Schwarzschild, MA (corresponding author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Mol Neurobiol Lab, Charlestown, MA 02129 USA.; Schwarzschild, MA (corresponding author), Harvard Univ, Sch Med, Charlestown, MA 02129 USA.	kuixu@hotmail.com; dilucadaniel@gmail.com; orrumarco@gmail.com; xuy@helix.mgh.harvard.edu; chenjf@bu.edu; michaels@helix.mgh.harvard.edu	Orro, Marco/ABE-4316-2021; Di Luca, Daniel Garbin/T-6211-2018	Di Luca, Daniel Garbin/0000-0002-1356-4919	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01ES010804, 5K24NS60991]; DOD grant [W81XWH-11-1-0150]; parkinson's disease Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES010804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24NS060991] Funding Source: NIH RePORTER	Source of support: This work is supported by NIH grants 5R01ES010804 and 5K24NS60991 and DOD grant W81XWH-11-1-0150. The parkinson's disease Foundation has provided funding supporting to Daniel Garbin Di Luca as a summer research fellow.	Antoniou K, 2005, PSYCHOPHARMACOLOGY, V183, P154, DOI 10.1007/s00213-005-0173-6; Ascherio A, 2004, AM J EPIDEMIOL, V160, P977, DOI 10.1093/aje/kwh312; Ascherio A, 2003, NEUROLOGY, V60, P790, DOI 10.1212/01.WNL.0000046523.05125.87; Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bastia E, 2005, NEUROPSYCHOPHARMACOL, V30, P891, DOI 10.1038/sj.npp.1300630; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Bockamp E, 2002, PHYSIOL GENOMICS, V11, P115, DOI 10.1152/physiolgenomics.00067.2002; Brambilla R, 2003, GLIA, V43, P190, DOI 10.1002/glia.10243; Brothers HM, 2010, NEUROSCI LETT, V480, P97, DOI 10.1016/j.neulet.2010.06.013; Carta AR, 2009, J NEUROCHEM, V111, P1478, DOI 10.1111/j.1471-4159.2009.06425.x; Chen JF, 2002, J BIOL CHEM, V277, P36040, DOI 10.1074/jbc.M206830200; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, P NATL ACAD SCI USA, V98, P1970, DOI 10.1073/pnas.98.4.1970; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Cunha RA, 2001, NEUROCHEM INT, V38, P107, DOI 10.1016/S0197-0186(00)00034-6; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Fernandez-Duenas V, 2014, ACS CHEM BIOL, V9, P2496, DOI 10.1021/cb5005383; Ferre S, 2008, J NEUROCHEM, V105, P1067, DOI 10.1111/j.1471-4159.2007.05196.x; Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2; Fisone G, 2004, CELL MOL LIFE SCI, V61, P857, DOI 10.1007/s00018-003-3269-3; FREDHOLM BB, 1982, EUR J PHARMACOL, V81, P673, DOI 10.1016/0014-2999(82)90359-4; Fredholm BB, 1996, ADV NEUROL, V71, P469; Fredholm BB, 1999, EUR J PHARMACOL, V380, P197, DOI 10.1016/S0014-2999(99)00533-6; Hasko G, 2005, TRENDS PHARMACOL SCI, V26, P511, DOI 10.1016/j.tips.2005.08.004; Hirsch E C, 1999, Adv Neurol, V80, P9; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Jackson-Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342; Joghataie MT, 2004, PARKINSONISM RELAT D, V10, P465, DOI 10.1016/j.parkreldis.2004.06.004; Kachroo A, 2007, SOC NEUR ANN M SAN D; Karcz-Kubicha M, 2003, EUR J NEUROSCI, V18, P296, DOI 10.1046/j.1460-9568.2003.02747.x; Kelsey JE, 2009, PSYCHOPHARMACOLOGY, V201, P529, DOI 10.1007/s00213-008-1319-0; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.ne.11.030188.000501; LANGSTON JW, 1984, BRAIN RES, V292, P390; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Liu R, 2012, AM J EPIDEMIOL, V175, P1200, DOI 10.1093/aje/kwr451; Lopes LV, 2004, BRIT J PHARMACOL, V141, P1006, DOI 10.1038/sj.bjp.0705692; Matos M, 2015, BIOL PSYCHIAT, V78, P763, DOI 10.1016/j.biopsych.2015.02.026; Matos M, 2012, GLIA, V60, P702, DOI 10.1002/glia.22290; Meredith GE, 2011, J PARKINSON DIS, V1, P19, DOI 10.3233/JPD-2011-11023; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; Nishizaki T, 2004, J PHARMACOL SCI, V94, P100, DOI 10.1254/jphs.94.100; Okusa MD, 1999, AM J PHYSIOL-RENAL, V277, pF404, DOI 10.1152/ajprenal.1999.277.3.F404; Orru M, 2013, NEUROPHARMACOLOGY, V67, P476, DOI 10.1016/j.neuropharm.2012.11.029; Palacios N, 2012, MOVEMENT DISORD, V27, P1276, DOI 10.1002/mds.25076; Pierri M, 2005, NEUROPHARMACOLOGY, V48, P517, DOI 10.1016/j.neuropharm.2004.11.009; Popoli P, 1995, EUR J PHARMACOL, V287, P215, DOI 10.1016/0014-2999(95)00679-6; Ran H, 2015, J NEUROPATH EXP NEUR, V74, P305, DOI 10.1097/NEN.0000000000000174; Rebola N, 2005, NEUROSCIENCE, V132, P893, DOI 10.1016/j.neuroscience.2005.01.014; Rebola N, 2011, J NEUROCHEM, V117, P100, DOI 10.1111/j.1471-4159.2011.07178.x; RICAURTE GA, 1987, BRAIN RES, V403, P43, DOI 10.1016/0006-8993(87)90120-X; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Saura J, 2005, J NEUROCHEM, V95, P919, DOI 10.1111/j.1471-4159.2005.03395.x; Schwarzschild MA, 2006, TRENDS NEUROSCI, V29, P647, DOI 10.1016/j.tins.2006.09.004; Shen HY, 2008, J NEUROSCI, V28, P2970, DOI 10.1523/JNEUROSCI.5255-07.2008; Sonsalla PK, 2012, EXP NEUROL, V234, P482, DOI 10.1016/j.expneurol.2012.01.022; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Sullivan GW, 1998, DRUG DEVELOP RES, V45, P103, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<103::AID-DDR4>3.0.CO;2-W; Aguiar LMV, 2006, PHARMACOL BIOCHEM BE, V84, P415, DOI 10.1016/j.pbb.2006.05.027; Xu K, 2006, J NEUROSCI, V26, P535, DOI 10.1523/JNEUROSCI.3008-05.2006; Xu K, 2002, NEUROSCI LETT, V322, P13, DOI 10.1016/S0304-3940(02)00069-1; Xu K, 2010, NEUROSCIENCE, V167, P475, DOI 10.1016/j.neuroscience.2010.02.020; Yu LQ, 2008, ANN NEUROL, V63, P338, DOI 10.1002/ana.21313; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	65	46	47	1	44	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 13	2016	322						129	137		10.1016/j.neuroscience.2016.02.035			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG8QX	WOS:000372349800012	26905951	Green Accepted, Bronze			2022-02-06	
J	Huber, BR; Meabon, JS; Hoffer, ZS; Zhang, J; Hoekstra, JG; Pagulayan, KF; McMillan, PJ; Mayer, CL; Banks, WA; Kraemer, BC; Raskind, MA; McGavern, DB; Peskind, ER; Cook, DG				Huber, B. R.; Meabon, J. S.; Hoffer, Z. S.; Zhang, J.; Hoekstra, J. G.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Banks, W. A.; Kraemer, B. C.; Raskind, M. A.; McGavern, D. B.; Peskind, E. R.; Cook, D. G.			BLAST EXPOSURE CAUSES DYNAMIC MICROGLIAL/MACROPHAGE RESPONSES AND MICRODOMAINS OF BRAIN MICROVESSEL DYSFUNCTION	NEUROSCIENCE			English	Article						blood-brain barrier; two-photon microscopy; neuropathology; microglia; macrophages	CHRONIC TRAUMATIC ENCEPHALOPATHY; IN-VIVO; MICROGLIAL ACTIVATION; WHITE-MATTER; MOUSE MODEL; INJURY; BLOOD; BARRIER; CORTEX; IMPACT	Exposure to blast overpressure (BOP) is associated with behavioral, cognitive, and neuroimaging abnormalities. We investigated the dynamic responses of cortical vasculature and its relation to microglia/macrophage activation in mice using intravital two-photon microscopy following mild blast exposure. We found that blast caused vascular dysfunction evidenced by microdomains of aberrant vascular permeability. Microglial/macrophage activation was specifically associated with these restricted microdomains, as evidenced by rapid microglial process retraction, increased ameboid morphology, and escape of blood-borne Q-dot tracers that were internalized in microglial/macrophage cell bodies and phagosome-like compartments. Microdomains of cortical vascular disruption and microglial/macrophage activation were also associated with aberrant tight junction morphology that was more prominent after repetitive (3 x) blast exposure. Repetitive, but not single, BOPs also caused TNF alpha elevation two weeks post-blast. In addition, following a single BOP we found that aberrantly phosphorylated tau rapidly accumulated in perivascular domains, but cleared within four hours, suggesting it was removed from the perivascular area, degraded, and/or dephosphorylated. Taken together these findings argue that mild blast exposure causes an evolving CNS insult that is initiated by discrete disturbances of vascular function, thereby setting the stage for more protracted and more widespread neuro-inflammatory responses. Published by Elsevier Ltd. on behalf of IBRO.	[Huber, B. R.] Boston Univ, VA Jamaica Plain, Dept Neurol, Sch Med, Jamaica Plain, MA USA; [Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] VA Puget Sound Healthcare Syst, Northwest Network Mental Illness Res Educ & Clin, Seattle, WA USA; [Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA; [Hoffer, Z. S.] US Army, Madigan Army Med Ctr, Joint Base Lewis Mcchord, WA USA; [Zhang, J.; Hoekstra, J. G.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98108 USA; [Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA; [Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA; [McGavern, D. B.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Cook, D. G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98108 USA		Cook, DG (corresponding author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, 1660 South Columbian Way, Seattle, WA 98108 USA.	dgcook@u.washington.edu	Pagulayan, Kati/AAR-9225-2020; Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619; Hoekstra, Jake/0000-0001-6597-5878	Department of Veterans Affairs Office of Research and Development Medical Research ServiceUS Department of Veterans Affairs; VA Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; University of Washington Royalty Research FundUniversity of Washington [R01AG046619]; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 AG000258]; VA CSR&D Career Development Award [IK2 CX00516]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG046619, P50AG005136, T32AG000258] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002311, IK2CX000516, I01RX001612, I01RX000521, I01BX002619] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (D.G.C., B.C.K.), VA Rehabilitation Research and Development Service (E.R.P.), University of Washington Royalty Research Fund (D.G.C.); R01AG046619 (W.A.B.); Northwest Network Mental Illness Research, Education and Clinical Center (E.R.P., B.R.H., J.S.M., K.F.P., P.J.M., C.L.M.), Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (B.R.H.); NIH T32 AG000258 (J.S.M.), VA CSR&D Career Development Award Program #IK2 CX00516 (K.F.P.). We thank Dr. Gerard Schellenberg (Univ. Pennsylvania) for providing Tau knock-out samples.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jiao Y, 1999, J NEUROSCI METH, V93, P149, DOI 10.1016/S0165-0270(99)00142-9; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kim HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088924; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McPherson CA, 2014, NEUROTOX RES, V25, P45, DOI 10.1007/s12640-013-9422-3; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Morrison HW, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-4; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xu HT, 2007, NAT NEUROSCI, V10, P549, DOI 10.1038/nn1883; Yang G, 2010, NAT PROTOC, V5, P201, DOI 10.1038/nprot.2009.222; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.3.CO;2-M	41	46	47	1	23	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 5	2016	319						206	220		10.1016/j.neuroscience.2016.01.022			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DD9RD	WOS:000370262400019	26777891	Green Accepted			2022-02-06	
J	Browning, M; Shear, DA; Bramlett, HM; Dixon, CE; Mondello, S; Schmid, KE; Poloyac, SM; Dietrich, WD; Hayes, RL; Wang, KKW; Povlishock, JT; Tortella, FC; Kochanek, PM				Browning, Megan; Shear, Deborah A.; Bramlett, Helen M.; Dixon, C. Edward; Mondello, Stefania; Schmid, Kara E.; Poloyac, Samuel M.; Dietrich, W. Dalton; Hayes, Ronald L.; Wang, Kevin K. W.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						rat; post-traumatic seizures; penetrating ballistic-like brain injury; fluid percussion; excitotoxicity; controlled cortical impact; biomarker; Keppra; neuroprotection; therapy	CONTROLLED CORTICAL IMPACT; SEIZURE PROPHYLAXIS; INTRAVENOUS LEVETIRACETAM; POSTTRAUMATIC EPILEPSY; STATUS EPILEPTICUS; MODEL; RAT; HYPOTHERMIA; DEFICITS; PROTEIN	Levetiracetam (LEV) is an antiepileptic agent targeting novel pathways. Coupled with a favorable safety profile and increasing empirical clinical use, it was the fifth drug tested by Operation Brain Trauma Therapy (OBTT). We assessed the efficacy of a single 15 min post-injury intravenous (IV) dose (54 or 170 mg/kg) on behavioral, histopathological, and biomarker outcomes after parasagittal fluid percussion brain injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI) in rats. In FPI, there was no benefit on motor function, but on Morris water maze (MWM), both doses improved latencies and path lengths versus vehicle (p < 0.05). On probe trial, the vehicle group was impaired versus sham, but both LEV treated groups did not differ versus sham, and the 54 mg/kg group was improved versus vehicle (p < 0.05). No histological benefit was seen. In CCI, there was a benefit on beam balance at 170 mg/kg (p < 0.05 vs. vehicle). On MWM, the 54 mg/kg dose was improved and not different from sham. Probe trial did not differ between groups for either dose. There was a reduction in hemispheric tissue loss (p < 0.05 vs. vehicle) with 170 mg/kg. In PBBI, there was no motor, cognitive, or histological benefit from either dose. Regarding biomarkers, in CCI, 24 h glial fibrillary acidic protein (GFAP) blood levels were lower in the 170 mg/kg group versus vehicle (p < 0.05). In PBBI, GFAP blood levels were increased in vehicle and 170 mg/kg groups versus sham (p < 0.05) but not in the 54 mg/kg group. No treatment effects were seen for ubiquitin C-terminal hydrolase-L1 across models. Early single IV LEV produced multiple benefits in CCI and FPI and reduced GFAP levels in PBBI. LEV achieved 10 points at each dose, is the most promising drug tested thus far by OBTT, and the only drug to improve cognitive outcome in any model. LEV has been advanced to testing in the micropig model in OBTT.	[Browning, Megan; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA; [Shear, Deborah A.; Schmid, Kara E.; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Ctr Pharmaceut Sci, Pittsburgh, PA 15260 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Caudle KL, 2014, J NEUROTRAUM, V31, pA80; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; Cuomo O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080852; Darrah SH, 2011, J NEUROTRAUM, V28, P43, DOI 10.1089/neu.2010.1521; Deshpande LS, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00011; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Mendoza-Torreblanca JG, 2013, EUR J NEUROSCI, V38, P3529, DOI 10.1111/ejn.12360; Halma E, 2014, SEIZURE-EUR J EPILEP, V23, P685, DOI 10.1016/j.seizure.2014.06.004; Kirmani BF, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00170; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Komur M, 2014, CHILD NERV SYST, V30, P1001, DOI 10.1007/s00381-014-2375-x; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; Lu XCM, 2011, J NEUROTRAUM, V28, P71, DOI 10.1089/neu.2010.1471; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Rowe AS, 2014, PHARMACOTHERAPY, V34, P396, DOI 10.1002/phar.1374; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Shetty AK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00172; Stienen MN, 2011, BRIT J PHARMACOL, V162, P491, DOI 10.1111/j.1476-5381.2010.01038.x; Szaflarski JP, 2014, NEUROPSYCH DIS TREAT, V10, P1469, DOI 10.2147/NDT.S50421; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Tomic MA, 2013, J PAIN, V14, P1371, DOI 10.1016/j.jpain.2013.06.003; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vogl C, 2012, MOL PHARMACOL, V82, P199, DOI 10.1124/mol.111.076687; Vossel KA, 2013, JAMA NEUROL, V70, P1158, DOI 10.1001/jamaneurol.2013.136; Wakita M, 2014, J PHARMACOL EXP THER, V348, P246, DOI 10.1124/jpet.113.208751; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wright C, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00192; Zou HC, 2015, BRAIN INJURY, V29, P78, DOI 10.3109/02699052.2014.955528; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	40	46	46	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					581	594		10.1089/neu.2015.4131			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800007	26671550				2022-02-06	
J	Andrews, AM; Lutton, EM; Merkel, SF; Razmpour, R; Ramirez, SH				Andrews, Allison M.; Lutton, Evan M.; Merkel, Steven F.; Razmpour, Roshanak; Ramirez, Servio H.			Mechanical Injury Induces Brain Endothelial-Derived Microvesicle Release: Implications for Cerebral Vascular Injury during Traumatic Brain Injury	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blood-brain barrier (BBB); traumatic brain injury; mechanical strain; extracellular microvesicles; tight junction proteins; neuroinflammation	IN-VITRO; BARRIER DISRUPTION; MICROPARTICLE FORMATION; ACTIN CYTOSKELETON; CELLS; MODEL; ACTIVATION; STRETCH; DYSFUNCTION; BIOGENESIS	It is well established that the endothelium responds to mechanical forces induced by changes in shear stress and strain. However, our understanding of vascular remodeling following traumatic brain injury (TBI) remains incomplete. Recently published studies have revealed that lung and umbilical endothelial cells produce extracellular microvesicles (eMVs), such as microparticles, in response to changes in mechanical forces (blood flow and mechanical injury). Yet, to date, no studies have shown whether brain endothelial cells produce eMVs following TBI. The brain endothelium is highly specialized and forms the blood -brain barrier (BBB), which regulates diffusion and transport of solutes into the brain. This specialization is largely due to the presence of tight junction proteins (TJPs) between neighboring endothelial cells. Following TBI, a breakdown in tight junction complexes at the BBB leads to increased permeability, which greatly contributes to the secondary phase of injury. We have therefore tested the hypothesis that brain endothelium responds to mechanical injury, by producing eMVs that contain brain endothelial proteins, specifically TJPs. In our study, primary human adult brain microvascular endothelial cells (BMVFC) were subjected to rapid mechanical injury to simulate the abrupt endothelial disruption that can occur in the primary injury phase of TBI. eMVs were isolated from the media following injury at 2, 6, 24, and 48h. Western blot analysis of eMVs demonstrated a time -dependent increase in TJP occludin, PFCAM-1 and ICAM-1 following mechanical injury. In addition, activation of ARF6, a small GTPase linked to extracellular vesicle production, was increased after injury. To confirm these results in vivo, mice were subjected to sham surgery or TBI and blood plasma was collected 24 h post -injury. Isolation and analysis of eMVs from blood plasma using cryo-FM and flow cytometry revealed elevated levels of vesicles containing occludin following brain trauma. These results indicate that following TBI, the cerebral endothelium undergoes vascular remodeling through shedding of eMVs containing TJPs and endothelial markers. The detection of this shedding potentially allows for a novel methodology for real-time monitoring of cerebral vascular health (remodeling), BBB status and neuroinflammation following a TBI event.	[Andrews, Allison M.; Lutton, Evan M.; Merkel, Steven F.; Razmpour, Roshanak; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA; [Andrews, Allison M.; Merkel, Steven F.; Ramirez, Servio H.] Shriners Hosp Crippled Children, Pediat Res Ctr, Philadelphia, PA USA; [Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19122 USA		Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA.; Ramirez, SH (corresponding author), Shriners Hosp Crippled Children, Pediat Res Ctr, Philadelphia, PA USA.; Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19122 USA.	servio.ramirez@temple.edu		ramirez, servio/0000-0002-4609-5653	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS086570]; Shriners Hospitals for Children [85110-PHI-14]; NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32 DA007237, P30-DA13429]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007237, P30DA013429] Funding Source: NIH RePORTER	We would like to thank the Penn Core Facility (particularly Ray Meade and Dr. Dewight Williams) for their help with cryo-EM. This study was supported (in part) by research funding from the NIH: 1R01NS086570 (to SHR) and the Shriners Hospitals for Children: 85110-PHI-14 (to SHR), NIH-NIDA T32 DA007237 (AA), and P30-DA13429 (SHR).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Aghajanian A, 2008, J THROMB HAEMOST, V6, P1453, DOI 10.1111/j.1538-7836.2008.03087.x; Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Bernas MJ, 2010, NAT PROTOC, V5, P1265, DOI 10.1038/nprot.2010.76; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Boulanger CM, 2006, HYPERTENSION, V48, P180, DOI 10.1161/01.HYP.0000231507.00962.b5; Brown TD, 2000, J BIOMECH, V33, P3, DOI 10.1016/S0021-9290(99)00177-3; Burger D, 2011, ARTERIOSCL THROM VAS, V31, P1898, DOI 10.1161/ATVBAHA.110.222703; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chironi GN, 2009, CELL TISSUE RES, V335, P143, DOI 10.1007/s00441-008-0710-9; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; Dignat-George F, 2011, ARTERIOSCL THROM VAS, V31, P27, DOI 10.1161/ATVBAHA.110.218123; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Figueroa DS, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4028037; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Friand V, 2015, BIOL CELL, V107, P331, DOI 10.1111/boc.201500010; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Ghossoub R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4477; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Issman L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083680; Jenkins NT, 2013, HYPERTENSION, V61, P615, DOI 10.1161/HYPERTENSIONAHA.111.00561; Jimenez JJ, 2003, THROMB RES, V109, P175, DOI 10.1016/S0049-3848(03)00064-1; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Lai CH, 2005, BRAIN RES REV, V50, P7, DOI 10.1016/j.brainresrev.2005.03.007; Latham SL, 2013, FASEB J, V27, P672, DOI 10.1096/fj.12-216531; Letsiou E, 2015, AM J RESP CELL MOL, V52, P193, DOI 10.1165/rcmb.2013-0347OC; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Muralidharan-Chari V, 2009, CURR BIOL, V19, P1875, DOI 10.1016/j.cub.2009.09.059; Pasquier J, 2014, CANCER MICROENVIRON, V7, P41, DOI 10.1007/s12307-013-0142-2; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rom S, 2015, J CEREBR BLOOD F MET, V35, P28, DOI 10.1038/jcbfm.2014.167; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Salvador E, 2013, JOVE-J VIS EXP, DOI 10.3791/50928; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; Shan RZ, 2016, J NEUROTRAUM, V33, P49, DOI 10.1089/neu.2014.3811; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Tan KT, 2005, ANN MED, V37, P61, DOI 10.1080/07853890410018943; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vion AC, 2013, PULM CIRC, V3, P95, DOI 10.4103/2045-8932.109921; Vion AC, 2013, CIRC RES, V112, P1323, DOI 10.1161/CIRCRESAHA.112.300818; Wang BW, 2003, CARDIOVASC RES, V59, P460, DOI 10.1016/S0008-6363(03)00428-0; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397, DOI 10.1152/jappl.1989.67.1.397	52	46	46	0	15	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	FEB 29	2016	10								43	10.3389/fncel.2016.00043			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE8WW	WOS:000370918400001	26973460	gold, Green Published			2022-02-06	
J	Figueiro, MG; Hunter, CM; Higgins, PA; Hornick, TR; Jones, GE; Plitnick, B; Brons, J; Rea, MS				Figueiro, Mariana G.; Hunter, Claudia M.; Higgins, Patricia A.; Hornick, Thomas R.; Jones, Geoffrey E.; Plitnick, Barbara; Brons, Jennifer; Rea, Mark S.			Tailored lighting intervention for persons with dementia and caregivers living at home	SLEEP HEALTH			English	Article						Alzheimer's disease; ADRD; dementia; Sleep; Light therapy; Short-wavelength light; Circadian rhythms; Depression	ALZHEIMERS-DISEASE; BRIGHT LIGHT; REST-ACTIVITY; SLEEP QUALITY; RHYTHM DISTURBANCES; ACTION SPECTRUM; THERAPY; EXPOSURES; PATTERNS	Objectives: Light therapy has shown promise as a nonpharmacological treatment to help regulate abnormal sleep-wake patterns and associated behavioral issues prevalent among individuals diagnosed with Alzheimer disease and related dementia (ADRD). The present study investigated the effectiveness of a lighting intervention designed to increase circadian stimulation during the day using light sources that have high short-wavelength content and high light output. Methods: Thirty-five persons with ADRD and 34 caregivers completed the 11-week study. During week 1, subjective questionnaires were administered to the study participants. During week 2, baseline data were collected using Daysimeters and actigraphs. Researchers installed the lighting during week 3, followed by 4 weeks of the tailored lighting intervention. During the last week of the lighting intervention, Daysimeter, actigraph, and questionnaire data were again collected. Three weeks after the lighting intervention was removed, a third data collection (post-intervention assessment) was performed. Results: The lighting intervention significantly increased circadian entrainment, as measured by phasor magnitude, and sleep efficiency, as measured by actigraphy data, and significantly reduced symptoms of depression in the participants with ADRD. The caregivers also exhibited an increase in circadian entrainment during the lighting intervention; a seasonal effect of greater sleep efficiency and longer sleep duration was also found for caregivers. Conclusions: Ambient lighting interventions designed to increase daytime circadian stimulation can be used to increase sleep efficiency in persons with ADRD and their caregivers and may also be effective for other populations such as healthy older adults with sleep problems, adolescents, and veterans with traumatic brain injury. (C) 2015 National Sleep Foundation. Published by Elsevier Inc. All rights reserved.	[Figueiro, Mariana G.; Hunter, Claudia M.; Jones, Geoffrey E.; Plitnick, Barbara; Brons, Jennifer; Rea, Mark S.] Rensselaer Polytech Inst, Lighting Res Ctr, 21 Union St, Troy, NY 12180 USA; [Higgins, Patricia A.] Case Western Reserve Univ, Sch Nursing, Cleveland, OH 44106 USA; [Higgins, Patricia A.; Hornick, Thomas R.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Hornick, Thomas R.] Louis Stokes Cleveland Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Cleveland, OH USA		Figueiro, MG (corresponding author), Rensselaer Polytech Inst, Lighting Res Ctr, 21 Union St, Troy, NY 12180 USA.	figuem@rpi.edu		Rea, Mark/0000-0001-8458-9876; Jones, Geoffrey/0000-0003-2453-4376	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034157]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034157] Funding Source: NIH RePORTER	The study was funded by the National Institute on Aging (grant no. R01AG034157). GE Lighting donated the lamps and ballasts used in the study. The authors would like to acknowledge Ashritha Epur of Case Western Reserve University and the Louis Stokes Cleveland Veterans Affairs Medical Center. Sharon Lesage, Erin Ryan, Brittany Wood, Rebekah Mullaney, and Dennis Guyon of the Lighting Research Center are also acknowledged for their technical and editorial assistance.	Alzheimer's Association, 2015, ESS DIAGN WORK; Ancoli-Israel S., 1989, B CLIN NEUROSCIENCES, V54, P127; Ancoli-Israel Sonia, 2003, Behav Sleep Med, V1, P22, DOI 10.1207/S15402010BSM0101_4; Benedict C, 2015, ALZHEIMERS DEMENT, V11, P1090, DOI 10.1016/j.jalz.2014.08.104; BLIWISE DL, 1993, SLEEP, V16, P40, DOI 10.1093/sleep/16.1.40; BLIWISE DL, 1995, J GERONTOL A-BIOL, V50, pM303, DOI 10.1093/gerona/50A.6.M303; Brainard GC, 2001, J NEUROSCI, V21, P6405; Buchanan DT, 2014, J CLIN SLEEP MED, V10, P1003, DOI 10.5664/jcsm.4038; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Colenda CC, 1997, ALZ DIS ASSOC DIS, V11, P175, DOI 10.1097/00002093-199709000-00011; Figueiro MG, 2013, LIGHTING RES TECHNOL, V45, P421, DOI 10.1177/1477153512450453; Figueiro MG, 2014, CLIN INTERV AGING, V9, P1527, DOI 10.2147/CIA.S68557; Figueiro MG, 2012, J ALZHEIMERS DIS, V31, P711, DOI 10.3233/JAD-2012-120484; Forbes D, 2014, COCHRANE DB SYST REV, V2; Gasio PF, 2003, EXP GERONTOL, V38, P207, DOI 10.1016/S0531-5565(02)00164-X; Hanford N, 2013, J ALZHEIMERS DIS, V33, P913, DOI 10.3233/JAD-2012-121645; Higgins PA, 2010, AM J ALZHEIMERS DIS, V25, P353, DOI 10.1177/1533317510363467; HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804; Ju YES, 2013, JAMA NEUROL, V70, P587, DOI 10.1001/jamaneurol.2013.2334; KATZ B, 1989, ANN NEUROL, V26, P221, DOI 10.1002/ana.410260207; Kouros CD, 2015, J SLEEP RES, V24, P24, DOI 10.1111/jsr.12226; Koyama E, 1999, PSYCHIAT CLIN NEUROS, V53, P227, DOI 10.1046/j.1440-1819.1999.00483.x; Lucey BP, 2014, NEUROBIOL AGING, V35, pS29, DOI 10.1016/j.neurobiolaging.2014.03.035; Lyketsos CG, 1999, INT J GERIATR PSYCH, V14, P520, DOI 10.1002/(SICI)1099-1166(199907)14:7<520::AID-GPS983>3.0.CO;2-M; Mishima K, 1998, CHRONOBIOL INT, V15, P647, DOI 10.3109/07420529808993200; MOORE RY, 1992, PROG BRAIN RES, V93, P101; Neumann PJ, 2000, J AM GERIATR SOC, V48, P1646, DOI 10.1111/j.1532-5415.2000.tb03877.x; Ownby RL, 2001, AM J GERIAT PSYCHIAT, V9, P217, DOI 10.1176/appi.ajgp.9.3.217; PRINZ PN, 1982, J AM GERIATR SOC, V30, P86, DOI 10.1111/j.1532-5415.1982.tb01279.x; Rea Mark S, 2010, J Circadian Rhythms, V8, P2, DOI 10.1186/1740-3391-8-2; Rea Mark S, 2008, J Circadian Rhythms, V6, P7, DOI 10.1186/1740-3391-6-7; Riemersma-van Der Lek RF, 2008, JAMA-J AM MED ASSOC, V299, P2642, DOI 10.1001/jama.299.22.2642; SATLIN A, 1991, NEUROPSYCHOPHARMACOL, V5, P115; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Sloane PD, 2015, LIGHTING RES TECHNOL, V47, P161, DOI 10.1177/1477153513517255; Sloane PD, 2007, J AM GERIATR SOC, V55, P1524, DOI 10.1111/j.1532-5415.2007.01358.x; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; Thapan K, 2001, J PHYSIOL-LONDON, V535, P261, DOI 10.1111/j.1469-7793.2001.t01-1-00261.x; Tonetti L, 2015, SLEEP MED, V16, P936, DOI 10.1016/j.sleep.2015.03.026; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; Wirth MD, 2015, ANN EPIDEMIOL, V25, P773, DOI 10.1016/j.annepidem.2015.05.001; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yamadera H, 2000, PSYCHIAT CLIN NEUROS, V54, P352, DOI 10.1046/j.1440-1819.2000.00711.x	43	46	47	6	18	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	2352-7218	2352-7226		SLEEP HEALTH	Sleep Health	DEC	2015	1	4					322	330		10.1016/j.sleh.2015.09.003			9	Clinical Neurology	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	VD5ZF	WOS:000437200600017	27066526	Green Accepted			2022-02-06	
J	Pietrosimone, B; Golightly, YM; Mihalik, JP; Guskiewicz, KM				Pietrosimone, Brian; Golightly, Yvonne M.; Mihalik, Jason P.; Guskiewicz, Kevin M.			Concussion Frequency Associates with Musculoskeletal Injury in Retired NFL Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						BRAIN; ANTERIOR CRUCIATE LIGAMENT; KNEE INJURY; ANKLE INJURY	LOWER-EXTREMITY INJURY; GAIT STABILITY; HIGH-SCHOOL; FOOTBALL; ADOLESCENTS; DEFICITS; PHASE; RISK; TIME	Objective Concussion is commonly associated with immediate and persistent alterations in motor function affecting postural control and gait. Patients with lower extremity joint injury have demonstrated functional alterations in the cerebral cortex, suggesting that musculoskeletal injury may be linked to alterations in brain function. Therefore, we examined the associations between concussion frequency and lower extremity musculoskeletal injury sustained during professional careers of National Football League (NFL) players in a cross-sectional study. Methods An inclusive health history survey was mailed to 3647 NFL players who retired during 1930-2001. Respondents reported total concussion frequency (zero, one, two, or three or more) and presence (yes/no) of specific knee and ankle musculoskeletal injury during their NFL career. Separate logistic regression models were used to estimate associations between concussion frequency and each musculoskeletal injury type, adjusting for number of years played in the NFL, body mass index while playing in the NFL, and playing position. Results Data from 2429 players (66.6% response rate) were available for analysis. Nearly 61% reported experiencing a concussion while competing in the NFL. Meniscal tear was the most commonly reported musculoskeletal injury (32%). Compared with NFL players who did not sustain a concussion, retired NFL players with one, two, or three or more concussions had between 18% and 63%, 15% and 126%, and 73% and 165% higher odds of reporting various musculoskeletal injuries, respectively. Conclusions A history of concussions was associated with a history of musculoskeletal injuries during NFL careers. These data suggest that a higher number of concussions is linked with higher odds of reporting a musculoskeletal injury.	[Pietrosimone, Brian; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Pietrosimone, Brian] Univ N Carolina, Neuromuscular Res Lab, Chapel Hill, NC 27599 USA; [Pietrosimone, Brian] Univ N Carolina, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Golightly, Yvonne M.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Golightly, Yvonne M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA; [Golightly, Yvonne M.; Mihalik, Jason P.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC 27599 USA		Pietrosimone, B (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab RM 032,210 South Rd Fetzer Hal, Chapel Hill, NC 27599 USA.	brian@unc.edu	Meijer, Anna/K-5118-2016	Golightly, Yvonne/0000-0003-1205-2759			Brophy RH, 2007, MED SCI SPORT EXER, V39, P22, DOI 10.1249/01.mss.0000241637.52231.18; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Chiu SL, 2013, GAIT POSTURE, V38, P717, DOI 10.1016/j.gaitpost.2013.03.010; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Eckner JT, 2011, PM&R, V3, P212, DOI 10.1016/j.pmrj.2010.12.003; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Golightly YM, 2009, J PHYS ACT HEALTH, V6, P638, DOI 10.1123/jpah.6.5.638; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Herman D., 2013, CLIN J SPORT MED, V23, P124; Hershman EB, 2012, AM J SPORT MED, V40, P2200, DOI 10.1177/0363546512458888; Hovda DA, 2014, PROG NEUROL SURG, V28, P28, DOI 10.1159/000358749; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; Kandel E.R., 1991, PRINCIPLES NEURAL SC, V3rd ed.; Kapreli E, 2009, AM J SPORT MED, V37, P2419, DOI 10.1177/0363546509343201; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kiesel KB, 2014, J SPORT REHABIL, V23, P88, DOI [10.1123/jsr.2012-0130, 10.1123/JSR.2012-0130]; Kontos AP, 2014, J INT NEUROPSYCH SOC, V20, P324, DOI 10.1017/S1355617713001471; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nachev P, 2007, NEUROIMAGE, V36, pT155, DOI 10.1016/j.neuroimage.2007.03.034; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pietrosimone B, J ATHL TRAI IN PRESS; Pietrosimone BG, 2012, J ATHL TRAINING, V47, P621, DOI 10.4085/1062-6050-47.6.11; Plisky PJ, 2006, J ORTHOP SPORT PHYS, V36, P911, DOI 10.2519/jospt.2006.2244; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Torry MR, 2005, J SPORT SCI MED, V4, P1	39	46	46	0	56	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	NOV	2015	47	11					2366	2372		10.1249/MSS.0000000000000684			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CT6RU	WOS:000362940900015	25871466				2022-02-06	
J	Twamley, EW; Thomas, KR; Gregory, AM; Jak, AJ; Bondi, MW; Delis, DC; Lohr, JB				Twamley, Elizabeth W.; Thomas, Kelsey R.; Gregory, Amber M.; Jak, Amy J.; Bondi, Mark W.; Delis, Dean C.; Lohr, James B.			CogSMART Compensatory Cognitive Training for Traumatic Brain Injury: Effects Over 1 Year	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognitive rehabilitation; depression; employment; posttraumatic stress disorder; rehabilitation; unemployment	MILD HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; METAANALYSIS; REHABILITATION; SYMPTOMS; MEMORY; REMEDIATION; EMPLOYMENT; VETERANS; QUALITY	Objective: There are very few evidence-based treatments for individuals with mild to moderate traumatic brain injuries. We developed and tested a 12-week, manualized, compensatory cognitive training intervention, Cognitive Symptom Management and Rehabilitation Therapy (CogSMART), which targeted postconcussive symptom management, prospective memory, attention, learning/memory, and executive functioning. The intervention focused on psychoeducation and compensatory strategies such as calendar use, self-talk, note taking, and a 6-step problem-solving method. Setting: VA Healthcare System. Participants: A total of 50 Veterans with mild to moderate traumatic brain injuries receiving supported employment. Design: Twelve-month randomized controlled trial with participants assigned to receive CogSMART or additional supported employment sessions for the first 12 weeks. Outcome assessments were administered at baseline and 3, 6, and 12 months. Main Measures: Assessments measured postconcussive symptoms, neuropsychological performance, functional capacity, psychiatric symptom severity, quality of life, and weeks worked during the 12-month trial. Results: Hierarchical linear modeling analyses using all 4 time points demonstrated significant CogSMART-associated reductions in postconcussive symptoms (r = -0.28, P =.026, d = 0.64) and improvements in prospective memory (r = 0.35, P =.031, d = 0.55) and quality of life (r = 0.34, P =.009, d = 1.0). The groups did not differ on weeks worked during the trial. Conclusion: CogSMART has the potential to improve postconcussive symptoms, cognitive performance, and self-rated quality of life in individuals with mild to moderate traumatic brain injuries.	[Twamley, Elizabeth W.; Jak, Amy J.; Delis, Dean C.; Lohr, James B.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Twamley, Elizabeth W.; Jak, Amy J.; Bondi, Mark W.; Lohr, James B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Thomas, Kelsey R.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Gregory, Amber M.] Univ Alabama Birmingham, Birmingham, AL USA; [Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA		Twamley, EW (corresponding author), VA San Diego Healthcare Syst, Neuropsychol Unit, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr 116A, San Diego, CA 92161 USA.	etwamley@ucsd.edu			Department of DefenseUnited States Department of Defense [W81XWH-08-2-0193]	This research was funded by Department of Defense Award W81XWH-08-2-0193 to Dr Twamley.	Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KA, 2009, ARCH PHYS MED REHAB, V90, pS52, DOI 10.1016/j.apmr.2009.05.019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Congressional Research Service, 2007, US MIL CAS STAT OP I; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Heaton R., 2000, WISCONSIN CARD SORTI; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hrobjartsson A, 2013, CAN MED ASSOC J, V185, pE201, DOI 10.1503/cmaj.120744; Institute of Medicine, 2011, COGN REH THER TRAUM; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEHMAN AF, 1988, EVAL PROGRAM PLANN, V11, P51, DOI 10.1016/0149-7189(88)90033-X; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Singer J, 2003, APPL LONGITUDINAL DA APPL LONGITUDINAL DA, DOI [10.1093/acprof:oso/ 9780195152968.003.0001, DOI 10.1093/ACPROF:OSO/9780195152968.003.0001]; Sitzer DI, 2006, ACTA PSYCHIAT SCAND, V114, P75, DOI 10.1111/j.1600-0447.2006.00789.x; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Twamley EW, 2013, J REHABIL RES DEV, V50, P663, DOI 10.1682/JRRD.2012.08.0137; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wilkinson G. S, 1993, WRAT 3 WIDE RANGE AC; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Woods SP, 2012, J INT NEUROPSYCH SOC, V18, P134, DOI 10.1017/S1355617711001263; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855; Zogg JB, 2012, J BEHAV MED, V35, P47, DOI 10.1007/s10865-011-9341-9	56	46	46	2	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					391	401		10.1097/HTR.0000000000000076			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300011	25033034				2022-02-06	
J	King, D; Hume, P; Gissane, C; Clark, T				King, D.; Hume, P.; Gissane, C.; Clark, T.			Use of the King-Devick test for sideline concussion screening in junior rugby league	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Brain injury; Vision; Eye-movement; Saccadic	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; SUBCONCUSSIVE IMPACTS; PLAYERS; TOOL; MANAGEMENT; PARENTS; UNION	Aim: To determine whether the King-Devick (K-D) test used as a sideline test in junior rugby league players over 12 matches in a domestic competition season could identify witnessed and incidentally identified episodes of concussion. Methods: A prospective observational cohort study of a club level junior rugby league team (n = 19) during the 2014 New Zealand competition season involved every player completing two pre-competition season baseline trials of the K-D test. Players removed from match participation, or who reported any signs or symptoms of concussion were assessed on the sideline with the K-D test and referred for further medical assessment. Players with a pre- to post-match K-D test difference >3 s were referred for physician evaluation. Results: The baseline test-retest reliability of the K-D test was high (r(s) = 0.86; p < 0.0001). Seven concussions were medically identified in six players who recorded pre- to post-match K-D test times greater than 3 s (mean change of 7.4 s). Post-season testing of players demonstrated improvement of K-D time scores consistent with learning effects of using the K-D test (67.7 s vs. 62.2 s). Discussion: Although no witnessed concussions occurred during rugby play, six players recorded pre- to post-match changes with a mean delay of 4 s resulting in seven concussions being subsequently confirmed post-match by health practitioners. All players were medically managed for a return to sports participation. Conclusion: The K-D test was quickly and easily administered making it a practical sideline tool as part of the continuum of concussion assessment tools for junior rugby league players. (C) 2015 Elsevier B.V. All rights reserved.	[King, D.; Hume, P.] Auckland Univ Technol, Fac Hlth & Environm Sci, AUT Millennium, SPRINZ, Auckland, New Zealand; [King, D.] Auckland Univ Technol, Fac Hlth & Environm Sci, Dept Paramed, Sch Clin Sci, Auckland, New Zealand; [Gissane, C.] St Marys Univ, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England; [Clark, T.] Australian Coll Phys Educ, Fac Human Performance, Olympic Pk, NSW, Australia		King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Hume, Patria/AAN-5514-2021; Gissane, Conor/I-3661-2019; Hume, Patria Anne/P-1084-2017	Hume, Patria/0000-0003-1847-8128; Gissane, Conor/0000-0003-4677-3853; Hume, Patria Anne/0000-0003-1847-8128; Clark, Dr Trevor/0000-0002-2853-0068			Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; Dhawan PSA, 2014, NEUROL CLIN PRACT, V82, pS11; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEUROOPHTHALMOL; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; King D., 2010, NZ J SPORTS MED, V37, P52; King D., 2014, NZ J SPORTS MED, V40, P8; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Krumholtz I, 2000, Optometry, V71, P426; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lin TP, 2014, PARKINSONISM RELAT D, V20, P226, DOI 10.1016/j.parkreldis.2013.10.009; Marinides Zoe, 2015, Neurol Clin Pract, V5, P25, DOI 10.1212/CPJ.0000000000000060; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moster S, 2014, J NEUROL SCI, V343, P105, DOI 10.1016/j.jns.2014.05.047; Onate JA., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Prasad S, 2010, NEUROL CLIN, V28, P641, DOI 10.1016/j.ncl.2010.03.006; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Spradley B., 2014, SPORT J         0314; Stepanek J, 2014, AVIAT SPACE ENVIR MD, V85, P700, DOI 10.3357/ASEM.3645.2014; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Upshaw JE, 2012, PEDIATR EMERG CARE, V28, P926, DOI 10.1097/PEC.0b013e318267f674; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	48	46	46	0	41	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2015	357	1-2					75	79		10.1016/j.jns.2015.06.069			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CS5SQ	WOS:000362138800012	26152829				2022-02-06	
J	Mendelow, AD; Gregson, BA; Rowan, EN; Francis, R; McColl, E; McNamee, P; Chambers, IR; Unterberg, A; Boyers, D; Mitchell, PM				Mendelow, A. David; Gregson, Barbara A.; Rowan, Elise N.; Francis, Richard; McColl, Elaine; McNamee, Paul; Chambers, Iain R.; Unterberg, Andreas; Boyers, Dwayne; Mitchell, Patrick M.		STITCH Trauma Investigators	Early Surgery versus Initial Conservative Treatment in Patients with Traumatic Intracerebral Hemorrhage (STITCH[Trauma]): The First Randomized Trial	JOURNAL OF NEUROTRAUMA			English	Article						craniotomy; controlled trial; intracerebral hemorrhage; traumatic brain injury; randomized	SURGICAL TRIAL; HEMATOMAS; STICH	Intraparenchymal hemorrhages occur in a proportion of severe traumatic brain injury TBI patients, but the role of surgery in their treatment is unclear. This international multi-center, patient-randomized, parallel-group trial compared early surgery (hematoma evacuation within 12 h of randomization) with initial conservative treatment (subsequent evacuation allowed if deemed necessary). Patients were randomized using an independent randomization service within 48 h of TBI. Patients were eligible if they had no more than two intraparenchymal hemorrhages of 10 mL or more and did not have an extradural or subdural hematoma that required surgery. The primary outcome measure was the traditional dichotomous split of the Glasgow Outcome Scale obtained by postal questionnaires sent directly to patients at 6 months. The trial was halted early by the UK funding agency (NIHR HTA) for failure to recruit sufficient patients from the UK (trial registration: ISRCTN19321911). A total of 170 patients were randomized from 31 of 59 registered centers worldwide. Of 82 patients randomized to early surgery with complete follow-up, 30 (37%) had an unfavorable outcome. Of 85 patients randomized to initial conservative treatment with complete follow-up, 40 (47%) had an unfavorable outcome (odds ratio, 0.65; 95% confidence interval, CI 0.35, 1.21; p=0.17), with an absolute benefit of 10.5% (CI, -4.4-25.3%). There were significantly more deaths in the first 6 months in the initial conservative treatment group (33% vs. 15%; p=0.006). The 10.5% absolute benefit with early surgery was consistent with the initial power calculation. However, with the low sample size resulting from the premature termination, we cannot exclude the possibility that this could be a chance finding. A further trial is required urgently to assess whether this encouraging signal can be confirmed.	[Mendelow, A. David; Gregson, Barbara A.; Rowan, Elise N.; Francis, Richard] Newcastle Univ, Neurosurg Trials Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [McColl, Elaine] Newcastle Univ, Newcastle Clin Trials Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [McNamee, Paul; Boyers, Dwayne] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland; [Chambers, Iain R.] James Cook Univ Hosp, Dept Med Phys, South Tees Hosp Fdn Trust, Middlesbrough, Cleveland, England; [Unterberg, Andreas] Heidelberg Univ, Dept Neurosurg, Heidelberg, Germany; [Mitchell, Patrick M.] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England		Gregson, BA (corresponding author), Wolfson Res Ctr, Neurosurg Trials Grp, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.	Barbara.Gregson@ncl.ac.uk	Mendelow, Alexander/AAW-2878-2021; Agrawal, Amit/C-1511-2011; McColl, Elaine/V-9906-2019; Abdullah, J/C-2828-2011; Boyers, Dwayne/AAJ-8774-2021; Smrcka, Martin/AAM-8872-2021	Agrawal, Amit/0000-0002-3287-5448; McColl, Elaine/0000-0001-8300-3204; Abdullah, J/0000-0002-0258-7410; Smrcka, Martin/0000-0002-9191-8700; Hutchinson, Peter/0000-0002-2796-1835; Francis, Richard/0000-0002-6568-1295	National Institute of Health Research (NIHR) Health Technology Assessment programNational Institute for Health Research (NIHR) [07/37/16]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish; Chief Scientist Office [HSRU1, HERU1] Funding Source: researchfish	This project was funded by the National Institute of Health Research (NIHR) Health Technology Assessment program (project no.: 07/37/16). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA program, NIHR, NHS, or the Department of Health.	BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Drummond M, 2009, VALUE HEALTH, V12, P409, DOI 10.1111/j.1524-4733.2008.00489.x; Fearnside M., 1997, NASOPHARYNGEAL CARCI, P1; Francis R., 2015, CHARACTERISTICS; Francis R, 2014, BRIT J NEUROSURG, V28, P663, DOI 10.3109/02688697.2014.881463; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; Gregson BA, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-193; Manca A, 2010, PHARMACOECONOMICS, V28, P1079, DOI 10.2165/11537760-000000000-00000; Marion DW, 2006, NEUROSURGERY, V58, P655; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Mendelow AD, 2005, LANCET, V365, P387; Mendelow AD, 2011, STROKE PATHOPHYSIOLO; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; National Institute for Health and Care Excellence, 2003, NICE CLIN GUID SETS; National Institute of Health and Care Excellence, 2007, CLIN GUID CG56 HEAD; Prasad K, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000200.pub2, 10.1002/14651858.CD002244.pub3]; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Siddique MS, 2002, J NEUROSURG, V96, P86, DOI 10.3171/jns.2002.96.1.0086; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; The World Bank W. D. I, 2014, GNI PER CAP	24	46	49	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1312	1323		10.1089/neu.2014.3644			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500005	25738794	Green Submitted, Green Published			2022-02-06	
J	Fagerholm, ED; Lorenz, R; Scott, G; Dinov, M; Hellyer, PJ; Mirzaei, N; Leeson, C; Carmichael, DW; Sharp, DJ; Shew, WL; Leech, R				Fagerholm, Erik D.; Lorenz, Romy; Scott, Gregory; Dinov, Martin; Hellyer, Peter J.; Mirzaei, Nazanin; Leeson, Clare; Carmichael, David W.; Sharp, David J.; Shew, Woodrow L.; Leech, Robert			Cascades and Cognitive State: Focused Attention Incurs Subcritical Dynamics	JOURNAL OF NEUROSCIENCE			English	Article						attention; criticality; EEG; fMRI; power law	POSTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; DEFAULT MODE; NEURONAL AVALANCHES; SUSTAINED ATTENTION; CORTICAL NETWORKS; ELECTRODE SYSTEM; EEG; CRITICALITY; ROBUST	The analysis of neuronal avalanches supports the hypothesis that the human cortex operates with critical neural dynamics. Here, we investigate the relationship between cascades of activity in electroencephalogram data, cognitive state, and reaction time in humans using a multimodal approach. We recruited 18 healthy volunteers for the acquisition of simultaneous electroencephalogram and functional magnetic resonance imaging during both rest and during a visuomotor cognitive task. We compared distributions of electroencephalogram-derived cascades to reference power laws for task and rest conditions. We then explored the large-scale spatial correspondence of these cascades in the simultaneously acquired functional magnetic resonance imaging data. Furthermore, we investigated whether individual variability in reaction times is associated with the amount of deviation from power law form. We found that while resting state cascades are associated with approximate power law form, the task state is associated with subcritical dynamics. Furthermore, we found that electroencephalogram cascades are related to blood oxygen level-dependent activation, predominantly in sensorimotor brain regions. Finally, we found that decreased reaction times during the task condition are associated with increased proximity to power law form of cascade distributions. These findings suggest that the resting state is associated with near-critical dynamics, in which a high dynamic range and a large repertoire of brain states may be advantageous. In contrast, a focused cognitive task induces subcritical dynamics, which is associated with a lower dynamic range, which in turn may reduce elements of interference affecting task performance.	[Fagerholm, Erik D.; Lorenz, Romy; Scott, Gregory; Dinov, Martin; Hellyer, Peter J.; Mirzaei, Nazanin; Leeson, Clare; Sharp, David J.; Leech, Robert] Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Ctr Neurosci, Div Brain Sci, London W12 0NN, England; [Carmichael, David W.] UCL Inst Child Hlth, Imaging & Biophys, London WC1N 1EH, England; [Shew, Woodrow L.] Univ Arkansas, Dept Phys, Fayetteville, AR 72701 USA		Fagerholm, ED (corresponding author), Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Ctr Neurosci, Div Brain Sci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	e.fagerholm03@imperial.ac.uk	Carmichael, David W/A-5391-2009; Hellyer, Peter J/F-7112-2013; Leech, Robert/AAE-8254-2019; Sharp, David J/A-2119-2013	Carmichael, David W/0000-0001-9972-0718; Hellyer, Peter J/0000-0002-5139-3401; Leech, Robert/0000-0002-5801-6318; Lorenz, Romy/0000-0002-7742-3162; Scott, Gregory/0000-0001-8063-5871	Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	This work was supported by the Medical Research Council (MRC). We thank the subjects who took part in this study.	Aarts E, 2014, NAT NEUROSCI, V17, P491, DOI 10.1038/nn.3648; Allen PJ, 1998, NEUROIMAGE, V8, P229, DOI 10.1006/nimg.1998.0361; Allen PJ, 2000, NEUROIMAGE, V12, P230, DOI 10.1006/nimg.2000.0599; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; Beggs JM, 2003, J NEUROSCI, V23, P11167; Beggs JM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00163; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; CHATRIAN GE, 1988, J CLIN NEUROPHYSIOL, V5, P183, DOI 10.1097/00004691-198804000-00005; Churchland MM, 2010, NAT NEUROSCI, V13, P369, DOI 10.1038/nn.2501; Clauset A, 2009, SIAM REV, V51, P661, DOI 10.1137/070710111; Cocchi L, 2013, TRENDS COGN SCI, V17, P493, DOI 10.1016/j.tics.2013.08.006; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Eichele H, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00065; Esterman M, 2014, J NEUROSCI, V34, P1724, DOI 10.1523/JNEUROSCI.2658-13.2014; Esterman M, 2013, CEREB CORTEX, V23, P2712, DOI 10.1093/cercor/bhs261; Friedman N, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.208102; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Gutberlet Ingmar, 2009, P23; Haldeman C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.058101; He BYJ, 2014, TRENDS COGN SCI, V18, P480, DOI 10.1016/j.tics.2014.04.003; He BJ, 2013, J NEUROSCI, V33, P4672, DOI 10.1523/JNEUROSCI.2922-12.2013; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kinouchi O, 2006, NAT PHYS, V2, P348, DOI 10.1038/nphys289; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Larremore DB, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.058101; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Meisel C, 2013, J NEUROSCI, V33, P17363, DOI 10.1523/JNEUROSCI.1516-13.2013; Oostenveld R, 2001, CLIN NEUROPHYSIOL, V112, P713, DOI 10.1016/S1388-2457(00)00527-7; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Scott G, 2014, J NEUROSCI, V34, P16611, DOI 10.1523/JNEUROSCI.3474-14.2014; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shew WL, 2013, NEUROSCIENTIST, V19, P88, DOI 10.1177/1073858412445487; Shew WL, 2009, J NEUROSCI, V29, P15595, DOI 10.1523/JNEUROSCI.3864-09.2009; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Ullsperger M, 2010, SIMULTANEOUS EEG FMR; von der Malsburg C, 2010, DYNAMIC COORDINATION; Yang HD, 2012, J NEUROSCI, V32, P1061, DOI 10.1523/JNEUROSCI.2771-11.2012	43	46	47	0	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 18	2015	35	11					4626	4634		10.1523/JNEUROSCI.3694-14.2015			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE9ZM	WOS:000352202300013	25788679	Green Published, Bronze			2022-02-06	
J	Ip, IK; Raja, AS; Gupta, A; Andruchow, J; Sodickson, A; Khorasani, R				Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin			Impact of clinical decision support on head computed tomography use in patients with mild traumatic brain injury in the ED	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							NEW-ORLEANS CRITERIA; PHYSICIAN ORDER ENTRY; EMERGENCY-DEPARTMENT; CT; RULE; IMPLEMENTATION; STRATEGIES; MANAGEMENT; SYSTEM; ADULTS	Background: Reduction of unnecessary head computed tomographies (CTs) in patients with mild traumatic brain injury (MTBI) was recently endorsed by American College of Emergency Physicians (ACEP) in the "Choosing Wisely" campaign. We examined the impact of computerized clinical decision support (CDS) on head CT utilization in MTBI emergency department (ED) visits. Methods: We conducted a 2-year cohort study at a level 1 trauma center and compared our results with the National Hospital Ambulatory Medical Care Survey from 2009 to 2010. All adult patients discharged from the ED with MTBI-associated diagnoses were included. After a baseline observation period at our institution, real-time CDS was implemented. Based upon the clinical history entered, low utility orders triggered an alert to clinicians, suggesting imaging studies might not adhere to evidence-based guidelines. Clinicians could cancel the order or ignore the alert. Primary outcome was intensity of head CT use in MTBI ED visits. Secondary outcomes included rates of delayed imaging and delays in diagnosing radiologically significant findings chi(2), logistic regression, and process control chart assessed preintervention and postintervention differences. Results: In study patients, 58.1% of MTBI-related visits resulted in head CT preintervention vs 50.3% postintervention (13.4% relative decrease, P = .005), a change not detected in controls (73.3% vs 76.9%, P = .272). Study cohort patients not receiving a head CT during their index visit were neither more nor less likely to receive one in the subsequent 7 days (6.7% preintervention vs 9.4% postintervention, P=.231). Rates of delayed diagnosis of radiologically significant findings were unchanged (0% vs 0%). Conclusions: Evidence-based CDS can reduce low utility imaging for MTBI. (C) 2014 Elsevier Inc. All rights reserved.	[Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin] Harvard Univ, Sch Med, Ctr Evidence Based Imaging, Boston, MA USA; [Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Ip, Ivan K.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Raja, Ali S.; Gupta, Anurag; Andruchow, James] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA USA; [Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA		Ip, IK (corresponding author), Brigham & Womens Hosp, Dept Radiol & Med, Ctr Evidence Based Imaging, 20 Kent St,Second Floor, Boston, MA 02445 USA.	iip@partners.org	Khorasani, Ramin/AAM-8526-2021; Raja, Ali S./AAE-5103-2019	Sodickson, Aaron/0000-0003-1275-681X			Andruchow JE, 2012, ARCH INTERN MED, V172, P660, DOI 10.1001/archinternmed.2011.2243; [Anonymous], 2001, MED I CROSSING QUALI; Ash JS, 2007, J AM MED INFORM ASSN, V14, P415, DOI 10.1197/jamia.M2373; Campbell EM, 2006, J AM MED INFORM ASSN, V13, P547, DOI 10.1197/jamia.M2042; Carspecken W, 2013, PEDIATRICS, V131, pE1970, DOI 10.1542/peds.2012-3252; Cheung YY, 2012, RADIOGRAPHICS, V32, P2113, DOI 10.1148/rg.327125713; Glatter R., 2013, FORBES; Gupta A, 2014, J AM MED INFORM ASS; Han YY, 2005, PEDIATRICS, V116, P1506, DOI 10.1542/peds.2005-1287; Harnan SE, 2011, J TRAUMA, V71, P245, DOI 10.1097/TA.0b013e31820d090f; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heskestad B, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-32; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Ip IK, 2012, J AM COLL RADIOL, V9, P129, DOI 10.1016/j.jacr.2011.10.010; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Magid S, 2012, APPL CLIN INFORM, V3, P377, DOI 10.4338/ACI-2012-01-RA-0002; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Melnick ER, 2010, ANN EMERG MED, V56, P317, DOI 10.1016/j.annemergmed.2010.03.006; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Prevedello LM, 2012, AM J MED, V125, P356, DOI 10.1016/j.amjmed.2011.06.023; Raja AS, 2012, RADIOLOGY, V262, P468, DOI 10.1148/radiol.11110951; Sharpe RE, 2013, J AM COLL RADIOL, V10, P599, DOI 10.1016/j.jacr.2013.01.023; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; Stiell IG, 2007, ACAD EMERG MED, V14, P955, DOI 10.1197/j.aem.2007.06.039; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Welch HG., 2011, OVERDIAGNOSED MAKING; Wilson IB, 2001, ARCH INTERN MED, V161, P256, DOI 10.1001/archinte.161.2.256	36	46	47	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAR	2015	33	3					320	325		10.1016/j.ajem.2014.11.005			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CE6GP	WOS:000351935100002	25572644				2022-02-06	
J	Bouzat, P; Marques-Vidal, P; Zerlauth, JB; Sala, N; Suys, T; Schoettker, P; Bloch, J; Daniel, RT; Levivier, M; Meuli, R; Oddo, M				Bouzat, Pierre; Marques-Vidal, Pedro; Zerlauth, Jean-Baptiste; Sala, Nathalie; Suys, Tamarah; Schoettker, Patrick; Bloch, Jocelyne; Daniel, Roy T.; Levivier, Marc; Meuli, Reto; Oddo, Mauro			Accuracy of Brain Multimodal Monitoring to Detect Cerebral Hypoperfusion After Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						brain multimodal monitoring; brain oxygen; cerebral blood flow; intracranial pressure; microdialysis; neuromonitoring; traumatic brain injury	TISSUE OXYGEN-TENSION; SEVERE HEAD TRAUMA; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; MICRODIALYSIS; CT; TOMOGRAPHY; DELIVERY; LACTATE	Objective: To examine the accuracy of brain multimodal monitoring consisting of intracranial pressure, brain tissue Po-2, and cerebral microdialysis in detecting cerebral hypoperfusion in patients with severe traumatic brain injury. Design: Prospective single-center study. Patients: Patients with severe traumatic brain injury. Setting: Medico-surgical ICU, university hospital. Intervention: Intracranial pressure, brain tissue Po-2, and cerebral microdialysis monitoring (right frontal lobe, apparently normal tissue) combined with cerebral blood flow measurements using perfusion CT. Measurements and Main Results: Cerebral blood flow was measured using perfusion CT in tissue area around intracranial monitoring (regional cerebral blood flow) and in bilateral supra-ventricular brain areas (global cerebral blood flow) and was matched to cerebral physiologic variables. The accuracy of intracranial monitoring to predict cerebral hypoperfusion (defined as an oligemic regional cerebral blood flow < 35 mU100g/min) was examined using area under the receiver-operating characteristic curves. Thirty perfusion CT scans (median, 27hr [interquartile range, 20-45] after traumatic brain injury) were performed on 27 patients (age, 39 yr [24-54 yr]; Glasgow Coma Scale, 7 [6-8]; 24/27 [89%] with diffuse injury). Regional cerebral blood flow correlated significantly with global cerebral blood flow (Pearson r = 0.70, p < 0.01). Compared with normal regional cerebral blood flow (n = 16), low regional cerebral blood flow (n = 14) measurements had a higher proportion of samples with intracranial pressure more than 20mm Hg (13% vs 30%), brain tissue Po-2, less than 20mm Hg (9% vs 20%), cerebral microdialysis glucose less than 1 mmol/L (22% vs 57%), and lactate/pyruvate ratio more than 40 (4% vs 14%; all p < 0.05). Compared with intracranial pressure monitoring alone (area under the receiver-operating characteristic curve, 0.74 [95% Cl, 0.61-0.87]), monitoring intracranial pressure + brain tissue Po, (area under the receiver-operating characteristic curve, 0.84 [0.74-0.93]) or intracranial pressure + brain tissue Po-2+ cerebral microdialysis (area under the receiver-operating characteristic curve, 0.88 [0.79-0.96]) was significantly more accurate in predicting low regional cerebral blood flow (both p < 0.05). Conclusion: Brain multimodal monitoring including intracranial pressure, brain tissue- Po-2, and cerebral microdialysis is more accurate than intracranial pressure monitoring alone in detecting cerebral hypoperfusion at the bedside in patients with severe traumatic brain injury and predominantly diffuse injury.	[Bouzat, Pierre; Sala, Nathalie; Suys, Tamarah; Oddo, Mauro] CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, Fac Biol & Med, Lausanne, Switzerland; [Bouzat, Pierre] Univ Grenoble 1, Grenoble, France; [Marques-Vidal, Pedro] CHUV Lausanne Univ Hosp, Dept Internal Med, Fac Biol & Med, Lausanne, Switzerland; [Zerlauth, Jean-Baptiste; Meuli, Reto] CHUV Lausanne Univ Hosp, Fac Biol & Med, Dept Radiol, Lausanne, Switzerland; [Schoettker, Patrick] CHUV Lausanne Univ Hosp, Fac Biol & Med, Dept Anesthesiol, Lausanne, Switzerland; [Bloch, Jocelyne; Daniel, Roy T.; Levivier, Marc] CHUV Lausanne Univ Hosp, Fac Biol & Med, Div Neurosurg, Lausanne, Switzerland		Oddo, M (corresponding author), CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, Fac Biol & Med, Lausanne, Switzerland.	mauro.oddo@chuv.ch	Bouzat, Pierre/AAC-4105-2019; Bloch, Jocelyne/A-9668-2017; Bouzat, Pierre/L-6881-2014; Oddo, Mauro/R-3370-2016; Schoettker, Patrick/AAE-4462-2020; Marques-Vidal, Pedro M/C-9449-2009	Bouzat, Pierre/0000-0003-4667-6738; Bloch, Jocelyne/0000-0002-6405-1590; Oddo, Mauro/0000-0002-6155-2525; Schoettker, Patrick/0000-0001-5370-048X; Marques-Vidal, Pedro M/0000-0002-4548-8500; Levivier, Marc/0000-0002-6273-2595	La Fondation des Gueules Cassees; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Novartis Foundation for Biomedical Research	Dr. Bouzat received research grants from La Fondation des Gueules Cassees. Dr. Oddo received research grants from the Swiss National Science Foundation and the Novartis Foundation for Biomedical Research. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Asgari S, 2013, NEUROCRIT CARE, V19, P56, DOI 10.1007/s12028-013-9821-6; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Carre E, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00146; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dagal A, 2011, CURR OPIN ANESTHESIO, V24, P131, DOI 10.1097/ACO.0b013e3283445898; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Eriksson EA, 2012, CLIN NEUROPHYSIOL, V123, P1255, DOI 10.1016/j.clinph.2011.08.035; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Huang APH, 2014, J NEUROSURG, V120, P473, DOI 10.3171/2013.10.JNS13103; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall RS, 2001, BRAIN, V124, P1208, DOI 10.1093/brain/124.6.1208; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Oddo M, 2012, CURR OPIN CRIT CARE, V18, P111, DOI 10.1097/MCC.0b013e32835132a5; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Valadka AB, 2002, ACT NEUR S, V81, P299; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2001, AM J NEURORADIOL, V22, P905	38	46	47	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2015	43	2					445	452		10.1097/CCM.0000000000000720			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ2YX	WOS:000348096200022	25393700				2022-02-06	
J	Semple, BD; Trivedi, A; Gimlin, K; Noble-Haeusslein, LJ				Semple, Bridgette D.; Trivedi, Alpa; Gimlin, Kayleen; Noble-Haeusslein, Linda J.			Neutrophil elastase mediates acute pathogenesis and is a determinant of long-term behavioral recovery after traumatic injury to the immature brain	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; neutrophil elastase; cell death; behavior; pathology; pediatric	SPINAL-CORD-INJURY; PERIOPERATIVE INFLAMMATORY RESPONSE; GLUTATHIONE-PEROXIDASE ACTIVITY; PEDIATRIC HEART-SURGERY; HEME OXYGENASE-1 HO-1; SERINE PROTEASES; MATRIX METALLOPROTEINASES; CARDIOPULMONARY BYPASS; INHIBITOR SIVELESTAT; OXIDATIVE STRESS	While neutrophil elastase (NE), released by activated neutrophils, is a key mediator of secondary pathogenesis in adult models of brain ischemia and spinal cord injury, no studies to date have examined this protease in the context of the injured immature brain, where there is notable vulnerability resulting from inadequate antioxidant reserves and prolonged exposure to infiltrating neutrophils. We thus reasoned that NE may be a key determinant of secondary pathogenesis, and as such, adversely influence long-term neurological recovery. To address this hypothesis, wild-type (WT) and NE knockout (KO) mice were subjected to a controlled cortical impact at postnatal day 21, approximating a toddler-aged child. To determine if NE is required for neutrophil infiltration into the injured brain, and whether this protease contributes to vasogenic edema, we quantified neutrophil numbers and measured water content in the brains of each of these genotypes. While leukocyte trafficking was indistinguishable between genotypes, vasogenic edema was markedly attenuated in the NE KO. To determine if early pathogenesis is dependent on NE, indices of cell death (TUNEL and activated caspase-3) were quantified across genotypes. NE KO mice showed a reduction in these markers of cell death in the injured hippocampus, which corresponded to greater preservation of neuronal integrity as well as reduced expression of heme oxygenase-1, a marker of oxidative stress. WT mice, treated with a competitive inhibitor of NE at 2, 6 and 12 h post-injury, likewise showed a reduction in cell death and oxidative stress compared to vehicle-treated controls. We next examined the long-term behavioral and structural consequences of NE deficiency. NE KO mice showed an improvement in long-term spatial memory retention and amelioration of injury-induced hyperactivity. However, volumetric and stereological analyses found comparable tissue loss in the injured cortex and hippocampus independent of genotype. Further, WT mice treated acutely with the NE inhibitor showed no long-term behavioral or structural improvements. Together, these findings validate the central role of NE in both acute pathogenesis and chronic functional recovery, and support future exploration of the therapeutic window, taking into account the prolonged period of neutrophil trafficking into the injured immature brain. (C) 2014 Elsevier Inc. All rights reserved.	[Semple, Bridgette D.; Trivedi, Alpa; Gimlin, Kayleen; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Semple, Bridgette D.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic 3000, Australia; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA		Semple, BD (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 513 Parnassus Ave,Room HSE-860, San Francisco, CA 94143 USA.	Bridgette.Semple@ucsf.edu; Alpa.Mahuvakar@ucsf.edu; Kayleen.Gimlin@ucsf.edu; Linda.Noble@ucsf.edu	Tercovich, Kayleen/I-8941-2018	Tercovich, Kayleen/0000-0003-0450-8912	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS050159, NS077767]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia; American Australian Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159, R01NS077767] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS R01 NS050159 and NS077767 (LJ. Noble- Haeusslein), a CJ Martin Biomedical Postdoctoral Fellowship from the National Health and Medical Research Council of Australia (B.D. Semple), and a Sir Keith Murdoch Postdoctoral Fellowship from the American Australian Association (B.D. Semple).	Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Allen C, 2012, J IMMUNOL, V189, P381, DOI 10.4049/jimmunol.1200409; Allport JR, 2002, J LEUKOCYTE BIOL, V71, P821; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL556; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Becker Kyra J, 2002, Curr Med Res Opin, V18 Suppl 2, ps18, DOI 10.1185/030079902125000688; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Cojocaru Inimioara Mihaela, 2006, Rom J Intern Med, V44, P317; Cousar JL, 2006, DEV NEUROSCI-BASEL, V28, P342, DOI 10.1159/000094160; Davis MJ, 2012, BEHAV BRAIN RES, V229, P21, DOI 10.1016/j.bbr.2011.12.037; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dredge BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021585; Easton AS, 2013, INT IMMUNOPHARMACOL, V17, P1218, DOI 10.1016/j.intimp.2013.06.015; Eisener-Dorman AF, 2009, BRAIN BEHAV IMMUN, V23, P318, DOI 10.1016/j.bbi.2008.09.001; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Faul M, 2010, TRAUMATIC BRAIN INJU; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447, DOI 10.1165/ajrcmb.26.4.4473; Fitrolaki DM, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-31; Frankowski H, 2012, METHODS MOL BIOL, V814, P221, DOI 10.1007/978-1-61779-452-0_15; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Gould TD, 2009, NEUROMETHODS, V42, P1, DOI 10.1007/978-1-60761-303-9_1; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Grenda DS, 2002, BLOOD, V100, P3221, DOI 10.1182/blood-2002-05-1372; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hirche TO, 2004, AM J RESP CELL MOL, V30, P576, DOI 10.1165/rcmb.2003-0253OC; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ikegame Y, 2010, HYPERTENS RES, V33, P703, DOI 10.1038/hr.2010.58; Inoue N, 2013, INT HEART J, V54, P149, DOI 10.1536/ihj.54.149; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Iwamoto Satoshi, 2009, Interact Cardiovasc Thorac Surg, V8, P606, DOI 10.1510/icvts.2008.197244; Iwatsuki K, 1998, NEUROL RES, V20, P397; Jackson PL, 2010, MOL MED, V16, P159, DOI 10.2119/molmed.2009.00109; Junger WG, 2013, SHOCK, V40, P366, DOI 10.1097/SHK.0000000000000038; Kawabata K, 2002, EUR J PHARMACOL, V451, P1, DOI 10.1016/S0014-2999(02)02182-9; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kikuchi T., 2006, J ANESTH, V20; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kohira S, 2013, ARTIF ORGANS, V37, P1027, DOI 10.1111/aor.12103; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Krams M, 2003, STROKE, V34, P2543, DOI 10.1161/01.STR.0000092527.33910.89; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Lee TW, 2008, NEURON GLIA BIOL, V4, P223, DOI 10.1017/S1740925X09990172; Liu Shimin, 2010, J Exp Stroke Transl Med, V3, P47; Matayoshi H, 2009, BRAIN RES, V1259, P98, DOI 10.1016/j.brainres.2008.12.070; Matsumoto S, 2009, J ANESTH, V23, P288, DOI 10.1007/s00540-008-0735-y; MEHTA JL, 1994, CARDIOVASC RES, V28, P947, DOI 10.1093/cvr/28.7.947; Meyer-Hoffert U, 2011, CURR OPIN HEMATOL, V18, P19, DOI 10.1097/MOH.0b013e32834115d1; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Nagy Z, 1998, BLOOD COAGUL FIBRIN, V9, P471, DOI 10.1097/00001721-199809000-00003; Natale JE, 2006, DEV NEUROSCI-BASEL, V28, P276, DOI 10.1159/000094154; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Noble LJ, 2002, J NEUROSCI, V22, P7526; PHAN SH, 1992, AM J RESP CELL MOL, V6, P270, DOI 10.1165/ajrcmb/6.3.270; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Pinheiro J., 2012, NLME LINEAR NONLINEA; Potts Mathew B, 2006, NeuroRx, V3, P143; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shapiro SD, 2002, AM J RESP CELL MOL, V26, P266, DOI 10.1165/ajrcmb.26.3.f233; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; SOMMERHOFF CP, 1991, EUR J PHARMACOL, V193, P153, DOI 10.1016/0014-2999(91)90030-T; Starcher B, 1996, J INVEST DERMATOL, V107, P159, DOI 10.1111/1523-1747.ep12329559; Stirling DP, 2009, J NEUROSCI, V29, P753, DOI 10.1523/JNEUROSCI.4918-08.2009; Stowe AM, 2009, NEUROBIOL DIS, V35, P82, DOI 10.1016/j.nbd.2009.04.006; Team R. C., 2012, R LANG ENV STAT COMP; Tiefenbacher CP, 1997, PFLUG ARCH EUR J PHY, V433, P563, DOI 10.1007/s004240050315; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Weinzierl M, 2004, BRAIN RES, V1030, P125, DOI 10.1016/j.brainres.2004.09.060; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; WILLIAMS JC, 1991, AM REV RESPIR DIS, V144, P875, DOI 10.1164/ajrccm/144.4.875; WOODMAN RC, 1993, BLOOD, V82, P2188; Yang Mu, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0826s56; Young ME, 2009, LEARN MOTIV, V40, P160, DOI 10.1016/j.lmot.2008.10.004; Young RE, 2007, BRIT J PHARMACOL, V151, P628, DOI 10.1038/sj.bjp.0707267; Young RE, 2004, J IMMUNOL, V172, P4493, DOI 10.4049/jimmunol.172.7.4493; Zeiher BG, 2002, CRIT CARE MED, V30, pS281, DOI 10.1097/00003246-200205001-00018; Zhou XH, 2012, FRONT BIOSCI-LANDMRK, V17, P2278, DOI 10.2741/4051	109	46	47	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2015	74						263	280		10.1016/j.nbd.2014.12.003			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB5GQ	WOS:000349655900025	25497734	Green Accepted			2022-02-06	
J	Dimitriadis, SI; Zouridakis, G; Rezaie, R; Babajani-Feremi, A; Papanicolaou, AC				Dimitriadis, Stavros I.; Zouridakis, George; Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.			Functional connectivity changes detected with magnetoencephalography after mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury; MEG; Tensors; Computational connectomics; Biomarkers; Diagnosis	RESTING-STATE ACTIVITY; SMALL-WORLD NETWORKS; IMAGING APPROACH; MEG; DYNAMICS; SCALE; CLASSIFICATION; FLUCTUATIONS; CONCUSSION; BIOMARKERS	Mild traumatic brain injury (mTBI) may affect normal cognition and behavior by disrupting the functional connectivity networks that mediate efficient communication among brain regions. In this study, we analyzed brain connectivity profiles from resting state Magnetoencephalographic (MEG) recordings obtained from 31 mTBI patients and 55 normal controls. We used phase-locking value estimates to compute functional connectivity graphs to quantify frequency-specific couplings between sensors at various frequency bands. Overall, normal controls showed a dense network of strong local connections and a limited number of long-range connections that accounted for approximately 20% of all connections, whereas mTBI patients showed networks characterized by weak local connections and strong long-range connections that accounted for more than 60% of all connections. Comparison of the two distinct general patterns at different frequencies using a tensor representation for the connectivity graphs and tensor subspace analysis for optimal feature extraction showed that mTBI patients could be separated from normal controls with 100% classification accuracy in the alpha band. These encouraging findings support the hypothesis that MEG-based functional connectivity patterns may be used as biomarkers that can provide more accurate diagnoses, help guide treatment, and monitor effectiveness of intervention in mTBI. (C) 2015 The Authors. Published by Elsevier Inc.	[Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, Dept Informat, Artificial Intelligence & Informat Anal Lab, Thessaloniki 54124, Greece; [Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, NeuroInformat Grp, Thessaloniki, Greece; [Zouridakis, George] Basque Ctr Cognit Brain & Language BCBL, Paseo Mikeletegi 69, Donostia San Sebastian 20009, Spain; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Clin Neurosci, Memphis, TN 38163 USA; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Le Bonheur Children3s Hosp, Neurosci Inst, Memphis, TN USA; [Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Engn Technol, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Comp Sci Elect & Comp Engn, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Biomed Engn, Houston, TX 77204 USA		Zouridakis, G (corresponding author), Univ Houston, Biomed Imaging Lab, 4730 Calhoun Rd Room 300, Houston, TX 77204 USA.	zouridakis@uh.edu	Zouridakis, George/R-8876-2019; DIMITRIADIS, STAVROS I/AAN-8992-2020	Zouridakis, George/0000-0002-7770-9857; DIMITRIADIS, STAVROS I/0000-0002-0000-5392; Basque Center on Cognition, Brain and Language, BCBL./0000-0002-8345-6892; Rezaie, Roozbeh/0000-0002-7494-339X	U.S. Department of Defense Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0131, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0133, W81XWH-08-2-0140, W81XWH-08-2-0135, W81XWH-08-2-0142]	This project is part of a larger study, the Integrated Clinical Protocol, conducted by the Investigators and staff of The Mission Connect Mild Traumatic Brain Injury Translational Research Consortium and supported by the U.S. Department of Defense Congressionally Directed Medical Research Program: W81XWH-08-2-0131, J. J. McCarthy, MD; W81XWH-08-2-0138, Brent Masel, MD; W81XWH-08-2-0132, C. S. Robertson, MD; W81XWH-08-2-0149, Eli Mizrahi, MD; W81XWH-08-2-0133, H. Levin, PhD; W81XWH-08-2-0140, Ponnada Narayana, PhD; W81XWH-08-2-0135, A. Papanicolaou, PhD and W81XWH-08-2-0142, Paul Swank, PhD.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Akil H, 2011, SCIENCE, V331, P708, DOI 10.1126/science.1199305; ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209; Assistant Secretary D.o.D., TRAUM BRAIN INJ DEF; Bardouille T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048682; Bassett DS, 2009, P NATL ACAD SCI USA, V106, P11747, DOI 10.1073/pnas.0903641106; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Borst C, 1999, ICRA '99: IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS 1-4, PROCEEDINGS, P1890, DOI 10.1109/ROBOT.1999.770384; Brookes MJ, 2012, NEUROIMAGE, V63, P910, DOI 10.1016/j.neuroimage.2012.03.048; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Congedo M, 2010, INT J PSYCHOPHYSIOL, V78, P89, DOI 10.1016/j.ijpsycho.2010.06.003; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Daubechies I., 1992, 10 LECT WAVELETS, V61, DOI 10.1063/14823127; de Pasquale F, 2012, NEURON, V74, P753, DOI 10.1016/j.neuron.2012.03.031; de Pasquale F, 2010, P NATL ACAD SCI USA, V107, P6040, DOI 10.1073/pnas.0913863107; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Delorme A, 2007, J NEUROSCI, V27, P11949, DOI 10.1523/JNEUROSCI.3477-07.2007; Delorme A, 2007, NEUROIMAGE, V34, P1443, DOI 10.1016/j.neuroimage.2006.11.004; Dimitriadis SI, 2013, NEUROIMAGE, V83, P307, DOI 10.1016/j.neuroimage.2013.06.036; Dimitriadis SI, 2012, IEEE T BIO-MED ENG, V59, P1302, DOI 10.1109/TBME.2012.2186568; Dimitriadis S. I., 2013, 35 ANN INT C IEEE EM; Dimitriadis S. I., 2015, CLIN NEUROPHYSIOL; Dimitriadis SI, 2015, ANN BIOMED ENG, V43, P977, DOI 10.1007/s10439-014-1143-0; Dimitriadis SI, 2010, J NEUROSCI METH, V193, P145, DOI 10.1016/j.jneumeth.2010.08.027; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Fisher RA, 1936, ANN EUGENIC, V7, P179, DOI 10.1111/j.1469-1809.1936.tb02137.x; Florin E, 2015, NEUROIMAGE, V111, P26, DOI 10.1016/j.neuroimage.2015.01.054; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Golub GH., 2013, MATRIX COMPUTATIONS MATRIX COMPUTATIONS, V4th; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hamalainen Matti S., 1995, Brain Topography, V7, P283, DOI 10.1007/BF01195254; Hastie T., 2003, ELEMENTS STAT LEARNI; He X, 2005, ADV NEURAL INFORM PR, V18; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Hillebrand A, 2012, NEUROIMAGE, V59, P3909, DOI 10.1016/j.neuroimage.2011.11.005; Hipp JF, 2012, NAT NEUROSCI, V15, P884, DOI 10.1038/nn.3101; Hipp JF, 2011, NEURON, V69, P387, DOI 10.1016/j.neuron.2010.12.027; HORN RA, 1990, SIAM J MATRIX ANAL A, V11, P481, DOI 10.1137/0611034; Huang GB, 2006, NEUROCOMPUTING, V70, P489, DOI 10.1016/j.neucom.2005.12.126; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Iakovidou N., 2013, 13 IEEE INT C BIOINF; Iakovidou ND, 2013, J NEUROSCI METH, V213, P204, DOI 10.1016/j.jneumeth.2012.12.018; Ioannides AA, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/452503; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Jirsa VK, 2010, ARCH ITAL BIOL, V148, P189; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim J, 2009, BIOMED ENG ONLINE, V8, DOI 10.1186/1475-925X-8-31; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Levin H. S., 2009, MISSION CONNECT MILD, DOI 10.21236/ADA550012; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Li Qiang, 2013, Journal of Highway and Transportation Research and Development (Chinese Edition), V30, P1, DOI 10.3969/j.issn.1002-0268.2013.12.001; Lu H., 2013, MULTILINEAR SUBSPACE, P2013; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Mallat S., 2008, WAVELET TOUR SIGNAL, V3; Mantini D, 2011, BRAIN CONNECT, V1, P49, DOI 10.1089/brain.2011.0001; Martino J, 2011, ANN NEUROL, V69, P521, DOI 10.1002/ana.22167; Marzetti L, 2013, NEUROIMAGE, V79, P172, DOI 10.1016/j.neuroimage.2013.04.062; Micheloyannis S, 2006, SCHIZOPHR RES, V87, P60, DOI 10.1016/j.schres.2006.06.028; Onton J, 2006, NEUROSCI BIOBEHAV R, V30, P808, DOI 10.1016/j.neubiorev.2006.06.007; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Pollonini L, 2010, IEEE ENG MED BIO, P1730, DOI 10.1109/IEMBS.2010.5626702; Quigley M, 2001, AM J NEURORADIOL, V22, P294; Richiardi J, 2011, NEUROIMAGE, V56, P616, DOI 10.1016/j.neuroimage.2010.05.081; Romero S, 2008, COMPUT BIOL MED, V38, P348, DOI 10.1016/j.compbiomed.2007.12.001; Rubinov M, 2013, TRENDS COGN SCI, V17, P641, DOI 10.1016/j.tics.2013.10.007; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sireci SG, 2003, J EDUC MEAS, V40, P277, DOI 10.1111/j.1745-3984.2003.tb01108.x; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O, 2012, DISCOVERING HUMAN CO; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2010, INT J PSYCHOPHYSIOL, V77, P186, DOI 10.1016/j.ijpsycho.2010.06.024; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; TEASDALE G, 1974, LANCET, V2, P81; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; van Dellen E, 2013, NEUROIMAGE-CLIN, V2, P1, DOI 10.1016/j.nicl.2012.10.007; van Walsum AMV, 2003, CLIN NEUROPHYSIOL, V114, P1034, DOI 10.1016/S1388-2457(03)00072-5; Zhu GW, 2009, J INT MED RES, V37, P983, DOI 10.1177/147323000903700402; Zouridakis G, 2012, J MECH MED BIOL, V12, DOI 10.1142/S0219519412400064	99	46	47	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	9						519	531		10.1016/j.nicl.2015.09.011			13	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI0LR	WOS:000373188400056	26640764	gold, Green Published			2022-02-06	
J	Winklewski, PJ; Radkowski, M; Demkow, U				Winklewski, Pawel J.; Radkowski, Marek; Demkow, Urszula			Cross-talk between the inflammatory response, sympathetic activation and pulmonary infection in the ischemic stroke	JOURNAL OF NEUROINFLAMMATION			English	Article						Stroke; Brain injury; Immune response; Sympathetic nervous system; Lung injury; Pneumonia	COMMUNITY-ACQUIRED PNEUMONIA; PITUITARY-ADRENAL AXIS; TRAUMATIC BRAIN-INJURY; ACUTE LUNG INJURY; CEREBRAL-ISCHEMIA; T-LYMPHOCYTES; NERVOUS-SYSTEM; SUBARACHNOID HEMORRHAGE; IMMUNE-SYSTEM; UP-REGULATION	The immune system response and inflammation play a key role in brain injury during and after a stroke. The acute immune response is responsible for secondary brain tissue damage immediately after the stroke, followed by immunosuppression due to sympathetic nervous system activation. The latter increases risk of infection complications, such as pneumonia. The pneumonia-related inflammatory state can release a bystander autoimmune response against central nervous system antigens, thereby initiating a vicious circle. The aim of this review is to summarize the relationship between ischemic stroke, sympathetic nervous system activation and pulmonary infection.	[Winklewski, Pawel J.] Med Univ Gdansk, Inst Human Physiol, PL-80210 Gdansk, Poland; [Radkowski, Marek] Med Univ Warsaw, Dept Immunopathol Infect & Parasit Dis, Warsaw, Poland; [Demkow, Urszula] Med Univ Warsaw, Dept Lab Diagnost & Clin Immunol Dev Age, Warsaw, Poland		Winklewski, PJ (corresponding author), Med Univ Gdansk, Inst Human Physiol, Tuwima St 15, PL-80210 Gdansk, Poland.	pawelwinklewski@wp.pl	Radkowski, Marek/V-3860-2018	Radkowski, Marek/0000-0003-1808-679X; Winklewski, Pawel/0000-0002-1671-2163			Ahnstedt H, 2012, ACTA PHYSIOL, V205, P266, DOI 10.1111/j.1748-1716.2011.02392.x; Ainslie Philip N, 2014, F1000Prime Rep, V6, P14, DOI 10.12703/P6-14; Ajmo CT, 2009, EXP NEUROL, V218, P47, DOI 10.1016/j.expneurol.2009.03.044; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Armstead WM, 2013, J NEUROTRAUM, V30, P1898, DOI 10.1089/neu.2013.2962; Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Avlonitis VS, 2005, AM J TRANSPLANT, V5, P684, DOI 10.1111/j.1600-6143.2005.00755.x; Bakovic D, 2013, CLIN PHYSIOL FUNCT I, V33, P30, DOI 10.1111/j.1475-097X.2012.01156.x; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Becker KJ, 2005, J CEREBR BLOOD F MET, V25, P1634, DOI 10.1038/sj.jcbfm.9600160; Becker KJ, 2011, STROKE, V42, P2763, DOI 10.1161/STROKEAHA.111.619593; Bellinger DL, 2008, CELL IMMUNOL, V252, P27, DOI 10.1016/j.cellimm.2007.09.005; Brait VH, 2012, J CEREBR BLOOD F MET, V32, P598, DOI 10.1038/jcbfm.2012.6; Brait VH, 2010, J CEREBR BLOOD F MET, V30, P1306, DOI 10.1038/jcbfm.2010.14; Cassaglia PA, 2008, AM J PHYSIOL-REG I, V294, pR1255, DOI 10.1152/ajpregu.00332.2007; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chang LL, 2011, BRAIN BEHAV IMMUN, V25, P260, DOI 10.1016/j.bbi.2010.09.017; Chao HJ, 2005, J NEUROIMMUNOL, V158, P159, DOI 10.1016/j.jneuroim.2004.09.008; Chiarella SE, 2014, J CLIN INVEST, V124, P2935, DOI 10.1172/JCI75157; Cobelens PM, 2010, CRIT CARE, V14, DOI 10.1186/cc9232; COLICE GL, 1985, CLIN CHEST MED, V6, P473; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; Davison DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11226; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Dziedzic T, 2007, J NEUROL SCI, V252, P53, DOI 10.1016/j.jns.2006.10.007; Dziewas R, 2004, J NEUROL NEUROSUR PS, V75, P852, DOI 10.1136/jnnp.2003.019075; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Faraco G, 2013, HYPERTENSION, V62, P759, DOI 10.1161/HYPERTENSIONAHA.113.01761; Flierl MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004414; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gendron A, 2002, BRAIN RES, V955, P85, DOI 10.1016/S0006-8993(02)03368-1; Gur AY, 2007, J NEUROL SCI, V257, P121, DOI 10.1016/j.jns.2007.01.024; Hamner JW, 2010, STROKE, V41, P102, DOI 10.1161/STROKEAHA.109.557132; Hannawi Y, 2013, CEREBROVASC DIS, V35, P430, DOI 10.1159/000350199; HARDY J, 1994, AM J VET RES, V55, P1570; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Immink RV, 2005, STROKE, V36, P2595, DOI 10.1161/01.STR.0000189624.06836.03; Ishikawa M, 2003, STROKE, V34, P1777, DOI 10.1161/01.STR.0000074921.17767.F2; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; Kahn JM, 2006, CRIT CARE MED, V34, P196, DOI 10.1097/01.CCM.0000194540.44020.8E; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kamel H, 2012, ARCH NEUROL-CHICAGO, V69, P576, DOI 10.1001/archneurol.2011.3590; Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60; Konoeda F, 2010, BIOCHEM BIOPH RES CO, V402, P500, DOI 10.1016/j.bbrc.2010.10.058; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lopez-Aguilar J, 2005, CRIT CARE MED, V33, P1077, DOI 10.1097/01.CCM.0000162913.72479.F7; Macrez R, 2011, LANCET NEUROL, V10, P471, DOI 10.1016/S1474-4422(11)70066-7; Maddahi A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-107; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; Martin A, 2008, MOL IMAGING, V7, P157, DOI 10.2310/7290.2008.00016; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; Meisel C, 2011, NEW ENGL J MED, V365, P2134, DOI 10.1056/NEJMcibr1112454; Mracsko E, 2014, BRAIN BEHAV IMMUN, V41, P200, DOI 10.1016/j.bbi.2014.05.015; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; Nieswandt B, 2011, J PHYSIOL-LONDON, V589, P4115, DOI 10.1113/jphysiol.2011.212886; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Pelosi P, 2005, CURR OPIN CRIT CARE, V11, P37, DOI 10.1097/00075198-200502000-00006; Planas AM, 2012, J IMMUNOL, V188, P2156, DOI 10.4049/jimmunol.1102289; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Prass K, 2006, STROKE, V37, P2607, DOI 10.1161/01.STR.0000240409.68739.2b; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Rassler B, 2012, SCI CAIRO, V2012; Riquelme R, 1996, AM J RESP CRIT CARE, V154, P1450, DOI 10.1164/ajrccm.154.5.8912763; Sammani S, 2011, AM J RESP CELL MOL, V45, P1022, DOI 10.1165/rcmb.2010-0267OC; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Stoll G, 2010, ANN NY ACAD SCI, V1207, P149, DOI 10.1111/j.1749-6632.2010.05730.x; Tanzi P, 2011, NEUROCRIT CARE, V14, P244, DOI 10.1007/s12028-010-9490-7; ter Laan M, 2013, BRIT J ANAESTH, V111, P361, DOI 10.1093/bja/aet122; Teramoto S, 2009, EXPERT REV NEUROTHER, V9, P1187, DOI 10.1586/ERN.09.72; THEODORE J, 1975, LANCET, V2, P749; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Walter U, 2013, EUR J NEUROL, V20, P153, DOI 10.1111/j.1468-1331.2012.03818.x; Wang JP, 2015, BRAIN BEHAV IMMUN, V43, P172, DOI 10.1016/j.bbi.2014.07.022; Winklewski PJ, 2013, BLOOD PRESSURE, V22, P27, DOI 10.3109/08037051.2012.701407; Woiciechowsky C, 1999, BRAIN RES, V816, P563, DOI 10.1016/S0006-8993(98)01238-4; Wong CHY, 2011, SCIENCE, V334, P101, DOI 10.1126/science.1210301; Wu S, 2006, EXP NEUROL, V200, P245, DOI 10.1016/j.expneurol.2006.01.027; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Yilmaz G, 2008, NEUROL RES, V30, P783, DOI 10.1179/174313208X341085; Zierath D, 2010, NEUROCRIT CARE, V12, P274, DOI 10.1007/s12028-009-9270-4	88	46	60	1	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	DEC 24	2014	11								213	10.1186/s12974-014-0213-4			8	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CA6SA	WOS:000349044600001	25539803	Green Published, gold			2022-02-06	
J	Marmarou, CR; Liang, X; Abidi, NH; Parveen, S; Taya, K; Henderson, SC; Young, HF; Filippidis, AS; Baumgarten, CM				Marmarou, Christina R. p; Liang, Xiuyin; Abidi, Naqeeb H.; Parveen, Shanaz; Taya, Keisuke; Henderson, Scott C.; Young, Harold F.; Filippidis, Aristotelis S.; Baumgarten, Clive M.			Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Edema; Aquaporin 4; Vasopressin; Astrocyte; SR49059	PHORBOL-MYRISTATE ACETATE; FIBRILLARY ACIDIC PROTEIN; ATRIAL-NATRIURETIC-PEPTIDE; CEREBRAL-ARTERY OCCLUSION; KINASE-C ACTIVATOR; ARGININE-VASOPRESSIN; AQUAPORIN-4 EXPRESSION; WATER PERMEABILITY; CEREBROSPINAL-FLUID; V-2 RECEPTORS	A secondary and often lethal consequence of traumatic brain injury is cellular edema that we posit is due to astrocytic swelling caused by transmembrane water fluxes augmented by vasopressin-regulated aquaporin-4 (AQP4). We therefore tested whether vasopressin la receptor (V1aR) inhibition would suppress astrocyte AQP4, reduce astrocytic edema, and thereby diminish TBI-induced edematous changes. V1aR inhibition by SR49059 significantly reduced brain edema after cortical contusion injury (CCI) in rat 5 h post-injury. Injured-hemisphere brain water content (n=6 animals/group) and astrocytic area (n=3/group) were significantly higher in CCI-vehicle (80.5 +/- 0.3%; 18.0 +/- 1.4 mu m(2)) versus sham groups (78.3 +/- 0.1%; 9.5 +/- 0.91 mu m(2)), and SR49059 blunted CCI-induced increases in brain edema (79.0 +/- 0.2%; 9.4 +/- 00.8 mu m(2)). CCI significantly up-regulated GFAP, V1aR and AQP4 protein levels and SR49059 suppressed injury induced up regulation (n=6/group). In CCI-vehicle, sham and CCI-SR49059 groups, GFAP was 1.58 +/- 0.04, 0.47 +/- 0.02, and 0.81+0.03, respectively; V1aR was 1.00 +/- 0.06, 0.45 +/- 0.05, and 0.46 +/- 0.09; and AQP4 was 2.03 +/- 0.34, 0.49 +/- 30.04, and 0.92 +/- 0.22. Confocal immunohistochemistry gave analogous results. In CCI-vehicle, sham and CCI-SR49059 groups, fluorescence intensity of GFAP was 349 +/- 38, 56 +/- 5, and 244 +/- 30, respectively, V1aR was 601 +/- 71, 117.8 +/- 14, and 390 +/- 76, and AQP4 was 818 +/- 117, 158 +/- 5, and 458 +/- 55 (n=3/group). The results support that edema was predominantly cellular following CCI and documented that VlaR inhibition with SR49059 suppressed injury-induced up regulation of GFAP, VIA and AQP4, blunting edematous changes. Our findings suggest V1aR inhibitors may be potential therapeutic tools to prevent cellular swelling and provide treatment for post-traumatic brain edema. (C) 2014 Elsevier B.V. All rights reserved.	[Marmarou, Christina R. p; Liang, Xiuyin; Abidi, Naqeeb H.; Parveen, Shanaz; Taya, Keisuke; Young, Harold F.; Filippidis, Aristotelis S.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Marmarou, Christina R. p; Baumgarten, Clive M.] Virginia Commonwealth Univ, Dept Phys & Biophys, Richmond, VA 23298 USA; [Henderson, Scott C.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Marmarou, CR (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, 9-036-9-039 Sanger Hall,1101 East Marshall St, Richmond, VA 23298 USA.	crmarmar@vcu.edu	Henderson, Scott/AAP-2785-2021	Henderson, Scott/0000-0002-1076-3867	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS019235]; NIH-NINDS Center Core grant [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS019235] Funding Source: NIH RePORTER	This work was supported by grant 5R01NS019235 from the National Institute of Health. Microscopy was performed at the VCU-Department of Anatomy and Neurobiology Microscopy Facility, supported in part with funding from NIH-NINDS Center Core grant (5P30NS047463). We wish to acknowledge the technical help of Mr. Andrew McCall, and the generous gift of SR49059 from Sanofi-Aventis.	Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amorini AM, 2003, ACT NEUR S, V86, P261; Bagheri M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076526; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Carrasco E, 2007, DIABETES CARE, V30, P2902, DOI 10.2337/dc07-0332; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CSERR HF, 1992, PROG BRAIN RES, V91, P3; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; DICKINSON LD, 1992, J CEREBR BLOOD F MET, V12, P681, DOI 10.1038/jcbfm.1992.93; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOCZI T, 1984, NEUROSURGERY, V14, P436, DOI 10.1227/00006123-198404000-00008; DOCZI T, 1982, NEUROSURGERY, V11, P402; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fattore L, 2002, NEUROSCIENCE, V110, P1, DOI 10.1016/S0306-4522(01)00598-X; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Filippidis AS, 2014, J NEUROTRAUM, V31, P1258, DOI 10.1089/neu.2013.3063; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Girardi E, 2004, NEUROCHEM RES, V29, P371, DOI 10.1023/B:NERE.0000013739.15160.a8; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Haj-Yasein NN, 2011, P NATL ACAD SCI USA, V108, P17815, DOI 10.1073/pnas.1110655108; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659; Huang WD, 2008, J ENDOCRINOL INVEST, V31, P996, DOI 10.1007/BF03345638; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P151, DOI 10.1007/s00701-012-1558-z; LANDGRAF R, 1992, PROG BRAIN RES, V91, P29; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LATZKOVITS L, 1993, AM J PHYSIOL, V264, pC603, DOI 10.1152/ajpcell.1993.264.3.C603; Liu XQ, 2010, NEUROCRIT CARE, V12, P124, DOI 10.1007/s12028-009-9277-x; Lo Pizzo M, 2013, NEUROL SCI, V34, P1309, DOI 10.1007/s10072-012-1233-4; Manaenko A, 2011, ACTA NEUROCHIR SUPPL, V111, P191, DOI 10.1007/978-3-7091-0693-8_32; Manaenko A, 2011, NEUROCHEM INT, V58, P542, DOI 10.1016/j.neuint.2011.01.018; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, AM J PHYSIOL, V267, pH514, DOI 10.1152/ajpheart.1994.267.2.H514; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; OSTROWSKI NL, 1994, ENDOCRINOLOGY, V135, P1511, DOI 10.1210/en.135.4.1511; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; RAICHLE ME, 1978, BRAIN RES, V143, P191, DOI 10.1016/0006-8993(78)90766-7; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rauen K, 2013, J NEUROTRAUM, V30, P1442, DOI 10.1089/neu.2012.2807; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; SORENSEN PS, 1985, J NEUROL NEUROSUR PS, V48, P50, DOI 10.1136/jnnp.48.1.50; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; SZOT P, 1994, MOL BRAIN RES, V24, P1, DOI 10.1016/0169-328X(94)90111-2; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Verkman AS, 2009, J EXP BIOL, V212, P1707, DOI 10.1242/jeb.024125; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001	78	46	47	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 18	2014	1581						89	102		10.1016/j.brainres.2014.06.005			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AQ1LE	WOS:000342542100009	24933327	Green Accepted			2022-02-06	
J	Dayan, PS; Holmes, JF; Atabaki, S; Hoyle, J; Tunik, MG; Lichenstein, R; Alpern, E; Miskin, M; Kuppermann, N				Dayan, Peter S.; Holmes, James F.; Atabaki, Shireen; Hoyle, John, Jr.; Tunik, Michael G.; Lichenstein, Richard; Alpern, Elizabeth; Miskin, Michelle; Kuppermann, Nathan		Traumatic Brain Injury Study Grp	Association of Traumatic Brain Injuries With Vomiting in Children With Blunt Head Trauma	ANNALS OF EMERGENCY MEDICINE			English	Article							DECISION RULE; INTRACRANIAL INJURY; COMPUTED-TOMOGRAPHY; PREDICTION; CONSCIOUSNESS; VARIABLES; RISK	Study objective: We aimed to determine the prevalence of traumatic brain injuries in children who vomit after minor blunt head trauma, particularly when the vomiting occurs without other-findings suggestive of traumatic brain injury (ie, isolated vomiting). We also aimed to determine the relationship between the timing and degree of vomiting and traumatic brain injury prevalence. Methods: This was a secondary analysis of children younger than 18 years with minor blunt head trauma. Clinicians assessed for history and characteristics of vomiting at the initial evaluation. We assessed for the prevalence of clinically important traumatic brain injury and traumatic brain injury on computed tomography (CT). Results: Of 42,112 children enrolled, 5,557 (13.2%) had a history of vomiting, of whom 815 of 5,392 (15.1%) with complete data had isolated vomiting. Clinically important traumatic brain injury Occurred in 2 of 815 patients (0.2%; 95% confidence interval [Cl] 0% to 0.9%) with isolated vomiting compared with 114 Of 4,577 (2.5%; 95% Cl 2.1% to 3.0%) with nonisolated vomiting (difference -2.3%, 95% Cl -2.8% to -1.5%). Of patients with isolated vomiting for whom CT was performed, traumatic brain injury on CT occurred in 5 of 298 (1.7%; 95% Cl 0.5% to 3.9%) compared with 211 of 3,284 (6.4%; 95% Cl 5.6% to 7.3%) with nonisolated vomiting (difference -4.7%; 95% Cl -6.0% to -2.4%). We found no significant independent associations between prevalence of clinically important traurhatic brain injury and traumatic brain injury on CT with either the timing of onset or time since the last episode of vomiting. Conclusion: Traumatic brain injury on CT is uncommon and clinically important traumatic brain injury is very uncommon in children with minor blunt head trauma when vomiting is their only sign or symptom. Observation in the emergency department before determining the need for CT appears appropriate for many of these children.	[Dayan, Peter S.] Columbia Univ, Coll Phys & Surg, Morgan Stanley Childrens Hosp, Div Pediat Emergency Med, New York, NY 10027 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Davis Sch Med, Dept Emergency Med, Davis, CA 95616 USA; [Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Davis Sch Med, Dept Pediat, Davis, CA 95616 USA; [Atabaki, Shireen] George Washington Univ, Sch Med, Dept Pediat, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Atabaki, Shireen] George Washington Univ, Sch Med, Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC USA; [Hoyle, John, Jr.] Helen DeVos Childrens Hosp, Div Emergency Med, Grand Rapids, MI USA; [Tunik, Michael G.] NYU, Sch Med, Dept Pediat, New York, NY USA; [Tunik, Michael G.] NYU, Sch Med, Dept Emergency Med, New York, NY USA; [Lichenstein, Richard] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Alpern, Elizabeth] Univ Penn, Sch Med, Div Emergency Med, Philadelphia, PA 19104 USA; [Miskin, Michelle] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA		Dayan, PS (corresponding author), Columbia Univ, Coll Phys & Surg, Morgan Stanley Childrens Hosp, Div Pediat Emergency Med, New York, NY 10027 USA.	psd6@columbia.edu		Alpern, Elizabeth/0000-0001-7887-3563; Tunik, Michael/0000-0002-2368-5933; Holubkov, Richard/0000-0003-0431-3381; Tsung, James/0000-0002-4718-8325	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U03MC00006, U03MC00003, U03MC00001, R40MC02461, U03MC00007, U03MC00008] Funding Source: Medline		Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; National Center for Injury Prevention and Control, TRAUM BRAIN INJ US; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Quayle KS, 1997, PEDIATRICS, V9, pE1; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; Sun BC, 2007, ANN EMERG MED, V49, P325, DOI 10.1016/j.annemergmed.2006.08.032	22	46	48	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	2014	63	6					657	665		10.1016/j.annemergmed.2014.01.009			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	AI7XA	WOS:000337115100006	24559605				2022-02-06	
J	Naidoo, J; De Jesus-Cortes, H; Huntington, P; Estill, S; Morlock, LK; Starwalt, R; Mangano, TJ; Williams, NS; Pieper, AA; Ready, JM				Naidoo, Jacinth; De Jesus-Cortes, Hector; Huntington, Paula; Estill, Sandi; Morlock, Lorraine K.; Starwalt, Ruth; Mangano, Thomas J.; Williams, Noelle S.; Pieper, Andrew A.; Ready, Joseph M.			Discovery of a Neuroprotective Chemical, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with Improved Druglike Properties	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							MOUSE MODEL; AMINOPROPYL CARBAZOLES; PARKINSONS-DISEASE; DERIVATIVES; MPTP; NEUROTOXIN; EFFICACY	(-)-P7C3-S243 is a neuroprotective aminopropyl carbazole with improved druglike properties compared with previously reported compounds in the P7C3 class. It protects developing neurons in a mouse model of hippocampal neurogenesis and protects mature neurons within the substantia nigra in a mouse model of Parkinson's disease. A short, enantioselective synthesis provides the neuroprotective agent in optically pure form. It is nontoxic, orally bioavailable, metabolically stable, and able to cross the blood-brain barrier. As such, it represents a valuable lead compound for the development of drugs to treat neurodegenerative diseases and traumatic brain injury.	[Naidoo, Jacinth; Huntington, Paula; Estill, Sandi; Morlock, Lorraine K.; Starwalt, Ruth; Williams, Noelle S.; Ready, Joseph M.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [De Jesus-Cortes, Hector] Univ Texas SW Med Ctr Dallas, Dept Neurosci, Dallas, TX 75390 USA; [De Jesus-Cortes, Hector; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [De Jesus-Cortes, Hector; Pieper, Andrew A.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA; [De Jesus-Cortes, Hector; Pieper, Andrew A.] Univ Iowa, Dept Vet Affairs, Carver Coll Med, Iowa City, IA 52242 USA; [Mangano, Thomas J.] Univ N Carolina, NIMH, Psychoact Drug Screening Program, Chapel Hill, NC 27599 USA		Pieper, AA (corresponding author), Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.	andrew-pieper@uiowa.edu; joseph.ready@utsouthwestern.edu	De Jesus-Cortes, Hector/ABC-9091-2020; Pieper, Andrew A/R-5552-2016	De Jesus-Cortes, Hector/0000-0001-6983-6963; Pieper, Andrew/0000-0001-6299-6577; Starwalt-Lee, Ruth/0000-0001-7196-012X	Edward N. and Della C. Thome Memorial Foundation; Welch FoundationThe Welch Foundation [I-1612]; NSFNational Science Foundation (NSF) [2012140236-02]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH087986]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH087986] Funding Source: NIH RePORTER	We thank Prof. Jef De Brabander (UT Southwestern) for helpful discussions regarding Cu-catalyzed amination and the NIH's Psychoactive Drug Screening Program at the University of North Carolina. Funding was provided by the Edward N. and Della C. Thome Memorial Foundation and the Welch Foundation (I-1612) (to J.M.R.) and the NSF (2012140236-02) (to H.D.J.-C.). Additional support was received from the NIH (R01 MH087986) to A.A.P. and an unrestricted endowment provided to Steven L. McKnight by an anonymous donor.	Asai-Coakwell M, 2013, HUM MOL GENET, V22, P1432, DOI 10.1093/hmg/dds560; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Bombrun A, 2003, J MED CHEM, V46, P4365, DOI 10.1021/jm034107j; Bordet T, 2010, PHARMACEUTICALS, V3, P345, DOI 10.3390/ph3020345; DAMATO RJ, 1986, SCIENCE, V231, P987, DOI 10.1126/science.3080808; Das P, 2014, TETRAHEDRON, V70, P1017, DOI 10.1016/j.tet.2013.12.021; Das P, 2013, TETRAHEDRON, V69, P7646, DOI 10.1016/j.tet.2013.04.128; De Brabander J. K., COMMUNICATION; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; Elmkaddem MK, 2010, CHEM COMMUN, V46, P925, DOI 10.1039/b916569j; Fukuda T, 2001, NEUROPATHOLOGY, V21, P323, DOI 10.1046/j.1440-1789.2001.00402.x; Hebert LE, 2004, NEUROLOGY, V62, P1645, DOI 10.1212/01.WNL.0000123018.01306.10; Jackson-Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; KLUNDER JM, 1989, J ORG CHEM, V54, P1295, DOI 10.1021/jo00267a014; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; McKnight S. L., 2013, U.S. Patent, Patent No. [8,604,074, 8604074]; McKnight S. L., 2013, U.S. Pat., Patent No. [8,362,277, 8362277]; Naidoo J, 2013, TETRAHEDRON LETT, V54, P4429, DOI 10.1016/j.tetlet.2013.06.024; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Struk L, 2012, SYNTHESIS-STUTTGART, V44, P735, DOI 10.1055/s-0031-1289687; Sunyach C, 2012, NEUROPHARMACOLOGY, V62, P2346, DOI 10.1016/j.neuropharm.2012.02.013; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Walker A.K., 2014, MOL PSYCHIA IN PRESS; Wang CG, 2013, J PHARMACEUT BIOMED, V75, P112, DOI 10.1016/j.jpba.2012.11.018; Zhao XQ, 2009, SYNLETT, P779, DOI 10.1055/s-0028-1087931	28	46	47	2	21	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	MAY 8	2014	57	9					3746	3754		10.1021/jm401919s			9	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy	AH1KN	WOS:000335879100012	24697290	Green Published, hybrid, Green Accepted			2022-02-06	
J	Puvenna, V; Brennan, C; Shaw, G; Yang, C; Marchi, N; Bazarian, JJ; Merchant-Borna, K; Janigro, D				Puvenna, Vikram; Brennan, Chanda; Shaw, Gerald; Yang, Cui; Marchi, Nicola; Bazarian, Jeffrey J.; Merchant-Borna, Kian; Janigro, Damir			Significance of Ubiquitin Carboxy-Terminal Hydrolase L1 Elevations in Athletes after Sub-Concussive Head Hits	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CARBOHYDRATE-DEFICIENT TRANSFERRIN; CEREBROSPINAL-FLUID; BARRIER DISRUPTION; PERIPHERAL MARKERS; BIOMARKER; PROTEIN; S100-BETA; IMPACT; DAMAGE	The impact of sub-concussive head hits (sub-CHIs) has been recently investigated in American football players, a population at risk for varying degrees of post-traumatic sequelae. Results show how sub-CHIs in athletes translate in serum as the appearance of reporters of blood-brain barrier disruption (BBBD), how the number and severity of sub-CHIs correlate with elevations of putative markers of brain injury is unknown. Serum brain injury markers such as UCH-L1 depend on BBBD. We investigated the effects of sub-CHIs in collegiate football players on markers of BBBD, markers of cerebrospinal fluid leakage (serum beta 2-transferrin) and markers of brain damage. Emergency room patients admitted for a clinically-diagnosed mild traumatic brain injury (mTBI) were used as positive controls. Healthy volunteers were used as negative controls. Specifically this study was designed to determine the use of UCH-L1 as an aid in the diagnosis of sub-concussive head injury in athletes. The extent and intensity of head impacts and serum values of S100B, UCH-L1, and beta-2 transferrin were measured pre-and post-game from 15 college football players who did not experience a concussion after a game. S100B was elevated in players experiencing the most sub-CHIs; UCH-L1 levels were also elevated but did not correlate with S100B or sub-CHIs. Beta-2 transferrin levels remained unchanged. No correlation between UCH-L1 levels and mTBI were measured in patients. Low levels of S100B were able to rule out mTBI and high S100B levels correlated with TBI severity. UCH-L1 did not display any interpretable change in football players or in individuals with mild TBI. The significance of UCH-L1 changes in sub-concussions or mTBI needs to be further elucidated.	[Puvenna, Vikram; Brennan, Chanda; Marchi, Nicola; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; [Brennan, Chanda; Marchi, Nicola; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Puvenna, Vikram; Brennan, Chanda; Marchi, Nicola; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA; [Brennan, Chanda; Janigro, Damir] Cleveland State Univ, Dept Clin Bioanalyt Chem, Cleveland, OH 44115 USA; [Bazarian, Jeffrey J.; Merchant-Borna, Kian] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.; Merchant-Borna, Kian] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Shaw, Gerald; Yang, Cui] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA		Janigro, D (corresponding author), Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.	janigrd@ccf.org	, Gerry/X-2377-2019; Marchi, Nicola/J-8607-2016	Marchi, Nicola/0000-0001-9124-0226	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH2TR000491, R21HD057256]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UH3TR000491, UH2TR000491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R41MH093302, R42MH093302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS077236, R01NS078307, R01NS043284] Funding Source: NIH RePORTER	This work was supported by: National Institutes of Health [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH2TR000491, and R21HD057256 to Damir Janigro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arndt T, 2001, CLIN CHEM, V47, P13; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Chan Danny T M, 2004, Asian J Surg, V27, P39, DOI 10.1016/S1015-9584(09)60242-6; Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Fazio V, 2004, ANN THORAC SURG, V78, P46, DOI 10.1016/j.athoracsur.2003.11.042; Fleming M, 2004, J AM BOARD FAM PRACT, V17, P247, DOI 10.3122/jabfm.17.4.247; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Ichikawa T, 2010, BIOCHEM BIOPH RES CO, V391, P852, DOI 10.1016/j.bbrc.2009.11.151; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2003, J NEUROSCI, V23, P1949; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Szabo Gyorgy, 2012, Orv Hetil, V153, P514, DOI 10.1556/OH.2012.29337; Warnecke A, 2004, ARCH OTOLARYNGOL, V130, P1178, DOI 10.1001/archotol.130.10.1178; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	34	46	47	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e96296	10.1371/journal.pone.0096296			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AG9HB	WOS:000335728900045	24806476	Green Submitted, gold, Green Published			2022-02-06	
J	Moore, E; Indig, D; Haysom, L				Moore, Elizabeth; Indig, Devon; Haysom, Leigh			Traumatic Brain Injury, Mental Health, Substance Use, and Offending Among Incarcerated Young People	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						psychological factors; alcohol-related disorders; juvenile delinquency; traumatic brain injury (TBI); cannabis-related disorders	AGE-CHILDREN-PRESENT; AFFECTIVE-DISORDERS; POPULATION; VALIDITY; RELIABILITY; TBI; IDENTIFICATION; SCHIZOPHRENIA; PREVALENCE; PRISONERS	Objective: Despite being at high risk, little is known about traumatic brain injuries (TBIs) among incarcerated young people. This study aims to describe the prevalence of TBI among incarcerated young people and assess the association with mental health, substance use, and offending behaviors. Setting: The 2009 NSW Young People in Custody Health Survey was conducted in 9 juvenile detention centers. Participants: A total of 361 young people agreed to participate, representing 80% of all incarcerated young people. Main Measures: Young people were asked if they ever had a head injury where they became unconscious or "blacked-out." The survey used the Kiddie Schedule for Affective Disorders for Children to assess for psychiatric disorders, the Alcohol Use Disorder Identification Test, and the Severity of Dependence Scale to measure problematic substance use. Results: The sample comprised 88% man, 48% Aboriginal, with an average age of 17 years. One-third (32%) of young people reported ever experiencing a TBI, and 13% reported multiple TBIs. The majority (92%) of "most serious" TBIs were defined as mild, and the most common cause was an assault (62% woman, 34% man). Young people who reported a history of TBI (compared with those reporting no TBI) were significantly more likely to be diagnosed with a mental health disorder, psychological distress, a history of bullying, problematic substance use, participation in fights, and offending behaviors. Reporting multiple (>2) TBIs conferred a higher risk of psychological disorders and problematic substance use. Conclusions: Incarcerated young people have high rates of TBI. Enhanced detection of TBI among incarcerated young people will assist clinicians in addressing the associated psychosocial sequelae.	[Moore, Elizabeth; Indig, Devon] Justice Hlth, Ctr Hlth Res Criminal Justice, Sydney, NSW, Australia; [Haysom, Leigh] Justice Hlth, Adolescent Hlth, Sydney, NSW, Australia; [Indig, Devon] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia		Moore, E (corresponding author), Justice Hlth, Ctr Hlth Res Criminal Justice, Sydney, NSW, Australia.	elizabeth.moore@justicehealth.nsw.gov.au		Indig, Devon/0000-0002-6741-5062	Juvenile Justice; Justice Health; Centre for Aboriginal Health in the New South Wales Ministry of Health; Centre for Aboriginal Health in the New South Wales Ministry of Health, Australia	The authors thank the research team members from Juvenile Justice and Justice Health, and to those other staff who provided operational support for the 2009 Young People in Custody Health Survey (2009 YPICHS). They also thank Juvenile Justice, Justice Health, and Centre for Aboriginal Health in the New South Wales Ministry of Health for funding the study, and to the young people who kindly participated in the YPICHS study.; The study was funded by Juvenile Justice, Justice Health, and Centre for Aboriginal Health in the New South Wales Ministry of Health, Australia.	Australian Bureau of Statistics, 2011, AUSTR NZ STAND OFF C; Axelson D, 2009, SCHEDULE AFFECTIVE D; Bernstein D., 1998, MANUAL CHILDHOOD TRA; Bernstein DP, 1997, J AM ACAD CHILD PSY, V36, P340, DOI 10.1097/00004583-199703000-00012; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Helps Y, 2008, INJURY RES STAT SERI, V45; Hux D, 1998, BRAIN INJURY, V12, P667; IBM, 2010, SPSS STAT VERS 19; Indig D, 2011, 2009 NSW YOUNG PEOPL; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kenny DT, 2007, CRIME JUSTICE B, P107; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lauth B, 2010, NORD J PSYCHIAT, V64, P409, DOI 10.3109/08039481003777484; Martin G, 2006, DRUG ALCOHOL DEPEN, V83, P90, DOI 10.1016/j.drugalcdep.2005.10.014; National Institute of Health Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain Injury, 1998, JAMA-J AM MED ASSOC, V282, P974; Oswald SH, 2010, J PEDIATR PSYCHOL, V35, P462, DOI 10.1093/jpepsy/jsp114; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Richards K, 2010, AUSTR I CRIMINOLOGY, P12; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Tasca M, 2012, VIOLENCE AGAINST WOM, V18, P672, DOI 10.1177/1077801212453985; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Williams H, 2010, TLS-TIMES LIT SUPPL, P20; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697	41	46	46	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					239	247		10.1097/HTR.0b013e31828f9876			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100012	23656964				2022-02-06	
J	Ilie, G; Mann, RE; Boak, A; Adlaf, EM; Hamilton, H; Asbridge, M; Rehm, J; Cusimano, MD				Ilie, Gabriela; Mann, Robert E.; Boak, Angela; Adlaf, Edward M.; Hamilton, Hayley; Asbridge, Mark; Rehm, Juergen; Cusimano, Michael D.			Suicidality, Bullying and Other Conduct and Mental Health Correlates of Traumatic Brain Injury in Adolescents	PLOS ONE			English	Article							RISK BEHAVIOR; CHILDREN; SCHOOL; QUESTIONNAIRE-12; CONCUSSION; SYMPTOMS; VALIDITY	Objective: Our knowledge on the adverse correlates of traumatic brain injuries (TBI), including non-hospitalized cases, among adolescents is limited to case studies. We report lifetime TBI and adverse mental health and conduct behaviours associated with TBI among adolescents from a population-based sample in Ontario. Method and Findings: Data were derived from 4,685 surveys administered to adolescents in grades 7 through 12 as part of the 2011 population-based cross-sectional Ontario Student Drug Use and Health Survey (OSDUHS). Lifetime TBI was defined as head injury that resulted in being unconscious for at least 5 minutes or being retained in the hospital for at least one night, and was reported by 19.5% (95% CI: 17.3,21.9) of students. When holding constant sex, grade, and complex sample design, students with TBI had significantly greater odds of reporting elevated psychological distress (AOR = 1.52), attempting suicide (AOR = 3.39), seeking counselling through a crisis help-line (AOR = 2.10), and being prescribed medication for anxiety, depression, or both (AOR = 2.45). Moreover, students with TBI had higher odds of being victimized through bullying at school (AOR = 1.70), being cyber-bullied (AOR = 2.05), and being threatened with a weapon at school (AOR = 2.90), compared with students who did not report TBI. Students with TBI also had higher odds of victimizing others and engaging in numerous violent as well as nonviolent conduct behaviours. Conclusions: Significant associations between TBI and adverse internalizing and externalizing behaviours were found in this large population-based study of adolescents. Those who reported lifetime TBI were at a high risk for experiencing mental and physical health harms in the past year than peers who never had a head injury. Primary physicians should be vigilant and screen for potential mental heath and behavioural harms in adolescent patients with TBI. Efforts to prevent TBI during adolescence and intervene at an early stage may reduce injuries and comorbid problems in this age group.	[Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada; [Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Mann, Robert E.; Boak, Angela; Adlaf, Edward M.; Hamilton, Hayley; Rehm, Juergen] Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Adlaf, Edward M.; Hamilton, Hayley; Rehm, Juergen; Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Mann, Robert E.; Asbridge, Mark] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada; [Mann, Robert E.; Asbridge, Mark] Dalhousie Univ, Dept Emergency Med, Halifax, NS, Canada		Ilie, G (corresponding author), St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	ilieg@smh.ca	Ilie, Gabriela/AAM-9122-2021; Cusimano, Michael/X-4059-2019; Ilie, Gabriela/J-6066-2014	Ilie, Gabriela/0000-0002-1602-6374	Canadian Institute of Health Research (CIHR)'s Team Grant in Traumatic Brain Injury and ViolenceCanadian Institutes of Health Research (CIHR) [FRN: 103946]; Ontario Neurotrauma Foundation; AUTO21, a member of the Networks of Centres of Excellence program; Natural Sciences and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada (NSERC); Social Sciences and Humanities Research CouncilSocial Sciences and Humanities Research Council of Canada (SSHRC); Industry Canada; Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario	This work was financially supported by the Canadian Institute of Health Research (CIHR)'s Team Grant in Traumatic Brain Injury and Violence (FRN: 103946) and by the Ontario Neurotrauma Foundation. Additional funding was obtained from a grant from AUTO21, a member of the Networks of Centres of Excellence program that is administered and funded by the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, in partnership with Industry Canada, and ongoing funding support from the Ontario Ministry of Health and Long-Term Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, JAMA-J AM MED ASSOC, V308, P2327; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Dicker BG, 1989, HEAD TRAUMA REHABIL, V4, P73; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Due P, 2005, EUR J PUBLIC HEALTH, V15, P128, DOI 10.1093/eurpub/cki105; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Finkelstein E., 2006, INCIDENCE EC BURDEN; Frances A, 2000, DSM 4 CLASSIFICATION; French DJ, 2004, EUR CHILD ADOLES PSY, V13, P1, DOI 10.1007/s00787-004-0345-7; Gainer RB, ATTEMPTED SUICIDE IS; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hux D, 1998, BRAIN INJURY, V12, P667; Ilie G, MENTAL HLTH SU UNPUB; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Laird RD, 2005, DEV PSYCHOPATHOL, V17, P127, DOI 10.1017/S0954579405050078; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; May A, 2011, ASSESSMENT, V18, P379, DOI 10.1177/1073191110374285; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Paglia-Boak A., 2011, CAMH RES DOCUMENT SE, V32; Pickett W, 2002, ARCH PEDIAT ADOL MED, V156, P786, DOI 10.1001/archpedi.156.8.786; Public Health Canada, 2011, BULL PREV SCH; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Tait RJ, 2003, AUST NZ J PSYCHIAT, V37, P374, DOI 10.1046/j.1440-1614.2003.01133.x; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Tate RL, 2004, BRAIN INJURY OUTCOME; Tonks J, 2010, NEUROPSYCHOL REHABIL, V20, P922, DOI 10.1080/09602011.2010.519209; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017	37	46	46	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2014	9	4							e94936	10.1371/journal.pone.0094936			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5PW	WOS:000336922600110	24736613	Green Published, gold			2022-02-06	
J	Chen, W; Qi, J; Feng, F; Wang, MD; Bao, G; Wang, T; Xiang, M; Xie, WF				Chen, Wei; Qi, Jun; Feng, Feng; Wang, Mao-de; Bao, Gang; Wang, Tuo; Xiang, Mu; Xie, Wan-fu			Neuroprotective effect of allicin against traumatic brain injury via Akt/endothelial nitric oxide synthase pathway-mediated anti-inflammatory and anti-oxidative activities	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Endothelial nitric oxide synthase; Akt; Inflammatory cytokines	CLOSED-HEAD INJURY; SIGNALING PATHWAYS; OXIDATIVE STRESS; CLINICAL-TRIALS; PROTEIN-KINASE; IN-VITRO; CELLS; INFLAMMATION; ACTIVATION; ISCHEMIA	Allicin, one of the main biologically active compounds derived from garlic, has been shown to exert various anti-oxidative and anti-inflammatory activities in in vitro and in vivo studies. Here, we sought to investigate the potential neuroprotective effects of allicin against traumatic brain injury (TBI) in rats. We found that allicin treatment (10 and 50 mg/kg, not 1 mg/kg) significantly reduced brain edema and motor functional deficits, as well as apoptotic neuronal cell death in injured cortex. These protective effects could be observed even if the administration was delayed to 4 h after injury. Moreover, allicin treatment decreased the expression levels of MDA and protein carbonyl, preserved the endogenous antioxidant enzyme activities, and suppressed the expression of inflammatory cytokines. The results of Western blot analysis showed that allicin increased the phosphorylation of Akt and endothelial nitric oxide synthase (eNOS). Blocking Akt/eNOS pathway activation by specific inhibitor LY294002 (10 mu L, 10 mmol/L) or L-NIO (0.5 mg/kg) partly reversed the protective effects of allicin and its anti-inflammatory activities. The allicin induced anti-oxidative activity was partly prevented by LY294002, but not L-NIO. In summary, our data strongly suggested that allicin treatment at an appropriate dose can exert protective effect against TBI through Akt/eNOS pathway-mediated anti-inflammatory and anti-oxidative activities. (C) 2014 Elsevier Ltd. All rights reserved.	[Chen, Wei; Wang, Mao-de; Bao, Gang; Wang, Tuo; Xie, Wan-fu] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shaanxi, Peoples R China; [Qi, Jun] Shannxi Blood Ctr, Inst Xian Blood Bank, Xian 710061, Shaanxi, Peoples R China; [Feng, Feng; Xiang, Mu] Fourth Mil Med Univ, Xijing Hosp, Dept Physiotherapy & Rehabil, Xian 710032, Shaanxi, Peoples R China		Xie, WF (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shaanxi, Peoples R China.	xijiaodaxiewanfu@163.com		Qi, Jun/0000-0002-8795-3140			Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bayston R, 2000, LANCET, V355, P1813, DOI 10.1016/S0140-6736(00)02275-3; BOLTON S, 1982, AM PHARM, V22, P40, DOI 10.1016/S0160-3450(16)31735-4; Chen T, 2013, CELL SIGNAL, V25, P2863, DOI 10.1016/j.cellsig.2013.09.004; Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055601; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chung LY, 2006, J MED FOOD, V9, P205, DOI 10.1089/jmf.2006.9.205; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fleming I, 2010, PFLUG ARCH EUR J PHY, V459, P793, DOI 10.1007/s00424-009-0767-7; Forstermann U, 2011, BRIT J PHARMACOL, V164, P213, DOI 10.1111/j.1476-5381.2010.01196.x; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gajkowska B, 1997, FOLIA NEUROPATHOL, V35, P171; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Gruhlke MCH, 2010, FREE RADICAL BIO MED, V49, P1916, DOI 10.1016/j.freeradbiomed.2010.09.019; He YL, 2012, BRAIN RES, V1433, P127, DOI 10.1016/j.brainres.2011.11.027; Li XH, 2010, NEUROSCIENCES, V15, P237; Liu C, 2010, J NUTR BIOCHEM, V21, P1238, DOI 10.1016/j.jnutbio.2009.11.001; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lundblad C, 2009, J NEUROTRAUM, V26, P1953, DOI 10.1089/neu.2009.0955; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nishio S, 1997, ACT NEUR S, V70, P84; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Ortiz PA, 2003, ACTA PHYSIOL SCAND, V179, P107, DOI 10.1046/j.1365-201X.2003.01207.x; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Peng XQ, 2010, ACTA PHARMACOL SIN, V31, P175, DOI 10.1038/aps.2009.190; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Srivastava K, 2012, CELL MOL NEUROBIOL, V32, P319, DOI 10.1007/s10571-011-9777-z; Wu QQ, 2013, EUR J PHARMACOL, V707, P87, DOI 10.1016/j.ejphar.2013.03.027; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	44	46	52	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	MAR	2014	68						28	37		10.1016/j.neuint.2014.01.015			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AF8SF	WOS:000334985200004	24530793				2022-02-06	
J	Tate, DF; York, GE; Reid, MW; Cooper, DB; Jones, L; Robin, DA; Kennedy, JE; Lewis, J				Tate, D. F.; York, G. E.; Reid, M. W.; Cooper, D. B.; Jones, L.; Robin, D. A.; Kennedy, J. E.; Lewis, J.			Preliminary findings of cortical thickness abnormalities in blast injured service members and their relationship to clinical findings	BRAIN IMAGING AND BEHAVIOR			English	Article						TBI; Blast Injury; Mild TBI; Cortical thickness; Cognition; Behavior; FreeSurfer; MANGO	TRAUMATIC BRAIN-INJURY; LONG-TERM; TINNITUS; DYSFUNCTION; ASSOCIATION; CONCUSSION; CAVITATION; MECHANISM; TRANSIENT; SYMPTOMS	Though cortical abnormalities have been demonstrated in moderate and severe traumatic brain injured (TBI) patients, there have been no studies examining cortical changes following blast related mild TBI (mTBI). The purpose of this study was to determine the effects and functional relevance of blast mTBI on cortical thickness in a small cohort of carefully screened blast injured US Service Members (SM). Twelve SM with mTBI acquired through blast injury were compared to 11 demographically matched control SM without TBI. Both mTBI and control participants were active duty and had completed a combat deployment. Subjects underwent MRI examination and the T1 weighted anatomic images were processed using the FreeSurfer suite of tools. Cortical thickness maps were compared between groups and examined for relationships with time since injury (TSI). Utilizing a large database of functional imaging results (BrainMap), significant regions of interest (ROI) were used to determine the behavioral profiles most consistently associated with the specific ROI. In addition, clinical variables were examined as part of post-hoc analysis of functional relevance. Group comparisons controlling for age demonstrated several significant clusters of cortical thinning for the blast injured SM. After multiple comparisons correction (False Discovery Rate (FDR)), two left hemisphere clusters remained significant (left superior temporal (STG) and frontal (SFG) gyri). No clusters were significantly correlated with TSI after FDR correction. Behavioral analysis for the STG and SFG clusters demonstrated three significant behavioral/cognitive sub-domains, each associated with audition and language. Blast injured SMs demonstrated distinct areas of cortical thinning in the STG and SFG. These areas have been previously shown to be associated with audition and language. Post-hoc analyses of clinical records demonstrated significant abnormal audiology reports for the blast injured SM suggesting that the thinning in these ROIs might be related to injury to the external auditory system rather than direct injury to the brain from the blast. It is clear that additional replication is needed in much larger cohorts. Importantly, the combination of imaging tools and methods in this study successfully demonstrated the potential to define unique ROIs and functional correlates that can be used to design future studies.	[Tate, D. F.; Reid, M. W.; Cooper, D. B.; Kennedy, J. E.] Inc San Antonio Mil Med Ctr SAMMC, Contractor Henry M Jackson Fdn Adv Mil Med, Def & Vet Brain Injury Ctr, San Antonio, TX 78234 USA; [York, G. E.] San Antonio Mil Med Ctr, LTC, MC, San Antonio, TX USA; [Jones, L.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Robin, D. A.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Lewis, J.] Air Force Med Support Agcy, LtCol, MC, Falls Church, VA USA		Tate, DF (corresponding author), Inc San Antonio Mil Med Ctr SAMMC, Contractor Henry M Jackson Fdn Adv Mil Med, Def & Vet Brain Injury Ctr, San Antonio, TX 78234 USA.	dftatephd@mac.com	Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; Jones, Lyell/0000-0002-5851-8705	 [W91YTZ-12-C-0132]	The views, opinions and/or findings contained in this manuscript are those of the authors and should not be construed as an official Department of Defense or Veterans Affairs position, policy or decision unless so designated by other documentation. Research on this article was done under Contract #W91YTZ-12-C-0132. In the conduct of this research, the investigators adhered to the policies regarding the protection of human subjects as prescribe by Code of Federal Regulations (CFR) Title 45, Volume 1, Part 46; Title 32, Chapter1, Part 219; and Title 21, Chapter 1, Part 50 (Protection of Human Subjects).	Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Brenner Lisa A, 2012, Front Neurol, V3, P31, DOI 10.3389/fneur.2012.00031; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Engvig A, 2010, NEUROIMAGE, V52, P1667, DOI 10.1016/j.neuroimage.2010.05.041; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Haier Richard J, 2009, BMC Res Notes, V2, P174, DOI 10.1186/1756-0500-2-174; Lancaster JL, 2012, FRONT NEUROINFORM, V6, DOI 10.3389/fninf.2012.00023; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lanting CP, 2009, HEARING RES, V255, P1, DOI 10.1016/j.heares.2009.06.009; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Martensson J, 2012, NEUROIMAGE, V63, P240, DOI 10.1016/j.neuroimage.2012.06.043; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Ramasamy A, 2011, J TRAUMA, V71, P1694, DOI 10.1097/TA.0b013e318227a999; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Saunders JC, 2007, J COMMUN DISORD, V40, P313, DOI 10.1016/j.jcomdis.2007.03.006; Schecklmann M, 2013, BRAIN STRUCT FUNCT, V218, P1061, DOI 10.1007/s00429-013-0520-z; Schneider P, 2009, NEUROIMAGE, V45, P927, DOI 10.1016/j.neuroimage.2008.12.045; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Sylvia FR, 2001, MIL MED, V166, P918, DOI 10.1093/milmed/166.10.918; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Yang S, 2012, J NEUROPHYSIOL, V108, P1567, DOI 10.1152/jn.00371.2012; Yue Q, 2013, NEUROSCIENCE, V237, P87, DOI 10.1016/j.neuroscience.2012.12.067	37	46	47	2	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	MAR	2014	8	1					102	109		10.1007/s11682-013-9257-9			8	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AB2QD	WOS:000331636300010	24100952	Green Accepted			2022-02-06	
J	Nadrop, B; Soreq, H				Nadrop, Bettina; Soreq, Hermona			Predicted overlapping microRNA regulators of acetylcholine packaging and degradation in neuroinflammation-related disorders	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						acetlycholinesterase; butyrylcholinesterase; choline acetyltransferase; vesicular acetylcholine transporter; microRNA-186; cholinergic signaling; primate-specific microRNAs	INFLAMMATORY-BOWEL-DISEASE; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; BLOOD MONONUCLEAR-CELLS; CHOLINERGIC GENE LOCUS; TRAUMATIC BRAIN-INJURY; HEART-FAILURE; ALZHEIMERS-DISEASE; PERIPHERAL-BLOOD; STROKE PATIENTS	MicroRNAs (miRNAs) can notably control many targets each and regulate entire cellular pathways, but whether miRNAs can regulate complete neurotransmission processes is largely unknown. Here, we report that miRNAs with complementary sequence motifs to the key genes involved in acetylcholine (ACh) synthesis and/or packaging show massive overlap with those regulating ACh degradation. To address this topic, we first searched for miRNAs that could target the 3'-untranslated regions of the choline acetyltransferase (ChAT) gene that controls ACh synthesis; the vesicular ACh transporter (VAChT), encoded from an intron in the ChAT gene and the ACh hydrolyzing genes acetyl- and/or butyrylcholinesterase (AChE, BChE). Intriguingly, we found that many of the miRNAs targeting these genes are primate-specific, and that changes in their levels associate with inflammation, anxiety, brain damage, cardiac, neurodegenerative, or pain-related syndromes. To validate the in vivo relevance of this dual interaction, we selected the evolutionarily conserved miR-186, which targets both the stress-inducible soluble "readthrough" variant AChE-R and the major peripheral cholinesterase BChE. We exposed mice to predator scent stress and searched for potential associations between consequent changes in their miR-186, AChE-R, and BChE levels. Both intestinal miR-186 as well as BChE and AChE-R activities were conspicuously elevated 1 week post-exposure, highlighting the previously unknown involvement of miR-186 and BChE in psychological stress responses. Overlapping miRNA regulation emerges from our findings as a recently evolved surveillance mechanism over cholinergic neurotransmission in health and disease; and the corresponding miRNA details and disease relevance may serve as a useful resource for studying the molecular mechanisms underlying this surveillance.	[Soreq, Hermona] Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; [Soreq, Hermona] Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, Ctr Bioengn, IL-91904 Jerusalem, Israel		Soreq, H (corresponding author), Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, Dept Biol Chem, Edmond J Safra Campus, IL-91904 Jerusalem, Israel.	hermona.soreq@mail.huji.ac.il		Nadorp, Bettina/0000-0003-1974-8425; Soreq, Hermona/0000-0002-0955-526X	European Research CouncilEuropean Research Council (ERC)European Commission [321501]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602133]; Hebrew University's Bioengineering program	The authors are grateful to Dr. Shani Shenhar-Tsarfaty, Mr. Yochai Wolf and Mr. Uriya Bekenstein, Jerusalem for helpful advice and discussions. This study was supported by a European Research Council Advanced Research Award 321501(to Hermona Soreq) and The European Commission FP-7 Health-2013-Innovation grant number 602133(to Hermona Soreq). Bettina Nadorp is an incumbent of a PhD fellowship from The Hebrew University's Bioengineering program.	Abdellatif M, 2011, PEDIATR CARDIOL, V32, P311, DOI 10.1007/s00246-010-9882-7; Arbel Y, 2014, MOL MED, V20, P38, DOI 10.2119/molmed.2013.00139; Archacki SR, 2003, PHYSIOL GENOMICS, V15, P65, DOI 10.1152/physiolgenomics.00181.2002; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Ben Assayag E, 2010, MOL MED, V16, P278, DOI 10.2119/molmed.2010.00015; Berson A, 2012, EMBO MOL MED, V4, P730, DOI 10.1002/emmm.201100995; Bhattacharyya M, 2013, MOL BIOSYST, V9, P457, DOI 10.1039/c2mb25434d; Bostjancic E, 2009, DIS MARKERS, V27, P255, DOI 10.3233/DMA-2009-0671; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen YW, 2012, INT J MOL MED, V29, P601, DOI 10.3892/ijmm.2012.894; Chen-Plotkin AS, 2012, J NEUROSCI, V32, P11213, DOI 10.1523/JNEUROSCI.0521-12.2012; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Danielsson K, 2012, J ORAL PATHOL MED, V41, P90, DOI 10.1111/j.1600-0714.2011.01084.x; Diaz-Prado S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-144; Dickinson BA, 2013, EUR J HEART FAIL, V15, P650, DOI 10.1093/eurjhf/hft018; Doeppner TR, 2013, ACTA NEUROPATHOL, V126, P251, DOI 10.1007/s00401-013-1142-5; Dutta R, 2013, ANN NEUROL, V73, P637, DOI 10.1002/ana.23860; Eiden LE, 1998, J NEUROCHEM, V70, P2227; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Eskildsen TV, 2013, INT J MOL SCI, V14, P11190, DOI 10.3390/ijms140611190; Etoh M, 2013, ARCH DERMATOL RES, V305, P9, DOI 10.1007/s00403-012-1287-4; Goren Y, 2012, EUR J HEART FAIL, V14, P147, DOI 10.1093/eurjhf/hfr155; Gupta MK, 2013, J MOL CELL CARDIOL, V62, P131, DOI 10.1016/j.yjmcc.2013.05.011; Hanieh H, 2013, EUR J IMMUNOL, V43, P2771, DOI 10.1002/eji.201343486; Hanin G, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00028; Hoekstra M, 2010, BIOCHEM BIOPH RES CO, V394, P792, DOI 10.1016/j.bbrc.2010.03.075; Iborra M, 2013, CLIN EXP IMMUNOL, V173, P250, DOI 10.1111/cei.12104; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Imai S, 2011, J NEUROSCI, V31, P15294, DOI 10.1523/JNEUROSCI.0921-11.2011; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Jin W, 2012, J BIOL CHEM, V287, P15672, DOI 10.1074/jbc.M111.322669; Junn E, 2009, P NATL ACAD SCI USA, V106, P13052, DOI 10.1073/pnas.0906277106; Kang JG, 2011, J PATHOL, V225, P378, DOI 10.1002/path.2962; Katare R, 2011, CIRC RES, V109, P894, DOI 10.1161/CIRCRESAHA.111.251546; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Keller A, 2011, NAT METHODS, V8, P841, DOI [10.1038/NMETH.1682, 10.1038/nmeth.1682]; Khaitovich P, 2006, NAT REV GENET, V7, P693, DOI 10.1038/nrg1940; Kress M, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00033; Kynast KL, 2013, PAIN, V154, P368, DOI 10.1016/j.pain.2012.11.010; Lau P, 2013, EMBO MOL MED, V5, P1613, DOI 10.1002/emmm.201201974; Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649; Lerman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020916; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Lukiw WJ, 2012, MOL NEUROBIOL, V46, P11, DOI 10.1007/s12035-012-8234-4; Lungu G, 2013, NEUROSCI LETT, V553, P153, DOI 10.1016/j.neulet.2013.08.001; Lupini Laura, 2013, Frontiers in Genetics, V4, P64, DOI 10.3389/fgene.2013.00064; Lusardi TA, 2010, J CEREBR BLOOD F MET, V30, P744, DOI 10.1038/jcbfm.2009.253; Maharshak N, 2013, INFLAMM BOWEL DIS, V19, P1346, DOI 10.1097/MIB.0b013e318281f47d; Manca S, 2011, EXP DERMATOL, V20, P932, DOI 10.1111/j.1600-0625.2011.01359.x; Martino S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/654346; Matsukawa T, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4164; Matsumoto S, 2013, CIRC RES, V113, P322, DOI 10.1161/CIRCRESAHA.113.301209; MCGEER PL, 1984, NEUROLOGY, V34, P741, DOI 10.1212/WNL.34.6.741; Meder B, 2011, BASIC RES CARDIOL, V106, P13, DOI 10.1007/s00395-010-0123-2; Meshorer E, 2005, MOL PSYCHIATR, V10, P985, DOI 10.1038/sj.mp.4001735; Meshorer E, 2006, TRENDS NEUROSCI, V29, P216, DOI 10.1016/j.tins.2006.02.005; Monastyrskaya K, 2013, AM J PATHOL, V182, P431, DOI 10.1016/j.ajpath.2012.10.020; Muinos-Gimeno M, 2009, HUM MUTAT, V30, P1062, DOI 10.1002/humu.21005; Murata K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069118; Murata K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3013; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Oliveira-Carvalho V, 2013, MOL BIOL REP, V40, P2663, DOI 10.1007/s11033-012-2352-y; Oshikawa Y, 2013, ACTA DERM-VENEREOL, V93, P273, DOI 10.2340/00015555-1459; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Paraskevi A, 2012, J CROHNS COLITIS, V6, P900, DOI 10.1016/j.crohns.2012.02.006; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Rink C, 2011, PHYSIOL GENOMICS, V43, P521, DOI 10.1152/physiolgenomics.00158.2010; Sakai A, 2013, BRAIN, V136, P2738, DOI 10.1093/brain/awt191; Santini P, 2014, RHEUMATOL INT, V34, P711, DOI 10.1007/s00296-013-2754-8; Schipper HM, 2007, GENE REGUL SYST BIO, V1, P263; Shaked I, 2009, IMMUNITY, V31, P965, DOI 10.1016/j.immuni.2009.09.019; Shaltiel G, 2013, BRAIN STRUCT FUNCT, V218, P59, DOI 10.1007/s00429-011-0376-z; Shenhar-Tsarfaty S, 2013, EUR J NEUROL, V20, P891, DOI 10.1111/ene.12074; Shenhar-Tsarfaty S, 2014, J MOL NEUROSCI, V53, P298, DOI 10.1007/s12031-013-0176-4; Sklan EH, 2004, P NATL ACAD SCI USA, V101, P5512, DOI 10.1073/pnas.0307659101; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sun Y, 2013, CNS NEUROSCI THER, V19, P813, DOI 10.1111/cns.12142; Takagi T, 2010, J GASTROEN HEPATOL, V25, pS129, DOI 10.1111/j.1440-1746.2009.06216.x; Tan KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007689; Tracey KJ, 2010, NAT IMMUNOL, V11, P561, DOI 10.1038/ni0710-561; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; Villa C, 2011, REJUV RES, V14, P275, DOI 10.1089/rej.2010.1123; Voellenkle C, 2010, PHYSIOL GENOMICS, V42, P420, DOI 10.1152/physiolgenomics.00211.2009; Wang HJ, 2012, J TRAUMA ACUTE CARE, V73, P850, DOI 10.1097/TA.0b013e31825a7560; Wang HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038885; Wang J, 2012, J CELL MOL MED, V16, P2150, DOI 10.1111/j.1582-4934.2012.01523.x; Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0; Wong HKA, 2013, HUM MOL GENET, V22, P3077, DOI 10.1093/hmg/ddt164; Wong MS, 2013, CELL REP, V3, P1028, DOI 10.1016/j.celrep.2013.03.011; Xie YF, 2011, INT J ORAL SCI, V3, P125, DOI 10.4248/IJOS11046; Xu N, 2011, J INVEST DERMATOL, V131, P1521, DOI 10.1038/jid.2011.55; Yu SQ, 2011, AM J RHINOL ALLERGY, V25, pE242, DOI 10.2500/ajra.2011.25.3682; Yuan M, 2013, ATHEROSCLEROSIS, V226, P447, DOI 10.1016/j.atherosclerosis.2012.11.026; Zhang HB, 2013, CARDIOVASC RES, V98, P269, DOI 10.1093/cvr/cvt030; Zhu HY, 2012, CARDIOVASC RES, V94, P284, DOI 10.1093/cvr/cvr291; Zimmerman G, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.4	102	46	46	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	FEB 10	2014	7								9	10.3389/fnmol.2014.00009			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AZ0UN	WOS:000347960400002	24574962	Green Published, gold			2022-02-06	
J	Goddard, L; Dritschel, B; Robinson, S; Howlin, P				Goddard, Lorna; Dritschel, Barbara; Robinson, Sally; Howlin, Patricia			Development of autobiographical memory in children with autism spectrum disorders: Deficits, gains, and predictors of performance	DEVELOPMENT AND PSYCHOPATHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; EPISODIC MEMORY; EMOTION RECOGNITION; OVERGENERAL MEMORY; ASPERGER-SYNDROME; SELF-RECOGNITION; ADULTS; AMNESIA; MIND	Autobiographical memory (AM) was assessed in 63 children (aged 8-17 years) with an autism spectrum disorder (ASD) and compared with 63 typically developing children matched for age, gender, IQ, and verbal ability. A range of methodologies was employed for eliciting past experience with particular focus on the ability to recall (a) specific events, (b) the recent and remote past, and (c) semantic versus episodic memories across different lifetime periods. Results indicated that the ASD group manifested difficulties in retrieving specific memories to word cues and had poorer access to the remote past. Deficits were found in the context of intact recent memory and preserved general memory abilities, with some impairment of visual memory. Problems in retrieving episodic and semantic AMs across the life span were also evident. Qualitative analysis of memory reports suggested that the ASD group was less likely to refer to emotion in their remote memories but more likely to describe emotions in their recent memories. Important predictors of AM performance in the ASD group were central executive abilities, in particular cognitive flexibility and verbal fluency.	[Goddard, Lorna] Univ London, London SE14 6NW, England; [Dritschel, Barbara] Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland; [Robinson, Sally; Howlin, Patricia] Kings Coll London, London WC2R 2LS, England		Goddard, L (corresponding author), Univ London, Dept Psychol, London SE14 6NW, England.	l.goddard@gold.ac.uk	Howlin, Patricia/A-7622-2011; Goddard, Lorna/R-8635-2016	Goddard, Lorna/0000-0001-8884-3253; Howlin, Patricia/0000-0002-1804-6053; Dritschel, Barbara/0000-0002-0909-6323	ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E004954/1] Funding Source: UKRI; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E004954/1] Funding Source: researchfish		Anderson DK, 2009, J ABNORM CHILD PSYCH, V37, P1019, DOI 10.1007/s10802-009-9326-0; Baron-Cohen S, 2001, INT REV RES MENT RET, V23, P169; Bekerian D., 2001, 3 INT C MEM VAL SPAI; Ben Shalom D, 2003, CORTEX, V39, P1129; Berument SK, 1999, BRIT J PSYCHIAT, V175, P444, DOI 10.1192/bjp.175.5.444; Bowler DM, 2004, J AUTISM DEV DISORD, V34, P533, DOI 10.1007/s10803-004-2548-7; Bowler DM, 2000, J AUTISM DEV DISORD, V30, P295, DOI 10.1023/A:1005575216176; Brewer W.F., 1986, AUTOBIOGRAPHICAL MEM, P25; BRITTLEBANK AD, 1993, BRIT J PSYCHIAT, V162, P118, DOI 10.1192/bjp.162.1.118; Brown BT, 2012, J AUTISM DEV DISORD, V42, P441, DOI 10.1007/s10803-011-1246-5; Bruck M, 2007, DEV PSYCHOPATHOL, V19, P73, DOI 10.1017/S0954579407070058; Burley, 1997, BRIT PICTURE VOCABUL; Cohen M.J., 1997, CHILDRENS MEMORY SCA; COLTHEART M, 1981, Q J EXP PSYCHOL-A, V33, P497, DOI 10.1080/14640748108400805; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Conway MA, 2001, J MEM LANG, V45, P493, DOI 10.1006/jmla.2001.2781; Conway MA, 2000, INT J PSYCHOL, V35, P113; Crane L, 2008, J AUTISM DEV DISORD, V38, P498, DOI 10.1007/s10803-007-0420-2; Crane L, 2010, J AUTISM DEV DISORD, V40, P383, DOI 10.1007/s10803-009-0875-4; Crane L, 2009, MEMORY, V17, P557, DOI 10.1080/09658210902960211; CROVITZ HF, 1974, B PSYCHONOMIC SOC, V4, P517; Culbertson W. C., 2005, TOWER LONDON DX; Dalgleish T, 2007, J EXP PSYCHOL GEN, V136, P23, DOI 10.1037/0096-3445.136.1.23; Dissanayake C, 2010, AUTISM, V14, P495, DOI 10.1177/1362361310366569; Dritschel B, 2010, AUTISM, V14, P509, DOI 10.1177/1362361310368407; Fivush R, 2006, BRIT J DEV PSYCHOL, V24, P235, DOI 10.1348/026151005X57747; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Gilboa A, 2004, CEREB CORTEX, V14, P1214, DOI 10.1093/cercor/bhh082; Goddard L, 1996, J ABNORM PSYCHOL, V105, P609, DOI 10.1037/0021-843X.105.4.609; Goddard L, 2007, J AUTISM DEV DISORD, V37, P291, DOI 10.1007/s10803-006-0168-0; Goldman S, 2008, J AUTISM DEV DISORD, V38, P1982, DOI 10.1007/s10803-008-0588-0; Gunter HL, 2002, J AUTISM DEV DISORD, V32, P263, DOI 10.1023/A:1016326701439; Heaton R. K., 2003, WCST 64 COMPUTERIZED; Heeren A, 2009, BEHAV RES THER, V47, P403, DOI 10.1016/j.brat.2009.01.017; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Hill EL, 2004, TRENDS COGN SCI, V8, P26, DOI 10.1016/j.tics.2003.11.003; Hill EL, 2006, NEUROPSYCHOLOGIA, V44, P2822, DOI 10.1016/j.neuropsychologia.2006.06.007; Howe ML, 1997, PSYCHOL REV, V104, P499, DOI 10.1037/0033-295X.104.3.499; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Klein SB, 1999, SOC COGNITION, V17, P413, DOI 10.1521/soco.1999.17.4.413; Kleinhans NM, 2010, NEUROPSYCHOLOGIA, V48, P3665, DOI 10.1016/j.neuropsychologia.2010.07.022; Lee LC, 2007, RES AUTISM SPECT DIS, V1, P126, DOI 10.1016/j.rasd.2006.08.004; Lee SJ, 2009, PSYCHIAT INVEST, V6, P156, DOI 10.4306/pi.2009.6.3.156; Lind SE, 2009, J AUTISM DEV DISORD, V39, P643, DOI 10.1007/s10803-008-0670-7; Losh M, 2003, J AUTISM DEV DISORD, V33, P239, DOI 10.1023/A:1024446215446; McDowd J, 2011, NEUROPSYCHOLOGY, V25, P210, DOI 10.1037/a0021531; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Millward C, 2000, J AUTISM DEV DISORD, V30, P15, DOI 10.1023/A:1005455926727; Mitchell P, 2008, J AUTISM DEV DISORD, V38, P1591, DOI 10.1007/s10803-007-0530-x; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; NELSON K, 1993, PSYCHOL SCI, V4, P7, DOI 10.1111/j.1467-9280.1993.tb00548.x; NELSON K, 2000, OXFORD HDB MEMORY, P283; O'Shea AG, 2005, DEV NEUROPSYCHOL, V27, P337, DOI 10.1207/s15326942dn2703_3; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1081, DOI 10.1111/j.1469-7610.1991.tb00351.x; Perner J, 2005, SCIENCE, V308, P214, DOI 10.1126/science.1111656; Perner J, 2007, INFANT CHILD DEV, V16, P471, DOI 10.1002/icd.517; Peterson C, 2011, CHILD DEV, V82, P1092, DOI 10.1111/j.1467-8624.2011.01597.x; Rabbit P., 1988, PRACTICAL ASPECTS ME, V1, P301; Raes F, 2010, J CLIN CHILD ADOLESC, V39, P276, DOI 10.1080/15374410903532684; Reese E, 1999, NARRAT INQ, V9, P215, DOI 10.1075/ni.9.2.02ree; Robinson S, 2009, BRAIN COGNITION, V71, P362, DOI 10.1016/j.bandc.2009.06.007; Rutter M., 2003, AUTISTIC DIAGNOSTIC; Rutter M., 2003, SOCIAL COMMUNICATION; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; St Jacques PL, 2007, MEMORY, V15, P129, DOI 10.1080/09658210601119762; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Valentino K, 2012, J CLIN CHILD ADOLESC, V41, P491, DOI 10.1080/15374416.2012.660689; Wechsler D., 2011, WECHSLER ABBREVIATED; WelchRoss MK, 1997, DEV PSYCHOL, V33, P618, DOI 10.1037/0012-1649.33.4.618; Williams D, 2010, AUTISM, V14, P474, DOI 10.1177/1362361310366314; WILLIAMS JMG, 1992, NATO ADV SCI INST SE, V65, P391; Williams JMG, 1999, Q J EXP PSYCHOL-A, V52, P555, DOI 10.1080/027249899390963	75	46	47	0	33	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0954-5794	1469-2198		DEV PSYCHOPATHOL	Dev. Psychopathol.	FEB	2014	26	1					215	228		10.1017/S0954579413000904			14	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	AD0UV	WOS:000332950500015	24284059	Green Submitted, Green Accepted			2022-02-06	
J	Axelrod, BN; Meyers, JE; Davis, JJ				Axelrod, Bradley N.; Meyers, John E.; Davis, Jeremy J.			Finger Tapping Test Performance as a Measure of Performance Validity	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance validity; Motor testing; Effort testing	TRAUMATIC BRAIN-INJURY; COMPLEX FIGURE TEST; SYMPTOM VALIDITY; SUSPECT EFFORT; RESPONSE BIAS; NEUROPSYCHOLOGICAL ASSESSMENT; CLASSIFICATION ACCURACY; DISABILITY CLAIMANTS; CROSS-VALIDATION; HEAD-INJURY	The Finger Tapping Test (FTT) has been presented as an embedded measure of performance validity in most standard neuropsychological evaluations. The present study evaluated the utility of three different scoring systems intended to detect invalid performance based on FTT. The scoring systems were evaluated in neuropsychology cases from clinical and independent practices, in which credible performance was determined based on passing all performance validity measures or failing two or more validity indices. Each FTT scoring method presented with specificity rates at approximately 90% and sensitivity of slightly more than 40%. When suboptimal performance was based on the failure of any of the three scoring methods, specificity was unchanged and sensitivity improved to 50%. The results are discussed in terms of the utility of combining multiple scoring measures for the same test as well as benefits of embedded measures administered over the duration of the evaluation.	[Axelrod, Bradley N.] John D Dingell DVAMC, Psychol Sect, Detroit, MI 48201 USA; [Meyers, John E.] Meyers Neuropsychol Serv, Mililani, HI USA; [Davis, Jeremy J.] Univ Utah, Sch Med, Salt Lake City, UT USA		Axelrod, BN (corresponding author), John D Dingell DVAMC, Psychol Sect, 4646 John R, Detroit, MI 48201 USA.	bradley.axelrod@va.gov					Arentsen TJ, 2013, CLIN NEUROPSYCHOL, V27, P1060, DOI 10.1080/13854046.2013.803603; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Davis JJ, 2013, J CLIN EXP NEUROPSYC, V35, P413, DOI 10.1080/13803395.2013.781134; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P1397, DOI 10.1080/13854046.2012.728627; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P850, DOI 10.1080/13854046.2012.686631; Davis JJ, 2011, ARCH CLIN NEUROPSYCH, V26, P768, DOI 10.1093/arclin/acr079; Delis D.C., 2000, CVLT 2 CALIFORNIA VE; Green P, 2004, GREENS MED SYMPTOM V; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Heaton R. K., 2004, REVISED COMPREHENSIV; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Meyers J. E., 2007, ASSESSMENT FEIGNED C; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Millis S. R., 2002, J FORENSIC NEUROPSYC, V2, P147; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reitan R, 1985, HALSTEAD REITAN NEUR; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ross SR, 2006, CLIN NEUROPSYCHOL, V20, P798, DOI 10.1080/13854040500328477; Schutte C., 2013, MILD TRAUMATIC BRAIN, P159; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Solomon RE, 2010, CLIN NEUROPSYCHOL, V24, P1243, DOI 10.1080/13854046.2010.514864; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Wolfson, 1993, HALSTEAD REITAN NEUR	50	46	47	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	5					876	888		10.1080/13854046.2014.907583			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AP4MM	WOS:000342051100012	24738938				2022-02-06	
J	Brezova, V; Moen, KG; Skandsen, T; Vik, A; Brewer, JB; Salvesen, O; Haberg, AK				Brezova, Veronika; Moen, Kent Goran; Skandsen, Toril; Vik, Anne; Brewer, James B.; Salvesen, Oyvind; Haberg, Asta K.			Prospective longitudinal MRI study of brain volumes and diffusion changes during the first year after moderate to severe traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Post-traumatic amnesia; Diffuse axonal injury; Glasgow Coma Scale; ADC; Outcome	HEAD-INJURY; AXONAL INJURY; WHITE-MATTER; WALLERIAN DEGENERATION; PROGRESSIVE ATROPHY; ALZHEIMERS-DISEASE; NEURONAL INJURY; TIME-COURSE; HIPPOCAMPUS; TENSOR	The objectives of this prospective study in 62 moderate-severe TBI patients were to investigate volume change in cortical gray matter (GM), hippocampus, lenticular nucleus, lobar white matter (WM), brainstem and ventricles using a within subject design and repeated MRI in the early phase (1-26 days) and 3 and 12 months postinjury and to assess changes in GM apparent diffusion coefficient (ADC) in normal appearing tissue in the cortex, hippocampus and brainstem. The impact of Glasgow Coma Scale (GCS) score at admission, duration of post-traumatic amnesia (PTA), and diffusion axonal injury (DAI) grade on brain volumes and ADC values over time was assessed. Lastly, we determined ifMRI-derived brain volumes from the 3-month scans provided additional, significant predictive value to 12-month outcome classified with the Glasgow Outcome Scale-Extended after adjusting for GCS, PTA and age. Cortical GM loss was rapid, largely finished by 3 months, but the volume reduction was unrelated to GCS score, PTA, or presence of DAI. However, cortical GM volume at 3 months was a significant independent predictor of 12-month outcome. Volume loss in the hippocampus and lenticular nucleus was protracted and statistically significant first at 12 months. Slopes of volume reduction over time for the cortical and subcortical GGM were significantly different. Hippocampal volume loss was most pronounced and rapid in individuals with PTA > 2 weeks. The 3-month volumes of the hippocampus and lentiform nucleus were the best independent predictors of 12-month outcome after adjusting for GCS, PTA and age. In the brainstem, volume loss was significant at both 3 and 12 months. Brainstem volume reduction was associated with lower GCS score and the presence of DAI. Lobar WM volume was significantly decreased first after 12 months. Surprisingly DAI grade had no impact on lobar WM volume. Ventricular dilation developed predominantly during the first 3 months, and was strongly associated with volume changes in the brainstem and cortical GM, but not lobar WM volume. Higher ADC values were detected in the cortex in individuals with severe TBI, DAI and PTA > 2 weeks, from 3 months. There were no associations between ADC values and brain volumes, and ADC values did not predict outcome. (C) 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license	[Brezova, Veronika] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Brezova, Veronika; Haberg, Asta K.] Univ Trondheim Hosp, St Olavs Hosp, Dept Med Imaging, Trondheim, Norway; [Moen, Kent Goran; Skandsen, Toril; Vik, Anne; Haberg, Asta K.] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, N-7491 Trondheim, Norway; [Moen, Kent Goran; Vik, Anne] St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Brewer, James B.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; [Salvesen, Oyvind] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, N-7491 Trondheim, Norway; [Brewer, James B.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA		Haberg, AK (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, N-7491 Trondheim, Norway.	asta.haberg@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Brandstack N, 2011, CLIN NEURORADIOL, V21, P75, DOI 10.1007/s00062-011-0058-5; Brewer JB, 2009, AM J NEURORADIOL, V30, P578, DOI 10.3174/ajnr.A1402; Cipolotti L, 2006, CURR OPIN NEUROL, V19, P593, DOI 10.1097/01.wco.0000247608.42320.f9; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Conti AC, 1998, J NEUROSCI, V18, P5663; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Eichenbaum H, 2007, ANNU REV NEUROSCI, V30, P123, DOI 10.1146/annurev.neuro.30.051606.094328; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox NC, 2001, LANCET, V358, P201, DOI 10.1016/S0140-6736(01)05408-3; Gao X., 2011, PLOS ONE, V6; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; GENTRY LR, 1994, RADIOLOGY, V191, P1; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gwet K. L., 2008, WILEY ENCY; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Holland D, 2012, HUM BRAIN MAPP, V33, P2586, DOI 10.1002/hbm.21386; Holland D, 2009, P NATL ACAD SCI USA, V106, P20954, DOI 10.1073/pnas.0906053106; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jenkins A., 1986, LANCET, V445- 4462874424; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Klimas A, 2013, CLIN IMAG, V37, P637, DOI 10.1016/j.clinimag.2013.01.013; LeGrand SA, 2007, J NEUROTRAUM, V24, P1437, DOI 10.1089/neu.2007.0293; Lin Y, 2013, INT J MED SCI, V10, P515, DOI 10.7150/ijms.5423; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Ng H., 1994, CLIN NEUROL NEUROSUR, V34; Ng K., 2008, ARCH PHYS MED REHAB; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Ozturk A, 2008, AM J NEURORADIOL, V29, P1124, DOI 10.3174/ajnr.A0998; Primus EA, 1997, BRAIN INJURY, V11, P577; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Thompson PM, 2004, NEUROIMAGE, V22, P1754, DOI 10.1016/j.neuroimage.2004.03.040; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Watanabe M, 2013, RADIOLOGY, V266, P575, DOI 10.1148/radiol.12112420; White NS, 2013, HUM BRAIN MAPP, V34, P327, DOI 10.1002/hbm.21454; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008	74	46	46	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	5						128	140		10.1016/j.nicl.2014.03.012			13	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB5LF	WOS:000349667800016	25068105	Green Published, gold			2022-02-06	
J	Moore, RD; Hillman, CH; Broglio, SP				Moore, Robert D.; Hillman, Charles H.; Broglio, Steven P.			The Persistent Influence of Concussive Injuries on Cognitive Control and Neuroelectric Function	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; inhibition; mental flexibility; attention; P3; N2	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE; RESPONSE-INHIBITION; INTEGRATIVE THEORY; TASK; MEMORY; SPORT; ABNORMALITIES; INTERFERENCE	Context: Increasing attention is being paid to the deleterious effects of sport-related concussion on cognitive and brain health. Objective: To evaluate the influence of concussion incurred during early life on the cognitive control and neuroelectric function of young adults. Design: Cross-sectional study. Setting: Research laboratory. Patients or Other Participants: Forty young adults were separated into groups according to concussive history (0 or 1+). Participants incurred all injuries during sport and recreation before the age of 18 years and were an average of 7.1 +/- 4.0 years from injury at the time of the study. Intervention(s): All participants completed a 3-stimulus oddball task, a numeric switch task, and a modified flanker task during which event-related potentials and behavioral measures were collected. Main Outcome Measure(s): Reaction time, response accuracy, and electroencephalographic activity. Results: Compared with control participants, the concussion group exhibited decreased P3 amplitude during target detection within the oddball task and during the heterogeneous condition of the switch task. The concussion group also displayed increased N2 amplitude during the heterogeneous version of the switch task. Concussion history was associated with response accuracy during the flanker task. Conclusions: People with a history of concussion may demonstrate persistent decrements in neurocognitive function, as evidenced by decreased response accuracy, deficits in the allocation of attentional resources, and increased stimulus-response conflict during tasks requiring variable amounts of cognitive control. Neuroelectric measures of cognitive control may be uniquely sensitive to the persistent and selective decrements of concussion.	[Moore, Robert D.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA		Broglio, SP (corresponding author), ATC, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Hillman, Charles/AAD-4828-2019; Meijer, Anna/K-5118-2016	Hillman, Charles/0000-0002-3722-5612	National Athletic Trainers' Association Research & Education Foundation	We thank the National Athletic Trainers' Association Research & Education Foundation for supporting this project.	Allport A., 1999, ATTENTION SPACE ACTI, P273; Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Aron AR, 2004, BRAIN, V127, P1561, DOI 10.1093/brain/awh169; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Bush G, 2006, NAT PROTOC, V1, P308, DOI 10.1038/nprot.2006.48; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Clark L, 2007, BIOL PSYCHIAT, V61, P1395, DOI 10.1016/j.biopsych.2006.07.020; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Diamond A., 2001, PRINCIPLES FRONTAL L, P466; DiGirolamo GJ, 2001, NEUROREPORT, V12, P2065, DOI 10.1097/00001756-200107030-00054; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Grunwald T, 1998, P NATL ACAD SCI USA, V95, P3193, DOI 10.1073/pnas.95.6.3193; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hillman CH, 2006, HEALTH PSYCHOL, V25, P678, DOI 10.1037/0278-6133.25.6.678; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kiesel A, 2010, PSYCHOL BULL, V136, P849, DOI 10.1037/a0019842; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; Koch I, 2010, PSYCHON B REV, V17, P1, DOI 10.3758/PBR.17.1.1; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Luna B, 2009, ADV CHILD DEV BEHAV, V37, P233, DOI 10.1016/S0065-2407(09)03706-9; Mansfield KL, 2012, PSYCHOPHYSIOLOGY, V49, P756, DOI 10.1111/j.1469-8986.2012.01368.x; Mayr U, 2006, J COGNITIVE NEUROSCI, V18, P14, DOI 10.1162/089892906775250085; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; National Center for Injury Prevention and Control, 2002, INJ FACT BOOK 2001 2; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Pelczar M, 1997, Neurol Neurochir Pol, V31, P989; Polich J, 2003, DETECTION CHANGE EVE, P83, DOI DOI 10.1007/978-1-4615-0294-4_; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Polich J, 2006, INT J PSYCHOPHYSIOL, V60, P172, DOI 10.1016/j.ijpsycho.2005.12.012; Pontifex MB, 2007, CLIN NEUROPHYSIOL, V118, P570, DOI 10.1016/j.clinph.2006.09.029; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Soltani Maryam, 2000, Critical Reviews in Neurobiology, V14, P199; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P364, DOI 10.1017/S0048577299970749; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Swainson R, 2003, J COGNITIVE NEUROSCI, V15, P785, DOI 10.1162/089892903322370717; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3	85	46	46	0	21	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2014	49	1					24	35		10.4085/1062-6050-49.1.01			12	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AQ3LX	WOS:000342696500004	24377962	Bronze, Green Published			2022-02-06	
J	Schonfeld, D; Fitz, BM; Nigrovic, LE				Schonfeld, Deborah; Fitz, Brianna M.; Nigrovic, Lise E.			Effect of the Duration of Emergency Department Observation on Computed Tomography Use in Children With Minor Blunt Head Trauma	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Meeting of the Pediatric-Academic-Societies	MAY, 2013	Washington, DC	Pediat Acad Soc			RADIATION-EXPOSURE; UNITED-STATES; PEDIATRIC CT; MANAGEMENT; INJURY; CANCER; RISKS	Study objective: We determine the effect of the duration of emergency department (ED) observation on computed tomography (CT) rate for children with minor blunt head trauma. Methods: We performed a prospective cohort study of children with blunt head trauma and a Glasgow Coma Scale score greater than 14. We defined time from injury as the time from head injury to initial physician (emergency attending physician or fellow) assessment. For children who were observed in the ED before CT decisionmaking, we defined ED observation time as time from initial physician assessment to the decision whether to obtain a CT. After adjusting for time from injury, patient age, sex, physician type, and study month, we measured the effect of ED observation time on CT rate in each of the 3 Pediatric Emergency Care Applied Research Network Traumatic Brain Injury risk groups. Results: Of the 1,605 eligible patients, we enrolled 1,381 (86%). Of the enrolled patients, 676 (49%) were observed in the ED and 272 (20%) had a CT performed. After adjustment, every hour of ED observation time was associated with a decrease in CT rate for children in all 3 traumatic brain injury risk groups: high risk (adjusted odds ratio [OR] 0.11; 95% confidence interval [Cl] 0.05 to 0.24), intermediate risk (adjusted OR 0.28; 95% Cl 0.21 to 0.36), and low. risk (adjusted OR 0.47; 95% Cl 0.31. to 0.73). All 8 children with a significant traumatic brain injury had an immediate CT. Conclusion: For children with minor blunt head trauma, ED observation time was associated with a time-dependent reduction in cranial CT rate, with no delay in the diagnosis of a significant traumatic brain injury.	[Schonfeld, Deborah; Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Fitz, Brianna M.] Boston Coll, Dept Psychol, Boston, MA USA		Nigrovic, LE (corresponding author), Boston Childrens Hosp, Div Emergency Med, Boston, MA USA.	lise.nigrovic@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997			[Anonymous], 2011, STAT DAT AN VERS 12; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Boutis K, 2013, PEDIATRICS; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Broder J, 2007, EMERG RADIOL, V14, P227, DOI 10.1007/s10140-007-0618-9; Choosing Wisely, AM AC PED 5 THINGS P; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Hostetler MA, 2007, PEDIATR EMERG CARE, V23, P507, DOI 10.1097/01.pec.0000280518.36408.74; IBM Corp, 2012, PASW STAT 21 VERS 21; Karpas A, 2013, PEDIATR EMERG CARE, V29, P30, DOI 10.1097/PEC.0b013e31827b5090; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983	24	46	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	DEC	2013	62	6					597	603		10.1016/j.annemergmed.2013.06.020			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	268PY	WOS:000328184200013	23910481				2022-02-06	
J	Tjarks, BJ; Dorman, JC; Valentine, VD; Munce, TA; Thompson, PA; Kindt, SL; Bergeron, MF				Tjarks, B. Joel; Dorman, Jason C.; Valentine, Verle D.; Munce, Thayne A.; Thompson, Paul A.; Kindt, Shanna L.; Bergeron, Michael F.			Comparison and utility of King-Devick and ImPACT (R) composite scores in adolescent concussion patients	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Diffuse axonal injury; Neuropsychological tests; Oculomotor dysfunction; Post-concussion syndrome; Return to play; Traumatic brain injury; Visual-motor deficits	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; AMYLOID PRECURSOR PROTEIN; RECREATION ACTIVITIES; AXONAL DAMAGE; EYE-MOVEMENTS; UNITED-STATES; HEAD-INJURY; MILD	The King-Devick (ICD) oculomotor test has recently been advocated for sideline diagnosis of concussion. Although visual processing and performance are often impaired in concussion patients, the utility of KD as a concussion diagnostic tool is not validated. Purpose: To examine the diagnostic value of KD, by comparing KD with post-concussion symptom scale (PCSS) and ImPACT (R) composite scores. We hypothesized that KD would be correlated with visual motor speed/memory (VMS, VIS) and reaction time (RI'), because all require cognitive visual processing. We also expected parallel changes in KD and PCSS across recovery. Methods: Thirty-five concussed individuals (12-19 y; 18 females, 17 males) were evaluated with PCSS, ImPACT composite and KD scores over four clinical visits (V). Results: LCD times improved with each visit (Delta V1-V2: 7.86 +/- 11.82; Delta V2-V3: 9.17 +/- 11.07; Delta V3-V4: 5.30 +/- 7.87 s) and paralleled improvements in PCSS (Delta V1-V2: 8.97 +/- 20.27; Delta V2-V3: 8.69 14.70; Delta V3-V4: 6.31 +/- 7.71), RT (Delta V1-V2: 0.05 +/- 021; Delta V2-V3: 0.09 +/- 0.19; Delta V3-V4 0.03 +/- 0.07) and VMS (Delta V1-V2: -5.27 +/- 6.98; Delta V2-V3: 2.61 +/- 6.48; Delta V3-V4: 2.35 +/- 5.22). Longer KD times were associated with slower RT (r = 0.67; P < 0.0001) and lower VMS (r = 0.70; P < 0.0001), respectively. Conclusion: Cognitive visual performance testing using KD has utility in concussion evaluation. Validation would further establish KD as an effective ancillary tool in longitudinal concussion management and research. (C) 2013 Elsevier B.V. All rights reserved.	[Tjarks, B. Joel] Univ S Dakota, Sanford Sch Med, Sioux Falls, SD 57105 USA; [Dorman, Jason C.; Munce, Thayne A.; Bergeron, Michael F.] Natl Inst Athlet Hlth & Performance, Sioux Falls, SD 57104 USA; [Valentine, Verle D.; Kindt, Shanna L.] Sanford Orthoped & Sports Med, Sioux Falls, SD 57104 USA; [Munce, Thayne A.; Bergeron, Michael F.] Univ S Dakota, Sanford Sch Med, Dept Pediat, Sioux Falls, SD 57105 USA; [Thompson, Paul A.] Methodol & Data Anal Ctr, Sioux Falls, SD 57104 USA; [Bergeron, Michael F.] Natl Youth Sports Hlth Safety Inst, Sioux Falls, SD 57104 USA		Tjarks, BJ (corresponding author), Univ S Dakota, Sanford Sch Med, 1400 W 22nd St, Sioux Falls, SD 57105 USA.	Brian.Tjarics@usd.edu	Meijer, Anna/K-5118-2016				Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; GLASS I, 1995, BRAIN INJURY, V9, P769, DOI 10.3109/02699059509008233; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEPORE FE, 1995, ARCH NEUROL-CHICAGO, V52, P924, DOI 10.1001/archneur.1995.00540330106022; Lieberman S, 1983, J Am Optom Assoc, V54, P631; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Resch J, 2010, THESIS U GEORGIA ATH; Richman J E, 1983, J Am Optom Assoc, V54, P617; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	36	46	46	0	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	NOV 15	2013	334	1-2					148	153		10.1016/j.jns.2013.08.015			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261OP	WOS:000327674800027	24007870				2022-02-06	
J	Truettner, JS; Motti, D; Dietrich, WD				Truettner, Jessie S.; Motti, Dario; Dietrich, W. Dalton			MicroRNA overexpression increases cortical neuronal vulnerability to injury	BRAIN RESEARCH			English	Article						microRNA; Traumatic brain injury; miR-34a; miR-451; miR-874; Transfection	TRAUMATIC BRAIN-INJURY; SUBCELLULAR STRESS-RESPONSE; THERAPEUTIC HYPOTHERMIA; PROTEIN PHOSPHATASE-1; CEREBRAL-ISCHEMIA; EXPRESSION; CELLS; ACTIVATION; CHAPERONES; REGULATORS	Previously we reported that several microRNAs (miRNA) are upregulated following experimentally induced traumatic brain injury (TBI) using both in vivo and in vitro approaches. Specific miRNAs were found to be sensitive to therapeutic hypothermia and may therefore be important targets for neuroprotective strategies. In this study we developed plasmid constructs that overexpress temperature sensitive miRNAs: miR-34a, miR-451, and miR-874. These constructs were transfected into cultured cortical neurons that were subjected to stretch injury using a cell injury controller device. Levels of expression of genes associated with stress, inflammation, apoptosis and transcriptional regulation were measured by qRT-PCR. mRNA levels of cytokines interleukin 1-beta (IL1-beta) and tumor necrosis factor alpha (TNF-alpha) as well as heat shock protein 70 (HSP70) and Caspase 11 were found to be increased up to 24 fold higher than controls in cells overexpressing these miRNAs. After moderate stretch injury, the expression of IL1-beta, TNF-alpha, HSP70 and Caspase 11 all increased over control levels found in uninjured cells suggesting that overexpression of these miRNAs increases cellular vulnerability. miR-34a directly inhibits Bcl2 and XIAP, both anti-apoptotic proteins. The observed increase in Caspase 11 with over-expression of miR-34a indicates that miR-34a may be inducing apoptosis by reducing the levels of antiapoptotic proteins. miR-34a is predicted to inhibit Jun, which was seen to decrease in cells overexpressing this miRNA along with Fos. Over expression of several miRNAs found to be induced by TBI in vivo (miR-34a, miR-451 and miR-874) leads to increased vulnerability in transfected neurons. Therapeutic hypothermia blunts the expression of these miRNAs in vivo and antisense silencing could be a potential therapeutic approach to targeting the consequences of TBI. (C) 2013 Elsevier B.V. All rights reserved.	[Truettner, Jessie S.; Motti, Dario; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA.	ddietrich@miami.edu		Motti, Dario/0000-0002-7714-4040	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS042133, RO1 NS30291]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	The authors wish to thank Doris Nonner for her expertise in isolating and culturing rat primary cortical neurons for this study. The authors have no conflicts of interest to report. This study was supported by grants from NIH: RO1 NS042133 and RO1 NS30291.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Avraham R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000876; Becker LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048474; Bijkerk Roel, 2012, Microrna, V1, P2; Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143; Cohen PTW, 2002, J CELL SCI, V115, P241; Conley YP, 2011, PM&R, V3, pS52, DOI 10.1016/j.pmrj.2011.04.004; Cui QH, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100089; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Duggal Jyoti, 2012, Microrna, V1, P26; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Esau CC, 2007, ADV DRUG DELIVER REV, V59, P101, DOI 10.1016/j.addr.2007.03.007; Fan Q, 2013, CELL BIOCHEM FUNCT, V31, P319, DOI 10.1002/cbf.2902; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Giffard RG, 2008, ANESTHESIOLOGY, V109, P339, DOI 10.1097/ALN.0b013e31817f4ce0; Hsieh C.H., 2012, J BIOMED SCI, V19, P1; Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012; KAUFMAN LM, 1983, SCIENCE, V220, P1394, DOI 10.1126/science.6857258; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; KEANE RW, 1992, TRANSPLANTATION, V54, P520, DOI 10.1097/00007890-199209000-00025; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Meng QH, 2011, PROTEIN CELL, V2, P889, DOI 10.1007/s13238-011-1113-3; Nakanishi K, 2010, SPINAL CORD, V48, P192, DOI 10.1038/sc.2009.89; Nohata N, 2011, BRIT J CANCER, V105, P833, DOI 10.1038/bjc.2011.311; Pietrini D, 2012, CURR DRUG TARGETS, V13, P925, DOI 10.2174/138945012800675641; Qureshi IA, 2010, ARCH NEUROL-CHICAGO, V67, P1316, DOI 10.1001/archneurol.2010.275; Rayner KJ, 2013, J LIPID RES, V54, P1174, DOI 10.1194/jlr.R034991; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rosenberger CM, 2012, J IMMUNOL, V189, P5965, DOI 10.4049/jimmunol.1201437; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Truettner JS, 2009, BRAIN RES, V1249, P9, DOI 10.1016/j.brainres.2008.10.032; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Varon J, 2012, AM J EMERG MED, V30, P800, DOI 10.1016/j.ajem.2011.03.007; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang T, 2012, DIGEST DIS SCI, V58, P706; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yablonska Svitlana, 2013, Microrna, V2, P2; Yang S., 2012, ONCOGENE, V24, P1; Zgavc T, 2013, BRAIN RES, V1501, P81, DOI 10.1016/j.brainres.2013.01.034	60	46	49	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 2	2013	1533						122	130		10.1016/j.brainres.2013.08.011			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	233UL	WOS:000325594900013	23948100	Green Accepted			2022-02-06	
J	Schirmer, CM; Elder, JB; Roitberg, B; Lobel, DA				Schirmer, Clemens M.; Elder, J. Bradley; Roitberg, Ben; Lobel, Darlene A.			Virtual Reality-Based Simulation Training for Ventriculostomy: An Evidence-Based Approach	NEUROSURGERY			English	Article						Education; Neurotrauma; Residency; Simulation; Ventriculostomy; Virtual reality	CONSTRUCT-VALIDATION; TECHNICAL SKILL; CURRICULUM; PLACEMENT; EDUCATION	BACKGROUND: Virtual reality (VR) simulation-based technologies play an important role in ne resident training. The Congress of Neurological Surgeons (CNS) Simulation Committee developed a simulation-based curriculum incorporating VR simulators to train residents in the management of common neurosurgical C disorders. OBJECTIVE: To enhance neurosurgical resident training for ventriculostomy placement using simulation-based training. METHODS: A course-based neurosurgical simulation curriculum was introduced at the Neurosurgical Simulation Symposium at the 2011 and 2012 CNS annual meetings. A trauma module was developed to teach ventriculostomy placement as one of the neurosurgical procedures commonly performed in the management of traumatic brain injury. The course offered both didactic and simulator-based instruction, incorporating written and practical pretests and posttests and questionnaires to assess improvement in skill level and to validate the simulators as teaching tools. RESULTS: Fourteen trainees participated in the didactic component of the trauma module. Written scores improved significantly from pretest (75%) to posttest (87.5%; P < .05). Seven participants completed the ventriculostomy simulation. Significant improvements were observed in anatomy (P < .04), burr hole placement (P < .03), final location of the catheter (P = .05), and procedure completion time (P < .004). Senior residents planned a significantly better trajectory (P < .01); junior participants improved most in terms of identifying the relevant anatomy (P < .03) and the time required to complete the procedure (P < .04). CONCLUSION: VR ventriculostomy placement as part of the CNS simulation trauma module complements standard training techniques for residents in the management of neurosurgical trauma. Improvement in didactic and hands-on knowledge by course participants demonstrates the usefulness of the VR simulator as a training tool.	[Schirmer, Clemens M.] Baystate Med Ctr, Div Neurosurg, Springfield, MA USA; [Schirmer, Clemens M.] Tufts Univ, Sch Med, Dept Neurosurg, Springfield, MA 01107 USA; [Elder, J. Bradley] Ohio State Univ, Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA; [Roitberg, Ben] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA; [Lobel, Darlene A.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA		Schirmer, CM (corresponding author), Tufts Univ, Sch Med, Dept Neurosurg, Baystate Med Ctr Neurosurg, 2 Med Ctr Dr,Ste 503, Springfield, MA 01107 USA.	cmschirmer@gmail.com		Schirmer, Clemens/0000-0003-1743-8781			Abboudi H, 2013, BJU INT, V111, P194, DOI 10.1111/j.1464-410X.2012.11270.x; Accreditation Council for Graduate Medical Education (ACGME), COMM PROGR REQ; Banerjee PP, 2007, J NEUROSURG, V107, P515, DOI 10.3171/JNS-07/09/0515; Banerjee PP, 2007, SIMUL HEALTHC, V2, P145; Britt RC, 2007, AM SURGEON, V73, P680; Faulkner H, 1996, ACAD MED, V71, P1363, DOI 10.1097/00001888-199612000-00023; Gallagher AG, 2004, JAMA-J AM MED ASSOC, V292, P3024, DOI 10.1001/jama.292.24.3024; Hooten KG, 2012, C NEUR SURG CNS ANN; John N W, 2000, Stud Health Technol Inform, V70, P146; Kelly DC, 2012, UROLOGY, V79, P1068, DOI 10.1016/j.urology.2012.01.028; Khan MS, 2013, BJU INT, V111, P518, DOI 10.1111/j.1464-410X.2012.11204.x; Krombach G, 2000, MINIM INVAS NEUROSUR, V43, P171, DOI 10.1055/s-2000-11376; Larsen OV, 2001, ST HEAL T, V81, P256; Lemole GM, 2007, NEUROSURGERY, V61, P142, DOI 10.1227/01.neu.0000279734.22931.21; Liss MA, 2012, J ENDOUROL, V26, P1629, DOI 10.1089/end.2012.0328; Lobel DA, 2013, NEUROSURGERY; Luciano C., 2005, 11 INT C HUM COMP IN; Mazzola CA, 2010, NEUROSURGERY, V67, P225, DOI 10.1227/01.NEU.0000372206.41812.23; Palter VN, 2013, ANN SURG, V257, P224, DOI 10.1097/SLA.0b013e31827051cd; Panchaphongsaphak B, 2006, ST HEAL T, V119, P428; Phillips NI, 2000, NEUROSURGERY, V46, P933, DOI 10.1097/00006123-200004000-00031; Plooy AM, 2012, GASTROINTEST ENDOSC, V76, P144, DOI 10.1016/j.gie.2012.03.246; Popp AJ, 2008, J NEUROSURG, V109, P576, DOI 10.3171/JNS/2008/109/10/0576; Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45; Singapogu RB, 2013, SURG ENDOSC, V27, P1653, DOI 10.1007/s00464-012-2648-y; Yudkowsky R, 2013, SIMUL HEALTHC, V8, P25, DOI 10.1097/SIH.0b013e3182662c69	26	46	47	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2013	73			1			66	73		10.1227/NEU.0000000000000074			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	300SG	WOS:000330483300013	24051886				2022-02-06	
J	Arun, P; Abu-Taleb, R; Oguntayo, S; Tanaka, M; Wang, Y; Valiyaveettil, M; Long, JB; Zhang, YM; Nambiar, MP				Arun, Peethambaran; Abu-Taleb, Rania; Oguntayo, Samuel; Tanaka, Mikiei; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Zhang, Yumin; Nambiar, Madhusoodana P.			Distinct patterns of expression of traumatic brain injury biomarkers after blast exposure: Role of compromised cell membrane integrity	NEUROSCIENCE LETTERS			English	Article						Blast exposure; Cell membrane integrity; GFAP; Tau; Polytrauma	FIBRILLARY ACIDIC PROTEIN; TOTAL TAU; SERUM; OVERPRESSURE; GFAP	Glial fibrillary acidic protein (GFAP), a protein enriched in astrocytes, and Tau, a protein abundant in neuronal microtubules, are being widely studied as biomarkers of brain injury, and persistent severity-dependent increases in brain and blood have been reported. Studies on the acute changes of these proteins after blast exposure are limited. Using a mouse model of closely-coupled repeated blast exposures, we have evaluated acute changes in the levels of GFAP and total Tau by Western blotting. Brain levels of GFAP and Tau proteins decreased significantly at 6 h and increased considerably at 24 h after repeated blast exposures. Plasma samples showed a similar initial decrease and later increase over this timeframe. This biphasic pattern points to possible absorption or sequestration of these proteins from plasma immediately after repeated blast exposures. Liver and spleen tissue showed significant increases in the levels of GFAP and Tau protein at 6 and 24 h post-blast exposures whereas semi-quantitative RT-PCR analysis of liver showed no significant changes in the levels of GFAP or Tau mRNAs. These results suggest that blast exposure causes transient changes in cell membrane integrity in multiple organs leading to abnormal migration of proteins from the tissues to the plasma and vice versa. This transient changes in cell membrane permeability and subsequent bidirectional movement of molecules may contribute to the pathophysiology of TBI and polytrauma after blast exposure. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Arun, Peethambaran; Abu-Taleb, Rania; Oguntayo, Samuel; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Tanaka, Mikiei; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Arun, P (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	peethambaran.arun.ctr@mail.mil					Arun P, 2012, INTERV MED APPL SCI, V4, P125, DOI 10.1556/IMAS.4.2012.3.2; Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Arun P, 2012, NEUROREPORT, V23, P342, DOI 10.1097/WNR.0b013e328351b58d; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; DEARMOND SJ, 1986, J NEUROCHEM, V47, P1749, DOI 10.1111/j.1471-4159.1986.tb13084.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Morales-Corraliza J., 2009, PLOS ONE, V4, pe7134; Morini Sergio, 2005, Italian Journal of Anatomy and Embryology, V110, P193; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	28	46	46	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 27	2013	552						87	91		10.1016/j.neulet.2013.07.047			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237YG	WOS:000325907000018	23933206	Green Published			2022-02-06	
J	Tan, T; Xie, JC; Liu, TT; Chen, XJ; Zheng, XB; Tong, ZQ; Tian, X				Tan, Tao; Xie, Jiacun; Liu, Tiaotiao; Chen, Xiaojia; Zheng, Xiaobo; Tong, Zhiqian; Tian, Xin			Low-frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) reverses A beta(1-42)-mediated memory deficits in rats	EXPERIMENTAL GERONTOLOGY			English	Article						Alzheimer's disease (AD); Repetitive transcranial magnetic stimulation (rTMS); Long-term potentiation (LTP); Nerve growth factor (NGF); Brain-derived neurotrophic factor (BDNF); NMDA receptor	LONG-TERM POTENTIATION; NERVE GROWTH-FACTOR; NONINVASIVE BRAIN-STIMULATION; SERUM BDNF LEVELS; NEUROTROPHIC FACTOR; NMDA RECEPTORS; MESSENGER-RNA; IN-VIVO; CORTICAL EXCITABILITY; SYNAPTIC PLASTICITY	Accumulating evidence shows the disruption of hippocampal neurotrophins secretion leads to memory deficits in Alzheimer's disease (AD) animal models. Invasive injection of exogenous neurotrophins into hippocampus reverses spatial memory deficits, but its clinical application is limited by traumatic brain injury during the injection procedure. Notably, recent studies have demonstrated that noninvasive repetitive transcranial magnetic stimulation (rTMS) increases endogenous neurotrophins contents in the brain of normal rats. Whether low-frequency rTMS can reverse A beta(1-42)-mediated decrease in hippocampal neurotrophins contents and spatial memory impairment is still unclear. Here, we reported that severe deficit in long-term potentiation (LTP) and spatial memory were observed in an A beta(1-42)-induced toxicity rat model. Furthermore, neurotrophins (NGF and BDNF) and NMDA-receptor levels were decreased after A beta injection. However, low-frequency rTMS markedly reversed the decrease in neurotrophins contents. And the rTMS-induced increment of neurotrophins up-regulated hippocampal NMDA-receptor expression. Moreover, low-frequency rTMS rescued deficits in LTP and spatial memory of rats with A beta-injection. These results indicate that low-frequency rTMS noninvasively and effectively increases hippocampal neurotrophins and NMDA-receptor contents in A beta(1-42)-induced toxicity model rats, which helps to enhance hippocampal LTP and reverses A beta(1-42)-mediated memory deficits. Crown Copyright (C) 2013 Published by Elsevier Inc. All rights reserved.	[Tan, Tao; Xie, Jiacun; Liu, Tiaotiao; Chen, Xiaojia; Zheng, Xiaobo; Tian, Xin] Tianjin Med Univ, Inst Biomed Engn, Tianjin 300070, Peoples R China; [Tan, Tao; Xie, Jiacun; Liu, Tiaotiao; Chen, Xiaojia; Zheng, Xiaobo; Tian, Xin] Tianjin Med Univ, Res Ctr Basic Med Sci, Lab Neural Engn, Tianjin 300070, Peoples R China; [Tian, Xin] Tianjin Neurol Inst, Tianjin 300070, Peoples R China; [Tong, Zhiqian] Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China		Tian, X (corresponding author), Tianjin Med Univ, Inst Biomed Engn, Tianjin 300070, Peoples R China.	tianx@tijmu.edu.cn	Tan, Tao/F-5535-2010	Tan, Tao/0000-0002-4571-3296	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61074131, 30770545]; Tianjin Medical University [2010GSI09]	We thank Prof. Rongqiao He for his expert help; Prof. Xiulan Zao for technical assistance and help on Immunohistochemistry staining and Ph.D. Zhiqian Tong for editing the manuscript. This study was supported by the National Natural Science Foundation of China (Nos. 61074131 and 30770545) and the "211 Project" Graduate Innovation Grant of Tianjin Medical University (No. 2010GSI09).	Abe K, 2009, PROG NEURO-PSYCHOPH, V33, P552, DOI 10.1016/j.pnpbp.2009.02.011; ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; Ahmed Z, 2006, BIOELECTROMAGNETICS, V27, P288, DOI 10.1002/bem.20211; Andersen P., 2007, SYNAPTIC PLASTICITY, P343; Angelucci F, 2004, NEUROREPORT, V15, P717, DOI 10.1097/00001756-200403220-00029; Arancibia S, 2008, NEUROBIOL DIS, V31, P316, DOI 10.1016/j.nbd.2008.05.012; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; BARKER AT, 1985, LANCET, V1, P1106; BARKER AT, 1994, J ROY SOC HEALTH, V114, P91, DOI 10.1177/146642409411400210; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Bentwich J, 2011, J NEURAL TRANSM, V118, P463, DOI 10.1007/s00702-010-0578-1; Bersani FS, 2013, NEUROCASE, V19, P451, DOI 10.1080/13554794.2012.690429; Bi H, 2002, J NEUROL SCI, V200, P11, DOI 10.1016/S0022-510X(02)00087-4; BLACKMAN CF, 1982, RADIAT RES, V92, P510, DOI 10.2307/3575923; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boroojerdi B, 2001, NEUROLOGY, V56, P526, DOI 10.1212/WNL.56.4.526; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Bruno MA, 2009, J NEUROPATH EXP NEUR, V68, P857, DOI 10.1097/NEN.0b013e3181aed9e6; Caldeira MV, 2007, MOL CELL NEUROSCI, V35, P208, DOI 10.1016/j.mcn.2007.02.019; Calon F, 2005, EUR J NEUROSCI, V22, P617, DOI 10.1111/j.1460-9568.2005.04253.x; Christensen R, 2008, EXP NEUROL, V210, P164, DOI 10.1016/j.expneurol.2007.10.009; Colaianna M, 2010, BRIT J PHARMACOL, V159, P1704, DOI 10.1111/j.1476-5381.2010.00669.x; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082; Cosgaya JM, 1996, J NEUROCHEM, V67, P98; Covaceuszach S, 2009, CURR ALZHEIMER RES, V6, P158, DOI 10.2174/156720509787602870; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; Danielyan A. A., 1999, Physiological Chemistry and Physics and Medical NMR, V31, P139; Filali M, 2011, NEUROPHARMACOLOGY, V60, P930, DOI 10.1016/j.neuropharm.2011.01.035; Foltys H, 2001, CLIN NEUROPHYSIOL, V112, P265, DOI 10.1016/S1388-2457(00)00539-3; Fregni Felipe, 2005, Curr Psychiatry Rep, V7, P381, DOI 10.1007/s11920-005-0041-4; Freitas C, 2011, EXP GERONTOL, V46, P611, DOI 10.1016/j.exger.2011.04.001; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; Gross M, 2007, ACTA PSYCHIAT SCAND, V116, P165, DOI 10.1111/j.1600-0447.2007.01049.x; Guerra Andrea, 2011, Int J Alzheimers Dis, V2011, P263817, DOI 10.4061/2011/263817; Haffen E, 2012, BRAIN STIMUL, V5, P264, DOI 10.1016/j.brs.2011.03.003; Harrison FE, 2009, PHARMACOL BIOCHEM BE, V93, P443, DOI 10.1016/j.pbb.2009.06.006; Hayashi T, 2004, ANN NEUROL, V56, P77, DOI 10.1002/ana.20151; Holsinger RMD, 2000, MOL BRAIN RES, V76, P347, DOI 10.1016/S0169-328X(00)00023-1; Jarvis CR, 1997, J NEUROPHYSIOL, V78, P2363, DOI 10.1152/jn.1997.78.5.2363; Kim DK, 2010, NEURAL REGEN RES, V5, P1365, DOI 10.3969/j.issn.1673-5374.2010.18.001; Lanctot KL, 2008, EXP NEUROL, V212, P251, DOI 10.1016/j.expneurol.2008.04.031; Lessmann V, 2003, PROG NEUROBIOL, V69, P341, DOI 10.1016/S0301-0082(03)00019-4; Levkovitz Y, 2001, NEUROPSYCHOPHARMACOL, V24, P608, DOI 10.1016/S0893-133X(00)00244-X; Liebetanz D, 2003, J PSYCHIATR RES, V37, P277, DOI 10.1016/S0022-3956(03)00017-7; Lu Y, 2008, NEUROBIOL LEARN MEM, V89, P312, DOI 10.1016/j.nlm.2007.08.018; Muller MB, 2000, NEUROPSYCHOPHARMACOL, V23, P205, DOI 10.1016/S0893-133X(00)00099-3; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nilsson P, 2010, J CELL MOL MED, V14, P741, DOI 10.1111/j.1582-4934.2010.01038.x; Nomura I, 2012, J NEUROPHYSIOL, V107, P2526, DOI 10.1152/jn.00589.2011; O'Hare E, 1999, BRAIN RES, V815, P1, DOI 10.1016/S0006-8993(98)01002-6; Ogiue-Ikeda M, 2003, BRAIN RES, V993, P222, DOI 10.1016/j.brainres.2003.09.009; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; Pennisi G, 2011, DEMENT GERIATR COGN, V31, P71, DOI 10.1159/000322798; Pilato F, 2012, MOL NEUROBIOL, V46, P563, DOI 10.1007/s12035-012-8302-9; Post A, 1999, EUR J NEUROSCI, V11, P3247, DOI 10.1046/j.1460-9568.1999.00747.x; Shankar GM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-48; Shin RW, 1997, J NEUROSCI, V17, P8187; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Spritzer MD, 2011, HORM BEHAV, V59, P484, DOI 10.1016/j.yhbeh.2011.01.009; [谭涛 TAN Tao], 2011, [生理学报, Acta Physiologica Sinica], V63, P225; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Todd G, 2006, J APPL PHYSIOL, V101, P500, DOI 10.1152/japplphysiol.01399.2005; Tokay T, 2009, NEUROSCI LETT, V461, P150, DOI 10.1016/j.neulet.2009.06.032; Tong ZQ, 2013, AGE, V35, P583, DOI 10.1007/s11357-012-9388-8; Trippe J, 2009, EXP BRAIN RES, V199, P411, DOI 10.1007/s00221-009-1961-8; Tsang SWY, 2008, NEUROBIOL AGING, V29, P1524, DOI 10.1016/j.neurobiolaging.2007.03.014; Wang F, 2010, J MOL NEUROSCI, V41, P145, DOI 10.1007/s12031-009-9311-7; Wang HY, 2011, J NEUROSCI, V31, P11044, DOI 10.1523/JNEUROSCI.2125-11.2011; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wassermann EM, 2012, PHARMACOL THERAPEUT, V133, P98, DOI 10.1016/j.pharmthera.2011.09.003; WESKAMP G, 1987, J NEUROCHEM, V48, P1779, DOI 10.1111/j.1471-4159.1987.tb05736.x; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Wu AD, 2008, NEUROTHERAPEUTICS, V5, P345, DOI 10.1016/j.nurt.2008.02.002; Yukimasa T, 2006, PHARMACOPSYCHIATRY, V39, P52, DOI 10.1055/s-2006-931542; ZAFRA F, 1992, J NEUROSCI, V12, P4793; Zanardini R, 2006, J AFFECT DISORDERS, V91, P83, DOI 10.1016/j.jad.2005.12.029; Zhang XQ, 2007, J HUAZHONG U SCI-MED, V27, P415, DOI 10.1007/s11596-007-0416-3; Zhou JP, 2008, BRAIN RES, V1191, P12, DOI 10.1016/j.brainres.2007.10.097	82	46	52	4	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	AUG	2013	48	8					786	794		10.1016/j.exger.2013.05.001			9	Geriatrics & Gerontology	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology	181WI	WOS:000321700300013	23665072				2022-02-06	
J	Kim, JH; Jang, BG; Choi, BY; Kim, HS; Sohn, M; Chung, TN; Choi, HC; Song, HK; Suh, SW				Kim, Jin Hee; Jang, Bong Geom; Choi, Bo Young; Kim, Hyeong Seop; Sohn, Min; Chung, Tae Nyoung; Choi, Hui Chul; Song, Hong Ki; Suh, Sang Won			Post-treatment of an NADPH oxidase inhibitor prevents seizure-induced neuronal death	BRAIN RESEARCH			English	Article						Temporal lobe epilepsy; Seizure; NADPH oxidase; Reactive oxygen species; Blood brain barrier; Neurodegeneration; Microglia; Neurotrophil infiltration	TEMPORAL-LOBE EPILEPSY; PILOCARPINE-INDUCED SEIZURES; OXIDATIVE STRESS; STATUS EPILEPTICUS; MICROGLIAL ACTIVATION; CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CELL-DEATH; RATS; SUPEROXIDE	The present study sought to evaluate the neuroprotective effects of apocynin, an NADPH oxidase assembly inhibitor, on seizure-induced neuronal death. Apocynin, also known as acetovanillone, is a natural organic compound isolated from the root of Canadian hemp (Apocynum cannabium). It has been extensively studied to determine its disease-fighting capabilities and application in several brain insults, such as traumatic brain injury and stroke. Here we tested the hypothesis that post-treatment of apocynin may prevent seizure-induced neuronal death by suppression of NADPH oxidase-mediated superoxide production. Temporal lobe epilepsy (TLE) was induced by intraperitoneal injection of pilocarpine (25 mg/kg) in male rats. Apocynin (30 mg/kg, i.p.) was injected into the intraperitoneal space two hours after seizure onset. A second injection was performed 24 h after seizure. To test whether apocynin inhibits NADPH oxidase activation-induced reactive oxygen species (ROS) production, dihydroethidium (dHEt, 5 mg/kg, i.p.) was injected before onset of seizure and ROS production was detected five hours after seizure onset. Neuronal oxidative injury (4HNE), neuronal death (Fluoro Jade-B), blood brain barrier (BBB) disruption (IgG leak), neurotrophil infiltration (MPO) and microglia activation (CD11b) in the hippocampus was evaluated at three days after status epilepticus (SE). Pilocarpine-induced seizure increased p47 immunofluorescence in the plasma membrane of hippocampal neurons at 12 h post-insult and apocynin treatment prevented this increase. The present study found that apocynin post-treatment decreased ROS production and lipid peroxidation after seizure and decreased the number of degenerating hippocampal neurons. Apocynin also reduced seizure-induced BBB disruption, neurotrophil infiltration and microglial activation. Taken together, the present results suggest that inhibition of NADPH oxidase by apocynin may have a high therapeutic potential to reduce seizure-induced neuronal dysfunction. (C) 2013 Elsevier B.V. All rights reserved.	[Kim, Jin Hee; Jang, Bong Geom; Choi, Bo Young; Kim, Hyeong Seop; Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, Chunchon 200702, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Inchon, South Korea; [Chung, Tae Nyoung] CHA Univ, Sch Med, CHA Bundang Med Ctr, Gyeonggi Do, South Korea; [Choi, Hui Chul; Song, Hong Ki] Hallym Univ, Hallym Inst Epelepsy Res, Chunchon 200702, South Korea		Song, HK (corresponding author), Hallym Univ, Hallym Inst Epelepsy Res, Chunchon 200702, South Korea.	hksong0@paran.com; swsuh@hallym.ac.kr	Chung, Tae Nyoung/AAN-7886-2020	Chung, Tae Nyoung/0000-0003-3537-4136; Choi, Bo Young/0000-0002-9579-3503; SOHN, MIN/0000-0003-4021-2051	Hallym University Specialization Fund [HRF-S-41]	This study was supported by a grant from the Hallym University Specialization Fund (HRF-S-41). The authors thank Aaron M. Hamby, University of California, Berkeley, for help with preparing the manuscript.	Ashrafi MR, 2007, EPILEPSIA, V48, P1750, DOI 10.1111/j.1528-1167.2007.01143.x; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Chang YC, 2003, ANN NEUROL, V54, P706, DOI 10.1002/ana.10789; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dodd-O JM, 2000, AM J PHYSIOL-HEART C, V279, pH303, DOI 10.1152/ajpheart.2000.279.1.H303; Frantseva MV, 2000, NEUROSCIENCE, V97, P431, DOI 10.1016/S0306-4522(00)00041-5; Freitas RM, 2005, FEBS J, V272, P1307, DOI 10.1111/j.1742-4658.2004.04537.x; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Holmes GL, 1998, ANN NEUROL, V44, P845, DOI 10.1002/ana.410440602; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Inamasu J, 2000, ACT NEUR S, V76, P525; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Liu JZ, 2010, SEIZURE-EUR J EPILEP, V19, P165, DOI 10.1016/j.seizure.2010.01.010; de Freitas RLM, 2010, BRAIN RES BULL, V81, P505, DOI 10.1016/j.brainresbull.2009.09.014; Muller CJ, 2009, EUR J PHARMACOL, V619, P15, DOI 10.1016/j.ejphar.2009.07.020; Murakami K, 1998, J NEUROSCI, V18, P205; Nairismagi J, 2006, EPILEPSIA, V47, P479, DOI 10.1111/j.1528-1167.2006.00455.x; Olney J W, 1986, Adv Neurol, V44, P857; Patel M, 2005, J NEUROCHEM, V92, P123, DOI 10.1111/j.1471-4159.2004.02838.x; PERSINGER MA, 1988, PHYSIOL BEHAV, V44, P27, DOI 10.1016/0031-9384(88)90342-3; Pestana RRF, 2010, NEUROSCI LETT, V484, P187, DOI 10.1016/j.neulet.2010.08.049; RACINE RJ, 1972, BRAIN RES, V47, P262, DOI 10.1016/0006-8993(72)90268-5; Ravizza T, 2008, NEUROBIOL DIS, V29, P142, DOI 10.1016/j.nbd.2007.08.012; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; RUTH RE, 1988, ACTA NEUROPATHOL, V76, P380, DOI 10.1007/BF00686975; Shapiro LA, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01491.x; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Tejada-Simon MV, 2005, MOL CELL NEUROSCI, V29, P97, DOI 10.1016/j.mcn.2005.01.007; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5	43	46	46	3	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 7	2013	1499						163	172		10.1016/j.brainres.2013.01.007			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	113ZX	WOS:000316710300016	23313582				2022-02-06	
J	McCarthy, MM; Voos, JE; Nguyen, JT; Callahan, L; Hannafin, JA				McCarthy, Moira M.; Voos, James E.; Nguyen, Joseph T.; Callahan, Lisa; Hannafin, Jo A.			Injury Profile in Elite Female Basketball Athletes at the Women's National Basketball Association Combine	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						ACL; meniscus; ankle sprain; WNBA	ANTERIOR CRUCIATE LIGAMENT; GENERALIZED JOINT LAXITY; HIGH-SCHOOL BASKETBALL; PROFESSIONAL BASKETBALL; RISK-FACTORS; PROSPECTIVE COHORT; MENSTRUAL-CYCLE; ANKLE INJURIES; ACL INJURIES; KNEE INJURY	Background: Anterior cruciate ligament (ACL) and meniscus injuries are common in female athletes participating in cutting and pivoting sports such as basketball. The epidemiological characteristics of injury in athletes seen at the Women's National Basketball Association (WNBA) combine and the effect of ACL reconstruction and meniscus surgery on longevity in the WNBA are unknown. Purpose: To evaluate the details and spectrum of injuries in athletes entering the WNBA combine and to assess the potential effect of specific injuries on the round drafted into the WNBA and career length. Study Design: Descriptive epidemiology study. Methods: Demographic data and the documented collegiate injury profile were reviewed from the WNBA database for all players entering the WNBA combine in 2000-2008. The study included injury data on 506 athletes. Complete demographic data were available for 496 players. Results: Of the athletes taking part in the combine, 45.2% were guards, 33.7% were forwards, and 21.1% were centers. Ankle sprain (47.8% of players), hand injury (20.8%), patellar tendinitis (17.0%), ACL injury (15.0%), meniscus injury (10.5%), stress fracture (7.3%), and concussion (7.1%) were the most common injuries reported. Seventy-three athletes (14.4%) reported ACL reconstruction before entering the WNBA combine, and meniscus surgery was the next most common surgery (n = 50 players; 9.9%). There were no differences in ACL or meniscus surgery when analyzed by player position or round drafted. History of ACL or meniscus surgery did not affect career length in the WNBA. Excluding ACL and meniscus surgery, other reported surgical procedures were knee arthroscopic surgery (11.7%), ankle reconstruction (2.6%), and shoulder stabilization (2.0%). Conclusion: The ankle is the most common site of injury and ACL reconstruction is the most common surgery in elite female athletes participating in the WNBA combine. A history of injury or surgery did not affect the round drafted or career length.	[McCarthy, Moira M.; Voos, James E.; Nguyen, Joseph T.; Callahan, Lisa; Hannafin, Jo A.] Hosp Special Surg, New York, NY 10021 USA		McCarthy, MM (corresponding author), Hosp Special Surg, 310 East 71st St,Suite 2E, New York, NY 10021 USA.	mccarthymo@hss.edu	Nguyen, Joseph/ABC-1527-2021	Nguyen, Joseph/0000-0003-1686-3911			Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; Alentorn-Geli E, 2009, KNEE SURG SPORT TR A, V17, P705, DOI 10.1007/s00167-009-0813-1; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Arendt EA, 1999, J ATHL TRAINING, V34, P86; Barrett G R, 1992, J Miss State Med Assoc, V33, P279; Boden BP, 2000, ORTHOPEDICS, V23, P573, DOI 10.3928/0147-7447-20000601-15; Brophy RH, 2009, AM J SPORT MED, V37, P2102, DOI 10.1177/0363546509349035; Deitch JR, 2006, AM J SPORT MED, V34, P1077, DOI 10.1177/0363546505285383; DeMorat G, 2004, AM J SPORT MED, V32, P477, DOI 10.1177/0363546503258928; DUFEK JS, 1991, SPORTS MED, V12, P326, DOI 10.2165/00007256-199112050-00005; Everhart JS, 2010, AM J SPORT MED, V38, P1667, DOI 10.1177/0363546510367424; FERRETTI A, 1992, AM J SPORT MED, V20, P203, DOI 10.1177/036354659202000219; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; GRAY J, 1985, INT J SPORTS MED, V6, P314, DOI 10.1055/s-2008-1025861; Gwinn DE, 2000, AM J SPORT MED, V28, P98, DOI 10.1177/03635465000280012901; Hashemi J, 2008, J BONE JOINT SURG AM, V90A, P2724, DOI 10.2106/JBJS.G.01358; HENRY JH, 1982, AM J SPORT MED, V10, P16, DOI 10.1177/036354658201000104; HERSKOWITZ A, 1993, CLIN SPORT MED, V12, P293; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Hewett TE, 2008, ORTHOPEDICS, V31, P26, DOI 10.3928/01477447-20080101-18; Hewett TE, 2007, AM J SPORT MED, V35, P659, DOI 10.1177/0363546506295699; Hickey GJ, 1997, CLIN J SPORT MED, V7, P252, DOI 10.1097/00042752-199710000-00002; Hosea TM, 2000, CLIN ORTHOP RELAT R, P45; Huston LJ, 1996, AM J SPORT MED, V24, P427, DOI 10.1177/036354659602400405; Ireland ML, 2002, ORTHOP CLIN N AM, V33, P637, DOI 10.1016/S0030-5898(02)00028-7; Kofotolis N, 2007, J ATHL TRAINING, V42, P388; KRINSKY MB, 1992, AM J SPORT MED, V20, P17, DOI 10.1177/036354659202000105; LaPrade RF, 1994, AM J SPORTS MED, V22, P203; Li G, 1999, J BIOMECH, V32, P395, DOI 10.1016/S0021-9290(98)00181-X; McKay G, 2001, J SCI MED SPORT, V4, P196, DOI 10.1016/S1440-2440(01)80030-X; McKay GD, 2001, BRIT J SPORT MED, V35, P103, DOI 10.1136/bjsm.35.2.103; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; Mihata LCS, 2006, AM J SPORT MED, V34, P899, DOI 10.1177/0363546505285582; Myer GD, 2008, AM J SPORT MED, V36, P1073, DOI 10.1177/0363546507313572; Myer GD, 2009, CLIN J SPORT MED, V19, P3, DOI 10.1097/JSM.0b013e318190bddb; Myklebust G, 1998, SCAND J MED SCI SPOR, V8, P149, DOI 10.1111/j.1600-0838.1998.tb00185.x; Owens BD, 2007, MIL MED, V172, P90, DOI 10.7205/MILMED.172.1.90; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Ramesh R, 2005, J BONE JOINT SURG BR, V87B, P800, DOI 10.1302/0301-620X.87B6.15833; Renstrom P, 2008, BRIT J SPORT MED, V42, P394, DOI 10.1136/bjsm.2008.048934; Rozzi SL, 1999, AM J SPORT MED, V27, P312, DOI 10.1177/03635465990270030801; Schmitz RJ, 2008, AM J SPORT MED, V36, P1380, DOI 10.1177/0363546508317411; SHAMBAUGH JP, 1991, MED SCI SPORT EXER, V23, P522; Silvers Holly J, 2005, Curr Sports Med Rep, V4, P341; Starkey C, 2000, J ATHL TRAINING, V35, P161; Trojian TH, 2006, AM J SPORT MED, V34, P895, DOI 10.1177/0363546505284384; Uhorchak JM, 2003, AM J SPORT MED, V31, P831, DOI 10.1177/03635465030310061801; Vauhnik R, 2011, J ATHL TRAINING, V46, P92, DOI 10.4085/1062-6050-46.1.92; Wojtys EM, 1998, AM J SPORT MED, V26, P614, DOI 10.1177/03635465980260050301; ZAGELBAUM BM, 1995, ARCH OPHTHALMOL-CHIC, V113, P749, DOI 10.1001/archopht.1995.01100060075035; Zazulak BT, 2007, AM J SPORT MED, V35, P368, DOI 10.1177/0363546506297909; ZELISKO JA, 1982, AM J SPORT MED, V10, P297, DOI 10.1177/036354658201000507	55	46	49	0	67	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAR	2013	41	3					645	651		10.1177/0363546512474223			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	098QG	WOS:000315563200023	23378506				2022-02-06	
J	Davis, JJ; Walter, KH; Chard, KM; Parkinson, RB; Houston, WS				Davis, Jeremy J.; Walter, Kristen H.; Chard, Kathleen M.; Parkinson, R. Bruce; Houston, Wes S.			Treatment Adherence in Cognitive Processing Therapy for Combat-Related PTSD With History of Mild TBI	REHABILITATION PSYCHOLOGY			English	Article						posttraumatic stress disorder; mild traumatic brain injury; cognitive processing therapy; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SELF-REPORTED SYMPTOMS; POSTCONCUSSIVE SYMPTOMS; VETERANS; REHABILITATION; AFGHANISTAN; DIAGNOSIS; FOOTBALL; EXPOSURE	Objective: This retrospective study examined treatment adherence in Cognitive Processing Therapy (CPT) for combat-related posttraumatic stress disorder (PTSD) in Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) with and without history of mild traumatic brain injury (mTBI). Method: Medical record review of consecutive referrals to an outpatient PTSD clinic identified veterans diagnosed with combat-related PTSD who began treatment with CPT. The sample (N = 136) was grouped according to positive (n = 44) and negative (n = 92) mTBI history. Groups were compared in terms of presenting symptoms and treatment adherence. Results: The groups were not different on a pretreatment measure of depression, but self-reported and clinician-rated PTSD symptoms were higher in veterans with history of mTBI. The treatment completion rate was greater than 61% in both groups. The number of sessions attended averaged 9.6 for the PTSD group and 7.9 for the mTBI/PTSD group (p = .05). Implications: Given the lack of marked group differences in treatment adherence, these initial findings suggest that standard CPT for PTSD may be a tolerable treatment for OEF/OIF veterans with a history of PTSD and mTBI as well as veterans with PTSD alone.	[Davis, Jeremy J.; Parkinson, R. Bruce; Houston, Wes S.] Cincinnati VA Med Ctr, Mental Hlth Care Line, Cincinnati, OH USA; [Davis, Jeremy J.] Univ Utah, Sch Med, Div Phys Med & Rehabil, Salt Lake City, UT 84112 USA; [Walter, Kristen H.] Cincinnati VA Med Ctr, Trauma Recovery Ctr, Cincinnati, OH USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Cincinnati VA Med Ctr, Trauma Recovery Ctr, Cincinnati, OH 45221 USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Dept Psychiat, Cincinnati, OH 45221 USA		Chard, KM (corresponding author), 3200 Vine St, Cincinnati, OH 45220 USA.	kathleen.chard@va.gov	Walter, Kristen H/S-1827-2019				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BLANCHARD EB, 1995, BEHAV RES THER, V33, P471, DOI 10.1016/0005-7967(94)00064-Q; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Chard KM, 2010, J TRAUMA STRESS, V23, P25, DOI 10.1002/jts.20500; Chard KM, 2005, J CONSULT CLIN PSYCH, V73, P965, DOI 10.1037/0022-006X.73.5.965; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Foa E.B., 2008, EFFECTIVE TREATMENTS; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Monson C. M., 2007, COGNITIVE PROCESSING; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Soo C, 2007, COCHRANE DB SYST REV, V3; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; *VET HLTH ADM DEP, 2004, VA DOD CLIN PRACT GU; Veterans Health Administration, 2007, SCREEN EV POSS TRAUM; Veterans Health Administration, 2005, IMPL NAT CLIN REM AF; Veterans Health Administration & Department of Defense, 2009, VA DOD CLIN PRACT GU; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238	63	46	46	0	23	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2013	58	1					36	42		10.1037/a0031525			7	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	095VA	WOS:000315361900005	23437998				2022-02-06	
J	Olsson, KA; Lloyd, OT; LeBrocque, RM; McKinlay, L; Anderson, VA; Kenardy, JA				Olsson, Katherine A.; Lloyd, Owen T.; LeBrocque, Robyne M.; McKinlay, Lynne; Anderson, Vicki A.; Kenardy, Justin A.			Predictors of child post-concussion symptoms at 6 and 18 months following mild traumatic brain injury	BRAIN INJURY			English	Article						Child; post-concussion; mild traumatic brain injury	HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; EVENT SCALE; MODERATE; RECOVERY; OUTCOMES; IMPACT	Background: A proportion of children will experience persistent post-concussion symptoms (PCS) following a mild traumatic brain injury (mTBI). As persistent PCS may be maintained by pathological and psychological factors, this study aimed to describe and evaluate potential pre- and post-injury parent and child predictors of persistent PCS. Methods: A total of 150 children with mTBI and their parents participated. Parents completed measures of their own distress and children's PCS and health-related quality-of-life (HRQoL) at baseline (reflecting pre-injury function). These measures, as well as measures of children's distress and cognitive function were administered at 6 and 18 months post-injury. Results: Children's PCS at 6 months post-injury were predicted by both pre-injury parent distress and children's pre-injury PCS. At 18 months post-injury, children's PCS were predicted by higher levels of parent distress and child PCS at 6 months post-injury, as well as poorer post-injury cognitive functioning. Change in PCS between 6-18 months post-injury was predicted by parent's pre-injury anxiety and children's HRQoL. Conclusions: Children at risk of persistent PCS can be identified by higher levels of pre- and post-injury PCS, parent distress and poorer post-injury cognition. These factors should be addressed by interventions aimed at minimizing the occurrence and impact of child PCS.	[Olsson, Katherine A.; LeBrocque, Robyne M.; Kenardy, Justin A.] Univ Queensland, Ctr Natl Res Disabil & Rehabil Med, Brisbane, Qld 4072, Australia; [Olsson, Katherine A.; Kenardy, Justin A.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia; [Lloyd, Owen T.; McKinlay, Lynne] Royal Childrens Hosp Brisbane, Queensland Paediat Rehabil Serv, Brisbane, Qld, Australia; [Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Kenardy, JA (corresponding author), Royal Brisbane & Womens Hosp, CONROD, Ground Floor,Edith Cavell Bldg, Herston, Qld 4029, Australia.	j.kenardy@uq.edu.au	Kenardy, Justin/F-2085-2010; Le Brocque, Robyne/F-4848-2010; Kenardy, Justin A/H-6603-2014; Olsson, Katherine A/K-9957-2016	Le Brocque, Robyne/0000-0002-4574-1254; Kenardy, Justin A/0000-0001-9475-8450; McKinlay, Lynne/0000-0002-6677-0628	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [301103]	The authors report no conflicts of interest. This study is supported by the National Health and Medical Research Council grant number 301103.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; [Anonymous], 2006, 2006 YB AUSTR; Baumert J, 2004, J AFFECT DISORDERS, V82, P29, DOI 10.1016/j.jad.2003.09.006; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Briere J., 1996, TRAUMA SYMPTOMS CHEC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Field A., 2017, DISCOVERING STAT USI, V5th; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Goldberg D., 1998, USERS GUIDE GEN HLTH; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kirk JW, 2005, DEV NEUROPSYCHOL, V28, P755, DOI 10.1207/s15326942dn2803_2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Landgraf JM, 1996, CHILD HLTH QUESTIONN; Manly T., 1999, TEST EVERYDAY ATTENT; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Olsson KA, 2008, BRAIN INJURY, V22, P595, DOI 10.1080/02699050802132453; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHSLER ABBREVIATED; Weiss D, 1997, ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	46	46	46	0	20	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2013	27	2					145	157		10.3109/02699052.2012.729286			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	083PX	WOS:000314478500003	23384213				2022-02-06	
J	Raj, R; Bendel, S; Reinikainen, M; Kivisaari, R; Siironen, J; Lang, M; Skrifvars, M				Raj, Rahul; Bendel, Stepani; Reinikainen, Matti; Kivisaari, Riku; Siironen, Jari; Lang, Maarit; Skrifvars, Markus			Hyperoxemia and long-term outcome after traumatic brain injury	CRITICAL CARE			English	Article						Arterial oxygen tension; Neurocritical care; Oxygenation; Traumatic brain injury; Hyperoxemia; Intensive care; Mortality; Mechanical ventilation	SEVERE HEAD-INJURY; ACUTE LUNG INJURY; TISSUE OXYGEN; NORMOBARIC HYPEROXIA; VENTILATED PATIENTS; ARTERIAL HYPEROXIA; PROGNOSTIC VALUE; INSPIRED OXYGEN; CARDIAC-ARREST; ASSOCIATION	Introduction: The relationship between hyperoxemia and outcome in patients with traumatic brain injury (TBI) is controversial. We sought to investigate the independent relationship between hyperoxemia and long-term mortality in patients with moderate-to-severe traumatic brain injury. Methods: The Finnish Intensive Care Consortium database was screened for mechanically ventilated patients with a moderate-to-severe TBI. Patients were categorized, according to the highest measured alveolar-arterial O-2 gradient or the lowest measured PaO2 value during the first 24 hours of ICU admission, to hypoxemia (<10.0 kPa), normoxemia (10.0 to 13.3 kPa) and hyperoxemia (>13.3 kPa). We adjusted for markers of illness severity to evaluate the independent relationship between hyperoxemia and 6-month mortality. Results: A total of 1,116 patients were included in the study, of which 16% (n = 174) were hypoxemic, 51% (n = 567) normoxemic and 33% (n = 375) hyperoxemic. The total 6-month mortality was 39% (n = 435). A significant association between hyperoxemia and a decreased risk of mortality was found in univariate analysis (P = 0.012). However, after adjusting for markers of illness severity in a multivariate logistic regression model hyperoxemia showed no independent relationship with 6-month mortality (hyperoxemia vs. normoxemia OR 0.88, 95% CI 0. 63 to 1.22, P = 0.43; hyperoxemia vs. hypoxemia OR 0.97, 95% CI 0.63 to 1.50, P = 0.90). Conclusion: Hyperoxemia in the first 24 hours of ICU admission after a moderate-to-severe TBI is not predictive of 6-month mortality.	[Raj, Rahul; Kivisaari, Riku; Siironen, Jari; Skrifvars, Markus] Univ Helsinki, Cent Hosp, Dept Neurosurg, FI-00029 Hus Helsinki, Finland; [Bendel, Stepani; Lang, Maarit] Kuopio Univ Hosp, Dept Intens Care Med, Kuopio 70211, Finland; [Reinikainen, Matti] North Karelia Cent Hosp, Dept Intens Care Med, Joensuu 80210, Finland; [Skrifvars, Markus] Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Helsinki, Finland		Raj, R (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, Topeliuksenkatu 5, FI-00029 Hus Helsinki, Finland.	rahul.br.raj@icloud.com	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591; Reinikainen, Matti/0000-0001-6878-3740	Helsinki University Hospital EVO grant [TYH2012142]; Medicinska Understodsforeningen Liv och Halsa	The study was funded by a Helsinki University Hospital EVO grant (TYH2012142) and Medicinska Understodsforeningen Liv och Halsa.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Altemeier WA, 2007, CURR OPIN CRIT CARE, V13, P73, DOI 10.1097/MCC.0b013e32801162cb; Asher SR, 2013, J NEUROSURG ANESTH, V25, P168, DOI 10.1097/ANA.0b013e318283d350; Bellomo R, 2011, CRIT CARE, V15, DOI 10.1186/cc10090; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brain Trauma Foundation, 2007, J NEUROTRAUMA S, V24, pS1; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Fehlings MG, 2007, J NEUROSURG, V106, P525, DOI 10.3171/jns.2007.106.4.525; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Gole Y, 2011, EUR J APPL PHYSIOL, V111, P937, DOI 10.1007/s00421-010-1711-4; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Longhi L, 2002, ACT NEUR S, V81, P315; Longmore JM, 2011, OXFORD HDB CLIN MED; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nangunoori R, 2012, NEUROCRIT CARE, V17, P131, DOI 10.1007/s12028-011-9621-9; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nelskyla A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-35; Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinikainen M, 2012, ACTA ANAESTH SCAND, V56, P1114, DOI 10.1111/j.1399-6576.2012.02669.x; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Sinclair SE, 2004, CRIT CARE MED, V32, P2496, DOI 10.1097/01.CCM.0000148231.04642.8D; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Young P, 2012, CRIT CARE RESUSC, V14, P14	50	46	47	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	4							R177	10.1186/cc12856			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AB1GO	WOS:000331539700050	23958227	Green Published, gold			2022-02-06	
J	Zuckerman, SL; Solomon, GS; Forbes, JA; Haase, RF; Sills, AK; Lovell, MR				Zuckerman, Scott L.; Solomon, Gary S.; Forbes, Jonathan A.; Haase, Richard F.; Sills, Allen K.; Lovell, Mark R.			Response to acute concussive injury in soccer players: is gender a modifying factor? Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						sports-related concussion; gender; soccer; trauma; mild traumatic brain injury; Immediate Postconcussion Assessment and Cognitive Testing	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; SEX-DIFFERENCES; HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; UNITED-STATES; IMPACT; SYMPTOMS; SCORES	Object. Several studies have suggested a gender difference in response to sports-related concussion (SRC). The Concussion in Sport group did not include gender as a modifying factor in SRC, concluding that the evidence at that point was equivocal. In the present study the authors endeavored to assess acute neurocognitive and symptom responses to an SRC in equivalent cohorts of male and female soccer players. The authors hypothesized that female athletes would experience greater levels of acute symptoms and neurocognitive impairment than males. Methods. Baseline symptom and neurocognitive scores were determined in 40 male and 40 female soccer players by using the Immediate Postconcussion Assessment and Cognitive Testing (ImPACT) scale prior to any SRC. After sustaining an SRC, each athlete completed postconcussion ImPACT tests and was carefully matched on a wide array of biopsychosocial variables. Baseline symptom and neurocognitive test scores were compared, and their acute symptoms and neurocognitive responses to concussive injury were assessed. Results. Specific a priori hypotheses about differences between males and females at baseline and at postconcussion measurements of verbal and visual memory ImPACT scores were evaluated according to simple main effects of the gender variable and according to baseline-to-postconcussion main effect and interaction of 2 x 2 split-plot ANOVA. Neither the interaction nor the main effects nor the simple main effects for either ImPACT variable were found to be statistically significant. Exploratory ANOVAs applied to the remaining ImPACT variables of visual-motor speed, reaction time, impulse control, and symptom total scores revealed only a single statistically significant baseline-to-postconcussion main effect for the symptom total. Conclusions. The results failed to replicate prior findings of gender-specific baseline neurocognitive differences in verbal and visual memory. The findings also indicated no differential gender-based acute response to concussion (symptoms or neurocognitive scores) among high school soccer players. The implications of these findings for the inclusion of gender as a modifying factor in this tightly matched cohort are addressed. Potential explanations for the null findings are discussed. (http://thejns.org/doi/abs/10.3171/2012.8.PEDS12139)	[Zuckerman, Scott L.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Sch Med, Nashville, TN 37232 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Psychiat, Nashville, TN 37232 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; [Forbes, Jonathan A.; Sills, Allen K.] SUNY Albany, Dept Educ & Counseling Psychol, Albany, NY 12222 USA; [Lovell, Mark R.] ImPACT Applicat, Pittsburgh, PA USA		Zuckerman, SL (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Sch Med, T-4224 Med Ctr N, Nashville, TN 37232 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019				Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cohen J., 2013, STAT POWER ANAL BEHA; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M, 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, IMPACT 2007 6 0 CLIN; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maxwell SE, 2004, DESIGNING EXPT ANAL, P920; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RENCHER AC, 1990, COMMUN STAT SIMULAT, V19, P535, DOI 10.1080/03610919008812874; RUTHERFORD WH, 1977, LANCET, V1, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X; [No title captured]	34	46	46	0	37	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2012	10	6					504	510		10.3171/2012.8.PEDS12139			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Surgery	042IE	WOS:000311464100010	23030348	Bronze			2022-02-06	
J	Wood, JN; Feudtner, C; Medina, SP; Luan, XQ; Localio, R; Rubin, DM				Wood, Joanne N.; Feudtner, Chris; Medina, Sheyla P.; Luan, Xianqun; Localio, Russell; Rubin, David M.			Variation in Occult Injury Screening for Children With Suspected Abuse in Selected US Children's Hospitals	PEDIATRICS			English	Article						child abuse; child maltreatment; femur fracture; traumatic brain injury	HEAD-INJURY; SKELETAL SURVEYS; YOUNG-CHILDREN; FRACTURES; INFANTS; CARE; IDENTIFICATION; MANAGEMENT; DIAGNOSIS; EVALUATE	OBJECTIVE: To describe variation across selected US children's hospitals in screening for occult fractures in children <2 years old diagnosed with physical abuse and in infants <1 year old who have injuries associated with a high likelihood of physical abuse. METHODS: We performed a retrospective study of children <2 years old with a diagnosis of physical abuse and infants <1 year old with non-motor vehicle crash-associated traumatic brain injuries or femur fractures admitted to 40 hospitals within the Pediatric Hospital Information System database from January 1, 1999, to December 31, 2009. We examined variation among the hospitals in the performance of screening for occult fractures as defined by receipt of skeletal survey or radionuclide bone scan. Marginal standardization implemented with logistic regression analysis was used to examine hospital variation after adjusting for patient demographic characteristics, injury severity, and year of admission. RESULTS: Screening for occult fractures was performed in 83% of the 10 170 children <2 years old with a diagnosis of physical abuse, 68% of the 9942 infants who had a traumatic brain injury, and 77% of the 2975 infants who had femur fractures. After adjustment for patient characteristics, injury severity, and year of admission, hospitals varied significantly in use of screening for occult fractures in all 3 groups of children. CONCLUSIONS: The observed variation in screening for occult fractures in young victims of physical abuse and infants who have injuries associated with a high likelihood of abuse underscores opportunities to improve the quality of care provided to this vulnerable population. Pediatrics 2012;130:853-860	[Wood, Joanne N.; Feudtner, Chris; Medina, Sheyla P.; Luan, Xianqun; Localio, Russell; Rubin, David M.] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Medina, Sheyla P.; Luan, Xianqun; Localio, Russell; Rubin, David M.] Childrens Hosp Philadelphia, PolicyLab, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Rubin, David M.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Localio, Russell] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA		Wood, JN (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434; Wood, Joanne/0000-0001-6431-8024	National Institute of Child Health and Human Development grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD071967-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD071967] Funding Source: NIH RePORTER	Dr Wood has received salary funding from the National Institute of Child Health and Human Development grant (1K23HD071967-01).	American College of Radiology, 2011, ACR SPR PRACT GUID S; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Christakis DA, 2005, PEDIATRICS, V115, P878, DOI 10.1542/peds.2004-1299; DeGraw M, 2010, PEDIATRICS, V125, pE295, DOI 10.1542/peds.2009-1478; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; Fisher BT, 2012, PHARMACOEPIDEM DR S, P244, DOI DOI 10.1002/9781119959946.CH16; Flaherty EG, 2000, ARCH PEDIAT ADOL MED, V154, P489, DOI 10.1001/archpedi.154.5.489; Flaherty EG, 2008, PEDIATRICS, V122, P611, DOI 10.1542/peds.2007-2311; Flaherty EG, 2006, CHILD MALTREATMENT, V11, P361, DOI 10.1177/1077559506292287; Gerber JS, 2010, PEDIATRICS, V126, P1067, DOI 10.1542/peds.2010-1275; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; GROSS RH, 1983, J PEDIATR ORTHOPED, V3, P341, DOI 10.1097/01241398-198307000-00012; Guerra CE, 2007, J GEN INTERN MED, V22, P1681, DOI 10.1007/s11606-007-0396-9; HAMPTON RL, 1985, AM J PUBLIC HEALTH, V75, P56, DOI 10.2105/AJPH.75.1.56; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hicks RA, 2007, PEDIATR EMERG CARE, V23, P308, DOI 10.1097/01.pec.0000270174.39228.30; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Karmazyn B, 2011, AM J ROENTGENOL, V197, pW159, DOI 10.2214/AJR.10.5733; King WK, 2006, PEDIATR EMERG CARE, V22, P211, DOI 10.1097/01.pec.0000208180.94166.dd; Kokorowski PJ, 2010, PEDIATRICS, V126, pE576, DOI 10.1542/peds.2010-0747; Korn E.L., 1999, ANAL HLTH SURVEYS; Lane WG, 2007, CLIN ORTHOP RELAT R, P219, DOI 10.1097/BLO.0b013e31805c0849; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; Madlon-Kay DJ, 2012, J AM BOARD FAM MED, V25, P437, DOI 10.3122/jabfm.2012.04.110307; Mandelstam SA, 2003, ARCH DIS CHILD, V88, P387, DOI 10.1136/adc.88.5.387; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; *NAT ASS CHILDR HO, 2006, DEF CHILDR HOSP ROL; National Association of Children's Hospitals and Related Institutions, 2009, RESP CHILD MALTR 200; National Association of Children's Hospitals and Related Institutions, 2006, 2005 SURV FIND CHILD; Oral R, 2003, PEDIATR EMERG CARE, V19, P148, DOI 10.1097/01.pec.0000081234.20228.33; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rogers W, 1993, STATA TECHNICAL B, V2; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schwend RM, 2000, J PEDIATR ORTHOPED, V20, P475, DOI 10.1097/00004694-200007000-00010; Sege RD, 2008, ARCH DIS CHILD, V93, P822, DOI 10.1136/adc.2006.100545; Sobota A, 2012, PEDIATR BLOOD CANCER, V58, P61, DOI 10.1002/pbc.23221; Tarini BA, 2007, J HOSP MED, V2, P69, DOI 10.1002/jhm.169; Thackeray JD, 2007, PEDIATR EMERG CARE, V23, P735, DOI 10.1097/PEC.0b013e3181568039; Tien I, 2002, PEDIATRICS, V110, P1226, DOI 10.1542/peds.110.6.1226; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; Vernacchio L, 2007, PEDIATRICS, V120, P281, DOI 10.1542/peds.2006-3601; Wood JN, 2009, PEDIATRICS, V123; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	52	46	46	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2012	130	5					853	860		10.1542/peds.2012-0244			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	029OT	WOS:000310505900054	23071208	Green Published			2022-02-06	
J	Klein, P; Herr, D; Pearl, PL; Natale, J; Levine, Z; Nogay, C; Sandoval, F; Trzcinski, S; Atabaki, SM; Tsuchida, T; van den Anker, J; Soldin, SJ; He, JP; McCarter, R				Klein, Pavel; Herr, Daniel; Pearl, Phillip L.; Natale, JoAnne; Levine, Zachary; Nogay, Claude; Sandoval, Fabian; Trzcinski, Stacey; Atabaki, Shireen M.; Tsuchida, Tammy; van den Anker, John; Soldin, Steven J.; He, Jianping; McCarter, Robert			Results of Phase 2 Safety and Feasibility Study of Treatment With Levetiracetam for Prevention of Posttraumatic Epilepsy	ARCHIVES OF NEUROLOGY			English	Article							SEIZURES; EPILEPTOGENESIS	Objectives: To evaluate the safety and tolerability of treatment with levetiracetam and determine the trough levels of levetiracetam in patients with traumatic brain injury (TBI) who are at high risk for posttraumatic epilepsy (PTE). Design: Open-label, nonrandomized phase 2 study with 2 arms comparing levetiracetam treatment vs observation. Setting: Two level 1 trauma centers. Patients: A total of 422 participants 6 years or older with TBI who have a 20% risk for PTE were screened. Of these participants, 205 (48.6%) were eligible. A total of 126 participants were enrolled: 86 adults and 40 children. A total of 66 participants were in the treatment group (46 adults and 20 children), and a total of 60 participants were in the observation group (40 adults and 20 children). Participants presenting within 8 hours after TBI received treatment, and those presenting more than 8 to 24 hours after TBI did not. Intervention: Treatment with levetiracetam (55 mg/kg/d) for 30 days starting within 8 hours after injury. Main Outcome Measures: Number of adverse events, mood score, number of infections, trough level of levetiracetam, and PTE. Results: Of the 66 participants treated with levetiracetam, 2 (3%) stopped treatment owing to toxicity (somnolence). The most common adverse events were fatigue, headache, and somnolence. Mood scores and number of infections did not differ between the treatment and observation groups. Mean trough levels of levetiracetam on days 2 to 30 ranged from 19.6 to 26.7 mu g/mL. At 2 years, 13 of 86 adults (15.1%) and 1 of 40 children (2.5%) developed PTE. At 2 years, 5 of 46 treated adults (10.9%) and 8 of 40 untreated adults (20.0%) developed PTE (relative risk, 0.47; P = .18). Conclusion: Treatment with 55 mg/kg/d of levetiracetam (a dose with an antiepileptogenic effect on animals) for patients with TBI at risk for PTE is safe and well tolerated, with plasma levels similar to those in animal studies. The findings support further evaluation of levetiracetam treatment for the prevention of PTE.	[Klein, Pavel] Midatlantic Epilepsy & Sleep Ctr, Bethesda, MD 20817 USA; [Klein, Pavel; Herr, Daniel; Levine, Zachary; Nogay, Claude; Sandoval, Fabian] MedStar Res Inst, Dept Neurol, Washington, DC USA; [Pearl, Phillip L.; Natale, JoAnne; Trzcinski, Stacey; Tsuchida, Tammy; van den Anker, John; He, Jianping; McCarter, Robert] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA; [Atabaki, Shireen M.] Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA		Klein, P (corresponding author), Midatlantic Epilepsy & Sleep Ctr, 6410 Rockledge Dr,Ste 410, Bethesda, MD 20817 USA.	kleinp@epilepsydc.com	Herr, Daniel/X-4215-2019	Pearl, Phillip/0000-0002-6373-1068; Herr, Daniel/0000-0001-8533-9000	UCB PharmaUCB Pharma SA; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS45656]; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS45656, R0158553]; General Clinical Research Center of Children's National Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD058553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045656] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010355] Funding Source: NIH RePORTER	Dr Klein received honoraria for serving on a scientific advisory board for UCB Pharma, has participated in clinical trials sponsored by UCB Pharma as the site principal investigator, and is on the speakers' bureau of UCB Pharma. He and Dr Herr received funding for this study from the National Institutes of Health (NIH; grant R01 NS45656). Dr Pearl also received funding for this study from NIH grant R01 NS45656 and receives funding from NIH grant R0158553. Dr Levine received honoraria for serving on a scientific advisory board for Medtronics and is on Medtronics' speakers' bureau. He and Drs van den Anker, Soldin, and McCarter also received funding for this study from NIH grant R01 NS45656.; This study was sponsored by the NIH (grant R01 NS45656). Study medication (levetiracetam) was provided free of charge by UCB Pharma. The study was supported by the NIH (grant R01 NS45656) and by the General Clinical Research Center of Children's National Medical Center.	[Anonymous], 1981, Epilepsia, V22, P489; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons AANS/CNS Joint Section on Neurotrauma and Critical Care, 2008, J NEUROTRAUM, V25, P276; Cramer JA, 2003, EPILEPSY BEHAV, V4, P124, DOI 10.1016/S1525-5050(03)00005-2; Crepeau AZ, 2010, EXPERT REV NEUROTHER, V10, P159, DOI [10.1586/ern.10.5, 10.1586/ERN.10.3]; Glauser TA, 2006, NEUROLOGY, V66, P1654, DOI 10.1212/01.wnl.0000217916.00225.3a; Harden C, 2001, EPILEPSIA, V42, P36, DOI 10.1046/j.1528-1157.2001.0420s4036.x; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Pharma UCB Pharma Inc., 1999, DAT FIL; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x	13	46	48	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	2012	69	10					1290	1295		10.1001/archneurol.2012.445			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	016TC	WOS:000309541400007	22777131	Green Accepted, Bronze			2022-02-06	
J	Nguyen, DH; Cho, N; Satkunendrarajah, K; Austin, JW; Wang, J; Fehlings, MG				Dung Hoang Nguyen; Cho, Newton; Satkunendrarajah, Kajana; Austin, James W.; Wang, Jian; Fehlings, Michael G.			Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Inflammation; Immuno-modulatory; Immunoglobulin G; Functional recovery	MICROVESSEL ENDOTHELIAL-CELLS; FUNCTIONAL RECOVERY; INFLAMMATORY RESPONSE; NEUROLOGICAL FUNCTION; NEUTROPHIL ELASTASE; MESSENGER-RNA; NITRIC-OXIDE; BRAIN-INJURY; EXPRESSION; METHYLPREDNISOLONE	Background: Evidence suggests that the inflammatory events in the acute phase of spinal cord injury (SCI) exacerbate the initial trauma to the cord leading to poor functional recovery. As a result, minimizing the detrimental aspects of the inflammatory response after SCI is a promising treatment strategy. In this regard, immunoglobulin G (IgG) from pooled human serum is a promising treatment candidate. Due to its putative, though poorly characterized immuno-modulatory effects, IgG has been used clinically to treat neuroinflammatory disorders such as Guillain-Barre syndrome, but its effects in neurotrauma remain largely unexplored. Methods: This study examines the potential neuroprotective effects of IgG in a well-characterized cervical model of SCI. Female Wistar rats were subject to moderate-severe clip compression injury at the C7-T1 level. IgG (0.4 g/kg) or saline was injected intravenously to randomly selected animals at 15 min post SCI. At several time points post SCI, biochemical assays, histology and immunohistochemistry analyses, and neurobehavioral assessments were used to examine the neuroprotective effects of IgG at the molecular, cellular, and neurobehavioral levels. Results: We found that intravenous treatment of IgG following acute clip-compression SCI at C7-T1 significantly reduced two important inflammatory cytokines: interleukin (IL)-1 beta and IL-6. This early reduction in pro-inflammatory signaling was associated with significant reductions in neutrophils in the spinal cord and reductions in the expression of myeloperoxidase and matrix metalloproteinase-9 in the injured spinal cord at 24 h after SCI. These beneficial effects of IgG were associated with enhanced tissue preservation, improved neurobehavioral recovery as measured by the BBB and inclined plane tests, and enhanced electrophysiological evidence of central axonal conduction as determined by motor-evoked potentials. Conclusion: The findings from this study indicate that IgG is a novel immuno-modulatory therapy which shows promise as a potential treatment for SCI.	[Dung Hoang Nguyen; Cho, Newton; Austin, James W.; Wang, Jian; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5T 2S8, Canada; [Dung Hoang Nguyen; Cho, Newton; Satkunendrarajah, Kajana; Austin, James W.; Wang, Jian; Fehlings, Michael G.] Toronto Western Res Inst, Div Genet & Dev, Toronto, ON, Canada; [Wang, Jian; Fehlings, Michael G.] Univ Hlth Network, Krembil Neurosci Ctr, Toronto, ON, Canada; [Wang, Jian; Fehlings, Michael G.] Univ Toronto, Div Neurosurg, Toronto, ON M5T 2S8, Canada; [Wang, Jian; Fehlings, Michael G.] Univ Toronto, Neurosci Program, Toronto, ON M5T 2S8, Canada		Fehlings, MG (corresponding author), Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364	Baxter Healthcare Corporation through Baxter BioScience Grant; Federick Banting and Charles Best Graduate Scholarship	The authors gratefully acknowledge the dedication and support of all members of the Fehlings laboratory in this study. The authors thank Stephanie Hewson for her editorial assistance. We acknowledge Baxter Healthcare Corporation for their financial support through the Baxter BioScience Grant. MGF holds the Gerald and Tootsie Halbert Chair in Neural Repair and Regeneration. DHN holds the Federick Banting and Charles Best Graduate Scholarship.	Abbas A.K., 2000, CELLULAR MOL IMMUNOL; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; BAINTON DF, 1968, J CELL BIOL, V39, P299, DOI 10.1083/jcb.39.2.299; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2008, EXP NEUROL, V214, P160, DOI 10.1016/j.expneurol.2008.09.006; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Cetin A, 2006, EUR SPINE J, V15, P1539, DOI 10.1007/s00586-006-0091-2; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cuzzocrea S, 1999, EUR CYTOKINE NETW, V10, P191; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Genovese T, 2008, SHOCK, V29, P32, DOI 10.1097/shk.0b013e318059053a; Ghasemlou N, 2010, BRAIN, V133, P126, DOI 10.1093/brain/awp304; Gok B, 2009, J CLIN NEUROSCI, V16, P549, DOI 10.1016/j.jocn.2008.04.024; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hurlbert RJ, 2002, CAN J NEUROL SCI, V29, P236, DOI 10.1017/S0317167100002006; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Kwon B.K., 2010, J NEUROTRAUM, V27, P1; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Kwon BK, 2010, SPINE, V35, pS263, DOI 10.1097/BRS.0b013e3181f3286d; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; Mukaino M, 2010, EXP NEUROL, V224, P403, DOI 10.1016/j.expneurol.2010.04.020; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Noble LJ, 2002, J NEUROSCI, V22, P7526; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Penkowa M, 1999, GLIA, V25, P343; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Sorensen PS, 2008, NEURODEGENER DIS, V5, P8, DOI 10.1159/000109932; Stangel M, 2006, J NEUROL, V253, P18, DOI 10.1007/s00415-006-5003-1; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, BRAIN RES, V799, P264, DOI 10.1016/S0006-8993(98)00459-4; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; WONG D, 1995, MICROVASC RES, V49, P325, DOI 10.1006/mvre.1995.1028; Wong D, 1996, J NEUROPATH EXP NEUR, V55, P225, DOI 10.1097/00005072-199602000-00011; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	63	46	51	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	SEP 21	2012	9								224	10.1186/1742-2094-9-224			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	045YV	WOS:000311733600001	22998664	gold, Green Published			2022-02-06	
J	Chen, CJ; Wu, CH; Liao, YP; Hsu, HL; Tseng, YC; Liu, HL; Chiu, WT				Chen, Chi-Jen; Wu, Chih-Hsiung; Liao, Yen-Peng; Hsu, Hui-Ling; Tseng, Ying-Chi; Liu, Ho-Ling; Chiu, Wen-Ta			Working Memory in Patients with Mild Traumatic Brain Injury: Functional MR Imaging Analysis	RADIOLOGY			English	Article							HEAD-INJURY; COGNITIVE REHABILITATION; AXONAL INJURY; BLOOD-FLOW; FMRI; EPIDEMIOLOGY; PERFORMANCE; CONCUSSION; ACTIVATION; PARADIGM	Purpose: To analyze brain activation patterns in response to tests of working memory after a mild traumatic brain injury (MTBI). Materials and Methods: Research ethics committee approval and patient written informed consent were obtained. Brain activation patterns in response to n-back working memory tasks (n = 1, 2, 3) were assessed with functional magnetic resonance (MR) imaging in 20 patients with MTBI within 1 month after their injury and in 18 healthy control subjects. In n-back working memory tasks, participants monitored a series of number stimuli and were to indicate when the presented number was the same as that presented n back previously. Nine (45%) MTBI patients underwent follow-up functional MR imaging studies 6 weeks later. Digit span, a memory test for how many numbers a person can remember in sequence, and continuous performance test (CPT), a test that measures a person's sustained and selective attention and impulsivity, were also performed before functional MR imaging studies and outside the imager for each participant. Clinical data were analyzed by using t and chi(2) tests. Within-group, between-group, and initial and follow-up differences of functional MR imaging data were analyzed by using one-sample, two-sample, and paired t tests, respectively. Results: Groups were similar for sex (P = .75), years of education (P = .069), digit span (P = .37 for total score), CPT (P = .31, .27, and .43 for omission error, commission error, and hit reaction time, respectively), and accuracy of n-back working memory performance (P = .90, .11, and .39 for one-, two-, and three-back tasks, respectively). Brain activation patterns differed between MTBI patients and controls in response to increasing working memory loads (P < .01, uncorrected). Control subjects maintained their ability to increase activation in the working memory circuitry with each increase in working memory load. In contrast, MTBI patients were impaired in their ability to increase activation in working memory circuitry under both moderate and high working memory load conditions. However, MTBI patients did show cerebral plasticity, as evidenced by more activation in some areas outside and inside the working memory circuitry as compared with control subjects (P < .01, uncorrected). In the 6-week follow-up study, compared with baseline, MTBI patients showed an improvement of activation in response to increasing working memory loads (P < .05, uncorrected). Conclusion: MTBI-induced differences in working memory functional activity were observed even though differences in behavioral performance between MTBI patients and controls were absent, which suggests that this approach may increase sensitivity to MTBI compared with neuropsychological evaluation alone. (C) RSNA, 2012	[Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei 11031, Taiwan; [Chen, Chi-Jen; Liao, Yen-Peng; Hsu, Hui-Ling; Tseng, Ying-Chi] Taipei Med Univ, Shuang Ho Hosp, Dept Radiol, New Taipei City, Taiwan; [Wu, Chih-Hsiung] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, New Taipei City, Taiwan; [Liu, Ho-Ling] Chang Gung Univ, Sch Med, Dept Med Imaging & Radiol Sci, Tao Yuan, Taiwan		Chiu, WT (corresponding author), Taipei Med Univ, Grad Inst Injury Prevent & Control, 250 Wu Hsing St, Taipei 11031, Taiwan.	wtchiu@tmu.edu.tw	Liao, Yen-Peng/AAE-3575-2021	Liao, Yen-Peng/0000-0001-5721-0357	National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC 98-2321-B-038-004-MY3, NSC-99-2811-B-038-024, NCS98-2321-B-038-003-MY3 (3-3), NCS98-2321-B-038-005-MY3 (3-3), NSC98-2314-B-038-012-MY3, NSC98-2314-B-038-011-MY3]; Taipei Medical University, Taiwan [TMU98-AE1-B15, 98YGH-TMU-04]	From the Departments of Radiology (C.J.C., Y.P.L., H. L. H., Y.C.T.) and Surgery (C. H. W.), Taipei Medical University/Shuang Ho Hospital, New Taipei City, Taiwan; Department of Medical Imaging and Radiological Sciences, Chang Gung University, School of Medicine, Guishan, Taoyuan, Taiwan (H. L. L.); and Graduate Institute of Injury Prevention and Control, Taipei Medical University, 250 Wu-Hsing St, Hsin-Yi District, Taipei 11031, Taiwan (W. T. C.). Received October 9, 2011; revision requested December 2; revision received February 10, 2012; accepted March 2; final version accepted March 30. Supported by grants NSC 98-2321-B-038-004-MY3, NSC-99-2811-B-038-024, NCS98-2321-B-038-003-MY3 (3-3), NCS98-2321-B-038-005-MY3 (3-3), NSC98-2314-B-038-012-MY3, and NSC98-2314-B-038-011-MY3 from the National Science Council, Taiwan, and grants TMU98-AE1-B15 and 98YGH-TMU-04 from Taipei Medical University, Taiwan.	Baddeley A.D., 1986, WORKING MEMORY; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Grady CL, 1999, COGNITIVE NEUROREHAB; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; LANGFITT TW, 1982, CLIN NEUR, V29, P353; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; Matthews PM, 2004, RESTOR NEUROL NEUROS, V22, P245; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; Ogawa S, 1998, ANNU REV BIOPH BIOM, V27, P447, DOI 10.1146/annurev.biophys.27.1.447; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1982, HEAD INJURY BASIC CL; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Sohlberg M., 2001, COGNITIVE REHABILITA; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAYLOR AR, 1966, LANCET, V2, P178; Thermenos HW, 2005, SCHIZOPHR RES, V74, P179, DOI 10.1016/j.schres.2004.07.021; U.S. Department of Health and Human Services, 1989, INT HEAD INJ TASK FO; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; Wishart HA, 2006, AM J PSYCHIAT, V163, P1603, DOI 10.1176/appi.ajp.163.9.1603	34	46	47	0	22	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2012	264	3					844	851		10.1148/radiol.12112154			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	003XU	WOS:000308645500026	22829681				2022-02-06	
J	Weaver, AA; Danelson, KA; Stitzel, JD				Weaver, Ashley A.; Danelson, Kerry A.; Stitzel, Joel D.			Modeling Brain Injury Response for Rotational Velocities of Varying Directions and Magnitudes	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Brain; Computational modeling; Computational simulation; Concussion; Finite element model; SIMon; Strain; Traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; PEDIATRIC HEAD-INJURY; HIGH-SCHOOL FOOTBALL; CORPUS-CALLOSUM; IMPACT; DAMAGE; ACCELERATIONS; BIOMECHANICS; CONCUSSIONS	An estimated 1.7 million people in the United States sustain a traumatic brain injury (TBI) annually. To investigate the effects of rotational motions on TBI risk and location, this study modeled rotational velocities of five magnitudes and 26 directions of rotation using the Simulated Injury Monitor finite element brain model. The volume fraction of the total brain exceeding a predetermined strain threshold, the Cumulative Strain Damage Measure (CSDM), was investigated to evaluate global model response. To evaluate regional response, this metric was computed relative to individual brain structures and termed the Structure Cumulative Strain Damage Measure (SCSDM). CSDM increased as input magnitude increased and varied with the direction of rotation. CSDM was 0.55-1.7 times larger in simulations with transverse plane rotation compared to those without transverse plane rotation. The largest SCSDM in the cerebrum and brainstem occurred with rotations in the transverse and sagittal planes, respectively. Velocities causing medial rotation of the cerebellum resulted in the largest SCSDM in this structure. For velocities of the same magnitude, injury risk calculated from CSDM varied from 0 to 97% with variations in the direction of rotation. These findings demonstrate injury risk, as estimated by CSDM and SCSDM, is affected by the direction of rotation and input magnitude, and these may be important considerations for injury prediction.	[Weaver, Ashley A.; Danelson, Kerry A.; Stitzel, Joel D.] Wake Forest Univ, Bowman Gray Sch Med, Virginia Tech Wake Forest Univ Ctr Injury Biomech, Winston Salem, NC 27157 USA		Stitzel, JD (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Virginia Tech Wake Forest Univ Ctr Injury Biomech, Med Ctr Blvd, Winston Salem, NC 27157 USA.	asweaver@wakehealth.edu; kdanelso@wakehealth.edu; jdstitzel@gmail.com	Stitzel, Joel/B-4045-2012; Weaver, Ashley/ABB-5845-2021	Stitzel, Joel/0000-0001-9762-3033; Weaver, Ashley/0000-0002-4383-0106; Danelson, Kerry/0000-0003-1815-8749			AAAM, 2008, ABBR INJ SCAL 2005; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Atabaki SM, 2007, PEDIATR REV, V28, P215, DOI 10.1542/pir.28-6-215; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F.A., 1994, STAPP CAR CRASH C SO, V38, P145; Bandak F. A., 2001, INT TECHN C ENH SAF; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bhatoe HS, 1999, ACTA NEUROCHIR, V141, P515, DOI 10.1007/s007010050333; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Doya K, 2000, CURR OPIN NEUROBIOL, V10, P732, DOI 10.1016/S0959-4388(00)00153-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; DUMA SM, 2009, EMBC 2009 ANN INT C, P1123; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Faul M, 2010, TRAUMATIC BRAIN INJU; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, STAPP CAR CRASH J, V16, P296; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hibbeler R., 1998, ENG MECH DYNAMICS; Holbourn AHS, 1943, LANCET, V2, P438; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LESSLEY D, 2004, 2004010288 SAE; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson Steven, 2009, Biomed Sci Instrum, V45, P113; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Takhounts E. G., 2011, 22 ENH SAF VEH C P; Takhounts E. G., 2003, STAPP CAR CRASH J, V47; Takhounts E. G., 2003, STAPP CAR CRASH J, V47; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thibault L. E., 1985, 856022 SAE INT; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	58	46	46	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2012	40	9					2005	2018		10.1007/s10439-012-0553-0			14	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	987FB	WOS:000307400900015	22441667				2022-02-06	
J	Wilde, EA; Ayoub, KW; Bigler, ED; Chu, ZD; Hunter, JV; Wu, TC; McCauley, SR; Levin, HS				Wilde, Elisabeth A.; Ayoub, Kareem W.; Bigler, Erin D.; Chu, Zili D.; Hunter, Jill V.; Wu, Trevor C.; McCauley, Stephen R.; Levin, Harvey S.			Diffusion tensor imaging in moderate-to-severe pediatric traumatic brain injury: changes within an 18 month post-injury interval	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Diffusion tensor imaging; Tract-based spatial statistics; Longitudinal; Children	WHITE-MATTER DEVELOPMENT; CORPUS-CALLOSUM; VOXELWISE ANALYSIS; AXONAL INJURY; CHILDREN; MICROSTRUCTURE; ADOLESCENCE; CHILDHOOD; MILD; PERFORMANCE	Traumatic brain injury (TBI) is a leading cause of death and disability in children, yet little is known regarding the pattern of TBI-related microstructural change and its impact on subsequent development. Diffusion tensor imaging (DTI) was used to examine between-group differences at two time points (planned intervals of 3 months and 18 months post-injury) and within-group longitudinal change in a group of children and adolescents aged 7-17 years with moderate-to-severe TBI (n = 20) and a comparison group of children with orthopedic injury (OI) (n = 21). In the 3- and 18-month cross-sectional analyses, tract-based spatial statistics (TBSS) generally revealed decreased fractional anisotropy (FA) and increased apparent diffusion coefficient (ADC) in the TBI group in regions of frontal, temporal, parietal, and occipital white matter as well as several deep subcortical structures, though areas of FA decrease were more prominent at the 3-month assessment, and areas of ADC increase were more prominent at the 18 month assessment, particularly in the frontal regions. In terms of the within-group changes over time, the OI group demonstrated primarily diffuse increases in FA over time, consistent with previous findings of DTI-measured white matter developmental change. The TBI group demonstrated primarily regions of FA decrease and ADC increase over time, consistent with presumed continued degenerative change, though regions of ADC decrease were also appreciated. These results suggest that TBI-related microstructural changes are dynamic in children and continue until at least 18 months post-injury. Understanding the course of these changes in DTI metrics may be important in TBI for facilitating advances in management and intervention.	[Wilde, Elisabeth A.; Ayoub, Kareem W.; Wu, Trevor C.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Ayoub, Kareem W.; Wu, Trevor C.; McCauley, Stephen R.; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Chu, Zili D.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Ayoub, Kareem W.] Rice Univ, Dept Bioengn, Houston, TX USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili D.; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA		Wilde, EA (corresponding author), Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by the National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). We also acknowledge the generous contribution of Mission Connect of the TIRR Foundation. We gratefully acknowledge the contribution of Ana C. Vasquez, Deleene Menefee, PhD., Summer Lane, Lori Cook, Sandra B. Chapman, PhD., and Gillian Hotz, PhD. in data collection, and Joshua Cooper and Alyssa P. Ibarra in manuscript preparation. We thank the participants and their families for their participation in this research. None of the authors have any financial or other relationship(s) that could be construed as a conflict of interest with respect to the content of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashtari M, 2007, NEUROIMAGE, V35, P501, DOI 10.1016/j.neuroimage.2006.10.047; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Clayden J. D., 2011, CEREB CORTE IN PRESS; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M, 2010, TRAUMATIC BRAIN INJU, P1; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; Muetzel RL, 2008, NEUROIMAGE, V39, P1918, DOI 10.1016/j.neuroimage.2007.10.018; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; TEASDALE G, 1974, LANCET, V2, P81; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	54	46	47	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2012	6	3					404	416		10.1007/s11682-012-9150-y			13	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998MZ	WOS:000308245300006	22399284				2022-02-06	
J	Greer, JE; Povlishock, JT; Jacobs, KM				Greer, John E.; Povlishock, John T.; Jacobs, Kimberle M.			Electrophysiological Abnormalities in Both Axotomized and Nonaxotomized Pyramidal Neurons following Mild Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							DORSAL-ROOT GANGLION; SPINAL SENSORY NEURONS; CORTICAL-NEURONS; NERVE INJURY; ATTENTION DEFICITS; AXONAL INJURY; IN-VITRO; DEPOLARIZATION; MECHANISMS; CORTEX	Mild traumatic brain injury (mTBI) often produces lasting detrimental effects on cognitive processes. The mechanisms underlying neurological abnormalities have not been fully identified, in part due to the diffuse pathology underlying mTBI. Here we employ a mouse model of mTBI that allows for identification of both axotomized and intact neurons in the living cortical slice via neuronal expression of yellow fluorescent protein. Both axotomized and intact neurons recorded within injured cortex are healthy with a normal resting membrane potential, time constant (tau), and input resistance (R-in). In control cortex, 25% of cells show an intrinsically bursting action potential (AP) firing pattern, and the rest respond to injected depolarizing current with a regular-spiking pattern. At 2 d postinjury, intrinsic bursting activity is lost within the intact population. The AP amplitude is increased and afterhyperpolarization duration decreased in axotomized neurons at 1 and 2 d postinjury. In contrast, intact neurons also show these changes at 1 d, but recover by 2 d postinjury. Two measures suggest an initial decrease in excitability in axotomized neurons followed by an increase in excitability within intact neurons. The rheobase is significantly increased in axotomized neurons at 1 d postinjury. The slope of the plot of AP frequency versus injected current is larger for intact neurons at 2 d postinjury. Together, these results demonstrate that intact and axotomized neurons are both affected by mTBI, resulting in different changes in neuronal excitability that may contribute to network dysfunction following TBI.	[Greer, John E.; Povlishock, John T.; Jacobs, Kimberle M.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Jacobs, KM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	kmjacobs@vcu.edu	Jacobs, Kimberle/AAW-7526-2020; Greer, John/K-1008-2012		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077675, HD055813, NS047463, NS007288]; NIH-NINDS Center CoreUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077675, T32NS007288, P30NS047463] Funding Source: NIH RePORTER	This work was supported by NIH Grants NS077675, HD055813, NS047463, and NS007288. Microscopy was performed at the Virginia Commonwealth University Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center Core Grant 5P30NS047463-02. We thank Makoto Ezure for help with data analysis and histology.	Abdulla FA, 2001, J NEUROPHYSIOL, V85, P630, DOI 10.1152/jn.2001.85.2.630; Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brumberg JC, 2000, J NEUROSCI, V20, P4829; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Cummins TR, 1997, J NEUROSCI, V17, P3503; ECCLES JC, 1958, J PHYSIOL-LONDON, V143, P11, DOI 10.1113/jphysiol.1958.sp006041; George AL, 2011, BRAIN RES, V1374, P116, DOI 10.1016/j.brainres.2010.12.020; GORDON T, 1987, J PHYSIOL-LONDON, V392, P213, DOI 10.1113/jphysiol.1987.sp016777; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guatteo E, 1996, BRAIN RES, V741, P1, DOI 10.1016/S0006-8993(96)00866-9; GUSTAFSSON B, 1979, J PHYSIOL-LONDON, V293, P197, DOI 10.1113/jphysiol.1979.sp012885; Ishikawa K, 1999, MUSCLE NERVE, V22, P502, DOI 10.1002/(SICI)1097-4598(199904)22:4<502::AID-MUS12>3.0.CO;2-K; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kole MHP, 2011, NEURON, V71, P671, DOI 10.1016/j.neuron.2011.06.024; LAIWAND R, 1988, J PHYSIOL-LONDON, V404, P749, DOI 10.1113/jphysiol.1988.sp017317; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mentis GZ, 2007, J PHYSIOL-LONDON, V582, P1141, DOI 10.1113/jphysiol.2007.133488; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; Nishimura Y, 2001, J NEUROPHYSIOL, V86, P771, DOI 10.1152/jn.2001.86.2.771; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Sancini G, 2001, EUR J NEUROSCI, V14, P1065, DOI 10.1046/j.0953-816x.2001.01723.x; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; TAKATA M, 1980, NEUROSCIENCE, V5, P413, DOI 10.1016/0306-4522(80)90116-5; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248, DOI 10.1152/jn.1996.75.1.248; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang W, 2011, ANAT REC, V294, P1406, DOI 10.1002/ar.21437; Wang XJ, 1999, NEUROSCIENCE, V89, P347, DOI 10.1016/S0306-4522(98)00315-7; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; Williams SR, 1999, J PHYSIOL-LONDON, V521, P467, DOI 10.1111/j.1469-7793.1999.00467.x; YAMUY J, 1992, NEUROBIOL AGING, V13, P231, DOI 10.1016/0197-4580(92)90035-V; Yu JN, 2008, FRONT NEURAL CIRCUIT, V2, DOI 10.3389/neuro.04.006.2008; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	47	46	46	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 9	2012	32	19					6682	6687		10.1523/JNEUROSCI.0881-12.2012			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	940DL	WOS:000303870100028	22573690	Bronze, Green Published, Green Accepted			2022-02-06	
J	Michetti, CP; Fakhry, SM; Ferguson, PL; Cook, A; Moore, FO; Gross, R				Michetti, Christopher P.; Fakhry, Samir M.; Ferguson, Pamela L.; Cook, Alan; Moore, Forrest O.; Gross, Ronald		AAST Ventilator-Associated Pneumon	Ventilator-associated pneumonia rates at major trauma centers compared with a national benchmark: A multi-institutional study of the AAST	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Ventilator-associated pneumonia; trauma; ventilator-associated pneumonia rates; trauma centers; multi-institutional study	NETWORK NHSN REPORT; RISK-FACTORS; INFECTION; TRACHEOBRONCHITIS; DIAGNOSIS; OUTCOMES; COMMON	BACKGROUND: Ventilator-associated pneumonia (VAP) rates reported by the National Healthcare Safety Network (NHSN) are used as a benchmark and quality measure, yet different rates are reported from many trauma centers. This multi-institutional study was undertaken to elucidate VAP rates at major trauma centers. METHODS: VAP rate/1,000 ventilator days, diagnostic methods, institutional, and aggregate patient data were collected retrospectively from a convenience sample of trauma centers for 2008 and 2009 and analyzed with descriptive statistics. RESULTS: At 47 participating Level I and II centers, the pooled mean VAP rate was 17.2 versus 8.1 for NHSN (2006-2008). Hospitals' rates were highly variable (range, 1.8-57.6), with 72.3% being above NHSN's mean. Rates differed based on who determined the rate (trauma service, 27.5; infection control or quality or epidemiology, 11.9; or collaborative effort, 19.9) and the frequency with which VAP was excluded based on aspiration or diagnosis before hospital day 5. In 2008 and 2009, blunt trauma patients had higher VAP rates (17.3 and 17.6, respectively) than penetrating patients (11.0 and 10.9, respectively). More centers used a clinical diagnostic strategy (57%) than a bacteriologic strategy (43%). Patients with VAP had a mean Injury Severity Score of 28.7, mean Intensive Care Unit length of stay of 20.8 days, and a 12.2% mortality rate. 50.5% of VAP patients had a traumatic brain injury. CONCLUSIONS: VAP rates at major trauma centers are markedly higher than those reported by NHSN and vary significantly among centers. Available data are insufficient to set benchmarks, because it is questionable whether any one data set is truly representative of most trauma centers. Application of a single benchmark to all centers may be inappropriate, and reliable diagnostic and reporting standards are needed. Prospective analysis of a larger data set is warranted, with attention to injury severity, risk factors specific to trauma patients, diagnostic method used, VAP definitions and exclusions, and reporting guidelines. (J Trauma. 2012; 72: 1165-1173. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Michetti, Christopher P.] Inova Reg Trauma Ctr, Dept Surg, Falls Church, VA 22042 USA; Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA		Michetti, CP (corresponding author), Inova Reg Trauma Ctr, Dept Surg, 3300 Gallows Rd, Falls Church, VA 22042 USA.	christopher.michetti@inova.org		Michetti, Christopher/0000-0002-3744-0603			Bregeon F, 2000, EUR RESPIR J, V16, P969, DOI 10.1183/09031936.00.16596900; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Cocanour Christine S, 2005, Surg Infect (Larchmt), V6, P65, DOI 10.1089/sur.2005.6.65; Cook A, 2010, J TRAUMA, V69, P1083, DOI 10.1097/TA.0b013e3181f9fb51; Cook DJ, 1998, JAMA-J AM MED ASSOC, V279, P1605, DOI 10.1001/jama.279.20.1605; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Croce MA, 2001, AM SURGEON, V67, P105; Croce MA, 1998, ANN SURG, V227, P743, DOI 10.1097/00000658-199805000-00015; Dallas J, 2011, CHEST, V139, P513, DOI 10.1378/chest.10-1336; Edwards JR, 2008, AM J INFECT CONTROL, V36, P609, DOI 10.1016/j.ajic.2008.08.001; Edwards JR, 2007, AM J INFECT CONTROL, V35, P290, DOI 10.1016/j.ajic.2007.04.001; Edwards JR, 2009, AM J INFECT CONTROL, V37, P783, DOI 10.1016/j.ajic.2009.10.001; Fabregas N, 1999, THORAX, V54, P867, DOI 10.1136/thx.54.10.867; Fagon JY, 2000, ANN INTERN MED, V132, P621, DOI 10.7326/0003-4819-132-8-200004180-00004; Hedrick TL, 2008, J TRAUMA, V64, P714, DOI 10.1097/TA.0b013e31811ec18e; Heyland D, 2006, NEW ENGL J MED, V355, P2619, DOI 10.1056/NEJMoa052904; Klompas M, 2007, ANN INTERN MED, V147, P803, DOI 10.7326/0003-4819-147-11-200712040-00013; McKibben L, 2005, AM J INFECT CONTROL, V33, P217, DOI 10.1016/j.ajic.2005.04.001; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; Miller PR, 2006, J TRAUMA, V60, P98, DOI 10.1097/01.ta.0000196379.74305.e4; Napolitano LM, 2003, AM J SURG, V186, p4S, DOI 10.1016/j.amjsurg.2003.10.002; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; Sawyer RG, 2010, CRIT CARE MED, V38, pS483, DOI 10.1097/CCM.0b013e3181ec68c9; Thomas BW, 2011, AM SURGEON, V77, P998; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Wunderink RC, 2011, CHEST, V139, P485, DOI 10.1378/chest.10-2641	26	46	46	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2012	72	5					1165	1172		10.1097/TA.0b013e31824d10fa			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	944JD	WOS:000304195100009	22673241				2022-02-06	
J	Sander, AM; Maestas, KL; Sherer, M; Malec, JF; Nakase-Richardson, R				Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark; Malec, James F.; Nakase-Richardson, Risa			Relationship of Caregiver and Family Functioning to Participation Outcomes After Postacute Rehabilitation for Traumatic Brain Injury: A Multicenter Investigation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Caregivers; Rehabilitation; Treatment outcome	COMMUNITY INTEGRATION QUESTIONNAIRE; HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; COGNITIVE REHABILITATION; COMMUNICATION ABILITIES; THERAPEUTIC ALLIANCE; SOCIAL INTEGRATION; ASSESSMENT DEVICE; FOLLOW-UP; VALIDITY	Sander AM, Maestas KL, Sherer M, Malec JF, Nakase-Richardson R. Relationship of caregiver and family functioning to participation outcomes after postacute rehabilitation for traumatic brain injury: a multicenter investigation. Arch Phys Med Rehabil 2012;93:842-8. Objective: To investigate the contribution of caregiver emotional functioning and family functioning to participation outcomes after postacute rehabilitation for traumatic brain injury (TBI). Design: Prospective cohort study. Setting: Three postacute comprehensive-integrated postacute rehabilitation programs associated with National Institute on Disability and Rehabilitation Research-funded TBI Model Systems Centers. Participants: Persons with medically documented TBI (N=136; 57% with severe TBI, 12% moderate, 31% mild), primarily men and 69% white. Interventions: Not applicable. Main Outcome Measures: Community Integration Questionnaire and Craig Handicap Assessment and Reporting Technique (CHART). Results: After accounting for age, education, sex, and race/ethnicity, there was a significant interaction between caregiver emotional functioning and time since injury for CHART Occupation and Social Integration Scale scores. Better emotional functioning in caregivers was associated with greater occupation and social integration outcomes for persons who entered the postacute rehabilitation program within 6 months of injury, but not for those >6 months postinjury. There was no relationship of family functioning to participation outcomes, and no interaction between family functioning and time since injury. Conclusions: Caregiver distress should be accounted for in studies investigating the effectiveness of postacute rehabilitation after TBI. Screening of caregivers early during postacute rehabilitation can target those who need assistance to improve their support of the person with TBI.	[Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Nakase-Richardson, Risa] James A Haley Vet Affairs Hosp, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Tampa, FL USA		Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu			National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133A70015, H133 B090023, H133A070043, H133P080007]	Supported in part by grants from the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. H133A70015, H133 B090023, H133A070043, H133P080007).	Aiken L. S., 2013, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Cantagallo A, 2000, EUROPA MED PHYS, V36, P171; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Evans CC, 2008, J HEAD TRAUMA REHAB, V23, P329, DOI 10.1097/01.HTR.0000336845.06704.bc; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Menard S.W., 1995, APPL LOGISTIC REGRES; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Myers R. H., 1990, CLASSICAL MODERN REG; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pledger C, 2003, AM PSYCHOL, V58, P279, DOI 10.1037/0003-066X.58.4.279; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P30, DOI 10.1097/HTR.0b013e3182048f7c; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; US Department of Education Office of Special Education and Rehabilitative Services National Institute on Disability and Rehabilitation Research, 2000, LONG RANG PLAN 1999; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; West M., 1990, SUPPORTED EMPLOYMENT; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	61	46	47	0	24	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2012	93	5					842	848		10.1016/j.apmr.2011.11.031			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	939DV	WOS:000303788500016	22417896				2022-02-06	
J	Lin, Y; Pan, YH; Shi, YF; Huang, XJ; Jia, NQ; Jiang, JY				Lin, Yong; Pan, Yaohua; Shi, Yinfeng; Huang, Xianjian; Jia, Nengqin; Jiang, Ji-yao			Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain	NANOTECHNOLOGY			English	Article							N-BUTYL CYANOACRYLATE; CEREBRAL ARTERIOVENOUS-MALFORMATIONS; BARRIER PERMEABILITY; EDEMA FORMATION; DRUG-DELIVERY; CORTICAL CONTUSION; N-BUTYL-2-CYANOACRYLATE; EMBOLIZATION; DISRUPTION; TRANSPORT	Poly(n-butyl-2-cyanoacrylate) (PBCA) nanoparticles have been successfully applied to deliver small-molecule drugs to the central nervous system (CNS). However, it is unclear whether PBCA nanoparticles can be used as the delivery system for large molecules to potentially treat traumatic brain injury (TBI). In this study, we tested the capacity of PBCA nanoparticles in passing through the blood-brain barrier (BBB) and transporting large molecules into normal and injured brains in the rat. We first synthesized PBCA nanoparticles by dispersion polymerization and then loaded the particles with either horseradish peroxidase (HRP, 44 kDa) or enhanced green fluorescent protein (EGFP, 29 kDa), which were further coated with polysorbate 80. Next, the polysorbate 80-coated HRP or EGFP-loaded PBCA nanoparticles were intravenously injected into the normal and brain-injured rats. We found that, at 45 min after injection, PBCA nanoparticle-delivered HRP or EGFP was hardly detected in the normal brains of the rats, but a small amount of EGFP carried by PBCA nanoparticles was noted in the normal brains 48 h after administration, which was further confirmed by immunolocalization with anti-EGFP antibodies. In contrast, at 4 h after TBI with a circulation time of 45 min, although the penetration of HRP or EGFP alone was hampered by the BBB, the PBCA nanoparticle-delivered HRP or EGFP was widely distributed near injured sites. Together, our findings provide histological evidence that PBCA nanoparticles can be used as an efficient delivery system for large molecules to overcome the barrier in the brain with TBI.	[Lin, Yong; Pan, Yaohua; Huang, Xianjian; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, Shanghai 200127, Peoples R China; [Shi, Yinfeng; Jia, Nengqin] Shanghai Normal Univ, Dept Chem, Life & Environm Sci Coll, Shanghai 200234, Peoples R China		Lin, Y (corresponding author), Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiangjyb@online.sh.cn			National Science and Nature Committee of China [30973086]; National Health Ministry of China [200802093]; Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1409800]; Program for Shanghai Outstanding Medical Academic Leader	This work was excellently supported by grants from the National Science and Nature Committee of China (no. 30973086), the National Health Ministry of China (no. 200802093), the Shanghai Science and Technology Committee (no. 10JC1409800) and the Program for Shanghai Outstanding Medical Academic Leader.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adelson PD, 1998, ACT NEUR S, V71, P104; ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44; Alyautdin RN, 1997, PHARMACEUT RES, V14, P325, DOI 10.1023/A:1012098005098; Amiel GE, 1999, J AM COLL SURGEONS, V189, P21, DOI 10.1016/S1072-7515(99)00068-X; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Behan N, 2001, BIOMATERIALS, V22, P1335, DOI 10.1016/S0142-9612(00)00286-6; Brown RC, 2004, BRAIN RES, V1014, P221, DOI 10.1016/j.brainres.2004.04.034; de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gilmore JL, 2008, J NEUROIMMUNE PHARM, V3, P83, DOI 10.1007/s11481-007-9099-6; Gulyaev AE, 1999, PHARM RES-DORDR, V16, P1564, DOI 10.1023/A:1018983904537; GUMERLOCK MK, 1992, J NEURO-ONCOL, V12, P33; Gupta R., 2006, NANOPARTICLE TECHNOL, P1; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; JAFAR JJ, 1993, J NEUROSURG, V78, P60, DOI 10.3171/jns.1993.78.1.0060; Jain KK, 2007, NEURODEGENER DIS, V4, P287, DOI 10.1159/000101884; Koffie RM, 2011, P NATL ACAD SCI USA, V108, P18837, DOI 10.1073/pnas.1111405108; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Mazal PR, 2006, PATHOLOGY, V38, P28, DOI 10.1080/00313020500455795; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NEUWELT EA, 1979, J CLIN INVEST, V64, P684, DOI 10.1172/JCI109509; Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Reimold I, 2008, EUR J PHARM BIOPHARM, V70, P627, DOI 10.1016/j.ejpb.2008.05.007; Reukov V, 2011, BIOTECHNOL BIOENG, V108, P243, DOI 10.1002/bit.22958; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; SOEHENDRA N, 1987, ENDOSCOPY, V19, P221, DOI 10.1055/s-2007-1018288; Starke RM, 2009, STROKE, V40, P2783, DOI 10.1161/STROKEAHA.108.539775; Suri Sarabjeet Singh, 2007, J Occup Med Toxicol, V2, P16, DOI 10.1186/1745-6673-2-16; Taira S, 2009, METHODS MOL BIOL, V544, P571, DOI 10.1007/978-1-59745-483-4_36; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8	44	46	47	2	35	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0957-4484	1361-6528		NANOTECHNOLOGY	Nanotechnology	APR 27	2012	23	16							165101	10.1088/0957-4484/23/16/165101			8	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Materials Science; Physics	923SN	WOS:000302639500001	22460562				2022-02-06	
J	Kang, EK; Kim, DY; Paik, NJ				Kang, Eun-Kyoung; Kim, Dae-Yul; Paik, Nam-Jong			TRANSCRANIAL DIRECT CURRENT STIMULATION OF THE LEFT PREFRONTAL CORTEX IMPROVES ATTENTION IN PATIENTS WITH TRAUMATIC BRAIN INJURY: A PILOT STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; attention; cognition; transcranial direct current stimulation	WORKING-MEMORY; COGNITIVE REHABILITATION; ASSISTIVE-TECHNOLOGY; DC STIMULATION; POLARIZATION; DEPRESSION; DISORDER; CHILDREN; SYSTEM	Objective: To determine whether a single session of anodal transcranial direct current stimulation to the left dorsolateral prefrontal cortex improves attention in patients with traumatic brain injury. Design: Double-blinded, cross-over design. Patients: Nine patients with attention deficit after traumatic brain injury. Methods: Patients underwent a computerized contrast reaction time task before and after the administration of real transcranial direct current stimulation (2 mA for 20 min) or sham transcranial direct current stimulation (2 mA for 1 min) to the left dorsolateral prefrontal cortex in a double-blind, crossover manner. Results: Immediately post-stimulation, the transcranial direct current stimulation group showed a tendency of shortened reaction time relative to baseline (87.3 +/- 7.8%), whereas the sham stimulation group (122.4 +/- 715.5%) did not (p = 0.056). However, this difference was not significant 3 or 24 h after stimulation (p > 0.05). The numbers of correct responses were not changed at any time after stimulation. Conclusion: Anodal transcranial direct current stimulation applied to the left dorsolateral prefrontal cortex improves attention compared with sham stimulation in patients with traumatic brain injury, which suggests a potential role for this intervention in improving attention during cognitive training after traumatic brain injury. A further prospective randomized trial is required to confirm the benefits conferred by transcranial direct current stimulation in this patient population.	[Kang, Eun-Kyoung; Paik, Nam-Jong] Seoul Natl Univ, Bundang Hosp, Dept Rehabil Med, Songnam, South Korea; [Kim, Dae-Yul] Univ Ulsan, Coll Med, Dept Rehabil Med, Asan Med Ctr, Seoul, South Korea; [Paik, Nam-Jong] Seoul Natl Univ, Coll Med, Dept Rehabil Med, Seoul, South Korea		Paik, NJ (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Rehabil Med, Coll Med, 166 Gumi Ro, Songnam 463707, Gyeonggi Do, South Korea.	njpaik@snu.ac.kr	Paik, Nam-Jong/D-5798-2012	Paik, Nam-Jong/0000-0002-5193-8678	Ministry for Health, Welfare & Family Affairs, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A101901]; Handok and Daewoong Pharmaceuticals Co., Ltd; SK Chemicals Ltd.	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (Grant number: A101901), and by research funds from Handok and Daewoong Pharmaceuticals Co., Ltd and SK Chemicals Ltd.	Ashman TA, 2006, MT SINAI J MED, V73, P999; Baddeley A.D., 1986, WORKING MEMORY; Boggio PS, 2007, J AFFECT DISORDERS, V101, P91, DOI 10.1016/j.jad.2006.10.026; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; CHELUNE GJ, 1986, CHILD PSYCHIAT HUM D, V16, P221, DOI 10.1007/BF00706479; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Elmer S, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-29; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2006, DEPRESS ANXIETY, V23, P482, DOI 10.1002/da.20201; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Kang EK, 2009, RESTOR NEUROL NEUROS, V27, P645, DOI 10.3233/RNN-2009-0514; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lopresti EF, 2008, IEEE ENG MED BIOL, V27, P29, DOI 10.1109/EMB.2007.907396; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Neligan A, 2009, J PEDIATR-US, V155, P449, DOI 10.1016/j.jpeds.2009.06.056; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2004, CLIN NEUROPHYSIOL, V115, P2419, DOI 10.1016/j.clinph.2004.05.001; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Priori A, 2009, BRAIN STIMUL, V2, P241, DOI 10.1016/j.brs.2009.02.004; Rango M, 2008, MAGN RESON MED, V60, P782, DOI 10.1002/mrm.21709; SHUE KL, 1992, BRAIN COGNITION, V20, P104, DOI 10.1016/0278-2626(92)90064-S; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Wassermann EM, 2005, TRENDS COGN SCI, V9, P503, DOI 10.1016/j.tics.2005.09.001; Zencius AH, 1998, BRAIN INJURY, V12, P53, DOI 10.1080/026990598122854; Zomeren A.H., 1994, CLIN NEUROPSYCHOLOGY; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	37	46	50	3	22	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	APR	2012	44	4					346	350		10.2340/16501977-0947			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	939WS	WOS:000303850800008	22434324	gold, Green Submitted			2022-02-06	
J	Bulger, EM; Guffey, D; Guyette, FX; MacDonald, RD; Brasel, K; Kerby, JD; Minei, JP; Warden, C; Rizoli, S; Morrison, LJ; Nichol, G				Bulger, Eileen M.; Guffey, Danielle; Guyette, Francis X.; MacDonald, Russell D.; Brasel, Karen; Kerby, Jeffery D.; Minei, Joseph P.; Warden, Craig; Rizoli, Sandro; Morrison, Laurie J.; Nichol, Graham		Resuscitation Outcomes Consortium	Impact of prehospital mode of transport after severe injury: A multicenter evaluation from the Resuscitation Outcomes Consortium	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Air medical; emergency medical services; transport: hypovolemic shock; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HYPERTONIC RESUSCITATION; GROUND TRANSPORT; HELICOPTER; MORTALITY; PATIENT; SYSTEM; AIR	BACKGROUND: There is ongoing controversy about the relative effectiveness of air medical versus ground transportation for severely injured patients. In some systems, air medical crews may provide a higher level of care but may require longer transport times. We sought to evaluate the impact of mode of transport on outcome based on analysis of data from two randomized trials of prehospital hypertonic resuscitation. METHODS: Injured patients were enrolled based on prehospital evidence of hypovolemic shock (systolic blood pressure <= 70 mm Hg or systolic blood pressure =71-90 mm Hg with heart rate >= 108 bpm) or severe traumatic brain injury (TBI; Glasgow Coma Scale score <= 8). Patient demographics, injury severity, and physiology were compared based on mode of transport. Multivariate logistic regression was used to determine the impact of mode of transport on 24-hour and 28-day survival for all patients and 6-month extended Glasgow Outcome Scale for patients with TBI, adjusting for differences in injury severity. RESULTS: Included were 2,049 patients, of which 703 (34%) were transported by air. Patients transported by air were more severely injured (mean Injury Severity Score, 30.3 vs. 22.8; p < 0.001), more likely to be in the TBI cohort (70% vs. 55.4%; p < 0.001), and more likely blunt mechanism (94.0% vs. 78.1%; p < 0.001). Patients transported by air had higher rates of prehospital intubation (81% vs. 36%; p < 0.001), received more intravenous fluids (mean 1.3 L vs. 0.8 L; p < 0.001), and had longer prehospital times (mean 76.1 minutes vs. 43.5 minutes; p < 0.001). Adjusted analysis revealed no significant impact of mode of transport on survival or 6-month neurologic outcome (air transport-28-day survival: odds ratio, 1.11; 95% confidence interval, 0.82-1.51; 6-month extended Glasgow Outcome Scale score <= 4: odds ratio, 0.94; 95% confidence interval, 0.68-1.31). CONCLUSION: There was no difference in the adjusted clinical outcome according to mode of transport. However, air medical transported more severely injured patients with more advanced life support procedures and longer prehospital time. (J Trauma. 2012; 72: 567-575. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Guffey, Danielle] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Nichol, Graham] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Guyette, Francis X.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [MacDonald, Russell D.; Morrison, Laurie J.] Univ Toronto, Div Emergency Med, Toronto, ON, Canada; [Rizoli, Sandro] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Brasel, Karen] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Kerby, Jeffery D.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Minei, Joseph P.] Univ Texas SW, Dept Surg, Dallas, TX USA; [Warden, Craig] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR USA		Bulger, EM (corresponding author), Box 359796 Harborview Med Ctr,325 9th Ave, Seattle, WA 98005 USA.	ebulger@u.washington.edu	Nichol, Graham/Z-4996-2019; morrison, laurie J/A-6325-2012	morrison, laurie J/0000-0001-8369-9774; Guffey, Danielle/0000-0003-3721-614X; Guyette, Francis/0000-0002-9151-4896	CIHRCanadian Institutes of Health Research (CIHR) Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01 HL077863, U01 HL077908, U01 HL077881, U01 HL077871, HL077887, HL077867, HL077866, HL077885, U01 HL077873, U01 HL077867, 5U01 HL077863, U01 HL077866, U01 HL077872, HL077873, HL077871, HL077881, HL077908, U01 HL077887, U01 HL077885, HL077865, HL077872, U01 HL077865] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077873, U01HL077881, U01HL077865, U01HL077885, U01HL077867, U01HL077863, U01HL077872, U01HL077908, U01HL077887, U01HL077866, U01HL077871] Funding Source: NIH RePORTER		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bledsoe BE, 2006, J TRAUMA, V60, P1257, DOI 10.1097/01.ta.0000196489.19928.c0; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Brown JB, 2010, J TRAUMA, V69, P1030, DOI 10.1097/TA.0b013e3181f6f450; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; Carr BG, 2006, PREHOSP EMERG CARE, V10, P198, DOI 10.1080/10903120500541324; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Diaz MA, 2005, J TRAUMA, V58, P148, DOI 10.1097/01.TA.0000124264.43941.41; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Jacobs L M, 1999, Conn Med, V63, P677; James DN, 2009, RESUSCITATION, V80, P650, DOI 10.1016/j.resuscitation.2009.02.020; Kerr W A, 1999, Prehosp Disaster Med, V14, P159; Koury S I, 1998, Prehosp Emerg Care, V2, P289, DOI 10.1080/10903129808958882; Lerner EB, 1999, ACAD EMERG MED, V6, P1127, DOI 10.1111/j.1553-2712.1999.tb00115.x; Mcvey J, 2010, PREHOSP EMERG CARE, V14, P45, DOI 10.3109/10903120903349788; Mitchell AD, 2007, CAN J SURG, V50, P129; Newgard CD, 2009, ACAD EMERG MED, V16, P1269, DOI 10.1111/j.1553-2712.2009.00604.x; Talving P, 2009, WORLD J SURG, V33, P2469, DOI 10.1007/s00268-009-0185-1; Taylor CB, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2009.09.030; Thomas SH, 2002, J TRAUMA, V52, P136, DOI 10.1097/00005373-200201000-00023; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	25	46	46	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2012	72	3					567	573		10.1097/TA.0b013e31824baddf			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	906TR	WOS:000301371100010	22491538	Green Accepted			2022-02-06	
J	Reeves, TM; Smith, TL; Williamson, JC; Phillips, LL				Reeves, Thomas M.; Smith, Terry L.; Williamson, Judy C.; Phillips, Linda L.			Unmyelinated Axons Show Selective Rostrocaudal Pathology in the Corpus Callosum After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal injury; Corpus callosum; Stereology; Traumatic brain injury; Ultrastructure; Unmyelinated axons	INTRAAXONAL NEUROFILAMENT COMPACTION; MYELINATED NERVE-FIBERS; FLUID PERCUSSION INJURY; WHITE-MATTER; SPINAL-CORD; HEAD-INJURY; RAT; CALPAIN; DAMAGE; PROTEOLYSIS	Axonal injury is consistently observed after traumatic brain injury (TBI). Prior research has extensively characterized the post-TBI response in myelinated axons. Despite evidence that unmyelinated axons comprise a numerical majority of cerebral axons, pathologic changes in unmyelinated axons after TBI have not been systematically studied. To identify morphologic correlates of functional impairment of unmyelinated fibers after TBI, we assessed ultrastructural changes in corpus callosum axons. Adult rats received moderate fluid percussion TBI, which produced diffuse injury with no contusion. Cross-sectional areas of 13,797 unmyelinated and 3,278 intact myelinated axons were stereologically measured at survival intervals from 3 hours to 15 days after injury. The mean caliber of unmyelinated axons was significantly reduced at 3 to 7 days and recovered by 15 days, but the time course of this shrinkage varied among the genu, mid callosum, and splenium. Relatively large unmyelinated axons seemed to be particularly vulnerable. Injury-induced decreases in unmyelinated fiber density were also observed, but they were more variable than caliber reductions. By contrast, no significant morphometric changes were observed in myelinated axons. The finding of a preferential vulnerability in unmyelinated axons has implications for current concepts of axonal responses after TBI and for development of specifically targeted therapies.	[Reeves, Thomas M.; Smith, Terry L.; Williamson, Judy C.; Phillips, Linda L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, Med Ctr, Richmond, VA 23298 USA		Reeves, TM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, Med Ctr, 1217 E Marshall St,Room 740,MCV Campus Box 980709, Richmond, VA 23298 USA.	tmreeves@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057758, NS056247, NS047463]; Virginia Commonwealth Neurotrauma Initiative [07-302F]; National Institutes of Health/National Institute of Neurological Disorders and Stroke CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056247, P30NS047463, R01NS057758] Funding Source: NIH RePORTER	Supported by the National Institutes of Health (Grants NS057758, NS056247, and NS047463) and Virginia Commonwealth Neurotrauma Initiative 07-302F. Microscopy was performed at Virginia Commonwealth University, Department of Anatomy and Neurobiology Microscopy Facility, which is supported, in part, with funding from National Institutes of Health/National Institute of Neurological Disorders and Stroke Center Core Grant NS047463.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Colley BS, 2010, EXP NEUROL, V224, P241, DOI 10.1016/j.expneurol.2010.03.026; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRAVEL C, 1990, J COMP NEUROL, V291, P147, DOI 10.1002/cne.902910110; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; JURASKA JM, 1988, BRAIN RES, V450, P1, DOI 10.1016/0006-8993(88)91538-7; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim JHY, 1996, BRAIN RES, V740, P47, DOI 10.1016/S0006-8993(96)00637-3; Larsen JO, 1998, J NEUROSCI METH, V85, P107, DOI 10.1016/S0165-0270(98)00129-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mouton P. R., 2002, PRINCIPLES PRACTICES; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Partadiredja G, 2003, J NEUROCYTOL, V32, P1165, DOI 10.1023/B:NEUR.0000021910.65920.41; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SEGGIE J, 1972, EXP NEUROL, V35, P215, DOI 10.1016/0014-4886(72)90148-3; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SMITH RS, 1970, AM J PHYSIOL, V219, P1256, DOI 10.1152/ajplegacy.1970.219.5.1256; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; WAXMAN SG, 1988, BRAIN RES, V453, P337, DOI 10.1016/0006-8993(88)90174-6; WAXMAN SG, 1976, EXP NEUROL, V53, P115, DOI 10.1016/0014-4886(76)90287-9; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x	62	46	46	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2012	71	3					198	210		10.1097/NEN.0b013e3182482590			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	897EM	WOS:000300627500002	22318124	Green Accepted, Bronze			2022-02-06	
J	Anderson, V; Le Brocque, R; Iselin, G; Eren, S; Dob, R; Davern, TJ; McKinlay, L; Kenardy, J				Anderson, Vicki; Le Brocque, Robyne; Iselin, Greg; Eren, Senem; Dob, Rian; Davern, Timothy J.; McKinlay, Lynne; Kenardy, Justin			Adaptive ability, behavior and quality of life pre and posttraumatic brain injury in childhood	DISABILITY AND REHABILITATION			English	Article						Adaptive behavior; behavior; child; executive function; quality of life; traumatic brain injury	CLOSED HEAD-INJURY; CHILDREN; EPIDEMIOLOGY; PREDICTORS; RECOVERY; EXPERIENCE; SEVERITY; SEQUELAE; OUTCOMES; TERM	Context: Traumatic brain injury (TBI) is a common, acquired childhood disability, which has been shown to have a significant impact on children's cognitive and educational function. While behavioral problems are also noted, there is ongoing debate about the contribution of preinjury factors in this domain. Few studies have attempted to measure the impact of these preinjury functions on postinjury behavior. Objective: To compare pre and postinjury adaptive ability, behavior, executive function and quality of life (QOL) and to identify factors that contribute to outcomes in these domains including injury severity, socio-demographic and preinjury characteristics. Design: Consecutive recruitments to a prospective, longitudinal study, utilizing a between factor design, with injury severity as the independent variable. Participants and methods: Children admitted to hospital with a diagnosis of TBI aged between 6 and 14 years (n = 205) were divided according to injury severity (mild, moderate and severe). Adaptive behavior (Vineland Adaptive Behavior Scales), child behavior (Child Behavior Checklist), everyday executive functions (Behavior Rating Inventory of Executive Function) and QOL (Child Health Questionnaire) assessed at 6 months post-TBI. Results and conclusions: Severity by time interactions were identified across a range of outcome domains demonstrating that more severe injury is associated with a decrease in functional ability at 6 months post-TBI. This effect was most pronounced for everyday executive skills, social function and internalizing aspects of child behavior. Preinjury function was a consistent predictor of postinjury status. Injury severity contributed little to the prediction of functional outcomes once preinjury functioning was accounted for in the model. Age at injury and family cohesion were relevant to specific outcome domains only. Socio-economic status did not contribute significantly to outcome at 6 months. Preinjury functioning as reported by parents in the acute phase may be a useful predictive tool for identifying children who may be at risk of functioning difficulties 6 months post-TBI.	[Anderson, Vicki; Eren, Senem] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, Vicki; Eren, Senem] Univ Melbourne, Melbourne, Vic, Australia; [Le Brocque, Robyne; Iselin, Greg; Kenardy, Justin] Univ Queensland, Sch Med, Ctr Natl Res Disabil & Rehabil Med, Brisbane, Qld, Australia; [Dob, Rian] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia; [Davern, Timothy J.] Monash Univ, Melbourne, Vic 3004, Australia; [McKinlay, Lynne] Royal Childrens Hosp, Queensland Paediat Rehabil Serv, Brisbane, Qld, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Kenardy, Justin A/H-6603-2014; Kenardy, Justin/F-2085-2010; Le Brocque, Robyne/F-4848-2010	Kenardy, Justin A/0000-0001-9475-8450; Le Brocque, Robyne/0000-0002-4574-1254; McKinlay, Lynne/0000-0002-6677-0628	NHMRCNational Health and Medical Research Council of Australia	NHMRC project grant (Kenardy, Anderson, Bellamy & McKinlay).	Achenbach TM, 1991, MANUAL CHILD BEHAV C; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Asarnow R, 1995, TRAUMATIC BRAIN INJU, P117; Braga L, 2000, BRAIN INJURY, V17, P1; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Ciccetti D., 1984, VINELAND ADAPTIVE BE; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia GA IP, 2000, BEHAV RATING INVENTO; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Johnson AR, 2009, DEV DISABIL RES REV, V15, P124, DOI 10.1002/ddrr.63; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; MCLENNAN W, 1997, AUSTR STANDARD CLASS; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; MOYES CD, 1980, CHILD CARE HLTH DEV, V6, P1, DOI 10.1111/j.1365-2214.1980.tb00791.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; van 't Hooft I, 2007, NEUROREHABILITATION, V22, P109; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Ware JE., 1996, CHQ USERS MANUAL; Wechsler D., 2011, WECHSLER ABBREVIATED; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker Mark, 2002, Pediatr Rehabil, V5, P51, DOI 10.1080/1363849021000041891	42	46	46	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2012	34	19					1639	1647		10.3109/09638288.2012.656789			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	979VS	WOS:000306850400006	22416951				2022-02-06	
J	Vanderploeg, RD; Groer, S; Belanger, HG				Vanderploeg, Rodney D.; Groer, Shirley; Belanger, Heather G.			Initial developmental process of a VA semistructured clinical interview for TBI identification	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injury; clinical reminder; concussion; diagnostic techniques; differential diagnosis; head injury; head trauma; interview; postconcussion syndrome; rehabilitation	TRAUMATIC BRAIN-INJURY; OIF/OEF SERVICE MEMBERS; NEUROPSYCHOLOGICAL OUTCOMES; DEMAND CHARACTERISTICS; EXPLOSION INJURIES; RELIABILITY; VALIDITY; IRAQ; DEPLOYMENT	Identification of a remote traumatic brain injury (TBI), particularly mild TBI, is a challenge. The acknowledged standard for determining a history of prior TBI is self-report elicited through a structured or in-depth clinical interview. In April 2007, the Veterans Health Administration (VHA) mandated that the four-section TBI Clinical Reminder screening instrument be completed on all individuals returning from deployment in the Operation Iraqi Freedom/Operation Enduring Freedom theaters of operation (VHA Directive 2007-013). If positive, a follow-up Second Level TBI Evaluation is to be completed. For validation studies of the TBI Clinical Reminder screening process and with the long-term goal of providing a structured methodology to complete the TBI history portion of the Second Level TBI Evaluation, we sought to develop a "criterion standard" semistructured clinical TBI identification interview. This tool was developed through consultation with TBI subject matter experts and built on the strengths of existing tools in the literature. This article describes the six-step developmental methodology and presents the resulting semistructured interview and accompanying manual.	[Vanderploeg, Rodney D.; Belanger, Heather G.] James A Haley Vet Hosp, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Groer, Shirley; Belanger, Heather G.] James A Haley Vet Hosp, Hlth Sci Res & Dev R&D Rehabil R&D Ctr Excel Maxi, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Defense & Vet Brain Injury Ctr, Tampa, FL USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Ave, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov			VAUS Department of Veterans Affairs; VHA [SDR HSRD 08-411- TBI]; James A. Haley Veterans' HospitalUS Department of Veterans Affairs	This material was based on work supported by the VA and VHA (grant SDR HSR&D 08-411- TBI Screening Instruments and Processes) and the James A. Haley Veterans' Hospital.	Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Cooper DB, 2008, ARCH CLIN NEUROPSYCH, V23, P731; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; DARKES J, 1993, J CONSULT CLIN PSYCH, V61, P344, DOI 10.1037/0022-006X.61.2.344; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Faith MS, 1998, OBES RES, V6, P134, DOI 10.1002/j.1550-8528.1998.tb00327.x; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GI, 2006, BRAIN INJURY MED PRI; Mercado JM, 2008, ARCH CLIN NEUROPSYCH, V23, P731; Mussack T, 2003, EUR J MED RES, V8, P457; Nichols AL, 2008, J GEN PSYCHOL, V135, P151, DOI 10.3200/GENP.135.2.151-166; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tanielian T., 2008, INVISIBLE WOUNDS WAR; van der Vaart W, 2007, APPL COGNITIVE PSYCH, V21, P227, DOI 10.1002/acp.1338; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Vanderploeg RD, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P279, DOI 10.1007/0-387-25610-5_16; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519	21	46	46	0	1	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	4					545	555		10.1682/JRRD.2011.04.0069			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	149EV	WOS:000319302700007	22773258	Bronze			2022-02-06	
J	Bruno, MA; Ledoux, D; Lambermont, B; Damas, F; Schnakers, C; Vanhaudenhuyse, A; Gosseries, O; Laureys, S				Bruno, Marie-Aurelie; Ledoux, Didier; Lambermont, Bernard; Damas, Francois; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Gosseries, Olivia; Laureys, Steven			Comparison of the Full Outline of UnResponsiveness and Glasgow Liege Scale/Glasgow Coma Scale in an Intensive Care Unit Population	NEUROCRITICAL CARE			English	Article						Coma; Full Outline of UnResponsiveness; Glasgow Coma Scale; Glasgow Liege Scale; Vegetative state; Minimally conscious state; Neurological assessment; Intensive care	MINIMALLY CONSCIOUS STATE; TRAUMATIC BRAIN-INJURY; 4 SCORE; VEGETATIVE STATE; INTERRATER RELIABILITY; VALIDATION; PAIN; PREDICTION; PERCEPTION; ACTIVATION	The Full Outline of UnResponsiveness (FOUR) has been proposed as an alternative for the Glasgow Coma Scale (GCS)/Glasgow LiSge Scale (GLS) in the evaluation of consciousness in severely brain-damaged patients. We compared the FOUR and GLS/GCS in intensive care unit patients who were admitted in a comatose state. FOUR and GLS evaluations were performed in randomized order in 176 acutely (< 1 month) brain-damaged patients. GLS scores were transformed in GCS scores by removing the GLS brainstem component. Inter-rater agreement was assessed in 20% of the studied population (N = 35). A logistic regression analysis adjusted for age, and etiology was performed to assess the link between the studied scores and the outcome 3 months after injury (N = 136). GLS/GCS verbal component was scored 1 in 146 patients, among these 131 were intubated. We found that the inter-rater reliability was good for the FOUR score, the GLS/GCS. FOUR, GLS/GCS total scores predicted functional outcome with and without adjustment for age and etiology. 71 patients were considered as being in a vegetative/unresponsive state based on the GLS/GCS. The FOUR score identified 8 of these 71 patients as being minimally conscious given that these patients showed visual pursuit. The FOUR score is a valid tool with good inter-rater reliability that is comparable to the GLS/GCS in predicting outcome. It offers the advantage to be performable in intubated patients and to identify non-verbal signs of consciousness by assessing visual pursuit, and hence minimal signs of consciousness (11% in this study), not assessed by GLS/GCS scales.	[Bruno, Marie-Aurelie; Ledoux, Didier; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Gosseries, Olivia; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Bruno, Marie-Aurelie; Ledoux, Didier; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Gosseries, Olivia; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Lambermont, Bernard] Univ Hosp Liege, Dept Intens Care, B-4000 Liege, Belgium; [Damas, Francois] Univ Liege, Dept Intens Care, Ctr Hosp Reg Citadelle, B-4000 Liege, Belgium		Laureys, S (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, Sart Tilman B30, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Ledoux, Didier/ABA-8401-2021; Gosseries, Olivia/AAB-6469-2020	Laureys, Steven/0000-0002-3096-3807; Ledoux, Didier/0000-0002-9314-6564; Gosseries, Olivia/0000-0001-9011-7496			Akavipat P, 2009, NEUROL MED-CHIR, V49, P565, DOI 10.2176/nmc.49.565; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; Bernat JL, 2010, NEUROLOGY, V75, pS33, DOI 10.1212/WNL.0b013e3181fb35dd; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BORN JD, 1982, NEUROCHIRURGIE, V28, P1; Bruno MA, 2011, CURR OPIN CRIT CARE, V17, P146, DOI 10.1097/MCC.0b013e328343476d; Cohen J, 2009, J NEUROSCI NURS, V41, P261, DOI 10.1097/JNN.0b013e3181b2c766; Demertzi A, 2009, PROG BRAIN RES, V177, P329, DOI 10.1016/S0079-6123(09)17722-1; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Fugate JE, 2010, NEUROCRIT CARE, V13, P205, DOI 10.1007/s12028-010-9407-5; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gotoh O, 1996, NEUROSURGERY, V39, P19, DOI 10.1097/00006123-199607000-00005; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Idrovo L, 2010, EUR NEUROL, V63, P364, DOI 10.1159/000292498; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Jennett B, 2005, PROG BRAIN RES, V150, P537, DOI 10.1016/S0079-6123(05)50037-2; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Laureys S, 2005, LANCET NEUROL, V4, P789, DOI 10.1016/S1474-4422(05)70230-1; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2007, CURR OPIN NEUROL, V20, P609, DOI 10.1097/WCO.0b013e3282f1d6dd; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Rordorf G, 2000, CRIT CARE MED, V28, P1301, DOI 10.1097/00003246-200005000-00007; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Schnakers C, 2010, EXPERT REV NEUROTHER, V10, P1725, DOI 10.1586/ERN.10.148; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; Stocchetti N, 2008, INTENS CARE MED, V34, P1774, DOI 10.1007/s00134-008-1168-7; TEASDALE G, 1974, LANCET, V2, P81; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	46	46	56	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2011	15	3					447	453		10.1007/s12028-011-9547-2			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	852NT	WOS:000297365400014	21526394	Green Submitted			2022-02-06	
J	Chrisman, SP; Schiff, MA; Rivara, FP				Chrisman, Sara P.; Schiff, Melissa A.; Rivara, Frederick P.			Physician Concussion Knowledge and the Effect of Mailing the CDC's "Heads Up" Toolkit	CLINICAL PEDIATRICS			English	Article						brain concussion; physicians; knowledge; practice guidelines as topic	RESPONSE RATES; BRAIN-INJURY; GUIDELINES; SPORTS; IMPACT	Background. The Centers for Disease Control and Prevention's (CDC) "Heads Up" toolkit was designed to educate physicians about concussion, but it has not been well studied. This study proposed to evaluate the effect of receiving the toolkit on physician concussion knowledge. Methods. The authors obtained a sample of physicians from the American Medical Association masterfile and randomly selected half to be mailed the CDC's "Heads Up" toolkit. All physicians were then sent a survey on concussion knowledge. Data were analyzed to evaluate the effect of the toolkit on concussion knowledge. Results. The survey was completed by 414 physicians (183 intervention, 231 control). There were no differences in general concussion knowledge between intervention and control groups, but physicians in the intervention group were significantly less likely to recommend next day return to play after a concussion (adjusted odds ratio = 0.31, 95% confidence interval = 0.12-0.76). Conclusions. Mailing the CDC's "Heads Up" toolkit appears to affect physicians' recommendations regarding returning to play after a concussion.	[Chrisman, Sara P.] Univ Washington, Dept Pediat, Seattle, WA 98145 USA; [Schiff, Melissa A.; Rivara, Frederick P.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA		Chrisman, SP (corresponding author), Univ Washington, Dept Pediat, POB 5371,M-S CW8-6, Seattle, WA 98145 USA.	sdow@u.washington.edu		Chrisman, Sara/0000-0001-5373-7223	Ruth L. Kirchstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This article was supported in part by a grant from the Ruth L. Kirchstein National Research Service Award.	Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; *CDCP, HEADS BRAIN INJ YOUR; CHOPP F, YOUTH SPORTS HEAD IN; Christakis DA, 1998, PEDIATRICS, V101, P825, DOI 10.1542/peds.101.5.825; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; VanGeest JB, 2007, EVAL HEALTH PROF, V30, P303, DOI 10.1177/0163278707307899	14	46	46	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228			CLIN PEDIATR	Clin. Pediatr.	NOV	2011	50	11					1031	1039		10.1177/0009922811410970			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	835FM	WOS:000296020900007	21646251				2022-02-06	
J	Irimia, A; Chambers, MC; Alger, JR; Filippou, M; Prastawa, MW; Wang, B; Hovda, DA; Gerig, G; Toga, AW; Kikinis, R; Vespa, PM; Van Horn, JD				Irimia, Andrei; Chambers, Micah C.; Alger, Jeffry R.; Filippou, Maria; Prastawa, Marcel W.; Wang, Bo; Hovda, David A.; Gerig, Guido; Toga, Arthur W.; Kikinis, Ron; Vespa, Paul M.; Van Horn, John D.			Comparison of Acute and Chronic Traumatic Brain Injury Using Semi-Automatic Multimodal Segmentation of MR Volumes	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance imaging; segmentation; TBI; visualization	DIFFUSE AXONAL INJURY; HEAD-INJURY; CLINICAL-APPLICATIONS; COMPUTED-TOMOGRAPHY; TUMOR SEGMENTATION; CEREBRAL ATROPHY; AXIAL TOMOGRAPHY; CHILDREN; LESIONS; STROKE	Although neuroimaging is essential for prompt and proper management of traumatic brain injury (TBI), there is a regrettable and acute lack of robust methods for the visualization and assessment of TBI pathophysiology, especially for of the purpose of improving clinical outcome metrics. Until now, the application of automatic segmentation algorithms to TBI in a clinical setting has remained an elusive goal because existing methods have, for the most part, been insufficiently robust to faithfully capture TBI-related changes in brain anatomy. This article introduces and illustrates the combined use of multimodal TBI segmentation and time point comparison using 3D Slicer, a widely-used software environment whose TBI data processing solutions are openly available. For three representative TBI cases, semi-automatic tissue classification and 3D model generation are performed to perform intra-patient time point comparison of TBI using multimodal volumetrics and clinical atrophy measures. Identification and quantitative assessment of extra-and intra-cortical bleeding, lesions, edema, and diffuse axonal injury are demonstrated. The proposed tools allow cross-correlation of multimodal metrics from structural imaging (e. g., structural volume, atrophy measurements) with clinical outcome variables and other potential factors predictive of recovery. In addition, the workflows described are suitable for TBI clinical practice and patient monitoring, particularly for assessing damage extent and for the measurement of neuroanatomical change over time. With knowledge of general location, extent, and degree of change, such metrics can be associated with clinical measures and subsequently used to suggest viable treatment options.	[Irimia, Andrei; Chambers, Micah C.; Toga, Arthur W.; Van Horn, John D.] Univ Calif Los Angeles, Lab Neuro Imaging, Dept Neurol, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Toga, Arthur W.] Univ Calif Los Angeles, Brain Res Inst, Dept Neurol, Los Angeles, CA 90095 USA; [Chambers, Micah C.] Univ Calif Los Angeles, Henri Samueli Sch Engn & Appl Sci, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Hovda, David A.] Univ Calif Los Angeles, Dept Radiol Sci, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Toga, Arthur W.] Univ Calif Los Angeles, Div Brain Mapping, Inst Neuropsychiat, Los Angeles, CA 90095 USA; [Filippou, Maria; Vespa, Paul M.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA; [Filippou, Maria; Vespa, Paul M.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA; [Prastawa, Marcel W.; Wang, Bo; Gerig, Guido] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT USA; [Prastawa, Marcel W.; Wang, Bo; Gerig, Guido] Univ Utah, Sch Comp, Salt Lake City, UT USA; [Kikinis, Ron] Harvard Univ, Sch Med, Dept Radiol, Surg Planning Lab, Boston, MA 02115 USA		Irimia, A (corresponding author), Univ Calif Los Angeles, Lab Neuro Imaging, Dept Neurol, Los Angeles, CA 90095 USA.	andrei.irimia@loni.ucla.edu	Irimia, Andrei/B-8275-2008; Prastawa, Marcel W/G-6335-2012	Irimia, Andrei/0000-0002-9254-9388; Prastawa, Marcel/0000-0002-0278-9637; Wang, Bo/0000-0002-0127-2281; Van Horn, John/0000-0003-1537-0816; Gerig, Guido/0000-0002-9547-6233; Filippou-Frye, Maria/0000-0001-5516-0384	National Alliance for Medical Image Computing (NA-MIC) under National Institutes of Health Roadmap Initiative [2U54EB005149]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB005149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS082086, P01NS058489] Funding Source: NIH RePORTER	We acknowledge the assistance of David McArthur, Maria Etcheparre, Silvain Gouttard, Steve Pieper, Stephen Aylward, Sonja Pujol, and the staff of the Laboratory of Neuro Imaging at UCLA. 3D Slicer is a multi-platform, free, and open source software package for visualization and medical image computing available from www.slicer.org. This work was supported by the National Alliance for Medical Image Computing (NA-MIC; www.na-mic.org), under National Institutes of Health Roadmap Initiative grant 2U54EB005149 to R. K. and sub-award to J. D. V. H., and by the NINDS, grant P01NS058489 to P. M. V.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chesnut RM, 1998, SURG NEUROL, V50, P187, DOI 10.1016/S0090-3019(98)00075-5; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; EARNEST MP, 1979, NEUROLOGY, V29, P1138, DOI 10.1212/WNL.29.8.1138; Faul M, 2010, TRAUMATIC BRAIN INJU; Filippi M, 1998, NEUROLOGY, V50, P238, DOI 10.1212/WNL.50.1.238; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; GYLDENSTED C, 1977, NEURORADIOLOGY, V14, P183, DOI 10.1007/BF00496982; HAHN FJY, 1976, NEURORADIOLOGY, V12, P137, DOI 10.1007/BF00341858; HUCKMAN MS, 1975, RADIOLOGY, V116, P85, DOI 10.1148/116.1.85; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Itti L, 2001, J NEUROIMAGING, V11, P412, DOI 10.1111/j.1552-6569.2001.tb00071.x; JONES KM, 1992, AM J ROENTGENOL, V158, P1313, DOI 10.2214/ajr.158.6.1590133; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lee Bruce, 2005, NeuroRx, V2, P372; Lehmann M, 2010, NEUROIMAGE, V49, P2264, DOI 10.1016/j.neuroimage.2009.10.056; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; MUGLER JP, 1990, MAGNET RESON MED, V15, P152, DOI 10.1002/mrm.1910150117; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Pohl KM, 2007, IEEE T MED IMAGING, V26, P1201, DOI 10.1109/TMI.2007.901433; Prastawa M, 2004, MED IMAGE ANAL, V8, P275, DOI 10.1016/j.media.2004.06.007; Prastawa M, 2003, ACAD RADIOL, V10, P1341, DOI 10.1016/S1076-6332(03)00506-3; Prastawa M, 2009, MED IMAGE ANAL, V13, P297, DOI 10.1016/j.media.2008.11.002; Prastawa M, 2008, LECT NOTES COMPUT SC, V5358, P562, DOI 10.1007/978-3-540-89639-5_54; ROBB RA, 1989, COMPUT MED IMAG GRAP, V13, P433, DOI 10.1016/0895-6111(89)90285-1; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; SYNEK V, 1976, NEUROLOGY, V26, P231, DOI 10.1212/WNL.26.3.231; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P897, DOI 10.1109/42.811270; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; Zollei L., 2007, P MED IM COMP COMP A, P39	56	46	47	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2287	2306		10.1089/neu.2011.1920			20	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600008	21787171	Green Submitted, Green Published			2022-02-06	
J	Jiang, Q; Qu, CS; Chopp, M; Ding, GL; Nejad-Davarani, SP; Helpern, JA; Jensen, JH; Zhang, ZG; Li, L; Lu, M; Kaplan, D; Hu, JN; Shen, YM; Kou, ZF; Li, QJ; Wang, SY; Mahmood, A				Jiang, Quan; Qu, Changsheng; Chopp, Michael; Ding, Guang Liang; Nejad-Davarani, Siamak P.; Helpern, Joseph A.; Jensen, Jens H.; Zhang, Zheng Gang; Li, Lian; Lu, Mei; Kaplan, David; Hu, Jiani; Shen, Yimin; Kou, Zhifeng; Li, Qingjiang; Wang, Shiyang; Mahmood, Asim			MRI evaluation of axonal reorganization after bone marrow stromal cell treatment of traumatic brain injury	NMR IN BIOMEDICINE			English	Article						MRI; DTI; traumatic brain injury; rat brain	CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; DIFFUSION MRI; STEM-CELLS; THERAPEUTIC BENEFIT; HEAD-INJURY; IN-VIVO; STROKE; RAT; TRANSPLANTATION	We treated traumatic brain injury (TBI) with human bone marrow stromal cells (hMSCs) and evaluated the effect of treatment on white matter reorganization using MRI. We subjected male Wistar rats (n = 17) to controlled cortical impact and either withheld treatment (controls; n = 9) or inserted collagen scaffolds containing hMSCs (n = 8). Six weeks later, the rats were sacrificed and MRI revealed selective migration of grafted neural progenitor cells towards the white matter reorganized boundary of the TBI-induced lesion. Histology confirmed that the white matter had been reorganized, associated with increased fractional anisotropy (FA; p < 0.01) in the recovery regions relative to the injured core region in both treated and control groups. Treatment with hMSCs increased FA in the recovery regions, lowered T-2 in the core region, decreased lesion volume and improved functional recovery relative to untreated controls. Immunoreactive staining showed axonal projections emanating from neurons and extruding from the corpus callosum into the ipsilateral cortex at the boundary of the lesion. Fiber tracking (FT) maps derived from diffusion tensor imaging confirmed the immunohistological data and provided information on axonal rewiring. The apparent kurtosis coefficient (AKC) detected additional axonal remodeling regions with crossing axons, confirmed by immunohistological staining, comparedwith FA. Our data demonstrate that AKC, FA, FTand T-2 can be used to evaluate treatment-induced white matter recovery, which may facilitate restorative therapy in patients with TBI. Copyright (C) 2011 John Wiley & Sons, Ltd.	[Jiang, Quan; Chopp, Michael; Ding, Guang Liang; Nejad-Davarani, Siamak P.; Zhang, Zheng Gang; Li, Lian; Li, Qingjiang; Wang, Shiyang] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA; [Qu, Changsheng; Mahmood, Asim] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; [Jiang, Quan; Chopp, Michael; Zhang, Zheng Gang; Wang, Shiyang] Oakland Univ, Dept Phys, Rochester, MI USA; [Jensen, Jens H.] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA; [Helpern, Joseph A.] Med Univ S Carolina, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA; [Jensen, Jens H.] NYU, Sch Med, Dept Physiol & Neurosci, New York, NY USA; [Lu, Mei] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA; [Kaplan, David] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Hu, Jiani; Shen, Yimin; Kou, Zhifeng] Wayne State Univ, Harper Hosp, MR Ctr, Detroit, MI USA		Jiang, Q (corresponding author), Henry Ford Hosp, Dept Neurol, NMR Lab, 2799 W Grand Blvd, Detroit, MI 48202 USA.		Wang, Shiyang/C-1729-2012; Jensen, Jens H/A-8334-2009; Nejad-Davarani, Siamak/AAH-8399-2021	Jensen, Jens H/0000-0003-3219-4287; Ding, Guangliang/0000-0003-1286-5901; Nejad-Davarani, Siamak/0000-0002-2415-6689; Li, Lian/0000-0003-0097-1184	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS38292, RO1 NS43324, RO1 HL64766, PO1 NS23393, R01 AG027852, PO1 NS42345]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038292, P01NS023393, R01NS064134, R01NS048349, P01NS042345, P50NS023393, R01NS043324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027852] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) grants RO1 NS38292, RO1 NS43324, RO1 HL64766, PO1 NS23393, R01 AG027852 and PO1 NS42345.	ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Alexander DC, 2005, NEUROIMAGE, V27, P357, DOI 10.1016/j.neuroimage.2005.04.008; Alexander DC, 2005, ANN NY ACAD SCI, V1064, P113, DOI 10.1196/annals.1340.018; Alexander DC, 2002, MAGN RESON MED, V48, P331, DOI 10.1002/mrm.10209; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cramer SC, 2006, STROKE, V37, P111, DOI 10.1161/01.STR.0000195135.70379.1f; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunnett SB, 2001, NAT REV NEUROSCI, V2, P365, DOI 10.1038/35072572; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fok-Seang J, 1998, EUR J NEUROSCI, V10, P2400, DOI 10.1046/j.1460-9568.1998.00251.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Imaizumi T, 2001, No To Shinkei, V53, P632; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; JENSEN JH, 2003, P 11 ANN M ISMRM TOR, P2154; Jiang Q, 2005, NEUROIMAGE, V28, P698, DOI 10.1016/j.neuroimage.2005.06.063; Jiang Q, 2002, J CEREBR BLOOD F MET, V22, P559, DOI 10.1097/00004647-200205000-00007; Jiang Q, 2001, J MAGN RESON IMAGING, V13, P178, DOI 10.1002/1522-2586(200102)13:2<178::AID-JMRI1027>3.0.CO;2-D; Jiang Q, 1997, J NEUROL SCI, V145, P15, DOI 10.1016/S0022-510X(96)00286-9; Jiang Q, 2006, NEUROIMAGE, V32, P1080, DOI 10.1016/j.neuroimage.2006.05.025; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lazar M, 2008, MAGN RESON MED, V60, P774, DOI 10.1002/mrm.21725; Li L, 2006, J CEREBR BLOOD F MET, V26, P1366, DOI 10.1038/sj.jcbfm.9600288; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Liu ZW, 2007, BRAIN RES, V1149, P172, DOI 10.1016/j.brainres.2007.02.047; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Mahmood A, 2007, NEUROSURGERY, V61, P206, DOI 10.1227/01.neu.0000279914.37559.de; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Napieralski JA, 1996, J COMP NEUROL, V373, P484; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Phinney DG, 2006, STEM CELLS, V24, P186, DOI 10.1634/stemcells.2004-0236; Prockop DJ, 2000, BIOCHEM SOC T, V28, P341, DOI 10.1042/0300-5127:0280341; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; SALTHOUSE TN, 1964, STAIN TECHNOL, V39, P123; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; von Bohlen und Halbach O, 1998, J NEUROSCI METH, V81, P169, DOI 10.1016/S0165-0270(98)00026-0; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zheng ZG, 2003, ANN NEUROL, V53, P259, DOI 10.1002/ana.10467	64	46	48	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	NOV	2011	24	9					1119	1128		10.1002/nbm.1667			10	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	840DT	WOS:000296419200012	21432927	Green Accepted			2022-02-06	
J	Feng, K; Hu, YT; Ma, ZZ				Feng, Kang; Hu, Yun Tao; Ma, Zhizhong			Prognostic Indicators for No Light Perception After Open-Globe Injury: Eye Injury Vitrectomy Study	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							MASSIVE SUPRACHOROIDAL HEMORRHAGE; TRAUMATIC CHOROIDAL RUPTURE; PARS-PLANA VITRECTOMY; SYMPATHETIC OPHTHALMIA; OCULAR SURVIVAL; CLASSIFICATION; SURGERY; EPIDEMIOLOGY; MANAGEMENT; SECONDARY	PURPOSE: To describe ocular characteristics, surgical interventions, and anatomic and visual outcomes of traumatized eyes with no light perception (NLP) following open-globe injury and to investigate prognostic predictors for NLP cases after open-globe injury. DESIGN: Interventional case series study. METHODS: Thirty-three traumatized eyes with NLP were selected from the Eye Injury Vitrectomy Study database, a hospital-based multicenter prospective cohort study. Inclusion criteria were NLP cases following open-globe injury with outcomes of anatomic restoration, phthisis bulbi, or enucleation. Exclusion criteria were cases with missing records, undergoing vitrectomy after injury at nonparticipating hospitals, direct optic head injury, endophthalmitis, and hypotonous or silicone oil-sustained eyes. All cases underwent vitreoretinal surgery or enucleation after exploratory surgery and were followed up for at least 6 months. Two outcomes were assessed: favorable outcome (anatomically restored eye globes with light perception [LP] or better vision) and unfavorable outcome (NLP, phthisis bulbi, or enucleation). RESULTS: The following 7 risk factors were significant between the 2 groups: rupture (P = .021); open globe III (P = .046); scleral wound >= 10 mm (P = .001); ciliary body damage (P < .001); severe intraocular hemorrhage (P = .005); closed funnel retinal detachment or retinal prolapse (P = .005); and choroidal damage (P =.001). CONCLUSIONS: These 7 risk factors are possible predictors of poor prognosis. Traumatized eyes with NLP can be anatomically restored with LP or better vision if vitreoretinal surgery is attempted, and a favorable anatomic and visual outcome is increased by having a decreased number of these risk factors. (Am J Ophthalmol 2011;152:654-662. (C) 2011 by Elsevier Inc. All rights reserved.)	[Feng, Kang; Hu, Yun Tao; Ma, Zhizhong] Peking Univ, Hosp 3, Ctr Eye, Beijing 100191, Peoples R China		Ma, ZZ (corresponding author), Peking Univ, Hosp 3, Ctr Eye, Huayuan N St 49, Beijing 100191, Peoples R China.	puh3_yk@bjmu.edu.cn		Feng, Kang/0000-0002-8923-932X	PEKING UNIVERSITY HEALTH SCIENCE CENTER; 211 Evidence-Based Medicine Discipline Groups, Beijing, China [03-9-02]	PUBLICATION OF THIS ARTICLE WAS FUNDED BY A GRANT FROM THE PEKING UNIVERSITY HEALTH SCIENCE CENTER, 211 Evidence-Based Medicine Discipline Groups, Beijing, China (No.03-9-02). The funding organization had no role in the design or conduct of this research. The authors indicate no financial conflict of interest. Involved in design of the study (Z.Z.M.); conduct of the study (K.F., Z.Z.M., Y.T.H.); collection of the data (Z.Z.M., Y.T.H., K.F.); analysis and interpretation of the data (K.F.); and review and approval of the manuscript (Z.Z.M.). This study was approved by the review board/ethics committee of the Peking University Third Hospital. Informed consent was obtained from every patient.	ALBERT DM, 1989, SURV OPHTHALMOL, V34, P1, DOI 10.1016/0039-6257(89)90125-2; Ament CS, 2006, ARCH OPHTHALMOL-CHIC, V124, P957, DOI 10.1001/archopht.124.7.957; Larque-Daza AB, 2010, EUR J OPHTHALMOL, V20, P578, DOI 10.1177/112067211002000307; Casson RJ, 2002, CLIN EXP OPHTHALMOL, V30, P15, DOI 10.1046/j.1442-9071.2002.00484.x; COLEMAN DJ, 1995, RETINA-J RET VIT DIS, V15, P312, DOI 10.1097/00006982-199515040-00008; du Toit N, 2008, BRIT J OPHTHALMOL, V92, P61, DOI 10.1136/bjo.2007.120600; Entezari M, 2006, INJURY, V37, P633, DOI 10.1016/j.injury.2006.02.043; Feretis E, 2006, EUR J OPHTHALMOL, V16, P835, DOI 10.1177/112067210601600608; FRENKEL REP, 1986, ARCH OPHTHALMOL-CHIC, V104, P1459; Gotzaridis EV, 2003, EYE, V17, P790, DOI 10.1038/sj.eye.6700472; Gurdal C, 2002, OCUL IMMUNOL INFLAMM, V10, P223, DOI 10.1076/ocii.10.3.223.15600; INGRAHAM HJ, 1989, AM J OPHTHALMOL, V108, P670, DOI 10.1016/0002-9394(89)90859-3; Kuhn F, 1996, GRAEF ARCH CLIN EXP, V234, P399, DOI 10.1007/BF00190717; Kuhn F, 2004, INJURY, V35, P690, DOI 10.1016/j.injury.2004.03.008; LAKHANPAL V, 1990, OPHTHALMOLOGY, V97, P1114; Matthews GP, 1998, OPHTHALMIC SURG LAS, V29, P48; Mei HF, 2009, RETINA-J RET VIT DIS, V29, P473, DOI 10.1097/IAE.0b013e318196b189; Morris R, 1999, VITREORETINAL SURG I, P113; Moshfeghi DM, 2000, SURV OPHTHALMOL, V44, P277, DOI 10.1016/S0039-6257(99)00112-5; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Rahman I, 2006, EYE, V20, P1336, DOI 10.1038/sj.eye.6702099; Raman SV, 2004, CAN J OPHTHALMOL, V39, P260, DOI 10.1016/S0008-4182(04)80123-6; Rofail M, 2006, CLIN EXP OPHTHALMOL, V34, P783, DOI 10.1111/j.1442-9071.2006.01309.x; Salehi-Had H, 2009, GRAEF ARCH CLIN EXP, V247, P477, DOI 10.1007/s00417-009-1035-4; Savar A, 2009, AM J OPHTHALMOL, V147, P595, DOI 10.1016/j.ajo.2008.10.017; Schepens C, 1983, RETINAL DETACHMENT A, P1006; Schmidt GW, 2008, OPHTHALMOLOGY, V115, P202, DOI 10.1016/j.ophtha.2007.04.008; Sobaci G, 2000, AM J OPHTHALMOL, V129, P47, DOI 10.1016/S0002-9394(99)00254-8; SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P202; WELCH JC, 1988, OPHTHALMOLOGY, V95, P1202; WOLTER JR, 1988, OPHTHALMIC SURG LAS, V19, P344; Yang SS, 2003, RETINA-J RET VIT DIS, V23, P139, DOI 10.1097/00006982-200304000-00001	32	46	56	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394			AM J OPHTHALMOL	Am. J. Ophthalmol.	OCT	2011	152	4					654	662		10.1016/j.ajo.2011.04.004			9	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	830LF	WOS:000295657800019	21726850				2022-02-06	
J	Doonan, F; O'Driscoll, C; Kenna, P; Cotter, TG				Doonan, Francesca; O'Driscoll, Carolyn; Kenna, Paul; Cotter, Thomas G.			Enhancing survival of photoreceptor cells in vivo using the synthetic progestin Norgestrel	JOURNAL OF NEUROCHEMISTRY			English	Article						bFGF; neuroprotection; Norgestrel; photoreceptor; progestin; retinal degeneration	FIBROBLAST-GROWTH-FACTOR; CILIARY NEUROTROPHIC FACTOR; INDUCED RETINAL DEGENERATION; TRAUMATIC BRAIN-INJURY; FACTOR MESSENGER-RNA; RETINITIS-PIGMENTOSA; GENE-EXPRESSION; UP-REGULATION; MOUSE RETINA; LIGHT DAMAGE	Retinal degenerations such as Retinitis Pigmentosa remain difficult to treat given the diverse array of genes responsible for their aetiology. Rather than concentrate on specific genes, our focus is on identifying therapeutic avenues for the treatment of retinal disease that target general survival mechanisms or pathways. Norgestrel is a synthetic progestin commonly used in hormonal contraception. Here, we report a novel anti-apoptotic role for Norgestrel in diseased mouse retinas in vivo. Dosing with Norgestrel protects photoreceptor cells from undergoing apoptosis in two distinct models of retinal degeneration; the light damage model and the Pde6b(rd10) model. Photoreceptor rescue was assessed by analysis of cell number, structural integrity and function. Improvements in cell survival of up to 70% were achieved in both disease models, indicating that apoptosis had been halted or at least delayed. A speculative mechanism of action for Norgestrel involves activation of survival pathways in the retina. Indeed, Norgestrel increases the expression of basic fibroblast growth factor which is known to both promote cell survival and inhibit apoptosis. In summary, our results demonstrate significant protection of photoreceptor cells which may be attributed to Norgestrel mediated activation of endogenous survival pathways within the retina.	[Doonan, Francesca; O'Driscoll, Carolyn; Cotter, Thomas G.] Univ Coll Cork, Dept Biochem, Biosci Res Inst, Cell Dev & Dis Lab, Cork, Ireland; [Kenna, Paul] Trinity Coll Dublin, Dept Genet, Smurfit Inst Genet, Dublin, Ireland		Cotter, TG (corresponding author), Univ Coll Cork, Dept Biochem, Biosci Res Inst, Cell Dev & Dis Lab, Cork, Ireland.	t.cotter@ucc.ie		Cotter, Thomas/0000-0003-4626-5613	Enterprise Ireland (EI); European Regional Development FundEuropean Commission; Science Foundation IrelandScience Foundation IrelandEuropean Commission	The authors gratefully acknowledge all members of the Biological Services Unit (BSU) for technical assistance. This work was supported by Enterprise Ireland (EI) the European Regional Development Fund and Science Foundation Ireland (SFI).	Aramant RB, 2004, PROG RETIN EYE RES, V23, P475, DOI 10.1016/j.preteyeres.2004.05.003; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1306, DOI 10.1001/archopht.122.9.1306; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176; BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223; Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328; Cayouette M, 1998, J NEUROSCI, V18, P9282; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Cheung AKH, 2005, DIABETES, V54, P3119, DOI 10.2337/diabetes.54.11.3119; Corrochano S, 2008, INVEST OPHTH VIS SCI, V49, P4188, DOI 10.1167/iovs.08-2182; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Doonan F, 2003, J NEUROSCI, V23, P5723; Doonan F, 2009, J NEUROCHEM, V109, P631, DOI 10.1111/j.1471-4159.2009.05995.x; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fayard B, 2005, J NEUROSCI RES, V80, P18, DOI 10.1002/jnr.20432; Fontaine V, 1998, J NEUROSCI, V18, P9662; Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508; Friberg PA, 2009, BIOL REPROD, V80, P1160, DOI 10.1095/biolreprod.108.073932; Frye CA, 2009, AGE, V31, P143, DOI 10.1007/s11357-009-9091-6; GAO H, 1995, DEV BIOL, V169, P168, DOI 10.1006/dbio.1995.1135; Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022; Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144; Geller SF, 2001, INVEST OPHTH VIS SCI, V42, P1363; Gibbs RB, 1999, BRAIN RES, V844, P20, DOI 10.1016/S0006-8993(99)01880-6; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Gonzalez SL, 2009, CELL MOL NEUROBIOL, V29, P27, DOI 10.1007/s10571-008-9291-0; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2000, MOL VIS, V6, P252; GUARNERI P, 1994, J NEUROCHEM, V63, P86; Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256; Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8; Kaldi I, 2004, EUR J OPHTHALMOL, V14, P306, DOI 10.5301/EJO.2008.1363; Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152; Lange CA, 2008, J STEROID BIOCHEM, V108, P203, DOI 10.1016/j.jsbmb.2007.09.019; LANTHIER A, 1988, BRAIN RES, V463, P403, DOI 10.1016/0006-8993(88)90419-2; Lee SY, 2011, J CELL PHYSIOL, V226, P1843, DOI 10.1002/jcp.22508; Liu CD, 1998, J NEUROSCI, V18, P1337; Lu Na, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P2026; Makrigiannakis A, 2000, ANN NY ACAD SCI, V900, P16; Moorthy K, 2005, EXP GERONTOL, V40, P295, DOI 10.1016/j.exger.2005.01.004; Nakazawa T, 2006, BRAIN RES, V1093, P141, DOI 10.1016/j.brainres.2006.03.084; Nutu M, 2007, MOL REPROD DEV, V74, P843, DOI 10.1002/mrd.20685; O'Driscoll C, 2008, J NEUROCHEM, V105, P524, DOI 10.1111/j.1471-4159.2007.05189.x; O'Driscoll C, 2007, J NEUROCHEM, V103, P860, DOI 10.1111/j.1471-4159.2007.04827.x; O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025; Olive DL, 2001, NEW ENGL J MED, V345, P266, DOI 10.1056/NEJM200107263450407; OSTEEN WK, 1977, EXP EYE RES, V25, P361, DOI 10.1016/0014-4835(77)90103-8; Pang JJ, 2008, INVEST OPHTH VIS SCI, V49, P4278, DOI 10.1167/iovs.07-1622; Pawlyk BS, 2002, INVEST OPHTH VIS SCI, V43, P1912; Peluso JJ, 1999, BIOL REPROD, V60, P290, DOI 10.1095/biolreprod60.2.290; Peluso JJ, 2009, J CLIN ENDOCR METAB, V94, P2644, DOI 10.1210/jc.2009-0147; Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027; Rider V, 1997, J ENDOCRINOL, V154, P75, DOI 10.1677/joe.0.1540075; RIDER V, 1994, J ENDOCRINOL, V140, P239, DOI 10.1677/joe.0.1400239; Roopa BA, 2003, HUM REPROD, V18, P1809, DOI 10.1093/humrep/deg329; Schuettauf F, 2004, CURR EYE RES, V29, P379, DOI 10.1080/02713680490517872; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Sun X, 2010, GENE THER, V17, P117, DOI 10.1038/gt.2009.104; Svensson EC, 2000, BIOL REPROD, V63, P1457, DOI 10.1095/biolreprod63.5.1457; Swiatek-De Lange M, 2007, GLIA, V55, P1061, DOI 10.1002/glia.20523; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907; Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47; Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927; Wickham LA, 2000, ACTA OPHTHALMOL SCAN, V78, P146, DOI 10.1034/j.1600-0420.2000.078002146.x; WONG F, 1993, ARCH OPHTHALMOL-CHIC, V111, P754, DOI 10.1001/archopht.1993.01090060042020	73	46	47	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	2011	118	5					915	927		10.1111/j.1471-4159.2011.07354.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	806HT	WOS:000293797600021	21689103	Bronze			2022-02-06	
J	Blumcke, I; Muhlebner, A				Bluemcke, I.; Muehlebner, A.			Neuropathological work-up of focal cortical dysplasias using the new ILAE consensus classification system - practical guideline article invited by the Euro-CNS Research Committee	CLINICAL NEUROPATHOLOGY			English	Article						epilepsy; seizures; hippocampal sclerosis; tumors; cortical dysplasia; dysmorphic	TEMPORAL-LOBE EPILEPSY; TUBEROUS SCLEROSIS COMPLEX; HIPPOCAMPAL SCLEROSIS; DUAL PATHOLOGY; MALFORMATIONS; CHILDREN; FEATURES; CELL; RECORDINGS; EXPRESSION	FCDs are increasingly recognized in patients with drug-resistant epilepsies, and many patients benefit from tailored resection strategies. Yet, postsurgical seizure control cannot be sufficiently predicted and specification of FCD variants remains difficult during presurgical monitoring. The International League against Epilepsy (ILAE) has published a new consensus classification system for focal cortical dysplasias (FCDs). Based on a review of imaging data, electro-clinical features and postsurgical seizure control correlation with neuropathological findings specify three clinico-pathological FCD subtypes: FCD Type I is characterized by aberrant radial (FCD Type Ia) or tangential lamination of the neocortex (FCD Type Ib) affecting one or multiple lobes. FCD Type II is characterized by cortical dyslamination and dysmorphic neurons without (Type IIa) or with balloon cells (Type IIb). It is important to note, that these types should not be associated with any other structural brain lesion (isolated FCD). In contrast, a new FCD Type III is introduced, which occurs in combination with hippocampal sclerosis (FCD Type IIIa), or with epilepsy-associated tumors (FCD Type IIIb). FCD Type IIIc is found adjacent to vascular malformations, whereas FCD Type IIId can be diagnosed in association with other epileptogenic lesions obtained in early life (i.e., traumatic injury, ischemic injury or encephalitis). Histopathological features are very similar to those observed in FCD Type I, but likely present postnatal development and maturation failures acquired by the principal lesion. This first international consensus classification may encourage neuropathologists to focus their attention onto this important histopathological group. Addressing more precisely defined clinico-pathological entities will also help to clarify underlying pathomechanisms and, thereby, improve treatment strategies for patients with difficult-to-treat epilepsies.	[Bluemcke, I.; Muehlebner, A.] Univ Hosp Erlangen, Dept Neuropathol, D-91054 Erlangen, Germany		Muhlebner, A (corresponding author), Univ Hosp Erlangen, Dept Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany.	angelika.muehlebner@uk-erlangen.de	Muhlebner, Angelika/L-3734-2019; Muhlebner, Angelika/ABC-9873-2021; Blumcke, Ingmar/D-4705-2018	Muhlebner, Angelika/0000-0001-9102-7353; Muhlebner, Angelika/0000-0001-9102-7353; Blumcke, Ingmar/0000-0001-8676-0788			Andres M, 2005, CEREB CORTEX, V15, P194, DOI 10.1093/cercor/bhh122; Battaglia G, 2009, EPILEPTIC DISORD, V11, P206, DOI 10.1684/epd.2009.0273; Blumcke I, 2007, ACTA NEUROPATHOL, V113, P235, DOI 10.1007/s00401-006-0187-0; Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x; Blumcke I, 2011, LANCET NEUROL, V10, P26, DOI 10.1016/S1474-4422(10)70225-8; Blumcke I, 2010, EPILEPTIC DISORD, V12, P172, DOI 10.1684/epd.2010.0321; Blumcke I, 2009, EPILEPTIC DISORD, V11, P181, DOI 10.1684/epd.2009.0261; Blumcke I, 2009, EPILEPSY BEHAV, V15, P34, DOI 10.1016/j.yebeh.2009.02.033; Blumcke I, 2004, ACTA NEUROPATHOL, V108, P89, DOI 10.1007/s00401-004-0873-8; Blumcke I, 1999, ACTA NEUROPATHOL, V97, P481, DOI 10.1007/s004010051017; CENDES F, 1995, NEUROLOGY, V45, P2058, DOI 10.1212/WNL.45.11.2058; Cepeda C, 2006, EPILEPSY BEHAV, V9, P219, DOI 10.1016/j.yebeh.2006.05.012; Chamberlain WA, 2009, EPILEPSIA, V50, P2593, DOI 10.1111/j.1528-1167.2009.02344.x; Chandra PS, 2007, NEUROLOGY, V68, P438, DOI 10.1212/01.wnl.0000252952.62543.20; Colombo N, 2009, EPILEPTIC DISORD, V11, P194, DOI 10.1684/epd.2009.0262; CROME L, 1957, J NEUROL NEUROSUR PS, V20, P117, DOI 10.1136/jnnp.20.2.117; Ding SL, 2009, J COMP NEUROL, V514, P595, DOI 10.1002/cne.22053; Fauser S, 2006, BRAIN, V129, P82, DOI 10.1093/brain/awh687; Fauser S, 2009, BRAIN, V132, P2079, DOI 10.1093/brain/awp145; Ferrier CH, 2007, J NEUROSURG, V107, P495, DOI 10.3171/JNS-07/09/0495; Garbelli R, 1999, BRAIN PATHOL, V9, P445, DOI 10.1111/j.1750-3639.1999.tb00534.x; Garbelli R, 2006, EPILEPSIA, V47, P1074, DOI 10.1111/j.1528-1167.2006.00577.x; Hildebrandt M, 2005, ACTA NEUROPATHOL, V110, P1, DOI 10.1007/s00401-005-1016-6; Kahane P, 2010, EPILEPSIA, V51, P59, DOI 10.1111/j.1528-1167.2009.02448.x; Kloosterhof NK, 2011, LANCET ONCOL, V12, P83, DOI 10.1016/S1470-2045(10)70053-X; Krsek P, 2008, ANN NEUROL, V63, P758, DOI 10.1002/ana.21398; Krsek P, 2009, EPILEPSIA, V50, P125, DOI 10.1111/j.1528-1167.2008.01682.x; Lombroso CT, 2000, EPILEPSIA, V41, P245, DOI 10.1111/j.1528-1157.2000.tb00148.x; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; Martinian L, 2009, NEUROPATH APPL NEURO, V35, P394, DOI [10.1111/j.1365-2990.2009.00996.x, 10.1111/j.1365-2990.2008.00996.x]; Meroni A, 2009, EPILEPSIA, V50, P116, DOI 10.1111/j.1528-1167.2008.01717.x; Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; Talos DM, 2008, ANN NEUROL, V63, P454, DOI 10.1002/ana.21342; Tassi L, 2010, EPILEPTIC DISORD, V12, P181, DOI 10.1684/epd.2010.0327; TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369; Thom M, 2009, J NEUROPATH EXP NEUR, V68, P928, DOI 10.1097/NEN.0b013e3181b05d67; Urbach H, 2002, EPILEPSIA, V43, P33, DOI 10.1046/j.1528-1157.2002.38201.x; WOLF HK, 1993, BRAIN PATHOL, V3, P371, DOI 10.1111/j.1750-3639.1993.tb00765.x; Yasin SA, 2010, ACTA NEUROPATHOL, V120, P85, DOI 10.1007/s00401-010-0677-y	40	46	55	0	8	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	JUL-AUG	2011	30	4					164	177		10.5414/NP300398			14	Clinical Neurology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	797CM	WOS:000293101700002	21726501				2022-02-06	
J	King, MD; McCracken, DJ; Wade, FM; Meiler, SE; Alleyne, CH; Dhandapani, KM				King, Melanie D.; McCracken, D. Jay; Wade, F. Marlene; Meiler, Steffen E.; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.			Attenuation of hematoma size and neurological injury with curcumin following intracerebral hemorrhage in mice	JOURNAL OF NEUROSURGERY			English	Article						hemorrhagic stroke; vasogenic edema; blood-brain barrier; hematoma; mouse; vascular disorders	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-BETA; BARRIER BREAKDOWN; VASOGENIC EDEMA; TRIAL; INTERLEUKIN-1-BETA; INFLAMMATION; ACTIVATION	Object. Intracerebral hemorrhage (ICH) is associated with significant morbidity and mortality. Acute hematoma enlargement is an important predictor of neurological injury and poor clinical prognosis; but neurosurgical clot evacuation may not be feasible in all patients and treatment options remain largely supportive. Thus, novel therapeutic approaches to promote hematoma resolution are needed. In the present study, the authors investigated whether the curry spice curcumin limited neurovascular injury following ICH in mice. Methods. Intracerebral hemorrhage was induced in adult male CD-1 mice by intracerebral administration of collagenase or autologous blood. Clinically relevant doses of curcumin (75-300 mg/kg) were administered up to 6 hours after ICH, and hematoma volume, inflammatory gene expression, blood-brain barrier permeability, and brain edema were assessed over the first 72 hours. Neurological assessments were performed to correlate neurovascular protection with functional outcomes. Results. Curcumin increased hematoma resolution at 72 hours post-ICH. This effect was associated with a significant reduction in the expression of the proinflammatory mediators, tumor necrosis factor a, interleukin-6, and interleukin-1 beta. Curcumin also reduced disruption of the blood-brain barrier and attenuated the formation of vasogenic edema following ICH. Consistent with the reduction in neuroinfiammation and neurovascular injury, curcumin significantly improved neurological outcome scores after ICH. Conclusions. Curcumin promoted hematoma resolution and limited neurological injury following ICH. These data may indicate clinical utility for curcumin as an adjunct therapy to reduce brain injury and improve patient outcome. (DOI: 10.3171/2011.2.JNS10784)	[King, Melanie D.; McCracken, D. Jay; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA 30809 USA; [Wade, F. Marlene; Meiler, Steffen E.] Georgia Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Augusta, GA 30809 USA		Dhandapani, KM (corresponding author), Georgia Hlth Sci Univ, Dept Neurosurg, 1120 15th St, Augusta, GA 30809 USA.	kdhandapani@mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117; McCracken, D. Jay/0000-0001-6305-707X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; American Heart AssociationAmerican Heart Association [BGIA2300135]; Alpha Omega Alpha Carolyn L. Kuckein Research Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institutes of Health (no. NS065172) and American Heart Association (no. BGIA2300135) to Dr. Dhandapani, and by an Alpha Omega Alpha Carolyn L. Kuckein Research Fellowship to Mr. McCracken.	Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; BALLA G, 1992, J BIOL CHEM, V267, P18148; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Christoforidis GA, 2007, STROKE, V38, P1799, DOI 10.1161/STROKEAHA.106.472282; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x; Dhandapani KM, 2007, J NEUROSCI RES, V85, P1033, DOI 10.1002/jnr.21182; Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024; Didier N, 2003, J NEUROCHEM, V86, P246, DOI 10.1046/j.1471-4159.2003.01829.x; Dziedzic T, 2002, STROKE, V33, P2334, DOI 10.1161/01.STR.0000027211.73567.FA; Fewel ME, 2003, NEUROSURG FOCUS, V15, pE1, DOI DOI 10.3171/F0C.2003.15.4.0; Garodia Prachi, 2007, J Soc Integr Oncol, V5, P25, DOI 10.2310/7200.2006.029; Hickenbottom SL, 1999, STROKE, V30, P2472, DOI 10.1161/01.STR.30.11.2472; Hua Y, 2006, NEUROSURGERY, V58, P542, DOI 10.1227/01.NEU.0000197333.55473.AD; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; Labovitz DL, 2001, CURR OPIN NEUROL, V14, P103, DOI 10.1097/00019052-200102000-00016; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Lu AG, 2006, J CEREBR BLOOD F MET, V26, P230, DOI 10.1038/sj.jcbfm.9600183; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Mendelow AD, 2003, ACT NEUR S, V86, P441; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Qin ZY, 2007, STROKE, V38, P1362, DOI 10.1161/01.STR.0000259660.62865.eb; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Rynkowski MA, 2008, NAT PROTOC, V3, P122, DOI 10.1038/nprot.2007.513; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Silakova JM, 2004, J PHARMACOL EXP THER, V309, P1060, DOI 10.1124/jpet.103.063867; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Wagner KR, 2006, ACTA NEUROCHIR SUPPL, V96, P177; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; WRIGHT JL, 1994, J NEURO-ONCOL, V20, P17, DOI 10.1007/BF01057957; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Zhao XR, 2007, J NEUROCHEM, V101, P652, DOI 10.1111/j.1471-4159.2006.04414.x	48	46	52	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2011	115	1					116	123		10.3171/2011.2.JNS10784			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	782JO	WOS:000292004700025	21417704	Green Accepted			2022-02-06	
J	Scott, JC; Woods, SP; Vigil, O; Heaton, RK; Schweinsburg, BC; Ellis, RJ; Grant, I; Marcotte, TD				Scott, J. Cobb; Woods, Steven Paul; Vigil, Ofilio; Heaton, Robert K.; Schweinsburg, Brian C.; Ellis, Ronald J.; Grant, Igor; Marcotte, Thomas D.		San Diego HIV Neurobehav Res Ctr	A Neuropsychological Investigation of Multitasking in HIV Infection: Implications for Everyday Functioning	NEUROPSYCHOLOGY			English	Article						HIV; cognition; neuropsychology; activities of daily living; executive functions	TRAUMATIC BRAIN-INJURY; STRATEGY APPLICATION; ECOLOGICAL VALIDITY; IMPAIRMENT; DAMAGE; PERFORMANCE; DEPENDENCE; PATTERNS	Objective: A subset of individuals with HIV-associated neurocognitive impairment experience related deficits in "real world" functioning (i.e., independently performing instrumental activities of daily living [IADL]). While performance-based tests of everyday functioning are reasonably sensitive to HIV-associated IADL declines, questions remain regarding the extent to which these tests' highly structured nature fully captures the inherent complexities of daily life. The aim of this study was to assess the predictive and ecological validity of a novel multitasking measure in HIV infection. Method: Participants included 60 individuals with HIV infection (HIV+) and 25 demographically comparable seronegative adults (HIV-). Participants were administered a comprehensive neuropsychological battery, questionnaires assessing mood and everyday functioning, and a novel standardized test of multitasking, which involved balancing the demands of four interconnected performance-based functional tasks (i.e., financial management, cooking, medication management, and telephone communication). Results: HIV+ individuals demonstrated significantly worse overall performance, fewer simultaneous task attempts, and increased errors on the multitasking test as compared to the HIV- group. Within the HIV+ sample, multitasking impairments were modestly associated with deficits on standard neuropsychological measures of executive functions, episodic memory, attention/working memory, and information processing speed, providing preliminary evidence for convergent validity. More importantly, multivariate prediction models revealed that multitasking deficits were uniquely predictive of IADL dependence beyond the effects of depression and global neurocognitive impairment, with excellent sensitivity (86%), but modest specificity (57%). Conclusions: Taken together, these data indicate that multitasking ability may play an important role in successful everyday functioning in HIV+ individuals.	[Scott, J. Cobb] San Diego State Univ, Joint Doctoral Program Clin Psychol, San Diego, CA 92182 USA; [Scott, J. Cobb; Woods, Steven Paul; Vigil, Ofilio; Heaton, Robert K.; Schweinsburg, Brian C.; Ellis, Ronald J.; Grant, Igor; Marcotte, Thomas D.] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA; [Schweinsburg, Brian C.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA		Scott, JC (corresponding author), VA Connecticut Healthcare Syst, Clin Neurosci Div 151E, Natl Ctr PTSD, 950 Campbell Ave, West Haven, CT 06516 USA.	cobb.scott@yale.edu	Ellis, Ronald/K-3543-2015	Ellis, Ronald/0000-0003-4931-752X; Woods, Steven Paul/0000-0003-0776-4233; Scott, J. Cobb/0000-0001-6538-9043	American Psychological Foundation [CSPAR-759, MH 62512]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062512] Funding Source: NIH RePORTER	This research was supported by CSPAR-759, MH 62512, and the 2007 Benton-Meier Scholarship from the American Psychological Foundation. Aspects of these data were presented at the 38th annual meeting of the International Neuropsychological Society in Acapulco, Mexico. Authors report no conflicts of interest affecting this article. The HNRC Group includes: Director, Igor Grant; Co-Directors: J. Hampton Atkinson, Ronald J. Ellis, and J. Allen McCutchan; Center Manager: Thomas D. Marcotte; Jennifer Marquie-Beck; Melanie Sherman; Naval Hospital San Diego: Braden R. Hale; Neuromedical Component: Ronald J. Ellis, J. Allen McCutchan, Scott Letendre, Edmund Capparelli, Rachel Schrier, Terry Alexander; Debra Rosario, Shannon LeBlanc; Neurobehavioral Component: Robert K. Heaton, Steven Paul Woods, Mariana Cherner, David J. Moore, Matthew Dawson; Neuroimaging Component: Terry Jernigan, Christine Fennema-Notestine, Sarah L. Archibald, John Hesselink, Jacopo Annese, Michael J. Taylor, Brian C. Schweinsburg; Neurobiology Component: Eliezer Masliah, Ian Everall, Cristian Achim; Neurovirology Component: Douglas Richman, David M. Smith; International Component: J. Allen McCutchan; Developmental Component: Ian Everall, Stuart Lipton; Participant Accrual and Retention Unit: J. Hampton Atkinson, Rodney von Jaeger; Data Management Unit: Anthony C. Gamst, Clint Cushman (Data Systems Manager), Daniel R. Masys (Senior Consultant); Statistics Unit: Ian Abramson, Florin Vaida, Reena Deutsch, and Tanya Wolfson.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Dawes S, 2008, J CLIN EXP NEUROPSYC, V30, P613, DOI 10.1080/13803390701565225; Dreher JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003227; Everall IP, 2005, NEUROTOX RES, V8, P51, DOI 10.1007/BF03033819; Foerde K, 2006, P NATL ACAD SCI USA, V103, P11778, DOI 10.1073/pnas.0602659103; Giovannetti T, 2007, NEUROPSYCHOLOGY, V21, P448, DOI 10.1037/0894-4105.21.4.448; Heaton R K, 1995, J Int Neuropsychol Soc, V1, P231; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; HEATON RK, 1994, PSYCHOSOM MED, V56, P8, DOI 10.1097/00006842-199401000-00001; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; McNair D.M., 1981, PROFILE MOOD STATES; Meyer DE, 1997, PSYCHOL REV, V104, P3, DOI 10.1037/0033-295X.104.1.3; Norman D.A., 1986, CONSCIOUSNESS SELF R; Ophir E, 2009, P NATL ACAD SCI USA, V106, P15583, DOI 10.1073/pnas.0903620106; Rippeth JD, 2004, J INT NEUROPSYCH SOC, V10, P1, DOI 10.1017/S1355617704101021; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Schwartz MF, 2006, COGN NEUROPSYCHOL, V23, P202, DOI 10.1080/02643290500202623; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Thoma P, 2008, BEHAV BRAIN RES, V194, P214, DOI 10.1016/j.bbr.2008.07.016; Tranel D, 2007, J CLIN EXP NEUROPSYC, V29, P319, DOI 10.1080/13803390600701376; Woods SP, 2006, J CLIN EXP NEUROPSYC, V28, P1030, DOI 10.1080/13803390500350985	32	46	46	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2011	25	4					511	519		10.1037/a0022491			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	787WQ	WOS:000292407800009	21401259	Green Accepted			2022-02-06	
J	Vas, AK; Chapman, SB; Cook, LG; Elliott, AC; Keebler, M				Vas, Asha K.; Chapman, Sandra B.; Cook, Lori G.; Elliott, Alan C.; Keebler, Molly			Higher-Order Reasoning Training Years After Traumatic Brain Injury in Adults	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adults; cognitive training; executive function; frontal lobe function; gist; reasoning; traumatic brain injury rehabilitation	COMMUNITY INTEGRATION QUESTIONNAIRE; FUNCTIONAL STATUS EXAMINATION; GLASGOW OUTCOME SCALE; CLOSED-HEAD-INJURY; FUZZY-TRACE THEORY; OF-THE-LITERATURE; COGNITIVE REHABILITATION; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; POSTTRAUMATIC AMNESIA	Objective: To conduct a feasibility study to compare the effects of top-down Strategic Memory and Reasoning Training (SMART) versus information-based Brain Health Workshop (BHW, control) on gist-reasoning (ie, abstracting novel meaning from complex information), memory, executive functions, and daily function in adults with traumatic brain injury. Participants: Twenty-eight participants (of the 35 recruited), 16 men & 12 women, aged 20 to 65 years (M = 43, SD = 11.34) at chronic stages posttraumatic brain injury (2 years or longer) completed the training. Fourteen participants that received SMART and 14 participants that completed BHW were assessed both pre- and posttraining. Thirteen of the SMART trained and 11 from BHW participated in a 6-month testing. Design: The study was a single blinded randomized control trial. Participants in both groups received a minimum of 15 hours of training over 8 weeks. Results: The SMART group significantly improved gist-reasoning as compared to the BHW group. Benefits of the SMART extended to untrained measures of working memory and participation in functional activities. Exploratory analyses suggested potential transfer effects of SMART on memory and executive functions. The benefits of the SMART program as compared to BHW were evident at immediately posttraining and 6 months posttraining. Conclusion: This study provides preliminary evidence that short-term intensive training in top-down modulation of information benefits gist-reasoning and generalizes to measures of executive function and real life function at chronic stages of post-TBI.	[Vas, Asha K.; Chapman, Sandra B.; Cook, Lori G.; Elliott, Alan C.; Keebler, Molly] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75235 USA		Chapman, SB (corresponding author), Univ Texas Dallas, Ctr BrainHlth, 2200 W Mockingbird Lane, Dallas, TX 75235 USA.	schapman@utdallas.edu			Dallas Foundation; Wood-Hayner-Yates TBI Research Fund; Julie and Ed Hawes, and the Dee Wyly Research fund	The authors thank the participants and their families for their interest and enthusiasm in taking part in the study. This research was supported by the Prothro-McDermott fund of the Dallas Foundation, Wood-Hayner-Yates TBI Research Fund, Julie and Ed Hawes, and the Dee Wyly Research fund. The authors also thank Kamini Krishnan, Michelle Kandalaft, and Nyaz Didehbani for their help with the assessments.	Adams C, 1997, J GERONTOL B-PSYCHOL, V52, pP187, DOI 10.1093/geronb/52B.4.P187; Ahmed S, 2000, BRAIN INJURY, V14, P765; Anand R, 2009, PERS NEUROPHYSIOL NE, V19, P117; Anand R, 2010, INT J GERIATR PSYCH, V25, P1; Beck A. T., 1996, MANUAL BECK DEPRESSI, VII; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; Benton A., 1976, MULTILINGUAL APHASIA; Binder D, 2008, BRAIN HLTH WORKSH TO; Brainerd CJ, 2002, CURR DIR PSYCHOL SCI, V11, P164, DOI 10.1111/1467-8721.00192; BROWN JI, 1993, NELSONDENNY READING; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, 2002, ALZ DIS ASSOC DIS, V16, P177, DOI 10.1097/00002093-200207000-00008; Chapman SB, 1998, APHASIOLOGY, V12, P1081, DOI 10.1080/02687039808249473; Chapman SB, ADOLESCENT IN PRESS; Chapman SB, 1999, INT J SPEECH-LANG PA, V1, P19; Chapman SB., 2006, BRAIN IMPAIR, V7, P223, DOI [DOI 10.1375/BRIM.7.3.223, 10.1375/brim.7.3.223]; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cook LG, 2007, CHILDRENS COMPREHENS, P218; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; D'Zurilla TJ., 1982, ADV COGNITIVE BEHAV, P201, DOI [10.1016/B978-0-12-010601-1.50010-3, DOI 10.1016/B978-0-12-010601-1.50010-3]; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Fisk GD, 1998, BRAIN INJURY, V12, P683; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gabrieli John D E, 2004, Cerebrum, V6, P39; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gamino JF, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00188; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Gamino JF, 2009, ADV ADHD, V3, P82; Gazzaley A, 2005, J COGNITIVE NEUROSCI, V17, P507, DOI 10.1162/0898929053279522; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JOANETTE Y, 1983, BRAIN LANG, V20, P217, DOI 10.1016/0093-934X(83)90043-3; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; McGraw-Hunter M, 2006, BRAIN INJURY, V20, P1061, DOI 10.1080/02699050600912163; Nichelli P, 1995, NEUROREPORT, V6, P2309, DOI 10.1097/00001756-199511270-00010; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Novakovic-Agopian T, 2010, J HEAD TRAUMA REHAB, V24, P436; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Plante E., 2006, LEARN DISABIL RES PR, V21, P61, DOI DOI 10.1111/J.1540-5826.2006.00207.X; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; REYNA VF, 1995, LEARN INDIVID DIFFER, V7, P1, DOI 10.1016/1041-6080(95)90031-4; Robertson DA, 2000, PSYCHOL SCI, V11, P255, DOI 10.1111/1467-9280.00251; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Schwartz DL, 1998, COGNITION INSTRUCT, V16, P475, DOI 10.1207/s1532690xci1604_4; Shores E A, 1995, Appl Neuropsychol, V2, P167; Simon D, 2001, REHABIL PSYCHOL, V46, P330; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; St George M, 1999, BRAIN, V122, P1317, DOI 10.1093/brain/122.7.1317; Stemmer B, 1999, BRAIN LANG, V68, P402, DOI 10.1006/brln.1999.2120; Stern L, 2009, VISUAL APPROACH SPSS; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Ulatowska HK, 1998, APHASIOLOGY, V12, P619, DOI 10.1080/02687039808249562; Uttl B, 2002, J CLIN EXP NEUROPSYC, V24, P1123, DOI 10.1076/jcen.24.8.1123.8375; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vas AK, 2010, BRAIN S CTR BRAINHEA; Von Cramon DY, 1992, NEUROPSYCHOL REHABIL, P203; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 2002, WAIS 3 WMS 3 TECHNIC; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong SBC, 2006, PROG BRAIN RES, V157, P173, DOI 10.1016/S0079-6123(06)57011-6	85	46	46	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2011	26	3					224	239		10.1097/HTR.0b013e318218dd3d			16	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	760CY	WOS:000290301800006	21552071				2022-02-06	
J	Sargin, D; El-Kordi, A; Agarwal, A; Muller, M; Wojcik, SM; Hassouna, I; Sperling, S; Nave, KA; Ehrenreich, H				Sargin, Derya; El-Kordi, Ahmed; Agarwal, Amit; Mueller, Michael; Wojcik, Sonja M.; Hassouna, Imam; Sperling, Swetlana; Nave, Klaus-Armin; Ehrenreich, Hannelore			Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice	BMC BIOLOGY			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERMANENT CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; REACTION-TIME-TASK; PREFRONTAL CORTEX; TRANSGENIC MICE; NERVOUS-SYSTEM; SPREADING DEPRESSION; RAT HIPPOCAMPAL	Background: Erythropoietin (EPO) and its receptor (EPOR) are expressed in the developing brain and their transcription is upregulated in adult neurons and glia upon injury or neurodegeneration. We have shown neuroprotective effects and improved cognition in patients with neuropsychiatric diseases treated with EPO. However, the critical EPO targets in brain are unknown, and separation of direct and indirect effects has remained difficult, given the role of EPO in hematopoiesis and brain oxygen supply. Results: Here we demonstrate that mice with transgenic expression of a constitutively active EPOR isoform (cEPOR) in pyramidal neurons of cortex and hippocampus exhibit enhancement of spatial learning, cognitive flexibility, social memory, and attentional capacities, accompanied by increased impulsivity. Superior cognitive performance is associated with augmented long-term potentiation of cEPOR expressing neurons in hippocampal slices. Conclusions: Active EPOR stimulates neuronal plasticity independent of any hematopoietic effects and in addition to its neuroprotective actions. This property of EPOR signaling should be exploited for defining novel strategies to therapeutically enhance cognitive performance in disease conditions.	[El-Kordi, Ahmed; Mueller, Michael; Nave, Klaus-Armin; Ehrenreich, Hannelore] DFG Res Ctr Mol Physiol Brain CMPB, D-37073 Gottingen, Germany; [Sargin, Derya; El-Kordi, Ahmed; Hassouna, Imam; Sperling, Swetlana; Ehrenreich, Hannelore] Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Agarwal, Amit; Nave, Klaus-Armin] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany; [Mueller, Michael] Univ Gottingen, Dept Neuro & Sensory Physiol, D-37073 Gottingen, Germany; [Wojcik, Sonja M.] Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany		Nave, KA (corresponding author), DFG Res Ctr Mol Physiol Brain CMPB, Humboldtallee 23, D-37073 Gottingen, Germany.	nave@em.mpg.de; ehrenreich@em.mpg.de	Agarwal, Amit/B-7735-2008; Muller, Michael/F-7222-2010	Agarwal, Amit/0000-0001-7948-4498; Muller, Michael/0000-0002-5863-1994; Ehrenreich, Hannelore/0000-0001-8371-5711	Max Planck SocietyMax Planck Society; DFG-Research Center for Molecular Physiology of the Brain (CMBP)German Research Foundation (DFG)	This study was supported by the Max Planck Society and the DFG-Research Center for Molecular Physiology of the Brain (CMBP). The authors thank Prof. Harvey F. Lodish, Cambridge, MA, for kindly providing the cEPOR construct. Belinda Hildebrandt and Anja Ronnenberg are acknowledged for their excellent technical help.	Adamcio B, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-37; Banks WA, 2004, EUR J PHARMACOL, V505, P93, DOI 10.1016/j.ejphar.2004.10.035; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Berridge KC, 2008, PSYCHOPHARMACOLOGY, V199, P457, DOI 10.1007/s00213-008-1099-6; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Byts N, 2008, CELL DEATH DIFFER, V15, P783, DOI 10.1038/cdd.2008.1; Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041; Chudasama Y, 2003, BEHAV BRAIN RES, V146, P105, DOI 10.1016/j.bbr.2003.09.020; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2007, MOL PSYCHIATR, V12, P206, DOI 10.1038/sj.mp.4001907; Ehrenreich H, 2005, P NATL ACAD SCI USA, V102, P862, DOI 10.1073/pnas.0406008102; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Ehrenreich H, 2008, J RENAL NUTR, V18, P146, DOI 10.1053/j.jrn.2007.10.029; Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203; El-Kordi A, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-37; Hepp S, 2005, J NEUROPHYSIOL, V94, P1091, DOI 10.1152/jn.00291.2005; Humby T, 1999, EUR J NEUROSCI, V11, P2813, DOI 10.1046/j.1460-9568.1999.00701.x; Humby Trevor, 2005, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0805hs31; Jelkmann W, 2005, CURR PHARM BIOTECHNO, V6, P65; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; Kuroda M, 1998, PROG NEUROBIOL, V54, P417, DOI 10.1016/S0301-0082(97)00070-1; Liu C, 1996, P ASSOC AM PHYSICIAN, V108, P449; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; Miskowiak KW, 2009, PSYCHOPHARMACOLOGY, V207, P133, DOI 10.1007/s00213-009-1641-1; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Moucadel V, 2005, J BIOL CHEM, V280, P13364, DOI 10.1074/jbc.M407326200; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; Neubauer AP, 2010, ANN NEUROL, V67, P657, DOI 10.1002/ana.21977; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Rotaru DC, 2005, J COMP NEUROL, V490, P220, DOI 10.1002/cne.20661; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sargin D, 2010, BEST PRACT RES-CLIN, V24, P573, DOI 10.1016/j.bpa.2010.10.005; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2009, NEUROTHERAPEUTICS, V6, P108, DOI 10.1016/j.nurt.2008.10.041; Sweatt JD, 1999, LEARN MEMORY, V6, P399, DOI 10.1101/lm.6.5.399; Takakusaki K, 2004, NEUROSCI RES, V50, P137, DOI 10.1016/j.neures.2004.06.015; Uylings HBM, 2003, BEHAV BRAIN RES, V146, P3, DOI 10.1016/j.bbr.2003.09.028; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wrenn CC, 2006, PHARMACOL BIOCHEM BE, V83, P428, DOI 10.1016/j.pbb.2006.03.003; Wustenberg T, 2011, MOL PSYCHIATR, V16, P26, DOI 10.1038/mp.2010.51; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	59	46	49	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1741-7007			BMC BIOL	BMC Biol.	APR 28	2011	9								27	10.1186/1741-7007-9-27			16	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	781KX	WOS:000291932000001	21527022	Green Published, gold			2022-02-06	
J	Guo, Y; Shin, KY; Hainley, S; Bruera, E; Palmer, JL				Guo, Ying; Shin, Ki Y.; Hainley, Susan; Bruera, Eduardo; Palmer, J. Lynn			Inpatient Rehabilitation Improved Functional Status in Asthenic Patients with Solid and Hematologic Malignancies	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Cancer; Rehabilitation; Asthenia; Functional Independence Measure	STEM-CELL TRANSPLANTATION; SPINAL-CORD COMPRESSION; TRAUMATIC BRAIN-INJURY; ACUTE MYELOID-LEUKEMIA; UNIFORM DATA SYSTEM; CANCER REHABILITATION; INDEPENDENCE MEASURE; INTENSIVE CHEMOTHERAPY; OUTCOMES; TUMORS	Guo Y, Shin KY, Hainley S, Bruera E, Palmer JL: Inpatient rehabilitation improved functional status in asthenic patients with solid and hematologic malignancies. Am J Phys Med Rehabil 2011; 90: 265-271. Objective: The aim of this study was to compare functional outcomes in asthenic patients with hematologic malignancies with those of asthenic patients with solid tumors after inpatient rehabilitation. We hypothesized that asthenic patients with hematologic malignancies are less likely than patients with solid tumors to make functional improvement after rehabilitation. Design: The records of 60 asthenic cancer patients (30 consecutive patients with solid tumors and 30 consecutive patients with hematologic malignancies) who underwent inpatient rehabilitation at a comprehensive cancer center between October 2005 and October 2007 were retrospectively reviewed. Patients with focal neurologic deficits were excluded. All patients admitted to the inpatient rehabilitation unit received 3 hrs of more of therapy per weekday. The main outcomes included total, motor, and cognitive Functional Independence Measure (FIM) scores, hospital and rehabilitation length of stay, and FIM efficiency. Results: The mean total FIM score significantly improved in patients with solid tumors (mean, 15; range, -6 to 38) and in patients with hematologic malignancies (mean, 17; range, -3 to 27); however, between-group differences in FIM scores were not significant (P = 0.31). The solid tumor patients were significantly older than the hematologic malignancy patients (71 +/- 11 vs. 64 +/- 12 yrs; P = 0.02), but the mean rehabilitation lengths of stay were the same for each group (9.5 days; P = 0.82). The mean FIM efficiency in the hematologic malignancy group was higher than that of the solid tumor group (1.9 vs. 1.4; P = 0.049). Conclusions: Asthenic patients with solid tumors or hematologic malignancies could benefit from inpatient rehabilitation and make significant functional gain.	[Guo, Ying] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414, Houston, TX 77030 USA; [Palmer, J. Lynn] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA		Guo, Y (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bruera, Eduardo/AAA-1550-2022	Fu, Jack/0000-0002-9397-0668; Guo, Ying/0000-0002-3715-4287	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NR010162-01A1, RO1CA122292-01, RO1CA124481-01]	Supported in part by National Institutes of Health grant numbers RO1NR010162-01A1, RO1CA122292-01, and RO1CA124481-01 (to E.B.).	*AM CANC SOC, 2004, CANC FACTS FIG 2004; Axdorph U, 2002, BRIT J HAEMATOL, V118, P1048, DOI 10.1046/j.1365-2141.2002.03765.x; Cheville AL, 2005, SEMIN ONCOL, V32, P219, DOI 10.1053/j.seminoncol.2004.11.009; Cole RP, 2000, ARCH PHYS MED REHAB, V81, P623, DOI 10.1053/mr.2000.3861; Eriks IE, 2004, SPINAL CORD, V42, P235, DOI 10.1038/sj.sc.3101555; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Evans WJ, 2007, AM J PHYS MED REHAB, V86, pS29, DOI 10.1097/PHM.0b013e31802ba53c; Fouladiun M, 2005, CANCER-AM CANCER SOC, V103, P2189, DOI 10.1002/cncr.21013; Fu JB, 2010, AM J PHYS MED REHAB, V89, P205, DOI 10.1097/PHM.0b013e3181ca2306; Ganz PA, 1999, MAYO CLIN PROC, V74, P939, DOI 10.4065/74.9.939; Garrard P, 2004, NEUROREHAB NEURAL RE, V18, P76, DOI 10.1177/0888439004266306; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Greenberg E, 2006, AM J PHYS MED REHAB, V85, P568, DOI 10.1097/01.phm.0000223218.38152.53; GREY N, 1993, PARAPLEGIA, V31, P457, DOI 10.1038/sc.1993.74; Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11-10-1121; Guo Y, 2005, SUPPORT CARE CANCER, V13, P169, DOI 10.1007/s00520-004-0680-8; Guo Y, 2008, AM J PHYS MED REHAB, V87, P647, DOI 10.1097/PHM.0b013e31817fb94e; Hartvig Per, 2006, J Oncol Pharm Pract, V12, P183, DOI 10.1177/1078155206070776; HARVEY R, 1982, JAMA-J AM MED ASSOC, P2127; Huang ME, 2001, ARCH PHYS MED REHAB, V82, P1540, DOI 10.1053/apmr.2001.26613; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Koistinen P, 2007, EUR J HAEMATOL, V78, P477, DOI 10.1111/j.1600-0609.2007.00846.x; Koreth J, 2007, BIOL BLOOD MARROW TR, V13, P183, DOI 10.1016/j.bbmt.2006.09.010; Lacy MQ, 2007, MAYO CLIN PROC, V82, P1179, DOI 10.4065/82.10.1179; LEHMANN JF, 1978, ARCH PHYS MED REHAB, V59, P410; Mallinson TR, 2008, ARCH PHYS MED REHAB, V89, P2066, DOI 10.1016/j.apmr.2008.05.014; Marciniak CM, 1996, ARCH PHYS MED REHAB, V77, P54, DOI 10.1016/S0003-9993(96)90220-8; Marciniak CM, 2001, ARCH PHYS MED REHAB, V82, P457, DOI 10.1053/apmr.2001.21862; McKinley WO, 2000, AM J PHYS MED REHAB, V79, P138, DOI 10.1097/00002060-200003000-00005; Movsas SB, 2003, ARCH PHYS MED REHAB, V84, P1642, DOI 10.1053/S0003-9993(03)00345-9; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Okamura J, 2007, INT J HEMATOL, V86, P118, DOI 10.1532/IJH97.07070; Parsch D, 2003, SPINAL CORD, V41, P205, DOI 10.1038/sj.sc.3101426; PULLICINO P, 1992, STROKE, V23, P919, DOI 10.1161/str.23.6.919a; Stineman MG, 1998, ARCH PHYS MED REHAB, V79, P497, DOI 10.1016/S0003-9993(98)90062-4; Tang V, 2007, SPINAL CORD, V45, P671, DOI 10.1038/sj.sc.3102024; Tay SS, 2009, ANN ACAD MED SINGAP, V38, P197; Toze CL, 2002, BEST PRACT RES CL HA, V15, P481, DOI 10.1053/beha.2002.0223	40	46	48	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2011	90	4					265	271		10.1097/PHM.0b013e3182063ba6			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	731OI	WOS:000288118600001	21273895				2022-02-06	
J	Ballenger-Browning, KK; Schmitz, KJ; Rothacker, JA; Hammer, PS; Webb-Murphy, JA; Johnson, DC				Ballenger-Browning, Kara K.; Schmitz, Kimberly J.; Rothacker, John A.; Hammer, Paul S.; Webb-Murphy, Jennifer A.; Johnson, Douglas C.			Predictors of Burnout Among Military Mental Health Providers	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; JOB STRESS; SOCIAL SUPPORT; CAREER SATISFACTION; WORKERS; NURSES; STAFF; PSYCHOLOGISTS; PROFESSIONALS	Mental health treatment of military service members places unique demands on providers as their patients experience combat stress. This study assessed levels and predictors of burnout among mental health providers (N = 97) at military facilities, using a self-administered survey of demographic and work-related measures and the Maslach Burnout Inventory. Burnout levels were comparable to studies of civilian mental health providers but were less severe than those of the Maslach Burnout Inventory normative sample. Working more hours, having more patients with personality disorders, increased patient caseloads, female gender, and being a psychiatrist were predictive of higher burnout scores. Having more confidants at work, a greater percentage of patients with traumatic brain injury, more clinical experience, and being a psychologist predicted lower burnout scores. These findings suggest that burnout levels among military providers are similar to those among civilian providers and may be alleviated by interventions targeting general institutional risk factors.	[Ballenger-Browning, Kara K.; Schmitz, Kimberly J.; Rothacker, John A.; Hammer, Paul S.; Webb-Murphy, Jennifer A.] USN, San Diego Med Ctr, NCCOSC, San Diego, CA 92134 USA; [Johnson, Douglas C.] USN, Hlth Res Ctr, San Diego, CA 92106 USA		Ballenger-Browning, KK (corresponding author), USN, San Diego Med Ctr, NCCOSC, 34960 Bob Wilson Dr,Suite 400, San Diego, CA 92134 USA.						Abualrub RF, 2008, J NURS MANAGE, V16, P227, DOI 10.1111/j.1365-2834.2007.00810.x; ACKERLEY GD, 1988, PROF PSYCHOL-RES PR, V19, P624, DOI 10.1037/0735-7028.19.6.624; Agius RM, 1996, OCCUP ENVIRON MED, V53, P217, DOI 10.1136/oem.53.4.217; Ahola K, 2006, SOC PSYCH PSYCH EPID, V41, P11, DOI 10.1007/s00127-005-0011-5; Balogun Joseph A, 2002, J Allied Health, V31, P131; BROLLIER C, 1987, Occupational Therapy in Mental Health, V7, P39, DOI 10.1300/J004v07n01_03; Bystritsky A, 2005, GEN HOSP PSYCHIAT, V27, P313, DOI 10.1016/j.genhosppsych.2005.05.005; Carney J., 1993, PSYCHOSOC REHABIL J, V16, P25; Castelo-Branco C, 2007, BJOG-INT J OBSTET GY, V114, P94, DOI 10.1111/j.1471-0528.2006.01155.x; CHEDEKEL L, 2008, MENTAL HLTH PROVIDER; Coffey M, 2001, J ADV NURS, V34, P397, DOI 10.1046/j.1365-2648.2001.01770.x; Evans S, 2006, BRIT J PSYCHIAT, V188, P75, DOI 10.1192/bjp.188.1.75; Farber B. A., 1990, PSYCHOTHER PRIV PRAC, V8, P14, DOI 10.1300/J294v08n01_07; Finch E. S., 1991, PSYCHOSOC REHABIL, V14, P15; FIRTH H, 1987, INT J NURS STUD, V24, P227, DOI 10.1016/0020-7489(87)90005-8; FORT RS, 2009, LOS ANGELES TIMES; GARZOTTO N, 1992, NEW TRENDS EXPT CLIN, V8, P113; Hannigan B, 2000, J Psychiatr Ment Health Nurs, V7, P127, DOI 10.1046/j.1365-2850.2000.00279.x; Harper H, 1997, Ment Health Care, V1, P18; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jenkins R, 2004, J ADV NURS, V48, P622, DOI 10.1111/j.1365-2648.2004.03240.x; Keeton K, 2007, OBSTET GYNECOL, V109, P949, DOI 10.1097/01.AOG.0000258299.45979.37; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Leiter MP, 1996, INT J SOC PSYCHIATR, V42, P90, DOI 10.1177/002076409604200203; LEITER MP, 1988, J ORGAN BEHAV, V9, P297, DOI 10.1002/job.4030090402; Lloyd C, 2004, SOC PSYCH PSYCH EPID, V39, P752, DOI 10.1007/s00127-004-0808-7; MASLACH C, 1988, REHABIL PSYCHOL, V33, P85, DOI 10.1037//0090-5550.33.2.85; Maslach C., 1996, MBI MASLACH BURNOUT; Maslach C, 1981, J OCCUPATIONAL BEHAV, V2, P15; MCDERMOTT D, 1984, J HUM STRESS, V10, P79, DOI 10.1080/0097840X.1984.9934962; McVicar A, 2003, J ADV NURS, V44, P633, DOI 10.1046/j.0309-2402.2003.02853.x; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; ODRISCOLL MP, 1988, WORK STRESS, V2, P199, DOI 10.1080/02678378808259167; PINES A, 1978, HOSP COMMUNITY PSYCH, V29, P233; Pranger T, 1992, OCCUPATIONAL THERAPY, V12, P77; Prosser D, 1999, SOC PSYCH PSYCH EPID, V34, P295, DOI 10.1007/s001270050147; RAQUEPAW JM, 1989, PROF PSYCHOL-RES PR, V20, P5; Reid Y, 1999, SOC PSYCH PSYCH EPID, V34, P301, DOI 10.1007/s001270050148; ROSS RR, 1989, J COUNS PSYCHOL, V36, P464, DOI 10.1037/0022-0167.36.4.464; Rupert PA, 2005, PROF PSYCHOL-RES PR, V36, P544, DOI 10.1037/0735-7028.36.5.544; RUSSELL DW, 1987, J APPL PSYCHOL, V72, P269, DOI 10.1037/0021-9010.72.2.269; Shanafelt TD, 2009, ANN SURG, V250, P463, DOI 10.1097/SLA.0b013e3181ac4dfd; Sherring Simon, 2009, Br J Nurs, V18, P1234; SKORUPA J, 1993, PROF PSYCHOL-RES PR, V24, P281, DOI 10.1037/0735-7028.24.3.281; SNIBBE JR, 1989, PSYCHOL REP, V65, P775, DOI 10.2466/pr0.1989.65.3.775; TRACY EM, 1992, RES SOCIAL WORK PRAC, V2, P465, DOI 10.1177/104973159200200403; vanWijk C, 1997, MIL MED, V162, P707, DOI 10.1093/milmed/162.10.707; WILCOXON SA, 1989, J RURAL COMMUNITY PS, V10, P3; Wykes T, 1997, SOC PSYCH PSYCH EPID, V32, P398; Zoroya G., 2007, US TODAY	51	46	47	1	23	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	MAR	2011	176	3					253	260		10.7205/MILMED-D-10-00269			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	825BN	WOS:000295246000004	21456349	Bronze			2022-02-06	
J	Walsh, ES; Rousseau, P; Hoshizaki, TB				Walsh, Evan; Rousseau, Philippe; Hoshizaki, Thomas			The influence of impact location and angle on the dynamic impact response of a Hybrid III headform	SPORTS ENGINEERING			English	Article						Neurotrauma; Biomechanics; mTBI; Angular acceleration; Sports helmets		To properly assess sports helmet performance, it is important to select impact conditions that yield high peak linear or angular accelerations. This was done by measuring the kinematic response of a Hybrid III headform when impacted with a modified Wayne State University linear impactor with special consideration for impact locations and angles. The 20 impact conditions (five locations and four angles) were then compared to published thresholds to identify the conditions, which were linked to an increased risk of head injury. These conditions were the following: 1A (linear 121.3g; angular 3.84 krad s(-2)), 2A (linear 102.1g; angular 9.28 krad s(-2)), 2C (linear 94.4g; angular 8.67 krad s(-2)), 3A (linear 132.8g; angular 9.38 krad s(-2))(,) 4A (linear 92.8g; angular 11.49 krad s(-2)), 4D (linear 113.3g; angular 12.86 krad s(-2)), 5A (linear 116.9g; angular 9.01 krad s(-2)) and 5D (linear 87.5g; angular 8.81 krad s(-2)). The results presented in this study were specific to the test rig used as well as the tested conditions; however, it is believed that a test protocol using the above impact conditions could identify the ability of sports helmets to reduce risk of head injuries.	[Walsh, Evan; Rousseau, Philippe; Hoshizaki, Thomas] Univ Ottawa, Neurotrauma Impact Sci Lab, 200 Lees Ave A106, Ottawa, ON K1S 5S9, Canada		Rousseau, P (corresponding author), Univ Ottawa, Neurotrauma Impact Sci Lab, 200 Lees Ave A106, Ottawa, ON K1S 5S9, Canada.	prous088@uottawa.ca					Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; American Society for Testing and Materials, 2007, F104507 ASTM, P10; Canadian Standard Association, 2009, Z262109 CANCSA; DAVIES J. M., 1998, P IRCOBI C BIOM IMP, P377; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Ewing C. L., 1975, P 19 STAPP CAR CRASH; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gimbel G, 2008, INT J SPORT SCI ENG, V2, P154; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hoshizaki TB, 2009, AM SOC TEST MATER, V1516, P107, DOI 10.1520/JAI101883; Hubbard RP, 1974, SAE TECHNICAL PAPER; Huston J, 1975, P INT IRCOBI C BIOM, P153; International Standard Organization, 2006, 83SC5N ISO TC; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; LOWENHIELM P, 1975, J BIOMECH, V8, P351, DOI 10.1016/0021-9290(75)90069-X; Madsen DP, 2008, EUR J ORTHODONT, V30, P532, DOI 10.1093/ejo/cjn031; Mertz HJ, 1985, SAE TECHNICAL PAPER; National Operating Committee on Standards for Athletic Equipment, 2007, STAND DROP TEST METH; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; OMMAYA A K, 1971, International Journal of Neuroscience, V1, P371, DOI 10.3109/00207457109146986; Ommaya A. K., 1967, P 11 STAPP CAR CRASH; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ono K, 1980, P 24 STAPP CAR CRASH, P103; Ono Koshiro, 2003, Traffic Inj Prev, V4, P141, DOI 10.1080/15389580309861; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rousseau P, 2009, AM SOC TEST MATER, V1516, P152, DOI 10.1520/JAI101877; Society of Automotive Engineers International, 2007, INSTR IMP TEST 1; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Willinger R, 2001, INT J CRASHWORTHINES, V6, P281, DOI 10.1533/cras.2001.0178; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	36	46	47	0	5	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1369-7072	1460-2687		SPORTS ENG	Sports Eng.	MAR	2011	13	3					135	143		10.1007/s12283-011-0060-9			9	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	V79FH	WOS:000212100400003					2022-02-06	
J	Amen, DG; Wu, JC; Taylor, D; Willeumier, K				Amen, Daniel G.; Wu, Joseph C.; Taylor, Derek; Willeumier, Kristen			Reversing Brain Damage in Former NFL Players: Implications for Traumatic Brain Injury and Substance Abuse Rehabilitation	JOURNAL OF PSYCHOACTIVE DRUGS			English	Article						brain trauma; football; MicroCog; rehabilitation; SPECT	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; PERFORMANCE; ATLAS; SPECT	Brain injuries are common in professional American football players. Finding effective rehabilitation strategies can have widespread implications not only for retired players but also for patients with traumatic brain injury and substance abuse problems. An open label pragmatic clinical intervention was conducted in an outpatient neuropsychiatric clinic with 30 retired NFL players who demonstrated brain damage and cognitive impairment. The study included weight loss (if appropriate); fish oil (5.6 grams a day); a high-potency multiple vitamin; and a formulated brain enhancement supplement that included nutrients to enhance blood flow (ginkgo and vinpocetine), acetylcholine (acetyl-l-carnitine and huperzine A), and antioxidant activity (alpha-lipoic acid and n-acetyl-cysteine). The trial average was six months. Outcome measures were Microcog Assessment of Cognitive Functioning and brain SPECT imaging. In the retest situation, corrected for practice effect, there were statistically significant increases in scores of attention, memory, reasoning, information processing speed and accuracy on the Microcog. The brain SPECT scans, as a group, showed increased brain perfusion, especially in the prefrontal cortex, parietal lobes, occipital lobes, anterior cingulate gyros and cerebellum. This study demonstrates that cognitive and cerebral blood flow improvements are possible in this group with multiple interventions.	[Amen, Daniel G.] UC Irvine Sch Med, Irvine, CA USA; [Wu, Joseph C.] Irvine Sch Med, Brain Imaging Ctr, UC, Irvine, CA USA; [Taylor, Derek; Willeumier, Kristen] Amen Clin Inc, Newport Beach, CA 92660 USA		Amen, DG (corresponding author), Amen Clin Inc, 4019 Westerly Pl,Suite 100, Newport Beach, CA 92660 USA.	docamen@amenclinic.com		Willeumier, Kristen/0000-0002-1229-8516			Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Amen DG, 2010, J PSYCHOACTIVE DRUGS, V42, P153, DOI 10.1080/02791072.2010.10400688; ARGUELLES S, 2010, BIOSCIENCE BIOT 0707; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ; Conklin SM, 2007, NEUROSCI LETT, V421, P209, DOI 10.1016/j.neulet.2007.04.086; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI [10.1517/14728220802517901, 10.1517/14728220802517901 ]; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Gold MS, 2009, BIOL PSYCHIAT, V66, P118, DOI 10.1016/j.biopsych.2009.02.021; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Gulyas B, 2002, ACTA NEUROL SCAND, V106, P325, DOI 10.1034/j.1600-0404.2002.01302.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Kennedy DO, 2010, PSYCHOPHARMACOLOGY, V211, P55, DOI 10.1007/s00213-010-1870-3; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; Michael-Titus AT, 2009, CLIN LIPIDOL, V4, P343, DOI 10.2217/CLP.09.19; MONTELEONE P, 1990, NEUROENDOCRINOLOGY, V52, P243, DOI 10.1159/000125593; OLSONMADDEN JH, 2010, J HEAD TRAUMA R 0420; Powell D, 2004, MICROCOG ASSESSMENT; POWELL DH, 1993, MANUAL MICROCOG ASSE; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Santos RF, 2003, PHARMACOPSYCHIATRY, V36, P127; Weir D. R., 2009, STUDY RETIRED NFL PL; Zhang HY, 2008, CELL MOL NEUROBIOL, V28, P173, DOI 10.1007/s10571-007-9163-z	26	46	47	4	32	HAIGHT-ASHBURY PUBL	SAN FRANCISCO	409 CLAYTON ST, SAN FRANCISCO, CA 94117 USA	0279-1072			J PSYCHOACTIVE DRUGS	J. Psychoact. Drugs	JAN-MAR	2011	43	1					1	5		10.1080/02791072.2011.566489			5	Psychology, Clinical; Substance Abuse	Social Science Citation Index (SSCI)	Psychology; Substance Abuse	749ES	WOS:000289447000001	21615001	Bronze			2022-02-06	
J	Dougherty, AL; MacGregor, AJ; Han, PP; Heltemes, KJ; Galarneau, MR				Dougherty, Amber L.; MacGregor, Andrew J.; Han, Peggy P.; Heltemes, Kevin J.; Galarneau, Michael R.			Visual dysfunction following blast-related traumatic brain injury from the battlefield	BRAIN INJURY			English	Article						TBI; ocular and visual disorder; combat injury; military	SEVERITY SCORE; NECK INJURIES; IMPAIRMENT; SOLDIERS; REGISTRY; HEAD; CARE; IRAQ	Primary objective: To assess the occurrence of ocular and visual disorders following blast-related traumatic brain injury (TBI) in Operation Iraqi Freedom. Research design: Retrospective cohort study. Methods and procedures: A total of 2254 US service members with blast-related combat injuries were identified for analysis from the Expeditionary Medical Encounter Database. Medical record information near the point of injury was used to assess factors associated with the diagnosis of ocular/visual disorder within 12 months after injury, including severity of TBI. Main outcomes and results: Of 2254 service members, 837 (37.1%) suffered a blast-related TBI and 1417 (62.9%) had other blast-related injuries. Two-hundred and one (8.9%) were diagnosed with an ocular or visual disorder within 12 months after blast injury. Compared with service members with other injuries, odds of ocular/visual disorder were significantly higher for service members with moderate TBI (odds ratio (OR) = 1.58, 95% confidence interval (CI) = 1.02-2.45) and serious to critical TBI (OR = 14.26, 95% CI = 7.00-29.07). Conclusions: Blast-related TBI is strongly associated with visual dysfunction within 1 year after injury and the odds of disorder appears to increase with severity of brain injury. Comprehensive vision examinations following TBI in theatre may be necessary.	[Dougherty, Amber L.; MacGregor, Andrew J.; Han, Peggy P.; Heltemes, Kevin J.; Galarneau, Michael R.] USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA		Dougherty, AL (corresponding author), USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Navy Bureau of Medicine and Surgery, Washington, DC [60808]	Declaration of interest: This work was supported by the US Navy Bureau of Medicine and Surgery, Washington, DC, under Work Unit No. 60808. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Dougherty AL, 2009, INJURY, V40, P772, DOI 10.1016/j.injury.2009.02.014; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IOM, 2009, GULF WAR HLTH, V7; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; McKenna K, 2006, BRAIN INJURY, V20, P507, DOI 10.1080/02699050600664368; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; REISTER FA, 1973, BATTLE CASUALTIES ME, pCH3; REISTER FA, 1975, MED STAT WORLD WAR 2, P21; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Suchoff Irwin B, 2008, Optometry, V79, P259, DOI 10.1016/j.optm.2007.10.012; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003	23	46	48	0	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2011	25	1					8	13		10.3109/02699052.2010.536195			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700002	21117919				2022-02-06	
J	Formisano, R; D'Ippolito, M; Risetti, M; Riccio, A; Caravasso, CF; Catani, S; Rizza, F; Forcina, A; Buzzi, MG				Formisano, Rita; D'Ippolito, Mariagrazia; Risetti, Monica; Riccio, Angela; Caravasso, Chiara Falletta; Catani, Sheila; Rizza, Federica; Forcina, Antonio; Buzzi, Maria Gabriella			Vegetative state, minimally conscious state, akinetic mutism and Parkinsonism as a continuum of recovery from disorders of consciousness: an exploratory and preliminary study	FUNCTIONAL NEUROLOGY			English	Article						disorders of consciousness; evaluation scales; minimally conscious state; vegetative state	TRAUMATIC BRAIN-INJURY; REHABILITATION; STIMULATION; AMANTADINE; DIAGNOSIS; CONSENSUS; LESIONS; PAIN; TIME	The aim of this study was to review the usefulness of clinical and instrumental evaluation in individuals with disorders of consciousness (DOC). Thirteen subjects with severe acquired brain injury (ABI) and a diagnosis of DOC were evaluated using the Coma Recovery Scale in its revised version (CRS-R) and a new global disability index, the Post-Coma Scale (PCS). These instruments were administered both by a neutral examiner (professional) and by a professional in the presence of a caregiver. All patients were also scored using the International Classification of Functioning, Disability and Health (ICF). A statistically significant correlation between CRS-R and PCS was demonstrated. However, there also emerged significant differences in responsiveness between professional versus caregiver+professional assessment using the two scales. The emotional stimulation provided by significant others (caregivers) during administration of DOC evaluation scales may improve the assessment of responsiveness.	[Formisano, Rita; D'Ippolito, Mariagrazia; Caravasso, Chiara Falletta; Catani, Sheila; Rizza, Federica; Buzzi, Maria Gabriella] IRCCS Santa Lucia Fdn, Postcoma Unit, I-00179 Rome, Italy; [Risetti, Monica; Riccio, Angela] IRCCS Santa Lucia Fdn, Lab Neuroelect Imaging & Brain Comp Interface, I-00179 Rome, Italy; [Caravasso, Chiara Falletta] IRCCS Santa Lucia Fdn, Dept Radiol, I-00179 Rome, Italy; [Forcina, Antonio] Univ Cassino, Dept Ind Engn, Cassino, Italy		Formisano, R (corresponding author), IRCCS Santa Lucia Fdn, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy.	r.formisano@hsantalucia.it	Buzzi, Maria Gabriella/K-5468-2016; Riccio, Angela/K-2745-2016; D'Ippolito, Mariagrazia/K-4010-2016	Buzzi, Maria Gabriella/0000-0003-1307-8707; Riccio, Angela/0000-0002-4098-9461; D'Ippolito, Mariagrazia/0000-0001-7818-7352; Falletta Caravasso, Chiara/0000-0003-3389-2853	European ICT Programme [FP7-247919 (DECODER)]	This work is supported by the European ICT Programme Project FP7-247919 (DECODER). This paper only reflects the authors' views and funding agencies are not liable for any use that may be made of the information contained herein.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Blandini F, 2010, FUNCT NEUROL, V25, P65; Danze F, 1993, Soins, P4; DE MORSIER G., 1960, PSYCHIAT ET NEUROL, V139, P60; Di Russo F, 2005, J NEUROTRAUM, V22, P297; Formisano R, 2005, ACT NEUR S, V93, P201; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Formisano R, 2004, BRAIN INJURY, V18, P103, DOI 10.1080/0269905031000149470; Formisano R, 1996, P 5 C INT ASS STUD T, P110; Formisano R, 2009, MED SCI MONITOR, V15, pCR101; Fujimoto K, 2006, J NEUROL, V253, P16, DOI 10.1007/s00415-006-3003-9; Gerstenbrand F., 1967, TRAUMATISCHE APALLIS; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Hughes S, 2005, BRAIN INJURY, V19, P1197, DOI 10.1080/02699050500309296; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P1082; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, LANCET, V1, P1031; Kassubek J, 2003, J NEUROL SCI, V212, P85, DOI 10.1016/S0022-510X(03)00106-0; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Laureys S, 2004, NEUROREHABILITATION, V19, P335; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; LINDENBERG R, 1964, Dtsch Z Nervenheilkd, V185, P637; Lombardi F, 2007, FUNCT NEUROL, V22, P47; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Orient-Lopez F, 2002, REV NEUROLOGIA, V35, P362, DOI 10.33588/rn.3504.2001457; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Peppe A, 1998, ELECTROEN CLIN NEURO, V106, P374, DOI 10.1016/S0013-4694(97)00075-8; Plum F, 1966, DIAGNOSIS STUPOR COM; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2009, ANN NY ACAD SCI, V1157, P101, DOI 10.1111/j.1749-6632.2008.04123.x; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Schnakers C, 2009, NEUROCASE, V15, P271, DOI 10.1080/13554790902724904; Sinforiani E, 2010, FUNCT NEUROL, V25, P205; Smith E, 2005, BMJ-BRIT MED J, V330, P406, DOI 10.1136/bmj.330.7488.406; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trojano L, 2009, J REHABIL MED, V41, P393, DOI 10.2340/16501977-0344; World Health Organization, 2007, INT CLASS FUNCT DIS; [No title captured]; [No title captured]	53	46	47	0	8	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264	1971-3274		FUNCT NEUROL	Funct. Neurol.	JAN-MAR	2011	26	1					15	24					10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	789OJ	WOS:000292524900003	21693084				2022-02-06	
J	Novikova, LN; Brohlin, M; Kingham, PJ; Novikov, LN; Wiberg, M				Novikova, Liudmila N.; Brohlin, Maria; Kingham, Paul J.; Novikov, Lev N.; Wiberg, Mikael			Neuroprotective and growth-promoting effects of bone marrow stromal cells after cervical spinal cord injury in adult rats	CYTOTHERAPY			English	Article						bone marrow; mesenchymal stromal cells; red nucleus; retrograde degeneration; spinal cord trauma; transplantation	AXOTOMIZED RUBROSPINAL NEURONS; OLFACTORY ENSHEATHING GLIA; ISCHEMIC BOUNDARY ZONE; TRAUMATIC BRAIN-INJURY; STEM-CELLS; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; AXONAL REGENERATION; CONTUSION INJURY; NERVOUS-SYSTEM	Background aims. Bone marrow stromal cells (BMSC) have been shown to provide neuroprotection after transplantation into the injured central nervous system. The present study investigated whether adult rat BMSC differentiated along a Schwann cell lineage could increase production of trophic factors and support neuronal survival and axonal regeneration after transplantation into the injured spinal cord. Methods. After cervical C4 hemi-section, 5-bromo-2-deoxyuridine (BrdU)/ green fluorescent protein (GFP)-labeled BMSC were injected into the lateral funiculus at 1 mm rostral and caudal to the lesion site. Spinal cords were analyzed 2-13 weeks after transplantation. Results and Conclusions. Treatment of native BMSC with Schwann cell-differentiating factors significantly increased production of brain-derived neurotrophic factor in vitro. Transplanted undifferentiated and differentiated BMSC remained at the injection sites, and in the trauma zone were often associated with neurofilament-positive fibers and increased levels of vascular endothelial growth factor. BMSC promoted extensive in-growth of serotonin-positive raphaespinal axons and calcitonin gene-related peptide (CGRP)-positive dorsal root sensory axons into the trauma zone, and significantly attenuated astroglial and microglial cell reactions, but induced aberrant sprouting of CGRP-immunoreactive axons in Rexed's lamina III. Differentiated BMSC provided neuroprotection for axotomized rubrospinal neurons and increased the density of rubrospinal axons in the dorsolateral funiculus rostral to the injury site. The present results suggest that BMSC induced along the Schwann cell lineage increase expression of trophic factors and have neuroprotective and growth-promoting effects after spinal cord injury.	[Novikova, Liudmila N.; Brohlin, Maria; Kingham, Paul J.; Novikov, Lev N.; Wiberg, Mikael] Umea Univ, Sect Anat, Dept Integrat Med Biol, SE-90187 Umea, Sweden; [Wiberg, Mikael] Umea Univ, Sect Hand & Plast Surg, Dept Surg & Perioperat Sci, SE-90187 Umea, Sweden		Novikova, LN (corresponding author), Umea Univ, Sect Anat, Dept Integrat Med Biol, SE-90187 Umea, Sweden.	liudmila.novikova@anatomy.umu.se	Novikov, Lev/I-1983-2012	Kingham, Paul/0000-0003-2596-5936; Novikov, Lev/0000-0001-5520-3890	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Umea University; County of Vasterbotten; Ake Wibergs Stiftelse; Magn. Bergvalls Stiftelse; Clas Groschinskys Minnesfond; Anna-Stina och John Mattsons Minnesstiftelse for sonen Johan; Gunvor and Josef Aner Foundation	This study was supported by the Swedish Medical Research Council, Umea University, County of Vasterbotten, Ake Wibergs Stiftelse, Magn. Bergvalls Stiftelse, Clas Groschinskys Minnesfond, Anna-Stina och John Mattsons Minnesstiftelse for sonen Johan and the Gunvor and Josef Aner Foundation. We thank Mrs G. Folkesson and Mrs G. Hallstrom for technical assistance.	Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Adams M, 2007, SPINAL CORD, V45, P2, DOI 10.1038/sj.sc.3101963; Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Brass LM, 2006, EXP NEUROL, V199, P16, DOI 10.1016/j.expneurol.2006.03.009; Brohlin M, 2009, NEUROSCI RES, V64, P41, DOI 10.1016/j.neures.2009.01.010; Caddick J, 2006, GLIA, V54, P840, DOI 10.1002/glia.20421; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen CJ, 2007, EXP NEUROL, V204, P443, DOI 10.1016/j.expneurol.2006.12.004; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chopp M, 2009, J NEUROSURG, V110, P1186, DOI 10.3171/2008.10.JNS081254; Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Deumens R, 2005, PROG NEUROBIOL, V77, P57, DOI 10.1016/j.pneurobio.2005.10.004; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dezawa M, 2008, MED MOL MORPHOL, V41, P14, DOI 10.1007/s00795-007-0389-0; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Franssen EHP, 2007, BRAIN RES REV, V56, P236, DOI 10.1016/j.brainresrev.2007.07.013; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Hejcl A, 2010, STEM CELLS DEV, V19, P1535, DOI 10.1089/scd.2009.0378; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Ide C, 2010, BRAIN RES, V1332, P32, DOI 10.1016/j.brainres.2010.03.043; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kamada T, 2011, NEUROPATHOLOGY, V31, P48, DOI 10.1111/j.1440-1789.2010.01130.x; Karussis D, 2008, J NEUROL SCI, V265, P131, DOI 10.1016/j.jns.2007.05.005; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Kocsis JD, 2004, J NEUROTRAUM, V21, P441, DOI 10.1089/089771504323004584; Kuroda Y, 2010, P NATL ACAD SCI USA, V107, P8639, DOI 10.1073/pnas.0911647107; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Lowry N, 2008, EXP NEUROL, V209, P510, DOI 10.1016/j.expneurol.2007.09.031; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Lu P, 2008, EXP NEUROL, V209, P313, DOI 10.1016/j.expneurol.2007.08.004; Ma JJ, 2001, EXP BRAIN RES, V139, P216, DOI 10.1007/s002210100769; Munoz-Quiles C, 2009, J NEUROPATH EXP NEUR, V68, P1294, DOI 10.1097/NEN.0b013e3181c34bbe; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Nandoe RDS, 2006, CELL TRANSPLANT, V15, P563, DOI 10.3727/000000006783981602; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; Novikov LN, 2002, BIOMATERIALS, V23, P3369, DOI 10.1016/S0142-9612(02)00037-6; Novikov LN, 2001, J NEUROSCI METH, V112, P145, DOI 10.1016/S0165-0270(01)00461-7; Novikova L, 1996, NEUROSCI LETT, V220, P203, DOI 10.1016/S0304-3940(96)13267-5; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Novikova LN, 2002, J COMP NEUROL, V452, P255, DOI 10.1002/cne.10381; Osaka M, 2010, BRAIN RES, V1343, P226, DOI 10.1016/j.brainres.2010.05.011; Oudega M, 2006, J NEUROTRAUM, V23, P453, DOI 10.1089/neu.2006.23.453; Park HW, 2010, GLIA, V58, P1118, DOI 10.1002/glia.20992; Parr AM, 2008, SURG NEUROL, V70, P600, DOI 10.1016/j.surneu.2007.09.043; PAXINOS G, 1985, RAT NERVOUS SYSTEM, P362; Pearse DD, 2006, J NEUROTRAUM, V23, P438, DOI 10.1089/neu.2006.23.437; Raisman G, 2004, NAT REV NEUROSCI, V5, P157, DOI 10.1038/nrn1328; Raisman G, 2011, EXP NEUROL, V229, P168, DOI 10.1016/j.expneurol.2010.05.007; Ratajczak MZ, 2009, AM J PATHOL, V174, P1985, DOI 10.2353/ajpath.2009.081143; Richter MW, 2008, EXP NEUROL, V209, P353, DOI 10.1016/j.expneurol.2007.06.011; Rossignol S, 2007, J NEUROSCI, V27, P11782, DOI 10.1523/JNEUROSCI.3444-07.2007; Ruitenberg MJ, 2003, J NEUROSCI, V23, P7045, DOI 10.1523/JNEUROSCI.23-18-07045.2003; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Schuhmann B, 2005, J NEUROIMMUNOL, V163, P15, DOI 10.1016/j.jneuroim.2005.01.023; Sharp J, 2009, NEUROSCI LETT, V456, P107, DOI 10.1016/j.neulet.2008.04.106; Shen LH, 2010, GLIA, V58, P1074, DOI 10.1002/glia.20988; Singec I, 2007, ANNU REV MED, V58, P313, DOI 10.1146/annurev.med.58.070605.115252; Someya Y, 2008, J NEUROSURG-SPINE, V9, P600, DOI 10.3171/SPI.2008.9.08135; Swanger SA, 2005, CELL TRANSPLANT, V14, P775, DOI 10.3727/000000005783982594; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wright KT, 2007, BIOCHEM BIOPH RES CO, V354, P559, DOI 10.1016/j.bbrc.2007.01.013; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yaghoobi MM, 2006, NEUROSCI LETT, V397, P149, DOI 10.1016/j.neulet.2005.12.009; Yoshihara H, 2006, BRAIN RES, V1119, P65, DOI 10.1016/j.brainres.2006.08.080; Zhukareva V, 2010, CYTOKINE, V50, P317, DOI 10.1016/j.cyto.2010.01.004; Zurita M, 2008, TRANSPLANTATION, V86, P845, DOI 10.1097/TP.0b013e318186198f	82	46	56	0	12	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1465-3249			CYTOTHERAPY	Cytotherapy		2011	13	7					873	887		10.3109/14653249.2011.574116			15	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	807BM	WOS:000293868300011	21521004				2022-02-06	
J	Saljo, A; Mayorga, M; Bolouri, H; Svensson, B; Hamberger, A				Saljo, Annette; Mayorga, Maria; Bolouri, Hayde; Svensson, Berndt; Hamberger, Anders			Mechanisms and pathophysiology of the low-level blast brain injury in animal models	NEUROIMAGE			English	Article						Blast overpressure; Brain injury; Brain edema; Cognitive function; Intracranial pressure; Shock tube	ADULT-RAT BRAIN; IMPULSE NOISE EXPOSURE; CLOSED-HEAD INJURY; INTRACRANIAL-PRESSURE; IMPEDANCE; EDEMA; EXPRESSION; APOPTOSIS; ISCHEMIA; INCREASE	The symptoms of primary blast-induced mTBI, posttraumatic stress disorder and depression overlap. Evidence of an organic basis for these entities has been scarce and controversial. We present a review of animal studies demonstrating that low-level blast causes pathophysiological and functional changes in the brain. We monitor a time period from minutes to approximately 1 week after blast exposure from multiple modes (air, underwater, localized and whole body). The most salient findings observed were (1) the peak pressures (P-max) in the brain, elicited from the blast from the firing of military weapons (P-max 23-45 kPa), have a similar magnitude as that registered in air close to the head. Corresponding measurements during the detonation pulse from explosives under water show a Pmax in the brain, which is only 10% of that in water outside the head. (2) The rise time of the pressure curve is 10 times longer in the brain as compared with the blast in air outside the head during firing of military weapons. (3) The lower frequencies in the blast wave appear to be transmitted more readily to the brain than the higher frequencies. (4) When animals are exposed to low levels of blast, the blast wave appears mostly transmitted directly to the brain during air exposure, not via the thorax or abdomen. (5) Low levels of blast cause brain edema, as indicated by increased bioelectrical impedance, an increase in the intracranial pressure, small brain hemorrhages and impaired cognitive function. Published by Elsevier Inc.	[Saljo, Annette] Univ Gothenburg, Sahlgren Acad, Sect Med Chem & Cell Biol, Inst Biomed,Dept Med Chem & Cell Biol, SE-40530 Gothenburg, Sweden		Saljo, A (corresponding author), Univ Gothenburg, Sahlgren Acad, Sect Med Chem & Cell Biol, Inst Biomed,Dept Med Chem & Cell Biol, POB 440, SE-40530 Gothenburg, Sweden.	annette.saljo@gu.se			Swedish Armed Forces/FMV; Svenska Militarlakareforeningen	The authors want to express their gratitude to Svante Hojer, Samba Sensors AB, Vastra Frolunda, Sweden, for sharing with us his knowledge on pressure sensors and pressure recording. We also thank Torsten Olsson, professor emeritus, Department of Signals and Systems, Chalmers University of Technology, Goteborg, Sweden, for introducing us into the field of electrical impedance and for carrying out experiments with us. The study was supported by grants from the Swedish Armed Forces/FMV and by Svenska Militarlakareforeningen.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ASCHAN, 1954, MED UNDERSOKNINGAR N; CELANDER H, 1954, USE COMPRESSED AIR O; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; CHAVKO M, 2009, TRANSFER ENERGY INSI; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLEMEDSON C J, 1951, Sven Lakartidn, V48, P1337; CLEMEDSON CJ, 1956, AM J PHYSIOL, V184, P119, DOI 10.1152/ajplegacy.1955.184.1.119; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; CLEMEDSON CJ, 1954, J APPL PHYSIOL, V7, P38, DOI 10.1152/jappl.1954.7.1.38; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Gerhardt KJ, 2000, MIL MED, V165, P153, DOI 10.1093/milmed/165.2.153; Harting MT, 2010, J SURG RES, V159, P557, DOI 10.1016/j.jss.2008.10.014; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; KLEIN HC, 1993, NEUROPATH APPL NEURO, V19, P57, DOI 10.1111/j.1365-2990.1993.tb00405.x; Lingwood BE, 2003, BRAIN RES, V969, P160, DOI 10.1016/S0006-8993(03)02295-9; MOBERG AS, 2001, THESIS U GOTHENBURG; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; MOORE DF, 2008, BLAST PHYS CENTRAL N, P243; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsson T, 2006, NEUROSCIENCE, V140, P505, DOI 10.1016/j.neuroscience.2006.02.034; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; TERANISHI K, 2009, BLAST INDUCED NEUROP; VANDEVORD P, 2009, INT STAT SCI M NO IM; VERHEUL B, 1994, NMR BIOMED, V7, P96, DOI 10.1002/nbm.1940070115; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Vink R, 2003, ACT NEUR S, V86, P257; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WILLIAMS CE, 1991, STROKE, V22, P516, DOI 10.1161/01.STR.22.4.516	40	46	46	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN	2011	54			1			S83	S88		10.1016/j.neuroimage.2010.05.050			6	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600012	20580846				2022-02-06	
J	Provenzano, FA; Jordan, B; Tikofsky, RS; Saxena, C; Van Heertum, RL; Ichise, M				Provenzano, Frank Anthony; Jordan, Barry; Tikofsky, Ronald S.; Saxena, Chitra; Van Heertum, Ronald L.; Ichise, Masanori			F-18 FDG PET imaging of chronic traumatic brain injury in boxers: a statistical parametric analysis	NUCLEAR MEDICINE COMMUNICATIONS			English	Article						boxers; chronic traumatic brain injury; positron emission tomography; statistical parametric mapping	CEREBRAL GLUCOSE-METABOLISM; PROFESSIONAL BOXERS; DIFFUSION; DEFICITS; RISK; SIGN; MRI	Purpose The participation in concussive susceptible sports such as boxing may cause chronic traumatic brain injury. The objective of this study was to determine whether there are unique patterns of reduced brain glucose metabolism in professional and amateur boxers. Method We compared the fluorine-18 fluorodeoxyglucose (F-18 FDG) PET brain scans of boxers (group) (N=19) with those of controls (group) (N=7) using both statistical parametric mapping and region of interest analysis. Results Boxers showed decreased F-18 FDG uptake by 8-15% in the following brain areas: posterior cingulate cortex, parieto-occipito, frontal lobes (Broca's area) bilaterally, and the cerebellum (P < 0.005) as compared with controls. Conclusion Our results suggest that F-18 FDG PET scans of boxers suspected of chronic traumatic brain injury show unique patterns of hypometabolism, and that these patterns may reflect the mechanisms of repeated traumatic brain injury unique to boxers. Nucl Med Commun 31: 952-957 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.	[Provenzano, Frank Anthony] Columbia Univ, Med Ctr, Taub Inst, White Plains, NY USA; [Tikofsky, Ronald S.; Saxena, Chitra; Van Heertum, Ronald L.; Ichise, Masanori] Columbia Univ, Med Ctr, Kreitchman PET Ctr, Dept Radiol, White Plains, NY USA; [Jordan, Barry] Burke Rehabil Hosp, White Plains, NY USA		Provenzano, FA (corresponding author), Columbia Univ, Med Ctr, Taub Inst, 630 W 168th St,PS Box 16, New York, NY 10032 USA.	fap2005@columbia.edu					Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bonte FJ, 2004, J NUCL MED, V45, P771; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; GUR RC, 1995, SCIENCE, V267, P528, DOI 10.1126/science.7824953; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; Houston AS, 1998, J NUCL MED, V39, P425; ICHISE M, 1994, J NUCL MED, V35, P217; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; KUNG S, 2005, J NUCL MED S, V46, P187; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Tikofsky R., 2009, FUNCTIONAL CEREBRAL; TIKOFSKY RS, 2010, FUNCTIONAL CEREBRAL, P161; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	23	46	47	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0143-3636			NUCL MED COMMUN	Nucl. Med. Commun.	NOV	2010	31	11					952	957		10.1097/MNM.0b013e32833e37c4			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	664VX	WOS:000282992400005	20717065				2022-02-06	
J	Abeare, CA; Cohen, JL; Axelrod, BN; Leisen, JCC; Mosley-Williams, A; Lumley, MA				Abeare, Christopher A.; Cohen, Jay L.; Axelrod, Bradley N.; Leisen, James C. C.; Mosley-Williams, Angelia; Lumley, Mark A.			Pain, Executive Functioning, and Affect in Patients With Rheumatoid Arthritis	CLINICAL JOURNAL OF PAIN			English	Article						pain; executive functioning; negative affect; positive affect; rheumatoid arthritis	TRAUMATIC BRAIN-INJURY; POSITIVE AFFECT; INDUCED MOOD; ATTENTION; FIBROMYALGIA; CATEGORIZATION; INTEGRATION; DEPRESSION; COGNITION; DEFICITS	Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease resulting in substantial pain. The physical and emotional effects of RA are well known, but little attention has been given to the potential cognitive effects of RA pain, although intact executive functioning in patients with chronic illness is crucial for the successful completion of many daily activities. We examined the relationship between pain and executive functioning in patients with RA, and also considered the influence of positive and negative affect in the relationship between pain and executive functioning. Methods: A sample of 157 adults with RA completed measures of pain and positive and negative affect and were tested for working memory and selective attention using the Letter Number Sequencing subtest from the Wechsler Adult Intelligence Scale-Third Edition and the Stroop Color Word Test tests, respectively. Results: Consistent with prior research, pain was inversely related to executive functioning, with higher pain levels associated with poorer performance on executive functioning tasks. This relationship was not moderated or mediated by negative affect; however, positive affect moderated the relationship between pain and executive functioning. For patients high in positive affect there was a significant inverse relationship between pain and executive functioning, whereas there was no such relationship for patients low in positive affect. Discussion: These findings are discussed in the context of cognitive research on the effects of positive affect on executive functioning and functional neuroanatomical research suggesting neurocognitive mechanisms for such moderation.	[Abeare, Christopher A.] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Cohen, Jay L.; Axelrod, Bradley N.] John D Dingell VAMC, Rheumatol Sect, Mental Hlth Serv, Psychol Sect, Detroit, MI USA; [Cohen, Jay L.; Lumley, Mark A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Leisen, James C. C.] Henry Ford Hlth Syst, Dept Med, Div Rheumatol, Detroit, MI USA; [Mosley-Williams, Angelia] John D Dingell Vet Affairs Med Ctr, Med Sect, Detroit, MI USA; [Mosley-Williams, Angelia] Wayne State Univ, Dept Internal Med, Div Rheumatol, Detroit, MI 48202 USA		Abeare, CA (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	cabeare@uwindsor.ca		Abeare, Christopher/0000-0002-7163-7434	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR049059] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR049059, R01 AR049059-01A1] Funding Source: Medline		Ashby FG, 1999, PSYCHOL REV, V106, P529, DOI 10.1037/0033-295X.106.3.529; Brown SC, 2002, PAIN, V96, P279, DOI 10.1016/S0304-3959(01)00457-2; Connelly M, 2007, PAIN, V131, P162, DOI 10.1016/j.pain.2007.01.002; COTE KA, 1997, J RHEUMATOL, V24, P14; Coull JT, 1998, J NEUROSCI, V18, P7426; Davis MC, 2004, J PERS, V72, P1133, DOI 10.1111/j.1467-6494.2004.00293.x; de Wied M, 2001, PAIN, V90, P163, DOI 10.1016/S0304-3959(00)00400-0; Dixon KE, 2007, HEALTH PSYCHOL, V26, P241, DOI 10.1037/0278-6133.26.3.241; Dreisbach G, 2004, J EXP PSYCHOL LEARN, V30, P343, DOI 10.1037/0278-7393.30.2.343; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; Finan PH, 2009, PSYCHOSOM MED, V71, P474, DOI 10.1097/PSY.0b013e31819e0a8b; Gimse R, 1997, J CLIN EXP NEUROPSYC, V19, P838, DOI 10.1080/01688639708403764; Grace GM, 1999, J CLIN EXP NEUROPSYC, V21, P477, DOI 10.1076/jcen.21.4.477.876; Hamilton NA, 2005, ANN BEHAV MED, V29, P216, DOI 10.1207/s15324796abm2903_8; Hampshire A, 2006, CEREB CORTEX, V16, P1679, DOI 10.1093/cercor/bhj116; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; ISEN AM, 1984, J PERS SOC PSYCHOL, V47, P1206, DOI 10.1037/0022-3514.47.6.1206; ISEN AM, 1992, MOTIV EMOTION, V16, P65, DOI 10.1007/BF00996487; Kreitler S, 2007, PAIN CLIN UPDATES, V15, P1; KREITLER S, 2007, HDB CHRONIC PAIN, P299; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Labouvie-Vief G, 2003, CURR DIR PSYCHOL SCI, V12, P201, DOI 10.1046/j.0963-7214.2003.01262.x; Meagher MW, 2001, PSYCHOSOM MED, V63, P79, DOI 10.1097/00006842-200101000-00010; MEENAN RF, 2005, ARTHRITIS RHEUM, V35, P1; Mitchell RLC, 2007, NEUROPSYCHOLOGIA, V45, P617, DOI 10.1016/j.neuropsychologia.2006.06.030; Mitchell RLC, 2005, BRAIN COGNITION, V59, P23, DOI 10.1016/j.bandc.2005.04.001; Nes LS, 2009, ANN BEHAV MED, V37, P173, DOI 10.1007/s12160-009-9096-5; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; Phillips LH, 2002, EMOTION, V2, P12, DOI 10.1037/1528-3542.2.1.12; Pincus T, 1998, BRIT J CLIN PSYCHOL, V37, P49, DOI 10.1111/j.2044-8260.1998.tb01278.x; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RADANOV BP, 1992, ACTA NEUROL SCAND, V85, P358; Rowe G, 2007, P NATL ACAD SCI USA, V104, P383, DOI 10.1073/pnas.0605198104; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; Strand EB, 2007, PAIN, V127, P204, DOI 10.1016/j.pain.2006.08.015; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Trennery M. R., 1989, STROOP NEUROPSYCHOLO; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Watson D., 1994, PANAS X MANUAL POSIT; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WEINBERGER DA, 1990, REPRESSION DISSOCIAT, P337; Weisenberg M, 1998, PAIN, V76, P365, DOI 10.1016/S0304-3959(98)00069-4; West S. G., 1991, MULTIPLE REGRESSION; Zautra A, 2001, J CONSULT CLIN PSYCH, V69, P786, DOI 10.1037//0022-006X.69.5.786; ZELMAN DC, 1991, PAIN, V46, P105, DOI 10.1016/0304-3959(91)90040-5	48	46	46	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	OCT	2010	26	8					683	689		10.1097/AJP.0b013e3181ed1762			7	Anesthesiology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anesthesiology; Neurosciences & Neurology	650AJ	WOS:000281818200005	20862788				2022-02-06	
J	Salonia, R; Empey, PE; Poloyac, SM; Wisniewski, SR; Klamerus, M; Ozawa, H; Wagner, AK; Ruppel, R; Bell, MJ; Feldman, K; Adelson, PD; Clark, RSB; Kochanek, PM				Salonia, Rosanne; Empey, Philip E.; Poloyac, Samuel M.; Wisniewski, Stephen R.; Klamerus, Megan; Ozawa, Haishin; Wagner, Amy K.; Ruppel, Randall; Bell, Michael J.; Feldman, Keri; Adelson, P. David; Clark, Robert S. B.; Kochanek, Patrick M.			Endothelin-1 Is Increased in Cerebrospinal Fluid and Associated with Unfavorable Outcomes in Children after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						abusive head trauma; cerebral blood flow; endothelin; hypoperfusion; inflicted childhood neurotrauma; pediatric brain injury; vasospasm	HEAD-INJURY; CEREBRAL AUTOREGULATION; MODERATE HYPOTHERMIA; BLOOD-FLOW; SEVERE TBI; INFANTS; PLASMA; THERAPY; HUMANS; ACID	Severe pediatric traumatic brain injury (TBI) is associated with unfavorable outcomes secondary to injury from activation of the inflammatory cascade, the release of excitotoxic neurotransmitters, and changes in the reactivity of cerebral vessels, causing ischemia. Hypoperfusion of injured brain tissues after TBI is also associated with unfavorable outcomes. Therapeutic hypothermia is an investigational treatment strategy for use in patients with severe TBI that has shown differential effects on various cerebrospinal fluid (CSF) mediators in pediatric patients. Endothelin-1 (ET-1) is a powerful vasoconstrictor that exerts its effects on the cerebrovascular endothelium for sustained periods after TBI. The purpose of this study was to determine if CSF concentrations of ET-1 are increased after severe TBI in children, and if they are associated with demographics and outcomes that are affected by therapeutic hypothermia. This was an ancillary study to a prospective, randomized-controlled trial of early hypothermia in a tertiary care pediatric intensive care unit. Children (n = 34, age 3 months-15 years) suffering from severe TBI were randomized to hypothermia (n = 19) and normothermia (n = 15) as part of the efficacy study. Children undergoing diagnostic lumbar puncture (n = 11) to rule out infection were used as controls. Patients received either mild to moderate hypothermia (32-33 degrees C) or normothermia as part of their treatment protocol. CSF was serially collected during the first 5 days after TBI. ET-1 concentrations were quantitated in patient and control CSF samples by a validated ELISA in duplicate with a limit of quantification of 0.195 pg/mL. CSF ET-1 concentrations were increased by two- to threefold in children after TBI compared to controls, and the increase was sustained for up to 5 days post-TBI. This relationship was not affected by hypothermia, and there were no differences in ET-1 response between children with inflicted and accidental TBI. Group-based trajectory analysis revealed two distinct groups with similar ET-1 levels over time. Univariate analysis showed a significant association between ET-1 levels and Glasgow Outcome Scale (GOS) scores, for which higher ET-1 levels over time were associated with unfavorable outcomes. ET-1 is increased in children with severe TBI and is associated with unfavorable outcomes. This increase in ET-1 may mediate the hypoperfusion or cerebrovascular dysfunction accompanying severe TBI in children. Importantly, hypothermia does not affect the brain's ET-1 response as measured in the CSF.	[Salonia, Rosanne; Ruppel, Randall; Bell, Michael J.; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Empey, Philip E.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Med, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Poloyac, Samuel M.] Univ Pittsburgh, Sch Med, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Sch Med, Dept Epidemiol & Biostat, Pittsburgh, PA USA; [Ozawa, Haishin; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Salonia, Rosanne; Empey, Philip E.; Poloyac, Samuel M.; Wagner, Amy K.; Ruppel, Randall; Bell, Michael J.; Feldman, Keri; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Poloyac, Samuel M.; Klamerus, Megan] Univ Pittsburgh, Sch Med, Sch Pharm, Pittsburgh, PA USA; [Adelson, P. David] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA		Salonia, R (corresponding author), Childrens Hosp UPMC, Dept Pediat Crit Care Med, 4401 Penn Ave, Pittsburgh, PA 15213 USA.	saloniar@upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015; Empey, Philip/L-9604-2019	Kochanek, Patrick M/0000-0002-2627-913X; Empey, Philip/0000-0001-7474-2339; Wisniewski, Stephen/0000-0002-3877-9860	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD040686-09, NS30318, GM 073031]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM073031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants 5T32HD040686-09 (to R.S. and P.M.K.), NS30318 (to P.M.K.), GM 073031 (to S.M.P.), and National Heart, Lung, and Blood Institute T32HL007820 (to Michael R. Pinsky).	ADELSON DP, 2003, PEDIATR CRIT CARE ME, V4, pS1; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Amin K, 2009, J NEUROTRAUM, V26, pA71; Andresen J, 2006, J APPL PHYSIOL, V100, P318, DOI 10.1152/japplphysiol.00937.2005; Armstead WM, 2004, CURR PHARM DESIGN, V10, P2185, DOI 10.2174/1381612043384178; BA S, 2005, AM J PHYSIOL-GASTR L, V288, pG860; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Gorlach C, 2001, PFLUG ARCH EUR J PHY, V441, P844, DOI 10.1007/s004240000495; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Ho MCY, 2001, FASEB J, V15, P618, DOI 10.1096/fj.99-1022com; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Kastner S, 2005, ACTA NEUROCHIR, V147, P1271, DOI 10.1007/s00701-005-0633-0; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Maier B, 2007, SHOCK, V27, P610, DOI 10.1097/shk.0b013e31802f9eaf; MUIZELAAR J, 1992, J NEUROTRAUM, V9, pS333; Nabika S, 2007, PEDIATR NEUROSURG, V43, P312, DOI 10.1159/000103313; Nagin D.S., 2005, GROUP BASED MODELING; Niyonkuru C, 2009, J NEUROTRAUM, V26, pA16; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; OZAWA H, 2009, PRACTICAL EXAMPLE TR; Ozawa H, 2009, J NEUROTRAUM, V26, pA71; PASAOGLU I, 1993, JPN HEART J, V34, P693; Poloyac SM, 2005, J NEUROSCI METH, V144, P257, DOI 10.1016/j.jneumeth.2004.11.015; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS579; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058	34	46	48	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1819	1825		10.1089/neu.2010.1402			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600006	20684675	Green Published			2022-02-06	
J	Dellavalle, B; Hempel, C; Kurtzhals, JAL; Penkowa, M				Dellavalle, Brian; Hempel, Casper; Kurtzhals, Jorgen A. L.; Penkowa, Milena			In Vivo Expression of Neuroglobin in Reactive Astrocytes During Neuropathology in Murine Models of Traumatic Brain Injury, Cerebral Malaria, and Autoimmune Encephalitis	GLIA			English	Article						neuroglobin; astrocytes; cerebral malaria; traumatic brain injury; EAE; kainic acid; inflammation	INFLAMMATORY RESPONSE; OXIDATIVE STRESS; METALLOTHIONEIN-I; TISSUE-REPAIR; NEURODEGENERATION; PROTECTS; ENCEPHALOMYELITIS; OVEREXPRESSION; LOCALIZATION; CYTOGLOBIN	Neuroglobin (Ngb) is proposed to be a neuron-specific, hypoxia-responsive, neuroprotective protein. However, results are conflicting concerning both Ngb's physiological and pathological significance. This study was designed to investigate the in vivo localization and regulation of Ngb in different neuropathological models representing traumatic injury, infectious, autoimmune, and excitotoxic pathogeneses. We profiled Ngb immunohistochemistry in murine models of traumatic brain injury, cerebral malaria, experimental autoimmune encephalitis, and kainic acid (KA)-mediated epileptic seizures that, to our knowledge, have not been studied in the context of Ngb. In control mice Ngb was expressed exclusively in neurons. In all pathological models except KA, in addition to neurons Ngb was present in reactive astrocytes. Ngb positive astrocytes were found within regions associated with most severe pathology and the astroglial scar. This is the first report of Ngb present in reactive astroglia and in scar-forming astrocytes in response to different pathological conditions relevant to human disease. In light of previously reported cyto-protective properties of Ngb, further insight may result in therapeutic ramifications. (C) 2010 Wiley-Liss, Inc.	[Dellavalle, Brian; Hempel, Casper; Penkowa, Milena] Univ Copenhagen, Panum Inst, Sect Neuroprotect, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark; [Dellavalle, Brian; Hempel, Casper; Kurtzhals, Jorgen A. L.] Copenhagen Univ Hosp, Ctr Med Parasitol, Dept Clin Microbiol, Copenhagen, Denmark; [Dellavalle, Brian; Hempel, Casper; Kurtzhals, Jorgen A. L.] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, DK-2200 Copenhagen, Denmark		Dellavalle, B (corresponding author), Univ Copenhagen, Panum Inst, Sect Neuroprotect, Dept Neurosci & Pharmacol, Bld 18-1-38, DK-2200 Copenhagen, Denmark.	briandellavalle@gmail.com	Kurtzhals, Jorgen AL/I-8921-2012; Hempel, Casper/C-9511-2013; Hempel, Casper/ABE-7065-2020; Kurtzhals, Jorgen/Y-3799-2019	Hempel, Casper/0000-0002-9816-4673; Hempel, Casper/0000-0002-9816-4673; Kurtzhals, Jorgen/0000-0003-2760-8713; DellaValle, Brian/0000-0002-1427-8244	NovoNordisk foundationNovo Nordisk Foundation; Faculty of Health Sciences at University of Copenhagen; Lundbeck FondenLundbeckfonden; IMK Almene Fond; Direktor Jacob Madsen og Hustru Olga Madsens Fond; Horsley Fonden; Vera og Carl Michaelsens Legat; Fonden til Laegevidenskabens Fremme; Eva & Henry Fraenkels Mindefond; Dir. Leo Nielsens Legat; Kathrine og Vigo Skovgaards Fond; Kong Christian d. X's fond; Th. Maigaard's Eftf. Fru Lily Benthine Lunds Fond [1/6 1978]; Toyota Fonden; Hotelejer Edvard Johnsen og hustrus fond; Karen A. Tolstrups Fond; Direktor Kurt Bonnelyckes Fond; Laegeforeningens Forskningsfond; Direktor Ib Henriksens Fond; Fonden [af 17-12-1981]; Laererinde Karen Svankjaer Ydes Fond; Laegernes Forsikringsforening; Kong Christian den Tiendes Fond	Grant sponsors: NovoNordisk foundation, Faculty of Health Sciences at University of Copenhagen, Lundbeck Fonden, IMK Almene Fond, Direktor Jacob Madsen og Hustru Olga Madsens Fond, Horsley Fonden, Vera og Carl Michaelsens Legat, Fonden til Laegevidenskabens Fremme, Eva & Henry Fraenkels Mindefond, Dir. Leo Nielsens Legat, Kathrine og Vigo Skovgaards Fond, Kong Christian d. X's fond, Th. Maigaard's Eftf. Fru Lily Benthine Lunds Fond of 1/6 1978, Toyota Fonden, Hotelejer Edvard Johnsen og hustrus fond, Karen A. Tolstrups Fond, Direktor Kurt Bonnelyckes Fond, Laegeforeningens Forskningsfond, Direktor Ib Henriksens Fond, Fonden af 17-12-1981, Laererinde Karen Svankjaer Ydes Fond, Laegernes Forsikringsforening, Kong Christian den Tiendes Fond.	Baxter AG, 2007, NAT REV IMMUNOL, V7, P904, DOI 10.1038/nri2190; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2009, J EXP BIOL, V212, P1423, DOI 10.1242/jeb.000729; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Casado Begona, 2005, Proteome Sci, V3, P2, DOI 10.1186/1477-5956-3-2; Chen XQ, 2005, GLIA, V50, P182, DOI 10.1002/glia.20147; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; Espejo C, 2005, NEUROSCIENCE, V132, P1135, DOI 10.1016/j.neuroscience.2005.01.057; Fago A, 2008, IUBMB LIFE, V60, P398, DOI 10.1002/iub.35; Fordel E, 2006, NEUROSCI LETT, V410, P146, DOI 10.1016/j.neulet.2006.09.027; Hankeln T, 2004, IUBMB LIFE, V56, P671, DOI 10.1080/15216540500037794; Hein-Kristensen L, 2009, EXP PARASITOL, V123, P152, DOI 10.1016/j.exppara.2009.06.010; Herold S, 2004, J BIOL CHEM, V279, P22841, DOI 10.1074/jbc.M313732200; Hundahl CA, 2008, NEUROENDOCRINOLOGY, V88, P183, DOI 10.1159/000135617; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Jin KL, 2008, NEUROSCI LETT, V430, P135, DOI 10.1016/j.neulet.2007.10.031; Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103; Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x; Lafon-Cazal M, 2003, J BIOL CHEM, V278, P24438, DOI 10.1074/jbc.M211980200; Li RC, 2008, NEUROBIOL AGING, V29, P1815, DOI 10.1016/j.neurobiolaging.2007.05.001; Linker RA, 2005, J AUTOIMMUN, V25, P199, DOI 10.1016/j.jaut.2005.09.019; Masmoudi-Kouki O, 2007, PEPTIDES, V28, P1753, DOI 10.1016/j.peptides.2007.05.015; Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1002/0471142735.im1501s88, 10.1002/0471142735.im1501s77]; Minagar A, 2003, MULT SCLER J, V9, P540, DOI 10.1191/1352458503ms965oa; Mitz SA, 2009, NEUROSCIENCE, V163, P552, DOI 10.1016/j.neuroscience.2009.06.058; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Penkowa M, 1999, J NEUROSCI, V19, P2535; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Shang AJ, 2006, BRAIN RES, V1078, P219, DOI 10.1016/j.brainres.2006.01.064; SMITH ME, 1987, J NEUROSCI RES, V18, P203, DOI 10.1002/jnr.490180129; Valassi E, 2008, NUTR METAB CARDIOVAS, V18, P158, DOI 10.1016/j.numecd.2007.06.004; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Wang XY, 2008, STROKE, V39, P1869, DOI 10.1161/STROKEAHA.107.506022; Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; Yu ZY, 2009, NEUROL RES, V31, P122, DOI 10.1179/174313209X389866	42	46	51	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG 1	2010	58	10					1220	1227		10.1002/glia.21002			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	618XJ	WOS:000279389100008	20544857				2022-02-06	
J	Fernandez-Espejo, D; Junque, C; Bernabeu, M; Roig-Rovira, T; Vendrell, P; Mercader, JM				Fernandez-Espejo, Davinia; Junque, Carme; Bernabeu, Montserrat; Roig-Rovira, Teresa; Vendrell, Pere; Mercader, Jose M.			Reductions of Thalamic Volume and Regional Shape Changes in the Vegetative and the Minimally Conscious States	JOURNAL OF NEUROTRAUMA			English	Article						disorders of consciousness; magnetic resonance imaging; shape analysis; traumatic brain injury; thalamus	TRAUMATIC BRAIN-INJURY; COLLEGE-OF-PHYSICIANS; BLUNT HEAD-INJURY; 1ST-EPISODE SCHIZOPHRENIA; NEUROPATHOLOGY; ABNORMALITIES; RECOVERY; AROUSAL; DISEASE; NUCLEI	The thalamus is known to play a key role in arousal regulation and support of human consciousness. Neuropathological studies have identified thalamic damage as one of the most common abnormalities present in the brains of patients who were in a vegetative state (VS) or a minimally-conscious state (MCS) state at the time of their deaths. Nonetheless, no in vivo studies of thalamic abnormalities in these patients have been conducted. Using high-resolution T1-weighted magnetic resonance images and a novel approach to shape analysis, we investigated thalamic global and regional changes in a sample of patients in a VS or an MCS. Group comparisons and correlations with clinical variables were performed for the total thalamic volume and for each surface vertex. Total thalamic volume was significantly lower in patients than in healthy volunteers. Shape analysis revealed significant bilateral regional atrophy in the dorso-medial body in patients compared to controls; this atrophy was more widespread in VS than in MCS patients. Lower thalamic volume was significantly correlated with worse Disability Rating Scale scores. Shape analysis suggested that the dorso-medial nucleus and the internal medullar lamina were the main regions responsible for this correlation. Our findings suggest that MCS and VS patients present different patterns of regional thalamic abnormalities, and that these differences partially explain their clinical profile.	[Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Inst Biomed Res August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Bernabeu, Montserrat] Inst Univ Neurorehabil Guttmann, Head Injury Unit, Badalona, Spain; [Roig-Rovira, Teresa] Inst Univ Neurorehabil Guttmann, Dept Neuropsychol, Badalona, Spain; [Mercader, Jose M.] Hosp Clin Barcelona, CDIC, Barcelona, Spain; [Mercader, Jose M.] Univ Barcelona, Dept Obstet & Gynaecol Pediat Radiol & Anat, E-08036 Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Junque, Carme/B-4400-2011; Vendrell, Pere/B-4392-2011; Fernandez-Espejo, Davinia/AAT-5481-2021	Junque, Carme/0000-0002-6381-3063; Vendrell, Pere/0000-0001-8918-5440; Fernandez-Espejo, Davinia/0000-0001-5941-7546	Spanish Ministry of Science and InnovationSpanish Government [SAF2007-66077]; Generalitat de CatalunyaGeneralitat de CatalunyaGeneral Electric [2009SGR0941]; Spanish Ministry for EducationSpanish Government [AP2006-0082]	This work was supported by grant SAF2007-66077 from the Spanish Ministry of Science and Innovation, and grant 2009SGR0941 from the Generalitat de Catalunya. D. Fernandez-Espejo was supported by a fellowship from the Spanish Ministry for Education (AP2006-0082).	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Bates D, 2003, CLIN MED, V3, P249; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Coscia DM, 2009, HUM BRAIN MAPP, V30, P1236, DOI 10.1002/hbm.20595; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hagen C, 1979, REHABILITATION HEAD; Harms MP, 2007, J NEUROSCI, V27, P13835, DOI 10.1523/JNEUROSCI.2571-07.2007; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kang DH, 2008, NEUROREPORT, V19, P609, DOI 10.1097/WNR.0b013e3282fa6db9; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; McKeown MJ, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-8; Monti MM, 2009, ANN NY ACAD SCI, V1157, P81, DOI 10.1111/j.1749-6632.2008.04121.x; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Patenaude B., 2007, THESIS U OXFORD; Qiu AQ, 2009, NEUROIMAGE, V47, P1163, DOI 10.1016/j.neuroimage.2009.04.027; Qiu AQ, 2009, NEUROIMAGE, V45, P656, DOI 10.1016/j.neuroimage.2009.01.013; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Tshibanda L, 2010, NEURORADIOLOGY, V52, P15, DOI 10.1007/s00234-009-0614-8; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001	29	46	47	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1187	1193		10.1089/neu.2010.1297			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100003	20392136				2022-02-06	
J	Brandi, G; Bechir, M; Sailer, S; Haberthur, C; Stocker, R; Stover, JF				Brandi, Giovanna; Bechir, Markus; Sailer, Susanne; Haberthuer, Christoph; Stocker, Reto; Stover, John F.			Transcranial color-coded duplex sonography allows to assess cerebral perfusion pressure noninvasively following severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Pulsatility index; Secondary brain damage; Transcranial Doppler	DOPPLER SONOGRAPHY; HEAD-INJURY; INTRACRANIAL-PRESSURE; SUBARACHNOID HEMORRHAGE; ULTRASONOGRAPHY; AUTOREGULATION; PULSATILITY; VELOCITY; THERAPY	Objective Assess optimal equation to noninvasively estimate intracranial pressure (eICP) and cerebral perfusion pressure (eCPP) following severe traumatic brain injury (TBI) using transcranial color-coded duplex sonography (TCCDS). Design and setting This is an observational clinical study in a university hospital. Patients A total of 45 continuously sedated (BIS<50), normoventilated (paCO(2)>35 mmHg), and non-febrile TBI patients. Methods eICP and eCPP based on TCCDS-derived flow velocities and arterial blood pressure values using three different equations were compared to actually measured ICP and CPP in severe TBI patients subjected to standard treatment. Optimal equation was assessed by Bland-Altman analysis. Results The equations: ICP = 10.927 x PI(pulsatility index) = 1.284 and CPP = 89.646 - 8: 258 x PI resulted in eICP and eCPP similar to actually measured ICP and CPP with eICP 10.6 +/- 4.8 vs. ICP 10.3 +/- 2.8 and eCPP 81.1 +/- 7.9 vs. CPP 80.9 +/- 2.1 mmHg, respectively. The other two equations, eCPP - (MABP x EDV)/mFV + 14 and eCPP - [mFV/(mFV - EDV)] x (MABP RRdiast), resulted in significantly decreased eCPP values: 72.9 +/- 10.1 and 67 +/- 19.5 mmHg, respectively. Superiority of the first equation was confirmed by Bland-Altman revealing a smallest standard deviations for eCPP and eICP. Conclusions TCCDS-based equation (ICP 10: 927 x PI - 1.284) allows to screen patients at risk of increased ICP and decreased CPP. However, adequate therapeutic interventions need to be based on continuously determined ICP and CPP values.	[Brandi, Giovanna; Bechir, Markus; Sailer, Susanne; Stocker, Reto; Stover, John F.] Univ Hosp Zuerich, Surg Intens Care, CH-8091 Zurich, Switzerland; [Brandi, Giovanna] Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Neurosurg Intens Care Unit, Dept Anesthesia & Crit Care Med, Milan, Italy; [Haberthuer, Christoph] Kantonsspital, Dept Anesthesiol, Luzern, Switzerland; [Stover, John F.] Univ Spital Zurich, CH-8091 Zurich, Switzerland		Stover, JF (corresponding author), Univ Spital Zurich, Ramistrasse 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch			Swiss National Research FoundationSwiss National Science Foundation (SNSF); SUVA Fonds	This study was supported in parts by grants from the Swiss National Research Foundation and the SUVA Fonds to JFS and RS.	Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; *BRAINIT, BRAINIT STAND HYDR P; Edouard AR, 2005, BRIT J ANAESTH, V94, P216, DOI 10.1093/bja/aei034; Kochanowicz J, 2006, NEURORADIOLOGY, V48, P31, DOI 10.1007/s00234-005-0009-4; Krejza J, 2007, AM J NEURORADIOL, V28, P1613, DOI 10.3174/ajnr.A0591; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; McMahon CJ, 2007, BRIT J NEUROSURG, V21, P21, DOI 10.1080/02688690701210539; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Rainov NG, 2000, NEUROSURG REV, V23, P34, DOI 10.1007/s101430050029; Schmidt EA, 2001, J NEUROL NEUROSUR PS, V70, P198, DOI 10.1136/jnnp.70.2.198; Soehle M, 2007, ACTA NEUROCHIR, V149, P575, DOI 10.1007/s00701-007-1149-6; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Swiat M, 2009, CRIT CARE MED, V37, P963, DOI 10.1097/CCM.0b013e31819b8165; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y	17	46	49	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUN	2010	152	6					965	972		10.1007/s00701-010-0643-4			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	597TA	WOS:000277783300006	20379747	Green Accepted, Green Submitted			2022-02-06	
J	Wagner, J; Dusick, JR; McArthur, DL; Cohan, P; Wang, C; Swerdloff, R; Boscardin, WJ; Kelly, DF				Wagner, Justin; Dusick, Joshua R.; McArthur, David L.; Cohan, Pejman; Wang, Christina; Swerdloff, Ronald; Boscardin, W. John; Kelly, Daniel F.			Acute Gonadotroph and Somatotroph Hormonal Suppression after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						estrogen; growth hormone; hypopituitarism; insulin-like growth factor-1; testosterone; traumatic brain injury	SEVERE HEAD-INJURY; TRANSIENT HYPOGONADOTROPIC HYPOGONADISM; CRITICALLY-ILL PATIENTS; BODY-MASS INDEX; GROWTH-HORMONE; CRITICAL ILLNESS; CLINICAL-TRIALS; MEDIATED NEUROPROTECTION; ENDOCRINE ABNORMALITIES; PROPOFOL INFUSION	Hormonal dysfunction is a known consequence of moderate and severe traumatic brain injury (TBI). In this study we determined the incidence, time course, and clinical correlates of acute post-TBI gonadotroph and somatotroph dysfunction. Patients had daily measurement of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, estradiol, growth hormone, and insulin-like growth factor-1 (IGF-1) for up to 10 days post-injury. Values below the fifth percentile of a healthy cohort were considered abnormal, as were non-measurable growth hormone (GH) values. Outcome measures were frequency and time course of hormonal suppression, injury characteristics, and Glasgow Outcome Scale (GOS) score. The cohort consisted of 101 patients (82% males; mean age 35 years; Glasgow Coma Scale [GCS] score <= 8 in 87%). In men, 100% had at least one low testosterone value, and 93% of all values were low; in premenopausal women, 43% had at least one low estradiol value, and 39% of all values were low. Non-measurable GH levels occurred in 38% of patients, while low IGF-1 levels were observed in 77% of patients, but tended to normalize within 10 days. Multivariate analysis revealed associations of younger age with low FSH and low IGF-1, acute anemia with low IGF-1, and older age and higher body mass index (BMI) with low GH. Hormonal suppression was not predictive of GOS score. These results indicate that within 10 days of complicated mild, moderate, and severe TBI, testosterone suppression occurs in all men and estrogen suppression occurs in over 40% of women. Transient somatotroph suppression occurs in over 75% of patients. Although this acute neuroendocrine dysfunction may not be TBI-specific, low gonadal steroids, IGF-1, and GH may be important given their putative neuroprotective functions.	[Kelly, Daniel F.] St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, Santa Monica, CA 90404 USA; [Wagner, Justin] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Dusick, Joshua R.; McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Div Endocrinol, Los Angeles, CA USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Gonda Diabet Ctr, Los Angeles, CA USA; [Wang, Christina; Swerdloff, Ronald] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Dept Med, Div Endocrinol, Torrance, CA USA; [Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA		Kelly, DF (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	kellyd@jwci.org	McArthur, David/E-6442-2013; Wagner, Justin/ABC-2668-2021	McArthur, David/0000-0003-3385-1314; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 40777, K23 RR 1729801, MO1 RR 00425, M01 RR 00865, M01 RR 19975]; UC Davis Medical Centers; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K23RR017298, M01RR000425, M01RR019975, M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040777] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants R01 NS 40777 to D. F. K.; K23 RR 1729801 to P. C.; and MO1 RR 00425, M01 RR 00865, and M01 RR 19975 to the GCRCs at Harbor-UCLA, UCLA, and UC Davis Medical Centers, respectively.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ALBANESE J, 1990, ANESTHESIOLOGY, V73, P214, DOI 10.1097/00000542-199008000-00004; Allen NE, 2002, CANCER CAUSE CONTROL, V13, P353, DOI 10.1023/A:1015238102830; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Cernak I, 1997, WORLD J SURG, V21, P240, DOI 10.1007/s002689900223; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Chisu V, 2006, ARCH ITAL BIOL, V144, P63; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dimopoulou I, 2005, NEUROCRIT CARE, V3, P224, DOI 10.1385/NCC:3:3:224; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Gapstur SM, 2002, CANCER EPIDEM BIOMAR, V11, P1041; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; GILMAN AG, 1980, GOODMAN GILMANS PHAR; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hana V, 2002, EUR J ENDOCRINOL, V147, P333, DOI 10.1530/eje.0.1470333; Harman SM, 2003, HORM RES, V60, P121, DOI 10.1159/000071236; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HEINEN E, 1981, HORM METAB RES, V13, P284, DOI 10.1055/s-2007-1019245; Huppenbauer CB, 2005, J NEUROSCI, V25, P4004, DOI 10.1523/JNEUROSCI.5279-04.2005; ILLIEVICH UM, 1993, ANESTH ANALG, V77, P155; JENNETT B, 1975, LANCET, V1, P480; Jensen TK, 2004, FERTIL STERIL, V82, P863, DOI 10.1016/j.fertnstert.2004.03.056; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kraus JF, 2003, ANN EMERG MED, V41, P18, DOI 10.1067/mem.2003.1; LEE SC, 1994, BRAIN INJURY, V8, P571; Leon-Sanz M, 1997, Eur J Med Res, V2, P477; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Maas AIR, 2004, ACT NEUR S, V89, P113; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Napoli R, 2003, J CLIN ENDOCR METAB, V88, P2817, DOI 10.1210/jc.2003-030144; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neuhaus J M, 1992, Stat Methods Med Res, V1, P249, DOI 10.1177/096228029200100303; Nguyen TVV, 2005, J NEUROCHEM, V94, P1639, DOI 10.1111/j.1471-4159.2005.03318.x; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; Qoubaitary A, 2006, J ANDROL, V27, P853, DOI 10.2164/jandrol.106.000281; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Ramsden M, 2003, NEUROSCIENCE, V122, P573, DOI 10.1016/j.neuroscience.2003.08.048; Rice JA, 2001, BIOMETRICS, V57, P253, DOI 10.1111/j.0006-341X.2001.00253.x; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Sattler FR, 2009, J CLIN ENDOCR METAB, V94, P1991, DOI 10.1210/jc.2008-2338; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Sierra A, 2003, ENDOCRINE, V21, P43, DOI 10.1385/ENDO:21:1:43; Silha JV, 2005, CLIN ENDOCRINOL, V63, P79, DOI 10.1111/j.1365-2265.2005.02303.x; SLAG MF, 1981, JAMA-J AM MED ASSOC, V245, P43, DOI 10.1001/jama.245.1.43; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomei G, 1991, J Neurosurg Sci, V35, P61; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; VANDENBERGHE G, 1994, J CLIN ENDOCR METAB, V79, P1141, DOI 10.1210/jc.79.4.1141; VandenBerghe G, 1997, J CLIN ENDOCR METAB, V82, P590, DOI 10.1210/jc.82.2.590; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; Ye P, 1999, ENDOCRINOLOGY, V140, P3063, DOI 10.1210/en.140.7.3063; Ye P, 2002, J NEUROSCI, V22, P6041; Zhang Y, 2004, J NEUROSCI, V24, P5315, DOI 10.1523/JNEUROSCI.0913-04.2004; Zhong J, 2005, J NEUROSCI RES, V80, P481, DOI 10.1002/jnr.20490	101	46	48	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1007	1019		10.1089/neu.2009.1092			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300005	20214417	Green Published			2022-02-06	
J	Baratz, R; Rubovitch, V; Frenk, H; Pick, CG				Baratz, Renana; Rubovitch, Vardit; Frenk, Hanan; Pick, Chaim G.			The Influence of Alcohol on Behavioral Recovery after mTBI in Mice	JOURNAL OF NEUROTRAUMA			English	Article						alcohol and drug abuse; axonal injury; behavioral assessment; binge alcohol drinking; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ACUTE ETHANOL INTOXICATION; ACUTE-PHASE RESPONSE; MINOR HEAD-INJURY; COGNITIVE DEFICITS; HOST-DEFENSE; ACETYLCHOLINE-RELEASE; BARRIER PERMEABILITY; HEMORRHAGIC-SHOCK; SPATIAL MEMORY	In the United States 258,000 people were injured in 2004 in motor vehicle accidents that were caused by drivers under the influence of alcohol. The majority of these drivers were binge drinkers, most notably young people who tend to drink heavily during the weekends, but rarely drink alcohol during the week. Since a large proportion of the injuries involved head injuries, the present study aimed at investigating the influence of binge alcohol drinking on mild traumatic brain injury (mTBI) in an animal model. Mice had access to 0%, 7.5%, 15%, or 30% alcohol solutions for 48 consecutive hours once a week for 4 weeks as the sole source of fluids (the remaining time they drank water). Three experiments were done. For the first one (alcohol-mTBI-alcohol) the animals were subjected to a controlled mTBI injury by applying a closed-head weight drop, or a sham procedure. After the mTBI/sham-mTBI the animals got alcohol and /water for the same regimen for 4 additional weeks. In the second experiment (alcohol only) after the 4 weeks of drinking blood samples were collected, at the same time as the animals that underwent sham-mTBI or mTBI procedures. In the third experiment (mTBI-alcohol) the mice were subjected to mTBI/sham-mTBI without any treatment, and after mTBI they had alcohol for 4 weeks in the same regimen as in the previous experiments. At the end of the pharmacological treatment all animals were assessed using different behavioral tests. mTBI mice exhibited lower memory ability in the Y-maze, higher anxiety in the elevated plus maze, and lower retention in the passive avoidance test than sham-mTBI animals. Alcohol reversed these effects at all doses. The results suggest that alcohol drinking before trauma might have a protective effect on recovery from brain trauma, but not if consumed after the trauma.	[Baratz, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Frenk, Hanan] Tel Aviv Univ, Dept Psychol, IL-69978 Tel Aviv, Israel; [Frenk, Hanan] Acad Coll Tel Aviv Yafo, Tel Aviv, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il					Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alkana R. L., 1996, Society for Neuroscience Abstracts, V22, P814; Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; BUNEGIN L, 1986, CRIT CARE MED, V14, P387, DOI 10.1097/00003246-198604000-00151; CASAMENTI F, 1993, NEUROSCIENCE, V56, P465, DOI 10.1016/0306-4522(93)90346-H; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Fadda F, 1999, BEHAV BRAIN RES, V103, P71, DOI 10.1016/S0166-4328(99)00025-X; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Flowers NT, 2008, ALCOHOL CLIN EXP RES, V32, P639, DOI 10.1111/j.1530-0277.2008.00622.x; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GLUCKMAN SJ, 1978, BLOOD, V52, P551; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Gururaj G, 2004, J Indian Med Assoc, V102, P157; Hanchar HJ, 2007, ALCOHOL CLIN EXP RES, V31, p290A; Iorio K., 1992, Society for Neuroscience Abstracts, V18, P978; Kang MH, 1996, BRAIN RES, V709, P221, DOI 10.1016/0006-8993(95)01274-5; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; KOLLS JK, 1995, AM J PHYSIOL-LUNG C, V268, pL991, DOI 10.1152/ajplung.1995.268.6.L991; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; LEKER RR, 2002, C RES PUBL NEUR ANT; LEKER RR, 2001, C RES PUBL NEUR ANT; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luke LC, 2002, EMERG MED J, V19, P542, DOI 10.1136/emj.19.6.542; Luo J, 2001, J NEUROCHEM, V76, P1354, DOI 10.1046/j.1471-4159.2001.00129.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Molina PE, 2004, ALCOHOL, V33, P217, DOI 10.1016/j.alcohol.2004.07.002; MOLLERMADSEN B, 1986, Z RECHTSMED, V97, P141; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; OIKARINEN K, 1992, ALCOHOL ALCOHOLISM, V27, P189; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; Popovic M, 2004, NEUROSCI LETT, V357, P79, DOI 10.1016/j.neulet.2003.10.046; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Puljula J, 2007, ALCOHOL ALCOHOLISM, V42, P474, DOI 10.1093/alcalc/agm003; Schepens PJ, 1998, ANN EMERG MED, V31, P633, DOI 10.1016/S0196-0644(98)70210-0; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Szabo G, 1999, ALCOHOL ALCOHOLISM, V34, P830, DOI 10.1093/alcalc/34.6.830; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; VINSON RB, 1998, AM J PHYSIOL, V44, pR1049; Wang JY, 1998, LIFE SCI, V63, P1571, DOI 10.1016/S0024-3205(98)00424-X; Wright RL, 2006, EUR J NEUROSCI, V24, P595, DOI 10.1111/j.1460-9568.2006.04948.x; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Zambell KL, 2004, ALCOHOL CLIN EXP RES, V28, P635, DOI 10.1097/01.ALC.0000122104.85971.55; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	64	46	46	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					555	563		10.1089/neu.2009.0891			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100009	20001584				2022-02-06	
J	Bao, YH; Liang, YM; Gao, GY; Pan, YH; Luo, QZ; Jiang, JY				Bao, Ying-hui; Liang, Yu-min; Gao, Guo-yi; Pan, Yao-hua; Luo, Qi-zhong; Jiang, Ji-yao			Bilateral Decompressive Craniectomy for Patients with Malignant Diffuse Brain Swelling after Severe Traumatic Brain Injury: A 37-Case Study	JOURNAL OF NEUROTRAUMA			English	Article						brain swelling; decompressive craniectomy; intracranial hypertension; traumatic brain injury	INTRACRANIAL HYPERTENSION; HEAD-INJURY; CEREBRAL EDEMA; MANAGEMENT; CRANIOTOMY; PRESSURE; CHILDREN; ICP	In this study we retrospectively analyzed the outcome of bilateral decompressive craniectomy (BDC) for 37 patients with bilateral malignant diffuse brain swelling following severe traumatic brain injury (TBI). Our 37 patients (Glasgow Coma Scale [GCS] score <= 8) were retrospectively analyzed from September 2005 through September 2008. All patients underwent bilateral frontotemporoparietal decompressive craniectomy followed by duraplasty. The intracranial pressure (ICP) and cerebral perfusion pressure (CPP) were measured before and after BDC, and Glasgow Outcome Scale (GOS) scores were measured after >6 months of follow-up. The mean ICP was 37.7 +/- 6.4mm Hg, and the mean CPP was 57.6 +/- 7.5mm Hg before BDC. The ICP significantly decreased to 27.4 +/- 7.2mm Hg (p<0.05) after bone removal, and the CPP significantly increased to 63.3 +/- 8.4mm Hg (p<0.05). The ICP had a larger decrease, to 11.2 +/- 7.1mm Hg (p<0.05), after opening and enlargement of the dura mater (p<0.05) compared to the levels seen after bone removal, and CPP significantly increased to 77.8 +/- 8.3mm Hg (p<0.05). After surgery, the ICP was elevated, but remained lower than the initial ICP (p<0.05), and was easily controlled by routine medical treatment in the ensuing days, and the CPP remained above the optimal threshold of 70mm Hg. The mean follow-up time was 9.4 +/- 3.2 months. In total, 20 patients (54.1%) had favorable outcomes, including 12 patients (32.5%; GOS 4) with moderate deficits, and 8 patients (21.6%; GOS 5) showed good recovery and social reintegration. Also, 17 patients (45.9%) had unfavorable outcomes, including 7 patients (18.9%; GOS 1) who died, 4 patients (10.8%; GOS 2) remained in a vegetative state, and 6 patients (16.2%; GOS 3) had severe deficits. The most common complication was hydrocephalus (7 patients, 18.9%). Our data show that BDC offers immediate reductions in intracranial hypertension, and perhaps contributes to satisfactory outcomes in patients with bilateral diffuse brain swelling following severe TBI.	[Bao, Ying-hui; Liang, Yu-min; Gao, Guo-yi; Pan, Yao-hua; Luo, Qi-zhong; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			National Key Basic Research ProjectNational Basic Research Program of China [2005CB522604]; National Health Science [200802093]; Science and Technology Committee of ShanghaiShanghai Science & Technology Committee [07JC14038, 08411951900, 0852nm04900]; Program for Shanghai Outstanding Medical Academic Leaders	This work was supported by grants from the National Key Basic Research Project (no. 2005CB522604), National Health Science Grant (no. 200802093), the Science and Technology Committee of Shanghai (no. 07JC14038, 08411951900, and 0852nm04900), and the Program for Shanghai Outstanding Medical Academic Leaders. We also want to give our heartfelt thanks to professor W. Dalton Dietrich for his revisions and valuable editorial comments.	Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; American Association of Neurological Surgeons, 1996, J NEUROTRAUM, V13, P639; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; El-Watidy S, 2005, PEDIATR NEUROSURG, V41, P151, DOI 10.1159/000085874; Elwatidy S, 2006, SAUDI MED J, V27, P1547; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kocher T, 1901, HIRNERSCHUTTERUNG HI; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Miyazaki Y, 1966, Shujutsu, V20, P845; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Mussack T, 2005, J TRAUMA, V58, P1061, DOI 10.1097/01.TA.0000171989.63817.8c; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Ong YK, 2002, CHILD NERV SYST, V18, P340, DOI 10.1007/s00381-002-0597-9; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Reithmeier T, 2005, CHILD NERV SYST, V21, P249, DOI 10.1007/s00381-004-1044-x; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; RINALDI A, 1990, ACT NEUR S, V51, P394; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schneider GH, 2002, ACT NEUR S, V81, P77; Scozzafava J, 2007, NEUROCRIT CARE, V6, P49, DOI 10.1385/NCC:6:1:49; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	43	46	69	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					341	347		10.1089/neu.2009.1040			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800007	19715392				2022-02-06	
J	Cappuccino, A; Bisson, LJ; Carpenter, B; Marzo, J; Dietrich, WD; Cappuccino, H				Cappuccino, Andrew; Bisson, Leslie J.; Carpenter, Bud; Marzo, John; Dietrich, W. Dalton, III; Cappuccino, Helen			The Use of Systemic Hypothermia for the Treatment of an Acute Cervical Spinal Cord Injury in a Professional Football Player	SPINE			English	Article						spinal cord injuries; hypothermia; cervical; football	TRAUMATIC BRAIN-INJURY; COMPRESSION INJURY; BLOOD-FLOW; MILD HYPOTHERMIA; RAT; DAMAGE; PATHOPHYSIOLOGY; TEMPERATURE; PROTECTION; RELEASE	Study Design. Case Report. Objective. We will describe the injury and clinical course of an NFL Football player who sustained a complete spinal cord injury and was treated with conventional care in addition to modest systemic hypothermia. Summary of Background Data. Systemically induced moderate hypothermia is a potentially neuroprotective intervention in acute spinal cord injury. However, case descriptions of human patients receiving systemic hypothermia after spinal cord injuries are lacking in the literature. Methods. Here, we present the case of a National Football League player who sustained a complete (ASIA A) spinal cord injury from a C3/4 fracture dislocation. Moderate systemic hypothermia was instituted immediately after his injury, in addition to standard medical/surgical treatment, including, surgical decompression and intravenous methylprednisolone. Results. The patient experienced significant and rapid neurologic improvement, and within weeks of his injury was walking with harness assistance. Since that time, the patient has continued to make significant progress in his rehabilitation (now ASIA D). Conclusion. The extent to which this hypothermia contributed to his neurologic recovery is difficult to determine. It is hoped that this case will draw attention to the need for further preclinical and clinical studies to elucidate the role of hypothermia in acute spinal cord injury. Until these studies are completed, it is impossible to advocate for systemic hypothermia as a standard of care.	[Cappuccino, Andrew] Buffalo Spine Surg, Lockport, NY USA; [Cappuccino, Andrew; Bisson, Leslie J.; Carpenter, Bud; Marzo, John] Team Orthoped Surgeon Buffalo Bills, Buffalo, NY USA; [Bisson, Leslie J.; Marzo, John] SUNY Buffalo, Dept Orthoped, Buffalo, NY 14260 USA; [Bisson, Leslie J.] Team Buffalo Sabres, Buffalo, NY USA; [Dietrich, W. Dalton, III] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Cappuccino, Helen] SUNY Buffalo, Roswell Pk Canc Inst, Sch Med & Biomed Sci, Buffalo, NY 14260 USA		Cappuccino, H (corresponding author), 46 Davison Ct, Lockport, NY 14094 USA.	helencapp@aol.com					Abou-Chebl A, 2004, NEUROCRIT CARE, V1, P131, DOI 10.1385/NCC:1:2:131; Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; ALAN S, 2008, NY TIMES        0115; ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; ALLEN BT, 1996, J VASC SURG, V19, P339; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Arrica M, 2007, SEMIN CARDIOTHORAC V, V11, P6, DOI 10.1177/1089253206297409; Aslam AF, 2006, AM J MED, V119, P297, DOI 10.1016/j.amjmed.2005.09.062; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Black James H, 2003, Semin Thorac Cardiovasc Surg, V15, P345, DOI 10.1053/S1043-0679(03)00086-8; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Cambria R P, 2000, Semin Vasc Surg, V13, P315; Casas CE, 2005, J NEUROSURG-SPINE, V2, P308, DOI 10.3171/spi.2005.2.3.0308; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; CHEN GY, 2000, J NEUROSURG, V93, P85; Cheung Ka Wai, 2006, CJEM, V8, P329; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Coleman William P, 2004, Spine J, V4, P373, DOI 10.1016/j.spinee.2003.12.006; Conrad MF, 2007, ANN THORAC SURG, V83, pS856, DOI 10.1016/j.athoracsur.2006.10.096; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 2006, 34 ANN M CERV SPIN R; DIETRICH WD, 1996, ADV NEUROL, V71, P194; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; Fehlings MG, 2005, INJURY, V36, P13, DOI 10.1016/j.injury.2005.06.011; Frelinger AL, 2003, AM J CARDIOL, V92, P1099, DOI 10.1016/j.amjcard.2003.06.007; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; GIBBONS KJ, 2008, CNSQ SPRING, P45; GOLDSTEIN J, LOWERING BODY TEMPER; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; HANSEBOUT RR, 1985, CAN J NEUROL SCI, V12, P83, DOI 10.1017/S0317167100046758; Hartemink KJ, 2004, CRIT CARE, V8, pR343, DOI 10.1186/cc2928; Heier T, 2006, ANESTHESIOLOGY, V104, P1070, DOI 10.1097/00000542-200605000-00025; Holzer M, 2002, NEW ENGL J MED, V346, P549; HORODYSKI MB, 2008, AM ORTH SOC SPORTS M, P87; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; KEVIN G, 2008, SPORTS ILLUSTRA 0114; Kleiner DM, 2001, PREHOSPITAL CARE SPI; Kouchoukos NT, 1999, ANN THORAC SURG, V67, P1940, DOI 10.1016/S0003-4975(99)00442-7; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kwon BK, 2008, SPINE J, V8, P859, DOI 10.1016/j.spinee.2007.12.006; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSALA M, 1993, J SURG RES, V55, P21, DOI 10.1006/jsre.1993.1103; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; METZLER M, CURR SURG, V1, P38; *NAT CTR CAT SPORT, 2005, 12 NAT CTR CAT SPORT; PETER A, 2007, ANN ACAD MED SINGAP, V36, P49; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; SAKAMOTO T, 1990, AM J PHYSIOL, V259, pH1649; SAKAMOTO T, 1989, J NEUROSURG, V70, P780, DOI 10.3171/jns.1989.70.5.0780; SCHWAB MS, 2000, STROKE, V29, P2461; Scivoletto G, 2004, ARCH PHYS MED REHAB, V85, P485, DOI 10.1016/S0003-9993(03)00766-4; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Torg JS, 2002, J BONE JOINT SURG AM, V84A, P112, DOI 10.2106/00004623-200201000-00017; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VALE FL, J NEUROSURG, V2, P239; Waters R L, 1998, J Spinal Cord Med, V21, P195; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 2001, SPINAL CORD, V39, P74, DOI 10.1038/sj.sc.3101127; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 1999, NEUROPATHOLOGY, V19, P172, DOI 10.1046/j.1440-1789.1999.00227.x; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206	72	46	50	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JAN 15	2010	35	2					E57	E62		10.1097/BRS.0b013e3181b9dc28			6	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	551WY	WOS:000274245300025	20081503				2022-02-06	
J	Lanctot, KL; Rapoport, MJ; Chan, F; Rajaram, RD; Strauss, J; Sicard, T; McCullagh, S; Feinstein, A; Kiss, A; Kennedy, JL; Bassett, AS; Herrmann, N				Lanctot, Krista L.; Rapoport, Mark J.; Chan, Florance; Rajaram, Ryan D.; Strauss, John; Sicard, Tricia; McCullagh, Scott; Feinstein, Anthony; Kiss, Alex; Kennedy, James L.; Bassett, Anne S.; Herrmann, Nathan			Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; serotonin receptors; serotonin transporter; brain derived neurotrophic factor (BDNF); methylenetetrahydrofolate reductase (MTHFR); tryptophan hydroxylase (TPH)	NEUROTROPHIC FACTOR BDNF; SEROTONIN TRANSPORTER; MAJOR DEPRESSION; ANTIDEPRESSANT RESPONSE; PROMOTER POLYMORPHISM; VAL66MET POLYMORPHISM; ALLELIC VARIATION; RECEPTOR GENE; ASSOCIATION; DISORDER	Objectives: To determine which serotonergic system-related single nucleotide polymorphisms (SNPs) predicted variation in treatment response to citalopram in depression following a traumatic brain injury (TBI). Methods: Ninety (50 M/40 F, aged 39.9, SD = 18.0 years) post-TBI patients with a major depressive episode (MDE) were recruited into a 6-week open-label study of citalopram (20 mg/day). Six functional SNPs in genes related to the serotonergic system were examined: serotonin transporter (5HTTLPR including rs25531), 5HT1A C-(1019)G and 5HT2A T-(102)C, methylene tetrahydrofolate reductase (MTHFR) C-(677) T, brain-derived neurotrophic factor (BDNF) val66met and tryptophan hydroxylase-2 (TPH2) G-(703)T. Regression analyses were performed using the six SNPs as independent variables: Model 1 with response (percentage Hamilton Depression (HAMD) change from baseline to endpoint) as the dependent variable and Model 2 with adverse event index as the dependent variable (Bonferroni corrected p-value < 0.025). Results: MTHFR and BDNF SNPs predicted greater treatment response (R-2 = 0.098, F = 4.65, p = 0.013). The 5HTTLPR predicted greater occurrence of adverse events (R-2 = 0.069, F = 5.72, p = 0.020). Conclusion: Results suggest that polymorphisms in genes related to the serotonergic system may help predict short-term response to citalopram and tolerability to the medication in patients with MDE following a TBI.	[Lanctot, Krista L.; Rapoport, Mark J.; Chan, Florance; Rajaram, Ryan D.; McCullagh, Scott; Feinstein, Anthony; Herrmann, Nathan] Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; [Lanctot, Krista L.; Rapoport, Mark J.; McCullagh, Scott; Feinstein, Anthony; Bassett, Anne S.; Herrmann, Nathan] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Lanctot, Krista L.] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; [Rapoport, Mark J.; McCullagh, Scott; Feinstein, Anthony; Bassett, Anne S.; Herrmann, Nathan] Univ Toronto, Dept Med, Toronto, ON, Canada; [Strauss, John; Sicard, Tricia; Kennedy, James L.] Ctr Addict & Mental Hlth, Toronto, ON, Canada		Lanctot, KL (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave,Room FG05, Toronto, ON M4N 3M5, Canada.	krista.lanctot@sunnybrook.ca	Lanctot, Krista L./AAY-4820-2020; Rapoport, Mark/AAD-8581-2020; Kennedy, James Lowery/AAZ-6947-2020	Lanctot, Krista L./0000-0001-7024-6637; Kennedy, James Lowery/0000-0002-8733-3806	Ontario Mental Health Foundation	This study was made possible by a grant from the Ontario Mental Health Foundation (KLL, MR, SM, AF, NH). Dr. Lanctot was supported by a Fellowship from the Ontario Mental Health Foundation.	Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Anttila S, 2007, J NEURAL TRANSM, V114, P1065, DOI 10.1007/s00702-007-0705-9; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Aydemir O, 2005, PROG NEURO-PSYCHOPH, V29, P261, DOI 10.1016/j.pnpbp.2004.11.009; Bjelland I, 2003, ARCH GEN PSYCHIAT, V60, P618, DOI 10.1001/archpsyc.60.6.618; Bocchio-Chiavetto L, 2008, NEUROSCI LETT, V437, P130, DOI 10.1016/j.neulet.2008.04.005; BOTTIGLIERI T, 1992, PSYCHOL MED, V22, P871, DOI 10.1017/S0033291700038447; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Castren E, 2007, CURR OPIN PHARMACOL, V7, P18, DOI 10.1016/j.coph.2006.08.009; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Choi MJ, 2006, BRAIN RES, V1118, P176, DOI 10.1016/j.brainres.2006.08.012; Daws LC, 2007, J NEUROCHEM, V101, P641, DOI 10.1111/j.1471-4159.2006.04392.x; Denys D, 2007, J CLIN PSYCHIAT, V68, P747, DOI 10.4088/JCP.v68n0512; Dias BG, 2003, NEUROPHARMACOLOGY, V45, P553, DOI 10.1016/S0028-3908(03)00198-9; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; Garriock HA, 2010, BIOL PSYCHIAT, V67, P133, DOI 10.1016/j.biopsych.2009.08.029; Gilbody S, 2007, AM J EPIDEMIOL, V165, P1, DOI 10.1093/aje/kwj347; Gratacos M, 2008, PHARMACOGENOMICS J, V8, P101, DOI 10.1038/sj.tpj.6500460; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Heils A, 1996, J NEUROCHEM, V66, P2621; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hong CJ, 2006, PHARMACOGENOMICS J, V6, P27, DOI 10.1038/sj.tpj.6500340; Hong CJ, 2003, NEUROPSYCHOBIOLOGY, V48, P186, DOI 10.1159/000074636; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Hu XZ, 2006, AM J HUM GENET, V78, P815, DOI 10.1086/503850; Hwang JP, 2006, NEUROBIOL AGING, V27, P1834, DOI 10.1016/j.neurobiolaging.2005.10.013; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kang R, 2009, J PSYCHOPHARMACOLOGY; Kim H, 2006, JAMA-J AM MED ASSOC, V296, P1609, DOI 10.1001/jama.296.13.1609; Kraft JB, 2005, BIOL PSYCHIAT, V58, P374, DOI 10.1016/j.biopsych.2005.04.048; Kraft JB, 2007, BIOL PSYCHIAT, V61, P734, DOI 10.1016/j.biopsych.2006.07.017; Lang UE, 2005, PSYCHOPHARMACOLOGY, V180, P95, DOI 10.1007/s00213-004-2137-7; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lemonde S, 2003, J NEUROSCI, V23, P8788; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Licinio J, 2009, ARCH GEN PSYCHIAT, V66, P488, DOI 10.1001/archgenpsychiatry.2009.38; Markianos M, 1996, ACTA NEUROCHIR, V138, P57, DOI 10.1007/BF01411725; Minov C, 2001, NEUROSCI LETT, V303, P119, DOI 10.1016/S0304-3940(01)01704-9; Morishita S, 2008, HUM PSYCHOPHARM CLIN, V23, P647, DOI 10.1002/hup.969; Murphy GM, 2004, ARCH GEN PSYCHIAT, V61, P1163, DOI 10.1001/archpsyc.61.11.1163; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; Oswald P, 2005, EUR NEUROPSYCHOPHARM, V15, P491, DOI 10.1016/j.euroneuro.2005.01.001; Papakostas GI, 2005, INT J NEUROPSYCHOPH, V8, P523, DOI 10.1017/S1461145705005195; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Perlis RH, 2003, BIOL PSYCHIAT, V54, P879, DOI 10.1016/S0006-3223(03)00424-4; Polesskaya OO, 2006, J NEUROSCI RES, V83, P362, DOI 10.1002/jnr.20732; Pollock BG, 2000, NEUROPSYCHOPHARMACOL, V23, P587, DOI 10.1016/S0893-133X(00)00132-9; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Ribeiro L, 2007, NEUROREPORT, V18, P1291, DOI 10.1097/WNR.0b013e328273bcb0; Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Salomon K, 2009, HEALTH PSYCHOL, V28, P157, DOI 10.1037/a0013001; Sayer N.A., 1993, PSYCHOL ASSESSMENT, V5, P350, DOI [10.1037/1040-3590.5.3.350, DOI 10.1037/1040-3590.5.3.350]; Schumacher J, 2005, BIOL PSYCHIAT, V58, P307, DOI 10.1016/j.biopsych.2005.04.006; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Serretti A, 2007, MOL PSYCHIATR, V12, P247, DOI 10.1038/sj.mp.4001926; Shimizu E, 2003, BIOL PSYCHIAT, V54, P70, DOI 10.1016/S0006-3223(03)00181-1; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Strauss J, 2005, MOL PSYCHIATR, V10, P861, DOI 10.1038/sj.mp.4001685; Trivedi Madhukar H, 2008, Dialogues Clin Neurosci, V10, P377; Tsai SJ, 2003, AM J MED GENET B, V123B, P19, DOI 10.1002/ajmg.b.20026; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vermeiden M, 2010, J PSYCHOPHARMACOL, V24, P497, DOI 10.1177/0269881109105137; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Wendland JR, 2006, MOL PSYCHIATR, V11, P224, DOI 10.1038/sj.mp.4001789; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Yoshida K, 2002, PROG NEURO-PSYCHOPH, V26, P383, DOI 10.1016/S0278-5846(01)00287-1; Zill P, 2004, MOL PSYCHIATR, V9, P1030, DOI 10.1038/sj.mp.4001525; Zintzaras E, 2006, PSYCHIAT GENET, V16, P105, DOI 10.1097/01.ypg.0000199444.77291.e2	79	46	50	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	7-8					959	969		10.3109/02699051003789229			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	620MW	WOS:000279505000005	20515362	Green Accepted			2022-02-06	
J	Leung, YKJ; Pankhurst, M; Dunlop, SA; Ray, S; Dittmann, J; Eaton, ED; Palumaa, P; Sillard, R; Chuah, MI; West, AK; Chung, RS				Leung, Y. K. J.; Pankhurst, M.; Dunlop, S. A.; Ray, S.; Dittmann, J.; Eaton, E. D.; Palumaa, P.; Sillard, R.; Chuah, M. I.; West, A. K.; Chung, R. S.			Metallothionein induces a regenerative reactive astrocyte phenotype via JAK/STAT and RhoA signalling pathways	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Astrogliosis; Regeneration	FOCAL CEREBRAL-ISCHEMIA; II-DEFICIENT MICE; FACTOR OLEIC-ACID; BRAIN-INJURY; NEURONAL DIFFERENTIATION; PROTECTIVE ROLE; PLUS II; CNS; EXPRESSION; DEGENERATION	Following central nervous system injury, astrocytes rapidly respond by undergoing a stereotypical pattern of molecular and morphological alterations termed "reactive" astrogliosis. We have reported previously that metallothioneins (MTs) are rapidly expressed by reactive astrocytes and that their secretion and subsequent interaction with injured neurons leads to improved neuroregeneration. We now demonstrate that exogenous MT induces a reactive morphology and elevated GFAP expression in cultured astrocytes. Furthermore, these astrogliotic hallmarks were mediated via JAK/STAT and RhoA signalling pathways. However, rather than being inhibitory, MT induced a form of astrogliosis that was permissive to neurite outgrowth and which was associated with decreased chondroitin sulphate proteoglycan (CSPG) expression. The results suggest that MT has an important role in mediating permissive astrocytic responses to traumatic brain injury. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.	[Leung, Y. K. J.; Pankhurst, M.; Ray, S.; Dittmann, J.; Eaton, E. D.; Chuah, M. I.; West, A. K.; Chung, R. S.] Univ Tasmania, Menzies Res Inst, Hobart, Tas 7001, Australia; [Dunlop, S. A.] Univ Western Australia, Sch Anim Biol, Nedlands, WA 6907, Australia; [Palumaa, P.; Sillard, R.] Tallinn Univ Technol, Dept Gene Technol, EE-12618 Tallinn, Estonia		Chung, RS (corresponding author), Univ Tasmania, Menzies Res Inst, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au	Palumaa, Peep/B-4668-2019; Dunlop, Sarah A/G-9357-2013; West, Adrian/AAR-8857-2021; Pankhurst, Michael/F-2585-2017; Chuah, Meng Inn/J-7671-2014; Chung, Roger/ABF-8395-2020	Palumaa, Peep/0000-0002-3505-3466; Pankhurst, Michael/0000-0002-0976-5742; Dunlop, Sarah/0000-0002-1306-3962; Chung, Roger/0000-0002-9286-947X	Australian Research CouncilAustralian Research Council [LP0774820]; Bestenbalt LLC (Estonia); Discovery project grants [DP0556630, DP0984673]; Jack & Ethel Goldin Foundation; National Health & Medical Research CouncilNational Health and Medical Research Council of Australia [254670, 352623]	This research was supported by the Australian Research Council through a Linkage (LP0774820) project grant in partnership with Bestenbalt LLC (Estonia), and Discovery (DP0556630, DP0984673) project grants. It was also supported by an Alzheimer's Australia grant (Jack & Ethel Goldin Foundation). SAD holds a National Health & Medical Research Council Senior Research Fellowship (ID: 254670). RSC holds a National Health & Medical Research Council Peter Doherty Fellowship (ID: 352623).	Ambjorn M, 2008, J NEUROCHEM, V104, P21, DOI 10.1111/j.1471-4159.2007.05036.x; Asher R A, 2001, Prog Brain Res, V132, P611; Asmussen JW, 2009, J NEUROSCI RES, V87, P2926, DOI 10.1002/jnr.22118; Bento-Abreu A, 2008, J NEUROCHEM, V106, P1149, DOI 10.1111/j.1471-4159.2008.05462.x; Bento-Abreu A, 2009, J NEUROCHEM, V111, P49, DOI 10.1111/j.1471-4159.2009.06304.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Chung RS, 2007, CELL MOL LIFE SCI, V64, P2716, DOI 10.1007/s00018-007-7267-8; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Chung RS, 2002, EXP NEUROL, V178, P1, DOI 10.1006/exnr.2002.8017; Chung RS, 2002, BIOCHEM J, V365, P323, DOI 10.1042/BJ20011751; Damiani CL, 2007, J NEUROCHEM, V100, P720, DOI 10.1111/j.1471-4159.2006.04321.x; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Kohler LB, 2003, BRAIN RES, V992, P128, DOI 10.1016/j.brainres.2003.08.049; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Natale JE, 2004, J NEUROSCI RES, V78, P303, DOI 10.1002/jnr.20265; O'Toole DA, 2007, CELL MOL LIFE SCI, V64, P1303, DOI 10.1007/s00018-007-7106-y; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Penkowa M, 2005, J NEUROSCI RES, V79, P522, DOI 10.1002/jnr.20387; Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; West AK, 2004, REV NEUROSCIENCE, V15, P157; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	34	46	51	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2010	221	1					98	106		10.1016/j.expneurol.2009.10.006			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	546RH	WOS:000273827500012	19837066				2022-02-06	
J	Lyons, RA; Finch, CF; McClure, R; van Beeck, E; Macey, S				Lyons, Ronan A.; Finch, Caroline F.; McClure, Rod; van Beeck, Ed; Macey, Steven			The injury List Of All Deficits (LOAD) Framework - conceptualising the full range of deficits and adverse outcomes following injury and violence	INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION			English	Article						burden of injury; disability; injury outcomes	TRAUMATIC BRAIN-INJURY; PUBLIC-HEALTH IMPACT; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS; CHILDHOOD EXPERIENCES; TRAFFIC FATALITIES; MAJOR TRAUMA; RISK-FACTORS; HEAD-INJURY; DRUG-USE	Over recent years, there has been increasing recognition that the burden of injuries and violence includes more than just the direct and indirect monetary costs associated with their medical outcomes. However, quantification of the total burden has been seriously hampered by lack of a framework for considering the range of outcomes which comprise the burden, poor identification of the outcomes and their imprecise measurement. This article proposes a new conceptual framework, the List of All Deficits (or LOAD) Framework, that has been developed from extensive expert discussion and consensus meetings to facilitate the measurement of the full burden of injuries and violence. The LOAD Framework recognises the multidimensional nature of injury burden across individual, family and societal domains. This classification of potential consequences of injury was built on the International Classification of Functioning concept of disability. Examples of empirical support for each consequence were obtained from the scientific literature. Determining the multidimensional injury burden requires the assessment and combination of 20 domains of potential consequences. The resulting LOAD Framework classification and concept diagram describes 12 groups of injury consequences for individuals, three for family and close friends and five for wider society. Understanding the extent of the negative implications (or deficits) of injury, through application of the LOAD Framework, is needed to put existing burden of injury studies into context and to highlight the inter-relationship between the direct and indirect burden of injury relative to other conditions.	[Lyons, Ronan A.; Macey, Steven] Swansea Univ, Sch Med, Swansea SA2 8PP, W Glam, Wales; [Finch, Caroline F.] Univ Ballarat, Sch Human Movement & Sport Sci, Ballarat, Vic 3353, Australia; [McClure, Rod] Monash Univ, Accid Res Ctr, Clayton, Vic 3800, Australia; [van Beeck, Ed] Erasmus Univ, Med Ctr, Rotterdam, Netherlands		Lyons, RA (corresponding author), Swansea Univ, Sch Med, Swansea SA2 8PP, W Glam, Wales.	r.a.lyons@swansea.ac.uk	Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X; McClure, Roderick/0000-0002-9067-8282	ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/G007543/1] Funding Source: UKRI; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/G007543/1] Funding Source: researchfish		Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4; Aoyagi K, 1998, J BONE MINER RES, V13, P1468, DOI 10.1359/jbmr.1998.13.9.1468; Australian Bureau of Statistics, 1999, DIS AG CAR SUMM FIND; Barnes PM, 2001, BRIT MED J, V323, P1034, DOI 10.1136/bmj.323.7320.1034; Barrett DH, 2002, PSYCHOSOMATICS, V43, P195, DOI 10.1176/appi.psy.43.3.195; Blandford JM, 2006, SEX TRANSM DIS, V33, pS117, DOI 10.1097/01.olq.0000235148.64274.2f; Boden LI, 1999, AM J IND MED, V36, P487, DOI 10.1002/(SICI)1097-0274(199911)36:5<487::AID-AJIM1>3.0.CO;2-2; Bonica J., 1990, MANAGEMENT PAIN; Boufous S, 2004, AUST NZ J PUBL HEAL, V28, P482, DOI 10.1111/j.1467-842X.2004.tb00032.x; Bradt DA, 2003, ACAD EMERG MED, V10, P650, DOI 10.1197/aemj.10.6.650; BURCHARDT T, 1999, EVOLUTION DISABILITY; Cameron CM, 2005, J TRAUMA, V59, P639, DOI 10.1097/01.ta.0000183222.79685.23; Casanueva C, 2009, CHILD ABUSE NEGLECT, V33, P84, DOI 10.1016/j.chiabu.2007.04.017; Chang JJ, 2008, CHILD ABUSE NEGLECT, V32, P819, DOI 10.1016/j.chiabu.2007.11.003; Checchi F, 2008, PLOS MED, V5, P1025, DOI 10.1371/journal.pmed.0050146; Chu L. C., 2005, Hong Kong Medical Journal, V11, P391; Cumming RG, 2000, J GERONTOL A-BIOL, V55, pM299, DOI 10.1093/gerona/55.5.M299; Denavas-Walt C., 2007, INCOME POVERTY HLTH, P60; DISELEWIS JE, 2002, BRAINSTARS BRAIN INJ; Dube SR, 2003, PREV MED, V37, P268, DOI 10.1016/S0091-7435(03)00123-3; DUCLOS PJ, 1989, INT J EPIDEMIOL, V18, P213, DOI 10.1093/ije/18.1.213; Edwards RR, 2007, ARCH PHYS MED REHAB, V88, pS36, DOI 10.1016/j.apmr.2007.05.031; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Finch C, 2001, MED SCI SPORT EXER, V33, P778; Finch C, 2006, J SCI MED SPORT, V9, P490, DOI 10.1016/j.jsams.2006.03.002; Finkelstein E., 2006, INCIDENCE EC BURDEN; FINLEY MA, 2002, J NEUROLOGICAL PHYSI, V26, P21; FORD DV, 2007, EXPL EX DAT HLTH RES; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; GOODCHILD M, 2002, 4171 BERL DEP LAB; *GOV W AUSTR IND L, 2006, FAM CAR PHYS IMP CAR; Greenhalgh DG, 2003, J BURN CARE REHABIL, V24, P159, DOI 10.1097/01.BCR.0000054173.57871.61; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; HIMMELSTEIN DU, 2005, HLTH AFF MILLWOOD S; Hindmarsh DM, 2009, OSTEOPOROSIS INT, V20, P221, DOI 10.1007/s00198-008-0641-z; Holbrook TL, 2007, J TRAUMA, V62, P577, DOI 10.1097/TA.0b013e318031aa97; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Holtslag HR, 2007, INJURY, V38, P280, DOI 10.1016/j.injury.2006.10.026; Holtslag HR, 2008, B WORLD HEALTH ORGAN, V86, P111, DOI 10.2471/BLT.06.033803; Hubbard JR, 1996, AM J DRUG ALCOHOL AB, V22, P215, DOI 10.3109/00952999609001655; Ikossi DG, 2005, J AM COLL SURGEONS, V200, P49, DOI 10.1016/j.jamcollsurg.2004.09.016; *INJ EXP GROUP, 2009, GLOB BURD DIS; Jamison DT, 1993, DIS CONTROL PRIORITI; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Karam EG, 2008, PLOS MED, V5, P579, DOI 10.1371/journal.pmed.0050061; KAUSAR R, 1999, ASIA PACIFIC DISABIL, V10, P58; Kitzmann KM, 2003, J CONSULT CLIN PSYCH, V71, P339, DOI 10.1037/0022-006X.71.2.339; KLEIN BP, 1984, J OCCUP ENVIRON MED, V26, P443, DOI 10.1097/00043764-198406000-00017; Kopits E, 2005, ACCIDENT ANAL PREV, V37, P169, DOI 10.1016/j.aap.2004.04.006; Kordi R, 2004, BRIT J SPORT MED, V38, P678, DOI 10.1136/bjsm.2004.011643; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Kuterovac-Jagodic G, 2003, J CLIN PSYCHOL, V59, P9, DOI 10.1002/jclp.10114; Kvist J, 2005, KNEE SURG SPORT TR A, V13, P393, DOI 10.1007/s00167-004-0591-8; Lachman ME, 1998, J GERONTOL B-PSYCHOL, V53, pP43, DOI 10.1093/geronb/53B.1.P43; Lewis M, 2000, WHO IS PAYING HLTH C; Li L, 1998, AM J DRUG ALCOHOL AB, V24, P405, DOI 10.3109/00952999809016906; Lindqvist K, 2002, CROAT MED J, V43, P386; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Mahapatra P, 2002, NATL MED J INDIA, V15, P90; Mashrek SR, 2008, PUBLIC HEALTH, V122, P1418, DOI 10.1016/j.puhe.2008.06.007; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; Meerding WJ, 2006, EUR J PUBLIC HEALTH, V16, P271, DOI 10.1093/eurpub/ckl006; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Miller TR, 2000, MED CARE, V38, P562, DOI 10.1097/00005650-200006000-00003; Mirzamani M, 2002, PSYCHOL REP, V90, P431, DOI 10.2466/pr0.2002.90.2.431; Morgan O, 2005, PLOS MED, V2, P491, DOI 10.1371/journal.pmed.0020184; Morgan OW, 2006, PLOS MED, V3, P809, DOI 10.1371/journal.pmed.0030195; Mulder S, 2002, INJURY PREV, V8, P74, DOI 10.1136/ip.8.1.74; Murray CJL., 1996, GLOBAL BURDEN DIS CO; Nicholl JP, 2006, BMJ-BRIT MED J, V332, P1510, DOI 10.1136/bmj.332.7556.1510-a; North CS, 2002, J TRAUMA STRESS, V15, P171, DOI 10.1023/A:1015286909111; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; OLIVER JE, 1993, AM J PSYCHIAT, V150, P1315; Organization W.H, 2008, GLOBAL BURDEN DIS 20; Paulozzi L., 2007, Morbidity and Mortality Weekly Report, V56, P1281; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Poudel-Tandukar K, 2004, JAMA-J AM MED ASSOC, V291, P2542, DOI 10.1001/jama.291.21.2542-a; Purtscher Katharina, 2005, Int J Inj Contr Saf Promot, V12, P119, DOI 10.1080/17457300500102955; RIVARA FP, 1995, ANN EMERG MED, V26, P609, DOI 10.1016/S0196-0644(95)70013-7; Rivara FP, 2008, ARCH SURG-CHICAGO, V143, P282, DOI 10.1001/archsurg.2007.61; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Rushby JF, 2001, HEALTH POLICY PLANN, V16, P326, DOI 10.1093/heapol/16.3.326; Sabri AA, 2006, PLOS MED, V3, P1452, DOI 10.1371/journal.pmed.0030382; Saxon L, 1999, SPORTS MED, V28, P123, DOI 10.2165/00007256-199928020-00005; Schaal S, 2006, J TRAUMA STRESS, V19, P95, DOI 10.1002/jts.20104; Scheffer AC, 2008, AGE AGEING, V37, P19, DOI 10.1093/ageing/afm169; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Stack S, 2003, J EPIDEMIOL COMMUN H, V57, P238, DOI 10.1136/jech.57.4.238; Thelin N, 2006, SCAND J MED SCI SPOR, V16, P329, DOI 10.1111/j.1600-0838.2005.00497.x; Thombs BD, 2008, J PSYCHOSOM RES, V64, P205, DOI 10.1016/j.jpsychores.2007.09.003; Thompson C, 2006, J Clin Forensic Med, V13, P186, DOI 10.1016/j.jcfm.2006.02.011; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; WANG JS, 1999, J TRANSPORTATION STA, V2, P19; WAUGH JH, 1994, MED J AUSTRALIA, V161, P594, DOI 10.5694/j.1326-5377.1994.tb127637.x; Weiss HB, 2008, ACCIDENT ANAL PREV, V40, P1088, DOI 10.1016/j.aap.2007.11.011; Wiebe DJ, 2006, INJURY PREV, V12, P347, DOI 10.1136/ip.2006.011494; Wilson HW, 2009, AM J PUBLIC HEALTH, V99, pS197, DOI 10.2105/AJPH.2007.131599; World Bank, 1993, WORLD DEV REP 1993 I; World Health Organization, 2001, INT CLASS FUNCT; Zaloshnja E, 2004, ACCIDENT ANAL PREV, V36, P801, DOI 10.1016/j.aap.2003.07.006; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	109	46	46	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1745-7300	1745-7319		INT J INJ CONTROL SA	Int. J. Inj. Control Saf. Promot.		2010	17	3					145	159	PII 925130240	10.1080/17457300903453104			15	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	635EE	WOS:000280637600003	19946813				2022-02-06	
J	Ord, JS; Boettcher, AC; Greve, KW; Bianchini, KJ				Ord, Jonathan S.; Boettcher, Anneliese C.; Greve, Kevin W.; Bianchini, Kevin J.			Detection of malingering in mild traumatic brain injury with the Conners' Continuous Performance Test-II	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Response bias; Malingering; Traumatic brain injury; Neuropsychological assessment; Continuous performance task; Attention	VERBAL-LEARNING TEST; VISUAL MEMORY TEST; NEUROCOGNITIVE DYSFUNCTION; NEUROPSYCHOLOGICAL EVALUATION; SPECIFICITY; SENSITIVITY; INDICATORS; VALIDATION; SCALES; MMPI-2	Classification accuracy for the detection of malingered neurocognitive dysfunction (MND) in mild traumatic brain injury (TBI) is examined for two selected measures from the Conners' Continuous Performance Test-II (CPT-II) using criterion-groups validation. Individual and joint classification accuracies are presented for Omissions and Hit Reaction Time Standard Error across a range of scores comparing mild TBI malingering (n = 27), mild TBI not-malingering (n = 31), and moderate-to-severe (M/S) TBI not-malingering (n = 24) groups. At cutoffs associated with at least 95% specificity in both mild and M/S TBI, sensitivity to MND in mild TBI was 30% for Omissions, 41% for Hit Reaction Time Standard Error, and 44% using both indicators. These results support the use of the CPT-II as a reliable indicator for the detection of malingering in TBI when used as part of a comprehensive diagnostic system.	[Greve, Kevin W.] Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA; [Boettcher, Anneliese C.; Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone K.B., 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Conners C. K., 2000, CONNERS CONTINUOUS P; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Gouvier WD, 1998, CRIT ISS NE, P55; Green P., 1996, MANUAL COMPUTERISED; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Henry GK, 2007, APPL NEUROPSYCHOL, V14, P267, DOI 10.1080/09084280701719245; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; Larrabee G.J., 2007, ASSESSMENT MALINGERE; LARRABEE GJ, 2007, EVALUATION MALINGERI, P334; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MEYERS JE, 2002, APPL NEUROPSYCHOL, V7, P133; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Quinn CA, 2003, ARCH CLIN NEUROPSYCH, V18, P379, DOI 10.1016/S0887-6177(02)00150-6; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rogers R, 1997, CLIN ASSESSMENT MALI, P373; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	40	46	47	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	4					380	387		10.1080/13803390903066881			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	589YV	WOS:000277191000005	19739010				2022-02-06	
J	Ownsworth, T; Quinn, H; Fleming, J; Kendall, M; Shum, D				Ownsworth, Tamara; Quinn, Hayley; Fleming, Jennifer; Kendall, Melissa; Shum, David			Error self-regulation following traumatic brain injury: A single case study evaluation of metacognitive skills training and behavioural practice interventions	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Metacognitive skills training; Error self-regulation; Rehabilitation; Behavioural observation; Traumatic brain injury	PSYCHOSOCIAL ADJUSTMENT; AWARENESS; INDIVIDUALS; FEEDBACK; TRIAL	The objective of the study was to evaluate the effects of metacognitive skills training (MST) and behavioural practice on error self-regulation during a naturalistic task after traumatic brain injury (TBI). A single-case study design was used and three participants (two males, one female) aged 26-43 years with severe TBI were included in the study. In the first study, after a four-session baseline of behavioural practice, two participants received eight MST sessions followed by four maintenance sessions. In the second study, a third participant received 16 sessions of behavioural practice to assess the extent to which error self-regulation improves through long-term task practice and therapist corrections. Participants prepared two different meals with a novel meal introduced later to examine skills generalisation. Behavioural outcomes included error frequency, checking and self-corrections. Data analysis involved a combination of visual analysis and two standard deviation (2-SD) band analysis. In the MST study, the two participants demonstrated a 38% and 76% reduction in error frequency (p .05), a significant decrease in checks (p .05), and a significant increase in self-corrections (p .05) relative to baseline. In the behavioural practice study, the participant demonstrated reduced errors (25%), although this was not statistically significant, and a significant increase in checks (p .05), but self-corrections did not significantly change (p .05). This exploratory research suggests that, firstly, by targeting error self-regulation MST can potentially promote independence on complex everyday tasks; and secondly, although behavioural practice alone may facilitate some functional gains, it fails to promote more independent self-regulatory behaviours.	[Ownsworth, Tamara; Quinn, Hayley; Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Ownsworth, Tamara; Quinn, Hayley; Shum, David] Griffith Univ, Appl Cognit Neurosci Res Ctr, Brisbane, Qld 4111, Australia; [Fleming, Jennifer] Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Dept Occupat Therapy, Brisbane, Qld 4102, Australia; [Kendall, Melissa] Princess Alexandra Hosp, Acquired Brain Injury Outreach Serv, Buranda, Qld, Australia; [Kendall, Melissa] Griffith Univ, Sch Human Serv, Nathan, Qld 4111, Australia		Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Fleming, Jennifer M/B-4436-2011; Ownsworth, Tamara/ABB-6961-2021; Shum, David/A-3914-2008	Ownsworth, Tamara/0000-0003-1835-7094; Shum, David/0000-0002-4810-9262	Griffith UniversityGriffith University	The authors would like to thank the participants and their families. We also extend our gratitude to Narina Jenkinson, for her skills and expertise in the project, and staff from the Acquired Brain Injury Outreach Service. A grant from Griffith University supported the project.	Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Domholdt E, 2005, REHABILITATION RES P; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Katz N, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P323; Kazdin A., 1982, SINGLE CASE RES DESI; Landa-Gonzalez BELKIS, 2001, Occup Ther Int, V8, P49, DOI 10.1002/oti.131; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; McGraw-Hunter M, 2006, BRAIN INJURY, V20, P1061, DOI 10.1080/02699050600912163; McNaughton S., 1987, PAUSE PROMPT PRAISE; NOURBAKHSH MR, 1994, PHYS THER, V74, P768, DOI 10.1093/ptj/74.8.768; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2008, J REHABIL MED, V40, P81, DOI 10.2340/16501977-0124; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Schlund MW, 1999, BRAIN INJURY, V13, P889; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Wilson BA, 2003, NEUROPSYCHOLOG REHAB, P1; [No title captured]	30	46	46	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	1					59	80	PII 912451940	10.1080/09602010902949223			22	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	530SB	WOS:000272611500004	19533497				2022-02-06	
J	Braet, W; Johnson, KA; Tobin, CT; Acheson, R; Bellgrove, MA; Robertson, IH; Garavan, H				Braet, Wouter; Johnson, Katherine A.; Tobin, Claire T.; Acheson, Ruth; Bellgrove, Mark A.; Robertson, Ian H.; Garavan, Hugh			Functional developmental changes underlying response inhibition and error-detection processes	NEUROPSYCHOLOGIA			English	Article						Response inhibition; fMRI; Developmental; Error awareness	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; ANTERIOR CINGULATE; EXECUTIVE FUNCTIONS; WORKING-MEMORY; LATE CHILDHOOD; PERFORMANCE; TASK; SENSITIVITY; ACTIVATION	This study examined the developmental trajectories associated with response inhibition and error processing as exemplar executive processes. We present fMRI data showing developmental changes to the functional networks underlying response inhibition and error-monitoring, comparing activation between adults and young adolescents performing the sustained attention to response task (SART). During successful inhibitions, we observed greater activation for the young adolescents than for the adults, in a widely distributed network including frontal, parietal and medial regions. When inhibition failed, however, adults showed increased activation compared to young adolescents in a number of regions, including bilateral parahippocampal gyrus, left and right lingual gyri, the right insula, and cerebellar regions. These differences largely remained even when the two groups were matched for performance, suggesting that performance differences are unlikely to be the driving factor behind these developmental differences. Instead, the neurodevelopmental trajectory of these important executive functions may reveal the basis for the immature executive functioning of the young adolescent. (C) 2009 Elsevier Ltd. All rights reserved.	[Braet, Wouter] Univ Louvain, Expt Psychol Lab, B-3000 Louvain, Belgium; [Braet, Wouter; Johnson, Katherine A.; Tobin, Claire T.; Acheson, Ruth; Robertson, Ian H.; Garavan, Hugh] Univ Dublin Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Braet, Wouter; Johnson, Katherine A.; Tobin, Claire T.; Acheson, Ruth; Robertson, Ian H.; Garavan, Hugh] Univ Dublin Trinity Coll, Sch Psychol, Dublin 2, Ireland; [Bellgrove, Mark A.] Queensland Brain Inst, Brisbane, Qld, Australia; [Bellgrove, Mark A.] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia		Braet, W (corresponding author), Univ Louvain, Expt Psychol Lab, Tiensestr 102, B-3000 Louvain, Belgium.	Wouter.braet@gmail.com	Bellgrove, Mark/AAB-3114-2019; Braet, Wouter/A-5061-2009; Johnson, Katherine A/K-8469-2015	Johnson, Katherine A/0000-0002-2029-163X; Bellgrove, Mark/0000-0003-0186-8349; Robertson, Ian H/0000-0001-8637-561X	Science Foundation IrelandScience Foundation IrelandEuropean Commission; Irish Health Research Board; Irish Higher Education Authority's Programme for Research in Third-Level Institutions; Australian National Health and Medical Research Council Howard Florey Centenary FellowshipNational Health and Medical Research Council of Australia; FWO Research Foundation FlandersFWO	This study was supported by grants from the Science Foundation Ireland, the Irish Health Research Board, the Irish Higher Education Authority's Programme for Research in Third-Level Institutions, the Australian National Health and Medical Research Council Howard Florey Centenary Fellowship, and the FWO Research Foundation Flanders. The authors would like to thank all participants, as well as the parents of the adolescents who took part in the study.	Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Booth JR, 2003, NEUROIMAGE, V20, P737, DOI 10.1016/S1053-8119(03)00404-X; Brown JW, 2005, SCIENCE, V307, P1118, DOI 10.1126/science.1105783; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Castellanos FX, 2005, BIOL PSYCHIAT, V57, P1416, DOI 10.1016/j.biopsych.2004.12.005; Chan RCK, 2004, CLIN NEUROPSYCHOL, V18, P114, DOI 10.1080/13854040490507208; Clark CR, 2006, ARCH CLIN NEUROPSYCH, V21, P449, DOI 10.1016/j.acn.2006.06.005; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cragg L, 2008, DEVELOPMENTAL SCI, V11, P819, DOI 10.1111/j.1467-7687.2008.00730.x; Daniel DB, 2000, PERCEPT MOTOR SKILL, V90, P483, DOI 10.2466/PMS.90.2.483-484; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Denckla M. B, 1996, ATTENTION MEMORY EXE; Durston S, 2006, DEVELOPMENTAL SCI, V9, P1, DOI 10.1111/j.1467-7687.2005.00454.x; Durston S, 2002, DEVELOPMENTAL SCI, V5, pF9, DOI 10.1111/1467-7687.00235; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fernandez G, 1998, J NEUROSCI, V18, P1841; Fronczek R, 2006, SLEEP, V29, P187; Garavan H, 2003, NEUROIMAGE, V20, P1132, DOI 10.1016/S1053-8119(03)00334-3; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gray JA., 2000, NEUROPSYCHOLOGY ANXI; GREEN JD, 1954, J NEUROPHYSIOL, V17, P533, DOI 10.1152/jn.1954.17.6.533; Hester R, 2008, CEREB CORTEX, V18, P1933, DOI 10.1093/cercor/bhm219; Jansma JM, 2004, SCHIZOPHR RES, V68, P159, DOI 10.1016/S0920-9964(03)00127-0; Johnson KA, 2008, AM J MED GENET B, V147B, P927, DOI 10.1002/ajmg.b.30718; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Jones LB, 2003, DEVELOPMENTAL SCI, V6, P498, DOI 10.1111/1467-7687.00307; Jonkman LM, 2007, CLIN NEUROPHYSIOL, V118, P1069, DOI 10.1016/j.clinph.2007.01.017; Jonkman LM, 2006, BRAIN RES, V1097, P181, DOI 10.1016/j.brainres.2006.04.064; Karatekin C, 2007, PSYCHOPHYSIOLOGY, V44, P128, DOI 10.1111/j.1469-8986.2006.00477.x; Kelly AMC, 2005, CEREB CORTEX, V15, P1089, DOI 10.1093/cercor/bhi005; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; Lin CCH, 1999, J ABNORM CHILD PSYCH, V27, P403, DOI 10.1023/A:1021932119311; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Magno E, 2006, J NEUROSCI, V26, P4769, DOI 10.1523/JNEUROSCI.0369-06.2006; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Murphy K, 2004, NEUROIMAGE, V22, P879, DOI 10.1016/j.neuroimage.2004.02.005; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.3.CO;2-J; Ramautar JR, 2006, BRAIN RES, V1105, P143, DOI 10.1016/j.brainres.2006.02.091; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rubia K, 2007, HUM BRAIN MAPP, V28, P1163, DOI 10.1002/hbm.20347; Rubia K, 2006, HUM BRAIN MAPP, V27, P973, DOI 10.1002/hbm.20237; Steven MC, 2007, BEHAV BRAIN RES, V181, P12, DOI 10.1016/j.bbr.2007.03.023; Stevens MC, 2009, HUM BRAIN MAPP, V30, P24, DOI 10.1002/hbm.20478; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Ungerleider LG, 2002, NEUROBIOL LEARN MEM, V78, P553, DOI 10.1006/nlme.2002.4091; Velanova K, 2008, CEREB CORTEX, V18, P2505, DOI 10.1093/cercor/bhn012; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	56	46	47	1	25	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	DEC	2009	47	14					3143	3151		10.1016/j.neuropsychologia.2009.07.018			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	529SQ	WOS:000272537900014	19651151	Green Accepted			2022-02-06	
J	Griesdale, DEG; Tremblay, MH; McEwen, J; Chittock, DR				Griesdale, Donald E. G.; Tremblay, Marie-Helene; McEwen, Jonathan; Chittock, Dean R.			Glucose Control and Mortality in Patients with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Glucose; Mortality; Intensive care unit; Hyperglycemia	INTENSIVE INSULIN THERAPY; BLOOD-GLUCOSE; HYPERGLYCEMIA	The optimal glucose range in patients with severe traumatic brain injury (TBI) remains unclear. The goal of this study was to examine the association of serum glucose levels on mortality in patients with severe TBI. As a secondary endpoint, we determined the risk of hyperglycemic and hypoglycemic events, and their association with mortality. We conducted a retrospective cohort study of patients admitted to the ICU between May 2000 and March 2006 with severe TBI (Glasgow Coma Scale a parts per thousand currency sign 8) who survived at least 12 h. Average daily morning glucose levels for the first 10 days of admission were calculated and divided into quintiles. A total of 170 patients were included in the analysis. We found no association between quintiles of mean daily morning glucose and hospital mortality. Episodes of hyperglycemia (a parts per thousand yen11.1 mmol/l or 200 mg/dl) during the first 10 days occurred in 65% of patients (5.4% of all glucose measurements). Using multivariable regression, a single episode of hyperglycemia was associated with 3.6-fold increased risk of hospital mortality (95%CI: 1.2-11.2, P = 0.02). Hypoglycemia (a parts per thousand currency sign4.4 mmol/l or 80 mg/dl) was present in 48% of patients (4.3% of all glucose measurements), and was not associated with mortality. Any episode of hyperglycemia (a parts per thousand yen11.1 mmol/l or 200 mg/dl) was associated with 3.6-fold increased risk of hospital mortality in patients with severe TBI and thus, should be avoided. Maintaining serum glucose a parts per thousand currency sign10 mmol/l appears to be a reasonable balance to avoid extremes of glucose control, but further studies are needed to determine the optimal glucose range.	[Griesdale, Donald E. G.; Chittock, Dean R.] Vancouver Gen Hosp, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Tremblay, Marie-Helene; McEwen, Jonathan] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Tremblay, Marie-Helene; McEwen, Jonathan] Vancouver Gen Hosp, Dept Anesthesia, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Chittock, Dean R.] Univ British Columbia, Dept Med, Div Crit Care Med, Vancouver, BC, Canada		Griesdale, DEG (corresponding author), Vancouver Gen Hosp, Program Crit Care Med, Room 2438,Jim Pattison Pavil,2nd Floor,855 W 12th, Vancouver, BC V5Z 1M9, Canada.	dgriesdale@post.harvard.edu	Griesdale, Donald/AAT-7762-2021	Griesdale, Donald/0000-0001-5985-8624			Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; Bilotta F, 2009, J NEUROSURG ANESTH, V21, P2, DOI 10.1097/ANA.0b013e31818f8a5c; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; De la Rosa GD, 2008, CRIT CARE, V12, DOI 10.1186/cc7017; Egi M, 2006, ANESTHESIOLOGY, V105, P244, DOI 10.1097/00000542-200608000-00006; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; GRIESDALE DE, 2009, CMAJ, V180, P799; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Preiser JC, 2007, INTENS CARE MED, V33, P570, DOI 10.1007/s00134-006-0485-y; Rodbard Helena W, 2007, Endocr Pract, V13 Suppl 1, P1; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vogelzang M, 2004, CRIT CARE, V8, pR122, DOI 10.1186/cc2840; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wass CT, 1996, MAYO CLIN PROC, V71, P801; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	31	46	52	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2009	11	3					311	316		10.1007/s12028-009-9249-1			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	521SH	WOS:000271943800003	19636972				2022-02-06	
J	Roozenbeek, B; Maas, AIR; Lingsma, HF; Butcher, I; Lu, J; Marmarou, A; McHugh, GS; Weir, J; Murray, GD; Steyerberg, EW				Roozenbeek, Bob; Maas, Andrew I. R.; Lingsma, Hester F.; Butcher, Isabella; Lu, Juan; Marmarou, Anthony; McHugh, Gillian S.; Weir, James; Murray, Gordon D.; Steyerberg, Ewout W.		IMPACT Study Grp	Baseline characteristics and statistical power in randomized controlled trials: Selection, prognostic targeting, or covariate adjustment?	CRITICAL CARE MEDICINE			English	Article						covariate adjustment; heterogeneity; randomized controlled trials; selection criteria; statistical power; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SAMPLE-SIZE REQUIREMENTS; CLINICAL-TRIALS; ADMISSION CHARACTERISTICS; MULTICENTER TRIAL; IMPACT; VALIDATION; EFFICACY; DESIGN	Objective. Heterogeneity of patients is a common problem in randomized controlled trials (RCTs) in various fields of clinical research. We aimed to investigate the potential benefits of different approaches for dealing with heterogeneity in a case study on traumatic brain injury (TBI). Design and Setting: Statistical modeling studies in three surveys and six randomized controlled trials. Patients: Individual patient data (n = 8033) from the IMPACT database. Interventions: We investigated the statistical power and efficiency of randomized controlled trials (RCTs) in relation to (1) selection according to baseline characteristics, (2) prognostic targeting (i.e., excluding those with a relatively extreme prognosis), and (3) covariate-adjusted analysis. Statistical power was expressed as the required sample size for obtaining 80% power and efficiency as the relative change in study duration, reflecting both gains in power and adverse effects on recruitment. Uniform and targeted treatment effects were simulated for 6 month unfavorable outcome. Results: For a uniform treatment effect, selection resulted in a sample size reduction of 33% in the surveys and 5% in the RCTs, but decreased recruitment by 65% and 41%, respectively. Hence, the relative study duration was prolonged (surveys: +95%; RCTs: +60%). Prognostic targeting resulted in sample size reductions of 28% and 17%, and increased relative study duration by +5% in surveys and +11% in the RCTs. Covariate adjustment reduced sample sizes by 30% and 16%, respectively, and did not affect recruitment. For a targeted treatment effect, the sample size reductions by selection (surveys: 47%; RCTs: 20%) and prognostic targeting (surveys: 49%; RCTs: 41%) were larger and adverse effects on recruitment smaller. Conclusions. The benefits of selection and prognostic targeting in terms of statistical power are reversed by adverse effects on recruitment. Covariate adjusted analysis in a broadly selected group of patients is advisable if a uniform treatment effect is assumed, since there is no decrease in recruitment. (Crit Care Med 2009; 37:2683-2690)	[Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Lu, Juan; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Butcher, Isabella; McHugh, Gillian S.; Weir, James; Murray, Gordon D.] Univ Edinburgh, Div Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland		Steyerberg, EW (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands.	e.steyerberg@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Lu, Juan/0000-0002-5389-7603; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-42691] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; FOULKES AM, 1991, J NEUROSURG, V75, pS8; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; The European Study Group on Nimodipine in Severe Head Injury, 1994, J NEUROSURG, V80, P797; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yusuf S, 1999, BMJ-BRIT MED J, V319, P564, DOI 10.1136/bmj.319.7209.564	20	46	46	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2009	37	10					2683	2690		10.1097/CCM.0b013e3181ab85ec			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	499OU	WOS:000270234700001	19885979				2022-02-06	
J	Leder, SB; Suiter, DM; Warner, HL				Leder, Steven B.; Suiter, Debra M.; Warner, Heather Lisitano			Answering Orientation Questions and Following Single-Step Verbal Commands: Effect on Aspiration Status	DYSPHAGIA			English	Article						Deglutition; Deglutition disorders; Cognition; Aspiration	FIBEROPTIC ENDOSCOPIC EVALUATION; DYSPHAGIA; VIDEOFLUOROSCOPY	In the acute-care setting patients with altered mental status as a result of such diverse etiologies as stroke, traumatic brain injury, degenerative neurologic impairments, dementia, or alcohol/drug abuse are routinely referred for dysphagia testing. A protocol for dysphagia testing was developed that began with verbal stimuli to determine patient orientation status and ability to follow single-step verbal commands. Although unknown, it would be beneficial to ascertain if this information on mental status was predictive of aspiration risk. The purpose of this investigation was to determine if there was a difference in odds for aspiration based upon correctly answering specific orientation questions, i.e., 1. What is your name? 2. Where are you right now? and 3. What year is it?, and following specific single-step verbal commands, i.e., 1. Open your mouth. 2. Stick out your tongue. and 3. Smile. In a consecutive retrospective manner data from 4070 referred patients accrued between 1 December 1999 and 1 January 2007 were analyzed. The odds of liquid aspiration were 31% greater for patients not oriented to person, place, and time (odds ratio [OR] = 1.305, 95% CI = 1.134-1.501). The odds of liquid aspiration (OR = 1.566, 95% CI = 1.307-1.876), puree aspiration (OR = 1.484, 95% CI = 1.202-1.831), and being deemed unsafe for any oral intake (OR = 1.688, 95% CI = 1.387-2.054) were, respectively, 57, 48, and 69% greater for patients unable to follow single-step verbal commands. Being able to answer orientation questions and follow single-step verbal commands provides information on odds of aspiration for liquid and puree food consistencies as well as overall eating status prior to dysphagia testing. Knowledge of potential increased odds of aspiration allows for individualization of dysphagia testing thereby optimizing swallowing success.	[Leder, Steven B.] Yale Univ, Sch Med, Otolaryngol Sect, Dept Surg, New Haven, CT 06520 USA; [Suiter, Debra M.] Univ Memphis, Sch Audiol & Speech Language Pathol, Memphis, TN 38105 USA; [Warner, Heather Lisitano] Yale New Haven Med Ctr, Speech & Swallow Ctr, New Haven, CT USA		Leder, SB (corresponding author), Yale Univ, Sch Med, Otolaryngol Sect, Dept Surg, POB 208041, New Haven, CT 06520 USA.	steven.leder@yale.edu					BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; Daniels SK, 2007, AM J SPEECH-LANG PAT, V16, P140, DOI 10.1044/1058-0360(2007/018); FEINBERG M J, 1990, Dysphagia, V5, P61, DOI 10.1007/BF02412646; Fleiss J.L., 1981, STAT METHODS RATES P; Kelly AM, 2006, CLIN OTOLARYNGOL, V31, P425, DOI 10.1111/j.1749-4486.2006.01292.x; Kelly AM, 2007, LARYNGOSCOPE, V117, P1723, DOI 10.1097/MLG.0b013e318123ee6a; Kuhlemeier KV, 2001, DYSPHAGIA, V16, P119, DOI 10.1007/s004550011003; Langmore S E, 1988, Dysphagia, V2, P216, DOI 10.1007/BF02414429; LANGMORE SE, 1991, ANN OTO RHINOL LARYN, V100, P678; Leder SB, 2005, DYSPHAGIA, V20, P157, DOI 10.1007/s00455-005-0009-x; Leder SB, 1997, J SPEECH LANG HEAR R, V40, P1352, DOI 10.1044/jslhr.4006.1352; Leder SB, 1998, ARCH PHYS MED REHAB, V79, P1264, DOI 10.1016/S0003-9993(98)90273-8; Logemann JA, 1998, EVALUATION TREATMENT; MARTIN BJW, 1990, J SPEECH HEAR DISORD, V55, P28, DOI 10.1044/jshd.5501.28; McCullough GH, 2005, J SPEECH LANG HEAR R, V48, P1280, DOI 10.1044/1092-4388(2005/089); Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955	17	46	47	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-051X			DYSPHAGIA	Dysphagia	SEP	2009	24	3					290	295		10.1007/s00455-008-9204-x			6	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	486HW	WOS:000269187900006	19263106				2022-02-06	
J	Sheedy, J; Harvey, E; Faux, S; Geffen, G; Shores, EA				Sheedy, Joanne; Harvey, Evelyn; Faux, Steven; Geffen, Gina; Shores, E. Arthur			Emergency Department Assessment of Mild Traumatic Brain Injury and the Prediction of Postconcussive Symptoms: A 3-Month Prospective Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain; concussion; injury; mild; prediction; traumatic	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; NATURAL-HISTORY; RAPID SCREEN; RISK-FACTORS; MODERATE; RECOVERY; DIAGNOSIS; TIME	Objective: To investigate the utility of a brief emergency department (ED) bedside screen for the prediction of postconcussive symptoms at 3 months following mild traumatic brain injury (MTBI). Participants: One hundred patients with MTBI (78% men; mean age = 33.6 years); 2 control groups (each n = 100), a "minor nonhead injury" group (77% men; mean age = 32.2 years) and an "uninjured ED visitor" group (78% men; mean age = 33.6 years). Main Measures: Brief measures of neuropsychological functioning, acute pain, and postural stability were collected in the ED; telephone follow-up at 3 months using the Rivermead Post-Concussion Symptoms Questionnaire was undertaken. Results: Neuropsychological deficits, acute pain, and postural instability in the ED were significantly associated with postconcussive symptoms at 3-month follow-up. A regression formula using 3 easily obtainable measures obtained during acute stage of injury-immediate and delayed memory for 5 words and a visual analog scale score of acute headache-provided 80% sensitivity and 76% specificity for the prediction of clinically significant symptoms at 3 months postinjury. Conclusion: A small combination of variables assessable in the ED may predict MTBI patients likely to experience persistent postconcussive symptoms.	[Sheedy, Joanne] St Vincents Hosp, Darlinghurst, NSW 2010, Australia; [Shores, E. Arthur] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Harvey, Evelyn] Westmead Hosp, Sydney, NSW, Australia; [Geffen, Gina] Univ Queensland, Sch Psychol, Cognit Psychophysiol Lab, Brisbane, Qld, Australia		Sheedy, J (corresponding author), St Vincents Hosp, Victoria St, Sydney, NSW 2010, Australia.	jmshe9@student.monash.edu	Faux, Steven/Y-3409-2019	Faux, Steven/0000-0001-8846-216X; Shores, Edwin A/0000-0003-1553-5131			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM ASS AUT MED, 1990, ABBR INJ SCAL 1990; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baddeley A., 1992, SPEED CAPACITY LANGU; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P624, DOI 10.1080/13803390490918589; De Monte VE., 2005, BRAIN IMPAIR, V6, P109, DOI [10.1375/brim.2005.6.2.109, DOI 10.1375/BRIM.2005.6.2.109]; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; HINTONBAYRE AD, 1997, SPORT HLTH, V15, P4; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; REITAN RM, 1999, BRAIN, V55, P549; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; RUBIN AM, 1995, AM J OTOL, V16, P216; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wechsler, 1997, WECHSLER ADULT INTEL; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755	55	46	47	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2009	24	5					333	343		10.1097/HTR.0b013e3181aea51f			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	509WG	WOS:000271049300004	19858967				2022-02-06	
J	Ronner, HE; Ponten, SC; Stam, CJ; Uitdehaag, BMJ				Ronner, H. E.; Ponten, S. C.; Stam, C. J.; Uitdehaag, B. M. J.			Inter-observer variability of the EEG diagnosis of seizures in comatose patients	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Electroencephalogram; Coma; (Non-convulsive) status epilepticus; Intensive care unit; Seizure	INTENSIVE-CARE-UNIT; LATERALIZED EPILEPTIFORM DISCHARGES; NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CLINICAL-FEATURES; CRITICALLY-ILL; PROGNOSIS; PATTERNS	Objective: To assess the inter-observer agreement of the electroencephalogram (EEG) diagnosis of (non-convulsive) seizures in comatose patients. Design/setting/patients: Nine clinicians with different levels of experience in clinical neurophysiology were asked to evaluate in a strictly controlled way 90 epochs (10 s each) of 30 EEG's of 23 comatose patients admitted to the intensive care unit (ICU). For each EEG clinicians had to decide whether there was an electrographic seizure or not. Furthermore, Young's EEG criteria for (non-convulsive) seizures were scored in detail for all EEG's. Agreement was determined by calculating kappa values. Results: The inter-observer agreement of an EEG diagnosis of seizure was limited. The overall kappa score for the five experienced raters was 0.5, and the kappa score for less experienced raters was 0.29. Kappa values for the individual Young's criteria were highly variable, indicating discrepancies in the interpretation of specific phenomena. Especially, some types of periodic discharges gave rise to different interpretations. Conclusions: The EEG diagnosis of (non-convulsive) seizures in ICU patients is not very reliable, even when strict criteria such as proposed by Young are applied. There is a need for less ambiguous EEG criteria for (non-convulsive) seizures and status epilepticus. (C) 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Ronner, H. E.; Ponten, S. C.; Stam, C. J.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Neurophysiol, NL-1007 MB Amsterdam, Netherlands; [Uitdehaag, B. M. J.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands		Ronner, HE (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Clin Neurophysiol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	HE.Ronner@vumc.nl; SC.Ponten@vumc.nl; CJ.Stam@vumc.nl; BMJ.Uitdehaag@vumc.nl			Dutch National Epilepsy Fund	The authors thank the observers: E. Vriens, C. de Langen, B. Jones, M. Laman, H. Hamburger, R. Strijers, R. Lazeron and E. Geiger for their participation in this study. S.C. Ponten was financially supported by the Dutch National Epilepsy Fund.	BRENNER RP, 1990, J CLIN NEUROPHYSIOL, V7, P249, DOI 10.1097/00004691-199004000-00007; Brenner RP, 2004, J CLIN NEUROPHYSIOL, V21, P319; Brenner RP, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.43.s.3.9.x; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DELAPAZ D, 1981, ARCH NEUROL-CHICAGO, V38, P713, DOI 10.1001/archneur.1981.00510110073012; Fountain NB, 2001, J CLIN NEUROPHYSIOL, V18, P345, DOI 10.1097/00004691-200107000-00006; Garcia-Morales I, 2002, J CLIN NEUROPHYSIOL, V19, P172, DOI 10.1097/00004691-200203000-00009; Garzon E, 2001, NEUROLOGY, V57, P1175, DOI 10.1212/WNL.57.7.1175; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Husain AM, 1999, J CLIN NEUROPHYSIOL, V16, P51, DOI 10.1097/00004691-199901000-00005; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PohlmannEden B, 1996, J CLIN NEUROPHYSIOL, V13, P519, DOI 10.1097/00004691-199611000-00007; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Stroink H, 2006, DEV MED CHILD NEUROL, V48, P374, DOI 10.1017/S0012162206000806; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Yemisci M, 2003, SEIZURE-EUR J EPILEP, V12, P465, DOI 10.1016/S1059-1311(02)00351-5; Young GB, 1996, NEUROLOGY, V47, P83	27	46	46	0	2	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311			SEIZURE-EUR J EPILEP	Seizure	MAY	2009	18	4					257	263		10.1016/j.seizure.2008.10.010			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	437CY	WOS:000265465000005	19046902	Bronze			2022-02-06	
J	Slobounov, S; Cao, C; Sebastianelli, W				Slobounov, Semyon; Cao, Cheng; Sebastianelli, Wayne			Differential effect of first versus second concussive episodes on wavelet information quality of EEG	CLINICAL NEUROPHYSIOLOGY			English	Article						MTBI; EEG information quality (EEE-IQ); Wavelet entropy; Differential recovery after MTBI	POSTURAL CONTROL; CEREBRAL CONCUSSION; QUANTITATIVE EEG; BRAIN-INJURY; HIGH-SCHOOL; RECOVERY; ENTROPY; COLLEGIATE; HYPOTHERMIA; FOOTBALL	Objective: Recent reports have suggested that long-term residual brain dysfunctions from mild traumatic brain injury (MTBI) that are often overlooked by clinical criteria may be detected using advanced research methods. The aim of the present study was to examine the feasibility of EEG wavelet information quality measures (EEG-IQ) in monitoring alterations of brain functions as well as to determine the differential rate of recovery between the first and second concussive episodes. Methods: Student-athletes at high risk for MTBI (n = 265) were tested prior to concussive episodes as a baseline. From this subject pool, twenty one athletes who suffered from two concussive episodes within one athletic season and were tested on days 7, 14 and 21 post-first and second injuries using a within-subjects design. Specifically, EEG was recorded and processed using wavelet entropy (EEG-IQ) algorithm along with a battery of neuropsychological (NS) tests. Spatial distribution of EEG-IQ and its dynamics in conjunction with NS data were analyzed prior to and after MTBI. Results: No neuropsychological deficits were present in concussed subjects beyond 7 days post-injury after first and second concussions. However, EEG-IQ measures were significantly reduced primarily at temporal, parietal and the occipital regions (ROIs) after first and especially after second MTBI (p < 0.01) beyond 7 days post-injury. Rate of recovery of EEG-IQ measures was significantly slower after second MTBI compared to those after the first concussion (p < 0.01). Conclusions: EEG-IQ measures may reveal alterations in the brain of concussed individuals that are most often overlooked by current assessment tools. In this regard, EEG-IQ may potentially be a valuable tool for assessing and monitoring residual brain dysfunction in "asymptomatic" MTBI subjects. Significance: The results demonstrate the potential utility of EEG-IQ measures to classify concussed individuals at various stages of recovery. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Slobounov, Semyon; Cao, Cheng] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Sebastianelli, Wayne] Penn State Univ, Athlet Med Clin, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 268 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This study was supported by NIH, NINDS Grant R01 NS056227-01A2.	Al-Nashash HA, 2005, IEEE T BIO-MED ENG, V52, P2119, DOI 10.1109/TBME.2005.857634; Al-Nashash HA, 2003, ANN BIOMED ENG, V31, P653, DOI 10.1114/1.1575757; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hornero R, 2003, SEVENTH INTERNATIONAL SYMPOSIUM ON SIGNAL PROCESSING AND ITS APPLICATIONS, VOL 2, PROCEEDINGS, P5, DOI 10.1109/ISSPA.2003.1224801; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jia XF, 2006, BRAIN RES, V1111, P166, DOI 10.1016/j.brainres.2006.04.121; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Koenig MA, 2006, NEUROL CLIN, V24, P89, DOI 10.1016/j.ncl.2005.11.003; Kranczioch C, 2008, CLIN NEUROPHYSIOL, V119, P1419, DOI 10.1016/j.clinph.2008.02.011; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; OKEN BS, 1986, ANN NEUROL, V19, P493, DOI 10.1002/ana.410190511; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rosso OA, 2003, SIGNAL PROCESS, V83, P1275, DOI 10.1016/S0165-1684(03)00054-9; Rosso OA, 2001, J NEUROSCI METH, V105, P65, DOI 10.1016/S0165-0270(00)00356-3; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shin HC, 2006, IEEE T BIO-MED ENG, V53, P1016, DOI 10.1109/TBME.2006.873394; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6	40	46	47	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAY	2009	120	5					862	867		10.1016/j.clinph.2009.03.009			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	455JM	WOS:000266755200005	19375981	Green Accepted			2022-02-06	
J	Caso, JR; Hurtado, O; Pereira, MP; Garcia-Bueno, B; Menchen, L; Alou, L; Gomez-Lus, ML; Moro, MA; Lizasoain, I; Leza, JC				Caso, Javier R.; Hurtado, Olivia; Pereira, Marta P.; Garcia-Bueno, Borja; Menchen, Luis; Alou, Luis; Luisa Gomez-Lus, Maria; Moro, Maria A.; Lizasoain, Ignacio; Leza, Juan C.			Colonic bacterial translocation as a possible factor in stress-worsening experimental stroke outcome	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						stress; stroke; bacterial translocation; intestinal barrier; stroke outcome	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TOLL-LIKE RECEPTOR-4; GASTROINTESTINAL-TRACT; BARRIER FUNCTION; INNATE IMMUNITY; INFLAMMATION; RATS; NEUROPROTECTION; PERMEABILITY	Caso JR, Hurtado O, Pereira MP, Garcia-Bueno B, Menchen L, Alou L, Gomez-Lus ML, Moro MA, Lizasoain I, Leza JC. Colonic bacterial translocation as a possible factor in stress-worsening experimental stroke outcome. Am J Physiol Regul Integr Comp Physiol 296: R979-R985, 2009. First published February 4, 2009; doi:10.1152/ajpregu.90825.2008.-Stress is known to be one of the risk factors of stroke, but only a few experimental studies have examined the possible mechanisms by which prior stress may affect stroke outcome. In stroke patients, infections impede neurological recovery and increase morbidity as well as mortality. We previously reported that stress induces a bacterial translocation and that prior immobilization stress worsens experimental stroke outcome through mechanisms that involve inflammatory mediators such as release of proinflammatory cytokines and enzyme activation. We now investigate whether bacterial translocation from the intestinal flora of rats with stress before experimental ischemia is involved in stroke outcome. We used an experimental paradigm consisting of exposure of Fischer rats to repeated immobilization sessions before permanent middle cerebral artery occlusion (MCAO). The presence of bacteria and the levels and expression of different mediators involved in the bacterial translocation were analyzed. Our results indicate that stress before stroke is related to the presence of bacteria in different organs (mesenteric nodes, spleen, liver, and lung) after MCAO and increases inflammatory colonic parameters (such as cyclooxygenase-2, inducible nitric oxide synthase, and myeloperoxidase), but decreases colonic immunoglobulin A, and these results are correlated with colonic inflammation and bacterial translocation. Understanding the implication of bacterial translocation during stress-induced stroke worsening is of great potential clinical relevance, given the high incidence of infections after severe stroke and their main role in mortality and morbidity in stroke patients.	[Caso, Javier R.; Hurtado, Olivia; Pereira, Marta P.; Garcia-Bueno, Borja; Menchen, Luis; Moro, Maria A.; Lizasoain, Ignacio; Leza, Juan C.] Univ Complutense, Fac Med, Dept Pharmacol, E-28040 Madrid, Spain; [Menchen, Luis] Univ Complutense, Fac Med, Dept Microbiol 1, E-28040 Madrid, Spain; [Menchen, Luis] Hosp Gen Univ Gregorio Maranon, Serv Aparato Digestivo, Madrid, Spain; [Menchen, Luis] CIBEREHD, Madrid, Spain; [Garcia-Bueno, Borja; Leza, Juan C.] CIBERSAM, Ctr Invest Biomed Red Salud Mental, Madrid, Spain		Leza, JC (corresponding author), Univ Complutense, Fac Med, Dept Pharmacol, E-28040 Madrid, Spain.	jcleza@med.ucm.es	Alou, Luis/B-8170-2011; Garcia-Bueno, Borja/ABG-7536-2020; Pereira, Marta/ABF-7999-2020; Pereira, Marta/L-3208-2014; Caso, Javier R./G-2243-2017; Moro, Maria Angeles/K-6396-2014; HURTADO, OLIVIA/E-7248-2012; Lizasoain, Ignacio/K-9844-2014; Gomez-Lus, Maria Luisa/N-5295-2016	Alou, Luis/0000-0002-0859-008X; Pereira, Marta/0000-0002-9347-957X; Pereira, Marta/0000-0002-9347-957X; Caso, Javier R./0000-0001-8622-749X; Moro, Maria Angeles/0000-0003-1010-8237; HURTADO, OLIVIA/0000-0001-5735-7092; Lizasoain, Ignacio/0000-0002-6028-7379; Gomez-Lus, Maria Luisa/0000-0002-8832-1751; LEZA, JUAN CARLOS/0000-0002-9901-0094; Menchen, Luis/0000-0001-9490-3726; Garcia Bueno, Borja/0000-0001-7320-1530	Spanish Ministry of Science and Technology and HealthSpanish Government [SAF2007-63138, RD06/0026/0005, S-BIO-0170/2006, SAF2005-05960, SAF2006-01753]	This work was supported by the following grants from the Spanish Ministry of Science and Technology and Health (CIBERSam): SAF2007-63138 (J. C. Leza), RD06/0026/0005 (I. Lizasoain), S-BIO-0170/2006 MULTIMAG (I. Lizasoain), SAF2005-05960 (I. Lizasoain), and SAF2006-01753 (M. A. Moro).	Ando T, 2000, AM J PHYSIOL-REG I, V279, pR2164, DOI 10.1152/ajpregu.2000.279.6.R2164; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cao CX, 2007, BIOCHEM BIOPH RES CO, V353, P509, DOI 10.1016/j.bbrc.2006.12.057; Caso JR, 2006, NEUROSCIENCE, V142, P59, DOI 10.1016/j.neuroscience.2006.06.009; Caso JR, 2008, CURR MOL MED, V8, P299, DOI 10.2174/156652408784533751; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; Caso JR, 2007, EUR NEUROPSYCHOPHARM, V17, P600, DOI 10.1016/j.euroneuro.2007.02.009; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Chamorro A, 2005, STROKE, V36, P1495, DOI 10.1161/01.STR.0000170644.15504.49; Collins SM, 2001, AM J PHYSIOL-GASTR L, V280, pG315, DOI 10.1152/ajpgi.2001.280.3.G315; Colon AL, 2004, DIGEST DIS SCI, V49, P1713, DOI 10.1023/B:DDAS.0000043391.64073.e4; De Cristobal J, 2001, J NEUROCHEM, V79, P456, DOI 10.1046/j.1471-4159.2001.00600.x; DeVries AC, 2001, P NATL ACAD SCI USA, V98, P11824, DOI 10.1073/pnas.201215298; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Ferrier L, 2003, GASTROENTEROLOGY, V125, P795, DOI 10.1016/S0016-5085(03)01057-6; GRISHAM MB, 1988, DIG DIS SCI S, V33, P6; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Iso H, 2002, CIRCULATION, V106, P1229, DOI 10.1161/01.CIR.0000028145.58654.41; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Lindsberg PJ, 2003, STROKE, V34, P2518, DOI 10.1161/01.STR.0000089015.51603.CC; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Madrigal JLM, 2003, BRAIN RES, V979, P137, DOI 10.1016/S0006-8993(03)02892-0; Meddings JB, 2000, GASTROENTEROLOGY, V119, P1019, DOI 10.1053/gast.2000.18152; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Ponferrada A, 2007, GASTROENTEROLOGY, V132, P1791, DOI 10.1053/j.gastro.2007.02.032; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; SAUNDERS PR, 1994, AM J PHYSIOL-GASTR L, V267, pG794, DOI 10.1152/ajpgi.1994.267.5.G794; Soderholm JD, 2001, AM J PHYSIOL-GASTR L, V280, pG7, DOI 10.1152/ajpgi.2001.280.1.G7; STENDAHL O, 1983, INT ARCH ALLER A IMM, V70, P277, DOI 10.1159/000233335; Sugo N, 2002, STROKE, V33, P1660, DOI 10.1161/01.STR.0000016967.76805.BF; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Truelsen T, 2003, STROKE, V34, P856, DOI 10.1161/01.STR.0000062345.80774.40; WIRA CR, 1990, J IMMUNOL, V144, P142	42	46	51	0	13	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	APR	2009	296	4					R979	R985		10.1152/ajpregu.90825.2008			7	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	424KH	WOS:000264565100015	19193944				2022-02-06	
J	Clark, ME; Walker, RL; Gironda, RJ; Scholten, JD				Clark, Michael E.; Walker, Robyn L.; Gironda, Ronald J.; Scholten, Joel D.			Comparison of Pain and Emotional Symptoms in Soldiers with Polytrauma: Unique Aspects of Blast Exposure	PAIN MEDICINE			English	Article						Chronic Pain; Trauma; Posttraumatic Stress Syndrome; Psychosocial Factors	FUNCTIONAL INDEPENDENCE MEASURE; POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; IRAQI FREEDOM; PERSISTENT PAIN; MENTAL-ILLNESS; REHABILITATION; RELIABILITY	To compare the physical and emotional presentation and pain treatment outcomes of service members who sustained polytrauma secondary to blast with those of soldiers injured by other means. Retrospective medical record review. One of four Veterans Affairs multidisciplinary inpatient Polytrauma Rehabilitation Centers. One hundred twenty-eight Operation Enduring Freedom and Operation Iraqi Freedom military personnel with serious polytrauma injuries and concomitant pain categorized into three groups based on type of injuries: blast injuries, combat injuries other than blast, and noncombat, nonblast injuries. Intensive, interdisciplinary inpatient rehabilitation and pain treatment. Pain intensity ratings; Functional Independence Measure scores; Rancho Los Amigos levels; and opioid analgesic doses. Service members injured via blast demonstrated a broader spectrum of physical injuries, higher levels of admission and discharge opioid analgesic use, reduced improvement in pain intensity following treatment, and much higher rates of posttraumatic stress disorder and other psychiatric diagnoses than those injured via other means. Blast injury may be associated with differential physical, emotional, and pain-related symptoms that pose increased challenges for successful treatment.	[Clark, Michael E.; Walker, Robyn L.; Gironda, Ronald J.] James A Haley Vet Affairs Hosp, Chron Pain Rehabil Program, Tampa, FL USA; [Clark, Michael E.; Gironda, Ronald J.; Scholten, Joel D.] Univ S Florida, Tampa, FL USA; [Scholten, Joel D.] James A Haley Vet Affairs Hosp, Polytrauma Rehabil Ctr, Tampa, FL USA		Clark, ME (corresponding author), Chron Pain Rehabil Program 2CW, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Michael.Clark8@va.gov			Department of Veterans Affairs Rehabilitation Research and DevelopmentUS Department of Veterans Affairs [SDR-07-047]; University of South Florida or the Departments of Defense or Veterans Affairs	Support for preparation of this article was provided in part by the Department of Veterans Affairs Rehabilitation Research and Development grant SDR-07-047 to the first author. All opinions expressed herein are those of the authors and do not in any way represent those of the University of South Florida or the Departments of Defense or Veterans Affairs.	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; BRAGANZA RJ, 2006, MANUAL PAIN MANAGEME, P231; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; CLARK ME, 2006, 2 ANN PAIN AW DAY C; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Cohen SP, 2005, ANESTH ANALG, V101, P1098, DOI 10.1213/01.ane.0000169332.45209.cf; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Gatchel RJ, 1995, SPINE, V20, P2702, DOI 10.1097/00007632-199512150-00011; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Hagen C., 1998, RANCHO LEVELS COGNIT; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HANDY K, 2007, FR0727 DEP DEF OFF S; Hanley M, 2004, DISABIL REHABIL, V26, P882, DOI 10.1080/09638280410001708896; Herbert J, 1997, BRIT MED J, V315, P530, DOI 10.1136/bmj.315.7107.530; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Jung BF, 2004, NEUROLOGY, V62, P1545, DOI 10.1212/01.WNL.0000123261.00004.29; Kalra R, 2008, FED PRACT, V25, P36; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Katz J, 2005, PAIN, V119, P16, DOI 10.1016/j.pain.2005.09.008; Katz J, 1996, CLIN J PAIN, V12, P50, DOI 10.1097/00002508-199603000-00009; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Pflanz S, 2001, MIL MED, V166, P457, DOI 10.1093/milmed/166.6.457; Roth RS, 2004, AM J PHYS MED REHAB, V83, P827, DOI 10.1097/01.PHM.0000140800.83146.FA; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seel RT, 2007, J HEAD TRAUMA REHAB, V22, P267, DOI 10.1097/01.HTR.0000290971.56130.c8; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Stojadinovic A, 2006, PAIN MED, V7, P330, DOI 10.1111/j.1526-4637.2006.00171.x	36	46	47	0	4	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1526-2375			PAIN MED	Pain Med.	APR	2009	10	3					447	455		10.1111/j.1526-4637.2009.00590.x			9	Anesthesiology; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anesthesiology; General & Internal Medicine	431QI	WOS:000265077500006	19416436				2022-02-06	
J	Tepas, JJ; Leaphart, CL; Pieper, P; Beaulieu, CL; Spierre, LR; Tuten, JD; Celso, BG				Tepas, Joseph J., III; Leaphart, Cynthia L.; Pieper, Pam; Beaulieu, Cynthia L.; Spierre, Louise R.; Tuten, James D.; Celso, Brian G.			The effect of delay in rehabilitation on outcome of severe traumatic brain injury	JOURNAL OF PEDIATRIC SURGERY			English	Article						Rehabilitation; Outcomes; FIM (functional independence measure); Pediatric trauma	FUNCTIONAL INDEPENDENCE; MORTALITY; CHILDREN; SYSTEM; WEEFIM	Background: Expeditious care within minutes of severe injury improves outcome and is the driving force for development of trauma care systems. Transition from hospital care to rehabilitation is an important step in recovery after trauma-related injury. We hypothesize that delay in the transition from acute care to rehabilitation adversely affects outcome and diminishes recovery after traumatic brain injury (TBI). Methods: After institutional review board approval, the trauma registry of our regional level I pediatric trauma center was queried for all children with severe blunt TBI (initial Glasgow Coma Scale score <= 8) that required inpatient rehabilitation. Records were stratified as severe TBI (Glasgow Coma Scale [GCS] scores 3, 4, 5) and moderate TBI (GSC scores 6, 7, 8). Intensity of acute care was defined by need for mechanical ventilation and length of intensive care unit stay. Outcome was defined by functional independence measurement (FIM) scores at time of transfer to inpatient rehabilitation. Linear regression was used to compare time in days between discharge from intensive care and admission to inpatient rehabilitation (delay) to rehabilitation efficiency (RE), defined as the ratio of FIM score improvement to length of stay for inpatient rehabilitation. Functional improvement was determined by analysis of FIM score improvement (Delta FIM) between initiation and completion of inpatient rehabilitation. Results: Between January 2000 and December 2006, 60 children (38 males, mean age, 11.2 years; 22 females, mean age, 10.6 years) with blunt TBI and an initial GCS score of 8 or lower required resuscitation, comprehensive critical care, and inpatient rehabilitation. Mean length of stay in the intensive care unit was 11.1 +/- 7.4 days. Fifty-two children required an average of 9.4 +/- 6.8 ventilator days. Delay ranged between 0 and 24 days (mean, 4.1 days) and was significantly correlated with RE and Delta FIM (,Correlation coefficient = -0.346, P = .0068). For children with the highest potential for salvage (GCS scores 6, 7, 8), RE correlation increased to -0.457 (P = .011), whereas those with most severe injury (GCS scores 3, 4, 5) demonstrated a weaker correlation that was not significant. For children with most severe injury (GCS scores 3,4,5), the con-elation of Delta FIM was significant (-0.38 P = .035); however, RE was not. Conclusions: These data demonstrate the price of delay of comprehensive rehabilitation, especially for the most vulnerable TBI children with best potential for salvage. The "golden hour," which has become the mantra for continued refinement of systems of emergency and trauma care, must progress without interruption to the "golden clay," during which comprehensive critical care seamlessly transitions to timely and aggressive rehabilitation to effect the greatest functional recovery. (C) 2009 Elsevier Inc. All rights reserved.	[Tepas, Joseph J., III; Leaphart, Cynthia L.; Pieper, Pam] Univ Florida, Coll Med Surg, Jacksonville, FL 32209 USA; [Beaulieu, Cynthia L.; Spierre, Louise R.] Brooks Rehabil Hosp, Jacksonville, FL 32216 USA; [Tuten, James D.] Version2Network, St Augustine, FL 32084 USA; [Celso, Brian G.] Univ Florida, Dept Psychiat, Coll Med, Jacksonville, FL 32209 USA		Tepas, JJ (corresponding author), Univ Florida, Div Pediat Surg, Coll Med Jacksonville, Jacksonville, FL 32209 USA.	jjt@jax.ufl.edu					Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; Gabbe BJ, 2008, ANN SURG, V247, P854, DOI 10.1097/SLA.0b013e3181656d1e; Gabbe BJ, 2007, J TRAUMA, V63, P1374, DOI 10.1097/01.ta.0000240481.55341.38; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Mullins RJ, 1998, J TRAUMA, V44, P17; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Pracht EE, 2008, J PEDIATR SURG, V43, P212, DOI 10.1016/j.jpedsurg.2007.09.047; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Srivastava R, 2007, J HOSP MED, V2, P165, DOI 10.1002/jhm.167; Willis CD, 2006, INJURY, V37, P1185, DOI 10.1016/j.injury.2006.07.011; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	15	46	46	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	FEB	2009	44	2					368	372		10.1016/j.jpedsurg.2008.10.089			5	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	415MY	WOS:000263939100014	19231536				2022-02-06	
J	Catroppa, C; Anderson, VA; Muscara, F; Morse, SA; Haritou, F; Rosenfeld, JV; Heinrich, LM				Catroppa, Cathy; Anderson, Vicki A.; Muscara, Frank; Morse, Sue A.; Haritou, Flora; Rosenfeld, Jeffrey V.; Heinrich, Liesl M.			Educational skills: Long-term outcome and predictors following paediatric traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Head injury; Children; Literacy; Arithmetic; Recovery	CLOSED-HEAD INJURY; ACADEMIC-PERFORMANCE; CHILDREN; RECOVERY; CHILDHOOD; ADOLESCENTS; BEHAVIOR; TBI; ACHIEVEMENT; SCHOOL	Given that reading, spelling and arithmetic skills are acquired through childhood, their development may be compromised following a childhood traumatic brain injury (TBI). The present study examined educational skills (reading accuracy, spelling and arithmetic) at a mean follow-up interval of 6.8 years post-injury in children who had sustained a mild, moderate, or severe TBI at two ages: 'Young' (age at injury: 3-7 years, n = 48) and 'Old': (age at injury: 8-12 years, n = 36). Comparisons between the young and old TBI groups resulted in inconsistent findings. While a dose-response relationship for severity was evident for the young group, this was not always the case for the old group. Significant predictors of outcome included both severity and acute intellectual function.	[Catroppa, Cathy; Anderson, Vicki A.; Muscara, Frank; Heinrich, Liesl M.] Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.; Morse, Sue A.; Haritou, Flora] Royal Childrens Hosp, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.; Muscara, Frank] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Melbourne, Vic 3004, Australia		Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; Heinrich, Liesl/0000-0001-5813-7235	Research Foundation; Royal Children's Hospital; National Health and Medical Research Council, AustraliaNational Health and Medical Research Council of Australia	Financial support, via successful grants, was provided by the Research Foundation, Royal Children's Hospital and the National Health and Medical Research Council, Australia. No conflict of interest was associated with this research.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2000, BRIT J CANCER, V82, P255; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; CARNEY J, 1990, Pediatrician, V17, P222; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Daniel A., 1983, POWER PRIVILEGE PRES; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 2004, HANDBOOK OF PEDIATRIC PSYCHOLOGY IN SCHOOL SETTINGS, P313; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; Nelson J E, 2002, Pediatr Rehabil, V5, P37, DOI 10.1080/1363849021000007088; NOLLER P, 1992, J ADOLESCENCE, V15, P101, DOI 10.1016/0140-1971(92)90041-3; Noller P, 1988, ICPS FAMILY FU UNPUB; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROWE JK, 1995, ROWE BEHAV RATING IN; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; SCHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592; Slater E.J., 1989, J ADOLESCENT RES, V4, P371; STALINGS G, 1996, J INT NEUROPSYCHOLOG; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D., 1987, MANUAL PRESCHOOL PRI; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	50	46	47	0	10	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	5					716	732		10.1080/09602010902732868			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	539EK	WOS:000273236200006	19306233				2022-02-06	
J	Hart, T				Hart, Tessa			Treatment definition in complex rehabilitation interventions	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Rehabilitation; Clinical trials; Treatment fidelity; Complex intervention; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; COGNITIVE-BEHAVIORAL-THERAPY; RANDOMIZED CONTROLLED-TRIAL; HEALTH-SERVICES RESEARCH; FOLLOW-UP; TREATMENT FIDELITY; ANGER MANAGEMENT; STROKE REHABILITATION; CAREGIVER BURDEN; IMPROVE HEALTH	Rehabilitation research is challenged to improve its evidence base, which requires more precise and more consistent conceptualisation and measurement of treatment ingredients. This paper presents the steps in defining and specifying treatments towards the construction of a therapy manual for experimental interventions, or a coding system for observational treatment research. Specifying the active ingredients, identifying the behavioural operations that are aligned with each, and developing procedural details and materials are discussed and illustrated using two on-going trials for treatment of traumatic brain injury. The process of assessing treatment fidelity, that is, the extent to which interventions are delivered, received and used as intended, is also discussed.	Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 60 E Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD050836] Funding Source: Medline		Addis ME, 1999, CLIN PSYCHOL-SCI PR, V6, P430, DOI 10.1093/clipsy/6.4.430; Beck R, 1998, COGNITIVE THER RES, V22, P63, DOI 10.1023/A:1018763902991; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; Bellg AJ, 2004, HEALTH PSYCHOL, V23, P443, DOI 10.1037/0278-6133.23.5.443; Bostrom J, 1996, APPL NURS RES, V9, P47, DOI 10.1016/S0897-1897(96)80402-2; Bradley F, 1999, BMJ-BRIT MED J, V318, P711; BURNS DD, 1992, J CONSULT CLIN PSYCH, V60, P441, DOI 10.1037/0022-006X.60.3.441; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Dayus B, 2000, NEUROPSYCHOL REHABIL, V10, P415, DOI 10.1080/096020100411998; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEFFENBACHER JL, 1992, J COUNS PSYCHOL, V39, P158, DOI 10.1037/0022-0167.39.2.158; Deffenbacher JL, 2002, COUNS PSYCHOL, V30, P262, DOI 10.1177/0011000002302004; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; EAMES P, 2001, NEUROBEHAVIORAL DISA; Eames P., 1990, NEUROBEHAVIORAL SEQU, P410; Estrada AU, 1999, J SEX MARITAL THER, V25, P151, DOI 10.1080/00926239908403989; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HART T, 2007, TREATMENT DEFINITION; HART T, 2009, DESIGNING IMPLEMENTI; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hawe P, 2004, J EPIDEMIOL COMMUN H, V58, P788, DOI 10.1136/jech.2003.014415; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Howard K.I., 1987, J INTEGRATIVE ECLECT, V6, P6; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Kolden GG, 2006, J CONSULT CLIN PSYCH, V74, P327, DOI 10.1037/0022-006X.74.2.327; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Litt MD, 2005, J CONSULT CLIN PSYCH, V73, P1015, DOI 10.1037/0022-006X.73.6.1015; LONG C, 1995, NEUROPSYCHOLOGICAL A; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Marshall WL, 2003, AGGRESS VIOLENT BEH, V8, P205, DOI 10.1016/S1359-1789(01)00065-9; Mateer C A, 1999, Semin Clin Neuropsychiatry, V4, P50; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Medical Research Council, 2000, FRAM DEV EV RCTS COM; Miller SJ, 2002, PSYCHOTHERAPY, V39, P184, DOI 10.1037/0033-3204.39.2.184; Moos RH, 2007, DRUG ALCOHOL DEPEN, V88, P109, DOI 10.1016/j.drugalcdep.2006.10.010; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Oakley A, 2006, BRIT MED J, V332, P413, DOI 10.1136/bmj.332.7538.413; Pantalon MV, 2004, AM J DRUG ALCOHOL AB, V30, P353, DOI 10.1081/ADA-120037382; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Silver J, 2007, BRAIN INJURY MED PRI, P963; Spillane V, 2007, J ADV NURS, V60, P343, DOI 10.1111/j.1365-2648.2007.04386.x; Strasser DC, 2008, ARCH PHYS MED REHAB, V89, P10, DOI 10.1016/j.apmr.2007.08.127; Strasser DC, 2005, ARCH PHYS MED REHAB, V86, P403, DOI 10.1016/j.apmr.2004.04.046; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D	63	46	46	1	8	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	6					824	840		10.1080/09602010902995945			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	539EL	WOS:000273236300004	19544183				2022-02-06	
J	Hu, ZG; Wang, HD; Qiao, L; Yan, W; Tan, QF; Yin, HX				Hu, Zhi-Gang; Wang, Han-Dong; Qiao, Liang; Yan, Wei; Tan, Qi-Fu; Yin, Hong-Xia			The protective effect of the ketogenic diet on traumatic brain injury-induced cell death in juvenile rats	BRAIN INJURY			English	Article						ketogenic diet; pediatric; traumatic brain injury; apoptosis	D-BETA-HYDROXYBUTYRATE; KETONE-BODIES; ADULT RATS; CORTICAL CONTUSION; GENE-EXPRESSION; TRANSGENIC MICE; NEURONAL DEATH; BCL-2 FAMILY; APOPTOSIS; ISCHEMIA	Background: The ketogenic diet (the KD) is an effective treatment for intractable epilepsy, especially in the paediatric population, and a growing number of studies have shown the neuroprotective role of the KD. However, few studies focused on the neuroprotective effects of the KD in traumatic brain injury (TBI). The present study aimed to investigate the effects of the KD on TBI. Methods and procedures: Male Sprague-Dawley rats (n = 60) were randomly divided into four groups according to the diet fed (the KD vs normal diet) and whether brain was injured or not. TBI was produced using Feeney weight drop model. Brain oedema was estimated by wet/dry weight ratio; Bax and Bcl-2 mRNA levels were determined by RealTime-PCR; Bax and Bcl-2 protein levels were detected by Western blot. Furthermore, cellular apoptosis in the penumbra area was examined using terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) method. Main outcomes and results: The results indicated that both Bax mRNA and protein levels were significantly elevated 72 hours after TBI and decreased by KD administration. Neither TBI nor the KD affected Bcl-2 mRNA and protein levels. KD administration also reduced brain oedema and cellular apoptosis. Conclusion: These results suggest that the KD might be a useful treatment for children suffering from the consequences of TBI.	[Hu, Zhi-Gang; Wang, Han-Dong; Qiao, Liang; Tan, Qi-Fu; Yin, Hong-Xia] Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, Nanjing 210002, Jiangsu Prov, Peoples R China; [Yan, Wei] Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020	Yan, Wei/0000-0002-1123-0835			Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Cheng BH, 2007, AUTON NEUROSCI-BASIC, V134, P38, DOI 10.1016/j.autneu.2007.02.002; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Eun SH, 2006, BRAIN DEV-JPN, V28, P566, DOI 10.1016/j.braindev.2006.03.011; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; HAWKINS RA, 1979, SCIENCE, V205, P325, DOI 10.1126/science.451608; Hochman A, 1998, J NEUROCHEM, V71, P741; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keene DL, 2006, PEDIATR NEUROL, V35, P1, DOI 10.1016/j.pediatrneurol.2006.01.005; Kossoff EH, 2006, EPILEPSIA, V47, P421, DOI 10.1111/j.1528-1167.2006.00438.x; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Papandreou D, 2006, BRIT J NUTR, V95, P5, DOI 10.1079/BJN20051591; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Veech RL, 2001, IUBMB LIFE, V51, P241; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; White FA, 1998, J NEUROSCI, V18, P1428; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YANG J, 1997, SCIENCE, V275, P1132; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	48	46	46	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					459	465	PII 910861424	10.1080/02699050902788469			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700010	19408168				2022-02-06	
J	Struhkamp, R; Mol, A; Swierstra, T				Struhkamp, Rita; Mol, Annemarie; Swierstra, Tsjalling			Dealing with In/dependence Doctoring in Physical Rehabilitation Practice	SCIENCE TECHNOLOGY & HUMAN VALUES			English	Article						physical rehabilitation; clinical trials; independence; care; daily life	TRAUMATIC BRAIN-INJURY; THERAPY INTENSITY; CARE; SCIENCE; COORDINATION; TECHNOLOGY; DISABILITY	By now, the laboratory tradition, crafting transportable knowledge that allows for comparison, has been amply studied. However, other knowledge traditions, notably that of the clinic, deserve further articulation. The authors contribute to this by unraveling some specificities of rehabilitation practice. How do laboratory and clinical traditions in rehabilitation relate to independence? The first seeks to quantify people's independence; the latter attends to qualitatively different ways of being independent. While measuring independence is a matter of aggregating scores on a priori established dimensions, clinical rehabilitation concerns coordinating different ways of being independent. While independence scales map a linear development in time, rehabilitation participants juggle with time, including uncertain futures in their present. In clinical practice, then, independence is neither a single, coherent, fact nor a clear-cut, stable goal. Instead, professionals as well as patients work by creatively doctoring with the large variety of elements that are relevant to daily life with long-term disabilities.	[Struhkamp, Rita] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Res Policy, Rotterdam, Netherlands; [Swierstra, Tsjalling] Univ Twente, Dept Philosophy, Enschede, Netherlands		Struhkamp, R (corresponding author), Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Res Policy, Rotterdam, Netherlands.						Akrich M, 2000, THEOR MED BIOETH, V21, P63, DOI 10.1023/A:1009943017769; Barnes M. D., 2000, TXB REHABILITATION M; BERG M, 1998, DIFFERENCES MED PRAC; Bowker Geoffrey C, 1999, SORTING THINGS OUT C; Canguilhem George, 1989, NORMAL PATHOLOGICAL; CASPER MJ, 1995, SCI TECHNOL HUM VAL, V20, P395, DOI 10.1177/016224399502000401; Charmaz, 1991, GOOD DAYS BAD DAYS S; Chen CC, 2002, ARCH PHYS MED REHAB, V83, P1514, DOI 10.1053/apmr.2002.35107; CHRISTIANSEN CH, 1998, REHABILITATION MED P, P137; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; GRANGER CV, 1996, PHYSICAL MED REHABIL, P239; Haraway Donna, 1991, SIMIANS CYBORGS; Harbers H, 2002, THEOR CULT SOC, V19, P207, DOI 10.1177/026327602761899228; Healy D., 2002, CREATION PSYCHOPHARM; KEITH RA, 1993, IMPROVING ASSESSMENT IN REHABILITATION AND HEALTH, P33; KELLYHAYES M, 1996, REHABILITATION NURSI, P144; Lettinga A, 1999, THEOR MED BIOETH, V20, P517, DOI 10.1023/A:1009947524766; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Mahoney FI, 1995, MD STATE MED J, V14, P56; Marks Harry M., 1997, PROGR EXPT SCI THERA; Mol A, 2006, QUAL HEALTH RES, V16, P405, DOI 10.1177/1049732305285856; Mol A, 2006, LOGICA ZORGEN ACTIEV; Mol A., 2002, BODY MULTIPLE ONTOLO; Moreira T, 2006, SOC STUD SCI, V36, P69, DOI 10.1177/0306312705053051; MORETTO MB, 2004, NEUROCHEM RES, V10, P1; Moser I., 2000, SCI CULT-UK, V9, P201, DOI [DOI 10.1080/713695234, 10.1080/713695234]; Moser I, 2006, SCI TECHNOL HUM VAL, V31, P537, DOI 10.1177/0162243906289611; Moser I, 2003, DIGITAL MEDIA REVISITED: THEORETICAL AND CONCEPTUAL INNOVATIONS IN DIGITAL DOMAINS, P491; NELIS A, 2000, CONTESTED FUTURES SO, P209; Patti F, 2003, J NEUROL, V250, P861, DOI 10.1007/s00415-003-1097-x; Pols J, 2006, SCI TECHNOL HUM VAL, V31, P409, DOI 10.1177/0162243906287544; Rapp R, 1998, SCI TECHNOL HUM VAL, V23, P45, DOI 10.1177/016224399802300103; Schlich T, 2007, SCI TECHNOL HUM VAL, V32, P65, DOI 10.1177/0162243906293886; SINGLETON V, 1993, SOC STUD SCI, V23, P227, DOI 10.1177/030631293023002001; Struhkamp R, 2005, CULT STUD, V19, P701, DOI 10.1080/09502380500365655; Struhkamp R, 2004, HEALTH CARE ANAL, V12, P131, DOI 10.1023/B:HCAN.0000041187.93819.17; Sunder Rajan Kaushik, 2006, BIOCAPITAL CONSTITUT; Timmermans S, 2003, GOLD STANDARD CHALLE; van Dijk AJ, 2001, REHABILITATION MED T; Vos R, 2000, THEOR MED BIOETH, V21, P1, DOI 10.1023/A:1009903321229; WADE DT, 1997, NEUROLOGICAL REHABIL, P147; Williams PM, 2000, AM J OTOLARYNG, V21, P38, DOI 10.1016/S0196-0709(00)80122-2; Winance M, 2006, SCI TECHNOL HUM VAL, V31, P52, DOI 10.1177/0162243905280023; World Health Organization, 2007, INT CLASS FUNCT DIS	45	46	47	2	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0162-2439			SCI TECHNOL HUM VAL	Sci. Technol. Hum. Values	JAN	2009	34	1					55	76		10.1177/0162243907312954			22	Social Issues	Social Science Citation Index (SSCI)	Social Issues	383YD	WOS:000261709400004					2022-02-06	
J	Diestel, A; Roessler, J; Berger, F; Schmitt, KRL				Diestel, Antje; Roessler, Joerg; Berger, Felix; Schmitt, Katharina R. L.			Hypothermia downregulates inflammation but enhances IL-6 secretion by stimulated endothelial cells	CRYOBIOLOGY			English	Article						Hypothermia; Endothelial cells; IL-6; ERK 1/2; Bcl-2; I kappa B-alpha; Inflammation	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CARDIAC-ARREST; APOPTOSIS; KINASE; ACTIVATION; EXPRESSION	Hypothermia is a standard method for organ protection during cardiac surgery in children. However, the mechanisms of hypothermia-induced cell protection have not yet been clearly established. Therefore, the aim of our studies was to elucidate molecular effects of clinically relevant mild and deep hypothermia on endothelial cells. The endothelium plays a pivotal role in the interaction between blood cells and actively participates in complex inflammatory events. We isolated primary human umbilical vein endothelial cells (HUVEC) and investigated cell viability, proliferation and inflammatory characteristics after TNF-alpha stimulation under mild (32 degrees C) and deep (17 degrees C) hypothermia in comparison to normothermia (37 degrees C). As a protective mechanism of endothelial cells kept under hypothermic conditions we found a significant upregulation of the antiapoptotic protein Bcl-2, resulting in the same cell viability under hypothermic conditions. Unexpectedly we demonstrated significantly higher IL-6 release after 6 h of mild hypothermia. In contrast, hypothermia diminished inflammatory chemokines such as IL-8, MCP-1 and COX-2 protein expression which could lead to reduced leukocyte recruitment under hypothermia. Underlying mechanisms of this downregulation were found to be reduced ERK 1/2 phosphorylation and incomplete I kappa B-alpha degradation resulting in reduced NF kappa B-dependent proinflammatory gene expression. The upregulation of BcI-2 protein and the higher IL-6 release after 6 h of mild hypothermia are new and interesting cellular mechanisms of hypothermia in endothelial cell biology. Both factors may play a major role as cell protective mechanisms in hypothermia. (C) 2008 Elsevier Inc. All rights reserved.	[Roessler, Joerg; Berger, Felix; Schmitt, Katharina R. L.] Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Paediat Cardiol, D-13353 Berlin, Germany; [Diestel, Antje; Berger, Felix] Charite, Dept Pediat Cardiol, D-13353 Berlin, Germany		Schmitt, KRL (corresponding author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Paediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	katharina.schmitt@charite.de		Berger, Felix/0000-0001-7881-1557	Fordergemeinschaft Deutsche Kinderherzzentren Bonn, Germany	Statement of funding: The is supported by Fordergemeinschaft Deutsche Kinderherzzentren Bonn, Germany.	[Anonymous], 2002, N ENGL J MED, V346, P549; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Cines DB, 1998, BLOOD, V91, P3527; Dinarello CA, 1996, INFECT DIS CLIN N AM, V10, P433, DOI 10.1016/S0891-5520(05)70306-8; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Fairchild KD, 2005, AM J PHYSIOL-CELL PH, V289, pC1114, DOI 10.1152/ajpcell.00152.2005; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; HANSEN TN, 1994, CRYOBIOLOGY, V31, P101, DOI 10.1006/cryo.1994.1013; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Jonas Richard A, 2002, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V5, P76, DOI 10.1053/pcsu.2002.31493; Kawaguchi AT, 1998, CIRCULATION, V98, pII385; Lee HS, 2002, NEUROSCI LETT, V329, P53, DOI 10.1016/S0304-3940(02)00591-8; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MENASCHE P, 1995, CIRCULATION, V92, P334, DOI 10.1161/01.CIR.92.9.334; Murphy AN, 1999, ANN NY ACAD SCI, V893, P19, DOI 10.1111/j.1749-6632.1999.tb07815.x; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nyhlen K, 2000, CYTOKINE, V12, P355, DOI 10.1006/cyto.1999.0557; Olsen TS, 2003, LANCET NEUROL, V2, P410, DOI 10.1016/S1474-4422(03)00436-8; Rasband W.S, 1997, IMAGEJ US; Roberts JR, 2002, CRYOBIOLOGY, V44, P161, DOI 10.1016/S0011-2240(02)00018-4; Sahuquillo J, 2004, CURR PHARM DESIGN, V10, P2193, DOI 10.2174/1381612043384051; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schmitt KRL, 2007, NEUROSCI RES, V59, P68, DOI 10.1016/j.neures.2007.05.011; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Teague TK, 1997, J IMMUNOL, V158, P5791; TILG H, 1994, BLOOD, V83, P113; Waxman AB, 2003, AM J RESP CELL MOL, V29, P513, DOI 10.1165/rcmb.2002-0044OC; Yumoto H, 2007, ORAL MICROBIOL IMMUN, V22, P36, DOI 10.1111/j.1399-302X.2007.00320.x; Zhu LP, 2001, J MOL CELL CARDIOL, V33, P2135, DOI 10.1006/jmcc.2001.1476	36	46	46	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0011-2240			CRYOBIOLOGY	Cryobiology	DEC	2008	57	3					216	222		10.1016/j.cryobiol.2008.08.005			7	Biology; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics; Physiology	383HU	WOS:000261665500005	18790695				2022-02-06	
J	Ashki, N; Hayes, KC; Bao, F				Ashki, N.; Hayes, K. C.; Bao, F.			The peroxynitrite donor 3-morpholinosydnonimine induces reversible changes in electrophysiological properties of neurons of the guinea-pig spinal cord	NEUROSCIENCE			English	Article						spinal cord injury; neurotrauma; axons; conduction; immuno-fluorescence; nitric oxide	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; CNS WHITE-MATTER; LIPID-PEROXIDATION; AXONAL CONDUCTION; URIC-ACID; MULTIPLE-SCLEROSIS; COMPRESSION INJURY; TYROSINE NITRATION	Elevated concentrations of nitric oxide (NO) and peroxynitrite (ONOO-) are present within the CNS following neurotrauma and are implicated in the pathogenesis of the accompanying neurologic deficits. We tested the hypothesis that elevated extracellular concentrations of ONOO-, introduced by the donor 3-morpholinosydnonimine (SIN-1), induce reversible axonal conduction deficits in neurons of the guinea-pig spinal cord. The compound action potential (CAP) and compound membrane potential (CMP) of excised ventral cord white matter were recorded before, during, and after, bathing the tissue (30 min) in varying concentrations (0.125-2.0 mM) of SIN-1 ( 3.75-60 mu M ONOO-). The principal results were rapid onset, concentration-dependent, reductions in amplitude of the CAP (P<0.05). At a concentration of 0.25 mM of SIN-1 the reduction in CAP amplitude was fully reversible and was not accompanied by any changes in CMP. At higher concentrations of SIN-1 (>= 0.5 mM) the reversibility was incomplete and there was concurrent depolarization of the CMP. These electrophysiological changes were not evident when the donor had been a priori depleted of ONOO- by uric acid or was co-administered with the ONOO- scavenger ebselen (3 mM). Immuno-fluorescence staining for nitrotyrosine (Ntyr) revealed extensive nitration of tyrosine residues in neurons exposed to higher concentrations of SIN-1. These results are the first to demonstrate that ONOO- induces reversible conduction deficits within axons of the spinal cord. The dissociation of CAP and CMP changes at low concentrations of SIN-1, when the CAP changes were reversible and there was no evidence of nitration of tyrosine residues, is consistent with ONOO--induced alteration in Na+ channel conductance in the axolemma. The results support the view that ONOO- contributes to both reversible and non-reversible neurologic deficits following neurotrauma. The reversal of immune-mediated conduction deficits may contribute to spontaneous neurologic deficits following neurotrauma. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Hayes, K. C.] Lawson Hlth Res Inst, London, ON N6C 5J1, Canada; [Ashki, N.; Hayes, K. C.] Univ Western Ontario, Neurosci Program, London, ON, Canada; [Bao, F.] Robarts Res Inst, BioTherapeut Res Grp, London, ON N6A 5C1, Canada		Hayes, KC (corresponding author), Lawson Hlth Res Inst, 801 Commissioners Rd E, London, ON N6C 5J1, Canada.	kchayes@uwo.ca			Rick Hansen Foundation	The authors are grateful to Dr. L. Weaver (Robarts Research Institute) for providing helpful advice and resources for the immuno-fluorescence studies. This work was supported by a grant from the Rick Hansen Foundation.	Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Alvarez MN, 2004, ARCH BIOCHEM BIOPHYS, V432, P222, DOI 10.1016/j.abb.2004.09.015; Ashki N, 2006, J NEUROTRAUM, V23, P1779, DOI 10.1089/neu.2006.23.1779; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Chang HT, 2007, SPINAL CORD, V45, P174, DOI 10.1038/sj.sc.3101910; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Garthwaite G, 2002, NEUROSCIENCE, V109, P145, DOI 10.1016/S0306-4522(01)00447-X; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Genovese T, 2007, FREE RADICAL BIO MED, V43, P763, DOI 10.1016/j.freeradbiomed.2007.05.012; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hosaka N, 2008, EUR SPINE J, V17, P281, DOI 10.1007/s00586-007-0477-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jiang J, 2007, EUR J PHARMACOL, V561, P54, DOI 10.1016/j.ejphar.2006.12.028; Kaegi S, 2002, EUR J NEUROSCI, V16, P249, DOI 10.1046/j.1460-9568.2002.02076.x; Kapoor R, 1999, ANN NY ACAD SCI, V893, P304, DOI 10.1111/j.1749-6632.1999.tb07843.x; KITA Y, 1994, EUR J PHARMACOL, V257, P123, DOI 10.1016/0014-2999(94)90703-X; Kuzkaya N, 2005, BIOCHEM PHARMACOL, V70, P343, DOI 10.1016/j.bcp.2005.05.009; Li MH, 2006, FREE RADICAL BIO MED, V41, P1079, DOI 10.1016/j.freeradbiomed.2006.06.010; Li Z, 1998, NEURON, V20, P1039, DOI 10.1016/S0896-6273(00)80484-5; Linares E, 2001, FREE RADICAL BIO MED, V30, P1234, DOI 10.1016/S0891-5849(01)00516-0; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu P, 2000, AM J PHYSIOL-CELL PH, V279, pC1970, DOI 10.1152/ajpcell.2000.279.6.C1970; Liu XZ, 1997, J NEUROSCI, V17, P5395; Martin-Romero FJ, 2004, J FLUORESC, V14, P17, DOI 10.1023/B:JOFL.0000014655.89256.bd; Meij JTA, 2004, MOL PHARMACOL, V66, P1043, DOI 10.1124/mol.104.001354; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mohiuddin I, 2006, J SURG RES, V133, P143, DOI 10.1016/j.jss.2005.10.008; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Pannu R, 2006, NEUROCHEM INT, V49, P170, DOI 10.1016/j.neuint.2006.04.010; Peluffo RD, 2004, BIOPHYS J, V87, P883, DOI 10.1529/biophysj.103.030643; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Renganathan M, 2002, J NEUROPHYSIOL, V87, P761, DOI 10.1152/jn.00369.2001; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572, DOI 10.1152/jn.1996.76.3.1572; Shrager P, 1998, J NEUROPHYSIOL, V79, P529, DOI 10.1152/jn.1998.79.2.529; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; STYS PK, 1992, J NEUROSCI, V12, P430; Stys PK, 1998, NEUROSCIENCE, V82, P21; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Weaver LC, 2001, J NEUROTRAUM, V18, P1107, DOI 10.1089/08977150152693782; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xu JH, 2006, NEUROSCI LETT, V399, P210, DOI 10.1016/j.neulet.2006.02.024; Xu LY, 2001, J IMMUNOL, V166, P5810, DOI 10.4049/jimmunol.166.9.5810	59	46	46	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	SEP 22	2008	156	1					107	117		10.1016/j.neuroscience.2008.06.050			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	352BE	WOS:000259469300011	18662749				2022-02-06	
J	Xiong, Y; Mahmood, A; Lu, DY; Qu, CS; Kazmi, H; Goussev, A; Zhang, ZG; Noguchi, CT; Schallerte, T; Chopp, M				Xiong, Ye; Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Kazmi, Humaira; Goussev, Anton; Zhang, Zheng Gang; Noguchi, Constance T.; Schallerte, Timothy; Chopp, Michael			Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system	BRAIN RESEARCH			English	Article						cell proliferation; erythropoietin receptor null; mouse; sensorimotor; spatial learning; traumatic brain injury	CONTROLLED CORTICAL IMPACT; RECOMBINANT-HUMAN-ERYTHROPOIETIN; NEURAL STEM-CELLS; SUBVENTRICULAR ZONE; SPATIAL MEMORY; POSTTRAUMATIC NEURODEGENERATION; ENHANCES NEUROGENESIS; CALCIUM PRECIPITATION; ADULT NEUROGENESIS; CEREBRAL-CORTEX	Erythropoietin (EPO) and its receptor (EPOR), essential for erythropoiesis, are expressed in the nervous system. Recombinant human EPO treatment promotes functional outcome after traumatic brain injury (TBI) and stroke, suggesting that the endogenous EPO/EPOR system plays an important role in neuroprotection and neurorestoration. This study was designed to investigate effects of the EPOR on histological and functional outcomes after TBI. Experimental TBI was induced in adult EPOR-null and wild-type mice by controlled cortical impact. Neurological function was assessed using the modified Morris Water Maze and footfault tests. Animals were sacrificed 35 days after injury and brain sections stained for immunohistochemistry. As compared to the wild-type injured mice, EPOR-null mice did not exhibit higher susceptibility to TBI as exemplified by tissue loss in the cortex, cell loss in the dentate gyrus, impaired spatial learning, angiogenesis and cell proliferation. We observed that less cortical neurogenesis occurred and that sensorimotor function (i.e., footfault) was more impaired in the EPOR-null mice after TBI. Co-accumulation of amyloid precursor protein (axonal injury marker) and calcium was observed in the ipsilateral thalamus in both EPOR-null and wild-type mice after TBI with more calcium deposits present in the wild-type mice. This study demonstrates for the first time that EPOR null in the nervous system aggravates sensorimotor deficits, impairs cortical neurogenesis and reduces thalamic calcium precipitation after TBI. (C) 2008 Elsevier B.V. All rights reserved.	[Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Xiong, Ye; Mahmood, Asim; Qu, Changsheng; Kazmi, Humaira; Goussev, Anton] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Lu, Dunyue] Suny Downstate Med Ctr, Dept Psychiat, Brooklyn, NY 11203 USA; [Noguchi, Constance T.] NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA; [Schallerte, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallerte, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Chopp, M (corresponding author), Henry Ford Hlth Syst, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS52280, P01 NS4234S]; NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [ZIADK025061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS052280] Funding Source: NIH RePORTER	This work was supported by NINDS grants R01 NS52280, P01 NS4234S and NIDDK Intramural Research.	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Jin G, 2003, NEUROL RES, V25, P249, DOI 10.1179/016164103101201454; KATO H, 1995, BRAIN RES BULL, V38, P25, DOI 10.1016/0361-9230(95)00067-O; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Keogh CL, 2007, J PHARMACOL EXP THER, V322, P521, DOI 10.1124/jpet.107.121392; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Mogensen J, 2008, BEHAV BRAIN RES, V186, P215, DOI 10.1016/j.bbr.2007.08.009; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Ramonet D, 2006, J NEUROSCI RES, V83, P147, DOI 10.1002/jnr.20711; Ramonet D, 2002, J PHYSIOLOGY-PARIS, V96, P307, DOI 10.1016/S0928-4257(02)00020-7; Rodriguez MJ, 2000, INT J DEV NEUROSCI, V18, P299, DOI 10.1016/S0736-5748(99)00098-2; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	53	46	50	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 16	2008	1230						247	257		10.1016/j.brainres.2008.06.127			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	359BW	WOS:000259962200026	18657521	Green Accepted			2022-02-06	
J	Bottai, D; Madaschi, L; Di Giulio, AM; Gorio, A				Bottai, Daniele; Madaschi, Laura; Di Giulio, Anna M.; Gorio, Alfredo			Viability-dependent promoting action of adult neural precursors in spinal cord injury	MOLECULAR MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS SURVIVE; CORTICOSPINAL NEURONS; MULTIPLE-SCLEROSIS; MOTOR FUNCTION; IN-VIVO; KAPPA-B; RECOVERY; DIFFERENTIATE; MICE	The aim of the study was the assessment of the effects of adult neural stem cell (INSC) transplantation in a mouse model of spinal cord injury (SCI). The contusion injury was performed by means of the Infinite Horizon Device to allow the generation of reproducible traumatic lesion to the cord. We administered green fluorescent-labeled (GFP-)NSCs either by intravenous (i.v) injection or by direct transplantation into the spinal cord (intraspinal route). We report that NSCs significantly improved recovery of hind limb function and greatly attenuated secondary degeneration. The i.v. route of NSC administration yielded better recovery than the intraspinal route of administration. About 2% of total i.v.-administered NSCs homed to the spinal cord injury site, and survived almost undifferentiated; thus the positive effect of NSC treatment cannot be ascribed to damaged tissue substitution. The NSCs homing to the injury site triggered, within 48 h, a large increase of the expression of neurotrophic factors and chemokines. One wk after transplantation, exogenous GFP-NSCs still retained their proliferation potential and produced neurospheres when recovered from the lesion site and cultured in vitro. At a later time, GFP-NSC were phagocytated by macrophages. We suggest that the process of triggering the recovery of function might be strongly related to the viability of GFP-NSC, still capable ex vivo of producing neurospheres, and their ability to modify the lesion environment in a positive fashion.	[Bottai, Daniele; Madaschi, Laura; Di Giulio, Anna M.; Gorio, Alfredo] Univ Milan, Fac Med, Dept Med Surg & Dent, I-20142 Milan, Italy; [Bottai, Daniele; Gorio, Alfredo] IRCCS Humanitas, Milan, Italy		Gorio, A (corresponding author), Univ Milan, Fac Med, Dept Med Surg & Dent, Via A di Rudini 8, I-20142 Milan, Italy.	alfredo.gorio@unimi.it	Bottai, Daniele/O-2586-2017	Bottai, Daniele/0000-0002-7951-9512; Di Giulio, Anna Maria/0000-0002-5702-4623	The Italian Ministry of Education; Montecatone Foundation, Imola (It)	We acknowledge the continuous support by Drs Guglielmo Brayda, Fabio Colbucci, Mauro Menarini, Roberto Piperno, Maria Taricco, Giulio Cicognani, of the Scientific Advisory Board of the Fondazione Montecatone. We would like to thank Raffaella Adami for the confocal images.; The project was supported by a grant from The Italian Ministry of Education in 2003 and in 2005, and by a generous donation from the Montecatone Foundation, Imola (It) to Alfredo Gorio.	Akerud P, 2002, MOL CELL NEUROSCI, V21, P205, DOI 10.1006/mvne.2002.1171; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gorio A, 2004, NEUROSCIENCE, V125, P179, DOI 10.1016/j.neuroscience.2003.10.046; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Gorio A, 2007, J PHARMACOL EXP THER, V322, P973, DOI 10.1124/jpet.107.123679; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hoffman RM, 2006, CELL CYCLE, V5, P232, DOI 10.4161/cc.5.3.2397; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Huang CJ, 2002, INT J DEV NEUROSCI, V20, P289, DOI 10.1016/S0736-5748(02)00022-9; Kim SS, 2005, J BIOMED MATER RES B, V75B, P369, DOI 10.1002/jbm.b.30302; Liker MA, 2003, BRAIN RES, V971, P168, DOI 10.1016/S0006-8993(03)02337-0; Lu P, 2001, J COMP NEUROL, V436, P456, DOI 10.1002/cne.1080; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Pluchino S, 2004, CURR OPIN NEUROL, V17, P247, DOI 10.1097/00019052-200406000-00003; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reier Paul J, 2004, NeuroRx, V1, P424, DOI 10.1602/neurorx.1.4.424; Rieske P, 2007, EUR J NEUROSCI, V25, P31, DOI 10.1111/j.1460-9568.2006.05254.x; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Romanko MJ, 2004, J CEREBR BLOOD F MET, V24, P814, DOI 10.1097/01.WCB.0000123906.17746.00; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Sayer FT, 2002, EXP NEUROL, V175, P282, DOI 10.1006/exnr.2002.7901; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schultz SS, 2006, J NEUROSCI METH, V152, P144, DOI 10.1016/j.jneumeth.2005.08.022; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759	41	46	48	0	5	FEINSTEIN INST MED RES	MANHASSET	350 COMMUNITY DR, MANHASSET, NY 11030 USA	1076-1551			MOL MED	Mol. Med.	SEP-OCT	2008	14	9-10					634	644		10.2119/2008-00077.Bottai			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	352YJ	WOS:000259533000013	18654659	Green Published, gold			2022-02-06	
J	Ityas, C; Beyer, GM; Dutton, RP; Scatea, TM; Hess, JR				Ityas, Can; Beyer, Ginine M.; Dutton, Richard P.; Scatea, Thomas M.; Hess, John R.			Recombinant factor VIIa for warfarin-associated intracranial bleeding	JOURNAL OF CLINICAL ANESTHESIA			English	Article						factor VIIa; traumatic brain injury; elderly; international normalization ratio; prothrombin time; trauma	CENTRAL-NERVOUS-SYSTEM; ACTIVATED FACTOR-VII; FRESH-FROZEN PLASMA; INTRACEREBRAL HEMORRHAGE; VITAMIN-K; PREINJURY WARFARIN; COMPLICATIONS; TRAUMA; ANTICOAGULATION; PROGRESSION	Study objective: To examine the efficacy of recombinant factor VIIa (rVIIa) in reversing warfarin-induced coagulopathy in trauma patients presenting with intracranial hemorrhage (ICH). Design: Retrospective, cohort-controlled database review. Setting: Level 1, university-affiliated trauma center. Patients: 54 patients presenting with ICH associated with chronic warfarin therapy, 30 of whom were treated with rVIIa, and the other 24 patients treated conventionally. Measurements: We examined initial and subsequent coagulation studies (prothrombin time, international normalized ratio [INR]), blood product requirement, and clinical outcome, including time to reverse anticoagulation, duration of reversal, and subsequent mortality. Main results: Patients treated with rVIIa required significantly less plasma (4 vs 7 units) to correct their INR, and corrected in a much shorter period of time (2.4 vs 10 hrs). The duration of corrected INR after rVIIa was dose-dependent. Conclusions: Factor rVIIa provides prompt correction of the INR of dose-dependent duration in patients with ICH intracranial hemorrhage associated with warfarin use. (C) 2008 Elsevier Inc. All rights reserved.	[Ityas, Can; Hess, John R.] Univ Maryland, Med Ctr, Blood Bank, Sch Med,Dept Med, Baltimore, MD 21201 USA; [Beyer, Ginine M.; Hess, John R.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Dutton, Richard P.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Scatea, Thomas M.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA		Hess, JR (corresponding author), Univ Maryland, Med Ctr, Blood Bank, Sch Med,Dept Med, NW50A, Baltimore, MD 21201 USA.	jhess@umm.edu	Hess, John R./K-4001-2013	Hess, John R./0000-0001-8596-4420			Ansell J, 2004, CHEST, V126, p204S, DOI 10.1378/chest.126.3_suppl.204S; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; CAIRD E, 2006, IRAN MED J, V99, P206; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Flaherty ML, 2007, NEUROLOGY, V68, P116, DOI 10.1212/01.wnl.0000250340.05202.8b; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Goldstein JN, 2006, STROKE, V37, P151, DOI 10.1161/01.STR.0000195047.21562.23; Huttner HB, 2006, STROKE, V37, P1465, DOI 10.1161/01.STR.0000221786.81354.d6; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Kucher N, 2004, AM J CARDIOL, V94, P403, DOI 10.1016/j.amjcard.2004.04.050; Lee SB, 2006, NEUROLOGY, V67, P1272, DOI 10.1212/01.wnl.0000238104.75563.2f; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Nicolini A, 2002, HAEMATOLOGICA, V87, P948; Punthakee X, 2002, THROMB RES, V108, P31, DOI 10.1016/S0049-3848(02)00398-5; Sam C, 2004, AM J CARDIOL, V94, P947, DOI 10.1016/j.amjcard.2004.06.038; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Veshchev Igor, 2002, Med Sci Monit, V8, pCS98; Yasaka M, 2002, THROMB RES, V108, P25, DOI 10.1016/S0049-3848(02)00402-4	22	46	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2008	20	4					276	279		10.1016/j.jclinane.2007.12.012			4	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	331LM	WOS:000258013700007	18617125				2022-02-06	
J	Kang, YJ; Ku, J; Han, K; Kim, SI; Yu, TW; Lee, JH; Park, CI				Kang, Youn Joo; Ku, Jeonghun; Han, Kiwan; Kim, Sun I.; Yu, Tae Won; Lee, Jang Han; Park, Chang Il			Development and clinical trial of virtual reality-based cognitive assessment in people with stroke: Preliminary study	CYBERPSYCHOLOGY & BEHAVIOR			English	Article							BRAIN-INJURY; REHABILITATION; ENVIRONMENTS; TECHNOLOGY; TELEREHABILITATION; PERFORMANCE; IMPAIRMENTS; ATTENTION; EXPOSURE; SYSTEM	Stroke and traumatic brain injury affect an increasing number of people, many of whom retain permanent damage in cognitive functions. Conventionally, cognitive function has been assessed by a paper-based neuropsychological evaluation. However these test environments differ substantially from everyday life. This problem can be overcome by using virtual reality (VR) to objectively evaluate behaviors and cognitive function in simulated daily activities. With our virtual shopping simulation, we compared people who had undergone a stroke with control participants in an immersive VR program that used a head-mounted display (HMD). We evaluated user satisfaction with the tests, complications, and the user interface. Significant differences were consistently found between the stroke group and the control group for the following tasks: stage 1 performance index, interaction error; stage 2 delayed recognition memory score, attention index; and stage 3 executive index (p < 0.001). Perceptive dysfunction, visuospatial dysfunction, level of computer experience, and level of education affected the performance of the stroke group. The frequency of complications in the stroke group, calculated using the cut-off score for the Simulator Sickness Questionnaire, was 9.6% for nausea, 41.9% for oculomotor complications, and 25.8% for disorientation. The frequency of complications between the stroke and control groups was not significantly different. Thirtyfive percent of participants in the stroke group and 13% in the control group reported difficulties with using the joystick. This computer-generated VR-based cognitive test shows promise in assessing cognitive function in patients with stroke. More refinements are needed in the user interface and the projection methods.	[Ku, Jeonghun] Hanyang Univ, Dept Biomed Engn, Neuromech Virtual Environm Lab, Seoul 133605, South Korea; [Kang, Youn Joo] Myongi Hosp, Dept Phys Med & Rehabil, Seoul, South Korea; [Yu, Tae Won] Sol Hosp, Med & Rehabil Ctr, Seoul, South Korea; [Lee, Jang Han] Chung Ang Univ, Dept Psychol, Seoul 156756, South Korea; [Park, Chang Il] Yonsei Univ, Coll Med, Dept Phys Med & Rehabil, Seoul 120749, South Korea		Ku, J (corresponding author), Hanyang Univ, Dept Biomed Engn, Neuromech Virtual Environm Lab, POB 55, Seoul 133605, South Korea.	kujh@bme.hanyang.ac.kr		Kang, Youn Joo/0000-0002-9938-5435			Burdea G, 2000, IEEE T REHABIL ENG, V8, P430, DOI 10.1109/86.867886; Calarusso RP, 1972, MOTOR FREE VISUAL PE; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Cunningham D, 1999, ST HEAL T, V62, P90; Cutmore TRH, 2000, INT J HUM-COMPUT ST, V53, P223, DOI 10.1006/ijhc.2000.0389; Davies R. C., 1999, International Journal of Virtual Reality, V4, P3; Di Girolamo S, 2001, ACTA OTO-LARYNGOL, V121, P211; Dizio P, 1992, PRESENCE-TELEOP VIRT, V1, P319; Girone M, 2000, Stud Health Technol Inform, V70, P89; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hettinger L. J., 1992, PRESENCE, V1, P306; Kennedy RS, 1993, INT J AVIAT PSYCHOL, V3, P203, DOI [10.1207/s15327108ijap0303_3, DOI 10.1207/S15327108IJAP0303_3]; Kesztyues TI, 2000, CYBERPSYCHOL BEHAV, V3, P343, DOI 10.1089/10949310050078788; Kim, 2001, KIMS FRONTAL EXECUTI; KIM HK, 1999, MEMORY TEST; KIM HK, 2001, P ANN M KOR PSYCH AS, P670; Kim Y.H., 2001, J KOREAN ACAD REHABI, V25, P209; Lee JH, 2003, CYBERPSYCHOL BEHAV, V6, P383, DOI 10.1089/109493103322278763; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Pugnetti L., 1998, CYBERPSYCHOLOGY BEHA, V1, P151, DOI DOI 10.1089/CPB.1998.1.151; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Riva G, 1999, Cyberpsychol Behav, V2, P577, DOI 10.1089/cpb.1999.2.577; Rizzo A, 1998, CYBERPSYCHOLOGY BEHA, V1, P59, DOI DOI 10.1089/CPB.1998.1.59; Rizzo AA, 1997, ST HEAL T, V44, P123; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rose FD, 1999, DISABIL REHABIL, V21, P548; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; Seymour NE, 2002, ANN SURG, V236, P458, DOI 10.1097/00000658-200210000-00008; Trepagnier CG, 1999, NEUROREHABILITATION, V12, P63; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	34	46	48	2	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	JUN	2008	11	3					329	339		10.1089/cpb.2007.0116			11	Communication; Psychology, Applied	Social Science Citation Index (SSCI)	Communication; Psychology	321PV	WOS:000257319900011	18537503				2022-02-06	
J	McLeod, TCV; Bay, RC; Heil, J; McVeigh, SD				Valovich McLeod, Tamara C.; Bay, R. Curtis; Heil, John; McVeigh, Scott D.			Identification of sport and recreational activity concussion history through the preparticipation screening and a symptom survey in young athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild brain injury; preparticipation examination; children; adolescent	COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; NCAA CONCUSSION; SCHOOL; PREVENTION; YOUTH	Objective: To evaluate the concussion history of young athletes using three questions on the preparticipation screening (PPS) and a concussion symptom survey (CSS). Design: Descriptive survey. Setting: Mass high school PPS. Patients or Other Participants: Five hundred twenty young athletes. Interventions: Athletes were asked about their concussion history using three different questions on the PPS. The CSS, a list of concussion-related symptoms, was also given to assess the history of concussion-related symptoms associated with a previous injury to the head. Main Outcome Measures: Positive concussion history was determined as a positive response on one of the three PPS questions or any one of the CSS responses and reported as frequencies and percentages. Kappa coefficients were used to evaluate the agreement between the responses on the three PPS questions. Results: There was little agreement among the three PPS questions, with kappa coefficients ranging from K = -0.018 to 0.342. Analysis of the CSS revealed that 286 athletes (55.0%) reported having at least one concussion symptom after a head injury. Of those reporting symptoms, 86.4% did not report a concussion history in sport, and 92.7% did not report a concussion history in recreational activities. Conclusions: The identification of concussion history may depend on the phrasing of questions on the PPS. Simply asking an athlete whether they had a concussion may not adequately identify athletes with concussion histories. Although recommendations have been made to avoid the terminology of ding and bell rung, it seems these terms may be needed to ensure adequate reporting of previous concussions in young athletes.	[Valovich McLeod, Tamara C.] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ 85206 USA; [Bay, R. Curtis] AT Still Univ, Arizona Sch Hlth Sci, Dept Interdisciplinary Hlth Sci, Mesa, AZ 85206 USA; [McVeigh, Scott D.] DGR Management Inc, Wyomissing, PA USA		McLeod, TCV (corresponding author), AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmelcod@atsu.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Bay, Ralph/0000-0003-3525-9269			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; KOESTER MC, 2003, CONT PEDIAT, V20, P85; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory Paul, 2005, Clin J Sport Med, V15, P48; *PREP PHYS EV WORK, 2005, PREP PHYS EV; RISSER WL, 1985, TEX MED, V81, P35; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	20	46	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2008	18	3					235	240		10.1097/JSM.0b013e3181705756			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	298SG	WOS:000255706800003	18469564				2022-02-06	
J	Kox, M; Pompe, JC; Pickkers, P; Hoedemaekers, CW; van Vugt, AB; van der Hoeven, JG				Kox, M.; Pompe, J. C.; Pickkers, P.; Hoedemaekers, C. W.; van Vugt, A. B.; van der Hoeven, J. G.			Increased vagal tone accounts for the observed immune paralysis in patients with traumatic brain injury	NEUROLOGY			English	Article							HEART-RATE-VARIABILITY; CHOLINERGIC ANTIINFLAMMATORY PATHWAY; VAGUS NERVE-STIMULATION; T-CELL FUNCTION; POWER SPECTRUM; ENDOTOXEMIA; SYSTEM; SUPPRESSION; IMPAIRMENT; ACTIVATION	Traumatic brain injury (TBI) is a leading cause of death and disability, especially in the younger population. In the acute phase after TBI, patients are more vulnerable to infection, associated with a decreased immune response in vitro. The cause of this immune paralysis is poorly understood. Apart from other neurologic dysfunction, TBI also results in an increase in vagal activity. Recently, the vagus nerve has been demonstrated to exert an anti-inflammatory effect, termed the cholinergic anti-inflammatory pathway. The anti-inflammatory effects of the vagus nerve are mediated by the alpha 7 nicotinic acetylcholine receptor present on macrophages and other cytokine-producing cells. From these observations, we hypothesize that the immune paralysis observed in patients with TBI may, at least in part, result from augmented vagal activity and subsequent sustained effects of the cholinergic anti-inflammatory pathway. This pathway may counteract systemic proinflammation caused by the release of endogenous compounds termed alarmins as a result of tissue trauma. However, sustained activity of this pathway may severely impair the body's ability to combat infection. Since the cholinergic anti-inflammatory pathway can be pharmacologically modulated in humans, it could represent a novel approach to prevent infections in patients with TBI.	[Kox, M.; Pompe, J. C.; Pickkers, P.; Hoedemaekers, C. W.; van der Hoeven, J. G.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Intens Care Med, NL-6500 HB Nijmegen, Netherlands; [Pompe, J. C.; van Vugt, A. B.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Surg, Sect Traumotol, NL-6500 HB Nijmegen, Netherlands		Pickkers, P (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Intens Care Med, Geert Grooteplein 10, NL-6500 HB Nijmegen, Netherlands.	p.pickkers@ic.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015; van der Hoeven, J.G./H-8048-2014; Kox, Matthijs/L-4454-2015; Pickkers, P./H-8080-2014	Pickkers, P./0000-0002-1104-4303			Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Borovikova LV, 2000, AUTON NEUROSCI-BASIC, V85, P141, DOI 10.1016/S1566-0702(00)00233-2; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Cooke WH, 2006, J TRAUMA, V60, P363, DOI 10.1097/01.ta.0000196623.48952.0e; Corcoran C, 2005, NEUROIMMUNOMODULAT, V12, P307, DOI 10.1159/000087109; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; Dempsey PW, 2003, CELL MOL LIFE SCI, V60, P2604, DOI 10.1007/s00018-003-3180-y; Freeman JV, 2006, PROG CARDIOVASC DIS, V48, P342, DOI 10.1016/j.pcad.2005.11.003; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Godin PJ, 1996, CRIT CARE MED, V24, P1117, DOI 10.1097/00003246-199607000-00009; Guyenet PG, 2006, NAT REV NEUROSCI, V7, P335, DOI 10.1038/nrn1902; Hamano R, 2006, SHOCK, V26, P358, DOI 10.1097/01.shk.0000228168.86845.60; HAUSER CJ, 1995, ARCH SURG-CHICAGO, V130, P1186; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; KAMATH MV, 1992, PACE, V15, P235, DOI 10.1111/j.1540-8159.1992.tb03067.x; Kawahara E, 2003, CIRC J, V67, P753; Keel M, 1996, J TRAUMA, V41, P430, DOI 10.1097/00005373-199609000-00008; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kessler W, 2006, LANGENBECK ARCH SURG, V391, P83, DOI 10.1007/s00423-006-0031-y; King ML, 1997, BRAIN INJURY, V11, P445; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; MATSUURA S, 1984, BRAIN RES, V305, P291, DOI 10.1016/0006-8993(84)90435-9; MILLER C H, 1991, Neurological Research, V13, P117; MONTANO N, 1994, CIRCULATION, V90, P1826, DOI 10.1161/01.CIR.90.4.1826; O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402; Ori Z, 1992, Cardiol Clin, V10, P499; Pavlov VA, 2006, BIOCHEM SOC T, V34, P1037, DOI 10.1042/BST0341037; Pavlov VA, 2005, BRAIN BEHAV IMMUN, V19, P493, DOI 10.1016/j.bbi.2005.03.015; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMOLDI O, 1990, AM J PHYSIOL, V258, pH967, DOI 10.1152/ajpheart.1990.258.4.H967; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Van Westerloo DJ, 2006, J THROMB HAEMOST, V4, P1997, DOI 10.1111/j.1538-7836.2006.02112.x; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Voldby B, 1988, Acta Neurochir Suppl (Wien), V45, P1; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Winchell RJ, 1996, J SURG RES, V63, P11, DOI 10.1006/jsre.1996.0214; Zedler S, 2006, CURR OPIN CRIT CARE, V12, P595, DOI 10.1097/MCC.0b013e3280106806	59	46	49	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 5	2008	70	6					480	485		10.1212/01.wnl.0000279479.69502.3e			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	258TS	WOS:000252893000011	18250293	Green Published			2022-02-06	
J	Bay, E; Donders, J				Bay, Esther; Donders, Jacobus			Risk factors for depressive symptoms after mild-to-moderate traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; stress; depressive symptoms; allostatic load; pain	POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; HEAD-INJURY; MAJOR DEPRESSION; POSTCONCUSSIVE SYMPTOMS; CORTISOL RESPONSES; CHRONIC PAIN; MANAGEMENT; DISABILITY; ADULTS	Primary objective: To determine the extent to which pre-injury psychosocial factors, injury-related variables and post-injury litigation, perceived stress, fatigue, pain and information processing speed contributed to depressive symptoms after traumatic brain injury (TBI). Research design: Cross-sectional outpatient follow-up at 1-36 months post-injury. Methods and procedures: Eighty-four adults recruited from outpatient clinics completed measures of depressive symptoms, measured with the Neurobehavioural Functioning Inventory, chronic stress and other symptoms. Hierarchial linear regression analysis was used to identify statistically significant covariates. Logistic regression analysis determined classification accuracy of these variables with regard to the presence or absence of borderline depression levels. Main outcomes: Perceived stress, pain and litigation status made independent contributions to the level of depressive symptoms, with perceived stress explaining the bulk of the variance and mediating the effect of milder injury severity. These variables had a classification accuracy of 77% with regard to post-injury depressive symptoms, with a sensitivity of 84% and a specificity of 69%. Conclusions: Perceived stress, one indicator of allostatic load, explains a considerable amount of the variance in depressive symptoms after mild-moderate TBI. The findings suggest a need for earlier identification of, as well as preventative education with, those who are stress-vulnerable.	[Bay, Esther] Michigan State Univ, E Lansing, MI 48824 USA; [Donders, Jacobus] Mary Fee Bed Rehabil Hosp, Grand Rapids, MI USA		Bay, E (corresponding author), Ctr Nursing Res, A417 W Fee, E Lansing, MI 48824 USA.	baye@msu.edu					Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Antoni MH, 2001, HEALTH PSYCHOL, V20, P20, DOI 10.1037/0278-6133.20.1.20; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; BAY E, 2004, INT J, V18, P213; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Blumenthal JA, 2005, JAMA-J AM MED ASSOC, V293, P1626, DOI 10.1001/jama.293.13.1626; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; BRESLAU N, 1986, ARCH GEN PSYCHIAT, V43, P309; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chamberlain DJ, 2006, J ADV NURS, V54, P407, DOI 10.1111/j.1365-2648.2006.03840.x; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; Davis SR, 1997, CURR OPIN OBSTET GYN, V9, P177; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Gaab J, 2006, PSYCHONEUROENDOCRINO, V31, P428, DOI 10.1016/j.psyneuen.2005.10.005; Gaab J, 2003, PSYCHONEUROENDOCRINO, V28, P767, DOI 10.1016/S0306-4530(02)00069-0; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GUALTIERI CT, 2001, J NEUROPSYCHIATRY CL, V18, P217; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Heim Christine, 2002, Semin Clin Neuropsychiatry, V7, P147, DOI 10.1053/scnp.2002.33127; HIBBARD MR, 2004, ARCHIVES PHYSL M S85, pS43; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hughes RB, 2005, WOMEN HEALTH ISS, V15, P14, DOI 10.1016/j.whi.2004.09.001; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kreutzer J, 1999, NEUROBEHAVIORAL FUNC, P1; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; LOVELL M, 2002, IMMEDIATE POST CONCU, P1; LOVELL M, 2002, BEST APPROACH CONCUS, P1; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lutgendorf SK, 2002, J UROLOGY, V167, P1338, DOI 10.1016/S0022-5347(05)65295-0; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McEwen B, 2002, END STRESS WE KNOW I, P1; McEwen BS, 2003, BIOL PSYCHIAT, V54, P200, DOI 10.1016/S0006-3223(03)00177-X; McEwen BS, 2001, ANN NY ACAD SCI, V933, P265, DOI 10.1111/j.1749-6632.2001.tb05830.x; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; *NATL MULT SCLER S, 1997, CONS MULT SCLE R CTR, V2007; Nemeroff CB, 1998, SCI AM, V278, P42, DOI 10.1038/scientificamerican0698-42; NEMEROFF CB, 2005, J CLIN PSYCHIAT S7, V66, pS5; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Pruessner JC, 1999, PSYCHOSOM MED, V61, P197, DOI 10.1097/00006842-199903000-00012; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Raskin SA, 1997, BRAIN INJURY, V11, P587, DOI 10.1080/026990597123287; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHRETIEN DJ, 2003, INT REV PSYCHIAT MED, V15, P341; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Szanton SL, 2005, BIOL RES NURS, V7, P7, DOI 10.1177/1099800405278216; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; Wessa M, 2006, PSYCHONEUROENDOCRINO, V31, P209, DOI 10.1016/j.psyneuen.2005.06.010; Williams RA, 2000, J PSYCHIAT RES, V34, P227, DOI 10.1016/S0022-3956(00)00012-1; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Young E A, 1997, Depress Anxiety, V5, P66, DOI 10.1002/(SICI)1520-6394(1997)5:2<66::AID-DA2>3.0.CO;2-3	97	46	49	0	42	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					233	241		10.1080/02699050801953073			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500004	18297595				2022-02-06	
J	Meier, R; Bechir, M; Ludwig, S; Sommerfeld, J; Keel, M; Steiger, P; Stocker, R; Stover, JF				Meier, Regula; Bechir, Markus; Ludwig, Silke; Sommerfeld, Jutta; Keel, Marius; Steiger, Peter; Stocker, Reto; Stover, John F.			Differential temporal profile of lowered blood glucose levels (3.5 to 6.5 mmol/l versus 5 to 8 mmol/l) in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							INTENSIVE-CARE-UNIT; INSULIN THERAPY; PERIINFARCT DEPOLARIZATIONS; HEAD-INJURY; HYPERGLYCEMIA; MICRODIALYSIS; PROTOCOL; METABOLISM; MANAGEMENT; LACTATE	Introduction Hyperglycaemia is detrimental, but maintaining low blood glucose levels within tight limits is controversial in patients with severe traumatic brain injury, because decreased blood glucose levels can induce and aggravate underlying brain injury. Methods In 228 propensity matched patients (age, sex and injury severity) treated in our intensive care unit (ICU) from 2000 to 2004, we retrospectively evaluated the influence of different predefined blood glucose targets (3.5 to 6.5 versus 5 to 8 mmol/l) on frequency of hypoglycaemic and hyperglycaemic episodes, insulin and norepinephrine requirement, changes in intracranial pressure and cerebral perfusion pressure, mortality and length of stay on the ICU. Results Mortality and length of ICU stay were similar in both blood glucose target groups. Blood glucose values below and above the predefined levels were significantly increased in the 3.5 to 6.5 mmol/l group, predominantly during the first week. Insulin and norepinephrine requirements were markedly increased in this group. During the second week, the incidences of intracranial pressure exceeding 20 mmHg and infectious complications were significantly decreased in the 3.5 to 6.5 mmol/l group. Conclusion Maintaining blood glucose within 5 to 8 mmol/l appears to yield greater benefit during the first week. During the second week, 3.5 to 6.5 mmol/l is associated with beneficial effects in terms of reduced intracranial hypertension and decreased rate of pneumonia, bacteraemia and urinary tract infections. It remains to be determined whether patients might profit from temporally adapted blood glucose limits, inducing lower values during the second week, and whether concomitant glucose infusion to prevent hypoglycaemia is safe in patients with post-traumatic oedema.	[Keel, Marius; Stover, John F.] Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland		Stover, JF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, Raemistr 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch					Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; BILOTTA F, 2008, NEUROCRIT C IN PRESS; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Clayton SB, 2006, CRIT CARE MED, V34, P2974, DOI 10.1097/01.CCM.0000248906.10399.CF; Cochran A, 2008, J BURN CARE RES, V29, P187, DOI 10.1097/BCR.0b013e318160d066; De Ciuceis C, 2008, J VASC RES, V45, P512, DOI 10.1159/000128604; de Courten-Myers GM, 2000, J CEREBR BLOOD F MET, V20, P82, DOI 10.1097/00004647-200001000-00012; Erol A, 2007, BIOESSAYS, V29, P811, DOI 10.1002/bies.20618; Gale SC, 2007, AM SURGEON, V73, P454; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Garg R, 2006, STROKE, V37, P267, DOI 10.1161/01.STR.0000195175.29487.30; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Grey Neil J, 2004, Endocr Pract, V10 Suppl 2, P46; Hattori N, 2004, J NUCL MED, V45, P775; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hui L, 2005, BRAIN RES, V1052, P1, DOI 10.1016/j.brainres.2005.05.043; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kanji S, 2004, INTENS CARE MED, V30, P804, DOI 10.1007/s00134-004-2252-2; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; Malliopoulou V, 2006, MOL CELL BIOCHEM, V284, P87, DOI 10.1007/s11010-005-9018-1; McMullin J, 2007, J CRIT CARE, V22, P112, DOI 10.1016/j.jcrc.2006.08.002; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Oldenborg PA, 1999, BIOSCIENCE REP, V19, P511, DOI 10.1023/A:1020286010551; Quinn JA, 2006, PHARMACOTHERAPY, V26, P1410, DOI 10.1592/phco.26.10.1410; Shi HL, 2006, NEUROSCI LETT, V410, P57, DOI 10.1016/j.neulet.2006.09.066; Strong AJ, 2000, STROKE, V31, P214, DOI 10.1161/01.STR.31.1.214; Strong AJ, 2007, CURR OPIN CRIT CARE, V13, P126, DOI 10.1097/MCC.0b013e32807faffb; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Thomson GA, 1997, ACTA DIABETOL, V34, P253, DOI 10.1007/s005920050084; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanhorebeek I, 2007, CRIT CARE MED, V35, pS496, DOI 10.1097/01.CCM.0000278051.48643.91; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vriesendorp TM, 2006, CRIT CARE MED, V34, P96, DOI 10.1097/01.CCM.0000194536.89694.06; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613	44	46	46	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	4							R98	10.1186/cc6974			13	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360UF	WOS:000260082700014	18680584	gold, Green Published, Green Accepted			2022-02-06	
J	You, ZR; Yang, JS; Takahashi, K; Yager, PH; Kim, HH; Qin, T; Stahl, GL; Alan, R; Ezekowitz, B; Carroll, MC; Whalen, MJ				You, Zerong; Yang, Jinsheng; Takahashi, Kazue; Yager, Phoebe H.; Kim, Hyung-Hwan; Qin, Tao; Stahl, Gregory L.; Alan, R.; Ezekowitz, B.; Carroll, Michael C.; Whalen, Michael J.			Reduced tissue damage and improved recovery of motor function after traumatic brain injury in mice deficient in complement component C4	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						complement; mice; behavior; traumatic brain injury; inflammation; genetics	CLOSED-HEAD INJURY; CENTRAL-NERVOUS-SYSTEM; STREPTOCOCCAL INFECTION; CEREBROSPINAL-FLUID; REPERFUSION INJURY; FACTOR-B; RATS; RECEPTORS; C3; ACTIVATION	Complement component C4 mediates C3-dependent tissue damage after systemic ischemia reperfusion injury. Activation of C3 also contributes to the pathogenesis of experimental and human traumatic brain injury (TBI); however, few data exist regarding the specific pathways (classic, alternative, and lectin) involved. Using complement knockout mice and a controlled cortical impact (CCI) model, we tested the hypothesis that the classic pathway mediates secondary damage after TBI. After CCI, C4c and C3d immunostaining were detected in cortical vascular endothelial cells in wild-type (WT) mice; however, C4c and C3d immunostaining were also detected in C1q(-/-) mice, and C3d immunostaining was detected in C4(-/-) mice. After CCI, WT and C1q(-/-) mice had similar motor deficits, Morris water maze performance, and brain lesion size. Naive C4(-/-) and WT mice did not differ in baseline motor performance, but C4(-/-) mice had reduced postinjury motor deficits (days 1 to 7, P < 0.05) and decreased brain tissue damage (days 14 and 35, P < 0.05) versus WT. Reconstitution of C4(-/-) mice with human C4 (hC4) reversed their protection against postinjury motor deficits (P < 0.05 versus vehicle), but administration of hC4 did not impair postinjury motor performance (versus vehicle) in WT mice. The protective effects of C4(-/-) were functionally distinct from the classic pathway and terminal complement, as C1q(-/-) and C3(-/-) mice had postinjury tissue damage and motor dysfunction similar to WT. Thus, C4 contributes to motor deficits and brain tissue damage after CCI by mechanism(s) fundamentally different from those involved in experimental systemic ischemia-reperfusion injury.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Boston, MA USA; Harvard Univ, Sch Med, CBR Inst Biomed Res Inc, Boston, MA USA		Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02129 USA.	mwhalen@partners.org		Stahl, Gregory/0000-0002-4805-8119	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL52886, HL56086] Funding Source: Medline; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI42788-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045776, R01NS47447] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R56HL056086, R01HL052886, R29HL052886, R01HL056086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI042788, R21AI042788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045776, R01NS047447] Funding Source: NIH RePORTER		Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; Boos LA, 2005, GLIA, V49, P158, DOI 10.1002/glia.20093; Botto M, 1998, EXP CLIN IMMUNOGENET, V15, P231, DOI 10.1159/000019076; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Chan RK, 2003, BRIT J SURG, V90, P1470, DOI 10.1002/bjs.4408; Chen ZB, 2000, J EXP MED, V192, P1339, DOI 10.1084/jem.192.9.1339; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; COOK HT, 2006, NAT MED, V5, P995; Fischer MB, 1996, J IMMUNOL, V157, P549; Hoffman KL, 2004, J NEUROSCI, V24, P1780, DOI 10.1523/JNEUROSCI.0887-03.2004; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KASUYA H, 1989, J NEUROSURG, V71, P741, DOI 10.3171/jns.1989.71.5.0741; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SCHWING C, 2002, KLINIKMANAG AKTUELL, V4, P8; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Taylor PR, 1998, J BIOL CHEM, V273, P1699, DOI 10.1074/jbc.273.3.1699; Ten VS, 2005, STROKE, V36, P2244, DOI 10.1161/01.STR.0000182237.20807.d0; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Van Beek J, 2000, GLIA, V31, P39, DOI 10.1002/(SICI)1098-1136(200007)31:1<39::AID-GLIA40>3.0.CO;2-1; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Williams JP, 1999, J APPL PHYSIOL, V86, P938, DOI 10.1152/jappl.1999.86.3.938; Yager P, 2005, J NEUROTRAUM, V22, P1250; Yang SX, 2006, J CEREBR BLOOD F MET, V26, P1490, DOI 10.1038/sj.jcbfm.9600305; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	37	46	46	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2007	27	12					1954	1964		10.1038/sj.jcbfm.9600497			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	231OB	WOS:000250957800007	17457366	Bronze			2022-02-06	
J	Harch, PG; Kriedt, C; Van Meter, KW; Sutherland, RJ				Harch, Paul G.; Kriedt, Christopher; Van Meter, Keith W.; Sutherland, Robert James			Hyperbaric oxygen therapy improves spatial learning and memory in a rat model of chronic traumatic brain injury	BRAIN RESEARCH			English	Article						hyperbaric oxygen; chronic traumatic brain injury	DECOMPRESSION ILLNESS; TEXTURE ANALYSIS; NEURONAL DEATH; BLOOD-FLOW; DIVERS; RESPONSES; METABOLISM; APOPTOSIS; ISCHEMIA; HISTORY	In the present experiment we use a rat model of traumatic brain injury to evaluate the ability of low-pressure hyperbaric oxygen therapy (HBOT) to improve behavioral and neurobiological outcomes. The study employed an adaptation of the focal cortical contusion model. 64 Male Long-Evans rats received unilateral cortical contusion and were tested in the Morris Water Task (MWT) 31-33 days post injury. Rats were divided into three groups: an untreated control group (N=22), an HBOT treatment group (N=19) and a sham-treated normobaric air group (N = 23). The HBOT group received 80 bid, 7 days/week 1.5 ATA/90-min HBOTs and the sham-treated normobaric air group the identical schedule of air treatments using a sham hyperbaric pressurization. All rats were subsequently retested in the MWT. After testing all rats were euthanized. Blood vessel density was measured bilaterally in hippocampus using a diaminobenzadine stain and was correlated with MWT performance. HBOT caused an increase in vascular density in the injured hippocampus (p < 0.001) and an associated improvement in spatial learning (p < 0.001) compared to the control groups. The increased vascular density and improved MWT in the HBOT group were highly correlated (p < 0.001). In conclusion, a 40-day series of 80 low-pressure HBOTs caused an increase in contused hippocampus vascular density and an associated improvement in cognitive function. These findings reaffirm the clinical experience of HBOT-treated patients with chronic traumatic brain injury. (c) 2007 Elsevier B.V. All rights reserved.	LSU Hlth Sci Ctr New Orleans, Dept Med, Sect Emergency Med, Harvey, LA 70058 USA; Baromed Res Inst, New Orleans, LA USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; LSU Hlth Sci Ctr New Orleans, Neurosci Ctr Excellence, Harvey, LA 70058 USA; Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada; Univ Lethbridge, Dept Psychol & Neurosci, Lethbridge, AB T1K 3M4, Canada		Harch, PG (corresponding author), LSU Hlth Sci Ctr New Orleans, Dept Med, Sect Emergency Med, 1816 Ind Blvd, Harvey, LA 70058 USA.	paulharchmd@aol.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bonomo SR, 1998, UNDERSEA HYPERBAR M, V25, P211; Calvert JW, 2003, J APPL PHYSIOL, V95, P2072, DOI 10.1152/japplphysiol.00630.2003; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GALL C, 1980, J COMP NEUROL, V193, P1047, DOI 10.1002/cne.901930416; GELDERD JB, 1980, UNDERSEA BIOMED RES, V7, P305; Ginaldi L., 1991, J HYPERBARIC MED, V6, P25; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; HAAMPANIEMI T, 1998, EXP NEUROL, V149, P433; Harch P. G., 2004, TXB HYPERBARIC MED, P471; Harch PG, 1996, TXB HYPERBARIC MED, P480; Harch PG, 1996, UNDERSEA HYPERB ME S, V23, P48; Harch PG, 2004, TXB HYPERBARIC MED, P223; Harch PG, 1999, TXB HYPERBARIC MED, P318; Harch PG, 1996, TREATMENT DECOMPRESS, P203; Hehenberger Karin, 1997, Wound Repair and Regeneration, V5, P147, DOI 10.1046/j.1524-475X.1997.50206.x; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; Houston AS, 1998, J NUCL MED, V39, P425; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; INAMOTO Y, 1991, BIOCHEM BIOPH RES CO, V179, P886, DOI 10.1016/0006-291X(91)91901-N; Ishii Y, 1999, TISSUE ENG, V5, P279, DOI 10.1089/ten.1999.5.279; Iwa T., 1970, P 4 INT C HYP MED, P388; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kondo A, 1996, NEUROPATH APPL NEURO, V22, P350, DOI 10.1111/j.1365-2990.1996.tb01114.x; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Macleod MA, 1996, NUCL MED COMMUN, V17, P795, DOI 10.1097/00006231-199609000-00010; MANSON PN, 1980, SURG FORUM, V31, P565; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; Marx RE, 1988, PROBLEM WOUNDS ROLE, P65; NEUBAUER RA, 1992, CLIN NUCL MED, V17, P477, DOI 10.1097/00003072-199206000-00010; Neubauer RA, 1998, NEUROL RES, V20, pS33; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Neubauer V, 2004, TXB HYPERBARIC MED, P287; PALMER AC, 1992, NEUROPATH APPL NEURO, V18, P113, DOI 10.1111/j.1365-2990.1992.tb00773.x; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; POLKINGHORNE PJ, 1988, LANCET, V2, P1381; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; Reivich M, 1974, Res Publ Assoc Res Nerv Ment Dis, V53, P125; RIEDER MJ, 1995, MICROVASC RES, V49, P180, DOI 10.1006/mvre.1995.1014; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Rossignol DA, 2006, MED HYPOTHESES, V67, P216, DOI 10.1016/j.mehy.2006.02.009; SAITO K, 1991, CLIN EXP IMMUNOL, V86, P322; SCHOLZ KH, 1990, ORG SYNTH, V7, P4; Sheikh AY, 2000, ARCH SURG-CHICAGO, V135, P1293, DOI 10.1001/archsurg.135.11.1293; SHERMAN DM, 1985, STAIN TECHNOL, V60, P89, DOI 10.3109/10520298509113897; Shields TG, 1997, OCCUP ENVIRON MED, V54, P247, DOI 10.1136/oem.54.4.247; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; Staff RT, 1996, J NUCL MED, V37, P1154; STAFF RT, 1995, NUCL MED COMMUN, V16, P438, DOI 10.1097/00006231-199506000-00003; Stoller KP, 2005, PEDIATRICS, V116, pE586, DOI 10.1542/peds.2004-2851; SUTHERLAND RJ, 1993, J NEUROTRAUMA, V10, pS162; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Thurman DJ, 2001, HEAD TRAUMA THERAPEU; Vila JF, 2005, UNDERSEA HYPERBAR M, V32, P341; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Weisz G, 1997, J CLIN IMMUNOL, V17, P154, DOI 10.1023/A:1027378532003; WU LC, 1995, GROWTH FACTORS, V12, P29, DOI 10.3109/08977199509003211; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	65	46	50	1	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 12	2007	1174						120	129		10.1016/j.brainres.2007.06.105			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	226TU	WOS:000250612200013	17869230				2022-02-06	
J	Middelkamp, W; Moulaert, VRMP; Verbunt, JA; van Heugten, CM; Bakx, WG; Wade, DT				Middelkamp, Wietske; Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.; van Heugten, Caroline M.; Bakx, Wilbert G.; Wade, Derick T.			Life after survival: long-term daily life functioning and quality of life of patients with hypoxic brain injury as a result of a cardiac arrest	CLINICAL REHABILITATION			English	Article							RESUSCITATION; QUESTIONNAIRE; PARTICIPATION; SEQUELAE; AUTONOMY	Objectives: To determine the level of daily functioning and quality of life of patients with hypoxic brain injury after a cardiac arrest and to investigate the predictive value of the duration of coma and post-traumatic amnesia in long-term functioning. Design: A retrospective cohort study. Setting: A Dutch rehabilitation centre. Subjects: Thirty-two patients with hypoxic brain injury caused by a cardiac arrest 2-7 years ago, who were admitted to a brain injury rehabilitation programme. Main outcome measures: Cognitive Failures Questionnaire (CFQ), Frenchay Activities Index (FAI), Impact on Participation and Autonomy Questionnaire (IPAQ) and Quality of Life after Brain Injury questionnaire (QOLIBRI). Data on duration of coma and post-traumatic amnesia were retrieved from medical files. Results: A significant association was found between duration of coma, complaints of cognitive functioning (r=0.57, P < 0.05) and quality of life after brain injury (r=-0.70, P < 0.01). Duration of post-traumatic amnesia was associated with both daily functioning (r=-0.70, P < 0.01) and quality of life (r=-0.70, P < 0.01). Furthermore complaints of cognitive functioning were associated with both the level of participation in society (r=0.76, P < 0.01) and quality of life (r=0.77,P < 0.01). Conclusions: Long-term outcome of patients with hypoxic brain injury after a cardiac arrest shows that this group is limited in cognitive and daily functioning, participation and quality of life. Based on the duration of coma and post-traumatic amnesia, an estimation of daily life functioning and quality of life 2-7 years after a cardiac arrest can be made.	Rehabil Fdn Limburg, Hoensbroeck Rehabil Ctr, NL-6430 AB Hoensbroek, Netherlands; Maastricht Univ, Fac Hlth Sci, Maastricht, Netherlands; Inst Rehabil Res, Hoensbroek, Netherlands; Oxford Ctr Enablement, Oxford, England		Verbunt, JA (corresponding author), Rehabil Fdn Limburg, Hoensbroeck Rehabil Ctr, POB 88, NL-6430 AB Hoensbroek, Netherlands.	j.verbunt@srl.nl		Wade, Derick/0000-0002-1188-8442			ALEM AP, 2004, AM J CARDIOL, V93, P131; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cardol M, 2001, ARCH PHYS MED REHAB, V82, P210, DOI 10.1053/apmr.2001.18218; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; Gorgels APM, 2003, EUR HEART J, V24, P1204, DOI 10.1016/S0195-668X(03)00191-X; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Lundgren-Nilsson A, 2005, RESUSCITATION, V66, P285, DOI 10.1016/j.resuscitation.2005.04.001; PONDS RWH, 1998, THESIS U MAASTRICHT; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sauve M J, 1996, Am J Crit Care, V5, P127; Sibley A, 2006, CLIN REHABIL, V20, P793, DOI 10.1177/0269215506070808; Sullivan M Terry, 2003, Home Healthc Nurse, V21, P197, DOI 10.1097/00004045-200303000-00024; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Waalewijn RA, 1998, RESUSCITATION, V38, P157, DOI 10.1016/S0300-9572(98)00102-6; Wade D T, 1985, Int Rehabil Med, V7, P176; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; World Health Organization, 2001, INT CLASS FUNCT DISA; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	21	46	48	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	MAY	2007	21	5					425	431		10.1177/0269215507075307			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	191NB	WOS:000248136800005	17613563				2022-02-06	
J	McHugh, GS; Butcher, I; Steyerberg, EW; Lu, J; Mushkudiani, N; Marmarou, A; Maas, AIR; Murray, GD				McHugh, Gillian S.; Butcher, Isabella; Steyerberg, Ewout W.; Lu, Juan; Mushkudiani, Nino; Marmarou, Anthony; Maas, Andrew I. R.; Murray, Gordon D.			Statistical approaches to the univariate prognostic analysis of the IMPACT database on traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						forest plots; GOS; ordinal data; proportional odds model; traumatic brain injury	MODELS	The univariate prognostic analysis of the IMPACT database on traumatic brain injury (TBI) poses the formidable challenge of how best to summarize a highly complex set of data in a way which is accessible without being overly simplistic. In this paper, we describe and illustrate the battery of statistical methods that have been used. Boxplots, histograms, tabulations, and splines were Used for initial data checking and in identifying appropriate transformations for more formal statistical modeling. Imputation techniques were used to minimize the problems associated with the analysis of incomplete data due to missing values. The associations between covariates and outcome (Glasgow Outcome Scale [GOS] assessed at 6 months) were expressed as odds ratios with supporting confidence intervals when the GOS was collapsed to a dichotomous scale. This was extended to use common odds ratios from proportional odds models to express associations over the full range of the GOS. Forest plots were used to illustrate the consistency of results from study to study within the IMPACT database. The overall prognostic strength of the prognostic factors was expressed as the proportion of variance explained (Nagelkerke's R-2 statistic). Many of our approaches are based on simple graphical displays of the data, but, where appropriate, we have also used methods that although established in the statistical literature are relatively novel in their application to TBI.	Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Erasmus MC, Ctr Clin Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA		McHugh, GS (corresponding author), Univ Edinburgh, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Gillian.McHugh@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Agresti A., 2019, INTRO CATEGORICAL DA; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Harrell FE, 2001, INT J TECHNOL ASSESS, V17, P17, DOI 10.1017/S0266462301104034; Harrell FE Jr, 2017, REGRESSION MODELING; JENNETT B, 1975, LANCET, V1, P480; Little RJA., 1987, STAT ANAL MISSING DA; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Royston P, 2000, STAT MED, V19, P1831, DOI 10.1002/1097-0258(20000730)19:14<1831::AID-SIM502>3.0.CO;2-1; Stone CJ., 1986, STAT SCI, V1, P312, DOI [10.1214/ss/1177013607, DOI 10.1214/ss/1177013607]; STONE CJ, 1985, P STAT COMPUTING SEC; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; Whitehead A., 2002, METAANALYSIS CONTROL	16	46	47	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					251	258		10.1089/neu.2006.0026			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900004	17375989				2022-02-06	
J	Douglas, JM; Bracy, CA; Snow, PC				Douglas, Jacinta M.; Bracy, Christine A.; Snow, Pamela C.			Exploring the factor structure of the La Trobe communication questionnaire: Insights into the nature of communication deficits following traumatic brain injury	APHASIOLOGY			English	Article							CLOSED HEAD-INJURY; DISCOURSE ASSESSMENT; COMPETENCE; ABILITIES; AWARENESS; CORTEX	Background: Self and close other reports of communication ability can provide a time-efficient means of evaluating conversational discourse after traumatic brain injury ( TBI). The La Trobe Communication Questionnaire (LCQ) measures perceived communication ability from various sources including self-perceptions and perceptions of others. Content and test-retest reliability and discriminant validity of the LCQ have been demonstrated previously with adults following TBI. Aims: This study was undertaken to explore the factor structure of the LCQ as revealed within the data collected from 88 adults with severe TBI and their close others. Methods & Procedures: Construct validity was examined using a Principal Component Factor Analytic procedure with Varimax rotation. Outcomes & Results: A seven-factor structure that accounted for 60.88% of the variance was revealed. Of the LCQ items, 27 clearly loaded on to one of the seven communication factors that were identified. Conclusions: The factor structure that emerged depicts the multidimensional nature of conversation and the complex interplay between cognitive and communication processes that social discourse demands. These results support the construct validity of the LCQ and indicate that it can be used as a reliable and valid measure of communication ability after severe TBI.	La Trobe Univ, Bundoora, Vic, Australia		Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Snow, Pamela/0000-0002-2426-8349			[Anonymous], 1988, ASHA, V30, P79; Bracy C., 2005, BRAIN IMPAIR, V6, P1, DOI DOI 10.1375/brim.6.1.1.65476; BRYANT FB, 1995, READING MULTIVARIATE; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho C. A., 1999, BRAIN DAM B; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Damico J. S., 1985, COMMUNICATION SKILLS, P165; DOUGLAS J, IN PRESS J HEAD TRAU; DOUGLAS J, 2004, EVIDENCE BASED PRACT; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Fidell L.S., 2001, USING MULTIVARIATE S; Fleming JM, 1996, BRAIN INJURY, V10, P1; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GARSON GD, 2005, STATNOTES ONLINE TXB; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [10.1007/BF02214959, DOI 10.1007/BF02214959]; Grafman J, 1999, LANCET, V354, P1921, DOI 10.1016/S0140-6736(99)90438-5; Grice H. P., 1975, SYNTAX SEMANTICS, P41; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Hutcheson G. D., 1999, MULTIVARIATE SOCIAL; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Lawley D.N., 1971, FACTOR ANAL STAT MET; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 2002, AWARNESS SOCIAL INFE; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; REILLY S, 2004, EVIDENCE BASED PRACT; Rolls ET, 1999, NEUROCASE, V5, P301, DOI 10.1093/neucas/5.4.301; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Snow PC, 2000, BRAIN INJURY, V14, P397; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Ylvisaker M., 2001, LANGUAGE INTERVENTIO	57	46	47	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2007	21	12					1181	1194		10.1080/02687030600980950			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	237FW	WOS:000251360600004					2022-02-06	
J	Gianotti, S; Hume, PA				Gianotti, Simon; Hume, Patria A.			Concussion sideline management intervention for rugby union leads to reduced concussion claims	NEUROREHABILITATION			English	Article						concussion; injury prevention intervention; concussion management; community; rugby; return on investment; education	SPORT; STATEMENT	The effectiveness of a concussion management education programme (CMEP) in rugby in reducing the number and cost of concussion/brain injury (CBI) moderate to serious claims (MSC) was assessed. A RugbySmart (TM) educational video and a sideline concussion check (SCC) tool comprised the CMEP. Over 30,000 SCC, providing information on management of suspected concussion among community level rugby players prior to seeking medical treatment, were distributed from July 2003 to June 2005. Each year approximately 10,000 coaches and 2,000 referees participated in RugbySmart (TM). From 2003 to 2005 new rugby CBI MSC reduced by 10.7% (actual) and 58.2% (forecast). Rugby player numbers, new non-sport CBI MSC and new sport MSC all increased by 13.6%, 16.9% and 24.6% respectively in the same period. The median number of days between CBI injury and the player seeking medical treatment decreased from six days to four days. Cost savings after CMEP were $USD690,690 (actual) to $USD3,354,780 (forecast). The two-year cost of CMEP was $USD54,810 returning $USD12.60 (actual) and $USD61.21 (forecast) for every $USD1 invested (ROI). CMEP provided community coaches and managers with education on minimum best practice for managing suspected concussion, contributed towards ROI and savings for CBI MSC in rugby.	Accid Compensat Corp, Wellington, New Zealand; Auckland Univ Technol, Inst Sport & Recreat Res New Zealand, Div Sch Sport & Recreat, Fac Hlth & Environm Sci, Auckland, New Zealand		Gianotti, S (corresponding author), Accid Compensat Corp, POB 242, Wellington, New Zealand.	simon.gianotti@acc.co.nz	Hume, Patria/AAN-5514-2021; Hume, Patria Anne/P-1084-2017	Hume, Patria/0000-0003-1847-8128; Hume, Patria Anne/0000-0003-1847-8128			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; CAMBELL D, 2004, RUGBY NEWS, P11; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; COLLINS MW, 2004, COMMUNICATION; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; GIANOTTI S, 2007, IN PRESS J SCI MED S; GIANOTTI S, 2003, DEV OFFICER RUGBYSMA; GILKSON T, 2004, COMMUNICATION; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HARTE D, 2004, MODELLING WORK RELAT, P65; HARTE D, 2004, MODELLING ACC CLAIM, P44; JEGATHEESON P, 2002, INJURY PREVENTION RE; KUNTER K, 1998, NATL ACAD NEUROPSYCH, V14, P19; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; MCCRORY P, 2002, BRIT J SPORT MED, V36, P315; *NZ RUGB FOOTB UN, 2001, COMP RUGBYSMART COAC, P1; *NZ RUGB FOOTB UN, 2004, RUGB PLAY NUMB SURG	21	46	46	0	27	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					181	189					9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800004	17917168				2022-02-06	
J	Kaminski, TW; Wikstrom, AM; Gutierrez, GM; Glutting, JJ				Kaminski, Thomas W.; Wikstrom, April M.; Gutierrez, Gregory M.; Glutting, Joseph J.			Purposeful heading during a season does not influence cognitive function or balance in female soccer players	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							POSTURAL STABILITY; FOOTBALL PLAYERS; BRAIN-INJURIES; CONCUSSION; IMPAIRMENT; TRAUMA; IMPACT	Soccer participation, especially among females, is growing in popularity in the United States. Purposeful heading, an important soccer skill, has recently been scrutinized for safety reasons. The purpose of this study was to determine whether there was a relationship between purposeful heading and scores on cognitive function and balance in high-school and collegiate female soccer players. Prior to and following the soccer season, all players and members of the control group were given a battery of neuropsychological and balance tests. There were no significant correlations found between the total number of game headers and performance on either balance or neuropsychological testing. Differences were noted in adjusted balance scores postseason between the collegiate players and the other two groups. However, no differences were revealed in neurocognitive performance between the three groups.	Univ Delaware, Dept Hlth Nutr & Exercise Sci, Athlet Training Res Lab, Newark, DE 19716 USA; Univ Delaware, Sch Educ, Newark, DE USA		Kaminski, TW (corresponding author), Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, 159 Fred Rust Ice Arens,541 S Coll Ave, Newark, DE 19716 USA.	kaminski@udel.edu	Gutierrez, Gregory/A-9420-2009	Gutierrez, Gregory/0000-0002-4261-8066			Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Barth JT, 1989, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; *HIFA, 2005, FIFA WOM WORLD CUP P; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski T. W., 2002, Medicine & Science in Sports & Exercise, V34, pS2, DOI 10.1097/00005768-200205001-00009; Lees K., 1988, SCI FOOTBALL, P385; MAGNUS BC, 2004, SPORT BIOMECH, V3, P209; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; *NCAA, 2003, NCAA INJ SURV SYST A; *NCAA, 2004, 198182200304 NCAA; *NCAA, 2005, 2004 05 WOM SOCC INJ; Oliaro SM, 1998, J ATHL TRAINING, V33, P36; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421	37	46	46	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2007	29	7					742	751		10.1080/13825580600976911			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	229CO	WOS:000250779200008	17852597				2022-02-06	
J	Offen, D; Barhum, Y; Levy, YS; Burshtein, A; Panet, H; Cherlow, T; Melamed, E				Offen, D.; Barhum, Y.; Levy, Y.-S.; Burshtein, A.; Panet, H.; Cherlow, T.; Melamed, E.			Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease	JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT			English	Article						multipotent mesenchymal stromal cells (MSCs); dopamine; dopaminergic neurons; Parkinson's disease (PD); stem cells	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; STROMAL CELLS; DOPAMINERGIC-NEURONS; IN-VITRO; RAT MODEL; SUBSTANTIA-NIGRA; ES CELLS; DIFFERENTIATION; MICE	Strategies of cell therapy for the treatment of Parkinson's disease (PD) are focused on replacing damaged neurons with cells to restore or improve function that is impaired due to cell population damage. In our studies, we used mesenchymal stromal cells (MSCs) from mouse bone marrow. Following our novel neuronal differentiation method, we found that the basic cellular phenotype changed to cells with neural morphology that express specific markers including those characteristic for dopaminergic neurons, such as tyrosine hydroxylase (TH). Intrastriatal transplantation of the differentiated MSCs in 6-hydroxydopamine-lesioned mice led to marked reduction in the amphetamine-induced rotations. Immunohistological analysis of the mice brains four months post transplantation, demonstrated that most of the transplanted cells survived in the striatum and expressed TH. Some of the TH positive cells migrated toward the substantia nigra. In conclusion, transplantation of bone marrow derived stem cells differentiated to dopaminergic-like cells, successfully improved behavior in an animal model of PD suggesting an accessible source of cells that may be used for autotransplantation in patient with PD.	Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsentein Med Res Ctr,Lab Neurosci, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Neurol, Petah Tiqwa, Israel		Offen, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsentein Med Res Ctr,Lab Neurosci, IL-49100 Petah Tiqwa, Israel.	doffen@post.tau.ac.il		Routtenberg, Tirza/0000-0002-7238-7764			Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; Arnhold S, 2006, EUR J CELL BIOL, V85, P551, DOI 10.1016/j.ejcb.2006.01.015; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Ben-Hur T, 2004, STEM CELLS, V22, P1246, DOI 10.1634/stemcells.2004-0094; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Blondheim NR, 2006, STEM CELLS DEV, V15, P141, DOI 10.1089/scd.2006.15.141; BOTTENSTEIN JE, 1985, CELL CULTURE NEUROSC, P1; Brederlau A, 2006, STEM CELLS, V24, P1433, DOI 10.1634/stemcells.2005-0393; CARMAN LS, 1991, BRAIN RES, V553, P275, DOI 10.1016/0006-8993(91)90835-J; Carson CT, 2006, NAT MED, V12, P1237, DOI 10.1038/nm1106-1237; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HEFTI F, 1985, NEUROPHARMACOLOGY, V24, P19, DOI 10.1016/0028-3908(85)90090-5; Hellmann MA, 2006, NEUROSCI LETT, V395, P124, DOI 10.1016/j.neulet.2005.10.097; HUDSON JL, 1993, BRAIN RES, V626, P167, DOI 10.1016/0006-8993(93)90576-9; Jackson-Lewis V, 2000, BRAIN RES, V866, P197, DOI 10.1016/S0006-8993(00)02243-5; Kan I, 2005, CURR DRUG TARGETS, V6, P31, DOI 10.2174/1389450053344902; Kan I, 2007, J LIPID RES, V48, P513, DOI 10.1194/jlr.C600022-JLR200; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kim DW, 2006, STEM CELLS, V24, P557, DOI 10.1634/stemcells.2005-0233; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Levy YS, 2004, J MOL NEUROSCI, V24, P353, DOI 10.1385/JMN:24:3:353; Levy YS, 2003, J MOL NEUROSCI, V21, P121, DOI 10.1385/JMN:21:2:121; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Lindvall Olle, 2004, NeuroRx, V1, P382; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mazzini L, 2006, NEUROL RES, V28, P523, DOI 10.1179/016164106X116791; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Park CH, 2005, J NEUROCHEM, V92, P1265, DOI 10.1111/j.1471-4159.2004.03006.x; Pavon N, 1998, REV NEUROLOGIA, V26, P915, DOI 10.33588/rn.26154.98016; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Sanchez-Pernaute R, 2005, STEM CELLS, V23, P914, DOI 10.1634/stemcells.2004-0172; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; THOMAS J, 1994, EXP NEUROL, V126, P159, DOI 10.1006/exnr.1994.1054; Winkler C, 2005, TRENDS NEUROSCI, V28, P86, DOI 10.1016/j.tins.2004.12.006; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365; Zeng XM, 2004, STEM CELLS, V22, P925, DOI 10.1634/stemcells.22-6-925; Zhang J, 2005, EXP NEUROL, V195, P16, DOI 10.1016/j.expneurol.2005.03.018; Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962	66	46	48	1	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-6995			J NEURAL TRANSM-SUPP	J. Neural Transm.-Suppl.		2007		72					133	143					11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	220XV	WOS:000250191500017	17982886				2022-02-06	
J	Scharlach, A; Li, W; Dalvi, TB				Scharlach, Andrew; Li, Wei; Dalvi, Tapashi B.			Family conflict as a mediator of caregiver strain	FAMILY RELATIONS			English	Article						caregiver distress; elder care; family caregiving; family stress	DECISION-MAKING SATISFACTION; TRAUMATIC BRAIN INJURY; GENDER-DIFFERENCES; PSYCHIATRIC MORBIDITY; ALZHEIMERS-DISEASE; STRESS PROCESS; IMPACT; CARE; PERCEPTIONS; PREVALENCE	The present study used structural equation modeling to examine the potential mediating effect of family conflict on caregiver strain in a randomly drawn household sample of 650 adults with primary care responsibility for an adult age 50 or older with a mental disability. Caregiver strain was directly influenced by the conflict, disagreements, and hardships experienced by the caregiver's family. Specifically, family conflict was found to mediate the impact of care recipient mental impairment and caregiver educational level on caregiver strain, and mediate partially the impact of caregiver income and caregiver-care recipient relationship. Findings suggest the importance of considering family-centered approaches when designing interventions to assist family caregivers.	Univ Calif Berkeley, Sch Social Welf, Berkeley, CA 94720 USA; Ctr Responsible Lending, Durham, NC 27701 USA; Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA		Scharlach, A (corresponding author), Univ Calif Berkeley, Sch Social Welf, 120 Haviland, Berkeley, CA 94720 USA.	Scharlach@berkeley.edu; wei.li@responsiblelending.org; tapashi@berkeley.edu					Amirkhanyan AA, 2003, GERONTOLOGIST, V43, P817, DOI 10.1093/geront/43.6.817; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BOSS P, 2004, CONT PERSPECTIVES FA, V4, P207; BRODY EM, 1989, GERONTOLOGIST, V29, P529, DOI 10.1093/geront/29.4.529; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; Deimling GT, 2001, J AGING HEALTH, V13, P47, DOI 10.1177/089826430101300103; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fiscella K, 1997, FAM PROCESS, V36, P25, DOI 10.1111/j.1545-5300.1997.00025.x; FISHER L, 1994, FAM PROCESS, V33, P305, DOI 10.1111/j.1545-5300.1994.00305.x; Franks MM, 1996, J GERONTOL B-PSYCHOL, V51, pP43, DOI 10.1093/geronb/51B.1.P43; Fredriksen-Goldsen K.I., 2001, FAMILIES WORK NEW DI; GARWICK AW, 1994, FAM PROCESS, V33, P327, DOI 10.1111/j.1545-5300.1994.00327.x; Gaugler Joseph E, 2003, Am J Alzheimers Dis Other Demen, V18, P300, DOI 10.1177/153331750301800505; Hooker K, 2000, GERONTOLOGIST, V40, P568, DOI 10.1093/geront/40.5.568; Ingersoll-Dayton B, 2003, J MARRIAGE FAM, V65, P201, DOI 10.1111/j.1741-3737.2003.00201.x; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kuypers J., 1983, FAM RELAT, P211; Lieberman MA, 1999, GERONTOLOGIST, V39, P159, DOI 10.1093/geront/39.2.159; LIEBERMAN MA, 1995, GERONTOLOGIST, V35, P94, DOI 10.1093/geront/35.1.94; MATTHEWS SH, 1988, J MARRIAGE FAM, V50, P185, DOI 10.2307/352438; McCubbin M., 1993, FAMILIES HLTH ILLNES, P21, DOI 10.4135/9781452274720.n8; MILLER B, 1990, J MARRIAGE FAM, V52, P311, DOI 10.2307/353028; MILLER B, 1992, GERONTOLOGIST, V32, P498, DOI 10.1093/geront/32.4.498; MUI AC, 1995, J MARRIAGE FAM, V57, P733, DOI 10.2307/353927; *NAT ALL CAR AM AS, 1997, FAM CAR US FIND NAT; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI 10.2307/2136676; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; PENROD JD, 1995, GERONTOLOGIST, V35, P489, DOI 10.1093/geront/35.4.489; Peters-Davis ND, 1999, GERONTOLOGIST, V39, P66, DOI 10.1093/geront/39.1.66; PRUCHNO R, 1998, J AM GERIATR SOC, V37, P697; Pruchno RA, 1997, GERONTOLOGIST, V37, P157, DOI 10.1093/geront/37.2.157; RODRIGUEZ J, 2003, GERONTOLOGIST, V43, P916; *SAS I, 1999, SAS 8 0 COMP SOFTW; Scharlach AE, 2006, J GERONTOL SOC WORK, V47, P133, DOI 10.1300/J083v47n01_09; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; SEMPLE SJ, 1992, GERONTOLOGIST, V32, P648, DOI 10.1093/geront/32.5.648; Smerglia VL, 1997, GERONTOLOGIST, V37, P658, DOI 10.1093/geront/37.5.658; Sobel M. E., 1982, SOCIOLOGICAL METHODO, P290, DOI [10.2307/270723, DOI 10.2307/270723]; SOBEL ME, 1986, SOCIOL METHODOL, P159, DOI DOI 10.2307/270922; STRAWBRIDGE WJ, 1991, GERONTOLOGIST, V31, P770, DOI 10.1093/geront/31.6.770; TENNSTEDT SL, 1989, GERONTOLOGIST, V29, P677, DOI 10.1093/geront/29.5.677; Weihs K, 2002, FAM SYST HEALTH, V20, P7, DOI [10.1037/h0089481, DOI 10.1037/H0089481]; Yee JL, 2000, GERONTOLOGIST, V40, P147, DOI 10.1093/geront/40.2.147	45	46	47	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0197-6664	1741-3729		FAM RELAT	Fam. Relat.	DEC	2006	55	5					625	635		10.1111/j.1741-3729.2006.00431.x			11	Family Studies; Social Work	Social Science Citation Index (SSCI)	Family Studies; Social Work	119GC	WOS:000242999800011		Green Published, Green Submitted			2022-02-06	
J	Gibson, LJ				Gibson, L. J.			Woodpecker pecking: how woodpeckers avoid brain injury	JOURNAL OF ZOOLOGY			English	Article						woodpeckers; pecking; brain injury; biomechanics	CONCUSSION; IMPACT	Woodpeckers are capable of repeated pecking on a tree at remarkably high decelerations (on the order of 10 000 m s(-2) or 1000 g). In this paper, I re-examine previous studies of pecking and scaling effects in brain injury. I find that there are three keys to woodpeckers' ability to withstand high decelerations: their small size, which reduces the stress on the brain for a given acceleration; the short duration of the impact, which increases the tolerable acceleration; and the orientation of the brain within the skull, which increases the area of contact between the brain and the skull.	MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA		Gibson, LJ (corresponding author), MIT, Dept Mat Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ljgibson@mit.edu	Gibson, Lorna J/K-4738-2012	/0000-0001-7559-7815			Bock WJ, 1999, ZOOL ANZ, V238, P27; BOCK WJ, 1964, J MORPHOL, V114, P1, DOI 10.1002/jmor.1051140102; Bock WJ, 1999, OSTRICH, V70, P23, DOI 10.1080/00306525.1999.9639746; BOCK WJ, 1966, AUK, V83, P10, DOI 10.2307/4082976; ELPHICK C, 2001, SIBLEY GUIDE BIRD LI; Hirschman A., 1976, LANCET, V307, P454, DOI [10.1016/s0140-6736(76)91477-x, DOI 10.1016/S0140-6736(76)91477-X]; Holbourn AHS, 1943, LANCET, V2, P438; MAY PRA, 1979, ARCH NEUROL-CHICAGO, V36, P370, DOI 10.1001/archneur.1979.00500420080011; McLean A. J., 1997, HEAD INJURY, P25; MLIKOVSKY J, 1989, Vestnik Ceskoslovenske Spolecnosti Zoologicke, V53, P252; Ommaya A. K., 1967, P 11 STAPP CAR CRASH, V670906; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; ONO K, 1980, P 24 STAPP CAR CRASH, P101; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; SPRING LOWELL W., 1965, CONDOR, V67, P457, DOI 10.2307/1365612; Winkler H, 1995, WOODPECKERS GUIDE WO	18	46	53	11	89	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0952-8369			J ZOOL	J. Zool.	NOV	2006	270	3					462	465		10.1111/j.1469-7998.2006.00166.x			4	Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Zoology	094MR	WOS:000241244000009		Green Published			2022-02-06	
J	Uzan, M; Erman, H; Tanriverdi, T; Sanus, GZ; Kafadar, A; Uzun, H				Uzan, M.; Erman, H.; Tanriverdi, T.; Sanus, G. Z.; Kafadar, A.; Uzun, H.			Evaluation of apoptosis in cerebrospinal fluid of patients with severe head injury	ACTA NEUROCHIRURGICA			English	Article						apoptosis; bcl-2; caspase-3; sFas; programmed cell death	TRAUMATIC BRAIN-INJURY; PROGRAMMED CELL-DEATH; FAS LIGAND; DNA FRAGMENTATION; PRACTICAL SCALE; BCL-2; EXPRESSION; CASPASE-3; RATS; ACTIVATION	Objective. To determine whether sFas, caspase-3, proteins which propagate apoptosis, and bcl-2, a protein which inhibits apoptosis, would be increased in cerebrospinal fluid (CSF) in patients with severe traumatic brain injury (TBI) and to examine the correlation of sFas, caspase-3, and bcl-2 with each other and with clinical variables. Methods. sFas, caspase-3, and bcl-2 were measured in CSF of 14 patients with severe TBI on days 1, 2, 3, 5, 7, and 10 post-trauma. The results were compared with CSF samples from control patients who had no brain and spinal pathology and had undergone spinal anesthesia for some other reason. Soluble Fas and bcl-2 were measured by ELISA while caspase-3 was measured enzymatically. Results. No sFas, caspase-3, and bcl-2 activities were found in CSF of controls, but activities significantly increased in CSF of patients at all time points post-trauma (p < 0.01). Caspase-3 significantly correlated to intracranial pressure (p = 0.01) and cerebral perfusion pressure (p = 0.04). Soluble Fas and caspase-3 peaks coincided on day 5 post-trauma and there was significant association between sFas and caspase-3 increase (p = 0.01). Conclusion. This study indicates a prolonged activation of pro-apoptotic (sFas, caspase-3) and anti-apoptotic (bcl-2) proteins after severe TBI in humans. The degree of activation of particularly caspase-3 may be related to the severity of the injury. Parallel increases of these three molecules may indicate a pivotal role of apoptosis in the pathophysiology of post-traumatic brain oedema, secondary cell destruction and chronic cell loss following severe TBI and may open new targets for post-traumatic therapeutic interventions.	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Biochem, Istanbul, Turkey		Uzan, M (corresponding author), POB 5, TR-34301 Istanbul, Turkey.	uzan@istanbul.edu.tr	Uzun, Hafize/D-4811-2019; Uzan, Mustafa/D-6571-2019; Kafadar, Ali/AAH-9387-2019; Sanus, Galip Zihni/D-6715-2019; Tanriverdi, Taner/C-9003-2019	Uzun, Hafize/0000-0002-1347-8498; Kafadar, Ali/0000-0002-3312-3192; Uzan, Mustafa/0000-0001-7214-380X			Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; JENNETT B, 1975, LANCET, V1, P480; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; Lazebnik YA, 1995, J CELL SCI, P41; LEZLINGER PM, 2002, J NEUROIMMUNOL, V122, P167; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	35	46	47	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2006	148	11					1157	1164		10.1007/s00701-006-0887-1			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	105EU	WOS:000242013600010	16964558				2022-02-06	
J	Hernandez, AV; Steyerberg, EW; Butcher, I; Mushkudiani, N; Taylor, GS; Murray, GD; Marmarou, A; Choi, SC; Lu, J; Habbema, JDF; Maas, AIR				Hernandez, Adrian V.; Steyerberg, Ewout W.; Butcher, Isabella; Mushkudiani, Nino; Taylor, Gillian S.; Murray, Gordon D.; Marmarou, Anthony; Choi, Sung C.; Lu, Juan; Habbema, J. Dik F.; Maas, Andrew I. R.			Adjustment for strong predictors of outcome in traumatic brain injury trials: 25% reduction in sample size requirements in the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						covariate adjustment; model performance; randomized clinical trials; reduction in sample size; traumatic brain injury	RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; HEAD-INJURY; COVARIATE ADJUSTMENT; NEUROPROTECTIVE AGENTS; EPIDEMIOLOGY; VALIDATION; REGRESSION	The aim of this study was to quantify the potential reduction in sample size that can be achieved by adjustment for predictors of outcome in traumatic brain injury (TBI) trials. We used individual patient data from seven therapeutic phase III randomized clinical trials (RCTs; n = 6166) in moderate or severe TBI, and three TBI surveys (n = 2238.). The primary outcome was the dichotomized Glasgow Outcome Scale at 6 months (favorable/unfavorable). Baseline predictors of outcome considered were age, motor score, pupillary reactivity, computed tomography (CT) classification, traumatic subarachnoid hemorrhage, hypoxia, hypotension, glycemia, and hemoglobin. We calculated the potential sample size reduction obtained by adjustment of a hypothetical treatment effect for one to seven predictors with logistic regression models. The distribution of predictors was more heterogeneous in surveys than in trials. Adjustment of the treatment effect for the strongest predictors (age, motor score, and pupillary reactivity) yielded a reduction in sample size of 16-23% in RCTs and 28-35% in surveys. Adjustment for seven predictors yielded a reduction of about 25% in most studies: 20-28% in RCTs and 32-39% in surveys. A major reduction in sample size can be obtained with covariate adjustment in TBI trials. Covariate adjustment for strong predictors should be incorporated in the analysis of future TBI trials.	Erasmus Univ, Erasmus MC, Med Ctr, Dept Publ Hlth,Ctr Med Decis Making, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Erasmus MC, Med Ctr, Dept Neurol Surg, NL-3000 DR Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh, Midlothian, Scotland; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Steyerberg, EW (corresponding author), Erasmus Univ, Erasmus MC, Med Ctr, Dept Publ Hlth,Ctr Med Decis Making, POB 2040, NL-3000 DR Rotterdam, Netherlands.	e.steyerberg@erasmusmc.nl	Hernandez, Adrian V./ABD-4616-2021; Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Hernandez, Adrian V./0000-0002-9999-4003; Maas, Andrew IR/0000-0003-1612-1264; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 RO1 NS-042691-001A] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Choi S C, 1998, J Biopharm Stat, V8, P367, DOI 10.1080/10543409808835246; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Edwards P, 2005, LANCET, V365, P1957; GAIL MH, 1984, BIOMETRIKA, V71, P431; Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5; Hernandez AV, 2006, ANN EPIDEMIOL, V16, P41, DOI 10.1016/j.annepidem.2005.09.007; Hernandez AV, 2005, NEUROSURGERY, V57, P1244, DOI 10.1227/01.NEU.0000186039.57548.96; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Little R, 2004, STAT SINICA, V14, P949; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARMAROU A, 2006, UNPUB J NEUROTRAUMA; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Masson F, 2000, ANN FR ANESTH, V19, P261; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; MUSHKUDANI N, 2004, MED DECIS MAKING, V24, P437; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; TAYLOR GS, 2006, UNPUB J NEUROTRAUMA; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	31	46	47	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1295	1303		10.1089/neu.2006.23.1295			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900002	16958582				2022-02-06	
J	Chronister, J; Chan, F				Chronister, Julie; Chan, Fong			A stress process model of caregiving for individuals with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article						caregiving; TBI; social support; coping; stress process	COMPETENCE RATING-SCALE; BLUNT HEAD-INJURY; SOCIAL SUPPORT; FAMILY NEEDS; PSYCHOSOCIAL ADAPTATION; PSYCHOLOGICAL DISTRESS; COPING STRATEGIES; LIFE; PREDICTORS; RELATIVES	Objective: To test a stress process model of caregiving for persons with traumatic brain injury. Design: A correlational study using path analysis. Participants: One hundred eight caregivers affiliated with community- or Web-based support groups. Main Outcome Measures: The Modified Caregiver Appraisal Scale, the World Health Organization Quality of Life-Brief Version, the Interpersonal Support Evaluation List, and the COPE. Results: The normed fit index, comparative fit index, and parsimony ratio indicated a good fit for the model, suggesting that coping, social support, and caregiving appraisal contribute to quality of life. A more parsimonious model was respecified and achieved a better fit with fewer paths and variables. Conclusions: Empirical support was found for the proposed caregiving stress process model, which appears to provide useful information for future research and clinical interventions.	CUNY Hunter Coll, Dept Educ Fdn & Counseling, New York, NY 10021 USA; Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA		Chronister, J (corresponding author), CUNY Hunter Coll, Dept Educ Fdn & Counseling, 695 Pk Ave,Room W 1127, New York, NY 10021 USA.	julie.chronister@hunter.cuny.edu					ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Aneshensel C. S., 1995, PROFILES CAREGIVING; ARBUCKLE JL, 1999, AMOS J 0 SOFTWARE US; BARUSCH AS, 1989, GERONTOLOGIST, V29, P667, DOI 10.1093/geront/29.5.667; BENTLER PM, 1987, SOCIOL METHOD RES, V16, P78, DOI 10.1177/0049124187016001004; BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877, DOI 10.1037/0022-3514.46.4.877; Bollen K. A., 1989, STRUCTURAL EQUATIONS, DOI 10.1002/9781118619179; Bradburn NM, 1969, STRUCTURE PSYCHOL WE; Brissette I, 2002, J PERS SOC PSYCHOL, V82, P102, DOI 10.1037//0022-3514.82.1.102; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Byrne B., 2001, STRUCTURAL EQUATION; CANTOR MH, 1983, GERONTOLOGIST, V23, P597, DOI 10.1093/geront/23.6.597; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; COHEN S, 1983, SOCIAL SUPPORT THEOR, P73; CREWE NM, 1980, MINN MED, V63, P586; DOUGLAS JM, 2000, DISABILITY REHABILIT, V22, P683; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fidell L.S., 2001, USING MULTIVARIATE S; Fitting M, 1985, GENERATIONS, V10, P23; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1984, STRESS; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Goode KT, 1998, HEALTH PSYCHOL, V17, P190, DOI 10.1037/0278-6133.17.2.190; GRAD J, 1963, LANCET, V1, P544; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; HOLAHAN CJ, 1990, J PERS SOC PSYCHOL, V58, P909, DOI 10.1037/0022-3514.58.5.909; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; HOYLE RH, 1994, J CONSULT CLIN PSYCH, V62, P429, DOI 10.1037/0022-006X.62.3.429; Hu L.T., 1995, STRUCTURAL EQUATION, P76, DOI DOI 10.1080/10705519909540118; James L. R., 1982, CAUSAL ANAL ASSUMPTI; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/h0080325; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Leathem J, 1996, BRAIN INJURY, V10, P27; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Livneh H, 2005, J COUNS DEV, V83, P12, DOI 10.1002/j.1556-6678.2005.tb00575.x; Livneh H, 2003, REHABIL COUNS BULL, V46, P194, DOI 10.1177/003435520304600401; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; Moos R., 1993, HDB STRESS THEORETIC, P234; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; *NIH CONS DEV PAN, 1999, JAMA-J AM MED ASSOC, V232, P974; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PAKENHAM KI, 2001, PSYCHOL HLTH MED, V0006, P00013, DOI DOI 10.1080/13548500125141; PANTING A, 1972, J REHABIL, V82, P33; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; Pot AM, 1998, PATIENT EDUC COUNS, V34, P43, DOI 10.1016/S0738-3991(98)00048-2; PRIGATANO GP, 1989, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRUCHNO RA, 1989, GERONTOLOGIST, V29, P159, DOI 10.1093/geront/29.2.159; ROESSLER RT, 1990, REHABIL COUNS BULL, V34, P82; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Tarter S B, 1990, Arch Clin Neuropsychol, V5, P15; THOITS PA, 1987, J HEALTH SOC BEHAV, V28, P7, DOI 10.2307/2137137; THOMSEN I, 1972, SCANDINAVIAN J REHAB, V6, P180; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wrubel J., 1989, PRIMACY CARING STRES; Zanetti O, 1998, INT J GERIATR PSYCH, V13, P358, DOI 10.1002/(SICI)1099-1166(199806)13:6<358::AID-GPS772>3.0.CO;2-J; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	87	46	48	0	18	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2006	51	3					190	201		10.1037/0090-5550.51.3.190			12	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	072OK	WOS:000239682500002					2022-02-06	
J	McCrory, P; Turner, M; LeMasson, B; Bodere, C; Allemandou, A				McCrory, P.; Turner, M.; LeMasson, B.; Bodere, C.; Allemandou, A.			An analysis of injuries resulting from professional horse racing in France during 1991-2001: a comparison with injuries resulting from professional horse racing in Great Britain during 1992-2001	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PEDIATRIC EQUESTRIAN INJURIES; RIDING INJURIES; ACCIDENTS; CHILDREN; HELMETS	Background: It has been previously shown that professional jockeys suffer high rates of fatal and non-fatal injuries in the pursuit of their occupation. Little is known, however, about differences in injury rates between countries. Aim: To determine the rate of fatal and non-fatal injuries in flat and jump jockeys in France and to compare the injury rates with those in Great Britain and Ireland Method: Prospectively collected injury data on professional jockeys were used as the basis of the analysis. Results: Limb fractures occur four times more often in both flat and jump racing in France than in Great Britain. Similarly dislocations are diagnosed 20 times more often in flat and three times more often in jump racing. This difference is surprising given that French jockeys have fewer falls per ride than their British counterparts in flat racing, although they do have more falls than the British in jump racing. Similarly concussion rates seem to be higher in French jockeys, although there may be a difference in the diagnostic methods used in the different countries. By contrast, soft tissue injuries account for a far smaller percentage of injuries than in Great Britain. Conclusion: There are striking differences in injury rates between countries which may be explained in part by a difference in track conditions - for example, harder tracks in France - or different styles of racing for example, larger fields of horses per race in France.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; Univ Melbourne, Inst Brain Res, Parkville, Vic 3052, Australia; Jockey Club, London WC2H 8AL, England; France Gallop, Paris, France; Assoc Format & Act Social Ecuries Courses, Maisons Laffitte, France		McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	TURNER, Michael/0000-0003-2323-2456			ARONSON H, 1993, AM J FOREN MED PATH, V14, P28, DOI 10.1097/00000433-199303000-00006; BARCLAY WR, 1978, JAMA-J AM MED ASSOC, V240, P1892, DOI 10.1001/jama.1978.03290170074037; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; Bernhang A M, 1983, Phys Sportsmed, V11, P90, DOI 10.1080/00913847.1983.11708437; BIXBYHAMMETT D, 1990, SPORTS MED, V9, P36, DOI 10.2165/00007256-199009010-00004; BIXBYHAMMETT DM, 1992, PEDIATRICS, V89, P1173; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BOND GR, 1995, PEDIATRICS, V95, P487; BUCKLEY SM, 1993, AUST J PUBLIC HEALTH, V17, P269; Butterwick DJ, 1996, CLIN J SPORT MED, V6, P171, DOI 10.1097/00042752-199607000-00006; Campbell-Hewson G L, 1999, Eur J Emerg Med, V6, P37; *CDC, 1990, JAMA-J AM MED ASSOC, V264, P18; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; Costa-Paz M, 1999, BRIT J SPORT MED, V33, P329, DOI 10.1136/bjsm.33.5.329; DEBENEDETTE V, 1987, PHYSICIAN SPORTSMED, V15, P237; DEBENEDETTE V, 1989, PHYSICIAN SPORTSMED, V17, P250, DOI 10.1080/00913847.1989.11709748; Douglas B L, 1995, CDS Rev, V88, P28; FOSTER JB, 1976, LANCET, V1, P981; GIEBEL G, 1993, CHIRURG, V64, P938; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; GREISS FC, 1984, AM J OBSTET GYNECOL, V150, P168, DOI 10.1016/S0002-9378(84)80010-1; GROSSMAN JAI, 1978, JAMA-J AM MED ASSOC, V240, P1881, DOI 10.1001/jama.240.17.1881; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; Hobbs Gregory D., 1994, Journal of Emergency Medicine, V12, P143, DOI 10.1016/0736-4679(94)90690-4; HUGHES KM, 1995, AM J EMERG MED, V13, P485, DOI 10.1016/0735-6757(95)90148-5; INGEMARSON H, 1989, J TRAUMA, V29, P25, DOI 10.1097/00005373-198901000-00005; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; LANDO L, 1976, PHYSICIAN SPORTSMED, V4, P124; Lloyd R G, 1987, Br J Sports Med, V21, P22; Marshall SW., 1994, NZ J SPORTS MED, V22, P18; MASTERS RG, 1991, CLIN J SPORT MED, V1, P123; McAbee GN, 1996, PEDIATR NEUROL, V15, P235, DOI 10.1016/S0887-8994(96)00162-2; McCrory P, 2005, MED SPORT SCI, V48, P8, DOI 10.1159/000084280; MCGEE C, 1987, BRIT J NEUROSURG, V1, P131; McLatchie G R, 1979, Br J Sports Med, V13, P29; MILLS NJ, 1989, INJURY, V20, P189, DOI 10.1016/0020-1383(89)90108-3; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON DE, 1994, AM J PREV MED, V10, P15, DOI 10.1016/S0749-3797(18)30641-X; NELSON DE, 1994, PHYSICIAN SPORTSMED, V22, P53, DOI 10.1080/00913847.1994.11710501; OFarrell DA, 1997, BRIT J SPORT MED, V31, P249, DOI 10.1136/bjsm.31.3.249; POUNDER DJ, 1984, MED J AUSTRALIA, V141, P632, DOI 10.5694/j.1326-5377.1984.tb113173.x; PRESS JM, 1995, CLIN J SPORT MED, V5, P236, DOI 10.1097/00042752-199510000-00005; Rathfelder F J, 1995, Sportverletz Sportschaden, V9, P77, DOI 10.1055/s-2007-993429; REEDER AI, 1991, CAN J SPORT SCI, V16, P308; REICH L, 1979, HNO, V27, P416; Sahlin Y, 1990, Br J Sports Med, V24, P40; SCHMIDT B, 1994, UNFALLCHIRURG, V97, P661; Silver J R, 1991, Br J Sports Med, V25, P105; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Whitlock M R, 1987, Br J Sports Med, V21, P25; 1996, MMWR MORB MORTAL WKL, V45, P209	52	46	48	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2006	40	7					614	618		10.1136/bjsm.2006.028449			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	056OH	WOS:000238533800010	16687479	Green Published			2022-02-06	
J	Slobounov, S; Tutwiler, R; Sebastianelli, W; Slobounov, E				Slobounov, Semyon; Tutwiler, Rick; Sebastianelli, Wayne; Slobounov, Elena			Alteration of postural responses to visual field motion in mild traumatic brain injury	NEUROSURGERY			English	Article						balance; mild traumatic brain injury; virtual reality graphics; visual field motion	RECOVERY	OBJECTIVE: Balance deficits in individual's experiencing mild traumatic brain injury have been documented in numerous recent studies. However, long-lasting balance deficits and specific mechanisms causing these deficits have not been systematically examined. This article aimed to present empirical evidence showing destabilizing. effects of visual field motion in concussed individuals up to 30 days postinjury. METHODS: Sixty student athletes participated in the pilot (n = 12) and major experiments (n = 48) before injury. Eight of these 48 subjects who experienced mild traumatic brain injury in athletic events were tested again on Days 3, 10, and 30 after the incident. Postural responses to visual field motion were recorded using a virtual reality environment in conjunction with balance (AMTI force plate) and motion tracking (Flock of Birds) technologies. RESULTS: The area of the center of pressure during upright stance did not change from Day 3 to 30 postinjury with respect to pre-injury status (P > .05). However, balance deficits induced by visual field motion were present up to 30 days postinjury. Destabilizing effect of visual field motion was observed via significant increase of the center of pressure data (P < .05) and reduced coherence value. CONCLUSION: Our data suggest the presence of residual sensory integration dysfunction in concussed individuals at least 30 days postinjury and may indicate a lower threshold for brain reinjury.	Penn State Univ, Dept Kinesiol, University Pk, PA USA; Penn State Univ, Appl Res Lab, University Pk, PA 16802 USA; Penn State Univ, Ctr Sports Med, University Pk, PA USA; Penn State Univ, Visualizat Grp, University Pk, PA USA		Slobounov, S (corresponding author), 19 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu					Barth JT, 2001, J ATHL TRAINING, V36, P253; Beer J, 2002, EXP BRAIN RES, V143, P78, DOI 10.1007/s00221-001-0947-y; CANTU R, 2006, FDN SPORT RELATED BR, P88; Cantu RC, 2001, J ATHL TRAINING, V36, P244; CLEMENT G, 1983, EXP BRAIN RES, V52, P429; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EHRENFRIED T, 2003, COGNITIVE BRAIN RES, V1, P34; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; HORAK FB, 1994, J NEUROPHYSIOL, V72, P479, DOI 10.1152/jn.1994.72.2.479; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ikeda T, 1997, ACTA OTO-LARYNGOL, V117, P815, DOI 10.3109/00016489709114206; Keshner E., 2004, INT C DIS VIRT REAL, V1; Keshner EA, 2004, ASSIST TECHNOL, V16, P54, DOI 10.1080/10400435.2004.10132074; Keshner EA, 2004, J VESTIBUL RES-EQUIL, V14, P307; KESHNER EA, 2000, J VESTIBUL RES-EQUIL, V7, P1; Kuno S, 1999, JPN J PHYSIOL, V49, P417, DOI 10.2170/jjphysiol.49.417; Lee D.N., 1975, J HUM MOVEMENT STUD, V1, P87; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; LESTIENNE F, 1977, EXP BRAIN RES, V28, P363; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mach, 1875, GRUNDLINIEN LEHRE BE; Nakamura S, 1999, PERCEPTION, V28, P893, DOI 10.1068/p2939; Previc F. H., 1991, J VESTIBUL RES-EQUIL, V1, P317; Randolph C, 2001, J ATHL TRAINING, V36, P288; RING C, 1988, ARCH PHYS MED REHAB, V69, P261; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Stoffregen TA, 1998, BRAIN RES BULL, V47, P437, DOI 10.1016/S0361-9230(98)00102-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Thurrell AEI, 2002, EXP BRAIN RES, V147, P558, DOI 10.1007/s00221-002-1296-1; VANASTEN WNJC, 1988, EXP BRAIN RES, V73, P371, DOI 10.1007/BF00248230; WADE MG, 1995, J GERONTOL B-PSYCHOL, V50, pP51, DOI 10.1093/geronb/50B.1.P51; WARREN R, 1976, J EXP PSYCHOL HUMAN, V2, P448, DOI 10.1037/0096-1523.2.3.448; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	37	46	46	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2006	59	1					134	139		10.1227/01.NEU.0000219197.33182.3F			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	061PV	WOS:000238885600031	16823309				2022-02-06	
J	Talvik, I; Metsvaht, T; Leito, K; Poder, H; Kool, P; Vali, M; Lintrop, M; Kolk, A; Talvik, T				Talvik, Inga; Metsvaht, Tuuli; Leito, Kaja; Poder, Haide; Kool, Pille; Vali, Marika; Lintrop, Mare; Kolk, Anneli; Talvik, Tiina			Inflicted traumatic brain injury (ITBI) or shaken baby syndrome (SBS) in Estonia	ACTA PAEDIATRICA			English	Article						inflicted brain injury; shaken baby syndrome; incidence; child abuse	SUBDURAL-HEMATOMA; INFANTS; OUTCOMES	Background: Inflicted traumatic brain injury (ITBI) or shaken baby syndrome (SBS) is recognized as a major cause of disability and death in the paediatric population. Aim: To find out the incidence of ITBI in Estonia. Methods: 26 cases of ITBI were recognized: four children died, 22 survived. Results: Of 26 children, 20 (77%) were boys and six (23%) were girls. Median age at admission to hospital was 3.9 mo, and the boys were younger than the girls.	Univ Tartu Hosp, Childrens Clin, Dept Neurol, EE-51014 Tartu, Estonia; Univ Tartu Hosp, Childrens Clin, Tartu, Estonia; Univ Tartu Hosp, Anaesthesiol & Intens Care Clin, Tartu, Estonia; Tallinn Childrens Hosp, Tallinn, Estonia; Tartu Univ Hosp, Radiol Dept, Tartu, Estonia; Univ Tartu, Dept Pathol Anat & Forens Med, Tartu, Estonia		Talvik, I (corresponding author), Univ Tartu Hosp, Childrens Clin, Dept Neurol, 6 Lunini Str, EE-51014 Tartu, Estonia.	inga.talvik@kliinikum.ee	Metsvaht, Tuuli/H-6897-2015	Metsvaht, Tuuli/0000-0003-3206-3092			Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Fung ELW, 2003, PEDIATR INT, V45, P497, DOI 10.1046/j.1442-200X.2003.01739.x; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kocher M S, 2000, J Am Acad Orthop Surg, V8, P10; Kujiraoka Y, 2004, NEUROL MED-CHIR, V44, P359, DOI 10.2176/nmc.44.359; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Morad Y, 2004, J AAPOS, V8, P521, DOI 10.1016/j.jaapos.2004.07.009; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; van der Wal MF, 1998, ARCH DIS CHILD, V79, P312, DOI 10.1136/adc.79.4.312	19	46	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	JUL	2006	95	7					799	804		10.1080/08035250500464923			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	057QL	WOS:000238610200007	16801174				2022-02-06	
J	Feeney, T; Ylvisaker, M				Feeney, Timothy; Ylvisaker, Mark			Context-sensitive cognitive-behavioural supports for young children with TBI: A replication study	BRAIN INJURY			English	Article						behaviour disorders; paediatric rehabilitation; traumatic brain injury; positive behaviour support; cognitive-behavioural intervention; functional assessment; school-based treatment; multi-component intervention; ecological validity	TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE INJURY; CLOSED-HEAD INJURY; SHORT-TERM; FAMILY; ADOLESCENTS; PREDICTORS; REHABILITATION; SEVERITY; RECOVERY	Objective: To replicate an investigation of the effects of a multi-component cognitive-behavioural intervention on the challenging behaviour of two young children with growing behavioural concerns after TBI. Experimental design: Single-subject reversal designs used to document the effects of the combined behavioural, cognitive and executive function intervention on the following dependent variables: frequency and intensity of aggressive behaviours, amount of work accomplished. Participants: Two young children with escalating behaviour problems after TBI. Intervention: Integrated components of positive behaviour supports, cognitive supports ( e. g. graphic organizers) and an executive function routine (goal-plan-do-review). Results: Reduced frequency and intensity of challenging behaviours; increased quantity of work completed. Conclusions: Positive replication of previous single-subject experiments demonstrating the potential for successfully treating behaviour disorders in young children with TBI using a support-oriented intervention that combines behavioural, cognitive and executive function components.	Sch & Community Support Serv, Schenectady, NY USA; Coll St Rose, Sch Educ, Albany, NY USA		Feeney, T (corresponding author), 1171 Van Antwerp Rd, New York 12309, NY USA.	ylvisakm@mail.strose.edu	Berger, Emily/N-7268-2017	Berger, Emily/0000-0001-5550-807X			Aman MG., 1994, ABERRANT BEHAV CHECK; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Barlow DH, 1984, SINGLE CASE EXPT DES; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; BIJOU SW, 1968, J APPL BEHAV ANAL, V1, P175, DOI 10.1901/jaba.1968.1-175; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; Bronson MB, 2000, SELF-REGULATION IN EARLY CHILDHOOD, P1; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Carr EG, 2002, J POSIT BEHAV INTERV, V4, P4, DOI 10.1177/109830070200400102; CARR EG, 1994, COMMUNICATION BASED; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; COSTEFF H, 1985, SCAND J REHABIL MED, P10; DAMASIO AR, 1994, DESCARTES ERRER EMOT; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Detterman DL, 1993, TRANSFER TRIAL INTEL; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; DURAND M, 1992, MOTIVATION ASSESSMEN; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P297; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; FEENEY T, 1997, STUDENTS ACQUIRED BR, P229; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Glesne C., 1992, BECOMING QUALITATIVE; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Harchik A E, 1993, Ann Clin Psychiatry, V5, P151, DOI 10.3109/10401239309148979; Hebb DO, 1947, AM PSYCHOL, V2, P737; KEPPEL G, 1991, DESIGN ANAL INVESTIG; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kolb B., 1995, BRAIN PLASTICITY BEH; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; MACE FC, 1990, J EXP ANAL BEHAV, V54, P163, DOI 10.1901/jeab.1990.54-163; Mace FC, 1997, J APPL BEHAV ANAL, V30, P1, DOI 10.1901/jaba.1997.30-1; MARLOWE WB, 1990, J CLIN EXP NEUROPSYC, V12, P105; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; McDonald S., 2005, BRAIN IMPAIR, V6, P58, DOI [DOI 10.1375/BRIM.6.1.56.65481, 10.1375/brim.6.1.56.65481]; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; REICHLE J, 1993, COMMUNICATIVE ALTERN; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Schlund MW, 2002, BRAIN INJURY, V16, P527, DOI 10.1080/02699050110113679; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Taylor S.J., 1984, INTRO QUALITATIVE RE, V2nd ed.; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, Vxiv; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, 2005, REHABILITATION TRAUM, P205; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	88	46	46	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	6					629	645		10.1080/02699050600744194			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100008	16754288				2022-02-06	
J	Goodman, D; Bradley, NL; Paras, B; Williamson, IJ; Bizzochi, J				Goodman, D; Bradley, NL; Paras, B; Williamson, IJ; Bizzochi, J			Video gaming promotes concussion knowledge acquisition in youth hockey players	JOURNAL OF ADOLESCENCE			English	Article						video games; youth; education; concussion	SCHOOL PERFORMANCE; COMPUTER GAMES; LIFE; AGGRESSION; TELEVISION; BEHAVIOR; EXPOSURE; VIOLENCE; HABITS	While the positive uses for video games in an educational setting have also been established, the educational aim is usually made explicit. The goal of this research was to develop a video game wherein the educational aspect was implicitly embedded in the video game, such that the gameing activity remained interesting and relevant. Following a pilot study to confirm the usability of an in-house developed game, two studies were conducted with 11-17 year old hockey players (N-1 = 130, N-2 = 39). Results demonstrated that participants playing the experimental version of the video game scored significantly higher on a concussion symptoms questionnaire, in a significantly faster time, than participants playing the control version of the game. Most participants indicated that they enjoyed the game and would play it again. These results suggest that educational material can be conveyed successfully and in an appealing manner via video game play. (c) 2005 The Association for Professionals in Services for Adolescents. Published by Elsevier Ltd. All rights reserved.	Simon Fraser Univ, Sch Kinesiol, Fac Sci Appl, Burnaby, BC V5A 1S6, Canada		Goodman, D (corresponding author), Simon Fraser Univ, Sch Kinesiol, Fac Sci Appl, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	goodman@sfu.ca					Anderson CA, 2000, J PERS SOC PSYCHOL, V78, P772, DOI 10.1037//0022-3514.78.4.772; Anderson CA, 2004, J ADOLESCENCE, V27, P113, DOI 10.1016/j.adolescence.2003.10.009; Anderson CA, 2004, J ADOLESCENCE, V27, P1, DOI 10.1016/j.adolescence.2003.10.001; Anderson CA, 2001, PSYCHOL SCI, V12, P353, DOI 10.1111/1467-9280.00366; Blumberg FC, 2004, J GEN PSYCHOL, V131, P151, DOI 10.3200/GENP.131.2.151-158; Blumberg FC, 1998, J APPL DEV PSYCHOL, V19, P615, DOI 10.1016/S0193-3973(99)80058-6; Blumberg FC, 2000, J APPL DEV PSYCHOL, V21, P641, DOI 10.1016/S0193-3973(00)00058-7; Brown SJ, 1997, MED INFORM, V22, P77, DOI 10.3109/14639239709089835; Dill KE, 1998, AGGRESS VIOLENT BEH, V3, P407, DOI 10.1016/S1359-1789(97)00001-3; Dustman RE, 1992, J GERONTOL, V47, P168; Funk JB, 2004, J ADOLESCENCE, V27, P23, DOI 10.1016/j.adolescence.2003.10.005; Gentile DA, 2004, J ADOLESCENCE, V27, P5, DOI 10.1016/j.adolescence.2003.10.002; Gentile DA, 2002, J APPL DEV PSYCHOL, V23, P157, DOI 10.1016/S0193-3973(02)00102-8; Hughes R, 1999, FAM RELAT, V48, P5; KOLKO DJ, 1985, J CONSULT CLIN PSYCH, V53, P223, DOI 10.1037/0022-006X.53.2.223; Krahe B, 2004, J ADOLESCENCE, V27, P53, DOI 10.1016/j.adolescence.2003.10.006; Lieberman D A, 2001, J Ambul Care Manage, V24, P26; Lieberman D. A., 1997, LEA COMMUN SER, P103; Pope A. T., 1996, CHILD STUDY J, V26, P39; Rieber LP, 1996, ETR&D-EDUC TECH RES, V44, P43, DOI 10.1007/BF02300540; Shewokis PA, 2003, PERCEPT MOTOR SKILL, V97, P581; Shewokis PA, 1997, PERCEPT MOTOR SKILL, V84, P3; Uhlmann E, 2004, J ADOLESCENCE, V27, P41, DOI 10.1016/j.adolescence.2003.10.004; Van Mierlo J, 2004, J ADOLESCENCE, V27, P97, DOI 10.1016/j.adolescence.2003.10.008; VANDENBULCK J, 2004, DREAMING, V14, P43, DOI DOI 10.1037/1053-0797.14.1.43; Vandewater EA, 2004, J ADOLESCENCE, V27, P71, DOI 10.1016/j.adolescence.2003.10.003; VanSchie EGM, 1997, J APPL SOC PSYCHOL, V27, P1175	27	46	47	0	14	ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0140-1971			J ADOLESCENCE	J. Adolesc.	JUN	2006	29	3					351	360		10.1016/j.adolescence.2005.07.004			10	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	057KQ	WOS:000238595100003	16169584				2022-02-06	
J	Sojka, P; Stalnacke, BM; Bjornstig, U; Karlsson, K				Sojka, Peter; Stalnacke, Britt-Marie; Bjornstig, Ulf; Karlsson, Kurt			One-year follow-up of patients with mild traumatic brain injury: Occurrence of post-traumatic stress-related symptoms at follow-up and serum levels of cortisol, S-100B and neuron-specific enolase in acute phase	BRAIN INJURY			English	Article						traumatic brain injury; head trauma; brain concussion; post-concussion symptoms biochemical marker; S100 proteins; cortisol; post-traumatic stress disorder	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PLASMA-CORTISOL; EVENT SCALE; DISORDER; PROTEIN; CATECHOLAMINES; INTOXICATION; SEVERITY	Objective: To investigate serum levels of cortisol ( a biochemical marker of stress), S-100B and neuron-specific enolase ( two biochemical markers of brain tissue injury), in acute phase in mild traumatic brain injury patients and the occurrence of post-traumatic stress-related symptoms 1 year after the trauma. Methods: Blood samples were taken in patients (n = 88) on admission and similar to 7 hours later for analysis. Occurrence of post-traumatic stress-related symptoms was assessed for 69 patients using items from the Impact of Event Scale questionnaire (IES) at follow-up at 15 +/- 4 months after the injury. Results: Serum levels of cortisol were more increased in the first sample (cortisol/1, 628.9 +/- 308.9 nmol L-1) than in the second blood sample (cortisol/2, 398.2 +/- 219.4 nmol L-1). The difference between these samples was statistically significant (p < 0.001). Altogether 12 patients (17%) showed post-traumatic stress related symptoms at the time of the follow-up. Stepwise forward logistic regression analysis of symptoms and serum concentrations of markers revealed that only S-100B in the second sample was statistically significantly (p < 0.05) associated to symptoms ( three symptoms of the avoidance sub-set of IES). Conclusion: A major increase in serum concentrations of cortisol indicates that high stress levels were reached by the patients, in particular shortly (similar to 3 hours) after the trauma. The association between the occurrence of post-traumatic stress related symptoms and serum levels of S-100B (generally considered as a biochemical marker of brain injury) seem to reflect the complexity of interactions between brain tissue injury and the ensemble of stress reactions.	Umea Univ Hosp, Dept Community Med & Rehabil, S-90185 Umea, Sweden; Umea Univ Hosp, Dept Surg & Peri Operat Sci, S-90185 Umea, Sweden; Umea Univ Hosp, Dept Med Biosci, S-90185 Umea, Sweden		Sojka, P (corresponding author), Umea Univ Hosp, Dept Community Med & Rehabil, Bldg 9A, S-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Baum A.A.G.N., 1995, MEASURING STRESS GUI, P175; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cernak I, 1999, BRAIN INJURY, V13, P1005; Deb S, 1999, AM J PSYCHIAT, V156, P374; Delahanty DL, 2000, BIOL PSYCHIAT, V48, P940, DOI 10.1016/S0006-3223(00)00896-9; Frias J, 2000, LIFE SCI, V67, P1081, DOI 10.1016/S0024-3205(00)00702-5; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; KATO K, 1983, J BIOCHEM-TOKYO, V94, P1009, DOI 10.1093/oxfordjournals.jbchem.a134397; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McFarlane AC, 1997, ANN NY ACAD SCI, V821, P437, DOI 10.1111/j.1749-6632.1997.tb48299.x; MIDDELBOE T, 1991, Acta Neurologica Scandinavica, V85, P5; Morgan CA, 2000, BIOL PSYCHIAT, V47, P891, DOI 10.1016/S0006-3223(99)00307-8; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; SUZUKI F, 1983, J BIOCHEM-TOKYO, V94, P1707; SUZUKI F, 1984, J NEUROCHEM, V42, P130, DOI 10.1111/j.1471-4159.1984.tb09708.x; SUZUKI F, 1986, BIOCHIM BIOPHYS ACTA, V889, P84, DOI 10.1016/0167-4889(86)90011-X; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; VanCauter E, 1996, J CLIN ENDOCR METAB, V81, P2468, DOI 10.1210/jc.81.7.2468; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Yehuda R, 1998, BIOL PSYCHIAT, V44, P1305, DOI 10.1016/S0006-3223(98)00276-5; Yehuda R, 1997, NATO ADV SCI I A-LIF, V291, P221	37	46	47	2	13	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	6					613	620		10.1080/02699050600676982			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100006	16754286				2022-02-06	
J	Nelson, TJ; Wall, DB; Stedje-Larsen, ET; Clark, RT; Chambers, LW; Bohman, HR				Nelson, TJ; Wall, DB; Stedje-Larsen, ET; Clark, RT; Chambers, LW; Bohman, HR			Predictors of mortality in close proximity blast injuries during operation Iraqi freedom	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							SUICIDE BOMBING ATTACKS; SYSTEM	BACKGROUND: Blast injury is an increasingly common problem faced by military surgeons in the field. Because of urban terrorism worldwide, blast injury is becoming more common in the civilian sector as well. Blast injuries are often devastating and can overwhelm medical resources. We sought to determine whether simple factors easily obtained from the clinical history and primary survey could be used to triage patients more effectively. STUDY DESIGN: A retrospective review of 18 consecutive close-proximity blast injury patients presenting to a forward deployed surgical unit in Iraq was performed. Patients' injuries and outcomes were recorded. We compared the presence of sustained hypotension, penetrating head injury, multiple (three or more) long-bone fractures, and associated fatalities (whether another patient involved in the same explosion died) between nonsurvivors and survivors using Fisher's exact test. RESULTS: All patients who presented alive but exhibited sustained hypotension (n = 5) died, versus 0% who did not exhibit sustained hypotension (n = 9, p < 0.01). There was no marked increase in mortality with presence of multiple long-bone fractures, penetrating head injury, or associated fatalities individually. Having two or more of these factors was associated with a mortality of 86% (6 of 7) versus 20% (2 of 10, p = 0.015) in those who had less than two factors. CONCLUSIONS: Blast injury can overwhelm military and civilian trauma systems alike. Sustained hypotension and presence of two or more easily determined factors, including three or more long-bone fractures, penetrating head injury, and associated fatalities, are associated with increased mortality and can potentially help triage patients and allocate scarce resources more efficiently.	USN, Hosp Camp Pendleton, Dept Surg, Camp Pendleton, CA 92055 USA; USN, San Diego Med Ctr, San Diego, CA 92152 USA; 1st Battal, 7th Marines, Twenty Nine Palms, CA USA; 1st Force Serv Support Grp, 1st Med Battal, Camp Pendleton, CA USA		Nelson, TJ (corresponding author), USN, Hosp Camp Pendleton, Dept Surg, Marine Corps Base, Camp Pendleton, CA 92055 USA.	tom.nelson2120@sbcglobal.net					Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Bellamy RF, 1995, ANESTHESIA PERIOPERA, P1; Bohman HR, 2005, MIL MED, V170, P297, DOI 10.7205/MILMED.170.4.297; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; CHAMBERS LW, 2005, AM ASS SURG TRAUM SE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107, DOI 10.1097/01.CCM.0000151072.17826.72; Kluger Y, 2004, J AM COLL SURGEONS, V199, P875, DOI 10.1016/j.jamcollsurg.2004.09.003; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Rodoplu Ulkumen, 2004, Prehosp Disaster Med, V19, P133; Ryan J, 2005, NEW ENGL J MED, V353, P543, DOI 10.1056/NEJMp058177; Singer Pierre, 2005, Crit Care Med, V33, pS61, DOI 10.1097/01.CCM.0000151068.33935.3E; 2004, NATO EMERGENCY WAR S	16	46	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	MAR	2006	202	3					418	422		10.1016/j.jamcollsurg.2005.11.011			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	024YZ	WOS:000236233800006	16500245				2022-02-06	
J	Ruitenberg, MJ; Vukovic, J; Sarich, J; Busfield, SJ; Plant, GW				Ruitenberg, MJ; Vukovic, J; Sarich, J; Busfield, SJ; Plant, GW			Olfactory ensheathing cells: Characteristics, genetic engineering, and therapeutic potential	JOURNAL OF NEUROTRAUMA			English	Article						gene therapy; neurotrophic factors; olfactory ensheathing glia; regeneration; spinal cord	PROMOTE AXONAL REGENERATION; SPINAL-CORD; SCHWANN-CELLS; IN-VIVO; DELAYED TRANSPLANTATION; FUNCTIONAL RECOVERY; CORTICOSPINAL TRACT; LOCOMOTOR RECOVERY; NGF-RECEPTOR; RAT	Injured neurons in the mammalian central nervous system (CNS) do not normally regenerate their axons after injury. Neurotrauma to the CNS usually results in axonal damage and subsequent loss of communication between neuronal networks, causing long-term functional deficits. For CNS regeneration, repair strategies need to be developed that promote regrowth of lesioned axon projections and restoration of neuronal connectivity. After spinal cord injury (SCI), cystic cavitations are often found, particularly in the later stages, due to the loss of neural tissue at the original impact site. Ultimately, for the promotion of axonal regrowth in these situations, some form of transplantation will be required to provide lesioned axons with a supportive substrate along which they can extend. Here, we review the use of olfactory ensheathing cells: their location and role in the olfactory system, their use as cellular transplants in SCI paradigms, alone or in combination with gene therapy, and the unique properties of these cells that may give them a potential advantage over other cellular transplants.	Univ Western Australia, Sch Anat & Human Biol, Reds Spinal Cord Res Lab, Perth, WA 6009, Australia; Univ Western Australia, Western Australian Med Res, Perth, WA 6009, Australia; Univ Western Australia, UWA Ctr Med Res, Perth, WA 6009, Australia		Plant, GW (corresponding author), Univ Western Australia, Sch Anat & Human Biol, Reds Spinal Cord Res Lab, Mail Bag Delivery Point M309,35 Stirling Highway, Perth, WA 6009, Australia.	gplant@anhb.uwa.edu.au	Vukovic, Jana/B-4845-2013	Vukovic, Jana/0000-0002-3739-1688; Ruitenberg, Marc/0000-0002-6917-0708			Andrews MR, 2004, EXP NEUROL, V190, P311, DOI 10.1016/j.expneurol.2004.08.011; Au E, 2003, GLIA, V41, P224, DOI 10.1002/glia.10160; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; Barnett SC, 2004, J NEUROTRAUM, V21, P375, DOI 10.1089/089771504323004520; Barnett Susan C, 1800, Methods Mol Biol, V198, P41; Bianco JI, 2004, GLIA, V45, P111, DOI 10.1002/glia.10298; Blesch A, 2001, GENE THER, V8, P954, DOI 10.1038/sj.gt.3301480; Blits B, 2004, EXP NEUROL, V189, P303, DOI 10.1016/j.expneurol.2004.05.014; Blits P, 2000, EXP NEUROL, V164, P25, DOI 10.1006/exnr.2000.7413; Boruch AV, 2001, GLIA, V33, P225, DOI 10.1002/1098-1136(200103)33:3<225::AID-GLIA1021>3.3.CO;2-P; Boyd JG, 2004, P NATL ACAD SCI USA, V101, P2162, DOI 10.1073/pnas.0303842101; Bunge MB, 2003, J REHABIL RES DEV, V40, P55, DOI 10.1682/JRRD.2003.08.0055; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cao L, 2004, BRAIN, V127, P535, DOI 10.1093/brain/awh072; CARR VM, 1993, EXP NEUROL, V124, P308, DOI 10.1006/exnr.1993.1201; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; Chuah MI, 2004, EXP NEUROL, V185, P15, DOI 10.1016/j.expneurol.2003.09.008; Chuah MI, 2002, MICROSC RES TECHNIQ, V58, P216, DOI 10.1002/jemt.10151; DEVON R, 1992, BRAIN RES, V589, P175; DOUCETTE R, 1989, J COMP NEUROL, V285, P514, DOI 10.1002/cne.902850407; DOUCETTE R, 1991, J COMP NEUROL, V312, P451, DOI 10.1002/cne.903120311; DOUCETTE R, 1990, GLIA, V3, P433, DOI 10.1002/glia.440030602; Dunning MD, 2004, J NEUROSCI, V24, P9799, DOI 10.1523/JNEUROSCI.3126-04.2004; Field PM, 2003, J NEUROCYTOL, V32, P317, DOI 10.1023/B:NEUR.0000010089.37032.48; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Franceschini IA, 1996, DEV BIOL, V173, P327, DOI 10.1006/dbio.1996.0027; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; Garcia-Alias G, 2004, J NEUROSCI RES, V75, P632, DOI 10.1002/jnr.20029; Gomez VM, 2003, J NEUROCYTOL, V32, P53, DOI 10.1023/A:1027328331832; GONG QZ, 1994, J COMP NEUROL, V344, P336, DOI 10.1002/cne.903440303; GOODMAN MN, 1993, BRAIN RES, V619, P199; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Iwashita Y, 2000, NEUROREPORT, V11, P1013, DOI 10.1097/00001756-200004070-00023; Kafitz KW, 1998, ANN NY ACAD SCI, V855, P266, DOI 10.1111/j.1749-6632.1998.tb10580.x; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; Lakatos A, 2000, GLIA, V32, P214, DOI 10.1002/1098-1136(200012)32:3<214::AID-GLIA20>3.0.CO;2-7; Lakatos A, 2003, EXP NEUROL, V184, P237, DOI 10.1016/S0014-4886(03)00270-X; Lee IH, 2004, EXP NEUROL, V187, P509, DOI 10.1016/j.expneurol.2004.02.007; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Li Y, 2004, EXP NEUROL, V188, P300, DOI 10.1016/j.expneurol.2004.04.021; Li Y, 2003, J NEUROSCI, V23, P727; Li Y, 1998, J NEUROSCI, V18, P10514; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Menei P, 1998, EUR J NEUROSCI, V10, P607, DOI 10.1046/j.1460-9568.1998.00071.x; Myckatyn TM, 2004, TRANSPL IMMUNOL, V12, P343, DOI 10.1016/j.trim.2003.12.017; Nash HH, 2002, J NEUROSCI, V22, P7111; Navarro X, 1999, ANN NEUROL, V45, P207, DOI 10.1002/1531-8249(199902)45:2<207::AID-ANA11>3.0.CO;2-K; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Plant GW, 2002, J NEUROSCI, V22, P6083; Plant GW, 2001, MOL CELL NEUROSCI, V17, P471, DOI 10.1006/mcne.2000.0948; PLANT GW, 2001, NEUROL DIS, V52, P529; Polentes J, 2004, NEUROBIOL DIS, V16, P638, DOI 10.1016/j.nbd.2004.04.009; Ramer LM, 2004, GLIA, V47, P189, DOI 10.1002/glia.20054; Ramer LM, 2004, J COMP NEUROL, V473, P1, DOI 10.1002/cne.20049; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; RAMONCUETO A, 1993, EUR J NEUROSCI, V5, P1172, DOI 10.1111/j.1460-9568.1993.tb00971.x; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099; Reier Paul J, 2004, NeuroRx, V1, P424, DOI 10.1602/neurorx.1.4.424; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; Riddell JS, 2004, GLIA, V47, P150, DOI 10.1002/glia.20041; Ruitenberg MJ, 2005, BRAIN, V128, P839, DOI 10.1093/brain/awh424; Ruitenberg MJ, 2003, J NEUROSCI, V23, P7045, DOI 10.1523/JNEUROSCI.23-18-07045.2003; Ruitenberg MJ, 2002, GENE THER, V9, P135, DOI 10.1038/sj.gt.3301626; Sasaki M, 2004, J NEUROSCI, V24, P8485, DOI 10.1523/JNEUROSCI.1998-04.2004; Schwob James E., 2002, Anatomical Record, V269, P33, DOI 10.1002/ar.10047; Takami T, 2002, J NEUROSCI, V22, P6670; Treloar HB, 1996, J NEUROBIOL, V31, P41, DOI 10.1002/(SICI)1097-4695(199609)31:1<41::AID-NEU4>3.0.CO;2-F; TURNQUIST PK, 1994, AGR ENG, V75, P12; VALVERDE F, 1993, DEV BRAIN RES, V71, P209, DOI 10.1016/0165-3806(93)90173-8; Verdu E, 2003, GLIA, V42, P275, DOI 10.1002/glia.10217; Verdu E, 2001, NEUROREPORT, V12, P2303, DOI 10.1097/00001756-200108080-00005; Weiler E, 1997, J NEUROSCI, V17, P3610; Williams SK, 2004, J COMP NEUROL, V470, P50, DOI 10.1002/cne.11045; Woodhall E, 2003, CELL MOL LIFE SCI, V60, P2241, DOI 10.1007/s00018-003-3265-7; Woodhall E, 2001, MOL BRAIN RES, V88, P203, DOI 10.1016/S0169-328X(01)00044-4; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309	81	46	57	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR-APR	2006	23	3-4					468	478		10.1089/neu.2006.23.468			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	039WF	WOS:000237337700018	16629630				2022-02-06	
J	Davis, DP; Vadeboncoeur, TF; Ochs, M; Poste, JC; Vilke, GM; Hoyt, DB				Davis, DP; Vadeboncoeur, TF; Ochs, M; Poste, JC; Vilke, GM; Hoyt, DB			The association between field Glasgow Coma Scale score and outcome in patients undergoing paramedic rapid sequence intubation	JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 17, 2004	Orlando, FL	Soc Acad Emergency Med		Glasgow Coma Scale; paramedic; prehospital; EMS; Rapid Sequence Intubation; traumatic brain injury; head trauma	RESPIRATORY-DISTRESS-SYNDROME; SEVERE HEAD-INJURIES; INDUCED LUNG INJURY; ISCHEMIC BRAIN-DAMAGE; TRAUMA PATIENTS; MECHANICAL VENTILATION; ENDOTRACHEAL INTUBATION; INTRACRANIAL-PRESSURE; EMERGENCY-DEPARTMENT; HYPOTENSION	Early intubation is standard for treating severe traumatic brain injury (TBI). Aeromedical crews and select paramedic agencies use rapid sequence intubation (RSI) to facilitate intubation after TBI, with Glasgow Coma Scale (GCS) score commonly used as a screening tool. To explore the association between paramedic GCS and outcome in patients with TBI undergoing prehospital RSI, paramedics prospectively enrolled adult major trauma victims with GCS 3-8 and clinical suspicion for head trauma to undergo succinylcholine-assisted intubation as part of the San Diego Paramedic RSI Trial. The following data were abstracted from paramedic debriefing interviews and the county trauma registry: demographics, mechanism, vital signs including GCS score, clinical evidence of aspiration before RSI, arrival laboratory values, hospital course, and outcome. Paramedic GCS calculations were confirmed during debriefing interviews. Patients were stratified by GCS score, with chi-square and receiver-operator-curve (ROC) analysis used to explore the relationship between GCS and hypoxia, head injury severity, aspiration, intensive care unit (ICU) length of stay, and outcome. Cohort analysis was used to explore potential reasons for early extubation and discharge from the ICU in some patients. A total of 412 patients were included in this analysis. A total of 81 patients (20%) were extubated and discharged from the ICU in 48 h or less; these patients had higher pre-RSI oxygen saturation (SaO(2)) values and higher arrival serum ethanol levels. Paramedic and physician GCS calculations had high agreement (kappa = 0.995). A statistically significant relationship was observed between GCS score and Head Abbreviated Injury Score (AIS), survival, and pre-RSI SaO(2) values. However, ROC analysis revealed a limited ability of GCS to predict the presence of severe TBI, injury severity, desaturation, aspiration, ICU length of stay, or ultimate survival. In conclusion, paramedics seem to accurately calculate GCS values before prehospital RSI. Although a relationship between paramedic GCS and outcome exists, the ability to predict the severity of injury, airway-related complications, ICU length of stay, and overall survival is limited using this single variable. Other factors should be considered to screen TBI patients for prehospital RSI. (c) 2005 Elsevier Inc.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; San Diego Cty Emergency Med Serv, San Diego, CA USA; Univ Calif San Diego, John Muir Coll, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA		Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr 8676, San Diego, CA 92103 USA.						Amin AP, 2000, SURGERY, V127, P245, DOI 10.1067/msy.2000.104296; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; COTTRELL JE, 1983, ANESTH ANALG, V62, P1006; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, IN PRESS J TRAUMA; Doran J V, 1995, Prehosp Disaster Med, V10, P259; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MACIVER IN, 1958, LANCET, V1, P390; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MILLAR C, 1994, CAN J ANAESTH, V41, P281, DOI 10.1007/BF03009904; MODICA PA, 1992, CAN J ANAESTH, V39, P236, DOI 10.1007/BF03008783; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Spaite DW, 2003, ANN EMERG MED, V42, P729, DOI 10.1016/S0196-0644(03)00822-9; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; TEASDALE G, 1974, LANCET, V2, P81; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; VILKE GM, 2004, PREHOSP EMERG CARE, V8, P88; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; WANG H, 2004, PREHOSP EMERG CARE, V8, P84; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014	60	46	47	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	NOV	2005	29	4					391	397		10.1016/j.jemermed.2005.04.012			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	979QI	WOS:000232959500004	16243194				2022-02-06	
J	Qu, CS; Lu, DY; Goussev, A; Schallert, T; Mahmood, A; Chopp, M				Qu, CS; Lu, DY; Goussev, A; Schallert, T; Mahmood, A; Chopp, M			Effects of atorvastatin on spatial memory, neuronal survival, and vascular density in female rats after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						neuroplasticity; spatial memory; traumatic brain injury; atorvastatin; rat	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; MARROW STROMAL CELLS; INTRACEREBRAL HEMORRHAGE; TRANSPLANTATION; SYNAPTOGENESIS; NEUROGENESIS; ANGIOGENESIS; ACQUISITION; IMPROVEMENT	Object. Atorvastatin administered after traumatic brain injury (TBI) induced by controlled cortical impact promotes functional improvement in male rats. Note, however, that parallel studies have not been performed in female rats. Therefore, the authors tested the effect of atorvastatin on TBI in female rats. Methods. Atorvastatin (I mg/kg/day) was orally administered for 7 consecutive days in female Wistar rats starting I day after TBI; control animals received saline. Modified neurological severity scores, the corner turn test, and the Morris water maze test were used to evaluate functional response to treatment. Rats were killed on Day 15 post-TBI, and brain tissue samples were processed for immunohistochemical staining. Atorvastatin administration after brain injury significantly promoted the restoration of spatial memory but did not reduce sensorimotor functional deficits. Treatment of TBI with atorvastatin increased neuronal survival in the CA3 region and the lesion boundary zone and prevented the loss of neuronal processes of damaged neurons in the hippocampal CA3 region but not in the lesion boundary zone on Day 15 after TBI. The protective effect of atorvastatin on the injured neurons perhaps is mediated by increasing the density of vessels in the lesion boundary zone and the hippocampus after TBI. Conclusions. These data indicate that atorvastatin is beneficial in the treatment of TBI in female rats, although the effect may differ between sexes.	Henry Ford Hosp, Dept Neurol, Hlth Sci Ctr, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Neurosurg, Hlth Sci Ctr, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA; Univ Texas, Dept Psychol, Austin, TX 78712 USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, Hlth Sci Ctr, K-11,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mercuro G, 2002, AM J CARDIOL, V90, P747, DOI 10.1016/S0002-9149(02)02602-4; REH T, 1982, J COMP NEUROL, V211, P276, DOI 10.1002/cne.902110306; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Yamada K, 1999, BRIT J PHARMACOL, V126, P235, DOI 10.1038/sj.bjp.0702309; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	28	46	47	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2005	103	4					695	701		10.3171/jns.2005.103.4.0695			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	971LG	WOS:000232385000017	16266052				2022-02-06	
J	Gupta, RK; Saksena, S; Agarwal, A; Hasan, KM; Husain, M; Gupta, V; Narayana, PA				Gupta, RK; Saksena, S; Agarwal, A; Hasan, KM; Husain, M; Gupta, V; Narayana, PA			Diffusion tensor imaging in late posttraumatic epilepsy	EPILEPSIA			English	Article						diffusion tensor imaging; traumatic brain injury; posttraumatic epilepsy; fractional anisotropy; magnetic resonance imaging	TRAUMATIC BRAIN-INJURY; VOXEL-BASED MORPHOMETRY; WATER DIFFUSION; AXONAL INJURY; WHITE-MATTER; HEAD-INJURY; SPIN-ECHO; FRACTIONAL ANISOTROPY; MULTIPLE-SCLEROSIS; CEREBRAL-ISCHEMIA	Purpose: The main objective of this study was to use diffusion tensor imaging (DTI) to search and quantify the extent of abnormality beyond the obvious lesions seen on the T-2 and fluid-attenuation inversion recovery (FLAIR) magnetic resonance images in patients with chronic traumatic brain injury (TBI) with and without epilepsy. Methods: DTI was performed on 23 chronic TBI patients (with late posttraumatic epilepsy, n = 14; without epilepsy, n = 9) and 11 age-matched controls. The ratios of fractional anisotropy (FA) and mean diffusivity (MD) between the regions of interest beyond the T-2/FLAIR-visualized abnormality and the corresponding contralateral normal-appearing region were calculated. FA and MD ratios were compared for relative changes in these parameters among the TBI subjects with and without epilepsy and controls. Tissue volumes exhibiting abnormalities on DTI also were measured in these patients. Results: The mean regional FA ratio was significantly lower, whereas the mean regional MD value was higher in patients with TBI compared with controls. The mean regional FA ratio was significantly lower in TBI patients with epilepsy (0.57 +/- 0.059) than in those without epilepsy (0.68 +/- 0.039). Although the regional MD ratio was higher in TBI patients with epilepsy (1.15 +/- 0.140) relative to those without epilepsy (1.09 +/- 0.141), the difference did not reach statistical significance. The tissue volume with low FA value also was found to be higher in TBI patients with epilepsy than without. Conclusions: Severity of injury as predicted by the DTI-derived increased volume of microstructure damage is associated with delayed posttraumatic epilepsy in TBI patients. These findings could be valuable in predicting epileptogenesis in patients with chronic TBI.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India; King George Med Hosp, Dept Neurol, Lucknow, Uttar Pradesh, India; King George Med Hosp, Dept Neurosurg, Lucknow, Uttar Pradesh, India; Univ Texas, Sch Med, Dept Diagnost & Intervent Imaging, Houston, TX USA		Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India.	rakeshree@hotmail.com	Hasan, Khader M./ABB-5767-2020				Alsop DC, 2002, EPILEPSIA, V43, P69, DOI 10.1046/j.1528-1157.2002.043s1069.x; Arfanakis K, 2002, MAGN RESON IMAGING, V20, P511, DOI 10.1016/S0730-725X(02)00509-X; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Batchelor PG, 2003, MAGN RESON MED, V49, P1143, DOI 10.1002/mrm.10491; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; Droogan AG, 1999, MAGN RESON IMAGING, V17, P653, DOI 10.1016/S0730-725X(99)00011-9; DUNN LT, 1994, ANN ROY COLL SURG, V76, P147; Eriksson SH, 2001, BRAIN, V124, P617, DOI 10.1093/brain/124.3.617; HARDIMAN O, 1988, NEUROLOGY, V38, P1041, DOI 10.1212/WNL.38.7.1041; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Hasan KM, 2004, MAGN RESON MED, V51, P413, DOI 10.1002/mrm.10682; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; JENNET WB, 2005, EPILEPSY AFTER NON M; Kazemi NJ, 1997, EPILEPSIA, V38, P670, DOI 10.1111/j.1528-1157.1997.tb01236.x; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kumar R, 2003, AM J NEURORADIOL, V24, P218; KURTZKE JF, 1987, CLIN NEUROLOGY, P1; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; Lim KO, 1999, ARCH GEN PSYCHIAT, V56, P367, DOI 10.1001/archpsyc.56.4.367; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lythgoe MF, 1997, MAGN RESON MED, V38, P662, DOI 10.1002/mrm.1910380421; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; TIEN RD, 1994, AM J ROENTGENOL, V162, P671, DOI 10.2214/ajr.162.3.8109520; VANGELDEREN P, 1994, MAGNET RESON MED, V31, P154, DOI 10.1002/mrm.1910310209; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wieshmann UC, 1999, MAGN RESON IMAGING, V17, P29, DOI 10.1016/S0730-725X(98)00153-2; Wieshmann UC, 1999, MAGN RESON IMAGING, V17, P1269, DOI 10.1016/S0730-725X(99)00082-X; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Yoo SY, 2002, AM J NEURORADIOL, V23, P809	51	46	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	SEP	2005	46	9					1465	1471		10.1111/j.1528-1167.2005.01205.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	959GV	WOS:000231507100014	16146442	Bronze			2022-02-06	
J	Hang, CH; Shi, JX; Li, JS; Wu, W; Yin, HX				Hang, CH; Shi, JX; Li, JS; Wu, W; Yin, HX			Concomitant upregulation of nuclear factor-kappa B activity, proinflammatory cytokines and ICAM-1 in the injured brain after cortical contusion trauma in a rat model	NEUROLOGY INDIA			English	Article						traumatic brain injury; nuclear factor-kappa B; proinflammatory cytokine; intercellular adhesion molecule-1; inflammation	TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; AXONAL INJURY; MESSENGER-RNA; EXPRESSION; TRANSCRIPTION; INFLAMMATION; ACTIVATION; IMPACT; ALPHA	Background: Nuclear factor kappa B (NF-kB), proinflammatory cytokines and intercellular adhesion molecule 1 (ICAM-1) are frequently upregulated in the injured brain after traumatic brain injury (TBI). However, the temporal pattern of upregulation is not well defined. Aims: The current study was undertaken to investigate the temporal profile of the expression of NF-kB, proinflammatory cytokines and ICAM-1 in the injured brain after cortical contusion trauma of the rat brain. Settings and Design: A rat model of cortical contusion was produced by a free-falling weight on the exposed dura of right parietal lobe. The rats were randomly divided into control group and TBI groups at hours 3, 12, 24 and 72, and on day 7. Material and Methods: NF-kB binding activity in the surrounding brain of injured area was studied by electrophoretic mobility shift assay (EMSA). The levels of TNF-alpha and IL-6 were detected using ELISA and ICAM-1 expression studied by immunohistochemistry. Statistical analysis: The data were analyzed by one-way ANOVA followed by Student-Newman-Keuls post hoc test. Relation between variables was analyzed using bivariate correlation with two-tailed test. Results: Compared with that of control group, NF-kB binding activity in the injured brain was significantly increased through 12 h and 7 days postinjury, with the maximum at 72 h. The concentrations of TNF-alpha and IL-6 in the injured brain were significantly increased from 3 h to 7 days and maximal at 24 h postinjury. The number of ICAM-1 immunostained microvessels was significantly increased in the injured brain from 24 h to 7 days postinjury, with its peak at 72 h. Concomitant upregulation of TNF-alpha, IL-6, ICAM-1 and the cytokine mediators NF-kB in the injured brain was observed in the injured brain after cortical contusion, and there was a highly positive relation among these variables. Conclusions: Cortical contusion trauma could induce a concomitant and persistent upregulation of NF-kB binding activity, TNF-alpha, IL-6 and ICAM-1 in the in jured rat brain which might play a central role in the injury-induced immune response of brain.	Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Sch Clin Med, Jinling Hosp, Res Inst Gen Surg, Nanjing 210002, Peoples R China		Hang, CH (corresponding author), Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	hang1965@public1.ptt.js.cn					Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Sullivan PG, 1999, J NEUROSCI, V19, P6248; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; Whalen MJ, 1998, ACT NEUR S, V71, P212; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	28	46	59	0	4	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	SEP	2005	53	3					312	317		10.4103/0028-3886.16930			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	979TG	WOS:000232967100018	16230799	Green Submitted			2022-02-06	
J	Jaffres, P; Brun, J; Declety, P; Bosson, JL; Fauvage, B; Schleiermacher, A; Kaddour, A; Anglade, D; Jacquot, C; Payen, JF				Jaffres, P; Brun, J; Declety, P; Bosson, JL; Fauvage, B; Schleiermacher, A; Kaddour, A; Anglade, D; Jacquot, C; Payen, JF			Transcranial Doppler to detect on admission patients at risk for neurological deterioration following mild and moderate brain trauma	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; mild head injury; moderate head injury; transcranial Doppler	SEVERE HEAD-INJURY; BLOOD-FLOW-VELOCITY; COMPUTERIZED-TOMOGRAPHY; CEREBRAL AUTOREGULATION; INTRACRANIAL-PRESSURE; EMERGENCY-DEPARTMENT; PULSATILITY INDEX; MANAGEMENT; REACTIVITY; DIAGNOSIS	Objective: To investigate the contribution of transcranial Doppler measurements obtained in the emergency room for detecting patients with secondary neurological deterioration after mild or moderate brain trauma. Design and setting: Prospective cohort study in the emergency room in a university teaching hospital. Patients: Seventy-eight adult patients admitted to the emergency room after a traumatic brain injury (TBI), including 42 patients with Glasgow Coma Score 14 15 and 36 with 9 - 13. Measurements and results: All patients had transcranial Doppler measurements on both middle cerebral arteries and computed tomography on admission. Neurological outcome was assessed 7 days after trauma. Of the patients included 7 and 10 had secondary neurological deterioration after mild and moderate TBI, respectively. On admission these groups of patients had significantly more injuries on computed tomography using the Trauma Coma Data Bank classification and higher pulsatility index using transcranial Doppler than the patients having no subsequent neurological worsening. Conclusions: Increased pulsatility index after mild or moderate TBI is a reason for concern about the possibility of further neurological deterioration. Computed tomography and Doppler measurements could be combined to detect on admission patients at risk for secondary neurological deterioration in order to improve their initial disposition.	Albert Michallon Hosp, Dept Anaesthesiol & Crit Care Med, F-38043 Grenoble, France; Albert Michallon Hosp, Div Biostat, Grenoble, France; Albert Michallon Hosp, Dept Emergency Med, Grenoble, France		Payen, JF (corresponding author), Albert Michallon Hosp, Dept Anaesthesiol & Crit Care Med, F-38043 Grenoble, France.	jfpayen@ujf-grenoble.fr	bosson, jean-luc/AAP-5163-2020; Payen, Jean-Francois/L-6667-2014	bosson, jean-luc/0000-0003-0967-6026; 			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kidwell CS, 2001, J NEUROIMAGING, V11, P229, DOI 10.1111/j.1552-6569.2001.tb00039.x; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Richards HK, 1998, ACT NEUR S, V71, P229; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shafe M, 2004, ACAD EMERG MED, V11, P774, DOI 10.1197/j.aem.2004.02.518; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; 1990, ABBREVIATED INUJURY	35	46	47	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2005	31	6					785	790		10.1007/s00134-005-2630-4			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932UC	WOS:000229578000006	15834704				2022-02-06	
J	Fahrig, T; Gerlach, I; Horvath, E				Fahrig, T; Gerlach, I; Horvath, E			A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury	MOLECULAR PHARMACOLOGY			English	Article							NF-KAPPA-B; DOPAMINERGIC-NEURONS; KINASE COMPLEX; C-JUN; ACTIVATION; STRESS; TRANSCRIPTION; EXPRESSION; INDUCTION; RECEPTOR	Many acute and chronic neurodegenerative diseases are characterized by a localized inflammatory response and constitutive activation of the transcription factors nuclear factor-kappa B (NF-kappa B) and activator protein-1 (AP-1) as well as their upstream activating signaling cascades. Ample evidence indicates the implication of these processes in the pathogenesis of several diseases of the central nervous system. In this study, we show that a synthetic derivative of the natural product rocaglaol (compound A) displays potent anti-inflammatory properties in human endothelial and murine glial cells in vitro. Compound A inhibited cytokine- and lipopolysaccharide-induced release of various cytokines/chemokines and of nitric oxide as well as expression of the adhesion molecule endothelial leukocyte adhesion molecule-1 and the inducible enzymes nitric-oxide synthase and cyclooxygenase-2. As shown by immunocytochemistry and immunoblotting, compound A inhibited NF-kappa B and AP-1 activity in mixed glial cultures. Compound A exhibited neuroprotective activity in vitro and in vivo. 1-Methyl-4-phenylpyridiniuminduced damage of mesencephalic dopaminergic neurons was significantly decreased, and long-term treatment of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-injected mice with compound A significantly and dose-dependently reduced dopaminergic neuronal cell death. In addition, shortterm application of compound A to rats suffering from traumatic brain injury induced by subdural hematoma resulted in a significant reduction of the cerebral infarct volume. These results suggest that by inhibiting NF-kappa B and AP-1 signaling, compound A is able to reduce tissue inflammation and neuronal cell death, resulting in significant neuroprotection in animal models of neurodegeneration.	Bayer HealthCare, Pharma Res CNS, D-51368 Leverkusen, Germany		Fahrig, T (corresponding author), Bayer HealthCare, Pharma Res CNS, D-51368 Leverkusen, Germany.	thomas.fahrig@bayorhealthcare.com	Mat Zain, Mazatulikhma/B-2025-2010				Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Basu A, 2002, J NEUROSCI, V22, P6071; Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200; Bezard E, 1997, NEUROSCI LETT, V234, P47, DOI 10.1016/S0304-3940(97)00663-0; Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Eijkenboom M, 2000, NEUROPHARMACOLOGY, V39, P817, DOI 10.1016/S0028-3908(00)00002-2; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Gearan T, 2001, PARKINSONISM RELAT D, V8, P19, DOI 10.1016/S1353-8020(00)00078-X; Hirsch EC, 2000, J NEUROL, V247, P58, DOI 10.1007/PL00007762; Hoozemans JJM, 2002, DRUGS TODAY, V38, P429, DOI 10.1358/dot.2002.38.6.678350; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143; Nelson EL, 1996, J COMP NEUROL, V369, P361, DOI 10.1002/(SICI)1096-9861(19960603)369:3<361::AID-CNE3>3.0.CO;2-3; Ping DS, 1999, J IMMUNOL, V162, P727; Pizzi M, 2002, J BIOL CHEM, V277, P20717, DOI 10.1074/jbc.M201014200; Proksch P, 2001, CURR ORG CHEM, V5, P923, DOI 10.2174/1385272013375049; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Roebuck KA, 1999, INT J MOL MED, V4, P223; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; Tong LQ, 2003, NEUROCHEM RES, V28, P111, DOI 10.1023/A:1021656430576; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhu XW, 2003, J NEUROCHEM, V85, P87, DOI 10.1046/j.1471-4159.2003.01645.x	40	46	50	0	7	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X	1521-0111		MOL PHARMACOL	Mol. Pharmacol.	MAY	2005	67	5					1544	1555		10.1124/mol.104.008177			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	916MA	WOS:000228387900021	15716464				2022-02-06	
J	Chambers, IR; Stobbart, L; Jones, PA; Kirkham, FJ; Marsh, M; Mendelow, AD; Minns, RA; Struthers, S; Tasker, RC				Chambers, IR; Stobbart, L; Jones, PA; Kirkham, FJ; Marsh, M; Mendelow, AD; Minns, RA; Struthers, S; Tasker, RC			Age-related differences in intracranial pressure and cerebral perfusion pressure in the first 6 hours of monitoring after children's head injury: association with outcome	CHILDS NERVOUS SYSTEM			English	Article						intracranial monitoring; intracranial hypertension; children; traumatic coma; age; thresholds; sensitivity; specificity	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; MANAGEMENT; ADULTS; COMA	Objectives: Severe head injury in childhood is associated with considerable mortality and morbidity. In this study we determined age-related differences in the relationship between outcome and intracranial pressure (ICP) and cerebral perfusion pressure (CPP) in the first 6 h of monitoring in a large cohort of head-injured children. Methods: Two hundred and thirty-five head-injured children (admitted to five UK hospitals over a 15-year period) in whom intracranial pressure monitoring was clinically indicated were studied. Results: Patients were divided into three age groups (2-6, 7-10 and 11-16 years). The sensitivity of ICP and CPP were similar. Differences were found in the specificity of ICP and CPP for each group and these were more marked for CPP. For a specificity of 50% the pressures were 53, 63 and 66 mmHg for the three age groups. Conclusions: There are age-related differences in the specificity of intracranial pressure and cerebral perfusion pressure in relation to outcome. These differences may be important in the clinical management of head-injured children. Thus cerebral perfusion pressures of 53, 63 and 66 mmHg should be the minimum to strive for in these three age groups respectively.	Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Univ, Sch Med, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Edinburgh, Edinburgh EH9 1UW, Midlothian, Scotland; Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland; Southampton Gen Hosp, Dept Child Hlth, Southampton SO16 6YD, Hants, England; Newcastle Univ, Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Great Ormond St Hosp Sick Children, Paediat Intens Care & Neurosci Unit, London WC1N 3JH, England; Addenbrookes Hosp, Paediat Intens Care Unit, Cambridge CB2 2QQ, England; Guys Hosp, Newcomen Ctr, London SE1 9RT, England		Chambers, IR (corresponding author), Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	i.r.chambers@ncl.ac.uk	Tasker, Robert C/R-5837-2019; Kirkham, Fenella/C-2442-2009; Mendelow, Alexander/AAW-2878-2021	Kirkham, Fenella/0000-0002-2443-7958; Tasker, Robert/0000-0003-3647-8113			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; HULL D, 1981, ESSENTIL PAEDIAT, P134; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILLER JD, 1994, LANCET, V344, P421; National Collaborating Centre for Acute Care, 2003, HEAD INJ TRIAG ASS I; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; TEASDALE GM, 2000, EARLY MANAGEMENT PAT; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	21	46	46	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2005	21	3					195	199		10.1007/s00381-004-1060-x			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	902OY	WOS:000227367600005	15580513				2022-02-06	
J	Lenzlinger, PM; Shimizu, S; Marklund, N; Thompson, HJ; Schwab, ME; Saatman, KE; Hoover, RC; Bareyre, FM; Motta, M; Luginbuhl, A; Pape, R; Clouse, AK; Morganti-Kossmann, C; Mcintosh, TK				Lenzlinger, PM; Shimizu, S; Marklund, N; Thompson, HJ; Schwab, ME; Saatman, KE; Hoover, RC; Bareyre, FM; Motta, M; Luginbuhl, A; Pape, R; Clouse, AK; Morganti-Kossmann, C; Mcintosh, TK			Delayed inhibition of Nogo-A does not alter injury-induced axonal sprouting but enhances recovery of cognitive function following experimental traumatic brain injury in rats	NEUROSCIENCE			English	Article						head injury; myelin inhibitors; tract-tracing; cognition; hippocampus	NEURITE GROWTH-INHIBITORS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; CORTICOSPINAL TRACT FIBERS; CEREBRAL-ARTERY OCCLUSION; MONOCLONAL-ANTIBODY IN-1; ADULT-RAT; HEAD-INJURY; CELL-DEATH	Traumatic brain injury causes long-term neurological motor and cognitive deficits, often with limited recovery. The inability of CNS axons to regenerate following traumatic brain injury may be due, in part, to inhibitory molecules associated with myelin. One of these myelin-associated proteins, Nogo-A, inhibits neurite outgrowth in vitro, and inhibition of Nogo-A in vivo enhances axonal outgrowth and sprouting and improves outcome following experimental CNS insults. However, the involvement of Nogo-A in the neurobehavioral deficits observed in experimental traumatic brain injury remains unknown and was evaluated in the present study using the 11C7 monoclonal antibody against Nogo-A. Anesthetized, male Sprague-Dawley rats were subjected to either lateral fluid percussion brain injury of moderate severity (2.5-2.6 atm) or sham injury. Beginning 24 h post-injury, monoclonal antibody 11C7 (n=17 injured, n=6 shams included) or control Ab (IgG) (n=16 injured, n=5 shams included) was infused at a rate of 5 mu l/h over 14 days into the ipsilateral ventricle using osmotic minipumps connected to an implanted cannula. Rats were assessed up to 4 weeks post-injury using tests for neurological motor function (composite neuroscore, and sensorimotor test of adhesive paper removal) and, at 4 weeks, cognition was assessed using the Morris water maze. Hippocampal CA3 pyramidal neuron damage and corticospinal tract sprouting, using an anterograde tracer (biotinylated dextran amine), were also evaluated. Brain injury significantly increased sprouting from the uninjured corticospinal tract but treatment with monoclonal antibody 11C7 did not further increase the extent of sprouting nor did it alter the extent of CA3 cell damage. Animals treated with 11C7 showed no improvement in neurologic motor deficits but did show significantly improved cognitive function at 4 weeks post-injury when compared with brain-injured, IgG-treated animals. To our knowledge, the present findings are the first to suggest that (1) traumatic brain injury induces axonal sprouting in the corticospinal tract and this sprouting may be independent of myelin-associated inhibitory factors and (2) that post-traumatic inhibition of Nogo-A may promote cognitive recovery unrelated to sprouting in the corticospinal tract or neuroprotective effects on hippocampal cell loss following experimental traumatic brain injury. (c) 2005 Published by Elsevier Ltd on behalf of IBRO.	Univ Penn, Dept Neurosurg, Traumat Bain Injury Lab, Philadelphia, PA 19104 USA; Univ Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Brain Res, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland; Monash Univ, Dept Trauma Surg, Clayton, Vic, Australia; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75648 Uppsala, Sweden.	niklas.marklund@neurokir.uu.se	Lenzlinger, Philipp/A-3822-2008; Schwab, Martin E/B-6818-2016	Marklund, Niklas/0000-0002-9797-5626; Morganti-Kossmann, Cristina/0000-0002-0807-2063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007413, R01NS040978, P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM-34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS-08803, T32 NS07413-04, R01-NS 40978] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; Bareyre FM, 2002, J NEUROSCI, V22, P7097; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brosamle C, 2000, J NEUROSCI, V20, P8061; Buki A, 2000, J NEUROSCI, V20, P2825; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Conte V., 2003, EUR J TRAUMA, V7, P335; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Dergham P, 2002, J NEUROSCI, V22, P6570; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fiedler M, 2002, PROTEIN ENG, V15, P931, DOI 10.1093/protein/15.11.931; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Grados-Munro EM, 2003, J NEUROSCI RES, V74, P479, DOI 10.1002/jnr.10803; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Li SX, 2003, J NEUROSCI, V23, P4219; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; *NAT AC SCI, 1996, GUID CAR US LAB AN; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Oertle T, 2003, J NEUROSCI, V23, P5393; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raineteau O, 2001, P NATL ACAD SCI USA, V98, P6929, DOI 10.1073/pnas.111165498; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SIMPSON FA, 1997, HEAD INJURY PATHOPHY; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Thurman DJ, 2001, HEAD TRAUMA, P327; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang XX, 2002, J NEUROSCI, V22, P5505; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Z'Graggen WJ, 2000, J NEUROSCI, V20, P6561, DOI 10.1523/JNEUROSCI.20-17-06561.2000	87	46	48	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2005	134	3					1047	1056		10.1016/j.neuroscience.2005.04.048			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	959BF	WOS:000231491200030	15979242				2022-02-06	
J	Lee, LL; Galo, E; Lyeth, BG; Muizelaar, JP; Berman, RF				Lee, LL; Galo, E; Lyeth, BG; Muizelaar, JP; Berman, RF			Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker	EXPERIMENTAL NEUROLOGY			English	Article						lateral fluid percussion; voltage-gated calcium channels; SNX185; traumatic brain injury; fluoro-jade; hippocampus; Morris water maze; beam walk test	ZICONOTIDE; ISCHEMIA; RELEASE; LOCALIZATION; ANTAGONISTS; POTASSIUM; PROTECTS; NEURONS; INFLUX	Overload of intracellular calcium ([Ca2+](i)) following traumatic brain injury (TBI) has been implicated in the pathogenesis of neuronal injury and death. Voltage-gated calcium channels (VGCCs) provide one of the major sources of Ca2+ entry into cells. Therefore, the potential neuroprotective activity of SNX-185, a specific N-type VGCC blocker, was tested in rats using the lateral fluid percussion (LFP) model of TBI. SNX-185 (50, 100, or 200 pmol) or vehicle was injected 5 min after injury into the CA2-3 subregion of the hippocampus ipsilateral to TBI. Acute neuronal degeneration was visualized in brain sections 24 h postinjury using the histofluorescent marker Fluoro-Jade (FJ), and the number of surviving neurons in the CA2-3 subregion of the hippocampus 42 days after injury was determined stereologically. Behavioral outcome after TBI and drug treatment was assessed in the beam walk test and Morris water maze. Direct injection of SNX-185 into the CA2-3 region of the hippocampus reduced neuronal injury 24 h after TBI and increased neuronal survival at 42 days at each of the three drug concentrations. Behavioral outcome in both the beam walk and Morris water maze were also improved by SNX-185, with 100 and 200 pmol, but not 50 pmol SNX-185 providing neuroprotection. These data support previous studies demonstrating substantial neuroprotection after TBI by treatment with N-type VGCC blockers. (C) 2004 Elsevier Inc. All rights reserved.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA		Berman, RF (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.	rfberman@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39090] Funding Source: Medline		Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; BOWERSOX SS, 1992, J CARDIOVASC PHARM, V20, P756, DOI 10.1097/00005344-199220050-00011; Bowersox SS, 1997, BRAIN RES, V747, P343; Brose WG, 1997, CLIN J PAIN, V13, P256, DOI 10.1097/00002508-199709000-00012; BUCHAN AM, 1994, J CEREBR BLOOD F MET, V14, P903, DOI 10.1038/jcbfm.1994.121; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Conti AC, 1998, J NEUROSCI, V18, P5663; Craig PJ, 1998, J COMP NEUROL, V397, P251; Currie KPM, 1997, J NEUROSCI, V17, P4570; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; HOVDA DA, 1994, ACTA NEUROCHIR, P521; Hu LY, 1999, BIOORG MED CHEM LETT, V9, P1121, DOI 10.1016/S0960-894X(99)00160-2; Hu LY, 1999, BIOORG MED CHEM LETT, V9, P2151, DOI 10.1016/S0960-894X(99)00359-5; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Latour I, 2003, GLIA, V41, P347, DOI 10.1002/glia.10162; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; McGuire D, 1997, J CARDIOVASC PHARM, V30, P400, DOI 10.1097/00005344-199709000-00019; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Newcomb R, 2000, PEPTIDES, V21, P491, DOI 10.1016/S0196-9781(00)00175-3; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.biochem.63.1.823; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; Ryder TR, 1999, BIOORG MED CHEM LETT, V9, P1813, DOI 10.1016/S0960-894X(99)00284-X; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Staats PS, 2004, JAMA-J AM MED ASSOC, V291, P63, DOI 10.1001/jama.291.1.63; TAKIZAWA S, 1995, J CEREBR BLOOD F MET, V15, P611, DOI 10.1038/jcbfm.1995.75; TSIEN RW, 1999, CALCIUM CELLULAR REG, P95; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; WANG YX, 1998, NAUNYNSCHMIEDEBERGS, V357; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wu LG, 1997, TRENDS NEUROSCI, V20, P204, DOI 10.1016/S0166-2236(96)01015-6; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1996, NEUROTRAUMA, P1421; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V150, P459, DOI 10.1111/j.1748-1716.1994.tb09713.x	54	46	47	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2004	190	1					70	78		10.1016/j.expneurol.2004.07.003			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	867DJ	WOS:000224822100006	15473981				2022-02-06	
J	Laatsch, LK; Thulborn, KR; Krisky, CM; Shobat, DM; Sweeney, JA				Laatsch, LK; Thulborn, KR; Krisky, CM; Shobat, DM; Sweeney, JA			Investigating the neurobiological basis of cognitive rehabilitation therapy with fMRI	BRAIN INJURY			English	Article							WORKING-MEMORY; LANGUAGE LATERALIZATION; ACTIVATION; REPRODUCIBILITY; RECOVERY; MAPS	The neurobiological changes occurring during cognitive rehabilitation therapy (CRT) have yet to be systematically studied. In the present study, functional magnetic resonance imaging ( fMRI) was used to demonstrate brain plasticity in response to CRT (n = 5) following mild traumatic brain injury. Neuropsychological tests and two fMRI activation tasks, a visually guided saccades and a reading comprehension task, were employed pre- and post-CRT. CRT was used to systematically address the identified deficits in visual scanning and language processing. As hypothesized, changes in the pattern and extent of activation within expected neuroanatomical areas occurred post-CRT. Changes in fMRI activation are discussed for each subject and related to changes on neuropsychological measures. This study demonstrates how fMRI can illustrate the neurobiological mechanisms of recovery in individual subjects. The variability in subject responses to CRT supports the notion of tailoring rehabilitation strategies to each subject in order to optimize recovery following brain injury.	Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Ctr Magnet Resonance Res, Chicago, IL USA; Univ Illinois, Coll Med, Ctr Cognit Med, Chicago, IL USA		Laatsch, LK (corresponding author), Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL 60607 USA.	llaatsch@ulc.edu	anand, amit/A-7222-2009; Thulborn, Keith Raymond/D-9183-2015	Thulborn, Keith Raymond/0000-0001-6197-4296; Sweeney, John/0000-0003-1752-2828			BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BRACY O, 1985, SOFT TOOLS COGNITIVE; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Calvert GA, 2000, BRAIN LANG, V71, P391, DOI 10.1006/brln.1999.2272; Carpenter PA, 1999, J COGNITIVE NEUROSCI, V11, P9, DOI 10.1162/089892999563210; Carpenter PA, 1999, NEUROIMAGE, V10, P216, DOI 10.1006/nimg.1999.0465; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DEROGATIS L, 1983, SCL 90R MANUAL; DIKMAN S, 1999, J INT NEUROPSYCH SOC, V51, P346; Eddy WF, 1996, P COMP STAT, P39; Fernandez G, 2003, NEUROLOGY, V60, P969, DOI 10.1212/01.WNL.0000049934.34209.2E; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GIANUTSOS R, 1984, COGNITIVE REHABILITA; GIANUTSOS R, 1990, QUEST COGNITIVE REHA; GLADSOJO J, 1999, NORMS LETT CATEGORY; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Heaton RK, 1991, COMPREHENSIVE NORMS; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kiehl KA, 2003, HUM BRAIN MAPP, V18, P42, DOI 10.1002/hbm.10074; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Lewis R., 1995, DIGIT VIGILANCE TEST; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Nybakken GE, 2002, NEURORADIOLOGY, V44, P403, DOI 10.1007/s00234-001-0722-6; PRICE C, 2001, HDB FUNCTIONAL NEURO, P1979; Ramsey NF, 1996, HUM BRAIN MAPP, V4, P113, DOI 10.1002/(SICI)1097-0193(1996)4:2<113::AID-HBM3>3.0.CO;2-6; Rees G, 2000, BRAIN, V123, P1624, DOI 10.1093/brain/123.8.1624; Reitan RM, 1985, HALSTEADREITAN NEURO; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosen HJ, 2000, NEUROLOGY, V55, P1883, DOI 10.1212/WNL.55.12.1883; Rutten GJM, 2002, BRAIN LANG, V80, P421, DOI 10.1006/brln.2001.2600; Small SL, 1998, BRAIN LANG, V62, P298, DOI 10.1006/brln.1998.1951; Sohlberg M., 2001, COGNITIVE REHABILITA; THULBORN K, 2001, CURRENT PROTOCOLS MR, P1979; THULBORN K, 1999, MED RADIOLOGY DIAGNO, P337; Thulborn K R, 1999, Top Magn Reson Imaging, V10, P37, DOI 10.1097/00002142-199902000-00004; Thulborn KR, 1999, STROKE, V30, P749, DOI 10.1161/01.STR.30.4.749; Thulborn KR, 2000, AM J NEURORADIOL, V21, P524; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilkinson, 1984, WIDE RANGE ACHIEVEME; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449	51	46	48	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					957	974		10.1080/02699050410001672369			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600001	15370896				2022-02-06	
J	Karlsson, J; Fong, KSK; Hansson, MJ; Elmer, E; Csiszar, K; Keep, MF				Karlsson, J; Fong, KSK; Hansson, MJ; Elmer, E; Csiszar, K; Keep, MF			Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis	JOURNAL OF NEUROSURGERY			English	Article						amyotrophic lateral sclerosis; mitochondria; neurodegenerative disease; Parkinson disease; G93A transgenic mouse; superoxide dismutase	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; SUPEROXIDE-DISMUTASE; CELL-DEATH; CYTOCHROME-C; RAT-BRAIN; DIFFERENTIAL EXPRESSION; OXIDATIVE INACTIVATION; PROLONGS SURVIVAL; INNER MEMBRANE	Object. The authors investigated whether cyclosporin A (CsA), a cyclophilin ligand with mitochondrial permeability transition pore-blocking and calcineurin-inhibiting properties, affects motor function, neuronal death, and life span in the G93A transgenic mouse model of familial amyotrophic lateral sclerosis (FALS). Methods. The G93A mice received weekly intracerebroventricular injections of CsA (20 mug/mouse/week) starting at the age of 65 days, and physical performance on an exercise wheel was monitored beginning at 84 days of age. Mice were allowed to survive for clinical observation of body weight, hindlimb weakness, and life span or until a defined end stage or were killed at 110 days of age for histological analysis. Conclusions. Treatment with CsA significantly delayed the onset of hindlimb weakness and also extended the time from its onset to paralysis. The overall life span of CsA-treated G93A mice was significantly extended, by 12% compared with vehicle-treated transgenic littermates. The CsA also prolonged physical performance on the exercise wheel and delayed weight loss. Histologically, there was significant preservation of both cervical and lumbar spine motor neurons and also tyrosine hydroxylase-positive dopaminergic substantia nigra neurons in 110-day-old CsA-treated mice compared with their transgenic littermates. The local administration of CsA directly into the brain ventricles is an effective means of central nervous system drug delivery (because CsA does not readily cross the blood-brain barrier), which in this study ameliorated clinical and neuropathological features of FALS in G93A mice. The remarkably low intrathecal CsA dose required for neuroprotection reduces potential adverse effects of systemic immunosuppression or nephrotoxicity seen with chronic systemic delivery of the drug.	Univ Hawaii, John A Burns Sch Med, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Lund Univ, Wallenberg Neruosci Ctr, Expt Brain Res Lab, Lund, Sweden; LLC, Maas BiolAB, Albuquerque, NM USA		Keep, MF (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Surg, Div Neurosurg, MSC 10 5610,1 Univ New Mexico, Albuquerque, NM 87131 USA.	mkeep@salud.unm.edu	Hansson, Magnus/G-4486-2014; Elmer, Eskil/F-9341-2014	Hansson, Magnus/0000-0002-0201-0638; Elmer, Eskil/0000-0001-7901-1826	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [2G12RR03061-16] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12RR003061] Funding Source: NIH RePORTER		Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.3.CO;2-O; Anneser JMH, 2001, NEUROREPORT, V12, P2663, DOI 10.1097/00001756-200108280-00015; APPEL SH, 1988, ARCH NEUROL-CHICAGO, V45, P381, DOI 10.1001/archneur.1988.00520280027011; BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; Borlongan CV, 1999, CELL TRANSPLANT, V8, P153, DOI 10.1177/096368979900800107; Borlongan CV, 2000, NEUROSCI LETT, V279, P73, DOI 10.1016/S0304-3940(99)00962-3; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Ferri A, 2001, J NEUROCHEM, V79, P531, DOI 10.1046/j.1471-4159.2001.00558.x; Ferri A, 2000, J NEUROCHEM, V75, P606, DOI 10.1046/j.1471-4159.2000.0750606.x; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Goldner FM, 1996, J COMP NEUROL, V372, P283; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; KEEP M, 2002, IMMUNOSUPPRESSANT AN, P3; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Knirsch U, 2001, BRAIN RES, V889, P234, DOI 10.1016/S0006-8993(00)03048-1; Kong JM, 1998, J NEUROSCI, V18, P3241; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; LAD RP, 1991, MOL BRAIN RES, V9, P239, DOI 10.1016/0169-328X(91)90007-K; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Matsuura K, 1997, EXP NEUROL, V146, P526, DOI 10.1006/exnr.1997.6575; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ochs G, 2000, AMYOTROPH LATERAL SC, V1, P201, DOI 10.1080/14660820050515197; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Penn RD, 1997, NEUROSURGERY, V40, P94, DOI 10.1097/00006123-199701000-00021; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SCHARFE T, 1989, UROL INT, V44, P1, DOI 10.1159/000281439; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Seaton TA, 1998, BRAIN RES, V809, P12, DOI 10.1016/S0006-8993(98)00790-2; SNOW BJ, 1990, ARCH NEUROL-CHICAGO, V47, P870, DOI 10.1001/archneur.1990.00530080052010; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Volkel H, 2001, FEBS LETT, V503, P201, DOI 10.1016/S0014-5793(01)02730-2; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Wu AS, 2003, J NEUROCHEM, V85, P142, DOI 10.1046/j.1471-4159.2003.01639.x; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZHANG ET, 1990, J ANAT, V170, P111; Zhang LC, 2003, BRAIN RES, V989, P1, DOI 10.1016/S0006-8993(03)03123-8; Zhang WH, 2003, ANN NEUROL, V53, P267, DOI 10.1002/ana.10476; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	76	46	47	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2004	101	1					128	137		10.3171/jns.2004.101.1.0128			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	834GD	WOS:000222398700020	15255263				2022-02-06	
J	Yoshino, O; Matsuno, H; Nakamura, H; Yudoh, K; Abe, Y; Sawai, T; Uzuki, M; Yonehara, S; Kimura, T				Yoshino, O; Matsuno, H; Nakamura, H; Yudoh, K; Abe, Y; Sawai, T; Uzuki, M; Yonehara, S; Kimura, T			The role of Fas-mediated apoptosis after traumatic spinal cord injury	SPINE			English	Article						apoptosis; Fas antigen; Fas ligand; lpr mice; secondary injury; spinal cord injury	PROGRAMMED CELL-DEATH; RHEUMATOID SYNOVIUM; DNA FRAGMENTATION; MOLECULAR-CLONING; LEUKEMIA-CELLS; MOUSE MODEL; IN-SITU; INDUCTION; EXPRESSION; ANTIGEN	Study Design. Functional recovery and histopathological change after spinal cord injury in the Fas-deficient mice and the wild-type mice were investigated. Objectives. To investigate the role of the Fas/Fas ligand ( FasL) system as a signal transduction pathway leading to apoptosis after spinal cord injury. Summary of Background Date. Apoptosis observed after spinal cord injury has recently gained widespread interest as a cause of collateral damage after the initial injury. Apoptosis mediated by the Fas antigen in the post-ischemic brain or spinal cord was reported. Recently, the upregulation of Fas after spinal cord injury was also reported. However, the influence of Fas-mediated apoptosis on the extent of the secondary spinal cord injury has not yet been clarified. Methods. We investigated Fas-mediated apoptosis after spinal cord injury and examined the behavioral changes and the histopathological changes after spinal cord injury using MRL/Mp-lpr/lpr (MRL/lpr) mice, which were Fas-deficient mutant mice, and MRL/Mp-+/+ (MRL/+) mice, which were Fas-positive wild-type mice. Results. Locomotor recovery after spinal cord injury in MRL/lpr mice was superior to that observed in MRL/+ mice. In addition, the damaged area in MRL/lpr mice was significantly smaller than that seen in MRL/+ mice. Further, the frequency of apoptotic cells in the injured spinal cord of MRL/lpr mice was significantly less than that in MRL/+ mice. Conclusion. We demonstrated the appearance of Fas-mediated apoptosis in the spinal cord after spinal cord injury. In addition, we elucidated for the first time that Fas-mediated apoptosis following spinal cord injury played an important role in the spinal cord damage and the ultimate neurologic injury.	Toyama Med & Pharmaceut Univ, Dept Orthopaed Surg, Toyama 9300194, Japan; Toin Yokohama Univ, Dept Biomed Engn, Yokohama, Kanagawa, Japan; St Marianna Univ, Inst Med Sci, Yokohama, Kanagawa, Japan; Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 020, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Tumor Biogenesis, Kyoto 606, Japan		Yoshino, O (corresponding author), Toyama Med & Pharmaceut Univ, Dept Orthopaed Surg, 2630 Sugitani, Toyama 9300194, Japan.	g7410006@ms.toyama-mpu.ac.jp					Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GELBARD HA, 1995, NEUROPATH APPL NEURO, V21, P208, DOI 10.1111/j.1365-2990.1995.tb01052.x; GUNJI H, 1991, CANCER RES, V51, P741; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; HILL IE, 1995, BRAIN RES, V676, P398, DOI 10.1016/0006-8993(95)00145-G; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Katoh K, 1996, NEUROSCI LETT, V216, P9; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; LI Y, 1995, AM J PATHOL, V146, P1045; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MATSUNO H, 1999, MECH LOADING BONE JO, P215; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; Morita I, 1998, INT J TISSUE REACT, V20, P37; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Okamoto K, 1998, GENE THER, V5, P331, DOI 10.1038/sj.gt.3300597; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Sakai K, 1998, ARTHRITIS RHEUM, V41, P1251, DOI 10.1002/1529-0131(199807)41:7<1251::AID-ART16>3.0.CO;2-B; Sakurai M, 1998, BRAIN RES, V797, P23, DOI 10.1016/S0006-8993(98)00290-X; SASANO H, 1995, J CLIN ENDOCR METAB, V80, P2378, DOI 10.1210/jc.80.8.2378; Sasano H, 1997, J BONE MINER RES, V12, P1416, DOI 10.1359/jbmr.1997.12.9.1416; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHIN RW, 1991, LAB INVEST, V64, P693; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	54	46	49	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 1	2004	29	13					1394	1404		10.1097/01.BRS.0000129894.34550.48			11	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	835DT	WOS:000222461200004	15223929				2022-02-06	
J	Brabeck, C; Beschorner, R; Conrad, S; Mittelbronn, M; Bekure, K; Meyermann, R; Schluesener, HJ; Schwab, JM				Brabeck, C; Beschorner, R; Conrad, S; Mittelbronn, M; Bekure, K; Meyermann, R; Schluesener, HJ; Schwab, JM			Lesional expression of RhoA and RhoB following traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						pharmacological target; regeneration; Rho GTPases; tissue remodeling; traumatic brain injury	ADP-RIBOSYLATING EXOENZYME; CENTRAL-NERVOUS-SYSTEM; CLOSTRIDIUM-BOTULINUM; AXONAL REGENERATION; ACTIN CYTOSKELETON; NEURITE OUTGROWTH; TYROSINE KINASE; HEAD-INJURY; G-PROTEIN; GTPASES	Inhibition of the small GTPase Rho or of its downstream target Rho-associated kinase (ROCK) has been shown to promote axon regeneration and to improve functional recovery following traumatic CNS lesions in the adult rat. In order to determine the expression pattern of RhoA and RhoB following human traumatic brain injury (TBI) and to assess whether Rho is a possible target for pharmacological intervention in humans, we investigated expression patterns of RhoA and RhoB in brain specimens from 25 patients who died after closed TBI in comparison to brain tissue derived from four neuropathologically unaffected control patients by immunohistochemistry. A highly significant lesional upregulation of both RhoA and RhoB was observed beginning several hours after the traumatic event and continuing for months after TBI. The cellular sources of both molecules included polymorphonuclear granulocytes, monocytes/macrophages, and reactive astrocytes. Additionally, expression of RhoA was also detected in neuronal cells in some of the cases. From our data, we conclude that inhibition of Rho is a promising mechanism for the development of new pharmacological interventions in human TBI. As the observed upregulation of RhoA and RhoB was still detectable months after TBI, we speculate that even delayed treatment with Rho inhibitors might be a therapeutic option.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Paris 06, CNRS, UMR 7102, Equipe Dev Neuronal, Paris, France		Schwab, JM (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; Mittelbronn, Michel/0000-0002-2998-052X; Schwab, Jan/0000-0001-6784-4919			Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Angkachatchai V, 1999, J IMMUNOL, V163, P3819; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Dergham P, 2002, J NEUROSCI, V22, P6570; Donovan FM, 1997, J NEUROSCI, V17, P5316; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jin Z, 1997, J NEUROSCI, V17, P6256; JUST I, 1995, BIOCHEMISTRY-US, V34, P334, DOI 10.1021/bi00001a041; JUST I, 1992, J BIOL CHEM, V267, P10274; Kanumilli S, 2002, NEUROPHARMACOLOGY, V42, P1, DOI 10.1016/S0028-3908(01)00161-7; Kawaguchi A, 2000, EUR J PHARMACOL, V403, P203, DOI 10.1016/S0014-2999(00)00593-8; Knaus UG, 2000, IMMUNOL RES, V21, P103, DOI 10.1385/IR:21:2-3:103; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Redmond L, 2001, CURR OPIN NEUROBIOL, V11, P111, DOI 10.1016/S0959-4388(00)00181-1; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Safavi-Abbasi S, 2001, GLIA, V36, P102, DOI 10.1002/glia.1099; Saito H, 2002, J LEUKOCYTE BIOL, V72, P829; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schwab JM, 2004, J NEUROPATH EXP NEUR, V63, P180, DOI 10.1093/jnen/63.2.180; SCHWAB JM, 2002, SOC NEUR ABSTR; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Suidan HS, 1997, GLIA, V21, P244, DOI 10.1002/(SICI)1098-1136(199710)21:2<244::AID-GLIA7>3.0.CO;2-6; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; Wilde C, 2002, BIOCHEMISTRY-US, V41, P1539, DOI 10.1021/bi015809i; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Woolf CJ, 2002, SCIENCE, V297, P1132, DOI 10.1126/science.1076247; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	46	46	46	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					697	706		10.1089/0897715041269597			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600006	15253798				2022-02-06	
J	Lew, HL; Lee, EH; Pan, SSL; Date, ES				Lew, HL; Lee, EH; Pan, SSL; Date, ES			Electrophysiologic abnormalities of auditory and visual information processing in patients with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article							EVENT-RELATED POTENTIALS; RESPONSE-MONITORING DYSFUNCTION; CLOSED-HEAD-INJURY; BIOLOGICAL DETERMINANTS; PREDICTING OUTCOMES; P300 ABNORMALITIES; ALZHEIMERS-DISEASE; EVOKED POTENTIALS; SCHIZOPHRENIA; LATENCY	Objective: Through both auditory and visual modalities, we sought to explore the efficacy of event-related potentials in detecting residual cognitive impairments in patients with traumatic brain injury (TBI). Design: Control subjects and TBI patients with favorable recovery were recruited. Pure tone and primary color discrimination tasks were utilized to elicit auditory and visual event-related potentials, respectively. All subjects were instructed to push a response button when they detected the target stimuli. Both behavioral and electrophysiologic responses were obtained simultaneously. We analyzed the event-related potential waveforms and examined the differences in amplitude, latency, behavioral reaction time, and response accuracy. Results: A total of 11 TBI patients and 11 control subjects were tested. Results showed that (1) TBI patients had significantly lower P300 amplitude in both auditory (11.2 vs. 22.7 muV) and visual (11.6 vs. 20.9 muV) domains, (2) TBI patients had significantly longer P300 latency in both auditory (355 vs. 294 msecs) and visual (376 vs. 341 msecs) modalities, and (3) although there was no significant difference in response accuracy (97.7% vs. 100%), reaction time for both auditory and visual tasks were significantly longer in TBI patients (auditory, 404 vs. 277 msecs; visual, 397 vs. 346 msecs). Conclusion: Although TBI patients with good recovery showed similar response accuracy when compared with control subjects, they demonstrated significantly poorer performance in both electrophysiologic and behavioral responses. Diminished amplitudes and prolonged latencies in P300 responses indicate impaired organization and categorization of incoming sensory information; prolonged behavioral reaction times suggest slowing in the response execution process. Clinical and theoretical implications and goals for continued research are discussed.	VAPAHCS, PM&R Serv, Comprehens Rehabil Ctr, Palo Alto, CA 94304 USA; Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA		Lew, HL (corresponding author), VAPAHCS, PM&R Serv, Comprehens Rehabil Ctr, MS-B117,3801, Palo Alto, CA 94304 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD01097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER		Bennington JY, 1999, INT J PSYCHOPHYSIOL, V34, P171, DOI 10.1016/S0167-8760(99)00070-7; BIRDSALL HH, 1994, OTOLARYNG HEAD NECK, V110, P53, DOI 10.1016/S0194-5998(94)70792-8; Cass M, 1997, BIOL PSYCHOL, V46, P51, DOI 10.1016/S0301-0511(96)05233-7; FORD JM, 1994, ELECTROEN CLIN NEURO, V90, P214, DOI 10.1016/0013-4694(94)90093-0; Ford JM, 1999, PSYCHOPHYSIOLOGY, V36, P667, DOI 10.1111/1469-8986.3660667; Ford JM, 2001, BIOL PSYCHIAT, V49, P848, DOI 10.1016/S0006-3223(00)01051-9; FORD JM, 1995, BIOL PSYCHOL, V39, P57, DOI 10.1016/0301-0511(94)00959-2; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; Friedman D, 2003, J CLIN EXP NEUROPSYC, V25, P702, DOI 10.1076/jcen.25.5.702.14578; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Ilan AB, 1999, CLIN NEUROPHYSIOL, V110, P367; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Knott V, 2003, CLIN ELECTROENCEPHAL, V34, P182, DOI 10.1177/155005940303400404; Lew H, 1997, J Am Acad Audiol, V8, P104; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; Lew HL, 2002, AM J PHYS MED REHAB, V81, P524, DOI 10.1097/00002060-200207000-00011; LEW HL, 1997, J NEUROVASC DIS, V2, P265; Mathalon DH, 2003, NEUROBIOL AGING, V24, P675, DOI 10.1016/S0197-4580(02)00154-9; Mathalon DH, 2002, J ABNORM PSYCHOL, V111, P22, DOI 10.1037//0021-843X.111.1.22; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; NISHIMURA N, 1995, PSYCHIAT CLIN NEUROS, V49, P79, DOI 10.1111/j.1440-1819.1995.tb01863.x; Olichney JM, 2002, J NEUROL NEUROSUR PS, V73, P377, DOI 10.1136/jnnp.73.4.377; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Polich J, 1998, J CLIN NEUROPHYSIOL, V15, P14, DOI 10.1097/00004691-199801000-00004; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; POLICH J, 2004, PM R CLIN N AM; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Viggiano MP, 1996, J CLIN EXP NEUROPSYC, V18, P631, DOI 10.1080/01688639608408288; WAYMAN JW, 1992, J ACOUST SOC AM, V91, P3527, DOI 10.1121/1.402841	36	46	52	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	2004	83	6					428	433		10.1097/00002060-200406000-00004			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	822QB	WOS:000221553600003	15166686				2022-02-06	
J	Alexander, S; Kerr, ME; Yonas, H; Marion, DW				Alexander, S; Kerr, ME; Yonas, H; Marion, DW			The effects of admission alcohol level on cerebral blood flow and outcomes after severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; cerebral blood flow; outcomes; traumatic brain injury	HEAD-INJURY; ETHANOL INTOXICATION; CONSCIOUS LEVEL; MANAGEMENT; DEFICITS; ABUSE; RATS	This study examined the relationship between admission serum alcohol level (ETOH) and cerebral blood flow (CBF) and outcomes in the adult traumatic brain injured (TBI) population. We hypothesized that individuals with ETOH > 100 mg/dL will have decreased blood flow on admission and poorer outcomes. Eighty subjects, age 16-65, with severe TBI (Glasgow Coma Score [GCS] less than or equal to 8) were entered into the study. Correlational analysis assessed the relationship between ETOH and admission severity of injury scores as measured by Marshall and APACHE III scores, CBF, and outcomes. Comparison of CBF and outcomes between groups based on admission serum ETOH level was conducted with analysis of variance and post hoe Scheffe analyses as well as regression analysis. There was a significant relationship between serum ETOH level and GCS (P = 0.02), but not APACHE III scores (p = 0.12) or Marshall scores (p = 0.27). There was a significant correlation between global CBF and serum ETOH level (p = 0.02). There was no statistically significant association between serum ETOH level and GOS at 3 (p = 0.97), 6 (p = 0.56), or 12 (p = 0.73) months after injury. The data indicated that serum ETOH levels > 100 mg/dL at the time of admission after a TBI were associated with a decrease in global CBF. Elevated serum ETOH level at time of injury did not, however, impact outcomes.	Univ Pittsburgh, Sch Nursing, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, Ctr Stroke Inst, Dept Neurol Surg, Pittsburgh, PA 15261 USA; Boston Univ, Boston Med Ctr, Dept Neurol Surg, Boston, MA 02215 USA		Alexander, S (corresponding author), Univ Pittsburgh, Sch Nursing, Dept Neurosurg, 360 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.	salexand@pitt.edu	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P50NS30318] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 40801] Funding Source: Medline		ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; Bastos M L, 1976, J Forensic Sci, V21, P176; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BULLOCK MR, 1996, J NEUROTRAUM, V13, P638; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Fabbri A, 2001, J TRAUMA, V50, P521, DOI 10.1097/00005373-200103000-00018; Field CA, 2001, J TRAUMA, V50, P13, DOI 10.1097/00005373-200101000-00002; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALBRAITH S, 1975, BRIT J SURG, V62, P152; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Marshall LF, 1991, J NEUROSURG S, V75, P14; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; POIRES SE, 1992, J TRAUMA, V32, P60; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SANO M, 1993, J STUD ALCOHOL, V54, P367; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; STEINBOK P, 1978, NEUROSURGERY, V3, P9, DOI 10.1227/00006123-197807000-00002; SUN H, 2001, CLIN EXP RES, V26, P663; Tate PS, 1999, BRAIN INJURY, V13, P767; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	32	46	47	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					575	583		10.1089/089771504774129900			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900008	15165365				2022-02-06	
J	Geffroy, A; Bronchard, R; Merckx, P; Seince, PF; Faillot, T; Albaladejo, P; Marty, J				Geffroy, A; Bronchard, R; Merckx, P; Seince, PF; Faillot, T; Albaladejo, P; Marty, J			Severe traumatic head injury in adults: Which patients are at risk of early hyperthermia?	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; hyperthermia; leukocytosis; diabetes insipidus; outcome	INTENSIVE-CARE-UNIT; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; NEURONAL DAMAGE; ACUTE STROKE; FEVER; TEMPERATURE; HYPOTHERMIA; ISCHEMIA; RATS	Objective. Prevention of secondary insults, such as hyperthermia, is a major goal after traumatic brain injury. The aim of our study was to identify risk factors for early hyperthermia in severe head-injured patients. Design. Retrospective cohort study. Setting. A 17-bed multidisciplinary ICU of a 700-bed teaching hospital. Patients. A total of 101 adult patients admitted from January 1999 to December 2001 requiring continuous monitoring of intracranial pressure according to international guidelines. Measurement and results. Forty-four patients experienced early hyperthermia (at least one episode of body temperature >38.5degreesC within the first 2 days). On univariate analysis five variables were associated with early hyperthermia: sex; body temperature; white blood cell count on admission; prophylactic use of acetaminophen; and diabetes insipidus within 2 days. On multivariate analysis, white blood cell count >14.5x10(9)/l on admission (odds ratio, 7.1; 95% confidence interval, 2.4-20.5; p=0.001) and a body temperature on admission >36degreesC (odds ratio, 6.7; 95% confidence interval, 2.3-20.1) were strong risk factors of early hyperthermia. Prophylactic use of acetaminophen was negatively associated with early hyperthermia (odds ratio, 0.1; 95% confidence interval, 0.02-0.4). Patients who experienced early hyperthermia were less prone to have good recovery (GOS=5; p=0.03). More patients with severe or moderate disability (GOS=3 or 4) experienced early hyperthermia (p=0.01). Conclusion. We identified a subgroup of patients at high risk of early hyperthermia, which is common in severe head-injured patients. These results could have clinical implications for prevention of hyperthermia after traumatic brain injury in adults.	Univ Paris 07, Beaujon Hosp, Dept Anesthesiol & Crit Care, Assistance Publ Hop Paris, F-92118 Clichy, France; Univ Paris 07, Beaujon Hosp, Dept Neurosurg, Assistance Publ Hop Paris, Clichy, France		Geffroy, A (corresponding author), Univ Paris 07, Beaujon Hosp, Dept Anesthesiol & Crit Care, Assistance Publ Hop Paris, 100 Bvd Gen Leclerc, F-92118 Clichy, France.	arnaud.geffroy@bjn.ap-hop-paris.fr	albaladejo, pierre/M-6901-2014				AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARPENTER MB, 1983, HUMAN ANATOMY, P552; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; FAN L, 1995, MOL BRAIN RES, V30, P125; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jorgensen HS, 1999, STROKE, V30, P2008, DOI 10.1161/01.STR.30.10.2008; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Peng RY, 1999, J AM COLL SURGEONS, V188, P685, DOI 10.1016/S1072-7515(99)00035-6; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Thompson HJ, 2003, J NEUROL NEUROSUR PS, V74, P614, DOI 10.1136/jnnp.74.5.614; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; 1999, ANN FR ANESTH REANIM, V18, P5	38	46	47	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2004	30	5					785	790		10.1007/s00134-004-2280-y			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817BW	WOS:000221154000009	15052388				2022-02-06	
J	Borgens, RB; Bohnert, D; Duerstock, B; Spomar, D; Lee, RC				Borgens, RB; Bohnert, D; Duerstock, B; Spomar, D; Lee, RC			Subcutaneous tri-block copolymer produces recovery from spinal cord injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						spinal cord; neurotrauma; copolymer; P188; polyethylene glycol	BEHAVIORAL RECOVERY; FUNCTIONAL RECOVERY; MOLECULAR REPAIR; NERVE MEMBRANES; POLOXAMER 188; GUINEA-PIGS; HEMISECTION; MACROPHAGE; ISCHEMIA; NEURONS	We have studied the ability of nonionic detergents and hydrophilic polymers to seal permeabilized membranes of damaged cells, rescuing them from progressive dissolution, degeneration, and death. We report that a single subcutaneous injection of the tri-block copolymer, Poloxamer 188 (P188) 6 hr after a severe compression of the adult guinea pig spinal cord is able to: (1) preserve the anatomic integrity of the cord; (2) produce a rapid recovery of nerve impulse conduction through the lesion; and (3) produce a behavioral recovery of a spinal cord dependent long tract spinal cord reflex. These observations stood out against a control group in blinded evaluation. Conduction through the lesion was monitored by stimulating the tibial nerve of the hind limb, and measuring the arrival of evoked potentials at the contralateral sensory cortex of the brain (somatosensory evoked potentials; SSEP). Behavioral recovery was determined by a return of sensitivity of formerly areflexic receptive fields of the cutaneous trunchi muscle (CTM) reflex. This contraction of back skin in response to tactile stimulation is totally dependent on the integrity of an identified bilateral column of ascending long tract axons. A statistically significant recovery of both SSEP conduction through the lesion and the CTM reflex occurred in P188-treated animals compared to vehicle-treated controls. Quantitative 3D computer reconstruction of the lesioned vertebral segment of spinal cord revealed a statistically significant sparing of spinal cord parenchyma and a significant reduction in cavitation of the spinal cord compared to control animals We determined that the proportion of P188-treated animals that recovered evoked potentials were nearly identical to that produced by a subcutaneous injection of polyethylene glycol (PEG). In contrast, P188 was not as effective as PEG in producing a recovery of CTM functioning. We discuss the likely differences in the mechanisms of action of these two polymers, and the possibilities inherent in a combined treatment. (C) 2004 Wiley-Liss, Inc.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Univ Chicago, Dept Surg Mol Med & Organismal Biol & Anat, Chicago, IL 60637 USA; Indiana Univ, Wishard Mem Hosp, Med Ctr, Div Neurosurg, Indianapolis, IN 46202 USA		Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu		Lee, Raphael C./0000-0002-6628-1867	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM061101, R01GM064757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM64757, R01 GM61101] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS 39288-01, 1R01 NS/HD39288-01A1] Funding Source: Medline		Bajaj CL, 1997, VISUALIZATION '97 - PROCEEDINGS, P167, DOI 10.1109/VISUAL.1997.663875; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 1982, INT REV CYTOL, V76, P245, DOI 10.1016/S0074-7696(08)61793-3; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 2003, RESTORING FUNCTION I; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Donaldson J, 2002, NEUROSURGERY, V50, P147, DOI 10.1097/00006123-200201000-00023; Duerstock BS, 2000, COMPUT MED IMAG GRAP, V24, P389, DOI 10.1016/S0895-6111(00)00034-3; Duerstock BS, 2002, J EXP BIOL, V205, P13; Follis F, 1996, J INVEST SURG, V9, P149, DOI 10.3109/08941939609012466; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hannig J, 2000, RADIAT RES, V154, P171, DOI 10.1667/0033-7587(2000)154[0171:SSOMPB]2.0.CO;2; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; LEE RC, 1994, ANN NY ACAD SCI, V720, P239, DOI 10.1111/j.1749-6632.1994.tb30453.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Leskovar A, 2000, J EXP BIOL, V203, P1783; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; MELLORS A, 1966, J BIOL CHEM, V241, P4353; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; Moriarty LJ, 1999, RESTOR NEUROL NEUROS, V14, P53; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Quick KL, 2000, J NEUROSCI METH, V97, P139, DOI 10.1016/S0165-0270(00)00179-5; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Terry MA, 1999, ANN NY ACAD SCI, V888, P274, DOI 10.1111/j.1749-6632.1999.tb07962.x; Tuszynski MH, 1999, J NEUROTRAUM, V16, P523, DOI 10.1089/neu.1999.16.523; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	42	46	47	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR 1	2004	76	1					141	154		10.1002/jnr.20053			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	809NV	WOS:000220644300014	15048938				2022-02-06	
J	Hoofien, D; Gilboa, A; Vakil, E; Barak, O				Hoofien, D; Gilboa, A; Vakil, E; Barak, O			Unawareness of cognitive deficits and daily functioning among persons with traumatic brain injuries	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MEMORY-METAMEMORY DISSOCIATIONS; SELF-AWARENESS; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; REHABILITATION; DYSFUNCTION; INFECTION; ADULTS	This study examines levels of unawareness of cognitive deficits and their relationship to functional outcome among persons with traumatic brain injury (TBI). Data from 61 persons with TBI and 34 family members consisting of various measures were used. The results suggest that awareness of cognitive deficits is not differentially distributed along a concrete-abstract continuum of cognitive domains. Awareness in this sample was significantly related to psychiatric symptomatology and partially associated with behavior disturbances and daily functioning, but not with vocational outcomes. Persons with TBI who over-estimated their cognitive abilities were found to function worse on most outcome measures, except vocation, than persons who did not overestimate their abilities.	Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; Bar Ilan Univ, Ramat Gan, Israel		Hoofien, D (corresponding author), Hebrew Univ Jerusalem, Dept Psychol, Mt Scopus, IL-91905 Jerusalem, Israel.	mshoofi@mscc.huji.ac.il		Gilboa, Asaf/0000-0002-4530-7490			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Benson D.F., 1986, FRONTAL LOBES; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; Derogatis L.R., 1977, SCL 90 MANUAL SCORIN; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Hinkin CH, 1996, J CLIN EXP NEUROPSYC, V18, P431, DOI 10.1080/01688639608408999; Hoofien D, 2001, BRAIN INJURY, V15, P189; Langer KG, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P75; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MAPOU RL, 1992, HDB HEAD TRAUMA ACUT, P75; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Melamed S, 1999, SCAND J REHABIL MED, V31, P23; MELAMED S, 1985, SCAND J REHABIL MED, P129; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Rourke SB, 1999, J CLIN EXP NEUROPSYC, V21, P757, DOI 10.1076/jcen.21.6.757.852; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Stuss D., 1991, AWARENESS DEFICIT BR, P63; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WHYTE J, 1986, J HEAD TRAUMA REHAB, V1, P64; [No title captured]	39	46	46	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2004	26	2					278	290		10.1076/jcen.26.2.278.28084			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	810QW	WOS:000220719800013	15202547				2022-02-06	
J	Shore, PM; Jackson, EK; Wisniewski, SR; Clark, RSB; Adelson, PD; Kochanek, PM				Shore, PM; Jackson, EK; Wisniewski, SR; Clark, RSB; Adelson, PD; Kochanek, PM			Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children	NEUROSURGERY			English	Article						adenosine; angiogenesis; child abuse; head injury; head trauma; pediatrics; purine; regeneration	HYPOXIA-RESPONSE ELEMENT; VEGF EXPRESSION; IN-VITRO; ADENOSINE; ANGIOGENESIS; BARRIER; INTERLEUKIN-6; PERMEABILITY; INFUSION; RECEPTOR	OBJECTIVE: Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis, the formation of which is triggered by hypoxia, cytokines, and growth factors and is also induced by activation of the adenosine 2B receptor. VEGF is neuroprotective in several models of experimental brain injury and is increased in brain after traumatic brain injury (TBI) in humans and experimental animals. Adenosine is a neuroprotective purine metabolite that increases in cerebrospinal fluid (CSF) after clinical TBI in children. We hypothesized that VEGF levels would 1) be increased in CSF after TBI in infants and children, and 2) be preceded by increases in CSF adenosine. To test this hypothesis, we designed a case-control study to compare the CSF of infants and children after severe TBI with that of uninjured children. METHODS: Using an Institutional Review Board-approved protocol, we compared CSF concentrations of VEGF (by enzyme-linked immunosorbent assay) and adenosine (by high-performance liquid chromatography) in 73 samples from 14 infants and children with severe TBI (Glasgow Coma Scale score less than or equal to8) with those in CSF from 5 noninjured control subjects. Patients received standard neurointensive care. RESULTS: Mean VEGF levels were increased after TBI versus control (39.8 +/- 6.2 versus 14.9 +/- 1.5 ng/dl, mean +/- standard error of the mean, P = 0.0002) and peaked at 91.6 +/- 26.4 ng/dl, approximately 6 times control (P = 0.001). Peak VEGF occurred at 22.4 hours after injury. There was a trend toward increased adenosine concentration after TBI versus control (18.3 +/- 3.5 versus 11.5 +/- 2.3 nmol/L), but this did not reach statistical significance. A multivariate regression model showed an independent, significant association between the concentrations of VEGF and adenosine. CONCLUSION: VEGF is increased in CSF after pediatric TBI, and this increase is associated with an increase in CSF adenosine. These results may imply that a component of the vascular regenerative response of the brain is initiated rapidly after TBI and continues for several days after injury. Further investigation is warranted to determine 1) whether this association is causative, 2) the role of adenosine in triggering the increase in CSF VEGF concentration, and 3) the exact role VEGF that plays after injury.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA		Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave,Hill Bldg,Suite 201, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-38087, NS-30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, R01NS038087, P20NS030318, P50NS030318] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; BERNINI JC, 1995, LANCET, V345, P544, DOI 10.1016/S0140-6736(95)90464-6; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Conklin BS, 2002, J SURG RES, V102, P13, DOI 10.1006/jsre.2001.6295; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; DeWitt DS, 2001, MO CL BI CC, P71; Dobolyi A, 1998, NEUROCHEM INT, V32, P247, DOI 10.1016/S0197-0186(97)00090-9; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Grant MB, 2001, INVEST OPHTH VIS SCI, V42, P2068; Gu JW, 1999, AM J PHYSIOL-HEART C, V277, pH595, DOI 10.1152/ajpheart.1999.277.2.H595; Harrigan MR, 2002, NEUROSURGERY, V50, P589, DOI 10.1097/00006123-200203000-00030; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Jackson EK, 1996, J PHARMACOL EXP THER, V279, P1250; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2001, HEAD TRAUMA, P141; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; MEYER R, 2002, CRIT CARE, V6, pP57; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PHILLIS JW, 1987, J CEREBR BLOOD F MET, V7, P679, DOI 10.1038/jcbfm.1987.122; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Salhia B, 2000, BRAIN RES, V883, P87, DOI 10.1016/S0006-8993(00)02825-0; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Taub PJ, 2000, PLAST RECONSTR SURG, V105, P1034, DOI 10.1097/00006534-200003000-00031; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; VANWYLEN DGL, 1989, J CEREBR BLOOD F MET, V9, P556, DOI 10.1038/jcbfm.1989.79; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	55	46	50	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2004	54	3					605	611		10.1227/01.NEU.0000108642.88724.DB			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	802FN	WOS:000220149500025	15028134				2022-02-06	
J	Hellmich, HL; Frederickson, CJ; DeWitt, DS; Saban, R; Parsley, MO; Stephenson, R; Velasco, M; Uchida, T; Shimamura, M; Prough, DS				Hellmich, HL; Frederickson, CJ; DeWitt, DS; Saban, R; Parsley, MO; Stephenson, R; Velasco, M; Uchida, T; Shimamura, M; Prough, DS			Protective effects of zinc chelation in traumatic brain injury correlate with upregulation of neuroprotective genes in rat brain	NEUROSCIENCE LETTERS			English	Article						zinc; traumatic brain injury; gene expression; neuroprotection; apoptosis	SYNAPTICALLY-RELEASED ZINC; HIPPOCAMPUS; DEATH	Chelation of excessive neuronal zinc ameliorates zinc neurotoxicity and reduces subsequent neuronal injury. To clarify the molecular mechanisms of this neuroprotective effect, we used a focused cDNA array of stress-response genes with zinc chelation (calcium EDTA) in our rat model of fluid percussion brain injury at 2 h, 24 h, and 7 days after injury. In parallel experiments, we compared neuronal cell death in TUNEL-stained brain sections in traumatized rats with and without calcium EDTA treatment. Zinc chelation induced the expression of several neuroprotective genes; neuroprotective gene expression correlated with substantially decreased numbers of TUNEL-positive cells. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Yokohama City Univ, Sch Med, Dept Neurol, Yokohama, Kanagawa 232, Japan; Univ Texas, Med Branch, Dept Biostat, Galveston, TX 77550 USA; Vel Lab Res, Houston, TX USA; Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA; Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77550 USA; Univ Texas, Med Branch, Ctr Biomed Engn, Galveston, TX 77550 USA		Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	De Velasco, Marco/R-1022-2019; Prough, Donald S/G-5793-2013	De Velasco, Marco/0000-0002-4011-6572; Prough, Donald S/0000-0001-7994-532X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038585, R01NS019355, R21NS042882, R43NS040215] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38585, NS19355, NS40215, NS42882] Funding Source: Medline		BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Conover WJ, 1999, PRACTICAL NONPARAMET, V3rd, P288; Conti AC, 1998, J NEUROSCI, V18, P5663; Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; Inguaggiato P, 2001, KIDNEY INT, V60, P2181, DOI 10.1046/j.1523-1755.2001.00046.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Manzanares D, 2001, J PROTEIN CHEM, V20, P181, DOI 10.1023/A:1010996528884; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Pan W, 2002, BIOINFORMATICS, V18, P546, DOI 10.1093/bioinformatics/18.4.546; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rubio E, 2002, EUR J NEUROSCI, V15, P1646, DOI 10.1046/j.1460-9568.2002.01998.x; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3	21	46	47	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 30	2004	355	3					221	225		10.1016/j.neulet.2003.10.074			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	766VQ	WOS:000188396500017	14732471				2022-02-06	
J	Shibuya, S; Miyamoto, O; Janjua, NA; Itano, T; Mori, S; Norimatsu, H				Shibuya, S; Miyamoto, O; Janjua, NA; Itano, T; Mori, S; Norimatsu, H			Post-traumatic moderate systemic hypothermia reduces TUNEL positive cells following spinal cord injury in rat	SPINAL CORD			English	Article						moderate hypothermia; TUNEL; spinal cord injury; rats	DELAYED NEURONAL DEATH; COMPRESSION INJURY; BRAIN INJURY; WALLERIAN DEGENERATION; MILD HYPOTHERMIA; ADULT RATS; APOPTOSIS; ISCHEMIA; TRAUMA; GERBIL	Study design: A standardized animal model of contusive spinal cord injury (SCI) with incomplete paraplegia was used to test the hypothesis that moderate systemic hypothermia reduces neural cell death. Terminal deoxynucleotidyl transferase [TdT]-mediated deoxyuridine triphosphate [dUTP] nick-end labeling (TUNEL) staining was used as a marker of apoptosis or cell damage. Objective: To determine whether or not moderate hypothermia could have a neuroprotective effect in neural cell death following spinal cord injury in rats. Setting: Kagawa Medical University, Japan. Methods: Male Sprague-Dawley (SD) rats (n = 39) weighing on average 300 g (280-320 g) were used to prepare SCI models. After receiving contusive injury at T11/12, rats were killed at 24 h, 72 h, or 7 days after injury. The spinal cord was removed en bloc and of examined at five segments: 5 and 10 mm rostral to the center of injury, center of injury, and 5 and 10 mm caudal to the center of injury. Rats that received hypothermia (32degreesC/4 h) were killed at the same time points as those that received normothermia (37degreesC/3 h). The specimens were stained with hematoxylin and eosin, and subjected to in situ nick-end labeling (TUNEL), a specific method for visualizing cell death in the spinal cord. Results: At 24 h postinjury, TUNEL positive cells (TPC) decreased significantly 10 mm rostral to center of injury in hypothermic animals compared to the normothermia group. At 72 h post-SCI, TPC also decreased significantly at 5 mm rostral, and 5 and 10 mm caudal to the lesion center compared to normothermic animals. At 7 days postinjury, a significant decrease of TPC was observed at the 5 mm rostral and 5 mm caudal sites compared to normothermic animals. Conclusion: These results indicate that systemic hypothermia has a neuroprotective effect following SCI by attenuating post-traumatic TPC.	Kagawa Med Univ, Dept Orthopaed Surg, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Neurobiol, Miki, Kagawa 7610793, Japan		Itano, T (corresponding author), Kagawa Med Univ, Dept Biol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.						Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; CHOI DW, 1987, J NEUROSCI, V7, P369; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hayashi R, 1998, J HISTOCHEM CYTOCHEM, V46, P1051, DOI 10.1177/002215549804600909; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; Katoh K, 1996, NEUROSCI LETT, V216, P9; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LIANG F, 1991, J COMP NEUROL, V311, P356, DOI 10.1002/cne.903110306; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; Miyamoto O, 2000, BRAIN RES, V873, P168, DOI 10.1016/S0006-8993(00)02521-X; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; NITATORI T, 1995, J NEUROSCI, V15, P1001; RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WALLACE MC, 1986, NEUROSURGERY, V18, P433; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, EUR J PHARMACOL, V218, P273, DOI 10.1016/0014-2999(92)90179-8; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206	46	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	JAN	2004	42	1					29	34		10.1038/sj.sc.3101516			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	761LA	WOS:000187909200005	14713941	Bronze			2022-02-06	
J	Baldo, V; Marcolongo, A; Floreani, A; Majori, S; Cristofoletti, M; Dal Zotto, A; Vazzoler, G; Trivello, R				Baldo, V; Marcolongo, A; Floreani, A; Majori, S; Cristofoletti, M; Dal Zotto, A; Vazzoler, G; Trivello, R			Epidemiological aspect of traumatic brain injury in Northeast Italy	EUROPEAN JOURNAL OF EPIDEMIOLOGY			English	Article						epidemiology; prevention; traumatic brain injuries	MORTALITY	Background: Traumatic brain injuries ( TBIs) remain an important public health problem in developed countries. Hospital records were reviewed to ascertain the epidemiology of TBIs in Northeast Italy. Methods: The annual rates of TBI-associated hospitalisation were estimated by analysing data collected from hospital records from 1996 to 2000. TBIs were identified according to the Centers for Disease Control and Prevention definition and the ICDMAP-90 was used to assess their severity. Findings: 55,368 TBIs were collected between 1996 and 2000, with an overall 29.4% decline in the number of cases. As for severity, moderate TBIs dropped by 34.1%, whereas a less conspicuous decline was observed for mild injuries. Severe injuries remained stable between 1996 and 1999, but rose in 2000, when the unclassified injuries were better distributed. Concerning outcome, fatal TBIs dropped slightly, but only in 2000. Causes of TBI were recorded in 59.2% of cases: 48.5% were motor vehicle accidents, 8.8% occurred at work and 12.2% at home. There were more males than females in all age groups. The highest number of cases per 100,000 person of motor vehicle accidents was recorded among 16 - 25 year-old and 36.5% occurred at weekends. Domestic accidents showed two age peaks, in children and the elderly. Occupational accidents occurred at all working ages, tending to decline with older age. Interpretation: Better health care and educational campaigns may have contributed to the declining rate of TBI-associated hospitalisation. Special efforts should be made to further reduce the motor vehicle accidents involving young people and welfare programs are needed to limit the risk of falls and contain functional impairment in the elderly.	Univ Padua, Inst Hyg, Dept Environm Med & Publ Hlth, I-35131 Padua, Italy; Hosp & Ambulatory Care, Planning Dept, Venice, Italy; Univ Verona, Inst Hyg, Dept Med & Publ Hlth, I-37100 Verona, Italy; Univ Padua, Dept Surg & Gastroenterol Sci, I-35100 Padua, Italy		Baldo, V (corresponding author), Univ Padua, Inst Hyg, Dept Environm Med & Publ Hlth, Via Loredan 18, I-35131 Padua, Italy.		Vincenzo, Baldo/D-7822-2018; Baldo, Vincenzo/V-4005-2019	Vincenzo, Baldo/0000-0001-6012-9453; Baldo, Vincenzo/0000-0001-6012-9453			AA W, 2001, EUR J EPIDEMIOL, V17, P437; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Ferrando J, 2000, Inj Prev, V6, P184, DOI 10.1136/ip.6.3.184; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Poidevin P, 2000, ANN FR ANESTH, V19, P282; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1997, INT CLASS DIS; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wong E, 2002, J EMERG MED, V22, P139, DOI 10.1016/S0736-4679(01)00455-3	16	46	48	0	7	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0393-2990			EUR J EPIDEMIOL	Eur. J. Epidemiol.	NOV	2003	18	11					1059	1063		10.1023/A:1026192020963			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	730YK	WOS:000185857600007	14620940				2022-02-06	
J	Steiner, LA; Coles, JP; Johnston, AJ; Czosnyka, M; Fryer, TD; Smielewski, P; Chatfield, DA; Salvador, R; Aigbirhio, FI; Clark, JC; Menon, DK; Pickard, JD				Steiner, LA; Coles, JP; Johnston, AJ; Czosnyka, M; Fryer, TD; Smielewski, P; Chatfield, DA; Salvador, R; Aigbirhio, FI; Clark, JC; Menon, DK; Pickard, JD			Responses of posttraumatic pericontusional cerebral blood flow and blood volume to an increase in cerebral perfusion pressure	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cerebral contusion; cerebral blood flow; cerebral blood volume; cerebral perfusion pressure; positron emission tomography	TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; FOCAL ISCHEMIA; TOMOGRAPHY; CONTUSIONS; RAT	In and around traumatic contusions, cerebral blood flow (CBF) is often near or below the threshold for ischemia. Increasing cerebral perfusion pressure (CPP) in patients with head injuries may improve CBF in these regions. However, the pericontusional response to this intervention has not been studied. Using positron emission tomography (PET), we have quantified the response to an increase in CPP in and around contusions in 18 contusions in 18 patients. Regional CBF and cerebral blood volume (CBV) were measured with PET at CPPs of 70 and 90 mmHg using norepinephrine to control CPP. Based upon computed tomography, regions of interest (ROIs) were placed as two concentric ellipsoids, each of 1-cm width, around the core of the contusions. Measurements were compared with a control ROI in tissue with normal anatomic appearance. Baseline CBF and CBV increased significantly with increasing distance from the core of the lesion. The increase in CPP led to small increases in CBF in all ROIs except the core. The largest absolute CBF increase was found in the control ROI. Relative CBF increases did not differ between ROIs so that ischemic areas remained ischemic. Pericontusional oedema on computed tomography was associated with lower absolute values of CBF and CBV but did not differ from nonoedematous tissue in the relative response to CPP elevation.	Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, England; Addenbrookes Hosp, Univ Dept Anesthesia, Cambridge, England; Addenbrookes Hosp, Acad Neurosurg, Cambridge, England		Steiner, LA (corresponding author), Univ Basel, Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland.	lsteiner@uhbs.ch	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019	Salvador, Raymond/0000-0001-5557-1562; Smielewski, Peter/0000-0001-5096-3938; Coles, Jonathan/0000-0003-4013-679X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390] Funding Source: UKRI		BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; KUROIWA T, 1994, ACTA NEUROCHIR, P158; MacGregor DG, 2000, EUR J NEUROSCI, V12, P58, DOI 10.1046/j.1460-9568.2000.00880.x; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MILLER JD, 1975, J NEUROL NEUROSUR PS, V38, P657, DOI 10.1136/jnnp.38.7.657; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schroder ML, 1998, ACT NEUR S, V71, P127; Schumann P, 1998, BRAIN, V121, P1369, DOI 10.1093/brain/121.7.1369; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEINER LA, 2002, J NEUROTRAUM, V19, P1301; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Talairach J., 1988, COPLANAR STEREOTAXIC; Videen TO, 1999, J COMPUT ASSIST TOMO, V23, P248, DOI 10.1097/00004728-199903000-00014; WHITTLE IR, 1990, ACT NEUR S, V51, P71	26	46	46	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2003	23	11					1371	1377		10.1097/01.WCB.0000090861.67713.10			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	741TY	WOS:000186477500014	14600445				2022-02-06	
J	Underhill, AT; Lobello, SG; Stroud, TP; Terry, KS; Devivo, MJ; Fine, PR				Underhill, AT; Lobello, SG; Stroud, TP; Terry, KS; Devivo, MJ; Fine, PR			Depression and life satisfaction in patients with traumatic brain injury: a longitudinal study	BRAIN INJURY			English	Article							INDEX	Primary objective: To assess the relationship between depression and life satisfaction among survivors of traumatic brain injury (TBI) over a 3-year period after injury. It was hypothesized that survivors of TBI with depression would have decreased life satisfaction. Research design: Two groups ( depression vs no depression) longitudinal design. Methods and procedures: Interviewed survivors of TBI (n = 324) by telephone at 24, 48 and 60 months after hospitalization. At the 24-month interview, 90 (27.8%) respondents reported a post-injury diagnosis of depression and 234 (72.2%) reported no diagnosis. Respondents then completed the Life Satisfaction Index I-A, which was repeated at the 48- and 60-month interviews. Main outcomes and results: The depression group had significantly lower life satisfaction than the no depression group at 24-, 48- and 60-month interviews. Conclusions: Depression and diminished life satisfaction among survivors of TBI are persistent problems that require the close attention of medical and rehabilitation professionals.	Univ Alabama, Sch Med, Injury Control Res Ctr, Birmingham, AL 35294 USA; UAB, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA; Auburn Univ, Montgomery, AL 36117 USA		Underhill, AT (corresponding author), Univ Alabama, Sch Med, Injury Control Res Ctr, 403 Community Hlth Serv Bldg,933 19th St S, Birmingham, AL 35294 USA.				ODCDC CDC HHS [R49 CCR403641] Funding Source: Medline		ADAMS DL, 1969, J GERONTOL, V24, P470, DOI 10.1093/geronj/24.4.470; *AM ASS AUT MED CO, 1985, ABBR INJ SCAL; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Garthe E, 1999, J TRAUMA, V47, P309, DOI 10.1097/00005373-199908000-00016; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Lecrubier Y, 2001, J CLIN PSYCHIAT, V62, P4; Lecrubier Y, 2000, EUR NEUROPSYCHOPHARM, V10, pS439, DOI 10.1016/S0924-977X(00)00111-5; LOHMANN N, 1977, J GERONTOL, V32, P73, DOI 10.1093/geronj/32.1.73; Maciejewski PK, 2001, PSYCHOL MED, V31, P593, DOI 10.1017/S0033291701003877; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; *NAT I MENT HLTH, 1996, PUBL NAT I MENT HLTH; *NAT I MENT HLTH, 2001, PUBL NAT I MENT HLTH; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; RAO V N, 1981, International Journal of Aging and Human Development, V14, P55, DOI 10.2190/DWM4-E05K-CNTD-XNAA; ROBINS LN, 1990, PSYCHIAT DISORDERS A; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; Wallace KA, 2002, EDUC PSYCHOL MEAS, V62, P674, DOI 10.1177/001316402128775085; [No title captured]	23	46	47	1	13	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2003	17	11					973	982		10.1080/0269905031000110418			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	725GE	WOS:000185534800004	14514448				2022-02-06	
J	Shiozaki, T; Nakajima, Y; Taneda, M; Tasaki, O; Inoue, Y; Ikegawa, H; Matsushima, A; Tanaka, H; Shimazu, T; Sugimoto, H				Shiozaki, T; Nakajima, Y; Taneda, M; Tasaki, O; Inoue, Y; Ikegawa, H; Matsushima, A; Tanaka, H; Shimazu, T; Sugimoto, H			Efficacy of moderate hypothermia in patients with severe head injury and intracranial hypertension refractory to mild hypothermia	JOURNAL OF NEUROSURGERY			English	Article						head injury; intracranial pressure; hypothermia	TRAUMATIC BRAIN INJURY; THERAPY; PRESSURE	Object. This study was performed to determine whether moderate hypothermia (31degreesC) improves clinical outcome in severely head injured patients whose intracranial hypertension cannot be controlled using mild hypothennia (34degreesC). Methods. Twenty-two consecutive severely head injured patients who fulfilled the following criteria were included in this study: an intracranial pressure (ICP) that remained higher than 40 mm Hg despite the use of mild hypothermia combined with conventional therapies; and a Glasgow Coma Scale score of 8 or less on admission. After the failure of mild hypothermia in combination with conventional therapies; patients were exposed to moderate hypothermia as quickly as possible. As brain temperature was reduced from 34 to 31degreesC, the volume of intravenous fluid infusion was increased significantly from 1.9 +/- 0.9 to 2.6 +/- 1.2 mg/kg/hr (p < 0.01), and the dose of dopamine infusion increased significantly from 4.3 +/- 3.1 to 8.2 +/- 4.4 mug/kg/min (p < 0.01). Nevertheless, mean arterial blood pressure and heart rate decreased significantly from 97.1 &PLUSMN; 13.1 to 85.1 &PLUSMN; 10.5 mm Hg (p &LT; 0.01) and from 92.2 &PLUSMN; 13.8 to 72.2 &PLUSMN; 14.3 beats/minute at (p &LT; 0.01) at 34 and 31&DEG;C, respectively. Arterial base excess was significantly aggravated from -3.3 &PLUSMN; 4 at 34&DEG;C to -5.6 &PLUSMN; 5.4 mEq/L (at 31&DEG;C; p &LT; 0.05). Likewise, serum potassium concentration, white blood cell counts, and platelet counts at 31&DEG;C decreased significantly compared with those at 34&DEG;C (p &LT; 0.01). In 19 (86%) of 22 patients, elevation of ICP could not be prevented using moderate hypothermia. In the remaining three patients, ICP was maintained below 40 mm Hg by inducing moderate hypothermia; however, these three patients died of multiple organ failure. These results clearly indicate that moderate hypothermia induces complications more severe than those induced by mild hypothennia without improving outcomes. Conclusions. The authors concluded that moderate hypothermia is not effective in improving clinical outcomes in severely head injured patients whose ICP remains higher than 40 mm Hg after treatment with mild hypothermia combined with conventional therapies.	Osaka Univ, Grad Sch Med, Dept Traumatol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neurosurg, Osaka 5650871, Japan; Kinki Univ, Sch Med, Dept Neurosurg, Osaka, Japan		Shiozaki, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol, 2-2 Yamada Oka, Osaka 5650871, Japan.						BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; HASHIGUCHI N, IN PRESS J TRAUMA; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Klementavicius R, 1996, J NEUROSURG, V85, P482, DOI 10.3171/jns.1996.85.3.0482; Kuwagata Y, 1999, J TRAUMA, V47, P666, DOI 10.1097/00005373-199910000-00010; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; TEASDALE G, 1974, LANCET, V2, P81; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007	17	46	56	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2003	99	1					47	51		10.3171/jns.2003.99.1.0047			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	696BN	WOS:000183865500009	12854743				2022-02-06	
J	Wagner, AK; Fabio, T; Zafonte, RD; Goldberg, G; Marion, DW; Peitzman, AB				Wagner, AK; Fabio, T; Zafonte, RD; Goldberg, G; Marion, DW; Peitzman, AB			Physical medicine and rehabilitation consultation - Relationships with acute functional outcome, length of stay, and discharge planning after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						physiatry; consultation; traumatic brain injury; rehabilitation; outcome; health care	VARIABLES; SEVERITY	Objective: Patients hospitalized with traumatic brain injury comprise a large portion of the population treated at trauma centers, and physiatry consultants evaluate many traumatic brain injury patients in this setting. The purpose of this study was to delineate relationships between physical medicine and rehabilitation consultation in this population and acute functional outcome, length of stay, and discharge planning. Design: Data were obtained for 1866 adult patients hospitalized with non-fatal traumatic brain injury. Functional outcome was determined using a modification of the FIM(TM). Descriptive and regression analyses were used to determine the relationship of physical medicine and rehabilitation consultation to acute discharge FIM score, length of stay, and discharge disposition. Results: Patients receiving physical medicine and rehabilitation consultation had more severe injuries, lower acute discharge FIM scores, and longer length of stay. However, multivariate analysis showed that earlier (<48 hr after admission) physical medicine and rehabilitation consultation resulted in significantly better FIM scores with transfers (odds ratio, 2.61; 95% confidence interval, 1.06-6.40) and locomotion (odds ratio, 3.54; 95% confidence interval, 1.34-9.32) and a significantly shorter acute length of stay (P = 0.001). Conclusions: Early physical medicine and rehabilitation consultation may positively impact functional status and length of stay for patients with traumatic brain injury during acute hospitalization. Additional work is needed to determine how physical medicine and rehabilitation consultation impacts rehabilitation-specific medical issues, long-term functional outcome, and healthcare costs.	Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Ctr Injury Res & Control, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Sect Trauma, Dept Surg, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	ODCDC CDC HHS [CCR310285-07] Funding Source: Medline		GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; LEHMAN LB, 1988, POSTGRAD MED, V83, P140; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MACKAY LE, 1994, J HEAD TRAUMA REHAB, V9, P11; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Melchiorre PJ, 1998, ARCH PHYS MED REHAB, V79, P62, DOI 10.1016/S0003-9993(98)90210-6; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Taheri PA, 1997, J TRAUMA, V43, P565, DOI 10.1097/00005373-199710000-00001; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; UNICO J, 2001, J NEUROTRAUM, V18, P1177; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198	15	46	50	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2003	82	7					526	536		10.1097/00002060-200307000-00006			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	694DC	WOS:000183757700006	12819540				2022-02-06	
J	Karmy-Jones, R; Hoffer, E; Meissner, M; Bloch, RD				Karmy-Jones, R; Hoffer, E; Meissner, M; Bloch, RD			Management of traumatic rupture of the thoracic aorta in pediatric patients	ANNALS OF THORACIC SURGERY			English	Article							ENDOVASCULAR STENT-GRAFTS; VASCULAR INJURIES; ANEURYSMS; REPAIR; PLACEMENT; CHILDREN; COARCTATION; DIAGNOSIS	Background. Traumatic rupture of the thoracic aorta (TRA) in the pediatric population is uncommon. Management of TRA in general has evolved to include selective nonoperative and endovascular stent graft approaches, although operative repair remains the standard. Methods. We conducted a retrospective chart review of patients younger than 16 years of age admitted to a single institution between March 1985 and February 2002. Results. Of 160 patients admitted with TRA, 11 were younger than 16 (11.9 +/- 3.5) years of age. Concomitant injuries included closed head injury (5 patients) and acute lung injury (6 patients). All were started on beta-blockers when the diagnosis was suspected. Laparotomy was required in 3 patients and orthopedic procedures in 5 patients. Six underwent operative repair (two primary repairs), with no mortality. Cross-clamp time was 30.4 +/- 2.6 minutes. One patient (operated on without bypass) was partially paralyzed. Two patients were managed nonoperatively, 1 with an intimal arch injury, who on subsequent follow-up has demonstrated healing, and 1 who died of head injury. Three patients were managed by endovascular stent grafts, 2 who died of closed head injury and 1 who at 1-year follow-up has fully recovered. The endovascular stent grafts were placed through the femoral artery in 2 patients and through an iliac conduit in 1 patient. No patient died of rupture. Conclusions. The approach to pediatric TRA should be identical to the adult, with early institution of beta-blockers. Depending on the clinical setting, a spectrum of options should be considered, including operation, nonoperation, and endovascular stent graft, although the choice of the latter must be tempered by the lack of long-term follow-up data. (C) 2003 by The Society of Thoracic Surgeons.	Univ Washington, Harborview Med Ctr, Div Cardiothorac Trauma, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Div Intervent Radiol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Div Vasc Traums, Seattle, WA 98104 USA		Karmy-Jones, R (corresponding author), Univ Washington, Harborview Med Ctr, Div Cardiothorac Trauma, 325 9Th Ave,Box 359796, Seattle, WA 98104 USA.						Ahn SH, 2001, J TRAUMA, V50, P949, DOI 10.1097/00005373-200105000-00033; BERGMAN K, 1990, J TRAUMA, V30, P604, DOI 10.1097/00005373-199005000-00013; Bruninx G, 1999, CARDIOVASC INTER RAD, V22, P515, DOI 10.1007/s002709900442; Cox CS, 1998, J PEDIATR SURG, V33, P462, DOI 10.1016/S0022-3468(98)90089-6; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; Dake MD, 1998, J THORAC CARDIOV SUR, V116, P689, DOI 10.1016/S0022-5223(98)00455-3; DELEZO JS, 1995, AM HEART J, V129, P1002, DOI 10.1016/0002-8703(95)90123-X; Deshpande A, 1998, J ENDOVASC SURG, V5, P120, DOI 10.1583/1074-6218(1998)005<0120:TOTFAO>2.0.CO;2; Dorros G, 1996, J ENDOVASC SURG, V3, P270, DOI 10.1583/1074-6218(1996)003<0270:AITCAE>2.0.CO;2; Fink C, 2000, CARDIOL YOUNG, V10, P644; Grabenwoger M, 2000, ANN THORAC SURG, V69, P441, DOI 10.1016/S0003-4975(99)01291-6; HOFFER E, 2001, EMERG RADIOL, V8, P233; Holmes JH, 2002, ANN THORAC SURG, V73, P1149, DOI 10.1016/S0003-4975(01)03585-8; Hormuth D, 1999, ARCH SURG-CHICAGO, V134, P759, DOI 10.1001/archsurg.134.7.759; Ishimaru S, 1998, J THORAC CARDIOV SUR, V115, P811, DOI 10.1016/S0022-5223(98)70360-5; Karmy-Jones R, 2001, AM SURGEON, V67, P61; Katayama Y, 2000, Jpn J Thorac Cardiovasc Surg, V48, P73; Katayama Y, 2000, JPN J THORAC CARDIOV, V48, P144; Kato N, 1997, RADIOLOGY, V205, P657, DOI 10.1148/radiology.205.3.9393517; Lowe LH, 1998, AM J ROENTGENOL, V170, P39, DOI 10.2214/ajr.170.1.9423595; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Mattison R, 2001, J TRAUMA, V51, P326, DOI 10.1097/00005373-200108000-00016; Mattox K L, 2000, Chest Surg Clin N Am, V10, P167; PEZZELLA AT, 1978, AM SURGEON, V44, P699; Rousseau H, 1999, CIRCULATION, V99, P498, DOI 10.1161/01.CIR.99.4.498; Ruchat P, 2001, J CARDIOVASC SURG, V42, P77; Semba C P, 1997, Vasc Med, V2, P98; Semba CP, 1997, J VASC INTERV RADIOL, V8, P337, DOI 10.1016/S1051-0443(97)70568-2; SPOUGE AR, 1991, PEDIATR RADIOL, V21, P324, DOI 10.1007/BF02011477; STRIFFELER H, 1993, EUR J PEDIATR SURG, V3, P50, DOI 10.1055/s-2008-1063509; Temudom T, 2000, ANN VASC SURG, V14, P230, DOI 10.1007/s100169910040; Thompson CS, 2002, J VASC SURG, V35, P1163, DOI 10.1067/mva.2002.122885; Thompson CS, 2002, J TRAUMA, V52, P1173, DOI 10.1097/00005373-200206000-00025; Trachiotis GD, 1996, ANN THORAC SURG, V62, P724, DOI 10.1016/S0003-4975(96)00355-4; Weigand MA, 1998, ANESTHESIOLOGY, V89, P1037, DOI 10.1097/00000542-199810000-00035; Yamashita S, 2001, J TRAUMA, V51, P587, DOI 10.1097/00005373-200109000-00032	36	46	46	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	MAY	2003	75	5					1513	1517	PII S0003-4975(02)04838-5	10.1016/S0003-4975(02)04838-5			5	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Respiratory System; Surgery	671YP	WOS:000182493400029	12735571				2022-02-06	
J	Reynolds, S; Paniak, C; Toller-Lobe, G; Nagy, J				Reynolds, S; Paniak, C; Toller-Lobe, G; Nagy, J			A longitudinal study of compensation-seeking and return to work in a treated mild traumatic brain injury sample	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						financial compensation; mild traumatic brain injury; return to work	CLOSED-HEAD-INJURY; RANDOMIZED TRIAL	Objective: In patients with mild traumatic brain injury (MTBI), to assess: (1) changes in financial compensation-seeking status over time and (2) the relationship between compensation-seeking and return to work. Design: Longitudinal evaluation of financial compensation-seeking status (i.e., at intake, 3 months postinjury, and 12 months postinjury) and relationship of such status to return to work. Setting: Outpatient rehabilitation clinic. Subjects: Ninety-seven patients with MTBI Main outcome measures: Compensation-seeking status at 3 and 12 months and days taken to return to preinjury vocational activity. Results: Those in litigation at intake generally continued to be in litigation at 3 and 12 months postinjury. Those seeking or receiving compensation via administrative means (e.g., sick pay or workers' compensation) at intake were generally not seeking or receiving compensation by 3 months or later, as was the case for most of those not seeking any financial compensation at intake. Patients seeking or receiving financial compensation via litigation and/or administrative means at intake took longer to return to work than did people who were not seeking or receiving compensation at intake. Conclusions: present study design does not allow for determination of the reasons for the strong relationship between financial compensation-seeking soon post-MTBI and a slow return to work. However, the strength of the present findings indicates that the presence or absence of financial compensation-seeking soon post-MTBI should be routinely evaluated when return to work is an issue.	Glenrose Rehabil Hosp, Psychol Serv, Edmonton, AB T5G 0B7, Canada; Glenrose Rehabil Hosp, Phys Therapy Serv, Edmonton, AB T5G 0B7, Canada; Glenrose Rehabil Hosp, Med Serv, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada		Paniak, C (corresponding author), Glenrose Rehabil Hosp, Psychol Serv, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						*AM MED ASS, 1995, AMA DRUG EV; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; DUSH DM, 1994, J PERS ASSESS, V62, P299, DOI 10.1207/s15327752jpa6202_10; Evans R. W., 1994, AM J FORENSIC PSYCH, V4, P19; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	14	46	46	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					139	147		10.1097/00001199-200303000-00005			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600005	12802223				2022-02-06	
J	Williams, WH				Williams, WH			Brain injury and emotion: An overview to a special issue on biopsychosocial approaches in neurorehabilitation	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY	Survivors of acquired brain injury (ABI) are at risk of a range of neuropsychiatric and behavioural disorders. Emotional disturbance, with reactive elements of mood disorder, such as depression and anxiety, appear particularly common. Specific anxiety disorders, such as post-traumatic stress disorder (PTSD) have also been identified. Pain syndromes are also common-particularly in those who have suffered Traumatic Brain Injuries (TBI). Survivors of ABI are often at risk of substance misuse and of irritability states. Their relationships may suffer from the stresses triggered by the aftermath of injury. Intimate, in particular, sexual relationships may be particularly affected. These effects are not, necessarily, only consequent of severe injuries, as mild TBI can also have, for some, significant neuropsychiatric effects. Assessment and management of such conditions are compromised by survivors of injury often having a limited insight into the sequelae of their injuries. Interventions for such disorders and forms of distress are increasingly available. This paper introduces the special issue of Neuropsychological Rehabilitation on biopsychosocial approaches in neurorehabilitation. A range of papers provide overviews for assessing and managing such neuropsychiatric, mood and behavioural (health and habit) disorders.	Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England; Oliver Zangwill Ctr, Ely, Cambs, England		Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England.			williams, huw/0000-0003-0670-2620			Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; HARRIS DP, 1997, J OUTCOMES MEASUREME, V1, P23; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Lewis G, 2001, J NEUROL NEUROSUR PS, V71, P431, DOI 10.1136/jnnp.71.4.431; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P11; Lishman WA, 1998, ORGANIC PSYCHIAT; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; ODDY M, 2001, NEUROBEHAVIOURAL DIS; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; WILLIAMS WH, 2003, STUDIES NEUROPSYCHOL; WILSON B, 1989, MODELS BRAIN INJURY, P117; Wood RL, 2001, NEUROBEHAVIOURAL DIS, P1; World Health Organization, 2007, INT CLASS FUNCT DIS; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	22	46	46	0	16	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		1	11		10.1080/09602010244000444			11	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500001	22004099				2022-02-06	
J	Johnstone, B; Vessell, R; Bounds, T; Hoskins, S; Sherman, A				Johnstone, B; Vessell, R; Bounds, T; Hoskins, S; Sherman, A			Predictors of success for state vocational rehabilitation clients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; rehabilitation, vocational; treatment outcomes	SUBSTANCE-ABUSE; HEAD-INJURIES; EMPLOYMENT; RETURN; WORK; INTEGRATION; OUTCOMES; SERVICES	Objectives: To determine the characteristics of individuals with traumatic brain injury (TBI) who request state vocational rehabilitation services and to determine the best predictors of their successful vocational outcomes. Design: Observational study. Setting: Vocational services data from the Missouri Division of Vocational Rehabilitation (DVR). Participants: Seventy-eight individuals with TBI who requested services from the Missouri DVR. Interventions: Not applicable. Main Outcome Measures: Demographic, injury severity, neuropsychologic variables, vocational services offered, and vocational status at time of case closure (successful, unsuccessful, services interrupted, no services provided). Results: Individuals requesting DVR services were primarily men (71%), white (82%), single (47%), of low average intelligence (Wechsler Adult Intelligence Scales-III full scale IQ score, 84.8), and of limited education (11.8y). The majority experienced a significant TBI (ie, 66% were hospitalized after their TBI; 56% reported loss of consciousness; 37% reported posttraumatic amnesia; 32% reported multiple TBIs; avg time since injury, 9.2y). At DVR case closure, 17% were rated as being successfully employed, with nearly all working in industrial, service, or clerical positions (2 in a sheltered workshop, 1 in a professional position). Stepwise logistic regressions indicated that delivery of DVR services (ie, vocational guidance and counseling, on-the-job training) predicted vocational outcome and demographic, injury severity, and neuropsychologic variables did not. Conclusions: DVR clients have multiple impairments that affect them several years postinjury; the provision of DVR services may be more important in determining vocational outcomes than traditional medical, psychologic, and demographic variables.	Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, Columbia, MO 65212 USA; Univ Missouri, Hlth Sci Ctr, Dept Biostat, Columbia, MO 65212 USA; Missouri Div Vocat Rehabil, Dept Elementary & Secondary Educ, Jefferson City, MO USA		Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, DC046-00, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			[Anonymous], TRAUMATIC BRAIN INJU; [Anonymous], 1998, NIH CONSENS STATEMEN, V16, P1; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; BOUNDS TA, IN PRESS J NEURO REH; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; DEFILIPPIS NA, 1991, MANUAL BOOKLET CATEG; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; GOODYEAR C, 1994, EARTH ISL J, V9, P2; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; KlOve H, 1963, MED CLIN N AM; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan R, 1985, HALSTEAD REITAN NEUR; REITAN RM, 1992, REITAN NEUROPSYCHOLO; ROESSLER RT, 1992, J REHABIL, V58, P17; *RUR POL RES I, METR NON METR COUNT; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; SEELMAN KD, P TIDE 3 C ASS TECHN; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Wechsler D, 1997, WMS 3 ADM SCORING MA; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Woodcock R.W., 1989, WOODCOCK JOHNSON TES	33	46	46	0	12	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					161	167		10.1053/apmr.2003.50098			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700003	12601645				2022-02-06	
J	McKeever, CK; Schatz, P				McKeever, CK; Schatz, P			Current issues in the identification, assessment, and management of concussions in sports-related injuries	APPLIED NEUROPSYCHOLOGY			English	Article						concussion; sports-related injury; mild traumatic brain injury; neuropsychological assessment; athletes; computerized assessment; baseline assessment; sideline assessment	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; STANDARDIZED ASSESSMENT; HIGH-SCHOOL; FOOTBALL	The recent literature has focused on the need for appropriate identification, assessment, and management of sports-related concussion. This article addresses current issues in the prevalence and assessment of sports-related concussion. Despite a paucity of research on female athletes and youth athletes, there is evidence that female athletes are at higher risk for injury than males and that concussions may affect children and young adolescents differently than older adolescents and adults. Sideline, baseline, and postconcussion assessments have become prevalent in documenting preinjury and postinjury performance, tracking recovery rates, and assisting return-to-play decisions. New computerized assessment procedures are growing in popularity and use. Future directions in the assessment and management of sports-related concussion include increased research on prevalence rates and effects of concussions for females and youth athletes, educating parents of youth athletes as well as family physicians on the importance of baseline and postconcussion cognitive assessments, and further validation of computerized assessment measures.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			ALVES WM, 1987, CLIN SPORT MED, V6, P211; Baker Robert J., 2000, Indian Journal of Pediatrics, V67, P317, DOI 10.1007/BF02820676; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT, 1989, MILD HEAD INJURY; Bernhardt DT, 2000, PEDIATR ANN, V29, P172, DOI 10.3928/0090-4481-20000301-11; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; *COGSTATE LTD, 1999, COGSP COMP SOFTW; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DICK RW, 1999, NCAA INJURY SURVEILL; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ECHEMENDIA RJ, 1997, NEUROPSYCHOLOGICAL A; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hatfield L, 2001, ARCH CLIN NEUROPSYCH, V16, P828; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 2000, IMMEDIATE POST CONCU; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2001, J ATHL TRAINING, V36, P288; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; Schatz P, 2001, ARCH CLIN NEUROPSYCH, V16, P746; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8	38	46	48	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					4	11		10.1207/S15324826AN1001_2			8	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900002	12734070				2022-02-06	
J	Vinchon, M; Noizet, O; Defoort-Dhellemmes, S; Soto-Ares, G; Dhellemmes, P				Vinchon, M; Noizet, O; Defoort-Dhellemmes, S; Soto-Ares, G; Dhellemmes, P			Infantile subdural hematomas due to traffic accidents	PEDIATRIC NEUROSURGERY			English	Article						subdural hematoma; traffic accident; pathophysiology	NONACCIDENTAL HEAD-INJURY; SHAKEN-BABY SYNDROME; IMPACT SYNDROME; TRAUMA; HEMORRHAGE; ABUSE; HYDROCEPHALUS; CHILDREN; INFANCY	The most common cause of subdural hematomas (SDH) in infants is shaken-baby syndrome (SBS). The pathogenesis and natural history of infantile SDH (ISDH) are poorly documented, because in SBS, the date of shaking is usually imprecise and the assault is often repeated. Victims of traffic accidents (TA) form a study group close to experimental conditions, because the trauma is unique, witnessed and dated. We reviewed 18 cases of SDH due to TA in infants under the age of 24 months. Our goal was to investigate the clinical and radiological data and natural history of SDH. A subdural collection was found on the day of trauma in 7 cases. In 3 of these, the collection was already hypodense. The perifalcine region was the most frequent site of intracranial bleeding. Blood hyperdensity was always found on CT scans performed during the first week, and turned hypodense on about the 9th day. Three patients had retinal hemorrhage, of a type distinct from that found in SBS. Drainage of the SDH was required in 14 cases after a mean delay of 13.5 +/- 5.8 days after trauma. Four patients also required a ventriculoperitoneal shunt because of associated hydrocephalus. Our data suggest that impaired CSF drainage plays a large role in the pathogenesis of ISDH. The fact that a single and recent trauma can result in mixeddensity ISDH can be of great importance in forensic medicine. (C) 2002 S. Karger AG, Basel	CHRU, Dept Pediat Neurosurg, F-59037 Lille, France; CHRU, Dept Pediat Intens Care, F-59037 Lille, France; CHRU, Dept Neuroophthalmol, F-59037 Lille, France; CHRU, Dept Neuroradiol, F-59037 Lille, France		Vinchon, M (corresponding author), CHRU, Dept Pediat Neurosurg, F-59037 Lille, France.			Vinchon, Matthieu/0000-0002-9122-6165			AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Barlow KM, 1999, ACTA PAEDIATR, V88, P734; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 1996, PEDIATR NEUROSURG, V25, P116, DOI 10.1159/000121108; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUNCAN CC, 1989, CONCEPTS PEDIAT NEUR, V9, P211; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Friede RL, 1989, DEV NEUROPATHOLOGY, P198; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hwang SK, 2000, CHILD NERV SYST, V16, P590, DOI 10.1007/s003810000312; IKEDA A, 1987, CHILD NERV SYST, V3, P19, DOI 10.1007/BF00707188; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Kaptain GJ, 2001, J NEUROSURG, V94, P538, DOI 10.3171/jns.2001.94.3.0538; Lasjaunias P, 1997, VASCULAR DIS NEONATE, P31; LEESTMA JE, 1995, PEDIAT NEUROPATHOLOG, P234; MACDONALD RL, 1994, PEDIATR NEUROSURG, V20, P73; Massicotte EM, 1999, J NEUROSURG, V91, P80, DOI 10.3171/jns.1999.91.1.0080; MORI K, 1993, CHILD NERV SYST, V9, P282, DOI 10.1007/BF00306274; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; Sargent S, 1996, J FORENSIC SCI, V41, P314; SUNDERLAND R, 1997, ARCH DIS CHILD, V76, P397; Tibbs RE, 1998, ANAT REC, V253, P167; Vinchon M, 2001, J NEUROSURG, V95, P249, DOI 10.3171/jns.2001.95.2.0249; Wilkins B, 1997, ARCH DIS CHILD, V76, P393, DOI 10.1136/adc.76.5.393	30	46	46	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	NOV	2002	37	5					245	253		10.1159/000066216			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	616EC	WOS:000179287900007	12411716				2022-02-06	
J	Lea, PM; Custer, SJ; Vicini, S; Faden, AI				Lea, PM; Custer, SJ; Vicini, S; Faden, AI			Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						glutamate receptor; excitotoxicity; stretch injury; head trauma; cortical neurons; neuronal-glial interaction	METABOTROPIC GLUTAMATE RECEPTORS; D-ASPARTATE RECEPTORS; TRAUMATIC BRAIN INJURY; SPINAL-CORD MOTONEURONS; RAT HIPPOCAMPAL SLICES; PROTEIN-KINASE-C; CORTICAL-NEURONS; IN-VITRO; INTRACELLULAR CALCIUM; AMPA RESPONSES	Neuronal stretching in culture has been used to model diffuse axonal injury caused by head trauma, and activation of N-methyl-D-aspartate receptors (NMDARs) has been implicated in the pathophysiology of such injury. Here we report the effects of modulating injury severity and the metabotropic glutamate receptor subtype 5 (mGluR5) on NMDAR activity after stretch injury. Following mild stretch, cortical neurons plated upon a confluent layer of astrocytes (NG) exhibited both increased maximal current (I-NMDA) and reduction in the voltage-dependent Mg2+ block. In contrast, neurons grown without an astrocyte monolayer (PN) only exhibited increased INMDA. In NG, surprisingly, pretreatment with either the mGluR5 agonist CHPG or the mGluR5 antagonist MPEP decreased the enhancement of I-NMDA. In contrast, in PN, MPEP similarly limited INMDA Changes, but CHPG was without effect. In both culture conditions, MPEP, but not CHPG, limited the stretch-reduced Mg2+ block. Severe stretch had,no effect on INMDA or the Mg2+ block in either culture condition, despite a correlation between injury severity and the release of lactose dehydrogenase measured postinjury. Neither CHPG nor MPEP had any direct effects upon the NMDA receptor. We conclude that mGIuR5 regulates NMDAR activity during mild stretch injury, but not severe injury, by modulating both the Mg2+ block and INMDA. (C) 2002 Elsevier Science Inc. All rights reserved.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Physiol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA		Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Vicini, Stefano/0000-0001-8671-5194			Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Alagarsamy S, 1999, NAT NEUROSCI, V2, P234, DOI 10.1038/6338; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Angenstein F, 1999, HIPPOCAMPUS, V9, P173, DOI 10.1002/(SICI)1098-1063(1999)9:2<173::AID-HIPO8>3.0.CO;2-K; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; Awad H, 2000, J NEUROSCI, V20, P7871; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; BORTOLOTTO ZA, 1995, NEUROPHARMACOLOGY, V34, P1003, DOI 10.1016/0028-3908(95)00054-A; Bruno V, 1998, PROG BRAIN RES, V116, P209, DOI 10.1016/S0079-6123(08)60439-2; Bruno V, 1999, NEUROPHARMACOLOGY, V38, P199, DOI 10.1016/S0028-3908(98)00159-2; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; Bruno V, 2001, EUR J NEUROSCI, V13, P1469, DOI 10.1046/j.0953-816x.2001.01541.x; Bruno V, 1996, ADV NEUROL, V71, P47; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Colwell CS, 1996, P NATL ACAD SCI USA, V93, P1200, DOI 10.1073/pnas.93.3.1200; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Contractor A, 1998, P NATL ACAD SCI USA, V95, P8969, DOI 10.1073/pnas.95.15.8969; Corsi L, 1998, J NEUROCHEM, V70, P1898; Daniels M, 2001, J BIOL CHEM, V276, P22446, DOI 10.1074/jbc.M101740200; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; GILL R, 1994, CEREBROVAS BRAIN MET, V6, P225; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hisatsune C, 1997, J BIOL CHEM, V272, P20805, DOI 10.1074/jbc.272.33.20805; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; Holohean AM, 1999, BRIT J PHARMACOL, V126, P333, DOI 10.1038/sj.bjp.0702263; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; KINNEY GA, 1993, J NEUROPHYSIOL, V69, P585, DOI 10.1152/jn.1993.69.2.585; Kreutz MR, 1998, J NEUROSCI, V18, P8278; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Skeberdis VA, 2001, NEUROPHARMACOLOGY, V40, P856, DOI 10.1016/S0028-3908(01)00005-3; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Temple MD, 2001, HEAD TRAUMA, P87; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Ugolini A, 1999, NEUROPHARMACOLOGY, V38, P1569, DOI 10.1016/S0028-3908(99)00095-7; Ugolini A, 1997, NEUROPHARMACOLOGY, V36, P1047, DOI 10.1016/S0028-3908(97)00103-2; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; ZHONG J, 1994, MOL PHARMACOL, V45, P846	66	46	46	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2002	73	2					287	298	PII S0091-3057(02)0082500	10.1016/S0091-3057(02)00825-0			12	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	585AT	WOS:000177501500002	12117582				2022-02-06	
J	Aitken, ME; Tilford, JM; Barrett, KW; Parker, JG; Simpson, P; Landgraf, J; Robbins, JM				Aitken, ME; Tilford, JM; Barrett, KW; Parker, JG; Simpson, P; Landgraf, J; Robbins, JM			Health status of children after admission for injury	PEDIATRICS			English	Article						pediatrics; injury; outcome; morbidity; Child Health Questionnaire	TRAUMATIC BRAIN INJURY; PEDIATRIC TRAUMA; COHORT; PERFORMANCE; MORBIDITY; RETURN; WORK	Objective. Injury is the major cause of death in children ages 1 to 19 in the United States and is a leading cause of morbidity. Few studies have described the impact of injuries on the health status of affected children over time or used newer, child-specific measures in this population. The objective of this study was to describe the health status of children in the 6 months after admission for injury using child-specific health status measures. Methods. Injured children who were ages 3 to 18 years and admitted to an academic children's hospital were evaluated at discharge and at 1 and 6 months after discharge with a battery of outcome measures. The Child Health Questionnaire (CHQ) measured health status. The scores on the Functional Independence Measure (FIM) or pediatric version of the FIM tracked physical function. Results. A total of 195 children were enrolled. Boys outnumbered girls (67% vs 33%). Injury mechanisms and severity scores were typical of pediatric injury populations reported in other studies. Most (90%) children had at least 1 area of functional limitation by FIM at discharge, and 57% had some impairment at 1 month. By 6 months, 28% reported some limitation. At discharge, CHQ summary scores for the injury group were markedly depressed compared with normative populations. Differences in both physical health and psychosocial health summary scores between the injured and normal children persisted through 6 months of follow-up. Scores on 11 of 12 subscales were significantly below the normal population at discharge. This was particularly evident for bodily pain (injury group mean 49.1 vs normative mean 81.7) and parental impact-emotional (43.9 vs 80.3), and physical functioning (50.9 vs 96.1). Significant differences persisted in all subscales at 1 month and in 6 subscales at 6 months. Conclusions. The CHQ provided useful information about the impact of injuries on children and their families over time. Significantly reduced scores in several domains of the CHQ highlight problem areas for injury patients, several of which persist through 6 months of follow-up. Low scores in areas of bodily pain and parental emotional burden suggest that improved management of these problems is required. Additional study of risk factors for persistent problems after injury may suggest ways to improve functional outcomes of injured children and reduce the impact on their families.	Arkansas Childrens Hosp, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Healthact Inc, Boston, MA USA		Aitken, ME (corresponding author), Arkansas Childrens Hosp, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	aitkenmarye@uams.edu	Aitken, Mary/ABG-6119-2021	Aitken, Mary/0000-0002-8318-9755; Robbins, James/0000-0003-2200-1947	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCH 054003-01-0] Funding Source: Medline		ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Davis T C, 1991, Fam Med, V23, P433; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; GRANGER CV, 1986, GUIDE USE UNIFORM DA; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HALEY SM, 1993, PHYS MED REH CLIN N, V43, P529; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; MCCARTHY ML, 1995, J TRAUMA, V39, P828, DOI 10.1097/00005373-199511000-00005; MERBITZ C, 1989, ARCH PHYS MED REHAB, V70, P308; *MICR CORP, 1997, ACCESS COMP PROGR; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Osberg JS, 1996, PEDIATRICS, V98, P890; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; *SAS I, 1998, SAS COMP PROGR; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Ware JE., 1996, CHQ USERS MANUAL; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008	28	46	46	0	0	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2002	110	2					337	342		10.1542/peds.110.2.337			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	581DA	WOS:000177274800028	12165587				2022-02-06	
J	Maxwell, RA; Chavarria-Aguilar, M; Cockerham, WT; Lewis, PL; Barker, DE; Durham, RM; Ciraulo, DL; Richart, CM				Maxwell, RA; Chavarria-Aguilar, M; Cockerham, WT; Lewis, PL; Barker, DE; Durham, RM; Ciraulo, DL; Richart, CM			Routine prophylactic vena cava filtration is not indicated after acute spinal cord injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	31st Annual Meeting of the Western-Trauma-Association	FEB 24-MAR 01, 2001	BIG SKY, MONTANA	Western Trauma Assoc		acute spinal cord injury; deep venous thrombosis prophylaxis; pulmonary embolism prophylaxis	DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; CALF COMPRESSION; FILTER INSERTION; DOSE HEPARIN; PREVENTION; TRAUMA	Background. Acute spinal cord injury (SCI) is a devastating problem, with over 10,000 new cases annually. Pulmonary embolism (PE) is a well-recognized risk in SCI patients, although no clear recommendations for prophylaxis exist. We therefore evaluated whether routine placement of prophylactic inferior vena cava filters is indicated in SCI patients. Methods. The trauma registry of a regional trauma center was used to identify patients sustaining acute SCI resulting in tetraplegia or paraplegia after blunt or penetrating trauma for a 5-year period beginning in January 1995. Patients were analyzed for demographics, mechanism of injury, Injury Severity Score, associated long bone or pelvic fracture, severe closed-head injury, type of deep venous thrombosis (DVT) prophylaxis, level of SCI, and incidence of DVT and PE. DVT prophylaxis was performed in all patients with sequential compression devices (SCDs') when extremity fracture status permitted. Data are expressed as mean +/- SD and analyzed using Fishers exact test. Results: There were 8,269 admissions during the study period, with an overall incidence of DVT and PE of 11.8% and 0.9%, respectively. There were Ill (1.3%) patients who sustained SCI, with an incidence of DVT and PE of 9.0% and 1.8%, respectively, and no deaths. Of these 111 patients, 41.4% were paraplegics and 58.6% were tetraplegics, and 17.1% of patients had severe closed-head injury. Mean hospital length of stay was 23 +/- 20 days for SCI patients. Surveillance duplex ultrasound was performed an average of 2.3 +/- 2.1 times during each hospitalization. Mean Injury Severity Score was 30.0 +/- 12.2. The incidence of DVT and PE in those patients with SCDs alone was 7.1% and 2.3%; for SCDs plus subcutaneous heparin, the incidence was 11.1% and 2.8%; and for SCDs plus low-molecular-weight heparin, the incidence was 7.4% and 0%, respectively, with no statistical difference between groups. The incidence of DVT in SCI patients with long bone fractures was 37.5%, which was significantly greater than the total SCI population (p < 0.021). Conclusion: The incidence of DVT and PE in SCI patients was similar to that of the overall trauma population when appropriate DVT prophylaxis was used. Subgroup analysis demonstrated that SCI associated with long bone fracture significantly increases the incidence of DVT. On the basis of the low incidence of PE in the present study, routine placement of prophylactic caval filters does not appear warranted in all SCI patients. However, SCI patients with long bone fractures, patients with DVT formation despite prophylactic anticoagulation, or patients with contraindications to anticoagulation may be appropriate candidates for prophylactic caval filtration.	Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, Chattanooga, TN 37403 USA; Univ S Florida, Tampa Gen Hosp, Coll Med, Dept Surg, Tampa, FL USA		Maxwell, RA (corresponding author), Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, 979 E 3rd St,Suite 401, Chattanooga, TN 37403 USA.						BORS E, 1954, SURG GYNECOL OBSTET, V99, P451; BRACH BB, 1977, J TRAUMA, V17, P289, DOI 10.1097/00005373-197704000-00005; Devivo Michael J., 1995, P289; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GREEN D, 1990, ANN INTERN MED, V113, P571, DOI 10.7326/0003-4819-113-8-571; GREEN D, 1982, PARAPLEGIA, V20, P227, DOI 10.1038/sc.1982.41; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; GREEN D, 1994, ARCH PHYS MED REHAB, V75, P290, DOI 10.1016/0003-9993(94)90031-0; GREENBERG DS, 1997, P SC97 HIGH PERF NET, P1; GUNDUZ S, 1993, PARAPLEGIA, V31, P606; Harris S, 1996, AM J PHYS MED REHAB, V75, P326, DOI 10.1097/00002060-199609000-00002; MERLI GJ, 1988, ARCH PHYS MED REHAB, V69, P661; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; PETAJA J, 1989, ACTA CHIR SCAND, V155, P241; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; ROSSI EC, 1980, BRIT J HAEMATOL, V45, P143, DOI 10.1111/j.1365-2141.1980.tb03819.x; SALZMAN EW, 1987, ANN SURG, V206, P636; Silver J R, 1974, Paraplegia, V12, P188; STOVER SL, 1986, SPINAL CORD INJURY F, P1; TRIBE C R, 1963, Paraplegia, V1, P19; Velmahos GC, 2000, J TRAUMA, V49, P1059, DOI 10.1097/00005373-200012000-00014; WILSON JT, 1994, NEUROSURGERY, V35, P234, DOI 10.1227/00006123-199408000-00008; Winemiller M H, 1999, J Spinal Cord Med, V22, P182; YELNIK A, 1991, PARAPLEGIA, V29, P253, DOI 10.1038/sc.1991.36	24	46	48	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2002	52	5					902	906		10.1097/00005373-200205000-00013			5	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	552DM	WOS:000175603600023	11988656				2022-02-06	
J	Schultheis, MT; Matheis, RJ; Nead, R; DeLuca, J				Schultheis, MT; Matheis, RJ; Nead, R; DeLuca, J			Driving behaviors following brain injury: Self-report and motor vehicle records	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						accidents; driving; motor vehicle; traumatic brain injury	DAMAGE	Background: This study examined both objective and subjective measures of driving behaviors occurring in the past 5 ears for 47 individuals with traumatic brain injury (TBI) and 22 health), controls (HQ, matched forage. gender, education, and years of driving experience, Results: Overall, subtle descriptive differences in driving characteristics were observed between the two groups. However, comparison of self-reported and documented reports of aberrant driving behaviors did not reveal a significantly greater number of accidents or violations among TBI participants compared with HC drivers. The results suggest that individuals with TBI, who successfully complete a driving evaluation program, are able to reintegrate into the driving community with minimal difficulty.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Kessler Inst Rehabil, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Newark, NJ 07103 USA		Schultheis, MT (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	mschultheis@kmrrec.org		Schultheis, Maria/0000-0002-6558-548X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD08589-01] Funding Source: Medline		BOAKE C, 1993, ARCH PHYS MED REHAB, V74, P1246; BOAKE M, 1998, J INT NEUROPSYCHOLL, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; HANDLER BS, 1995, J REHABIL, V61, P43; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	16	46	49	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2002	17	1					38	47		10.1097/00001199-200202000-00006			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	519MM	WOS:000173730100007	11860328				2022-02-06	
J	Broholm, H; Madsen, FF; Wagner, AA; Laursen, H				Broholm, H; Madsen, FF; Wagner, AA; Laursen, H			Papillary glioneuronal tumor - a new tumor entity	CLINICAL NEUROPATHOLOGY			English	Article						papillary; glioneuronal tumor; low grade; frontal; immunohistochemistry	NEUROCYTOMA; LOBE	Glioneuronal neoplasms of the CNS comprises a heterogeneous group of generally low-grade tumors expressing glial and neuronal cells of varying differentiation. Recently, a new variant of the glioneuronal tumors has been identified. We present a case of a glioneuronal tumor located in the left frontal lobe of a 16-year-old boy who developed seizures 6 months after brain concussion. MR scan demonstrated an irregular, but well circumscribed, mixed cystic and solid tumor with contrast enhancement in the solid part. Histology showed a papillary glioneuronal tumor. The tumor is indolent with no sign of recurrence after gross total resection.	Univ Copenhagen Hosp, Rigshosp, Neuropathol Lab, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Dept Neuroradiol, DK-2100 Copenhagen, Denmark		Broholm, H (corresponding author), Univ Copenhagen Hosp, Rigshosp 6301, Neuropathol Lab, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	hbroholm@rh.dk					Biernat W, 2000, BRAIN PATHOL, V10, P313; Blumcke I, 1999, MICROSC RES TECHNIQ, V46, P53; Bouvier-Labit C, 2000, ACTA NEUROPATHOL, V99, P321, DOI 10.1007/PL00007445; Giangaspero F, 1997, AM J SURG PATHOL, V21, P206, DOI 10.1097/00000478-199702000-00011; Hamilton R, 1997, BRAIN PATHOL, V7, P713, DOI 10.1111/j.1750-3639.1997.tb01086.x; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kim DH, 1997, ACTA NEUROPATHOL, V94, P187, DOI 10.1007/s004010050692; KLEIHUES P, 2000, WHO CLASSIFICATION T, P96; Komori T, 1998, AM J SURG PATHOL, V22, P1171, DOI 10.1097/00000478-199810000-00002; Komori T, 1996, J NEUROPATH EXP NEUR, V55, P654; MCLENDON RE, 2000, PATHOLOGY TUMORS CEN, P232; Prayson RA, 2000, ARCH PATHOL LAB MED, V124, P1820; Teo JGC, 1999, AM J SURG PATHOL, V23, P502, DOI 10.1097/00000478-199905000-00002	13	46	49	0	0	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	JAN-FEB	2002	21	1					1	4					4	Clinical Neurology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	518FY	WOS:000173657000001	11846038				2022-02-06	
J	Robertson, CL; Bell, MJ; Kochanek, PM; Adelson, PD; Ruppel, RA; Carcillo, JA; Wisniewski, SR; Mi, ZC; Janesko, KL; Clark, RSB; Marion, DW; Graham, SH; Jackson, EK				Robertson, CL; Bell, MJ; Kochanek, PM; Adelson, PD; Ruppel, RA; Carcillo, JA; Wisniewski, SR; Mi, ZC; Janesko, KL; Clark, RSB; Marion, DW; Graham, SH; Jackson, EK			Increased adenosine in cerebrospinal fluid after severe traumatic brain injury in infants and children: Association with severity of injury and excitotoxicity	CRITICAL CARE MEDICINE			English	Article						head injury; purine; pediatrics; Glasgow Coma Scale; glutamate; shaken baby syndrome; child abuse	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; AMINO-ACID RELEASE; GLUTAMATE-EVOKED RELEASE; ENDOGENOUS ADENOSINE; INTERSTITIAL ADENOSINE; RECEPTOR STIMULATION; NMDA RECEPTORS; FOCAL ISCHEMIA; RAT STRIATUM	Objectives. To measure adenosine concentration in the cerebrospinal fluid of infants and children after severe traumatic brain injury and to evaluate the contribution of patient age, Glasgow Coma Scale score, mechanism of injury, Glasgow Outcome Score, and time after injury to cerebrospinal fluid adenosine concentrations. To evaluate the relationship between cerebrospinal fluid adenosine and glutamate concentrations in this population. Design. Prospective survey. Setting. Pediatric intensive care unit in a university-based children's hospital. Patients: Twenty-seven critically ill infants and children who had severe traumatic brain injury (Glasgow Coma Scale <8), who required placement of an intraventricular catheter and drainage of cerebrospinal fluid as part of their neurointensive care. Interventions. None. Measurements and Main Results: Patients ranged in age from 2 months to 14 yrs. Cerebrospinal fluid samples (n = 304) were collected from 27 patients during the first 7 days after traumatic brain injury. Control cerebrospinal fluid samples were obtained from lumbar puncture on 21 infants and children without traumatic brain injury or meningitis. Adenosine concentration was measured by using high-pressure liquid chromatography. Adenosine concentration was increased markedly in cerebrospinal fluid of children after traumatic brain injury vs. controls (p < .001). The increase in cerebrospinal fluid adenosine was independently associated with Glasgow Coma Scale less than or equal to4 vs. >4 and time after injury (both p < .005). Cerebrospinal fluid adenosine concentration was not independently associated with either age (less than or equal to4 vs. >4 yrs), mechanism of injury (abuse vs. other), or Glasgow Outcome Score (good/moderately disabled vs. severely disabled, vegetative, or dead). Of the 27 patients studied, 18 had cerebrospinal fluid glutamate concentration previously quantified by high-pressure liquid chromatography. There was a strong association between increases in cerebrospinal fluid adenosine and glutamate concentrations (p < .005) after injury. Conclusions: Cerebrospinal fluid adenosine concentration is increased in a time- and severity-dependent manner in infants and children after severe head injury. The association between cerebrospinal fluid adenosine and glutamate concentrations may reflect an endogenous attempt at neuroprotection against excitotoxicity after severe traumatic brain injury.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA; Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; Childrens Natl Med Ctr, Dept Crit Care Med, Washington, DC 20010 USA; Va Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Gen Clin Res Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Injury Control & Res, Pittsburgh, PA USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@anes.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; ARANDA JV, 1989, DEV PHARMACOL THERAP, V13, P96, DOI 10.1159/000457590; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bona E, 1997, NEUROPHARMACOLOGY, V36, P1327, DOI 10.1016/S0028-3908(97)00139-1; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BUCHLI R, 1994, PEDIATR RES, V35, P431, DOI 10.1203/00006450-199404000-00009; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; CHEN Y, 1992, BRIT J PHARMACOL, V106, P632, DOI 10.1111/j.1476-5381.1992.tb14387.x; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Delaney SM, 1998, J PHARMACOL EXP THER, V285, P561; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DUNWIDDIE TV, 1990, ADENOSINE ADENOSINE, P143; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; GAO Y, 1994, LIFE SCI, V55, pPL61, DOI 10.1016/0024-3205(94)00889-2; Geiger Jonathan D., 1997, P55; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HERON A, 1994, BRAIN RES, V641, P217, DOI 10.1016/0006-8993(94)90149-X; HOEHN K, 1990, J NEUROCHEM, V54, P256, DOI 10.1111/j.1471-4159.1990.tb13309.x; HOEHN K, 1990, J NEUROCHEM, V54, P1716, DOI 10.1111/j.1471-4159.1990.tb01226.x; Jackson EK, 1996, J PHARMACOL EXP THER, V279, P1250; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM YB, 1994, J NEUROSURG, V81, P877, DOI 10.3171/jns.1994.81.6.0877; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Latini S, 1999, BRIT J PHARMACOL, V128, P1035, DOI 10.1038/sj.bjp.0702888; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MATSUMOTO K, 1992, BRAIN RES, V579, P309, DOI 10.1016/0006-8993(92)90066-I; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Miller LP, 1999, STROKE THERAPY, P131; MILLER LP, 1992, J NEUROTRAUM, V9, pS563; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEWBY AC, 1991, PURINE PYRIMIDINE ME, P265; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OREGAN MH, 1992, NEUROSCI LETT, V138, P169, DOI 10.1016/0304-3940(92)90498-V; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Popoli P, 1995, EUR J PHARMACOL, V287, P215, DOI 10.1016/0014-2999(95)00679-6; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; SIMPSON RE, 1992, J NEUROCHEM, V58, P1683, DOI 10.1111/j.1471-4159.1992.tb10041.x; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; Von Lubitz DKJE, 1999, EUR J PHARMACOL, V365, P9, DOI 10.1016/S0014-2999(98)00788-2; von Lubitz DKJE, 1999, ANN NY ACAD SCI, V890, P93; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; WINN HR, 1981, AM J PHYSIOL, V241, pH235, DOI 10.1152/ajpheart.1981.241.2.H235; WINN HR, 1980, AM J PHYSIOL, V239, pH636, DOI 10.1152/ajpheart.1980.239.5.H636; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; Zauner A, 1996, ACT NEUR S, V67, P40	67	46	49	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2001	29	12					2287	2293		10.1097/00003246-200112000-00009			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505HN	WOS:000172907500009	11801827				2022-02-06	
J	Faden, AI				Faden, AI			Neuroprotection and traumatic brain injury - The search continues	ARCHIVES OF NEUROLOGY			English	Article							APOPTOTIC CELL-DEATH; SEVERE HEAD-INJURY; PHARMACOLOGICAL TREATMENT; TRIALS; STRATEGIES; RAT	During the last decade, experimental studies of traumatic brain injury (TBI) have provided important new insights into the pathophysiological mechanisms leading to posttraumatic tissue damage and associated neurological dysfunction. The concept of delayed or secondary tissue injury has strong experimental support and a cascade of secondary injury factors has been delineated.(1,2) These observations have led to the application of targeted pharmaco therapies, whose aim is to block specific pathobiological pathways.(2,3) Such research has been aided by the development of rodent models of head injury that simulate critical components of clinical neurotrauma, as well as by the development of novel neuroprotective agents.(3,4) These experimental studies have identified mechanisms of delayed tissue damage and have demonstrated the effectiveness of a number of pharmacological treatment strategies.(1-4) However, despite this enormous experimental promise, the clinical studies to date have been disappointing.(5,6) Here we explore the conceptual and methodological issues that have contributed to this discrepancy between preclinical and clinical studies.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Dept Neurosci, EP-12 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.						Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock JT., 1996, NEUROTRAUMA, P1325; RINK A, 1995, AM J PATHOL, V147, P1575; TEASDALE G, 1990, ACT NEUR S, V51, P315; Temple MD, 2001, HEAD TRAUMA, P87; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	21	46	49	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	2001	58	10					1553	1555		10.1001/archneur.58.10.1553			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	480CL	WOS:000171444400004	11594912	Bronze			2022-02-06	
J	Lees-Haley, PR; Fox, DD; Courtney, JC				Lees-Haley, PR; Fox, DD; Courtney, JC			A comparison of complaints by mild brain injury claimants and other claimants describing subjective experiences immediately following their injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; postconcussive symptoms	BASE RATES; SYNDROME QUESTIONNAIRE; SYMPTOMS; HEAD	This study compares the rate of postconcussive (PCS) symptoms at the time of injury for mild traumatic brain injury (MTBI; N=24) claimants and claimants reporting other forms of injury (OI; N=66). On checklists surveying their complaints immediately after their injury, MTBI and OI claimants reported similar levels of many PCS complaints, e.g., dazed, confused, dizzy, disoriented, trouble concentrating, numbness or loss of sensation, and loss of memory for some of what happened. One in four of the OI samples reported partial loss of consciousness (LOC), and one-third reported loss of memory for some of what happened. About 67% of the MTBI sample reported being confused and 71% dazed, but so did many of the OI sample (52% dazed, 65% confused). The authors suggest that classical PCS complaints experienced immediately after an injury are so nonspecific that they have little diagnostic specificity. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Lees Haley Psychol Corp, Woodland Hills, CA 91364 USA; Clin Neuropsychol PC, Mishawaka, IN USA		Lees-Haley, PR (corresponding author), Lees Haley Psychol Corp, 21331 Costanso St, Woodland Hills, CA 91364 USA.						Axelrod BN, 1998, ARCH CLIN NEUROPSYCH, V13, P543, DOI 10.1016/S0887-6177(97)00044-9; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870	12	46	47	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	OCT	2001	16	7					689	695		10.1016/S0887-6177(00)00092-5			7	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	473RK	WOS:000171061700006	14589787	Bronze			2022-02-06	
J	Chan, RCK				Chan, RCK			A further study on the sustained attention response to task (SART): the effect of age, gender and education	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; CHILDREN; DISABILITIES	The present study aimed to investigate the potential effect of age, gender and education upon the theoretically sound measure of sustained attention-Sustained Attention Response to Task (SART)-amongst a control sample and patients with traumatic brain injury (TBI). The SART is a simple and brief computer-assisted programme for assessing sustained attention over a short period of time. Two further studies on the use of the SART among the Hong Kong Chinese were conducted. In particular, experiment 1 recruited a control group to study the potential impact of age, education, and gender upon the performance of the SART. Experiment 2 was aimed to establish the discriminative validity of the SART upon the attentional slip in a larger sample of patients with TBI and the normal controls. The potential impact of age, gender, and education upon the SART performance was found to be minimal. In keeping with previous studies, the present findings demonstrate that SART is able to discriminate the patients with TBI from normal controls.	Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China		Chan, RCK (corresponding author), Queen Mary Hosp, Dept Psychiat, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Brand EFJM, 1996, CHILD NEUROPSYCHOL, V2, P109, DOI 10.1080/09297049608401356; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Davies DR., 1982, PSYCHOL VIGILANCE; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Lee TMC, 1999, ARCH CLIN NEUROPSYCH, V14, P730; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P465, DOI 10.1076/1380-3395(200008)22:4;1-0;FT465; LOEB M, 1963, J ACOUST SOC AM, V35, P884, DOI 10.1121/1.1918621; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; LONG GM, 1981, HUM FACTORS, V23, P285; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T., 1997, METHODOL FRONTAL EXE, P135; MCKAY K, 1994, DEV NEUROPSYCHOL, V10, P221; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PARASURAMAN R, 1984, SUSTAINED ATTENTION, P62; Robertson I., 1994, TEST EVERYDAY ATTENT; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUCKERT L, 1996, NEUROPSYCHOLOGIA, V34, P953; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SMILEY AM, 1990, ACCIDENT ANAL PREV, V22, P443, DOI 10.1016/0001-4575(90)90039-N; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Wechsler D, 1981, WECHSLER ADULT INTEL; Westling DL, 1999, EDUC TRAIN MENT RET, V34, P43; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wickens C. D., 1993, WORKLOAD TRANSITION, P139	28	46	51	1	21	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					819	829		10.1080/02699050110034325			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400007	11516350				2022-02-06	
J	Bazarian, JJ; Veenema, T; Brayer, AF; Lee, E				Bazarian, JJ; Veenema, T; Brayer, AF; Lee, E			Knowledge of concussion guidelines among practitioners caring for children	CLINICAL PEDIATRICS			English	Article							CLINICAL-PRACTICE GUIDELINES; HEAD-INJURIES; 2ND IMPACT; SPORTS; PREVENTION	The objective of this study in Rochester, NY was to determine clinicians' knowledge of the Colorado Medical Society Guidelines (CMSG) on return to contact sports after a concussion. A survey was mailed to 1,140 pediatric, family practice, and emergency physicians, as well as 302 pediatric and family practice nurse practitioners in the Rochester, NY, area. Participants were gir-en 3 hypothetical concussion scenarios and asked to pick 1 of 4 multiple-choice time intervals for when they would advise return to contact sports. Answers were compared with the latest version of the CMSG. The survey response rate was 57%. Only 7.6% responded correctly for Grade 1 concussion scenario, 56% for the Grade 2 scenario, and 28% for the Grade 3 scenario. Only 5.6% listed the CMSG as the source of the return-to-play advice they gave. Thus, respondents' knowledge of the CMSG was low, with few giving return-to-play advice consistent with the CMSG and even fewer acknowledging the CMSG as the source of such advice. Improving the availability of the CMSG may improve clinicians' knowledge and use of these guidelines.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; St Lukes Roosevelt Hosp Ctr, Dept Emergency Med, New York, NY USA		Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Med Box 4-9200,601 Elmwood Ave, Rochester, NY 14642 USA.			Veenema, Tener/0000-0001-8977-9900			Bergman DA, 1999, PEDIATRICS, V104, P1407; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1992, SPORTS MED, V14, P65; CANTU RC, 1988, SPORTS MED DIGEST, V10, P2; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Davis DA, 1997, CAN MED ASSOC J, V157, P408; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; FITZPATRICK MH, 1996, AM COLL EM PHYS SCI; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GRONWALL D, 1975, LANCET, V2, P995; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; *SPORTS MED COMM C, 1991, GUID MAN CONC SPORTS; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	25	46	46	0	15	WESTMINSTER PUBL INC	GLEN HEAD	708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA	0009-9228			CLIN PEDIATR	Clin. Pediatr.	APR	2001	40	4					207	212		10.1177/000992280104000405			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	422UR	WOS:000168138100005	11336419				2022-02-06	
J	Bentzer, P; Mattiasson, G; McIntosh, TK; Wieloch, T; Grande, PO				Bentzer, P; Mattiasson, G; McIntosh, TK; Wieloch, T; Grande, PO			Infusion of prostacyclin following experimental brain injury in the rat reduces cortical lesion volume	JOURNAL OF NEUROTRAUMA			English	Article						brain contusion; endothelium; lateral fluid percussion; microvessels; prostacyclin; rat; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; MISSILE HEAD-INJURY; CAT SKELETAL-MUSCLE; VASCULAR-PERMEABILITY; NEURONAL DEGENERATION; NITRIC-OXIDE; CELL LOSS; CONTUSION; ANALOG; ILOPROST	Endothelial-derived prostacyclin is an important regulator of microvascular function, and its main actions are inhibition of platelet/leukocyte aggregation and adhesion, and vasodilation. Disturbances in endothelial integrity following traumatic brain injury (TBI) may result in insufficient prostacyclin production and participate in the pathophysiological sequelae of brain injury. The objective of this study was to evaluate the potential therapeutic effects of a low-dose prostacyclin infusion on cortical lesion volume, CA3 neuron survival and functional outcome following TBI in the rat. Anesthetized animals (sodium pentobarbital, 60 mg/kg, i.p.) were subjected to a lateral fluid percussion brain injury (2.5 atm) or sham injury. Following TBI, animals were randomized to receive a constant infusion of either prostacyclin (1 ng/kg . min(-l) i.v.) or vehicle over 48 h. All sham animals received vehicle (n = 6). Evaluation of neuromotor function, lesion volume, and CA3 neuronal loss was performed blindly. By 7 days postinjury, cortical lesion volume was significantly reduced by 43% in the prostacyclin-treated group as compared to the vehicle treated group (p < 0.01; n = 12 prostacyclin, n = 12 vehicle). No differences were observed in neuromotor function (48 h and 7 days following TBI), or in hippocampal cell loss (7 days following TBI) between the prostacyclin- and vehicle-treated groups. We conclude that prostacyclin in a low dose reduces loss of neocortical neurons following TBI and may be a potential clinical therapeutic agent to reduce neuronal cell death associated with brain trauma.	Univ Lund, Dept Physiol Sci, SE-22362 Lund, Sweden; Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Brain Res, S-22185 Lund, Sweden; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Bentzer, P (corresponding author), Univ Lund, Dept Physiol Sci, Solvegatan 19, SE-22362 Lund, Sweden.			Wieloch, Tadeusz/0000-0002-7669-2520			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Al-Turki A, 1998, CRIT CARE MED, V26, P917, DOI 10.1097/00003246-199805000-00029; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; AWAD I, 1983, STROKE, V14, P203, DOI 10.1161/01.STR.14.2.203; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bentzer P, 1999, J VASC RES, V36, P516, DOI 10.1159/000025695; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1990, ACT NEUR S, V51, P286; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dogan A, 1996, GEN PHARMACOL-VASC S, V27, P1163; ERLANSSON M, 1991, PROSTAGLANDINS, V41, P157, DOI 10.1016/0090-6980(91)90028-E; FENSTERMACHER JD, 1984, EDEMA, P383; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; GRANDE PO, 1997, J TRAUMA, V42, P23; GRYGLEWSKI RJ, 1988, HYPERTENSION, V12, P530, DOI 10.1161/01.HYP.12.6.530; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HICKS RR, 1993, NEUROTRAUMA, V10, P405; HIGGS EA, 1978, PROSTAGLANDINS, V16, P17, DOI 10.1016/0090-6980(78)90197-1; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; JOHNSON G, 1990, CIRC RES, V66, P1362, DOI 10.1161/01.RES.66.5.1362; Karasawa Y., 1999, Society for Neuroscience Abstracts, V25, P583; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Kraus JF, 1993, HEAD INJURY, P1; LEFER AM, 1994, METHOD FIND EXP CLIN, V16, P623; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Maeda T, 1997, ACT NEUR S, V70, P102; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Moller AD, 1999, J VASC RES, V36, P245, DOI 10.1159/000025648; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200, DOI 10.1152/ajpheart.1997.273.1.H200; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; Paxinos G, 1996, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RABOW L, 1989, ACTA NEUROCHIR, V100, P155, DOI 10.1007/BF01403604; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Scheeren T, 1997, INTENS CARE MED, V23, P146, DOI 10.1007/s001340050309; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHIMA K, 1995, ACTA NEUROCHIR, V137, P89, DOI 10.1007/BF02188788; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; TANAKA K, 1988, STROKE, V19, P1267, DOI 10.1161/01.STR.19.10.1267; Taoka Y, 1997, J NEUROSURG, V86, P1007, DOI 10.3171/jns.1997.86.6.1007; TERAWAKI T, 1988, EUR J PHARMACOL, V152, P63, DOI 10.1016/0014-2999(88)90836-9; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; ZUSMAN RM, 1981, NEW ENGL J MED, V304, P934, DOI 10.1056/NEJM198104163041603	61	46	47	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					275	285		10.1089/08977150151070919			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000005	11284548				2022-02-06	
J	Gasparovic, C; Arfai, N; Smid, N; Feeney, DM				Gasparovic, C; Arfai, N; Smid, N; Feeney, DM			Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury	JOURNAL OF NEUROTRAUMA			English	Article						brain; diaschisis; injury; metabolism; MRS; N-acetylaspartate; spectroscopy	MAGNETIC-RESONANCE-SPECTROSCOPY; CEREBRAL GLUCOSE-UTILIZATION; MITOCHONDRIAL DYSFUNCTION; HEAD-INJURY; CORTICAL INJURY; AXONAL INJURY; BLOOD-FLOW; METABOLISM; TRAUMA; DEPRESSION	Magnetic resonance spectroscopy (MRS) studies on traumatic brain injury (TBI) have shown that the neuronal metabolite N-acetylaspartate (NAA) may be reduced in regions of brain remote from sites of focal injury. Such reductions have generally been attributed to diffuse axonal injury (DAI) or neuron death. The aim of the present study was to investigate the contribution of metabolic depression, in the absence of DAI or cell death, to remote NAA reduction after TBI, The right sensorimotor cortices of adult rats were injured by weight drop. Two and six days later, tissue slices from the ipsilateral occipital cortex, or from the same region in uninjured rats, were superfused and examined by H-1-MRS. The occipital cortex has been shown to have negligible DAI or cell death but marked transient metabolic depression in this model of TBI, Two days after injury, the ratio of the NAA peak height to the total creatine peak height (NAA/TCr) was 14% lower than in control samples. Six days after injury, NAA/TCr recovered to within 7% of the control value. The time course of NAA/TCr decrease and recovery was similar to the time courses of widespread depression and recovery of 2-deoxyglucose uptake and mitochondrial alpha -glycerophosphate dehydrogenase activity measured previously in this model of TBI. Together, these results suggest that at least one component of remote NAA depression after TBI may be associated with a widespread and reversible metabolic depression that is unrelated to either DAI or cell death.	Univ New Mexico, Sch Med, Clin & Magnet Resonance Res Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Gasparovic, C (corresponding author), Univ New Mexico, Sch Med, Clin & Magnet Resonance Res Ctr, 1201 Yale NE, Albuquerque, NM 87131 USA.	chuck@unm.edu	Gasparovic, Charles/E-7289-2010				Alavi A, 1997, J NUCL MED, V38, P1717; BACHELARD HS, 1985, BIOCHEM SOC T, V13, P835, DOI 10.1042/bst0130835; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DellaCorte F, 1997, ACTA NEUROCHIR, V139, P636; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1995, IMAGING NEUROLOGIC R, P91; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FEENEY DM, 1995, P 2 INT WORLD C BIOM; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Gasparovic C, 1999, BRAIN RES PROTOC, V4, P97, DOI 10.1016/S1385-299X(99)00010-0; Gasparovic C, 1998, J NEUROCHEM, V71, P1727; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hovda D.A., 1996, NEUROTRAUMA, P1459; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kalra S, 1998, NEUROREPORT, V9, P1757, DOI 10.1097/00001756-199806010-00016; Kalra S, 1999, J NEUROL SCI, V165, pS27, DOI 10.1016/S0022-510X(99)00023-4; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; Queen SA, 1996, BRAIN RES, V724, P246, DOI 10.1016/0006-8993(96)00308-3; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Scremin OU, 1997, J NEUROTRAUM, V14, P573, DOI 10.1089/neu.1997.14.573; SIGNORETTI S, 1999, 17 ANN NAT NEUR SOC; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	41	46	54	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					241	246		10.1089/08977150151070856			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000002	11284545				2022-02-06	
J	Potter, DD; Bassett, MRA; Jory, SH; Barrett, K				Potter, DD; Bassett, MRA; Jory, SH; Barrett, K			Changes in event-related potentials in a three-stimulus auditory oddball task after mild head injury	NEUROPSYCHOLOGIA			English	Article						attention; memory; ERP; oddball; P-3; novelty; mild; closed; traumatic; head; brain; injury	NEUROPSYCHOLOGICAL DEFICITS; BRAIN POTENTIALS; ATTENTION; SYMPTOMS; SEQUELAE; P300; DISTRACTIBILITY; MECHANISMS	Previous research has demonstrated changes in event-related potentials in a variety of cognitive tasks after severe closed head injury. We sought to establish if similar changes were present in patients who had sustained only apparently mild head injury (MHI) by recording event-related potentials in a group of 24 mild head injured and 24 control participants during a three-stimulus auditory target detection task. For this 'oddball' task participants were required to press a button every time they heard a rare target tone and to ignore rare novel sounds and frequent non-target tones. Neuropsychological test results indicated that the mild head injured group had mild memory and attention impairments. Analysis of behavioural performance on the three-stimulus 'oddball' task showed no difference in reaction times or error rates between the two groups. Target condition N2 deflections appeared to be larger in the mild head injured but peak amplitude measures revealed that this effect was not significant. There were no significant differences in the amplitude or latency of the P3b evoked by target stimuli or the P3a evoked by novel stimuli. However, a putative 'O-wave' or 'reorienting negativity' following the P3a was more negative in the mild head injured group suggesting increased activation of components of the attention network. These findings lend support to the hypothesis that MHI can cause subtle cognitive impairments that are associated with abnormal allocation of attention resources in the context of normal behavioural performance. (C) 2001 Elsevier Science Ltd. All rights reserved.	Keele Univ, Dept Psychol, Keele, Staffs, England; Haywood Hosp, Neurobehav Unit, Stoke On Trent, Staffs, England		Potter, DD (corresponding author), Keele Univ, Dept Psychol, Keele, Staffs, England.	d.d.potter@dundee.ac.uk					BARIBEAU J, 1990, PSYCHOPHYSIOLOGICAL, P161; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; Gronwall D, 1989, MILD HEAD INJURY, P153; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jory SH, 2000, J PSYCHOPHYSIOL, V14, P187; JORY SH, IN PRESS J PSYCHOPHY; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Loveless NE, 1979, ORIENTING REFLEX HUM, P77; Nelson H.E., 1982, NATL ADULT READING T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nobre AC, 2000, NEUROIMAGE, V11, P210, DOI 10.1006/nimg.2000.0539; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; POTTER DD, 1999, J PSYCHOPHYSIOLOGY, P13; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; ROHRBAUGH JW, 1984, VARIETIES ATTENTION; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Schroger E, 1998, NEUROREPORT, V9, P3355, DOI 10.1097/00001756-199810260-00003; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O, 1991, COMPENDIUM NEUROPSYC; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VONZOMEREN AH, 1984, CLOSED HEAD INJURY; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058	53	46	49	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2001	39	13					1464	1472		10.1016/S0028-3932(01)00057-4			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	487WM	WOS:000171902100011	11585614				2022-02-06	
J	Butler, PV				Butler, PV			Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury	AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY			English	Article						Capgras syndrome; content-specific delusions; Cotard's syndrome; delusional misidentification; depersonalisation; derealisation	MISIDENTIFICATION; IDENTITY	Objective: The aim of this paper is to document regular nocturnal intensification of delusional nihilistic and persecutory ideas (Cotard delusion) linked with extreme depersonalisation and hypervivid dreaming. Clinical Picture: A 17-year-old man presented with Cotard and Capgras delusions after sustaining multiple cognitive impairments secondary to traumatic brain injury. Treatment and outcome: Delusional ideation fully resolved within 14 days of commencement of olanzapine 5 mg daily. Conclusion: This patient's experience of perceptual abnormalities and impairments in meta-abilities related to self-monitoring and critical inferencing lends support to multicomponent sensory processing accounts of brain injury related, content-specific delusional syndromes.	Royal Rehabil Ctr, Ryde, NSW 2112, Australia		Butler, PV (corresponding author), Royal Rehabil Ctr, Ryde, NSW 2112, Australia.						BANOV MD, 1993, COMPR PSYCHIAT, V34, P414, DOI 10.1016/0010-440X(93)90068-F; BERSON RJ, 1983, AM J PSYCHIAT, V140, P969; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Cotard J., 1882, ARCH NEUROL-PARIS, V4, P152; *CTR FUNCT ASS RES, 1990, AUSTR GUID US UN DAT; Edelstyn NMJ, 1999, INT J GERIATR PSYCH, V14, P48, DOI 10.1002/(SICI)1099-1166(199901)14:1<48::AID-GPS891>3.3.CO;2-S; ELLIS HD, 1990, BRIT J PSYCHIAT, V157, P239, DOI 10.1192/bjp.157.2.239; ENOCH MD, 1979, UNCOMMON PSYCHIAT SY, P1; ENOCH MD, 1979, UNCOMMON PSYCHIAT SY, P116; FLEMINGER S, 1994, PSYCHOPATHOLOGY, V27, P161, DOI 10.1159/000284865; Hirstein W, 1997, P ROY SOC B-BIOL SCI, V264, P437, DOI 10.1098/rspb.1997.0062; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P455; Miller L., 1994, J COGNITIVE REHABILI, V12, P12; RAMACHANDRAN VS, 1999, PHANTOMS BRAIN, P158; SCHNAPER N, 1975, J TRAUMA, V15, P94, DOI 10.1097/00005373-197502000-00002; TEASDALE G, 1974, LANCET, V2, P81; WEINSTEIN E, 1996, METHOD MADNESS, P13; WRIGHT S, 1993, BRIT J CLIN PSYCHOL, V32, P345, DOI 10.1111/j.2044-8260.1993.tb01065.x; Young A.W., 1996, METHOD MADNESS CASE, P147; [No title captured]	20	46	48	0	14	BLACKWELL SCIENCE ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0004-8674			AUST NZ J PSYCHIAT	Aust. N. Z. J. Psych.	AUG	2000	34	4					684	687		10.1080/j.1440-1614.2000.00758.x			4	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	339AG	WOS:000088455000018	10954402				2022-02-06	
J	Hausmann, R; Betz, P				Hausmann, R; Betz, P			The time course of the vascular response to human brain injury - an immunohistochemical study	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						brain injury; cortical contusion; vascular reaction; immunohistochemistry; wound age	HUMAN GLIOMA; TENASCIN-C; EXPRESSION; ASTROCYTOMAS; PROTEIN; VESSELS	In a total of 104 individuals who had sustained traumatic brain injury (TBI), the time-dependent vascular response was investigated at the injured cortical area during the first 30 weeks after the trauma. The immunohistochemical staining of the cerebral blood vessels was performed with antibodies against laminin, type IV collagen, tenascin, thrombomodulin and factor VIII associated antigen. Compared to the immunoreactivity in unaltered control tissue, a significantly increased vascular expression could be detected in cortical contusions after a postinfliction interval of at least 3 h for factor VIII, after 1.6 days for tenascin or after 6.8 days for thrombomodulin, whereas the immunostaining for laminin and type IV collagen was regularly positive even in the vascular endothelium of uninjured brain tissue.	Univ Erlangen Nurnberg, Dept Legal Med, D-91054 Erlangen, Germany		Hausmann, R (corresponding author), Univ Erlangen Nurnberg, Dept Legal Med, Univ Str 22, D-91054 Erlangen, Germany.						Alvarez-Dolado M, 1998, NEUROSCIENCE, V84, P309, DOI 10.1016/S0306-4522(97)00511-3; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; Chintala SK, 1996, CANCER LETT, V101, P107, DOI 10.1016/0304-3835(96)04124-9; EISENMENGER W, 1977, THESIS MUNCHEN; Ferhat L, 1996, J NEUROCYTOL, V25, P535, DOI 10.1007/BF02284821; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; ISAKA T, 1994, ACTA NEUROPATHOL, V87, P81; MARUNO M, 1994, J NEURO-ONCOL, V19, P155, DOI 10.1007/BF01306457; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; ORITA T, 1989, ACTA NEUROPATHOL, V77, P397, DOI 10.1007/BF00687374; Sasaki O, 1988, No To Shinkei, V40, P469; ZAGZAG D, 1995, CANCER RES, V55, P907; [No title captured]; [No title captured]	16	46	46	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0937-9827			INT J LEGAL MED	Int. J. Legal Med.	AUG	2000	113	5					288	292		10.1007/s004149900126			5	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	350EV	WOS:000089088600008	11009065				2022-02-06	
J	Raju, U; Gumin, GJ; Tofilon, PJ				Raju, U; Gumin, GJ; Tofilon, PJ			Radiation-induced transcription factor activation in the rat cerebral cortex	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY			English	Article							NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR EXPRESSION; TRAUMATIC BRAIN INJURY; GENE-EXPRESSION; MESSENGER-RNA; IONIZING-RADIATION; IN-VIVO; C-FOS; DEPENDENT ACTIVATION	Purpose: To determine the effects of ionising radiation on the DNA-binding activity of the injury-related transcription factors AP-1, Sp-1, p53 and NF kappa B in the rat brain. Materials and methods: Male Sprague-Dawley rats were irradiated with Cs-137 gamma-rays at 3.8 Gy/min and the cerebral cortex was isolated at intervals up to 24 h . Nuclear protein extract of the cerebral cortex was analysed by electrophoretic mobility shift assay for DNA-binding activity of AP-1, Sp-1, p53 and NF kappa B. In addition, total RNA was extracted from the cerebral cortex and subjected to northern analysis. Results: The DNA-binding activity of each of the transcription factors increased in a time- and dose-dependent manner after irradiation. Maximum increase in the activity of AP-1, Sp-1, and p53 DNA binding was seen after exposure to 10 Gy and then decreased after higher doses. In contrast, NF kappa B DNA-binding activity continued to increase out to at least 30 Gy. The levels of bFGF and p21(WAF-1) mRNA increased after irradiation, suggesting an increase in the transactivating activity of AP-1, Sp-1, and p53. Conclusions: These data indicate that the response of the CNS to irradiation includes the activation of a similar set of transcription factors as previously observed after other types of insults.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA		Tofilon, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672, R01CA072156] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 16672, CA 72156] Funding Source: Medline		Azuma Y, 1996, NEUROCHEM INT, V29, P323, DOI 10.1016/0197-0186(95)00147-6; Barger SW, 1996, MOL BRAIN RES, V40, P116; Chiang CS, 1997, INT J RADIAT BIOL, V72, P45; DANIELSON PE, 1988, DNA CELL BIOL, V7, P920; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Feng ZH, 1999, MOL BRAIN RES, V69, P144, DOI 10.1016/S0169-328X(99)00099-6; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HERDEGEN T, 1995, J COMP NEUROL, V354, P39, DOI 10.1002/cne.903540105; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Hong JH, 1997, MOL BRAIN RES, V48, P223, DOI 10.1016/S0169-328X(97)00095-8; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/0306-4522(96)00174-1; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Keyeux A, 1997, RADIAT RES, V147, P621, DOI 10.2307/3579629; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; Lezoualc'h F, 1998, MOL PSYCHIATR, V3, P15, DOI 10.1038/sj.mp.4000295; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; Li YQ, 1996, CANCER RES, V56, P5417; Liu W, 1999, MOL BRAIN RES, V63, P248, DOI 10.1016/S0169-328X(98)00285-X; MacCallum DE, 1996, ONCOGENE, V13, P2575; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MYERS R, 1986, BRIT J CANCER, V53, P221; Nakagomi T, 1996, NEUROL RES, V18, P559; Noel F, 1997, RADIAT RES, V147, P484, DOI 10.2307/3579506; Pennypacker K, 1997, HISTOL HISTOPATHOL, V12, P1125; Raju U, 1997, J BIOL CHEM, V272, P24624, DOI 10.1074/jbc.272.39.24624; Raju U, 1999, RADIAT ONCOL INVESTI, V7, P145, DOI 10.1002/(SICI)1520-6823(1999)7:3<145::AID-ROI2>3.0.CO;2-R; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHULTHEISS TE, 1992, BRIT J RADIOL, V65, P737, DOI 10.1259/0007-1285-65-777-737; SCHULTHEISS TE, 1995, INT J RADIAT ONCOL, V31, P1093, DOI 10.1016/0360-3016(94)00655-5; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tomasevic G, 1999, NEUROSCIENCE, V90, P781, DOI 10.1016/S0306-4522(98)00484-9; VALK PE, 1991, AM J ROENTGENOL, V156, P689; VANDERKOGEL AJ, 1986, BRIT J CANCER, V53, P207; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WOOD KA, 1995, J NEUROSCI, V15, P5851; Xiang H, 1998, J NEUROSCI, V18, P1363; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Zhou DH, 1999, RADIAT RES, V151, P703, DOI 10.2307/3580209	52	46	49	0	2	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0955-3002			INT J RADIAT BIOL	Int. J. Radiat. Biol.	AUG	2000	76	8					1045	1053					9	Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	344EY	WOS:000088747300003	10947117				2022-02-06	
J	Vigue, B; Ract, C; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B				Vigue, B; Ract, C; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B			Relationship between intracranial pressure, mild hypothermia and temperature-corrected PaCO2 in patients with traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						carbon dioxide; hypothermia; intracranial pressure; jugular venous blood oxygen saturation; traumatic brain injury	CEREBRAL BLOOD-FLOW; MODERATE HYPOTHERMIA; CARDIOPULMONARY BYPASS; CARBON-DIOXIDE; VALIDATION; METABOLISM; VELOCITY; ARTERIAL; TENSION; PH	Objective: To study the effects of mild hypothermia and associated changes in temperature-corrected PaCO2 (cPaCO(2)) on intracranial pressure (ICP), mean velocity of the middle cerebral artery (Vm), and venous jugular saturation in O-2 (SjvO(2)) in patients with severe traumatic brain injury (TBI). Design: Prospective, observational study. Setting: Intensive care unit. Patients: Severe TBI patients mechanically ventilated, sedated and paralyzed. Interventions: Twenty patients were subjected to four consecutive periods: (a) normocapnia-normothermia; (b) hypocapnia-normothermia, where hypocapnia was induced by an increase in minute volume: (c) hypocapnia-hypothermia, where hypocapnia was induced by hypothermia maintaining the ventilatory settings constant; (d) normocapnia-hypothermia, where normocapnia was achieved by a decrease in minute volume. Measurements and results: cPaCO(2) was 41 +/- 8 mmHg in periods 1 and 4, and 31 +/- 7 mmHg in periods 2 and 3. Core temperature was 37.1 +/- 0.8 degrees C in periods 1 and 2, and 34.1 +/- 1.1 degrees C in periods 3 and 4. End-tidal CO2 and cPaCO(2) values showed no difference between periods 1 and 4 and periods 2 and 3. ICP and Vm were dependent on cPaCO(2) but independent of core temperature values. SjvO(2) was related to cPaCO(2) and was significantly higher during period 3 than during period 2 (P < 0.05). Conclusion: The decrease in ICP was similar when hypocapnia was induced by hyperventilation or as a result of hypothermia alone. The relationship between cPaCO(2) and ICP might predict variations in ICP during changes in core temperature. Further studies are needed to confirm the cerebral metabolic effects of moderate hypothermia in TBI patients.	Univ Bicetre, Hop Bicetre, Dept Anesthesiol, F-94275 Le Kremlin Bicetre, France; Univ Toronto, Dept Anesthesiol, Toronto, ON, Canada		Vigue, B (corresponding author), Univ Bicetre, Hop Bicetre, Dept Anesthesiol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.						ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BRIAN JE, 1998, ANESTHESIOLOGY, V69, P547; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; DEXTER F, 1995, ANESTHESIOLOGY, V83, P405, DOI 10.1097/00000542-199508000-00021; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; HAGERDAL M, 1975, ACTA ANAESTH SCAND, P25; Huber P, 1967, Invest Radiol, V2, P17, DOI 10.1097/00004424-196701000-00016; Kofstad J, 1996, SCAND J CLIN LAB INV, V56, P21, DOI 10.3109/00365519609088622; MADDEN JA, 1993, PHARMACOL THERAPEUT, V59, P229, DOI 10.1016/0163-7258(93)90045-F; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; MORRAY JP, 1990, ANESTHESIOLOGY, V72, P510, DOI 10.1097/00000542-199003000-00020; MURKIN JM, 1987, ANESTH ANALG, V66, P825; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; PROUGH DS, 1986, ANESTHESIOLOGY, V64, P576, DOI 10.1097/00000542-198605000-00006; REAM AK, 1982, ANESTHESIOLOGY, V56, P41, DOI 10.1097/00000542-198201000-00009; ROGERS AT, 1988, ANESTHESIOLOGY, V69, P547, DOI 10.1097/00000542-198810000-00015; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIESJO BK, 1972, KIDNEY INT, V1, P360, DOI 10.1038/ki.1972.47; Sitzwohl C, 1998, ANESTH ANALG, V86, P1131, DOI 10.1097/00000539-199805000-00043; TIAN R, 1995, CIRC RES, V76, P269, DOI 10.1161/01.RES.76.2.269; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; VOLPE JJ, 1982, PEDIATRICS, V70, P147	25	46	48	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2000	26	6					722	728		10.1007/s001340051238			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334WH	WOS:000088208300012	10945389				2022-02-06	
J	Genis, L; Chen, Y; Shohami, E; Michaelson, DM				Genis, L; Chen, Y; Shohami, E; Michaelson, DM			Tau hyperphosphorylation in apolipoprotein E-deficient and control mice after closed head injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						Alzheimer disease; apolipoprotein E; closed head injury; microtubule associated protein tau; phosphorylation	PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; MONOCLONAL-ANTIBODIES; MICROTUBULE-BINDING; PHOSPHORYLATION; PROTEIN; EPITOPES; BRAIN	Apolipoprotein E (apoE)-deficient mice have learning and memory impairments that are associated with specific neurochemical changes and hyperphosphorylation of distinct epitopes of the cytoskeletal protein tau. Furthermore, such mice are highly susceptible to the sequelae of brain trauma and their ability to recover from head injury is impaired. in the present study we investigated the extent that the neuronal maintenance and repair impairments of apoE-deficient mice are related to aberrations at the tau phosphorylation level. This was pursued by subjecting control and apoE-deficient mice to closed head injury (CHI) and examination, utilizing immunoblot assays, of the resulting effects on tau phosphorylation. The results thus obtained revealed that tau of apoE-deficient mice is hyperphosphorylated before CHI and that this insult results in transient tau hyperphosphorylation, whose extent and time course in the two mouse groups varied markedly. Tau hyperphosphorylation in the injured controls was maximal by about 4 hr after injury and reverted to basal levels by 24 hr, In contrast, almost no head injury-induced tau hyperphosphorylation was observed in the apoE-deficient mice at 4 hr after injury. Some tau hyper-phosphorylation was detected in the head-injured apoE-deficient mice after longer time intervals, but its extent was markedly lower than the maximal values obtained in the head injured controls. These findings show that the chronic neuronal impairments brought about by apoE deficiency and the acute response to head injury are both associated with hyperphosphorylation of the same tau domain and that the ability of apoE-deficient mice to mount the acute tau hyperphosphorylation response to head injury is impaired. (C) 2000 Wiley-Liss, Inc.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel		Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.						BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1993, J NEUROCHEM, V60, P1372, DOI 10.1111/j.1471-4159.1993.tb03298.x; Chapman S, 1998, J NEUROCHEM, V70, P708; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Genis I, 1999, J NEUROCHEM, V72, P206, DOI 10.1046/j.1471-4159.1999.0720206.x; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1993, TINS, V11, P460; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; Kosik Kenneth S., 1994, P335; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P262; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Reynolds CH, 1997, J NEUROCHEM, V69, P191; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P243; Zelman FP, 1996, J NEUROSCI RES, V46, P90, DOI 10.1002/(SICI)1097-4547(19961001)46:1<90::AID-JNR11>3.0.CO;2-G	24	46	49	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2000	60	4					559	564		10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	310ME	WOS:000086831300015	10797559				2022-02-06	
J	Reeves, TM; Kao, CQ; Phillips, LL; Bullock, MR; Povlishock, JT				Reeves, TM; Kao, CQ; Phillips, LL; Bullock, MR; Povlishock, JT			Presynaptic excitability changes following traumatic brain injury in the rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; presynaptic volley; paired-pulse facilitation; hippocampus; rat	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; COMBINED FLUID PERCUSSION; EXCITATORY AMINO-ACIDS; HIPPOCAMPAL PYRAMIDAL CELLS; PAIRED-PULSE FACILITATION; EXTRACELLULAR POTASSIUM; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; DENTATE GYRUS	Pathological processes affecting presynaptic terminals may contribute to morbidity following traumatic brain injury (TBI). Posttraumatic widespread neuronal depolarization and elevated extracellular potassium and glutamate are predicted to alter the transduction of action potentials in terminals into reliable synaptic transmission and postsynaptic excitation. Evoked responses to orthodromic single- and paired-pulse stimulation were examined in the CA1 dendritic region of hippocampal slices removed from adult rats following fluid percussion TBI. The mean duration of the extracellularly recorded presynaptic volley (PV) increased from 1.08 msec in controls to 1.54 msec in slices prepared at 1 hr postinjury. There was a time-dependent recovery of this injury effect, and PV durations at 2 and 7 days postinjury were not different from controls. In slices removed at 1 hr postinjury, the initial slopes of field excitatory postsynaptic potentials (fEPSPs) were reduced to 36% of control values, and input/output plots revealed posttraumatic deficits in the transfer of excitation from pre- to postsynaptic elements. Manipulating potassium currents with 1.0 mM tetraethylammonium or elevating potassium ion concentration to 7.5 mM altered evoked responses but did not replicate the injury effects to PV duration. Paired-pulse facilitation of fEPSP slopes was significantly elevated at all postinjury survivals: 1 hr, 2 days, and 7 days. These results suggest two pathological processes with differing time courses: 1) a transient impairment of presynaptic terminal functioning affecting PV durations and the transduction of afferent activity in the terminals to reliable synaptic excitation and 2) a more protracted deficit to the plasticity mechanisms underlying paired-pulse facilitation. (C) 2000 Wiley-Liss, Inc.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Sch Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Div Neurosurg, Richmond, VA 23298 USA		Reeves, TM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Sch Med, Box 980709, Richmond, VA 23298 USA.	tmreeves@hsc.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587, NS20193] Funding Source: Medline		Adams P R, 1986, Adv Neurol, V44, P137; AGHAJANIAN GK, 1989, SYNAPSE, V3, P331, DOI 10.1002/syn.890030406; ALREJA M, 1995, J NEUROSCI METH, V59, P67, DOI 10.1016/0165-0270(94)00195-M; ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463; ANDERSEN P, 1978, BRAIN RES, V144, P11, DOI 10.1016/0006-8993(78)90431-6; ATTWELL PJE, 1995, BRAIN RES, V698, P155, DOI 10.1016/0006-8993(95)00886-U; BLISS TVP, 1983, J PHYSIOL-LONDON, V341, P617, DOI 10.1113/jphysiol.1983.sp014828; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1995, P 9 INT S ICP BRAIN, P64; CHOI DW, 1987, J NEUROSCI, V7, P369; Cochilla AJ, 1999, J NEUROSCI, V19, P193, DOI 10.1523/JNEUROSCI.19-01-00193.1999; COLBERT CM, 1992, J NEUROPHYSIOL, V68, P1; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dobrunz LE, 1997, P NATL ACAD SCI USA, V94, P14843, DOI 10.1073/pnas.94.26.14843; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Grover LM, 1998, J NEUROPHYSIOL, V79, P1167, DOI 10.1152/jn.1998.79.3.1167; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; HESS G, 1992, NEUROREPORT, V3, P361, DOI 10.1097/00001756-199204000-00018; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kamiya H, 1998, J PHYSIOL-LONDON, V509, P833, DOI 10.1111/j.1469-7793.1998.833bm.x; KAO CQ, 1998, J NEUROTRAUM, V15, P876; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWASAKI K, 1988, BRAIN RES, V457, P322, DOI 10.1016/0006-8993(88)90702-0; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; LAERUM H, 1994, BRAIN RES, V637, P349; LEUNG LS, 1994, BRAIN RES, V650, P75; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LOMO T, 1971, EXP BRAIN RES, V12, P46; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mattson MP, 1999, J NEUROSCI RES, V58, P2, DOI 10.1002/(SICI)1097-4547(19991001)58:1<2::AID-JNR2>3.3.CO;2-K; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Patel DR, 1997, EUR J PHARMACOL, V332, P143, DOI 10.1016/S0014-2999(97)01077-7; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; POOLOS NP, 1990, BRAIN RES, V508, P7, DOI 10.1016/0006-8993(90)91110-3; POOLOS NP, 1987, J NEUROPHYSIOL, V58, P404, DOI 10.1152/jn.1987.58.2.404; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; RINGHAM GL, 1975, J PHYSIOL-LONDON, V251, P395, DOI 10.1113/jphysiol.1975.sp011100; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SILVER IA, 1990, J GEN PHYSIOL, V95, P837, DOI 10.1085/jgp.95.5.837; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STORM JF, 1990, PROG BRAIN RES, V83, P161; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.neuro.14.1.93; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	79	46	46	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2000	60	3					370	379		10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	308PM	WOS:000086722100012	10797540				2022-02-06	
J	Boone, KB; Lu, P; Sherman, D; Palmer, B; Back, C; Shamieh, E; Warner-Chacon, K; Berman, NG				Boone, KB; Lu, P; Sherman, D; Palmer, B; Back, C; Shamieh, E; Warner-Chacon, K; Berman, NG			Validation of a new technique to detect malingering of cognitive symptoms: The b Test	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							FEIGNED MEMORY IMPAIRMENT; DIGIT RECOGNITION TEST; CLOSED-HEAD INJURY; PREMORBID INTELLIGENCE; PERFORMANCE; DEFICITS; AMNESIA; IDENTIFICATION; PATTERN; ABILITY	We administered the b Test, a new measure to identify malingering requiring recognition of overlearned information, to 34 suspected malingerers and to 161 subjects in various clinical groups (moderate to severe head injury, elderly depressed learning disability, schizophrenia, right and left CVA, and elderly normals). Comparisons of groups revealed more commission and omission errors in the suspected mn(malingerers relative to all groups except the right stroke patients. In addition, suspected malingerers rook longer lo complete the task than all groups except right and left stroke patients and normal elderly. A cutoff of >2 commission errors produced a sensitivity of 76.5% mid specificity for all comparison groups combined of 82.6%. Lower sensitivity rates were documented for omissions (58.8 using cutoff of >40) and time (57.6% using cutoff of >12 minutes), brit specificity remained high at 85.1% and 83.9%, respectively. Thus, the b Test shows considerable potential as a malingering detection tool. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA; Pepperdine Univ, Malibu, CA 90265 USA		Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, Box 495,ABPP ABCN,1000 W Carson St,Bldg F-9, Torrance, CA 90509 USA.		Palmer, Barton/ABA-7519-2020; Palmer, Barton/A-6030-2019	Palmer, Barton/0000-0002-7618-3144; Palmer, Barton/0000-0002-7618-3144			American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Arnett PA, 1997, ARCH CLIN NEUROPSYCH, V12, P513; ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; BACK C, 1994, DISS ABSTR INT, V55, P582; Back C., 1996, ASSESSMENT, V3, P449, DOI [https://doi.org/10.1177/107319119600300411, DOI 10.1177/107319119600300411]; BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BARRASH J, 1998, J INT NEUROPSYCH SOC, V4, P27; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; BERNARD LC, 1993, ARCH CLIN NEUROPSYCH, V8, P539, DOI 10.1016/0887-6177(93)90054-5; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BLACK FW, 1986, J CLIN PSYCHOL, V42, P770, DOI 10.1002/1097-4679(198609)42:5<770::AID-JCLP2270420516>3.0.CO;2-P; Bowen M, 1997, CLIN NEUROPSYCHOL, V11, P433, DOI 10.1080/13854049708400474; Chouinard M J, 1997, J Int Neuropsychol Soc, V3, P545; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CRAWFORD JR, 1992, BRIT J PSYCHIAT, V161, P69, DOI 10.1192/bjp.161.1.69; CRAWFORD JR, 1987, BRIT J CLIN PSYCHOL, V26, P313, DOI 10.1111/j.2044-8260.1987.tb01366.x; Davis HP, 1997, ARCH CLIN NEUROPSYCH, V12, P145, DOI 10.1016/S0887-6177(96)00011-X; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Griffin GAE, 1997, J CLIN PSYCHOL, V53, P757, DOI 10.1002/(SICI)1097-4679(199711)53:7<757::AID-JCLP14>3.0.CO;2-K; GUDJONSSON GH, 1986, BRIT J CLIN PSYCHOL, V25, P35, DOI 10.1111/j.2044-8260.1986.tb00668.x; HAYS JR, 1993, PERCEPT MOTOR SKILL, V76, P1331, DOI 10.2466/pms.1993.76.3c.1331; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Martin RC, 1998, CLIN NEUROPSYCHOL, V12, P84, DOI 10.1076/clin.12.1.84.1722; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; NELSON HE, 1975, BRIT J SOC CLIN PSYC, V14, P259, DOI 10.1111/j.2044-8260.1975.tb00178.x; Osimani A, 1997, J NEUROL NEUROSUR PS, V62, P617, DOI 10.1136/jnnp.62.6.617; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PAUL DS, 1992, INT J CLIN NEUROPSYC, V14, P1; PHILPOTT LM, 1993, DISS ABSTR INT, V53, P5001; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Ray EC, 1997, ARCH CLIN NEUROPSYCH, V12, P491; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; RUBINSKY EW, 1986, BEHAVIORAL SCI LAW, V4, P27; RUDDLE HV, 1982, BRIT J CLIN PSYCHOL, V21, P159, DOI 10.1111/j.2044-8260.1982.tb00548.x; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SCHRETLEN D, 1992, PSYCHOL ASSESSMENT, V14, P77; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; [No title captured]	60	46	46	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2000	15	3					227	241		10.1016/S0887-6177(99)00014-1			15	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	288UF	WOS:000085582300003	14590550	Bronze			2022-02-06	
J	Turkstra, LS				Turkstra, LS			Should my shirt be tucked in or left out? The communication contest of adolescence	APHASIOLOGY			English	Article							TRAUMATIC BRAIN INJURY; DISCOURSE; CHILDREN; LANGUAGE; SKILLS; RULES	Adolescence is a time of significant psychosocial development. Sophisticated communication skills also emerge during this time, helping adolescents to meet increasingly complex social needs. These developments shape the functional communication goals for adolescents with traumatic brain (TBI). The purpose of this paper is to present the major characteristics of psychosocial development in adolescence, and to relate this information to adolescents with TBI. Data on daily social communication in adolescence are also presented, to complement the psychosocial data and facilitate the identification of functional communication goals.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA		Turkstra, LS (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.		Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921			[Anonymous], 1959, IDENTITY LIFE CYCLE; ARGYLE M, 1986, INT J PSYCHOL, V21, P287, DOI 10.1080/00207598608247591; ARGYLE M, 1985, BRIT J SOC PSYCHOL, V24, P125, DOI 10.1111/j.2044-8309.1985.tb00671.x; Begali V., 1992, HEAD INJURY CHILDREN; Belenky M.F., 1986, WOMENS WAYS KNOWING; BLOSSER J, 1994, PEDIAT TRAMATIC BRAI; BLUMKULKA S, 1990, J PRAGMATICS, V14, P259, DOI 10.1016/0378-2166(90)90083-P; BOURGAULT R, 1985, COMMUNICATION SKILLS, P241; Brice A, 1996, LANG SPEECH HEAR SER, V27, P68, DOI 10.1044/0161-1461.2701.68; Brown L.M., 1992, M CROSSROADS; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COHEN B, 1989, AI EXPERT, V4, P22; Cooper D., 1988, LATER LANGUAGE DEV A, P225; CSIKSZENTMIHALY.M, 1986, BEING ADOLESCENT CON; Damon W., 1983, SOCIAL PERSONALITY D; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EHRLICH J, 1985, COGNITIVE REHABILITA, P32; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; FEENEY TJ, 1998, STUDENTS ACQUIRED BR, P229; Hansen DJ, 1996, BEHAV MODIF, V20, P281, DOI 10.1177/01454455960203003; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HECHT ML, 1993, AFRICAN AM COMMUNICA; HOLMES CB, 1988, HEAD INJURED COLLEGE; Kenny D.A., 1991, STUDYING INTERPERSON, P275; Kim YoungYun, 1986, INTERETHNIC COMMUNIC; Lehr E., 1990, COMMUNITY INTEGRATIO, P301; LURIA AR, 1973, MACLEANS MAGAZI 0119, P44; Muuss R. E., 1996, THEORIES ADOLESCENCE; Nippold M. A., 1988, LATER LANGUAGE DEV; Paul R., 1995, LANGUAGE DISORDERS I; RADER MC, 1993, WHAT WE KNOW ED STUD; RAFFAELLI M, 1989, J YOUTH ADOLESCENCE, V18, P567, DOI 10.1007/BF02139074; Sillars A., 1991, STUDYING INTERPERSON, P197; SMITH F, 1990, VOCATIONAL ED J  NOV, P28; STEINBERG L, 1991, YUO YOUR ADOLESCENT; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Towne R.L., 1993, LANG SPEECH HEAR SER, V24, P100; *TUCS UN SCH DISTR, 1994, PROF 21 CENT GRAD; Udehn L., 2002, METHODOLOGICAL INDIV; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Worthington J, 1989, Rehabil Nurs, V14, P118; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU	46	46	46	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	APR	2000	14	4					349	364		10.1080/026870300401405			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	315AV	WOS:000087091200002					2022-02-06	
J	Bogner, JA; Corrigan, JD; Bode, RK; Heinemann, AW				Bogner, JA; Corrigan, JD; Bode, RK; Heinemann, AW			Rating scale analysis of the Agitated Behavior Scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Agitated Behavior Scale; agitation; anoxia; brain injury; dementia	BRAIN INJURY	Objective: Evaluate the measurement properties of the Agitated Behavior Scale (ADS) using rating scale analysis. Samples: Sample 1: 900 observations of 100 individuals with traumatic brain injury; Sample 2: 204 observations of 102 persons with dementia: Sample 3: 241 observations of 6 individuals with anuria. Results: The calibration indicated that the raring scale was used as intended. The hierarchies of item difficulty were similar across samples. Person and item separation values were within the acceptable range for the TBI sample, Generally, the items work well together, however 3 items misfit the measurement model moderately. Conclusions: Agitation as measured by the ABS is best represented as a unitary construct. Results provide additional support for the reliability and validity of the ABS.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Northwestern Univ, Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA; Northwestern Univ, Sch Med, Rehabil Inst Chicago, Rehabil Serv Evaluat Serv, Chicago, IL USA		Bogner, JA (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021; Corrigan, John D./E-2921-2011	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; 			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BOGNER J, 1995, NEUROREHABILITATION, V5, P293, DOI 10.3233/NRE-1995-5403; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; COHENMANSFIELD J, 1989, J GERONTOL, V44, P77; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1995, NEUROREHABILITATION, V5, P205, DOI 10.3233/NRE-1995-5303; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Corrigan JD, 1996, AM J ALZHEIMERS DIS, V11, P20; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; LINACRE JM, 1999, WINSTEPS PC COMPATIB; MALKMUS D, 1980, REHABILITATION HEAD; TERI L, 1992, ALZ DIS ASSOC DIS, V6, P77, DOI 10.1097/00002093-199206020-00003; Wright B, 1982, RATING SCALE ANAL RA	15	46	46	0	13	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2000	15	1					656	669		10.1097/00001199-200002000-00005			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	287MX	WOS:000085510800006	10745182				2022-02-06	
J	Dietzmann, K; von Bossanyi, P; Krause, D; Wittig, H; Mawrin, C; Kirches, E				Dietzmann, K; von Bossanyi, P; Krause, D; Wittig, H; Mawrin, C; Kirches, E			Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: An immunohistochemical study	PATHOLOGY RESEARCH AND PRACTICE			English	Article						neurotrauma; necrosis; microglia; astrocytes; plasminogen activator system; plasminogen activator inhibitor; serine proteases; brain degradation; laminin; tetranectin	MATRIX METALLOPROTEINASE EXPRESSION; NECROSIS-FACTOR-ALPHA; EXTRACELLULAR-MATRIX; PROTEOLYTIC ACTIVITY; NEURONAL DEATH; MESSENGER-RNA; IN-VITRO; TISSUE; CELL; RAT	Plasminogen activators as inducible extracellular serine proteases are involved in a variety of processes, such as the degradation of brain structures. In regions of brain degradation, an increase in the expression of genes encoding cytokines and proteinases has recently been demonstrated. We tested the hypothesis, whether the plasminogen activator system as well as the plasminogen activator inhibitors are expressed and possibly involved in a proteolytic cascade that breaks down the extracellular matrix as a result of ischemic or posttraumatic brain destructions. To study this supposition, we investigated immunohistochemically the expression of tPA, uPA and its receptor, the plasminogen activator inhibitors PAI-1 and PAI-2, tetranectin as well as the laminin breakdown as an event of secondary brain injury. Brain tissue from 21 autopsy cases with severe brain injuries, material from 14 ischemic infarcts and 11 controls with acute hypoxia were used. All components of the plasminogen activator system studied were overexpressed immunohistochemically in reactive astrocytes, microglia and endothelial cells around the lesion zone. Tetranectin showed an analogous distribution to the plasminogen activator system. A reduced immunoreactivity of laminin within the identical region of destruction was detected concomitant with laminin remnants in perivascular macrophages, so that a remarkable role of the plasmin cascade in the degradation of extracellular matrix proteins in the brain is taken into consideration.	Univ Magdeburg, Inst Neuropathol, Sch Med, Dept Neuropathol, D-39120 Magdeburg, Germany; Univ Magdeburg, Sch Med, Dept Legal Med, D-39120 Magdeburg, Germany		Dietzmann, K (corresponding author), Univ Magdeburg, Inst Neuropathol, Sch Med, Dept Neuropathol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Knut.Dietzmann@Medizin.Uni-Magdeburg.DE	Wittig, Holger/AAA-5421-2021	Wittig, Holger/0000-0002-3454-0721			Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Blomgren K, 1997, ANN NY ACAD SCI, V825, P104, DOI 10.1111/j.1749-6632.1997.tb48420.x; Boudaoud L, 1997, SPINAL CORD, V35, P151, DOI 10.1038/sj.sc.3100373; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHRISTENSEN L, 1989, HISTOCHEMISTRY, V92, P29, DOI 10.1007/BF00495012; CHURLIAEV IUA, 1996, ANESTEZIOL REANIMAT, V1, P37; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; CONSTANTINI V, 1996, CANCER, V77, P1079; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; EDGAR D, 1991, J CELL SCI, P9; FABERELMAN A, 1995, J NEUROCHEM, V65, P1524; GOLDBERG WJ, 1992, BRAIN RES, V581, P81, DOI 10.1016/0006-8993(92)90346-B; HIBINO T, 1988, FEBS LETT, V231, P202, DOI 10.1016/0014-5793(88)80731-2; Hogdall C K, 1998, APMIS Suppl, V86, P1; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KEETON M, 1993, AM J PATHOL, V142, P59; KINDER DH, 1993, ONCOL RES, V5, P409; KOBAYASHI H, 1994, CANCER RES, V54, P6539; KRISTENSEN P, 1985, J CELL BIOL, V101, P305, DOI 10.1083/jcb.101.1.305; MACDONALD RL, 1992, J NEUROSURG, V76, P81, DOI 10.3171/jns.1992.76.1.0081; Masos T, 1997, MOL BRAIN RES, V47, P157, DOI 10.1016/S0169-328X(97)00040-5; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; McIntosh TK, 1996, LAB INVEST, V74, P315; MOHANAM S, 1993, CANCER RES, V53, P4143; MORI S, 1992, HISTOCHEMISTRY, V97, P237, DOI 10.1007/BF00267633; MURPHY P, 1992, EXP CELL RES, V198, P93, DOI 10.1016/0014-4827(92)90153-Y; MURTOMAKI S, 1995, DEV BIOL, V168, P635, DOI 10.1006/dbio.1995.1108; NAKAJIMA K, 1992, BRAIN RES, V577, P285, DOI 10.1016/0006-8993(92)90285-H; PRESTA M, 1990, J NEUROCHEM, V55, P1647, DOI 10.1111/j.1471-4159.1990.tb04951.x; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; REITH A, 1992, BIOCHEM BIOPH RES CO, V186, P348, DOI 10.1016/S0006-291X(05)80814-9; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAKATA Y, 1988, J BIOL CHEM, V263, P1960; SAKSELA O, 1985, J CELL PHYSIOL, V122, P125, DOI 10.1002/jcp.1041220119; Seeds NW, 1996, SEMIN NEUROSCI, V8, P405, DOI 10.1006/smns.1996.0049; SEUBERT P, 1988, BRAIN RES, V459, P226, DOI 10.1016/0006-8993(88)90638-5; Seyfried D, 1997, J NEUROSURG, V87, P716, DOI 10.3171/jns.1997.87.5.0716; STEPHENS R, 1992, FIBRINOLYSIS, V6, P35; TRANQUE P, 1994, ENDOCRINOLOGY, V134, P2606, DOI 10.1210/en.134.6.2606; Tsirka SE, 1997, J MOL MED, V75, P341, DOI 10.1007/s001090050119; vanderLaan LJW, 1997, J NEUROSCI RES, V50, P539, DOI 10.1002/(SICI)1097-4547(19971115)50:4<539::AID-JNR5>3.0.CO;2-F; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WARE JH, 1995, J NEUROBIOL, V28, P9, DOI 10.1002/neu.480280103; YAMAMOTO M, 1994, CANCER RES, V54, P5016	50	46	50	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.		2000	196	1					15	21		10.1016/S0344-0338(00)80017-5			7	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	278FX	WOS:000084979000003	10674268				2022-02-06	
J	Li, YC; Liu, L; Chiu, WT; Jian, WS				Li, YC; Liu, L; Chiu, WT; Jian, WS			Neural network modeling for surgical decisions on traumatic brain injury patients	INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS			English	Article						medical decision support system; computer-assisted medical decision; decision theory; intracranial hematoma; traumatic brain injury; logistic regression; neural networks	MYOCARDIAL-INFARCTION; DIAGNOSIS; PREDICTION; CURVES	Computerized medical decision support systems have been a major research topic in recent years. Intelligent computer programs were implemented to aid physicians and other medical professionals in making difficult medical decisions. This report compares three different mathematical models for building a traumatic brain injury (TBI) medical decision support system (MDSS). These models were developed based on a large TBI patient database. This MDSS accepts a set of patient data such as the types of skull fracture, Glasgow Coma Scale (GCS), episode of convulsion and return the chance that a neurosurgeon would recommend an open-skull surgery for this patient. The three mathematical models described in this report including a logistic regression model, a multi-layer perceptron (MLP) neural network and a radial-basis-function (RBF) neural network. From the 12 640 patients selected from the database. A randomly drawn 9480 cases were used as the training group to develop/train our models. The other 3160 cases were in the validation group which we used to evaluate the performance of these models. We used sensitivity, specificity, areas under receiver-operating characteristics (ROC) curve and calibration curves as the indicator of how accurate these models are in predicting a neurosurgeon's decision on open-skull surgery. The results showed that, assuming equal importance of sensitivity and specificity, the logistic regression model had a (sensitivity, specificity) of (73%, 68%), compared to (80%, 80%) from the RBF model and (88%, 80%) from the MLP model. The resultant areas under ROC curve for logistic regression, RBF and MLP neural networks are 0.761, 0.880 and 0.897, respectively (P < 0.05). Among these models, the logistic regression has noticeably poorer calibration. This study demonstrated the feasibility of applying neural networks as the mechanism for TBI decision support systems based on clinical databases. The results also suggest that neural networks may be a better solution for complex, non-linear medical decision support systems than conventional statistical techniques such as logistic regression. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Taipei Med Coll, Grad Inst Med Informat, Taipei 110, Taiwan; Taipei Med Coll, Ctr Biomed Informat, Taipei, Taiwan; Taipei Med Coll, Dept Med, Taipei, Taiwan; Wanfang Hosp, Taipei, Taiwan; Taipei Med Coll, Sch Healthcare Adm, Taipei, Taiwan		Li, YC (corresponding author), Taipei Med Coll, Grad Inst Med Informat, 250 Wu Hsin Rd, Taipei 110, Taiwan.		Li, Yu-Chuan/E-9476-2011	Jian, Wen-Shan/0000-0002-1739-4398; Li, Yu-Chuan (Jack)/0000-0001-6497-4232			Barreto J M, 1993, Artif Intell Med, V5, P515, DOI 10.1016/0933-3657(93)90041-Z; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, CANCER LETT, V77, P85, DOI 10.1016/0304-3835(94)90090-6; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; BERGERON BP, 1994, COMPUT BIOL MED, V24, P157, DOI 10.1016/0010-4825(94)90073-6; BUCHMAN TG, 1994, CRIT CARE MED, V22, P750, DOI 10.1097/00003246-199405000-00008; Chang PL, 1996, COMPUT MED IMAG GRAP, V20, P43, DOI 10.1016/0895-6111(96)00029-8; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; CHIU WT, 1993, J TRAUMA, V35, P206, DOI 10.1097/00005373-199308000-00006; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; DEDOMBAL FT, 1990, BAILLIERE CLIN OB GY, V4, P841, DOI 10.1016/S0950-3552(05)80347-5; DYBOWSKI R, 1995, LANCET, V346, P1203, DOI 10.1016/S0140-6736(95)92904-5; EVANS RS, 1994, ADV EXP MED BIOL, V349, P87; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; Li Y C, 1993, Proc Annu Symp Comput Appl Med Care, P471; LI YC, 1993, AM MED INF ASS SPR C, P95; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; NIELEN M, 1995, J DAIRY SCI, V78, P1050, DOI 10.3168/jds.S0022-0302(95)76721-2; SAHASAKUL Y, 1990, BRIT HEART J, V64, P182; SELKER HP, 1995, J INVEST MED, V43, P468; WU YZ, 1993, RADIOLOGY, V187, P81, DOI 10.1148/radiology.187.1.8451441; WYATT J, 1995, LANCET, V346, P1175, DOI 10.1016/S0140-6736(95)92893-6; YATES JF, 1982, ORGAN BEHAV HUM PERF, V30, P132, DOI 10.1016/0030-5073(82)90237-9	25	46	48	0	9	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1386-5056			INT J MED INFORM	Int. J. Med. Inform.	JAN	2000	57	1					1	9		10.1016/S1386-5056(99)00054-4			9	Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Health Care Sciences & Services; Medical Informatics	283HZ	WOS:000085271500001	10708251				2022-02-06	
J	Solbakk, AK; Reinvang, I; Nielsen, C; Sundet, K				Solbakk, AK; Reinvang, I; Nielsen, C; Sundet, K			ERP indicators of disturbed attention in mild closed head injury: A frontal lobe syndrome?	PSYCHOPHYSIOLOGY			English	Article						attention; mild closed head injury; frontal injury; event-related potentials; processing negativity; P3; reaction time	EVENT-RELATED POTENTIALS; HUMAN PREFRONTAL CORTEX; AUDITORY ODDBALL TASK; SELECTIVE ATTENTION; BRAIN POTENTIALS; LESIONS; P300; DISTRACTIBILITY; SYMPTOMS; DEFICITS	The purpose of the study was to examine the hypothesis that distractibility is a fundamental characteristic of mild closed head injury (MHI). The claim that cognitive symptoms in MHI are due to a mild type of frontotemporal injury was also investigated. Cognitive event-related potentials (ERPs), accuracy and reaction time to target stimuli in a dichotic listening paradigm, and neuropsychological test results were studied in patients with MHI (N = 15), patients with verified frontal lobe damage (N = 10), and healthy controls (N = 13). Information processing reflecting target detection (N2, P3b) and sustained selective attention (processing negativity) was studied. The MHI and frontal patients did not differ on behavioral measures, except that the MHI group had significantly longer reaction times to target stimuli in the ERP task. Both patient groups had deviant ERPs compared with controls, but their ERP patterns differed in important respects. Contrary to expectations, the MHI patients had the most abnormal ERPs. They showed significantly smaller N2 and Nd amplitudes than frontal patients and controls, indicating that the mediating cognitive mechanisms were not equivalent in MHI and frontal injury. The data suggest that MHI patients allocated less processing resources to the task than either the control subjects or the patients with frontal lobe damage.	Univ Oslo, Inst Psychol, Blindern, Norway; Natl Hosp Norway, Dept Psychosomat & Behav Med, Oslo, Norway		Solbakk, AK (corresponding author), Univ Oslo, Inst Psychol, POB 1094, Blindern, Norway.	a.k.solbakk@psykologi.uio.no					ALHO K, 1992, PSYCHOPHYSIOLOGY, V29, P247, DOI 10.1111/j.1469-8986.1992.tb01695.x; ALHO K, 1987, ELECTROEN CLIN NEURO, V68, P458, DOI 10.1016/0168-5597(87)90057-8; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Baddeley A.D., 1994, NEUROPSYCHOLOGY, V8, P485, DOI [10.1037/0894-4105.8.4.485, DOI 10.1037/0894-4105.8.4.485]; Baribeau J, 1989, J NEUROL REHABIL, V3, P71; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Boller F, 1995, ANN NY ACAD SCI, V769, P23, DOI 10.1111/j.1749-6632.1995.tb38129.x; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, P269; CHAO LL, 1995, NEUROREPORT, V6, P1605, DOI 10.1097/00001756-199508000-00005; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Jacobs A, 1996, J NUCL MED, V37, P1605; KNIGHT RT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P139; KNIGHT RT, 1981, ELECTROEN CLIN NEURO, V52, P571, DOI 10.1016/0013-4694(81)91431-0; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V504, P338, DOI 10.1016/0006-8993(89)91381-4; KNIGHT RT, 1995, ADV NEUROL, V66, P21; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEVIN HS, 1987, NEUROBEHAVIORAL RECO, P221; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAATANEN R, 1982, PSYCHOL BULL, V92, P605; NAATANEN R, 1995, HDB NEUROPSYCHOLOGY, P75; Naatanen R, 1992, ATTENTION BRAIN FUNC; NIELSEN CS, 1997, READPEACK DATA PROGR; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REINVANG I, 1999, J CLIN EXPT NEUROPSY; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SEGALOWITZ SJ, 1995, SOC PSYCH RES TOR ON; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; SERVANSCHREIBER D, 1990, SCIENCE, V249, P892, DOI 10.1126/science.2392679; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STAM CJ, 1993, BRAIN, V116, P1139, DOI 10.1093/brain/116.5.1139; STECKLER T, 1995, BEHAV BRAIN RES, V67, P165, DOI 10.1016/0166-4328(94)00157-B; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212; YAMAGUCHI S, 1990, BRAIN RES, V521, P281, DOI 10.1016/0006-8993(90)91553-S	55	46	46	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	NOV	1999	36	6					802	817					16	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	249BB	WOS:000083311300013	10554593				2022-02-06	
J	Golding, EM; Steenberg, ML; Contant, CF; Krishnappa, I; Robertson, CS; Bryan, RM				Golding, EM; Steenberg, ML; Contant, CF; Krishnappa, I; Robertson, CS; Bryan, RM			Cerebrovascular reactivity to CO2 and hypotension after mild cortical impact injury	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						autoregulation; carbon dioxide reactivity; rat; secondary injury; traumatic brain injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; MYOGENIC RESPONSE; COMATOSE PATIENTS; CARBON-DIOXIDE; RATS; AUTOREGULATION; METABOLISM; CIRCULATION	Cerebrovascular reactivity to CO2 or hypotension was studied in vivo and in vitro [pressurized arteries (similar to 82 mu m) and arterioles (similar to 30 mu m)] at 1 h after mild controlled cortical impact (CCI) injury in rats. The cortical perfusion response [assessed using laser-Doppler flowmetry (LDF)] to altered CO2 was diminished (up to 81%) after mild CCI injury. The responses to CO2 alterations in arteries and arterioles isolated from the injured cortex were similar to responses in vessels isolated from sham-injured animals. After mild CCI injury, the autoregulatory response to hypotension (measured using LDF) was maintained or even enhanced, depending on the method used to measure the response. Vessels isolated from the injury site showed a response to changes in pressure similar to that in vessels isolated from sham-injured rats. We conclude that mild CCI injury produces complicated alterations in cerebrovascular control. Whereas the autoregulatory response to hypotension was maintained or even enhanced, the in vivo vascular response to CO2 was severely compromised. The altered response to CO2 was not caused by an intrinsic vascular perturbation but rather an altered milieu alter mild CCI injury.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA		Golding, EM (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.	egolding@bcm.tmc.edu					ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Brian JE, 1996, CLIN EXP PHARMACOL P, V23, P449, DOI 10.1111/j.1440-1681.1996.tb02760.x; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BRYAN RM, 1988, BRAIN RES, V475, P397, DOI 10.1016/0006-8993(88)90634-8; BRYAN RM, 1995, AM J PHYSIOL-HEART C, V269, pH1171; CHEN RYZ, 1984, STROKE, V15, P343, DOI 10.1161/01.STR.15.2.343; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt D S, 1995, New Horiz, V3, P376; DIRNAGL U, 1993, NEUROL RES, V15, P128; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Golding EM, 1998, BRAIN RES, V785, P293, DOI 10.1016/S0006-8993(97)01419-4; GRUBB RL, 1982, ANESTHESIOLOGY, V56, P3, DOI 10.1097/00000542-198201000-00002; HARPER SL, 1984, HYPERTENSION, V6, P408, DOI 10.1161/01.HYP.6.3.408; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jones SC, 1999, AM J PHYSIOL-HEART C, V276, pH1253, DOI 10.1152/ajpheart.1999.276.4.H1253; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KJALLQUIST A, 1969, ACTA PHYSIOL SCAND, V76, P485; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; MILLER JD, 1975, J NEUROL NEUROSUR PS, V38, P657, DOI 10.1136/jnnp.38.7.657; MIRRO R, 1992, STROKE, V23, P1613, DOI 10.1161/01.STR.23.11.1613; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; WAHL M, 1970, PFLUG ARCH EUR J PHY, V316, P152, DOI 10.1007/BF00586483; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	39	46	46	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	OCT	1999	277	4					H1457	H1466		10.1152/ajpheart.1999.277.4.H1457			10	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Physiology	259XN	WOS:000083919400025		Bronze			2022-02-06	
J	Cifu, DX; Huang, ME; Kolakowsky-Hayner, SA; Seel, RT				Cifu, DX; Huang, ME; Kolakowsky-Hayner, SA; Seel, RT			Age, outcome, and rehabilitation costs after paraplegia caused by traumatic injury of the thoracic spinal cord, conus medullaris, and cauda equina	JOURNAL OF NEUROTRAUMA			English	Article						age; costs; outcome; paraplegia; rehabilitation	BRAIN INJURY; OLDER ADULT	The object of this study was to investigate the relationships of age on neurologic and functional outcome, hospitalization length of stay (LOS), and hospital charges after spinal cord injury (SCI). At 20 medical centers, 2,169 consecutive adult patients with paraplegia SCI were assessed in acute care and inpatient rehabilitation. Outcome and treatment measures included the ASIA motor index score, functional independence measure, discharge to community ratio, LOS, and hospital charges. Age differences were examined by separating the sample into 11 age categories and conducting one-way analyses of variance on treatment, medical expense, and outcome measures that included the Functional Independence Measure (FIM) and ASIA motor index scores. Cramer's statistic was used to derive a chi-square value that indicated whether variables differed significantly in terms of age. Post-hoc Tukey tests were also performed. Age-related differences were found with multiple demographic variables. Significant differences between age categories were found with regard to the following treatment measures: ASIA motor index scores at acute-care admission and at discharge, rehabilitation LOS, inpatient rehabilitation hospitalization charges, total LOS, total hospitalization charges, FIM scores at inpatient rehabilitation admission and discharge, FIM change, and FIM efficiency. In conclusion, in patients with paraplegia, age appears to adversely affect functional outcome, rehabilitation LOS, and hospital costs. However, neurologic recovery as defined by the ASIA motor scores does not appear to be related to age.	Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Huang, ME (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B80029] Funding Source: Medline		ALANDER DH, 1994, SPINE, V19, P2299, DOI 10.1097/00007632-199410150-00008; Bruning JL., 1997, COMPUTATIONAL HDB ST, V4th ed.; Burns SP, 1997, ARCH PHYS MED REHAB, V78, P1169, DOI 10.1016/S0003-9993(97)90326-9; CHARLES ED, 1978, PARAPLEGIA, V15, P302, DOI 10.1038/sc.1977.46; CHEN D, 1996, PHYSICAL MED REHABIL, P1149; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; CIFU DX, 1995, NEUROREHABILITATION, V5, P245, DOI 10.3233/NRE-1995-5307; CIFU DX, IN PRESS NEUROREHABI; DEVIVO MJ, 1990, ARCH NEUROL-CHICAGO, V47, P687, DOI 10.1001/archneur.1990.00530060101026; Ditunnio John F. Jr., 1995, P170; EISENBERG MG, 1985, PARAPLEGIA, V23, P335, DOI 10.1038/sc.1985.53; Go Bette K., 1995, P21; HALL JV, 1994, CONTEMP ECON POLICY, V12, P1, DOI 10.1111/j.1465-7287.1994.tb00441.x; Hays W. L., 1994, STATISTICS; International standards for neurological and functional classifications of spinal cord injury, 1982, INT STAND NEUR FUNCT; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KEITH RA, 1987, ADV CLIN REHABILITAT, V2, P6; KIWERSKI JE, 1992, INJURY, V23, P397, DOI 10.1016/0020-1383(92)90016-L; LEHMAN B, 1988, POSTGRAD GERIATR, V83, P140; McGlinchey-Berroth R, 1995, J Spinal Cord Med, V18, P183; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P102, DOI 10.1097/00002060-199903000-00002; Menter Robert R., 1995, P272; MEYERS AR, 1985, ARCH PHYS MED REHAB, V66, P704; *NAT SPIN CORD INJ, 1998, SPIN CORD INJ FACTS; Ota T, 1996, SPINAL CORD, V34, P531, DOI 10.1038/sc.1996.96; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; ROTH EJ, 1992, PARAPLEGIA, V30, P520, DOI 10.1038/sc.1992.109; Stover Samuel L., 1995, P317; WATERS RL, 1991, CLIN ORTHOP RELAT R, P14; Watson N, 1976, Paraplegia, V14, P36; YARKONY GM, 1988, J CLIN EPIDEMIOL, V41, P173, DOI 10.1016/0895-4356(88)90091-1	31	46	48	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					805	815		10.1089/neu.1999.16.805			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700006	10521140				2022-02-06	
J	Trembovler, V; Beit-Yannai, E; Younis, F; Gallily, R; Horowitz, M; Shohami, E				Trembovler, V; Beit-Yannai, E; Younis, F; Gallily, R; Horowitz, M; Shohami, E			Antioxidants attenuate acute toxicity of tumor necrosis factor-alpha induced by brain injury in rat	JOURNAL OF INTERFERON AND CYTOKINE RESEARCH			English	Article							CLOSED-HEAD INJURY; NF-KAPPA-B; TNF-ALPHA; TRANSCRIPTION FACTOR; CYTOKINE EXPRESSION; NITROXIDE RADICALS; OXIDATIVE STRESS; NERVOUS-SYSTEM; BARRIER; MECHANISMS	Tumor necrosis factor-alpha alpha (TNF-alpha) and reactive oxygen species (ROS) are produced in the brain after traumatic injury and have deleterious effects. In a rat model of closed head injury (CHI), the synthetic antioxidant from the nitroxide family, Tempol, improved recovery and protected the blood-brain barrier. Similar protection was found after CHI in heat-acclimated rats, in which the endogenous antioxidants have been shown to be elevated after CHI, The present study examined the relationship between TNF-alpha and ROS after CHI, namely, whether after CHI, antioxidants that afforded cerebroprotection also attenuated brain levels of TNF-alpha, Three groups of rats were subjected to CHI: (1) control, nontreated, (2) Tempol-treated, and (3) heat-acclimated (30 days at 34 degrees C). Four hours after injury (time for peak production of TNF-alpha), the activity of TNF-alpha was measured. Although clinical recovery was facilitated in rats of the two treated groups, TNF-alpha activity was as high as in the traumatized, untreated rats. Moreover, direct injection of TNF-alpha into mouse brain induced disruption of the blood-brain barrier, indicating its acute harmful effect. This toxic effect was attenuated by before and after treatment with Tempol, Our results support the hypothesis that in vivo antioxidants neutralize TNF-alpha toxicity, probably by interfering with activation of the transcription factor NF-kappa-B.	Hebrew Univ Jerusalem, Sch Pharm & Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm & Med, Dept Immunol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm & Med, Dept Physiol, IL-91120 Jerusalem, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.		Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; CLAUDIO L, 1994, LAB INVEST, V70, P850; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dong WM, 1998, J INTERF CYTOK RES, V18, P629, DOI 10.1089/jir.1998.18.629; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GINSBURG I, 1992, INFLAMMATION, V16, P519, DOI 10.1007/BF00918977; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; LEVI E, 1993, J APPL PHYSIOL, V75, P883; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; McIntosh TK, 1996, LAB INVEST, V74, P315; Meistrell ME, 1997, SHOCK, V8, P341; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; POGREBNIAK H, 1991, J SURG RES, V50, P469, DOI 10.1016/0022-4804(91)90026-I; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHOHAMI E, 1994, RESTOR NEUROL NEUROS, V6, P107, DOI 10.3233/RNN-1994-6204; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WRIGHT JL, 1994, J NEURO-ONCOL, V20, P17, DOI 10.1007/BF01057957; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	30	46	47	1	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	1079-9907			J INTERF CYTOK RES	J. Interferon Cytokine Res.	JUL	1999	19	7					791	795		10.1089/107999099313640			5	Biochemistry & Molecular Biology; Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Immunology	224LA	WOS:000081899500012	10454350				2022-02-06	
J	Feinberg, TE; Eaton, LA; Roane, DM; Giacino, JT				Feinberg, TE; Eaton, LA; Roane, DM; Giacino, JT			Multiple Fregoli delusions after traumatic brain injury	CORTEX			English	Article						Fregoli syndrome; misidentification	RIGHT-HEMISPHERE DAMAGE; REDUPLICATIVE PARAMNESIA; FALSE RECOGNITION; CAPGRAS-SYNDROME; MISIDENTIFICATION; DISEASE; ATROPHY	A 61 year old man after a traumatic brain injury resulting in right frontal and left temporoparietal contusions developed florid Fregoli-type misidentifications. Extensive neuropsychological testing demonstrated significant deficits in executive and memory functions. The patient's neuropsychological profile closely resembled that seen in previously reported patients with Capgras syndrome. Our findings are consistent with the hypothesis that a combination of executive and memory deficits may account for cases of delusional misidentification associated with brain lesions. However, the form which the delusion takes may be influenced by other factors including motivation.	Beth Israel Med Ctr, Yarmon Neurobehav & Alzheimers Dis Ctr, New York, NY 10003 USA; JFK Johnson Rehabil Inst, Dept Neuropsychol, Edison, NJ USA; Beth Israel Med Ctr, Dept Psychiat, New York, NY 10003 USA		Feinberg, TE (corresponding author), Beth Israel Med Ctr, Yarmon Neurobehav & Alzheimers Dis Ctr, 317 East 17th St,Fierman Hall,9th Floor, New York, NY 10003 USA.		Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			ALEXANDER MP, 1979, NEUROLOGY, V29, P334, DOI 10.1212/WNL.29.3.334; Capgras J., 1923, B SOC CLIN MED MENTA, V11, P6; CHRISTODOULOU GN, 1978, AM J PSYCHIAT, V135, P249; CHRISTODOULOU GN, 1976, ACTA PSYCHIAT SCAND, V54, P305, DOI 10.1111/j.1600-0447.1976.tb00125.x; CHRISTODOULOU GN, 1986, DELUSIONAL MISIDENTI, V164; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Courbon P., 1927, ANN MED-PSYCHOL, V85, P289; Courbon P., 1932, ANN MED-PSYCHOL, V90, P401; Critchley M., 1953, PARIETAL LOBES; DELIS D, 1987, CALIFORNIA VERBAL LE; Denman S. B., 1984, MANUAL DENMAN NEUROP; DEPAUW KW, 1987, J NERV MENT DIS, V175, P433, DOI 10.1097/00005053-198707000-00008; DEPAUW KW, 1994, PSYCHOPATHOLOGY, V27, P123, DOI 10.1159/000284858; ELLIS HD, 1994, PSYCHOPATHOLOGY, V27; ELLIS W V, 1990, Pain Clinic, V3, P239; Feinberg T.E., 1989, NEUROPSY NEUROPSY BE, V2, P39; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1080/13554799708404037; FEINBERG TE, 1997, BEHAV NEUROLOGY NEUR, P391; FLEMINGER S, 1994, PSYCHOPATHOLOGY, V27, P161, DOI 10.1159/000284865; FORSTL H, 1991, PSYCHOL MED, V21, P905, DOI 10.1017/S0033291700029895; Heaton R.K., 1981, WISCONSIN CARD SORTI; JOSEPH AB, 1987, J CLIN PSYCHIAT, V48, P409; JOSEPH AB, 1985, AM J PSYCHIAT, V142, P146; JOSEPH AB, 1986, DELUSIONAL MISIDENTI; Kaplan E, 1983, BOSTON NAMING TEST; Korsakoff S S, 1891, ALLG Z PSYCHIAT, V47, P390; Korsakoff SS, 1955, NEUROLOGY, V5, P394; LEVIN M, 1945, J MENT SCI, V91, P447, DOI 10.1192/bjp.91.385.447; MENDEZ MF, 1992, J NERV MENT DIS, V180, P94, DOI 10.1097/00005053-199202000-00005; OConnor M, 1996, NEUROPSY NEUROPSY BE, V9, P265; Paterson A, 1944, BRAIN, V67, P54, DOI 10.1093/brain/67.1.54; Pick A, 1903, BRAIN, V26, P242, DOI 10.1093/brain/26.2.242; Rapcsak SZ, 1996, CORTEX, V32, P593, DOI 10.1016/S0010-9452(96)80033-5; RAPCSAK SZ, 1994, CORTEX, V30, P565, DOI 10.1016/S0010-9452(13)80236-5; REITAN RM, 1985, HELSTEADREITAN NEURO; Roane DM, 1998, J NEUROPSYCH CLIN N, V10, P194, DOI 10.1176/jnp.10.2.194; RUFF RL, 1981, J NEUROL NEUROSUR PS, V44, P382, DOI 10.1136/jnnp.44.5.382; Spreen O., 1977, NEUROSENSORY CTR COM, VRev; STATON RD, 1982, CORTEX, V18, P23, DOI 10.1016/S0010-9452(82)80016-6; TALLAND GA, 1961, J NERV MENT DIS, V132, P361, DOI 10.1097/00005053-196105000-00001; TAYLOR J, 1958, SELECTED WRITINGS J; VI JJ, 1930, ANN MED-PSYCHOL, V88, P214; VICTOR M, 1955, NEUROLOGY, V5, P394, DOI 10.1212/WNL.5.6.394; VICTOR M, 1989, WERNICKEKORSAKOFF SY; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; Williams HW, 1938, AM J PSYCHIAT, V95, P395, DOI 10.1176/ajp.95.2.395; [No title captured]	49	46	47	0	5	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	JUN	1999	35	3					373	387		10.1016/S0010-9452(08)70806-2			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	219WG	WOS:000081630400005	10440075				2022-02-06	
J	Silber, JH; Gleeson, SP; Zho, HQ				Silber, JH; Gleeson, SP; Zho, HQ			The influence of chronic disease on resource utilization in common acute pediatric conditions - Financial concerns for children's hospitals	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article; Proceedings Paper	15th Annual Meeting of the Association-for-Health-Services-Research	JUN 21-23, 1998	WASHINGTON, D.C.	Assoc Hlth Serv Res			PROSPECTIVE PAYMENT SYSTEM; DIAGNOSIS-RELATED-GROUPS; CASE-MIX; MEASURING SEVERITY; CHRONIC ILLNESSES; MANAGED CARE; IMPACT; REIMBURSEMENT; MORTALITY; COST	Objectives: To estimate the resource utilization in hospitalizations for common pediatric conditions dr procedures involving patients with chronic disease vs those with no chronic disease and to develop an economic model of hospital per-patient profit (or loss) when insurance contracts fail to account for the presence of chronic disease. Setting and Design: A retrospective analysis of selected acute pediatric conditions found in the 1991 and 1992 MedisGroups National Comparative Data Base. Patients: We studied 30379 pediatric admissions for common acute conditions, including concussion; croup, pneumonia, appendicitis, gastroenteritis, fractures, cellulitis, urinary tract infection, and viral illness. Main Outcome Measures: Hospital length of stay and total hospital charges. Results: For patients without chronic disease, mean (geometric) length of stay was 2.53 vs 3.05 days (P<.001) for patients with at least I chronic disease. For patients without chronic disease, mean (arithmetic) total hospital charge was $2614 vs $3663 (P<.001) for patients with at least 1 chronic disease. Assuming 75% of patients with chronic disease are admitted to a children's hospital vs 25% to a general hospital, overall loss per patient at the children's hospital ranged between 1.5% and 2.9%, depending on assumptions regarding cost-to-charge ratios and the treatment of charge outliers. Pneumonia cases were associated with a 4.0% to 5.85% loss. Conclusions: Length of stay and charges are higher for everyday pediatric conditions or procedures when patients also have a chronic disease. If insurance contracts fail to account for chronic disease, then children's hospitals will realize significant financial losses, and over time this will lead to a decline in their financial viability, a reduction in quality, or a change in their mission.	Childrens Hosp Philadelphia, Ctr Outcomes Res, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Dept Anesthesia, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Div Epidemiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Div Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA		Silber, JH (corresponding author), Childrens Hosp Philadelphia, Ctr Outcomes Res, Dept Pediat, Abramson Bldg,Room 702,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Silberj@wharton.upenn.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006560] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01-HS06560] Funding Source: Medline		*AM AC PED COMM IN, 1994, 1994 REDBR, P280; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; BUTLER JRG, 1995, DEV HLTH EC PUBLIC P, P1; Coile R C Jr, 1995, Healthc Financ Manage, V49, P60; Durbin DR, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.3.e8; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; Fishman P, 1997, HEALTH AFFAIR, V16, P239, DOI 10.1377/hlthaff.16.3.239; FREEMAN JL, 1995, MED CARE, V33, P806, DOI 10.1097/00005650-199508000-00006; FROEHLICH H, 1991, J PEDIATR-US, V118, P693, DOI 10.1016/S0022-3476(05)80028-9; Gabel J, 1997, HEALTH AFFAIR, V16, P134, DOI 10.1377/hlthaff.16.3.134; GAY EG, 1990, SOC SCI MED, V31, P1103; Gay JC, 1997, PEDIATR ANN, V26, P655, DOI 10.3928/0090-4481-19971101-07; Glied SA, 1996, HEALTH SERV RES, V31, P593; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; HINZ CA, 1991, HLTH CARE STRATEGIC, V9, P19; IEZZONI LI, 1993, MED CARE, V31, P277, DOI 10.1097/00005650-199303000-00009; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; Ireys HT, 1997, PEDIATRICS, V100, P197, DOI 10.1542/peds.100.2.197; Ireys HT, 1996, PEDIATRICS, V98, P178; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOY SA, 1990, J TRAUMA, V30, P866, DOI 10.1097/00005373-199007000-00017; Kaufman S L, 1982, Inquiry, V19, P167; LAVE JR, 1970, AM ECON REV, V60, P379; LICHTIG LK, 1989, MED CARE, V27, P491, DOI 10.1097/00005650-198905000-00005; Long M J, 1986, Health Care Financ Rev, V8, P55; MAXWELL JH, 1987, INQUIRY-J HEALTH CAR, V24, P57; NEFF JM, 1995, JAMA-J AM MED ASSOC, V274, P1866, DOI 10.1001/jama.274.23.1866; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; Ozatalay S, 1987, J Med Syst, V11, P331, DOI 10.1007/BF00996348; PAULY MV, 1997, FUTURE US HLTH CARE, P353; PHELAN PD, 1993, J PAEDIATR CHILD H, V29, P266, DOI 10.1111/j.1440-1754.1993.tb00509.x; Shwartz M, 1995, INQUIRY-J HEALTH CAR, V32, P476; SILBER JH, 1995, JAMA-J AM MED ASSOC, V274, P317, DOI 10.1001/jama.274.4.317; SKOLNICK AA, 1993, JAMA-J AM MED ASSOC, V270, P2151, DOI 10.1001/jama.270.18.2151; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; THOMAS JW, 1989, INQUIRY-J HEALTH CAR, V26, P483; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39; Ungerleider RM, 1997, ANN THORAC SURG, V64, P44, DOI 10.1016/S0003-4975(97)00503-1	42	46	46	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	FEB	1999	153	2					169	179					11	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Pediatrics	164PZ	WOS:000078473900009	9988247				2022-02-06	
J	Regan, RF; Guo, YP				Regan, RF; Guo, YP			Toxic effect of hemoglobin on spinal cord neurons in culture	JOURNAL OF NEUROTRAUMA			English	Article						free radical; hemorrhage; iron; lipid peroxidation; spinal cord injury; traumatic brain injury	CORTICAL CELL-CULTURE; ACUTE SUBDURAL-HEMATOMA; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; EXCITOTOXIC INJURY; NERVOUS-SYSTEM; FREE-RADICALS; RAT-BRAIN; IRON; GLUTATHIONE	The vulnerability of spinal cord neurons to hemoglobin was quantitatively assessed in primary cultures derived from fetal mice. Exposure to hemoglobin for 28 h in a serum-free medium resulted in concentration-dependent neuronal death, with an EC50 of 0.9 mu M; glia were not injured, Neuronal death was decreased by the ferric iron chelator deferoxamine, the a-tocopherol analogue Trolox C, ascorbate, and exogenous catalase, but was potentiated by superoxide dismutase, Neuronal death was also increased by depletion of cellular glutathione with the gamma-glutamylcysteine synthetase inhibitor buthionine sulfoxamine; inhibition of endogenous catalase with 3-amino-1,2,4-triazole had no significant effect. These results suggest that hemoglobin is toxic to spinal neurons via an iron-dependent, oxidative mechanism involving a hydrogen peroxide intermediate, and support the hypothesis that hemoglobin release may contribute to neuronal loss after spinal cord trauma.	Thomas Jefferson Univ, Div Emergency Med, Philadelphia, PA 19107 USA		Regan, RF (corresponding author), Thomas Jefferson Univ, Div Emergency Med, 1020 Sansom St, Philadelphia, PA 19107 USA.						BARROWS LJ, 1955, BRAIN, V78, P59, DOI 10.1093/brain/78.1.59; BUCKMAN TD, 1993, J NEUROCHEM, V60, P2046, DOI 10.1111/j.1471-4159.1993.tb03489.x; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P143, DOI 10.1016/0165-022X(88)90045-0; DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2; DEGIROLAMI U, 1997, GREENFIELDS NEUROPAT, P1111; DICKINSON TK, 1995, J COMP NEUROL, V355, P67, DOI 10.1002/cne.903550109; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; GUTTERIDGE JMC, 1985, BIOCHIM BIOPHYS ACTA, V834, P144, DOI 10.1016/0005-2760(85)90149-3; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Halliwell B., 1989, FREE RADICALS BIOL M, VSecond; KAJIKAWA H, 1979, Neurologia Medico-Chirurgica, V19, P61, DOI 10.2176/nmc.19.61; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LAZAROW PB, 1987, J INHERIT METAB DIS, V10, P11, DOI 10.1007/BF01812843; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; MAVELLI I, 1982, BIOCHEM J, V204, P535, DOI 10.1042/bj2040535; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MISRA HP, 1972, J BIOL CHEM, V247, P6960; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1072, DOI 10.1111/j.1471-4159.1983.tb09053.x; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; Regan RF, 1996, NEUROSCI LETT, V213, P9, DOI 10.1016/0304-3940(96)12823-8; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; REGAN RF, 1995, BRAIN RES, V682, P144, DOI 10.1016/0006-8993(95)00330-S; REGAN RF, 1997, SOC NEUR ABSTR, V23, P2193; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; ROSEN AD, 1979, EXP NEUROL, V66, P277, DOI 10.1016/0014-4886(79)90080-3; RUBINSTEIN JD, 1992, FREE RADICAL BIO MED, V13, P627, DOI 10.1016/0891-5849(92)90037-H; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SATO PH, 1992, J NEUROCHEM, V58, P2263, DOI 10.1111/j.1471-4159.1992.tb10972.x; SCHAICH KM, 1992, LIPIDS, V27, P209, DOI 10.1007/BF02536181; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; WILLMORE LJ, 1991, INT J DEV NEUROSCI, V9, P175, DOI 10.1016/0736-5748(91)90009-B; WINSLOW RM, 1992, BIOMATER ARTIF CELLS, V20, P413; WINTERBOURN CC, 1979, BIOCHEM J, V182, P625, DOI 10.1042/bj1820625; Yip S, 1996, BRAIN RES, V713, P134, DOI 10.1016/0006-8993(95)01499-3; Zhang JR, 1996, J NEUROCHEM, V66, P355	39	46	53	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1998	15	8					645	653		10.1089/neu.1998.15.645			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	111KP	WOS:000075436500008	9726263				2022-02-06	
J	Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; DeKosky, ST; Dixon, CE				Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; DeKosky, ST; Dixon, CE			Chronic effects of traumatic brain injury on hippocampal vesicular acetylcholine transporter and M-2 muscarinic receptor protein in rats	EXPERIMENTAL NEUROLOGY			English	Article						cortical impact; cholinergic; VAChT; M-2 muscarinic; rat	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION INJURY; CHOLINE-ACETYLTRANSFERASE; NEUTROPHIL ACCUMULATION; COGNITIVE IMPAIRMENT; EXPRESSION; ACTIVATION; DEFICITS; NECROSIS; RELEASE	Experimental traumatic brain injury (TBI) produces cholinergic neurotransmission deficits that may contribute to chronic spatial memory deficits. Cholinergic neurotransmission deficits may be due to presynaptic alterations in the storage and release of acetylcholine (ACh) or from changes in the receptors for ACh. The vesicular ACh transporter (VAChT) mediates accumulation of ACh into secretory vesicles, and M-2 receptors can modulate cholinergic neurotransmission via a presynaptic inhibitory feedback mechanism. We examined the effects of controlled cortical impact (CCI) injury on hippocampal VAChT and M-2 muscarinic subtype receptor protein levels at four time points: 1 day, 1 week, 2 weeks, and 4 weeks following injury. Rats were anesthetized and surgically prepared for controlled cortical impact injury (4 m/s, 2.5- to 2.9-mm depth) and sham surgery. Animals were sacrificed and coronal sections (35 mu m thick) were cut through the dorsal hippocampus for VAChT and M-2 immunohistochemistry. Semiquantitative measurements of VAChT and M-2 protein in hippocampal homogenates from injured and sham rats were assessed using Western blot analysis. Immunohistochemistry showed no obvious changes in VAChT and M-2 immunoreactivity at 1 day and 1 week postinjury. At 2 and 4 weeks postinjury, an increase in hippocampal VAChT protein and a corresponding loss of hippocampal M-2 protein was observed compared to sham controls. Consistent with these results, Western blot analyses at 4 weeks postinjury demonstrated a 40-50% increase in VAChT and a 25-30% decrease in M-2. These changes may represent a compensatory response of cholinergic neurons to increase the efficiency of ACh neurotransmission chronically after TBI, by upregulating the storage capacity and subsequent release of ACh and downregulating presynaptic inhibitory receptors. (C) 1998 Academic Press.	Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Neurol, Pittsburgh, PA 15260 USA		Ciallella, JR (corresponding author), Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021	DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30313, NS33150] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		Barnes PJ, 1997, LIFE SCI, V60, P1015, DOI 10.1016/S0024-3205(97)00042-8; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BLASCOIBANEZ JM, 1995, EUR J NEUROSCI, V7, P2170, DOI 10.1111/j.1460-9568.1995.tb00638.x; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gilmor ML, 1996, J NEUROSCI, V16, P2179; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J HEAD TRAUMA REHAB, V7, P16; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVEY AI, 1995, J NEUROSCI, V15, P4077; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POSMANTUR R, 1996, J NEUROPATHOL EXP NE, V55, P65; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	44	46	48	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	1998	152	1					11	19		10.1006/exnr.1998.6831			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	106KC	WOS:000075127600002	9682008				2022-02-06	
J	Dearden, NM				Dearden, NM			Mechanisms and prevention of secondary brain damage during intensive care	CLINICAL NEUROPATHOLOGY			English	Article						secondary brain damage, prevention; secondary insults, systemic and intracranial, mechanisms	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURED PATIENTS; VENOUS OXYGEN-SATURATION; BLOOD-FLOW; MANAGEMENT	The injured brain map be damaged by primary impact, secondary injury from secondary damage due to initiation of destructive inflammatory and biochemical cascades by the primary injury or secondary ischemic injury following secondary insults that initiate or augment these immunological and biochemical cascades. Cerebral ischemia will arise whenever delivery of oxygen and substrates to the brain fall below metabolic needs. Many factors lead to the development of secondary insults to the injured brain during initial resuscitation, transport, surgery, and subsequent intensive care. Continuous monitoring of cerebral oxygenation (jugular oximetry, brain tissue PO2) and cerebral blood flow velocity (transcranial Doppler ultrasonography) in patients with brain trauma reveals multiple episodes of transient hypoperfusion with an adverse relationship between incidence and outcome. Secondary brain insults arise through systemic or intracranial mechanisms that reduce cerebral blood flow from compromised CPP, vascular distortion or cerebrovascular narrowing or lower oxygen delivery from hypoxemia associated with airway obstruction, pulmonary pathology, or anemia. Secondary brain ischemia remains a common pathway to secondary brain damage in most critically ill neurosurgical patients. In the future prevention of secondary brain injury may well hinge on giving a cocktail of novel agents that modify destructive biochemical and inflammatory pathways, each having a potential therapeutic window possibly in a subgroup of patients. To date, phase 3 clinical trials of several agents including PEGSOD and tyrilizad mesylate have failed to show relevant efficacy after brain trauma or subarachnoid hemorrhage. The therapeutic role of calcium channel blockers in traumatic subarachnoid hemorrhage is currently under investigation following the results of subgroup metaanalysis. Several phase 3, NMDA receptor antagonist studies are underway in brain trauma with results expected soon. Although we know that secondary insults promote excitotoxic secondary brain damage there is currently no pharmacological intervention with proven efficacy and, therefore, detection and correction of secondary insults appear to offer the best therapeutic strategy. After brain trauma, systemic hypotension, compromised CPP, raised ICP, elevated temperature, hypoxemia, and jugular bulb venous desaturation are associated with poor prognosis. Clinical trials of moderate hypothermia following brain trauma are ongoing. Following adult brain trauma maintenance of CPP above at least 65 mmHg (probably > 40 mmHg in children below 8 years) seems important to improve outcome indicating the need for continuous ICP monitoring during intensive care of brain-injured patients.	Univ Leeds, Gen Infirm, Dept Anaesthesia, Leeds LS1 3EX, W Yorkshire, England		Dearden, NM (corresponding author), Univ Leeds, Gen Infirm, Dept Anaesthesia, Great George St, Leeds LS1 3EX, W Yorkshire, England.						ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; CHAMBERS R, 1996, JD MILL S 16 18 OCT; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; deDeyne C, 1996, ACTA NEUROCHIR, V138, P1409, DOI 10.1007/BF01411119; GENTLEMAN D, 1992, INT SURG, V77, P297; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; JONES PA, 1996, JD MILL S 16 18 OCT; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAAS AIR, 1996, JD MILL S 16 18 OCT; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; ROBERTS WJ, 1992, APS J, V1, P12; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCHETTI N, 1996, JD MILL S 16 18 OCT	26	46	49	0	0	DUSTRI-VERLAG DR KARL FEISTLE	MUNCHEN-DEISENHOFEN	BAHNHOFSTRABE 9 POSTFACH 49, W-8024 MUNCHEN-DEISENHOFEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	JUL-AUG	1998	17	4					221	228					8	Clinical Neurology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	100QF	WOS:000074826300009	9707338				2022-02-06	
J	Sherer, M; Oden, K; Bergloff, P; Levin, E; High, WM				Sherer, M; Oden, K; Bergloff, P; Levin, E; High, WM			Assessment and treatment of impaired awareness after brain injury: implications for community re-integration	NEUROREHABILITATION			English	Article						impaired awareness; traumatic brain injury; rehabilitation; treatment; community re-integration	HEAD-INJURY; BEHAVIORAL LIMITATIONS; RATING-SCALE; DEFICITS; ADULTS; REHABILITATION; UNAWARENESS; DYSFUNCTION; ANOSOGNOSIA; RECOVERY	Impaired self-awareness of deficits is a common finding in patients who have suffered traumatic brain injury. Impaired awareness can limit motivation for treatment and contribute to poor outcome. Consequently, it is important for brain injury rehabilitation professionals to understand this phenomenon and utilize treatment approaches that may improve patient awareness. The present article reviews the existing literature on measurement of impaired awareness, characteristics of impaired awareness, the relationship of impaired awareness to functional outcome, possible treatment approaches for impaired awareness and empirical investigations of interventions to improve awareness. The treatment strategies we use to address impaired awareness in our community re-integration program for brain injury survivors are described in detail. These approaches include: establishment of the therapeutic alliance, family interventions, peer feedback, education, roleplaying, videotape feedback, real world experiences, therapeutic milieu and psychotherapy. (C) 1998 Elsevier Science Ireland Ltd.	Inst Rehabil & Res, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA		Sherer, M (corresponding author), Mississippi Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.						Alexy WD, 1983, COGNITIVE REHABILITA, V1, P8; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BABINSKI MJ, 1914, REV NEUROL, V12, P845; Barco PP, 1991, COGNITIVE REHABILITA, P129; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Bisiach E., 1991, AWARENESS DEFICIT BR, P17; Bloom B. S., 1956, CLASSIFICATION ED GO, V1; BUTLER RW, 1988, PROF PSYCHOL-RES PR, V19, P536, DOI 10.1037/0735-7028.19.5.536; Campodonico J. R., 1995, PSYCHOL ASSESSMENT M, P393; Chittum WR, 1996, BRAIN INJURY, V10, P763; CICERONE KD, 1989, REHABIL PSYCHOL, V34, P105, DOI 10.1037//0090-5550.34.2.105; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GRAHAM DI, 1993, HEAD INJURY, P91; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; HELFFENSTEIN DA, 1982, CLIN NEUROPSYCHOLOGY, V4, P139; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JOHNSON RP, 1987, CLIN REHABIL, V1, P319; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; Langer KG., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [DOI 10.1080/09602019208401395, 10.1080/09602019208401395]; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, UNPUB CLIN RATING SC; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P67; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Schank R.C., 1990, INTERACT LEARN ENVIR, V1, P231, DOI [10.1080/104948290010401, DOI 10.1080/104948290010401]; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; SHERER M, IN PRESS BRAIN INJ; SHERER M, UNPUB CHARACTERISTIC; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; SHERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Von Monakow A, 1885, ARCH PSYCHIAT, V16, P151, DOI DOI 10.1007/BF02227304; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217; [No title captured], DOI DOI 10.1097/00001199-199412000-00004	53	46	46	1	20	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	JAN	1998	10	1					25	37		10.1016/S1053-8135(97)00042-5			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	YV946	WOS:000071880300004	24525814				2022-02-06	
J	Farmer, JE; Johnson-Gerard, M				Farmer, JE; Johnson-Gerard, M			Misconceptions about traumatic brain injury among educators and rehabilitation staff: A comparative study	REHABILITATION PSYCHOLOGY			English	Article							SCHOOL REENTRY; CHILDREN	This study compared the responses of 184 educators and 111 rehabilitation specialists on a measure of knowledge about childhood traumatic brain injury (TBI). Educators displayed more misconceptions about TBI overall compared to rehabilitation staff. They underestimated the effect of TBI on cognition, behavior, and continued development. More specifically, educators showed more misconceptions than the rehabilitation staff in the following areas: coma, memory and new learning, anger management, and factors affecting recovery. An important task for rehabilitation staff members is to clarify educator misconceptions about TBI as children transition to school. Information provided should increase the level of teacher preparation and help to maximize children's academic success and adaptation following TBI.	Ctr Innovat Special Educ, Columbia, MO USA; Univ Missouri, Sch Med, Columbia, MO 65211 USA		Farmer, JE (corresponding author), Rusk Rehabil Ctr, Dept Phys Med & Rehabil, 501, Columbia, MO 65212 USA.						ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; BRYAN MR, 1995, ED MANUAL WHAT ED NE, P117; DEPOMPEI R, 1993, STAFF DEV CLIN INTER, P229; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; GOLDBERG A, 1996, ACQUIRED BRAIN INJUR; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; HANSON SL, 1992, PHYSICAL MED REHABIL, P483; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; Lash M., 1995, ED MANUAL WHAT ED NE, P41; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Savage R. C., 1994, ED DIMENSIONS ACQUIR; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wolcott G. F, 1995, ED MANUAL WHAT ED NE; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P25, DOI 10.1097/00001199-199512000-00006	23	46	46	0	3	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	WIN	1997	42	4					273	286					14	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	ZC599	WOS:000072597600002					2022-02-06	
J	Coplin, WM; OKeefe, GE; Grady, MS; Grant, GA; March, KS; Winn, HR; Lam, AM				Coplin, WM; OKeefe, GE; Grady, MS; Grant, GA; March, KS; Winn, HR; Lam, AM			Thrombotic, infectious, and procedural complications of the jugular bulb catheter in the intensive care unit	NEUROSURGERY			English	Article						complications; critical care; head injury; jugular vein; monitoring; venous thromboembolism	DEEP VENOUS THROMBOSIS; SUBCLAVIAN VEIN-THROMBOSIS; COLOR DOPPLER ULTRASOUND; LARGE-BORE CATHETERS; ACUTE BRAIN INJURY; UPPER-EXTREMITY; CEREBRAL OXYGENATION; PULMONARY-EMBOLISM; HEAD-INJURY; DIAGNOSIS	OBJECTIVE: An assessment of the thrombotic infectious, and technical complications of continuous jugular bulb catheter monitoring in the intensive care unit (ICU) was made. METHODS: Over a 1-year period, 44 patients suffering from traumatic brain injury, subarachnoid hemorrhage, or stroke received jugular bulb catheter monitoring in the ICU. They were followed for catheter insertion complications and the development of bacteremia. In 20 patients chosen randomly, an ultrasonographic evaluation was performed after removal of the catheter for an assessment of internal jugular vein thrombosis. RESULTS: Of the 44 patients, 1 became bacteremic; the source was identified as a thoracostomy site. Among the complications related to the 44 catheter insertions, there were 2 instances of carotid artery puncture (4.5%), 1 misplaced catheter (thoracic placement), and 1 clinically insignificant hematoma. Of the 20 patients investigated with ultrasonography, 8 (40%) had nonobstructive, subclinical internal jugular vein thrombi after jugular bulb catheter monitoring (95% confidence interval, 19-61%). The median monitoring duration was 3 days (range, 1-6 d). No clinical factor was identified to be associated with thrombus formation. CONCLUSION: We conclude the following: 1) the risk of bacteremia related to the jugular bulb catheter was negligible; 2) complications related to catheter insertion were rare and clinically insignificant; and 3) the incidence of subclinical internal jugular vein thrombosis after jugular bulb catheter monitoring is considerable. Although it is worthy to note this complication, no patient with a thrombus became symptomatic in the present series. The risk-benefit assessment of this monitoring technique must include consideration of subclinical thrombosis.	UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT ANESTHESIOL,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT SURG,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NURSING EDUC,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DIV PULM & CRIT CARE MED,SEATTLE,WA 98104						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030305] Funding Source: NIH RePORTER		Agraharkar M, 1995, ASAIO J, V41, P169; ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; Bambauer R, 1992, ASAIO J, V38, P96, DOI 10.1097/00002480-199204000-00006; BAMBAUER R, 1994, ARTIF ORGANS, V18, P318, DOI 10.1111/j.1525-1594.1994.tb02204.x; BAXTER GM, 1991, BRIT J RADIOL, V64, P777, DOI 10.1259/0007-1285-64-765-777; BLACK MD, 1993, CHEST, V103, P1887, DOI 10.1378/chest.103.6.1887; CAMPBELL CB, 1977, SURGERY, V82, P816; CORONA ML, 1990, MAYO CLIN PROC, V65, P979, DOI 10.1016/S0025-6196(12)65159-3; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1993, CRIT CARE MED, V21, P1242, DOI 10.1097/00003246-199308000-00027; DIEBOLD J, 1991, PATHOL RES PRACT, V187, P260; DONAYRE CE, 1986, AM J SURG, V152, P179, DOI 10.1016/0002-9610(86)90238-2; DORFMAN GS, 1989, RADIOLOGY, V173, P159, DOI 10.1148/radiology.173.1.2675182; FUMAGALLI P, 1995, BRIT J ANAESTH, V74, P345, DOI 10.1093/bja/74.3.345; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HAHN U, 1995, J CLIN APHERESIS, V10, P12, DOI 10.1002/jca.2920100104; HAIRE WD, 1991, J VASC SURG, V13, P391, DOI 10.1067/mva.1991.25130; HAIRE WD, 1991, J ULTRAS MED, V10, P493, DOI 10.7863/jum.1991.10.9.493; HIRSCH DR, 1995, JAMA-J AM MED ASSOC, V274, P335, DOI 10.1001/jama.274.4.335; HORATTAS MC, 1988, SURGERY, V104, P561; JAKOBSEN M, 1989, J CEREBR BLOOD F MET, V9, P717, DOI 10.1038/jcbfm.1989.101; KARNIK R, 1993, CLIN CARDIOL, V16, P26, DOI 10.1002/clc.4960160106; KOKSOY C, 1995, CLIN RADIOL, V50, P687, DOI 10.1016/S0009-9260(05)83313-6; MATTA BF, 1994, ANESTH ANALG, V79, P745; MONREAL M, 1991, CHEST, V99, P280, DOI 10.1378/chest.99.2.280; NAKAJIMA T, 1993, ANESTH ANALG, V77, P1111; OLSEN KS, 1994, J NEUROSURG ANESTH, V6, P233; PRESCOTT SM, 1979, CIRCULATION, V59, P350, DOI 10.1161/01.CIR.59.2.350; PRINCE SR, 1976, ANESTHESIOLOGY, V44, P170, DOI 10.1097/00000542-197602000-00022; ROBERTSON C, 1993, ACTA NEUROCHIR SUPP, V59, P98; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSS AHM, 1982, JPEN-PARENTER ENTER, V6, P61, DOI 10.1177/014860718200600161; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHOLZ KH, 1990, THORAC CARDIOV SURG, V38, P69, DOI 10.1055/s-2007-1013996; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SNYDER RH, 1988, ANN SURG, V208, P651, DOI 10.1097/00000658-198811000-00018; SWINTON NW, 1968, CIRCULATION, V38, P737, DOI 10.1161/01.CIR.38.4.737	41	46	48	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUL	1997	41	1					101	107		10.1097/00006123-199707000-00022			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XH585	WOS:A1997XH58500055	9218301				2022-02-06	
J	Dings, J; Meixensberger, J; Roosen, K				Dings, J; Meixensberger, J; Roosen, K			Brain tissue pO(2)-monitoring: Catheter stability and complications	NEUROLOGICAL RESEARCH			English	Article						brain tissue pO(2); complications; brain oxygenation; head injury; subarachnoid hemorrhage; catheter stability	VENOUS OXYGEN-SATURATION; HEAD-INJURED PATIENTS; CEREBRAL BLOOD-FLOW; PRESSURE	The authors report on the stability and complications of 73 LICOX brain ti-pO(2)-microcatheters in 70 patients. Mean monitoring time was 7.5 +/- 4.0 days. Patients prone to cerebral hypoxia (after severe head injury (GCS < 9) or a subarachnoid hemorrhage) had a ti-pO(2)-microcatheter inserted next to the ICP-probe in the typical frontal position. After the first 15 insertions, instead of the 3-way-screw (needing a 6 mm burrhole), a I-way-screw (needing a 2.7 mm burrhole) was used for fixation in the bone; by doing so, the procedure can be performed in the ICU and takes only 15 min. Whenever possible a calibration at room air (to determine the sensitivity-drift) and in oxygen free solution (to determine the zero-drift) was performed after removal of the catheters. Ideally the expected pO(2) at room air was around 154 mmHg (temperature dependent) and at zero calibration 0 mmHg. Mean sensitivity-drift for 54 catheters was -8.5 +/- 15.4%. Dividing the catheters into groups, depending on the duration of monitoring (1-4, 5-8 and 9-16 days), revealed that the greatest part of the (negative) sensitivity-drift occurred during day 1-4 after insertion. After 1 week of monitoring sometimes a positive drift occurred (being far less than the negative drift during the first 4 days). Compared to the old catheters (-10.3 +/- 17.3%) ion the first half of the patients) the new ones showed a lower sensitivity-drift (-6.8 +/- 13.4%). The zero-drift of 56 catheters was low with mean drift after 7.5 +/- 4.0 days of 1.5 +/- 1.5 mmHg. Here also the highest drift occurred on day 1-4 after insertion. No infection was seen and 2 times (2.7%) a small hematoma, not needing evacuation occurred. As the ti-pO(2)-catheter (having a smaller diameter) and the ICP-catheter were inserted at the same time, one cannot distinguish which catheter caused the hematoma. A possible explanation for the occurrence of the two hematomas is the insertion of the catheters too close to the midline. The authors conclude that LICOX ti-pO(2)-monitoring is a safe and reliable method. Further decrease of the complication rate and increase of the catheter-stability may be expected.			Dings, J (corresponding author), UNIV WURZBURG, DEPT NEUROSURG, JOSEPH SCHNEIDER STR 11, D-97080 WURZBURG, GERMANY.						BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CARTER LP, 1991, SURG NEUROL, V35, P36, DOI 10.1016/0090-3019(91)90199-J; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; Luerssen T.G.S.P., 1989, INTRACRANIAL PRESSUR, P35; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; METZ C, 1993, ANASTH INTENSIVMED, V34, P345; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Piek J, 1994, Zentralbl Neurochir, V55, P48; PIEK J, 1993, INTRACRANIAL PRESSUR, V8, P11; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38	13	46	49	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1997	19	3					241	245		10.1080/01616412.1997.11740806			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XC468	WOS:A1997XC46800005	9192373				2022-02-06	
J	Imaizumi, S; Kondo, T; Deli, MA; Gobbel, G; Joo, F; Epstein, CJ; Yoshimoto, T; Chan, PH				Imaizumi, S; Kondo, T; Deli, MA; Gobbel, G; Joo, F; Epstein, CJ; Yoshimoto, T; Chan, PH			The influence of oxygen free radicals on the permeability of the monolayer of cultured brain endothelial cells	NEUROCHEMISTRY INTERNATIONAL			English	Article; Proceedings Paper	Workshop on Antioxidants	NOV 12, 1994	HOLLYWOOD, FL				CUZN-SUPEROXIDE-DISMUTASE; TRANSGENIC MICE; HYDROGEN-PEROXIDE; ISCHEMIC-INJURY; NITRIC-OXIDE; INFARCTION; HYPOXIA; MODEL	Free radicals have been implicated in the pathogenesis of vasogenic brain edema caused by ischemic or traumatic injury. It has been reported that in transgenic mice overexpressing the human CuZn-superoxide dismutase, brain edema is decreased in many cerebral disorders. To investigate the effects of free radicals on the permeability of the blood-brain barrier, we established an in vitro model system of the blood-brain barrier using brain endothelial cells cultivated from transgenic mice and non-transgenic mice. The blood-brain barrier model is originated by a monolayer of brain endothelial cells cultured on a membrane which has 0.45-mu m pores. Electrical resistance across the cell monolayer, which reflects the paracellular flux of ionic molecules, was measured. The blood-brain barrier models were incubated with menadione (vitamin K-3, an intracellular O-2(-) producing agent), and segmental changes in the electrical resistance across the monolayer were compared between the transgenic and the non-transgenic mice. Superoxide dismutase activity of the cultured brain endothelial cells was 1.7 times higher in the transgenic than in the non-transgenic mice (n = 3, P < 0.001). The electrical resistance was reduced by menadione in the transgenic but not in the non-transgenic mice (n = 7, P < 0.05) in the early stage. Moreover, desferroxamine mesylate (Fe2+ chelating agent) inhibited the menadione-induced early decrease in electrical resistance in the transgenic mice (n = 7, P < 0.05). These results suggest that the permeability of the blood-brain barrier may be affected by hydroxyl radicals and/or peroxynitrite rather than the O-2(-) itself. Copyright (C) 1996 Elsevier-Science Ltd.	TOHOKU UNIV, SCH MED, DEPT NEUROSURG, SENDAI, MIYAGI 980, JAPAN; BIOL RES CTR, DEPT NEUROPHYSIOL, H-6701 SZEGAD, HUNGARY; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA		Imaizumi, S (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT NEUROL & NEUROSURG, C-224, 521 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.		Deli, Maria A./I-2885-2019	Deli, Maria A./0000-0001-6084-6524			ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; AFANASEV IB, 1990, ARCH BIOCHEM BIOPHYS, V281, P245, DOI 10.1016/0003-9861(90)90439-6; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; CHAN PH, 1994, ANN NY ACAD SCI, V738, P93; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; GOBBEL GT, 1994, BRAIN RES, V653, P23, DOI 10.1016/0006-8993(94)90367-0; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; IMAIZUMI S, 1990, JPN J STROKE, V12, P592; JOO F, 1973, CYTOBIOS, V8, P41; JOO F, 1989, Neurological Research, V11, P67; JOO F, 1992, J NEUROCHEM, V58, P1, DOI 10.1111/j.1471-4159.1992.tb09272.x; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KONDO T, 1994, CELL TRANSPLANT, V3, pS35, DOI 10.1177/096368979400301S14; MAO GD, 1993, J BIOL CHEM, V268, P416; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mikawa S., 1994, Society for Neuroscience Abstracts, V20, P195; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SAUGSTAD OD, 1980, EUR SURG RES, V12, P123, DOI 10.1159/000128117; SUNDQVIST T, 1991, J CELL PHYSIOL, V148, P152, DOI 10.1002/jcp.1041480118	24	46	47	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	AUG	1996	29	2					205	211		10.1016/0197-0186(95)00120-4			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Neurosciences & Neurology	UY764	WOS:A1996UY76400014	8837050				2022-02-06	
J	Bohbot, V; Otahal, P; Liu, Z; Nadel, L; Bures, J				Bohbot, V; Otahal, P; Liu, Z; Nadel, L; Bures, J			Electroconvulsive shock and lidocaine reveal rapid consolidation of spatial working memory in the water maze	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							TASK	Head trauma leading to concussion and electroconvulsive shock (ECS) in humans causes amnesia for events that occurred shortly before the injury (retrograde amnesia). The present experiment investigated the amnesic effect of lidocaine and ECS in 25 rats trained on a corking memory version of the Morris water task Each day, the escape platform was moved to a new location; learning was evidenced by a decrease in the latency to find the platform from the first to the second trial. ''Consolidation'' of this newly encoded spatial engram was disrupted by bilateral inactivation of the dorsal hippocampus with 1 mu l of 4% lidocaine applied as soon as possible after the first trial. When trial 2 was given after recovery from the lidocaine (30 min after the injection), a normal decrease in latency indicated that the new engram was not disrupted, When trial 2 was given under the influence of lidocaine (5 min after injection), absence of latency decrease demonstrated both the success of the inactivation and the importance of hippocampus for the task To examine the role of events immediately after learning, ECS (30 or 100 mA, 50 Hz, 1.2 sec) Was applied 0 sec to 45 sec after a single escape to the new platform location. A 2-h delay between ECS and trial 2 allowed the effects of ECS to dissipate. ECS applied 45 sec or 30 sec after trial 1 caused no retrograde amnesia: escape latencies on trial 2 were the same as in control rats. However, ECS applied 0 sec or 15 sec after trial 1 induced clear retrograde amnesia: escape latencies on trial 2 were no shorter than on trial 1. It is concluded that the consolidation of a newly formed memory for spatial location can only be disrupted by ECS within 30 sec after learning.	ACAD SCI CZECH REPUBL,INST PHYSIOL,CR-14220 PRAGUE 4,CZECH REPUBLIC; UNIV ARIZONA,DEPT PSYCHOL,TUCSON,AZ 85721; ARIZONA RES LABS,TUCSON,AZ 85721					Otahal, Pavel/0000-0002-5513-4159			BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; FENTON AA, 1994, NEUROSCIENCE, V58, P481, DOI 10.1016/0306-4522(94)90074-4; FIFKOVA E, 1967, ELECTROPHYSIOLOGICAL, P653; HOLZHAUER MS, 1986, PHYSIOL BEHAV, V38, P551, DOI 10.1016/0031-9384(86)90424-5; LYNCH S, 1973, AM J PSYCHOL, V86, P643, DOI 10.2307/1421950; MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; PANAKHOVA E, 1984, INT J PSYCHOPHYSIOL, V2, P5, DOI 10.1016/0167-8760(84)90066-7; Ribot T, 1882, DISEASES MEMORY; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; Zubin J, 1941, P SOC EXP BIOL MED, V48, P596	13	46	46	1	8	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 30	1996	93	9					4016	4019		10.1073/pnas.93.9.4016			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK557	WOS:A1996UK55700052	8633008	Green Published, Bronze			2022-02-06	
J	Miller, RD; Monsul, NT; Vender, JR; Lehmann, JC				Miller, RD; Monsul, NT; Vender, JR; Lehmann, JC			NMDA- and endothelin-1-induced increases in blood-brain barrier permeability quantitated with Lucifer yellow	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						blood-brain barrier; cerebrovasculature; excitatory amino acid; N-Methyl-D-aspartate; endothelin-1 (ET-I); selfotel; Lucifer yellow	D-ASPARTATE; RECEPTORS; CGS-19755; CELLS	At 48 h following intrastriatal injection of N-methyl-D-aspartate (NMDA; 100 nmol/mu l) or endothelin-1 (ET-1; 143 pmol/mu l), significant increases in brain penetration of the highly polar, fluorescent tracer Lucifer yellow were observed. The competitive NMDA receptor antagonist selfotel (CGS-19755; 30 nmol/mu l, i.c.) significantly reduced the NMDA-induced increases in blood-brain barrier permeability, but not those induced by ET-1. These results suggest that NMDA receptors can mediate increases in blood-brain barrier permeability but do not primarily mediate increases in blood-brain barrier permeability caused by ET-1. This is the first study to our knowledge investigating the relationship between excitotoxicity and disruption of the blood-brain barrier, a major pathophysiological event in stroke and traumatic brain injury.	MED COLL PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,PHILADELPHIA,PA 19102; MED COLL PENN,DEPT PHYSIOL & BIOPHYS,PHILADELPHIA,PA 19102						NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 49898] Funding Source: Medline		ALTURA BM, 1991, STROKE, V23, P153; BEART PM, 1988, J CEREBR BLOOD F MET, V8, P879, DOI 10.1038/jcbfm.1988.146; BOAST CA, 1988, BRAIN RES, V442, P345, DOI 10.1016/0006-8993(88)91522-3; DIRNAGL U, 1993, PROG BRAIN RES, V96, P49; DUX E, 1991, J CEREB BLOOD FLO S2, V11, pS105; FUXE K, 1991, METHODS NEUROSCIENCE, V7, P256; HARDEBO JE, 1989, ACTA PHYSIOL SCAND, V136, P483, DOI 10.1111/j.1748-1716.1989.tb08690.x; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; KOHZUKI M, 1991, NEUROSCIENCE, V42, P245, DOI 10.1016/0306-4522(91)90162-H; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LEHMANN J, 1988, J PHARMACOL EXP THER, V246, P65; LIN WW, 1990, BIOCHEM BIOPH RES CO, V167, P593, DOI 10.1016/0006-291X(90)92066-9; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIMOTO S, 1990, BRAIN RES, V508, P283, DOI 10.1016/0006-8993(90)90407-3	15	46	46	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	MAR	1996	136	1-2					37	40		10.1016/0022-510X(95)00309-P			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UC708	WOS:A1996UC70800006	8815176				2022-02-06	
J	Panizzon, KL; Dwyer, BE; Nishimura, RN; Wallis, RA				Panizzon, KL; Dwyer, BE; Nishimura, RN; Wallis, RA			Neuroprotection against CA1 injury with metalloporphyrins	NEUROREPORT			English	Article						cerebral ischemia; hypoxia; traumatic brain injury; heme oxygenase; metalloporphyrins; LTP; oxidative stress; slice	LONG-TERM POTENTIATION; HEME OXYGENASE; CARBON-MONOXIDE; NITRIC-OXIDE; HYPERBILIRUBINEMIA; SUPPRESSION; HIPPOCAMPUS; INHIBITORS	THE hippocampal slice was used to examine neuroprotection with metalloporphyrins, a class of drug which inhibits heme oxygenase and which has been found to be effective in the treatment of neonatal hyperbilirubinemia. Tin-protoporphyrin given during hypoxia significantly improved recovery of CA1 antidromic PS to a mean of 82 +/- 2% of initial amplitude, while unmedicated slices regained only 6 +/- 3% of initial amplitude. Tin-protoporphyrin also protected against fluid percussion injury with an EC(50) Of 10 mu M when given after trauma. This protection extended to induction of long-term potentiation. Tin-mesoporphyrin and zinc-protoporphyrin protected against trauma with EC(50)'s of 4 and 32 mu M. Treatment with Sn-PP also protected against exposure to hydrogen peroxide, but not NMDA, AMPA, glycine or nitric oxide. These findings indicate that metalloporphyrins protect against CA1 neuronal injury through direct neural effects.	VET AFFAIRS MED CTR 111 N1,NEURONAL INJURY LAB,SEPULVEDA,CA 91343; VET AFFAIRS MED CTR 111 N1,IN VITRO REMYELINAT LAB,SEPULVEDA,CA 91343; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; VET AFFAIRS MED CTR,MOLEC NEUROBIOL LAB,WHITE RIVER JCT,VT 05009; DARTMOUTH COLL SCH MED,DIV NEUROL,DEPT MED,HANOVER,NH 03755								DRUMMOND GS, 1986, J CLIN INVEST, V77, P971, DOI 10.1172/JCI112398; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; DWYER BE, 1995, NEUROREPORT, V6, P973, DOI 10.1097/00001756-199505090-00006; FAIRCHILD MD, 1988, BRAIN RES, V453, P357, DOI 10.1016/0006-8993(88)90178-3; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; KAPPAS A, 1988, PEDIATRICS, V81, P485; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LUO DS, 1994, EUR J PHARM-MOLEC PH, V267, P263, DOI 10.1016/0922-4106(94)90149-X; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; PANIZZON KL, 1994, NEUROLOGY, V20; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TRUKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732; VALAES T, 1994, PEDIATRICS, V93, P1; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VREMAN HJ, 1993, PEDIATR RES, V33, P195; WALLIS RA, 1993, NEUROREPORT, V5, P245; WALLIS RA, 1994, BRAIN RES, V664, P115, DOI 10.1016/0006-8993(94)91961-5; WALLIS RA, 1993, EUR J PHARMACOL, V238, P165, DOI 10.1016/0014-2999(93)90844-8; WALLIS RA, IN PRESS BRAIN RES; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZORUMSKI CF, 1993, BIOCHEM PHARMACOL, V46, P777, DOI 10.1016/0006-2952(93)90484-E	25	46	49	0	0	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	JAN 31	1996	7	2					662	666		10.1097/00001756-199601310-00067			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UC299	WOS:A1996UC29900067	8730852				2022-02-06	
J	Lee, ST; Lui, TN; Wong, CW; Yeh, YS; Tzaan, WC				Lee, ST; Lui, TN; Wong, CW; Yeh, YS; Tzaan, WC			Early seizures after moderate closed head injury	ACTA NEUROCHIRURGICA			English	Article						seizures; head injury; posttraumatic seizures	EPILEPSY; TRAUMA; MILD	The incidence and clinical significance was studied in 2574 closed head injury patients, each of them having a Glasgow Coma Scale (GCS) 9 to 12 after trauma. All patients underwent computerized tomography (CT) after being admitted to the emergency service. One hundred and six patients (4.1%) experienced seizures within 1 week after head injury; 46 of these (1.8% of the series) had seizures within 24 hours after trauma. There was no statistically significant difference between the early seizure and seizure free group of patients in gender, age and GCS with the exception of cause of injury (p < 0.01). The incidence of intracerebral parenchymal damage was found to be higher with seizures developing between day 2 and day 7 (80%) than those with seizures developing within 24 hours (54.3%). Analysing the data revealed that early posttraumatic seizures were not related to the presence of intra cerebral parenchymal damage on CT scan. The occurrence of early seizures did not affect the mortality and outcome of moderate closed head injury patients.	CHANG GUNG & MED & ENGN COLL,TAYUAN,TAIWAN		Lee, ST (corresponding author), CHANG GUNG MEM HOSP,DEPT NEUROSURG,5 FU SHING ST,TAYUAN 333,TAIWAN.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BAILEY BN, TXB HEAD INJURY, P308; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; EISENBERG HM, 1989, MILD MODERATE HEAD I, P95; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT B, 1981, MANAGEMENT HEAD INJU, P301; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MILLER JD, 1989, MILD MODERATE HEAD I, P117; PITTS LH, 1989, MILD MODERATE HEAD I, P107; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	20	46	47	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	137	3-4					151	154		10.1007/BF02187187			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TL370	WOS:A1995TL37000011	8789655				2022-02-06	
J	MATHERN, GW; BABB, TL; VICKREY, BG; MELENDEZ, M; PRETORIUS, JK				MATHERN, GW; BABB, TL; VICKREY, BG; MELENDEZ, M; PRETORIUS, JK			TRAUMATIC COMPARED TO NONTRAUMATIC CLINICAL-PATHOLOGICAL ASSOCIATIONS IN TEMPORAL-LOBE EPILEPSY	EPILEPSY RESEARCH			English	Article						HIPPOCAMPAL SCLEROSIS; ETIOLOGY; COMPLEX PARTIAL SEIZURES; PATHOGENESIS	CONCUSSIVE BRAIN INJURY; HEAD-INJURY; VULNERABILITY; RAT	This study determined differences in clinical-pathologic characteristics of intractable temporal lobe epilepsy (TLE) patients whose mechanism of cerebral injury and chronic seizures involved a prior history of cerebral trauma compared to those with non-traumatic initial injuries. TLE patients (n = 120) from a single epilepsy center were retrospectively and blindly catalogued into pathogenic groups (independent variables) based on if there was a significant Birth injury (n = 11) or Cerebral trauma (n = 26). These two 'trauma' categories were compared to TLE patients with non-seizure non-trauma histories (Non-St/Non-Trauma; n = 17), or a first Prolonged seizure (n = 66). The four groups were compared for differences in the time course of their clinical injuries and seizures, quantified hippocampal neuron counts, other temporal neocortical pathologies, and seizure outcomes (dependent variables). Between group statistically significant (at least P < 0.05) results showed: (1) In Birth injury, 33% had Ammon's Horn (AH) neuron loss under 50%, 54% had other temporal neocortical pathologies, they showed the most CA4 neuron loss, and the worse seizure outcomes. (2) Cerebral trauma were older when injured, 29% had AH loss under 50%, 50% showed other pathologies, and they had the best seizure outcomes. (3) Non-St/Non-Trauma showed the least AH and CA4 neuron losses, only 12% had other temporal pathologies, and they had seizure outcomes that were intermediate. (4) Prolonged seizure showed the youngest age of habitual TLE onsets, the greatest AH, CA1, and prosubiculum neuron loss, only 11% had other temporal pathologies, and their seizure outcomes were excellent. These results indicate that in intractable surgically treated TLE, a history of cerebral trauma or birth injury as the pathogenic mechanism of their seizures show different clinical-pathologic features and seizure outcomes compared to non-trauma patients. This supports the notion that in TLE there are different pathogenic mechanisms associated with different types of initial injuries and that patients will have different responses to surgical therapy.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,REED NEUROL RES CTR,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,REED NEUROL RES CTR,BRAIN RES INST,LOS ANGELES,CA 90024		MATHERN, GW (corresponding author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,REED NEUROL RES CTR,DIV NEUROSURG,LOS ANGELES,CA 90024, USA.		Mathern, Gary W./J-2483-2016		AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS002808, U54NS081764, K08NS001603] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01 HS06856] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS 01603, NS 02808] Funding Source: Medline		ABOUKHALIL B, 1993, EPILEPSIA, V34, P878, DOI 10.1111/j.1528-1157.1993.tb02105.x; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; BABB TL, 1984, EPILEPSIA, V25, P729, DOI 10.1111/j.1528-1157.1984.tb03484.x; BABB TL, 1991, EPILEPSY SURGERY, P719; Bruton C., 1988, NEUROPATHOLOGY TEMPO; COHADON F, 1991, J NEUROL SCI, V103, pS27; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; CRANDALL PH, 1963, J NEUROSURG, V20, P827, DOI 10.3171/jns.1963.20.10.0827; CRANDALL PH, 1987, SURGICAL TREATMENT E, P377; DENO RL, 1933, J PSYCHOL NEUROL, V45, P113; Dinner Dudley S., 1993, P654; EARLE KM, 1953, AMA ARCH NEUROL PSY, V69, P27, DOI 10.1001/archneurpsyc.1953.02320250033003; Engel, 1987, SURG TREATMENT EPILE, P553; ENGEL J, 1991, PRINCIPLES NEUROSURG, P319; Engel JJ, 1993, SURG TREATMENT EPILE, P743; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GADA GF, 1990, NEUROLOGICAL SURGERY, P1965; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1975, EPILEPSY NONMISSILE; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MALAMUD N, 1958, TEMPORAL LOBE EPILEP, P149; MATHERN GW, 1994, DEV BRAIN RES, V78, P70, DOI 10.1016/0165-3806(94)90011-6; MATHERN GW, 1994, UNPUB BRAIN; MATHERN GW, 1991, IN PRESS J NEUROSURG; MATHERN GW, 1994, IN PRESS J NEUROSURG; McCormick W.F., 1985, NEUROSURGERY, P1544; MOURITZENDAM A, 1980, EPILEPSIA, V21, P617; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; TEMKIN O, 1945, FALLING SICKNESS; VICKREY BG, 1992, MED CARE, V30, P299, DOI 10.1097/00005650-199204000-00002; WEISER HG, 1993, SURGICAL TREATMENT E, P49; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1990, NEUROLOGICAL SURGERY, P2243; [No title captured]	42	46	47	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	OCT	1994	19	2					129	139		10.1016/0920-1211(94)90023-X			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PN683	WOS:A1994PN68300005	7843168				2022-02-06	
J	CHRISTEY, GL; NELSON, DE; RIVARA, FP; SMITH, SM; CONDIE, C				CHRISTEY, GL; NELSON, DE; RIVARA, FP; SMITH, SM; CONDIE, C			HORSEBACK RIDING INJURIES AMONG CHILDREN AND YOUNG-ADULTS	JOURNAL OF FAMILY PRACTICE			English	Article						SPORTS; ATHLETIC INJURIES; HEAD INJURIES; ACCIDENT PREVENTION; HEAD PROTECTIVE DEVICES	EQUESTRIAN INJURIES; ACCIDENTS; SPORTS	Background. Horseback riding injuries are responsible for an estimated 2300 hospital admissions annually among persons younger than 25 years of age in the United States, but injury rates, patterns of injury, and risk factors for this population have not been well studied. Methods. Study participants were selected from a list provided by a national mail-order company that sells riding equipment. A total of 557 persons younger than 25 years of age who rode horses at least six times a year completed survey questionnaires. Results. Among the study participants, 34 (6.1%) had been hospitalized at least once because of a riding injury and 153 (27.5%) had been treated by a physician within the previous 2 years for such an injury. The overall injury rate was 0.6 per 1000 riding hours. Among those injured, sprains or strains (41.8%), lacerations or bruises (40.0%), and fractures or dislocations (33.3%) were the most common types of injury. A total of 27.5% of those injured sustained concussions or other head injuries. Riding 15 to 24 hours per month (odds ratio [OR]=2.04), being female (OR=1.81), and riding English style (OR=1.77) were the characteristics most strongly correlated with injury. Conclusions. Horseback riding injuries among participants in this study tended to be serious. Family physicians should inform their patients who ride horses about the risks associated with equestrian activities and should emphasize helmet use.	CTR DIS CONTROL & PREVENT, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, BEHAV SURVEILLANCE BRANCH, ATLANTA, GA 30341 USA; CHRISTCHURCH SCH MED, CHRISTCHURCH, NEW ZEALAND; CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, ATLANTA, GA USA; HARBORVIEW INJURY PREVENT CTR, SEATTLE, WA USA; UNIV WASHINGTON, SCH PUBL HLTH, SEATTLE, WA 98195 USA; UNIV CANBERRA, FAC MANAGEMENT, BELCONNEN, AUSTRALIA						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 002570] Funding Source: Medline		BARBER HM, 1973, BRIT MED J, V3, P532, DOI 10.1136/bmj.3.5879.532; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; Bernhang A M, 1983, Phys Sportsmed, V11, P90, DOI 10.1080/00913847.1983.11708437; BIXBYHAMMETT D, 1990, SPORTS MED, V9, P36, DOI 10.2165/00007256-199009010-00004; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BIXBYHAMMETT DM, 1985, PHYSICIAN SPORTSMED, V13, P105, DOI 10.1080/00913847.1985.11708882; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; DANIELSSON LG, 1973, ACTA ORTHOP SCAND, V44, P597, DOI 10.3109/17453677308989097; EASTWOOD FR, 1969, NEW ENGL J MED, V271, P411; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; INGEMARSON H, 1989, J TRAUMA, V29, P25, DOI 10.1097/00005373-198901000-00005; MAHALEY MS, 1976, 18TH P AMA C MED ASP, P37; McGhee C N, 1987, Br J Neurosurg, V1, P131, DOI 10.3109/02688698709034348; McLatchie G R, 1979, Br J Sports Med, V13, P29; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON DE, 1994, AM J PREV MED, V10, P15, DOI 10.1016/S0749-3797(18)30641-X; POUNDER DJ, 1984, MED J AUSTRALIA, V141, P632, DOI 10.5694/j.1326-5377.1984.tb113173.x; WILLIAMS LP, 1975, 103RD P ANN APHA M W; ZARICZNYJ B, 1980, AM J SPORT MED, V8, P318, DOI 10.1177/036354658000800504; 1990, MMWR-MORBID MORTAL W, V39, P329; 1988, ANN BOOK ASTM STANDA; 1990, 1990 91 HORSE IND DI; 1992, DHHS PHS921232 PUBL; 1992, MMWR-MORBID MORTAL W, V41, P335; 1984, P HOUSE DELEGATES, P360; 1992, PEDIATRICS, V89, P512	26	46	46	0	9	DOWDEN HEALTH MEDIA	MONTVALE	110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA	0094-3509			J FAM PRACTICE	J. Fam. Pract.	AUG	1994	39	2					148	152					5	Primary Health Care; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB544	WOS:A1994PB54400013	8057065				2022-02-06	
J	RIVADEPATY, I; FARDEAU, C; MARIANI, J; BOUCHAUD, C; DELHAYEBOUCHAUD, N				RIVADEPATY, I; FARDEAU, C; MARIANI, J; BOUCHAUD, C; DELHAYEBOUCHAUD, N			CONTRIBUTION OF PERIPHERAL MACROPHAGES AND MICROGLIA TO THE CELLULAR REACTION AFTER MECHANICAL OR NEUROTOXIN-INDUCED LESIONS OF THE RAT-BRAIN	EXPERIMENTAL NEUROLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; WALLERIAN DEGENERATION; INFLAMMATORY RESPONSE; CORPUS-CALLOSUM; OPTIC-NERVE; CELLS; 3-ACETYLPYRIDINE; EXPRESSION; INJECTION; AXOTOMY	Lesions of the central nervous system result in invasion of peripheral phagocytes and/or in situ activation and proliferation of microglia, depending on the direct or indirect nature of the injury. Neurotoxins which are widely used to induce neurodegeneration have been reported to elicit a pure microglial reaction when administered intraventricularly. However, the mechanical lesion at the injection site, although remote from the lesioned area, could give access to blood-derived cells. Therefore, this study compares the phagocytic reaction occurring after a traumatic lesion of the brain causing a breakdown of the blood-brain barrier (BBB), or after degeneration of the inferior olivary neurons induced by intraperitoneal administration of 3-acetylpyridine, a process that respects the integrity of the BBB as suggested by the results of intravascular injection of Evans blue. The identification of the macrophages at the lesion site used specific binding of the B-4 isolectin from Griffonia simplicifolia, preloading of the peripheral monocytes/macrophages with trypan blue, and characteristic morphological features. In traumatically lesioned rats, the lectin-labeled macrophages were mainly large rounded peripheral cells recruited 1-3 days postlesion, whereas in chemically lesioned rats, the cellular reaction appeared 24-36 h postinjection and peaked between 3 and 12 days before undergoing a slow decline. Lectin binding and morphological characteristics indicated that these small cells were reactive microglia. These results confirm that a brain injury leaving the BBB intact involves essentially the recruitment and/or the proliferation of microglia. (C) 1994 Academic Press, Inc.	UNIV PARIS 06,F-75005 PARIS,FRANCE		RIVADEPATY, I (corresponding author), INST NEUROSCI,DEV NEUROBIOL LAB,CNRS,URA 1488,F-75005 PARIS,FRANCE.			Mariani, Jean/0000-0002-2701-1581; Fardeau, Christine/0000-0003-1935-2711			AKIYAMA H, 1989, BRAIN RES, V489, P247, DOI 10.1016/0006-8993(89)90857-3; ALLIOT F, 1991, P NATL ACAD SCI USA, V88, P1541, DOI 10.1073/pnas.88.4.1541; ANDERSON WA, 1980, J COMP NEUROL, V190, P157, DOI 10.1002/cne.901900111; BALABAN CD, 1985, BRAIN RES REV, V9, P21, DOI 10.1016/0165-0173(85)90017-7; BARRON KD, 1990, BRAIN RES, V523, P219, DOI 10.1016/0006-8993(90)91490-8; BIGNAMI A, 1981, J NEUROPATH EXP NEUR, V40, P537, DOI 10.1097/00005072-198109000-00005; BOOTH PL, 1991, BRAIN RES, V548, P163, DOI 10.1016/0006-8993(91)91118-K; CHEVREMONT M, 1960, NOTIONS CYTOLOGIE HI, P589; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; COFFEY PJ, 1988, NEUROSCI LETT, V84, P178, DOI 10.1016/0304-3940(88)90404-1; CUPEDO RN, 1989, ACTA MORPHOL NEERLAN, V26, P19; DELHAYEBOUCHAUD N, 1988, CR ACAD SCI III-VIE, V307, P69; DENK H, 1968, ACTA NEUROPATHOL BER, V10, P349; DESCLIN JC, 1974, BRAIN RES, V77, P349, DOI 10.1016/0006-8993(74)90627-1; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; FULCRAND J, 1977, J COMP NEUROL, V176, P189, DOI 10.1002/cne.901760204; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; HARDEBO JE, 1980, EXP NEUROL, V70, P155, DOI 10.1016/0014-4886(80)90013-8; HAYES CE, 1974, J BIOL CHEM, V249, P1904; HORTEGA PD, 1932, CYTOLOGY CELLULAR PA, P483; IMAMOTO K, 1978, J COMP NEUROL, V180, P139, DOI 10.1002/cne.901800109; JORDAN FL, 1988, BRAIN RES REV, V13, P165, DOI 10.1016/0165-0173(88)90019-7; KERNS JM, 1973, J COMP NEUROL, V151, P237, DOI 10.1002/cne.901510303; LING EA, 1980, J COMP NEUROL, V193, P631, DOI 10.1002/cne.901930304; LING EA, 1987, J NEUROCYTOL, V16, P373, DOI 10.1007/BF01611348; LING EA, 1992, HISTOL HISTOPATHOL, V7, P93; LING EA, 1981, ADV CELL NEUROBIOL, V2, P33; MADDOX DE, 1982, P NATL ACAD SCI-BIOL, V79, P166, DOI 10.1073/pnas.79.1.166; MARTY S, 1991, NEUROSCIENCE, V45, P529, DOI 10.1016/0306-4522(91)90268-S; MATSUYAMA H, 1975, ACTA PATHOL JAPON, V25, P691; MILLIGAN CE, 1991, J COMP NEUROL, V314, P136, DOI 10.1002/cne.903140113; MURABE Y, 1981, CELL TISSUE RES, V218, P75; OEHMICHEN M, 1975, MONONUCLEAR PHAGOCYT, P223; Ogawa Matsuo, 1992, Neurodegeneration, V1, P37; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; SCHELPER RL, 1986, J NEUROPATH EXP NEUR, V45, P1, DOI 10.1097/00005072-198601000-00001; STAGAARD M, 1987, J NEUROCYTOL, V16, P131, DOI 10.1007/BF02456704; STOLL G, 1989, J NEUROSCI, V9, P2327; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; THOMAS WE, 1992, BRAIN RES REV, V17, P61; TORVIK A, 1975, BRAIN RES, V95, P519, DOI 10.1016/0006-8993(75)90125-0; Volkman A, 1970, Ser Haematol, V3, P62; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P215, DOI 10.1111/j.1365-2184.1972.tb00360.x; WISLOCKI GB, 1952, J COMP NEUROL, V96, P371, DOI 10.1002/cne.900960302	50	46	47	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	1994	128	1					77	87		10.1006/exnr.1994.1114			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PC985	WOS:A1994PC98500008	8070525				2022-02-06	
J	AHUJA, A; GLASAUER, FE; ALKER, GJ; KLEIN, DM				AHUJA, A; GLASAUER, FE; ALKER, GJ; KLEIN, DM			RADIOLOGY IN SURVIVORS OF TRAUMATIC ATLANTOOCCIPITAL DISLOCATION	SURGICAL NEUROLOGY			English	Article						ATLANTOOCCIPITAL DISLOCATION; DIAGNOSIS; RADIOLOGY; TRAUMATIC	ATLANTOOCCIPITAL DISLOCATION; INJURIES; JUNCTION; CHILDREN; ANATOMY	Traumatic atlanto-occipital dislocation is fatal, but survivals are reported. Six cases of survival after atlanto-occipital dislocation are presented. Lateral cervical spine radiographs demonstrated retropharyngeal swelling in all patients, and Powers' ratio was abnormal in five of six patients. Reformatted computed tomography (CT) images or three-dimensional CT were useful in confirming the diagnosis. Initial treatment consisted of immobilization with halo or collar, and, in one patient, Crutchfield tongs. Reduction of the dislocation was associated with decreasing Powers' ratio in five long-term survivors. Residual neurologic deficits, however, were seen in these patients. Atlanto-occipital dislocation should be suspected in trauma patients with findings of brain stem injury-especially agonal respirations, irregular heart rate, lower cranial nerve abnormality, and asymmetrical motor deficits.			AHUJA, A (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT NEUROSURG,3 GATES CIRCLE,BUFFALO,NY 14209, USA.						ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; BELZBERG AJ, 1991, J NEUROSURG, V75, P478, DOI 10.3171/jns.1991.75.3.0478; Blackwood NJ, 1908, ANN SURG, V47, P654, DOI 10.1097/00000658-190805000-00003; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; COLLALTO PM, 1986, J BONE JOINT SURG AM, V68A, P1106, DOI 10.2106/00004623-198668070-00024; DAVIS D, 1971, J NEUROSURG, V34, P603, DOI 10.3171/jns.1971.34.5.0603; DIBENEDETTO T, 1990, SPINE, V15, P595, DOI 10.1097/00007632-199006000-00031; DUBLIN AB, 1980, J NEUROSURG, V52, P541, DOI 10.3171/jns.1980.52.4.0541; DVORAK J, 1987, SPINE, V12, P183, DOI 10.1097/00007632-198703000-00016; EISMONT FJ, 1978, J BONE JOINT SURG AM, V60, P397, DOI 10.2106/00004623-197860030-00024; EVARTS CM, 1970, J BONE JOINT SURG AM, VA 52, P1653, DOI 10.2106/00004623-197052080-00017; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; GERLOCK AJ, 1983, NEUROSURGERY, V13, P316, DOI 10.1227/00006123-198309000-00019; GOLDBERG AL, 1991, J COMPUT ASSIST TOMO, V15, P174, DOI 10.1097/00004728-199101000-00034; JEVTICH V, 1989, SPINE, V14, P123, DOI 10.1097/00007632-198901000-00027; KAUFMAN RA, 1987, AM J NEURORADIOL, V8, P995; KAUFMAN RA, 1982, AM J NEURORADIOL, V3, P415; LEE C, 1991, J TRAUMA, V31, P401, DOI 10.1097/00005373-199103000-00017; LEE C, 1987, AM J NEURORADIOL, V8, P19; LEVINE AM, 1989, CLIN ORTHOP RELAT R, V239, P53; MONTANE I, 1991, SPINE, V16, P112, DOI 10.1097/00007632-199116020-00002; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PANG D, 1980, NEUROSURGERY, V7, P503, DOI 10.1227/00006123-198011000-00017; PAPADOPOULOS SM, 1991, NEUROSURGERY, V28, P574, DOI 10.1227/00006123-199104000-00015; POWERS B, 1979, NEUROSURGERY, V4, P12, DOI 10.1097/00006123-197901000-00004; PUTNAM WE, 1986, J AM OSTEOPATH ASSOC, V86, P798; RASOOL MN, 1987, S AFR MED J, V72, P295; ROCKSWOLD GL, 1979, MINN MED, V62, P151; SCHNEIDER R, 1961, J NEUROSURG, V18, P348, DOI 10.3171/jns.1961.18.3.0348; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; WATRIDGE CB, 1985, NEUROSURGERY, V17, P345, DOI 10.1227/00006123-198508000-00021; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WHITE AA, 1978, ORTHOP CLIN N AM, V9, P867; WHOLEY MH, 1958, RADIOLOGY, V71, P350, DOI 10.1148/71.3.350; WOODRING JH, 1981, AM J NEURORADIOL, V2, P251	36	46	49	0	1	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.	FEB	1994	41	2					112	118		10.1016/0090-3019(94)90107-4			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	NL663	WOS:A1994NL66300005	8115947				2022-02-06	
J	LYETH, BG; JIANG, JY; ROBINSON, SE; GUO, HZ; JENKINS, LW				LYETH, BG; JIANG, JY; ROBINSON, SE; GUO, HZ; JENKINS, LW			HYPOTHERMIA BLUNTS ACETYLCHOLINE INCREASE IN CSF OF TRAUMATICALLY BRAIN INJURED RATS	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						TRAUMATIC BRAIN INJURY; HYPOTHERMIA; ACETYLCHOLINE; CHOLINE; CSF; PLASMA	CHOLINE UPTAKE; SYNAPTOSOMES; ISCHEMIA; BEHAVIOR; ACIDS; MODEL	Activation of muscarinic acetylcholine (ACh) receptors contributes to the pathophysiological consequences of moderate experimental traumatic brain injury (TBI). Hypothermia (30-degrees-C) provides protection in experimental TBI. We measured ACh levels in CSF and plasma 5 min after moderate fluid percussion TBI under normothermic or hypothermic conditions, because ACh in the CSF has been correlated with the severity of behavioral deficits after TBI. Three groups were examined: TBI with hypothermic brain (30-degrees-C), TBI with normothermic brain (37-degrees-C), or sham TBI with normothermic brain (37-degrees-C). ACh concentrations in CSF were significantly higher in 37-degrees-C TBI rats, but not in 30-degrees-C TBI rats compared to shams. ACh concentratons in plasma did not differ between groups. These results suggest that a contributing factor to the neuroprotective effects of moderate hypothermia in TBI may be related to the reduction of excessive ACh levels in the central nervous system following injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298		LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024413, P01NS012587, P50NS012587, R01NS019550] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19550, NS 24413, NS 12587] Funding Source: Medline		BOKSA P, 1988, J NEUROCHEM, V50, P1309, DOI 10.1111/j.1471-4159.1988.tb10609.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ENTERS EK, 1992, BRAIN RES, V576, P271; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOPE RS, 1991, NEUROCHEM RES, V16, P1219, DOI 10.1007/BF00966699; KAKIHANA M, 1989, ARCH GERONTOL GERIAT, V8, P247, DOI 10.1016/0167-4943(89)90007-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P884; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MACEDO TM, 1983, NEUROPHARMACOLOGY, V22, P233, DOI 10.1016/0028-3908(83)90014-X; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; ROBINSON S E, 1991, Society for Neuroscience Abstracts, V17, P721; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1986, J NEUROCHEM, V46, P1632, DOI 10.1111/j.1471-4159.1986.tb01786.x; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SCREMIN OU, 1989, STROKE, V20, P1524, DOI 10.1161/01.STR.20.11.1524; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; YAMAMURA HI, 1973, J NEUROCHEM, V21, P1355, DOI 10.1111/j.1471-4159.1973.tb06022.x	34	46	49	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	APR	1993	18	3					247	256		10.1007/BF03160117			10	Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	KZ118	WOS:A1993KZ11800004	8507303				2022-02-06	
J	PRASAD, MR; TZIGARET, CM; SMITH, D; SOARES, H; MCINTOSH, TK				PRASAD, MR; TZIGARET, CM; SMITH, D; SOARES, H; MCINTOSH, TK			DECREASED ALPHA-1-ADRENERGIC RECEPTORS AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							INCREASED PROSTAGLANDIN SYNTHESIS; RAT-BRAIN; HEAD-INJURY; RECOVERY; RELEASE; NORADRENALINE; BINDING; CORTEX; NEUROTRANSMITTER; NOREPINEPHRINE	The magnitude of neuronal damage in central nervous system (CNS) injury may be related, in part, to alterations in the balance between excitatory and inhibitory neurotransmitters. Previous studies have implicated a role of central inhibitory noradrenergic mechanisms in the pathophysiologic sequelae of traumatic brain injury. In the present study, we examined alpha1-adrenergic receptor binding after parasaggital lateral fluid percussion (FP) brain injury of moderate severity (2.3 atm) in the rat. At 30 min following injury, the specific binding of [H-3]prazosin to membranes isolated from left cortex (injury site) was reduced by 37 % in brain-injured animals when compared to sham-operated noninjured animals (p < 0.05). However, there were no significant differences in [H-3]prazosin binding to membranes of either contralateral (right) cortex or left and right hippocampi between brain-injured and sham-operated animals. Conversely, at 24 h posttrauma, specific binding to membranes of left cortex, cortex adjacent to injury site, contralateral (right) cortex, and left hippocampus was reduced by 25 %, 16 %, 27 %, and 24 %, respectively (all p < 0. 05). Scatchard analysis revealed that a reduction of [H-3]prazosin binding to membranes of injured animals resulted from a decrease in alpha1-receptor binding density (B-max) but not from changes in ligand affinity. Histopathologic assessment of neuronal damage at 24 h postinjury revealed neuronal loss within injury site cortex and left hippocampus but no clearly discernible cell loss in contralateral right cortex, suggesting that the decrease in B-max might be a consequence of early pathophysiology of trauma rather than of neuronal cell loss. We suggest that alterations in alpha1-adrenergic receptors after brain injury may result in decreased inhibitory neurotransmitter action of norepinephrine and may thus contribute to the pathophysiology of traumatic brain injury.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV CONNECTICUT,CTR HLTH,DEPT SURG,SURG RES CTR,CNS INJURY LAB,FARMINGTON,CT 06032		PRASAD, MR (corresponding author), UNIV KENTUCKY,SCH MED,MED CTR,DEPT SURG,LEXINGTON,KY 40536, USA.		smith, douglas/A-1321-2007	Tigaret, Cezar/0000-0001-5848-6697	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26818] Funding Source: Medline		ARAKI T, 1989, ACTA NEUROL SCAND, V80, P451, DOI 10.1111/j.1600-0404.1989.tb03908.x; BATTAGLIA G, 1983, J NEUROCHEM, V41, P538, DOI 10.1111/j.1471-4159.1983.tb04772.x; BLENDY JA, 1990, J NEUROSCI, V10, P2580; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BUCHWEITZ E, 1982, J PHARMACOL EXP THER, V223, P322; Cooper P.R., 1985, CENTRAL NERVOUS SYST; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROWDER JM, 1987, EUR J PHARMACOL, V143, P343, DOI 10.1016/0014-2999(87)90458-4; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DISBREY DB, 1970, HISTOLOGICAL LABORAT, P230; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FELDSTEIN JB, 1986, AM J PHYSIOL, V251, pC230, DOI 10.1152/ajpcell.1986.251.2.C230; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOBAYASHI H, 1985, EXPERIENTIA, V41, P427, DOI 10.1007/BF01966140; KOBAYASHI H, 1985, CIRC RES, V56, P402, DOI 10.1161/01.RES.56.3.402; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5661; LOWRY OH, 1951, J BIOL CHEM, V261, P7710; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; NISHINO K, 1989, J CEREBR BLOOD F MET, V9, P358, DOI 10.1038/jcbfm.1989.54; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; Palkovits M., 1988, MAPS GUIDE MICRODISS; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TAFT W C, 1991, Society for Neuroscience Abstracts, V17, P164; VINK R, 1988, J BIOL CHEM, V263, P757; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WEISS HR, 1988, EUR J PHARMACOL, V148, P107, DOI 10.1016/0014-2999(88)90459-1	44	46	50	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FAL	1992	9	3					269	279		10.1089/neu.1992.9.269			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	JW451	WOS:A1992JW45100007	1335519				2022-02-06	
J	ANDERSON, PA; BOHLMAN, HH				ANDERSON, PA; BOHLMAN, HH			ANTERIOR DECOMPRESSION AND ARTHRODESIS OF THE CERVICAL-SPINE - LONG-TERM MOTOR IMPROVEMENT .2. IMPROVEMENT IN COMPLETE TRAUMATIC QUADRIPLEGIA	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							CORD INJURIES; COMPRESSION; FRACTURES; CLASSIFICATION; DISLOCATIONS	Fifty-one patients who had complete motor quadriplegia secondary to a fracture or dislocation of the cervical spine were managed by anterior cervical decompression and arthrodesis with iliac bone grafts between 1973 and 1983. In all patients, myelography demonstrated that displaced fragments of bone and disc were compressing the anterior aspect of the spinal cord. Decompression was performed in an attempt to gain further improvement of the motor-roots in the upper extremities and thereby to improve the ability of the patients to care for themselves. The average interval from the injury to the decompression was fifteen months (range, one month to eight years). Two patients died within two months after the operation, one had a respiratory arrest that resulted in brain damage one day after the operation, and two died from cardiovascular disease more than one year after the operation. The remaining forty-six patients were followed for an average of five years (range, two to thirteen years). Neurological improvement of at least two new functional motor-root levels was documented in seven patients and of one level, in eighteen. Increased motor strength by two or three grades was seen in six patients. Noteworthy motor improvement did not occur in the remaining twenty patients. The mean modified Barthel index (used to measure improvement in the ability to perform activities of daily living) increased from 17 to 33 (of a possible 100) points. Functionally important improvement of the caudad part of the cord occurred in only one patient. In one patient, neural injury, with loss of one motor-root level, occurred, with only partial improvement. At the latest follow-up examination, the result was poor in nine of eleven patients who had decompression eighteen months or more after the injury. Only two of these patients had any improvement in the Barthel index, and then of only 5 points each. The result also was poor in the five patients who were more than fifty-three years old; two had no improvement in the Barthel index, one improved by 5 points, and two died.	VET ADM MED CTR, ACUTE SPINAL CORD INJURY SERV, CLEVELAND, OH 44106 USA; HIGHLAND VIEW HOSP, CLEVELAND, OH USA; UNIV HOSP CLEVELAND, CTR RECONSTRUCT & TRAUMAT SPINE SURG, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT ORTHOPAED SURG, CLEVELAND, OH 44106 USA								ALLEN BL, 1982, SPINE, V7, P1, DOI 10.1097/00007632-198200710-00001; BAILEY RW, 1960, J BONE JOINT SURG AM, V42, P565, DOI 10.2106/00004623-196042040-00001; BOHLMAN HH, 1979, J BONE JOINT SURG AM, V61, P1119, DOI 10.2106/00004623-197961080-00001; BOHLMAN HH, 1982, EARLY MANAGEMENT ACU, P315; BOHLMAN HH, 1981, CLIN ORTHOP RELAT R, V154, P57; BOHLMAN HH, 1992, SPINE, V2, P973; BOSCH A, 1971, J AMER MED ASSOC, V216, P473; CHEN L, 1990, J NEUROSURG, V72, P600, DOI 10.3171/jns.1990.72.4.0600; CLOWARD RB, 1961, J NEUROSURG, V18, P201, DOI 10.3171/jns.1961.18.2.0201; COOPER PR, 1984, J NEUROSURG, V61, P281, DOI 10.3171/jns.1984.61.2.0281; DOLAN EJ, 1980, J NEUROSURG, V53, P749, DOI 10.3171/jns.1980.53.6.0749; Frankel H L, 1969, Paraplegia, V7, P179; Guttmann L., 1976, SPINAL CORD INJURIES; HANSEBOUT RR, 1982, EARLY MANAGEMENT ACU, P181; HOPPENFELD S, 1976, PHYSICAL EXAMINATION; HORSEY WJ, 1982, EARLY MANAGEMENT ACU, P305; JACOBS B, 1975, CLIN ORTHOP RELAT R, P18; JELSMA RK, 1982, SURG NEUROL, V18, P156, DOI 10.1016/0090-3019(82)90383-4; JELSMA RK, 1982, SURG NEUROL, V18, P79, DOI 10.1016/0090-3019(82)90357-3; LOEWEN SC, 1988, PHYS THER, V68, P1077, DOI 10.1093/ptj/68.7.1077; LUCAS JT, 1979, AM SURGEON, V45, P151; LUCAS JT, 1979, NEUROVASCULAR SURGER, V7, P281; MAHONEY F I, 1965, Md State Med J, V14, P61; MICHAELIS LS, 1976, HDB CLIN NEUROLOGY, V26, P307; Morgan T H, 1971, Paraplegia, V9, P14; PIERCE DS, 1972, AAOS INSTR COURSE LE, V21, P102; RAYNOR R B, 1977, Spine, V2, P39, DOI 10.1097/00007632-197703000-00004; RAYNOR RB, 1968, J NEUROSURG, V28, P311, DOI 10.3171/jns.1968.28.4.0311; RIVLIN AS, 1978, SURG NEUROL, V10, P39; ROSSIER AB, 1977, SURG NEUROL, V7, P55; Schneider R C, 1973, Clin Neurosurg, V20, P424; SCHNEIDER RC, 1955, J NEUROSURG, V12, P95, DOI 10.3171/jns.1955.12.2.0095; SCHNEIDER RC, 1956, J BONE JOINT SURG AM, V38, P985, DOI 10.2106/00004623-195638050-00003; STAUFFER ES, 1975, CLIN ORTHOP RELAT R, V112, P9; VERBIEST H, 1962, J NEUROSURG, V19, P389, DOI 10.3171/jns.1962.19.5.0389; Verbiest H, 1973, Clin Neurosurg, V20, P334	36	46	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JUN	1992	74A	5					683	692		10.2106/00004623-199274050-00007			10	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	JD677	WOS:A1992JD67700007	1624484				2022-02-06	
J	COELHO, CA; LILES, BZ; DUFFY, RJ				COELHO, CA; LILES, BZ; DUFFY, RJ			DISCOURSE ANALYSES WITH CLOSED HEAD INJURED ADULTS - EVIDENCE FOR DIFFERING PATTERNS OF DEFICITS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						COMMUNICATIVE DISORDERS; HEAD INJURIES; LINGUISTICS; SPEECH DISORDERS; VERBAL BEHAVIOR		To better characterize the verbal impairments of higher level closed head injured (CHI) adults, we used narrative stories to longitudinally sample their discourse abilities. Stories were analyzed at the levels of intersentential cohesion and story grammar. Two differing patterns of deficits that emerged are described. In the first, a CHI subject demonstrated excessive verbalization characterized by poorly organized, but task-appropriate, content. In the second, a CHI subject demonstrated fair to good organization but little appropriate content. Prognostically, the presence of appropriate, although disorganized, content was an early indication that the subject was able to appreciate potential relationships of characters in the stimulus picture. The second pattern represented a more severe cognitive dysfunction. This subject's attempts at stories, although well organized, were merely elaborate descriptions of the picture. Discourse analyses appear to be well suited for the assessment of CHI adults.	UNIV CONNECTICUT,DEPT COMMUN SCI,STORRS,CT 06268		COELHO, CA (corresponding author), GAYLORD HOSP,DEPT COMMUN DISORDERS,POB 400,WALLINGFORD,CT 06492, USA.						COELHO CA, 1990, J PSYCHOLINGUIST RES, V19, P405, DOI 10.1007/BF01068887; HAGEN C, 1980, REHABILITATION HEAD, P8; Hunt K., 1970, MONOGRAPHS SOC RES C, V35; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Stein N. L., 1979, NEW DIRECTIONS DISCO, P53	7	46	47	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1991	72	7					465	468					4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	FP702	WOS:A1991FP70200004	2059117				2022-02-06	
J	VAKIL, E; BLACHSTEIN, H; HOOFIEN, D				VAKIL, E; BLACHSTEIN, H; HOOFIEN, D			AUTOMATIC TEMPORAL-ORDER JUDGMENT - THE EFFECT OF INTENTIONALITY OF RETRIEVAL ON CLOSED-HEAD-INJURED PATIENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							INFORMATION; MEMORY	Closed-head-injured (CHI) and control groups were tested on a temporal order task under intentional and incidental retrieval conditions. Subjects were given five presentations of a list of nouns. In the incidental retrieval condition, subjects were told that they were to remember the words but that the order was not important. In the intentional retrieval condition, subjects were given the words in an order different from that in which they were originally presented and were asked to reorder the words to match the original order. For both conditions we compared the order in which words were recalled to the order in which they were originally presented. The results suggest that temporal order memory had more effortful characteristics in the intentional than in the incidental retrieval condition. The two groups did not differ significantly in the incidental retrieval condition. However, while the control group showed a significant improvement in the intentional retrieval condition, CHI groups performance did not significantly change. This study highlights two major points: (1) intentionality at the retrieval stage determines the effortfulness with which information is processed; (2) the more automatic the tasks, the better it is preserved following closed-head injury.	BAR ILAN UNIV,RAMAT GAN,ISRAEL		VAKIL, E (corresponding author), NATL INST REHAB BRAIN INJURED,RECANATI REHAB CTR,89 ITZHAK SADEH ST,IL-67228 TEL AVIV,ISRAEL.						HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; HUPPERT FA, 1976, CORTEX, V12, P3, DOI 10.1016/S0010-9452(76)80024-X; JANOWSKY JS, 1988, PSCYHOBIOLOGY, V17, P1; KOHL D, 1985, MEMORY DYSFUNCTION I, P460; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Meudell P, 1982, NORMALITY PATHOLOGY, P203; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; NAVEHBENJAMIN M, 1987, J EXP PSYCHOL LEARN, V13, P595, DOI 10.1037/0278-7393.13.4.595; PARKIN AJ, 1982, CORTEX, V18, P417, DOI 10.1016/S0010-9452(82)80040-3; TWEEDY JR, 1988, J CLIN EXP NEUROPSYC, V10, P664, DOI 10.1080/01688638808402803; TZENG OJL, 1979, J EXP PSYCHOL-HUM L, V5, P52, DOI 10.1037/0278-7393.5.1.52; VAKIL E, 1985, FEB INT NEUR SOC C S; VAKIL E, 1990, UNPUB TEMPORAL ORDER; WINOCUR G, 1978, NEUROPSYCHOLOGIA, V16, P671, DOI 10.1016/0028-3932(78)90002-7; ZACKS RT, 1984, MEM COGNITION, V12, P387, DOI 10.3758/BF03198299	16	46	46	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR	1991	13	2					291	298		10.1080/01688639108401044			8	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	FL580	WOS:A1991FL58000008	1864916				2022-02-06	
J	ERB, DE; POVLISHOCK, JT				ERB, DE; POVLISHOCK, JT			NEUROPLASTICITY FOLLOWING TRAUMATIC BRAIN INJURY - A STUDY OF GABAERGIC TERMINAL LOSS AND RECOVERY IN THE CAT DORSAL LATERAL VESTIBULAR NUCLEUS	EXPERIMENTAL BRAIN RESEARCH			English	Article						BRAIN TRAUMA; DEGENERATION; NEUROPLASTICITY; GABAERGIC SYNAPSES; CAT	FLUID-PERCUSSION INJURY; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; DENTATE GYRUS; SPINAL-CORD; ENTORHINAL LESIONS; RAT-BRAIN; REINNERVATION; DAMAGE; DECARBOXYLASE	Terminal loss and recovery were assessed in the cat dorsal lateral vestibular nucleus (dLVN) following diffuse axonal damage caused by experimental traumatic brain injury. Using sterile technique, anesthetized adult cats received a moderate fluid-percussion traumatic brain injury. After predetermined survival periods of 7-368 days, the animals were perfused and the dLVN prepared for the immunocytochemical visualization of GABAergic puncta/terminals at the light (LM) and electron (EM) microscopic levels. In controls, the Deiters' neuronal somata within the dLVN were encompassed by numerous GABA-immunoreactive puncta/terminals. Within 7 days of injury, axonal damage was seen scattered throughout the dLVN, and associated with this, some neuronal somata demonstrated a dramatic loss of perisomatic GABA-immunoreactive puncta, while other somata appeared unchanged. Ultrastructural examination demonstrated that the loss of immunoreactive puncta observed with LM was directly correlated with the presence of degenerating GABAergic terminals. Overall, these neuronal somata showed a reduction of perisomatic puncta/terminals to values approximately 25% of controls. Over a thirty day posttraumatic course, this pattern of scattered perisomatic puncta/terminal loss persisted, with some puncta/terminal return by 60 days postinjury. During the next six months, a recovery of the immunoreactive puncta/terminals was observed in relation to the deafferented somata, with perisomatic terminal numbers now reaching 75% of control values. Over the 7 to 12 month postinjury period, recovery continued, with virtually complete recovery observed in the later phases of this period. Importantly, throughout this recovery period, there was a consistent correlation between the light and electron microscopic findings. The observed diffuse pattern of terminal loss, followed a prolonged adaptive recovery process, suggests that traumatic injury with its attendant diffuse axonal injury and related diffuse deafferentation creates a unique environment for rather complete and adaptive synaptic recovery. As diffuse axonal injury is a common feature of human traumatic brain injury, we believe that these studies, performed in cat, help explain some of the initial morbidity as well as some of the partial recovery seen in head-injured man.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,BOX 709,MCV STN,RICHMOND,VA 23298						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-20193, NS-07288] Funding Source: Medline		ADAMS J, 1980, J CLIN PATHOL, V33, P2231; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BERNSTEIN JJ, 1973, BRAIN BEHAV EVOLUT, V8, P135, DOI 10.1159/000124351; BREGMAN BS, 1982, SCIENCE, V217, P553, DOI 10.1126/science.7089581; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FONNUM F, 1970, BRAIN RES, V20, P259, DOI 10.1016/0006-8993(70)90293-3; GAGE FH, 1983, BRAIN RES, V268, P27, DOI 10.1016/0006-8993(83)90387-6; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HOUSER CR, 1984, NEUROSCI LETT, V47, P213, DOI 10.1016/0304-3940(84)90516-0; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KATSUMARU H, 1986, J NEUROSCI, V6, P2864; LEVIN H, 1986, J NEUROSURG, V74, P132; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LYNCH G, 1972, BRAIN RES, V42, P311, DOI 10.1016/0006-8993(72)90533-1; Marmarou A, 1990, Adv Neurol, V52, P233; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; NYGREN LG, 1974, BRAIN RES, V78, P377, DOI 10.1016/0006-8993(74)90922-6; OTTERSEN OP, 1984, J COMP NEUROL, V229, P374, DOI 10.1002/cne.902290308; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PICKEL VM, 1973, BRAIN RES, V59, P169, DOI 10.1016/0006-8993(73)90258-8; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; POVLISHOCK JT, 1982, NEURAL TRAUMA SEMINA, P15; RAISMAN G, 1973, BRAIN RES, V50, P241, DOI 10.1016/0006-8993(73)90729-4; RAISMAN G, 1969, BRAIN RES, V14, P25, DOI 10.1016/0006-8993(69)90029-8; STEWARD O, 1976, BRAIN RES, V114, P181, DOI 10.1016/0006-8993(76)90665-X; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; STORMMATHISEN J, 1976, GABA NERVOUS SYSTEM, P149; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WALBERG F, 1961, EXP NEUROL, V3, P32, DOI 10.1016/0014-4886(61)90005-X; WALBERG F, 1990, EXP BRAIN RES, V79, P547; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	48	46	47	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0014-4819			EXP BRAIN RES	Exp. Brain Res.		1991	83	2					253	267					15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EV505	WOS:A1991EV50500002	2022238				2022-02-06	
J	JENSEN, OK; NIELSEN, FF				JENSEN, OK; NIELSEN, FF			THE INFLUENCE OF SEX AND PRE-TRAUMATIC HEADACHE ON THE INCIDENCE AND SEVERITY OF HEADACHE AFTER HEAD-INJURY	CEPHALALGIA			English	Article							CONCUSSION	Pre- and post-traumatic headache of 168 individuals aged 18-60 years was registered 9-12 months after a head trauma. Headache before the trauma was reported by 39.9%, women being in the majority. After the trauma 64.3% were suffering from headache. Post-traumatic headache was reported by 64 patients (38.1%), of whom 22 patients experienced an increase of already existing headache and 42 patients complained of new headache. Patients suffering from headache before the trauma were not more at risk of having post-traumatic headache than patients who did not suffer from headache before the trauma. Patients who experienced an increase of already-existing pre-traumatic headache used more analgesics than patients first suffering from headache after the trauma. Post-traumatic headache was reported by more women than men (p < 0.02), the corresponding relative risk being 1.6. Both the use of analgesics and the frequency of headache showed a significant increase for patients with post-traumatic headache when compared with a "control group" of 41 patients with unchanged headache and when compared with all patients with headache before the trauma. There was no significant difference in the location of pain between the groups analysed.	AARHUS UNIV, CTY HOSP, DEPT ORTHOPAED SURG, DK-8000 AARHUS, DENMARK; AARHUS UNIV, CTY HOSP, DEPT RHEUMATOL, DK-8000 AARHUS, DENMARK				Jensen, Ole Kudsk/R-8957-2019	Jensen, Ole Kudsk/0000-0001-8196-5661			Cartlidge N E, 1981, HEAD INJURY; Dalsgaard-Nielsen T, 1970, Headache, V10, P14, DOI 10.1111/j.1526-4610.1970.hed1001014.x; FRIEDMAN AP, 1969, LATE EFFECTS HEAD IN, P55; JENSEN OK, IN PRESS OPEN STUDY; JENSEN OK, IN PRESS RELATION PO; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Peatfield R, 1986, HEADACHE; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; WILKINSON M, 1980, UPSALA J MED SCI, P48	10	46	46	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	DEC	1990	10	6					285	293		10.1046/j.1468-2982.1990.1006285.x			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU540	WOS:A1990EU54000003	2289229				2022-02-06	
J	HIGH, WM; LEVIN, HS; GARY, HE				HIGH, WM; LEVIN, HS; GARY, HE			RECOVERY OF ORIENTATION FOLLOWING CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG D73,GALVESTON,TX 77550; DEL ORO INST REHABIL,DEPT NEUROPSYCHOL,HOUSTON,TX; CTR DIS CONTROL,ATLANTA,GA 30333						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P539, DOI 10.1136/jnnp.30.6.539; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1983, CORTEX, V19, P427, DOI 10.1016/S0010-9452(83)80025-2; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; NATELSON BH, 1979, ARCH NEUROL-CHICAGO, V36, P444, DOI 10.1001/archneur.1979.00500430074014; RIBOT T, 1885, DISEASES MEMORY; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1946, BRAIN, V69, P183; SANDERS HI, 1971, BRAIN, V94, P661, DOI 10.1093/brain/94.4.661; [No title captured]; [No title captured]	17	46	46	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1990	12	5					703	714		10.1080/01688639008401013			12	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	EE600	WOS:A1990EE60000007	2258432				2022-02-06	
J	GOLDSTEIN, FC; LEVIN, HS; BOAKE, C; LOHREY, JH				GOLDSTEIN, FC; LEVIN, HS; BOAKE, C; LOHREY, JH			FACILITATION OF MEMORY PERFORMANCE THROUGH INDUCED SEMANTIC PROCESSING IN SURVIVORS OF SEVERE CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT NEUROSURG,GALVESTON,TX 77550; DALLAS REHABIL INST,DEPT BEHAV MED,DALLAS,TX 75235; FT HAYS STATE UNIV,DEPT PSYCHOL,HAYS,KS 67601								BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bousfield WA, 1953, J GEN PSYCHOL, V49, P229, DOI 10.1080/00221309.1953.9710088; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Butters N., 1980, ALCOHOLIC KORSAKOFFS; CERMAK LS, 1974, BRAIN LANG, V1, P141, DOI 10.1016/0093-934X(74)90030-3; CERMAK LS, 1978, J EXP PSYCHOL-HUM L, V4, P165, DOI 10.1037/0278-7393.4.2.165; CERMAK LS, 1976, BRAIN LANG, V3, P375, DOI 10.1016/0093-934X(76)90033-X; CORKIN S, 1982, ALZHEIMERS DISEASE R, V19, P149; CRAIK FIM, 1975, J EXP PSYCHOL GEN, V104, P268, DOI 10.1037/0096-3445.104.3.268; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; CUSHMAN LA, 1988, J CLIN EXP NEUROPSYC, V10, P685, DOI 10.1080/01688638808402807; FREEDMAN M, 1986, BRAIN COGNITION, V5, P108, DOI 10.1016/0278-2626(86)90063-1; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HARRIS JE, 1980, MEM COGNITION, V8, P31, DOI 10.3758/BF03197549; HASHER L, 1984, AM PSYCHOL, V39, P1372, DOI 10.1037/0003-066X.39.12.1372; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; Lorge Irving, 1944, TEACHERS WORDBOOK 30; MCDOWALL J, 1981, NEUROPSYCHOLOGIA, V19, P43, DOI 10.1016/0028-3932(81)90042-7; MCDOWALL J, 1979, MEM COGNITION, V7, P232, DOI 10.3758/BF03197543; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; OCONNOR M, 1986, NEUROPSYCHOLOGICAL R, P260; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; RUBIN DC, 1981, NEUROPSYCHOLOGIA, V19, P137, DOI 10.1016/0028-3932(81)90053-1; SALMON DP, 1986, NEUROPSYCHOLOGICAL R, P280; *SAS I INC, 1985, SAS STAT GUID PERS C; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; SQUIRE LR, 1986, BEHAV NEUROSCI, V100, P866, DOI 10.1037/0735-7044.100.6.866; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1984, BEHAV BRAIN SCI, V7, P257, DOI 10.1017/S0140525X00044617; Tulving E., 1983, ELEMENTS EPISODIC ME; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler, 1997, WECHSLER ADULT INTEL; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; WILSON B, 1982, CORTEX, V18, P581, DOI 10.1016/S0010-9452(82)80055-5; [No title captured]; [No title captured]	50	46	46	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR	1990	12	2					286	300		10.1080/01688639008400975			15	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	DB328	WOS:A1990DB32800010	2341558				2022-02-06	
J	Donnelly, J; Czosnyka, M; Adams, H; Cardim, D; Kolias, AG; Zeiler, FA; Lavinio, A; Aries, M; Robba, C; Smielewski, P; Hutchinson, PJA; Menon, DK; Pickard, JD; Budohoski, KP				Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Cardim, Danilo; Kolias, Angelos G.; Zeiler, Frederick A.; Lavinio, Andrea; Aries, Marcel; Robba, Chiara; Smielewski, Peter; Hutchinson, Peter J. A.; Menon, David K.; Pickard, John D.; Budohoski, Karol P.			Twenty-Five Years of Intracranial Pressure Monitoring After Severe Traumatic Brain Injury: A Retrospective, Single-Center Analysis	NEUROSURGERY			English	Article						Traumatic brain injury; Intracranial pressure; Cerebral hemodynamics; Autoregulation; Outcome	CEREBRAL PERFUSION-PRESSURE; CEREBROVASCULAR REACTIVITY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; MANAGEMENT; AUTOREGULATION; BEDSIDE; CARE; THRESHOLDS; TRIAL	BACKGROUND Intracranial pressure (ICP) is a clinically important variable after severe traumatic brain injury (TBI) and has been monitored, along with clinical outcome, for over 25 yr in Addenbrooke's hospital, Cambridge, United Kingdom. This time period has also seen changes in management strategies with the implementation of protocolled specialist neurocritical care, expansion of neuromonitoring techniques, and adjustments of clinical treatment targets. OBJECTIVE To describe the changes in intracranial monitoring variables over the past 25 yr. METHODS Data from 1146 TBI patients requiring ICP monitoring were analyzed. Monitored variables included ICP, cerebral perfusion pressure (CPP), and the cerebral pressure reactivity index (PRx). Data were stratified into 5-yr epochs spanning the 25 yr from 1992 to 2017. RESULTS CPP increased sharply with specialist neurocritical care management (P<0.0001) (introduction of a specific TBI management algorithm) before stabilizing from 2000 onwards. ICP decreased significantly over the 25 yr of monitoring from an average of 19 to 12 mmHg (P<0.0001) but PRx remained unchanged. The mean number of ICP plateau waves and the number of patients developing refractory intracranial hypertension both decreased significantly. Mortality did not significantly change in the cohort (22%). CONCLUSION We demonstrate the evolving trends in neurophysiological monitoring over the past 25 yr from a single, academic neurocritical care unit. ICP and CPP were responsive to the introduction of an ICP/CPP protocol while PRx has remained unchanged.	[Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Cardim, Danilo; Kolias, Angelos G.; Aries, Marcel; Smielewski, Peter; Hutchinson, Peter J. A.; Pickard, John D.; Budohoski, Karol P.] Univ Cambridge, Brain Phys Lab, Div Neurosurg, Dept Clin Neurosci,Addenbrookes Hosp, Cambridge, England; [Donnelly, Joseph] Univ Auckland, Dept Anaesthesiol, Auckland, New Zealand; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Cardim, Danilo] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver Gen Hosp, Vancouver, BC, Canada; [Kolias, Angelos G.; Hutchinson, Peter J. A.; Menon, David K.; Budohoski, Karol P.] Univ Cambridge Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England; [Zeiler, Frederick A.; Lavinio, Andrea; Robba, Chiara; Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Aries, Marcel] Maastricht Univ, Med Ctr, Dept Intens Care, Univ Maastricht, Maastricht, Netherlands; [Robba, Chiara] Univ Genoa, IRCCS Oncol, Policlin San Martino, Dept Anaesthesia & Intens Care, Genoa, Italy; [Hutchinson, Peter J. A.; Pickard, John D.; Budohoski, Karol P.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge, England		Donnelly, J (corresponding author), Univ Auckland, Dept Anaesthesiol, Auckland City Hosp, Level 12 Auckland Support Bldg,2 Pk Rd, Auckland, New Zealand.	donnellyj87@gmail.com	Cardim, Danilo Augusto/B-8447-2012; Donnelly, Joseph/N-6803-2019; Robba, Chiara/AAS-7421-2020	Cardim, Danilo Augusto/0000-0002-9261-1321; Donnelly, Joseph/0000-0002-6502-8069; Kolias, Angelos/0000-0003-3992-0587; Hutchinson, Peter/0000-0002-2796-1835; Zeiler, Frederick/0000-0003-1737-0510	National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award; NIHR Research Professorship; Woolf Fisher Scholarship (New Zealand); European Union Framework Program 7 grant (CENTER-TBI) [602150]; National Institute of Health Research Medtech; In vitro diagnostics co-operatives in Cambridge; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1002277, G0001237, G0600986, G9439390, G0601025, G0502030] Funding Source: UKRI	These studies were supported by National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to Dr Menon, and an NIHR Research Professorship to Dr Hutchinson. Dr Donnelly is supported by a Woolf Fisher Scholarship (New Zealand). Dr Zeiler has received salary support for dedicated research time from the Cambridge Commonwealth Trust Scholarship, the University of Manitoba Clinician Investigator Program, and the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, during which this project was completed. Dr Hutchinson andDrMenon were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150). Dr Zeiler and Dr Cardim have received PhD funding from the Cambridge Commonwealth Trust. Dr Kolias, Dr Hutchinson, Dr Menon, and Dr Budohoski declare funding from the NIHR Global Health Research Group on Neurotrauma, which was commissioned by the NIHR using Official Development Assistance (ODA) funding (project 16/137/105). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, National Institute for Health Research or the Department of Health. The authors have the following potential conflicts of interest: Dr Czosnyka receives part of licensing fees for ICM+, owned and distributed by Cambridge Enterprise Ltd; paid lectures for Integra Lifescience Speakers' Bureau; and is partially supported by National Institute of Health Research Medtech and In vitro diagnostics co-operatives in Cambridge. Dr Smielewski receives part of the licensing fees for the software ICM (Cambridge Enterprise Ltd, Cambridge UK), used in this project for data collection and data preprocessing. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. Dr Menon has had consultancy, research collaboration, or trial data monitoring interactions with Solvay Ltd; GlaxoSmithKline Ltd; Brainscope Ltd; Ornim Medical; Shire Medical, and Neurovive Ltd; Calico Inc; Pfizer Ltd; Pressura Ltd; Glide Pharma Ltd; and NeuroPro Ltd.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Beck B, 2018, J NEUROTRAUM, V35, P1021, DOI 10.1089/neu.2017.5287; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Bratton S, 2007, J NEUROTRAUM, V24, P59, DOI DOI 10.1089/neu.2007.9987; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; BUXTON RL, 1970, LANCET, V2, P498; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Donnelly J, 2017, J CEREBR BLOOD F MET, V37, P694, DOI 10.1177/0271678X16639060; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donnelly J, 2015, NEUROCRIT CARE, V22, P20, DOI 10.1007/s12028-014-0042-4; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; GUILLAUME J, 1951, PRESSE MED, V59, P953; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Lawrence T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012197; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Lewis PM, 2015, PEDIATR CRIT CARE ME, V16, P739, DOI 10.1097/PCC.0000000000000471; Lundberg N, 1959, ACTA PSYCHIAT SCAND, V36, P1; McCullough AL, 2014, BRIT J ANAESTH, V113, P202, DOI 10.1093/bja/aeu204; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PRICE DJ, 2012, INTRACRANIAL PRESSUR, V14, P1; R Core Team, 2017, R LANG ENV STAT COMP; Rao V, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-78; Ripley B.D, 2002, MODERN APPL STAT S, DOI DOI 10.1007/978-0-387-21706-2; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Sekhon MS, 2015, NEUROCRIT CARE, V23, P210, DOI 10.1007/s12028-015-0141-x; Smirl JD, 2014, J APPL PHYSIOL, V116, P1614, DOI 10.1152/japplphysiol.01266.2013; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Thomas E, 2015, BRIT J ANAESTH, V115, P487, DOI 10.1093/bja/aev233; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Young AMH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148817; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965	53	45	45	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2019	85	1					E75	E82		10.1093/neuros/nyy468			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	IV6CO	WOS:000484356700018	30476233	Green Submitted			2022-02-06	
J	Harmon, KG; Clugston, JR; Dec, K; Hainline, B; Herring, SA; Kane, S; Kontos, AP; Leddy, JJ; McCrea, MA; Poddar, SK; Putukian, M; Wilson, JC; Roberts, WO				Harmon, Kimberly G.; Clugston, James R.; Dec, Katherine; Hainline, Brian; Herring, Stanley A.; Kane, Shawn; Kontos, Anthony P.; Leddy, John J.; McCrea, Michael A.; Poddar, Sourav K.; Putukian, Margot; Wilson, Julie C.; Roberts, William O.			American Medical Society for Sports Medicine Position Statement on Concussion in Sport	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; sport; athlete; youth	KING-DEVICK TEST; HIGH-SCHOOL FOOTBALL; CEREBRAL-BLOOD-FLOW; EXTREMITY MUSCULOSKELETAL INJURY; CHRONIC TRAUMATIC ENCEPHALOPATHY; METABOLIC BRAIN VULNERABILITY; VOLUNTARY EXERCISE; TEMPORAL WINDOW; SCREENING TOOL; NUTRITIONAL SUPPLEMENTS	Sport-related concussion (SRC) is a common injury in recreational and organized sport. Over the past 30 years, there has been significant progress in our scientific understanding of SRC, which in turn has driven the development of clinical guidelines for diagnosis, assessment, and management of SRC. In addition to a growing need for knowledgeable health care professionals to provide evidence-based care for athletes with SRC, media attention and legislation have created awareness and, in some cases, fear about many issues and unknowns surrounding SRC. The American Medical Society for Sports Medicine formed a writing group to review the existing literature on SRC, update its previous position statement, 1 and address current evidence and knowledge gaps regarding SRC. The absence of definitive outcomes-based data is challenging and requires relying on the best available evidence integrated with clinical experience and patient values. This statement reviews the definition, pathophysiology, and epidemiology of SRC, the diagnosis and management of both acute and persistent concussion symptoms, the short-and long-term risks of SRC and repetitive head impact exposure, SRC prevention strategies, and potential future directions for SRC research. The American Medical Society for Sports Medicine is committed to best clinical practices, evidence-based research, and educational initiatives that positively impact the health and safety of athletes.	[Harmon, Kimberly G.] Univ Washington, Dept Family Med, 3800 Montlake Blvd, Seattle, WA 98195 USA; [Harmon, Kimberly G.] Univ Washington, Dept Orthopaed & Sports Med, 3800 Montlake Blvd, Seattle, WA 98195 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth, Gainesville, FL USA; [Clugston, James R.] Univ Florida, Dept Family Med & Neurol, Gainesville, FL USA; [Dec, Katherine] Virginia Commonwealth Univ, Dept Phys Med & Rehabil & Orthopaed Surg, Richmond, VA USA; [Hainline, Brian] Natl Collegiate Athlet Assoc, Indianapolis, IN USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Kane, Shawn] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27514 USA; [Kontos, Anthony P.] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA; [Clugston, James R.; Leddy, John J.] SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, Buffalo, NY USA; [Dec, Katherine; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Poddar, Sourav K.] Univ Colorado, Dept Family Med & Orthoped, Denver, CO 80202 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Internal Medicine Sports Med, Rutgers Robert Wood Johnson Med Sch, Princeton, Princeton, NJ 08544 USA; [Wilson, Julie C.] Univ Colorado, Dept Orthoped, Aurora, CO USA; [Roberts, William O.] Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN USA		Harmon, KG (corresponding author), Univ Washington, Dept Family Med, 3800 Montlake Blvd, Seattle, WA 98195 USA.; Harmon, KG (corresponding author), Univ Washington, Dept Orthopaed & Sports Med, 3800 Montlake Blvd, Seattle, WA 98195 USA.	kharmon@uw.edu		Roberts, William O/0000-0003-4517-4330; Clugston, James/0000-0002-2103-1039			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Ashbaugh A, 2016, CURR SPORT MED REP, V15, P16, DOI 10.1249/JSR.0000000000000219; Asken BM, 2018, AM J SPORT MED, V46, P1465, DOI 10.1177/0363546518757984; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bernhardt D, 2010, PREPARTICIPATION PHY; Besnier F, 2017, ANN PHYS REHABIL MED, V60, P27, DOI 10.1016/j.rehab.2016.07.002; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Bretzin AC, 2018, AM J SPORT MED, V46, P2263, DOI 10.1177/0363546518778251; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, J NEUROTRAUM, V34, P2675, DOI 10.1089/neu.2016.4767; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Davis-Hayes C, 2018, NEUROL-CLIN PRACT, V8, P40, DOI 10.1212/CPJ.0000000000000424; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Dhawan PS, 2017, NEUROL-CLIN PRACT, V7, P464, DOI 10.1212/CPJ.0000000000000381; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Echemendia RJ, 2018, BRIT J SPORT MED, V52, P1149, DOI 10.1136/bjsports-2016-097090; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Eckner JT, 2011, PM&R, V3, P1092, DOI 10.1016/j.pmrj.2011.04.022; Eddy R, 2020, CLIN J SPORT MED, V30, P239, DOI 10.1097/JSM.0000000000000586; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Emery CA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097452; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Fuller GW, 2019, BRIT J SPORT MED, V53, P1526, DOI 10.1136/bjsports-2017-098560; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Garcia GGP, 2018, SPORTS MED, V48, P1739, DOI 10.1007/s40279-018-0880-x; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hecimoyich M, 2018, J SCI MED SPORT, V21, P1004, DOI 10.1016/j.jsams.2018.03.011; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Hoffman NL, 2020, CLIN J SPORT MED, V30, pS29, DOI 10.1097/JSM.0000000000000538; Houck Z, 2016, AM J SPORT MED, V44, P2269, DOI 10.1177/0363546516645070; Howell DR, 2020, CLIN J SPORT MED, V30, pS42, DOI 10.1097/JSM.0000000000000570; Hugentobler JA, 2015, INT J SPORTS PHYS TH, V10, P676; Iverson GL, 2018, J ALZHEIMERS DIS, V61, P17, DOI 10.3233/JAD-170654; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Krolikowski MP, 2017, AM J SPORT MED, V45, P468, DOI 10.1177/0363546516669701; Lawrence DW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196062; Leddy JJ, 2018, CLIN J SPORT MED; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2018, CURR SPORT MED REP, V17, P262, DOI 10.1249/JSR.0000000000000505; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lucas JA, 2018, BRIT J SPORT MED; Mainwaring L, 2018, INT J PSYCHOPHYSIOL, V132, P39, DOI 10.1016/j.ijpsycho.2018.01.007; Makdissi M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097470; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAvoy K, 2018, NEUROREHABILITATION, V42, P325, DOI 10.3233/NRE-172381; McCarty CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0459; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McLeod TCV, 2015, BRAIN INJURY, V29, P175, DOI 10.3109/02699052.2014.965206; Mead GE, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004366.pub6, 10.1002/14651858.CD004366.pub4]; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; National Collegiate Athletic Association (NCAA), 2016, INT CONS DIAGN MAN S; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Norheim N, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2018-000412; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; O'Neill JA, 2017, REHABIL PSYCHOL, V62, P300, DOI 10.1037/rep0000155; Oliver JM, 2018, SPORTS MED, V48, pS39, DOI 10.1007/s40279-017-0847-3; Oliver JM, 2016, MED SCI SPORT EXER, V48, P974, DOI 10.1249/MSS.0000000000000875; Patricios J, 2017, BRIT J SPORT MED, V51, P888, DOI 10.1136/bjsports-2016-097441; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2005, J ATHL TRAINING, V40, P139; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, pe000012, DOI DOI 10.1136/BMJSEM-2015-000012; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schmidt JD, 2017, J NEUROTRAUM, V34, P1571, DOI 10.1089/neu.2016.4668; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Seidman DH, 2015, J NEUROL SCI, V356, P97, DOI 10.1016/j.jns.2015.06.021; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stovitz SD, 2017, CURR SPORT MED REP, V16, P50, DOI 10.1249/JSR.0000000000000326; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Trojian TH, 2017, CURR SPORT MED REP, V16, P247, DOI 10.1249/JSR.0000000000000387; Tsushima WT, 2018, ARCH CLIN NEUROPSYCH; Tucker R, 2017, BRIT J SPORT MED, V51, P1147, DOI 10.1136/bjsports-2017-097883; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	128	45	45	2	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2019	29	2					87	100		10.1097/JSM.0000000000000720			14	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	IQ4QE	WOS:000480734500002	30730386	Bronze			2022-02-06	
J	Doran, SJ; Ritzel, RM; Glaser, EP; Henry, RJ; Faden, AI; Loane, DJ				Doran, Sarah J.; Ritzel, Rodney M.; Glaser, Ethan P.; Henry, Rebecca J.; Faden, Alan I.; Loane, David J.			Sex Differences in Acute Neuroinflammation after Experimental Traumatic Brain Injury Are Mediated by Infiltrating Myeloid Cells	JOURNAL OF NEUROTRAUMA			English	Article						macrophage; microglia; neuroinflammation; sex differences; traumatic brain injury	GENDER-DIFFERENCE; INFARCT VOLUME; HEAD-INJURY; RAT MODEL; MILD; NEURODEGENERATION; PREDICTORS; MICROGLIA; RECOVERY; MODERATE	The inflammatory response to moderate-severe controlled cortical impact (CCI) in adult male mice has been shown to exhibit greater glial activation compared with age-matched female mice. However, the relative contributions of resident microglia and infiltrating peripheral myeloid cells to this sexually dimorphic neuroinflammatory responses remains unclear. Here, 12-week-old male and female C57Bl/6 mice were subjected to sham or CCI, and brain samples were collected at 1, 3, or 7 days post-injury for flow cytometry analysis of cytokines, reactive oxygen species (ROS), and phagocytosis in resident microglia (CD45(int)CD11b+) versus infiltrating myeloid cells (CD45(hi)CD11b+). Motor (rotarod, cylinder test), affect (open field), and cognitive (Y-maze) function tests also were performed. We demonstrate that male microglia had increased phagocytic activity and higher ROS levels in the non-injured brain, whereas female microglia had increased production of tumor necrosis factor (TNF) alpha and interleukin (IL)-1 beta. Following CCI, males showed a significant influx of peripheral myeloid cells by 1 day post-injury followed by proliferation of resident microglia at 3 days. In contrast, myeloid infiltration and microglial activation responses in female CCI mice were significantly reduced. No sex differences were observed for TNF alpha, IL-1 beta, transforming growth factor beta, NOX2, ROS production, or phagocytic activity in resident microglia or infiltrating cells at any time. However, across these functions, infiltrating myeloid cells were significantly more reactive than resident microglia. Female CCI mice also had improved motor function at 1 day post-injury compared with male mice. Thus, we conclude that sexually dimorphic responses to moderate-severe CCI result from the rapid activation and infiltration of pro-inflammatory myeloid cells to brain in male, but not female, mice.	[Doran, Sarah J.; Ritzel, Rodney M.; Glaser, Ethan P.; Henry, Rebecca J.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Doran, Sarah J.; Ritzel, Rodney M.; Glaser, Ethan P.; Henry, Rebecca J.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA		Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@som.umaryland.edu	Loane, David/ABD-5177-2021	Loane, David/0000-0003-0393-3503; Henry, Rebecca/0000-0001-8548-1170; Faden, Alan I./0000-0003-0128-2348; Ritzel, Rodney/0000-0002-0160-2930	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313, F32NS105355, T32AI095190]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI095190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082308, F32NS105355, R01NS037313] Funding Source: NIH RePORTER	We would like to acknowledge Victoria Meadows, B.Sc., Nivedita Hegdekar, B.Sc., Nicholas Braganca, B.Sc., and Wesley Shoap, B.Sc., for their technical assistance. We thank Xiaoxuan Fan, Ph.D., and Karen Underwood, B.Sc., of the University of Maryland Greenebaum Comprehensive Cancer Center Flow Cytometry Facility for support with flow cytometry studies. This work was supported by National Institutes of Health grants R01NS082308 (D.J. Loane), R01NS037313 (A.I. Faden), F32NS105355 (R.M. Ritzel), and T32AI095190 (S.J. Doran).	Acaz-Fonseca E, 2015, GLIA, V63, P1966, DOI 10.1002/glia.22867; Albrecht JS, 2016, J TRAUMA ACUTE CARE, V81, P486, DOI 10.1097/TA.0000000000001118; Armstead WM, 2017, J NEUROTRAUM, V34, P1666, DOI 10.1089/neu.2016.4770; Bai RJ, 2017, NEUROCHEM RES, V42, P2892, DOI 10.1007/s11064-017-2310-0; Bai RJ, 2017, MED SCI MONITOR, V23, P1707, DOI 10.12659/MSM.901124; Banerjee A, 2013, TRANSL STROKE RES, V4, P554, DOI 10.1007/s12975-013-0268-z; Baum J, 2016, WORLD NEUROSURG, V90, P525, DOI 10.1016/j.wneu.2015.12.012; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Caplan HW, 2017, J NEUROSCI RES, V95, P509, DOI 10.1002/jnr.23854; Clevenger AC, 2018, J MOL NEUROSCI, V64, P410, DOI 10.1007/s12031-018-1038-x; Dale DC, 2008, BLOOD, V112, P935, DOI 10.1182/blood-2007-12-077917; Dotson AL, 2017, J NEUROSCI RES, V95, P437, DOI 10.1002/jnr.23784; Dotson AL, 2015, J NEUROIMMUNOL, V278, P289, DOI 10.1016/j.jneuroim.2014.11.020; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Jirapongsananuruk O, 2003, J ALLERGY CLIN IMMUN, V111, P374, DOI 10.1067/mai.2003.58; Khaksari M, 2018, TRANSL STROKE RES, V9, P393, DOI 10.1007/s12975-017-0588-5; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar KP, 2018, CELL TISSUE RES, V371, P551, DOI 10.1007/s00441-017-2753-2; Langlois J.A., 2004, TRAUMATIC BRAIN INJU, P1; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; McFadyen MP, 2003, GENES BRAIN BEHAV, V2, P214, DOI 10.1034/j.1601-183X.2003.00028.x; Meyer MR, 2011, ACTA PHYSIOL, V203, P259, DOI 10.1111/j.1748-1716.2010.02237.x; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Russell KL, 2011, J NEUROSCI METH, V199, P214, DOI 10.1016/j.jneumeth.2011.05.008; Schellinck HM, 2010, ADV STUD BEHAV, V41, P255, DOI 10.1016/S0065-3454(10)41007-4; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Spychala MS, 2017, J NEUROSCI RES, V95, P462, DOI 10.1002/jnr.23962; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Taylor AN, 2018, J NEUROTRAUM, V35, P630, DOI 10.1089/neu.2017.5238; Tosun C, 2013, BRAIN SCI, V3, P215, DOI 10.3390/brainsci3010215; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Wright DK, 2017, ANN CLIN TRANSL NEUR, V4, P640, DOI 10.1002/acn3.441; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052	61	45	46	2	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2019	36	7					1040	1053		10.1089/neu.2018.6019		NOV 2018	14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HR6CG	WOS:000450730100001	30259790	Green Published, Bronze			2022-02-06	
J	Johnson, JJ; Loeffert, AC; Stokes, J; Olympia, RP; Bramley, H; Hicks, SD				Johnson, Jeremiah J.; Loeffert, Andrea C.; Stokes, Jennifer; Olympia, Robert P.; Bramley, Harry; Hicks, Steven D.			Association of Salivary MicroRNA Changes With Prolonged Concussion Symptoms	JAMA PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; MILD; BIOMARKERS; CHILDREN; DIAGNOSIS; PROGNOSIS; KNOWLEDGE	IMPORTANCE Approximately one-third of children who experience a concussion develop prolonged concussion symptoms. To our knowledge, there are currently no objective or easily administered tests for predicting prolonged concussion symptoms. Several studies have identified alterations in epigenetic molecules known as microRNAs (miRNAs) following traumatic brain injury. No studies have examined whether miRNA expression can detect prolonged concussion symptoms. OBJECTIVE To evaluate the efficacy of salivary miRNAs for identifying children with concussion who are at risk for prolonged symptoms. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study at the Penn State Medical Center observed 52 patients aged 7 to 21 years presenting for evaluation of concussion within 14 days of initial head injury, with follow-up at 4 and 8 weeks, EXPOSURES All patients had a clinical diagnosis of concussion. MAIN OUTCOMES AND MEASURES Salivary miRNA expression was measured at the time of initial clinical presentation in all patients, Patients with a Sport Concussion Assessment Tool (SCAT3) symptom score of 5 or greater on self-report or parent report 4 weeks after injury were designated as having prolonged symptoms. RESULTS Of the 52 included participants, 22 (42%) were female, and the mean (SD) age was 14 (3) years. Participants were split into the prolonged symptom group (n = 30) and acute symptom group (n = 22). Concentrations of 15 salivary miRNAs spatially differentiated prolonged and acute symptom groups on partial least squares discriminant analysis and demonstrated functional relationships with neuronal regulatory pathways. Levels of 5 miRNAs (miR-320c-1. miR-133a-5p. miR-769-5p, let-7a-3p. and miR-1307-3p) accurately identified patients with prolonged symptoms on logistic regression (area under the curve, 0.856; 95% CI, 0.822-0.890). This accuracy exceeded accuracy of symptom burden on child (area under the curve, 0.649; 95% CI, 0.388-0.887) or parent (area under the curve, 0.562; 95% CI, 0.219-0.734) SCAT3 score. Levels of 3 miRNAs were associated with specific symptoms 4 weeks after injury; miR-320c-1 was associated with memory difficulty (R, 0.55; false detection rate, 0,02), miR-S29 was associated with headaches (R, 0.47; false detection rate, 0.04), and let-7b-5p was associated with fatigue (R, 0.45; false detection rate, 0.04). CONCLUSIONS AND RELEVANCE Salivary miRNA levels may identify the duration and character of concussion symptoms. This could reduce parental anxiety and improve care by providing a tool for concussion management. Further validation of this approach is needed.	[Johnson, Jeremiah J.; Loeffert, Andrea C.; Stokes, Jennifer; Olympia, Robert P.; Bramley, Harry; Hicks, Steven D.] Penn State Univ, Penn State Coll Med, Dept Pediat, Mail Code HS83,500 Univ Dr, Hershey, PA 17033 USA; [Olympia, Robert P.] Penn State Univ, Penn State Coll Med, Dept Emergency Med, Hershey, PA 17033 USA		Hicks, SD (corresponding author), Penn State Univ, Penn State Coll Med, Dept Pediat, Mail Code HS83,500 Univ Dr, Hershey, PA 17033 USA.	shicks1@pennstatehealth.psu.edu		Hicks, Steven/0000-0002-9579-6798	Children's Miracle Network [417-51HY-4BFB]; Quadrant Biosciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR002015, UL1TR002014] Funding Source: NIH RePORTER	This study was supported by grant 417-51HY-4BFB from the Children's Miracle Network to Dr Hicks and a research agreement with Drs Loeffert and Hicks from Quadrant Biosciences (formerly Motion Intelligence).	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, PEDIATR EMERG CARE, V29, P458, DOI 10.1097/PEC.0b013e31828a202d; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Bramley H, 2016, SPORTS MED ARTHROSC, V24, P123, DOI 10.1097/JSA.0000000000000111; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Chandran R, 2017, BRAIN INJURY, V31, P106, DOI 10.1080/02699052.2016.1213420; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Hicks SD, J NEUROTRAUMA; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; McCarthy MT, 2015, ANN NY ACAD SCI, V1345, P89, DOI 10.1111/nyas.12736; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11; Yang T, 2016, J NEUROCHEM, V137, P122, DOI 10.1111/jnc.13534; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zaits MN, 2014, MOL PSYCHIATR, V19, P848, DOI 10.1038/mp.2013.93; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	39	45	46	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JAN	2018	172	1					65	73		10.1001/jamapediatrics.2017.3884			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	FR5ZE	WOS:000419144300017	29159407	Green Published, Bronze			2022-02-06	
J	Yang, LD; Tucker, D; Dong, Y; Wu, CY; Lu, YJ; Li, Y; Zhang, J; Liu, TCY; Zhang, QG				Yang, Luodan; Tucker, Donovan; Dong, Yan; Wu, Chongyun; Lu, Yujiao; Li, Yong; Zhang, Juan; Liu, Timon Cheng-Yi; Zhang, Quanguang			Photobiomodulation therapy promotes neurogenesis by improving post-stroke local microenvironment and stimulating neuroprogenitor cells	EXPERIMENTAL NEUROLOGY			English	Article						Photobiomodulation; Ischemic stroke; Neurogenesis; Inflammation; Mitochondrial function	LEVEL LASER THERAPY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TERM NEUROLOGICAL DEFICITS; CYTOCHROME-C-OXIDASE; STEM-CELLS; MITOCHONDRIAL-FUNCTION; CORTICAL NEUROGENESIS; INFLAMMATORY RESPONSES; PHOTOTHROMBOTIC STROKE	Recent work has indicated that photobiomodulation (PBM) may beneficially alter the pathological status of several neurological disorders, although the mechanism currently remains unclear. The current study was designed to investigate the beneficial effect of PBM on behavioral deficits and neurogenesis in a photothrombotic (PT) model of ischemic stroke in rats. From day 1 to day 7 after the establishment of PT model, 2-minute daily PBM (CW, 808 nm, 350 mW/cm(2), total 294 J at scalp level) was applied on the infarct injury area (1.8 mm anterior to the bregma and 2.5 mm lateral from the midline). Rats received intraperitoneal injections of 5-bromodeoxyuridine (BrdU) twice daily (50 mg/kg) from day 2 to 8 post-stoke, and samples were collected at day 14. We demonstrated that PBM significantly attenuated behavioral deficits and infarct volume induced by PT stroke. Further investigation displayed that PBM remarkably enhanced neurogenesis and synaptogenesis, as evidenced by immunostaining of BrdU, Ki67, DCX, MAP2, spinophilin, and synaptophysin. Mechanistic studies suggested beneficial effects of PBM were accompanied by robust suppression of reactive gliosis and the production of pro-inflammatory cytokines. On the contrary, the release of anti-inflammatory cytokines, cytochrome c oxidase activity and ATP production in peri-infarct regions were elevated following PBM treatment. Intriguingly, PBM could effectively switch an M1 microglial phenotype to an anti-inflammatory M2 phenotype. Our novel findings indicated that PBM is capable of promoting neurogenesis after ischemic stroke. The underlying mechanisms may rely on: 1) promotion of proliferation and differentiation of internal neuroprogenitor cells in the peri-infarct zone; 2) improvement of the neuronal microenvironment by altering inflammatory status and promoting mitochondrial function. These findings provide strong support for the promising therapeutic effect of PBM on neuronal repair following ischemic stroke.	[Yang, Luodan; Wu, Chongyun; Liu, Timon Cheng-Yi; Zhang, Quanguang] South China Normal Univ, Coll Phys Educ & Sports Sci, Lab Laser Sports Med, Guangzhou, Guangdong, Peoples R China; [Yang, Luodan; Tucker, Donovan; Dong, Yan; Lu, Yujiao; Li, Yong; Zhang, Juan; Zhang, Quanguang] Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, 1120 15th St, Augusta, GA 30912 USA		Zhang, QG (corresponding author), Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, 1120 15th St, Augusta, GA 30912 USA.	qzhang@augusta.edu			National Institute of Neurological Disorders and Stroke, National Institutes of Health, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS086929]; American Heart AssociationAmerican Heart Association [15GRNT25240004]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61575065, 11604104]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086929] Funding Source: NIH RePORTER	This study was supported by Research Grant NS086929 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, USA; an American Heart Association Grant-in-Aid 15GRNT25240004, and National Natural Science Foundation of China: 61575065 & 11604104.	Ahmed ME, 2016, NEUROSCIENCE, V336, P39, DOI 10.1016/j.neuroscience.2016.08.036; Alcantara CC, 2013, LASER SURG MED, V45, P246, DOI 10.1002/lsm.22129; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Andrabi SS, 2017, DIS MODEL MECH, V10, P787, DOI 10.1242/dmm.025692; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barakat R, 2016, MED PRIN PRACT, V25, P3, DOI 10.1159/000435858; Bernstein BW, 2003, J NEUROSCI, V23, P1; Bolanos JP, 2006, ANTIOXID REDOX SIGN, V8, P955, DOI 10.1089/ars.2006.8.955; Braeuninger Stefan, 2009, Exp Transl Stroke Med, V1, P8, DOI 10.1186/2040-7378-1-8; Chen YM, 2013, NEUROSCI LETT, V553, P99, DOI 10.1016/j.neulet.2013.07.049; Choi JY, 2017, EXP NEUROBIOL, V26, P33, DOI 10.5607/en.2017.26.1.33; Couch Y., 2017, STROKE; da Silva CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142816; Demidova-Rice TN, 2007, LASER SURG MED, V39, P706, DOI 10.1002/lsm.20549; Demyanenko SV, 2015, BIOCHEMISTRY-MOSCOW+, V80, P790, DOI 10.1134/S0006297915060152; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Eissa M., 2017, LASERS MED SCI; Esenwa CC, 2016, NAT REV NEUROL, V12, P594, DOI 10.1038/nrneurol.2016.125; Ferraresi C, 2015, PHOTOCHEM PHOTOBIOL, V91, P411, DOI 10.1111/php.12397; Fike JR, 2009, SEMIN RADIAT ONCOL, V19, P122, DOI 10.1016/j.semradonc.2008.12.003; Fukuoka CY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169443; Giannakopoulou A, 2017, J NEUROSCI RES, V95, P1446, DOI 10.1002/jnr.23982; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang YY, 2013, J BIOPHOTONICS, V6, P829, DOI 10.1002/jbio.201200157; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kawamura R, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0334-z; Kim JY, 2014, CURR MED CHEM, V21, P2076, DOI 10.2174/0929867321666131228205146; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Landes T, 2011, BBA-MOL CELL RES, V1813, P540, DOI 10.1016/j.bbamcr.2011.01.021; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2016, BRAIN RES, V1646, P125, DOI 10.1016/j.brainres.2016.04.039; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Li M, 2016, STROKE, V47, P187, DOI 10.1161/STROKEAHA.115.009687; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu YJ, 2017, J ALZHEIMERS DIS, V56, P1469, DOI 10.3233/JAD-160869; Lu YJ, 2017, NEUROBIOL AGING, V49, P165, DOI 10.1016/j.neurobiolaging.2016.10.003; Mantineo M, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.9.098002; Medeiros DM, 2002, J BIOENERG BIOMEMBR, V34, P389, DOI 10.1023/A:1021206220851; Miao YP, 2016, BRAIN RES BULL, V121, P9, DOI 10.1016/j.brainresbull.2015.11.019; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Narne P, 2017, MOL CELL NEUROSCI, V82, P176, DOI 10.1016/j.mcn.2017.05.008; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Ozturk S, 2014, WORLD NEUROSURG, V81, pE35, DOI 10.1016/j.wneu.2012.10.074; Parent JM, 1997, J NEUROSCI, V17, P3727; PASTORE D, 1994, BIOCHEM MOL BIOL INT, V34, P817; Pevsner PH, 2001, J PHARMACOL TOXICOL, V45, P227, DOI 10.1016/S1056-8719(01)00153-8; Plane JM, 2004, NEUROBIOL DIS, V16, P585, DOI 10.1016/j.nbd.2004.04.003; Salehpour F, 2017, NEUROBIOL AGING, V58, P140, DOI 10.1016/j.neurobiolaging.2017.06.025; Schmidt Antje, 2012, Exp Transl Stroke Med, V4, P13, DOI 10.1186/2040-7378-4-13; Schroeter M, 2002, J NEUROSCI METH, V117, P43, DOI 10.1016/S0165-0270(02)00072-9; Shanina EV, 2005, BEHAV BRAIN RES, V158, P69, DOI 10.1016/j.bbr.2004.08.007; Sharp WW, 2014, FASEB J, V28, P316, DOI 10.1096/fj.12-226225; Shimazaki Takuya, 2008, Tanpakushitsu Kakusan Koso, V53, P311; Sieber MW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026288; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Thunshelle C, 2016, PHOTOMED LASER SURG, V34, P587, DOI 10.1089/pho.2015.4051; Trensz F, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395-016-0109-3; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Voloboueva LA, 2011, J NEUROSCI RES, V89, P1989, DOI 10.1002/jnr.22768; Wang LL, 2017, INT J DEV NEUROSCI, V57, P77, DOI 10.1016/j.ijdevneu.2017.01.002; Wang Q, 2015, INT J DEV NEUROSCI, V43, P50, DOI 10.1016/j.ijdevneu.2015.04.009; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Winklewski PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0213-4; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2016, J BIOPHOTONICS, V9, P1263, DOI 10.1002/jbio.201500336; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yan T, 2015, NEUROSCI BULL, V31, P717, DOI 10.1007/s12264-015-1567-z; Yang XD, 2017, BRAIN BEHAV IMMUN, V64, P162, DOI 10.1016/j.bbi.2017.03.003; Yu B, 2014, INT J MOL SCI, V15, P4142, DOI 10.3390/ijms15034142; Yuan JC, 2017, ONCOTARGET, V8, P19855, DOI 10.18632/oncotarget.15774; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhao N., 2016, MOL NEUROBIOL; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547; Zuo W, 2016, BRIT J PHARMACOL, V173, P1665, DOI 10.1111/bph.13468	86	45	45	3	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.		2018	299		A				86	96		10.1016/j.expneurol.2017.10.013			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FR7PD	WOS:000419261500008	29056360	Bronze, Green Published, Green Accepted			2022-02-06	
J	Hyman, SA; Shotwell, MS; Michaels, DR; Han, X; Card, EB; Morse, JL; Weinger, MB				Hyman, Steve Alan; Shotwell, Matthew S.; Michaels, Damon R.; Han, Xue; Card, Elizabeth Borg; Morse, Jennifer L.; Weinger, Matthew B.			A Survey Evaluating Burnout, Health Status, Depression, Reported Alcohol and Substance Use, and Social Support of Anesthesiologists	ANESTHESIA AND ANALGESIA			English	Article							MIDDLE-CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; ACUTE SUBDURAL HEMATOMAS; ACUTE ISCHEMIC-STROKE; SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; MALIGNANT INFARCTION; TERRITORY INFARCTION	BACKGROUND: Burnout affects all medical specialists, and concern about it has become common in today's health care environment. The gold standard of burnout measurement in health care professionals is the Maslach Burnout Inventory-Human Services Survey (MBI-HSS), which measures emotional exhaustion, depersonalization (DP), and personal accomplishment. Besides affecting work quality, burnout is thought to affect health problems, mental health issues, and substance use negatively, although confirmatory data are lacking. This study evaluates some of these effects. METHODS: In 2011, the American Society of Anesthesiologists and the journal Anesthesiology cosponsored a webinar on burnout. As part of the webinar experience, we included access to a survey using MBI-HSS, 12-item Short Form Health Survey (SF-12), Social Support and Personal Coping (SSPC-14) survey, and substance use questions. Results were summarized using sample statistics, including mean, standard deviation, count, proportion, and 95% confidence intervals. Adjusted linear regression methods examined associations between burnout and substance use, SF-12, SSPC-14, and respondent demographics. RESULTS: Two hundred twenty-one respondents began the survey, and 170 (76.9%) completed all questions. There were 266 registrants total (31 registrants for the live webinar and 235 for the archive event), yielding an 83% response rate. Among respondents providing job titles, 206 (98.6%) were physicians and 2 (0.96%) were registered nurses. The frequency of high-risk responses ranged from 26% to 59% across the 3 MBI-HSS categories, but only about 15% had unfavorable scores in all 3. Mean mental composite score of the SF-12 was 1 standard deviation below normative values and was significantly associated with all MBI-HSS components. With SSPC-14, respondents scored better in work satisfaction and professional support than in personal support and workload. Males scored worse on DP and personal accomplishment and, relative to attending physicians, residents scored worse on DP. There was no significant association between MBI-HSS and substance use. CONCLUSIONS: Many anesthesiologists exhibit some high-risk burnout characteristics, and these are associated with lower mental health scores. Personal and professional support were associated with less emotional exhaustion, but overall burnout scores were associated with work satisfaction and professional support. Respondents were generally economically satisfied but also felt less in control at work and that their job kept them from friends and family. The association between burnout and substance use may not be as strong as previously believed. Additional work, perhaps with other survey instruments, is needed to confirm our results.	[Hyman, Steve Alan; Michaels, Damon R.; Weinger, Matthew B.] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37212 USA; [Shotwell, Matthew S.; Morse, Jennifer L.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Han, Xue] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA; [Card, Elizabeth Borg] Vanderbilt Univ, Med Ctr, Dept Nursing Res, Vanderbilt Nursing, Nashville, TN USA; [Weinger, Matthew B.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA; [Weinger, Matthew B.] Vanderbilt Univ, Sch Med, Dept Med Educ, Nashville, TN 37212 USA; [Weinger, Matthew B.] VA Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA		Hyman, SA (corresponding author), Vanderbilt Univ, Dept Anesthesiol, Med Ctr, 1301 Med Ctr Dr, Nashville, TN 37205 USA.	steve.hyman@vanderbilt.edu			Vanderbilt Institute for Clinical and Translational Research (VICTR) [VR8248]	Vanderbilt Institute for Clinical and Translational Research (VICTR, #VR8248).	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Ahmed AI, 2010, NEUROCRIT CARE, V13, P393, DOI 10.1007/s12028-010-9420-8; Alotaibi NM, 2017, J NEUROSURG; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Poca MA, 2010, J NEUROSURG, V112, P648, DOI 10.3171/2009.7.JNS081677; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V365, P376; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cossu G, 2016, MINERVA ANESTESIOL, V82, P684; Cruz-Flores S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003435.pub2; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; Fung C, 2012, STROKE, V43, P3207, DOI 10.1161/STROKEAHA.112.666537; Grindlinger GA, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3251-9; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; Heiss WD, 2016, CEREBROVASC DIS, V41, P1, DOI 10.1159/000441627; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2017, J CRIT CARE, V39, P185, DOI 10.1016/j.jcrc.2017.03.006; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2016, J NEUROSURG, V125, P775, DOI 10.3171/2016.3.JNS1683; Honeybul S, 2013, J NEUROSURG, V119, P1566, DOI 10.3171/2013.8.JNS13857; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P2403, DOI 10.1056/NEJMc1613479; Huttner HB, 2009, LANCET NEUROL, V8, P949, DOI 10.1016/S1474-4422(09)70224-8; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kirkman MA, 2014, BRIT J ANAESTH, V112, P35, DOI 10.1093/bja/aet418; Kirkman Matthew A, 2016, Anesthesiol Clin, V34, P511, DOI 10.1016/j.anclin.2016.04.005; Kirkman MA, 2014, INTENS CARE MED, V40, P640, DOI 10.1007/s00134-014-3266-z; Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Kolias AG, 2012, ACTA NEUROCHIR, V154, P1563, DOI 10.1007/s00701-012-1349-6; Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7; Larach DR, 2009, NEUROCRIT CARE, V11, P106, DOI 10.1007/s12028-008-9180-x; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; Lu XC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07070; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Makarenko S, 2016, J CLIN NEUROSCI, V26, P8, DOI 10.1016/j.jocn.2015.05.065; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Muehlschlegel S, 2015, NEUROCRIT CARE, V23, P127, DOI 10.1007/s12028-014-0097-2; Neugebauer H, 2014, NEUROCRIT CARE, V21, P27, DOI 10.1007/s12028-014-9956-0; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Perez-Bovet J, 2012, ACTA NEUROCHIR, V154, P1717, DOI 10.1007/s00701-012-1323-3; Pizzi MA, 2016, J STROKE CEREBROVASC, V25, P2312, DOI 10.1016/j.jstrokecerebrovasdis.2016.05.025; QIZILBASH N, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000064; Qureshi AI, 2003, CRIT CARE MED, V31, P272, DOI 10.1097/00003246-200301000-00043; Rahme R, 2012, J NEUROSURG, V117, P749, DOI 10.3171/2012.6.JNS111140; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Ropper AH, 2012, NEW ENGL J MED, V367, P746, DOI 10.1056/NEJMct1206321; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sahuquillo J, 2013, CURR OPIN CRIT CARE, V19, P101, DOI 10.1097/MCC.0b013e32835eba1a; Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364; Schuss P, 2013, J NEUROL, V260, P2149, DOI 10.1007/s00415-013-6950-y; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Tahir Rizwan A, 2016, Surg Neurol Int, V7, pS381, DOI 10.4103/2152-7806.183492; Timmons SD, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Torbey MT, 2015, NEUROCRIT CARE, V22, P146, DOI 10.1007/s12028-014-0085-6; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vinciguerra L, 2017, NEUROCRIT CARE, V27, P122, DOI 10.1007/s12028-016-0361-8; Weil AG, 2011, CAN J NEUROL SCI, V38, P434, DOI 10.1017/S0317167100011835; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wilson MH, 2016, J CEREBR BLOOD F MET, V36, P1338, DOI 10.1177/0271678X16648711; Yang MH, 2015, SURG-J R COLL SURG E, V13, P230, DOI 10.1016/j.surge.2014.12.002; Yuan Q, 2015, J NEUROSURG, V122, P574, DOI 10.3171/2014.10.JNS1460	85	45	46	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2017	125	6					2009	2018		10.1213/ANE.0000000000002298			10	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	FQ8BK	WOS:000418587700027	28991114	Bronze			2022-02-06	
J	Campbell, JC; Anderson, JC; McFadgion, A; Gill, J; Zink, E; Patch, M; Callwood, G; Campbell, D				Campbell, Jacquelyn C.; Anderson, Jocelyn C.; McFadgion, Akosoa; Gill, Jessica; Zink, Elizabeth; Patch, Michelle; Callwood, Gloria; Campbell, Doris			The Effects of Intimate Partner Violence and Probable Traumatic Brain Injury on Central Nervous System Symptoms	JOURNAL OF WOMENS HEALTH			English	Article						intimate partner violence; traumatic brain injury; central nervous system symptoms	AFRICAN-AMERICAN; OUTCOMES; WOMEN; FREQUENCY; SEVERITY; RISK	Introduction: Abused women often report a wide range of physical and psychological symptoms that present challenges to providers. Specifically, injuries to the head or strangulation, may initiate neurological changes that contribute to central nervous system (CNS) symptoms. These symptoms are often attributed to mental health diagnoses in this population. The purpose of this analysis is to examine the prevalence of and associations between reported probable traumatic brain injury (TBI) and CNS symptoms in a sample of women of African descent. Methods: A convenience sample of 901 women of African descent from Baltimore, MD and the US Virgin Islands, aged 18-55, was used to examine relationships among self-reported intimate partner violence (IPV), TBI, and CNS symptoms. Data were collected via Audio Computer-Assisted Self-Interview. Results: Abused women who experienced a probable TBI were more likely to report CNS symptoms than those who did not. When controlling for demographics, IPV, and mental health symptoms, probable TBI was associated with a two point increase in CNS symptom frequency score (95% confidence interval: 1.55-2.93, p<0.001). Conclusions: Women who reported both probable TBI and IPV were more likely than their abused counterparts who reported no TBI to report CNS symptoms. This relationship held true even when controlling for symptoms of depression and post-traumatic stress disorder (PTSD). Clinicians working with women should be aware of TBI as a possible etiology for symptoms in abused women. Appropriate screening and treatment protocols should be designed and implemented across medical settings to improve outcomes for women who have experienced IPV and TBI.	[Campbell, Jacquelyn C.; Anderson, Jocelyn C.; Zink, Elizabeth; Patch, Michelle] Johns Hopkins Univ, Sch Nursing, Community & Publ Hlth Nursing, Baltimore, MD 21205 USA; [Anderson, Jocelyn C.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [McFadgion, Akosoa] Howard Univ, Off Interpersonal Violence Prevent, Washington, DC 20059 USA; [Gill, Jessica] NINR, Bethesda, MD 20892 USA; [Callwood, Gloria; Campbell, Doris] Univ Virgin Isl, Caribbean Exploratory Res Ctr, St Thomas, VI USA		Campbell, JC (corresponding author), Johns Hopkins Univ, Sch Nursing, Dept Community & Publ Hlth Nursing, 525 North Wolfe St, Baltimore, MD 21205 USA.	jcampbe1@jhu.edu	Gill, Gill M/Q-2020-2017	Patch, Michelle/0000-0003-3639-6003	National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD002286]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH100995]; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD087162]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD087162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH100995] Funding Source: NIH RePORTER	This work was supported by the National Institute on Minority Health and Health Disparities (P20MD002286). Dr. J.C.A received support from the National Institute of Mental Health (F31MH100995) and the National Institute of Child Health and Development (T32HD087162). The opinions, findings, conclusion, and recommendations expressed are those of the authors and do not necessarily reflect the view of the NIH.	Anderson CA, 2010, NEUROREHABILITATION, V26, P47, DOI 10.3233/NRE-2010-0535; Anderson JC, 2015, J EMERG NURS, V41, P36, DOI 10.1016/j.jen.2014.01.015; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Black M C., 2011, NATL INTIMATE PARTNE; Breiding MJ, 2008, AM J PREV MED, V34, P112, DOI 10.1016/j.amepre.2007.10.001; Canady RB, 2009, J NURS MEAS, V17, P91, DOI 10.1891/1061-3749.17.2.91; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; Faugno D, 2013, ADV EMERG NURS J, V35, P314, DOI 10.1097/TME.0b013e3182aa05d3; Faul M, 2010, TRAUMATIC BRAIN INJU; Freedy JR, 2010, FAM PRACT, V27, P615, DOI 10.1093/fampra/cmq049; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; IBM SPSS Statistics for Windows, 2013, IBM SPSS STAT WIND C; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lui G, 2015, ACTA RADIOL, V56, P1256; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; MARSHALL LL, 1992, J FAM VIOLENCE, V7, P103, DOI 10.1007/BF00978700; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller C. D., 1993, RELIABILITY VALIDITY; Minen MT, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0697-7; New York State Office for the Prevention of Domestic Violence, DOM AB TRAUM BRAIN I; Picard M, 1991, HELPS BRAIN INJURY S; Pritchard AJ, 2017, TRAUMA VIOLENCE ABUS, V18, P407, DOI 10.1177/1524838015622439; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sabri B, 2013, J INTERPERS VIOLENCE, V28, P3223, DOI 10.1177/0886260513496902; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shah MK, 2007, J NEUROL SCI, V260, P95, DOI 10.1016/j.jns.2007.04.012; Smith DJ, 2001, J EMERG MED, V21, P323, DOI 10.1016/S0736-4679(01)00402-4; Smith P H, 1995, Womens Health, V1, P273; St Ivany A, 2016, FAM COMMUNITY HEALTH, V39, P129, DOI 10.1097/FCH.0000000000000094; Stockman JK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.24772; Strack GB, 2001, J EMERG MED, V21, P303, DOI 10.1016/S0736-4679(01)00399-7; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Valera E, 2016, BRAIN IMAGING BEHAV, DOI 10.1007/s11682-016-9643-1; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Wilbur L, 2001, J EMERG MED, V21, P297, DOI 10.1016/S0736-4679(01)00398-5; World Health Organization, 2012, UNDERSTANDING ADDRES	42	45	45	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	JUN	2018	27	6					761	767		10.1089/jwh.2016.6311		OCT 2017	7	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	GJ4CY	WOS:000414469900001	29083256	Green Published			2022-02-06	
J	Sen, T; Gupta, R; Kaiser, H; Sen, N				Sen, Tanusree; Gupta, Rajaneesh; Kaiser, Helen; Sen, Nilkantha			Activation of PERK Elicits Memory Impairment through Inactivation of CREB and Downregulation of PSD95 After Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						CREB; GSK3B; PERK; PSD95; TBI	UNFOLDED PROTEIN RESPONSE; HIPPOCAMPAL SYNAPTIC PLASTICITY; ENDOPLASMIC-RETICULUM STRESS; GLYCOGEN-SYNTHASE KINASE-3; TRANSLATIONAL CONTROL; ALZHEIMERS-DISEASE; EIF2-ALPHA KINASES; CELL-SURVIVAL; MOUSE MODEL; ER STRESS	The PKR-like ER kinase (PERK), a transmembrane protein, resides in the endoplasmic reticulum (ER). Its activation serves as a key sensor of ER stress, which has been implicated in traumatic brain injury (TBI). The loss of memory is one of the most common symptoms after TBI, but the precise role of PERK activation in memory impairment after TBI has not been well elucidated. Here, we have shown that blocking the activation of PERK using GSK2656157 prevents the loss of dendritic spines and rescues memory deficits after TBI. To elucidate the molecular mechanism, we found that activated PERK phosphorylates CAMP response element binding protein (CREB) and PSD95 directly at the S129 and T19 residues, respectively. Phosphorylation of CREB protein prevents its interaction with a coactivator, CREB-binding protein, and subsequently reduces the BDNF level after TBI. Conversely, phosphorylation of PSD95 leads to its downregulation in pericontusional cortex after TBI in male mice. Treatment with either GSK2656157 or overexpression of a kinase-dead mutant of PERK (PERK-K618A) rescues BDNF and PSD95 levels in the pericontusional cortex by reducing phosphorylation of CREB and PSD95 proteins after TBI. Similarly, administration of either GSK2656157 or overexpression of PERK-K618A in primary neurons rescues the loss of dendritic outgrowth and number of synapses after treatment with a PERK activator, tunicamycin. Therefore, our study suggests that inhibition of PERK phosphorylation could be a potential therapeutic target to restore memory deficits after TBI.	[Sen, Tanusree; Sen, Nilkantha] Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,A504, Pittsburgh, PA 15213 USA; [Gupta, Rajaneesh; Kaiser, Helen] Augusta Univ, Dept Neurosci & Regenerat Med, Augusta, GA 30907 USA		Sen, N (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,A504, Pittsburgh, PA 15213 USA.	senn@pitt.edu	Sen, Nilkantha/AAW-9788-2020; Gupta, Rajaneesh/AAD-5893-2019	Gupta, Rajaneesh/0000-0003-0212-6478	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NS094516, RO1EY025622]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY025622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094516] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grants RO1NS094516 and RO1EY025622 to N.S. and R.G.). We thank Dr. Alexis Stranahan from Augusta University for Dil staining to study synaptic morphology.	Andres RH, 2011, STROKE, V42, P2923, DOI 10.1161/STROKEAHA.110.606368; Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109; Banhegyi G, 2007, ANN NY ACAD SCI, V1113, P58, DOI 10.1196/annals.1391.007; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Beique JC, 2003, J PHYSIOL-LONDON, V546, P859, DOI 10.1113/jphysiol.2002.031369; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011; Cheng DM, 2006, MOL CELL PROTEOMICS, V5, P1158, DOI 10.1074/mcp.D500009-MCP200; Chi XX, 2007, J NEUROPHYSIOL, V98, P2683, DOI 10.1152/jn.00437.2007; Costa-Mattioli M, 2005, NATURE, V436, P1166, DOI 10.1038/nature03897; Costa-Mattioli M, 2007, CELL, V129, P195, DOI 10.1016/j.cell.2007.01.050; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Di Giovanni S, 2005, J BIOL CHEM, V280, P2084, DOI 10.1074/jbc.M411975200; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; El-Hussein AE, 2000, SCIENCE, V290, P1364; Erion JR, 2014, J NEUROSCI, V34, P2618, DOI 10.1523/JNEUROSCI.4200-13.2014; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Halliday M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.49; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Herold S, 2011, MOL CELL NEUROSCI, V46, P79, DOI 10.1016/j.mcn.2010.08.008; Jouvert P, 2004, J NEUROSCI, V24, P10716, DOI 10.1523/JNEUROSCI.1398-04.2004; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Krishnamoorthy J, 2014, CELL CYCLE, V13, P801, DOI 10.4161/cc.27726; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Liu Z, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.183; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Ma T, 2013, NAT NEUROSCI, V16, P1299, DOI 10.1038/nn.3486; Marciniak SJ, 2006, J CELL BIOL, V172, P201, DOI 10.1083/jcb.200508099; Mir S, 2014, MOL CELL, V56, P786, DOI 10.1016/j.molcel.2014.10.019; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Nelson CD, 2013, J NEUROSCI, V33, P12122, DOI 10.1523/JNEUROSCI.0131-13.2013; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Ohno M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00022; Park K, 2013, FUTUR NEUROL, V8, P555, DOI 10.2217/FNL.13.35; Pereira CMF., 2013, ISRN CELL BIOL, V2013, P1, DOI [10.1155/2013/256404, DOI 10.1155/2013/256404]; Radford H, 2015, ACTA NEUROPATHOL, V130, P633, DOI 10.1007/s00401-015-1487-z; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900; Schaffer DJ, 2010, BRAIN RES, V1362, P32, DOI 10.1016/j.brainres.2010.09.041; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; Sen N, 2012, MOL CELL, V45, P13, DOI 10.1016/j.molcel.2011.10.021; Sen N, 2011, P NATL ACAD SCI USA, V108, P20178, DOI 10.1073/pnas.1117820108; Sen N, 2009, NEURON, V63, P81, DOI 10.1016/j.neuron.2009.05.024; Sen T, 2016, NEUROPHARMACOLOGY, V107, P79, DOI 10.1016/j.neuropharm.2016.03.009; Stranahan AM, 2007, HIPPOCAMPUS, V17, P1017, DOI 10.1002/hipo.20348; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Trinh MA, 2012, CELL REP, V1, P676, DOI 10.1016/j.celrep.2012.04.010; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Uchida M, 2006, J CELL SCI, V119, P3067, DOI 10.1242/jcs.03043; Uchida S, 2010, J NEUROSCI, V30, P15007, DOI 10.1523/JNEUROSCI.1436-10.2010; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764; Wu K, 2004, BRAIN RES, V1008, P284, DOI 10.1016/j.brainres.2004.02.051; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002	69	45	47	1	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 14	2017	37	24					5900	5911		10.1523/JNEUROSCI.2343-16.2017			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4VC	WOS:000403232000011	28522733	Green Published, Bronze			2022-02-06	
J	Rangaprakash, D; Deshpande, G; Daniel, TA; Goodman, AM; Robinson, JL; Salibi, N; Katz, JS; Denney, TS; Dretsch, MN				Rangaprakash, D.; Deshpande, Gopikrishna; Daniel, Thomas A.; Goodman, Adam M.; Robinson, Jennifer L.; Salibi, Nouha; Katz, Jeffrey S.; Denney, Thomas S., Jr.; Dretsch, Michael N.			Compromised Hippocampus-Striatum Pathway as a Potential Imaging Biomarker of Mild-Traumatic Brain Injury and Posttraumatic Stress Disorder	HUMAN BRAIN MAPPING			English	Article						functional magnetic resonance imaging; functional connectivity; dynamic connectivity; posttraumatic stress disorder; mild traumatic brain injury; network dynamics; hippocampus	MULTIPLE MEMORY-SYSTEMS; RESTING-STATE FMRI; FUNCTIONAL CONNECTIVITY; HUMAN THALAMUS; WAR VETERANS; DIFFUSION; NETWORKS; CLASSIFICATION; MODULATION; METAANALYSIS	Objectives: Military service members risk acquiring posttraumatic stress disorder (PTSD) and mild-traumatic brain injury (mTBI), with high comorbidity. Owing to overlapping symptomatology in chronic mTBI or postconcussion syndrome (PCS) and PTSD, it is difficult to assess the etiology of a patient's condition without objective measures. Using resting-state functional MRI in a novel framework, we tested the hypothesis that their neural signatures are characterized by functionally hyperconnected brain regions which are less variable over time. Additionally, we predicted that such connectivities possessed the highest ability in predicting the diagnostic membership of a novel subject (top-predictors) in addition to being statistically significant. Methods: U.S. Army Soldiers (N=87) with PTSD and comorbid PCS1PTSD were recruited along with combat controls. Static and dynamic functional connectivities were evaluated. Group differences were obtained in accordance with our hypothesis. Machine learning classification (MLC) was employed to determine top predictors. Results: From whole-brain connectivity, we identified the hippocampus-striatum connectivity to be significantly altered in accordance with our hypothesis. Diffusion tractography revealed compromised white-matter integrity between aforementioned regions only in the PCS1PTSD group, suggesting a structural etiology for the PCS1PTSD group rather than being an extreme subset of PTSD. Employing MLC, connectivities provided worst-case accuracy of 84% (9% more than psychological measures). Additionally, the hippocampus-striatum connectivities were found to be top predictors and thus a potential biomarker of PTSD/mTBI. Conclusions: PTSD/mTBI are associated with hippocampal-striatal hyperconnectivity from which it is difficult to disengage, leading to a habit-like response toward episodic traumatic memories, which fits well with behavioral manifestations of combat-related PTSD/mTBI. (C) 2017 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc.	[Rangaprakash, D.; Deshpande, Gopikrishna; Robinson, Jennifer L.; Salibi, Nouha; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, AU MRI Res Ctr, Auburn, AL 36849 USA; [Rangaprakash, D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Deshpande, Gopikrishna; Daniel, Thomas A.; Goodman, Adam M.; Robinson, Jennifer L.; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA; [Deshpande, Gopikrishna; Robinson, Jennifer L.; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Auburn Univ, Alabama Adv Imaging Consortium, Birmingham, AL 35203 USA; [Deshpande, Gopikrishna; Robinson, Jennifer L.; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Univ Alabama Birmingham, Birmingham, AL 35294 USA; [Daniel, Thomas A.] Westfield State Univ, Dept Psychol, Westfield, MA USA; [Goodman, Adam M.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; [Salibi, Nouha] Siemens Healthcare, MR R&D, Malvern, PA USA; [Dretsch, Michael N.] US Army Aeromed Res Lab, Ft Rucker, AL 36362 USA; [Dretsch, Michael N.] HQ TRADOC, Human Dimens Div, Ft Eustis, VI 23604 USA		Deshpande, G (corresponding author), Auburn Univ, Dept Elect & Comp Engn, AU MRI Res Ctr, Auburn, AL 36849 USA.; Deshpande, G (corresponding author), Auburn Univ, Dept Psychol, Auburn, AL 36849 USA.; Deshpande, G (corresponding author), Auburn Univ, Alabama Adv Imaging Consortium, Birmingham, AL 35203 USA.; Deshpande, G (corresponding author), Univ Alabama Birmingham, Birmingham, AL 35294 USA.; Dretsch, MN (corresponding author), US Army Aeromed Res Lab, Ft Rucker, AL 36362 USA.; Dretsch, MN (corresponding author), HQ TRADOC, Human Dimens Div, Ft Eustis, VI 23604 USA.	gopi@auburn.edu; michael.n.dretsch.mil@mail.mil	Goodman, Adam/AAI-3643-2021	Goodman, Adam/0000-0002-7550-679X; Denney, Thomas/0000-0002-6695-4777; Rangaprakash, D/0000-0001-9553-1354	U.S. Army Medical Research and Materiel Command (MRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [00007218]	Contract grant sponsor: U.S. Army Medical Research and Materiel Command (MRMC); Contract grant number: 00007218	Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Boccia M, 2016, BRAIN IMAGING BEHAV, V10, P226, DOI 10.1007/s11682-015-9387-3; Brodersen KH, 2014, NEUROIMAGE-CLIN, V4, P98, DOI 10.1016/j.nicl.2013.11.002; Chen G, 2011, RADIOLOGY, V259, P213, DOI 10.1148/radiol.10100734; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cisler JM, 2014, J PSYCHIATR RES, V48, P47, DOI 10.1016/j.jpsychires.2013.09.013; Costanzo ME, 2014, NEUROSCI LETT, V577, P11, DOI 10.1016/j.neulet.2014.05.054; Craddock RC, 2012, HUM BRAIN MAPP, V33, P1914, DOI 10.1002/hbm.21333; Craddock RC, 2009, MAGN RESON MED, V62, P1619, DOI 10.1002/mrm.22159; Deshpande G, 2009, P ISMRM 17 SCI M HON; Deshpande G, 2006, LECT NOTES COMPUT SC, V4091, P17; Deshpande G, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00670; Deshpande G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014277; Dickstein BD, 2015, ASSESSMENT, V22, P289, DOI 10.1177/1073191114548683; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Favaro A, 2014, PSYCHIAT RES-NEUROIM, V223, P157, DOI 10.1016/j.pscychresns.2014.05.006; Foerde K, 2006, P NATL ACAD SCI USA, V103, P11778, DOI 10.1073/pnas.0602659103; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Ghiglieri V, 2011, PROG NEUROBIOL, V94, P102, DOI 10.1016/j.pneurobio.2011.04.005; Goodman J, 2012, REV NEUROSCIENCE, V23, P627, DOI 10.1515/revneuro-2012-0049; Greiser KH, 2009, EUR J EPIDEMIOL, V24, P123, DOI 10.1007/s10654-009-9317-z; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Handwerker DA, 2004, NEUROIMAGE, V21, P1639, DOI 10.1016/j.neuroimage.2003.11.029; Hansen ECA, 2015, NEUROIMAGE, V105, P525, DOI 10.1016/j.neuroimage.2014.11.001; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; Hayes JP, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00089; Henry RG, 2003, J MAGN RESON IMAGING, V18, P420, DOI 10.1002/jmri.10379; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Jia H, 2014, BRAIN CONNECT, V4, P741, DOI 10.1089/brain.2014.0300; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Keilholz SD, 2013, BRAIN CONNECT, V3, P31, DOI 10.1089/brain.2012.0115; Kennis M, 2015, HUM BRAIN MAPP, V36, P99, DOI 10.1002/hbm.22615; Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303; Li X, 2014, HUM BRAIN MAPP, V35, P1761, DOI 10.1002/hbm.22290; Liu F, 2015, BRAIN TOPOGR, V28, P221, DOI 10.1007/s10548-014-0386-2; Majeed W, 2011, NEUROIMAGE, V54, P1140, DOI 10.1016/j.neuroimage.2010.08.030; Marquand AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069237; Mattfeld AT, 2015, HIPPOCAMPUS, V25, P900, DOI 10.1002/hipo.22411; Mattfeld AT, 2011, CEREB CORTEX, V21, P647, DOI 10.1093/cercor/bhq144; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Packard MG, 2009, BRAIN RES, V1293, P121, DOI 10.1016/j.brainres.2009.03.029; Pereira F, 2009, NEUROIMAGE, V45, pS199, DOI 10.1016/j.neuroimage.2008.11.007; Power JD, 2015, NEUROIMAGE, V105, P536, DOI 10.1016/j.neuroimage.2014.10.044; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Sakoglu U, 2010, MAGN RESON MATER PHY, V23, P351, DOI 10.1007/s10334-010-0197-8; Schwabe L, 2013, BIOL PSYCHIAT, V74, P801, DOI 10.1016/j.biopsych.2013.06.001; Schwabe L, 2012, J NEUROSCI, V32, P11042, DOI 10.1523/JNEUROSCI.1484-12.2012; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Thompson GJ, 2013, HUM BRAIN MAPP, V34, P3280, DOI 10.1002/hbm.22140; Vapnik V., 2013, NATURE STAT LEARNING; Wang L., 2005, SUPPORT VECTOR MACHI; Weathers F.W, 2015, PTSD CHECKLIST DSM 5; Woo CW, 2015, PAIN, V156, P1379, DOI 10.1097/j.pain.0000000000000223; Wu GR, 2013, MED IMAGE ANAL, V17, P365, DOI 10.1016/j.media.2013.01.003; Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013; Yeh P, 2015, P ANN M ORG HUM BRAI; Yousef M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-144	63	45	46	2	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2017	38	6					2843	2864		10.1002/hbm.23551			22	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EZ7XV	WOS:000404939900005	28295837	Green Published, hybrid			2022-02-06	
J	Hutchison, MG; Mainwaring, L; Senthinathan, A; Churchill, N; Thomas, S; Richards, D				Hutchison, Michael G.; Mainwaring, Lynda; Senthinathan, Arrani; Churchill, Nathan; Thomas, Scott; Richards, Doug			Psychological and Physiological Markers of Stress in Concussed Athletes Across Recovery Milestones	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; emotions; heart rate variability; mild traumatic brain injury; physiological; psychological; recovery; sport; stress	HEART-RATE-VARIABILITY; TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; PARTIAL LEAST-SQUARES; RECURRENT CONCUSSION; HIGH-SCHOOL; GENDER; FMRI; SYMPTOMS	Background: Sport-related concussions are associated with a range of physical, cognitive, and behavioral disturbances that are highly variable across individuals. Much remains unknown about the effects of sport concussion, and changes in markers of psychological and physiological stress over the recovery timeline. Objective: To examine psychological (mood, stress, sleep quality, and symptoms) and physiological (heart rate variability and salivary cortisol) measures in concussed athletes over clinical recovery milestones. Setting: University athletic program, sport medicine clinic, Canada. Participants: A sample of 52 interuniversity athletes (32 male and 20 female), 26 with concussion and 26 healthy controls. Design: Case-control repeated measures study at 3 time points of the clinical recovery process. Measures were administered to a matched control sample of uninjured athletes as well. Main Measures: Physiological measures were heart rate variability and salivary cortisol; psychological measures were mood, perceived stress, and quality of sleep. Results: Psychological measures were significantly worse for concussed athletes relative to controls at the symptomatic phase (acute injury), but significantly better at return-to-play (RTP). Multivariate analysis of heart rate variability identified main effects of sex and concussion, with reduced high-frequency heart rate variability for females and concussed athletes extending into the post-RTP phase. An interaction effect was also observed, showing the cardiac response of female athletes was more sensitive to concussion compared with males. Conversely, male athletes showed greater suppression of low-frequency heart rate variability associated with mood disturbances. Conclusion: This integrated study of psychological and physiological markers in concussed athletes confirmed the resolution of mood disturbances, symptoms, and sleep quality by RTP, but identified autonomic nervous system disturbances, as measured by depressed heart rate variability beyond RTP.	[Hutchison, Michael G.; Mainwaring, Lynda; Senthinathan, Arrani; Thomas, Scott; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Hutchison, Michael G.; Churchill, Nathan] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada		Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Thomas, Scott G/G-4522-2012	Thomas, Scott G/0000-0002-5564-4271	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [2012-ABI-CAT1-971]	This study was supported by a grant from Canadian Institute of Health Research (CIHR)-2012-ABI-CAT1-971 awarded to L. Mainwaring.	Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Antelmi I, 2004, AM J CARDIOL, V93, P381, DOI 10.1016/j.amjcard.2003.09.065; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Bashirelahi KB, 2014, J NEUROTRAUM, V31, pA39; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berntson GG, 2004, DYNAMIC ELECTROCARDIOGRAPHY, P57, DOI 10.1002/9780470987483.ch7; Camm AJ, 1996, CIRCULATION, V93, P1043; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; Critchley HD, 2005, J COMP NEUROL, V493, P154, DOI 10.1002/cne.20749; Dart AM, 2002, CARDIOVASC RES, V53, P678, DOI 10.1016/S0008-6363(01)00508-9; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Hutchison MG, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00046; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kemp AH, 2010, BIOL PSYCHIAT, V67, P1067, DOI [10.1016/j.biopsych.2009.12.012, 10.1016/j.biopsych.2009.11.019]; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kostyun RO, 2015, AM J SPORT MED, V43, P633, DOI 10.1177/0363546514560727; La Fountaine MF, 2011, J ATHL TRAINING, V46, P230; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; LIAO DP, 1995, AM J CARDIOL, V76, P906, DOI 10.1016/S0002-9149(99)80260-4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nguyen DV, 2002, BIOINFORMATICS, V18, P1216, DOI 10.1093/bioinformatics/18.9.1216; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rosipal R, 2006, LECT NOTES COMPUT SC, V3940, P34, DOI 10.1007/11752790_2; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Tolkunov D, 2010, NEUROIMAGE, V50, P72, DOI 10.1016/j.neuroimage.2009.12.021; Vrijkotte TGM, 2000, HYPERTENSION, V35, P880, DOI 10.1161/01.HYP.35.4.880; Wilberger J, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P45, DOI 10.1007/0-387-32565-4_3; Zhang L, 2002, ANAL CHEM, V74, P4097, DOI 10.1021/ac020023r; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	61	45	46	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E38	E48		10.1097/HTR.0000000000000252			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900011	27603761				2022-02-06	
J	Nielson, JL; Cooper, SR; Yue, JK; Sorani, MD; Inoue, T; Yuh, EL; Mukherjee, P; Petrossian, TC; Paquette, J; Lum, PY; Carlsson, GE; Vassar, MJ; Lingsma, HF; Gordon, WA; Valadka, AB; Okonkwo, DO; Manley, GT; Ferguson, AR				Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Sorani, Marco D.; Inoue, Tomoo; Yuh, Esther L.; Mukherjee, Pratik; Petrossian, Tanya C.; Paquette, Jesse; Lum, Pek Y.; Carlsson, Gunnar E.; Vassar, Mary J.; Lingsma, Hester F.; Gordon, Wayne A.; Valadka, Alex B.; Okonkwo, David O.; Manley, Geoffrey T.; Ferguson, Adam R.		TRACK-TBI Investigators	Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis	PLOS ONE			English	Article							COMMON DATA ELEMENTS; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; POLYMORPHISM; COMT; CLASSIFICATION; PREDICTION; PROTEIN	Background Traumatic brain injury (TBI) is a complex disorder that is traditionally stratified based on clinical signs and symptoms. Recent imaging and molecular biomarker innovations provide unprecedented opportunities for improved TBI precision medicine, incorporating patho-ana-tomical and molecular mechanisms. Complete integration of these diverse data for TBI diag-nosis and patient stratification remains an unmet challenge. Methods and findings The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot multicenter study enrolled 586 acute TBI patients and collected diverse common data elements (TBI-CDEs) across the study population, including imaging, genetics, and clinical outcomes. We then applied topology-based data-driven discovery to identify natural sub-groups of patients, based on the TBI-CDEs collected. Our hypothesis was two-fold: 1) A machine learning tool known as topological data analysis (TDA) would reveal data-driven patterns in patient outcomes to identify candidate biomarkers of recovery, and 2) TDA-iden-tified biomarkers would significantly predict patient outcome recovery after TBI using more traditional methods of univariate statistical tests. TDA algorithms organized and mapped the data of TBI patients in multidimensional space, identifying a subset of mild TBI patients with a specific multivariate phenotype associated with unfavorable outcome at 3 and 6 months after injury. Further analyses revealed that this patient subset had high rates of post-trau-matic stress disorder (PTSD), and enrichment in several distinct genetic polymorphisms associated with cellular responses to stress and DNA damage (PARP1), and in striatal dopamine processing (ANKK1, COMT, DRD2). Conclusions TDA identified a unique diagnostic subgroup of patients with unfavorable outcome after mild TBI that were significantly predicted by the presence of specific genetic polymorphisms. Machine learning methods such as TDA may provide a robust method for patient stratifica-tion and treatment planning targeting identified biomarkers in future clinical trials in TBI patients.	[Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Inoue, Tomoo; Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam R.] Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94110 USA; [Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Sorani, Marco D.; Inoue, Tomoo; Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Cooper, Shelly R.; Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Petrossian, Tanya C.; Paquette, Jesse; Lum, Pek Y.; Carlsson, Gunnar E.] Ayasdi Inc, Palo Alto, CA USA; [Lingsma, Hester F.] Erasmus MC, Publ Hlth, Rotterdam, Netherlands; [Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; [Ferguson, Adam R.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA		Manley, GT; Ferguson, AR (corresponding author), Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94110 USA.; Manley, GT; Ferguson, AR (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Ferguson, AR (corresponding author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA.	manleyg@neurosurg.ucsf.edu; adam.ferguson@ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Hemphill, Claude/0000-0003-4019-7525; Petrossian, Tanya/0000-0002-1205-9144; Bodien, Yelena/0000-0003-4858-2903; Wang, Kevin/0000-0002-9343-6473; Markowitz, Amy/0000-0001-9314-2814; Martin, Alastair/0000-0002-7963-4000; Ferguson, Adam/0000-0001-7102-1608; Badjatia, Neeraj/0000-0003-1509-9034; Cooper, Shelly/0000-0003-0026-6688; Nielson, Jessica/0000-0002-3677-3959; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Department of Defense (DoD)United States Department of Defense [W81XWH-131-0441]; National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS067092, NS069409, NS069409-0251]; Craig H. Neilsen Foundation (ARF); Wings for Life Foundation (ARF); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, R01NS067092] Funding Source: NIH RePORTER	This work was funded by the following: Department of Defense (DoD) grant W81XWH-131-0441 (GTM): http://cdmrp.army.mil/funding/phtbi.shtml; National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) grants NS067092 (ARF), NS069409 (GTM) and NS069409-0251 (GTM): http://www.runds.nih.govt/; Craig H. Neilsen Foundation (ARF): http://chnfoundation.org/; and Wings for Life Foundation (ARF): http://www.wingsforlrie.com/en/.	Benedetti F, 2009, PSYCHOPHARMACOLOGY, V203, P155, DOI 10.1007/s00213-008-1381-7; Bodenmann S, 2009, CLIN PHARMACOL THER, V85, P296, DOI 10.1038/clpt.2008.222; Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X; CDC, GET FACTS CONC TRAUM; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chan JM, 2013, P NATL ACAD SCI USA, V110, P18566, DOI 10.1073/pnas.1313480110; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kyeong S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137296; Li L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9364; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lum PY, 2013, SCI REP, V3, P1518; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marshall Lawrence F., 2009, J NEUROSURGERY PUBLI; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; Nielson JL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9581; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Romano D, 2014, HUM BRAIN MAPP, V35, P4904, DOI 10.1002/hbm.22521; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sarikonda G, 2014, J AUTOIMMUNITY; Sarnaik AA, 2010, J NEUROTRAUM, V27, P465, DOI 10.1089/neu.2009.1171; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; The National Institute of Neurlogical Disorders and Stroke, 2015, NINDS COMM DAT EL TR; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Yue JK, 2016, NEUROGENETICS; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	41	45	45	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2017	12	3							e0169490	10.1371/journal.pone.0169490			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN5BR	WOS:000396021100002	28257413	Green Published, gold			2022-02-06	
J	Saber, M; Kokiko-Cochran, O; Puntambekar, SS; Lathia, JD; Lamb, BT				Saber, Maha; Kokiko-Cochran, Olga; Puntambekar, Shweta S.; Lathia, Justin D.; Lamb, Bruce T.			Triggering Receptor Expressed on Myeloid Cells 2 Deficiency Alters Acute Macrophage Distribution and Improves Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; immunohistochemistry; inflammation; neurodegenerative disorders; traumatic brain injury	ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; RISK-FACTOR; EX-VIVO; TREM2; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY	Traumatic brain injury (TBI) affects 1.7 million persons annually in the United States (Centers for Disease Control and Prevention). There is increasing evidence that persons exposed to TBI have increased risk of the development of multiple neurodegenerative conditions, including Alzheimer disease (AD). TBI triggers a strong neuroinflammatory response characterized by astrogliosis, activation of microglia, and infiltration of peripheral monocytes. Recent evidence suggests that alterations in innate immunity promote neurodegeneration. This includes genetic studies demonstrating that mutations in triggering receptor expressed on myeloid cells 2 (TREM2) is associated with a higher risk for not only AD but also multiple neurodegenerative diseases. To examine whether TREM2 deficiency affects pathological outcomes of TBI, Trem2 knockout (Trem2(-/-)) and C57BL/6J (B6) mice were given a lateral fluid percussion injury (FPI) and sacrificed at 3 and 120 days post-injury (DPI) to look at both acute and chronic consequences of TREM2 deficiency. Notably, at 3 DPI, B6 mice exposed to TBI exhibited increased expression of TREM2 in the brain. Further, Trem2(-/-) mice exposed to TBI exhibited enhanced macrophage activation near the lesion, but significantly less macrophage activation away from the lesion when compared with B6 mice exposed to TBI. In addition, at 120 DPI, Trem2(-/-) mice exposed to TBI demonstrated reduced hippocampal atrophy and rescue of TBI-induced behavioral changes when compared with B6 mice exposed to TBI. Taken together, this study suggests that TREM2 deficiency influences both acute and chronic responses to TBI, leading to an altered macrophage response at early time points, and improved pathological and functional outcomes at later time points.	[Saber, Maha; Lamb, Bruce T.] Cleveland Clin, Dept Neurosci, Cleveland, OH 44106 USA; [Lathia, Justin D.] Cleveland Clin, Dept Cellular Mol Med, Cleveland, OH 44106 USA; [Saber, Maha] Case Western Reserve Univ, Dept Mol Med, Cleveland, OH 44106 USA; [Kokiko-Cochran, Olga; Puntambekar, Shweta S.; Lamb, Bruce T.] Stark Neurosci Res Inst, Indianapolis, IN USA		Lamb, BT (corresponding author), Indiana Univ Sch Med, Stark Neurosci Res Inst, Neurosci Bldg,Suite 414 320 W 15th St,NB Bldg, Indianapolis, IN 46202 USA.	btlamb@iu.edu		Saber, Maha/0000-0001-6120-3993	Department of DefenseUnited States Department of Defense [W81XWH-14-1-0265]	This work was supported by the Department of Defense (W81XWH-14-1-0265, Bruce Lamb).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Bamberger ME, 2002, NEUROSCIENTIST, V8, P276, DOI 10.1177/1073858402008003013; Basiratnia Reza, 2015, Adv Biomed Res, V4, P192, DOI 10.4103/2277-9175.166153; Becher B, 1996, GLIA, V18, P1; Borroni B, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.09.017; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Chincarini A, 2016, NEUROIMAGE, V125, P834, DOI 10.1016/j.neuroimage.2015.10.065; Dardiotis E, 2012, BRAIN INJURY PATHOGE, P23; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doragna D, 2003, J NEUROL NEUROSUR PS, V74, P825, DOI 10.1136/jnnp.74.6.825-a; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Driscoll I, 2012, ACTA NEUROPATHOL, V124, P823, DOI 10.1007/s00401-012-1025-1; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; FORD AL, 1995, J IMMUNOL, V154, P4309; Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009; Franzblau M, 2013, MED HYPOTHESES, V81, P842, DOI 10.1016/j.mehy.2013.09.012; Gao XL, 2013, MOL MED REP, V7, P921, DOI 10.3892/mmr.2013.1268; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guderian S, 2015, J NEUROSCI, V35, P14123, DOI 10.1523/JNEUROSCI.0801-15.2015; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2009, J NEUROCHEM, V109, P1144, DOI 10.1111/j.1471-4159.2009.06042.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ito H, 2012, EUR J IMMUNOL, V42, P176, DOI 10.1002/eji.201141679; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kokiko-Cochran O., 2015, J NEUROTRAUMA; Komada M, 2008, J VIS EXP, Vpii, P1088; Llado A, 2007, J NEURAL TRANSM, V114, P1051, DOI 10.1007/s00702-007-0716-6; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malik M, 2013, J NEUROSCI, V33, P13320, DOI 10.1523/JNEUROSCI.1224-13.2013; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Numasawa Y, 2011, EUR J NEUROL, V18, P1179, DOI 10.1111/j.1468-1331.2010.03311.x; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027; Pang FC, 2002, INT J GERIATR PSYCH, V17, P29, DOI 10.1002/gps.510; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pottier C, 2013, J ALZHEIMERS DIS, V35, P45, DOI 10.3233/JAD-122311; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rayaprolu S, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-19; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Schmidt OI, 2007, ORTHOPADE, V36, P248, DOI 10.1007/s00132-007-1061-z; Sessa G, 2004, EUR J NEUROSCI, V20, P2617, DOI 10.1111/j.1460-9568.2004.03729.x; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Sieber MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052982; Singaraja RR, 2013, CLIN GENET, V83, P525, DOI 10.1111/cge.12108; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Takahashi K, 2007, PLOS MED, V4, P675, DOI 10.1371/journal.pmed.0040124; Thrash JC, 2009, NEUROCHEM RES, V34, P38, DOI 10.1007/s11064-008-9657-1; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Wu K, 2015, J EXP MED, V212, P681, DOI 10.1084/jem.20141732; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	81	45	47	2	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					423	+		10.1089/neu.2016.4401			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800018	26976047				2022-02-06	
J	Churchill, NW; Hutchison, MG; Richards, D; Leung, G; Graham, SJ; Schweizer, TA				Churchill, Nathan W.; Hutchison, Michael G.; Richards, Doug; Leung, General; Graham, Simon J.; Schweizer, Tom A.			The first week after concussion: Blood flow, brain function and white matter microstructure	NEUROIMAGE-CLINICAL			English	Article						Concussion; MRI; Cerebral blood flow; Functional MRI; Diffusion tensor imaging	DEFAULT-MODE NETWORK; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; RECURRENT CONCUSSION; COGNITIVE DYSFUNCTION; INJURY; CONNECTIVITY; INDIVIDUALS; DEPRESSION; ANISOTROPY	Concussion is a major health concern, associated with short-term deficits in physical function, emotion and cognition, along with negative long-term health outcomes. However, we remain in the early stages of characterizing MRI markers of concussion, particularly during the first week post-injury when symptoms are most severe. In this study, 52 varsity athletes were scanned using Magnetic Resonance Imaging (MRI), including 26 athletes with acute concussion (scanned 1-7 days post-injury) and 26 matched control athletes. A comprehensive set of functional and structural MRI measures were analyzed, including cerebral blood flow (CBF) and global functional connectivity (Gconn) of grey matter, along with fractional anisotropy (FA) and mean diffusivity (MD) of white matter. An analysis comparing acutely concussed athletes and controls showed limited evidence for reliable mean effects of acute concussion, with only MD showing spatially extensive differences between groups. We subsequently demonstrated that the number of days post-injury explained a significant proportion of inter-subject variability in MRI markers of acutely concussed athletes. Athletes scanned at early acute injury (1-3 days) had elevated CBF and Gconn and reduced FA, but those scanned at late acute injury (5-7 days) had the opposite response. In contrast, MD showed a more complex, spatially-dependent relationship with days post-injury. These novel findings highlight the variability of MRI markers during the acute phase of concussion and the critical importance of considering the acute injury time interval, which has significant implications for studies relating acute MRI data to concussion outcomes. (C) 2017 The Authors. Published by Elsevier Inc.	[Churchill, Nathan W.; Hutchison, Michael G.; Leung, General; Schweizer, Tom A.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1M8, Canada; [Hutchison, Michael G.; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, 55 Harbord St, Toronto, ON M5S 2W6, Canada; [Leung, General] Univ Toronto, Dept Med Imaging, Keenan Res Ctr, Li Ka Shing Knowledge Inst,St Michaels Hosp, 209 Victoria St, Toronto, ON M5B 1M8, Canada; [Graham, Simon J.] Univ Toronto, Sunnybrook Hosp, Dept Med Biophys, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Graham, Simon J.] Sunnybrook Res Inst, Phys Sci, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada		Churchill, NW (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1M8, Canada.	nchurchill.research@gmail.com; michael.hutchison@utoronto.ca; doug.richards@utoronto.ca; leungge@smh.ca; sgraham@sri.utoronto.ca; schweizert@smh.ca			Defence Research & Development Canada (DRDC); Canadian Institutes of Military and Veterans Health (CIMVHR) grant [W7714-145967]; Canadian Institutes of Health Research (CIHR) Project GrantCanadian Institutes of Health Research (CIHR) [RN294001-367456]	This research received funding from the Defence Research & Development Canada (DRDC) and the Canadian Institutes of Military and Veterans Health (CIMVHR) grant W7714-145967. This study was approved by the Canadian Forces Surgeon General's Health Research Program. This study was also partially funded by a Canadian Institutes of Health Research (CIHR) Project Grant RN294001-367456.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Churchill N, 2017, J NEUROTRAUM, V34, P765, DOI 10.1089/neu.2016.4531; Cole MW, 2012, J NEUROSCI, V32, P8988, DOI 10.1523/JNEUROSCI.0536-12.2012; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Covassin T, 2003, J ATHL TRAINING, V38, P238; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham D., 2002, TRAUMA GREENFIELDS N; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Hutchison MG, 2017, J HEAD TRAUMA REHAB, V32, pE38, DOI 10.1097/HTR.0000000000000252; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Monaco EA, 2015, NEUROSURGERY, V76, pN10, DOI 10.1227/NEU.0000000000000700; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	50	45	45	2	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						480	489		10.1016/j.nicl.2017.02.015			10	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FB2OY	WOS:000405984300051	28280686	Green Published, gold			2022-02-06	
J	LoBue, C; Wadsworth, H; Wilmoth, K; Clem, M; Hart, J; Womack, KB; Didehbani, N; Lacritz, LH; Rossetti, HC; Cullum, CM				LoBue, Christian; Wadsworth, Hannah; Wilmoth, Kristin; Clem, Matthew; Hart, John, Jr.; Womack, Kyle B.; Didehbani, Nyaz; Lacritz, Laura H.; Rossetti, Heidi C.; Cullum, C. Munro			Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease	CLINICAL NEUROPSYCHOLOGIST			English	Article						National Alzheimer's Coordinating Center (NACC); traumatic brain injury (TBI); dementia; Alzheimer's disease (AD); age of onset	APOLIPOPROTEIN-E; HEAD-INJURY; RISK-FACTORS; COGNITIVE IMPAIRMENT; DEMENTIA; ALLELE; DIAGNOSIS; PATHOLOGY; THERAPY; HEALTH	Objective: This study examined whether a history of traumatic brain injury (TBI) is associated with earlier onset of Alzheimer disease (AD), independent of apolipoprotein epsilon 4 status (Apoe4) and gender. Method: Participants with a clinical diagnosis of AD (n=7625) were obtained from the National Alzheimer's Coordinating Center Uniform Data Set, and categorized based on self-reported lifetime TBI with loss of consciousness (LOC) (TBI+ vs. TBI-) and presence of Apoe4. ANCOVAs, controlling for gender, race, and education were used to examine the association between history of TBI, presence of Apoe4, and an interaction of both risk factors on estimated age of AD onset. Results: Estimated AD onset differed by TBI history and Apoe4 independently (p's<.001). The TBI+ group had a mean age of onset 2.5years earlier than the TBI- group. Likewise, Apoe4 carriers had a mean age of onset 2.3years earlier than non-carriers. While the interaction was non-significant (p=.34), participants having both a history of TBI and Apoe4 had the earliest mean age of onset compared to those with a TBI history or Apoe4 alone (M-Difference=2.8 and 2.7years, respectively). These results remained unchanged when stratified by gender. Conclusions: History of self-reported TBI can be associated with an earlier onset of AD-related cognitive decline, regardless of Apoe4 status and gender. TBI may be related to an underlying neurodegenerative process in AD, but the implications of age at time of injury, severity, and repetitive injuries remain unclear.	[LoBue, Christian; Wadsworth, Hannah; Wilmoth, Kristin; Clem, Matthew; Hart, John, Jr.; Womack, Kyle B.; Didehbani, Nyaz; Lacritz, Laura H.; Rossetti, Heidi C.; Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.; Lacritz, Laura H.; Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.; Didehbani, Nyaz] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX USA		LoBue, C (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.	Christian.lobue@utsouthwestern.edu	Cullum, C. Munro/AAC-2496-2019; Wilmoth, Kristin/ABB-4014-2020; Womack, Kyle/O-5422-2018	Cullum, C. Munro/0000-0001-9706-5465; Wilmoth, Kristin/0000-0003-4192-8756; Womack, Kyle/0000-0002-6060-9075; Didehbani, Nyaz/0000-0001-6121-5759	University of Texas Southwestern Alzheimer's Disease Center [NIH/NIA] [P3012300-19]; Texas Alzheimer's Research and Care Consortium (TARCC); NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG010124]; The NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681, U01 AG032984]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG016976, P50AG005133, P30AG019610, P30AG010124, P30AG008017, P50AG016574, P30AG008051, P50AG005136, P50AG005681, P50AG005131, P50AG005134, P50AG033514, P30AG013854, P30AG013846, P30AG028383, U01AG032984, P30AG035982, P50AG008702, P30AG010161, P30AG012300, P50AG025688, P30AG010129, P50AG016573, P50AG005142, P30AG010133, P50AG005138, P50AG016570, P50AG005146, P50AG023501] Funding Source: NIH RePORTER	This work was supported by the University of Texas Southwestern Alzheimer's Disease Center [NIH/NIA grant number P3012300-19] and the Texas Alzheimer's Research and Care Consortium (TARCC). NACC data are funded by NIA [grant number P30 AG019610] (PI Eric Reiman, MD), [grant number P30 AG013846] (PI Neil Kowall, MD), [grant number P50 AG008702] (PI Scott Small, MD), [grant number P50 AG025688] (PI Allan Levey, MD, PhD), [grant number P30 AG010133] (PI Andrew Saykin, PsyD), [grant number P50 AG005146] (PI Marilyn Albert, PhD), [grant number P50 AG005134] (PI Bradley Hyman, MD, PhD), [grant number P50 AG016574] (PI Ronald Petersen, MD, PhD), [grant number P50 AG005138] (PI Mary Sano, PhD), [grant number P30 AG008051] (PI Steven Ferris, PhD), [grant number P30 AG013854] (PI M. Marsel Mesulam, MD), [grant number P30 AG008017] (PI Jeffrey Kaye, MD), [grant number P30 AG010161] (PI David Bennett, MD), [grant number P30 AG010129] (PI Charles DeCarli, MD), [grant number P50 AG016573] (PI Frank LaFerla, PhD), [grant number P50 AG016570] (PI David Teplow, PhD), [grant number P50 AG005131] (PI Douglas Galasko, MD), [grant number P50 AG023501] (PI Bruce Miller, MD), [grant number P30 AG035982] (PI Russell Swerdlow, MD), [grant number P30 AG028383] (PI Linda Van Eldik, PhD), [grant number P30 AG010124] (PI John Trojanowski, MD, PhD), [grant number P50 AG005133] (PI Oscar Lopez, MD), [grant number P50 AG005142] (PI Helena Chui, MD), [grant number P30 AG012300] (PI Roger Rosenberg, MD), [grant number P50 AG005136] (PI Thomas Montine, MD, PhD), [grant number P50 AG033514] (PI Sanjay Asthana, MD, FRCP), [grant number P50 AG005681] (PI John Morris, MD); Alzheimer's Disease Genetic Consortium (ADGC) is funded by NIA [grant number U01 AG032984].	Altmann A, 2014, ANN NEUROL, V75, P563, DOI 10.1002/ana.24135; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Corder EH, 2004, ANN NY ACAD SCI, V1019, P24, DOI 10.1196/annals.1297.005; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Faul M, 2010, TRAUMATIC BRAIN INJU, V2, P1; Fleisher AS, 2013, NEUROBIOL AGING, V34, P1, DOI 10.1016/j.neurobiolaging.2012.04.017; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kok E, 2009, ANN NEUROL, V65, P650, DOI 10.1002/ana.21696; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; Luchsinger JA, 2005, NEUROLOGY, V65, P545, DOI 10.1212/01.wnl.0000172914.08967.dc; Maiti TK, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.8.FOCUS15329; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Miller MA, 2010, BRAIN INJURY, V24, P1468, DOI 10.3109/02699052.2010.520299; Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Naj AC, 2014, JAMA NEUROL, V71, P1394, DOI 10.1001/jamaneurol.2014.1491; Nelson PT, 2009, J NEUROPATH EXP NEUR, V68, P1, DOI 10.1097/NEN.0b013e3181919a48; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Thal DR, 2014, J ALZHEIMERS DIS, V42, pS421, DOI 10.3233/JAD-141461; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Ungar L, 2014, BRAIN IMAGING BEHAV, V8, P262, DOI 10.1007/s11682-013-9272-x; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Xu W, 2015, J NEUROL NEUROSUR PS, V86, P1299, DOI 10.1136/jnnp-2015-310548	49	45	45	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					85	98		10.1080/13854046.2016.1257069			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300005	27855547	Green Accepted			2022-02-06	
J	Noy, S; Krawitz, S; Del Bigio, MR				Noy, Shawna; Krawitz, Sherry; Del Bigio, Marc R.			Chronic Traumatic Encephalopathy-Like Abnormalities in a Routine Neuropathology Service	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Autopsy; Brain injury; Chronic traumatic encephalopathy; Concussion; Contusion; Neurofibrillary tangles; Tau	BRAIN-INJURY; TAU; DISEASE; PHOSPHORYLATION; DEPOSITION; PATHOLOGY	Chronic traumatic encephalopathy (CTE) has been described mainly in professional athletes and military personnel and is characterized by deposition of hyperphosphorylated tau at the depths of cortical sulci and around blood vessels. To assess CTE-like changes in a routine neuropathology service, we prospectively examined 111 brains (age 18-60 years). The presence of tau-immunoreactive deposits was staged using guidelines described by others and was correlated with the medical history. 72/111 cases were negative for CTE-like changes; 34/111 were CTE stage <1; 3/111 were CTE stage 1; and 2/111 were CTE stage 2. The combined history of head injury and alcohol and/or drug abuse was a significant predictor of any CTE-like changes. Age was also a significant predictor; most with any CTE-like changes were >40 years old. CTE-like changes were not identified at sites of contusion. Among a separate group studied retrospectively, we identified 4 cases that met full criteria for CTE. We conclude that CTE-like findings are not confined to professional athletes; the risk factors of head injury and substance abuse are similar in the routine population. However, the significance of very small hyperphosphorylated tau deposits remains to be determined. In addition, the absence of typical CTE-like deposits near contusion sites keeps open the question of pathogenesis.	[Noy, Shawna] Univ Manitoba, Max Rady Coll Med, Dept Pathol & Postgrad Med Educ, Winnipeg, MB, Canada; [Krawitz, Sherry; Del Bigio, Marc R.] Univ Manitoba, Max Rady Coll Med, Dept Pathol, Winnipeg, MB, Canada; [Krawitz, Sherry; Del Bigio, Marc R.] Diagnost Serv Manitoba, Winnipeg, MB, Canada		Del Bigio, MR (corresponding author), Univ Manitoba, Max Rady Coll Med, Dept Pathol, Brodie Ctr 401, 715 McDermot Ave, Winnipeg, MB R3E 3P5, Canada.	marc.delbigio@umanitoba.ca					Aho L, 2009, J NEUROSCI RES, V87, P2786, DOI 10.1002/jnr.22091; Armstrong RA, 2017, NEUROPATH APPL NEURO, V43, P154, DOI 10.1111/nan.12323; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Castellani RJ, 2015, LAB INVEST, V95, P576, DOI 10.1038/labinvest.2015.54; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; CULLEN KM, 1995, NEUROPATH APPL NEURO, V21, P312, DOI 10.1111/j.1365-2990.1995.tb01065.x; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Goldstein LE, 2013, US patent application, Patent No. [US 14,398,099 A1, 14398099]; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Lucke-Wold BP, 2016, J NEUROSURG, V124, P687, DOI 10.3171/2015.3.JNS141802; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; MANLOW A, 1992, J NEUROPATH EXP NEUR, V51, P298, DOI 10.1097/00005072-199205000-00008; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Puvenna V, 2016, BRAIN RES, V1630, P225, DOI 10.1016/j.brainres.2015.11.007; Ramage SN, 2005, NEUROPATH APPL NEURO, V31, P439, DOI 10.1111/j.1365-2990.2005.00670.x; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209	36	45	45	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2016	75	12					1145	1154		10.1093/jnen/nlw092			10	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	EK0CY	WOS:000393595400004	27815395	Bronze			2022-02-06	
J	Di Battista, AP; Rizoli, SB; Lejnieks, B; Min, A; Shiu, MY; Peng, HT; Baker, AJ; Hutchison, MG; Churchill, N; Inaba, K; Nascimento, BB; Manoel, ALD; Beckett, A; Rhind, SG				Di Battista, Alex P.; Rizoli, Sandro B.; Lejnieks, Brandon; Min, Arimie; Shiu, Maria Y.; Peng, Henry T.; Baker, Andrew J.; Hutchison, Michael G.; Churchill, Nathan; Inaba, Kenji; Nascimento, Bartolomeu B.; Manoel, Airton Leonardo de Oliveira; Beckett, Andrew; Rhind, Shawn G.			SYMPATHOADRENAL ACTIVATION IS ASSOCIATED WITH ACUTE TRAUMATIC COAGULOPATHY AND ENDOTHELIOPATHY IN ISOLATED BRAIN INJURY	SHOCK			English	Article						Catecholamines; D-dimer; hemostasis; norepinephrine; syndecan-1; thrombin-activatable fibrinolysis inhibitor; thrombomodulin; tissue factor pathway inhibitor; tissue plasminogen activator; vascular adhesion protein-1	DISSEMINATED INTRAVASCULAR COAGULATION; PARTIAL THROMBOPLASTIN TIME; HEAD-INJURY; GLYCOCALYX DEGRADATION; HYPERCOAGULABLE STATE; PROTHROMBIN TIME; SEVERE SEPSIS; IN-VIVO; DAMAGE; INFLAMMATION	Background: Acute coagulopathy after traumatic brain injury (TBI) involves a complex multifactorial hemostatic response that is poorly characterized. Objectives: To examine early posttraumatic alterations in coagulofibrinolytic, endothelial, and inflammatory blood biomarkers in relation to sympathetic nervous system (SNS) activation and 6-month patient outcomes, using multivariate partial least-squares (PLS) analysis. Patients and Methods: A multicenter observational study of 159 adult isolated TBI patients admitted to the emergency department at an urban level I trauma center, was performed. Plasma concentrations of 6 coagulofibrinolytic, 10 vascular endothelial, 19 inflammatory, and 2 catecholamine biomarkers were measured by immunoassay on admission and 24 h postinjury. Neurological outcome at 6 months was assessed using the Extended Glasgow Outcome Scale. PLS-discriminant analysis was used to identify salient biomarker contributions to unfavorable outcome, whereas PLS regression analysis was used to evaluate the covariance between SNS correlates (catecholamines) and biomarkers of coagulopathy, endotheliopathy, and inflammation. Results: Biomarker profiles in patients with an unfavorable outcome displayed procoagulation, hyperfibrinolysis, glycocalyx and endothelial damage, vasculature activation, and inflammation. A strong covariant relationship was evident between catecholamines and biomarkers of coagulopathy, endotheliopathy, and inflammation at both admission and 24 h postinjury. Conclusions: Biomarkers of coagulopathy and endotheliopathy are associated with poor outcome after TBI. Catecholamine levels were highly correlated with endotheliopathy and coagulopathy markers within the first 24 h after injury. Further research is warranted to characterize the pathogenic role of SNS-mediated hemostatic alterations in isolated TBI.	[Di Battista, Alex P.; Shiu, Maria Y.; Peng, Henry T.; Rhind, Shawn G.] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada; [Di Battista, Alex P.; Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Rizoli, Sandro B.; Lejnieks, Brandon; Min, Arimie; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Anesthesia & Surg, Toronto, ON, Canada; [Hutchison, Michael G.; Rhind, Shawn G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Hutchison, Michael G.; Churchill, Nathan] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Inaba, Kenji] Univ Southern Calif, Div Trauma & Crit Care, Los Angeles, CA USA; [Inaba, Kenji] LA Cty & USC Med Ctr, Los Angeles, CA USA; [Nascimento, Bartolomeu B.] Univ Toronto, Dept Surg, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Beckett, Andrew] 1 Canadian Field Hosp, Canadian Forces Hlth Serv, Petawawa, ON, Canada; [Beckett, Andrew] McGill Univ, Ctr Hlth, Trauma Program, Montreal, PQ, Canada		Di Battista, AP (corresponding author), Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada.	dibattista.alex@gmail.com	INABA, KENJI/AAC-8532-2020; de Oliveira Manoel, Airton Leonardo/C-4724-2018; Peng, Henry/ABA-1912-2021	de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013; Peng, Henry/0000-0001-5276-9573; Di Battista, Alex/0000-0002-3325-6833; Rhind, Shawn/0000-0003-2300-0620			Abdelmalik PA, 2016, NEUROCRIT CARE, V24, P361, DOI 10.1007/s12028-015-0191-0; Bishop CM, 2006, INFORM SCI STAT, V1, P738; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P1395, DOI 10.1097/TA.0b013e31825b9f05; Canonico B, 2010, CYTOM PART B-CLIN CY, V78B, P267, DOI 10.1002/cyto.b.20510; Cap A, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12914; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Chignalia AZ, 2016, SHOCK, V45, P338, DOI 10.1097/SHK.0000000000000513; Choudhry MA, 2007, INJURY, V38, P1382, DOI 10.1016/j.injury.2007.09.027; Conway EM, 2012, SEMIN IMMUNOPATHOL, V34, P107, DOI 10.1007/s00281-011-0282-8; Davenport RA, 2016, CURR OPIN ANESTHESIO, V29, P212, DOI 10.1097/ACO.0000000000000295; Manoel ALD, 2015, NEUROCRIT CARE, V22, P34, DOI 10.1007/s12028-014-0026-4; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Dobson GP, 2015, J TRAUMA ACUTE CARE, V79, P301, DOI 10.1097/TA.0000000000000729; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Flierl MA, 2008, MOL MED, V14, P195, DOI 10.2119/2007-00105.Flierl; Gando S, 2013, J THROMB HAEMOST, V11, P826, DOI 10.1111/jth.12190; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Garber BG, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0325-5; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Armitage EG, 2015, ELECTROPHORESIS, V36, P3050, DOI 10.1002/elps.201500352; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hemker HC, 2004, CURR OPIN HEMATOL, V11, P170, DOI 10.1097/01.moh.0000130314.33410.d7; ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618; Johansson PI, 2010, MED HYPOTHESES, V75, P564, DOI 10.1016/j.mehy.2010.07.031; Johansson PI, 2014, J CRIT CARE, V29, P327, DOI 10.1016/j.jcrc.2013.10.028; Johansson PI, 2011, CRIT CARE, V15, DOI 10.1186/cc10553; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2012, J TRAUMA ACUTE CARE, V72, P428, DOI 10.1097/TA.0b013e31821e0f93; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P121, DOI 10.1097/TA.0b013e3182a9cc95; Kunio NR, 2012, AM J SURG, V203, P584, DOI 10.1016/j.amjsurg.2011.12.011; Levi M, 2010, CRIT CARE MED, V38, pS26, DOI 10.1097/CCM.0b013e3181c98d21; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Nieuwdorp M, 2006, DIABETES, V55, P480, DOI 10.2337/diabetes.55.02.06.db05-1103; Ostrowski SR, 2015, J CRIT CARE, V30, P90, DOI 10.1016/j.jcrc.2014.10.006; Ostrowski SR, 2013, J CRIT CARE, V28, P586, DOI 10.1016/j.jcrc.2013.04.010; Ostrowski SR, 2013, CRIT CARE, V17, DOI 10.1186/cc12532; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Ostrowski SR, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0918-5; Pannell D, 2011, J TRAUMA, V71, pS401, DOI 10.1097/TA.0b013e318232e53f; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Reid MW, 2015, MOL CELL NEUROSCI, V66, P123, DOI 10.1016/j.mcn.2015.03.014; Schafer AI, 2007, CARDIOVASCULAR MED, VIII, P2423; Schreiber M, 2009, J TRAUMA, V67, P275; Schrieber M, 2007, J TRAUMA, V63, P1261; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tien Homer, 2015, Can J Surg, V58, pS91; Tien HCN, 2010, AM J PREV MED, V38, P331, DOI 10.1016/j.amepre.2009.12.012; van der Poll T, 2011, CURR OPIN INFECT DIS, V24, P273, DOI 10.1097/QCO.0b013e328344c078; Versteeg HH, 2013, PHYSIOL REV, V93, P327, DOI 10.1152/physrev.00016.2011; von Kanel R, 2000, EUR J HAEMATOL, V65, P357, DOI 10.1034/j.1600-0609.2000.065006357.x; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; White NJ, 2015, J THROMB HAEMOST, V13, P978, DOI 10.1111/jth.12919; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1; Xu L, 2015, BLOOD COAGUL FIBRIN, V26, P152, DOI 10.1097/MBC.0000000000000211; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	60	45	45	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2016	46	3		1			96	103		10.1097/SHK.0000000000000642			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	DX3HG	WOS:000384263600014	27206278	Green Published			2022-02-06	
J	Herman, DC; Barth, JT				Herman, Daniel C.; Barth, Jeffrey T.			Drop-Jump Landing Varies With Baseline Neurocognition: Implications for Anterior Cruciate Ligament Injury Risk and Prevention	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	41st Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUL, 2015	Orlando, FL	Amer Orthopaed Soc Sports Med		ACL; biomechanics; motion analysis; injury prevention	NEUROPSYCHOLOGICAL TEST PROTOCOL; LOWER-EXTREMITY BIOMECHANICS; SPORTS-RELATED CONCUSSION; TASK; COHORT; RETURN; PLAY; TOOL	Background: Neurocognitive status may be a risk factor for anterior cruciate ligament (ACL) injury. Neurocognitive domains such as visual attention, processing speed/reaction time, and dual-tasking may influence ACL injury risk via alterations to neuromuscular performance during athletic tasks. However, the relationship between neurocognition and performance during athletic tasks is not yet established. Hypothesis: Athletes with low baseline neurocognitive scores will demonstrate poorer jump landing performance compared with athletes with high baseline neurocognitive score. Study Design: Controlled laboratory study. Methods: Neurocognitive performance was measured using the Concussion Resolution Index (CRI). Three-dimensional kinematic and kinetic data of the dominant limb were collected for 37 recreational athletes while performing an unanticipated jump-landing task. Healthy, nonconcussed subjects were screened using a computer-based neurocognitive test into a high performers (HP; n = 20; average CRI percentile, 78th) and a low performers (LP; n = 17; average CRI percentile, 41st) group. The task consisted of a forward jump onto a force plate with an immediate rebound to a second target that was assigned 250 milliseconds before landing on the force plate. Kinematic and kinetic data were obtained during the first jump landing. Results: The LP group demonstrated significantly altered neuromuscular performance during the landing phase while completing the jump-landing task, including significantly increased peak vertical ground-reaction force (mean SD of LP vs HP: 1.81 0.53 vs 1.38 +/- 0.37 body weight [BW]; P < .01), peak anterior tibial shear force (0.91 +/- 0.17 vs 0.72 +/- 0.22 BW; P < .01), knee abduction moment (0.47 +/- 0.56 vs 0.03 +/- 0.64 BW x body height; P = .03), and knee abduction angle (6.1 degrees +/- 4.7 degrees vs 1.3 degrees +/- 5.6 degrees; P = .03), as well as decreased trunk flexion angle (9.6 degrees +/- 9.6 degrees vs 16.4 degrees +/- 11.2 degrees; P < .01). Conclusion: Healthy athletes with lower baseline neurocognitive performance generate knee kinematic and kinetic patterns that are linked to ACL injury. Clinical Relevance: Neurocognitive testing using the CRI may be useful for identification of athletes at elevated risk for future ACL injury.	[Herman, Daniel C.; Barth, Jeffrey T.] Univ Virginia, Charlottesville, VA USA; [Herman, Daniel C.] Univ Florida, Dept Orthopaed & Rehabil, Gainesville, FL USA; [Barth, Jeffrey T.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA		Herman, DC (corresponding author), Univ Florida, Dept Orthopaed & Rehabil, Div Phys Med & Rehabil, POB 112727, Gainesville, FL 32608 USA.	hermadc@ortho.ufl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD001097] Funding Source: Medline		Beynnon BD, 2014, AM J SPORT MED, V42, P1806, DOI 10.1177/0363546514540862; Brown TN, 2009, BRIT J SPORT MED, V43, P1049, DOI 10.1136/bjsm.2008.055954; Chappell JD, 2005, AM J SPORT MED, V33, P1022, DOI 10.1177/0363546504273047; Dai BY, 2012, RES SPORTS MED, V20, P180, DOI 10.1080/15438627.2012.680990; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Goetschius J, 2012, AM J SPORT MED, V40, P1978, DOI 10.1177/0363546512456972; Herman DC, 2008, AM J SPORT MED, V36, P733, DOI 10.1177/0363546507311602; Herman DC, 2015, CURR SPORT MED REP, V14, P194, DOI 10.1249/JSR.0000000000000157; Herman DC, 2009, AM J SPORT MED, V37, P1301, DOI 10.1177/0363546509332253; Herman DC, SPORTS MED IN PRESS; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Joseph AM, 2013, J ATHL TRAINING, V48, P810, DOI 10.4085/1062-6050-48.6.03; Joy EA, 2013, J STRENGTH COND RES, V27, P2263, DOI 10.1519/JSC.0b013e31827ef12e; Kamath GV, 2014, AM J SPORT MED, V42, P1638, DOI 10.1177/0363546514524164; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Mall NA, 2014, AM J SPORT MED, V42, P2363, DOI 10.1177/0363546514542796; Miranda DL, 2013, J BIOMECH, V46, P567, DOI 10.1016/j.jbiomech.2012.09.023; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Saunders N, 2010, BRIT J SPORT MED, V44, P1128, DOI 10.1136/bjsm.2009.069039; Shultz SJ, 2012, J ELECTROMYOGR KINES, V22, P124, DOI 10.1016/j.jelekin.2011.11.001; Smith HC, 2012, SPORTS HEALTH, V4, P69, DOI 10.1177/1941738111428281; Smith HC, 2012, AM J SPORT MED, V40, P521, DOI 10.1177/0363546511429776; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Weinhandl JT, 2010, J APPL BIOMECH, V26, P444, DOI 10.1123/jab.26.4.444; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4	30	45	45	1	34	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2016	44	9					2347	2353		10.1177/0363546516657338			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Sport Sciences	DV6CU	WOS:000383019300025	27474381	Green Accepted			2022-02-06	
J	Tan, XL; Wright, DK; Liu, SJ; Hovens, C; O'Brien, TJ; Shultz, SR				Tan, Xin L.; Wright, David K.; Liu, Shijie; Hovens, Christopher; O'Brien, Terence J.; Shultz, Sandy R.			Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes	NEUROPHARMACOLOGY			English	Article						concussion; chronic traumatic encephalopathy; MRI; diffusion tensor imaging; traumatic brain injury; tauopathy	FLUID PERCUSSION INJURY; OXIDATIVE STRESS; ANIMAL-MODEL; RAT MODEL; REDUCES NEUROINFLAMMATION; ALZHEIMERS-DISEASE; PHOSPHORYLATION; NEURODEGENERATION; UBIQUITIN; ANTIBODY	Mild traumatic brain injuries may result in cumulative brain damage and neurodegenerative disease. To date, there is no pharmaceutical intervention known to prevent these consequences. Hyperphosphorylated tau has been associated in this process, and protein phosphatase 2A 55 kDa regulatory B subunit (PP2A/PR55) - the major tau phosphatase-is decreased after a brain insult. Sodium selenate up-regulates PP2A/PR55 and dephosphorylates tau, and may hold promise as a treatment in the mild brain injury setting. Here we investigated sodium selenate treatment in rats given repeated mild traumatic brain injuries. Rats were given three mild fluid percussion injuries or three sham-injuries, and treated with sodium selenate (1 mg/kg/day) or saline-vehicle for three months before undergoing behavioral testing, MRI, and post-mortem analysis of brain tissue. Repeated mild traumatic brain injuries increased the phosphorylation of tau and decreased PP2A/PR55, whilst inducing brain atrophy and cognitive and sensorimotor deficits. Sodium selenate treatment increased PP2A/PR55, and decreased tau phosphorylation, brain damage, and cognitive and motor impairments in rats given repeated mild traumatic brain injuries. Our findings implicate PP2A/PR55 and tau as important mechanisms in the pathophysiological aftermath of repeated mild brain traumas, and support sodium selenate as a novel and translatable treatment for these common injuries. (C) 2016 Elsevier Ltd. All rights reserved.	[Tan, Xin L.; Liu, Shijie; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Hovens, Christopher] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic 3050, Australia		Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Off 1 02, Melbourne Brain Ctr, Parkville, Vic 3052, Australia.	sshultz@unimelb.edu.au	O'Brien, Terence/L-8102-2013; O'Brien, Terence/AAU-5525-2021	O'Brien, Terence/0000-0002-7198-8621; Hovens, Christopher/0000-0002-0610-1289; Wright, David/0000-0002-7535-8651	NHMRCNational Health and Medical Research Council of Australia [1062653]; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); NHMRCNational Health and Medical Research Council of Australia	This study was funded by a grant to SRS from the NHMRC (#1062653), and fellowships to SRS from the Canadian Institute of Health Research and the NHMRC. The authors declare that there are no competing financial interests in relation to this work.	Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bolognin S, 2012, ACTA NEUROPATHOL, V123, P133, DOI 10.1007/s00401-011-0908-x; Calamante F, 2010, NEUROIMAGE, V53, P1233, DOI 10.1016/j.neuroimage.2010.07.024; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Dias-Santagata D, 2007, J CLIN INVEST, V117, P236, DOI 10.1172/JCI28769; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gendron TF, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-13; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gotz J, 2010, BBA-MOL BASIS DIS, V1802, P860, DOI 10.1016/j.bbadis.2009.09.008; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Koh PO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054217; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lauckner J, 2003, NEUROBIOL AGING, V24, P767, DOI 10.1016/S0197-4580(02)00228-2; Lee MJ, 2013, PROG NEUROBIOL, V105, P49, DOI 10.1016/j.pneurobio.2013.03.001; Li B, 2007, ACTA NEUROPATHOL, V113, P501, DOI 10.1007/s00401-007-0207-8; Liang ZH, 2009, J ALZHEIMERS DIS, V17, P531, DOI 10.3233/JAD-2009-1069; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu S., 2016, BRAIN IN PRESS; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Oberg EA, 2012, J BIOL CHEM, V287, P43378, DOI 10.1074/jbc.M112.420281; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2015, BEHAV BRAIN RES, V278, P542, DOI 10.1016/j.bbr.2014.10.050; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2014, NEUROTHERAPEUTICS, V11, P347, DOI 10.1007/s13311-014-0258-1; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P287, DOI 10.1093/jnen/63.4.287; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun KJ, 2013, BRAIN RES, V1506, P132, DOI 10.1016/j.brainres.2013.02.011; Tournier JD, 2013, NMR BIOMED, V26, P1775, DOI 10.1002/nbm.3017; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; Wang T, 2013, RESTOR NEUROL NEUROS, V31, P647, DOI 10.3233/RNN-130316; Weaver LC, 2015, EXP NEUROL, V271, P409, DOI 10.1016/j.expneurol.2015.07.003; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Zheng P, 2014, MOL NEUROBIOL, V49, P1532, DOI 10.1007/s12035-013-8601-9; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880	67	45	45	1	44	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	SEP	2016	108						382	393		10.1016/j.neuropharm.2016.05.001			12	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	DQ1IA	WOS:000378953500038	27163189				2022-02-06	
J	Hwang, J; Castelli, DM; Gonzalez-Lima, F				Hwang, Jungyun; Castelli, Darla M.; Gonzalez-Lima, F.			Cognitive enhancement by transcranial laser stimulation and acute aerobic exercise	LASERS IN MEDICAL SCIENCE			English	Article						Low-level laser therapy; Photobiomodulation; Cognitive enhancement; Transcranial laser stimulation; Acute aerobic exercise	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; WORKING-MEMORY; SLEEP-DEPRIVATION; INFRARED LIGHT; PERFORMANCE; LEVEL; THERAPY; TASK; MECHANISMS	This is the first randomized, controlled study comparing the cognitive effects of transcranial laser stimulation and acute aerobic exercise on the same cognitive tasks. We examined whether transcranial infrared laser stimulation of the prefrontal cortex, acute high-intensity aerobic exercise, or the combination may enhance performance in sustained attention and working memory tasks. Sixty healthy young adults were randomly assigned to one of the following four treatments: (1) low-level laser therapy (LLLT) with infrared laser to two forehead sites while seated (total 8 min, 1064 nm continuous wave, 250 mW/cm(2), 60 J/cm(2) per site of 13.6 cm(2)); (2) acute exercise (EX) of high-intensity (total 20 min, with 10-min treadmill running at 85-90 % VO(2)max); (3) combined treatment (LLLT + EX); or (4) sham control (CON). Participants were tested for prefrontal measures of sustained attention with the psychomotor vigilance task (PVT) and working memory with the delayed match-to-sample task (DMS) before and after the treatments. As compared to CON, both LLLT and EX reduced reaction time in the PVT [F(1.56) = 4.134, p = 0.01, eta (2) = 0.181] and increased the number of correct responses in the DMS [F(1.56) = 4.690, p = 0.005, eta (2) = 0.201], demonstrating a significant enhancing effect of LLLT and EX on cognitive performance. LLLT + EX effects were similar but showed no significantly greater improvement on PVT and DMS than LLLT or EX alone. The transcranial infrared laser stimulation and acute aerobic exercise treatments were similarly effective for cognitive enhancement, suggesting that they augment prefrontal cognitive functions similarly.	[Hwang, Jungyun; Castelli, Darla M.] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA; [Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA; [Gonzalez-Lima, F.] Univ Texas Austin, Inst Neurosci, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA		Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Dept Psychol, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA.; Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Inst Neurosci, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA.	gonzalezlima@utexas.edu	Castelli, Darla/G-1307-2015	Castelli, Darla/0000-0002-8862-578X; Hwang, Jungyun/0000-0001-7538-4414; Gonzalez-Lima, Francisco/0000-0001-9856-0775	FGL from an institutional research fellowship from the College of Liberals Arts of the University of Texas at Austin	The authors thank the Kinetic kidz laboratory members including Yen T. Chen, Jihoon Kim, Yeonhak Jung, Jeremy Setty, Hannah G. Calvert, and Elizabeth M. Glowacki for their help with data collection. The authors would also like to thank Dr. Douglas Barrett for their support with the cognitive tasks and Dr. R. Matthew Brothers and Dr. John L. Ivy for their support of our research. JH did this study in partial fulfillment of the requirements for a Ph.D. degree at The University of Texas at Austin. Research reported in this publication was supported by FGL from an institutional research fellowship from the College of Liberals Arts of the University of Texas at Austin. FGL holds the endowed George I. Sanchez Centennial Professorship in Liberal Arts and Sciences.	Ando S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063630; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Basner M, 2011, ACTA ASTRONAUT, V69, P949, DOI 10.1016/j.actaastro.2011.07.015; Blanco NJ, 2017, J NEUROPSYCHOL, V11, P14, DOI 10.1111/jnp.12074; Castaneda AE, 2008, J AFFECT DISORDERS, V106, P1, DOI 10.1016/j.jad.2007.06.006; Chang YK, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00156; Chudasama Y, 2010, ENCY PSYCHOPHARMACOL, VI, P372; Coles K, 2008, J SPORT SCI, V26, P333, DOI 10.1080/02640410701591417; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; DINGES DF, 1985, BEHAV RES METH INSTR, V17, P652, DOI 10.3758/BF03200977; Drummond SPA, 2005, SLEEP, V28, P1059; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gligoroska Jasmina Pluncevic, 2012, Mater Sociomed, V24, P198, DOI 10.5455/msm.2012.24.198-202; Gonzalez-Lima F, 2014, BIOCHEM PHARMACOL, V88, P584, DOI 10.1016/j.bcp.2013.11.010; Gonzalez-Lima F, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00036; Griffin EW, 2011, PHYSIOL BEHAV, V104, P934, DOI 10.1016/j.physbeh.2011.06.005; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; Ide K, 2000, PROG NEUROBIOL, V61, P397, DOI 10.1016/S0301-0082(99)00057-X; Kamijo K, 2004, CLIN NEUROPHYSIOL, V115, P2693, DOI 10.1016/j.clinph.2004.06.016; Kaufman N. L., 1990, KAUFMAN BRIEF INTELL, P1; Lara T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088820; Lawrence NS, 2003, J COGNITIVE NEUROSCI, V15, P1028, DOI 10.1162/089892903770007416; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099222; Maguire EA, 1999, BRAIN, V122, P1839, DOI 10.1093/brain/122.10.1839; Martins AQ, 2013, PSYCHOL SPORT EXERC, V14, P323, DOI 10.1016/j.psychsport.2012.11.010; MILLER LS, 1992, PHYSIOL BEHAV, V52, P839, DOI 10.1016/0031-9384(92)90359-A; Mueller ST, 2014, J NEUROSCI METH, V222, P250, DOI 10.1016/j.jneumeth.2013.10.024; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Nieder A, 2004, P NATL ACAD SCI USA, V101, P7457, DOI 10.1073/pnas.0402239101; Ogoh S, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12163; Ogoh S, 2009, J APPL PHYSIOL, V107, P1370, DOI 10.1152/japplphysiol.00573.2009; Picard M, 2014, P NATL ACAD SCI USA, V111, P7, DOI 10.1073/pnas.1321881111; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Scott JPR, 2006, PHYSIOL BEHAV, V87, P396, DOI 10.1016/j.physbeh.2005.11.009; Shansky RM, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00123; Sibley BA, 2007, J SPORT EXERCISE PSY, V29, P783, DOI 10.1123/jsep.29.6.783; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Yanagisawa H, 2010, NEUROIMAGE, V50, P1702, DOI 10.1016/j.neuroimage.2009.12.023; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	46	45	45	2	29	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-8921	1435-604X		LASER MED SCI	Lasers Med. Sci.	AUG	2016	31	6					1151	1160		10.1007/s10103-016-1962-3			10	Engineering, Biomedical; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Surgery	DR4CQ	WOS:000379849500014	27220529				2022-02-06	
J	D'Andrea, A; Conte, M; Cavallaro, M; Scarafile, R; Riegler, L; Cocchia, R; Pezzullo, E; Carbone, A; Natale, F; Santoro, G; Caso, P; Russo, MG; Bossone, E; Calabro, R				D'Andrea, Antonello; Conte, Marianna; Cavallaro, Massimo; Scarafile, Raffaella; Riegler, Lucia; Cocchia, Rosangela; Pezzullo, Enrica; Carbone, Andreina; Natale, Francesco; Santoro, Giuseppe; Caso, Pio; Russo, Maria Giovanna; Bossone, Eduardo; Calabro, Raffaele			Transcranial Doppler ultrasonography: From methodology to major clinical applications	WORLD JOURNAL OF CARDIOLOGY			English	Article						Transcranial Doppler ultrasonography; Lindegaard ratio; Paradoxical embolism; Microembolic signals; Middle cerebral artery; Patent foramen ovale; Cryptogenic STroke; Vasospasm; Acute subarachnoid hemorrhage; Ischemic stroke	PATENT FORAMEN OVALE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; DYNAMIC CEREBRAL AUTOREGULATION; TISSUE-PLASMINOGEN ACTIVATOR; TO-LEFT SHUNT; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW VELOCITY; HEALTH-CARE PROFESSIONALS; CAROTID-ARTERY STENOSIS; ATRIAL SEPTAL ANEURYSM	Non-invasive Doppler ultrasonographic study of cerebral arteries [transcranial Doppler (TCD)] has been extensively applied on both outpatient and inpatient settings. It is performed placing a low-frequency (<= 2 MHz) transducer on the scalp of the patient over specific acoustic windows, in order to visualize the intracranial arterial vessels and to evaluate the cerebral blood flow velocity and its alteration in many different conditions. Nowadays the most widespread indication for TCD in outpatient setting is the research of right to left shunting, responsable of so called "paradoxical embolism", most often due to patency of foramen ovale which is responsable of the majority of cryptogenic strokes occuring in patients younger than 55 years old. TCD also allows to classify the grade of severity of such shunts using the so called "microembolic signal grading score". In addition TCD has found many useful applications in neurocritical care practice. It is useful on both adults and children for day-to-day bedside assessment of critical conditions including vasospasm in subarachnoidal haemorrhage (caused by aneurysm rupture or traumatic injury), traumatic brain injury, brain stem death. It is used also to evaluate cerebral hemodynamic changes after stroke. It also allows to investigate cerebral pressure autoregulation and for the clinical evaluation of cerebral autoregulatory reserve.	[D'Andrea, Antonello; Conte, Marianna; Cavallaro, Massimo; Scarafile, Raffaella; Riegler, Lucia; Cocchia, Rosangela; Pezzullo, Enrica; Carbone, Andreina; Natale, Francesco; Santoro, Giuseppe; Caso, Pio; Russo, Maria Giovanna; Calabro, Raffaele] Univ Naples 2, Integrated Diagnost Cardiol, AORN dei Colli, Monaldi Hosp, Corso Vittorio Emanuele 121A, I-80121 Naples, Italy; [Bossone, Eduardo] Univ Hosp, Dept Cardiol & Cardiac Surg, I-84131 Salerno, Italy		D'Andrea, A (corresponding author), Univ Naples 2, Integrated Diagnost Cardiol, AORN dei Colli, Monaldi Hosp, Corso Vittorio Emanuele 121A, I-80121 Naples, Italy.	antonellodandrea@libero.it	Santoro, Giuseppe/AAC-2104-2019; Bossone, Eduardo/Z-1305-2019; Santoro, Giuseppe/AAV-3233-2021	RUSSO, Maria Giovanna/0000-0003-3860-6158; carbone, andreina/0000-0002-2190-7010			AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R., 1986, TRANSCRANIAL DOPPLER, P22, DOI [10.1007/978-3-7091-8864-4_3, DOI 10.1007/978-3-7091-8864-4_3]; Adams RJ, 2005, PEDIATR RADIOL, V35, P229, DOI 10.1007/s00247-005-1409-7; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; Alexandrov AV, 2001, CIRCULATION, V103, P2897, DOI 10.1161/01.CIR.103.24.2897; Antignani P L, 2012, Int Angiol, V31, P1; Anzola GP, 2004, STROKE, V35, P2140, DOI 10.1161/01.STR.0000137764.07815.de; Arenillas JF, 2001, STROKE, V32, P2898, DOI 10.1161/hs1201.099652; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; Babikian V, 1993, J Neuroimaging, V3, P242; Baracchini C, 2000, STROKE, V31, P2942, DOI 10.1161/01.STR.31.12.2942; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; BOGDAHN U, 1990, STROKE, V21, P1680, DOI 10.1161/01.STR.21.12.1680; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P153, DOI 10.1097/MCC.0000000000000071; BRUNO A, 1988, STROKE, V19, P135, DOI 10.1161/01.STR.19.10.1300; CABANES L, 1993, STROKE, V24, P1865, DOI 10.1161/01.STR.24.12.1865; Camerlingo M, 1996, ITAL J NEUROL SCI, V17, P215, DOI 10.1007/BF01995686; Chang JJ, 2016, AM J NEURORADIOL, V37, P408, DOI 10.3174/ajnr.A4548; Christou I, 2001, J NEUROIMAGING, V11, P236, DOI 10.1111/j.1552-6569.2001.tb00040.x; Christou I, 2000, STROKE, V31, P1812, DOI 10.1161/01.STR.31.8.1812; Clarke N R A, 2004, Eur J Echocardiogr, V5, P176, DOI 10.1016/S1525-2167(03)00076-3; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; D'Andrea A, 2011, J CARDIOVASC MED, V12, P527, DOI 10.2459/JCM.0b013e32834976d6; Daniels Cathy, 2004, Eur J Echocardiogr, V5, P449, DOI 10.1016/j.euje.2004.04.004; Demchuk AM, 2001, STROKE, V32, P89, DOI 10.1161/01.STR.32.1.89; Demchuk AM, 2000, J NEUROIMAGING, V10, P1; DITULLIO M, 1992, ANN INTERN MED, V117, P461, DOI 10.7326/0003-4819-117-6-461; Dorsch N, 2011, ACTA NEUROCHIR SUPPL, V110, P5, DOI 10.1007/978-3-7091-0353-1_1; DROSTE DW, 1989, STROKE, V20, P1005, DOI 10.1161/01.STR.20.8.1005; Ducrocq X, 1998, J NEUROL SCI, V160, P41, DOI 10.1016/S0022-510X(98)00188-9; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Ghosh S, 2007, POSTGRAD MED J, V83, P173, DOI 10.1136/pgmj.2006.051094; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Godart F, 2000, EUR HEART J, V21, P483, DOI 10.1053/euhj.1999.1944; Gonzalez NR, 2007, J NEUROSURG, V107, P1101, DOI 10.3171/JNS-07/12/1101; Gonzalez-Alujas T, 2011, REV ESP CARDIOL, V64, P133, DOI [10.1016/j.rec.2010.10.014, 10.1016/j.recesp.2010.10.009]; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; Hara H, 2005, J AM COLL CARDIOL, V46, P1768, DOI 10.1016/j.jacc.2005.08.038; HARDERS A, 1985, Neurological Research, V7, P129; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; Homma S, 2002, CIRCULATION, V105, P2625, DOI 10.1161/01.CIR.0000017498.88393.44; Inzitari D, 2006, NEUROL SCI, V27, pS225, DOI 10.1007/s10072-006-0622-y; Inzitari D., 2000, Neurological Sciences, V21, P5; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jauss M, 2000, CEREBROVASC DIS, V10, P490, DOI 10.1159/000016119; Johansson MC, 2010, J AM SOC ECHOCARDIOG, V23, P1136, DOI 10.1016/j.echo.2010.08.004; Kaps M, 2008, EUR NEUROL, V59, P9, DOI 10.1159/000114455; Kerut EK, 2001, J AM COLL CARDIOL, V38, P613, DOI 10.1016/S0735-1097(01)01427-9; Keyrouz SG, 2007, CRIT CARE, V11, DOI 10.1186/cc5958; Knauth M, 1997, BRIT MED J, V314, P701, DOI 10.1136/bmj.314.7082.701; Kuhl HP, 1999, J AM COLL CARDIOL, V34, P1823, DOI 10.1016/S0735-1097(99)00412-X; KUSHNER MJ, 1991, NEUROLOGY, V41, P109, DOI 10.1212/WNL.41.1.109; Lamy C, 2002, STROKE, V33, P706, DOI 10.1161/hs0302.104543; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; Lange MC, 2010, J NEUROL SCI, V293, P106, DOI 10.1016/j.jns.2010.02.003; Lefevre J, 2008, ARCH CARDIOVASC DIS, V101, P213, DOI 10.1016/S1875-2136(08)73695-7; LEVINE BD, 1994, CIRCULATION, V90, P298, DOI 10.1161/01.CIR.90.1.298; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; Llompart-Pou JA, 2013, ISRN CRITICAL CARE, DOI [10.5402/2013/167468, DOI 10.5402/2013/167468]; Lysakowski C, 2001, STROKE, V32, P2292, DOI 10.1161/hs1001.097108; Marinoni M, 1997, ULTRASOUND MED BIOL, V23, P1275, DOI 10.1016/S0301-5629(97)00077-X; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN PJ, 1994, STROKE, V25, P390, DOI 10.1161/01.STR.25.2.390; McGirt Matthew J, 2003, J Stroke Cerebrovasc Dis, V12, P88, DOI 10.1053/jscd.2003.10; Meier B, 2003, CIRCULATION, V107, P5, DOI 10.1161/01.CIR.0000046073.34261.C1; MELTZER RS, 1980, J CLIN ULTRASOUND, V8, P121, DOI 10.1002/jcu.1870080205; Mojadidi MK, 2014, JACC-CARDIOVASC IMAG, V7, P236, DOI 10.1016/j.jcmg.2013.12.011; Monteiro LM, 2006, INTENS CARE MED, V32, P1937, DOI 10.1007/s00134-006-0353-9; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; Moreno J A, 2000, Neurosurg Focus, V8, pe8; Nicoletto Heather A, 2009, Am J Electroneurodiagnostic Technol, V49, P14; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 2008, CARDIOVASC ENG, V8, P42, DOI 10.1007/s10558-007-9044-6; Panerai RB, 2009, CLIN AUTON RES, V19, P197, DOI 10.1007/s10286-009-0011-8; Papaioannou V, 2008, GREEK EJ PERIOP MED, V6, P95; Patel PM, 2009, MILLERS ANESTHESIA, P305; Paulus J, 2014, INTENS CARE MED, V40, P1783, DOI 10.1007/s00134-014-3447-9; Platt Orah S, 2006, Hematology Am Soc Hematol Educ Program, P54; Poularas J, 2006, TRANSPL P, V38, P1213, DOI 10.1016/j.transproceed.2006.02.127; Pristipino C, 2013, G ITAL CARDIOL, V14, P699, DOI 10.1714/1335.14838; Puppo C, 2008, NEUROCRIT CARE, V8, P344, DOI 10.1007/s12028-008-9069-8; Rajamani K, 2001, BIOMED PHARMACOTHER, V55, P247, DOI 10.1016/S0753-3322(01)00063-4; Rasulo EA, 2008, EUR J ANAESTH, V25, P167, DOI 10.1017/S0265021507003341; Razumovsky AY, 1999, ACTA NEUROL SCAND, V99, P65; Reinhard M, 2003, STROKE, V34, P2138, DOI 10.1161/01.STR.0000087788.65566.AC; Rigamonti A, 2008, CAN J ANAESTH, V55, P112, DOI 10.1007/BF03016323; Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264; Saqqur M, 2007, CRIT CARE MED, V35, pS216, DOI 10.1097/01.CCM.0000260633.66384.FB; Sarkar S, 2007, POSTGRAD MED J, V83, P683, DOI 10.1136/pgmj.2007.058602; Schondorf R, 2001, J APPL PHYSIOL, V91, P2493, DOI 10.1152/jappl.2001.91.6.2493; Serena J, 1998, STROKE, V29, P1322, DOI 10.1161/01.STR.29.7.1322; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Skjelland M, 2009, STROKE, V40, P230, DOI 10.1161/STROKEAHA.107.513341; Sloan MA, 2004, NEUROLOGY, V62, P1468, DOI 10.1212/WNL.62.9.1468; Sorensen SG, 2010, J INTERV CARDIOL, V23, P575, DOI 10.1111/j.1540-8183.2010.00587.x; Souteyrand G, 2006, EUR J ECHOCARDIOGR, V7, P147, DOI 10.1016/j.euje.2005.04.007; Stolz E, 2008, STROKE, V39, P3255, DOI 10.1161/STROKEAHA.108.522714; Sviri GE, 2006, NEUROSURGERY, V59, P360, DOI 10.1227/01.NEU.0000223502.93013.6E; Tegeler CH, 2013, J NEUROIMAGING, V23, P466, DOI 10.1111/j.1552-6569.2012.00711.x; Tiecks FP, 1996, STROKE, V27, P1177, DOI 10.1161/01.STR.27.7.1177; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Topcuoglu M. Akif, 2002, Curr Treat Options Cardiovasc Med, V4, P373, DOI 10.1007/s11936-002-0017-1; Tsivgoulis G, 2007, STROKE, V38, P1245, DOI 10.1161/01.STR.0000259712.64772.85; Tsivgoulis G, 2009, CURR NEUROL NEUROSCI, V9, P46, DOI 10.1007/s11910-009-0008-7; Ursino M, 2003, MED ENG PHYS, V25, P655, DOI 10.1016/S1350-4533(02)00251-5; Van Camp G, 2000, AM J CARDIOL, V86, P1284, DOI 10.1016/S0002-9149(00)01224-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Velat GJ, 2011, WORLD NEUROSURG, V76, P446, DOI 10.1016/j.wneu.2011.02.030; Washington CW, 2011, NEUROCRIT CARE, V15, P312, DOI 10.1007/s12028-011-9594-8; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y; White RP, 1997, STROKE, V28, P1340, DOI 10.1161/01.STR.28.7.1340; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1003, DOI 10.1212/WNL.45.5.1003; Woods TD, 2006, J AM SOC ECHOCARDIOG, V19, P215, DOI 10.1016/j.echo.2005.09.023; Wozniak MA, 1996, J NEUROIMAGING, V6, P87, DOI 10.1111/jon19966287; Wu LA, 2004, ARCH INTERN MED, V164, P950, DOI 10.1001/archinte.164.9.950; Zoghbi WA, 2014, JACC-CARDIOVASC IMAG, V7, P251, DOI 10.1016/j.jcmg.2014.01.007; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X	129	45	45	0	1	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1949-8462			WORLD J CARDIOL	World J. Cardiol.	JUL 26	2016	8	7					383	400		10.4330/wjc.v8.i7.383			18	Cardiac & Cardiovascular Systems	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	DV6ZC	WOS:000383084600001	27468332	hybrid, Green Published			2022-02-06	
J	Broglio, SP; Williams, RM; O'Connor, KL; Goldstick, J				Broglio, Steven P.; Williams, Richelle M.; O'Connor, Kathryn L.; Goldstick, Jason			Football Players' Head-Impact Exposure After Limiting of Full-Contact Practices	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; traumatic brain injuries; protective equipment	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; ICE HOCKEY PLAYERS; NEUROCOGNITIVE PERFORMANCE; BRAIN-INJURY; CONCUSSION; NEURODEGENERATION; SPORT; RISK; BIOMECHANICS	Context: Sporting organizations limit full-contact football practices to reduce concussion risk and based on speculation that repeated head impacts may result in long-term neurode-generation. Objective: To directly compare head-impact exposure in high school football players before and after a statewide restriction on full-contact practices. Design: Cross-sectional study. Setting: High school football field. Patients or Other Participants: Participants were varsity football athletes from a single high school. Before the rule change, 26 athletes (age = 16.2 +/- 0.8 years, height = 179.6 +/- 6.4 cm, weight = 81.9 +/- 13.1 kg) participated. After the rule change, 24 athletes (age = 15.9 +/- 0.8 years, height = 178.3 +/- 6.5 cm, weight = 76.2 +/- 11.6 kg) participated. Nine athletes participated in both years of the investigation. Main Outcome Measure(s): Head-impact exposure was monitored using the Head Impact Telemetry System while the athletes participated in football games and practices in the seasons before and after the rule change. Head-impact frequency, location, and magnitude (ie, linear acceleration, rotational acceleration, and Head Impact Telemetry severity profile [HITsp], respectively) were measured. Results: A total of 15 398 impacts (592 impacts per player per season) were captured before the rule change and 8269 impacts (345 impacts per player per season) after the change. An average 42% decline in impact exposure occurred across all players, with practice-exposure declines occurring among linemen (46% decline); receivers, cornerbacks, and safeties (41% decline); and tight ends, running backs (including fullbacks), and linebackers (39% decline). Impact magnitudes remained largely unchanged between the years. Conclusions: A rule change limiting full-contact high school football practices appears to have been effective in reducing head-impact exposure across all players, with the largest reduction occurring among linemen. This finding is likely associated with the rule modification, particularly because the coaching staff and offensive scheme remained consistent, yet how this reduction influences concussion risk and long-term cognitive health remains unknown.	[Broglio, Steven P.; Williams, Richelle M.; O'Connor, Kathryn L.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Goldstick, Jason] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Broglio, Steven P.; Goldstick, Jason] Univ Michigan, Injury Ctr, Ann Arbor, MI 48109 USA		Broglio, SP (corresponding author), Univ Michigan, Injury Ctr, NeuroTrauma Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu		Van Pelt, Kathryn/0000-0002-5494-2357; Williams, Richelle/0000-0003-4728-7443	National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS081691]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS081691] Funding Source: NIH RePORTER	We thank Brian Lemons and the players and staff at Father Gabriel Richard High School for their support with this project. Dr Broglio and Mrs Williams received funding from the National Institutes of Health National Institute of Neurological Disorders and Stroke (1R15NS081691).	[Anonymous], COLL BARG AGR; [Anonymous], LTD CONT PRACT RUL; [Anonymous], NEW FOOTB PRACT POL; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bloser F., 1994, NFL MORTALITY STUDY; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Cobb Bryan R, 2014, Biomed Sci Instrum, V50, P285; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Daniel Ray W, 2014, Biomed Sci Instrum, V50, P291; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan W, 2015, NEUROLOGY, V85, P1504, DOI 10.1212/WNL.0000000000001893; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; National Collegiate Athletic Association, FOOTB PRACT GUID; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tsyvaer AT, 1981, BRIT J SPORT MED, V15, P163; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	51	45	45	0	14	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL	2016	51	7					511	518		10.4085/1062-6050-51.7.04			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EI9VP	WOS:000392857800002	27333460	Bronze, Green Published			2022-02-06	
J	Cardim, D; Robba, C; Donnelly, J; Bohdanowicz, M; Schmidt, B; Damian, M; Varsos, GV; Liu, XY; Cabeleira, M; Frigieri, G; Cabella, B; Smielewski, P; Mascarenhas, S; Czosnyka, M				Cardim, Danilo; Robba, Chiara; Donnelly, Joseph; Bohdanowicz, Michal; Schmidt, Bernhard; Damian, Maxwell; Varsos, Georgios V.; Liu, Xiuyun; Cabeleira, Manuel; Frigieri, Gustavo; Cabella, Brenno; Smielewski, Peter; Mascarenhas, Sergio; Czosnyka, Marek			Prospective Study on Noninvasive Assessment of Intracranial Pressure in Traumatic Brain-Injured Patients: Comparison of Four Methods	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; noninvasive ICP monitoring; transcranial Doppler	CEREBRAL PERFUSION-PRESSURE; TRANSCRANIAL DOPPLER SONOGRAPHY; CRITICAL CLOSING PRESSURE; PULSATILITY INDEX; CLINICAL-EXPERIENCE; BLOOD-FLOW; ICP; ULTRASONOGRAPHY; PREDICTION; DYNAMICS	Elevation of intracranial pressure (ICP) may occur in many diseases, and therefore the ability to measure it noninvasively would be useful. Flow velocity signals from transcranial Doppler (TCD) have been used to estimate ICP; however, the relative accuracy of these methods is unclear. This study aimed to compare four previously described TCD-based methods with directly measured ICP in a prospective cohort of traumatic brain-injured patients. Noninvasive ICP (nICP) was obtained using the following methods: 1) a mathematical "black-box" model based on interaction between TCD and arterial blood pressure (nICP_BB); 2) based on diastolic flow velocity (nICP_FVd); 3) based on critical closing pressure (nICP_CrCP); and 4) based on TCD-derived pulsatility index (nICP_PI). In time domain, for recordings including spontaneous changes in ICP greater than 7 mm Hg, nICP_PI showed the best correlation with measured ICP (R = 0.61). Considering every TCD recording as an independent event, nICP_BB generally showed to be the best estimator of measured ICP (R = 0.39; p < 0.05; 95% confidence interval [CI] = 9.94 mm Hg; area under the curve [AUC] = 0.66; p < 0.05). For nICP_FVd, although it presented similar correlation coefficient to nICP_BB and marginally better AUC (0.70; p < 0.05), it demonstrated a greater 95% CI for prediction of ICP (14.62 mm Hg). nICP_CrCP presented a moderate correlation coefficient (R = 0.35; p < 0.05) and similar 95% CI to nICP_BB (9.19 mm Hg), but failed to distinguish between normal and raised ICP (AUC = 0.64; p > 0.05). nICP_PI was not related to measured ICP using any of the above statistical indicators. We also introduced a new estimator (nICP_Av) based on the average of three methods (nICP_BB, nICP_FVd, and nICP_CrCP), which overall presented improved statistical indicators (R = 0.47; p < 0.05; 95% CI = 9.17 mm Hg; AUC = 0.73; p < 0.05). nICP_PI appeared to reflect changes in ICP in time most accurately. nICP_BB was the best estimator for ICP "as a number." nICP_Av demonstrated to improve the accuracy of measured ICP estimation.	[Cardim, Danilo; Donnelly, Joseph; Varsos, Georgios V.; Liu, Xiuyun; Cabeleira, Manuel; Cabella, Brenno; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Robba, Chiara] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; [Bohdanowicz, Michal; Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Schmidt, Bernhard] Univ Hosp Chemnitz, Dept Neurol, Chemnitz, Germany; [Damian, Maxwell] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Neurol, Cambridge, England; [Frigieri, Gustavo; Mascarenhas, Sergio] Univ Sao Paulo, Phys Inst Sao Carlos, Sao Carlos, SP, Brazil		Cardim, D (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	dac69@cam.ac.uk	Cabella, Brenno C.T./G-6169-2012; Donnelly, Joseph/N-6803-2019; Robba, Chiara/AAS-7421-2020; Liu, Xiuyun/V-4427-2017; Cardim, Danilo Augusto/B-8447-2012; Donnelly, Joseph/E-9235-2018	Cabella, Brenno C.T./0000-0003-2214-645X; Donnelly, Joseph/0000-0002-6502-8069; Liu, Xiuyun/0000-0001-9540-4865; Cardim, Danilo Augusto/0000-0002-9261-1321; Donnelly, Joseph/0000-0002-6502-8069; czosnyka, marek/0000-0003-2446-8006; Smielewski, Peter/0000-0001-5096-3938	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: Medline		Alperin NJ, 2000, RADIOLOGY, V217, P877, DOI 10.1148/radiology.217.3.r00dc42877; Asil T, 2003, J ULTRAS MED, V22, P1049, DOI 10.7863/jum.2003.22.10.1049; Bartusis L, 2012, ELEKTRON ELEKTROTECH, V122, P45, DOI 10.5755/j01.eee.122.6.1194; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Budohoski Karol P, 1800, Acta Neurochir Suppl, V114, P121, DOI 10.1007/978-3-7091-0956-4_22; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; CZOSNYKA M, 1994, ULTRASOUND MED BIOL, V20, P391, DOI 10.1016/0301-5629(94)90008-6; Czosnyka M, 1996, J NEUROSURG, V84, P79, DOI 10.3171/jns.1996.84.1.0079; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; DAHL A, 1992, STROKE, V23, P15, DOI 10.1161/01.STR.23.1.15; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; Eide PK, 2010, J NEUROSURG, V113, P1317, DOI 10.3171/2010.7.JNS10483; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Frank AM, 2000, ZBL NEUROCHIR, V61, P177, DOI 10.1055/s-2000-15597; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; HANLO PW, 1995, ULTRASOUND MED BIOL, V21, P613, DOI 10.1016/0301-5629(94)00147-6; Hosmer D, 1989, APPL LOGISTIC REGRES; Jones HA, 2009, NURS CRIT CARE, V14, P303, DOI 10.1111/j.1478-5153.2009.00352.x; Kashif FM, 2008, COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2, P369, DOI 10.1109/CIC.2008.4749055; Kashif FM, 2012, SCI TRANSL MED, V129, P44; KASUGA Y, 1987, J NEUROSURG, V66, P907, DOI 10.3171/jns.1987.66.6.0907; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Marmarelis P. Z., 1978, ANAL PHYSL SYSTEM; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Michaeli D, 2002, J NEUROSURG, V96, P1132, DOI 10.3171/jns.2002.96.6.1132; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; NICHOL J, 1951, AM J PHYSIOL, V164, P330, DOI 10.1152/ajplegacy.1951.164.2.330; Popovic Djordje, 2009, Recent Patents on Biomedical Engineering, V2, P165, DOI 10.2174/1874764710902030165; Prunet B, 2012, AM J EMERG MED, V30, P936, DOI 10.1016/j.ajem.2011.05.005; Puppo Corina, 2012, Acta Neurochir Suppl, V114, P283, DOI 10.1007/978-3-7091-0956-4_55; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; Ragauskas A, 2003, MED ENG PHYS, V25, P667, DOI 10.1016/S1350-4533(03)00082-1; REID A, 1989, J NEUROL NEUROSUR PS, V52, P610, DOI 10.1136/jnnp.52.5.610; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Schmidt B, 1997, STROKE, V28, P2465, DOI 10.1161/01.STR.28.12.2465; Schmidt B, 2000, J NEUROSURG, V92, P793, DOI 10.3171/jns.2000.92.5.0793; Schmidt Bernhard, 2002, Eur J Ultrasound, V16, P37, DOI 10.1016/S0929-8266(02)00044-7; Shimbles S, 2005, PHYSIOL MEAS, V26, P1085, DOI 10.1088/0967-3334/26/6/017; Steinbach GC, 2005, AVIAT SPACE ENVIR MD, V76, P85; Ueno T, 1998, ACT NEUR S, V71, P66; Varsos GV, 2015, J NEUROSURG, V123, P638, DOI 10.3171/2014.10.JNS14613; Varsos GV, 2013, J CEREBR BLOOD F MET, V33, P235, DOI 10.1038/jcbfm.2012.161; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Wakerley B, 2014, J NEUROIMAGING, V24, P302, DOI 10.1111/j.1552-6569.2012.00745.x; Wakerley BR, 2015, J NEUROIMAGING, V25, P111, DOI 10.1111/jon.12100; Zhao YL, 2005, ACTA NEUROCHIR SUPPL, V95, P351	49	45	47	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					792	802		10.1089/neu.2015.4134			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900010	26414916	Green Published, Green Accepted			2022-02-06	
J	Yi, LZ; Shi, ST; Wang, Y; Huang, W; Xia, ZA; Xing, ZH; Peng, WJ; Wang, Z				Yi, Lunzhao; Shi, Shuting; Wang, Yang; Huang, Wei; Xia, Zi-an; Xing, Zhihua; Peng, Weijun; Wang, Zhe			Serum Metabolic Profiling Reveals Altered Metabolic Pathways in Patients with Post-traumatic Cognitive Impairments	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; MOUSE MODEL; HEAD-INJURY; RISK-FACTOR; D-SERINE; PLASMA; BIOMARKERS; ACID	Cognitive impairment, the leading cause of traumatic brain injury (TBI)-related disability, adversely affects the quality of life of TBI patients, and exacts a personal and economic cost that is difficult to quantify. The underlying pathophysiological mechanism is currently unknown, and an effective treatment of the disease has not yet been identified. This study aimed to advance our understanding of the mechanism of disease pathogenesis; thus, metabolomics based on gas chromatography/mass spectrometry (GC-MS), coupled with multivariate and univariate statistical methods were used to identify potential biomarkers and the associated metabolic pathways of post-TBI cognitive impairment. A biomarker panel consisting of nine serum metabolites (serine, pyroglutamic acid, phenylalanine, galactose, palmitic acid, arachidonic acid, linoleic acid, citric acid, and 2,3,4-trihydroxybutyrate) was identified to be able to discriminate between TBI patients with cognitive impairment, TBI patients without cognitive impairment and healthy controls. Furthermore, associations between these metabolite markers and the metabolism of amino acids, lipids and carbohydrates were identified. In conclusion, our study is the first to identify several serum metabolite markers and investigate the altered metabolic pathway that is associated with post-TBI cognitive impairment. These markers appear to be suitable for further investigation of the disease mechanisms of post-TBI cognitive impairment.	[Yi, Lunzhao] Kunming Univ Sci & Technol, Yunnan Food Safety Res Inst, Kunming 650500, Peoples R China; [Shi, Shuting] Cent S Univ, Coll Chem & Chem Engn, Res Ctr Modernizat Tradit Chinese Med, Changsha 410083, Peoples R China; [Wang, Yang; Huang, Wei; Xia, Zi-an; Xing, Zhihua] Cent S Univ, Xiangya Hosp, Inst Integrated Med, Changsha 410008, Hunan, Peoples R China; [Peng, Weijun; Wang, Zhe] Cent S Univ, Xiangya Hosp 2, Dept Integrated Chinese & Western Med, Changsha 410011, Hunan, Peoples R China		Peng, WJ; Wang, Z (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Integrated Chinese & Western Med, Changsha 410011, Hunan, Peoples R China.	pengweijun1987@gmail.com; ericwangzhe@126.com	yi, lunzhao/AAS-3256-2021		Young Scientists Fund of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21465016]	This study was financially supported by the Young Scientists Fund of the National Natural Science Foundation of China (Grant No. 81303074) and the National Natural Science Foundation of China (Grant No. 21465016).	Adibhatla Rao Muralikrishna, 2008, V49, P241, DOI 10.1007/978-1-4020-8831-5_9; Bachstetter AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0289-5; Bales KR, 2010, NEUROPHARMACOLOGY, V59, P295, DOI 10.1016/j.neuropharm.2010.01.005; Chen YR, 2015, J CANCER RES CLIN, V141, P705, DOI 10.1007/s00432-014-1846-5; De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Drago F, 1988, Funct Neurol, V3, P137; Ellis JK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-61; Fisher DR, 2017, NUTR NEUROSCI, V20, P103, DOI 10.1179/1476830514Y.0000000150; Glenn Thomas C, 2013, Acta Neurochir Suppl, V118, P115, DOI 10.1007/978-3-7091-1434-6_20; Gonzalez-Dominguez R, 2015, J PHARMACEUT BIOMED, V107, P75, DOI 10.1016/j.jpba.2014.10.010; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hashimoto K, 2004, PROG NEURO-PSYCHOPH, V28, P385, DOI 10.1016/j.pnpbp.2003.11.009; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iuliano L, 2013, J ALZHEIMERS DIS, V36, P545, DOI 10.3233/JAD-122224; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Li NJ, 2015, J CHROMATOGR B, V985, P54, DOI 10.1016/j.jchromb.2015.01.016; Lin Z, 2014, ANAL CHIM ACTA, V827, P22, DOI [10.1016/j.aca.2014.04.008, 10.1016/j.aca.2014.04.039]; Liu S, 2015, BIOCHEM BIOPH RES CO, V461, P186, DOI 10.1016/j.bbrc.2015.04.031; Louin G, 2007, NITRIC OXIDE-BIOL CH, V17, P91, DOI 10.1016/j.niox.2007.05.006; Madeira C, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.52; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Maitre L, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-110; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Norup A, 2011, NEUROPSYCHOL REHABIL, V21, P306, DOI 10.1080/09602011.2011.558766; Patil S, 2006, NEUROSCI LETT, V406, P55, DOI 10.1016/j.neulet.2006.07.015; Peng WJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/261409; PEPEU G, 1989, PROG NEURO-PSYCHOPH, V13, pS77, DOI 10.1016/0278-5846(89)90112-7; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plassman Brenda L, 2015, Handb Clin Neurol, V128, P711, DOI 10.1016/B978-0-444-63521-1.00044-3; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Robertson CL, 2013, J NEUROTRAUM, V30, P2066, DOI 10.1089/neu.2013.3007; Sanchez-Mejia RO, 2008, NAT NEUROSCI, V11, P1311, DOI 10.1038/nn.2213; Sanchez-Mejia RO, 2010, BBA-MOL CELL BIOL L, V1801, P784, DOI 10.1016/j.bbalip.2010.05.013; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Teul J, 2011, J PHARMACEUT BIOMED, V56, P343, DOI 10.1016/j.jpba.2011.05.020; Trushina E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063644; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang G, 2014, J PROTEOME RES, V13, P2649, DOI 10.1021/pr5000895; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wang HL, 2014, J ALZHEIMERS DIS, V39, P841, DOI 10.3233/JAD-131463; Wang JH, 2010, SEMIN NEPHROL, V30, P500, DOI 10.1016/j.semnephrol.2010.07.007; Wang ZY, 2015, BIOL PHARM BULL, V38, P1049, DOI 10.1248/bpb.b15-00147; Weng R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11864; Wissmann P, 2013, J NEUROL SCI, V329, P29, DOI 10.1016/j.jns.2013.03.007; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Xu XH, 2012, NEUROSCI BULL, V28, P641, DOI 10.1007/s12264-012-1272-0; Yang SG, 2012, J NEUROTRAUM, V29, P2696, DOI 10.1089/neu.2012.2442; Yi LZ, 2014, RSC ADV, V4, P59094, DOI 10.1039/c4ra09860a	57	45	47	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 17	2016	6								21320	10.1038/srep21320			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD9GN	WOS:000370233800001	26883691	gold, Green Published			2022-02-06	
J	Furman, JL; Sompol, P; Kraner, SD; Pleiss, MM; Putman, EJ; Dunkerson, J; Abdul, HM; Roberts, KN; Scheff, SW; Norris, CM				Furman, Jennifer L.; Sompol, Pradoldej; Kraner, Susan D.; Pleiss, Melanie M.; Putman, Esther J.; Dunkerson, Jacob; Abdul, Hafiz Mohmmad; Roberts, Kelly N.; Scheff, Stephen W.; Norris, Christopher M.			Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and Plasticity in a Rat Model of Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						astrocytes; brain injury; calcineurin; calcium; glia; synapse	LONG-TERM DEPRESSION; FIBRILLARY ACIDIC PROTEIN; ACTIVATED T-CELLS; TRANSCRIPTION FACTOR; REACTIVE ASTROCYTES; ALZHEIMERS-DISEASE; NUCLEAR FACTOR; DUAL ROLE; NFAT; BETA	Increasing evidence suggests that the calcineurin (CN)-dependent transcription factor NFAT (Nuclear Factor of Activated T cells) mediates deleterious effects of astrocytes in progressive neurodegenerative conditions. However, the impact of astrocytic CN/NFAT signaling on neural function/recovery after acute injury has not been investigated extensively. Using a controlled cortical impact (CCI) procedure in rats, we show that traumatic brain injury is associated with an increase in the activities of NFATs 1 and 4 in the hippocampus at 7 d after injury. NFAT4, but not NFAT1, exhibited extensive labeling in astrocytes and was found throughout the axon/dendrite layers of CA1 and the dentate gyrus. Blockade of the astrocytic CN/NFAT pathway in rats using adeno-associated virus (AAV) vectors expressing the astrocyte-specific promoter Gfa2 and the NFAT-inhibitory peptide VIVIT prevented the injury-related loss of basal CA1 synaptic strength and key synaptic proteins and reduced the susceptibility to induction of long-term depression. In conjunction with these seemingly beneficial effects, VIVIT treatment elicited a marked increase in the expression of the prosynaptogenic factor SPARCL1 (hevin), especially in hippocampal tissue ipsilateral to the CCI injury. However, in contrast to previous work on Alzheimer's mouse models, AAV-Gfa2-VIVIT had no effects on the levels of GFAP and Iba1, suggesting that synaptic benefits of VIVIT were not attributable to a reduction in glial activation per se. Together, the results implicate the astrocytic CN/NFAT4 pathway as a key mechanism for disrupting synaptic remodeling and homeostasis in the hippocampus after acute injury.	[Furman, Jennifer L.; Pleiss, Melanie M.; Norris, Christopher M.] Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA; [Sompol, Pradoldej; Kraner, Susan D.; Pleiss, Melanie M.; Putman, Esther J.; Dunkerson, Jacob; Abdul, Hafiz Mohmmad; Roberts, Kelly N.; Scheff, Stephen W.; Norris, Christopher M.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Norris, CM (corresponding author), Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA.	cnorr2@uky.edu		Kraner, Susan/0000-0002-1062-4007	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG027297, AG000242, AG047762]; Kentucky Spinal Cord and Head Injury Research trust [12-10A, 12-16A]; PhRMA Foundation; Irene and Eric Simon Brain Research Foundation; Hazel Embry Research Trust; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242, R01AG027297, F31AG047762, RF1AG027297] Funding Source: NIH RePORTER	This work was supported by grants the National Institutes of Health (Grant AG027297 to C.M.N., Grant AG000242 to P.S., and Grant AG047762 to M.M.P.); the Kentucky Spinal Cord and Head Injury Research trust (Grant 12-10A to C.M.N. and Grant 12-16A to S.W.S.); the PhRMA Foundation (graduate fellowships to J.L.F. and M.M.P.); the Irene and Eric Simon Brain Research Foundation (undergraduate fellowship to E.J.P.); and the Hazel Embry Research Trust. We thank Linda Simmerman and Adam Bachstetter for technical assistance.	Abdul HM, 2011, AGING CELL, V10, P103, DOI 10.1111/j.1474-9726.2010.00645.x; Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Albrecht D, 2012, MOL CELL NEUROSCI, V49, P364, DOI 10.1016/j.mcn.2012.01.005; Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; Ansari MA, 2013, J NEUROTRAUM, V30, P1542, DOI 10.1089/neu.2013.2910; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bales JW, 2010, J NEUROTRAUM, V27, P109, DOI 10.1089/neu.2009.1072; Blakely PK, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00344; Burda JE, 2015, EXP NEUROL; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Canellada A, 2008, GLIA, V56, P709, DOI 10.1002/glia.20647; Caraveo G, 2014, P NATL ACAD SCI USA, V111, pE3544, DOI 10.1073/pnas.1413201111; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.3.CO;2-9; Celsi F, 2007, NEUROBIOL DIS, V26, P342, DOI 10.1016/j.nbd.2006.12.022; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de Leeuw B, 2006, J NEUROSCI RES, V83, P744, DOI 10.1002/jnr.20776; Dumas TC, 2012, HIPPOCAMPUS, V22, P188, DOI 10.1002/hipo.20881; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Foster TC, 2007, NEUROBIOL LEARN MEM, V87, P522, DOI 10.1016/j.nlm.2006.12.009; Furman JL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0158-7; Furman JL, 2012, J NEUROSCI, V32, P16129, DOI 10.1523/JNEUROSCI.2323-12.2012; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Hashimoto T, 1998, J NEUROCHEM, V70, P1289; Hassoun PM, 2009, J AM COLL CARDIOL, V54, pS10, DOI 10.1016/j.jacc.2009.04.006; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hildinger M, 2001, J VIROL, V75, P6199, DOI 10.1128/JVI.75.13.6199-6203.2001; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Huang W, 2005, P NATL ACAD SCI USA, V102, P12242, DOI 10.1073/pnas.0505138102; Jones EV, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/321209; Jones EV, 2011, J NEUROSCI, V31, P4154, DOI 10.1523/JNEUROSCI.4757-10.2011; Kataoka A, 2009, J NEUROCHEM, V108, P115, DOI 10.1111/j.1471-4159.2008.05744.x; Kucukdereli H, 2011, P NATL ACAD SCI USA, V108, pE440, DOI 10.1073/pnas.1104977108; Lee Y, 2008, GLIA, V56, P481, DOI 10.1002/glia.20622; Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012; Liu F, 2005, J BIOL CHEM, V280, P1790, DOI 10.1074/jbc.M410775200; Lively S, 2008, NEUROCHEM RES, V33, P1692, DOI 10.1007/s11064-008-9606-z; Lively S, 2011, J NEUROPATH EXP NEUR, V70, P913, DOI 10.1097/NEN.0b013e318231151e; Lundkvist A, 2004, J CELL SCI, V117, P3481, DOI 10.1242/jcs.01221; Ma T, 2012, J NEUROSCI, V32, P13701, DOI 10.1523/JNEUROSCI.2107-12.2012; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; Mathis DM, 2011, JOVE-J VIS EXP, DOI 10.3791/2330; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; Nagamoto-Combs K, 2010, J NEUROSCI, V30, P9641, DOI 10.1523/JNEUROSCI.0828-10.2010; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Neria F, 2013, GLIA, V61, P1052, DOI 10.1002/glia.22494; Nguyen T, 2008, INT J DEV NEUROSCI, V26, P141, DOI 10.1016/j.ijdevneu.2007.10.004; Norris CM, 2016, EXP NEUROL, V276, P5, DOI 10.1016/j.expneurol.2015.11.006; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Norris CM, 1996, J NEUROSCI, V16, P5382; O'Dell T J, 1994, Learn Mem, V1, P129; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Parpura V, 2012, J NEUROCHEM, V121, P4, DOI 10.1111/j.1471-4159.2012.07664.x; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perez-Ortiz JM, 2008, EUR J NEUROSCI, V27, P2453, DOI 10.1111/j.1460-9568.2008.06197.x; Rosenkranz K, 2012, J PROTEOME RES, V11, P5794, DOI 10.1021/pr3005869; Sama DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038170; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Sattler R, 2006, HANDB EXP PHARM, V175, P277; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Serrano-Perez MC, 2011, GLIA, V59, P94, DOI 10.1002/glia.21079; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shioda N, 2006, J NEUROCHEM, V98, P310, DOI 10.1111/j.1471-4159.2006.03874.x; Shiratori M, 2010, J NEUROCHEM, V114, P810, DOI 10.1111/j.1471-4159.2010.06809.x; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Sullivan MM, 2004, INT J BIOCHEM CELL B, V36, P991, DOI 10.1016/j.biocel.2004.01.017; Tomimoto H, 1997, ACTA NEUROPATHOL, V94, P146, DOI 10.1007/s004010050686; Vihma H, 2008, GENOMICS, V92, P279, DOI 10.1016/j.ygeno.2008.06.011; Vouimba RM, 2000, BRAIN RES BULL, V53, P783, DOI 10.1016/S0361-9230(00)00377-4; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; WIGSTROM H, 1986, J PHYSIOL-PARIS, V81, P228; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010; Yan HQ, 2014, BRAIN RES, V1548, P63, DOI 10.1016/j.brainres.2013.12.028; Yu HX, 2007, CARDIOVASC DRUG REV, V25, P175, DOI 10.1111/j.1527-3466.2007.00011.x; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	87	45	52	1	21	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	FEB 3	2016	36	5					1502	1515		10.1523/JNEUROSCI.1930-15.2016			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DC4HR	WOS:000369182200008	26843634	Green Published, Bronze			2022-02-06	
J	Nelson, LD; Guskiewicz, KM; Barr, WB; Hammeke, TA; Randolph, C; Ahn, KW; Wang, YZ; McCrea, MA				Nelson, Lindsay D.; Guskiewicz, Kevin M.; Barr, William B.; Hammeke, Thomas A.; Randolph, Christopher; Ahn, Kwang Woo; Wang, Yanzhi; McCrea, Michael A.			Age Differences in Recovery After Sport-Related Concussion: A Comparison of High School and Collegiate Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; adolescents; adults	MILD HEAD-INJURY; POSTURAL STABILITY; FOOTBALL PLAYERS; PROLONGED RECOVERY; MANAGEMENT; BRAIN; PERFORMANCE; SEVERITY; SYMPTOMS; IMPACT	Context: Younger age has been hypothesized to be a risk factor for prolonged recovery after sport-related concussion, yet few studies have directly evaluated age differences in acute recovery. Objective: To compare clinical recovery patterns for high school and collegiate athletes. Design: Prospective cohort study. Setting: Large, multicenter prospective sample collected from 1999-2003 in a sports medicine setting. Subjects: Concussed athletes (n = 621; 545 males and 76 females) and uninjured controls (n = 150) participating in high school and collegiate contact and collision sports (79% in football, 15.7% in soccer, and the remainder in lacrosse or ice hockey). Main Outcome Measure(s): Participants underwent evaluation of symptoms (Graded Symptom Checklist), cognition (Standardized Assessment of Concussion, paper-and-pencil neuropsychological tests), and postural stability (Balance Error Scoring System). Athletes were evaluated preinjury and followed serially at several time points after concussive injury: immediately, 3 hours postinjury, and at days 1, 2, 3, 5, 7, and 45 or 90 (with neuropsychological measures administered at baseline and 3 postinjury time points). Results: Comparisons of concussed high school and collegiate athletes with uninjured controls suggested that high school athletes took 1 to 2 days longer to recover on a cognitive (Standardized Assessment of Concussion) measure. Comparisons with the control group on other measures (symptoms, balance) as well as direct comparisons between concussed high school and collegiate samples revealed no differences in the recovery courses between the high school and collegiate groups on any measure. Group-level recovery occurred at or before 7 days postinjury on all assessment metrics. Conclusions: The findings suggest no clinically significant age differences exist in recovery after sport-related concussion, and therefore, separate injury-management protocols are not needed for high school and collegiate athletes.	[Nelson, Lindsay D.; Hammeke, Thomas A.; Ahn, Kwang Woo; McCrea, Michael A.] Med Coll Wisconsin, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC USA; [Barr, William B.] NYU, Sch Med, New York, NY 10003 USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Chicago, IL 60611 USA; [Wang, Yanzhi] Univ Illinois, Coll Med, Peoria, IL 61656 USA		Nelson, LD (corresponding author), Med Coll Wisconsin, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu	Meijer, Anna/K-5118-2016	Barr, William/0000-0001-7711-7758	NCAA and the National Operating Committee on Standards for Athletic Equipment; Centers for Disease Control and Prevention's National Center for Injury Prevention and Control, University of North Carolina Injury Prevention Research Center; Waukesha Memorial Hospital Foundation; National Academy of Neuropsychology; National Federation of State High School Associations; NFL Charities; Green Bay Packer Foundation; Milwaukee Bucks; Herbert H. Kohl Charities; Waukesha Service Club; Medical College of Wisconsin General Clinical Research Center (National Institutes of Health) [M01 RR00058]; Michael Emme; Centers for Disease Control and Prevention's National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER	This research was supported by the NCAA and the National Operating Committee on Standards for Athletic Equipment, Centers for Disease Control and Prevention's National Center for Injury Prevention and Control, University of North Carolina Injury Prevention Research Center, Waukesha Memorial Hospital Foundation, National Academy of Neuropsychology, National Federation of State High School Associations, NFL Charities, Green Bay Packer Foundation, Milwaukee Bucks, Herbert H. Kohl Charities, Waukesha Service Club, Michael Emme, and the Medical College of Wisconsin General Clinical Research Center (M01 RR00058 from the National Institutes of Health).	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Golden CJ., 2002, STROOP COLOR WORD TE; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2014, J INT NEUROPSYCH SOC, V20, P324, DOI 10.1017/S1355617713001471; Landis Matthew J, 2007, WMJ, V106, P312; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Reitan R, 1985, HALSTEAD REITAN NEUR; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rubin D.B., 1987, MULTIPLE IMPUTATION; Smith A., 1982, SYMBOL DIGIT MODALIT; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor AM, 2012, CURR OPIN PEDIATR, V24, P717, DOI 10.1097/MOP.0b013e32835a279b; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	56	45	45	1	26	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	FEB	2016	51	2					142	152		10.4085/1062-6050-51.4.04			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	DK2OW	WOS:000374755300006	26974186	Bronze, Green Published, Green Submitted			2022-02-06	
J	Edlow, BL; Copen, WA; Izzy, S; Bakhadirov, K; van der Kouwe, A; Glenn, MB; Greenberg, SM; Greer, DM; Wu, O				Edlow, Brian L.; Copen, William A.; Izzy, Saef; Bakhadirov, Khamid; van der Kouwe, Andre; Glenn, Mel B.; Greenberg, Steven M.; Greer, David M.; Wu, Ona			Diffusion tensor imaging in acute-to-subacute traumatic brain injury: a longitudinal analysis	BMC NEUROLOGY			English	Article						Traumatic axonal injury (TAI); Fractional anisotropy (FA); Corpus callosum; Disability rating scale (DRS)	WHITE-MATTER INJURY; AXONAL INJURY; OUTCOME PREDICTION; HEAD TRAUMA; BIOMARKERS; MRI; SPECTROSCOPY; ANISOTROPY; FEATURES; DAMAGE	Background: Diffusion tensor imaging (DTI) may have prognostic utility in patients with traumatic brain injury (TBI), but the optimal timing of DTI data acquisition is unknown because of dynamic changes in white matter water diffusion during the acute and subacute stages of TBI. We aimed to characterize the direction and magnitude of early longitudinal changes in white matter fractional anisotropy (FA) and to determine whether acute or subacute FA values correlate more reliably with functional outcomes after TBI. Methods: From a prospective TBI outcomes database, 11 patients who underwent acute (<= 7 days) and subacute (8 days to rehabilitation discharge) DTI were retrospectively analyzed. Longitudinal changes in FA were measured in 11 white matter regions susceptible to traumatic axonal injury. Correlations were assessed between acute FA, subacute FA and the disability rating scale (DRS) score, which was ascertained at discharge from inpatient rehabilitation. Results: FA declined from the acute-to-subacute period in the genu of the corpus callosum (0.70 +/- 0.02 vs. 0.55 +/- 0.11, p < 0.05) and inferior longitudinal fasciculus (0.54+/-0.07 vs. 0.49+/-0.07, p < 0.01). Acute correlations between FA and DRS score were variable: higher FA in the body (R = -0.78, p = 0.02) and splenium (R = -0.83, p = 0.003) of the corpus callosum was associated with better outcomes (i.e. lower DRS scores), whereas higher FA in the genu of the corpus callosum (R = 0.83, p = 0.02) corresponded with worse outcomes (i.e. higher DRS scores). In contrast, in the subacute period higher FA in the splenium correlated with better outcomes (R = -0.63, p < 0.05) and no inverse correlations were observed. Conclusions: White matter FA declined during the acute-to-subacute stages of TBI. Variability in acute FA correlations with outcome suggests that the optimal timing of DTI for TBI prognostication may be in the subacute period.	[Edlow, Brian L.; Izzy, Saef; Bakhadirov, Khamid; Greenberg, Steven M.; Greer, David M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Copen, William A.; Wu, Ona] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Edlow, Brian L.; van der Kouwe, Andre; Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Glenn, Mel B.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Greer, David M.] Yale Univ, Sch Med, Dept Neurol, Yale New Haven Hosp, New Haven, CT 06510 USA		Edlow, BL (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.	bedlow@mgh.harvard.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Greer, David/0000-0002-2026-8333; Wu, Ona/0000-0002-5509-9461	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R25NS065743, K23NS094538, R01NS059775, P41EB015896]; American Academy of Neurology/American Brain Foundation; National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133A020513]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059775, R25NS065743, K23NS094538] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health (R25NS065743, K23NS094538, R01NS059775, and P41EB015896), the American Academy of Neurology/American Brain Foundation, and the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (H133A020513).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jansen JFA, 2007, INVEST RADIOL, V42, P327, DOI 10.1097/01.rli.0000262757.10271.e5; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones NR, 1998, J CLIN NEUROSCI, V5, P73, DOI 10.1016/S0967-5868(98)90207-7; Kessler LG, 2015, STAT METHODS MED RES, V24, P9, DOI 10.1177/0962280214537333; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang JY, 2012, NEUROIMAGE, V60, P1127, DOI 10.1016/j.neuroimage.2011.12.062; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	49	45	51	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	JAN 11	2016	16								2	10.1186/s12883-015-0525-8			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA4SU	WOS:000367791600001	26754948	Green Published, gold			2022-02-06	
J	Lucke-Wold, BP; Logsdon, AF; Smith, KE; Turner, RC; Alkon, DL; Tan, ZJ; Naser, ZJ; Knotts, CM; Huber, JD; Rosen, CL				Lucke-Wold, Brandon P.; Logsdon, Aric F.; Smith, Kelly E.; Turner, Ryan C.; Alkon, Daniel L.; Tan, Zhenjun; Naser, Zachary J.; Knotts, Chelsea M.; Huber, Jason D.; Rosen, Charles L.			Bryostatin-1 Restores Blood Brain Barrier Integrity following Blast-Induced Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Blood brain barrier; Bryostatin-1; Protein kinase C; Tight junction proteins	PROTEIN-KINASE-C; PKC-EPSILON; ISCHEMIC-STROKE; OCCLUDIN EXPRESSION; NEURONAL INJURY; ANIMAL-MODEL; IN-VIVO; ACTIVATION; RAT; ALPHA	Recent wars in Iraq and Afghanistan have accounted for an estimated 270,000 blast exposures among military personnel. Blast traumatic brain injury (TBI) is the 'signature injury' of modern warfare. Blood brain barrier (BBB) disruption following blast TBI can lead to long-term and diffuse neuroinflammation. In this study, we investigate for the first time the role of bryostatin-1, a specific protein kinase C (PKC) modulator, in ameliorating BBB breakdown. Thirty seven Sprague-Dawley rats were used for this study. We utilized a clinically relevant and validated blast model to expose animals to moderate blast exposure. Groups included: control, single blast exposure, and single blast exposure + bryostatin-1. Bryostatin-1 was administered i.p. 2.5 mg/kg after blast exposure. Evan's blue, immunohistochemistry, and western blot analysis were performed to assess injury. Evan's blue binds to albumin and is a marker for BBB disruption. The single blast exposure caused an increase in permeability compared to control (t = 4.808, p < 0.05), and a reduction back toward control levels when bryostatin-1 was administered (t = 5.113, p < 0.01). Three important PKC isozymes, PKC alpha, PKC delta, and PKC epsilon, were co-localized primarily with endothelial cells but not astrocytes. Bryostatin-1 administration reduced toxic PKC alpha levels back toward control levels (t = 4.559, p < 0.01) and increased the neuroprotective isozyme PKC epsilon (t = 6.102, p < 0.01). Bryostatin-1 caused a significant increase in the tight junction proteins VE-cadherin, ZO-1, and occludin through modulation of PKC activity. Bryostatin-1 ultimately decreased BBB breakdown potentially due to modulation of PKC isozymes. Future work will examine the role of bryostatin-1 in preventing chronic neurodegeneration following repetitive neurotrauma.	[Lucke-Wold, Brandon P.; Turner, Ryan C.; Tan, Zhenjun; Naser, Zachary J.; Knotts, Chelsea M.; Rosen, Charles L.] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Lucke-Wold, Brandon P.; Logsdon, Aric F.; Smith, Kelly E.; Turner, Ryan C.; Tan, Zhenjun; Naser, Zachary J.; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Smith, Kelly E.; Huber, Jason D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Alkon, Daniel L.] Blanchette Rockefeller Neurosci Inst, Morgantown, WV 26506 USA; [Naser, Zachary J.] Drexel Univ, Coll Med, Off Profess Studies Hlth Sci, Philadelphia, PA 19102 USA; [Rosen, Charles L.] W Virginia Univ, Sch Med, Hlth Sci Ctr, Dept Neurosurg, Morgantown, WV 26506 USA		Rosen, CL (corresponding author), W Virginia Univ, Sch Med, Hlth Sci Ctr, Dept Neurosurg, 1 Med Ctr Dr,Suite 4300,POB 9183, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu	Lucke-Wold, Brandon/AAW-1881-2021; Lucke-Wold, Brandon/AAW-3525-2021	Lucke-Wold, Brandon/0000-0001-6577-4080; Fraser, Kelly/0000-0003-1563-050X; Turner, Ryan/0000-0001-5523-0645	West Virginia University Health Sciences Center Office of Research and Graduate Education; WVU Department of Neurosurgery; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM08174]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942, S06GM008174, T32GM081741] Funding Source: NIH RePORTER	The authors would like to thank Ryan W. Holt for his help with IHC and western blot analysis. We thank Diana Richardson CDC/NIOSH for tissue preparation for IHC. The authors also thank Dr. Rae Matsumoto and Dr. Steven Frisch for use of western blot resources in their respective laboratories. We thank James E. Robson and Peter Bennett for construction of the blast model and Dr. Robert Gettens and Nic St. John for design of the blast model. A Research Funding and Development Grant (RFDG) from the West Virginia University Health Sciences Center Office of Research and Graduate Education supported this work along with WVU Department of Neurosurgery. R.C.T. was supported by a NIH training grant (GM08174).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Amtul Z, 2014, REV NEUROSCIENCE, V25, P481, DOI 10.1515/revneuro-2013-0041; Arun P, 2013, NEUROSCI RES, V76, P98, DOI 10.1016/j.neures.2013.02.009; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Barzilai A, 2013, DNA REPAIR, V12, P543, DOI 10.1016/j.dnarep.2013.04.007; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; BERKOW RL, 1993, CANCER RES, V53, P2810; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Chamorro D, 2009, MOL BIOL CELL, V20, P4120, DOI 10.1091/mbc.E08-11-1129; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; De Bock M, 2014, BBA-MOL CELL RES, V1843, P2211, DOI 10.1016/j.bbamcr.2014.04.016; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; Eckert A, 2014, BBA-MOL BASIS DIS, V1842, P1258, DOI 10.1016/j.bbadis.2013.08.013; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Ekinci FJ, 1997, INT J DEV NEUROSCI, V15, P867, DOI 10.1016/S0736-5748(97)00037-3; Feng SJ, 2013, NEUROCHEM INT, V63, P69, DOI 10.1016/j.neuint.2013.04.011; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Giordano G, 2005, J NEUROCHEM, V92, P143, DOI 10.1111/j.1471-4159.2004.02852.x; Girolamo F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084883; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goncalves A, 2012, DIABETES OBES METAB, V14, P454, DOI 10.1111/j.1463-1326.2011.01548.x; Guo DR, 2012, MOL CELL NEUROSCI, V50, P82, DOI 10.1016/j.mcn.2012.03.008; Hang Y, 2012, J MOL NEUROSCI, V46, P236, DOI 10.1007/s12031-011-9584-5; Hongpaisan J, 2011, J NEUROSCI, V31, P630, DOI 10.1523/JNEUROSCI.5209-10.2011; Hoozemans JJM, 2012, INT J BIOCHEM CELL B, V44, P1295, DOI 10.1016/j.biocel.2012.04.023; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Kamat PK, 2014, MOL NEUROBIOL, V50, P852, DOI 10.1007/s12035-014-8699-4; Kang JH, 2008, PROTEOMICS, V8, P2006, DOI 10.1002/pmic.200701045; Karasu A, 2010, ULUS TRAVMA ACIL CER, V16, P390; Kim H, 2012, NEUROSCIENCE, V226, P348, DOI 10.1016/j.neuroscience.2012.08.055; Kim YA, 2010, NEUROSCI LETT, V468, P254, DOI 10.1016/j.neulet.2009.11.007; Kizub IV, 2014, INT J CARDIOL, V174, P230, DOI 10.1016/j.ijcard.2014.04.117; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Lallemend F, 2005, J CELL SCI, V118, P4511, DOI 10.1242/jcs.02572; Lanz TV, 2013, P NATL ACAD SCI USA, V110, P14735, DOI 10.1073/pnas.1302569110; Lim CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097756; Lin HW, 2012, ADV EXP MED BIOL, V737, P63, DOI 10.1007/978-1-4614-1566-4_10; Liu WJ, 2014, BRAIN RES, V1573, P17, DOI 10.1016/j.brainres.2014.05.022; Lucke-Wold BP, 2015, J ALZHEIMERS DIS, V43, P711, DOI 10.3233/JAD-141422; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Luo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.116; Marcelo A, 2015, METAB BRAIN DIS, V30, P1, DOI 10.1007/s11011-014-9576-6; Mogha A, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2011.58; Morrow CMK, 2010, PHILOS T R SOC B, V365, P1679, DOI 10.1098/rstb.2010.0025; Muoio V, 2014, ACTA PHYSIOL, V210, P790, DOI 10.1111/apha.12250; Muscella A, 2008, J CELL PHYSIOL, V217, P103, DOI 10.1002/jcp.21478; Naviaux RK, 2014, MITOCHONDRION, V16, P7, DOI 10.1016/j.mito.2013.08.006; Nelson TJ, 2009, TRENDS BIOCHEM SCI, V34, P136, DOI 10.1016/j.tibs.2008.11.006; Novokhatska T, 2013, EUR J PHARMACOL, V718, P401, DOI 10.1016/j.ejphar.2013.08.003; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Roh DH, 2010, NEUROSCI LETT, V477, P95, DOI 10.1016/j.neulet.2010.04.041; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Shao BL, 2014, REDOX BIOL, V2, P694, DOI 10.1016/j.redox.2014.05.005; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Sun MK, 2008, P NATL ACAD SCI USA, V105, P13620, DOI 10.1073/pnas.0805952105; Sun MK, 2006, CNS DRUG REV, V12, P1, DOI 10.1111/j.1527-3458.2006.00001.x; Sun MK, 2014, J PHARMACOL EXP THER, V349, P393, DOI 10.1124/jpet.114.214098; Sun MK, 2014, PROG MOL BIOL TRANSL, V122, P31, DOI 10.1016/B978-0-12-420170-5.00002-7; Sun MK, 2013, BEHAV PHARMACOL, V24, P222, DOI 10.1097/FBP.0b013e3283618afe; Sun MK, 2009, P NATL ACAD SCI USA, V106, P14676, DOI 10.1073/pnas.0907842106; Tan ZJ, 2013, STROKE, V44, P3490, DOI 10.1161/STROKEAHA.113.002411; Teng JCW, 2008, N-S ARCH PHARMACOL, V378, P1, DOI 10.1007/s00210-008-0288-5; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Xia YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068891; Xu C, 2014, NEUROSCIENCE, V268, P75, DOI 10.1016/j.neuroscience.2014.03.008; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yang L, 2012, METHODS MOL BIOL, V814, P451, DOI 10.1007/978-1-61779-452-0_30; Yen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068595; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yoo J, 2003, AM J PHYSIOL-CELL PH, V285, pC300, DOI 10.1152/ajpcell.00267.2002; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	90	45	46	0	39	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	DEC	2015	52	3					1119	1134		10.1007/s12035-014-8902-7			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CS2LW	WOS:000361903400005	25301233	Green Accepted			2022-02-06	
J	Rowson, B; Rowson, S; Duma, SM				Rowson, Bethany; Rowson, Steven; Duma, Stefan M.			Hockey STAR: A Methodology for Assessing the Biomechanical Performance of Hockey Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Linear; Rotational; Acceleration; Risk; Impact	CHRONIC TRAUMATIC ENCEPHALOPATHY; INJURY SURVEILLANCE SYSTEM; HEAD IMPACT BIOMECHANICS; SCHOOL FOOTBALL PLAYERS; ICE HOCKEY; DESCRIPTIVE EPIDEMIOLOGY; PROFESSIONAL FOOTBALL; CONCUSSION EDUCATION; RISK; SPORT	Optimizing the protective capabilities of helmets is one of several methods of reducing brain injury risk in sports. This paper presents the experimental and analytical development of a hockey helmet evaluation methodology. The Summation of Tests for the Analysis of Risk (STAR) formula combines head impact exposure with brain injury probability over the broad range of 227 head impacts that a hockey player is likely to experience during one season. These impact exposure data are mapped to laboratory testing parameters using a series of 12 impact conditions comprised of three energy levels and four head impact locations, which include centric and non-centric directions of force. Injury risk is determined using a multivariate injury risk function that incorporates both linear and rotational head acceleration measurements. All testing parameters are presented along with exemplar helmet test data. The Hockey STAR methodology provides a scientific framework for manufacturers to optimize hockey helmet design for injury risk reduction, as well as providing consumers with a meaningful metric to assess the relative performance of hockey helmets.	[Rowson, Bethany; Rowson, Steven; Duma, Stefan M.] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA 24061 USA		Rowson, B (corresponding author), Virginia Tech, Dept Biomed Engn & Mech, 313 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	bethmv2@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	Virginia Tech Department of Biomedical Engineering and Mechanics; Virginia Tech Institute of Critical Technologies and Applied Sciences	The authors appreciate the support and assistance from the faculty, students, and staff at the Virginia Tech - Wake Forest Center for Injury Biomechanics. We are also grateful for the financial support from the Virginia Tech Department of Biomedical Engineering and Mechanics, and the Virginia Tech Institute of Critical Technologies and Applied Sciences.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Cobb B. R., 2014, P I MECH ENG P-J SPO; Council N.R., 2014, SPORTS REL CONC YOUT; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gadd C.W., 1966, PROCEEDINGS OF THE 1; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Gwin J. T., 2009, J ASTM INT, V6, P1; Hackney J.R, 1995, SAE TECHNICAL PAPER; Hardy, 2003, P INT RES C BIOM IMP; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; Hershman L. L., 2001, ENHANCED SAFETY VEHI, P1; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Odelgard B, 1989, ASTM STP; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Rowson S., 2014, VIRGINIA TECH HELMET; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, J NEUROSURG, V119, P805, DOI 10.3171/2013.3.JNS121735; Rowson S, 2013, P I MECH ENG P-J SPO, V227, P12, DOI 10.1177/1754337112442620; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thibault L., 1971, P 15 STAPP CAR CRASH; Unterharnscheidt FJ., 1971, P 15 STAPP CAR CRASH; Versace J, 1971, SAE TECHNICAL PAPER; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	58	45	46	2	25	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2015	43	10					2429	2443		10.1007/s10439-015-1278-7			15	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	CR5NS	WOS:000361390400011	25822907	Green Published, hybrid			2022-02-06	
J	Taka, E; Mazzio, EA; Goodman, CB; Redmon, N; Flores-Rozas, H; Reams, R; Darling-Reed, S; Soliman, KFA				Taka, Equar; Mazzio, Elizabeth A.; Goodman, Carl B.; Redmon, Natalie; Flores-Rozas, Hernan; Reams, Renee; Darling-Reed, Selina; Soliman, Karam F. A.			Anti-inflammatory effects of thymoquinone in activated BV-2 microglial cells	JOURNAL OF NEUROIMMUNOLOGY			English	Article						Cytokines; Nitric oxide; Microglial cells, Parkinson's, neurodegeneration; Thymoquinone; Black cumin seed	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; MOUSE DENDRITIC CELLS; NIGELLA-SATIVA; PARKINSONS-DISEASE; OXIDATIVE STRESS; IN-VITRO; INFLAMMATORY RESPONSES; OSTEOPONTIN EXPRESSION; LIPID-PEROXIDATION	Thymoquinone (TQ), the main pharmacological active ingredient within the black cumin seed (Nigella sativa) is believed to be responsible for the therapeutic effects on chronic inflammatory conditions such as arthritis, asthma and neurodegeneration. In this study, we evaluated the potential anti-inflammatory role of TQ in lipopolysaccharide (LPS)-stimulated BV-2 murine microglia cells. The results obtained indicate that TQ was effective in reducing NO2- with an IC50 of 5.04 mu M, relative to selective iNOS inhibitor LNIL-L-N6-(1-iminoethyl)lysine (IC50 4.09 mu M). TQ mediated reduction in NO2- was found to parallel the decline of iNOS protein expression as confirmed by immunocytochemistry. In addition, we evaluated the anti-inflammatory effects of TQ on ninety-six (96) cytokines using a RayBio AAM-CYT-3 and 4 cytokine antibody protein array. Data obtained establish a baseline protein expression profile characteristic of resting BV-2 cells in the order of osteopontin > MIP-1alpha > MIP-1 g> IGF-1 and MCP-I. In the presence of LPS [1 ug/ml], activated BV-2 cells produced a sharp rise in specific pro-inflammatory cytokines/chemokine's IL-6, IL-12p40/70, CCL12 /MCP-5, CCL2/MCP-1, and G-CSF which were attenuated by the addition of TQ (10 mu M). The TQ mediated attenuation of MCP-5, MCP-1 and IL-6 protein in supernatants from activated BV-2 cells were corroborated by independent ELISA. Moreover, the data obtained from the (RTPCR)-P-2 demonstrated a similar pattern where the LPS mediated elevation of mRNA for IL-6, CCL12/MCP-5, CCL2/MCP-1 were significantly attenuated by TQ (10 mu M). Also, in this study, consistent data were obtained for both protein antibody array densitometry and ELISA assays. In addition, TQ was found to reduce LPS mediated elevation in gene expression of Cxcl10 and a number of other cytokines in the panel. These findings demonstrate the significant anti-inflammatory properties of TQ in LPS activated microglial cells. Therefore, the obtained results might indicate the usefulness of TQ in delaying the onset of inflammation-mediated neurodegenerative disorders involving activated microglia cells. 2015 Elsevier B.V. All rights reserved.	[Taka, Equar; Mazzio, Elizabeth A.; Goodman, Carl B.; Redmon, Natalie; Flores-Rozas, Hernan; Reams, Renee; Darling-Reed, Selina; Soliman, Karam F. A.] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA		Soliman, KFA (corresponding author), Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Room 104 Dyson Pharm Bldg,1520 ML King Blvd, Tallahassee, FL 32307 USA.	karam.soliman@famu.edu			National Institute of Minority Health and Health Disparities of the National Institutes of Health [8 G12MD007582-28, 1P20 MD006738-01]; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD006738, G12MD007582] Funding Source: NIH RePORTER	This research was supported by the National Institute of Minority Health and Health Disparities of the National Institutes of Health through Grant Number 8 G12MD007582-28 and Grant Number 1P20 MD006738-01. We would like to also thank Elisabetta Blasi (Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy) for providing the BV-2 microglial cell line.	Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221-1691(13)60075-1; Al-Majed AA, 2006, EUR J PHARMACOL, V543, P40, DOI 10.1016/j.ejphar.2006.05.046; Ali BH, 2003, PHYTOTHER RES, V17, P299, DOI 10.1002/ptr.1309; Alkharfy KM, 2011, INT IMMUNOPHARMACOL, V11, P250, DOI 10.1016/j.intimp.2010.11.032; Ammar ESM, 2011, INT IMMUNOPHARMACOL, V11, P2232, DOI 10.1016/j.intimp.2011.10.013; Basarslan F, 2012, HUM EXP TOXICOL, V31, P726, DOI 10.1177/0960327111433185; Batool Sidra, 2013, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V12, P129; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Brown A, 2012, TRANSL NEUROSCI, V3, P288, DOI 10.2478/s13380-012-0028-7; Butt MS, 2010, CRIT REV FOOD SCI, V50, P654, DOI 10.1080/10408390902768797; Dariani S, 2013, J MOL NEUROSCI, V51, P679, DOI 10.1007/s12031-013-0043-3; Del Rio P, 2011, GLIA, V59, P821, DOI 10.1002/glia.21155; Evans SM, 2001, TOXICOL IN VITRO, V15, P579, DOI 10.1016/S0887-2333(01)00064-9; Furusawa JI, 2009, INT IMMUNOPHARMACOL, V9, P499, DOI 10.1016/j.intimp.2009.01.031; Gilhotra N, 2011, PHARMACOL REP, V63, P660, DOI 10.1016/S1734-1140(11)70577-1; Gyoneva S, 2014, NEUROBIOL DIS, V67, P191, DOI 10.1016/j.nbd.2014.03.004; Hasegawa-Ishii S, 2011, BRAIN BEHAV IMMUN, V25, P83, DOI 10.1016/j.bbi.2010.08.006; Hirai S, 2007, LIFE SCI, V81, P1272, DOI 10.1016/j.lfs.2007.09.001; Hosseinzadeh H, 2007, PHYTOMEDICINE, V14, P621, DOI 10.1016/j.phymed.2006.12.005; Idris-Khodja N, 2012, N-S ARCH PHARMACOL, V385, P749, DOI 10.1007/s00210-012-0749-8; Jan HJ, 2010, NEURO-ONCOLOGY, V12, P58, DOI 10.1093/neuonc/nop013; Jang TC, 2006, AM J PATHOL, V168, P1676, DOI 10.2353/ajpath.2006.050400; Jung HW, 2013, AM J CHINESE MED, V41, P99, DOI 10.1142/S0192415X13500080; Kalkonde YV, 2007, BRAIN RES, V1128, P1, DOI 10.1016/j.brainres.2006.08.041; Kim M, 2013, BMB REP, V46, P398, DOI 10.5483/BMBRep.2013.46.8.237; Kim S, 2013, J PHARM PHARMACOL, V65, P895, DOI 10.1111/jphp.12049; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kundu JK, 2013, BIOCHEM BIOPH RES CO, V438, P721, DOI 10.1016/j.bbrc.2013.07.110; Landa P, 2013, NAT PROD COMMUN, V8, P105; Liao Yuan, 2011, Zhonghua Bing Li Xue Za Zhi, V40, P585; Lu Y, 2013, NEUROSCIENCE, V241, P22, DOI 10.1016/j.neuroscience.2013.03.003; Manivannan J, 2013, NEUROSCIENCE, V253, P40, DOI 10.1016/j.neuroscience.2013.08.023; Mansour MA, 2002, CELL BIOCHEM FUNCT, V20, P143, DOI 10.1002/cbf.968; Matusan-Ilijas K, 2008, PATHOL ONCOL RES, V14, P293, DOI 10.1007/s12253-008-9058-4; Mayer AMS, 2011, TOXICOL SCI, V121, P63, DOI 10.1093/toxsci/kfr045; Mohamed A., 2005, V41, P388; Mohamed A, 2003, BIOMED SCI INSTRUM, V39, P440; More SV, 2013, J PHARMACOL SCI, V121, P119, DOI 10.1254/jphs.12170FP; Nili-Ahmadabadi A, 2011, DARU, V19, P282; Okamura T, 2012, J NEUROSCI RES, V90, P2127, DOI 10.1002/jnr.23105; Padhye Subhash, 2008, Cancer Ther, V6, P495; Park SY, 2012, NEUROCHEM INT, V61, P767, DOI 10.1016/j.neuint.2012.06.020; Passos GF, 2009, AM J PATHOL, V175, P1586, DOI 10.2353/ajpath.2009.081113; Radad K, 2014, EXP TOXICOL PATHOL, V66, P13, DOI 10.1016/j.etp.2013.07.002; Ramsey CP, 2014, EXP NEUROL, V256, P126, DOI 10.1016/j.expneurol.2013.05.014; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Rizzo F, 2014, CELL MOL LIFE SCI, V71, P999, DOI 10.1007/s00018-013-1480-4; Russo I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-52; Sacino AN, 2014, J NEUROSCI, V34, P12368, DOI 10.1523/JNEUROSCI.2102-14.2014; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016/j.intimp.2005.06.008; Sankaranarayanan C, 2011, CHEM-BIOL INTERACT, V190, P148, DOI 10.1016/j.cbi.2011.02.029; Shabana A, 2013, CARDIOVASC TOXICOL, V13, P9, DOI 10.1007/s12012-012-9181-z; Shivers KY, 2014, BBA-MOL BASIS DIS, V1842, P1707, DOI 10.1016/j.bbadis.2014.06.020; Soliman ML, 2013, LIPIDS, V48, P651, DOI 10.1007/s11745-013-3799-x; Tambuyzer BR, 2012, CELL BIOL INT, V36, P1233, DOI 10.1042/CBI20120172; Tekeoglu I, 2007, PHYTOTHER RES, V21, P895, DOI 10.1002/ptr.2143; Tesarova H, 2011, NAT PROD COMMUN, V6, P213; Ullah I, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-11; Umar S, 2012, CHEM-BIOL INTERACT, V197, P40, DOI 10.1016/j.cbi.2012.03.003; Uzawa A, 2010, MULT SCLER J, V16, P1443, DOI 10.1177/1352458510379247; Wilkins Renee, 2011, Biomed Sci Instrum, V47, P222; Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016/j.bcp.2011.09.029; Xuan NT, 2010, CELL PHYSIOL BIOCHEM, V25, P307, DOI 10.1159/000276563; Yamaguchi Y, 2013, J BIOL CHEM, V288, P3097, DOI 10.1074/jbc.M112.362954; Yang WT, 2012, CELL PHYSIOL BIOCHEM, V29, P21, DOI 10.1159/000337583; Ye JM, 2013, NEUROSCI LETT, V553, P72, DOI 10.1016/j.neulet.2013.08.020; Yeh CH, 2014, ENVIRON TOXICOL, V29, P1162, DOI 10.1002/tox.21847	68	45	46	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	SEP 15	2015	286						5	12		10.1016/j.jneuroim.2015.06.011			8	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CQ9RG	WOS:000360952100002	26298318	Green Accepted			2022-02-06	
J	Sours, C; Zhuo, JC; Roys, S; Shanmuganathan, K; Gullapalli, RP				Sours, Chandler; Zhuo, Jiachen; Roys, Steven; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Disruptions in Resting State Functional Connectivity and Cerebral Blood Flow in Mild Traumatic Brain Injury Patients	PLOS ONE			English	Article							NEUROPSYCHOLOGICAL ASSESSMENT METRICS; MODE NETWORK CONNECTIVITY; DEFAULT-MODE; HEAD-INJURY; PERFUSION; DEFICITS; RELIABILITY; PERFORMANCE; TASK; RECOVERY	Mild traumatic brain injury (mTBI) is often occult to conventional imaging techniques. However, there is growing evidence that mTBI patients who lack evidence of structural intracranial injury may develop post-concussive syndrome (PCS). We investigated longitudinal alterations in resting state functional connectivity (rs-FC) in brain networks in a population of 28 patients compared to 28 matched control participants. Rs-FC and cerebral blood flow (CBF) within the nodes of the Default Mode Network (DMN) and Task Positive Network (TPN) were assessed at three time points including acute, sub-acute, and chronic stages following mTBI. Participants received the Automated Neuropsychological Assessment Metrics (ANAM) to assess cognitive performance. Main findings indicate that despite normalized cognitive performance, chronic mTBI patients demonstrate increased rs-FC between the DMN and regions associated with the salience network (SN) and TPN compared to the control populations, as well as reduced strength of rs-FC within the DMN at the acute stage of injury. In addition, chronic mTBI patients demonstrate an imbalance in the ratio of CBF between nodes of the DMN and TPN. Furthermore, preliminary exploratory analysis suggests that compared to those without chronic PCS, patients with chronic PCS reveal an imbalance in the ratio of CBF between the DMN nodes and TPN nodes across multiple stages of recovery. Findings suggest that the altered network perfusion with the associated changes in rs-FC may be a possible predictor of which mTBI patients will develop chronic PCS.	[Sours, Chandler; Zhuo, Jiachen; Roys, Steven; Gullapalli, Rao P.] Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [Sours, Chandler; Zhuo, Jiachen; Roys, Steven; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA		Sours, C (corresponding author), Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA.	csours001@umm.edu			Department of DefenseUnited States Department of Defense [W81XWH-08-1-0725, W81XWH-12-1-0098]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F31NS081984]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081984] Funding Source: NIH RePORTER	Support for this work was in part provided by the Department of Defense (W81XWH-08-1-0725 & W81XWH-12-1-0098 to RPG). CS was supported by an predoctoral grant from the National Institute of Neurological Disorders and Stroke (1F31NS081984). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; De Havas JA, 2012, NEUROIMAGE, V59, P1745, DOI 10.1016/j.neuroimage.2011.08.026; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Franco AR, 2013, BRAIN CONNECT, V3, P363, DOI 10.1089/brain.2012.0134; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jann K, 2013, BRAIN TOPOGR, V26, P569, DOI 10.1007/s10548-013-0280-3; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kindler J, 2013, SCHIZOPHR B; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Li ZJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044556; Liu TT, 2013, NEUROIMAGE, V80, P339, DOI 10.1016/j.neuroimage.2013.04.071; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Mannfolk P, 2011, J MAGN RESON IMAGING, V34, P511, DOI 10.1002/jmri.22654; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M., 2000, STANDARDIZED ASSESSM; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Ponsford J, 2013, J NEUROTRAUMA; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Prakash RS, 2012, BEHAV BRAIN RES, V230, P192, DOI 10.1016/j.bbr.2012.01.058; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Reich S, 2005, VALIDATION ANAM TEST; Sambataro F, 2010, NEUROBIOL AGING, V31, P839, DOI 10.1016/j.neurobiolaging.2008.05.022; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sours C, 2014, BRAIN IMAGING BEHAV; Sours C, 2015, BRAIN CONNECT, V5, P442, DOI 10.1089/brain.2014.0333; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; The World Health Organization, 2010, INT CLASS DIS; Wang JJ, 2003, J MAGN RESON IMAGING, V18, P404, DOI 10.1002/jmri.10372; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Woodward ND, 2011, SCHIZOPHR RES, V130, P86, DOI 10.1016/j.schres.2011.03.010; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	67	45	46	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2015	10	8							e0134019	10.1371/journal.pone.0134019			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO1VB	WOS:000358942700032	26241476	Green Published, gold, Green Submitted			2022-02-06	
J	Bosarge, PL; Shoultz, TH; Griffin, RL; Kerby, JD				Bosarge, Patrick L.; Shoultz, Thomas H.; Griffin, Russell L.; Kerby, Jeffrey D.			Stress-induced hyperglycemia is associated with higher mortality in severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Stress-induced hyperglycemia; traumatic brain injury; glycosylated hemoglobin A; HgA1c; stress response; physiologic wounds and injuries; complications; mortality	INTENSIVE INSULIN THERAPY; CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; GLYCEMIC CONTROL; ADMISSION HYPERGLYCEMIA; BLOOD-GLUCOSE; MYOCARDIAL-INFARCTION; DIABETIC STATUS; IMPACT; METABOLISM	BACKGROUND An association between stress-induced hyperglycemia (SIH) and increased mortality has been demonstrated following trauma. Experimental animal model data regarding the association between hyperglycemia and outcomes following traumatic brain injury (TBI) are inconsistent, suggesting that hyperglycemia may be harmful, neutral, or beneficial. The purpose of this study was to examine the effects of SIH versus diabetic hyperglycemia (DH) on severe TBI. METHODS Admission glycosylated hemoglobin (HbA1c), glucose levels, and comorbidity data were collected during a 4-year period from September 2009 to December 2013 for patients with severe TBI (i.e., admission Glasgow Coma Scale [GCS] score of 3-8 and head Abbreviated Injury Scale [AIS] score 3). Diabetes mellitus was determined by patient history or admission HbA1c of 6.5% or greater. SIH was determined by the absence of diabetes mellitus and admission glucose of 200 mg/dL or greater. A Cox proportional hazards model adjusted for age, sex, injury mechanism, and Injury Severity Score (ISS) was used to calculate hazard ratios (HRs) and associated 95% confidence intervals (CIs) for the association between SIH and the outcomes of interest. RESULTS During the study period, a total of 626 patients were included in the study group, having severe TBI defined by both GCS score of 3 to 8 and head AIS score being 3 or greater and also had available HbA1c and admission glucose levels. A total of 184 patients were admitted with hyperglycemia; 152 patients (82.6%) were diagnosed with SIH, and 32 patients (17.4%) were diagnosed with DH. When comparing patients with severe TBI adjusted for age, sex, injury mechanism, ISS, Revised Trauma Score (RTS), and lactic acid greater than 2.5 mmol/L, patients with SIH had a 50% increased mortality (HR, 1.49; 95% CI, 1.13-1.95) compared with the nondiabetic normoglycemia patients. DH patients did not have a significant increase in mortality (HR, 0.94; 95% CI, 0.56-1.58). CONCLUSION SIH is associated with higher mortality after severe TBI. This association was not observed among patients with DH, which suggests that hyperglycemia related to diabetes is of less importance compared with SIH in terms of mortality in the acute trauma and TBI patient. Further research is warranted to identify mechanisms causing SIH and subsequent worse outcomes after TBI. LEVEL OF EVIDENCE Prognostic/epidemiologic study, leve III.	[Bosarge, Patrick L.; Shoultz, Thomas H.; Griffin, Russell L.; Kerby, Jeffrey D.] Univ Alabama Birmingham, Div Trauma Burns & Surg Crit Care, Birmingham, AL USA		Bosarge, PL (corresponding author), Univ Birmingham, Univ Alabama, Alabama Med Ctr, Div Trauma Burns & Surg Crit Care, 112 Lyons Harrison Res Bldg,701 19th St, South Birmingham, AL 35294 USA.	pbosarge@uabmc.edu					Ahmad R, 2007, ARCH SURG-CHICAGO, V142, P613, DOI 10.1001/archsurg.142.7.613; Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Amer Diabet Assoc, 2009, DIABETES CARE, V32, pS62, DOI [10.2337/dc09-S062, 10.2337/dc11-S011, 10.2337/dc12-S064]; BELLODI G, 1989, AM J CARDIOL, V64, P885, DOI 10.1016/0002-9149(89)90836-9; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bochicchio GV, 2007, J TRAUMA, V63, P1353, DOI 10.1097/TA.0b013e31815b83c4; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Bosarge Patrick L, 2013, Adv Surg, V47, P287; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Centers for Disease Control and Prevention, 2014, NAT DIAB STAT REP; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Egi M, 2008, CRIT CARE MED, V36, P2249, DOI 10.1097/CCM.0b013e318181039a; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Hill J, 2010, J NEUROTRAUM, V27, P1439, DOI 10.1089/neu.2010.1328; Hurt RT, 2012, JPEN-PARENTER ENTER, V36, P721, DOI 10.1177/0148607112436978; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kerby JD, 2012, ANN SURG, V256, P446, DOI 10.1097/SLA.0b013e3182654549; Krinsley JS, 2006, SEMIN THORAC CARDIOV, V18, P317, DOI 10.1053/j.semtcvs.2006.12.003; Krinsley JS, 2012, CURR OPIN CLIN NUTR, V15, P151, DOI 10.1097/MCO.0b013e32834f0009; Kutcher ME, 2011, J TRAUMA, V71, P1108, DOI 10.1097/TA.0b013e318232e35b; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Moro N, 2013, BRAIN RES, V1535, P124, DOI 10.1016/j.brainres.2013.08.044; Nathan DM, 2007, DIABETOLOGIA, V50, P2239, DOI 10.1007/s00125-007-0803-0; Peppa M, 2011, CURR DIABETES REV, V7, P416, DOI 10.2174/157339911797579188; Rady MY, 2005, MAYO CLIN PROC, V80, P1558, DOI 10.4065/80.12.1558; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Saudek CD, 2006, JAMA-J AM MED ASSOC, V295, P1688, DOI 10.1001/jama.295.14.1688; Scalea TM, 2007, ANN SURG, V246, P605, DOI 10.1097/SLA.0b013e318155a789; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Toschlog EA, 2007, J TRAUMA, V62, P1370, DOI 10.1097/TA.0b013e318047b7dc; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; Wahl WL, 2008, J TRAUMA, V65, P42, DOI 10.1097/TA.0b013e318176c54e; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	46	45	55	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2015	79	2					289	294		10.1097/TA.0000000000000716			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	CS2II	WOS:000361892800019	26218699				2022-02-06	
J	Walker, MC				Walker, Matthew Charles			Hippocampal Sclerosis: Causes and Prevention	SEMINARS IN NEUROLOGY			English	Article						hippocampal sclerosis; status epileptics; epilepsy; neuroprotection	TEMPORAL-LOBE EPILEPSY; FEBRILE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE; VOLUME LOSS; ENTORHINAL CORTEX; OXIDATIVE STRESS; GRADING SYSTEM; SEIZURES; INHIBITION	Hippocampal sclerosis is the commonest cause of drug-resistant epilepsy in adults, and is associated with alterations to structures and networks beyond the hippocampus. In addition to being a cause of epilepsy, the hippocampus is vulnerable to damage from seizure activity. In particular, prolonged seizures (status epilepticus) can result in hippocampal sclerosis. The hippocampus is also vulnerable to other insults including traumatic brain injury, and inflammation. Hippocampal sclerosis can occur in association with other brain lesions; the prevailing view is that it is probably a secondary consequence. In such instances, successful surgical treatment usually involves the resection of both the lesion and the involved hippocampus. Experimental data have pointed to numerous neuroprotective strategies to prevent hippocampal sclerosis. Initial neuroprotective strategies aimed at glutamate receptors may be effective, but later, metabolic pathways, apoptosis, reactive oxygen species, and inflammation are involved, perhaps necessitating the use of interventions aimed at multiple targets. Some of the therapies that we use to treat status epilepticus may neuroprotect. However, prevention of neuronal death does not necessarily prevent the later development of epilepsy or cognitive deficits. Perhaps, the most important intervention is the early, aggressive treatment of seizure activity, and the prevention of prolonged seizures.	UCL, UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England		Walker, MC (corresponding author), UCL, UCL Inst Neurol, Dept Clin & Expt Epilepsy, Queen Sq, London WC1N 3BG, England.	m.walker@ucl.ac.uk	Walker, Matthew C/C-1577-2008	Walker, Matthew C/0000-0002-0812-0352	Epilepsy Research UK; FP7-HEALTH project [602102]; Department of Health National Institute for Health Research Biomedical Research Centres' funding scheme	I thank Epilepsy Research UK and FP7-HEALTH project 602102 (EPITARGET) for their support. This work was undertaken at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health National Institute for Health Research Biomedical Research Centres' funding scheme.	Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5; Barron DS, 2013, NEUROIMAGE-CLIN, V2, P25, DOI 10.1016/j.nicl.2012.11.004; Baulac M, 1998, ANN NEUROL, V44, P223, DOI 10.1002/ana.410440213; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bernasconi N, 2001, NEUROLOGY, V56, P1335, DOI 10.1212/WNL.56.10.1335; Bianchin MM, 2012, PATHOG GLOB HEALTH, V106, P280, DOI 10.1179/2047773212Y.0000000027; Blumcke I, 2013, EPILEPSIA, V54, P1315, DOI 10.1111/epi.12220; Blumcke I, 2012, BRAIN PATHOL, V22, P347, DOI 10.1111/j.1750-3639.2012.00584.x; Blumcke I, 2002, BRAIN PATHOL, V12, P199; Borelli P, 2008, EPILEPSIA, V49, P1333, DOI 10.1111/j.1528-1167.2008.01694.x; Bouchet C, 1825, ARCH GEN MED, V9, P510; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Briellmann RS, 2002, ANN NEUROL, V51, P641, DOI 10.1002/ana.10171; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CENDES F, 1995, NEUROLOGY, V45, P2058, DOI 10.1212/WNL.45.11.2058; Coan AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085843; Collins R C, 1983, Adv Neurol, V34, P277; Corsellis J A, 1983, Adv Neurol, V34, P129; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies KG, 1995, BRIT J NEUROSURG, V9, P759; Davies KG, 1996, EPILEPSY RES, V24, P119, DOI 10.1016/0920-1211(96)00008-3; DEGIORGIO CM, 1992, EPILEPSIA, V33, P23, DOI 10.1111/j.1528-1157.1992.tb02278.x; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Epstein LG, 2012, EPILEPSIA, V53, P1481, DOI 10.1111/j.1528-1167.2012.03542.x; Fernandez G, 1998, NEUROLOGY, V50, P909, DOI 10.1212/WNL.50.4.909; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; FUJIKAWA DG, 1994, EPILEPSY RES, V17, P207, DOI 10.1016/0920-1211(94)90051-5; HARDIMAN O, 1988, NEUROLOGY, V38, P1041, DOI 10.1212/WNL.38.7.1041; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Henshall DC, 2005, J CEREBR BLOOD F MET, V25, P1557, DOI 10.1038/sj.jcbfm.9600149; Hetman M, 2004, EUR J BIOCHEM, V271, P2050, DOI 10.1111/j.1432-1033.2004.04133.x; Janszky J, 2005, BRAIN, V128, P395, DOI 10.1093/brain/awh358; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; JONES RSG, 1989, EXP NEUROL, V104, P155, DOI 10.1016/S0014-4886(89)80009-3; Kasperaviciute D, 2013, BRAIN, V136, P3140, DOI 10.1093/brain/awt233; Keller SS, 2015, ANN NEUROL; Kovac S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.390; Kovac S, 2013, NEUROPHARMACOLOGY, V69, P96, DOI 10.1016/j.neuropharm.2012.05.012; Lewis DV, 2014, ANN NEUROL, V75, P178, DOI 10.1002/ana.24081; Lewis DV, 2002, PROG BRAIN RES, V135, P263; Li LM, 1999, BRAIN, V122, P799, DOI 10.1093/brain/122.5.799; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luo Y, 2006, J BIOL CHEM, V281, P16436, DOI 10.1074/jbc.M512430200; MELDRUM B, 1991, EPILEPSY RES, V10, P55, DOI 10.1016/0920-1211(91)90095-W; Meldrum BS, 2002, PROG BRAIN RES, V135, P487; Milder JB, 2010, NEUROBIOL DIS, V40, P238, DOI 10.1016/j.nbd.2010.05.030; Narkilahti S, 2003, EUR J NEUROSCI, V18, P1486, DOI 10.1046/j.1460-9568.2003.02874.x; Ostendorf AP, 2015, CNS DRUGS, V29, P91, DOI 10.1007/s40263-014-0223-x; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; PFLEGER L, 1880, ALLG Z PSYCHIAT, V36, P359; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/eoph.5.4.777.30162; Prasad A, 2002, ANN NEUROL, V51, P175, DOI 10.1002/ana.10085; Rice AC, 1998, EPILEPSIA, V39, P1148, DOI 10.1111/j.1528-1157.1998.tb01305.x; Rowley S, 2013, FREE RADICAL BIO MED, V62, P121, DOI 10.1016/j.freeradbiomed.2013.02.002; Schoene-Bake JC, 2014, HUM BRAIN MAPP, V35, P4718, DOI 10.1002/hbm.22506; Sinjab B, 2013, EPILEPSIA, V54, P2125, DOI 10.1111/epi.12403; Sommer W., 1880, ARCH PSYCHIATRIE NER, V10, P631, DOI [10.1007/BF02224538, DOI 10.1007/BF02224538]; Tanaka H, 2000, BRAIN RES, V886, P190, DOI 10.1016/S0006-8993(00)02951-6; Thom M, 2005, BRAIN, V128, P1344, DOI 10.1093/brain/awh475; Thom M, 2010, EPILEPSIA, V51, P1801, DOI 10.1111/j.1528-1167.2010.02681.x; Treiman DM, 2006, EPILEPSY RES, V68, pS77, DOI 10.1016/j.eplepsyres.2005.07.020; Van Paesschen W, 1998, EPILEPSIA, V39, P633; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Wagner J, 2014, J NEUROL NEUROSURG P; Walker M, 2005, BRIT MED J, V331, P673, DOI 10.1136/bmj.331.7518.673; Walker M., 2007, HIPPOCAMPUS BOOK, P769; Watson C, 1996, J EPILEPSY, V9, P56, DOI 10.1016/0896-6974(95)00060-7; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; WYLER AR, 1992, J EPILEPSY, V5, P220, DOI 10.1016/S0896-6974(05)80120-3; Yilmazer-Hanke DM, 2000, J NEUROPATH EXP NEUR, V59, P907, DOI 10.1093/jnen/59.10.907; Yoong M, 2013, EPILEPSIA, V54, P2108, DOI 10.1111/epi.12426	76	45	46	2	5	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	JUN	2015	35	3					193	200		10.1055/s-0035-1552618			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK1YU	WOS:000356006700003	26060898	Bronze, Green Published			2022-02-06	
J	Zhou, GW; Brodsky, JR				Zhou, Guangwei; Brodsky, Jacob R.			Objective Vestibular Testing of Children with Dizziness and Balance Complaints Following Sports-Related Concussions	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article						sports-related concussions; dizziness; vertigo; imbalance; vestibular function	TRAUMATIC BRAIN-INJURY; DYNAMIC VISUAL-ACUITY; HEAD-INJURY; POSTURAL STABILITY; CEREBRAL CONCUSSION; HEARING-LOSS; HIGH-SCHOOL; DEFICITS; REHABILITATION; INDIVIDUALS	Objective To conduct objective assessment of children with balance and vestibular complaints following sports-related concussions and identify the underlying deficits by analyzing laboratory test outcomes. Study Designs Case series with chart review. Setting Pediatric tertiary care facility. Subjects and Methods Medical records were reviewed of 42 pediatric patients with balance and/or vestibular complaints following sports-related concussions who underwent comprehensive laboratory testing on their balance and vestibular function. Patients' characteristics were summarized and results analyzed. Results More than 90% of the children with protracted dizziness or imbalance following sports-related concussion had at least 1 abnormal finding from the comprehensive balance and vestibular evaluation. The most frequent deficit was found in dynamic visual acuity test, followed by Sensory Organization Test and rotational test. Patient's balance problem associated with concussion seemed to be primarily instigated by vestibular dysfunction. Furthermore, semicircular canal dysfunction was involved more often than dysfunction of otolith organs. Yet, <10% of the children experienced a hearing loss following sports-related concussion. Conclusions Vestibular impairment is common among children with protracted dizziness or imbalance following sports-related concussion. Our study demonstrated that proper and thorough evaluation is imperative to identify these underlying deficits and laboratory tests were helpful in the diagnosis and recommendation of following rehabilitations.	[Zhou, Guangwei; Brodsky, Jacob R.] Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Waltham, MA 02453 USA; [Zhou, Guangwei; Brodsky, Jacob R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA		Zhou, GW (corresponding author), Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Balance & Vestibular Program, 9 Hope Ave, Waltham, MA 02453 USA.	guangwei.zhou@childrens.harvard.edu		Brodsky, Jacob/0000-0001-9656-5855			Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dannenbaum E, 2005, J OTOLARYNGOL, V34, P13, DOI 10.2310/7070.2005.03105; Dannenbaum E, 2009, OTOL NEUROTOL, V30, P368, DOI 10.1097/MAO.0b013e31819bda35; Dault MC, 2002, BRAIN INJURY, V16, P231, DOI 10.1080/02699050110103300; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; Herdman SJ, 1998, AM J OTOL, V19, P790; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; MAKISHIMA K, 1976, LARYNGOSCOPE, V86, P1303, DOI 10.1288/00005537-197609000-00002; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peters BT, 2012, J VESTIBUL RES-EQUIL, V22, P145, DOI 10.3233/VES-2012-0440; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Tian JR, 2001, ANN NY ACAD SCI, V942, P501; YLIKOSKI J, 1982, AM J OTOL, V3, P343; Zhou GW, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000037	45	45	45	0	23	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	JUN	2015	152	6					1133	1139		10.1177/0194599815576720			7	Otorhinolaryngology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology; Surgery	CJ7QJ	WOS:000355692300028	25820582				2022-02-06	
J	Yan, EB; Frugier, T; Lim, CK; Heng, B; Sundaram, G; Tan, M; Rosenfeld, JV; Walker, DW; Guillemin, GJ; Morganti-Kossmann, MC				Yan, Edwin B.; Frugier, Tony; Lim, Chai K.; Heng, Benjamin; Sundaram, Gayathri; Tan, May; Rosenfeld, Jeffrey V.; Walker, David W.; Guillemin, Gilles J.; Morganti-Kossmann, Maria Cristina			Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans	JOURNAL OF NEUROINFLAMMATION			English	Article						Patients; Traumatic brain injury; Kynurenine pathway; Tryptophan metabolism; Quinolinic acid	INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; HUNTINGTONS-DISEASE; CEREBROSPINAL-FLUID; TRYPTOPHAN DEGRADATION; LIPID-PEROXIDATION; OXIDATIVE STRESS; HUMAN NEURONS; RAT-BRAIN	During inflammation, the kynurenine pathway (KP) metabolises the essential amino acid tryptophan (TRP) potentially contributing to excitotoxicity via the release of quinolinic acid (QUIN) and 3-hydroxykynurenine (3HK). Despite the importance of excitotoxicity in the development of secondary brain damage, investigations on the KP in TBI are scarce. In this study, we comprehensively characterised changes in KP activation by measuring numerous metabolites in cerebrospinal fluid (CSF) from TBI patients and assessing the expression of key KP enzymes in brain tissue from TBI victims. Acute QUIN levels were further correlated with outcome scores to explore its prognostic value in TBI recovery. Methods: Twenty-eight patients with severe TBI (GCS <= 8, three patients had initial GCS = 9-10, but rapidly deteriorated to <= 8) were recruited. CSF was collected from admission to day 5 post-injury. TRP, kynurenine (KYN), kynurenic acid (KYNA), QUIN, anthranilic acid (AA) and 3-hydroxyanthranilic acid (3HAA) were measured in CSF. The Glasgow Outcome Scale Extended (GOSE) score was assessed at 6 months post-TBI. Post-mortem brains were obtained from the Australian Neurotrauma Tissue and Fluid Bank and used in qPCR for quantitating expression of KP enzymes (indoleamine 2,3-dioxygenase-1 (IDO1), kynurenase (KYNase), kynurenine amino transferase-II (KAT-II), kynurenine 3-monooxygenase (KMO), 3-hydroxyanthranilic acid oxygenase (3HAO) and quinolinic acid phosphoribosyl transferase (QPRTase) and IDO1 immunohistochemistry. Results: In CSF, KYN, KYNA and QUIN were elevated whereas TRP, AA and 3HAA remained unchanged. The ratios of QUIN: KYN, QUIN: KYNA, KYNA: KYN and 3HAA: AA revealed that QUIN levels were significantly higher than KYN and KYNA, supporting increased neurotoxicity. Amplified IDO1 and KYNase mRNA expression was demonstrated on post-mortem brains, and enhanced IDO1 protein coincided with overt tissue damage. QUIN levels in CSF were significantly higher in patients with unfavourable outcome and inversely correlated with GOSE scores. Conclusion: TBI induced a striking activation of the KP pathway with sustained increase of QUIN. The exceeding production of QUIN together with increased IDO1 activation and mRNA expression in brain-injured areas suggests that TBI selectively induces a robust stimulation of the neurotoxic branch of the KP pathway. QUIN's detrimental roles are supported by its association to adverse outcome potentially becoming an early prognostic factor post-TBI.	[Yan, Edwin B.] Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia; [Frugier, Tony] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia; [Lim, Chai K.; Heng, Benjamin; Guillemin, Gilles J.] Macquarie Univ, Fac Med & Hlth Sci, Neuroinflammat Grp, Sydney, NSW 2109, Australia; [Sundaram, Gayathri] St Vincents Ctr Appl Med Res, Peter Duncan Neurosci Res Unit, Appl Neurosci Program, Sydney, NSW, Australia; [Tan, May] Hosp Queen Elizabeth, Kota Kinabalu 88586, Sabah, Malaysia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Cent Clin Sch, Dept Surg, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Monash Inst Med Engn, Melbourne, Vic 3004, Australia; [Walker, David W.] Monash Med Ctr, Hudson Inst Med Res, Ritchie Ctr, Melbourne, Vic, Australia; [Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Epidemiol & Prevent Med, Australian New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Morganti-Kossmann, Maria Cristina] Univ Arizona, Barrow Neurol Inst, Dept Child Hlth, Phoenix, AZ USA		Yan, EB (corresponding author), Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia.	edwin.yan@monash.edu	Guillemin, Gilles J/C-3878-2015; Lim, Edwin/R-5001-2019; Sundaram, Gayathri/AAN-3599-2020; Heng, Ruiwen benjamin/U-7383-2019	Guillemin, Gilles J/0000-0001-8105-4470; Lim, Edwin/0000-0003-3526-8405; Heng, Ruiwen benjamin/0000-0002-0247-2920; Sundaram, Gayathri/0000-0001-8610-1598; Frugier, Tony/0000-0002-1275-5158; Morganti-Kossmann, Cristina/0000-0002-0807-2063	Victorian Neurotrauma Initiative/Traffic Accident Commission [D009]; National Health Medical Research CouncilNational Health and Medical Research Council of Australia [436815]; Australian Research Council (Future Fellowship)Australian Research Council; Florey Institute of Neuroscience and Mental Health; Alfred and the Victorian Forensic Institute of Medicine; Australia's National Health & Medical Research Council; Parkinson's VictoriaParkinson's UK	This study was funded by the Victorian Neurotrauma Initiative/Traffic Accident Commission project grant D009 and Research Fellowships to EBY and MCM.-K and National Health Medical Research Council Project Grant #436815. GJG is funded by the Australian Research Council (Future Fellowship). Post-mortem brain tissues were received from the Victorian Brain Bank Network, supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian Forensic Institute of Medicine and funded by Australia's National Health & Medical Research Council and Parkinson's Victoria.	Baratte S, 1998, MOL BRAIN RES, V59, P50, DOI 10.1016/S0169-328X(98)00136-3; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Braidy N, 2009, NEUROTOX RES, V16, P77, DOI 10.1007/s12640-009-9051-z; Chen YQ, 2011, J NEUROCHEM, V118, P816, DOI 10.1111/j.1471-4159.2010.07159.x; Chen YQ, 2010, NEUROTOX RES, V18, P132, DOI 10.1007/s12640-009-9129-7; CHRISTENSEN HN, 1994, J EXP BIOL, V196, P51; Costantino G, 2014, FUTURE MED CHEM, V6, P841, DOI [10.4155/FMC.14.35, 10.4155/fmc.14.35]; Darlington LG, 2007, EUR J NEUROSCI, V26, P2211, DOI 10.1111/j.1460-9568.2007.05838.x; Darlington LG, 2010, INT J TRYPTOPHAN RES, V3, P51, DOI 10.4137/IJTR.S4282; Fallarino F, 2012, EUR J IMMUNOL, V42, P1932, DOI 10.1002/eji.201242572; Forrest CM, 2006, CLIN EXP PHARMACOL P, V33, P1078, DOI 10.1111/j.1440-1681.2006.04490.x; Forrest CM, 2010, J NEUROCHEM, V112, P112, DOI 10.1111/j.1471-4159.2009.06442.x; FOSTER AC, 1984, NEUROSCI LETT, V48, P273, DOI 10.1016/0304-3940(84)90050-8; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Goda K, 1996, ADV EXP MED BIOL, V398, P247; Guillemin GJ, 2007, J NEUROSCI, V27, P12884, DOI 10.1523/JNEUROSCI.4101-07.2007; Guillemin GJ, 2012, FEBS J, V279, P1355, DOI 10.1111/j.1742-4658.2012.08493.x; Guillemin GJ, 2012, FEBS J, V279, P1356, DOI 10.1111/j.1742-4658.2012.08485.x; Guillemin GJ, 2005, NEUROPATH APPL NEURO, V31, P395, DOI 10.1111/j.1365-2990.2005.00655.x; Guillemin GJ, 2003, ADV EXP MED BIOL, V527, P167; Guillemin GJ, 2002, REDOX REP, V7, P199, DOI 10.1179/135100002125000550; HABERNY KA, 1992, NEUROSCI LETT, V146, P187, DOI 10.1016/0304-3940(92)90074-H; Han Q, 2008, BIOSCIENCE REP, V28, P205, DOI 10.1042/BSR20080085; Han Q, 2010, CELL MOL LIFE SCI, V67, P353, DOI 10.1007/s00018-009-0166-4; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; Iwahashi H, 1999, CHEM-BIOL INTERACT, V118, P201, DOI 10.1016/S0009-2797(99)00080-0; Kalonia Harikesh, 2009, Inflammopharmacology, V17, P211, DOI 10.1007/s10787-009-0012-1; Kerr SJ, 1998, AIDS, V12, P355, DOI 10.1097/00002030-199804000-00003; Kheramin S, 2002, PSYCHOPHARMACOLOGY, V165, P9, DOI 10.1007/s00213-002-1228-6; Mackay GM, 2009, CLIN EXP PHARMACOL P, V36, P425, DOI 10.1111/j.1440-1681.2008.05077.x; MARTIN A, 1992, J NEUROPSYCH CLIN N, V4, P270; MCMENAMY RH, 1965, J BIOL CHEM, V240, P4235; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Moroni F, 1999, EUR J PHARMACOL, V375, P87, DOI 10.1016/S0014-2999(99)00196-X; Nemeth H, 2005, CURR NEUROVASC RES, V2, P249, DOI 10.2174/1567202054368326; Pellegrin K, 2005, SHOCK, V23, P209, DOI 10.1097/01.shk.000150773.16613.d3; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Ploder M, 2009, CLIN SCI, V116, P593, DOI 10.1042/CS20080319; Salazar C, 2009, FEBS J, V276, P3177, DOI 10.1111/j.1742-4658.2009.07027.x; Santamaria A, 2001, NEUROREPORT, V12, P2693, DOI 10.1097/00001756-200108280-00020; Santamaria A, 2001, NEUROREPORT, V12, P871, DOI 10.1097/00001756-200103260-00049; Sarkhosh K, 2003, WOUND REPAIR REGEN, V11, P337, DOI 10.1046/j.1524-475X.2003.11505.x; Sarkhosh K, 2003, J CELL BIOCHEM, V90, P206, DOI 10.1002/jcb.10593; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; Schwarcz R, 2012, NAT REV NEUROSCI, V13, P465, DOI 10.1038/nrn3257; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Smythe GA, 2002, ANAL BIOCHEM, V301, P21, DOI 10.1006/abio.2001.5490; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; STONE TW, 1981, EUR J PHARMACOL, V72, P411, DOI 10.1016/0014-2999(81)90587-2; Stoy N, 2005, J NEUROCHEM, V93, P611, DOI 10.1111/j.1471-4159.2005.03070.x; Swanson KA, 2004, AM J RESP CELL MOL, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Ting KK, 2007, NEUROTOX RES, V12, P247, DOI 10.1007/BF03033908; Vandresen-Filho S, 2015, NEUROL SCI; VONRUECKER AA, 1989, BIOCHEM BIOPH RES CO, V163, P836, DOI 10.1016/0006-291X(89)92298-5; Wang YX, 2010, BRAIN BEHAV IMMUN, V24, P201, DOI 10.1016/j.bbi.2009.06.152; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yamada A, 2009, J NEUROCHEM, V110, P791, DOI 10.1111/j.1471-4159.2009.06175.x; Yan E, 2005, NEUROSCIENCE, V134, P867, DOI 10.1016/j.neuroscience.2005.04.056; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zwilling D, 2011, CELL, V145, P863, DOI 10.1016/j.cell.2011.05.020	69	45	45	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 30	2015	12								110	10.1186/s12974-015-0328-2			17	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CK1OO	WOS:000355976800001	26025142	Green Published, gold			2022-02-06	
J	Storzbach, D; O'Neil, ME; Roost, SM; Kowalski, H; Iverson, GL; Binder, LM; Fann, JR; Huckans, M				Storzbach, Daniel; O'Neil, Maya Elin; Roost, Saw-Myo; Kowalski, Halina; Iverson, Grant L.; Binder, Laurence M.; Fann, Jesse R.; Huckans, Marilyn			Comparing the Neuropsychological Test Performance of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans with and without Blast Exposure, Mild Traumatic Brain Injury, and Posttraumatic Stress Symptoms	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injuries; Blast injuries; Explosions; Military personnel; Combat disorders; Stress disorders; Post-traumatic; Cognitive symptoms	OUTCOMES; SOLDIERS; HEALTH	To compare neuropsychological test performance of Veterans with and without mild traumatic brain injury (MTBI), blast exposure, and posttraumatic stress disorder (PTSD) symptoms. We compared the neuropsychological test performance of 49 Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans diagnosed with MTBI resulting from combat blast-exposure to that of 20 blast-exposed OEF/OIF Veterans without history of MTBI, 23 OEF/OIF Veterans with no blast exposure or MTBI history, and 40 matched civilian controls. Comparison of neuropsychological test performance across all four participant groups showed a complex pattern of mixed significant and mostly nonsignificant results, with omnibus tests significant for measures of attention, spatial abilities, and executive function. The most consistent pattern was the absence of significant differences between blast-exposed Veterans with MTBI history and blast-exposed Veterans without MTBI history. When blast-exposed Veteran groups with and without MTBI history were aggregated and compared to non-blast-exposed Veterans, there were significant differences for some measures of learning and memory, spatial abilities, and executive function. However, covariation for severity of PTSD symptoms eliminated all significant omnibus neuropsychological differences between Veteran groups. Our results suggest that, although some mild neurocognitive effects were associated with blast exposure, these neurocognitive effects might be better explained by PTSD symptom severity rather than blast exposure or MTBI history alone.	[Storzbach, Daniel; O'Neil, Maya Elin; Roost, Saw-Myo; Kowalski, Halina; Huckans, Marilyn] Portland VA Med Ctr, Portland, OR USA; [Storzbach, Daniel; O'Neil, Maya Elin; Binder, Laurence M.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Storzbach, Daniel; Binder, Laurence M.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [O'Neil, Maya Elin] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Fann, Jesse R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA		O'Neil, ME (corresponding author), Portland VA Med Ctr R&D 66, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	maya.oneil@va.gov		Iverson, Grant/0000-0001-7348-9570	VA Merit Review Award from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and DevelopmentUS Department of Veterans Affairs [B5060R]; Veterans Affairs Health Services Research and Development Center of Innovation grant; Center to Improve Veteran Involvement in Care [CIN 13-404]; Agency for Healthcare Research QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1 K12 HS019456 01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS019456, K12HS022981] Funding Source: NIH RePORTER	This work was supported by VA Merit Review Award #B5060R to D.S. from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development, a Veterans Affairs Health Services Research and Development Center of Innovation grant, Center to Improve Veteran Involvement in Care, Award #CIN 13-404, and an Agency for Healthcare Research & Quality-funded PCOR K12 award to MEO (#1 K12 HS019456 01). This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center, Portland, Oregon. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. All authors declare no conflicts of interests involved in the research presented in the manuscript. The corresponding author (M.E.O.) declares she had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. D. Storzbach and M. O'Neil contributed equally to this work.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Kamphaus, 2003, REYNOLDS INTELLECTUA; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Murphy KR, 2004, STAT POWER ANAL; Nelson N. W., 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S1355617711001548; Sheehan D., 2006, MINI INT NEUROPSYCHI; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2011, J INT NEUROPSYCH SOC, V17, P1, DOI 10.1017/S1355617710001116; Verfaellie M., 2009, POSTTRAUMATIC STRESS, V1, P1; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Weathers FW, 1996, MEASUREMENT STRESS T, P250; WechslerD, 2001, WECHSLER TEST ADULT	25	45	45	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2015	21	5					353	363		10.1017/S1355617715000326			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	CL9QK	WOS:000357313000004	26029852	Bronze			2022-02-06	
J	Fan, W; Zhu, X; Wu, L; Wu, Z; Li, D; Huang, F; He, H				Fan, W.; Zhu, X.; Wu, L.; Wu, Z.; Li, D.; Huang, F.; He, H.			Propofol: an anesthetic possessing neuroprotective effects	EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES			English	Article						Propofol; Neuroprotection; Cerebral ischemia; Brain injury	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; REDUCES INFARCT SIZE; PROTEIN-KINASE-C; RAT CEREBROCORTICAL NEURONS; OXYGEN-GLUCOSE DEPRIVATION; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; OXIDATIVE STRESS; CULTURED ASTROCYTES	Propofol is a short-acting intravenous anaesthetic agent and widely used not only in operating rooms but also in the intensive care unit (ICU). Apart from its multiple anaesthetic advantages, the neuroprotective effect of propofol has been demonstrated in diverse models of neuronal injury. The effect of propofol results from activation of gamma-aminobutyric acid (GABA) receptor, modulation excitatory amino acid transmitter system and protecting brain cells against oxidative stress. Moreover, propofol is able to supress apoptosis and inflammation and to regulate neuroprotection-associated proteins or ion homeostasis to act its neuroprotective effects. This review focuses on the research progress of the neuroprotective effects of propofol and its mechanisms of action to date. The implications for possible use for the clinical setting are also discussed.	[Fan, W.; Wu, L.; Wu, Z.; Huang, F.; He, H.] Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China; [Fan, W.] Sun Yat Sen Univ, Affiliated Hosp Stomatol, Dept Anesthesiol, Guangzhou 510275, Guangdong, Peoples R China; [Zhu, X.] Guangdong Med Coll, Guangdong Prov Key Lab Med Mol Diag, Dongguan, Guangdong, Peoples R China; [Li, D.] Georgia Regents Univ, Inst Mol Med & Genet, Augusta, GA USA		He, H (corresponding author), Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.	HeHW@mail.sysu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271166, 81371107]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [10451008901006145]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [11ykpy50]	This work is supported in part by the National Natural Science Foundation of China (No. 81271166, 81371107), Natural Science Foundation of Guangdong Province (No. 10451008901006145) and Fundamental Research Funds for the Central Universities (No. 11ykpy50).	AARTS L, 1995, FEBS LETT, V357, P83, DOI 10.1016/0014-5793(94)01337-Z; Acquaviva R, 2005, CURR NEUROVASC RES, V2, P141, DOI 10.2174/1567202053586820; Acquaviva R, 2004, ANESTHESIOLOGY, V101, P1363; Adembri C, 2006, ANESTHESIOLOGY, V104, P80, DOI 10.1097/00000542-200601000-00014; Adembri C, 2007, CNS DRUG REV, V13, P333, DOI 10.1111/j.1527-3458.2007.00015.x; Andrews DT, 2012, ANAESTH INTENS CARE, V40, P46, DOI 10.1177/0310057X1204000106; Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017; Berns M, 2009, J INT MED RES, V37, P680, DOI 10.1177/147323000903700311; Boland A, 2000, EUR J PHARMACOL, V404, P21, DOI 10.1016/S0014-2999(00)00496-9; Bowery NG, 2006, BRIT J PHARMACOL, V147, pS109, DOI 10.1038/sj.bjp.0706443; Cai JS, 2011, NEUROCHEM RES, V36, P1724, DOI 10.1007/s11064-011-0487-1; Chen L, 2008, ACTA ANAESTH SCAND, V52, P413, DOI 10.1111/j.1399-6576.2007.01560.x; Chen LH, 2003, CHINESE MED J-PEKING, V116, P292; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cui DR, 2013, NEUROSCIENCE, V246, P117, DOI 10.1016/j.neuroscience.2013.04.054; Cui DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035324; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Ding ZY, 2013, CELL BIOCHEM BIOPHYS, V67, P615, DOI 10.1007/s12013-013-9549-0; Do SH, 2003, NEUROSCI LETT, V343, P113, DOI 10.1016/S0304-3940(03)00358-6; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Engelhard K, 2004, EUR J ANAESTH, V21, P530, DOI 10.1017/S0265021504007057; Engelhard K, 2003, ANESTH ANALG, V97, P1155, DOI 10.1213/01.ANE.0000078576.93190.6F; Engelhard K, 2006, CURR OPIN ANESTHESIO, V19, P504, DOI 10.1097/01.aco.0000245275.76916.87; Ergun R, 2002, NEUROSURG REV, V25, P95, DOI 10.1007/s101430100171; Feiner JR, 2005, ANESTH ANALG, V100, P215, DOI 10.1213/01.ANE.0000142129.17005.73; Feng C S, 2004, CHIN MED J, V84, P2110; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006; Grasshoff C, 2005, EUR J ANAESTH, V22, P467, DOI 10.1017/S0265021505000803; Grasshoff C, 2002, ANESTH ANALG, V95, P920, DOI 10.1213/01.ANE.0000025705.93185.09; Gui B, 2012, INFLAMMATION, V35, P1632, DOI 10.1007/s10753-012-9478-x; Haeseler G, 2008, BRIT J PHARMACOL, V155, P265, DOI 10.1038/bjp.2008.255; Hans P, 1997, J NEUROSURG ANESTH, V9, P234, DOI 10.1097/00008506-199707000-00006; HANS P, 1994, J NEUROSURG ANESTH, V6, P249; Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad; Harman F, 2012, CHILD NERV SYST, V28, P1055, DOI 10.1007/s00381-012-1782-0; He JG, 2013, NEUROL SCI, V34, P165, DOI 10.1007/s10072-012-0978-0; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; Huang WC, 2009, IMMUNOLOGY, V128, pe275, DOI 10.1111/j.1365-2567.2008.02959.x; Hutchens MP, 2006, NEUROCRIT CARE, V4, P54, DOI 10.1385/NCC:4:1:054; Ichinose K, 2006, RESUSCITATION, V70, P275, DOI 10.1016/j.resuscitation.2005.12.011; Iijima T, 2006, BRAIN RES, V1099, P25, DOI 10.1016/j.brainres.2006.04.117; Ishii H, 2002, BRIT J ANAESTH, V88, P412, DOI 10.1093/bja/88.3.412; ISHII H, 1994, ACTA NEUROCHIR, P238; Ito H, 1999, ACTA ANAESTH SCAND, V43, P153, DOI 10.1034/j.1399-6576.1999.430206.x; Jevtovic-Todorovic V, 2001, BRAIN RES, V913, P185, DOI 10.1016/S0006-8993(01)02800-1; JevtovicTodorovic V, 1997, J CEREBR BLOOD F MET, V17, P168, DOI 10.1097/00004647-199702000-00006; Jiao S, 2007, J NEUROCHEM, V100, P979, DOI 10.1111/j.1471-4159.2006.04261.x; Kanbak M, 2004, CAN J ANAESTH, V51, P712, DOI 10.1007/BF03018431; Kaptanoglu E, 2002, J NEUROSURG ANESTH, V14, P114, DOI 10.1097/00008506-200204000-00005; Karen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064480; Kawaguchi Masahiko, 2005, J Anesth, V19, P150, DOI 10.1007/s00540-005-0305-5; Kitamura Y, 2003, J NEUROSCI RES, V71, P544, DOI 10.1002/jnr.10514; Kobayashi K, 2008, ANESTHESIOLOGY, V109, P426, DOI 10.1097/ALN.0b013e318182a903; Kobayashi M, 2007, J NEUROSURG ANESTH, V19, P171, DOI 10.1097/ANA.0b013e318051743d; KOCHS E, 1992, ANESTHESIOLOGY, V76, P245, DOI 10.1097/00000542-199202000-00014; Koerner IP, 2006, CURR OPIN ANESTHESIO, V19, P481, DOI 10.1097/01.aco.0000245271.84539.4c; Kotani Y, 2008, CNS NEUROSCI THER, V14, P95, DOI 10.1111/j.1527-3458.2008.00043.x; Kotani Y, 2008, J CEREBR BLOOD F MET, V28, P354, DOI 10.1038/sj.jcbfm.9600532; Krasowski MD, 2001, J PHARMACOL EXP THER, V297, P338; Kubo K, 2011, BRAIN RES, V1387, P125, DOI 10.1016/j.brainres.2011.02.079; Kumagai H, 2006, EUR J CARDIO-THORAC, V29, P714, DOI 10.1016/j.ejcts.2006.01.042; Larsson M, 2011, NEUROSCIENTIST, V17, P256, DOI 10.1177/1073858409349913; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lee H, 2005, J NEUROSURG ANESTH, V17, P144, DOI 10.1097/01.ana.0000167143.67673.53; Lee SR, 1999, NEUROL RES, V21, P225, DOI 10.1080/01616412.1999.11740922; Lee Y, 2000, J KOREAN MED SCI, V15, P627, DOI 10.3346/jkms.2000.15.6.627; Li Q, 2002, EXP NEUROL, V177, P531, DOI 10.1006/exnr.2002.7994; Liang C, 2013, J NEUROSURG ANESTH, V25, P311, DOI 10.1097/ANA.0b013e31828c6af5; Lingamaneni R, 2001, ANESTHESIOLOGY, V95, P1460, DOI 10.1097/00000542-200112000-00027; Liu J, 2012, CLIN EXP MED, V12, P31, DOI 10.1007/s10238-011-0139-4; Ma G, 2013, J CARDIOTHOR VASC AN, V27, P510, DOI 10.1053/j.jvca.2012.10.013; Ma Jie, 2009, Yaoxue Xuebao, V44, P344; Maines MD, 2004, ANTIOXID REDOX SIGN, V6, P797, DOI 10.1089/1523086041798105; Manataki AD, 2001, SURG ENDOSC, V15, P950, DOI 10.1007/s004640090104; Menku A, 2010, TURK NEUROSURG, V20, P57; Minami K, 1996, N-S ARCH PHARMACOL, V353, P572; Morris DR, 2013, CURR OPIN CLIN NUTR, V16, P708, DOI 10.1097/MCO.0b013e328364f39c; Nakanishi M, 2007, ANESTH ANALG, V104, P1136, DOI 10.1213/01.ane.0000260615.12553.4e; Ouyang W, 2003, MOL PHARMACOL, V64, P373, DOI 10.1124/mol.64.2.373; Pittman JE, 1997, ANESTHESIOLOGY, V87, P1139, DOI 10.1097/00000542-199711000-00018; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Qin X, 2013, J PHYSIOL BIOCHEM, V69, P707, DOI 10.1007/s13105-013-0247-6; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Ratnakumari L, 1996, BRIT J PHARMACOL, V119, P1498, DOI 10.1111/j.1476-5381.1996.tb16064.x; Ratnakumari L, 1997, ANESTHESIOLOGY, V86, P428, DOI 10.1097/00000542-199702000-00018; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Sagara Y, 1999, J NEUROCHEM, V73, P2524, DOI 10.1046/j.1471-4159.1999.0732524.x; Schlunzen L, 2012, ACTA ANAESTH SCAND, V56, P248, DOI 10.1111/j.1399-6576.2011.02561.x; Schoen J, 2011, BRIT J ANAESTH, V106, P840, DOI 10.1093/bja/aer091; Shu LW, 2012, NEUROCHEM RES, V37, P49, DOI 10.1007/s11064-011-0582-3; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Singh S, 2012, EUR REV MED PHARMACO, V16, P1651; Sitar SM, 1999, ANESTHESIOLOGY, V90, P1446, DOI 10.1097/00000542-199905000-00030; Snyder GL, 2007, NEUROPHARMACOLOGY, V53, P619, DOI 10.1016/j.neuropharm.2007.07.008; Solaroglu I, 2004, BIOL NEONATE, V85, P221, DOI 10.1159/000075835; Song CY, 2011, EUR J PHARMACOL, V653, P16, DOI 10.1016/j.ejphar.2010.10.072; Stratford N, 1998, EUR J ANAESTH, V15, P158, DOI 10.1046/j.1365-2346.1998.00261.x; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Szewczyk B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00033; Tanaka T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029378; Tawfeeq NA, 2009, INJURY, V40, pS75, DOI 10.1016/j.injury.2009.10.040; Traber MG, 2007, FREE RADICAL BIO MED, V43, P4, DOI 10.1016/j.freeradbiomed.2007.03.024; Trapani G, 2000, CURR MED CHEM, V7, P249, DOI 10.2174/0929867003375335; Vasileiou I, 2009, EUR J PHARMACOL, V605, P1, DOI 10.1016/j.ejphar.2009.01.007; Velly LJ, 2003, ANESTHESIOLOGY, V99, P368, DOI 10.1097/00000542-200308000-00018; Wang HY, 2009, BRAIN RES, V1297, P177, DOI 10.1016/j.brainres.2009.08.054; Wang HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065187; Wang HY, 2011, J NEUROCHEM, V119, P210, DOI 10.1111/j.1471-4159.2011.07400.x; Wang JP, 2002, EUR J PHARMACOL, V452, P303, DOI 10.1016/S0014-2999(02)02332-4; Wang L, 2008, J NEUROSURG ANESTH, V20, P124, DOI 10.1097/ANA.0b013e3181667c27; Wang MJ, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-99; Wang P, 2013, EUR REV MED PHARMACO, V17, P1722; WERNER C, 1992, J NEUROSURG ANESTH, V4, P41, DOI 10.1097/00008506-199201000-00008; Wu GJ, 2011, BRAIN RES, V1384, P42, DOI 10.1016/j.brainres.2011.02.004; Wu XJ, 2007, ACTA PHARMACOL SIN, V28, P1123, DOI 10.1111/j.1745-7254.2007.00610.x; Xi HJ, 2011, BRAIN RES, V1410, P24, DOI 10.1016/j.brainres.2011.06.060; Xue QS, 2004, ACTA PHARMACOL SIN, V25, P115; Yamaguchi S, 1999, CAN J ANAESTH, V46, P593, DOI 10.1007/BF03013553; Yamasaki T, 1999, EUR J ANAESTH, V16, P320, DOI 10.1046/j.1365-2346.1999.00478.x; Yano T, 2000, BRAIN RES, V883, P69, DOI 10.1016/S0006-8993(00)02889-4; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x; Yun JY, 2007, EUR J PHARMACOL, V565, P83, DOI 10.1016/j.ejphar.2007.02.045; Zhan RZ, 2001, CRIT CARE MED, V29, P808, DOI 10.1097/00003246-200104000-00026; Zhang YY, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-20; Zhao XC, 2013, NEUROCHEM RES, V38, P530, DOI 10.1007/s11064-012-0945-4; Zheng YY, 2008, ANESTH ANALG, V107, P2009, DOI 10.1213/ane.0b013e318187c313; Zhu SM, 2009, ANESTH ANALG, V109, P1493, DOI 10.1213/ANE.0b013e3181b893f3	129	45	47	2	8	VERDUCI PUBLISHER	ROME	VIA GREGORIO VII, ROME, 186-00165, ITALY	1128-3602			EUR REV MED PHARMACO	Eur. Rev. Med. Pharmacol. Sci.	APR	2015	19	8					1520	1529					10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	CI1WG	WOS:000354535200027	25967729				2022-02-06	
J	Heinemann, AW; Magasi, S; Hammel, J; Carlozzi, NE; Garcia, SF; Hahn, EA; Lai, JS; Tulsky, D; Gray, DB; Hollingsworth, H; Jerousek, S				Heinemann, Allen W.; Magasi, Susan; Hammel, Joy; Carlozzi, Noelle E.; Garcia, Sofia F.; Hahn, Elizabeth A.; Lai, Jin-Shei; Tulsky, David; Gray, David B.; Hollingsworth, Holly; Jerousek, Sara			Environmental Factors Item Development for Persons With Stroke, Traumatic Brain Injury, and Spinal Cord Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Environment; Qualitative research; Questionnaires; Rehabilitation	INTERNATIONAL CLASSIFICATION; OUTCOMES ASSESSMENT; PARTICIPATION; HEALTH; PEOPLE; DISABILITIES; IMPAIRMENTS; ISSUES; PROMIS	Objectives: To describe methods used in operationalizing environmental factors; to describe the results of a research project to develop measures of environmental factors that affect participation; and to define an initial item set of facilitators and barriers to participation after stroke, traumatic brain injury, and spinal cord injury. Design: Instrument development included an extensive literature review, item classification and selection, item writing, and cognitive testing following the approach of the Patient-Reported Outcomes Measurement Information System. Setting: Community. Participants: Content area and outcome measurement experts (n=10) contributed to instrument development; individuals (n=200) with the target conditions participated in focus groups and in cognitive testing (n=15). Interventions: None. Main Outcome Measures: Environmental factor items were categorized in 6 domains: assistive technology; built and natural environment; social environment; services, systems, and policies; access to information and technology; and economic quality of life. Results: We binned 2273 items across the 6 domains, winnowed this pool to 291 items for cognitive testing, and recommended 274 items for pilot data collection. Conclusions: Five of the 6 domains correspond closely to the International Classification of Functioning, Disability and Health taxonomy of environmental factors; the sixth domain, economic quality of life, reflects an important construct that reflects financial resources that affect participation. Testing with a new and larger sample is underway to evaluate reliability, validity, and sensitivity. (C) 2015 by the American Congress of Rehabilitation Medicine	[Heinemann, Allen W.; Jerousek, Sara] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA; [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Magasi, Susan; Hammel, Joy] Univ Illinois, Dept Occupat Therapy, Chicago, IL USA; [Hammel, Joy] Univ Illinois, Dept Disabil & Human Dev, Chicago, IL USA; [Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Garcia, Sofia F.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; [Garcia, Sofia F.; Hahn, Elizabeth A.; Lai, Jin-Shei] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Tulsky, David] NYU, Ctr Ambulatory Care, Langone Med Ctr, Dept Rehabil Med, New York, NY USA; [Tulsky, David] NYU, Ctr Ambulatory Care, Langone Med Ctr, Dept Orthoped Surg, New York, NY USA; [Tulsky, David] NYU, Ctr Ambulatory Care, Langone Med Ctr, Dept Gen Med, New York, NY USA; [Tulsky, David] Kessler Fdn, W Orange, NJ USA; [Gray, David B.; Hollingsworth, Holly] Washington Univ, Program Occupat Therapy, St Louis, MO USA		Heinemann, AW (corresponding author), Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Tulsky, David/0000-0002-4335-4509	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant [H133B090024]; National Center for Complementary and Alternative MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U54AR0579510]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U54AR057951] Funding Source: NIH RePORTER	Supported by the National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant (no. H133B090024) awarded to the Rehabilitation Institute of Chicago; and a portion of Garcia's time was supported by the National Center for Complementary and Alternative Medicine and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (award no. U54AR0579510).	Alvarelhao J, 2012, J REHABIL MED, V44, P1, DOI 10.2340/16501977-0905; Badley EM, 2008, SOC SCI MED, V66, P2335, DOI 10.1016/j.socscimed.2008.01.026; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; DeWalt DA, 2007, MED CARE, V45, pS12, DOI 10.1097/01.mlr.0000254567.79743.e2; Escorpizo Reuben, 2011, Am J Phys Med Rehabil, V90, pS66, DOI 10.1097/PHM.0b013e318230fbf9; Field M.J., 2007, FUTURE DISABILITY AM; Garcia SF, 2007, J CLIN ONCOL, V25, P5106, DOI 10.1200/JCO.2007.12.2341; Garcia SF, 2015, ARCH PHYS MED REHAB, V96, P596, DOI 10.1016/j.apmr.2014.06.019; Gray DB, 2006, ARCH PHYS MED REHAB, V87, P189, DOI 10.1016/j.apmr.2005.09.014; Hahn EA, 2003, ARCH PHYS MED REHAB, V84, pS35, DOI 10.1053/apmr.2003.50245; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hammel J, 2015, ARCH PHYS MED REHAB, V96, P578, DOI 10.1016/j.apmr.2014.12.008; Heinemann AW, 2013, ARCH PHYS MED REHAB, V94, P2157, DOI 10.1016/j.apmr.2013.05.017; Hollingsworth H, 2010, ARCH PHYS MED REHAB, V91, P1174, DOI 10.1016/j.apmr.2010.04.019; Magasi S, 2015, ARCH PHYS MED REHAB, V96, P569, DOI 10.1016/j.apmr.2014.12.002; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Mallinson T, 2010, ARCH PHYS MED REHAB, V91, pS29, DOI 10.1016/j.apmr.2010.04.027; National Institute of Health, 2012, PROMIS INSTR DEV PSY; Noreau L, 2010, ARCH PHYS MED REHAB, V91, pS44, DOI 10.1016/j.apmr.2009.10.037; Rao D, 2009, QUAL LIFE RES, V18, P585, DOI 10.1007/s11136-009-9475-1; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Reinhardt JD, 2010, TOPICS SPINAL CORD I, V15, P26, DOI DOI 10.1310/SCI1504-26; Stenner A., 1998, THE LEXILE FRAMEWORK; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; Tulsky DS, 2015, ARCH PHYS MED REHAB, V96, P604, DOI 10.1016/j.apmr.2014.02.030; Tulsky DS, 2011, ARCH PHYS MED REHAB, V92, pS44, DOI 10.1016/j.apmr.2011.04.024; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; World Health Organization, 2007, INT CLASS FUNCT DIS	28	45	47	0	25	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2015	96	4					589	595		10.1016/j.apmr.2013.11.024			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	CE9RC	WOS:000352180100003	24378804	Green Accepted			2022-02-06	
J	Lavigne, G; Khoury, S; Chauny, JM; Desautels, A				Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex			Pain and sleep in post-concussion/mild traumatic brain injury	PAIN			English	Article						Pain; Widespread pain; Diffuse pain; Central pain; Sleep; Minor traumatic brain injury; Biomarkers; BDNF genotype; Depression; Anxiety; Hyperarousal; Chronification	BDNF VAL66MET POLYMORPHISM; PERSISTENT POSTSURGICAL PAIN; POSTTRAUMATIC HEADACHE; RISK-FACTORS; NEUROTROPHIC FACTOR; PRACTICE PARAMETERS; WAKE DISTURBANCES; PREVALENCE; INSOMNIA; DISORDERS	Concussion after a force to the head is called mild traumatic brain injury (mTBI). Approximately 1 in 5 patients with mTBI will develop chronic pain (headache and widespread pain, possibly of central origin) and/or sleep problems (insomnia, disordered breathing, periodic limb movements). However, the predisposing mechanisms for chronic pain in patients with mTBI are unknown. Mild traumatic brain injury is a rare model to prospectively assess the risk factors and mechanisms for pain chronification from the injury onset in the absence of pretrauma comorbidity or medication. In the acute phase, headaches and sleep disturbances seem to predict the poorest long-term cognitive and mood outcomes. Although recent studies suggest that certain brain biomarkers and mood alterations (eg, anxiety, depression) contribute, the causality of chronic pain remains unclear. In mTBI patients with pain, poor sleep quality was correlated with fast beta and gamma electroencephalographic activity in frontal, central, and occipital electroencephalographic (EEG) derivations in all sleep stages. Sleep recuperative function seems to be disturbed by persistent wake EEG activity, corroborating patient complaints such as feeling awake when asleep. Pain and sleep management in mTBI is not yet evidence-based. Treatments include cognitive behavioral and light therapies, medications, and continuous positive airway pressure (CPAP) or oral appliances for disordered sleep breathing. Customized approaches are indicated for mTBI, pain, and sleep complaints. Further studies in pediatric, sport, and transportation populations are needed to prevent TBI chronification. Improvements are emerging in biomarker sensitivity and specificity and management strategies for TBI, pain, and sleep comorbidities.	[Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Univ Montreal, Dept Med Family Med Emergency Med, Montreal, PQ H3C 3J7, Canada; [Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Univ Montreal, Dept Neurosci, Montreal, PQ H3C 3J7, Canada; [Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Hop Sacre Coeur Montreal, Res Ctr, Trauma Unit, Montreal, PQ, Canada; [Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Hop Sacre Coeur Montreal, Ctr Adv Study Sleep Med, Montreal, PQ, Canada; [Khoury, Samar; Desautels, Alex] McGill Univ, Dept Anesthesia, Montreal, PQ H3A 2T5, Canada; [Desautels, Alex] Hop Sacre Coeur Montreal, Fac Med, Serv Neurol, Montreal, PQ, Canada		Lavigne, G (corresponding author), Univ Montreal, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	gilles.lavigne@umontreal.ca	Meijer, Anna/K-5118-2016		Fonds de Recherche du Quebec-Sante/Quebec Pain Research Network partnership; Ronald Denis Trauma Foundation, Montreal, Canada	The first author (GL) holds a Canada Research Chair in Pain, Sleep and Trauma. The author's projects cited in this review were funded by the Fonds de Recherche du Quebec-Sante/Quebec Pain Research Network partnership and the Ronald Denis Trauma Foundation, Montreal, Canada.	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Apkarian AV, 2013, CURR OPIN NEUROL, V26, P360, DOI 10.1097/WCO.0b013e32836336ad; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Aurora RN, 2012, SLEEP, V35, P1039, DOI 10.5665/sleep.1988; Aurora RN, 2012, SLEEP, V35, P17, DOI 10.5665/sleep.1580; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bachmann V, 2012, SLEEP, V35, P335, DOI 10.5665/sleep.1690; Bastuji H, 2008, PAIN, V137, P589, DOI 10.1016/j.pain.2007.10.027; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bonnet MH, 2010, SLEEP MED REV, V14, P9, DOI 10.1016/j.smrv.2009.05.002; Burgess HJ, 2002, SLEEP MED REV, V6, P407, DOI 10.1053/smrv.2001.0215; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cao M, 2014, J CLIN SLEEP MED, V10, P855, DOI 10.5664/jcsm.3954; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casey CY, 2008, PAIN, V134, P69, DOI 10.1016/j.pain.2007.03.032; Castillo RC, 2006, PAIN, V124, P321, DOI 10.1016/j.pain.2006.04.020; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Cervero F, 1996, PROG BRAIN RES, V110, P3; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chen PY, 2014, J HEAD TRAUMA REHABI; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Choiniere M, 2014, CAN MED ASSOC J, V186, pE213, DOI 10.1503/cmaj.131012; Clay FJ, 2010, J PAIN, V11, P420, DOI 10.1016/j.jpain.2009.12.002; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Davidson J., 2014, NEUROSCIENTIST; De Beaumont L, 2013, BEHAV BRAIN RES, V253, P152, DOI 10.1016/j.bbr.2013.07.002; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Doufas AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040891; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Finnerup NB, 2013, PAIN, V154, pS71, DOI 10.1016/j.pain.2012.12.007; Finnerup NB, 2012, CURR PAIN HEADACHE R, V16, P207, DOI 10.1007/s11916-012-0259-x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gagnon JF, 2002, NEUROLOGY, V59, P585, DOI 10.1212/WNL.59.4.585; Ganti L, 2013, ADV PREV MED, V2013, DOI DOI 10.1155/2013/450195; Gauthier L, 2012, CAN RESPIR J, V19, P307, DOI 10.1155/2012/631803; Gosselin N, 2012, J NEUROTRAUM, V29, P2625, DOI 10.1089/neu.2012.2312; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Guilleminault C, 2010, LUNG, V188, P459, DOI 10.1007/s00408-010-9254-3; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Hanlon EC, 2011, CURR TOP MED CHEM, V11, P2472; Hornyak M, 2014, SLEEP MED REV, V18, P153, DOI 10.1016/j.smrv.2013.03.004; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jamora CW, 2013, BRAIN INJURY, V27, P1134, DOI 10.3109/02699052.2013.804196; Jazi MS, 2014, COMPUT METHOD BIOMEC, V17, P1368, DOI 10.1080/10255842.2012.748755; Jungquist CR, 2012, PAIN MANAG NURS, V13, P70, DOI 10.1016/j.pmn.2010.04.003; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Katz J, 2009, EXPERT REV NEUROTHER, V9, P723, DOI [10.1586/ern.09.20, 10.1586/ERN.09.20]; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Khoury S, 2014, 15 WORLD C PAIN INT; Khoury S, 2010, 13 WORLD C PAIN INT; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P458, DOI 10.1097/PEC.0000000000000161; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lautenbacher S, 2009, CLIN J PAIN, V25, P92, DOI 10.1097/AJP.0b013e3181850dce; Lavigne G, 2000, PAIN, V84, P283, DOI 10.1016/S0304-3959(99)00213-4; LAVIGNE G, 2007, SLEEP PAIN, P235; Lavigne G. J., 2011, PRINCIPLES PRACTICE, P1442; Lavigne GJ, 2011, CURR RHEUMATOL REP, V13, P535, DOI 10.1007/s11926-011-0209-3; Lavigne GJ, 2011, SLEEP MED, V12, P179, DOI 10.1016/j.sleep.2010.07.015; Lavigne GJ, 2007, SLEEP DISORDERS THEI, P193; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Lotsch J, 2013, PHARMACOL THERAPEUT, V139, P60, DOI 10.1016/j.pharmthera.2013.04.004; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Mansour AR, 2014, RESTOR NEUROL NEUROS, V32, P129, DOI 10.3233/RNN-139003; Mansour AR, 2013, PAIN, V154, P2160, DOI 10.1016/j.pain.2013.06.044; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; McDermid AJ, 1996, PAIN, V66, P133, DOI 10.1016/0304-3959(96)03059-X; Melemedjian OK, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-12; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Menon JP, 2012, IEEE ENG MED BIO, P1354, DOI 10.1109/EMBC.2012.6346189; Mogil JS, 2012, TRENDS GENET, V28, P258, DOI 10.1016/j.tig.2012.02.004; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin-Moncet O, 2014, J NEUROPHYSIOL, V111, P2094, DOI 10.1152/jn.00388.2013; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Nordstrom A, 2014, BR J SPORTS MED; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Obermann M, 2010, CEPHALALGIA, V30, P528, DOI 10.1111/j.1468-2982.2009.01972.x; Obermann M, 2009, EXPERT REV NEUROTHER, V9, P1361, DOI [10.1586/ern.09.84, 10.1586/ERN.09.84]; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Ohayon MM, 2005, J PSYCHIAT RES, V39, P151, DOI 10.1016/j.jpsychires.2004.07.001; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Ponsford JL, 2013, NEUROREHABIL NEURAL; Prichep LS, 2014, J NEUROTRAUMA; Radresa O, 2014, J TRAUMA ACUTE CARE, V76, P1142, DOI 10.1097/TA.0000000000000188; Rao V, 2014, BRAIN INJURY, V28, P20, DOI 10.3109/02699052.2013.847210; Rose AR, 2014, J CLIN SLEEP MED, V10, P847, DOI 10.5664/jcsm.3950; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Sarhan M, 2013, INT J NEUROPSYCHOPH, V16, P1649, DOI 10.1017/S146114571200168X; Schug SA, 2011, PAIN CLIN UPDATE, P19; Schug SA, 2012, PAIN, V153, P1344, DOI 10.1016/j.pain.2012.02.041; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Smith MT, 2008, PAIN, V138, P497, DOI 10.1016/j.pain.2008.01.028; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Strigo IA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.116; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Tang NKY, 2007, J SLEEP RES, V16, P85, DOI 10.1111/j.1365-2869.2007.00571.x; Tang NKY, 2012, SLEEP, V35, P675, DOI 10.5665/sleep.1830; Tang Nicole K Y, 2009, Curr Rheumatol Rep, V11, P451; Taylor PA, 2014, BRAIN INJURY, V28, P879, DOI 10.3109/02699052.2014.888478; Theodorou AA, 2007, J CLIN SLEEP MED, V3, P347; Tracey I, 2011, NAT REV NEUROL, V7, P173, DOI 10.1038/nrneurol.2011.4; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Ucar T, 2005, ACTA NEUROL SCAND, V112, P163, DOI 10.1111/j.1600-0404.2005.00463.x; Venkatesan UM, 2015, J NEUROTRAUM, V32, P252, DOI 10.1089/neu.2013.3318; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vitiello MV, 2013, J AM GERIATR SOC, V61, P947, DOI 10.1111/jgs.12275; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Whittom S, 2010, SLEEP MED, V11, P351, DOI 10.1016/j.sleep.2009.12.008; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Wortzel HS, 2014, NEUROREHABILITATION, V34, P613, DOI 10.3233/NRE-141086; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Zelman DC, 2005, J PAIN SYMPTOM MANAG, V29, P401, DOI 10.1016/j.jpainsymman.2004.06.018; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	154	45	46	3	45	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	APR	2015	156	4		1			S75	S85		10.1097/j.pain.0000000000000111			11	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	CF1TP	WOS:000352331100011	25789439				2022-02-06	
J	Quintard, H; Patet, C; Suys, T; Marques-Vidal, P; Oddo, M				Quintard, Herve; Patet, Camille; Suys, Tamarah; Marques-Vidal, Pedro; Oddo, Mauro			Normobaric Hyperoxia is Associated with Increased Cerebral Excitotoxicity After Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Oxygen; Hyperoxia; Brain; Traumatic brain injury; Glutamate; Cerebral microdialysis; Excitotoxicity	SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; ARTERIAL HYPEROXIA; OXYGEN-TOXICITY; METABOLISM; RESUSCITATION; MORTALITY; GLUTAMATE; THERAPY; IMPROVEMENT	Normobaric oxygen therapy is frequently applied in neurocritical care, however, whether supplemental FiO(2) has beneficial cerebral effects is still controversial. We examined in patients with severe traumatic brain injury (TBI) the effect of incremental FiO(2) on cerebral excitotoxicity, quantified by cerebral microdialysis (CMD) glutamate. This was a retrospective analysis of a database of severe TBI patients monitored with CMD and brain tissue oxygen (PbtO(2)). The relationship of FiO(2)-categorized into four separate ranges (< 40, 41-60, 61-80, and > 80 %)-with CMD glutamate was examined using ANOVA with Tukey's post hoc test. A total of 1,130 CMD samples from 36 patients-monitored for a median of 4 days-were examined. After adjusting for brain (PbtO(2), intracranial pressure, cerebral perfusion pressure, lactate/pyruvate ratio, Marshall CT score) and systemic (PaCO2, PaO2, hemoglobin, APACHE score) covariates, high FiO(2) was associated with a progressive increase in CMD glutamate [8.8 (95 % confidence interval 7.4-10.2) A mu mol/L at FiO(2) < 40 % vs. 12.8 (10.9-14.7) A mu mol/L at 41-60 % FiO(2), 19.3 (15.6-23) A mu mol/L at 61-80 % FiO(2), and 22.6 (16.7-28.5) A mu mol/L at FiO(2) > 80 %; multivariate-adjusted p < 0.05]. The threshold of FiO(2)-related increase in CMD glutamate was lower for samples with normal versus low PbtO(2) < 20 mmHg (FiO(2) > 40 % vs. FiO(2) > 60 %). Hyperoxia (PaO2 > 150 mmHg) was also associated with increased CMD glutamate (adjusted p < 0.001). Incremental normobaric FiO(2) levels were associated with increased cerebral excitotoxicity in patients with severe TBI, independent from PbtO(2) and other important cerebral and systemic determinants. These data suggest that supra-normal oxygen may aggravate secondary brain damage after severe TBI.	[Quintard, Herve; Patet, Camille; Suys, Tamarah; Oddo, Mauro] CHU Vaudois, Univ Lausanne Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, CH-1011 Lausanne, Switzerland; [Marques-Vidal, Pedro] CHU Vaudois, Univ Lausanne Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland		Oddo, M (corresponding author), CHU Vaudois, Univ Lausanne Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Marques-Vidal, Pedro M/C-9449-2009; Oddo, Mauro/R-3370-2016	Marques-Vidal, Pedro M/0000-0002-4548-8500; Oddo, Mauro/0000-0002-6155-2525; Patet, Camille/0000-0001-7009-2543	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; Novartis Foundation for Biomedical Research; Societe Francaise d'Anesthesie et Reanimation (SFAR)	This work was supported by grants from the Swiss National Science Foundation (Grant No. 320030_138191, to Mauro Oddo), the Novartis Foundation for Biomedical Research (to Mauro Oddo) and the Societe Francaise d'Anesthesie et Reanimation (SFAR) (to Herve Quintard). The authors thank Professor Lucas Liaudet, MD, for helpful scientific discussion.	Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Blasiole B, 2013, ANESTHESIOLOGY, V118, P649, DOI 10.1097/ALN.0b013e318280a42d; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Brower RG, 2003, CRIT CARE MED, V31, pS312, DOI 10.1097/01.CCM.0000057909.18362.F6; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; D'Agostino DP, 2013, AM J PHYSIOL-REG I, V304, pR829, DOI 10.1152/ajpregu.00506.2012; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Fletcher JJ, 2010, NEUROCRIT CARE, V13, P47, DOI 10.1007/s12028-010-9345-2; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; McCarthy MC, 2009, SURGERY, V146, P585, DOI 10.1016/j.surg.2009.06.059; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MOODY RA, 1970, J NEUROSURG, V32, P51, DOI 10.3171/jns.1970.32.1.0051; Muthuraju S, 2013, J BIOSCIENCES, V38, P93, DOI 10.1007/s12038-012-9290-7; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Oddo M, 2012, CURR OPIN CRIT CARE, V18, P111, DOI 10.1097/MCC.0b013e32835132a5; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Puccio AM, 2009, J NEUROTRAUM, V26, P1241, DOI [10.1089/neu.2008.0624, 10.1089/neu.2008-0624]; Rangel-Castilla L, 2010, J NEUROTRAUM, V27, P1853, DOI 10.1089/neu.2010.1339; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rostami E, 2013, RESP PHYSIOL NEUROBI, V189, P537, DOI 10.1016/j.resp.2013.08.010; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schmitz T, 2011, J NEUROSCI, V31, P4327, DOI 10.1523/JNEUROSCI.3942-10.2011; Sjoberg F, 2013, J INTERN MED, V274, P505, DOI 10.1111/joim.12139; Solberg R, 2012, FREE RADICAL BIO MED, V53, P1061, DOI 10.1016/j.freeradbiomed.2012.07.022; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Thomas PM, 2003, EPILEPSY RES, V54, P73, DOI 10.1016/S0920-1211(03)00035-4; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wang MJ, 2009, AM J RESP CELL MOL, V40, P260, DOI 10.1165/rcmb.2008-0135OC	51	45	49	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2015	22	2					243	250		10.1007/s12028-014-0062-0			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CD9VK	WOS:000351447100010	25168744	Green Submitted			2022-02-06	
J	Lindley, RI; Wardlaw, JM; Whiteley, WN; Cohen, G; Blackwell, L; Murray, GD; Sandercock, PAG				Lindley, Richard I.; Wardlaw, Joanna M.; Whiteley, William N.; Cohen, Geoff; Blackwell, Lisa; Murray, Gordon D.; Sandercock, Peter A. G.		IST-3 Collaborative Grp	Alteplase for Acute Ischemic Stroke Outcomes by Clinically Important Subgroups in the Third International Stroke Trial	STROKE			English	Article						alteplase; intracranial hemorrhages; stroke; thrombolytic therapy; treatment outcome	TISSUE-PLASMINOGEN ACTIVATOR; TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS THROMBOLYSIS; STATISTICAL-ANALYSIS; 6 H; IST-3; METAANALYSIS; IMPACT; SCALE	Background and Purpose-Our aim was to identify whether particular subgroups of patients had an unacceptably high risk of symptomatic intracranial hemorrhage or low chance of benefit when treated with alteplase (recombinant tissue-type plasminogen activator). Methods-Third International Stroke Trial was an international randomized trial of the intravenous (IV) recombinant plasminogen activator alteplase (0.9 mg/kg) versus control in 3035 (1515 versus 1520) patients. We analyzed the effect of recombinant tissue-type plasminogen activator on 6-month functional outcome, early death, and symptomatic intracranial hemorrhage (both <= 7 days). We tested for any differences in treatment effect between subgroups by a test of interaction. Our 13 protocol prespecified subgroups were time to randomization, age, sex, stroke subtype, atrial fibrillation, early ischemic change (clinician and expert panel), prior antiplatelet use, stroke severity, diastolic and systolic blood pressure at randomization, center's thrombolysis experience, and trial phase. Analyses were adjusted for key baseline prognostic factors. Results-There were no significant interactions in the subgroups analyzed that were consistent across all 3 outcomes. Treatment with recombinant tissue-type plasminogen activator increased the odds of symptomatic intracranial hemorrhage by a greater amount in patients taking prior antiplatelets than those who were not (P=0.019 for test of interaction), but had no clear detrimental effect on functional outcome at 6 months in this group (P=0.781 for test of interaction). Conclusions-Among the types of patient in the Third International Stroke Trial, this secondary analysis did not identify any subgroups for whom treatment should be avoided. Given the limitations of the analysis, we found no clear evidence to avoid treatment in patients with prior ischemic stroke, diabetes mellitus, or hypertension.	[Lindley, Richard I.] Univ Sydney, Sydney, NSW 2006, Australia; [Wardlaw, Joanna M.; Whiteley, William N.; Cohen, Geoff; Murray, Gordon D.; Sandercock, Peter A. G.] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Blackwell, Lisa] Univ Oxford, Oxford, England		Lindley, RI (corresponding author), Westmead Hosp, Sydney Med Sch, Dept Geriatr Med, Sydney, NSW 2006, Australia.	richard.lindley@sydney.edu.au	Wardlaw, Joanna M/Y-3456-2019; Lueck, Christian J/O-4031-2016; Lindley, Richard/B-8148-2013; Hankey, Graeme J/H-4968-2014; Armit, Chris/AAZ-5613-2020; Muir, Keith W/A-7670-2011	Wardlaw, Joanna M/0000-0002-9812-6642; Lueck, Christian J/0000-0003-1537-7612; Lindley, Richard/0000-0002-0104-5679; Hankey, Graeme J/0000-0002-6044-7328; Armit, Chris/0000-0002-9952-8141; Muir, Keith W/0000-0001-9535-022X; celani, maria grazia/0000-0002-0739-4140; Whiteley, William/0000-0002-4816-8991; Tyrrell, Pippa/0000-0001-9609-1231; Engelter, Stefan/0000-0003-3855-6234	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0400069, G0902303] Funding Source: Medline; Chief Scientist Office Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0902303, G0800803, G0400069] Funding Source: UKRI		BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Frank B, 2013, STROKE, V44, P727, DOI 10.1161/STROKEAHA.112.674622; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Lindley Richard I, 2004, J Stroke Cerebrovasc Dis, V13, P235, DOI 10.1016/j.jstrokecerebrovasdis.2004.03.003; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; Lyden PD, 2012, STROKE, V43, P1691, DOI 10.1161/STROKEAHA.112.656876; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mishra NK, 2011, NEUROLOGY, V77, P1866, DOI 10.1212/WNL.0b013e318238ee42; Mishra NK, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6046; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Sandercock P, 2013, LANCET NEUROL, V12, P768, DOI 10.1016/S1474-4422(13)70130-3; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sandercock P, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-252; Sandercock P, 2012, INT J STROKE, V7, P186, DOI 10.1111/j.1747-4949.2012.00782.x; Sandercock P, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-37; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Whiteley W, 2006, INT J STROKE, V1, P172, DOI 10.1111/j.1747-4949.2006.00043.x; Whiteley WN, 2012, STROKE, V43, P2904, DOI 10.1161/STROKEAHA.112.665331	25	45	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAR	2015	46	3					746	756		10.1161/STROKEAHA.114.006573			11	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	CC3XP	WOS:000350284900035	25613308	Bronze			2022-02-06	
J	Zhang, J; Teng, ZQ; Song, YP; Hu, M; Chen, C				Zhang, Jian; Teng, Zhaoqian; Song, Yunping; Hu, Mei; Chen, Chu			Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Alzheimer's disease; 2-arachidonoylglycerol; chronic traumatic encephalopathy; monoacylglycerol lipase; neurodegeneration; trauma brain injury	BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL; SPECTRUM; 2-AG; MICE; NEURODEGENERATION; PATHOGENESIS; IMPAIRMENTS; METABOLISM	Emerging evidence suggests that the risk of developing chronic traumatic encephalopathy (CTE), a progressive neurodegenerative disease, is significantly increased in military personnel and contact sports players who have been exposed to repetitive trauma brain injury (TBI). Unfortunately there are no effective medications currently available for prevention and treatment of CTE. Here we demonstrate that inhibition of monoacylglycerol lipase (MAGL), the key enzyme that metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG) in the brain, significantly reduced CTE-like neuropathologic changes in a mouse model of repetitive mild closed head injury (rmCHI). Inhibition of 2-AG metabolism promoted neurologic recovery following rmCHI and reduced proinflammatory cytokines, astroglial reactivity, expression of amyloid precursor protein and the enzymes that make A beta, as well as formation of A beta. Importantly, neurodegeneration, TDP-43 protein aggregation, and tau phosphorylation, which are the neuropathologic hallmarks of CTE, were significantly suppressed by MAGL inactivation. Furthermore, alterations in expression of glutamate receptor subunits and impairments in basal synaptic transmission, long-term synaptic plasticity, and spatial learning and memory were recovered by inhibition of 2-AG metabolism in animals exposed to rmCHI. Our results suggest that MAGL inhibition, which boosts 2-AG and reduces 2-AG metabolites prostaglandins in the brain, may lead to a new therapy for CTE.	[Zhang, Jian; Teng, Zhaoqian; Song, Yunping; Hu, Mei; Chen, Chu] Louisiana State Univ, Neurosci Ctr Excellence, Sch Med, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Chen, Chu] Louisiana State Univ, Dept Otorhinolaryngol, Sch Med, Hlth Sci Ctr, New Orleans, LA 70112 USA		Chen, C (corresponding author), Louisiana State Univ, Neurosci Ctr Excellence, Sch Med, Hlth Sci Ctr, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	cchen@lsuhsc.edu	Teng, Zhao-Qian/AAD-1033-2021; Teng, Zhao-Qian/J-6260-2015	Teng, Zhao-Qian/0000-0002-7232-3381; Teng, Zhao-Qian/0000-0002-7232-3381	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS076815]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076815] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grant NS076815.	Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen RQ, 2013, CELL, V155, P1154, DOI 10.1016/j.cell.2013.10.042; Chen RQ, 2012, CELL REP, V2, P1329, DOI 10.1016/j.celrep.2012.09.030; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Lakis N, 2013, NEUROL RES, V35, P290, DOI 10.1179/1743132813Y.0000000177; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Long JZ, 2009, CHEM BIOL, V16, P744, DOI 10.1016/j.chembiol.2009.05.009; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Piro JR, 2012, CELL REP, V1, P617, DOI 10.1016/j.celrep.2012.05.001; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu JY, 2015, NEUROSCIENTIST, V21, P152, DOI 10.1177/1073858414524632; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200; Zhang J, 2014, J NEUROSCI, V34, P14919, DOI 10.1523/JNEUROSCI.1165-14.2014	40	45	45	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2015	35	3					443	453		10.1038/jcbfm.2014.216			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CC5IZ	WOS:000350393600013	25492114	Green Published, Bronze			2022-02-06	
J	Kesinger, MR; Kumar, RG; Wagner, AK; Puyana, JC; Peitzman, AP; Billiar, TR; Sperry, JL				Kesinger, Matthew Ryan; Kumar, Raj G.; Wagner, Amy K.; Puyana, Juan Carlos; Peitzman, Andrew P.; Billiar, Timothy R.; Sperry, Jason L.			Hospital-acquired pneumonia is an independent predictor of poor global outcome in severe traumatic brain injury up to 5 years after discharge	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						TBI; pneumonia; hospital-acquired pneumonia; outcomes; rehabilitation	VENTILATOR-ASSOCIATED PNEUMONIA; NOSOCOMIAL PNEUMONIA; HEAD-INJURY; REHABILITATION; INFLAMMATION; DISABILITY; INSTITUTE; HEALTH; IMPACT	BACKGROUND: Long-term outcomes following traumatic brain injury (TBI) correlate with initial head injury severity and other acute factors. Hospital-acquired pneumonia (HAP) is a common complication in TBI. Limited information exists regarding the significance of infectious complications on long-term outcomes after TBI. We sought to characterize risks associated with HAP on outcomes 5 years after TBI. METHODS: This study involved data from the merger of an institutional trauma registry and the Traumatic Brain Injury Model Systems outcome data. Individuals with severe head injuries (Abbreviated Injury Scale [AIS] score >= 4) who survived to rehabilitation were analyzed. Primary outcome was Glasgow Outcome Scale-Extended (GOSE) at 1, 2, and 5 years. GOSE was dichotomized into low (GOSE score <6) and high (GOSE score >= 6). Logistic regression was used to determine adjusted odds of low GOSE score associated with HAP after controlling for age, sex, head and overall injury severity, cranial surgery, Glasgow Coma Scale (GCS) score, ventilation days, and other important confounders. A general estimating equation model was used to analyze all outcome observations simultaneously while controlling for within-patient correlation. RESULTS: A total of 141 individuals met inclusion criteria, with a 30% incidence of HAP. Individuals with and without HAP had similar demographic profiles, presenting vitals, head injury severity, and prevalence of cranial surgery. Individuals with HAP had lower presenting GCS score. Logistic regression demonstrated that HAP was independently associated with low GOSE scores at follow-up (1 year: odds ratio [OR], 6.39; 95% confidence interval [CI], 1.76-23.14; p = 0.005) (2 years: OR, 7.30; 95% CI, 1.87-27.89; p = 0.004) (5-years: OR, 6.89; 95% CI, 1.42-33.39; p = 0.017). Stratifying by GCS score of 8 or lower and early intubation, HAP remained a significant independent predictor of low GOSE score in all strata. In the general estimating equation model, HAP continued to be an independent predictor of low GOSE score (OR, 4.59; 95% CI, 1.82-11.60; p = 0.001). CONCLUSION: HAP is independently associated with poor outcomes in severe TBI extending 5 years after injury. This suggests that precautions should be taken to reduce the risk of HAP in individuals with severe TBI. (Copyright (C) 2015 by Wolters Kluwer Health, Inc. All rights reserved.) LEVEL OF EVIDENCE: Prognostic study, level III.	[Puyana, Juan Carlos; Peitzman, Andrew P.; Billiar, Timothy R.; Sperry, Jason L.] Univ Pittsburgh, Dept Surg, Div Trauma & Gen Surg, Pittsburgh, PA 15213 USA; [Kumar, Raj G.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Kesinger, Matthew Ryan] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA		Sperry, JL (corresponding author), Univ Pittsburgh, Dept Surg, 200 Lothrop St, Pittsburgh, PA 15213 USA.	sperryjl@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [TL1TR000145, R25 MH054318]; NIH NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093032]; NIDRR [H133A120087]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25MH054318] Funding Source: NIH RePORTER	This study was funded in part by NIH TL1TR000145, NIH R25 MH054318, NIH NIGMS K23GM093032, and NIDRR H133A120087.	Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cordaro M., 2014, J NEUROTRAUMA; Croce MA, 2013, J TRAUMA ACUTE CARE, V74, P354, DOI 10.1097/TA.0b013e31827a0c65; Deans KJ, 2013, J TRAUMA ACUTE CARE, V75, P157, DOI 10.1097/TA.0b013e3182984acb; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M, 2010, TRAUMATIC BRAIN INJU; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; GOODPASTURE HC, 1977, J NEUROSURG, V47, P228, DOI 10.3171/jns.1977.47.2.0228; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Heimes J, 2011, SURG INFECT, V12, P99, DOI 10.1089/sur.2009.028; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Holevar M, 2009, J TRAUMA, V67, P870, DOI 10.1097/TA.0b013e3181b5a960; Hoth JJ, 2003, J TRAUMA, V55, P249, DOI 10.1097/01.TA.0000083334.93868.65; Irdesel J, 2007, NEUROCIRUGIA, V18, P5; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kallel H, 2005, J TRAUMA, V59, P705, DOI 10.1097/01.ta.0000177749.09844.c6; Kumar R., 2014, J HEAD TRAUMA REHABI; Leone M, 2002, CRIT CARE MED, V30, P1741, DOI 10.1097/00003246-200208000-00011; Liberati A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub3; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Monton C, 1999, CRIT CARE MED, V27, P1745, DOI 10.1097/00003246-199909000-00008; Moore F, 2013, J TRAUMA ACUTE CARE, V74, P360; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shermer CR, 2007, J TRAUMA, V63, P1268; Sigurdardottir S, 2014, J HEAD TRAUMA REHABI; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wang KW, 2013, J NEUROSURG, V118, P358, DOI 10.3171/2012.10.JNS127; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	42	45	56	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2015	78	2					396	402		10.1097/TA.0000000000000526			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	CA3TF	WOS:000348828300026	25757128	Green Accepted			2022-02-06	
J	Chio, CC; Lin, MT; Chang, CP				Chio, Chung-Ching; Lin, Mao-Tsun; Chang, Ching-Ping			Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury	CURRENT MEDICINAL CHEMISTRY			English	Article						Brain; cytokines; free radicals; microglia; traumatic injury	NECROSIS-FACTOR-ALPHA; HYPERBARIC-OXYGEN THERAPY; IMPROVES FUNCTIONAL RECOVERY; GLYCINE-PROLINE-GLUTAMATE; MESENCHYMAL STEM-CELLS; TNF-ALPHA; PROINFLAMMATORY CYTOKINE; DOUBLECORTIN EXPRESSION; MITOCHONDRIAL-FUNCTION; CEREBRAL-ISCHEMIA	Microglia and several inflammatory cytokines and neurotrophic growth factors are involved in traumatic brain injury (TBI). Tumor necrosis factor-alpha (TNF-alpha) can be released by microglia, astrocytes, and neurons. TNF-alpha has been reported to be both proneurogenic and antineurogenic, depending upon the model, method, and cell-derived region. There are two subtypes of microglia: M1 and M2. The former (or M1 subtype of non-phagocytic microglia) is able to secrete higher levels of TNF-alpha but lower levels of interleukin (IL)-10 (IL-10), an anti-inflammatory cytokine. Both the proinflammatory and the pro-apoptotic function can also be promoted by activation of tumor necrosis factor-receptor 1 (TNF-R1). In contrast, M2 activation produces lower levels of TNF-alpha but higher levels of IL-10. Pro-growth and survival pathways can be promoted by the activation of TNF-R2. During the acute stage of TBI, both M1 subtype of microglia and TNF-R1 are activated to cause higher levels of TNF-alpha but lower levels of IL-10, which lead to suppressed neurogenesis, neuronal loss and organ dysfunction (so-called microglial activation I). In contrast, activation of both M2 subtype of microglia and TNF-R2 is able to promote neurogenesis and tissue recovery (so-called microglial activation II). The severity of TBI depends upon the net effects between microglial activation I and microglial activation II. Indeed, by using rodent models of TBI, therapeutic evaluation studies reveal that several agents or strategies attenuate contused brain volume and neurological deficits by inhibiting microglial activation I but inducing microglial activation II. For example, etanercept therapy might attenuate contused brain volume and neurological deficits by inactivating the M1 subtype and TNF-R1 to reduce the microglial activation I response, but it might promote neurogenesis and functional recovery by activating the M2 subtype and TNF-R2. Therefore, based on microglial responses I and II, we conclude that future studies should focus on multiple therapeutic agents and strategies for optimal TBI therapy.	Southern Taiwan Univ Sci & Technol, Dept Surg, Tainan, Taiwan; Southern Taiwan Univ Sci & Technol, Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Chang, Ching-Ping] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan		Chang, CP (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.	jessica@mail.stust.edu.tw		Chang, Ching-Ping/0000-0003-0890-9414	Ministry of Science and Technology, Taiwan, R.O.CMinistry of Science and Technology, Taiwan [NSC 102-2628-B-384001-MY3, NSC 102-2314-B-384-003-MY2]; Mr. Wen-Lung Hsu Foundation of Chi Mei Medical Center (Tainan, Taiwan)	This work was supported by the Ministry of Science and Technology, Taiwan, R.O.C (NSC 102-2628-B-384001-MY3 and NSC 102-2314-B-384-003-MY2) and the Mr. Wen-Lung Hsu Foundation of Chi Mei Medical Center (Tainan, Taiwan).	Alexi T, 1999, EXP NEUROL, V159, P84, DOI 10.1006/exnr.1999.7168; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Batchelor DC, 2003, ANAL BIOCHEM, V323, P156, DOI 10.1016/j.ab.2003.08.032; Bell S, 2000, LANCET, V355, P858, DOI 10.1016/S0140-6736(99)00442-0; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Caso JR, 2006, NEUROSCIENCE, V142, P59, DOI 10.1016/j.neuroscience.2006.06.009; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen SH, 2005, CRIT CARE MED, V33, P1377, DOI 10.1097/01.CCM.0000165966.28936.89; Chen SH, 2014, CELL TRANSPLANT, V23, P959, DOI 10.3727/096368913X667006; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chio C. C., 2012, SCIENCE S, V338, P59; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Forrest EH, 2002, LIVER, V22, P317, DOI 10.1034/j.1600-0676.2002.01649.x; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; GILAD GM, 1995, LIFE SCI, V58, pPL41, DOI 10.1016/0024-3205(95)02274-0; Guan Jian, 2008, Recent Pat CNS Drug Discov, V3, P112, DOI 10.2174/157488908784534630; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Iosif RE, 2008, J CEREBR BLOOD F MET, V28, P1574, DOI 10.1038/jcbfm.2008.47; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Kuo JR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/145214; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Long JM, 1998, NEUROBIOL AGING, V19, P497, DOI 10.1016/S0197-4580(98)00088-8; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Perry SW, 2002, J NEUROVIROL, V8, P611, DOI 10.1080/13550280290101021; Ren H, 2001, Chin J Traumatol, V4, P239; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Tremblay ME, 2012, GLIA, V60, P541, DOI 10.1002/glia.22287; Tsuji M, 2000, PEDIATR RES, V47, P79, DOI 10.1203/00006450-200001000-00015; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Walker FR, 2014, BRAIN BEHAV IMMUN, V37, P1, DOI 10.1016/j.bbi.2013.12.010; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Welser JV, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-89; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Yu CG, 2000, NEUROREPORT, V11, P3203, DOI 10.1097/00001756-200009280-00031; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; Zou JX, 2002, CLIN EXP RHEUMATOL, V20, pS34	124	45	50	0	19	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.		2015	22	6					759	770		10.2174/0929867321666141106124657			12	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	CB1LI	WOS:000349388600008	25386818				2022-02-06	
J	Zhang, Y; Simpson-Durand, CD; Standifer, KM				Zhang, Y.; Simpson-Durand, C. D.; Standifer, K. M.			Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						PTSD; elevated plus maze; pain sensitivity; nociceptin; orphanin FQ; nociceptin; orphanin FQ peptide receptor; single-prolonged stress; hypocortisolism; allodynia; JTC-801; von Frey test	NEUROPATHIC-PAIN; ORPHANIN FQ; PHARMACOLOGICAL EVALUATION; CEREBROSPINAL-FLUID; MESSENGER-RNA; NERVE INJURY; AGONIST; ORL1; PROTEIN; BRAIN	Background and PurposeSingle-prolonged stress (SPS), a rat model of post-traumatic stress disorder (PTSD), also induces long-lasting hyperalgesia associated with hypocortisolism and elevated nociceptin/orphanin FQ (N/OFQ) levels in serum and CSF. Here, we determined the effect of JTC-801 (N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride), a nociceptin/orphanin FQ peptide (NOP) receptor antagonist, on symptoms of pain and anxiety in rats after SPS exposure, and examined N/OFQ-NOP receptor system changes. Experimental ApproachMale Sprague Dawley rats received JTC-801 (6mgkg(-1) i.p., once daily) during days 7-21 of SPS. The ability of JTC-801 to inhibit N/OFQ-stimulated [S-35]-GTPS binding was confirmed in rat brain membranes. Anxiety-like behaviour and pain sensitivity were monitored by changes in elevated plus maze performance and withdrawal responses to thermal and mechanical stimuli. Serum corticosterone and N/OFQ content in CSF, serum and brain tissues were determined by radioimmunoassay; NOP receptor protein and gene expression in amygdala, hippocampus and periaqueductal grey (PAG) were examined by immunoblotting and real-time PCR respectively. Key ResultsJTC-801 treatment reversed SPS-induced mechanical allodynia, thermal hyperalgesia, anxiety-like behaviour and hypocortisolism. Elevated N/OFQ levels in serum, CSF, PAG and hippocampus at day 21 of SPS were blocked by JTC-801; daily JTC-801 treatment also reversed NOP receptor protein and mRNA up-regulation in amygdala and PAG. Conclusion and ImplicationsJTC-801 reversed SPS-induced anxiety- and pain-like behaviours, and NOP receptor system up-regulation. These findings suggest that N/OFQ plays an important role in hyperalgesia and allodynia maintenance after SPS. NOP receptor antagonists may provide effective treatment for co-morbid PTSD and pain. Linked ArticlesThis article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit	[Zhang, Y.; Simpson-Durand, C. D.; Standifer, K. M.] Univ Oklahoma, Dept Pharmaceut Sci, Coll Pharm, Hlth Sci Ctr, Oklahoma City, OK 73117 USA; [Standifer, K. M.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Cell Biol,Oklahoma Ctr Neurosci, Oklahoma City, OK 73117 USA		Standifer, KM (corresponding author), Univ Oklahoma, Dept Pharmaceut Sci, Coll Pharm, Hlth Sci Ctr, 1110 N Stonewall Ave,Suite 326, Oklahoma City, OK 73117 USA.	Kelly-Standifer@ouhsc.edu			Department of the Army DMRDP [W81XWH-11-2-0077]	This study was supported by the Department of the Army DMRDP W81XWH-11-2-0077. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, is the awarding and administering acquisition office.	Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Andero R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005656; Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; Briscini L, 2002, EUR J PHARMACOL, V447, P59, DOI 10.1016/S0014-2999(02)01833-2; Cohen H, 2009, J NEUROENDOCRINOL, V21, P898, DOI 10.1111/j.1365-2826.2009.01913.x; Cornefjord M, 2004, SPINE, V29, P1862, DOI 10.1097/01.brs.0000137070.16592.b2; Corradini L, 2001, BRAIN RES, V905, P127, DOI 10.1016/S0006-8993(01)02520-3; Del Giudice MR, 2011, EUR J MED CHEM, V46, P1207, DOI 10.1016/j.ejmech.2011.01.040; Delaney G, 2012, J NEUROENDOCRINOL, V24, P1527, DOI 10.1111/j.1365-2826.2012.02361.x; Devine DP, 2003, J NEUROENDOCRINOL, V15, P69, DOI 10.1046/j.1365-2826.2003.00868.x; Devine DP, 2001, NEUROSCIENCE, V102, P541, DOI 10.1016/S0306-4522(00)00517-0; Duzzioni M, 2011, BEHAV BRAIN RES, V222, P206, DOI 10.1016/j.bbr.2011.03.056; Fernandez F, 2004, NEUROPSYCHOPHARMACOL, V29, P59, DOI 10.1038/sj.npp.1300308; Gavioli EC, 2007, PEPTIDES, V28, P1229, DOI 10.1016/j.peptides.2007.04.012; Goeldner C, 2012, PSYCHOPHARMACOLOGY, V222, P203, DOI 10.1007/s00213-012-2636-x; Green MK, 2007, NEUROPEPTIDES, V41, P399, DOI 10.1016/j.npep.2007.09.002; Green MK, 2009, NEUROPEPTIDES, V43, P507, DOI 10.1016/j.npep.2009.08.003; Gunduz O, 2011, PHARMACOL BIOCHEM BE, V99, P540, DOI 10.1016/j.pbb.2011.05.029; Hammamieh R, 2012, BEHAV BRAIN RES, V235, P55, DOI 10.1016/j.bbr.2012.07.022; Heinricher MM, 1997, J NEUROPHYSIOL, V78, P3351, DOI 10.1152/jn.1997.78.6.3351; Jenck F, 2000, P NATL ACAD SCI USA, V97, P4938, DOI 10.1073/pnas.090514397; Jia M, 2012, JOVE-J VIS EXP, DOI 10.3791/3361; Joseph T, 2007, PEPTIDES, V28, P1433, DOI 10.1016/j.peptides.2007.05.009; Khroyan TV, 2011, J PHARMACOL EXP THER, V339, P687, DOI 10.1124/jpet.111.184663; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/jphysiol.2010.192278]; King MA, 1997, NEUROSCI LETT, V223, P113, DOI 10.1016/S0304-3940(97)13414-0; Ko MH, 2002, NEUROREPORT, V13, P1631, DOI 10.1097/00001756-200209160-00012; Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572; Leggett JD, 2006, NEUROSCIENCE, V141, P2051, DOI 10.1016/j.neuroscience.2006.05.036; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Liberzon I, 1999, J NEUROENDOCRINOL, V11, P11; Liberzon I, 1997, PSYCHONEUROENDOCRINO, V22, P443, DOI 10.1016/S0306-4530(97)00044-9; Liu EH, 2012, NEUROSCI LETT, V506, P104, DOI 10.1016/j.neulet.2011.10.059; Lu SX, 2011, EUR J PHARMACOL, V661, P63, DOI 10.1016/j.ejphar.2011.04.034; Ma F, 2005, BRAIN RES, V1043, P214, DOI 10.1016/j.brainres.2005.01.037; Mabuchi T, 2003, EUR J NEUROSCI, V17, P1384, DOI 10.1046/j.1460-9568.2003.02575.x; Marti M, 2003, BRIT J PHARMACOL, V138, P91, DOI 10.1038/sj.bjp.0705005; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Meewisse ML, 2007, BRIT J PSYCHIAT, V191, P387, DOI 10.1192/bjp.bp.106.024877; Mogil JS, 1996, NEUROSCIENCE, V75, P333, DOI 10.1016/0306-4522(96)00338-7; Moore RJ, 2000, NEUROPHARMACOLOGY, V39, P282, DOI 10.1016/S0028-3908(99)00112-4; Morris MC, 2012, CLIN PSYCHOL REV, V32, P301, DOI 10.1016/j.cpr.2012.02.002; Nativio P, 2012, STRESS, V15, P378, DOI 10.3109/10253890.2011.627071; Odagaki Y, 2006, PROG NEURO-PSYCHOPH, V30, P1304, DOI 10.1016/j.pnpbp.2006.05.007; Olszewski PK, 2010, AM J PHYSIOL-REG I, V299, pR655, DOI 10.1152/ajpregu.00556.2009; Ozaki S, 2000, EUR J PHARMACOL, V402, P45, DOI 10.1016/S0014-2999(00)00520-3; Pan ZZ, 2000, NEURON, V26, P515, DOI 10.1016/S0896-6273(00)81183-6; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Pulliam JVK, 2010, J PSYCHIATR RES, V44, P106, DOI 10.1016/j.jpsychires.2009.05.005; Raffaeli W, 2006, J PAIN SYMPTOM MANAG, V32, P372, DOI 10.1016/j.jpainsymman.2006.05.013; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scoto GM, 2009, LIFE SCI, V85, P206, DOI 10.1016/j.lfs.2009.05.021; Sestili I, 2004, EUR J MED CHEM, V39, P1047, DOI 10.1016/j.ejmech.2004.09.009; Shinkai H, 2000, J MED CHEM, V43, P4667, DOI 10.1021/jm0002073; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Suyama H, 2003, NEUROSCI LETT, V351, P133, DOI 10.1016/S0304-3940(03)00502-0; Tamai H, 2005, EUR J PHARMACOL, V510, P223, DOI 10.1016/j.ejphar.2005.01.033; Tian JH, 1997, BRIT J PHARMACOL, V120, P676, DOI 10.1038/sj.bjp.0700942; Uchiyama H, 2008, NEUROSCI LETT, V431, P66, DOI 10.1016/j.neulet.2007.11.023; Vitale G, 2006, PEPTIDES, V27, P2193, DOI 10.1016/j.peptides.2006.04.003; Witkin JM, 2014, PHARMACOL THERAPEUT, V141, P283, DOI 10.1016/j.pharmthera.2013.10.011; Yamada H, 2002, BRIT J PHARMACOL, V135, P323, DOI 10.1038/sj.bjp.0704478; Yamamoto S, 2009, DEPRESS ANXIETY, V26, P1110, DOI 10.1002/da.20629; Yamamoto T, 1997, NEUROSCIENCE, V81, P249, DOI 10.1016/S0306-4522(97)00166-8; Zaratin PF, 2004, J PHARMACOL EXP THER, V308, P454, DOI 10.1124/jpet.103.055848; Zhang Y, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-76	66	45	45	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	JAN	2015	172	2			SI		571	582		10.1111/bph.12701			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	AX3FU	WOS:000346826500029	24666365	Green Published, Bronze			2022-02-06	
J	Shimoda, K; Maeda, T; Tado, M; Yoshino, A; Katayama, Y; Bullock, MR				Shimoda, Kentaro; Maeda, Takeshi; Tado, Masahiro; Yoshino, Atsuo; Katayama, Yoichi; Bullock, M. Ross			Outcome and Surgical Management for Geriatric Traumatic Brain Injury: Analysis of 888 Cases Registered in the Japan Neurotrauma Data Bank	WORLD NEUROSURGERY			English	Article						Elderly; Surgical management; Traumatic brain injury	ACUTE SUBDURAL-HEMATOMA; HEAD-INJURY; INTRACRANIAL HEMATOMAS; OLDER PATIENTS; MAJOR TRAUMA; MORTALITY; AGE; CARE; EVACUATION; SURVIVAL	OBJECTIVE: As the aged population is rapidly growing globally, geriatric traumatic brain injury (TBI) becomes an increasing problem. There are higher mortality and poorer functional outcome in the geriatric TBI population (>= 65 years) compared with younger groups despite neurosurgical interventions. Therefore, current treatment priorities and cost-effectiveness should be critically examined. We evaluated the benefit of surgical management in the elderly (>= 65 years) after TBI. METHODS: A total of 3194 patients with confirmed TBI were enrolled from 1998 to 2011, in the Japan Neurotrauma Data Bank. Retrospective analysis was conducted from the Japan Neurotrauma Data Bank on 888 (28%) patients (>= years) who did and did not undergo surgery. In particular, the effect of low Glasgow coma scale (GCS) (3-5) was compared with outcome with and without surgery. RESULTS: Of all the patients 65 years of age and over, 478 (54%) were given surgical management (craniectomy, craniotomy, or burr-hole evacuation). This group of patients had significantly more favorable outcome at 6 months (18% vs. 7%) and less mortality (62% vs. 81%). However, within this surgical group, patients with initial GCS scores of 3-5 had significantly more unfavorable outcome (96% vs. 79%) and more mortality (87% vs. 57%) compared with those with GCS scores of 6-15. CONCLUSIONS: We confirmed that age is a major determinant of outcome after TBI. In addition, we found that neurosurgical management is associated with the improvement of the prognosis and a decrease in the rate of mortality in geriatric TBI. However, surgical management was not shown to be an effective treatment in elderly patients with GCS scores of 3-5.	[Shimoda, Kentaro; Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Shimoda, Kentaro; Maeda, Takeshi; Tado, Masahiro; Yoshino, Atsuo; Katayama, Yoichi] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo 173, Japan		Maeda, T (corresponding author), Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo 173, Japan.	maeda.takeshi@nihon-u.ac.jp			General Insurance Association of Japan; Mitsui Sumitomo Insurance Welfare FoundationMitsui Sumitomo Insurance Welfare Foundation; Japan Brain Foundation	Partial support was provided through The General Insurance Association of Japan, Mitsui Sumitomo Insurance Welfare Foundation, and the Japan Brain Foundation.	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bullock AR, 2006, NEUROSURGERY, V58, pVI; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; CARRILLO EH, 1993, SURG GYNECOL OBSTET, V176, P559; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Damadi AA, 2008, J TRAUMA, V64, P745, DOI 10.1097/TA.0b013e3180341fc6; DAY RJ, 1994, MED J AUSTRALIA, V160, P675, DOI 10.5694/j.1326-5377.1994.tb125903.x; DEMARIA EJ, 1987, J TRAUMA, V27, P1200; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mulligan P, 2013, J NEUROSCI RURAL PRA, V4, P250, DOI 10.4103/0976-3147.118760; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567; National Institute of Population and Social Security Research, 2012, EST POP JAP; O'Neill S, 2012, ARCH GERONTOL GERIAT, V54, pE426, DOI 10.1016/j.archger.2012.01.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Petridis AK, 2009, CENT EUR NEUROSURG, V70, P73, DOI 10.1055/s-0029-1224096; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; Ross A M, 1992, J Neurosci Nurs, V24, P88; Roth BJ, 2001, INJURY, V32, P551, DOI 10.1016/S0020-1383(01)00079-1; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	45	45	45	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	DEC	2014	82	6								10.1016/j.wneu.2014.08.014			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AY5TZ	WOS:000347635900118	25128777	hybrid			2022-02-06	
J	Bean, CN; Fortier, M; Post, C; Chima, K				Bean, Corliss N.; Fortier, Michelle; Post, Courtney; Chima, Karam			Understanding How Organized Youth Sport May Be Harming Individual Players within the Family Unit: A Literature Review	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article						sport; negative; family; youth; parent; sibling; review	TRAUMATIC BRAIN-INJURY; JUNIOR TENNIS PLAYERS; ILLICIT DRUG-USE; PHYSICAL-ACTIVITY; EATING-DISORDERS; MENTAL-HEALTH; HIGH-SCHOOL; MOTIVATIONAL CLIMATE; POSITION STATEMENT; PSYCHOMETRIC PROPERTIES	Within the United States, close to 45 million youths between the ages of 6 and 18 participate in some form of organized sports. While recent reviews have shown the positive effects of youth sport participation on youth health, there are also several negative factors surrounding the youth sport environment. To date, a comprehensive review of the negative physical and psychological effects of organized sport on youth has not been done and little thus far has documented the effect organized sport has on other players within a family, particularly on parents and siblings. Therefore the purpose of this paper is to conduct a review of studies on the negative effects of organized sport on the youth athlete and their parents and siblings. Articles were found by searching multiple databases (Physical Education Index and Sociology, Psychology databases (Proquest), SPORTDiscus and Health, History, Management databases (EBSCOhost), Science, Social Science, Arts and Humanities on Web of Science (ISI), SCOPUS and Scirus (Elsevier). Results show the darker side of organized sport for actors within the family unit. A model is proposed to explain under which circumstances sport leads to positive versus negative outcomes, ideas for future research are drawn and recommendations are made to optimize the youth sport experience and family health.	[Bean, Corliss N.; Fortier, Michelle; Post, Courtney; Chima, Karam] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada		Fortier, M (corresponding author), Univ Ottawa, Sch Human Kinet, 125 Univ Private, Ottawa, ON K1N 6N5, Canada.	cbean@uottawa.ca; mfortier@uottawa.ca; cpost015@uottawa.ca; kchima@rogers.com					Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; Alexander K., 2011, EXPERIENCES CHILDREN; Amorose AJ, 2009, RES Q EXERCISE SPORT, V80, P386, DOI 10.1080/02701367.2009.10599575; Anderson JR, 2005, FAM RELAT, V54, P654, DOI 10.1111/j.1741-3729.2005.00349.x; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Baker J, 2003, HIGH ABIL STUD, V14, P85, DOI 10.1080/13598130304091; Balish SM, 2014, PSYCHOL SPORT EXERC, V15, P429, DOI 10.1016/j.psychsport.2014.04.003; Barber H., 1999, J SPORT BEHAV, V22, P1; Barnett LA, 2008, J PARK RECREAT ADM, V26, P28; Bartholomew K., 2011, SPORT EXERCISE PSYCH, V7, P23, DOI DOI 10.1123/jsep.33.1.75; Basak W.A., CONCUSSION EPIDEMIC; Baxter-Jones ADG, 2003, J SPORT MED PHYS FIT, V43, P250; Bean C.N., 2014, WOMEN SPORT IN PRESS; Bean C.N., 2014, DOES SPORT HEL UNPUB; Bernhardt D.T., 2014, PREPARTICIPATION PHY, P179; Biddle SJH, 2011, BRIT J SPORT MED, V45, P886, DOI 10.1136/bjsports-2011-090185; Bloom G, 2010, ENGL LITERARY RENAIS, V40, P329, DOI 10.1111/j.1475-6757.2010.01071.x; Boyer C, 2011, OBSERVATIONAL ANAL I; Bratland-Sanda S, 2013, EUR J SPORT SCI, V13, P499, DOI 10.1080/17461391.2012.740504; Bremmer K., 2012, J FAM THEORY REV, V4, P235, DOI [10.1111/j.1756-2589.2012.00129.x, DOI 10.1111/J.1756-2589.2012.00129.X]; Bridge MW, 2013, J SPORT SCI, V31, P87, DOI 10.1080/02640414.2012.721560; Brown WJ, 2005, AM J PREV MED, V29, P265, DOI 10.1016/j.amepre.2005.06.009; BUHRMESTER D, 1990, CHILD DEV, V61, P1387, DOI 10.2307/1130750; Busser J. A., 2010, Managing Leisure, V15, P128, DOI 10.1080/13606710903448210; Cairney J., 2014, INT REV SPO IN PRESS; Camire M, 2011, J SPORT PSYCHOL ACTI, V2, P92, DOI 10.1080/21520704.2011.584246; Campbell K., 2013, SELLING DREAM; Canada Hockey, HOCK CAN 94 ANN GEN; Capranica L, 2011, INT J SPORT PHYSIOL, V6, P572, DOI 10.1123/ijspp.6.4.572; Carson, 2008, INT REV SPORT EXER P, V1, P58, DOI [10.1080/17509840701834573, DOI 10.1080/17509840701834573]; Carter JC, 2001, BEHAV RES THER, V39, P625, DOI 10.1016/S0005-7967(00)00033-4; CASHER BB, 1977, RES QUART, V48, P33, DOI 10.1080/10671315.1977.10762146; Chircop A, 2015, HEALTH PROMOT INT, V30, P418, DOI 10.1093/heapro/dat056; Chircop A, 2015, CRIT PUBLIC HEALTH, V25, P178, DOI 10.1080/09581596.2014.887831; Cicirelli V.G., 1995, SIBLING RELATIONSHIP; Clark W., KIDS SPORTS; Coakley J., 2006, Leisure Studies, V25, P153, DOI 10.1080/02614360500467735; Cobb KL, 2003, MED SCI SPORT EXER, V35, P711, DOI 10.1249/01.MSS.0000064935.68277.E7; Coble C.J., 2010, FEMALE PARENT COACH; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; Cote J, 1999, SPORT PSYCHOL, V13, P395, DOI 10.1123/tsp.13.4.395; Cote J., 2007, HDB SPORT PSYCHOL, V3, P184, DOI DOI 10.1002/9781118270011.CH8; Cote J., 2007, SPORT PSYCHOL CANADI, P270; Cote J, COACHING YOUTH M CHA; Cote J, 2009, INT J SPORT EXERC PS, V7, P7, DOI 10.1080/1612197X.2009.9671889; Cote J, 2008, INT STUD PHYS EDUC Y, P34; Cotunga Nancy, 2005, J Sch Nurs, V21, P323; Cowdery RS, 2005, FAM RELAT, V54, P335, DOI 10.1111/j.1741-3729.2005.00321.x; Crowe K., BODYCHECKING RISKS Y; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Cuskelly G., 2006, SPORT MANAGEMENT REV, V9, P141, DOI DOI 10.1016/S1441-3523(06)70023-7; Daly KJ., 2001, MINDING TIME FAMILY, P163, DOI 10.1016/S1530-3535(01)80029-7; Daly M., 2004, WELFARE STATE CHANGE, P135; Danish S., 2004, World Leisure Journal, V46, P38; Datko K, HIGH COST YOUTH SPOR; Coelho GMD, 2010, APPETITE, V55, P379, DOI 10.1016/j.appet.2010.08.003; Ferreira JED, 2008, APPETITE, V51, P249, DOI 10.1016/j.appet.2008.02.015; Deci E.L., 1985, INTRINSIC MOTIVATION; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; DiFiori JP, 2014, CLIN J SPORT MED, V24, P3, DOI 10.1097/JSM.0000000000000060; Dixon MA, 2009, SPORT MANAG REV, V12, P34, DOI DOI 10.1016/J.SMR.2008.09.002; Dixon MA, 2008, SOCIOL SPORT J, V25, P538, DOI 10.1123/ssj.25.4.538; Donnelly P., SOCHI INSPIRATION WO; Dorsch T.E., 2013, PARENT SPORT SOCIALI; Dorsch TE, 2009, J SPORT EXERCISE PSY, V31, P444, DOI 10.1123/jsep.31.4.444; Duda J. L, 2014, INT J SPORT EXER PSY, P1; Duda J. L., 2005, ORG ACTIVITIES CONTE, P311, DOI DOI 10.4324/9781410612748; Dyck V., 2006, Leisure Studies, V25, P201, DOI 10.1080/02614360500418589; Eccles J., 2002, COMMUNITY PROGRAMS P, P66; Eime RM, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-98; Eklund R. C., 2007, HDB SPORT PSYCHOL, V3; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emrich E, 2009, INT REV SOCIOL SPORT, V44, P151, DOI 10.1177/1012690209104797; Engh F., 2002, WHY JOHNNY HATES SPO; ERICSSON KA, 2003, EXPERT PERFORMANCE S, P49; Ewing M., 1990, PRESIDENTS COUNCIL P, V2, P1; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finch CF, 2011, SPORTS MED, V41, P59, DOI 10.2165/11537260-000000000-00000; Flintoff Anne, 2002, GENDER SPORT READER; Fogelholm M, 1999, MED SCI SPORT EXER, V31, P229, DOI 10.1097/00005768-199902000-00005; FORTIER MS, 1995, INT J SPORT PSYCHOL, V26, P24; Fraser-Thomas J., 2013, CONDITIONS CHILDRENS, P179; Fraser-Thomas J. L., 2005, Physical Education and Sport Pedagogy, V10, P19, DOI 10.1080/1740898042000334890; Fraser-Thomas J, 2008, PSYCHOL SPORT EXERC, V9, P645, DOI 10.1016/j.psychsport.2007.08.003; Fraser-Thomas J, 2009, SPORT PSYCHOL, V23, P3, DOI 10.1123/tsp.23.1.3; Fredricks JA, 2005, J SPORT EXERCISE PSY, V27, P3, DOI 10.1123/jsep.27.1.3; Fredricks JA, 2002, DEV PSYCHOL, V38, P519, DOI 10.1037/0012-1649.38.4.519; Fredricks JA, 2006, DEV PSYCHOL, V42, P698, DOI 10.1037/0012-1649.42.4.698; Gagne M, 2007, INTRINSIC MOTIVATION, P243; Gillis C., NEW HOCKEY FIGHTS; Goldberg S, QUITTING ACTIVITIES; Goodger K, 2007, SPORT PSYCHOL, V21, P127, DOI 10.1123/tsp.21.2.127; Gottschalk AW, 2011, SPORTS MED ARTHROSC, V19, P2, DOI 10.1097/JSA.0b013e31820b95fc; Gould D., 1988, CHILDREN IN SPORT, V3, P161; Gould D, 2008, SPORT PSYCHOL, V22, P18, DOI 10.1123/tsp.22.1.18; Gould D, 2010, J PHYS EDUC RECREAT, V81, P33, DOI 10.1080/07303084.2010.10598525; Government of Canada, 2013, ORG SPORT CAN; Griffin B.M., 2014, ONLY 6 WORDS PARENTS; Grundtner Koch C.E., 2012, THESIS U ST THOMAS S; Guevremont Anne, 2008, Health Rep, V19, P65; Gustafsson H, 2008, PSYCHOL SPORT EXERC, V9, P800, DOI 10.1016/j.psychsport.2007.11.004; Gustafsson H, 2007, SPORT PSYCHOL, V21, P21, DOI 10.1123/tsp.21.1.21; Hageman W., STUDY FINDS PARENTAL; Halldorsson V, 2014, INT REV SOCIOL SPORT, V49, P311, DOI 10.1177/1012690213507718; Harris BS, 2014, J CLIN SPORT PSYCHOL, V8, P1, DOI 10.1123/jcsp.2014-0009; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Harwood C, 2009, J SPORT SCI, V27, P339, DOI 10.1080/02640410802603871; Harwood C, 2009, PSYCHOL SPORT EXERC, V10, P447, DOI 10.1016/j.psychsport.2009.01.005; Harwood CG, 2015, PSYCHOL SPORT EXERC, V16, P24, DOI 10.1016/j.psychsport.2014.03.001; Hausenblas HA, 1999, J SPORT EXERCISE PSY, V21, P230, DOI 10.1123/jsep.21.3.230; Hedstrom R, 2004, RES YOUTH SPORTS CRI; Helliker K, PROBLEM SPORTS PAREN; Hemond C, 2012, CAN MED ASSOC J, V184, P861, DOI 10.1503/cmaj.109-4167; Herron R.M., 2013, MEDIA IMPACT MENTAL; Hodge K, 2009, SPORT PSYCHOL, V23, P186, DOI 10.1123/tsp.23.2.186; Hoefer WR, 2001, AM J PREV MED, V21, P48, DOI 10.1016/S0749-3797(01)00314-2; Hohepa M, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-54; Holder MD, 2009, J HEALTH PSYCHOL, V14, P378, DOI 10.1177/1359105308101676; Hollander D. B., 1995, Journal of Sport Behavior, V18, P3; Holt NL, 2008, PSYCHOL SPORT EXERC, V9, P663, DOI 10.1016/j.psychsport.2007.08.001; Holt NL, 2008, INT STUD PHYS EDUC Y, P122; Howell A.J., 2013, RES APPL INTERVENTIO, P59; Hyman M., 2012, MOST EXPENSIVE GAME; Institute of Medicine, 2013, SPORTS REL CONC YOUT; Janssen I, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-40; Jayanthi N., 2011, J MED SCI TENNIS, V16, P14; Jayanthi N, 2013, SPORTS HEALTH, V5, P251, DOI 10.1177/1941738112464626; Johnson JN, 2013, BRIT J SPORT MED, V47, P28, DOI 10.1136/bjsports-2012-091751; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Johnson LSM, 2011, CAN MED ASSOC J, V183, P921, DOI 10.1503/cmaj.110282; Kaleth AS, 2010, J PHYS EDUC RECREAT, V81, P29, DOI 10.1080/07303084.2010.10598524; Kanters M. A., 2008, Journal of Sport Behavior, V31, P64; Kay T., 2000, European Physical Education Review, V6, P151, DOI 10.1177/1356336X000062004; Keegan R, 2010, J APPL SPORT PSYCHOL, V22, P87, DOI 10.1080/10413200903421267; Keyes C. L., 2013, MENTAL WELLBEING INT, P3; Keyes CLM, 2005, J CONSULT CLIN PSYCH, V73, P539, DOI 10.1037/0022-006X.73.3.539; Keyes CLM, 2010, CORSINI ENCY PSYCHOL; Keyes CLM, 2006, AM J ORTHOPSYCHIAT, V76, P395, DOI 10.1037/0002-9432.76.3.395; King WJ, 2006, CAN MED ASSOC J, V175, P163, DOI 10.1503/cmaj.060620; Kirk D., 1997, EUR J PHYS ED, V2, P51, DOI DOI 10.1080/1740898970020105; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Kwan M, 2014, ADDICT BEHAV, V39, P497, DOI 10.1016/j.addbeh.2013.11.006; Lally P, 2008, J APPL SPORT PSYCHOL, V20, P42, DOI 10.1080/10413200701788172; Lamers SMA, 2012, EUR J PSYCHOL ASSESS, V28, P290, DOI 10.1027/1015-5759/a000109; Lamers SMA, 2011, J CLIN PSYCHOL, V67, P99, DOI 10.1002/jclp.20741; Lauer L, 2010, J CLIN SPORT PSYCHOL, V4, P69, DOI 10.1123/jcsp.4.1.69; LaVoi NM., 2012, SPORT COACH REV, V1, P17, DOI [10.1080/21640629.2012.695891, DOI 10.1080/21640629.2012.695891]; Lemon J., PARENT PARENT SPEND; Lisha NE, 2010, ADDICT BEHAV, V35, P399, DOI 10.1016/j.addbeh.2009.12.032; Lisha NE, 2014, J DRUG ISSUES, V44, P83, DOI 10.1177/0022042613491107; Lonsdale C, 2009, J SPORT SCI, V27, P785, DOI 10.1080/02640410902929366; Luke A, 2011, CLIN J SPORT MED, V21, P307, DOI 10.1097/JSM.0b013e3182218f71; MacDonald DJ, 2011, SPORT PSYCHOL, V25, P32, DOI 10.1123/tsp.25.1.32; MAFFULLI N, 1992, BRIT MED BULL, V48, P561, DOI 10.1093/oxfordjournals.bmb.a072563; Maffulli N, 2010, PHYSICIAN SPORTSMED, V38, P29, DOI 10.3810/psm.2010.06.1780; Malina RM, 2010, CURR SPORT MED REP, V9, P364, DOI 10.1249/JSR.0b013e3181fe3166; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marsiglio W, 2000, J MARRIAGE FAM, V62, P1173, DOI 10.1111/j.1741-3737.2000.01173.x; Martens MP, 2006, J APPL SPORT PSYCHOL, V18, P136, DOI 10.1080/10413200600653758; Martinsen M, 2013, MED SCI SPORT EXER, V45, P1188, DOI 10.1249/MSS.0b013e318281a939; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; Maslach C., 1984, APPL SOC PSYCHOL ANN, V5, P133, DOI DOI 10.1037/0021-9010.93.3.5688; Mazer C., 2013, PARENTAL INVOLVEMENT; McArdle W., 2007, EXERCISE PHYSL ENERG; McCann S., 2005, OLYMP COACH, V1, P17; McCarthy PJ, 2008, PSYCHOL SPORT EXERC, V9, P142, DOI 10.1016/j.psychsport.2007.01.005; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; McLean JA, 2003, APPETITE, V40, P185, DOI 10.1016/S0195-6663(02)00125-3; McLeod TCV, 2011, J ATHL TRAINING, V46, P206, DOI 10.4085/1062-6050-46.2.206; Merglen A., 2013, ARCH DIS CHILD; Merkel DL, 2013, OPEN ACCESS J SPORTS, V4, P151, DOI 10.2147/OAJSM.S33556; Metzl JD, 2001, PEDIATRICS, V108, P421, DOI 10.1542/peds.108.2.421; Meyers D., HAPPY GIRL SAD GIRL; Moore MJ, 2005, J ADOLESCENT HEALTH, V36, P486, DOI 10.1016/j.jadohealth.2004.02.031; Mostafavifar AM, 2013, BRIT J SPORT MED, V47, P1060, DOI 10.1136/bjsports-2012-092005; Nattiv Aurelia, 2007, Med Sci Sports Exerc, V39, P1867; Nelson TF, 2011, CURR SPORT MED REP, V10, P360, DOI 10.1249/JSR.0b013e318237bf74; Newhouse-Bailey M.J., UNDERSTANDING IMPACT; Newton M, 2000, J SPORT SCI, V18, P275, DOI 10.1080/026404100365018; Nicholls J.G., 1989, LEARN INDIVID DIFFER, V1, P63, DOI DOI 10.1016/1041-6080(89)90010-1; NICHOLLS JG, 1984, PSYCHOL REV, V91, P328, DOI 10.1037/0033-295X.91.3.328; Norman L, 2012, INT REV SOCIOL SPORT, V47, P705, DOI 10.1177/1012690211420487; Ntoumanis N, 2012, DEV PSYCHOL, V48, P213, DOI 10.1037/a0024934; Ommundsen Y., 2014, HDB CHILD WELL BEING, P911; Paiement CA, 2007, RES Q EXERCISE SPORT, V78, pA84; Partridge J. A., 2008, ADV SPORT PSYCH, P269; Patel DR, 2003, J ADOLESCENT RES, V18, P280, DOI 10.1177/0743558403018003006; Paterno MV, 2013, ORTHOP CLIN N AM, V44, P553, DOI 10.1016/j.ocl.2013.06.009; Pelletier LG, 2001, MOTIV EMOTION, V25, P279, DOI 10.1023/A:1014805132406; Petersen I., 2013, ACTA PSYCHIAT SCAND, V15, P411; Petitpas AJ, 2005, SPORT PSYCHOL, V19, P63, DOI 10.1123/tsp.19.1.63; Pike A., 2009, CHILDHOOD, V79, P217; Popay J., 2006, MOVING EFFECTIVENESS; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Quested E, 2011, PSYCHOL SPORT EXERC, V12, P159, DOI 10.1016/j.psychsport.2010.09.003; Raedeke TD, 2001, J SPORT EXERCISE PSY, V23, P281, DOI 10.1123/jsep.23.4.281; Rajabali F., CONCUSSION CHILDREN; Raudsepp L, 2000, EUR J PHYS ED, V5, P169, DOI DOI 10.1080/1740898000050205; Ricciardelli LA, 2004, PSYCHOL BULL, V130, P179, DOI 10.1037/0033-2909.130.2.179; ROTELLA RJ, 1991, ELEM SCHOOL J, V91, P421, DOI 10.1086/461664; Russell W. D., 2013, Journal of Sport Behavior, V36, P82; RYAN J, 1995, LITTLE GIRLS PRETTY; Sallis JF, 1999, HEALTH PSYCHOL, V18, P410, DOI 10.1037/0278-6133.18.4.410; Sandle T., CONCUSSIONS YOUTH SP; Sanlier N, 2008, APPETITE, V51, P641, DOI 10.1016/j.appet.2008.05.058; Sarrazin P, 2002, EUR J SOC PSYCHOL, V32, P395, DOI 10.1002/ejsp.98; SCANLAN TK, 1993, J SPORT EXERCISE PSY, V15, P1, DOI 10.1123/jsep.15.1.1; Schaufeli WB, 2009, CAREER DEV INT, V14, P204, DOI 10.1108/13620430910966406; Schtscherbyna A, 2009, NUTRITION, V25, P634, DOI 10.1016/j.nut.2008.11.029; Scool and Sports, MUCH DO PAR REALL SP; Sebire SJ, 2009, J SPORT EXERCISE PSY, V31, P189, DOI 10.1123/jsep.31.2.189; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Shearer C, 2012, CAN J PUBLIC HEALTH, V103, pS55, DOI 10.1007/BF03403836; Small EW, 2007, PEDIATRICS, V119, P1242, DOI 10.1542/peds.2007-0887; Smink FRE, 2012, CURR PSYCHIAT REP, V14, P406, DOI 10.1007/s11920-012-0282-y; Smith RE, 2007, J SPORT EXERCISE PSY, V29, P39, DOI 10.1123/jsep.29.1.39; Smoll F., 2002, CHILDREN YOUTH SPORT, V2, P211; Alvarez MS, 2012, J CLIN SPORT PSYCHOL, V6, P166, DOI 10.1123/jcsp.6.2.166; Sonderlund AL, 2014, J SCI MED SPORT, V17, P2, DOI 10.1016/j.jsams.2013.03.011; Statistics Canada, 2011, GEN SOC SURV 2010 OV; Stein CJ, 2014, SPINAL INJURIES COND, P47; Stoneman Z., 1982, FAMILY STRENGTHS, P113; STOP Sport Injuries, AB STOP SPORTS INJ; Strachan L, 2009, J APPL SPORT PSYCHOL, V21, P340, DOI 10.1080/10413200903018667; Sundgot-Borgen J, 2004, CLIN J SPORT MED, V14, P25, DOI 10.1097/00042752-200401000-00005; Sundgot-Borgen J, 2013, BRIT J SPORT MED, V47, P1012, DOI 10.1136/bjsports-2013-092966; Superville D., OBAMA DRAW ATTENTION; Surya M., 2012, PHENEX J, V4, P1; Taliaferro LA, 2010, J SCHOOL HEALTH, V80, P399, DOI 10.1111/j.1746-1561.2010.00520.x; Terry-McElrath YM, 2011, AM J PREV MED, V40, P530, DOI 10.1016/j.amepre.2010.12.021; Theisen D, 2013, J SCI MED SPORT, V16, P200, DOI 10.1016/j.jsams.2012.07.007; Thompson S, 1999, MOTHERS TAXI SPORT W; Thorsteinsdottir G, 2008, EUR J PSYCHIAT, V22, P107, DOI 10.4321/s0213-61632008000200007; Timperio AF, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-15; Tomlin D.L., 2013, J INT SOC SPORT NUTR, V10, DOI [10.1186/1550-2738-10-38, DOI 10.1186/1550-2738-10-38]; Townsend M., 2001, ACHPER Healthy Lifestyles Journal, V48, P10; Trussell D.E., 2009, ORG YOUTH SPORT PARE; Trussell DE, 2007, J LEISURE RES, V39, P366, DOI 10.1080/00222216.2007.11950112; Turocy P.S., 2011, J ATHL TRAINING, V46, P206; Ullrich-French S, 2009, PSYCHOL SPORT EXERC, V10, P87, DOI 10.1016/j.psychsport.2008.06.007; Vardar Erdal, 2007, Eat Behav, V8, P143, DOI 10.1016/j.eatbeh.2006.03.002; Venning A, 2013, AUST PSYCHOL, V48, P299, DOI 10.1111/j.1742-9544.2012.00068.x; Wall M., 2007, Physical Education and Sport Pedagogy, V12, P77, DOI 10.1080/17408980601060358; WANKEL LM, 1989, J SPORT EXERCISE PSY, V11, P355, DOI 10.1123/jsep.11.4.355; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Weiss MR, 2001, PEDIATR EXERC SCI, V13, P131, DOI 10.1123/pes.13.2.131; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, P286; Weiss MR, 2004, DEV SPORT EXERCISE P, P145, DOI DOI 10.1016/J.PSYCHSPORT.2010.05.001; WEISS MR, 1995, PEDIATR EXERC SCI, V7, P36; Wichstrom T, 2009, ADDICTION, V104, P138, DOI 10.1111/j.1360-0443.2008.02422.x; Wiersma LD, 2000, PEDIATR EXERC SCI, V12, P13, DOI 10.1123/pes.12.1.13; Wiersma LD, 2008, J LEISURE RES, V40, P505, DOI 10.1080/00222216.2008.11950150; Wilson L.L., WEIGHTY MATTERS; Wolfenden LE, 2005, J APPL SPORT PSYCHOL, V17, P108, DOI 10.1080/10413200590932416; World Health Organization, NUTR AD ISS CHALL HL; Wuerth S, 2004, PSYCHOL SPORT EXERC, V5, P21, DOI 10.1016/S1469-0292(02)00047-X; Yard EE, 2006, J ATHL TRAINING, V41, P441; YIANNAKIS A, 1976, RES QUART, V47, P62, DOI 10.1080/10671315.1976.10615341	260	45	46	0	54	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1660-4601			INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	OCT	2014	11	10					10226	10268		10.3390/ijerph111010226			43	Environmental Sciences; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	AS6FA	WOS:000344358700019	25275889	gold, Green Published, Green Submitted			2022-02-06	
J	Staib-Lasarzik, I; Kriege, O; Timaru-Kast, R; Pieter, D; Werner, C; Engelhard, K; Thal, SC				Staib-Lasarzik, Irina; Kriege, Oliver; Timaru-Kast, Ralph; Pieter, Dana; Werner, Christian; Engelhard, Kristin; Thal, Serge C.			Anesthesia for Euthanasia Influences mRNA Expression in Healthy Mice and after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						anesthesia; gene expression; early regulated genes; organ sampling; real-time PCR; traumatic brain injury	GENE-EXPRESSION; NEURONAL INJURY; HEAT-SHOCK; C-FOS; ISCHEMIA; STRESS; RAT; NEUROPROTECTION; ISOFLURANE; INDUCTION	Tissue sampling for gene expression analysis is usually performed under general anesthesia. Anesthetics are known to modulate hemodynamics, receptor-mediated signaling cascades, and outcome parameters. The present study determined the influence of anesthetic paradigms typically used for euthanization and tissue sampling on cerebral mRNA expression in mice. Naive mice and animals with acute traumatic brain injury induced by controlled cortical impact (CCI) were randomized to the following euthanasia protocols (n = 10-11/group): no anesthesia (NA), 1 min of 4 vol% isoflurane in room air (ISO), 3 min of a combination of 5 mg/kg midazolam, 0.05 mg/kg fentanyl, and 0.5 mg/kg medetomidine intra-peritoneally (COMB), or 3 min of 360 mg/kg chloral hydrate intraperitoneally (CH). mRNA expression of actin-1-related gene (Act1), FBJ murine osteosarcoma viral oncogene homolog B (FosB), tumor necrosis factor alpha (TNF alpha), heat shock protein beta-1 (HspB1), interleukin (IL)-6, tight junction protein 1 (ZO-1), IL-1 beta, cyclophilin A, micro RNA 497 (miR497), and small cajal body-specific RNA 17 were determined by real-time polymerase chain reaction (PCR) in hippocampus samples. In naive animals, Act1 expression was downregulated in the CH group compared with NA. FosB expression was downregulated in COMB and CH groups compared with NA. CCI reduced Act1 and FosB expression, whereas HspB1 and TNF alpha expression increased. After CCI, HspB1 expression was significantly higher in ISO, COMB, and CH groups, and TNF alpha expression was elevated in ISO and COMB groups. MiR497, IL-6, and IL-1 beta were upregulated after CCI but not affected by anesthetics. Effects were independent of absolute mRNA copy numbers. The data demonstrate that a few minutes of anesthesia before tissue sampling are sufficient to induce immediate mRNA changes, which seem to predominate in the early-regulated gene cluster. Anesthesia-related effects on gene expression might explain limited reproduciblity of real-time PCR data between studies or research groups and should therefore be considered for quantitative PCR data.	[Staib-Lasarzik, Irina; Kriege, Oliver; Timaru-Kast, Ralph; Pieter, Dana; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, D-55131 Mainz, Germany		Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729	German Research Foundation (DFG)German Research Foundation (DFG) [TH1430/3-1]; Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF 01EO1003]	This work was supported by the German Research Foundation (DFG grant TH1430/3-1 to Dr. Thal) and by the Federal Ministry of Education and Research (BMBF 01EO1003). The data presented in this manuscript are part of the doctoral theses presented by Oliver Kriege to the Medical Faculty of the Johannes Gutenberg-University, Mainz, Germany.	Briet F, 2009, CAN J ANAESTH, V56, P921, DOI 10.1007/s12630-009-9201-z; Cao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051431; Ebihara K, 2011, NEUROSCI LETT, V496, P90, DOI 10.1016/j.neulet.2011.03.087; Falvo JV, 2010, CURR DIR AUTOIMMUN, V11, P27, DOI 10.1159/000289196; Franklin TB, 2005, INT J HYPERTHER, V21, P379, DOI 10.1080/02656730500069955; Hamaya Y, 2000, ANESTH ANALG, V90, P1177, DOI 10.1097/00000539-200005000-00034; Janssen BJA, 2004, AM J PHYSIOL-HEART C, V287, pH1618, DOI 10.1152/ajpheart.01192.2003; Johnson PL, 2011, J PSYCHOPHARMACOL, V25, P26, DOI 10.1177/0269881109353464; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Kim GS, 2012, NEUROBIOL DIS, V46, P440, DOI 10.1016/j.nbd.2012.02.008; Kulisch C, 2011, J NEUROSCI METH, V201, P340, DOI 10.1016/j.jneumeth.2011.08.022; Lasarzik I, 2011, J NEUROSURG ANESTH, V23, P215, DOI 10.1097/ANA.0b013e31821a1150; Li H, 2013, NEUROBIOL DIS, V54, P216, DOI 10.1016/j.nbd.2012.12.014; Liu CY, 2012, J NEUROCHEM, V120, P830, DOI 10.1111/j.1471-4159.2011.07624.x; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Nellgard B, 2000, ANESTH ANALG, V91, P145, DOI 10.1097/00000539-200007000-00027; Olsvik PA, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-48; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; SHARP FR, 1994, NEUROTOXICOLOGY, V15, P51; Stetler RA, 2012, J NEUROSCI, V32, P2667, DOI 10.1523/JNEUROSCI.5169-11.2012; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Trosse C, 2010, FISH PHYSIOL BIOCHEM, V36, P1217, DOI 10.1007/s10695-010-9401-z; Valentine H, 2012, J AM ASSOC LAB ANIM, V51, P50; Wu X, 2012, NEUROBIOL AGING, V33, P1364, DOI 10.1016/j.neurobiolaging.2010.11.002; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	29	45	45	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1664	1671		10.1089/neu.2013.3243			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400008	24945082	Green Published			2022-02-06	
J	Juratli, TA; Zang, B; Litz, RJ; Sitoci, KH; Aschenbrenner, U; Gottschlich, B; Daubner, D; Schackert, G; Sobottka, SB				Juratli, Tareq A.; Zang, Benedikt; Litz, Rainer J.; Sitoci, Kerim-Hakan; Aschenbrenner, Ulf; Gottschlich, Birgit; Daubner, Dirk; Schackert, Gabriele; Sobottka, Stephan B.			Early Hemorrhagic Progression of Traumatic Brain Contusions: Frequency, Correlation with Coagulation Disorders, and Patient Outcome: A Prospective Study	JOURNAL OF NEUROTRAUMA			English	Article						hemorrhagic progression of a contusion; long-term outcome; modified Rankin scale; traumatic brain contusions; trauma-induced coagulopathy	SEVERE HEAD-INJURY; INTRAVASCULAR COAGULATION; INTRACRANIAL HEMORRHAGE; COAGULOPATHY; IMPACT	The focus of this paper is to identify and quantify risk factors for early hemorrhagic progression of brain contusions (HPC) in patients with traumatic brain injury (TBI) and to evaluate their impact on patients' outcome. Further, based on abnormal values in routine blood tests, the role of trauma-induced coagulopathy is analyzed in detail. Therefore, a prospective study of 153 TBI patients was completed at one institution between January 2008 and June 2012. The collected data included demographics, initial Glasgow Coma Scale pupillary response, initial and 6 h follow-up computed tomography scan findings, coagulation parameters (international normalized ratio, partial thromboplastin time, platelet count, fibrinogen, D-dimer and factor XIII), as well as outcome data using the modified Rankin score at discharge and after one year. The overall rate of early HPC within the first 6 h was 43.5%. The frequency of coagulopathy was 47.1%. When analyzing for risk factors that independently influenced outcome in the form of mRS >= 4 at both points, the following variables appeared: elevated D-dimer level (>= 10,000 mu g/L), HPC, and initial brain contusions >= 3 cm. Patients sustaining early HPC had a hazard ratio of 5.4 for unfavorable outcome at discharge (p=0.002) and of 3.9 after one year (p=0.006). Overall, patients who developed early HPC were significantly more likely to be gravely disabled or to die. Unfavorable neurological outcome after an isolated TBI is determined largely by early HPC and coagulopathy, which seem to occur very frequently in TBI patients, irrespective of the severity of the trauma.	[Juratli, Tareq A.; Zang, Benedikt; Sitoci, Kerim-Hakan; Schackert, Gabriele; Sobottka, Stephan B.] Univ Hosp Dresden, Dept Neurosurg, Dresden, Germany; [Aschenbrenner, Ulf] Univ Hosp Dresden, Dept Trauma & Reconstruct Surg, Dresden, Germany; [Gottschlich, Birgit] Univ Hosp Dresden, Dept Anesthesiol & Intens Care Med, Dresden, Germany; [Daubner, Dirk] Univ Hosp Dresden, Dept Neuroradiol, Dresden, Germany; [Litz, Rainer J.] Berufsgenossenschaftliches Univ Klinikum Bergmann, Dept Anesthesiol & Intens Care Med, Bochum, Germany		Juratli, TA (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus Dresden, Dept Neurosurg, Fetscherstr 74, D-01307 Dresden, Germany.	tareq.juratli@uniklinikum-dresden.de	Juratli, Tareq/J-6832-2014	Juratli, Tareq/0000-0003-2236-6719			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; ATWOOD WH, 1959, AM J MED SCI, V238, P720, DOI 10.1097/00000441-195912000-00006; Bakhtiari K, 2004, CRIT CARE MED, V32, P2416, DOI 10.1097/01.CCM.0000147769.07699.E3; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Cortiana M, 1986, J Neurosurg Sci, V30, P133; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MISHLER JM, 1975, VOX SANG, V28, P218, DOI 10.1111/j.1423-0410.1975.tb02760.x; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schochl H., 2013, J NEUROTRAUM, V28, P2033; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1	30	45	56	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1521	1527		10.1089/neu.2013.3241			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700007	24738836				2022-02-06	
J	Yang, ZH; Lin, F; Robertson, CS; Wang, KKW				Yang, Zhihui; Lin, Fan; Robertson, Claudia S.; Wang, Kevin K. W.			Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calpain; caspase; neurodegeneration; TDP-43; traumatic brain injury	DNA-BINDING PROTEIN-43; FRONTOTEMPORAL LOBAR DEGENERATION; C-TERMINAL FRAGMENTS; ALZHEIMERS-DISEASE; DEPENDENT CLEAVAGE; CSF BIOMARKERS; AGGREGATION; INCLUSIONS; TARGET; FLUID	Transactivation response DNA-binding protein 43 (TDP-43) proteinopathy has recently been reported in chronic traumatic encephalopathy, a neurodegenerative condition linked to prior history of traumatic brain injury (TBI). While TDP-43 appears to be vulnerable to proteolytic modifications under neurodegenerative conditions, the mechanism underlying the contribution of TDP-43 to the pathogenesis of TBI remains unknown. In this study, we first mapped out the calpain or caspase-3 TDP-43 fragmentation patterns by in vitro protease digestion. Concurrently, in cultured cerebrocortical neurons subjected to cell death challenges, we identified distinct TDP-43 breakdown products (BDPs) of 35,33, and 12 kDa that were indicative of dual calpain/caspase attack. Cerebrocortical culture incubated with calpain and caspase-fragmented TDP-43 resulted in neuronal injury. Furthermore, increased TDP-43 BDPs as well as redistributed TDP-43 from the nucleus to the cytoplasm were observed in the mouse cortex in two TBI models: controlled cortical impact injury and overpressure blast-wave-induced brain injury. Finally, TDP-43 and its 35 kDa fragment levels were also elevated in the cerebrospinal fluid (CSF) of severe TBI patients. This is the first evidence that TDP-43 might be involved in acute neuroinjury and TBI pathology, and that TDP-43 and its fragments may have biomarker utilities in TBI patients.	[Yang, Zhihui; Lin, Fan; Wang, Kevin K. W.] Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat & Neurosci, Gainesville, FL 32611 USA; [Robertson, Claudia S.] Baylor Coll Med, Ben Taub Gen Hosp, Houston, TX 77030 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Yang, ZH (corresponding author), Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat & Neurosci, 1149 Newell,Dr L4-100, Gainesville, FL 32611 USA.	zhihuiyang@ufl.edu; kwang@ufl.edu		Wang, Kevin/0000-0002-9343-6473	BSCIRTF fund from the State of Florida	This study is in part supported by BSCIRTF fund from the State of Florida.	Andersson M, 2011, INT J GERIATR PSYCH, V26, P100, DOI 10.1002/gps.2496; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cushman M, 2010, J CELL SCI, V123, P1191, DOI 10.1242/jcs.051672; Dormann D, 2009, J NEUROCHEM, V110, P1082, DOI 10.1111/j.1471-4159.2009.06211.x; Forman MS, 2007, CURR OPIN NEUROBIOL, V17, P548, DOI 10.1016/j.conb.2007.08.005; Foulds P, 2008, ACTA NEUROPATHOL, V116, P141, DOI 10.1007/s00401-008-0389-8; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Hook GR, 2014, J NEUROTRAUM, V31, P515, DOI [10.1089/neu.2013.2944, 10.1089/NEU.2013.2944]; Igaz LM, 2008, AM J PATHOL, V173, P182, DOI 10.2353/ajpath.2008.080003; Igaz LM, 2011, J CLIN INVEST, V121, P726, DOI 10.1172/JCI44867; Johnson BS, 2009, J BIOL CHEM, V284, P20329, DOI 10.1074/jbc.M109.010264; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Kadokura A, 2009, NEUROPATHOLOGY, V29, P566, DOI 10.1111/j.1440-1789.2009.01017.x; Klimowicz-Bodys MD, 2012, THERIOGENOLOGY, V77, P628, DOI 10.1016/j.theriogenology.2011.09.001; Kuo PH, 2009, NUCLEIC ACIDS RES, V37, P1799, DOI 10.1093/nar/gkp013; Lee EB, 2012, NAT REV NEUROSCI, V13, P38, DOI 10.1038/nrn3121; Li Y, 2010, P NATL ACAD SCI USA, V107, P3169, DOI 10.1073/pnas.0913602107; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nonaka T, 2009, HUM MOL GENET, V18, P3353, DOI 10.1093/hmg/ddp275; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Rohn TT, 2008, BRAIN RES, V1228, P189, DOI 10.1016/j.brainres.2008.06.094; Rohn Troy T, 2009, Int J Physiol Pathophysiol Pharmacol, V1, P25; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Schwab C, 2008, J NEUROPATH EXP NEUR, V67, P1159, DOI 10.1097/NEN.0b013e31818e8951; Tabaraud F, 2012, ACTA NEUROL SCAND, V125, P416, DOI 10.1111/j.1600-0404.2011.01592.x; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 2013, SYSTEMS BIOMARKERS A; Wilson AC, 2011, INT J CLIN EXP PATHO, V4, P147; Yamashita T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2303; Yang CX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015878; Yokota O, 2009, ACTA NEUROPATHOL, V117, P429, DOI 10.1007/s00401-009-0493-4; Zhang YJ, 2007, J NEUROSCI, V27, P10530, DOI 10.1523/JNEUROSCI.3421-07.2007; Zhang YJ, 2009, P NATL ACAD SCI USA, V106, P7607, DOI 10.1073/pnas.0900688106; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	40	45	45	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2014	34	9					1444	1452		10.1038/jcbfm.2014.105			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AO4WT	WOS:000341342800005	24917042	Green Published, Bronze			2022-02-06	
J	Dayan, PS; Holmes, JF; Schutzman, S; Schunk, J; Lichenstein, R; Foerster, LA; Hoyle, J; Atabaki, S; Miskin, M; Wisner, D; Zuspan, SJ; Kuppermann, N				Dayan, Peter S.; Holmes, James F.; Schutzman, Sara; Schunk, Jeffrey; Lichenstein, Richard; Foerster, Lillian A.; Hoyle, John, Jr.; Atabaki, Shireen; Miskin, Michelle; Wisner, David; Zuspan, Sally Jo; Kuppermann, Nathan		Pediat Emergency Care Appl Res	Risk of Traumatic Brain Injuries in Children Younger than 24 Months With Isolated Scalp Hematomas	ANNALS OF EMERGENCY MEDICINE			English	Article							BLUNT HEAD TRAUMA; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; SKULL FRACTURE; INFANTS; EMERGENCY	Study objective: We aimed to determine the association between scalp hematoma characteristics and traumatic brain injuries in young children with blunt head trauma who have no other symptoms or signs suggestive of traumatic brain injuries (defined as "isolated scalp hematomas"). Methods: This was a secondary analysis of children younger than 24 months with minor blunt head trauma from a prospective cohort study in 25 Pediatric Emergency Care Applied Research Network emergency departments. Treating clinicians completed a structured data form. For children with isolated scalp hematomas, we determined the prevalence of and association between scalp hematoma characteristics and (1) clinically important traumatic brain injury (death, neurosurgery for traumatic brain injury, intubation >24 hours for traumatic brain injury, or positive computed tomography (CT) scan in association with hospitalization >= 2 nights for traumatic brain injury); and (2) traumatic brain injury on CT. Results: Of 10,659 patients younger than 24 months were enrolled, 2,998 of 10,463 (28.7%) with complete data had isolated scalp hematomas. Clinically important traumatic brain injuries occurred in 12 patients (0.4%; 95% confidence interval [CI] 0.2% to 0.7%); none underwent neurosurgery (95% CI 0% to 0.1%). Of 570 patients (19.0%) for whom CTs were obtained, 50 (8.8%; 95% CI 6.6% to 11.4%) had traumatic brain injuries on CT. Younger age, non-frontal scalp hematoma location, increased scalp hematoma size, and severe injury mechanism were independently associated with traumatic brain injury on CT. Conclusion: In patients younger than 24 months with isolated scalp hematomas, a minority received CTs. Despite the occasional presence of traumatic brain injuries on CT, the prevalence of clinically important traumatic brain injuries was very low, with no patient requiring neurosurgery. Clinicians should use patient age, scalp hematoma location and size, and injury mechanism to help determine which otherwise asymptomatic children should undergo neuroimaging after minor head trauma.	Columbia Univ, Coll Phys & Surg, Div Emergency Med, New York, NY 10027 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Wisner, David] Univ Calif Davis, Sch Med, Dept Surg, Sacramento, CA 95817 USA; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; [Schutzman, Sara] Childrens Hosp Boston, Div Emergency Med, Boston, MA USA; [Schunk, Jeffrey; Miskin, Michelle; Zuspan, Sally Jo] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Lichenstein, Richard] Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; [Foerster, Lillian A.] Holy Cross Hosp, Silver Spring Emergency Phys, Silver Spring, MD USA; [Hoyle, John, Jr.] Helen DeVos Childrens Hosp, Grand Rapids, MI USA; [Atabaki, Shireen] Childrens Natl Med Ctr, Emergency Div, Washington, DC USA		Dayan, PS (corresponding author), Columbia Univ, Coll Phys & Surg, Div Emergency Med, New York, NY 10027 USA.	psd6@columbia.edu		Holubkov, Richard/0000-0003-0431-3381	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Training, and Education (DRTE); Emergency Medical Services of Children (EMSC) Program [R40MC02461]; EMSC program of the MCHB/HRSA [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the folllowing details: This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Training, and Education (DRTE); and the Emergency Medical Services of Children (EMSC) Program (R40MC02461). The Pediatric Emergency Care Applied Research Network is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685 from the EMSC program of the MCHB/HRSA.	Bin SS, 2010, PEDIATR EMERG CARE, V26, P633, DOI 10.1097/PEC.0b013e3181ef0440; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; National Center for Injury Prevention and Control, TRAUM BRAIN INJ US; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, PEDIATRICS	16	45	45	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2014	64	2					153	162		10.1016/j.annemergmed.2014.02.003			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	AM9PV	WOS:000340214400010	24635991				2022-02-06	
J	Wagner, AK; Scanlon, JM; Becker, CR; Ritter, AC; Niyonkuru, C; Dixon, CE; Conley, YP; Price, JC				Wagner, Amy K.; Scanlon, Joelle M.; Becker, Carl R.; Ritter, Anne C.; Niyonkuru, Christian; Dixon, Clifton E.; Conley, Yvette P.; Price, Julie C.			The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						beta-CFT; dopamine; genetic variation; PET imaging; raclopride; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MONOAMINE TRANSPORTERS; PARKINSONS-DISEASE; PET; AVAILABILITY; ASSOCIATION; C-11; POLYMORPHISMS; IMPAIRMENT; NUCLEUS	Dopamine (DA) neurotransmission influences cognition and recovery after traumatic brain injury (TBI). We explored whether functional genetic variants affecting the DA transporter (DAT) and D2 receptor (DRD2) impacted in vivo dopaminergic binding with positron emission tomography (PET) using [C-11]beta CFT and [C-11]raclopride. We examined subjects with moderate/severe TBI (N=12) similar to 1 year post injury and similarly matched healthy controls (N=13). The variable number of tandem repeat polymorphism within the DAT gene and the Taql restriction fragment length polymorphism near the DRD2 gene were assessed. TBI subjects had age-adjusted DAT-binding reductions in the caudate, putamen, and ventral striatum, and modestly increased D2 binding in ventral striatum versus controls. Despite small sample sizes, multivariate analysis showed lower caudate and putamen DAT binding among DAT 9-allele carriers and DRD2 A2/A2 homozygotes with TBI versus controls with the same genotype. Among TBI subjects, 9-allele carriers had lower caudate and putamen binding than 10/10 homozygotes. This PET study suggests a hypodopaminergic environment and altered DRD2 autoreceptor DAT interactions that may influence DA transmission after TBI. Future work will relate these findings to cognitive performance; future studies are required to determine how DRD2/DAT1 genotype and DA-ligand binding are associated with neurostimulant response and TBI recovery.	[Wagner, Amy K.; Scanlon, Joelle M.; Ritter, Anne C.; Niyonkuru, Christian; Dixon, Clifton E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Dixon, Clifton E.; Conley, Yvette P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Becker, Carl R.; Price, Julie C.] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA; [Dixon, Clifton E.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu; pricjc@upmc.edu		Conley, Yvette/0000-0002-1784-6067	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162, K01 MH01976]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH001976] Funding Source: NIH RePORTER	Support for this work was provided by NIH R01 HD048162; K01 MH01976.	Abdolmaleky Hamid Mostafavi, 2008, V448, P187, DOI 10.1007/978-1-59745-205-2_9; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bertolino A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009348; Bruck A, 2001, NEUROSCI LETT, V311, P81, DOI 10.1016/S0304-3940(01)02124-3; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1027, DOI 10.1017/S1355617703970068; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Forsback S, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-3; Frank MJ, 2009, NEUROSCIENCE, V164, P131, DOI 10.1016/j.neuroscience.2009.04.048; Genro JP, 2008, AM J MED GENET B, V147B, P1568, DOI 10.1002/ajmg.b.30863; Gu ZQ, 2010, NEUROSCI LETT, V482, P31, DOI 10.1016/j.neulet.2010.06.085; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; HALLDIN C, 1991, NUCL MED BIOL, V18, P871; Heinz A, 2000, NEUROPSYCHOPHARMACOL, V22, P133, DOI 10.1016/S0893-133X(99)00099-8; Hoffman AF, 1998, J PHARMACOL EXP THER, V287, P487; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Laruelle M, 2002, METHODS, V27, P287, DOI 10.1016/S1046-2023(02)00085-3; Lin ZC, 2011, PROG MOL BIOL TRANSL, V98, P1, DOI 10.1016/B978-0-12-385506-0.00001-6; Logan J, 2003, NUCL MED BIOL, V30, P833, DOI 10.1016/S0969-8051(03)00114-8; Mcdougall SA, 2011, SYNAPSE, V65, P583, DOI 10.1002/syn.20877; Meltzer CC, 1999, J NUCL MED, V40, P2053; NAGREN K, 1995, NUCL MED BIOL, V22, P235, DOI 10.1016/0969-8051(94)00083-V; Noble EP, 1997, AM J MED GENET, V74, P162; Ouchi Y, 1999, ANN NEUROL, V45, P601, DOI 10.1002/1531-8249(199905)45:5<601::AID-ANA8>3.0.CO;2-0; Rinne JO, 2000, ARCH NEUROL-CHICAGO, V57, P470, DOI 10.1001/archneur.57.4.470; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; Rohde LA, 2003, SYNAPSE, V48, P87, DOI 10.1002/syn.10186; Rumpel R, 2013, NEUROBIOL DIS, V59, P230, DOI 10.1016/j.nbd.2013.07.016; Seeman P, 2006, SYNAPSE, V60, P205, DOI 10.1002/syn.20298; Troiano AR, 2010, SYNAPSE, V64, P146, DOI 10.1002/syn.20708; van Dyck CH, 2005, J NUCL MED, V46, P745; Volkow ND, 1998, AM J PSYCHIAT, V155, P344; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WONG DF, 1993, SYNAPSE, V15, P130, DOI 10.1002/syn.890150205; Wu YJ, 2002, J CEREBR BLOOD F MET, V22, P1440, DOI 10.1097/01.WCB.0000033967.83623.34; Xu XH, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-3; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061; Zhen J, 2012, J NEUROSCI METH, V203, P19, DOI 10.1016/j.jneumeth.2011.08.044	45	45	45	2	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2014	34	8					1328	1339		10.1038/jcbfm.2014.87			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AM4ZG	WOS:000339864100009	24849661	Green Published, Bronze			2022-02-06	
J	Williams, MW; Rapport, LJ; Millis, SR; Hanks, RA				Williams, Michael W.; Rapport, Lisa J.; Millis, Scott R.; Hanks, Robin A.			Psychosocial Outcomes After Traumatic Brain Injury: Life Satisfaction, Community Integration, and Distress	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; life satisfaction; emotional distress; community integration; confirmatory factor analysis	QUALITY-OF-LIFE; 1ST 5 YEARS; HEALTH; INDIVIDUALS; DEPRESSION; VALIDITY; RELIABILITY; VALIDATION; PREDICTORS; SEQUELAE	Objective: To examine the relationship between life satisfaction, community integration, and emotional distress in adults with traumatic brain injury (TBI). Method: This was an archival study of a longitudinal data set on the outcome and recovery process of persons with TBI. Participants were 253 consecutive adults with mild complicated, moderate, and severe TBI who were enrolled in a large, longitudinal study of persons with TBI. Main measures included the Satisfaction with Life Scale, the Positive Affective and Negative Affective Schedule, the Craig Hospital Assessment and Reporting Technique Short-Form, the Community Integration Measure, and the Brief Symptom Inventory-18. Results: The three-factor model adequately fit the data, and a higher-order model did not necessarily improve model fit but revealed significant relationships with first-order constructs and one second-order construct. Conclusions: Life satisfaction, community integration, and emotional distress were found to be related yet unique concepts in persons with TBI. Life satisfaction was positively related to community involvement and inversely related to emotional distress. Community integration was inversely related to emotional distress. In addition, these concepts are related to a higher-order concept of psychosocial status, a global representation of subjective and objective functioning. These findings demonstrate the interrelated and dynamic nature of psychosocial well-being after brain injury and highlight the need for integrative and holistic treatment plans.	[Williams, Michael W.; Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Millis, Scott R.; Hanks, Robin A.] Wayne State Univ, Sch Medicine, Dept Phys Med & Rehabil, Detroit, MI 48202 USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 5057 Woodward Ave,7th Floor, Detroit, MI 48202 USA.	Rapport@wayne.edu		Rapport, Lisa/0000-0001-8014-9523			BARRERA M, 1986, AM J COMMUN PSYCHOL, V14, P413, DOI 10.1007/BF00922627; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Braden CA, 2012, BRAIN INJURY, V26, P1315, DOI 10.3109/02699052.2012.706351; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; Derogatis L.R., 2001, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Faul M, 2010, TRAUMATIC BRAIN INJU; Griffen JA, 2010, REHABIL PSYCHOL, V55, P292, DOI 10.1037/a0020503; Griffen JA, 2009, TOP STROKE REHABIL, V16, P212, DOI 10.1310/tsr1603-212; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Jewkes R, 1996, SOC SCI MED, V43, P555, DOI 10.1016/0277-9536(95)00439-4; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Jones TG, 2003, CLIN NEUROPSYCHOL, V17, P3, DOI 10.1076/clin.17.1.3.15626; Joreskog KG., 2006, LISREL 8 80 WINDOWS; Kaplan SP, 1991, CLIN NEUROPSYCHOL, V5, P360; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Mellick D., 2000, CRAIG HANDICAP ASSES; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Rapport LJ, 2008, ARCH PHYS MED REHAB, V89, P922, DOI 10.1016/j.apmr.2008.01.009; Raykov T., 2000, 1 COURSE STRUCTURAL; Reistetter TA, 2005, NEUROREHABILITATION, V20, P139; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Roebuck-Spencer T, 2008, TXB CLIN NEUROPSYCHO, P411; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063	47	45	45	0	22	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2014	59	3					298	305		10.1037/a0037164			8	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	AN2RH	WOS:000340432500006	25019312				2022-02-06	
J	Beghi, E; Hesdorffer, D				Beghi, Ettore; Hesdorffer, Dale			Prevalence of epilepsy-An unknown quantity	EPILEPSIA			English	Article						Epidemiology; Incidence; Prevalence; Mortality; Remission; Epilepsy	SOCIOECONOMIC-STATUS; NATURAL-HISTORY; UNTREATED POPULATION; DEVELOPING-COUNTRIES; UNPROVOKED SEIZURES; SOCIAL DEPRIVATION; MORTALITY; RISK; MINNESOTA; COMMUNITY	The incidence, prevalence, and mortality of epilepsy vary across countries with different economies. Differences can be explained by methodological problems, premature mortality, seizure remission, socioeconomic factors, and stigma. Diagnostic misclassification-one possible explanation-may result from inclusion of patients with acute symptomatic or isolated unprovoked seizures. Other sources of bias include age and ethnic origin of the target population, definitions of epilepsy, retrospective versus prospective ascertainment, sources of cases, and experienced and perceived stigma. Premature mortality is an issue in low-income countries (LICs), where treatment gap, brain infections, and traumatic brain injuries are more common than in high-income countries (HICs). Death rates may reflect untreated continued seizures or inclusion of acute symptomatic seizures. Lack of compliance with antiepileptic drugs has been associated with increased risk for death, increased hospital admissions, motor vehicle accidents, and fractures in poor communities. Epilepsy is a self-remitting clinical condition in up to 50% of cases. Studies in untreated individuals from LICs have shown that the proportion of remissions overlaps that of countries where patients receive treatment. When the identification of patients is based on spontaneous reports (e. g., door-to-door surveys), patients in remission may be less likely to disclose the disease for fear of stigmatization with no concurrent benefits. This might lead to underascertainment of cases when assessing the lifetime prevalence of epilepsy. In LICs, the proportion of people living in poverty is greater than in HICs. Poverty is associated with risk factors for epilepsy, risk for developing epilepsy, and increased mortality. The high incidence and prevalence of epilepsy found in LICs is also observed in low income individuals from HICs. Epileptogenic conditions are associated with an increased mortality. This may partly explain the difference between incidence and lifetime prevalence of epilepsy in LICs. Poverty within LICs and HICs could be a preventable cause of mortality in epilepsy.	[Beghi, Ettore] IRCCS Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20156 Milan, Italy; [Hesdorffer, Dale] Columbia Univ, Dept Epidemiol, New York, NY USA; [Hesdorffer, Dale] Columbia Univ, GH Sergievsky Ctr, New York, NY USA		Beghi, E (corresponding author), IRCCS Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, Via Giuseppe La Masa 19, I-20156 Milan, Italy.	ettore.beghi@mari-onegri.it	Beghi, Ettore/AAA-7426-2020	Beghi, Ettore/0000-0003-2542-0469	UCB-PharmaUCB Pharma SA; Sanofi-AventisSanofi-Aventis; GlaxoSmithKlineGlaxoSmithKline; EisaiEisai Co Ltd; Upsher Smith	Dr. Beghi serves on the editorial advisory boards of Epilepsia, Amyotrophic Lateral Sclerosis, Clinical Neurology & Neurosurgery, and Neuro-epidemiology; has received money for board membership by Viropharma and Eisai; has received funding for travel and speaker honoraria from UCB-Pharma, Sanofi-Aventis, and GlaxoSmithKline, and has received funding for educational presentations from GlaxoSmithKline. Dr. Hesdorffer serves as an associate editor of Epilepsia, is on the editorial boards of Epilepsy & Behavior, and Epilepsy Research, and is a contributing editor for Epilepsy Currents. She has received consultant fees from Eisai and Upsher Smith and has received speaker honoraria from UCB-Pharma. We confirm that we have read the Journal position on issue involved in ethical publication and affirm that this report is consistent with these guidelines.	ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; Annegers JR, 1984, ADV EPILEPTOL, P521; [Anonymous], 1993, EPILEPSIA, V34, P592; Beghi E, 2009, EXPERT REV NEUROTHER, V9, P291, DOI 10.1586/14737175.9.2.291; Bell GS, 2014, EPILEPSIA, V55, P958, DOI 10.1111/epi.12605; Bhalla D, 2013, EPILEPSIA, V54, P1342, DOI 10.1111/epi.12218; Carpio A, 2005, EPILEPSIA, V46, P28, DOI 10.1111/j.1528-1167.2005.00404.x; Chang CL, 2002, J CLIN EPIDEMIOL, V55, P741, DOI 10.1016/S0895-4356(02)00413-4; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Faggiano F, 1997, IARC Sci Publ, P65; Faught E, 2008, NEUROLOGY, V71, P1572, DOI 10.1212/01.wnl.0000319693.10338.b9; Forsgren L, 2005, EPILEPSIA, V46, P18, DOI 10.1111/j.1528-1167.2005.00403.x; GIUFFRA LA, 1994, PSYCHOL MED, V24, P375, DOI 10.1017/S0033291700027355; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; Guthmundsson K, 1997, Nord Med, V112, P169; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Hemmingsson T, 1999, SOC SCI MED, V49, P1051, DOI 10.1016/S0277-9536(99)00191-4; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; Hesdorffer DC, 2005, EPILEPSIA, V46, P1297, DOI 10.1111/j.1528-1167.2005.10705.x; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Jones IR, 1997, BRIT MED J, V314, P794, DOI 10.1136/bmj.314.7083.794; Kaiboriboon K, 2013, NEUROLOGY, V80, P1942, DOI 10.1212/WNL.0b013e318293e1b4; Kaiser C, 1998, EPILEPSY RES, V30, P247, DOI 10.1016/S0920-1211(98)00007-2; Karp A, 2004, AM J EPIDEMIOL, V159, P175, DOI 10.1093/aje/kwh018; KERANEN T, 1993, BRIT MED J, V307, P483, DOI 10.1136/bmj.307.6902.483; Kotsopoulos IAW, 2002, EPILEPSIA, V43, P1402, DOI 10.1046/j.1528-1157.2002.t01-1-26901.x; Logroscino G, 2005, EPILEPSIA, V46, P3, DOI 10.1111/j.1528-1167.2005.00399.x; Meyer AC, 2010, B WORLD HEALTH ORGAN, V88, P260, DOI 10.2471/BLT.09.064147; Modi AC, 2011, JAMA-J AM MED ASSOC, V305, P1669, DOI 10.1001/jama.2011.506; Morgan CLI, 2000, J NEUROL NEUROSUR PS, V69, P13, DOI 10.1136/jnnp.69.1.13; Mu J, 2011, NEUROLOGY, V77, P132, DOI 10.1212/WNL.0b013e318223c784; Ngugi AK, 2011, NEUROLOGY, V77, P1005, DOI 10.1212/WNL.0b013e31822cfc90; Nguyen AT, 2010, EPILEPSIA, V51, P2377, DOI 10.1111/j.1528-1167.2010.02699.x; Nicoletti A, 2009, EPILEPSIA, V50, P2199, DOI 10.1111/j.1528-1167.2009.02174.x; Noronha ALA, 2007, EPILEPSIA, V48, P880, DOI 10.1111/j.1528-1167.2006.00974.x; PLACENCIA M, 1992, BRAIN, V115, P771, DOI 10.1093/brain/115.3.771; PLACENCIA M, 1994, J NEUROL NEUROSUR PS, V57, P320, DOI 10.1136/jnnp.57.3.320; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SENANAYAKE N, 1993, B WORLD HEALTH ORGAN, V71, P247; SHAMANSKY SL, 1979, EPILEPSIA, V20, P457, DOI 10.1111/j.1528-1157.1979.tb04828.x; Sillanpaa M, 2006, BRAIN, V129, P617, DOI 10.1093/brain/awh726; TEKLEHAIMANOT R, 1990, EPILEPSY RES, V7, P230, DOI 10.1016/0920-1211(90)90020-V; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; Tuan NA, 2008, EPILEPSIA, V49, P1634, DOI 10.1111/j.1528-1167.2008.01663.x; Vrijheid M, 2000, ARCH DIS CHILD, V82, P349, DOI 10.1136/adc.82.5.349; WATTS AE, 1992, EPILEPSIA, V33, P464, DOI 10.1111/j.1528-1157.1992.tb01692.x	50	45	47	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2014	55	7					963	967		10.1111/epi.12579			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN4YI	WOS:000340595500007	24966095	Bronze			2022-02-06	
J	Pearce, AJ; Hoy, K; Rogers, MA; Corp, DT; Maller, JJ; Drury, HGK; Fitzgerald, PB				Pearce, Alan J.; Hoy, Kate; Rogers, Mark A.; Corp, Daniel T.; Maller, Jerome J.; Drury, Hannah G. K.; Fitzgerald, Paul B.			The Long-Term Effects of Sports Concussion on Retired Australian Football Players: A Study Using Transcranial Magnetic Stimulation	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; motor cortex inhibition; motor execution slowness; sports concussion; TMS	HUMAN MOTOR CORTEX; TRAUMATIC BRAIN-INJURY; INTRACORTICAL INHIBITION; CORTICAL INHIBITION; PARKINSONS-DISEASE; COMMUNITY-LEVEL; HEAD-INJURY; FACILITATION; HUMANS; RESPONSES	This study investigated corticomotor excitability and inhibition, cognitive functioning, and fine motor dexterity in retired elite and amateur Australian football (AF) players who had sustained concussions during their playing careers. Forty male AF players who played at the elite level (n = 20; mean age 49.7 +/- 5.7 years) or amateur level (n = 20; mean age 48.4 +/- 6.9 years), and had sustained on average 3.2 concussions 21.9 years previously, were compared with 20 healthy age-matched male controls (mean age 47.56 +/- 6.85 years). All participants completed assessments of fine dexterity, visuomotor reaction time, spatial working memory (SWM), and associative learning (AL). Transcranial magnetic stimulation (TMS) was used to measure corticospinal excitability: stimulus-response (SR) curves and motor evoked potential (MEP) 125% of active motor threshold (aMT); and intracortical inhibition: cortical silent period (cSP), short-interval intracortical inhibition (SICI), and long-interval intracortical inhibition (LICI). Healthy participants performed better in dexterity (p = 0.003), reaction (p = 0.003), and movement time (p = 0.037) than did both AF groups. Differences between AF groups were found in AL (p = 0.027) and SWM (p = 0.024). TMS measures revealed that both AF groups showed reduced cSP duration at 125% aMT (p > 0.001) and differences in SR curves (p > 0.001) than did healthy controls. Similarly, SICI (p = 0.012) and LICI (p = 0.009) were reduced in both AF groups compared with controls. Regression analyses revealed a significant contribution to differences in motor outcomes with the three measures of intracortical inhibition. The measures of inhibition differed, however, in terms of which performance measure they had a significant and unique predictive relationship with, reflecting the variety of participant concussion injuries. This study is the first to demonstrate differences in motor control and intracortical inhibition in AF players who had sustained concussions during their playing career two decades previously.	[Pearce, Alan J.; Rogers, Mark A.; Corp, Daniel T.; Drury, Hannah G. K.] Deakin Univ, Sch Psychol, Cognit Neurosci Lab, Melbourne, Vic 3125, Australia; [Hoy, Kate; Maller, Jerome J.; Fitzgerald, Paul B.] The Alfred, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Hoy, Kate; Maller, Jerome J.; Fitzgerald, Paul B.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia		Pearce, AJ (corresponding author), Deakin Univ, Sch Psychol, 225 Burwood Highway, Melbourne, Vic 3125, Australia.	alan.pearce@deakin.edu.au	Pearce, Alan J/W-1195-2018; Fitzgerald, Paul B/A-1225-2008; Maller, Jerome J/H-4963-2014	Pearce, Alan J/0000-0002-9264-9880; Fitzgerald, Paul B/0000-0003-4217-8096; Maller, Jerome J/0000-0003-4685-1508; Hoy, Kate/0000-0003-0694-9674; Rogers, Mark/0000-0002-6808-9545; Corp, Daniel/0000-0003-2435-077X	NHMRCNational Health and Medical Research Council of Australia; Cervel Neurotech	Jerome Maller and Paul Fitzgerald are supported by NHMRC fellowships. P. B. F. has received equipment for research from Brainsway, Ltd., Cervel Neurotech, MagVenture A/S, and Medtronic Ltd., and has received funding for research from Cervel Neurotech. The other authors have nothing to disclose.	Abbruzzese G, 1999, J PHYSIOL-LONDON, V514, P895, DOI 10.1111/j.1469-7793.1999.895ad.x; AFL Medical Officers Association, 2011, MAN CONC AUSTR FOOTB; Bares M, 2003, EUR J NEUROL, V10, P385, DOI 10.1046/j.1468-1331.2003.00610.x; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Berardelli A, 1996, BRAIN, V119, P71, DOI 10.1093/brain/119.1.71; Berardelli A, 2008, BRAIN STIMUL, V1, P183, DOI 10.1016/j.brs.2008.06.005; Berger MAM, 2009, APPL ERGON, V40, P145, DOI 10.1016/j.apergo.2008.01.014; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Braham R, 2004, J SCI MED SPORT, V7, P451, DOI 10.1016/S1440-2440(04)80263-9; Braham R, 2004, J SCI MED SPORT, V7, P96, DOI 10.1016/S1440-2440(04)80048-3; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; CORLETT EN, 1971, OCCUP PSYCHOL, V45, P57; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Espay AJ, 2006, ANN NEUROL, V59, P825, DOI 10.1002/ana.20837; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gabbe B, 2002, J SCI MED SPORT, V5, P149, DOI 10.1016/S1440-2440(02)80036-6; Gilbert F, 2012, MED J AUSTRALIA, V196, P561, DOI 10.5694/mja11.11218; GLOSS DS, 1981, PERCEPT MOTOR SKILL, V53, P659, DOI 10.2466/pms.1981.53.2.659; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harris AW, 2012, CLIN J SPORT MED, V22, P91, DOI 10.1097/JSM.0b013e31823776cb; Jordan BD, 2000, NEUROLOGY, V54, pA410; Kaye AH, 2012, MED J AUSTRALIA, V196, P547, DOI 10.5694/mja12.10539; King T, 2013, J SCI MED SPORT, V16, P302, DOI 10.1016/j.jsams.2012.09.003; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liepert J, 1998, EXP BRAIN RES, V118, P421, DOI 10.1007/s002210050296; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McGinley M, 2010, EXP GERONTOL, V45, P671, DOI 10.1016/j.exger.2010.04.005; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nowinski Chris, 2013, Cerebrum, V2013, P2; Pearce AJ, 2013, BRAIN STIMUL, V6, P306, DOI 10.1016/j.brs.2012.05.010; Pearce AJ, 2010, J SCI MED SPORT, V13, P167, DOI 10.1016/j.jsams.2008.12.632; Pearce AJ, 2009, J SCI MED SPORT, V12, P280, DOI 10.1016/j.jsams.2007.12.005; Pierantozzi M, 2004, BRAIN RES, V1028, P1, DOI 10.1016/j.brainres.2004.06.009; Poldrack RA, 2006, TRENDS COGN SCI, V10, P59, DOI 10.1016/j.tics.2005.12.004; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Takeuchi N, 2006, BRAIN INJURY, V20, P991, DOI 10.1080/02699050600909771; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; WILSON SA, 1993, NEUROSCI LETT, V154, P52, DOI 10.1016/0304-3940(93)90169-L; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	53	45	45	1	48	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1139	1145		10.1089/neu.2013.3219			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500002	24579780				2022-02-06	
J	Simkin, DR; Thatcher, RW; Lubar, J				Simkin, Deborah R.; Thatcher, Robert W.; Lubar, Joel			Quantitative EEG and Neurofeedback in Children and Adolescents Anxiety Disorders, Depressive Disorders, Comorbid Addiction and Attention-deficit/Hyperactivity Disorder, and Brain Injury	CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Quantitative EEG; Neurofeedback; LORETA; Anxiety disorders; Depression; Addiction; ADHD; Brain injury in children and adolescents	DEFICIT HYPERACTIVITY DISORDER; RESOLUTION ELECTROMAGNETIC TOMOGRAPHY; ELECTROENCEPHALOGRAPHIC BIOFEEDBACK; MARIJUANA USE; HEAD-INJURY; WISC-R; QEEG; ADHD; THERAPY; LONG	This article explores the science surrounding neurofeedbdck. Both surface neurofeedback (using 2-4 electrodes) and newer interventions, such as real-time z-score neurofeedback (electroencephalogram [EEG] biofeedback) and low-resolution electromagnetic tomography neurofeedback, are reviewed. The limited literature on neurofeedback research in children and adolescents is discussed regarding treatment of anxiety, mood, addiction (with comorbid attention-deficit/hyperactivity disorder), and traumatic brain injury. Future potential applications, the use of quantitative EEG for determining which patients will be responsive to medications, the role of randomized controlled studies in neurofeedback research, and sensible clinical guidelines are considered.	[Simkin, Deborah R.] Amer Acad Child & Adolescent Psychiat, Memory & Cognit Ctr, Comm Integrat Med, Destin, FL 32541 USA; [Simkin, Deborah R.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA; [Thatcher, Robert W.] Appl Neurosci Res Inst, Neuroimaging Lab, Seminole, FL 33772 USA; [Lubar, Joel] Univ Tennessee, Knoxville, TN USA; [Lubar, Joel] Southeastern Neurofeedback Inst Inc, Pompano Beach, FL 33062 USA		Simkin, DR (corresponding author), 4641 Gulfstarr Dr,Suite 106, Destin, FL 32541 USA.	deb62288@aol.com					ABRAHAM HD, 1989, AM J PSYCHIAT, V146, P947; Adolphs RJ, 2004, PRINCIPLES PRACTICE, P451; Arnold LE, 2013, J ATTEN DISORD, V17, P420, DOI 10.1177/1087054713482580; Arnold LE, 2012, J ATTEN DISORD, V17, P1; Arns M, 2014, BIOL PSYCHOL, V95, P108, DOI 10.1016/j.biopsycho.2013.11.013; Arns M, 2013, AM J PSYCHIAT, V170, P799, DOI 10.1176/appi.ajp.2013.13020208; Arns M, 2012, APPL PSYCHOPHYS BIOF, V37, P171, DOI 10.1007/s10484-012-9191-4; Arns M, 2009, CLIN EEG NEUROSCI, V40, P180, DOI 10.1177/155005940904000311; AYERS M, 1995, BIOFEEDBACK SELF-REG, V20, P318; Bares M, 2012, J PSYCHIATR RES, V46, P219, DOI 10.1016/j.jpsychires.2011.09.006; Bauer LO, 2001, NEUROPSYCHOPHARMACOL, V25, P332, DOI 10.1016/S0893-133X(01)00236-6; Beauregard M, 2006, APPL PSYCHOPHYSIOL B, V31; Bosch-Bayard J, 2001, CLIN ELECTROENCEPHAL, V32, P47, DOI 10.1177/155005940103200203; Brodmann K ., 1909, VERGLEICHENDE LOKALI; Brodmann VK, 1909, LOCALIZATION CEREBRA; BUCHSBAUM MS, 1985, BIOL PSYCHIAT, V20, P832, DOI 10.1016/0006-3223(85)90208-2; Buckholtz JW, 2012, NEURON, V74, P990, DOI 10.1016/j.neuron.2012.06.002; Buzsaki Gyorgy, 2006, RHYTHMS BRAIN; Cannon RL, 2012, LOW RESOLUTION BRAIN, P3; Canterberry M, 2013, NICOTINE TOB RES, V15, P2120, DOI 10.1093/ntr/ntt122; Chabot RJ, 2005, CHILD ADOL PSYCH CL, V14, P21, DOI 10.1016/j.chc.2004.07.005; Chabot RJ, 2001, J NEUROPSYCH CLIN N, V13, P171, DOI 10.1176/appi.neuropsych.13.2.171; Chabot RJ, 1996, CLIN ELECTROENCEPHAL, V27, P26, DOI 10.1177/155005949602700105; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Clarke AR, 2001, PSYCHIAT RES, V103, P205, DOI 10.1016/S0165-1781(01)00277-3; Collura T., 2010, J NEUROTHERAPY, V14, P22, DOI [DOI 10.1080/10874200903543963, 10.1080/10874200903543963]; Collura TF, 2008, INTRO QEEG NEUROFEED, P123; Cook IA, 2002, NEUROPSYCHOPHARMACOL, V27, P120, DOI 10.1016/S0893-133X(02)00294-4; Coutin-Churchman P, 2003, CLIN NEUROPHYSIOL, V114, P2294, DOI 10.1016/S1388-2457(03)00228-1; CZOBOR P, 1991, BIOL PSYCHIAT, V30, P927, DOI 10.1016/0006-3223(91)90006-8; DeBoer P, 1996, J PHARMACOL EXP THER, V277, P775; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; DUFFY FH, 1994, CLIN ELECTROENCEPHAL, V25, pR6, DOI 10.1177/155005949402500403; Earnest C., 1999, J NEUROTHER, V3, P28; Egner T, 2003, NEUROREPORT, V14, P1221, DOI 10.1097/00001756-200307010-00006; Eismont EV, 2011, NEUROPHYSIOLOGY+, V43, P53, DOI 10.1007/s11062-011-9185-5; Faraone SV, 2010, EUR CHILD ADOLES PSY, V19, P353, DOI 10.1007/s00787-009-0054-3; First, 2008, J NEUROTHERAPY, V12, P79, DOI DOI 10.1080/10874200802219947; Foster D, 2013, INT SOC NEUR RES C D; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hajek T, 2013, AM AC CHILD AD PSYCH; Hammond D.C., 2011, J NEUROTHER, V15, P305, DOI [10.1080/10874208.2011.623090, DOI 10.1080/10874208.2011.623090]; Hansen ES, 2003, CLIN ELECTROENCEPHAL, V34, P70, DOI 10.1177/155005940303400205; He Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005226; Huang-Storms L, 2006, J NEUROTHERAPY, V10, P3, DOI DOI 10.1300/J184V10N04_; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Hughes SW, 2007, INT J PSYCHOPHYSIOL, V64, P3, DOI 10.1016/j.ijpsycho.2006.08.004; Hunter AM, 2010, ACTA PSYCHIAT SCAND, V122, P461, DOI 10.1111/j.1600-0447.2010.01560.x; Hunter AM, 2007, PSYCHIAT CLIN N AM, V30, P105, DOI 10.1016/j.psc.2006.12.002; Hwang K, 2012, CEREBRAL CORTEX; Ikarashi Y, 1997, NEUROCHEM INT, V30, P191, DOI 10.1016/S0197-0186(96)00024-1; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; JENIKE MA, 1984, J CLIN PSYCHIAT, V45, P122; Jiang L, 2011, NEUROSCI LETT, V505, P160, DOI 10.1016/j.neulet.2011.10.011; John E, 1993, ELECTROENCEPHALOGRAP, V3rd, P989; John ER, 2005, PROG BRAIN RES, V150, P143, DOI 10.1016/S0079-6123(05)50011-6; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1983, PROG NEUROBIOL, V21, P239, DOI 10.1016/0301-0082(83)90014-X; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kentgen LM, 2000, J ABNORM PSYCHOL, V109, P797, DOI 10.1037/0021-843X.109.4.797; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Leuchter AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032508; Levesque J, 2006, NEUROSCI LETT, V394, P216, DOI 10.1016/j.neulet.2005.10.100; LEVY F, 1991, AUST NZ J PSYCHIAT, V25, P277, DOI 10.3109/00048679109077746; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; Lubar JF, 1981, ARCH NEUROL-CHICAGO, V38, P699; LUBAR JO, 1984, BIOFEEDBACK SELF-REG, V9, P1, DOI 10.1007/BF00998842; Michel CM., 2009, ELECT NEUROIMAGING; Monastra VJ, 2005, APPL PSYCHOPHYS BIOF, V30, P95, DOI 10.1007/s10484-005-4305-x; Monastra VJ, 2005, CHILD ADOL PSYCH CL, V14, P55, DOI 10.1016/j.chc.2004.07.004; Monastra VJ, 2002, APPL PSYCHOPHYS BIOF, V27, P231, DOI 10.1023/A:1021018700609; Nazari M.A., 2012, NEUROSCI MED, V2, P78, DOI [10.4236/nm.2011.22012, DOI 10.4236/NM.2011.22012]; Niedermeyer E, 1997, CLIN ELECTROENCEPHAL, V28, P130, DOI 10.1177/155005949702800303; Nunez P.L., 1994, NEOCORTICAL DYNAMICS; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 2003, CLIN NEUROPHYSIOL, V114, P2225, DOI 10.1016/S1388-2457(03)00310-9; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Pascual-Marqui RD, 1999, PSYCHIAT RES-NEUROIM, V90, P169, DOI 10.1016/S0925-4927(99)00013-X; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Peniston E. G., 1991, MED PSYCHOTHERAPY, V4, P47, DOI DOI 10.1021/MA0483701; Peniston EG, 1991, MED PSYCHOTHERAPY, V2, P37; Phillips ML, 2013, AM AC CHILD AD PSYCH; Power JD, 2010, NEURON, V67, P735, DOI 10.1016/j.neuron.2010.08.017; Prichep L, 1996, RES MONOGRAPH, V162, P142; PRICHEP L S, 1992, Brain Topography, V4, P249, DOI 10.1007/BF01135562; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Prichep LS, 2002, CLIN ELECTROENCEPHAL, V33, P8, DOI 10.1177/155005940203300104; PRICHEP LS, 1993, PSYCHIAT RES-NEUROIM, V50, P25; PRICHEP LS, 1986, BRAIN ELECTRICAL POT, P223; Raymond J, 2005, COGNITIVE BRAIN RES, V23, P287, DOI 10.1016/j.cogbrainres.2004.10.023; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROEMER RA, 1991, NEUROPSYCHOBIOLOGY, V24, P121; RUSSELL V, 1995, BRAIN RES, V676, P343, DOI 10.1016/0006-8993(95)00135-D; Sherlin L, 2010, J NEUROTHERAPY, V14, P66, DOI DOI 10.1080/10874201003773880; Small JG, 1993, ELECTROENCEPHALOGRAP, P581; Sonuga-Barke EJS, 2013, AM J PSYCHIAT, V170, P275, DOI 10.1176/appi.ajp.2012.12070991; Struve FA, 1998, CLIN ELECTROENCEPHAL, V29, P31, DOI 10.1177/155005949802900110; STRUVE FA, 1994, CLIN ELECTROENCEPHAL, V25, P63, DOI 10.1177/155005949402500207; SUFFIN SC, 1995, CLIN ELECTROENCEPHAL, V26, P76, DOI 10.1177/155005949502600204; Sunrmeli T, 2007, J NEUROTHERAPY, V11, P63, DOI DOI 10.1300/J184v11n01_07; Surmeli T, 2010, CLIN EEG NEUROSCI, V41, P32, DOI 10.1177/155005941004100108; TALAIRACH J, 1998, CO PLANAR STEREOTAXI; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211; Thatcher R. W., 2003, Journal of Neurotherapy, V7, P87, DOI 10.1300/J184v07n03_05; Thatcher RW, 2011, NEUROPSYCHIATRY-LOND, V1, P495, DOI 10.2217/npy.11.45; Thatcher RW, 2012, HUM BRAIN MAPP, V33, P1062, DOI 10.1002/hbm.21271; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P1, DOI 10.1177/155005940503600103; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thatcher RW, 2008, INTRO QEEG NEUROFEED; Thatcher RW, 2012, HDB QUANTITATIVE ELE, P10; THATCHER RW, 1994, FUNCTIONAL NEUROIMAG, P269; THATCHER RW, 1996, DEV NEUROIMAGING MAP; Thornton KE, 2008, APPL PSYCHOPHYS BIOF, V33, P101, DOI 10.1007/s10484-008-9056-z; Thornton KE, 2009, APPL PSYCHOPHYS BIOF, V34, P59, DOI 10.1007/s10484-009-9075-4; Tiesinga PH, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00196; Tomarken AJ, 2004, BIOL PSYCHOL, V67, P77, DOI 10.1016/j.biopsycho.2004.03.011; VALDES P, 1992, Brain Topography, V4, P259, DOI 10.1007/BF01135563; van Dongen-Boomsma M, 2013, J CLIN PSYCHIAT, V74, P821, DOI 10.4088/JCP.12m08321; Walker J.E., 2007, HDB NEUROFEEDBACK, P341; Walker JE, 2005, CHILD ADOL PSYCH CL, V14, P163, DOI 10.1016/j.chc.2004.07.009; WANG B, 1994, FUNCTIONAL NEUROIMAG, P251; WHEELER RE, 1993, PSYCHOPHYSIOLOGY, V30, P82, DOI 10.1111/j.1469-8986.1993.tb03207.x	126	45	46	6	85	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1056-4993	1558-0490		CHILD ADOL PSYCH CL	Child Adolesc. Psychiatr. N. Am.	JUL	2014	23	3					427	+		10.1016/j.chc.2014.03.001			39	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	AL8TH	WOS:000339411900002	24975621				2022-02-06	
